<SEC-DOCUMENT>0001802768-23-000007.txt : 20230215
<SEC-HEADER>0001802768-23-000007.hdr.sgml : 20230215
<ACCEPTANCE-DATETIME>20230215090327
ACCESSION NUMBER:		0001802768-23-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230215
DATE AS OF CHANGE:		20230215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Royalty Pharma plc
		CENTRAL INDEX KEY:			0001802768
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39329
		FILM NUMBER:		23633803

	BUSINESS ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 883-0200

	MAIL ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rprx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9,d:7624980bc44b4db29e5ea00d25f439ff--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rprx="http://royaltypharma.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rprx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8xLTEtMS0xLTEzMzY2OA_b83f6d66-7b9d-4ed4-ae70-8c85b7c822ba">0001802768</ix:nonNumeric><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8yLTEtMS0xLTEzMzY2OA_08dd9013-4a6c-4b31-8941-f424ec4c8662">2022</ix:nonNumeric><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8zLTEtMS0xLTEzMzY2OA_7554435e-0158-48aa-b12e-52f093589f3e">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV80LTEtMS0xLTEzMzY2OA_316e939f-7920-4f90-9f76-9b07b8a301ee">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia13e806ca6da4fa5b16131baa358c469_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTAtMS0xLTEzMzY2OA_88944e72-0e6d-43cf-9aca-c19425f17385">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" name="us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" name="us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rprx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a353e18b5564d8c99b2d3b373d4a329_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic682e5b806304506930fd5fd21e6c21a_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1909231d99304e4a834f210d58e1fa93_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd27d5636b244ddd89fd2e8030b54641_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192dc6dc29504992a09bfae83dcce963_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iabe3448245414e18a4b4313799d4a486_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158874ffe5c04ef4b93cee255fec0dfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a118afd54f1420497a8451111036378_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idd431f21346c42daa2c77e7ca72e959c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92cf91b49d444b89c5ca4d63d6e997a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b14c23fc6244f59ebfbae3ac633db6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dfb9308ae154def8f8c57d02cde386a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie008f8c9d7654553948cf5d03673f74b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa24c4f1c1cf4fa4a7afb95c44a5b6f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccebf37c46634c398d67ec2e7c9899b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db1d86622b54d0aa7386b802e458701_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if34a184452ef4fa88c4aa26700a19e27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ad5247fc86440e9432a456ffbf26ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8885fde0c1284600a478a453d7f04c9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb811a285154e8abc06e48048183949_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8405fbbc504757866319d871cfe818_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2626c942e9294d08899937a29e6df6d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21985f335d0445f5a86183ee1ff7f4b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f248f1983243fd9644c279de47a32c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd0b8d23d7d46f28641ee528276a6bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e797a142c1d4e669b384c7cb83c9dee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6924ffcc56464af49725a154112a2c81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209869199a674f339c33431cd676e2a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13e806ca6da4fa5b16131baa358c469_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fbcf597b512467294d0d8a431cff682_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2485d51e396d457d82d53b0d720876f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cbf4efe96145bc9b29ae5fcb436732_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd60620e8d7464586752970db0211e9_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe5497d8e994e039ef92e85073e55a8_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida16729ea6c0450498d0894c41753058_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ffbc7e40f849c79a2370de012b62a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193b3040cd2347e7addc1373ea7a38fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921629adeeab477cbc0cc2df2b75eef0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3be8c068c0e4210b0b20061ca476efd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f8305cf2864dbda8cea2f22f63e356_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ea0ca2684e4b76aaeb8cfe35fffb2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e0f207870b4fc7922227f8a820157a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67d04637150e49448bad7423d2ea8dbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1d98977d25401ab5199bd95b2ac683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06aaf4b76d2b48d6a71c3deedfa9f5d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e1faf18b8b44d991d1d1a4c417f179_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638daa38667341c8878e93ae45445868_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af311935ef147839b589ff0401a4cc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f5fba4c66c4d59b458232cfefd397b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388294e0fecc48b7acef50ad301ac37c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca490efe8f34a918c292b71f44885d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ebba7acc969439b987dcc2d0fba6673_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec2f808579b4b78902a87ec4cc91f2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i852db36c0318454ea53dd42de40f5456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f12c6f1519441d92c1fb354e0c1a55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143cf5791aaf471fa5e1a7b574902892_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec20854f553421a86396e564097af71_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43eea863eed4e989a4af810e68237ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd8756959c734531850ee0869d7a395d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4bbb534e9247e69a9f399be66e680d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd19d54ace74630abbabeca7a180eb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2563f49c9d244ee28c8dcc79a588677d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia422b9c6dc3d49fa986c24ca134e7dfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02e089bd28e49abaff42a3961b0d5db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762c4b988d95468ca6e9ff58ce974d4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1fc390f90a425883695c27f2ee9af6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia953612cc13a40389485402ddbb1c92a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280e643fdef0483689f89d2627e67117_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955ef8f092f6410b8368691a366b3ccd_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00f566083814766b799de815b74eb68_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6272e7fd11d44329684f5f26db3b0e5_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabc44fc792946909b8b90c908c11b2a_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ff36e2c24f4dfba76ba7b4b27451b6_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OldCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abe73d17656428c858e609114abb39a_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIFTSeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9572c0d747ab4d80a3666c92eef2f3e7_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92461c4b3514d22afb54b7350b5a973_I20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec997943fd44095835407fd6f299a6d_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d4834e0547457480186ed9fe6cfbed_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromSellingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5b5a5cdfc4467896657cf7dc34567d_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cdeed76822f459e89ec58e43a1d83ea_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c853fcbec74369a6114e07a900dfc8_I20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie00852d0b4174efbaafedf7b99cbfe00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="noncontrolling_interest"><xbrli:measure>rprx:noncontrolling_interest</xbrli:measure></xbrli:unit><xbrli:context id="i9e6a1451ee4f45f286b64a9a27bc35ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6036429cbf7d478bb21d142552f11fd3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50014516371a4a1d80e1b25e358497c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>rprx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-07</xbrli:startDate><xbrli:endDate>2022-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>rprx:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5062756e7634788ade2313173101917_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:DevelopmentFundBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b27d2843a794aa78e16c71951dd44e8_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic197bc2dabd546778e0292339fc66971_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298d7c29452d4bcdbaf7cd89d8fc8533_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c3a6ae85e346a0a5e3381b803dd465_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8d155decaa4354a46677a02d47d72b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69adb70664a447e79c77ca4463c73f8c_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0d89f6c512426b935355784dc5eca8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8926e1456d5b484da7113982a2cc6f8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b454c53374c471884c05778788c7dae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d8cbe5699f4354a0a0fb8aa7ac335c_D20221003-20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5453ca3d1fa434f832ded0a6cbd1d30_D20221003-20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia387ad8558934defb6159f7305efa385_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cb276a5c674234b53a15b315d62a67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808aa487867047a1aeeed484938b9306_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4bf194cfc2e4ae29733f8ea9a9e30c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7aecdb813e34569b6db97dce91bbfab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83621d3576df4e908ddd466a0e61f733_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec09d9a909cb4c17866b5eb148734cbb_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d67c1c36ac474584018997072ac0ba_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf0a219828db455db7c7f67f043e8346_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15fe3c8a0254d78944bd1d10ea2a29a_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b09b987997c4801be4424e787583ad3_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie250c596f2414ce2a10252ee5fe6b000_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ee900d9be64dff809bae93067b329b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b84d20eec148e8a629524fec68a0a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i584e4daf7e194c5892cde63718b1c7ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ab4d2a31844b79b2cc049b2d2d82a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee5401a91f4148caa202184655267c97_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf13c3669b9445de801580639f1dcd01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377698d44a004b60a93b6e026bb496b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51deee71524e45f2b92578b1b7a69a43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78355224105441eeb9b89315786e6bb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da8d7006a174307ad5d37753b978bd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18b06181b4d43fbb3e315553e743a9c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6913761eb9d476a89d786eb84437c8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bde215a2f7d41c19e08a08fda54ecec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b208c40e457458888bdd3417e87cc6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a25c9fbeac4e028b27a42ea86ea95b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib489dd79da964d4f9415ec89293c3ae7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81792be75c1c4c2d9399629e922cab13_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb080182b0d4caaa2be643121414d08_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f43d56301b49e996fc395673d519ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7ceeaef8dc42f28a13e4f9c0bb24d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c740405d5a64a9b80be8f8b658e7edb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09689e7a29b04e63b1743e322c38e197_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0fb45740e6145a5b10b66dd36b462b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib406778ea8824af6aae3c5dfb2e1610f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a21bed221044a0890c2c913d788b8a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186084ca8b944fd98cdadde833e23388_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796975e015ca44e1a9105072f8fc8ba5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1873077ea3a4449b93ac140b1258d597_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4a77eb1b3c42f690d02b5f7c117bb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4228e1020e84d28a5d3606eb13fba5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce834481aa64cca87e9f3cc25a312ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba512b3b31444ed910800ea1536abc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29550347abe146f89941dfcd98915c01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd2992133f24f0f9d76c8ca5fe08441_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdfec8d4041469bb92dd0165296ed5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1f65e37bdc4ae98f2ef6443c0e36d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb596f160574fde859a997dd3688a51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1505389d35a4fe697a3107d3e1a4e20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3ab05ebb3f4cefb671b072e85ae362_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0a251553004651bae3fe39fca66f0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2611175ae914a0cb275393ef07b82b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3e7cecd2194bba94c9ea68302d6da5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2fb97cbac8b416db2ba868db73a9261_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63036932758473e8e19c69328045159_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b041c7b1fd843f4801f45f69864a734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513ac86b5f644e0abbd6fd515bf19a93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia930877a154f4ea397b7a9ed77275162_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd6c9fd69b64ac3ada61bea9f9a809e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6606a8ffd244eb8b5538e380fb0155d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2ed614ee654625b83a27f5186d6d46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf13afac5c747a58a510a05b6306845_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib747f5c2a7ac44d2adede24f51ea0ed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4e09328663481a88570d82f2b0b2da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f44f16ba8447af88c5f94ba782e24e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886a32de12484bc3a8fa2095f96ce3aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b749d46341641ce864db1980ea0eadd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d1f95532784cb4b004e23c96a53c2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7913fe2f2f1f4f17975329f9e86b47f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8167718861cf4cc097ec7bc1722c4abe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie34968ddaef047e5aee9da6ed328c6a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc45285d96740488e652d34212bd6bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a6ca2229ea245549c7358f77e0511f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe6b624b7369483aab919710178f1675_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea5eb15f1b3454786bccad98927ed9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a230a360ef4bd6bdd4b1fde0b5e287_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2bf206b0fe441d9a604aa40decf5e98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie196b18bfc6e42cdbb8fc1c9cf933b38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671467da1004443aadefa5fc4adc8a66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d09b91ce0940f8bf8d043a117aa8b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9965e6b7e930491083134897c58109bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db25f68b5f64a1b83cb921118b07a8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de25f5e6375404c800880744168d22f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3db62c54fe54935bfbb368cd4dcd185_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311eff96434042c48fc1a0da1a969d9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89a50ad7a634d438a6aea813c2e2267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4aabe1887bb4026b0b128e258134f11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d1415d925c4be3a6b3679f2f242c45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef49f9006f64af4b44d5878e8dab385_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96f43839fad463b8054251eb61aaf8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568a2e5375d9455592a7ac8716ee21fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c890bd4904a4b3987af9a1db0691475_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4355b2c313964e16a9cc70955cb99e95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87bec58187049c0b4315cc2e7e75220_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30b1de3d1e04b99b1569a7a6cca90fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40c65086ad44d44b48a424f98b6eba8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief66559de8974b67ad08f5c7e106bc13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0284f5e21ce642a7876ab339f755553c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70136bdb09f640f6a595ebcc3b848490_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18426df2a74c460381450590d12af14e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386b4142f4104da8bbeb674cc226ccf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c35e8641845417891560b40c078c58b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b89ba5713246ecb69cbe5915280e12_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic244222348804b5795bfab47417210e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffc8574733247448667f38369095447_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b7ad3a58f94ab791be7207d0fe8590_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if339554672b642ae891f1ba2a6cbf38c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b55421b8464ed6a1a539d99d821dba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84360bddd1754c6aa91800aaa849b568_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ee4838df9e479ca3a26e0b99bd5d60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85817d340b744538889a7450f9dbd2e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a9073c101943dcb449f3c807e6fabc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2169911e4a4795a6d397f381a2d74e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8693ab100ea8484492349f889e6977b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8240f1e3dadf4870b07c601e66065543_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6203b19a65da4c90ac16749d22ed023f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0796e20c9d41059187f605c28f22c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0371a080d9412b814cd70dc8e5ad90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6e062894f1415ba03737996d595769_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806d566ae63e4dd1bb3b094e2720d64b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf58ad8accb4f42904d7cca513f316e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9ad39844434b80bc9e6f439efedad1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd997478ad974d568fbddf3f973a46e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie99e011b5e4c43d9b3b72a4b809c2f49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41f6ecb8c944a33bdde5a9125f24870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a0bb5b28394f50af0be743d1778ecc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47c45e714054471849ababb1fb4798c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e61aeea53b148b68f5668ae4c89ca1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bf0e3d7700c4f61bcb0877b468b7e92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8413cab6c79345889a6dcd08bb93b8a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc4135d264f4850ac652f81ebdd7653_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8dafb087fc4a46989b1599f69c7c66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12caaaf5dc4b4f7bb3868430bd3b390e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:CytokineticsCommercialLaunchFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4a1403d54240dea67d826b88016777_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c629d986ffc48cfa2eb9caa4dd6242b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb876c0578a24141af7bab85dbf86a2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc4b8074b244545ab8c7b941208037b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892ba36fbecd4c5c828c453e8b75d851_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94aede0a88af4f98b9e9b7e04739e350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac2696acac7403eabc89c247ae97720_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291d6a5f159947a298875759e6b12a1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403646e7babf4420ba107143a3a7a49c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eabb1130de844f0a07dc3f24ad506bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TrelegyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56dbca1ce972434cb58c60cd86493a5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663288bef185415e913cccac3fdce980_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338803206bb64a83b9b1b2ea2de4bb21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5208a4b0fa34da2ad818a6631d4834a_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtilimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cf7b243e4b44089454ec775107f6b1_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:GantenerumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4429291ceec343fd99325883de8cd9b9_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:RochesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c43f443bf14a7bbbc638ead341d873_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154af41306544e04b3092509a83bb96f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9499567243fb4bb6a99f9c18d1a4b027_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3fcb3410a948649edfbf04b196d762_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d319ef128f4f8885c3dadade2065f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib252428d952a4cf3902a48bd039d459d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153bc6bd9c0047408ceded26b5f9e59a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9b2898f14b4fc8b46de629cd65f242_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fbcaa672be248e197fc3072f0903674_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8076ed02354170b8e1aef0696b1dd1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb803d1f20cc4fce8c2f9ab745affbd7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850f55de08b348c6896f173a3de0636e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14cea8f163049d485a56b89150c4bc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c12de839c544f5bb19445f982348c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91fcca9afda04cc6ba4981ca2685afe6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b06f23fa444477b8d31b04cd8b75199_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84614dd16a8241bc9bb8d393780ce7a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8da099dd6c543afb79c83d2662bba53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ef2537a2d647a4b5b8a82e00bf960a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:CytokineticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ff8205a3ec46f18544e77a5fe83eab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:TheravanceBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ecf49a29ae4381b6950b4facb564aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:MerckToFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3edb74e20d194d1cb5aaf64169b64925_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffdc417e74646e7a3d9fc1fea36076e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41d6ba411fa44fe8f54e00c9719be69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93638517e843430abd0622cd117849fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementWithBioCrystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c83ded7cd649d49c712b21a4451c82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8faa4e13bd38491daf38566f6eebb9b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa254b18546f40f685306a6288911d2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506d480262374d17bc6c2d61664062dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8198214b15354bb4a8f445cec4dbc5e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i026f9953369d49eea32d8638a01cd4ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320c72757fa545478705ae929cf21624_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03ffc7bd4c74c5ca68cf23404563dd7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36467572e76c44bab1b0c5564c2c4f5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e5e2ba7c2b48ad8d172dab75994092_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13d0bca9e81479fac36370bd642690c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0acbd3d4d824163a23c1f2c06b0d15a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aad990d21894f778fa32056c3d7f296_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6788ce3a13ed48968ef184ebb77330c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6276f25d8444c9ab2361232593a04a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838c7cff011e48c7b534f0f3eedaa181_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd566c8dcd3c4e5b9f6aec7f920d2ee9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba5ff526d64b44c38b351540afac0ce9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149da048776c4462b194bf3e704f0d93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cdc999f38464531a986434571af11df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8928daca3b419895b3307d21daa429_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5d9597c55743f0b0ea434a2f05583e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b0dac23f424541b08adeb45318f282_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df2b8b2b611422b93e15b5384fee55a_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81df3e9523394784bee4f0ab4f95754b_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841ed43575b4462d8d7e171a31c3a0ea_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i384458f232644f91aa9aeae55e9bf165_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d165cc588cb42c7a715455ac1f644a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6668080e1a943078f97f24224e6214b_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ec196b42b349799568466b38b36d11_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef9b1f654c54a45a6014f3846682ac2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e5ff3a9e2243d18e1771b08d510e30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f37019f75444bfb079f9eae44011a7_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0477a1e950d844878b385b517d204739_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc82c34f1b1841fb9acad0573bb9c2af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0913b22937e94ce69dadc8d8ef64f99d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ded29aec73342379a32b7f0d37ce932_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b646b86d4204e5ab0e00d75294a4677_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa789f47637b468b8e0a81f1258d7822_D20221031-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28f0ac392314518bd09f5981a109a33_I20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida442f1cecf14df5945065908673a6d0_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f70bcb4de984b258954aedd1f27e7db_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c86a83a372f42caa003779427589736_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b4057d220b45ad8565474419d30930_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="class"><xbrli:measure>rprx:class</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>rprx:vote</xbrli:measure></xbrli:unit><xbrli:context id="iebf80945d01e4cda8265a7a35cb92256_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id583806a07ed4cd8bfd78850b5f779a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6cc65a06afd46199b75bfd37257d1bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0509ce4690e4e7589a22610857ffc76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d596cf933ba4342a229fa9b82d58290_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fcd0fcdf8b845239f1f57b6fe825b41_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2009985eb36743ad88c72d8e11fbaea0_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e55b25dde154b019f47eae3a218e41e_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e9d4812c374bfb90bd218fd00ab822_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f9625cef1e4423ba1d7b313528b32b_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3b4d885275470faa50792d4a4bce70_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1895d5cab12548d4b8aa19c4ea3f7bc4_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0475cdd9f0f940c2b84d9176875725f0_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4c363df47947bbb51883fe4178ece5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82fdaebc451745f9b2bb4e66ff3dc751_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0662e7e53b4956bd13f22f2295afdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e9ab43b7524668a5566f0c037e8e3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdd18cadc3747e1bea0a4efcb970f3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5dd6dc7e594c9f91e9eccb9dce463b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0835b7194744e4c9e4f528591ea0b3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf340aa855a942858168f3ecce184356_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic272076b47ca427798a7eb4b50714520_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie580dc2708034fd4b6b4cfd3e17819c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife94ebe41b0c47e3ba05d415807efda4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida148d60e093484bb7aecaf26959ca76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03743a114d964d26b43b9ebb04e7dd8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73f9519d5db426a8cec4e56bf77101b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1f278076d844b99be68cf3e9873d75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief164fe055724316addcd160fcd29535_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6b542ff447402ab303deafe356aa4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89cd3ad806e748eb9957406a9dba417e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858eae6f03ab4f6095837812fe2050e8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f6894c03c244809fd48ceb945f3ef4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a476c779a0f4059929c8b1c13bcb11c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib698c75befc449c9b5e6d1b50a9022ff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f144445f0e4c28a6b92715967d2981_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8140079fb2406ca4822f6e2dbf5f31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e504b2ac6f44869467d497b88bcd64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048f1daf85ab40479caf539c7b2a985f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34aa33e8820445b893a30e990847995_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a8a06b5b3141b6b061529bf42fe3a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bfaf7eb7d04751af4ffb41e99d27d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79bf03ace46488f877dae1dc4f250f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15818908d4464f36813ed35be63cb421_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b423fa12d043fb86870ee9477f4152_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799427d0838947d38f9dbd8016b9306e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc155b4bacf429796772ce27e94cbda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic382ad4d1e4b4ca887dcde3037d6a744_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32472808f32c48669cdcdb6fb300ef19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ab9056722446e7a354e96a0a2398a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40a8232720454e84ab4193b8ecf8a19a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7d2cfb65f04eeb990ed450281e3d84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80e60d8ab83494c9238a91d2d655393_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb555ed4cafa441b8b4640b8ea55f77e_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac904b7432ab421db7ac86aa4c7b05f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab860d9e81b6417c8a8c4038bbe057ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a92b3734ca649b4894cb7e1fc75d883_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9bfddb245a424897b5627ca71545ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71576f7e90f47a7ac7433ab13a80a52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d178fad8c34db685697ae7ed68e651_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:PurchasingAndDonatingVentilatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rprx:PabloLegorretaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75854c27514042c189af622ae1d3b9b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393ab282388f413799453b142053e5c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58be7d678254e86aa0bb99632dcf71b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61936b93228428ab0a7f8fc0e01f96c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6 id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i7624980bc44b4db29e5ea00d25f439ff_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU3_1734e219-5a00-4249-9c6c-d9d4171542bd">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.327%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6OTEyMjUzZDU3ZTViNDM4OGFjMjEwNmJiOTU0YmQzNDMvdGFibGVyYW5nZTo5MTIyNTNkNTdlNWI0Mzg4YWMyMTA2YmI5NTRiZDM0M18wLTAtMS0xLTEzMzY2OA_cf607cd5-b86e-44ff-b0b8-6070163670c4">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the fiscal year ended <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18xMjk_56f5a1f2-9385-444a-8b31-5cafc4e3c937"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18xMjk_028de732-1719-4813-b832-89b7c0fc14df">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.327%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6NThlMDk2YzRlMDUzNDExYWFmZjEyNjY5MzU2YjE0ODYvdGFibGVyYW5nZTo1OGUwOTZjNGUwNTM0MTFhYWZmMTI2NjkzNTZiMTQ4Nl8wLTAtMS0xLTEzMzY2OA_a6df59e3-78eb-43c5-9114-d59825b7ccdf">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from _________ to __________                   </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODUz_252fd5e6-2a9a-4a65-9245-07e0b56b3192">001-39329</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU4_903afd74-c79f-4d55-b5c7-b8127c0a147e">Royalty Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:178.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18wLTAtMS0xLTEzMzY2OA_19a11dfb-0df7-48f4-be93-2e38382212c4">England and Wales</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18wLTMtMS0xLTEzMzY2OA_1603e5cf-13e6-4115-85a1-3753f412662f">98-1535773</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18zLTAtMS0xLTEzMzY2OA_a06fc916-8955-45a0-b140-65d94ddc626f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Street</span></ix:nonNumeric></div></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3XzQ_99fdf318-0891-45c5-bdc7-b676bc367d87">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3Xzg_faf6a6ae-8680-4728-8787-9d6b8f706810">New York</ix:nonNumeric> <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3XzEx_f8974c9c-07a5-402c-bbb0-d99b0c24bbda">10022</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYy_1c82012f-602d-47d4-a486-de30e3f3b630">212</ix:nonNumeric>) <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU1_d0137972-e216-4c67-9188-c655cfa8e3e5">883-0200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTAtMS0xLTEzMzY2OA_3b866200-79bf-4835-931c-06786a70eeb7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, par value $0.0001</span></ix:nonNumeric></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTEtMS0xLTEzMzY2OA_a23bf11e-1b85-4333-8b50-384e6a214602">RPRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTItMS0xLTEzMzY2OA_a38f9c3f-bebf-435d-9d77-9107d33012df">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;<ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYz_7ab2ddc5-f40a-4446-a260-9f0323418764">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU0_bf8402ca-be32-42f4-845a-92f92173103e">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU5_5264c862-6c2f-41b7-a3dc-9fba6a611674">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU2_e48de55f-f03f-4898-be27-0828a8675398">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.553%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8wLTAtMS0xLTEzMzY2OA_11ebdae4-ba2c-414a-abae-34bd0b542a7f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8xLTMtMS0xLTEzMzY2OA_2e2ef32f-0389-4e9d-979b-d3e3ada797da">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8yLTMtMS0xLTEzMzY2OA_69a9f5ad-ba26-4404-a7a4-c02ee107b10c">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYw_d3c7c164-9ae1-4e1a-bc2e-4514ee782aef">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;&#160;Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMTMzNjA4MTM5NTYyNA_97c1ff52-d555-4c73-981b-b36f7a3336de">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">he registrant as of June 30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i8a353e18b5564d8c99b2d3b373d4a329_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18yOTE5_28dd7fbc-2d35-4125-a62a-03f593d4a601">18.5</ix:nonFraction>&#160;billion based upon the closing price reported for such date on the Nasdaq Stock Market LLC. This determination of affiliate status is not necessarily a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">conclusive determination for any other purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of February&#160;10, 2023, Royalty Pharma plc had <ix:nonFraction unitRef="shares" contextRef="ic682e5b806304506930fd5fd21e6c21a_I20230210" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMTY0_1095bbc7-b4ac-4805-a4d2-437295a34078">443,166,030</ix:nonFraction> Class A ordinary shares outstanding and <ix:nonFraction unitRef="shares" contextRef="i1909231d99304e4a834f210d58e1fa93_I20230210" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMjA3_afc38bb4-9ef4-4daa-aa25-195f1f55ef8a">164,057,651</ix:nonFraction> Class B ordinary shares outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODY2_a14d25ea-a743-4375-8eef-a1d86ccfa02a" escape="true">Portions of the registrant&#8217;s definitive proxy statement for the 2023 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2022. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_16">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_19">21</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_22">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_25">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_28">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_31">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_37">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_37">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_40">Reserved</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">]</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_40">51</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_43">51</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_85">85</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_88">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_88">87</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_178">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_178">128</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_181">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_181">128</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_184">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_184">128</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_965">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_965">128</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_190">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_190">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_193">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_193">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_196">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_196">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_199">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_199">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_202">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_202">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_208">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_208">130</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_211">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_211">132</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_214">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_214">132</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Special Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;predicts,&#8221; &#8220;project,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of the numerous risks outlined in Part I under Item 1A. under &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">These risks and uncertainties include factors related to, among other topics:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales risks of biopharmaceutical products on which we receive royalties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of RP Management, LLC (the &#8220;Manager&#8221;) to locate suitable assets for us to acquire;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the assumptions underlying our business model;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully execute our royalty acquisition strategy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to leverage our competitive strengths;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual and potential conflicts of interest with the Manager and its affiliates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager or its affiliates to attract and retain highly talented professionals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of changes to tax legislation and our tax position; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks, uncertainties and other factors we identify elsewhere in this Annual Report on Form 10-K and in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Annual Report on Form 10-K should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Annual Report on Form 10-K to conform our prior statements to actual results or revised expectations.</span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_13"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BUSINESS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies, which includes royalties on more than 35 commercial products, including Vertex&#8217;s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen&#8217;s Tysabri, AbbVie and Johnson &amp; Johnson&#8217;s Imbruvica, Astellas and Pfizer&#8217;s Xtandi, GSK&#8217;s Trelegy, Novartis&#8217; Promacta, Pfizer&#8217;s Nurtec ODT, Johnson &amp; Johnson&#8217;s Tremfya, Roche&#8217;s Evrysdi, Gilead&#8217;s Trodelvy, and 12 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early-stage development risk, therapeutic area constraints, high research and development (&#8220;R&amp;D&#8221;) costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The success of our business has been the result of a focused strategy of actively identifying and tracking the development and commercialization of key new therapies, allowing us to move quickly to make acquisitions when opportunities arise. We acquire royalties on approved products, often in the early stages of their commercial launches, and development-stage product candidates with strong proof of concept data, mitigating development risk and expanding our opportunity set. From 2012, when we began acquiring royalties on development-stage product candidates, through January 31, 2023, we have entered into transactions to acquire biopharmaceutical royalties, milestones and related assets with an aggregated transaction value of $24&#160;billion, representing approximately 60% of all royalty transactions by value announced during this period.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we generated net cash from operating activities of $2.1&#160;billion, Adjusted Cash Receipts (as defined in &#8220;Non-GAAP Financial Results&#8221;) of $2.8 billion, Adjusted EBITDA (as defined in &#8220;Non-GAAP Financial Results&#8221;) of $2.6&#160;billion and Adjusted Cash Flow (as defined in &#8220;Non-GAAP Financial Results&#8221;) of $2.2&#160;billion. We deployed $2.5&#160;billion of cash in 2022 to acquire royalties, milestones and related assets.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Portfolio Overview</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 commercial products and 12 development-stage product candidates. We believe that end market sales of the therapies in our portfolio are important drivers of our financial performance as a substantial portion of our royalties are based on end market sales. In addition, end market sales are a strong indicator of the importance of the therapies to both patients and the marketers. The following table provides an overview of our current portfolio of royalties: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalties</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketer(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Detail </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Royalty Receipts (in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 End Market Sales (in millions) (1)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Approved Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cystic fibrosis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$811</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$8,931</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Migraine</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing forms of multiple sclerosis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie, Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematological malignancies and chronic graft versus host disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,820</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer, Astellas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,817</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic immune thrombocytopenic purpura and aplastic anemia </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,088</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaque psoriasis and psoriatic arthritis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,668</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease and asthma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,142</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck &amp; Co., others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,512</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exelixis, Ipsen, Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kidney, liver and thyroid cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,940</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Farxiga/Onglyza</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,638</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal muscular atrophy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,173</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck &amp; Co.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prophylaxis of CMV in adult recipients of stem cell transplant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Breast cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">680</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hereditary angioedema prophylaxis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,881</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ultragenyx, Kyowa Kirin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X-linked hypophoshatemia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Migraine prevention &amp; episodic cluster headache</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alnylam</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary hyperoxaluria type 1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinraza (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal muscular atrophy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,762</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Airsupra (5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asthma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other products (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$3,231</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Development-Stage Product Candidates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aficamten</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cytokinetics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Obstructive hypertrophic cardiomyopathy (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ampreloxetine</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Theravance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Symptomatic nOH with multiple system atrophy (Phase 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BCX10013 </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Once-daily Factor D Inhibitor (Phase 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MK-8189</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Schizophrenia (Phase 2b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular disease (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Omecamtiv mecarbil (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cytokinetics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Heart failure (under FDA review)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pelabresib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Myelofibrosis (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pelacarsen (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular disease (Phase 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seltorexant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MDD with insomnia symptoms (Phase 3) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trontinemab (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease (Phase 2a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tulmimetostat (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematological malignancies and solid tumors (Phase 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zavegepant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acute migraine (under FDA review) and prevention (Phase 3) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">CMV is cytomegalovirus, nOH is neurogenic orthostatic hypotension and MDD is major depressive disorder. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Amounts shown in the table may not add due to rounding.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes: </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Represents end market sales for 2022 as reported by respective product marketers or, where marketers have not reported end market sales by February 10, 2023, based on Visible Alpha projections as of February 7, 2023. Sales shown for Crysvita represent Europe, the Middle East and Africa only. For the majority of our royalties, royalty receipts lag product performance by one quarter and can generally be estimated by applying our publicly disclosed royalty rate to the preceding quarter&#8217;s marketer-announced net revenues on a product-by-product basis.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalty receipts includes quarterly redemption payments of $15.6 million related to the Series A Biohaven Preferred Shares and the accelerated redemption payments of $479.5 million for all outstanding Series A and Series B Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The remaining amounts are related to royalty receipts from Nurtec ODT.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalties were acquired in January 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Airsupra, formerly known as PT027, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in January 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from equity method investees on the Statements of Cash Flows), Cimzia, Entyvio, Gavreto, HIV Franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and distributions from the Legacy SLP Interest.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">The financial royalty asset associated with omecamtiv mecarbil was written off in 2020 given the uncertainty around the future of omecamtiv mecarbil at the time.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">The financial royalty asset associated with gantenerumab was written off in 2022 as a result of Roche&#8217;s statement that it would discontinue clinical trials of gantenerumab. Roche continues to test a different formulation of gantenerumab called trontinemab.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt"> Product formerly known as CPI-0209.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Biopharmaceutical Industry and the Role of Royalties</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is supported by significant growth and unprecedented innovation within the biopharmaceutical industry. Global prescription pharmaceutical sales are projected to grow from approximately $1.2 trillion in 2022 to approximately $1.5 trillion in 2027, representing a CAGR of 6% according to EvaluatePharma despite more than $140 billion in cumulative sales being lost to expected patent expiries during the same period. The growth of the biopharmaceutical industry is driven by global secular trends, including population growth, increased life expectancy and growth of the middle classes in emerging markets. In addition, a dramatic acceleration of medical research in recent years has led to a better understanding of the molecular origins of disease and identification of potential targets for therapeutic intervention. This has accelerated R&amp;D opportunities for new drugs. The pace of biopharmaceutical innovation coupled with the proliferation of new biotechnology companies and the increasing cost of drug development has created a significant capital need over recent years that we believe will provide a sustainable tailwind for our business.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalties play a fundamental and growing role in the biopharmaceutical industry. As a result of the increasing cost and complexity of drug development, the creation of a new drug today typically involves a number of industry participants. Academia and other research institutions conduct basic research and license new technologies to industry for further development. Biotechnology companies typically in-license these new technologies, add value through applied research and early-stage clinical development, and then either out-license the resulting development-stage product candidates to large biopharmaceutical companies for late-stage clinical development and commercialization, or commercialize the products themselves. As new drugs are transferred along this value chain, royalties are created as compensation for the licensing or selling institutions. Biotechnology companies are also increasingly creating royalties on existing products within their portfolios, known as synthetic royalties, in order to provide a source of non-dilutive capital to fund their businesses. As a result of this industry paradigm, the development of a single new drug can lead to the creation of multiple royalties. Given our leadership position within the biopharmaceutical royalty sector, we are able to capitalize on the growing volumes of royalties that are created as new therapies are developed to address unmet medical needs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Business Model</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the following elements of our business and product portfolio provide a unique and compelling proposition to investors seeking exposure to the biopharmaceutical sector. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our portfolio provides direct exposure to a broad array of blockbuster therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 31, 2023, our portfolio included royalties on 15 therapies that each generated end-market sales of more than $1 billion in 2022, including five therapies that each generated end-market sales of more than $3 billion. The therapies within our royalty portfolio are marketed by leading global biopharmaceutical companies for whom these products are important sources of revenue. Given the marketers&#8217; significant focus on and investment in these products, they are motivated to invest substantial resources in driving continued sales growth. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our portfolio is highly diversified across products, therapeutic areas and marketers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 31, 2023, our portfolio consists of royalties on more than 35 marketed biopharmaceutical therapies which address a wide range of therapeutic areas, including rare diseases, cancer, neurology, immunology, hematology and diabetes. In 2022, no individual therapy accounted for more than 21% of our royalty receipts, no therapeutic area accounted for more than 29% of our royalty receipts and no marketer represented more than 25% of our royalty receipts. The royalties in our portfolio entitle us to payments based directly on the top-line sales of the associated therapies, rather than the profits of these therapies. As such, the diversification of our profits directly reflects the diversification of our royalty receipts, rather than varying levels of product-level profitability, as would typically be expected within a biopharmaceutical company. The graphic below shows the diversification within our 2022 royalty receipts by product, therapeutic area and marketer.</span></div><div style="text-align:center;text-indent:24.5pt"><img src="rprx-20221231_g1.jpg" alt="rprx-20221231_g1.jpg" style="height:238px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Royalty receipts for Nurtec ODT includes redemption payments that were accelerated related to Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in 2022. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The key growth-driving royalties in our portfolio are protected by long patent lives. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimated weighted average royalty duration of our portfolio is approximately 13 years based on projected cumulative cash royalty receipts. Our largest marketed royalty in 2022 was on Vertex&#8217;s cystic fibrosis franchise, and existing patent applications covering Trikafta, the most significant product in that franchise, are expected to provide exclusivity through 2037. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Several of our marketed royalties have unlimited durations and could provide cash flows for many years after key patents have expired. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Simple and efficient operating model generates substantial cash flow for reinvestment in new biopharmaceutical royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our capital-efficient operating model requires limited operating expenses and no material capital investment in fixed assets or infrastructure in order to support the ongoing growth of our business. As a result, we generate high Adjusted Cash Flow relative to our Adjusted Cash Receipts. Our high cash flow conversion provides us with significant capital that we can deploy for new royalty acquisitions and also use to grow our dividend to shareholders. In 2022, we generated net cash from operating activities of $2.1&#160;billion, Adjusted Cash Receipts of $2.8&#160;billion, Adjusted EBITDA of $2.6&#160;billion and Adjusted Cash Flow of $2.2&#160;billion. We deployed $2.5&#160;billion of cash in 2022 to acquire royalties, milestones and related assets.  </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business model captures many of the most attractive aspects of the biopharmaceutical industry, but with reduced exposure to many common industry challenges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The biopharmaceutical industry benefits from a number of highly attractive characteristics, including long product life cycles, significant barriers to entry and non-cyclical revenues. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies from across the biopharmaceutical industry. We focus on the acquisition of royalties on approved products or development-stage product candidates that have generated strong proof of concept data, avoiding the risks associated with early stage R&amp;D. By acquiring royalties, we are able to realize payments based directly on the top-line sales of leading biopharmaceutical therapies, without the costs associated with fixed R&amp;D, manufacturing and commercial infrastructure. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our unique role in the biopharmaceutical ecosystem positions us to benefit from multiple compounding growth drivers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understanding of the molecular origins of disease, technological innovation leading to the creation of new treatment modalities, an increasing number of biopharmaceutical industry participants with significant capital needs, competitive industry dynamics which reward companies that can rapidly execute broad clinical development programs, increasing FDA drug approvals which reached an all-time high in 2018 and the potential for multiple royalties to be created from each new drug that reaches the market.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have the ability to access innovation from across the biopharmaceutical ecosystem. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We closely follow a broad range of therapeutic areas and treatment modalities and are therefore able to move quickly when we identify compelling opportunities to acquire new royalties.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have deep access to attractively priced investment grade debt that provides a significant cost of capital advantage. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that we have an attractive cost of capital that enables us to acquire high-quality biopharmaceutical royalties at competitive prices while still creating value for our shareholders. As of December 31, 2022, we had an aggregate principal amount of $7.3 billion of senior unsecured notes outstanding with a weighted average coupon of 2.24% and a weighted-average maturity of approximately 12 years. In addition, we have an undrawn $1.5 billion senior unsecured revolving credit facility. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a talented, long-tenured team with extensive experience and deep industry relationships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our team has significant experience identifying, evaluating and acquiring royalties on biopharmaceutical therapies. Together they have been responsible for approximately $30&#160;billion of acquisitions of biopharmaceutical royalties, milestones and related assets since 1996 through January 31, 2023. Our acquisitions have included many of the industry&#8217;s leading therapies across the past three decades, such as Trikafta, Tremfya, Imbruvica, Tecfidera, Xtandi, Truvada, Lyrica, Humira, Remicade, Rituxan and Neupogen. Our long history of collaboration has resulted in deep relationships with a broad range of participants across the biopharmaceutical industry.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are the leader in acquiring biopharmaceutical royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We are the leader within the space, having executed transactions with an aggregate announced transaction value of more than $24&#160;billion since 2012 through January 31, 2023. We estimate this to represent an estimated market share of approximately 60% of all royalty transactions by value announced during this period. This compares to our next nearest competitor, which we believe has executed $3 billion of transactions, which we estimate to represent market share of 8%. Given the scale of our business relative to our competitors, we have a particularly strong leadership position within large royalty transactions. Since 2012, there have been 13 royalty transactions with an aggregate value of more than $500 million each. We executed 11 of these 13 transactions, for a total aggregate transaction value of approximately $16 billion of cash and estimated market share of 86%, in this transaction size range. The charts below show our market share since 2012 across all transaction sizes and in royalty transactions with an aggregate value of more than $500 million. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:24.5pt"><img src="rprx-20221231_g2.jpg" alt="rprx-20221231_g2.jpg" style="height:331px;margin-bottom:5pt;vertical-align:text-bottom;width:651px"/></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Includes transactions through January 31, 2023; excludes royalty debt transactions from market share calculations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy  </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to grow our business by continuing to partner with constituents across the biopharmaceutical value chain to fund innovation. Our growth strategy is tailored to the needs of our partners through a variety of structures:</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third-party Royalties &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Synthetic Royalties &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales by the developer or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&amp;D for biopharmaceutical companies in exchange for future royalties and milestones if the product or indication we are funding is approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Launch and Development Capital &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Mergers and Acquisitions (&#8220;M&amp;A&#8221;) Related &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities such as our strategic alliance with MSCI Inc. (&#8220;MSCI&#8221;) to develop thematic life sciences indexes.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2012 through 2022, we deployed $8.3&#160;billion of cash to acquire royalties, milestones and related assets on development-stage product candidates. As of January 31, 2023, products underlying $6.4&#160;billion of these acquisitions have already been approved, representing a success rate to date of 77%, while products underlying $0.8&#160;billion were not approved and products underlying $1.1&#160;billion are still in development.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><img src="rprx-20221231_g3.jpg" alt="rprx-20221231_g3.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes: </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:9.84pt">Reflects cash deployed for royalty acquisitions from 2012 through 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:9.84pt">Not approved includes investments in vosaroxin, palbociclib, Merck KGaA&#8217;s anti-IL17 nanobody M1095, BCX9930, gantenerumab and otilimab.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In recent years, we have increased the scope of our investments beyond royalties to include additional assets such as equity investments and the acquisition of businesses with significant royalty assets. Our broad scope increases our total addressable market and has allowed us to provide a broad range of solutions to our partners across the biopharmaceutical ecosystem.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We have a strong base of institutional knowledge of important therapeutic areas and key industry trends. Our team of scientific experts actively monitors the evolving treatment landscape across many therapeutic areas and treatment modalities in order to identify new opportunities. We analyze a wide range of scientific data and stay in constant communication with leading physicians, scientists, biopharmaceutical executives and venture capital firms. This allows us to quickly assess and gain conviction in the value of assets when acquisition opportunities arise.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We take a disciplined approach in assessing opportunities and seek to acquire exposure to therapies based on the following key product characteristics: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Clinically validated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have received regulatory approval or have strong clinical proof-of-concept data that gives us confidence in the clinical and commercial profile. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">High unmet need:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">therapies that address areas of significant unmet medical need that also represent large commercial opportunities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Significant benefits to patients:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have potential to disrupt or significantly enhance the treatment paradigm for patients and physicians based on compelling clinical data. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Unique competitive positioning:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that are well-positioned to be leaders in their respective categories and are expected to maintain a competitive advantage in the long-term. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth potential:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies where we see strong long-term potential, based on our in-depth evaluation and in-house expertise. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Strong marketer:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies marketed by biopharmaceutical companies that have the resources, capabilities and commitment to successfully develop them and maximize their commercial potential. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have strong patent portfolios and offer durable, long-term cash flows. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Attractive value proposition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that we believe provide value-add to the healthcare system. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our focus is to create significant long-term value for our shareholders by acquiring both approved and development-stage product candidates through a variety of structures. In evaluating these acquisition opportunities, we focus on the following financial characteristics: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Long duration cash flows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we prioritize long-duration assets over short-duration assets that may boost near-term financial performance. The durability of our cash flows also allows us to add leverage to our portfolio, enhancing returns and providing capital that we can use to acquire additional assets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Attractive risk-adjusted returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we focus on generating attractive returns on our investments on a risk-adjusted basis. We evaluate opportunities across the risk spectrum and do not target the same return for all assets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth and scale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we seek assets that are accretive to our long-term growth profile and additive to our overall scale. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conduct extensive due diligence when evaluating potential new opportunities. We have end-to-end capabilities that span clinical and commercial analysis, valuation and transaction structuring. We have a highly focused and experienced team that conducts proprietary primary market research, forms its own views on the clinical and commercial outlook for the product, and builds its own financial models, allowing us to generate direct insights and allowing us to take significant accountability and ownership for our investments. We invest significant time and resources across all levels of the organization, including senior leadership, in the evaluation of potential opportunities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Portfolio</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Products </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key royalties in our marketed portfolio related to approved products include the ones listed below. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Descriptions of estimated royalty expiration dates are based on our estimates of patent expiry dates (which may include estimated patent term extensions) or estimates of the dates on which the royalties otherwise expire and are based on each product&#8217;s key geographies; duration may differ in other geographies. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. In addition, the royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cystic fibrosis franchise </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cystic fibrosis franchise consists of our right to receive royalty payments on the sale of various products marketed by Vertex for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor). Vertex&#8217;s cystic fibrosis franchise represents the leading treatments for cystic fibrosis, providing treatment options for approximately 90% of cystic fibrosis patients.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added the cystic fibrosis franchise to our portfolio in November 2014 and purchased an additional residual royalty interest in November 2020. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Total global end market sales for the cystic fibrosis franchise during 2022 were approximately $8.9&#160;billion and we collected $811&#160;million in related royalty receipts over the same period. Global end market sales of the cystic fibrosis franchise are projected to grow to approximately $10.5&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tysabri </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tysabri (natalizumab) is a monoclonal antibody marketed by Biogen for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Tysabri competes in the high efficacy segment of the multiple sclerosis market, often reserved for patients with aggressive disease at onset and patients who have failed front-line therapies. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Tysabri to our portfolio in February 2017. Our right to receive royalties is perpetual. Total global end market sales for Tysabri during 2022 are estimated to be approximately $2.0&#160;billion and we collected $370&#160;million in related royalty receipts over the same period. Global end market sales of Tysabri are projected to be approximately $1.4&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Imbruvica </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Imbruvica (ibrutinib) is a first-in-class small molecule Bruton&#8217;s tyrosine kinase inhibitor that is the leading therapy in chronic lymphocytic leukemia, relapsed/refractory mantle cell lymphoma and other blood cancers. Imbruvica is marketed by AbbVie and Janssen, a subsidiary of Johnson &amp; Johnson. A robust clinical program supports Imbruvica&#8217;s use across a wide range of patient populations and cancer types, including 12 FDA approvals in seven distinct indications.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Imbruvica to our portfolio in July 2013. We estimate that our royalties will substantially end between 2027 and 2032. Total global end market sales for Imbruvica during 2022 were approximately $5.8&#160;billion and we collected $313&#160;million in related royalty receipts over the same period. Global end market sales of Imbruvica are projected to be approximately $3.5&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Xtandi </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Xtandi (enzalutamide) is an oral, small molecule androgen receptor inhibitor marketed by Pfizer and Astellas for the treatment of non-metastatic and metastatic castration-resistant prostate cancer as well as metastatic castration sensitive prostate cancer.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Xtandi to our portfolio in March 2016. We estimate that our royalties will substantially end between 2027 and 2028. Total global end market sales for Xtandi during 2022 were approximately $4.8&#160;billion and we collected $187&#160;million in related royalty receipts over the same period. Global end market sales of Xtandi are projected to grow to approximately $5.2&#160;billion in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Promacta </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Promacta (eltrombopag) is an oral, small molecule activator of the thrombopoietin receptor used to increase the number of platelets in the blood, marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Promacta to our portfolio in March 2019. We estimate that our royalties will substantially end between 2025 and 2028. Total global end market sales for Promacta during 2022 were approximately $2.1&#160;billion and we collected $182&#160;million in related royalty receipts over the same period. Global end market sales of Promacta are projected to be approximately $525&#160;million in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tremfya</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tremfya (guselkumab) is an anti-interleukin 23 marketed by Johnson &amp; Johnson for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis. Tremfya is also in clinical development for ulcerative colitis and Crohn&#8217;s disease.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Tremfya to our portfolio in July 2021. We estimate that our royalties will substantially end between 2031 and 2032. Total global end market sales for Tremfya during 2022 were approximately $2.7&#160;billion and we collected $97 million in related royalty receipts over the same period. Global end market sales of Tremfya are projected to grow to approximately $6.0 billion in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nurtec ODT/Biohaven payment</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nurtec ODT (rimegepant) is an oral, small molecule calcitonin gene-related peptide receptor antagonist marketed by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pfizer for the acute treatment and prevention of migraine. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Nurtec ODT to our portfolio in June 2018 and purchased an additional interest in Nurtec ODT as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. Total global end market sales for Nurtec ODT during 2022 are estimated to be approximately $764&#160;million and we collected $18&#160;million in royalty receipts on Nurtec ODT over the same period. Additionally, we received $542&#160;million from the  redemption of all outstanding Series A and Series B Biohaven Preferred Shares in 2022. The Series A and Series B Biohaven Preferred Shares were fully redeemed following Pfizer&#8217;s acquisition of Biohaven in October 2022. We will only receive royalties from underlying product sales beginning in 2023. Global end market sales of Nurtec ODT are projected to grow to approximately $2.7&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Trelegy </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trelegy is a combination of an inhaled corticosteroid and two bronchodilators in a single delivery device administered once-daily for the maintenance treatment of chronic obstructive pulmonary disease and the maintenance treatment of asthma in patients aged 18 years and older. Trelegy is marketed by GSK. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Trelegy to our portfolio in July 2022. We estimate that our royalties will substantially end between 2029 and 2030. Total global end market sales for Trelegy during 2022 were approximately</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$2.1&#160;billion. Subsequent to adding Trelegy to our portfolio in July 2022, we collected $90&#160;million in related royalty receipts. Global end market sales of Trelegy are projected to grow to approximately $3.5&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cabometyx/Cometriq</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cabometyx (cabozantinib) is a multi-tyrosine kinase inhibitor approved for the treatment of patients with advanced renal cell carcinoma (RCC) both as monotherapy and in combination with Bristol Myers Squibb&#8217;s Opdivo (nivolumab) as a first line treatment. Cabometyx is also approved for hepatocellular carcinoma in patients previously treated with sorafenib. Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis in the United States and by Ipsen in regions outside the United States and Japan. Cabometyx is marketed in Japan by Takeda.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Cabometyx/Cometriq to our portfolio in March 2021. We estimate that our royalties will substantially end between 2026 and 2029. Total global end market sales for Cabometyx/Cometriq during 2022 were approximately $1.9&#160;billion and we collected $55&#160;million in related royalty receipts over the same period. Global end market sales of Cabometyx/Cometriq are projected to grow to approximately $2.8&#160;billion in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Farxiga/Onglyza</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Farxiga (dapagliflozin) is a first-in-class selective inhibitor of human sodium-glucose co-transporter 2 indicated as both monotherapy and as part of combination therapy with Onglyza, a dipeptidyl peptidase-4 inhibitor, to improve glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes. Farxiga received FDA approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction in both patients with and without type 2 diabetes. Farxiga and Onglyza are both marketed by AstraZeneca.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Farxiga/Onglyza to our portfolio in November 2017. We estimate that our royalties will substantially end in 2025. Total global end market sales for Farxiga/Onglyza during 2022 were approximately $4.6&#160;billion and we collected $44&#160;million in related royalty receipts over the same period. Global end market sales of Farxiga/Onglyza are projected to be approximately $4.4&#160;billion in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Evrysdi </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evrysdi (risdiplam) is a survival motor neuron 2 splicing modifier marketed by Roche, and is the first oral treatment approved for infants, children and adults with all types of spinal muscular atrophy. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Evrysdi to our portfolio in July 2020. Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. Total global end market sales for Evrysdi during 2022 were approximately $1.2&#160;billion and we collected $41&#160;million in related royalty receipts over the same period. Global end market sales of Evrysdi are projected to grow to approximately $2.8&#160;billion in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prevymis</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prevymis (letermovir) is a first-in-class prophylactic marketed by Merck &amp; Co. for the prophylaxis of cytomegalovirus infection and disease in adults who have received an allogeneic hematopoietic stem cell transplant.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Prevymis to our portfolio in June 2020. We estimate that our royalties will substantially end in 2029. Total global end market sales for Prevymis during 2022 were approximately $428&#160;million and we collected $37&#160;million in related royalty receipts over the same period. Global end market sales of Prevymis are projected to grow to approximately $525&#160;million in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Trodelvy </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate for the treatment of adult patients with metastatic triple-negative breast cancer and pre-treated hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Trodelvy was initially developed by Immunomedics and is now marketed by Gilead following the acquisition of Immunomedics in 2020. Gilead is exploring monotherapy and combinations of Trodelvy across numerous cancer indications and lines of therapy. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Trodelvy to our portfolio in January 2018. Our right to receive royalties is perpetual. Total global end market sales for Trodelvy during 2022 were approximately $680&#160;million and we collected $25&#160;million in related royalty receipts over the same period. Global end market sales of Trodelvy are projected to grow to approximately $2.6&#160;billion in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Orladeyo</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Orladeyo (berotralstat) is a first-in-class oral inhibitor of plasma kallikrein marketed by BioCryst for the prevention of hereditary angioedema attacks.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Orladeyo to our portfolio in December 2020 and purchased an additional interest as part of our expanded funding agreement with BioCryst in November 2021. Our right to receive royalties is perpetual, but we expect that the 2036-2039 patent expirations for Orladeyo may result in potential sales declines based on potential generic entry. Total global end market sales for Orladeyo during 2022 are estimated to be approximately $252&#160;million and we collected $22&#160;million in related royalty receipts over the same period. Global end market sales of Orladeyo are projected to grow to approximately $725&#160;million in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Erleada</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Erleada (apalutamide) is an oral, small molecule androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration sensitive prostate cancer. It is marketed by Johnson &amp; Johnson.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Erleada to our portfolio in February 2019. We estimate that our royalties will substantially end in 2032. Total global end market sales for Erleada during 2022 were approximately $1.9&#160;billion and we collected $21&#160;million in related royalty receipts over the same period. Global end market sales of Erleada are projected to grow to approximately $4.3&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Crysvita </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crysvita (burosumab) is a monoclonal antibody that is approved in the European Union for the treatment of fibroblast growth factor-23 related hypophosphataemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults. Crysvita is also approved in the European Union for X-linked in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. Crysvita is marketed by Kyowa Kirin and Ultragenyx.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added a royalty on Crysvita sales in Europe to our portfolio in December 2019. Our royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million. We estimate that our royalties will substantially end between 2033 and 2038. Total end market sales for Crysvita during 2022 are estimated to be approximately $220&#160;million and we collected approximately $20&#160;million in related royalty receipts over the same period. End market sales of Crysvita are projected to grow to approximately $575&#160;million in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Emgality</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emgality (galcanezumab-gnlm) is a monoclonal antibody calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine and for the treatment of episodic cluster headache marketed by Lilly.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Emgality to our portfolio in March 2019. We estimate that our royalties will substantially end in 2033. Total global end market sales for Emgality during 2022 were approximately $651&#160;million and we collected $19&#160;million in related royalty receipts over the same period. Global end market sales of Emgality are projected to grow to approximately $1.0&#160;billion in 2027, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Oxlumo</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Oxlumo (lumasiran) is a small interfering ribonucleic acid therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1 marketed by Alnylam. Oxlumo was approved by the FDA in November 2020.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Oxlumo to our portfolio in April 2021. We estimate that our royalties will substantially end between 2034 and 2035. Total global end market sales for Oxlumo during 2022 are estimated to be approximately $67 million and we collected $3 million in related royalty receipts over the same period. Global end market sales of Oxlumo are projected to grow to approximately $325&#160;million in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Spinraza</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Spinraza is for the treatment for spinal muscular atrophy marketed by Biogen. We added Spinraza to our portfolio in January 2023. We estimate that our royalties will substantially end between 2030 and 2035. Total global end market sales for Spinraza during 2022 are estimated to be approximately $1.8&#160;billion. Global end market sales of Spinraza are projected to be approximately $1.4&#160;billion in 2027, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Airsupra</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Airsupra, formerly known as PT027, is a fixed dose combination of the inhaled corticosteroid, budesonide and albuterol, a short-acting beta-2 agonist for the treatment of asthma. Airsupra was approved by the FDA in January 2023.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have an equity investment in the Avillion entities, one of which is a party to a co-development agreement with AstraZeneca to advance Airsupra through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. We estimate that distributions from Avillion II for our portion of royalties will substantially end in 2030, but AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80&#160;million to Avillion II to exercise an option to commercialize Airsupra in the United States. We expect to receive our pro rata portion of the exercise fee of approximately $35 million, subject to any holdback for expenses, in 2023. Global end market sales of Airsupra are projected to grow to approximately $550&#160;million in 2027, according to Visible Alpha.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development-Stage Product Candidates </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current portfolio includes 12 development-stage product candidates. These development-stage product candidates have not yet been approved, and therefore have not generated any royalties (and we have not collected any related royalty receipts) to date. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Aficamten </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aficamten is a small molecule cardiac myosin inhibitor in Phase 3 development by Cytokinetics for obstructive hypertrophic cardiomyopathy (oHCM). We added aficamten to our portfolio in January 2022. If approved, global end market sales of aficamten are projected to grow to approximately $1.5&#160;billion&#160;in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ampreloxetine</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ampreloxetine is an investigational once-daily norepinephrine reuptake inhibitor in Phase 3 development by Theravance for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. We added ampreloxetine to our portfolio in July 2022. If approved, global end market sales of ampreloxetine are projected to grow to approximately $150&#160;million&#160;in 2030, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BCX10013</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BCX10013 is an oral, once-daily Factor D inhibitor for the treatment of complement-mediated diseases. We added BCX10013 to our portfolio as part of our expanded funding agreement with BioCryst in November 2021. In December 2022, BioCryst decided to focus its complement inhibitor development efforts on BCX10013 after discontinuing the development of BCX9930. Visible Alpha does not currently have estimates available for global end market sales of BCX10013 in 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MK-8189</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MK-8189 is an oral PDE10A inhibitor in Phase 2B development by Merck for the treatment of schizophrenia. We added MK-8189 to our portfolio in October 2022. If approved, global end market sales of MK-8189 are projected to grow to approximately $150 million in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Olpasiran</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Olpasiran is a small interfering RNA (siRNA) in Phase 3 development by Amgen designed to lower levels of lipoprotein(a), a genetically-determined independent risk factor for cardiovascular disease. We added olpasiran to our portfolio in November 2022. If approved, global end market sales of olpasiran are projected to grow to approximately $875&#160;million in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Omecamtiv mecarbil </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Omecamtiv mecarbil is an oral, small molecule cardiac myosin activator developed by Cytokinetics and under FDA regulatory review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for the treatment of heart failure with reduced ejection fraction. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added omecamtiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mecarbil to our portfolio in 2017. In November 2020, results from the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure were presented at the American Hearth Association Scientific Sessions which showed that the trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mecarbil when Amgen and Servier elected to terminate their collaboration agreement. Following the Phase 3 results and termination of the collaboration announced in 2020, given the uncertainty around the future of omecamtiv mecarbil at the time, we recognized an impairment charge of $65 million related to the write-off of the associated financial royalty asset of $90 million and its associated provision of $25 million in 2020. If approved, global end market sales of omecamtiv mecarbil are projected to grow to approximately $300&#160;million in 2030, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pelabresib </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pelabresib is a bromodomain and extra-terminal inhibitor in Phase 3 development by MorphoSys for myelofibrosis. We added pelabresib to our portfolio in July 2021. If approved, global end market sales of pelabresib are projected to grow to approximately $375&#160;million in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pelacarsen </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pelacarsen is in Phase 3 development by Novartis for the treatment specifically targeting elevated lipoprotein(a), and independent, inherited and causal risk factor for cardiovascular disease. We added pelacarsen to our portfolio in January 2023. If approved, global end market sales of pelacarsen are projected to grow to approximately $825 million in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Seltorexant</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seltorexant is a selective orexin 2 receptor antagonist in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson &amp; Johnson. We added seltorexant to our portfolio in January 2021. If approved, global end market sales of seltorexant are projected to grow to approximately $225 million in 2030, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Trontinemab</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trontinemab is a fully human monoclonal antibody that targets and binds to aggregated forms of beta-amyloid and activates immune cells in the brain to clear amyloid plaque and prevent further accumulation. Trontinemab is in Phase 2a development and uses Roche&#8217;s brain shuttle technology, which is designed to transfer the drug across the blood brain barrier and increase the antibody concentration in the brain. We added trontinemab to our portfolio in July 2021. Visible Alpha does not currently have estimates available for global end market sales of trontinemab in 2030.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tulmimetostat </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tulmimetostat, formerly known as CPI-0209, is a second-generation enhancer of zeste homolog 2 inhibitor, in Phase 2 development by MorphoSys for hematological malignancies and solid tumors. We added tulmimetostat to our portfolio in July 2021. If approved, global end market sales of tulmimetostat are projected to grow to approximately $25 million in 2030, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Zavegepant </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zavegepant is a small molecule calcitonin gene-related peptide receptor antagonist under FDA regulatory review for the acute treatment of migraine and in Phase 3 development for the prevention of migraine. If approved, zavegepant will be marketed by Pfizer following its acquisition of Biohaven in October 2022.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added zavegepant to our portfolio in June 2018 and purchased an additional interest as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. As a result of an additional transaction in 2020, we are also entitled to success-based milestone payments, the first of which would be paid upon initial FDA approval of zavegepant. If approved, global end market sales of zavegepant are projected to grow to approximately $850&#160;million in 2030, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Royalty Portfolio Summary</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below provides a summary of the estimated royalty expiration and the royalty rates for our portfolio: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Royalty&#160;Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Approved Products</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For combination therapies, sales are allocated equally to each of the active pharmaceutical ingredients; tiered royalties ranging from single digit to subteen percentages on annual worldwide net sales of ivacaftor, lumacaftor and tezacaftor, and mid-single digit percentages on annual worldwide net sales of elexacaftor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nurtec ODT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. 0.4% incremental royalty on all Nurtec ODT worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Perpetual</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales above $2.0 billion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties in the mid-single digits on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty of slightly less than 4% on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalty ranging from 4.7% to 9.4% on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit, tiered royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029-2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties are tiered based on annual net sales at 6.5% up to $750 million, 8.0% on sales between $750 million and $1.25 billion, 9.0% on sales between $1.25 billion and $2.25 billion, 10.0% over $2.25 billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026-2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3% royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Farxiga/Onglyza</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments equivalent to low-single digit downward tiered royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030-2035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties of 3.4% on worldwide net sales up to $500 million, 4.7% on net sales between $500 million and $1 billion, 6.0% on net sales between $1 billion and $2 billion 6.9% on net sales over $2 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-double digit royalty on annual worldwide net sales up to $300 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Perpetual</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15% royalty on annual worldwide net sales up to $2 billion, declining stepwise based on sales tiers to 1.75% on net sales above $6 billion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2036-2039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.50% royalty on direct annual net sales of up to $350 million, 4.50% on sales between $350 million and $550 million, and no royalties on sales over $550 million; tiered percentage of sublicense revenue in certain territories</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-single digit royalties on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033-2038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10% royalty on EU, U.K. and Switzerland net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-single digit royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties in the mid- to high-single digits based on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Spinraza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030-2035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties on up to $1.5 billion of annual worldwide net sales at rates ranging from 2.8% to 3.8% through 2027 and increasing to 5.0% to 6.8% in 2028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Airsupra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties in the low-single digits on annual U.S. net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Development-Stage Product Candidates</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aficamten </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% royalty on annual worldwide net sales up to $1 billion and 3.5% on net sales above $1 billion, subject to certain potential step-downs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ampreloxetine</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low- to mid-single digit royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BCX10013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0% royalty on annual worldwide net sales up to $1.5 billion and 2.0% royalty on annual worldwide net sales between $1.5 billion and $3.0 billion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MK-8189</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Up to low-double digit tiered royalties on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Omecamtiv mecarbil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032-2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pelabresib</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0% royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pelacarsen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upward-tiered mid-single digit royalties on worldwide net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(17)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seltorexant </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trontinemab</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties ranging between 3.3% and 4.2% on annual worldwide net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(18)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tulmimetostat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(19)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0% royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Zavegepant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. Up to a 3.0% incremental royalty on zavegepant worldwide net sales up to $1.5 billion and up to 2.0% incremental royalty on zavegepant worldwide net sales above $1.5 billion</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">The royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">We will pay Theravance Biopharma, Inc. 85% of the royalties in respect of ex-U.S. net sales after June 30, 2029 and 85% of the royalties in respect of U.S. net sales after December 31, 2030.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalties on net sales of cabozantinib products in the United States through September 2026 and non-U.S. markets through the full term of the royalty. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">We are entitled to approximately 43% of the tiered royalties ranging from 8% to 16% for Evrysdi.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalty is perpetual; years shown represent estimated United States patent expiration for Orladeyo and potential sales decline based on timing of generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">We acquired an interest in Ionis Pharmaceuticals, Inc.&#8217;s (&#8220;Ionis&#8221;) royalty in Biogen's Spinraza in January 2023. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our royalty interest in Spinraza will revert to Ionis after we receive aggregate Spinraza royalties equal to $475 million or $550 million, depending on the timing and occurrence of certain events.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">We are entitled to 25% of Ionis&#8217; Spinraza royalty payments of 11% to 15% on annual worldwide net sales through 2027, increasing to 45% of royalty payments in 2028.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">Product formerly known as PT027.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents the portion of the royalties on Airsupra that we are entitled to based on our minority ownership stake in Avillion II.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">We acquired an interest in Ionis&#8217; royalty in Novartis' pelacarsen in January 2023. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">We are entitled to 25% of Ionis&#8217; pelacarsen royalty payments of mid-teens to low-20% on annual worldwide net sales.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">We are entitled to 60% of MorphoSys&#8217; trontinemab royalty payments ranging from 5.5% to 7% of worldwide net sales.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.34pt">Product formerly known as CPI-0209.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that our royalties will expire when expected. Any reductions in the durations of royalties relative to our estimates may adversely affect our financial condition and results of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Risk Factors&#8221; in Item 1A, Risk Factors for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fixed Payment Arrangements </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below provides a summary of our fixed payment arrangements: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:18.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Arrangement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Key Terms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Zavegepant Success-Based Milestones</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Success-based milestone payments from 1.9 to 2.95 times the funded amount of $250.0 million, depending on specific zavegepant regulatory approvals. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Success-based milestone payment of $475.0 million, or 1.9 times the funded amount, if zavegepant&#8217;s first regulatory approval in migraine is achieved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Incremental payments of up to 1.05 times the funded amount may be triggered by certain additional regulatory approvals. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Each milestone event achieved will result in an accelerated lump sum payment. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MorphoSys Development Funding Bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Not applicable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Payments to us of approximately 2.2 times the $300.0 million funded amount. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Expected payments in 36 consecutive quarterly payments from the fourth quarter of 2024. </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cytokinetics Commercial Launch Funding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Up to five tranches totaling $300.0 million, including first $50.0 million tranche funded in the first quarter of 2022. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Payments to us of 1.9 times the amount drawn, except for the second and third tranches, which each total 2.0 times the amount drawn.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Required draw of $50.0 million if a certain contingency is met and optional draw of the remaining $200.0 million if certain regulatory and clinical development milestones are met. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Each subsequent tranche has a 12-month draw period once certain clinical and regulatory milestones are met. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">34 consecutive quarterly payments to us on the last business day of the seventh quarter following the quarter of the funding date for each tranche. </span></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:9.84pt">Our fixed payment arrangements are subject to the underlying contractual agreements and legal instruments from which they arise and may be subject to reduction, accelerations, and other adjustments in accordance with the respective terms of such agreements and instruments.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face competition from other entities that acquire biopharmaceutical royalties, including competitors to the Manager that are in the similar business of acquiring biopharmaceutical royalties. There are a limited number of suitable and attractive acquisition opportunities available in the market. Therefore, competition to acquire such assets is intense. The Manager is subject to competition from other potential royalty buyers, including from the companies that market the products on which royalties are paid, financial institutions and other entities. These other potential royalty buyers may be larger and better capitalized than us. The Manager may not be able to identify and obtain a sufficient number of asset acquisition opportunities to invest the full amount of capital that may be available to us. We also compete with other forms of financing available to biopharmaceutical companies, such as equity, debt or convertible debt financing and licensing opportunities. If biopharmaceutical companies opt to finance through such other means, we may not be able to acquire additional assets or grow our business. There can be no assurance that we will continue to acquire biopharmaceutical products and companies that hold biopharmaceutical royalties that are acceptable to us. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The products that provide the basis for the cash flows of the biopharmaceutical products in which we invest are also subject to intense competition. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted. There can be no assurance that one or more products will not be rendered obsolete or non-competitive by new or alternate products or improvements made to existing products, either by the current marketer of such products or by another marketer. Adverse competition, obsolescence, governmental and regulatory action, or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which serve as the security or other support for the payments due under the biopharmaceutical products that we hold. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitive factors affecting the market position and success of each product include: </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effectiveness; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">safety and side effect profile; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">price, including third-party insurance reimbursement policies; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">timing, introduction and marketer support of the product; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">efficacy and execution of marketing and commercialization strategy; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market acceptance; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> manufacturing, supply and distribution; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">governmental regulation, including price caps; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">availability of lower-cost generics or biosimilars; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">intellectual property protection and exclusivity; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment innovations that eliminate or minimize the need for a product; and </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product liability claims. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Products for which we have a royalty receivable or other interest may be rendered obsolete or non-competitive by new or alternate products, including generics or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies, products on which we have a royalty may become unattractive to commercialize or obsolete. If a product&#8217;s market acceptance is diminished or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, may not be made on time or at all, which may affect our ability to realize the benefits of the royalty receivable or other interest in such product and may result in us incurring asset impairment charges. Further, any product for which we have a royalty receivable or other interest that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Many approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. Any of these developments could adversely affect products for which we have a royalty, and consequently could adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Responsibility </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharma industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies. Our sustainability efforts reflect the uniqueness of our business model. We believe that our environmental, social and governance (ESG) strategy, policies and practices will create sustainable long-term value for our company, our employees, our shareholders and other stakeholders while also helping us reduce risk and identify new opportunities.  </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Governance</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk management, compliance and high ethical standards are foundational to our culture. One of our most valuable assets is our reputation for integrity, professionalism, fairness and good stewardship. Our strong corporate governance program, from board oversight to robust management practices, aligns the interests of our stakeholders and underpins our market-leading position and the high esteem with which we are held in the life sciences industry.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Culture</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our people are the key to our success and are what sets us apart. We seek to have a well-rounded, diverse workplace, which reflects our shareholders and other stakeholders with whom we collaborate, and the communities in which we live and work. We value diverse teams and backgrounds: as of December 31, 2022, 52% of the workforce of our Manager are women and approximately 33% of the workforce of our Manager are ethnically diverse. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Social</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We collaborate with organizations seeking to address health needs, improve health outcomes, spur innovation and expand patient care opportunities. Approximately one-fourth (by value) of the royalty transactions we have completed since 2012 have been with leading academic and non-profit institutions. By partnering with these institutions, we have provided capital which has been used to further scientific research (for example, the Cystic Fibrosis Foundation). Our philanthropy seeks to address the challenges of a complex and evolving world by providing funds and resources to support programs that enable innovation in the life sciences, reduce the risk of disease, strengthen access to healthcare and ensure equal access to quality healthcare. We are committed to good corporate citizenship and actively support the work of a number of patient advocacy groups and medical research foundations, including the Leukemia &amp; Lymphoma Society, National Multiple Sclerosis Society, Lupus Research Alliance, Melanoma Research Alliance and Prostate Cancer Foundation.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employees </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our directors and executive officers manage our operations and activities. However, we do not currently have any employees or any officers other than our executive officers. Pursuant to the management agreements entered into in connection with our initial public offering (collectively, the &#8220;Management Agreement&#8221;) with the Manager, the Manager performs corporate and administration services for us. </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, the Manager had 75 employees. None of these employees are represented by labor unions or covered by any collective bargaining agreement. We believe that the Manager&#8217;s relations with its employees are satisfactory. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Human Capital</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we are &#8220;externally managed,&#8221; we do not employ our own personnel, but instead depend upon the Manager and its executive officers and employees for all of the services we require. Under the Management Agreement, the Manager manages the assets of our business and sources and evaluates royalty acquisitions. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Manager is responsible for the selection of these executive officers and other personnel, and our Board of Directors reviews personnel with the Manager with the objective of evaluating the Manager&#8217;s internal capabilities. The Management Development and Compensation Committee of our Board of Directors in consultation with the Manager also plans for the succession of senior management of the Manager. The Management Agreement requires the Manager&#8217;s executives to devote substantially all of their time to managing us, Royalty Pharma Investments 2019 ICAV (&#8220;RPI&#8221; or &#8220;RPI 2019 ICAV&#8221;) and any legacy vehicles related to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;) unless otherwise approved by our Board of Directors. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Governmental Regulation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations could subject us to administrative and legal proceedings and actions by various governmental bodies. See &#8220;Risk Factors&#8221; in Item 1A, Risk Factors for further information. Our compliance with these laws and regulations has not had a material impact on our capital expenditures, earnings, financial condition or competitive position in excess of those affecting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">others in our industry.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we do not currently anticipate material capital expenditures arising from environmental regulation. We believe that climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">U.S. Investment Company Act Status </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, according to certain SEC staff interpretations, generally may be available to an issuer that invests at least 55% of its assets in &#8220;notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,&#8221; which we refer to as ICA Exception Qualifying Assets, and that does not issue any redeemable securities, face-amount certificates of the installment type or periodic payment plan certificates. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalties that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.  </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the parent of one or more subsidiaries that rely on Section 3(c)(5)(A), we currently are exempted from registration as an investment company based on Section 3(a)(1)(C) and/or Section 3(c)(6) of the U.S. Investment Company Act. To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term &#8220;investment securities&#8221; does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). For a subsidiary to be &#8220;majority-owned,&#8221; a parent entity must own a majority of the voting securities of the applicable security. Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff&#8217;s no-action letter such that royalties are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our no longer qualifying for an exemption from registration as an investment company would materially and adversely affect the value of your Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our predecessor was founded in 1996 and we were incorporated under the laws of England and Wales on February 6, 2020. We are a holding company, and our principal asset is a controlling equity interest in Royalty Pharma Holdings Ltd (&#8220;RP Holdings&#8221;). Our principal executive offices are located at 110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, New York, NY 10022, and our telephone number is (212) 883-0200. Our Internet site is www.royaltypharma.com. Our website and the information contained therein or connected thereto is not incorporated into this Annual Report on Form 10-K. Our agent for service in the United States is CSC North America located at 251 Little Falls Drive, Wilmington, Delaware, 19808.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reports filed with or furnished to the SEC pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available, free of charge, on the Investors section of our website at https://royaltypharma.com as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website at http://www.sec.gov that contains reports, and other information regarding us and other companies that file materials with the SEC electronically. We use the Investor section of our website as a means of disclosing material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts. Statements and information concerning our status as a Passive Foreign Investment Company (&#8220;PFIC&#8221;) for U.S. taxpayers are also available, free of charge, on the Investors section of our website under &#8220;Tax Information.&#8221; The information contained on or connected to the websites referenced in this Annual Report on Form 10-K is not incorporated by reference into this filing. Further, references to website URLs are intended to be inactive textual references only.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Described below are certain risks that we believe apply to our business. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary of Risk Factors</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Business </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales risks of biopharmaceutical products on which we receive royalties;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the growth of the royalty market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager to identify suitable assets for us to acquire;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">potential strategic acquisitions of biopharmaceutical companies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our use of leverage in connection with our capital deployment; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to leverage our competitive strengths;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">marketers of products that generate our royalties are outside of our control and are responsible for development, pursuit of ongoing regulatory approval, commercialization, manufacturing and marketing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">governmental regulation of the biopharmaceutical industry;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interest rate risk, foreign exchange fluctuations and inflation;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reliance on the Manager for all services we require and key members of the Manager</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;s senior advisory team;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual and potential conflicts of interest with the Manager and its affiliates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager or its affiliates to attract and retain highly talented professionals;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the assumptions underlying our business model;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reliance on a limited number of products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the competitive nature of the biopharmaceutical industry; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Organization and Structure </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our organizational structure, including our status as a holding company;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Class A Ordinary Shares </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">volatility of the market price of our Class A ordinary shares;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our incorporation under English law;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Taxation </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of changes to tax legislation and our tax position; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of COVID-19, or the future outbreak of any other infectious or contagious diseases, on our operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Business </span></div><div><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Biopharmaceutical products are subject to sales risks. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, changes in the marketer&#8217;s strategic priorities, obsolescence, lack of acceptance by government healthcare programs and private insurance plans, loss of patent protection, government regulations, the impact of the COVID-19 global pandemic or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our royalties may be reduced or cease. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of deployment, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure, participants and growth rate, changes in preferred methods of financing and capital raising in the biopharmaceutical industry, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or fewer royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to numerous factors including the structure of the transaction, or circumstances relating to the underlying products. As a result, we may not be able to continue to grow as we have in the past, or at all. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisitions of royalties on development-stage biopharmaceutical product candidates are subject to a number of uncertainties. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may acquire more royalties on development-stage product candidates that have not yet received marketing approval by any regulatory authority. There can be no assurance that the FDA, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. For example, in June 2021, we acquired from MorphoSys the right to receive royalties and certain milestone payments on gantenerumab, an anti-amyloid-beta monoclonal antibody that was in Phase 3 development for Alzheimer&#8217;s disease by Roche. Subsequently on November 30, 2022, Roche stated that it would discontinue clinical trials of gantenerumab after the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer&#8217;s disease did not meet their primary endpoint of slowing clinical decline. As a result, we concluded that a non-cash impairment charge of $273.6 million related to the financial royalty asset associated with gantenerumab was required. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA, MHRA, the EMA, PMDA or other regulatory authority approves a development-stage product candidate that generates our royalties, the labeling, packaging, manufacturing, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, including for certain patient populations, and could include withdrawal of the product from the market. Uncertainty relating to development-stage product candidates also make it more difficult to develop precise and accurate assumptions for our internal models relating to any such development-stage product candidate, which can result in reduced royalties compared to estimates.   </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or R&amp;D programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in diminished returns, or potentially reduced royalties for us, adversely affecting our results of operations. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could adversely affect our business, financial condition and results of operations. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we believe that we can evaluate the likelihood of a development-stage product candidate&#8217;s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our strategy of acquiring royalty interests in development-stage product candidates, including by co-funding clinical development and acquiring securities of biopharmaceutical companies, is subject to risks and uncertainties. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of that asset and when we do so, we do not control its clinical development. In these situations, the innovators may not complete activities on schedule or in accordance with our expectations or in compliance with applicable laws and regulations. Failure by one or more of these third parties to meet their obligations or our expectations, comply with applicable laws or regulations or any disruption in the relationships between us and these third parties, could delay or prevent the development, approval, manufacturing or commercialization of the development-stage product candidate for which we have provided funding. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to further expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we may acquire equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate in value. We will likely not control the company in which we acquire securities, and as a result, we may have limited ability to determine its management, operational decisions and policies. Further, while we may seek to mitigate the risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our activities we receive material non-public information about other companies from time to time. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may undertake strategic acquisitions of biopharmaceutical companies with significant royalty assets. Our failure to realize expected benefits of such acquisitions or our incurrence of unanticipated liabilities, could adversely affect our business, financial condition and results of operations. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may acquire companies with significant royalty assets or where we believe we could create significant synthetic royalties. These acquired or created royalty assets may not perform as we project. Moreover, the acquisition of operating biopharmaceutical companies will result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs and an expansion of our operations and expense structure, thereby potentially decreasing our profitability. The diversion of our management&#8217;s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business operations. Despite our business, financial and legal due diligence efforts, we have limited experience in assessing acquisition opportunities, and we ultimately may be unsuccessful in ascertaining or evaluating all risks associated with such acquisitions. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. As a result, our acquisition of biopharmaceutical companies could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use borrowed funds to finance a significant portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders. The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. Additional risks related to our leverage include: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our royalties may be used as collateral for our borrowings; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the event of a default under secured borrowings, if any, one or more of our creditors or their assignees could obtain control of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we have to comply with various financial covenants in the agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our ability to pay dividends to our shareholders may be restricted; and</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we are &#8220;externally managed,&#8221; we do not employ our own personnel, but instead depend upon the Manager, its executive officers and its employees for all of the services we require. The Manager selects and manages the acquisition of royalties and similar payment streams that meet our investment criteria and provides all our other administrative services. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Management Agreement has an initial term of ten years, after which it can be renewed for an additional term of three years, unless either we or the Manager provide notice of non-renewal 180 days prior the expiration of the initial term or renewal term. The Manager may not be removed during the initial or any renewal term without cause. While our Management Agreement requires its executives to devote substantially all their time to managing us and any legacy vehicles related to RPI or Old RPI unless otherwise approved by the board of directors, such resources may prove to be inadequate to meet our needs. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The success of our business depends upon key members of the Manager&#8217;s senior advisory team who may not continue to work for the Manager. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We depend on the expertise, skill and network of business contacts of the advisory professionals of the Manager, who evaluate, negotiate, structure, execute, monitor and service our assets in accordance with the terms of the Management Agreement. Our future success depends to a significant extent on the continued service and coordination of the advisory professionals of the Manager, particularly Mr. Legorreta. Pursuant to the Management Agreement, executives of the Manager must devote substantially all of their business time to managing us, unless otherwise approved by the board of directors. Despite this, Mr. Legorreta and other key advisory professionals may have other demands on their time, and we cannot assure you that they will continue to be actively involved in our business. Each of these individuals is an employee of the Manager and is not subject to an employment contract with us. The departure of any of these individuals or competing demands on their time could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key advisory professionals of the Manager have relationships with participants in the biopharmaceutical industry, financial institutions and other advisory professionals, which we rely upon to source potential asset acquisition opportunities. If the key advisory professionals of the Manager fail to maintain such relationships, or to develop new relationships with other sources, we may not be able to grow our portfolio. In addition, we can offer no assurance that these relationships, even if maintained, will generate asset acquisition opportunities for us in the future. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Management Agreement, the Manager cannot manage another entity that invests in or acquires royalties other than any legacy vehicle related to RPI or Old RPI. Every executive of our Manager is subject to a non-compete agreement that is effective for 18 months following termination of their employment with the Manager for any reason. We are a beneficiary of these agreements. In addition, executives of the Manager must devote substantially all of their time to managing us and any legacy vehicle related to RPI or Old RPI, unless otherwise approved by the board of directors. Despite this, the ability of our Manager and its officers and employees to engage in other business activities, subject to the terms of our Management Agreement, may reduce the amount of time our Manager, its officers or other employees spend managing us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, there could be conflicts of interest between us and our advisory personnel. For instance, Mr. Legorreta, our Chief Executive Officer, is also a co-founder of and has significant influence over Pharmakon Advisors, which shares physical premises with the Manager. Pharmakon manages BioPharma Credit PLC (LSE: BPCR) and other investment vehicles that collectively are leading providers of debt capital to the biopharmaceutical industry. Mr. Legorreta has a substantial investment in BioPharma Credit. In addition, Mr. Legorreta serves as the chairperson of the board of directors of ProKidney Corp. and he has founded and participates in foundations that receive and provide medical research funding. Even though he has the involvement with Pharmakon, BioPharma Credit PLC, ProKidney Corp. and the foundations described above, Mr. Legorreta does not have any material constraints on the time he has available to devote to us and the Manager. From time to time, the Manager and Pharmakon may pursue similar investment opportunities for their respective clients, although we believe that actual conflicts of interest are rare due to the differing investment strategies of Pharmakon and us, and the fact that royalty holders, rather than Pharmakon and us, determine the type of transaction they seek. Under arrangements with Pharmakon, the Manager subleases office space to Pharmakon, and the parties may provide research, business development, legal, compliance, financial and administrative services to one another. The Manager and Pharmakon reimburse each other to the extent that one of them provides materially more services to the other than they receive in return. In consideration of the support provided to Pharmakon by the Manager, certain employees of the Manager receive compensation from Pharmakon. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the structure of our Manager&#8217;s compensation arrangements may have unintended consequences. We have agreed to pay our Manager or its affiliates quarterly operating and personnel expenses (the &#8220;Operating and Personnel Payments&#8221;), a portion of which is based on the mark-to-market value of security investments, including equity securities and derivative financial instruments, at the end of each quarter and is payable to the Manager regardless of whether we realize any gain on the security investments when sold. Consequently, the Manager may be incentivized to have us make security investments regardless of our expected gain on such investments, which may not align with our or our shareholders&#8217; interests. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">To service our indebtedness and meet our other ongoing liquidity needs, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. If we cannot generate the required cash, we may not be able to make the required payments under our indebtedness.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, our total principal amount of senior unsecured notes outstanding was $7.3&#160;billion. In addition, we have up to $1.5&#160;billion of available revolving commitments under our unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;). Except for RP Holdings, our subsidiaries that do not guarantee the senior unsecured notes will have no obligation, contingent or otherwise, to pay amounts due under the senior unsecured notes or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. We cannot assure you that our business will generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent sufficient cash flow and the ability to refinance, we could also be forced to sell assets to make up for any shortfall in our payment obligations. However, the terms of the agreements that govern our existing outstanding debt limit, our and our subsidiaries&#8217; ability to sell assets and also restrict the use of proceeds from such a sale. Accordingly, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations on our indebtedness.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to interest rate, foreign exchange and inflation risk. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to interest rate fluctuation exposure through any borrowings under our Revolving Credit Facility and our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. In addition, the discontinuation, modification or other reform of the London Interbank Offered Rate (&#8220;LIBOR&#8221;), or the replacement of LIBOR with a different reference rate, such as the Secured Overnight Financing Rate (&#8220;SOFR&#8221;), could create uncertainty regarding the nature of potential changes to and future utilization of specific reference rates, require us to amend certain agreements or increase our interest expense. To the extent that interest rates generally increase, our borrowing costs will increase and our leveraging strategy will become more costly, leading to diminished net profits. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain products pay royalties in currencies other than U.S. dollars, which creates foreign currency risk primarily with respect to the Euro, Canadian dollar, British pound, Swiss franc and Japanese yen, as our functional and reporting currency is the U.S. dollar. In addition, our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. We are also subject to foreign exchange rate risk caused by significant events with macroeconomic impacts, including, but not limited to, the Russia-Ukraine war, COVID-19 pandemic and actions taken by central banks to counter inflation. Changes in the value of currencies relative to the U.S. dollar, or high inflation in countries using a currency other than the U.S. dollar, can impact our revenues, costs and expenses and our financial guidance. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about the biopharmaceutical products underlying the royalties we buy available to us may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations, exclusivity terms, license terms or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be, and in the past have been, adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. The risks relating to these assumptions may be exacerbated for development-stage product candidates due to the uncertainties around their development, labeling, regulatory approval, commercialization timing, manufacturing and supply, competing products or related factors. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties may also prove, and in the past have proven, to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect or at all, which could adversely affect our financial condition and results of operation. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;), we classify most royalty assets that we acquire as financial assets that are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount, net of any purchased receivables. A critical component of such forecast is our assumptions regarding duration of the royalty. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The royalty duration is important for purposes of accurately measuring interest income over the life of a royalty. In making assumptions around the royalty duration for terms that are not contractually fixed, we consider the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an unexpected shortening of a royalty term were to occur, it could result in a reduction in the effective interest rate, a decline in income from royalties, and a significant reduction in royalty payments compared to expectations, or a permanent impairment. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method as a result of which our GAAP results of operations can be volatile and unpredictable. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with GAAP, most of the royalty assets we acquire are treated as investments in cash flow streams and are thus classified as financial assets. Under this classification, our financial royalty assets are treated as having a yield component that resembles loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the non-cash charges associated with the application of the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts, including a non-cash expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts&#8217; consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing non-cash provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts&#8217; consensus sales forecasts associated with the Trikafta approval. The financial statement impact caused by the application of the effective interest accounting methodology could result in a negative perception of our results in a given period. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our current asset portfolio includes royalties relating to over 35 marketed products and 12 development-stage product candidates, the top five product franchises accounted for 69% of our royalty receipts in the year ended December 31, 2022. In addition, our asset portfolio may not be fully diversified by geographic region or other criteria. Any significant deterioration in the cash flows from the top products in our asset portfolio could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face competition in acquiring royalties and locating suitable royalties to acquire. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Biopharmaceutical products are subject to substantial competition. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new or alternate products or improvements on which we are not entitled to a royalty made to existing products, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitive factors affecting the market position and success of each product include: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">effectiveness;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">safety and side effect profile;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">price, including third-party insurance reimbursement policies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">timing, introduction and marketer support of the product;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">efficacy and execution of marketing and commercialization strategy;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">market acceptance; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">manufacturing, supply and distribution;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">governmental regulation, including price caps;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">availability of lower-cost generics or biosimilars;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">intellectual property protection and exclusivity;  </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">treatment innovations that eliminate or minimize the need for a product; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">product liability claims. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Products for which we have a royalty receivable or other interest may be rendered obsolete or non-competitive by new or alternate products, including generics or biosimilars, improvements on existing products, marketing or commercialization strategies, or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies, products on which we have a royalty may become unattractive to commercialize or obsolete. If a product&#8217;s market acceptance is diminished or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, may not be made on time or at all, which may affect our ability to realize the benefits of the royalty receivable or other interest in such product and may result in us incurring asset impairment charges. Further, any product for which we have a royalty receivable or other interest that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Many approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. Any of these developments could adversely affect products for which we have a royalty, and consequently could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Marketers of products that generate our royalties are outside of our control. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of our royalty receivables, our cash flow consists primarily of payments supported by royalties paid by marketers. These marketers may have interests that are different from our interests. For example, these marketers may be motivated to maximize income by allocating resources to other products and, in the future, may decide to focus less attention on the products generating our royalties or by allocating resources to develop products that do not generate royalties to us. There can be no assurance that any marketer or person with whom the marketer has a working relationship has adequate resources or motivation to continue to produce, market and sell the products generating our royalties. Aside from any limited audit rights relating to the activities of the marketers that we may have in certain circumstances pursuant to the terms of our arrangements with the licensor, we do not have oversight rights with respect to the marketers&#8217; operations and do not have rights allowing us to direct their operations or strategy nor do our agreements contain performance standards for their operations. The calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of our counterparties&#8217; sales and accounting functions. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we may be able to receive certain information relating to sales of products through the exercise of audit rights and review of royalty reports we receive from the licensor, such information may be received many months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on our part. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have limited information on the marketers&#8217; operations. We will not have the right to review or receive certain information relating to products that the marketers may have, including the results of any studies conducted by the marketers or others, or complaints from doctors or users of products. The market performance of the products generating our royalties may therefore be diminished by any number of factors relating to the marketers that are outside of our control. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, the holders of royalties on products have granted exclusive regulatory approval, commercialization, manufacturing and marketing rights to the marketers of such products. The marketers have full control over those efforts and sole discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the marketer&#8217;s efforts and is beyond our control. If a marketer does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a marketer engages in illegal or otherwise unauthorized practices, the product&#8217;s sales may not generate sufficient royalties, or the product&#8217;s sales may be suspended, and consequently, could adversely affect our business. In addition, if marketers of biopharmaceutical products decide to discontinue product programs or we believe the commercial prospects of assets have been reduced, we may recognize material non-cash impairment charges related to the financial royalty asset associated with those programs or assets. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements relating to the products generating our royalties may be terminated, which may adversely affect sales of such products and therefore the payments we receive. For example, under certain license agreements, marketers retain the right to unilaterally terminate the agreements with the licensors. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate its license agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of any such termination, a licensor may no longer receive all of the payments it expected to receive from the licensee and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license agreement that has been terminated. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, license agreements may fail to provide significant protection for the licensor in case of the licensee&#8217;s failure to perform or in the event of disputes. License agreements which relate to the products underlying our royalties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what the licensor believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our royalties and adversely affect our business, financial condition and results of operations. If a marketer were to default on its obligations under a license agreement, the licensor&#8217;s remedy may be limited either to terminating certain licenses related to certain countries or to generally terminate the license agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor and we may be required to rely on the resources and willingness of the licensor to enforce its rights against the licensee. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In any of these situations, if the expected payments under the license agreements do not materialize, this could result in a significant loss to us and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a marketer were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due under a license agreement, pending a resolution of the insolvency proceeding. Any unpaid royalty payments due for the period prior to the filing of the bankruptcy proceeding would be unsecured claims against the marketer, which might not be paid in full or at all. While royalty payments due for periods after the filing may qualify as administrative expenses entitled to a higher priority, the actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under the license agreement. The licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, the marketer could elect to reject the license agreement, which would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The investigation of each specific target royalty and the negotiation, drafting and execution of relevant agreements, disclosure and other documents requires substantial management time and attention and results in substantial costs for accountants, attorneys and others. If a decision is made not to complete a specific acquisition, the costs incurred for the proposed transaction would not be recoverable from a third party. Furthermore, even if an agreement is reached relating to a specific target asset, we may fail to consummate the acquisition for any number of reasons, including, in the case of an acquisition of a royalty through a business combination with a public company, approval by the target company&#8217;s public shareholders. Multiple unsuccessful attempts to acquire new royalties could hurt our reputation, result in significant costs and an inefficient use of the Manager&#8217;s time. The opportunity cost of diverting management and financial resources could negatively impact our ability to locate and acquire other assets. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations, pricing pressures and the regulation of the healthcare industry. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In both U.S. and non-U.S. markets, sales of biopharmaceutical products, and the success of such products, depends in part on governmental regulation and the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs in addition to private insurance plans.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States, pharmaceutical product pricing is subject to enhanced government regulation, public scrutiny and calls for reforms. For example, in August 2022, President Biden signed into law the Inflation Reduction Act (&#8220;IRA&#8221;), which includes significant drug pricing provisions, including (i) inflation rebates, where drug manufacturers must pay a rebate to the government if the prices of their covered single-source drugs and biologics rise faster than the rate of inflation; (ii) Medicare Part D redesign where beneficiaries&#8217; out-of-pocket costs are capped, payment obligation for initial coverage is redistributed with drug manufacturers paying 10% on all drugs and the coverage gap is eliminated, as well as requiring Part D plans to pay a larger portion of the catastrophic phase with drug manufacturers covering 20% of the costs; and (iii) Medicare negotiation, which requires the Department of Health and Human Services (&#8220;HHS&#8221;) to negotiate prices for certain drugs covered by Medicare Part B and Part D through a drug price negotiation program. In October 2022, President Biden signed an executive order that instructs HHS to consider whether to select for testing new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. In addition, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the &#8220;ACA&#8221;) was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts and taxes that had a significant effect on the expenses and profitability on the companies that manufacture the products that generate our royalties. These companies and their products face uncertainty due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the IRA and the ACA. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other U.S. federal or state legislative or regulatory action or policy efforts could adversely affect the healthcare industry, including, among others, additional transparency and limitations related to product pricing, review the relationship between pricing and manufacturer patient programs, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the United States at prices that are regulated by governments of various foreign countries, revisions to reimbursement of biopharmaceutical products under government programs, restrictions on U.S. direct-to-consumer advertising or limitations on interactions with healthcare professionals. No assurances can be provided that these laws and regulations will not adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The growth of large managed care organizations and prescription benefit managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust the price of products based on their value. There can be no assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return. These pricing pressures may adversely affect our current royalties and the attractiveness of future acquisitions of royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outside the United States, numerous major markets, including the EU, Japan and China, have pervasive government regulation of healthcare and government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, the products generating our royalties are subject to government decision-making and budgetary actions. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, many of the products in our portfolio benefit from regulatory exclusivity. If, in an effort to regulate pricing, regulatory exclusivity is not maintained, our business, financial condition and results of operations may be adversely impacted. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to contain the U.S. federal deficit, the biopharmaceutical industry could be considered a potential source of savings via legislative proposals. Government action to reduce U.S. federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The procedures to approve biopharmaceutical products for commercialization vary among countries and can involve additional testing and time. Such procedures may include on-site inspections by regulatory authorities at clinical trial sites or manufacturing facilities, which inspections may be delayed by travel restrictions imposed in response to the COVID-19 pandemic or other pandemics. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and many include additional risks, such as pricing approval. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that any of these regulatory approvals will be granted or not be revoked or restricted in a manner that would adversely affect the sales of such products and on the ability of payors to make payments with respect to such royalties to us. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the approval of, and ongoing regulation by, the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the MHRA and the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA&#8217;s current &#8220;Good Manufacturing Practice&#8221; regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Licensees generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product liability claims may diminish the returns on biopharmaceutical products. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we believe that we will not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of the product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our right to receive royalties generally depends on the existence of valid and enforceable claims of registered or issued patents in the United States and elsewhere in the world. The products on which we receive payments are dependent on patent protection and on the fact that the manufacturing, marketing and selling of such products do not infringe, misappropriate or otherwise violate intellectual property rights of third parties. Typically, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights, but must rely on the willingness and ability of our partners or their marketers to do so. There can be no assurance that these third parties will vigorously prosecute, maintain, enforce or defend such rights. Even if such third parties seek to prosecute, maintain, enforce or defend such rights, they may not be successful. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. Furthermore, changes in patent laws or interpretation of patent laws in the United States and in other jurisdictions could increase the uncertainties surrounding the successful prosecution of patent applications and the successful enforcement or defense of issued patents by our partners, all of which could diminish the value of patent protection relating to the biopharmaceutical assets. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights of our partners and their marketers are highly uncertain. In addition, such third parties&#8217; pending and future patent applications may not result in patents being issued which protect their products, development-stage product candidates and technologies or which effectively prevent others from commercializing competitive products, development-stage product candidates and technologies. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if the patent applications our partners and their marketers license or own do issue as patents, they may not issue in a form that will provide them with any meaningful protection, prevent competitors or other third parties from competing with them or otherwise provide them with any competitive advantage. Competitors or other third parties may be able to circumvent patents of our partners and their marketers by developing similar or alternative products in a non-infringing manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit the ability of our partners and their marketers from preventing others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of their products, development-stage product candidates and technologies. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any loss or reduction in the scope or duration of patent protection for any product that generates our royalties, or any failure to successfully prosecute, maintain, enforce or defend any patents that protect any such product may result in a decrease in the sales of such product and any associated royalties payable to us. Any such event would adversely affect the ability of the payor to make payments of royalties to us or may otherwise reduce the value of our royalty interest, and could consequently adversely affect our business, financial condition and results of operations. In cases where our contractual arrangements with our partner permit us to do so, we could participate in patent suits brought by third parties but this could result in substantial litigation costs, divert management&#8217;s attention from our core business and there can be no assurance that such suits would be successful. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The commercial success of a product depends, in part, on avoiding infringement, misappropriation or other violations of the intellectual property rights and proprietary technologies of others. Third-party issued patents or patent applications claiming subject matter necessary to manufacture and market a product could exist or issue in the future. Such third-party patents or patent applications may include claims directed to the composition, manufacturing, mechanism of action or other unique features of a product. There can be no assurance that a license would be available to marketers for such subject matter if such infringement were to exist or, if offered, would be offered on reasonable or commercially feasible terms. Without such a license, it may be possible for third parties to assert infringement or other intellectual property claims against the marketer of such product based on such patents or other intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if the marketer was able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies. In addition, if a marketer of a product that generates our royalties is required to obtain a license from a third party, the marketer may, in some instances, have the right to offset the licensing and royalty payments to such third party against royalties that would be owed to our partner, which may ultimately reduce the value of our royalty interest. An adverse outcome in infringement or other intellectual property-related proceedings could subject a marketer to significant liabilities to third parties, require disputed rights to be licensed from third parties or require the marketer to cease or modify its manufacturing, marketing and distribution of any affected product, any of which could reduce the amount of cash flow generated by the affected products and any associated royalties payable to us and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketers of the products that generate our royalties depend, in part, on trade secrets, know-how and technology, which are not protected by patents, to maintain the products&#8217; competitive position. This information is typically protected through confidentiality agreements with parties that have access to such information, such as collaborative partners, licensors, employees and consultants. Any of these parties may breach the agreements and disclose the confidential information or competitors might independently develop or learn of the information in some other way, which could harm the competitive position of the products and therefore reduce the amount of cash flow generated by our royalty interest. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The internal computer systems of our counterparties may fail or suffer security breaches, which could result in a significant disruption of their ability to operate their business effectively, adversely affect the cash flow generated by the related biopharmaceutical products, and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The internal computer systems and cloud-based computing services of our counterparties and those of their current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We have been subject to cyber-based attacks and unauthorized access in the past. If such an event were to occur in the future and cause interruptions in their operations, it could result in a disruption of their development and commercialization programs and business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. To the extent that any disruption or security breach were to result in a loss of, or damage to, a counterparties&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, our partners&#8217; operations may be harmed and the development and commercialization of their products, development-stage product candidates and technologies could be delayed. Such an event may reduce the amount of cash flow generated by the related biopharmaceutical products and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to pay periodic dividends to our shareholders or make share repurchases may be limited by applicable provisions of English law and contractual restrictions and obligations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under English law, we will only be able to declare dividends, make distributions or repurchase shares (other than out of the proceeds of a new issuance of shares for that purpose) out of profits available for distribution. Profits available for distribution are accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of our distributable reserves is a cumulative calculation. We may be profitable in a single financial year but unable to pay a dividend or make share repurchases if our accumulated, realized profits do not offset all previous years&#8217; accumulated, realized losses. Additionally, we may only make a distribution if our net assets are not less than the amount of our aggregate called-up share capital and distributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the terms of our indebtedness or other contractual obligations, the approval and payment of any interim dividends are at the sole discretion of our board of directors, which may change our dividend policy at any time and the payment of any final dividends will be subject to majority approval by holders of our Class A ordinary shares and Class B ordinary shares and in each case will be paid out of profits available for that purpose under English law. Our Articles of Association authorize the board of directors to approve interim dividends without shareholder approval to the extent that such dividends appear justified by profits available for such purpose. The board of directors may also recommend final dividends be approved and declared by shareholders at an annual general meeting. No such dividend may exceed the amount recommended by the board of directors. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that any dividends, whether quarterly or otherwise, will or can be paid or that any shares will or can be repurchased. Whether we pay dividends to our shareholders or make share repurchases depends on a number of factors, including among other things, general economic and business conditions, our strategic plans and prospects, our business and acquisition opportunities, our financial condition and results of operations, working capital requirements and anticipated cash needs, contractual restrictions and obligations, including fulfilling our current and future capital commitments, legal, tax and regulatory restrictions, other restrictions and implications on the payment of dividends by us to our shareholders or making any share repurchases and such other factors as our board of directors may deem relevant. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A shareholder who receives a distribution under circumstances where he or she knows or has reasonable grounds for believing that the distribution is unlawful in the circumstances is obliged to repay such distribution (or that part of it, as the case may be) to us. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, as interpreted by the SEC staff, requires each such subsidiary to invest at least 55% of its assets in &#8220;notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,&#8221; which we refer to as the ICA Exception Qualifying Assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalty interests that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term investment securities does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to our predecessor or otherwise restricts the conclusions in the SEC staff&#8217;s no-action letter such that royalty interests are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain conditions, at the end of each fiscal quarter, an affiliate of the Manager is entitled to a distribution in the form of equity from RP Holdings in respect of each portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such portfolio)) for such portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The right to Equity Performance Awards may create an incentive for the Manager to make riskier or more speculative asset acquisitions. In addition, the Manager may cause us to incur more debt, finance additional asset acquisitions or otherwise use more leverage in connection with asset acquisitions, as generally the use of leverage can increase the rate of return on an investment and therefore our profits. Under certain circumstances, the use of borrowed money may pose higher risks for our business or increase the likelihood of default, which would disfavor our shareholders. In addition, there is no correlation between our profits and the obligation of our board of directors to pay dividends to shareholders. Consequently, shareholders may receive limited or no dividends while an affiliate of the Manager remains entitled to Equity Performance Awards based on our Net Economic Profit. In addition, even though Equity Performance Awards are payable on a portfolio-by-portfolio basis (with portfolios comprised of investments made during sequential two-year periods) in order to reduce the risks that affiliates of the Manager will be paid Equity Performance Awards on individual investments even though our overall portfolio of investments is not performing well, Equity Performance Awards may nevertheless be payable to affiliates of the Manager when our overall portfolio of investments is not performing as well as the individual portfolios that are used as the basis for measuring the Equity Performance Awards. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our board of directors may make decisions with respect to the cash generated from our operations that may result in no dividends paid to our shareholders or no repurchases made of our ordinary shares. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is under no obligation to pay dividends, make distributions or repurchase our ordinary shares and it may decide to use cash to fund asset acquisitions or operations in lieu of paying dividends, making distributions or repurchasing our ordinary shares. We will pay Equity Performance Awards to an affiliate of the Manager based on our Net Economic Profit regardless of whether any dividends are paid to our shareholders or any ordinary shares are repurchased. Our board of directors&#8217; decisions with respect to our cash may result in no dividends to our shareholders and no ordinary shares repurchased. Furthermore, our board of directors&#8217; decisions with respect to dividends or repurchases of ordinary shares may adversely affect the market price of our Class A ordinary shares. In the event that we generate positive income, but pay limited or no dividends, holders of Class A ordinary shares may, if they have made certain elections for U.S. federal income tax purposes with respect to their Class A ordinary shares, have a tax liability on our income in excess of the actual cash dividends received by such holders. If our board of directors decides to approve limited or no dividends or repurchases of ordinary shares, the primary remedy for holders of Class A ordinary shares will be to sell their shares at the prevailing market price, including at a loss, which may be low due to unfavorable or inconsistent dividends or repurchases of our ordinary shares. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have discretion as to the types of assets that we may acquire. While we expect the Manager to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There could be a change of control of the Manager and, in such a case, the new controlling party may have a different philosophy, employ less experienced advisory professionals, be unsuccessful in identifying asset acquisition opportunities or have a track record that is not as successful as that of the Manager prior to such a change of control. If the foregoing were to occur, we could experience difficulty in making new asset acquisitions, and the value of our existing assets, our business, financial condition and results of operations could materially suffer. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Manager&#8217;s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager does not assume any responsibility other than to render the services called for under the Management Agreement. The Manager and its affiliates (including RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;)) and their respective officers, directors, equity holders, members, employees, agents and partners, and any other person who is entitled to indemnification (each, an &#8220;Indemnitee&#8221;) is not liable to us, any subsidiary of ours, our directors, our shareholders or any subsidiary&#8217;s shareholders or partners for acts or omissions performed in accordance with to the Management Agreement, except those resulting from acts constituting fraud, bad faith, willful misconduct, gross negligence (as interpreted under New York law) and a material breach of the Management Agreement that is not cured or a violation of applicable securities laws. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, to the fullest extent permitted by law, we have agreed to indemnify the Indemnitees from and against any and all claims, liabilities, damages, losses, penalties, actions, judgments, costs and expenses (including amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating or defending against any claim or alleged claim) of any nature whatsoever, known or unknown, liquidated or unliquidated that are incurred by any Indemnitee or to which such Indemnitee may be subject by reason of its activities on behalf of us or any of our subsidiaries to the extent that such Indemnitee&#8217;s conduct did not constitute fraud, bad faith, willful misconduct, gross negligence (as interpreted under New York law), material breach of the Management Agreement that is not cured or a violation of applicable securities laws. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operational risks may disrupt our businesses, result in losses or limit our growth. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely heavily on the Manager&#8217;s financial, accounting, information and other data processing systems and cloud computing services, as well as those of our current and future collaborators, contractors or consultants. Such systems are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, pandemics, such as the COVID-19 pandemic, terrorism, war and telecommunication and electrical failures. If any of these events occur and such systems do not operate properly or are disabled or if there is any unauthorized disclosure of data, whether as a result of tampering, a breach of network security systems, a cyber-incident or attack or otherwise, we could suffer substantial financial loss, increased costs, a disruption of our business, loss of trade secrets or other proprietary information, liability to us, regulatory intervention or reputational damage. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, federal, state and international laws and regulations relating to data privacy and protection, such as the European Union&#8217;s General Data Protection Regulation, which took effect in May 2018, and the California Consumer Privacy Act, which took effect in January 2020, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts or data privacy and protection compliance efforts fail. In addition, we operate a business that is highly dependent on information systems and technology. The Manager&#8217;s information systems and technology may not continue to be able to accommodate our growth, and the cost of maintaining such systems may increase. Such a failure to accommodate growth, or an increase in costs related to such information systems, could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A disaster or a disruption in the public infrastructure that supports our business, including a disruption involving electronic communications or other services used by us or third parties with whom we conduct business, could adversely affect our ability to continue to operate our business without interruption. Our disaster recovery programs and those of the Manager may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse us for our losses, if at all. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, sustaining our growth may require us or the Manager to commit additional management, operational and financial resources to identify new professionals to join the team and to maintain appropriate operational and financial systems to adequately support expansion. Due to the fact that the market for hiring talented professionals is competitive, we may not be able to grow at the pace we desire. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. </span></div><div style="margin-bottom:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 (&#8220;Bribery Act&#8221;), the U.S. Foreign Corrupt Practices Act of 1977, as amended the (&#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and the marketers of products that generate our royalties operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the &#8220;Trade Control laws.&#8221; </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the marketers of products that generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the marketers of products that generate are royalties are found to be in violation of any of these laws or any other governmental regulations, we or marketers of products that generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or marketers of products that generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The EU directive on alternative investment fund managers (the &#8220;AIFM Directive&#8221;) may significantly increase our compliance costs. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AIFM Directive has been implemented into the national law of the majority of member states of the European Economic Area and the United Kingdom (each an &#8220;AIFM state&#8221;). The AIFM Directive sets out minimum conditions related to the marketing of interests in alternative investment funds (such as our Class A ordinary shares) in the AIFM states and may impact our ability to attract investors in the AIFM states and may significantly increase our and the Manager&#8217;s compliance costs. Such conditions include requirements for us to register with the competent authority in the relevant AIFM state in order to market the Class A ordinary shares to investors, requirements to file periodic reports with the competent authority in the relevant AIFM state and requirements to comply with disclosure and reporting obligations in respect of investors in the relevant AIFM state. Such reports and disclosures may become publicly available. While such conditions are met in relation to the AIFM states where our Class A ordinary shares will be marketed, there can be no guarantee that this will continue to be the case. The AIFM Directive does not, however, prohibit an investor in such AIFM state from subscribing for our Class A ordinary shares at their own initiative in circumstances where such Class A ordinary shares have not been marketed in such AIFM state and we may issue our Class A ordinary shares to such investors, as long as they have provided us and the Manager with representations that they have done so at their own initiative. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each AIFM state, our Class A ordinary shares may only be offered to investors in accordance with local measures implementing the AIFM Directive. Investors, together with any person making or assisting in the decision to invest in us, who are situated, domiciled or who have a registered office, in an AIFM state where our Class A ordinary shares are not being offered pursuant to private placement rules implementing the AIFM Directive may invest, or effect an investment in our Class A ordinary shares, but only in circumstances where they do so at their own initiative. Any investor acquiring our Class A ordinary shares at their own initiative in such AIFM state should note that as we have not been registered for marketing in that AIFM state, no reports will be filed with the competent authority in the relevant AIFM state by or in respect of us and no investor shall be entitled to receive any disclosure or report that is mandated in respect of an alternative investment fund being marketed pursuant to the AIFM Directive. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The United Kingdom implemented the AIFM Directive through the Alternative Investment Managers Regulations 2013 and the Financial Conduct Authority&#8217;s Handbook. Following the United Kingdom&#8217;s withdrawal the European Union and the expiration of the transitional period, the rules applicable to the marketing of interests in alternative investment funds in the United Kingdom and the other AIFM states remained largely aligned. However, there are now areas of divergence which are likely to grow as the United Kingdom seeks to adopt a new post-Brexit financial services regulatory regime. Such divergence may make it more time consuming and complex for us to market our Class A ordinary shares to investors in the United Kingdom and other AIFM states which, in turn, may significantly increase our and the Manager&#8217;s compliance costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Organization and Structure </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a holding company with no operations and rely on our subsidiaries to provide us with the funds necessary to meet our financial obligations and to pay dividends. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a holding company with no material direct operations. Our principal asset is our controlling equity interest in RP Holdings. As a result, we are dependent on loans, dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations and to pay dividends or make distributions to our shareholders. Our subsidiaries are legally distinct from us and may be prohibited or restricted from providing loans, paying dividends or otherwise making funds available to us under certain conditions. If the cash we receive from our subsidiaries is insufficient for us to fund our financial obligations, we may be required to raise cash through the incurrence of debt, the issuance of equity or the sale of assets to fund. However, there is no assurance that we would be able to raise cash by these means. If the ability of any of our subsidiaries to pay dividends or make distributions or payments to us is materially restricted by regulatory or legal requirements, bankruptcy or insolvency, or our need to maintain our financial strength ratings, or is limited due to operating results or other factors, it could adversely affect our ability to meet our financial obligations and to pay dividends or make distributions to our shareholders. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our structure will result in tax distributions as a result of the RP Holdings Class C Special Interest. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is treated as a partnership for U.S. federal income tax purposes and has owners that are subject to U.S. federal income taxation. RP Holdings is required to make cash distributions, or tax distributions, to the direct owner or beneficial owners of the RP Holdings Class C Special Interest, calculated using an assumed tax rate that is generally uniform for all recipients regardless of their tax status. Funds used by RP Holdings to satisfy its tax distribution obligations will not be available for reinvestment in our business. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Ordinary Shares </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The market price of our Class A ordinary shares has been and may in the future be volatile, which could cause the value of our shareholders&#8217; investment to decline. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our Class A ordinary shares has been and may be volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. During the year ended December 31, 2022, the per share trading price of our Class A ordinary shares fluctuated from a low of $37.46 to a high of $44.65. Market volatility, as well as general economic, market or political conditions, could reduce the market price of Class A ordinary shares in spite of our operating performance. In addition to the factors discussed in this Annual Report on Form 10-K, our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including: </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market conditions in the broader stock market in general, or in our industry in particular; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">variations in our quarterly operating results or dividends to shareholders; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additions or departures of key management personnel at the Manager; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">timing and rate of capital deployment, including relative to estimates;</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes in our portfolio mix or acquisition strategy;</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to meet analysts&#8217; earnings estimates; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">publication of research reports about our industry; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">third-party healthcare reimbursement policies and practices; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">litigation and government investigations; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">no results, or projected results, from marketers of products that generate our royalties; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">results from, and any delays to, the clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets or other issues relating to such products, including regulatory approval or commercialization; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adverse market reaction to any indebtedness that we may incur or securities we may issue in the future; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes in market valuations of similar companies or speculation in the press or investment community; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">announcements by our competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">economic and political conditions or events, such as the COVID-19 pandemic, inflation and rising interest rates and global conflicts, including the Russia-Ukraine war; and </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adverse publicity about us or the industries in which we participate or individual scandals. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our shareholders from reselling their Class A ordinary shares at or above the purchase price. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock markets in general have from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company&#8217;s securities, securities class action litigation has often been instituted against public companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints other than shareholder complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that such shareholder finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits. If a court were to find either choice of forum provision contained in our Articles of Association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named herein. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a public limited company with our registered office in England and our subsidiaries are incorporated in various jurisdictions, including jurisdictions outside the United States. One of our directors is not a resident of the United States, and a substantial portion of our assets and the assets of this director are located outside the United States. As a result, it may be difficult for investors to effect service of process on this director in the United States or to enforce judgments obtained in U.S. courts against us or this director based on the civil liability provisions of the U.S. securities laws or otherwise. Even if shareholders are successful in bringing an action of this kind, the laws of England may render shareholders unable to enforce a judgment against our assets or the assets of our directors and executive officers. In addition, it is doubtful whether English courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would likely be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. As a result of the above, shareholders may have more difficulty in protecting their interest through actions against our management, directors or other shareholders than they would as shareholders of a U.S. public company. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are incorporated under English law. The rights of our shareholders are governed by English law, including the provisions of the Companies Act 2006 (the &#8220;U.K. Companies Act&#8221;), and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.K. City Code on Takeovers and Mergers (the &#8220;Takeover Code&#8221;) applies, among other things, to an offer for a public company whose registered office is in the United Kingdom (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the United Kingdom (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the &#8220;Takeover Panel&#8221;) to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the &#8220;residency test.&#8221; Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, including the structure of our board of directors, the functions of the directors and where they are resident. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given that our central management and control is situated outside the United Kingdom (or the Channel Islands or the Isle of Man), we do not anticipate that we will be subject to the Takeover Code. However, if at the time of a takeover offer, the Takeover Panel determines that we have our place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man), we would be subject to a number of rules and restrictions, including but not limited to the following: (i) our ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) we might not, without the approval of our shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out acquisitions or disposals; and (iii) we would be obliged to provide equality of information to all bona fide competing bidders. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under English law, and whether or not we are subject to the Takeover Code, an offeror for us that has acquired (i) 90% in value of; and (ii) 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for us is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a public limited company incorporated under the laws of England and Wales. English law provides that a board of directors may only allot shares (or rights to subscribe for or convert into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to allot additional shares for a period expiring on May 31, 2025, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period). </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period expiring on May 31, 2025, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period). </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">English law prohibits us from repurchasing our shares by way of &#8220;off market purchases&#8221; without the prior approval of shareholders by ordinary resolution (i.e., majority of votes cast by our shareholders), and other formalities. Such approval may be for a maximum period of up to five years but may be sought more frequently. English law prohibits us from conducting &#8220;on market purchases&#8221; as our shares are listed on the NASDAQ and will not be traded on a recognized investment exchange in the United Kingdom.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our shareholders approved the authorization of certain &#8220;off market purchases&#8221; that will expire five years from June 23, 2022 unless renewed by our shareholders prior to the expiration date. We cannot assure shareholders that situations will not arise where such shareholder approval requirements for any of these actions would deprive our shareholders of substantial capital management benefits. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The United Kingdom&#8217;s withdrawal from the European Union and differing regulatory regimes may have a negative effect on global economic conditions, financial markets and our business, which could reduce the market price of our Class A ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The withdrawal of the United Kingdom from the European Union (commonly referred to as &#8220;Brexit&#8221;) took effect on January 31, 2020. On December 30, 2020, the United Kingdom passed legislation giving effect to a trade and cooperation agreement, with the EU, which became effective on May 1, 2021. The trade and cooperation agreement covers the general objectives and framework of the relationship between the United Kingdom and the European Union, including as it related to trade, transport, visas, judicial, law enforcement and security matters, and provides for continued participation in community programs and mechanisms for dispute resolution. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the United Kingdom and the European Union. Currently, the United Kingdom has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012, as amended. The regulatory regime in the United Kingdom therefore mostly aligns with EU regulations, however it is possible that these regimes will diverge in future as the trade and cooperation agreement does not provide for mutual recognition of U.K. and EU pharmaceutical legislation. Brexit and its related effects could adversely affect our operations and the market price of our Class A ordinary shares. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our Class A ordinary shares are not eligible for continued deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The facilities of The Depository Trust Company (&#8220;DTC&#8221;) are a widely-used mechanism that allow for rapid electronic transfers of securities between the participants in the DTC system, which include many banks and brokerage firms. While our Class A ordinary shares are eligible for deposit and clearing within the DTC system, DTC has discretion to cease to act as a depository and clearing agency for our Class A ordinary shares, including to the extent that any changes in U.K. law change the stamp duty or stamp duty reserve tax (&#8220;SDRT&#8221;) position in relation to the Class A ordinary shares. If DTC determined that the Class A ordinary shares were not eligible for continued deposit and clearance within its facilities, our Class A ordinary shares may not be eligible for continued listing on the NASDAQ and trading in the Class A ordinary shares would be disrupted. While we would pursue alternative arrangements to preserve our listing and maintain trading, any such disruption could adversely affect the market price of our Class A ordinary shares and our access to the capital markets. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain qualified board members. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we are subject to the reporting requirements of the Exchange Act, the requirements of the U.S. Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley Act&#8221;), and the requirements of the U.K. Companies Act and, if applicable, the Takeover Code. The requirements of these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to file with the SEC annual and quarterly information and other reports that are specified in the Exchange Act, and therefore will need to have the ability to prepare financial statements that are compliant with all SEC reporting requirements on a timely basis. In addition, we are subject to other reporting and corporate governance requirements, including certain requirements of Nasdaq and certain provisions of the Sarbanes-Oxley Act and the regulations promulgated thereunder, which will impose significant compliance obligations upon us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to comply with Section 404 of the Sarbanes-Oxley Act, which requires management assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to regulatory consequences, including sanctions by the SEC, negatively affect investor confidence in our financial statements, restrict access to capital markets and adversely impact the market price of our Class A ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our compliance with the requirements under the Exchange Act, the Sarbanes-Oxley Act, the U.K. Companies Act and, if applicable, the Takeover Code and the rules and regulations thereunder increases our legal and financial compliance costs and makes some activities more time consuming and costly. These rules and regulations have made it more difficult and more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may in the future be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We may not be able to predict or estimate accurately the amount of additional costs we may incur or the timing of such costs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Taxation </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our tax treatment, including Irish, U.K. and U.S. federal income tax treatment, depends in some instances on determinations of fact and interpretations of complex provisions of applicable tax law for which no clear precedent or authority may be available. You should be aware that our tax position is not free from doubt, and that applicable tax rules are generally subject to ongoing review by legislative and administrative bodies and relevant tax authorities, as well as by the Organization for Economic Co-operation and Development (&#8220;OECD&#8221;), which is continuously considering recommendations for changes to existing tax rules. Furthermore, over 130 member jurisdictions of the G20/OECD Inclusive Framework have joined the Two-Pillar Solution to Address the Tax Challenges of the Digitalization of the Economy as part of the OECD&#8217;s base erosion and profit sharing project (&#8220;BEPS&#8221;), which includes a reallocation of taxing rights among market jurisdictions and a global minimum tax rate of 15%. As proposals to change tax laws and the implementation of the BEPS framework remain subject to further negotiation, we are currently unable to predict the extent to which any changes to tax laws, statutes, rules, regulations or ordinances will occur and, if so, the ultimate impact on our business. These review processes could result in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications and interpretations. No ruling will be sought from the relevant tax authority regarding any of the tax issues discussed herein, and no assurance can be given that the relevant tax authorities will not challenge any of our tax positions and that such challenge would not succeed. If any such position is successfully challenged, our tax liabilities could materially increase, which would adversely affect our profitability and cash flows. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been significant changes both made and proposed to international tax laws that increase the complexity, burden and cost of tax compliance for all multinational companies. We expect to continue to monitor these and other developments in international tax law. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries expect to receive revenue from both U.S. and non-U.S. sources. We expect that our subsidiaries generally will be eligible for benefits under the applicable income tax treaties between Ireland and the jurisdictions where income is sourced. However, no assurances can be provided in this regard, and it is possible that a taxing authority could successfully assert that any of our subsidiaries does not qualify for treaty benefits as a result of its failure to satisfy the applicable requirements to be eligible to claim treaty benefits. If a taxing authority were to challenge our position regarding the application of an applicable income tax treaty, we could become subject to increased withholding taxes, and such taxes could be significant. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, with respect to certain U.S.-source income, we expect that our subsidiaries will be eligible for benefits under the U.S.-Ireland income tax treaty (the &#8220;Treaty&#8221;), and, under that Treaty, will not be subject to any U.S. withholding taxes on such U.S.-source payments. Our current treaty position with respect to U.S.-source payments relies in part on U.S. citizens or tax residents (as defined for purposes of the Treaty) owning, directly or indirectly, at least 50% of the beneficial interest in, or at least 50% of the aggregate vote and value of, each of our subsidiaries that earns U.S.-source income. Our treaty position is based on the current U.S. status of the majority of the existing indirect investors in RP Holdings and Old RPI. Subject to certain exceptions, the existing indirect U.S. investors in RP Holdings have the right to exchange their interests for our publicly traded Class A ordinary shares. Such publicly traded Class A ordinary shares could be further transferred on the public market to other persons. Therefore, it is possible that over time U.S. persons will own indirectly in the aggregate less than 50% of the interests in our subsidiaries. We currently expect that our Class A ordinary shares and other existing indirect interests in RP Holdings and Old RPI in the aggregate will continue to be owned in sufficient amount by U.S. citizens or tax residents, and that we will be able to establish such ownership, for purposes of satisfying the 50% ownership requirement under the Treaty. However, there is no assurance that RP Holdings and Old RPI will continue to be owned directly or indirectly by sufficient U.S. citizens or residents or that we will be able to establish to the IRS&#8217; satisfaction such ownership for purposes of satisfying the 50% U.S. ownership requirement under the Treaty. It is possible that if the indirect U.S. ownership in our subsidiaries becomes lower than 50% (or we cannot establish such ownership) we may in the future be able to qualify for another applicable exemption from U.S. withholding under the Treaty, but there can be no assurance in this regard. A substantial portion of our revenue is, and is expected to continue to be, derived from U.S.-source royalties. Therefore, if our subsidiaries failed to qualify for an exemption from U.S. withholding tax under the Treaty (by satisfying either the 50% U.S. ownership requirement or an alternative Treaty exemption) and such royalties were subject to a 30% U.S. withholding tax, our financial position, profitability and cash flows could be adversely affected. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, on August 25, 2016, the Irish Department of Finance announced that, in the context of the publication by the United States Treasury Department of a revised U.S. Model Income Tax Convention in February 2016, discussions have begun with the United States Treasury on updating certain elements of the Treaty. It is at this time not clear what elements of the Treaty may be updated, or when any such updates would go into effect. However, certain elements of the revised U.S. Model Income Tax Convention could, if included in an update to the Treaty, result in our subsidiaries being unable to qualify for the benefits of the Treaty or eliminate or reduce the benefits of the Treaty that otherwise would have been available to us. If our subsidiaries are unable to qualify for the benefits of the Treaty, or if any benefits of the Treaty that otherwise would have been available to us are eliminated or reduced, then all or a portion of our income may become subject to increased withholding taxes, and such taxes could be very significant and materially and adversely affect our financial position, profitability and cash flows. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our subsidiaries are considered to be engaged in a U.S. trade or business, we could be liable for significant U.S. taxation. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, if a foreign corporation, such as Royalty Pharma plc, is considered to be engaged in a U.S. trade or business, such corporation&#8217;s share of any income that is effectively connected with such U.S. trade or business will be subject to regular U.S. federal income taxation (currently imposed at a maximum rate of 21%) on a net basis and, potentially, an additional 30% U.S. &#8220;branch profits&#8221; tax on distributions attributable to income that is effectively connected with such U.S. trade or business. In addition, it is possible that such corporation could be subject to taxation on a net basis by state or local jurisdictions within the United States. We intend to conduct our activities, through our subsidiaries, such that no income realized by us will be effectively connected with the conduct of a U.S. trade or business or otherwise subject to regular U.S. federal income taxation on a net basis. If we are able to conduct our activities in this way, income or gains realized by us will not be subject to U.S. net federal income taxation. However, no assurance can be provided in this regard. The proper characterization of our income and gains for U.S. tax purposes is not certain, and it is possible that all or a portion of our income and gains could be characterized as income that is &#8220;effectively connected&#8221; with the conduct of a U.S. trade or business. If our income and gains were characterized as effectively connected with a U.S. trade or business, we would be subject to significant U.S. taxes plus interest and possible penalties, and our financial position, cash flows and profitability could be materially and adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect to operate, and expect that RP Holdings will operate, so as to be treated solely as a resident of the U.K. for tax purposes, but changes to our management and organizational structure or to the tax residency laws of other jurisdictions where we operate may cause the relevant tax authorities to treat us or RP Holdings as also being a resident of another jurisdiction for tax purposes. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under current U.K. tax law, a company that is incorporated in the U.K. is regarded as resident for tax purposes in the U.K. unless (i) it is concurrently treated as resident for tax purposes in another jurisdiction (applying the rules of that other jurisdiction for determining tax residency) that has a double tax treaty with the U.K. and (ii) there is a residency tie-breaker provision in that tax treaty which allocates tax residence to that other jurisdiction. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based upon our anticipated management and organizational structure, we believe that we and RP Holdings should be regarded as tax resident solely in the U.K. However, because this analysis is highly factual and may depend on future changes in our management and organizational structure, as well as future changes in the tax residency laws of other jurisdictions where we operate, there can be no assurance regarding the determination of our tax residence in the future. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As U.K. tax resident companies, we and RP Holdings will be subject to U.K. corporation tax on our worldwide taxable profits and gains. Should we (or RP Holdings) be treated as resident in a jurisdiction other than the U.K., we (or RP Holdings, as applicable) could be subject to taxation in that jurisdiction and may be required to comply with a number of material and formal tax obligations, including withholding tax or reporting obligations provided under the relevant tax law, which could result in additional costs and expenses. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We believe that we should not be subject to material U.K. corporation tax in respect of certain profits of our non-U.K. tax resident subsidiaries as a result of the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules but it cannot be guaranteed that this will continue to be the case. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As U.K. tax resident companies, we and RP Holdings will be subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. The types of profits of a Controlled Foreign Company that can potentially be subject to a U.K. corporation tax charge under the U.K. CFC Rules include business profits of the Controlled Foreign Company that are attributable to assets or risks that are managed by activities in the U.K., or certain finance profits of the Controlled Foreign Company that arise from capital or other assets contributed, directly or indirectly, to the Controlled Foreign Company from a connected U.K. tax resident company. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We and RP Holdings will therefore be required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets or our financing arrangements, however no assurances can be given that this will continue to be the case. The U.K. CFC Rules are highly complex and fact-dependent, and changes to, or adverse interpretations of, these rules, or changes in the future activities of RPI or other non-U.K. companies in which we hold an interest, directly or indirectly, may alter this position and could impact our group&#8217;s effective tax rate. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. However, a number of conditions must be met in order for such dividends to qualify for this tax exemption, including (in respect of dividends paid by RPI, which are tax resident in Ireland) conditions relating to the application of Irish tax law. As such, it cannot be guaranteed that these conditions for the U.K. tax exemption in respect of distributions will continue at all times to be satisfied. If distributions received by us or by RP Holdings were not to fall within an exempt class, such distributions would likely be subject to U.K. corporation tax at the then prevailing corporation tax rate. </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even where distributions fall within an exempt class, certain anti-avoidance and recharacterization rules may also apply. For instance, if RPI were to constitute an &#8220;offshore fund&#8221; for U.K. tax purposes that has at any time in an accounting period more than 60% by market value of its investments in debt securities, money placed at interest (other than cash awaiting investment), certain contracts for differences, or in holdings in other offshore funds with, broadly, more than 60% of their investments similarly invested, RP Holdings&#8217; shareholding in RPI may be subject to U.K. corporation tax as a deemed &#8220;loan relationship&#8221;, with the result that dividends received by RP Holdings from RPI could be subject to U.K. tax as deemed interest and RP Holdings may be subject to U.K. corporation tax on increases in the fair market value of its shareholding in RPI. The term &#8220;offshore fund&#8221; is defined for U.K. tax purposes through a characteristics-based approach and, broadly, can include arrangements constituted by a non-U.K. resident body corporate in which a reasonable investor would expect to be able to realize their investment entirely, or almost entirely, by reference to net asset value. We believe and have been advised that RP Holdings&#8217; shareholding in RPI should not fall within these rules, however no guarantee can be offered that this will continue to be the case. Changes to, or adverse interpretations of, the offshore funds rules, or changes in the nature of our investments, may alter this position and could impact our group&#8217;s effective rate. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect to be classified as a PFIC for U.S. federal income tax purposes, which could subject U.S. holders of our Class A ordinary shares to adverse U.S. federal income tax consequences.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Distributions that we pay to individual and other non-corporate U.S. holders will not be eligible for taxation at reduced rates, which could potentially adversely affect the value of our Class A ordinary shares.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We generally expect that our income, which consists primarily of passive income, and our assets, which consist primarily of assets that produce passive income, will result in our treatment as a PFIC for the current taxable year and future taxable years. We intend to annually furnish U.S. holders a &#8220;PFIC Annual Information Statement&#8221; with the information required to allow shareholders to make a qualified electing fund (&#8220;QEF&#8221;) election for United States federal income tax purposes on our website. U.S. holders who do not make a QEF election with respect to us or a mark-to-market election with respect to our Class A ordinary shares will be subject to potentially material adverse tax consequences, including (i) the treatment of any gain on disposition of our Class A ordinary shares as ordinary income and (ii) the application of a deferred interest charge on such gain and the receipt of certain distributions on our Class A ordinary shares. In addition, regardless of whether a QEF or mark-to-market election is made with respect to us, U.S. holders will be required to file an annual report on IRS Form 8621 containing such information with respect to its interest in a PFIC as the IRS may require. Failure to file IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in audit by the IRS. Further, if we are a PFIC for any taxable year during which a U.S. holder owns our Class A ordinary shares, we generally would continue to be treated as a PFIC with respect to that U.S. holder for all succeeding years during which such person holds our Class A ordinary shares, even if we ceased to meet the threshold requirements for PFIC status, unless the U.S. holder makes a special &#8220;purging&#8221; election on IRS Form 8621. The effect of these adverse tax consequences could adversely affect our U.S. shareholders and make </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">investment in our Class A ordinary shares less attractive to U.S. investors.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions made to non-corporate U.S. holders will not be eligible for taxation at reduced tax rates generally applicable to dividends paid by certain U.S. corporations and &#8220;qualified foreign corporations&#8221; because of our status as a PFIC. The more favorable rates applicable to qualifying corporate dividends could cause individuals to perceive investment in our Class A ordinary shares to be less attractive than investment in the shares of other corporations because of our PFIC status, and this perception could adversely affect the value of our Class A ordinary shares.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our financial statements are prepared in accordance with GAAP, which are periodically revised, interpreted or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies. It is possible that future accounting standards we are required to adopt may require changes to the current accounting treatment that we apply to our consolidated financial statements and may require us to make significant changes to our systems. Such changes could adversely affect our financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19, or the future outbreak of any other infectious or contagious diseases, could adversely affect our results of operations, financial condition and cash flows.  </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outbreak of COVID-19 and its variants has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. COVID-19 and other future health outbreaks and pandemics could lead to quarantines, mandating business and school closures and restricting travel, or trigger global economic slowdowns or global recessions. COVID-19 or another pandemic could adversely affect us due to, among other factors: </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a general decline in business activity; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the destabilization of the markets could negatively impact our partners in the biopharmaceutical industry and the sales of products generating our royalties; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the potential negative impact on the health of our Manager&#8217;s highly qualified personnel, especially if a significant number of them are impacted; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a deterioration in our ability to ensure business continuity during a disruption; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruptions, shortages, delivery delays and potential discontinuation of supply to our partners, which could (i) delay the clinical trials of the development-stage product candidates underlying our assets and result in a loss of our market share for products generating our royalties or development-stage product candidates underlying our assets, if approved, and (ii) hinder our partners&#8217; ability to timely distribute products generating our royalties and satisfy customer demand; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">travel restrictions, shelter-in-place policies or restrictions and other disruptions, which could cause or continue to cause delays and other direct impacts at our partners&#8217; manufacturing sites, which could impact the ability of our partners to manufacture development-stage product candidates underlying our biopharmaceutical assets and products generating our royalties; and </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">potential interruptions to our partners&#8217; clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets, including: (i) the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns; (ii) changes in hospital or research institution policies or government regulations, which could delay or adversely impact our partners&#8217; ability to conduct their clinical trials; and (iii) pauses to or delays of trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our partners&#8217; development-stage product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis due to reasons related to the pandemic, each of which could cause or continue to cause a disruption or delay to the development or the approval of development-stage product candidates underlying our biopharmaceutical assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Nevertheless, COVID-19 and other future health outbreaks and pandemics present material uncertainty which could adversely affect our results of operations, financial condition and cash flows. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal claims and proceedings could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may be subject to a wide variety of legal claims and proceedings. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ESG matters and any related reporting obligations may impact our business.</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. and international regulators, investors and other stakeholders are increasingly focused on ESG matters. For example, new U.S. and international laws and regulations relating to ESG matters, including human capital, diversity, sustainability, climate change and cybersecurity, are under consideration or being adopted, which may include specific, target-driven disclosure requirements or obligations. Our response will require additional investments and implementation of new practices and reporting processes, all entailing additional compliance risk. In addition, we have announced a number of ESG initiatives and goals, which will require ongoing investment, and there is no assurance that we will achieve any of these goals or that our initiatives will achieve their intended outcomes. Perceptions of our efforts to achieve these goals often differ widely and present risks to our reputation. Any harm to our reputation resulting from our failure or perceived failure to meet such goals could impact employee retention, the willingness of our partners to do business with us, or investors&#8217; willingness to purchase or hold our ordinary shares, any of which could adversely affect our business, financial condition and results of operations. In addition, our ability to implement some initiatives or achieve some goals is dependent on external factors. For example, our ability to meet certain sustainability goals or initiatives may depend in part on third-party collaboration, mitigation innovations or the availability of economically feasible solutions.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PROPERTIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Street, New York, NY 10022, and are provided by the Manager. We believe that our office facilities are suitable and adequate for our business as it is contemplated to be conducted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to various claims, charges and litigation matters arising in the ordinary course of business. Management and legal counsel regularly review the probable outcome of such proceedings. While we cannot feasibly predict the outcome of these matters with certainty, we believe, based on examination of these matters, experience to date and discussions with counsel, that the ultimate liability, individually or in the aggregate, will not adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class A ordinary shares are traded in the Nasdaq Global Select Market under the symbol &#8220;RPRX&#8221;. Our Class B ordinary shares are not listed on any stock exchange nor traded on any public market. As of February&#160;10, 2023, there were 2 shareholders of record of our Class A ordinary shares and 2 shareholders of record of our Class B ordinary shares. The number of record holders does not include persons who held our Class A ordinary shares in nominee or &#8220;street name&#8221; accounts through brokers or other institutions on behalf of shareholders. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividends</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we declared and paid four quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $333.3 million to holders of our Class A ordinary shares. Future dividends are subject to declaration by the board of directors. To the extent approved and payable, we intend to pay dividends on or about March 15, June 15, September 15 and December 15 to holders of record on or about the twentieth day of each such prior month.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Item 12, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for information regarding securities authorized for issuance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock Performance Graph</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the cumulative total stockholder return, calculated on a dividend-reinvested basis, on our Class A ordinary shares, the Standard &amp; Poor&#8217;s 500 Index (&#8220;S&amp;P 500&#8221;) and the Nasdaq Composite Index (&#8220;Nasdaq Composite&#8221;). The graph assumes an initial investment of $100 in our Class A ordinary shares at the market close on June 16, 2020, which was our initial trading day and its relative performance is tracked through December 31, 2022. The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our Class A ordinary shares.</span></div><div style="text-align:center"><img src="rprx-20221231_g4.jpg" alt="rprx-20221231_g4.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:800px"/></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above performance graph shall not be deemed soliciting material or to be filed with the SEC for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any of our other filings under the Exchange Act or the Securities Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[Reserved]</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations, cash flows and other changes in financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements and the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the initial public offering (&#8220;IPO&#8221;) of our Class A ordinary shares on June 16, 2020. &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. </span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies, which includes royalties on more than 35 commercial products, including Vertex&#8217;s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen&#8217;s Tysabri, AbbVie and Johnson &amp; Johnson&#8217;s Imbruvica, Astellas and Pfizer&#8217;s Xtandi, GSK&#8217;s Trelegy, Novartis&#8217; Promacta, Pfizer&#8217;s Nurtec ODT, Johnson &amp; Johnson&#8217;s Tremfya, Roche&#8217;s Evrysdi, Gilead&#8217;s Trodelvy and 12 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties or milestones, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high R&amp;D costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Approved Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2022, we have deployed $17.0&#160;billion of cash to acquire royalties, milestones and related assets on approved products. From 2012 through 2022, we have deployed $12.1&#160;billion to acquire royalties, milestones and related assets on approved products. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Development-Stage Product Candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2022, we have deployed $8.3&#160;billion to acquire royalties, milestones and related assets on development-stage product candidates. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we classify our acquisitions in these two broad categories, several of our approved product transactions are driven by the long-term expanded potential of these existing commercial products in indications that are unapproved at the time of acquisition. Similarly, some of our development-stage product candidate transactions are specifically related to indications that are unapproved at the time of acquisition, on products that are already approved and commercialized in other indications. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.</span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Synthetic Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales by the developer or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&amp;D for biopharmaceutical companies in exchange for future royalties and milestones if the product or indication we are funding is approved. </span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Launch and Development Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company. </span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Mergers and Acquisitions (&#8220;M&amp;A&#8221;) Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities such as our strategic alliance with MSCI Inc. (&#8220;MSCI&#8221;) to develop thematic life science indexes.   </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Background and Format of Presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Offer&#8221;) to facilitate our IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership interests in the various partnerships (the &#8220;Legacy Investors Partnerships&#8221;) that owned Old RPI, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership, or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;). The Exchange Offer together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following our IPO, we operate and control the business affairs of RP Holdings. We include RP Holdings and its subsidiaries in our consolidated financial statements. RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As a result of the Exchange Offer, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">y</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">From the consummation of the Exchange Offer until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships could participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of the Legacy Investors Partnerships and Old RPI became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following management&#8217;s determination that a high degree of common ownership existed in Old RPI both before and after the Exchange Offer, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the date of the Exchange Offer.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2022, we became an indirect owner of an 82% economic interest in Royalty Pharma Investments ICAV (&#8220;RPI ICAV&#8221;), which was previously owned directly by Old RPI.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of the royalties we acquire are treated as investments in cash flow streams and are classified as financial assets measured under the effective interest method in accordance with GAAP. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The measurement of income from our financial royalty assets requires significant judgments and estimates, including management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are updated each reporting period primarily using sell-side equity research analysts&#8217; consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the non-cash charges associated with applying the effective interest method accounting methodology to our financial royalty assets, our consolidated income statement activity can be volatile and unpredictable. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition which generates a corresponding cumulative allowance that reduces the gross asset balance, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014, we acquired the cystic fibrosis franchise and beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense in our consolidated income statements. Over the course of 10 quarters, we continued to recognize non-cash provision expense as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts&#8217; consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income over the course of 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing non-cash provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts&#8217; consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model in our consolidated income statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe there is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations have historically been financed primarily with cash flows generated by our royalties. Given the importance of cash flows and their predictability to management&#8217;s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP consolidated statements of cash flows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash collections from financial royalty assets, Cash collections from intangible royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty cash collections, Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled &#8220;Non-GAAP Financial Results.&#8221; </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP measures used by our peers in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the section titled &#8220;Non-GAAP Reconciliations&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Portfolio Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 marketed therapies and 12 development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty receipts for 2022 and 2021 in order of contributions to royalty receipts for 2022 (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Receipts</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketer(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie, Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Astellas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., others</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Ipsen, Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ultragenyx, Kyowa Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alnylam</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,231,256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,608,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts include quarterly redemption payments of $15.6 million in 2021 and 2022 related to the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows). In 2022, amounts also include the accelerated redemption payments of $479.5 million for all outstanding Series A and Series B Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The remaining amounts are related to royalty receipts from Nurtec ODT.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda. Our royalty receipts substantially ended in the second quarter of 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows), Cimzia, Entyvio, Gavreto, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and distributions from the Legacy SLP Interest. Other products for 2021 include a one-time milestone payment of $45.0 million that we received on Soliqua. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Highlights </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Net cash provided by operating activities totaled $2.1 billion and $2.0 billion for 2022 and 2021, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted Cash Receipts (a non-GAAP metric) totaled $2.8&#160;billion and $2.1&#160;billion for 2022 and 2021, respectively.  </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted EBITDA (a non-GAAP metric) totaled $2.6&#160;billion and $1.9&#160;billion for 2022 and 2021, respectively.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted Cash Flow (a non-GAAP metric) totaled $2.2&#160;billion and $1.6&#160;billion for 2022 and 2021, respectively.  </span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Results of Operations </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us and which are attributable to:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1. The Legacy Investors Partnerships&#8217; ownership of approximately 18% of Old RPI and Royalty Pharma Investments ICAV (&#8220;RPI ICAV&#8221;). The value of this non-controlling interest will decline over time as the assets in Old RPI and RPI ICAV expire.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2. A de minimis interest in RPCT held by RPSFT. The value of this non-controlling interest was substantially eliminated as of December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Legacy Investors Partnership together with RPSFT are referred as the &#8220;legacy non-controlling interests.&#8221; The legacy non-controlling interests are the only historical non-controlling interests that existed prior to our IPO.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, following the consummation of our IPO, we also report non-controlling interests related to:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3. The Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of RP Holdings Class B Interests which was approximately 27% of RP Holdings as of December 31, 2022. RP Holdings Class B Interests are exchangeable into Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Continuing Investors Partnerships are referred as the &#8220;continuing non-controlling interests.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4. RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of the results of operations of RP Holdings, Old RPI, RPI ICAV and RPCT are consolidated into our financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and other revenues </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty income generally arising from successful commercialization of products developed through R&amp;D funding arrangements, and a declining contribution of royalty revenue from our intangible royalty assets for which patent rights have materially expired. Most of our royalties are classified as financial assets as our ownership rights are generally protective and passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize interest income related to our financial royalty assets. Royalty revenue solely relates to our intangible royalty assets from our DPP-IV products for which the patent rights are licensed to various counterparties. For 2022 and 2021, the royalty payors accounting for greater than 10% of our total income and other revenues in any one year are shown in the table below: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.830%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Payor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Income from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts&#8217; consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts&#8217; consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variables affecting the recognition of interest income from financial royalty assets under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts&#8217; consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (e.g., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Revenue from intangible royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees. Our royalties on Januvia and Janumet expired in the first quarter of 2022. Our royalties on other DPP-IV products have also substantially ended and we do not expect any material revenue from the other DPP-IV products in the future periods.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Other royalty income </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income primarily includes income from financial royalty assets that have been fully amortized and income from synthetic royalties and milestones arising out of R&amp;D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a fully amortized financial royalty asset beyond the estimated duration. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Other royalty income also includes income from royalties that are recorded at fair value on our consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes the following: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">non-cash expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">non-cash expense or income related to the provision for current expected credit losses, which reflects the activity for the period, primarily due to new financial royalty assets with limited protective rights and changes to cash flow estimates for financial royalty assets with limited protective rights.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly in the income statement through the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision). </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The same variables and management&#8217;s estimates affecting the recognition of interest income on our financial royalty assets noted above also directly impact the provision. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. It includes development-stage funding payments that are made upfront or upon pre-approval milestones, and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General and administrative expenses </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative (&#8220;G&amp;A&#8221;) expenses include primarily Operating and Personnel Payments (defined below), legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in G&amp;A expenses, are calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in losses/(earnings) of equity method investees </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity in losses/(earnings) of equity method investees primarily includes the results of our share of income or loss from the following non-consolidated affiliates:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. Legacy SLP Interest </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. The Avillion Entities</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Avillion Entities (as defined below) partner with global biopharmaceutical companies to perform R&amp;D in exchange for success-based milestones or royalties if products are commercialized. Our investments in Avillion Financing I, LP (&#8220;Avillion I&#8221;) and BAv Financing II, LP (&#8220;Avillion II&#8221; and, together with Avillion I, the &#8220;Avillion Entities&#8221;) are accounted for using the equity method.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other (income)/expenses, net </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (income)/expenses, net primarily includes the changes in fair market value of our equity securities, derivative instruments and available for sale debt securities, including related forwards and funding commitments, and interest income. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interests </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net income attributable to non-controlling interests includes income attributable to the legacy non-controlling interests and the continuing non-controlling interests. As the Legacy Investors Partnerships and RPSFT no longer participate in investment opportunities, the related net income attributable to the legacy non-controlling interests is expected to decline over time. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the continuing non-controlling interests includes RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the RP Holdings Class C Special Interest held by EPA Holdings once certain performance conditions have been met. Future net income attributable to the non-controlling interest related to RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to non-controlling interests above can fluctuate significantly from period to period, primarily driven by volatility in the income statement activity of the respective underlying entity as a result of the non-cash charges associated with applying the effective interest accounting methodology to our financial royalty assets as described in section titled &#8220;Understanding Our Financial Reporting.&#8221;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this section, we discuss the results of our operations for 2022 compared to 2021. For a discussion of 2021 compared to 2020, please refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The comparison of our historical results of operations for 2022 and 2021 are as follows (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income and other revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,125,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,065,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(133,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income and other revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,237,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,289,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development funding expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,930,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,071,402&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,430,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,123,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense/(income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses of equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112,513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,011,137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(434,241)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(576,896)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Percentage change is not meaningful. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and other revenues </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income from financial royalty assets </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets by top products for 2022 and 2021 is as follows, in order of contribution to income in 2022 (in thousands):</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total income from financial royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,125,096</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,065,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets increased by $60.0&#160;million, or 2.9%, in 2022 compared to 2021, primarily driven by income from recently acquired assets, including Tremfya and Trelegy, in addition to the strong performance of the cystic fibrosis franchise primarily driven by the strong uptake of Kaftrio in countries outside the United States and the performance of Trikafta in the United States, including its uptake in children 6 through 11 years old. The increase in income was partially offset by the maturing of our royalties from the HIV franchise and declines in sell-side equity research analysts&#8217; consensus sales forecasts for Imbruvica and Tazverik. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from intangible royalty assets </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets decreased by $133.8&#160;million, or 78.1%, in 2022 compared to 2021, primarily driven by the maturity of our royalties on Januvia and Janumet in the first quarter of 2022 and the recognition of underpaid prior period royalties on Tradjenta in 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty income </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty inco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">me increased by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $21.5&#160;million, or 40.5%, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2021,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> primarily related to growth in the ongoing product launches of Trodelvy and Nurtec ODT that arose from our R&amp;D funding agreements with Immunomedics and Biohaven, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Provision activity is a combination of income and expense items. The provision breakdown by royalty asset (exclusive of the provision for current expected credit losses) based on the largest contributors to each year&#8217;s provision income or expense (in thousands) is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,098,042</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">465,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">904,244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">452,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we recorded provision expense of $904.2&#160;million, comprised of $1,098.0&#160;million and $193.8&#160;million in provision expense for changes in expected cash flows and provision income for current expected credit losses, respectively. We recorded provision expense for changes in expected cash flows for Imbruvica, Tysabri and Tazverik primarily due to significant declines in sell-side equity research analysts&#8217; consensus sales forecasts. The provision income for credit losses was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the decline in the financial asset value and changes in payors for certain products with stronger credit profiles, which was partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, we recorded provision expense of $452.8&#160;million, of which $465.8&#160;million and $12.9&#160;million related to provision expense for changes in expected cash flows and provision income for current expected credit losses, respectively. We recorded provision expense for Tazverik, Imbruvica, Emgality and the cystic fibrosis franchise, primarily due to significant declines in sell-side equity research analysts&#8217; consensus sales forecasts. The provision expense was partially offset by provision income from a significant increase in sell-side equity research analysts&#8217; consensus sales forecasts for Tysabri. The current expected credit loss activity in 2021 resulted in provision income that was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value. This was partially offset by provision expense for credit losses recognized as a result of the increases to our portfolio of financial royalty assets with limited protective rights, primarily related to zavegepant from a $100.0 million funding payment that we made to Biohaven upon the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense decreased by $23.0&#160;million, or 11.5%, in 2022 compared to 2021. In 2022, we recognized upfront R&amp;D funding expense of $175.0&#160;million in exchange for royalties and milestones on development-stage products from Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;), Theravance Biopharma, Inc (&#8220;Theravance&#8221;) and MSD International Business GmbH (&#8220;Merck&#8221;). In 2021, we recognized upfront R&amp;D funding expense of $193.2&#160;million in exchange for royalties on development-stage products from BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;) and MorphoSys AG (&#8220;MorphoSys&#8221;). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">G&amp;A expenses </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">G&amp;A expenses increased by $44.5&#160;million, or 24.3%, in 2022 compared to 2021, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments.</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial royalty asset impairment</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty asset impairment was $615.8 million in 2022 due to the recognition of non-cash impairment charges of $273.6 million, $160.1&#160;million and $182.1 million related to gantenerumab, otilimab and Gavreto, respectively. In November 2022, Roche stated that it would discontinue clinical trials of gantenerumab. In October 2022, GSK announced that it has decided not to progress with regulatory submissions for otilimab. These announcements contributed to our conclusion to impair these two assets. Additionally, during the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto due to the uncertainty of Gaverto&#8217;s commercial outlook. There was no comparable activity in 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in losses of equity method investees </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity in losses of equity method investees decreased by $10.5&#160;million, or 54.0%, in 2022 compared to 2021, primarily driven by lower equity in losses from the Avillion Entities. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest expense </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense increased by $21.8&#160;million, or 13.1%, in 2022 compared to 2021, primarily driven by the issuance of $1.3 billion senior unsecured notes in July 2021 (&#8220;2021 Notes&#8221;). The weighted average coupon rate was 2.24% and 2.18% in 2022 and 2021, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the &#8220;Liquidity and Capital Resources&#8221; section for additional discussion of the Notes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other (income)/expenses, net</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income, net of $119.9&#160;million in 2022 was primarily comprised of $96.6&#160;million of gains on derivative financial instruments related to our Milestone Acceleration Option that increased in value with the announcement and subsequent completion of Pfizer&#8217;s acquisition of Biohaven in October 2022. In addition, we recorded $78.3&#160;million of interest income, primarily related to the full accelerated redemption of our Series A Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven. The other income was partially offset by net losses on equity securities of $33.4&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other expense, net of $3.9&#160;million in 2021 was primarily comprised of net losses on equity securities of $48.1 million, including losses on MorphoSys ordinary shares and Epizyme common stock, partially offset by a gain on Biohaven common shares; and losses of $21.5 million on our derivative financial instruments related to our treasury rate lock contracts that were unwound and settled in connection with the issuance of the 2021 Notes. The losses were partially offset by interest income of $50.9 million related to our Series A Biohaven Preferred Shares and a gain of $17.9 million on the unrealized change in fair value of our available for sale debt securities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interests </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Legacy Investors Partnerships decreased by $113.7&#160;million in 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">compared to 2021, primarily driven by lower net income attributable to Old RPI and RPI ICAV as a result of increased provision expense recognized in 2022. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Continuing Investors Partnerships decreased by $273.5&#160;million in 2022 compared to 2021, primarily driven by lower net income attributable to RP Holdings in 2022 as a result of increased provision expense and impairment charges recorded in 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships&#8217; ownership of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to RPSFT decreased by $47.0&#160;million in 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">compared to 2021. We expect net income attributable to RPSFT to continue to decline as the assets held by RPCT mature. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Key Developments and Upcoming Events Relating to Our Portfolio</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below: </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Products </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Cystic fibrosis franchise.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Vertex announced EC approval for Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 and older who have at least one F508del mutation.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Vertex announced that the FDA approved Trikafta for the treatment of children with cystic fibrosis ages 6 through 11 who have at least one F508del</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mutation or have certain mutations that are responsive to Trikafta based on in vitro data. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Vertex announced that the EC granted approval for the label expansion of Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2022, Vertex announced the submission of a New Drug Application (&#8220;NDA&#8221;) with the FDA for Trikafta in patients ages 2 through 5 years. Regulatory filings were also submitted with the European Medicines Agency (&#8220;EMA&#8221;) and the Medicines and Healthcare products Regulatory Agency. Vertex has indicated it expects an FDA decision on its Trikafta NDA patients ages 2 through 5 years in the second quarter of 2023, with a PDUFA target action date of April 28, 2023.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tysabri. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a complete response letter from the FDA for its supplemental biologics license application for subcutaneous Tysabri. The complete response letter indicated that the FDA was unable to approve Biogen&#8217;s filing as submitted. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, Biogen announced results from Phase 3b NOVA study evaluation every six-week dosing with Tysabri intravenous administration in relapsing-remitting multiple sclerosis. Results show that every six-week Tysabri intravenous administration provides a high level of efficacy in controlling multiple sclerosis disease activity in patients who switched from the approved every four-week dosing regimen. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Imbruvica. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Johnson &amp; Johnson announced Phase 3 GLOW study results for fixed-duration Imbruvica in combination with Venetoclax demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of chronic lymphocytic leukemia. The study also showed improved duration of remission and significantly improved depth of remission. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Johnson &amp; Johnson announced primary results from the Phase 3 SHINE study, which demonstrated that the combination of once-daily oral Imbruvica plus bendamustine-rituximab (BR) and rituximab maintenance significantly reduced the risk of disease progression or death by 25% compared to patients who received placebo plus BR and rituximab maintenance in patients aged 65 years or older with newly diagnosed mantle cell lymphoma. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, AbbVie and Johnson &amp; Johnson announced that the FDA approved Imbruvica for the treatment of pediatric patients one year and older with chronic graft-versus-host disease.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, Johnson &amp; Johnson announced that the EC granted marketing authorization for the expanded use of Imbruvica in an all-oral, fixed-duration treatment combination with venetoclax for adults with previously untreated chronic lymphocytic leukemia. The approval is based on the pivotal Phase 3 GLOW study and the fixed-duration cohort of the Phase 2 CAPTIVATE study.  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Xtandi. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, Astellas and Pfizer announced that the EC approved Xtandi for the treatment of patients with metastatic hormone-sensitive prostate cancer. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Astellas and Pfizer announced that Xtandi plus androgen deprivation therapy reduced the risk of death by 34% compared to placebo plus androgen deprivation therapy in the Phase 3 ARCHES study in men with metastatic hormone-sensitive prostate cancer. The primary results from the ARCHES trial were published in 2019.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, Pfizer announced positive top-line results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi compared to placebo plus Xtandi in men with metastatic castration-resistant prostate cancer. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival. The safety of Talzenna plus Xtandi was generally consistent with the known safety profile of each medicine. Pfizer intends to share data with global regulatory authorities to potentially support a regulatory filing.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2023, Astellas indicated that there could be a potential readout of the Phase 3 EMBARK trial for high-risk non-metastatic prostate cancer in the first quarter of 2023.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Nurtec ODT. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, Biohaven announced that the FDA approved Nurtec ODT for the preventative treatment of migraine, indicated for adult patients with episodic migraine who experience less than 15 headache days per month.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2022, Pfizer and Biohaven announced that the EC has granted marketing authorization for Vydura (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Pfizer acquired all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash for a total of approximately $11.6 billion. Pfizer also made payments at closing to settle Biohaven&#8217;s third-party debt and to redeem Biohaven&#8217;s outstanding redeemable preferred shares.</span></div><div style="padding-left:45pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Trodelvy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Gilead announced the FDA granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase 3 ASCENT study. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Gilead announced that the FDA granted an accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Gilead announced superior outcomes to standard of care in second-line treatment of metastatic TNBC in the Phase 3 ASCENT study. Trodelvy more than doubled overall survival as a second-line treatment in the new ASCENT subgroup analysis. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Gilead announced a collaboration with Merck &amp; Co. to investigate Trodelvy in combination with Keytruda as a first-line treatment for people with locally advanced or metastatic TNBC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC&#8217;s decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician&#8217;s choice of chemotherapy.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck &amp; Co. to evaluate the combination of Trodelvy and Merck &amp; Co.&#8217;s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck &amp; Co. will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, Gilead and Merck &amp; Co. established an agreement where Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Gilead announced results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy versus physicians&#8217; choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint of progression-free survival with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death. The first interim analysis of the key secondary endpoint of overall survival demonstrated a trend in improvement. Patients will be followed for a subsequent overall survival analysis. The safety profile for Trodelvy was consistent with prior studies.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2022, Gilead announced positive overall survival results from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator physicians&#8217; choice of chemotherapy in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy. The TROPiCS-02 study met its primary endpoint of progression-free survival earlier this year, and demonstrated improved median progression-free survival in both HER2-low and IHC0 groups.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2023, Gilead announced the U.S. FDA approved Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Cabometyx. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb&#8217;s Opdivo. The approval was based on the Phase 3 CheckMate -9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, Exelixis announced that their partners Takeda and Ono received approval in Japan for Cabometyx in combination with Opdivo for the treatment of unresectable or metastatic RCC. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer, which included patients with metastatic castration-resistant prostate cancer who had been previously treated with novel hormone therapies enzalutamide or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis announced that it will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. Exelixis believes that CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Exelixis announced FDA approved Cabometyx for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. The approval was based on the Phase 3 COSMIC-311 pivotal trial.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, Exelixis announced results from the final analysis of the second primary endpoint of overall survival from the Phase 3 COSMIC-312 trial, which evaluated cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The final analysis showed neither improvement nor detriment in overall survival for cabozantinib in combination with atezolizumab versus sorafenib.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Ipsen announced that it received approval from the EC for Cabometyx as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Exelixis announced detailed results from COSMIC-313, an ongoing Phase 3 trial evaluating Cabometyx, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, which met its primary endpoint, demonstrating significant improvement in progression-free survival at the primary analysis. At a prespecified interim analysis for the secondary endpoint of overall survival, the combination of Cabometyx, nivolumab and ipilimumab did not demonstrate a significant benefit. Following discussions with FDA, Exelixis does not intend to submit a supplemental NDA based on currently available data, but will plan to discuss a potential regulatory submission with FDA when results of the next overall survival analysis are available.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, Exelixis announced that the Phase 3 CONTACT-01 study of Cabometyx in combination with atezolizumab versus docetaxel in patients with metastatic non-small cell lung cancer without actionable mutations who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy, did not meet its primary endpoint of overall survival at the final analysis. Detailed findings from CONTACT-01 are expected to be submitted for presentation at a future medical meeting.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exelixis has indicated it expects Phase 3 data in the first half of 2023 from CONTACT-03 in advanced or metastatic RCC and in the second half of 2023 from CONTACT-02 in metastatic castration-resistant prostate cancer. Additionally, the next overall survival analysis from COSMIC-313, the Phase 3 trial in advanced intermediate- or poor-risk RCC, is expected in 2023.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Evrysdi. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Roche announced that the EC approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four splicing modifier of motor neuron 2 copies. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Evrysdi was approved in Japan for the treatment of SMA. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, Roche announced that the FDA has approved a label extension for Evrysdi to include infants under two months old with SMA. The approval is based on the interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic infants treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Orladeyo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic hereditary angioedema (HAE) medication approved in the region.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, BioCryst announced that the EC approved Orladeyo for the prevention of recurrent HAE attacks in patients 12 years and older. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, BioCryst announced approval of Japanese National Health Insurance System price listing of Orladeyo for prophylactic treatment of HAE.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Oxlumo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the FDA accepted Alnylam&#8217;s supplemental NDA for lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1. The FDA has set an action date for October 6, 2022. Additionally, a Type II Variation for lumasiran to amend the label in patients with advanced primary hyperoxaluria Type 1 was submitted and validated by the EMA in December 2021. </span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Alnylam announced that the FDA approved a label expansion for Oxlumo, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of Oxlumo in patients with severe renal impairment, including those on hemodialysis.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tremfya. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, Johnson &amp; Johnson announced results from the Phase 2a VEGA proof-of-concept study. Results showed that the combination of Tremfya and golimumab, a tumor necrosis factor-alpha antagonist, induced higher rates of clinical response, clinical remission, endoscopic improvement and a composite histologic-endoscopic endpoint at 12 weeks than either treatment alone in adults with moderately to severely active ulcerative colitis. Rates of adverse events were comparable among treatment groups.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Johnson &amp; Johnson announced results from the Phase 2b QUASAR Induction Study 1 in ulcerative colitis. Results showed that a significantly greater proportion of adults with moderately to severely active ulcerative colitis who previously had an inadequate response or intolerance to conventional therapies or selected advanced therapies and were treated with Tremfya achieved clinical response at week 12 (Tremfya 200 mg: 61.4% and Tremfya 400 mg: 60.7%), the study&#8217;s primary endpoint compared with placebo (27.6%). Safety data at week 12 was consistent with the safety profile for Tremfya in approved indications.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Johnson &amp; Johnson announced new results from the Phase 2b QUASAR Induction Study 1. Results showed that continued treatment with Tremfya in adults with moderately to severely active ulcerative colitis with inadequate responses to previous treatments allowed a mean of 52.1% of IV Tremfya week 12 clinical nonresponders to achieve clinical response at week 24. Clinical response at weeks 12 or 24 of the study was ultimately achieved by 80.2% of patients who were randomized to IV Tremfya 200mg and by 78.5% of patients who were randomized to IV Tremfya 400mg.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tazverik. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, Ipsen completed its acquisition of Epizyme. Ipsen acquired all the outstanding shares of Epizyme at a price of $1.45 per share plus a contingent value right of $1 per share.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Airsupra. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating Airsupra (albuterol/budesonide), formerly known as PT027, in patients with asthma. Airsupra is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, Airsupra demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, Airsupra showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of Airsupra in both trials was consistent with the known profiles of the components.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announced that FDA accepted for filing the NDA for AstraZeneca&#8217;s Airsupra. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation of asthma. The co-development partnership between AstraZeneca and Avillion also recently expanded to include the BATURA study, a randomized Phase 3b decentralized trial to further assess the role of Airsupra in preventing asthma exacerbations.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2022, the FDA Pulmonary-Allergy Drugs Advisory Committee voted 16 to 1 that the data support a favorable benefit risk assessment for the use of Airsupra for the treatment of asthma in people aged 18 years or older.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, AstraZeneca announced the U.S. approval of Airsupra for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development-Stage Product Candidates </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Aficamten.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In December 2021, Cytokinetics announced the FDA granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (&#8220;oHCM&#8221;) based on results from REDWOOD-HCM. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting left ventricular outflow tract pressure gradient (&#8220;LVOT-G&#8221;) as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of greater than 50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">BCX10013.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In January 2023, BioCryst announced that initial data from ongoing Phase 1 single ascending dose and multiple ascending dose trials in healthy volunteers showed rapid and sustained suppression of the alternative pathway of the complement system. BCX10013 was safe and generally well-tolerated at all doses studied to date. BioCryst plans to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria, to evaluate once-daily dosing. BioCryst expects to confirm the optimal dosing for pivotal trials by the end of the year, move directly into a pivotal trial in patients with immunoglobulin A nephropathy, and rapidly expand into pivotal trials in additional indications.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">BCX9930. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, BioCryst announced that it would discontinue the development of BCX9930 based on new competitive data recently presented at the American Society of Hematology annual meeting. BioCryst will fully focus its complement inhibitor development efforts on BCX10013, a potential once-daily, oral Factor D inhibitor currently in clinical development. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Gantenerumab.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In November 2022, Roche stated that it would discontinue clinical trials of gantenerumab after the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer&#8217;s disease did not meet their primary endpoint of slowing clinical decline. Roche continues to study trontinemab, its brain shuttle version of gantenerumab, in a Phase 2a study.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Omecamtiv mecarbil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2022, Cytokinetics announced that the FDA has accepted and filed its NDA for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction (HFrEF) who were receiving standard of care plus omecamtiv mecarbil.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, Cytokinetics announced results from METEORIC-HF, a Phase 3 trial evaluating the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity in patients with HFrEF. After 20 weeks of treatment, there was no change in peak oxygen uptake in patients treated with omecamtiv mecarbil versus placebo.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, the U.S. FDA Cardiovascular and Renal Drugs Advisory Committee voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of HFrEF. The NDA for omecamtiv mecarbil is currently under review by the FDA, with a PDUFA target action date of February 28, 2023. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Otilimab.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In October 2022, GSK announced that two of the three Phase trials met their primary endpoints, but the limited efficacy demonstrated in the ContRAst Phase 3 program did not support a suitable benefit/risk profile for otilimab as a potential treatment for rheumatoid arthritis. As a result, GSK decided not to progress with regulatory submissions.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Pelabresib.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In December 2021, MorphoSys presented data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibitor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume from baseline at week 24 and 60% (n=47) maintained a greater than or equal to 35% reduction in spleen volume at week 48. Most patients also saw their symptoms reduced, with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MorphoSys has indicated it expects topline data from the Phase 3 MANIFEST-2 study of pelabresib in myelofibrosis in early 2024.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tulmimetostat: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, MorphoSys announced preliminary Phase 1/2 results of tulmimetostat, formerly known as CPI-0209, an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1, in heavily pretreated patients with advanced cancers. Results showed responses or disease stabilization in five cohorts with evaluable patients. The safety profile of tulmimetostat was consistent with the mechanism of action of EZH2 inhibition. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Zavegepant. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Biohaven announced that it enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine. Accordingly, per the agreement with Biohaven announced in August 2020, we paid $100 million to Biohaven for the achievement of this milestone, bringing total zavegepant funding to $250 million. In October 2022, Pfizer acquired Biohaven. Pfizer expects data from the trial in the third quarter of 2023.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at two hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, Biohaven announced that the FDA accepted for review a NDA for zavegepant nasal spray for the acute treatment of migraine in adults. The PDUFA date is in the first quarter of 2023.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Results </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Non-GAAP Reconciliations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) total royalty receipts: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty cash collections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plus (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">less (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions to legacy non-controlling interests - royalty receipts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to the Legacy Investors Partnerships and RPSFT. Adjusted Cash Receipts is most directly comparable to the GAAP measure of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement (defined below) as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Payments for rebates</span><span style="color:#626c80;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the statements of cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cash Flow is defined as Adjusted EBITDA less (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Development-stage funding payments - ongoing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development-stage funding payments - upfront and milestone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest received, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in equity method investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (5) Other (including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative collateral posted, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivative collateral received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) plus (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contributions from legacy non-controlling interests - R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all directly reconcilable to the statements of cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP measures used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a discussion of our cash flow results on a GAAP basis for 2022 and 2021, refer to &#8220;Liquidity and Capital Resources.&#8221; The following is a discussion of our results on a non-GAAP basis for 2022 and 2021. For a discussion comparing our results on a non-GAAP basis for 2021 and 2020, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below includes the royalty receipts and non-GAAP financial results for 2022 and 2021 by product in order of contribution to royalty receipts for 2022 (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,231,256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,608,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">622,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,789,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,128,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">660,355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,969)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,511)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,458)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,566,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,944,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">621,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,106)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,876)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,770&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from legacy non-controlling interests - R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,235,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,573,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">661,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fully diluted Class A ordinary shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Percentage change is not meaningful. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts include quarterly redemption payments of $15.6 million in 2021 and 2022 related to the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows). In 2022, amounts also include the accelerated redemption payments of $479.5 million for all outstanding Series A and Series B Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The remaining amounts are related to royalty receipts from Nurtec ODT.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda. Our royalty receipts substantially ended in the second quarter of 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows), Cimzia, Entyvio, Gavreto, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and distributions from the Legacy SLP Interest. Other products for 2021 include a one-time milestone payment of $45.0 million that we received on Soliqua.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted Cash Receipts (non-GAAP) </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts increased by $660.4&#160;million to $2.8&#160;billion in 2022 compared to 2021, primarily driven by the accelerated redemption of all outstanding Series A and Series B Biohaven Preferred Shares received following Pfizer&#8217;s acquisition of Biohaven in October 2022. We also saw an increase in royalty receipts from the cystic fibrosis franchise and new assets acquired in 2022, primarily Trelegy. The increase was partially offset by a decline in royalty receipts from maturing royalties, such as the HIV franchise and Januvia, Janumet and other DPP-IVs, as well as unfavorable foreign exchange movements. The increase in Adjusted Cash Receipts was further driven by a decrease in distributions of royalty receipts to legacy non-controlling interests due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below we discuss the key drivers of royalty receipts. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Royalty Receipts</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:19pt">Cystic fibrosis franchise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $108.9&#160;million in 2022 compared to 2021. The increase was primarily driven by the strong uptake of Kaftrio in countries outside the United States and the performance of Trikafta in the United States, including its uptake in children 6 through 11 years old.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Nurtec ODT/Biohaven payment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211; Royalty receipts from Nurtec ODT, which is marketed by Pfizer for the acute treatment of migraine, were $17.6&#160;million and the redemption payments on Biohaven Series A and Series B Preferred Shares were $542.0&#160;million in 2022. The increase of $9.9&#160;million in royalty receipts from Nurtec ODT compared to 2021 was driven by strong volume growth. The increase of $479.5&#160;million in redemption payments compared to 2021 was driven by the accelerated redemption payments for all outstanding Series A and Series B Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tysabri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, were relatively consistent in 2022 compared to 2021.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Imbruvica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson &amp; Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by $40.2&#160;million in 2022 compared to 2021. The decrease was largely due to increased competition in the chronic lymphocytic leukemia market and a decrease in new patient starts in the United States relative to pre-COVID levels.  </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Xtandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $28.6&#160;million in 2022 compared to 2021, primarily driven by demand across various prostate cancer indications and a true-up of royalties from prior periods.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Promacta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia (ITP) and aplastic anemia, increased by $8.0&#160;million in 2022 compared to 2021. This growth was largely driven by increased use in chronic ITP and further uptake as first-line treatment for severe aplastic anemia in the United States.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tremfya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Tremfya, which is marketed by Johnson &amp; Johnson for the treatment of plaque psoriasis and active psoriatic arthritis, increased by $61.6&#160;million in 2022 compared to 2021. The increase was largely driven by market growth and continued market share gains. We acquired the Tremfya royalty in July 2021 and we began to record royalty receipts in the third quarter of 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Trelegy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; Royalty receipts from Trelegy, which is marketed by GSK for the maintenance treatment of chronic obstructive pulmonary disease and asthma, were $89.9&#160;million in 2022, primarily due to strong patient demand across all regions and growth of the single inhaler triple therapy market. We acquired the Trelegy royalty in July 2022 and we began to record royalty receipts in the third quarter of 2022.</span></div><div style="padding-left:9pt;text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Januvia, Janumet, Other DPP-IVs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from the DPP-IVs for type 2 diabetes, which include Januvia and Janumet, both marketed by Merck &amp; Co., decreased by $78.2&#160;million in 2022 compared to 2021. Royalty receipts from Januvia, Janumet and other DPP-IVs substantially ended in the second quarter of 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Cabometyx/Cometriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, increased by $21.7&#160;million in 2022 compared to 2021. The increase was primarily due to the uptake of Cabometyx in combination with Opdivo as a first-line treatment for patients with advanced renal cell carcinoma, including longer duration of therapy. We acquired the Cabometyx/Cometriq royalty in March 2021 and we began to record royalty receipts in the second quarter of 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to legacy non-controlling interests - royalty receipts</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions of royalty receipts to legacy non-controlling interests decreased by $37.6&#160;million to $442.0&#160;million in 2022 compared to 2021, which positively impacted Adjusted Cash Receipts. The decrease in distributions of royalty receipts to legacy non-controlling interests is primarily due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT. Partially offsetting these decreases was a distribution to legacy non-controlling interests related to the accelerated redemption of all outstanding Biohaven Series A Preferred Shares that we received following Pfizer&#8217;s acquisition of Biohaven in October 2022. </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted EBITDA (non-GAAP)</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted EBITDA increased by $621.9&#160;million to $2.6&#160;billion in 2022 compared to 2021 as a result of the factors noted above in &#8220;Adjusted Cash Receipts (non-GAAP).&#8221; The increase was partially offset by payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, which increased in 2022 as our Operating and Personnel Payments are a fixed percentage of 6.5% of cash receipts from our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted Cash Flow (non-GAAP)</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Flow increased by $661.8&#160;million to $2.2&#160;billion in 2022 compared to 2021 primarily for the same reasons noted above in &#8220;Adjusted Cash Receipts (non-GAAP)&#8221; and &#8220;Adjusted EBITDA (non-GAAP).&#8221;</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-GAAP Reconciliations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses our performance, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in evaluating our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within our Credit Agreement (defined below). Noncompliance with the interest coverage ratio and leverage ratio covenants under the Credit Agreement (defined below) could result in our lenders requiring us to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our Credit Agreement (defined below) from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management uses Adjusted Cash Flow to evaluate its ability to generate cash from operations, the performance of the business and our performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company&#8217;s metric may not be directly comparable to another&#8217;s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The non-GAAP financial measures used in this Annual Report on Form 10-K have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted Cash Receipts, we start with the GAAP line item, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and adjust for the following items from the statements of cash flows: to add back (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which are classified as cash inflows from investing activities (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, net of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (4) Development-stage funding payments, (5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Payments for rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (7) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions to legacy non-controlling interests - royalty receipts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which represents distributions to the Legacy Investors Partnerships and RPSFT and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or, Adjusted Cash Receipts.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted EBITDA, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and adjust for the following items from the statements of cash flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (redemption of Biohaven Preferred Shares), (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which are classified as cash inflows from investing activities, (3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest received,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (4) Development-stage funding payments and (5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to legacy non-controlling interests - royalty receipts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (2) Derivative collateral posted or (received), net.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted Cash Flow, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and adjust for the following items from the statements of cash flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (redemption of Biohaven Preferred Shares), (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions from equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> classified as cash inflows from investing activities, and (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contributions from legacy non-controlling interests - R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to legacy non-controlling interests - royalty receipts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Investments in equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow data (GAAP basis)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,143,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,029,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,870,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,143,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,789,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,128,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,143,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,566,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,944,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,143,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees (2) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in equity method investees (2), (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from legacy non-controlling interests - R&amp;D (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,235,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,573,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares in 2021 and 2022 and the accelerated redemption payments of all outstanding Series A and Series B Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022 are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the statements of cash flows. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The table below shows the line item for each adjustment and the direct location for such line item on the statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statements of Cash Flows Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Contributions from legacy non-controlling interests - R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Our lenders consider all payments made to support R&amp;D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing development-stage funding payments and upfront and milestone development-stage funding payments are reported as R&amp;D funding expense in net income and are added back in aggregate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We consider all payments to fund our operating joint ventures that are performing R&amp;D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investments Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for royalties on products that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. We have established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, milestones and related assets, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we invested $2.5&#160;billion to acquire royalties, milestones and related assets. While volatility exists in the total amount of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included below are tables of investment activities over each of the last three years based on the type of investment at the acquisition date (in thousands). Announced transactions amounts reflect maximum transaction value for transactions entered into over each of the last three years. Capital deployed amounts reflect cash paid at the acquisition date and any subsequent associated contractual payments reflected in the period in which cash was paid. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Announced Transactions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Upfront payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,132,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,022,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,307,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,069,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential payments/milestones</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,442,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total announced transaction value </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,973,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,464,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,012,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,444,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital Deployed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved/marketed royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,726,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,819,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,404,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development-stage royalties (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total capital deployed</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,488,835</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,517,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,650,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,298,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Development-stage royalties include: direct R&amp;D funding arrangements and funding arrangements executed through our joint venture partnership with the Avillion Entities, investments in development-stage product candidates and investments in securities primarily made in connection with acquisitions of royalties on development-stage products from the seller. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Summary of Royalty Acquisition Activity </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2023, we acquired royalty interests in Spinraza and pelacarsen from Ionis for an upfront payment of $500 million and committed up to $625 million in additional payments contingent upon the achievement of certain pelacarsen milestones. Spinraza is approved for the treatment of spinal muscular atrophy and pelacarsen is in Phase 3 development by Novartis for the treatment of cardiovascular disease.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2022, we acquired a royalty interest in olpasiran from Arrowhead Pharmaceuticals for an upfront payment of $250 million and certain contingent clinical, regulatory, and sales-based milestones of up to $160 million. Olpasiran is currently in Phase 3 development for the treatment of atherosclerotic cardiovascular disease and is licensed to Amgen.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2022, we entered into a R&amp;D funding agreement with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. We funded $50 million upon closing, and if Merck decides to proceed with Phase 3, we have the option to fund up to an additional $375 million. In exchange, we are eligible to receive milestone payments associated with certain regulatory approvals as well as royalties on annual worldwide sales of any approved product. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy for an upfront payment of $1.31 billion and up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2022, we acquired an ex-U.S. royalty interest in Gavreto from Blueprint Medicines for an upfront payment of $175 million and contingent sales-based milestones up to $165 million. During the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $182.1&#160;million.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, we acquired common stock and a revenue participation right from ApiJect Holdings, Inc. for $50 million. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, we acquired a royalty interest in aficamten, a development-stage product for oHCM, for an upfront payment of $50&#160;million and two additional contingent $50&#160;million payments which are triggered upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. In February 2022, one of the $50 million contingent milestone payments was triggered following Cytokinetics&#8217; announcement that it initiated the clinical trial for oHCM. Additionally, we entered into a funding agreement to provide Cytokinetics long-term capital of up to $300&#160;million (&#8220;Cytokinetics Commercial Launch Funding&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50&#160;million that was funded upon closing. In June 2022, we amended the funding agreement to increase the required draw amount and further amended the funding agreement in December 2022 to extend the draw periods and increase the repayments terms of the second and third tranche.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846 thousand shares of BioCryst common stock, which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, we announced a long-term strategic funding partnership with MorphoSys to support its acquisition of Constellation Pharmaceuticals, Inc. (&#8220;Constellation&#8221;), which closed on July 15, 2021. We agreed to provide up to $2.025&#160;billion of funding to MorphoSys, comprised of an upfront payment of $1.425&#160;billion, additional milestone payments of up to $150&#160;million, up to $350&#160;million of capital (&#8220;Development Funding Bonds&#8221;) in exchange for royalties and fixed payments on the Development Funding Bonds, once drawn. In connection with the closing of its acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition. In September 2022, we funded $300 million under the Development Funding Bonds. In the fourth quarter of 2022, we recognized impairment charges of $433.7&#160;million related to otilimab and gantenerumab, two of the development stage products that we acquired royalties on from MorphoSys.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, we acquired a royalty interest in Oxlumo from Dicerna Pharmaceuticals, Inc. for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. Oxlumo, which has been approved by the FDA and EMA for the treatment of primary hyperoxaluria type 1, is marketed by Alnylam.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GSK for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the United States and Europe.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson &amp; Johnson. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in April 2021, we entered into an agreement with MSCI to develop thematic life sciences indexes. In return, we will receive a portion of MSCI&#8217;s revenues from those indexes. The financial impact associated with this transaction was not material in 2022.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary source of liquidity is cash provided by operations. For 2022 and 2021, we generated $2.1&#160;billion and $2.0&#160;billion, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We believe that our existing capital resources, cash provided by operating activities and access to our undrawn Revolving Credit Facility (defined below) will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&amp;D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&amp;D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In July 2021, we issued $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of December 31, 2022. As of December 31, 2022 and 2021, the par value of our total outstanding borrowings was $7.3&#160;billion. A summary of our borrowing activities, balances and compliance with certain debt covenants under various financing arrangements is included in Note 11&#8211;Borrowings within the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control. </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following table and analysis of cash flow changes presents a summary of our cash flow activity for 2022 compared to 2021 (in thousands). For a discussion of cash flow activities for 2021 compared to 2020, please refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,143,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,029,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,870,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,329,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Analysis of Cash Flow Changes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities increased by $126.4&#160;million in 2022 compared to 2021, primarily driven by an increase in cash collections from financial royalty assets of $191.4 million. The increase in royalty receipts was partially offset by lower cash collections from intangible assets of $78.2 million, as our royalty receipts on Januvia, Janumet and other DPP-IVs substantially ended in the second quarter of 2022, and higher interest paid of $39.7&#160;million, primarily due to the interest payments made on the 2021 Notes commencing in 2022.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investing Activities</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities decreased by $840.9&#160;million in 2022 compared to 2021, primarily driven by a $449.9&#160;million decrease in cash used for acquisitions of financial royalty assets and the $479.5 million receipt of accelerated redemption payments for all outstanding Series A and Series B Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The lower use of cash was further driven by a $156.2&#160;million increase in the overall net cash provided by marketable securities and higher proceeds from equity securities in 2022. The lower use of cash was partially offset by the funding of $300 million under the Development Funding Bonds with MorphoSys in 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash used in financing activities in 2022 was $944.9&#160;million compared to cash provided by financing activities of $385.1&#160;million in 2021, driven by $1.3&#160;billion in net proceeds received from the 2021 Notes issuance in July 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sources of Capital </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, our cash and cash equivalents and marketable securities totaled $1.7&#160;billion and $24.4 million, respectively. As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5&#160;billion and $581.9 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Borrowings </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our borrowings as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2021 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total senior unsecured debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,116,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,118,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 26, 2021, we issued the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the &#8220;2020 Notes&#8221;) with a weighted average coupon rate of 2.13% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. We refer to the 2020 Notes and 2021 Notes, collectively, as the &#8220;Notes.&#8221; Indentures governing the Notes contain certain covenants with which we were in compliance as of December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the &#8220;Credit Agreement&#8221;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. The Credit Agreement contains certain customary covenants, which we were in compliance with as of December 31, 2022. The Revolving Credit Facility remains undrawn and available to us as of December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uses of Capital </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisitions of Royalties </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Synthetic Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales by the developer or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&amp;D for biopharmaceutical companies in exchange for future royalties and milestones if the product or indication we are funding is approved. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Launch and Development Capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">M&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities such as our strategic alliance with MSCI to develop thematic life sciences indexes.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Distributions to Shareholders</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid dividends to holders of our Class A ordinary shares of $333.3 million and $285.2 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and 2021, respectively. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Funding Arrangements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, we entered into a long-term funding agreement with Cytokinetics to provide up to $300 million of capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) available in five tranches to support Cytokinetics for further development of aficamten and potential commercialization of omecamtiv mecarbil. We funded the initial tranche of $50 million of the Cytokinetics Commercial Launch Funding upon closing. During 2022, we amended the funding agreement to increase the required draw amount, extend the draw period and modify the return for the second and third tranches. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of December 31, 2022, we expect $125 million of the optional $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may have other funding arrangements where we are contractually obligated to fund R&amp;D activities performed by our development partners. We also have funding arrangements related to our equity method investments in the Avillion Entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital, which approximates $43.8&#160;million as of December 31, 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. These contingent milestone payments are not considered contractual obligations. In 2022, we made a $50 million milestone payment to Cytokinetics which was triggered following Cytokinetics&#8217; announcement that it initiated the first pivotal clinical trial in oHCM. In </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, we made a $100 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Service </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As of December 31, 2022, the future principal and interest payments under our Notes over the next five years and thereafter are as follows (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,300,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,691,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes unamortized debt discount and issuance costs of $183.7&#160;million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Personnel Payments</span></div><div style="padding-left:13.5pt;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments are determined based on cash receipts, the amounts are variable. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantor Financial Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the &#8220;Guarantor Subsidiary&#8221;). Our remaining subsidiaries (the &#8220;Non-Guarantor Subsidiaries&#8221;) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of December 31, 2022, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3&#160;billion and $7.1&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following financial information presents summarized combined balance sheet information as of December 31, 2022, and summarized combined statement of operations information for 2022 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings&#8217; most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of December 31, 2022 or for the year ended 2022 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.632%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Summarized Combined Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current intercompany notes receivable due from Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">269,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,986,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,053,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current intercompany notes payable due to Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">269,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6,118,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current intercompany notes payable due to Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,655,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Summarized Combined Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">208,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">192,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our most critical accounting policies relate to our financial royalty assets and the full descriptions can be found in Note 2&#8211;Summary of Significant Accounting Policies to our consolidated financial statements. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. These estimates and judgments arise because of the inherent uncertainty in predicting future events.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate for the current period is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Factors Impacting Expected Future Cash Flows</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts and timing of forecasted expected future cash flows are largely influenced by sell-side equity research analyst coverage, commercial performance of the product and the royalty duration.</span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:19pt">Analyst coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends and available sell-side equity research analyst consensus sales estimates. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:19pt">Commercial performance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and for which sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:19pt">Royalty duration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant Assumptions Applied in Developing Forecasted Expected Future Cash Flows</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most significant assumptions used in forecasting the expected future cash flows for our royalties and requiring management&#8217;s judgement include (1) estimates of the duration of the royalty and (2) sales trends and product growth rates in outer years of the royalty term, which are primarily derived from statistical models. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty duration is important for purposes of accurately measuring interest income over the life of a financial royalty asset. In making assumptions around the royalty duration for terms that are not contractually fixed, management considers the strength of existing patent protection, timing for expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalty-bearing pharmaceutical products have limited or no coverage by sell-side equity research analysts, or where sell-side equity research analyst estimates are not available for the full term of our royalty, particularly for the later years in a product&#8217;s life, we generally incorporate a statistical curve developed using historical sales data and available consensus sales projections to forecast product sales over the remaining life of the product. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we believe interest income from financial royalty assets and the associated non-cash provision for changes in future cash flows are not indicative of our near-term financial performance and should not be used as a source for predicting future income or growth trends, changes in the aforementioned assumptions could result in a material impact to our financial statements. A shortened royalty term can result in a reduction in interest income, significant reductions in total royalty payments over time compared to expectations or a permanent impairment. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected) this would result in the immediate recognition of non-cash provision expense even though the applicable cash inflows will not be realized for many years into the future. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below is a summary of the sensitivity of our current year results in relation to the royalty duration for our top three financial royalty assets based on net carrying value as of December 31, 2022. Because these are long-dated financial royalty assets, we have assumed a change of two years in the estimated duration to sensitize the financial statement impact. The effect of a change in estimated duration is the factor that would have the most significant impact on our consolidated statement of operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have not been any significant changes to the estimated duration of expected future cash flows for our top three financial royalty assets during 2022, 2021 and 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the duration of these financial royalty assets were extended two years by assuming the statistically projected growth trends continue and all other royalty terms and assumptions remain unchanged, any impact to interest income would be recognized prospectively over the remaining expected life of the financial asset. Therefore, the impact to interest income is not disclosed below. However, an extended duration for a financial royalty asset could result in the reduction of any existing cumulative allowance for changes in expected future cash flows, which would be recognized in the current period as provision income and is reflected in the table below for these top three financial royalty assets. If the duration for these financial royalty assets were reduced by two years by eliminating the corresponding forecasted expected future cash flows in that two year period while keeping all other royalty terms and assumptions unchanged, we would recognize immediate incremental provision expense in the current period as a result of applying the prospective method of the effective interest rate methodology. The extension and reduction in royalty terms are modelled in isolation for purposes of the sensitivity disclosures below and does not include any consideration of the related allowance for current expected credit losses. The measurement of interest income from our financial royalty assets is recalculated each reporting period, which requires updates to various inputs and assumptions, including estimated royalty duration. Therefore, any actual impact to recognition of provision income or expense would be different than the sensitivity disclosure below. The impact of these sensitivity assumptions is summarized as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Duration Assumption Applied </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision Income for Changes in Expected Cash Flows</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Duration Assumption Applied</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision Expense for Changes in Expected Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;+ 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,908)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;- 2 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+ 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;- 2 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+ 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;- 2 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 2&#8211;Summary of Significant Accounting Policies to our consolidated financial statements for additional information on recently issued accounting standards. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Market Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the nature of the marketable securities we hold. In order to manage our exposures, we follow established risk management policies and procedures, including the use of derivative financial instruments, such as swaps, rate locks and forwards. We do not enter into derivative instruments for trading or speculative purposes. The counterparties to these contracts are all major financial institutions. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign Currency Exchange Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. The current portion of Financial royalty assets accounts for the most common type of transactional exposure. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. In addition, certain products pay royalties in currencies other than U.S. dollars, which also creates foreign currency risk primarily with respect to the Euro, British pound, Canadian dollar, Swiss franc and Japanese yen, as our functional and reporting currency is the U.S. dollar. To manage foreign currency exchange risk, we may periodically utilize non-deliverable forward exchange or other hedging contracts. We do not currently have any foreign exchange contracts in place. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Rate Risk </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to interest rate fluctuation exposure through our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. As of December 31, 2022, we held cash and cash equivalents of $1.7 billion, of which $1.7&#160;billion was cash and $5.1&#160;million was invested in interest-bearing money market funds. We also held $24.4 million in marketable securities at December 31, 2022, which were invested in certificates of deposit and government securities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, we had cash and cash equivalents of $1.5 billion, of which $887.8 million was cash, $598.3 million was invested in interest-bearing money market funds and $55.0 million was invested in commercial paper and certificates of deposit. We also held $581.9 million in marketable securities which were invested in commercial paper and certificates of deposit. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The objectives of our investment policy are the preservation of capital and fulfillment of liquidity needs. In order to maximize income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income and debt securities. Because of the short term maturities of our cash equivalents and the short term nature of our marketable securities, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents or marketable securities. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our debt portfolio is managed on a consolidated basis and management makes financing decisions to achieve the lowest cost of debt capital and to maximize portfolio objectives. As of December 31, 2022, 100% of our outstanding debt has fixed interest rates. We have a $1.5 billion Revolving Credit Facility with a variable interest rate that remained undrawn as of December 31, 2022. We are subject to interest rate fluctuation exposure related to the Revolving Credit Facility, if drawn. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may manage our exposure to interest rate volatility on future debt issuances by entering into treasury rate lock contracts to lock in the rate on the interest payments related to anticipated debt issuances. In June 2021, we executed treasury rate lock contracts with notional amounts totaling $600.0 million to fix the interest rate on a portion of the principal related to our 2021 Notes issued in July 2021. The treasury lock contracts were terminated in July 2021.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit and Counterparty Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to credit risk related to the counterparties with which we do business. We are subject to credit risk from our royalty assets, our receivables and our financial instruments, primarily derivative and available for sale debt securities. The majority of our royalty assets and receivables arise from contractual royalty agreements that pay royalties on the sales of underlying pharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading biopharmaceutical industry participants, including, among others, AbbVie, Amgen, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/Genentech and Vertex. For 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31% and 32% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, representing the largest individual marketer and payor of our royalties. Refer to &#8220;Understanding Our Results of Operations&#8221; within this MD&amp;A for a discussion of the royalty payors accounting for 10% or more of our total income and other revenues for 2022 and 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements, derivative financial instruments, and available for sale debt securities so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets or available for sale debt securities or on the settlement of our derivative financial instruments. If a counterparty becomes bankrupt, or otherwise fails to perform its obligations under a derivative financial instruments due to financial difficulties, we may experience significant delays in obtaining any recovery under the derivative financial instruments in a bankruptcy or other reorganization proceeding. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_91"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Index to Audited Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_94">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> (PCAOB ID: <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85MS9mcmFnOjBiMjI4MWVjYjhiNzQyYTlhYTcyZDFiZGFjMmY0NmY3L3RhYmxlOjVlMGFkMWY5YjM3ODRhOGZiNWQwODI3YjQxYmVhMGMzL3RhYmxlcmFuZ2U6NWUwYWQxZjliMzc4NGE4ZmI1ZDA4MjdiNDFiZWEwYzNfMC0wLTEtMS0xMzM2NjgvdGV4dHJlZ2lvbjo1MWRkMjNkMjU1ZWY0ZTAyOTI1MjM4ZmFlZGU2ZTgyOV83Mg_97521820-2e79-41fd-b149-f9e17d1ad979">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_94">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_97">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_97">91</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_100">Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_100">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_103">Consolidated Statements of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_103">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_106">Consolidated Statements of Shareholders&#8217; Equity for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_106">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_109">Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_109">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_112">Notes to Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7624980bc44b4db29e5ea00d25f439ff_112">97</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of Royalty Pharma plc</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Royalty Pharma plc (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 15, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation of Financial Royalty Assets and related Interest Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As disclosed in Note 6 to the consolidated financial statements, the Company&#8217;s total financial royalty assets, net, were carried at $14,184,425 thousand as of December 31, 2022. For the year ended December 31, 2022, the Company recognized income from financial royalty assets of $2,125,096 thousand. As explained in Note 2 to the consolidated financial statements, the Company&#8217;s financial royalty assets are measured at amortized cost using the prospective effective interest rate method.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing the valuation of the financial royalty assets and related interest income involved complex auditor judgment, because the assumptions used by management to forecast the expected cash flows from the underlying royalties are forward-looking and are therefore affected by future economic and market conditions, such as the impact of the entry of competing or generic products to the market, among other uncertainties. The key assumptions used in the valuation of the financial royalty assets and related interest income are product growth rates applied to forecasted sales in the later years in the royalty life and the royalty duration.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls related to the valuation of financial royalty assets and related interest income. This included testing controls over management&#8217;s review of the significant assumptions and other inputs used in estimating the royalty duration and product growth rates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above. For example, with the support of statistical modelling specialists, we evaluated management&#8217;s statistical methodology for sales growth forecasts and performed sensitivity analysis over the resulting forecasted product sales. We also tested the inputs to the model, principally comprising historic product sales and third-party analyst estimates of nearer-term sales amounts, by comparing to analyst reports or published sales information. For royalty duration, among other procedures, we compared management&#8217;s assessment of the likely date of expiry of the Company&#8217;s cash flows against original purchase agreements, as well as independently assessing the royalty duration against available published information sources, such as those from regulatory bodies, counterparties, and product marketers.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We assessed the historical accuracy of management&#8217;s estimates by comparing expected cash flows to actual cash receipts. We also evaluated the related disclosures in the consolidated financial statements.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">/s/ <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5MA_45b51f95-b290-4a3c-96a0-e86fd79b8aff">Ernst &amp; Young LLP</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have served as the Company&#8217;s auditor since 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5MQ_28aa2426-64fc-433d-9376-168ac9473444">New York, New York</ix:nonNumeric></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 15, 2023</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the Shareholders and the Board of Directors of Royalty Pharma plc</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited Royalty Pharma plc&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Royalty Pharma plc (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 15, 2023 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">/s/ <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5Mg_d2633a45-1cb7-4f95-9b92-06c0d6379bfd">Ernst &amp; Young LLP</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY4OQ_2ed13444-6a02-499f-ad0e-1df930afdb6a">New York, New York</ix:nonNumeric></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 15, 2023</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except par value)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNC0xLTEtMS0xMzM2Njg_f5facb7c-3494-4e4d-8518-3d3846890182">1,710,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNC0zLTEtMS0xMzM2Njg_b3fa924c-4c12-457d-a25a-efdddfb9536f">1,541,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNi0xLTEtMS0xMzM2Njg_0c73bbea-d075-4f73-87fe-6ce935498ccd">24,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNi0zLTEtMS0xMzM2Njg_d28d87f2-aa76-4d85-b6a3-969c97a3b308">581,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNy0xLTEtMS0xMzM2Njg_6fac4180-0842-4db8-9913-aeaedcf04d90">691,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNy0zLTEtMS0xMzM2Njg_932d5589-aaf1-481c-9153-1b41098a8474">614,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfOC0xLTEtMS0xMzM2Njg_03564153-b3f1-41ed-ac31-965a48c4a118">16,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfOC0zLTEtMS0xMzM2Njg_15453630-8516-4a9e-a995-0c10cba522c8">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTAtMS0xLTEtMTMzNjY4_5e7b84d4-25a7-4bdd-865d-f8bdf6fd3a66">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTAtMy0xLTEtMTMzNjY4_03f97110-e39c-494b-a673-c10af1319828">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTItMS0xLTEtMTMzNjY4_ad1d3a48-617e-478b-9f42-d0eeee07cb48">19,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTItMy0xLTEtMTMzNjY4_2de0600f-babd-44d3-9e55-d419342a1a33">15,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTMtMS0xLTEtMTMzNjY4_ff9bfa4e-a773-4cc0-a30d-aff0569637b7">90,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTMtMy0xLTEtMTMzNjY4_823c884e-f956-4086-976b-0b7144ea840a">6,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTQtMS0xLTEtMTMzNjY4_4c4eb8a1-468a-4c6c-8a81-3ed556bef652">2,554,908</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTQtMy0xLTEtMTMzNjY4_c40b52e5-0cd6-4283-8dab-011cf64cfcc0">2,878,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTYtMS0xLTEtMTMzNjY4_a7c5b01c-4ab8-4d7a-8d76-b7656fc725a8">13,493,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTYtMy0xLTEtMTMzNjY4_6c98f6fa-3a5e-4c1a-aeca-7ba7d926c7bf">13,718,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible royalty assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTctMS0xLTEtMTMzNjY4_66b1122e-22b9-478c-a489-aacedc85dc61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTctMy0xLTEtMTMzNjY4_b578bec7-e1f4-4b3e-90dc-2e8d65e03693">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTgtMS0xLTEtMTMzNjY4_0c0dfbd5-69aa-4114-a6e3-d9d3e83d0833">112,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTgtMy0xLTEtMTMzNjY4_ec102f72-a2db-4aa8-8705-7b0d4a0a193f">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTktMS0xLTEtMTMzNjY4_20d192db-c495-4b53-8b09-55a3beefdb4c">226,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTktMy0xLTEtMTMzNjY4_1d0cf894-116f-42a2-9d08-7314f6b40391">204,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjEtMS0xLTEtMTMzNjY4_a10e8dc8-f8a3-42da-9a3c-f2644e575348">397,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjEtMy0xLTEtMTMzNjY4_391799a3-10b9-407a-be21-632f92329848">435,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjItMS0xLTEtMTMzNjY4_15d2b941-55dc-4f4d-95ba-3152f6fa4ac4">29,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjItMy0xLTEtMTMzNjY4_39a1e39a-8747-4f7c-bd01-d24f68dfa93b">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjQtMS0xLTEtMTMzNjY4_03919e79-91b8-4da3-bee6-c0b92c930802">16,813,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjQtMy0xLTEtMTMzNjY4_62bbfed1-387e-4d9a-b139-b9dbf41aa794">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions payable to legacy non-controlling interests</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjgtMS0xLTEtMTMzNjY4_72c51c49-eb0b-45ba-97d8-0b384b83f3a3">94,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjgtMy0xLTEtMTMzNjY4_76cef67b-17c6-4be0-abc8-fcfa4e81132b">107,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjktMS0xLTEtMTMzNjY4_eb8120ad-ef16-4f53-90b5-0a075f4824d5">7,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjktMy0xLTEtMTMzNjY4_f76148c3-2c7e-4c9c-8aad-26b585b77ca9">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzAtMS0xLTEtMTMzNjY4_77d47ef5-9700-4ca9-a52d-23c51c6ab055">54,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzAtMy0xLTEtMTMzNjY4_57d119d1-4476-4f4b-ab6c-f19221944c1b">57,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzMtMS0xLTEtMTMzNjY4_f6cdbdbf-bb53-4698-9d1e-04d76194bacd">997,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzMtMy0xLTEtMTMzNjY4_cac6c638-2c66-4d65-9a16-4605dcd2bd30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzUtMS0xLTEtMTMzNjY4_f4cd8379-e563-4dd1-9204-935f7169ca2d">12,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzUtMy0xLTEtMTMzNjY4_2a6a88f6-60cf-4fda-ad04-d3fdda4da76f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzYtMS0xLTEtMTMzNjY4_43ef7bd2-e3a0-476a-a724-c1e4cc787af6">1,166,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzYtMy0xLTEtMTMzNjY4_853c6d6b-b93f-4570-9c2f-785efbaaa403">171,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzgtMS0xLTEtMTMzNjY4_dd89248f-2395-49ee-a64b-fe1ec61cf8d6">6,118,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzgtMy0xLTEtMTMzNjY4_887c9111-e381-496e-9aad-c5480377f75c">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDAtMS0xLTEtMTMzNjY4_d713fe0f-173c-426c-acc6-df0ef800dea4">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDAtMy0xLTEtMTMzNjY4_e920607b-d791-4d3c-9d54-d1b6696247cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDItMS0xLTEtMTMzNjY4_b16fdc27-197e-46bf-b683-8a8c66c0c575">7,288,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDItMy0xLTEtMTMzNjY4_eb914729-c011-43cd-ba65-e6acd13ec2be">7,267,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDQtMS0xLTEtMTMzNjY4_be0ed706-27c7-496f-98b7-a885287dcedf"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDQtMy0xLTEtMTMzNjY4_2e2ff8ff-8b6d-4b40-b19c-753d175564f0"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class&#160;A ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfMjk_be8b00db-c196-47cf-b6ef-4c33d8b3d3fc"><ix:nonFraction unitRef="usdPerShare" contextRef="iabe3448245414e18a4b4313799d4a486_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfMjk_c9a9da05-a8c1-41fe-b343-fd197b1505e8">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iabe3448245414e18a4b4313799d4a486_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNDM_428463dc-c724-4adf-8e09-8ff538848777"><ix:nonFraction unitRef="shares" contextRef="iabe3448245414e18a4b4313799d4a486_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNDM_678aeeb9-3fc8-4616-9361-079643a33373">443,166</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNTA_281b90c5-c675-40a3-81e7-208887a70648"><ix:nonFraction unitRef="shares" contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNTA_80f618f2-98e7-43e6-8639-4629a19207aa">432,963</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe3448245414e18a4b4313799d4a486_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMS0xLTEtMTMzNjY4_abdc8129-21f5-469b-8461-45452f260fc0">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMy0xLTEtMTMzNjY4_e1d7ffb8-764b-40da-bb64-a7d62b46c07e">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class&#160;B ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfMjk_033a6e9e-71f8-4cba-afed-da1758e0d2a3"><ix:nonFraction unitRef="usdPerShare" contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfMjk_a378fd2d-dece-4d20-a38c-a87c338d58cc">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNDM_3e726c3b-17d2-4cc3-9f5b-06779b53be93"><ix:nonFraction unitRef="shares" contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNDM_af12d1df-f20c-4e9e-8e97-a1b135f0c0b2">164,058</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNTA_9bb75ace-6379-454d-b7cc-c422aa195b6c"><ix:nonFraction unitRef="shares" contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNTA_d871d1ff-9715-4947-a22d-78217f310ccd">174,213</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMS0xLTEtMTMzNjY4_056be7ad-bc3f-4a32-8227-63d9255777a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMy0xLTEtMTMzNjY4_eccae1ac-c71c-46be-8990-6e7220417cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class R redeemable shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i4a118afd54f1420497a8451111036378_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfMzE_8b551814-1d25-4844-a96a-4aa35f2476c6"><ix:nonFraction unitRef="gbpPerShare" contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfMzE_b2efa519-7e42-48e6-a125-4a16fec7b041">1</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4a118afd54f1420497a8451111036378_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNDU_3801d3fe-eedb-474f-be42-e25b40098a20"><ix:nonFraction unitRef="shares" contextRef="i4a118afd54f1420497a8451111036378_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNDU_b0d008d3-e69e-4971-8aa9-1ac8cc03b4ce">50</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNTI_781a6018-8cae-47f3-b0a4-a434cb4ac7f2"><ix:nonFraction unitRef="shares" contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNTI_ee3f9ff4-19fd-46bc-b5c5-07300c1d5875">50</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a118afd54f1420497a8451111036378_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMS0xLTEtMTMzNjY4_83d6de46-e2c3-46c8-b4f4-0269b8c2647f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMy0xLTEtMTMzNjY4_89f622ef-1bfe-4672-b004-e4583bef3f2e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMjE_6c655bfa-fb86-40a8-9dce-d07126f33db4"><ix:nonFraction unitRef="usdPerShare" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMjE_aab22686-09d0-4976-8c38-c6dc2c4d223a">0.000001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMzU_b295dae5-446b-4dbb-bc81-cfa9e27f5402"><ix:nonFraction unitRef="shares" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMzU_c112a10c-e25a-4f39-bc12-4551bc2e8e4d">371,325</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfNDI_41ed4dcc-b00c-454a-8c55-ffa9fc0d7178"><ix:nonFraction unitRef="shares" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfNDI_fef69477-a485-482a-88b3-7cefc3ea1b47">361,170</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMS0xLTEtMTMzNjY4_6e392303-8222-459a-b0ae-30948d37145d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMy0xLTEtMTMzNjY4_1fdaf359-f0b0-45e4-9f60-20f39a837975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTEtMS0xLTEtMTMzNjY4_ef00e64d-d174-4549-9a00-1c0337eecbe9">3,666,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTEtMy0xLTEtMTMzNjY4_0c07e47b-ae87-4c17-9004-07ae2c8d9c68">3,507,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTItMS0xLTEtMTMzNjY4_cf829afb-8a50-4731-903e-e50064abbdb6">1,964,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTItMy0xLTEtMTMzNjY4_315c7d90-e8f6-4b30-9fac-c06a081fbd95">2,255,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTMtMS0xLTEtMTMzNjY4_daa235ec-5320-40ba-ba73-8eb97ac724e1">3,897,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTMtMy0xLTEtMTMzNjY4_f24f0aaa-9160-42df-86fc-728c0e0e198b">4,471,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTQtMS0xLTEtMTMzNjY4_34befaa9-6a84-4028-af8f-f7fec3b3b533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTQtMy0xLTEtMTMzNjY4_fec27380-3c34-4f4b-97bd-46f0e61c8ab8">16,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTUtMS0xLTEtMTMzNjY4_a102153d-0756-4c3e-bcb0-ddb323b1e2aa">2,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTUtMy0xLTEtMTMzNjY4_fa3707c4-b3c6-498f-aec3-58dd7456a7aa">2,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTctMS0xLTEtMTMzNjY4_19cd6a98-187e-4ce2-a3df-6b56d879c69b">9,525,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTctMy0xLTEtMTMzNjY4_18f7616e-035b-4f33-bd86-1743628a457d">10,248,545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTktMS0xLTEtMTMzNjY4_2c2ead79-2439-4c72-ac46-4c7f6919039a">16,813,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTktMy0xLTEtMTMzNjY4_b6076bfb-8f8a-4d49-9ad9-cc6d12030ad2">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income and other revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92cf91b49d444b89c5ca4d63d6e997a_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtMS0xLTEtMTMzNjY4_0021544c-b1f3-4298-be72-6a0bb91a0ef8">2,125,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b14c23fc6244f59ebfbae3ac633db6_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtMy0xLTEtMTMzNjY4_b4dfa867-a864-4362-928d-cd9812c312f6">2,065,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfb9308ae154def8f8c57d02cde386a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtNS0xLTEtMTMzNjY4_79ab3fb9-d148-491a-9a33-56cdedcbc6f8">1,959,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie008f8c9d7654553948cf5d03673f74b_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtMS0xLTEtMTMzNjY4_ea0df987-1ecc-4cec-b444-62ececb2bdb5">37,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa24c4f1c1cf4fa4a7afb95c44a5b6f6_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtMy0xLTEtMTMzNjY4_df2d97c4-f286-4d0d-9f5e-9b2127f14995">171,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccebf37c46634c398d67ec2e7c9899b7_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtNS0xLTEtMTMzNjY4_bbc146e0-1c0c-45c7-a89c-4fe52c48ee7f">143,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db1d86622b54d0aa7386b802e458701_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtMS0xLTEtMTMzNjY4_2da0cadc-1eb8-4169-9401-10d032fa229a">74,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34a184452ef4fa88c4aa26700a19e27_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtMy0xLTEtMTMzNjY4_2f95c60e-809e-4d1e-bab7-2d79a745cb3d">53,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ad5247fc86440e9432a456ffbf26ab_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtNS0xLTEtMTMzNjY4_a3092614-38e6-4ef9-8cbe-85b22329a820">18,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total income and other revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtMS0xLTEtMTMzNjY4_05c58905-0353-4857-bfa4-caa6ccb3cf5f">2,237,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtMy0xLTEtMTMzNjY4_0cda0a4a-c475-4352-a78c-b4c11c76726c">2,289,463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtNS0xLTEtMTMzNjY4_ceb75dfd-8f78-4ceb-9390-c27276131f00">2,122,353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktMS0xLTEtMTMzNjY4_025ddfd2-f087-4231-a9e3-f440c5271c70">904,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktMy0xLTEtMTMzNjY4_44532908-b1f2-455d-aa98-8a6a22f06eab">452,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktNS0xLTEtMTMzNjY4_f6b6bc15-aaab-4431-baf6-287d18b5e111">230,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development funding expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTEtMS0xLTEzMzY2OA_7c97b3e3-be02-4485-8aeb-8e35d7f1f1c8">177,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTMtMS0xLTEzMzY2OA_1a71c053-b340-46bf-a774-c47fd20f328e">200,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTUtMS0xLTEzMzY2OA_6d5331e8-fc16-4011-9974-e785ab58087c">26,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTEtMS0xLTEzMzY2OA_a6cea9ac-1ad3-4ba6-96a5-faff5509e13f">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTMtMS0xLTEzMzY2OA_28969b19-41ba-4ddd-b792-3c1d6d0d8ffb">22,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTUtMS0xLTEzMzY2OA_d35bfb76-1da2-45c2-8294-ec61f63d4a83">23,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTEtMS0xLTEzMzY2OA_36694e76-c779-4133-bc7b-35581f5ea3b7">227,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTMtMS0xLTEzMzY2OA_d6db8032-b647-4912-a516-8c9f00839113">182,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTUtMS0xLTEzMzY2OA_3f1024c2-6aef-4365-a25d-6f5bc00687bc">181,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTEtMS0xLTEzMzY2OA_c3a89500-1b74-482d-ae3b-c9c612011839">615,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTMtMS0xLTEzMzY2OA_b7762781-573c-448f-b0f5-0a0ca1ec101b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTUtMS0xLTEzMzY2OA_f558745b-b43d-4da2-a35a-18aef29344b9">65,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTEtMS0xLTEzMzY2OA_68ba5276-9ca5-4851-a208-a5534b479fd5">1,930,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTMtMS0xLTEzMzY2OA_485ad893-e5f4-41e9-ae31-3362a6086f1d">858,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTUtMS0xLTEzMzY2OA_5ac9aea5-62b6-46c8-b5fb-5a1cd17708d8">526,954</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTEtMS0xLTEzMzY2OA_e96526a0-900e-4040-aaa3-c57f10c490cb">307,065</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTMtMS0xLTEzMzY2OA_c4cea92d-a910-485d-a853-0d35c018544c">1,430,715</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTUtMS0xLTEzMzY2OA_83e73dfd-ce66-4a00-a21b-ed88b49111bb">1,595,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other expense/(income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTEtMS0xLTEzMzY2OA_2bf46a31-7f1d-464f-8636-fd636d527bbf">8,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTMtMS0xLTEzMzY2OA_d7215ce3-5eb6-4663-ad33-994ea654b17a">19,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTUtMS0xLTEzMzY2OA_38530756-f098-43da-a012-afb4c4b9d717">44,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTEtMS0xLTEzMzY2OA_48e81430-833a-4305-831a-390aa3cd349d">187,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTMtMS0xLTEzMzY2OA_d18c5c54-e9ca-44d5-a2b4-13f7981dcfbc">166,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTUtMS0xLTEzMzY2OA_6d591215-2bd5-4a91-885f-8f70985d6672">157,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTEtMS0xLTEzMzY2OA_05b0477f-af8c-41ab-b93b-17b11b5a0b66">96,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTMtMS0xLTEzMzY2OA_3b8de12e-e380-48e0-a04d-99e2cd0ab0df">21,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTUtMS0xLTEzMzY2OA_9ae301aa-874e-4efe-800f-a289d714de65">42,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTEtMS0xLTEzMzY2OA_d0ed15fa-360a-41b0-a076-be06c896342e">33,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTMtMS0xLTEzMzY2OA_60d19304-d8b3-4f53-94a1-70e2e980652e">48,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTUtMS0xLTEzMzY2OA_a3f8bef2-3656-4602-bbbf-dbce227156d4">247,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTEtMS0xLTEzMzY2OA_8bb3ef57-3890-4e7b-a06d-f08df698533d">6,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTMtMS0xLTEzMzY2OA_4ed5a0d5-5394-4382-ab65-498da74f9816">17,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTUtMS0xLTEzMzY2OA_e4b7ae26-0563-4782-9848-18225f422ef9">18,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTEtMS0xLTEzMzY2OA_88e49814-eba4-4ab2-83a0-97d881566087">78,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTMtMS0xLTEzMzY2OA_de9402b5-6ada-42f7-adb6-0fedde428ca5">53,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTUtMS0xLTEzMzY2OA_4ef5ebf4-628d-49e9-8b38-573e31d20058">28,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTEtMS0xLTEzMzY2OA_e71c99ae-cf09-448f-a94e-815462f8b50f">14,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTMtMS0xLTEzMzY2OA_ddc994d4-5500-4658-9db0-ef35b220c825">5,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTUtMS0xLTEzMzY2OA_3c3cac62-14a6-453e-9135-2d77c11b6357">32,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other expenses/(income), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTEtMS0xLTEzMzY2OA_812af143-b89d-43e3-a1a8-87d9da27532b">77,001</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTMtMS0xLTEzMzY2OA_e586d9b5-1826-4043-a52b-93ec706619df">189,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTUtMS0xLTEzMzY2OA_52bf9a10-9d20-4825-b50d-b1f283b8ad59">106,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTEtMS0xLTEzMzY2OA_71681c85-6669-47b4-8bd8-65803454422f">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTMtMS0xLTEzMzY2OA_2841a79e-c45e-4b34-8a26-154ffd30d7c5">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTUtMS0xLTEzMzY2OA_9b497956-598e-47af-abec-8e9bd40c7027">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTEtMS0xLTEzMzY2OA_3bfb7ef9-5709-43d6-9639-2da07ada2677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTMtMS0xLTEzMzY2OA_d42605c3-1860-476d-a8f4-58038caa38f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTUtMS0xLTEzMzY2OA_57efd025-a8c0-4bad-a5ef-421fe176bfe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTEtMS0xLTEzMzY2OA_e79f9801-e762-47b6-9bf8-3c5eca5a36e8">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTMtMS0xLTEzMzY2OA_485bbb14-b712-446e-b785-b131601863e2">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTUtMS0xLTEzMzY2OA_eb13c7b2-73dc-4d14-922f-13bda93a4650">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTEtMS0xLTEzMzY2OA_7b3000eb-3a77-4c33-948d-6aa81f46f612">187,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTMtMS0xLTEzMzY2OA_762acff6-0ea0-4f4d-8909-52d43669ce0c">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTUtMS0xLTEzMzY2OA_d3546f6d-121d-4524-8eaa-d007b17a9449">726,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income attributable to Royalty Pharma plc</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTEtMS0xLTEzMzY2OA_8237052f-580b-4f98-bb99-455555ec5b08">42,832</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTMtMS0xLTEzMzY2OA_f1bb8ea3-8562-4577-b77a-d9d1b12b270d">619,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTUtMS0xLTEzMzY2OA_731ce9c6-8fad-40ed-b06b-7583cad6f192">975,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share (1):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average Class A ordinary shares outstanding (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9">437,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f">414,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57">375,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6">437,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425">414,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5">375,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.84pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba" footnoteRole="http://www.xbrl.org/2003/role/footnote">In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;). See Note 13&#8211;Earnings per Share.</ix:footnote></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItMS0xLTEtMTMzNjY4_e79f9801-e762-47b6-9bf8-3c5eca5a36e8">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItMy0xLTEtMTMzNjY4_485bbb14-b712-446e-b785-b131601863e2">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItNS0xLTEtMTMzNjY4_eb13c7b2-73dc-4d14-922f-13bda93a4650">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of loss on interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtMS0xLTEtMTMzNjY4_43d947b5-4474-4ab5-8699-cfdc9b9b8caa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtMy0xLTEtMTMzNjY4_50386616-3ac6-48b2-b63f-b8f99d144ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtNS0xLTEtMTMzNjY4_b6f13caf-b721-4f42-8554-ebed466cfb94">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtMS0xLTEtMTMzNjY4_0f6497eb-841e-4de8-979d-fb1580f9937f">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtMy0xLTEtMTMzNjY4_659924ae-6128-4590-be09-360273af7b1f">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtNS0xLTEtMTMzNjY4_e7886f70-22eb-4d6f-ba1e-59d210aed5f9">83,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtMS0xLTEtMTMzNjY4_4027acf5-b927-4994-a2fc-d04bdc7ec23f">53,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtMy0xLTEtMTMzNjY4_1bf72636-5848-40f3-bd96-acc54903fa5e">50,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtNS0xLTEtMTMzNjY4_e6c091e4-8890-497b-a5e6-397855f59f1e">20,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss)/income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctMS0xLTEtMTMzNjY4_84d7bb91-16ca-4fd9-948b-91affb53462f">29,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctMy0xLTEtMTMzNjY4_f4c151fa-3a81-4db8-b6a3-3b75ce4ca016">39,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctNS0xLTEtMTMzNjY4_f833a058-14eb-46cc-9bdc-b924999cfc94">66,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtMS0xLTEtMTMzNjY4_86c1a96c-288d-424b-9276-ebddb153ffaf">200,632</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtMy0xLTEtMTMzNjY4_0a757ff5-9bcc-4f33-b67d-33a610ef555d">1,201,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtNS0xLTEtMTMzNjY4_751a38e9-7d1c-457e-8c41-450f926a23c0">1,768,589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTEtMS0xLTEzMzY2OA_0b8b66cf-65b3-4e25-b8e5-937fa7ced3a9">175,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTMtMS0xLTEzMzY2OA_08b56913-8882-4898-aa1b-0732904e5382">604,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTUtMS0xLTEzMzY2OA_9c297fee-34b0-4c88-8cd7-aa65f03b9561">739,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive income attributable to Royalty Pharma plc</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTEtMS0xLTEzMzY2OA_df6c79af-e770-4362-a526-a2ec0ec79181">25,214</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTMtMS0xLTEzMzY2OA_7d23b16e-1c38-4949-b344-4a02e65fac0b">597,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTUtMS0xLTEzMzY2OA_89b8631b-8c96-4a4e-9ef8-34ef12c762fd">1,028,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">In thousands, except for share amounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.644%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unitholders&#8217;/ Shareholders&#8217; Contributions</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8885fde0c1284600a478a453d7f04c9e_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMS0xLTEtMTMzNjY4_2f6d90c4-668b-4008-9145-463ccf4ab78d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8885fde0c1284600a478a453d7f04c9e_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMi0xLTEtMTMzNjY4_27f125ff-8ec8-44ff-aa93-d791ea603422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMy0xLTEtMTMzNjY4_4d93a0e6-0a61-4ec6-9c60-5e3c6f8502a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNC0xLTEtMTMzNjY4_aef3056e-0e7d-4fb9-a5d0-c965673f662f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedb811a285154e8abc06e48048183949_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNS0xLTEtMTMzNjY4_1dde1ec2-644b-4120-8eac-a93ae3d94114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb811a285154e8abc06e48048183949_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNi0xLTEtMTMzNjY4_f8c11674-1b6e-4314-8f76-90e280fec908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b8405fbbc504757866319d871cfe818_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNy0xLTEtMTMzNjY4_85092397-3fb8-4414-80df-763ea67060ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8405fbbc504757866319d871cfe818_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktOC0xLTEtMTMzNjY4_c26bb37d-496d-47ac-87b3-60c766cbcc46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2626c942e9294d08899937a29e6df6d9_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktOS0xLTEtMTMzNjY4_f2e59bd7-470c-4d1e-9943-b3e6385cc85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21985f335d0445f5a86183ee1ff7f4b2_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTAtMS0xLTEzMzY2OA_5608b933-8ecc-4119-adf2-3dc17832b38e">3,282,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f248f1983243fd9644c279de47a32c_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTEtMS0xLTEzMzY2OA_ed3555ea-ec97-4575-8f92-e62de6feaa2d">2,825,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd0b8d23d7d46f28641ee528276a6bc_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTItMS0xLTEzMzY2OA_b3dddc25-eab5-4e64-9e57-0c7160857cb0">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTMtMS0xLTEzMzY2OA_d59a0306-0072-4715-b41d-bb1e5d6729ca">35,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e797a142c1d4e669b384c7cb83c9dee_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTQtMS0xLTEzMzY2OA_9939212c-c0cd-477c-a086-76cd373398a5">4,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6924ffcc56464af49725a154112a2c81_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTUtMS0xLTEzMzY2OA_f3ef5d04-eadf-4036-8c52-61a11beb9540">6,141,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTEwLTEtMS0xMzM2Njg_1285d94c-729c-4601-a74a-69c7f8c5b706">307,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTEzLTEtMS0xMzM2Njg_552c1152-934c-46c4-ad7e-34fe49efe242">1,174,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTE1LTEtMS0xMzM2Njg_62450973-4b27-48bb-a6f1-1fbf39119773">1,482,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231" decimals="-3" sign="-" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTEwLTEtMS0xMzM2Njg_a1fe50b4-3eb8-4f09-a4be-14ccc24733a7">1,037,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTEzLTEtMS0xMzM2Njg_aab486c9-fa36-4d1f-81f3-e7e28039c379">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTE1LTEtMS0xMzM2Njg_496f0d0d-c1d5-462c-ab84-99fcc4b5d788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTAtMS0xLTEzMzY2OA_88944e72-0e6d-43cf-9aca-c19425f17385">Cumulative adjustment for adoption of ASU 2016-13</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fbcf597b512467294d0d8a431cff682_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTExLTEtMS0xMzM2Njg_161efeb8-cb84-4ee2-80a5-4f9e0b54acea">192,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2485d51e396d457d82d53b0d720876f9_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTE1LTEtMS0xMzM2Njg_43d7dc36-3a91-4af5-b15d-2abea7622d55">192,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTExLTEtMS0xMzM2Njg_9512016b-ddfa-4921-b75a-c59ad1ef4aa4">313,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTEzLTEtMS0xMzM2Njg_2a15107a-534a-4f92-881d-adc369bc41e8">792,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTE1LTEtMS0xMzM2Njg_21db476a-3274-4b9a-8b66-8def53fc8430">1,105,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Initial share issuance upon registration of Royalty Pharma plc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231" decimals="INF" name="rprx:StockIssuedDuringPeriodSharesIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTUtMS0xLTEzMzY2OA_8e30b853-59eb-4884-b47e-d17105e4fb9c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTYtMS0xLTEzMzY2OA_079b937e-f989-4b6f-9c50-3f8edd2b9ee7">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTE1LTEtMS0xMzM2Njg_b0bdea5f-8941-415f-8391-f3769d80933a">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89cbf4efe96145bc9b29ae5fcb436732_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTExLTEtMS0xMzM2Njg_0aa9d5b5-da39-4ab6-a3a0-e9fbfb129544">479,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTEzLTEtMS0xMzM2Njg_d0256836-9d21-4b07-97a3-7ee3be690cad">145,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd60620e8d7464586752970db0211e9_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTE1LTEtMS0xMzM2Njg_e7e0a5bb-6925-4977-a4a4-1d5177966b4f">624,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class B ordinary shares to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231" decimals="INF" name="rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTMtMS0xLTEzMzY2OA_0d84c723-3f90-4d98-b491-ac0aee484e6f">535,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedToPartnerships" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTQtMS0xLTEzMzY2OA_d097c65b-a3a0-4eab-82ee-19be87e60e01">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedToPartnerships" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTE1LTEtMS0xMzM2Njg_f4032739-ea13-4167-8f34-75ed7b53bea6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="INF" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEtMS0xLTEzMzY2OA_c637f824-bd95-4714-88e0-b043e741e951">294,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTItMS0xLTEzMzY2OA_4afcd792-4162-436a-a190-8deac3a9367b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231" decimals="INF" sign="-" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTMtMS0xLTEzMzY2OA_5aae822e-a56a-4ffe-a03d-f798aa24a1e9">294,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTQtMS0xLTEzMzY2OA_dbbfc272-05df-43f6-9457-fb3e345caebf">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231" decimals="INF" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTctMS0xLTEzMzY2OA_9b648b44-e7ea-463f-a866-837bcdee30ed">294,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTktMS0xLTEzMzY2OA_9654ef7f-44f2-440d-a17a-cacc38243b27">1,402,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEwLTEtMS0xMzM2Njg_66200037-4d61-4685-b984-865acc10d865">2,553,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTExLTEtMS0xMzM2Njg_959cf0e4-a9da-4f29-9d9f-0b27ad9bd365">1,261,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEyLTEtMS0xMzM2Njg_45f0865e-3d7e-4f22-82c2-355e1f0fa457">24,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEzLTEtMS0xMzM2Njg_0f79c7af-c61e-4985-a6dd-55d7a84faa0c">2,433,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTE0LTEtMS0xMzM2Njg_2f58fbe7-85da-4aed-92a6-67425c94a076">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTE1LTEtMS0xMzM2Njg_7862a1f8-bec4-4698-8a1e-3a89a670f399">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTEtMS0xLTEzMzY2OA_7a98733f-1bc2-4cda-96d4-ce9dfc777dae">71,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTItMS0xLTEzMzY2OA_9638b7dd-7eae-42d3-be04-97851b7a1281">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTktMS0xLTEzMzY2OA_d6d2599b-2834-4d1b-af2e-e46ac0110a73">1,150,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTEzLTEtMS0xMzM2Njg_78a989d2-dac9-4760-a77a-758ae81ed72f">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTE1LTEtMS0xMzM2Njg_d9045d22-56e8-4ee3-b9a3-196a68156468">1,908,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTEtMS0xLTEzMzY2OA_626fd311-1b9d-4a59-9013-4ad198475c6b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTktMS0xLTEzMzY2OA_fa149ac5-bf76-48bf-bf92-6b9226ff0dad">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTE1LTEtMS0xMzM2Njg_e1b10c55-7dfd-43f0-a86f-6bb6216f1419">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEtMS0xLTEzMzY2OA_77b7e72b-abac-4517-96d6-1e7a87271bff">22,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTItMS0xLTEzMzY2OA_03f97a84-05df-42c0-a688-13e9a90294d3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231" decimals="INF" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTMtMS0xLTEzMzY2OA_2869a9b3-6809-4237-a8f3-1c79866890c5">22,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTctMS0xLTEzMzY2OA_c238f068-ee24-4cf7-a538-96ce9ae2fcb5">22,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTktMS0xLTEzMzY2OA_ffc551c9-9213-4af0-b368-fee02b5d54bb">307,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEyLTEtMS0xMzM2Njg_17cf0560-d767-4452-99d1-687611115883">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEzLTEtMS0xMzM2Njg_0062a84b-b772-4e98-b66f-09346af206e3">309,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTE0LTEtMS0xMzM2Njg_c8f757aa-25f6-45a4-95ae-d5e6906558fb">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTE1LTEtMS0xMzM2Njg_f4bd5a85-8ac3-43f0-be6c-db7ff6cbcac1">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOjIxNDc1OWM0NWNmYzRkYzZiNTViNTY3NzY2NzVmYWE3XzE1_71d8394e-a21f-444a-b2b8-68aa91dd878e">0.30</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTExLTEtMS0xMzM2Njg_5d61c20e-93ef-4739-9a6e-b29f6762bd98">112,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTE1LTEtMS0xMzM2Njg_4cc09c18-c5c7-4393-aa10-513e7653fe88">112,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe5497d8e994e039ef92e85073e55a8_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTExLTEtMS0xMzM2Njg_0dc3daad-e23f-4f57-9cd9-da28a4a96eab">495,198</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida16729ea6c0450498d0894c41753058_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTEzLTEtMS0xMzM2Njg_8cf6ac84-fa2b-4ad7-bb68-129ea2b0103d">581,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTE1LTEtMS0xMzM2Njg_57f1bd4c-0e13-4411-af14-ad83a5715a51">1,077,069</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of loss on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI1LTEyLTEtMS0xMzM2Njg_fa8f306f-70ad-4a4a-a296-2d6eb2d440a4">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI1LTE1LTEtMS0xMzM2Njg_3b5276f7-23db-4b30-986e-a4171417a15f">4,066</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTEyLTEtMS0xMzM2Njg_788d2100-dd45-472a-bbd0-8d3e9c12a2a4">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTEzLTEtMS0xMzM2Njg_55d847db-aadf-4584-aba2-a2d4c35d8301">22,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTE1LTEtMS0xMzM2Njg_b08620b8-7999-477b-a855-60d6aced0b39">83,120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTEyLTEtMS0xMzM2Njg_55228df1-9423-4ece-b91d-d2c4a4ef40a9">10,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTEzLTEtMS0xMzM2Njg_98edca71-5323-4d59-be2f-74e40ab0151d">9,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTE1LTEtMS0xMzM2Njg_ff377aa0-0495-4cce-bdcc-634e618b77dc">20,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEtMS0xLTEzMzY2OA_caff5455-1f57-4976-8c70-d2ca9bfb4d35">388,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTItMS0xLTEzMzY2OA_6af9867a-30f7-4361-b295-c0a7eb63b99a">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTMtMS0xLTEzMzY2OA_05451fe5-9e1c-4007-8699-dac7a1a19fcd">218,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTQtMS0xLTEzMzY2OA_f83f88b8-93f3-45a1-84eb-b5920967988a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTUtMS0xLTEzMzY2OA_6c2157d9-526f-43ab-9daa-72c0f04a858a">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTYtMS0xLTEzMzY2OA_a102d308-ea6d-4355-a5dc-3ba76a0c5e57">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTctMS0xLTEzMzY2OA_9ed89a76-0f9c-40cb-8c41-17af75749cd3">316,407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTgtMS0xLTEzMzY2OA_230449d4-31f1-4492-bb1d-f6f3bad92399">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f8305cf2864dbda8cea2f22f63e356_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTktMS0xLTEzMzY2OA_6e6c707b-3c9e-4241-9fd1-81c3ba1b12c0">2,865,964</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ea0ca2684e4b76aaeb8cfe35fffb2a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEwLTEtMS0xMzM2Njg_d3496272-a97a-468e-a96c-003457364c27">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTExLTEtMS0xMzM2Njg_bb8053ee-c8ea-40e0-b278-5e0c6bc7f973">1,920,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e0f207870b4fc7922227f8a820157a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEyLTEtMS0xMzM2Njg_3b92fa94-7445-42b2-a009-a105521ab68a">34,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEzLTEtMS0xMzM2Njg_6462d61b-a041-460c-a5d3-1200b7e302e1">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f1d98977d25401ab5199bd95b2ac683_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTE0LTEtMS0xMzM2Njg_7c92d5e0-9e40-4ec4-8759-3e3309d056b0">2,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTE1LTEtMS0xMzM2Njg_225a07f8-ac69-4c0f-ae0f-6bd1ff2e9baa">9,895,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">In thousands, except for share amounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.641%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMS0xLTEtMTMzNjY4_caff5455-1f57-4976-8c70-d2ca9bfb4d35">388,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMi0xLTEtMTMzNjY4_6af9867a-30f7-4361-b295-c0a7eb63b99a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMy0xLTEtMTMzNjY4_05451fe5-9e1c-4007-8699-dac7a1a19fcd">218,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNC0xLTEtMTMzNjY4_f83f88b8-93f3-45a1-84eb-b5920967988a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNS0xLTEtMTMzNjY4_6c2157d9-526f-43ab-9daa-72c0f04a858a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNi0xLTEtMTMzNjY4_a102d308-ea6d-4355-a5dc-3ba76a0c5e57">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNy0xLTEtMTMzNjY4_9ed89a76-0f9c-40cb-8c41-17af75749cd3">316,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItOC0xLTEtMTMzNjY4_230449d4-31f1-4492-bb1d-f6f3bad92399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f8305cf2864dbda8cea2f22f63e356_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItOS0xLTEtMTMzNjY4_6e6c707b-3c9e-4241-9fd1-81c3ba1b12c0">2,865,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTEtMS0xLTEzMzY2OA_bb8053ee-c8ea-40e0-b278-5e0c6bc7f973">1,920,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e0f207870b4fc7922227f8a820157a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTItMS0xLTEzMzY2OA_3b92fa94-7445-42b2-a009-a105521ab68a">34,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTMtMS0xLTEzMzY2OA_6462d61b-a041-460c-a5d3-1200b7e302e1">5,077,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f1d98977d25401ab5199bd95b2ac683_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTQtMS0xLTEzMzY2OA_7c92d5e0-9e40-4ec4-8759-3e3309d056b0">2,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTUtMS0xLTEzMzY2OA_225a07f8-ac69-4c0f-ae0f-6bd1ff2e9baa">9,895,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzMtMTMtMS0xLTEzMzY2OA_58512f2d-6cab-484d-90bb-cf3c86424ad0">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzMtMTUtMS0xLTEzMzY2OA_04c0293a-905b-4d22-bf83-2e3ed5ca7921">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzQtMTMtMS0xLTEzMzY2OA_9e8d5ff7-bd18-460a-b471-7c315213cbca">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzQtMTUtMS0xLTEzMzY2OA_64a338c9-99b5-45be-af0d-a256ecb71791">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246M2E0Y2EyNmViYjAyNGU3MTkyMTJjNjc0ZTU3ODVjMTBfMTU_52190445-72dd-4d3c-88f2-8c9387d6d02a">0.68</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMTEtMS0xLTEzMzY2OA_7e44a916-fc26-41e4-a7f9-68f5c909a702">285,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMTUtMS0xLTEzMzY2OA_2a2dc9fa-063a-49e6-a1ac-e43116da0027">285,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMS0xLTEtMTMzNjY4_a805b977-4677-4a0e-861b-b60d48754d86">44,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMi0xLTEtMTMzNjY4_ce6d3768-3208-4580-a6b7-8ee49c92d035">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i06aaf4b76d2b48d6a71c3deedfa9f5d6_D20210101-20211231" decimals="INF" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMy0xLTEtMTMzNjY4_7e241194-0ae8-4379-9ee7-c9d6a8ab6dcc">44,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84e1faf18b8b44d991d1d1a4c417f179_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtNy0xLTEtMTMzNjY4_19f2788c-61dd-4954-9736-337b63195664">44,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638daa38667341c8878e93ae45445868_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtOS0xLTEtMTMzNjY4_21391e9d-91ef-4a12-9acb-181b6e1e0cb1">639,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTItMS0xLTEzMzY2OA_819927b0-4109-4ff3-b6c2-ee58ffe995d7">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTMtMS0xLTEzMzY2OA_97f3bea1-f615-4a86-89c3-7edb0fcb6df9">642,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af311935ef147839b589ff0401a4cc0_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTQtMS0xLTEzMzY2OA_4f0ad4fc-eae0-43c0-aa38-0c952bc16ef9">398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTUtMS0xLTEzMzY2OA_46338205-8306-4dc1-89f1-516195f629f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctMS0xLTEtMTMzNjY4_996d9e8e-e99e-4d8b-bd3e-c1df5727d83d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638daa38667341c8878e93ae45445868_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctOS0xLTEtMTMzNjY4_96c52086-aa25-406f-bd2a-204cf4003fa1">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctMTUtMS0xLTEzMzY2OA_5d037665-db9a-4223-9fd9-62c53eed548f">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTEtMS0xLTEzMzY2OA_8d455da9-f2b8-4f05-8563-6a191f9721c9">619,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTMtMS0xLTEzMzY2OA_09840526-69b8-4d55-a3f1-27a14752625c">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTUtMS0xLTEzMzY2OA_ac69a0ff-e264-4f89-9302-b7c499d5d748">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTEyLTEtMS0xMzM2Njg_115c3312-2f12-4e9e-b0c9-272d1951f49e">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTEzLTEtMS0xMzM2Njg_fe36128d-ed18-48c1-8acf-561152241847">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTE1LTEtMS0xMzM2Njg_684cee1a-fa0c-4a13-a600-60b9248ae261">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTEyLTEtMS0xMzM2Njg_5b0ead00-35b8-4555-9bc1-6798b5298d95">28,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTEzLTEtMS0xMzM2Njg_b89f2955-1940-47d7-98ad-c22ca53772a1">22,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTE1LTEtMS0xMzM2Njg_86c0ee20-6b57-4207-a090-571b67543539">50,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7f5fba4c66c4d59b458232cfefd397b_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEtMS0xLTEzMzY2OA_acbf6ecc-148b-4f41-93e6-3cab747b9116">432,963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f5fba4c66c4d59b458232cfefd397b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTItMS0xLTEzMzY2OA_7898e690-c452-4bc8-adaa-5ed542e21ba5">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i388294e0fecc48b7acef50ad301ac37c_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTMtMS0xLTEzMzY2OA_d778bfd2-6eb8-4b4d-b6b3-f11c9f3df485">174,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388294e0fecc48b7acef50ad301ac37c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTQtMS0xLTEzMzY2OA_19969b1a-5d4b-45c0-bda3-674eadca16f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ca490efe8f34a918c292b71f44885d9_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTUtMS0xLTEzMzY2OA_47dceb0a-0458-4e2c-831e-197d73d732ed">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca490efe8f34a918c292b71f44885d9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTYtMS0xLTEzMzY2OA_5883613e-b631-425d-b1ea-60bfe300b87c">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ebba7acc969439b987dcc2d0fba6673_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTctMS0xLTEzMzY2OA_02c86bc0-b9dc-4278-8f9a-87e4eb32f64c">361,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebba7acc969439b987dcc2d0fba6673_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTgtMS0xLTEzMzY2OA_920910e2-8f00-4a97-8866-a7c1e38f91f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec2f808579b4b78902a87ec4cc91f2b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTktMS0xLTEzMzY2OA_150b48c4-cdf7-430b-9c14-3bd1322f6372">3,507,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852db36c0318454ea53dd42de40f5456_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTExLTEtMS0xMzM2Njg_f00241eb-64f7-4a03-9b40-7be1184d8f6b">2,255,179</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f12c6f1519441d92c1fb354e0c1a55_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEyLTEtMS0xMzM2Njg_94d2dbab-17a1-4d6f-aafd-e984e52dba31">16,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEzLTEtMS0xMzM2Njg_0803099c-8296-4588-85cb-201a8f9f79e8">4,471,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i143cf5791aaf471fa5e1a7b574902892_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTE0LTEtMS0xMzM2Njg_e28dd15c-96d9-4182-89f8-61a3da842c11">2,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTE1LTEtMS0xMzM2Njg_e82ca9dd-7a7b-4f19-8639-e16738ab6b42">10,248,545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE0LTEzLTEtMS0xODg4MTI_9215db52-c4b6-4d58-91ec-a933df51a975">11,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE0LTE1LTEtMS0xODg4MTI_65dd6b0b-fc98-4668-bc22-be1522e0da7c">11,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE1LTEzLTEtMS0xODg4MTI_7552f6b3-42a5-4491-ad1a-0c5675965c9f">604,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE1LTE1LTEtMS0xODg4MTI_8d7d9d57-af13-4796-98e9-1d39bb1206ff">604,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTAtMS0xLTE4ODgxMi90ZXh0cmVnaW9uOmZiZGQ4ZTJiNGYzMTQ3Yzk5YTdlZDkzOTI2ODZhOTcxXzU0OTc1NTgxMzg5MjM_42d6a16c-a901-4e37-8cf4-8f238211c16b">0.76</ix:nonFraction> per class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTExLTEtMS0xODg4MTI_ffc9c5b1-8301-49ec-bf0d-1f7d5059e12c">333,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTE1LTEtMS0xODg4MTI_e0e01790-8744-4c65-8279-b59e79dab51d">333,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEtMS0xLTE4ODgxMg_1a1c5e6c-0476-4a6c-b16c-2257bdd60f35">10,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTItMS0xLTE4ODgxMg_08935afa-e756-4c54-9378-b0967d9341c7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9ec20854f553421a86396e564097af71_D20220101-20221231" decimals="INF" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTMtMS0xLTE4ODgxMg_f24bffb1-b61a-4c53-b70b-5e74633a7c88">10,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id43eea863eed4e989a4af810e68237ed_D20220101-20221231" decimals="INF" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTctMS0xLTE4ODgxMg_968da5b8-3b77-4177-9cd7-eb6e39830031">10,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTktMS0xLTE4ODgxMg_8c774dba-33ba-4913-83d3-356394c471c6">156,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEyLTEtMS0xODg4MTI_60661919-b762-493d-86c1-7a0966a0eb07">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEzLTEtMS0xODg4MTI_e3d4f2e6-5a3d-4b9c-a65b-419bc818aad5">157,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd8756959c734531850ee0869d7a395d_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTE0LTEtMS0xODg4MTI_ac7068ab-5542-4d8f-89dd-9e2cd561d5e2">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTE1LTEtMS0xODg4MTI_fb393b44-946c-4ab6-a2d0-ced6a2d0c60c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTEtMS0xLTE4ODgxMg_eac933e3-f5ac-4465-a974-899e1990b6b6">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTktMS0xLTE4ODgxMg_43317987-1848-4152-864e-c2a9c2a0b202">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTE1LTEtMS0xODg4MTI_f35adf1f-e8db-4dbb-b2d4-49dba4f329e1">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTExLTEtMS0xODg4MTI_627113a2-1002-4072-a7ef-12a20a0ed79a">42,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTEzLTEtMS0xODg4MTI_e1715b49-1392-4059-9e4d-c11ae254320b">187,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTE1LTEtMS0xODg4MTI_992e1127-85f3-4765-a80f-aeffaa948f8b">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTEyLTEtMS0xODg4MTI_ebd391a6-f9c5-4d1e-8153-ccee0d19c7e8">14,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTEzLTEtMS0xODg4MTI_09b72629-f63a-4746-b0a6-b013bce622e8">9,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTE1LTEtMS0xODg4MTI_02e2a847-fc6e-409e-8698-25a928dac688">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTEyLTEtMS0xODg4MTI_d8c12338-4ca2-469d-bcd3-2774696fa557">31,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTEzLTEtMS0xODg4MTI_4765ea44-3f77-4f7d-a46c-2acae2e46def">21,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTE1LTEtMS0xODg4MTI_6160f5c8-86f2-40fa-9700-86b270fb08cd">53,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4bbb534e9247e69a9f399be66e680d_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEtMS0xLTE4ODgxMg_0d30d78c-b72b-42da-b706-c65c8495c8f5">443,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4bbb534e9247e69a9f399be66e680d_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTItMS0xLTE4ODgxMg_21548e65-5885-4fa0-bdcf-0da7341db919">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabd19d54ace74630abbabeca7a180eb9_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTMtMS0xLTE4ODgxMg_7405b6d5-e976-4ff8-a08b-8c23f30a3ffc">164,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd19d54ace74630abbabeca7a180eb9_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTQtMS0xLTE4ODgxMg_29c305c9-66cb-4c0a-bb2f-fa62481ebb1b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2563f49c9d244ee28c8dcc79a588677d_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTUtMS0xLTE4ODgxMg_51482ffd-a2b5-41c2-b545-d4c51210bcbb">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2563f49c9d244ee28c8dcc79a588677d_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTYtMS0xLTE4ODgxMg_a189c780-bca5-43d5-8ea8-16589aec3661">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTctMS0xLTE4ODgxMg_bc6cc020-45dc-4b21-bfae-71609d81b7ea">371,325</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTgtMS0xLTE4ODgxMg_f6ce6eaa-ed39-45f3-8202-f15d42dde9ea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia422b9c6dc3d49fa986c24ca134e7dfe_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTktMS0xLTE4ODgxMg_9e74939f-484c-4b68-87af-ea1529327c4a">3,666,160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02e089bd28e49abaff42a3961b0d5db_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTExLTEtMS0xODg4MTI_ef16486b-651b-4360-8c9b-097a4249545a">1,964,689</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762c4b988d95468ca6e9ff58ce974d4f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEyLTEtMS0xODg4MTI_c8da362a-7a30-4fc1-b794-1e66ee62899b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1fc390f90a425883695c27f2ee9af6_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEzLTEtMS0xODg4MTI_109a80af-59e7-4162-8107-edd3ca42c3d5">3,897,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia953612cc13a40389485402ddbb1c92a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTE0LTEtMS0xODg4MTI_4f05b525-0250-4ba2-9304-d173ac0d86b5">2,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTE1LTEtMS0xODg4MTI_42052544-5ea9-478c-8e9a-045b15e311bf">9,525,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtMS0xLTEtMTMzNjY4_a4b5462d-23b4-4a1f-acaf-58431013f538">2,507,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtMy0xLTEtMTMzNjY4_5fa0203d-6b1c-40aa-975a-2484c72b1119">2,315,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtNS0xLTEtMTMzNjY4_c8140275-a088-42c8-9f1b-ef2b4504b899">2,121,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtMS0xLTEtMTMzNjY4_e0f82edf-b6d5-4847-8ef0-ef70245db15c">72,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtMy0xLTEtMTMzNjY4_6725f5e6-e9a1-44ae-92f1-2b6235fc2826">151,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtNS0xLTEtMTMzNjY4_f3292716-2489-4fe0-95d5-3d5336d579e2">143,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty cash collections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtMS0xLTEtMTMzNjY4_989aa86c-3d51-4f03-a02f-27fcd790d751">69,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtMy0xLTEtMTMzNjY4_a23946cd-4178-4e0b-944e-c0496f1649b6">44,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtNS0xLTEtMTMzNjY4_7c4883b7-ea52-40b9-a58a-2dbe63a81736">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtMS0xLTEtMTMzNjY4_a039c45f-a0b1-481c-9e1f-d2677e225579">39,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtMy0xLTEtMTMzNjY4_758059c0-2b19-40da-99cb-4f854be213e5">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtNS0xLTEtMTMzNjY4_5a12c893-fe10-4685-ac6c-8c5892291a1f">42,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctMS0xLTEtMTMzNjY4_acbdbf1c-3af1-4878-9990-0bc9d3abd99e">24,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctMy0xLTEtMTMzNjY4_b2c59d03-1a3d-42ae-a3a6-e615916309a5">3,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctNS0xLTEtMTMzNjY4_b8c98d87-c27a-4b4d-a0c0-16a849ee4b37">7,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtMS0xLTEtMTMzNjY4_7aff184e-ec10-4b53-ac3c-ea39bebc4b2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtMy0xLTEtMTMzNjY4_a669f371-388b-4cbf-ac86-1a5ddbbc184c">34,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtNS0xLTEtMTMzNjY4_d1694eff-182b-4b3e-87e9-d755f78e62d8">45,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral posted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktMS0xLTEtMTMzNjY4_1479a902-fb17-4f9e-ba49-bd29e9d899ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktMy0xLTEtMTMzNjY4_604f3496-2b3b-4fad-965a-fd19b1a3ccb8">34,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktNS0xLTEtMTMzNjY4_16239da8-87df-4515-9e82-8895673b8f02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTEtMS0xLTEzMzY2OA_8ba1dace-b704-4e84-921b-b1a006f5464c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTMtMS0xLTEzMzY2OA_aae1feee-9fb6-412f-9feb-43e50d073bb7">16,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTUtMS0xLTEzMzY2OA_00898745-e06d-4dc2-b16b-f7b076ca5d13">35,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development-stage funding payments - ongoing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTEtMS0xLTEzMzY2OA_63a2408c-34b2-4217-bc5d-c6a0b7ef1fe0">2,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTMtMS0xLTEzMzY2OA_02dab5d5-4792-46b2-b08a-deb0a2ede144">6,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTUtMS0xLTEzMzY2OA_248ee991-875b-4fe8-9083-157bdbe0f83f">20,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Development-stage funding payments - upfront and milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTEtMS0xLTEzMzY2OA_be98fddb-7fae-4a10-8c49-a6176bf93040">175,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTMtMS0xLTEzMzY2OA_c2d1383d-eaff-4fde-b6cd-da103e3eb472">193,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTUtMS0xLTEzMzY2OA_c4574e53-acff-470d-a512-c4e49fb93b1b">5,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTEtMS0xLTEzMzY2OA_0dda1b44-2b00-4ce3-80e4-f51ce6d55848">222,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTMtMS0xLTEzMzY2OA_f3045c03-2b70-47ee-9237-e3da52ba249c">184,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTUtMS0xLTEzMzY2OA_ec78d6a7-88de-44fe-ab9e-bc944e170dae">179,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTEtMS0xLTEzMzY2OA_ecebc471-03cb-4c36-9421-cead3bbae9f2">170,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTMtMS0xLTEzMzY2OA_a95fa19e-114b-4006-9158-2da6b37fe5e7">130,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTUtMS0xLTEzMzY2OA_22d7ae09-1e9a-47a9-8768-a8837450aa33">103,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTEtMS0xLTEzMzY2OA_e204bbce-549e-46cb-ad4b-3ab2e8ada84e">2,143,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTMtMS0xLTEzMzY2OA_1b2826ca-a123-45e1-b6f7-7672148b24b6">2,017,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTUtMS0xLTEzMzY2OA_88772489-4420-4d88-ae25-db0a67c12e04">2,034,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTEtMS0xLTEzMzY2OA_a43b5d68-9bcb-4dde-89b9-dc4c0aa9c134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTMtMS0xLTEzMzY2OA_4881fb95-e29b-41d5-a2ee-bb1167d326d7">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTUtMS0xLTEzMzY2OA_1c2b93a2-7c36-46d8-b5e3-68a5614a070a">15,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTEtMS0xLTEzMzY2OA_02f54d40-77a9-414b-a7ec-d7429475227b">9,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTMtMS0xLTEzMzY2OA_b5375276-6c64-43ed-9730-88ee7711a4c1">34,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTUtMS0xLTEzMzY2OA_4104d3a9-64c8-4c60-acaa-c6c37ed24a44">40,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTEtMS0xLTEzMzY2OA_d6c11972-3edc-4a12-a833-cea88217ec59">87,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTMtMS0xLTEzMzY2OA_f17343c0-573d-41d0-85af-ff40782319a9">135,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTUtMS0xLTEzMzY2OA_36ed0b29-4d17-486c-b9e1-b40417891f7f">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTEtMS0xLTEzMzY2OA_dde5b5f3-b848-405c-9ae1-cd505c5308cb">211,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTMtMS0xLTEzMzY2OA_e5fc8681-8882-492b-88b9-73adaac3bfc7">115,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTUtMS0xLTEzMzY2OA_039868b0-1d0d-4d63-9acf-9899c3d97f63">384,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTEtMS0xLTEzMzY2OA_dad203df-4105-412d-812a-88e4b79036a0">479,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTMtMS0xLTEzMzY2OA_f90a4651-2a64-4bea-b683-18a16be3e5f6">70,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTUtMS0xLTEzMzY2OA_86b4407a-e509-49d3-93e0-213f000b2b6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTEtMS0xLTEzMzY2OA_b03d30e2-a93b-4b28-8306-fee7f7038073">542,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTMtMS0xLTEzMzY2OA_da2507e2-97bd-4433-9fb2-e6bb80443f15">62,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTUtMS0xLTEzMzY2OA_9654934b-0d42-4c38-8ede-153aced4935c">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTEtMS0xLTEzMzY2OA_cdd5854e-ec53-4d90-b7a4-f410ac66992c">234,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTMtMS0xLTEzMzY2OA_4f5ebb00-5de9-4ca6-96f1-b9c3e048a7e1">1,196,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTUtMS0xLTEzMzY2OA_c39aaf64-12c3-4030-8ff9-6bc57eacd05e">1,705,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTEtMS0xLTEzMzY2OA_e6a7c325-1951-4595-9693-9365b7167495">792,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTMtMS0xLTEzMzY2OA_b07d7f54-4338-4a96-ab10-47558c975de2">1,597,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTUtMS0xLTEzMzY2OA_39beb6d8-f9cb-4ee4-8720-2068d53dc55b">815,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTEtMS0xLTEzMzY2OA_d9577a6d-1bee-4d09-b0fc-ca714bfba11d">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTMtMS0xLTEzMzY2OA_e7daa522-9253-4405-ab80-727d3223fc30">2,191,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTUtMS0xLTEzMzY2OA_12970e43-9107-4278-9a45-4fc8d99f05f2">2,182,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of other financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTEtMS0xLTEzMzY2OA_735a46a4-44ab-40cd-9b3c-e7b40b7b78d8">21,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTMtMS0xLTEzMzY2OA_536d40ca-b913-47a2-bda5-d5ac3cbffa82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTUtMS0xLTEzMzY2OA_50f7b692-1916-42ab-b2d7-aec86afb0b02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTEtMS0xLTEzMzY2OA_059142c5-d26a-4411-9635-80e70c2a30d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTMtMS0xLTEzMzY2OA_085158be-b1d3-4ee6-bf69-a172aa04dc9c">18,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTUtMS0xLTEzMzY2OA_46354eee-fa4d-4ae5-9a72-dcc02025c27b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTEtMS0xLTEzMzY2OA_80b1ae26-494f-468f-8ee2-4fbc78c49372">1,029,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTMtMS0xLTEzMzY2OA_d863fea5-9938-40c1-bac6-830efb7e02a4">1,870,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTUtMS0xLTEzMzY2OA_e5891ef0-d340-40a7-a8c5-46877979b09e">2,759,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to shareholders/unitholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTEtMS0xLTEzMzY2OA_4c49ef5d-fbf8-4f6b-b20e-6488efe3ccf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTMtMS0xLTEzMzY2OA_8f7265ac-8331-4f6d-a695-04d6c4b9a100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTUtMS0xLTEzMzY2OA_43e5a923-5d80-44d0-a511-aed46b3729e6">285,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - royalty receipts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTEtMS0xLTEzMzY2OA_2830e177-43c7-4256-8a0e-d83143dee01e">441,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTMtMS0xLTEzMzY2OA_150f999d-f260-4400-9b4d-2de9e826c6d8">479,604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTUtMS0xLTEzMzY2OA_43307db6-b4d7-4ff0-a23a-2306e32fa4a0">543,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to legacy non-controlling interests - other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTEtMS0xLTIzNTE3NQ_5128f5c6-9c7e-48ad-8ec1-60c262a32b2e">31,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTMtMS0xLTIzNTE3NQ_153ab701-3318-410c-bf9b-acbb6a8fe6de">20,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTUtMS0xLTIzNTE3NQ_4c53f1f9-35bf-427e-a102-62416bfce332">67,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to continuing non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTEtMS0xLTEzMzY2OA_ace21dbf-8614-4561-8ed0-4ffe3bc942f5">144,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTMtMS0xLTEzMzY2OA_00f99ee9-bbfa-453a-bd3a-d812439d6234">133,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTUtMS0xLTEzMzY2OA_b3095dce-2d99-4dae-b6ad-5cc57c591024">113,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTEtMS0xLTEzMzY2OA_71c6d56d-1c03-45d0-a48b-272c7efe077a">333,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTMtMS0xLTEzMzY2OA_cb23f444-d703-4821-9ea5-3c5a36c15b49">285,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTUtMS0xLTEzMzY2OA_54c1bd45-6d20-45ca-a693-60905e714584">112,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span id="i2659098258014980a9d2b6d48ae6d601_40-0-1-1-133668"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from legacy non-controlling interests - R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTEtMS0xLTEzMzY2OA_20373b4a-d9fc-4f77-8738-b7277e81e820">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTMtMS0xLTEzMzY2OA_c282e394-73db-4368-89c2-c51a7ce77b37">7,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTUtMS0xLTEzMzY2OA_2361b717-984f-485c-ab80-75ba66ebb75a">8,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from non-controlling interests - other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTEtMS0xLTEzMzY2OA_a612e264-92df-4770-9b80-a9c974976e1d">6,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTMtMS0xLTEzMzY2OA_26b1edad-5f2a-4ec0-b3c8-c805da486490">36,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTUtMS0xLTEzMzY2OA_ff2e4a23-7b7f-4249-bb12-3220ad37bdf7">58,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scheduled repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTEtMS0xLTEzMzY2OA_12908f57-513b-49b0-8de4-b550e4b28d61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTMtMS0xLTEzMzY2OA_cb4e0f83-2a0d-4a44-9f84-5125e3bb1ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTUtMS0xLTEzMzY2OA_9e1596c2-8745-4b18-a4a7-3d80e90de839">94,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTEtMS0xLTEzMzY2OA_6bf829d8-c64e-4fe5-887a-52e9cb5cc278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTMtMS0xLTEzMzY2OA_95dc9ca1-3ab2-4354-b7e9-a5baec7d5b0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTUtMS0xLTEzMzY2OA_e4e603ed-7322-40d9-9f9e-20c85732d87b">11,116,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTEtMS0xLTEzMzY2OA_7e4e1125-54c1-468b-99a5-8eb3bdab8f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTMtMS0xLTEzMzY2OA_f7afa381-70a1-49d8-8746-31a0a1bc2974">1,272,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTUtMS0xLTEzMzY2OA_02dbbc78-ee6e-4b98-bcd4-fcb7b81dc895">11,891,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issuance costs and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTEtMS0xLTEzMzY2OA_e3624a50-7531-4b17-819b-80085ea7dd0b">1,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTMtMS0xLTEzMzY2OA_408a53d5-384e-490b-a981-ca6a4abcf42e">13,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTUtMS0xLTEzMzY2OA_8713e3b0-0653-490f-9a06-a74d30c6a30a">46,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTEtMS0xLTEzMzY2OA_e624e010-cdb4-48d4-a606-0bb5ac8c749c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTMtMS0xLTEzMzY2OA_ffc621c7-b249-4978-aa75-b612d1c08729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTUtMS0xLTEzMzY2OA_1ffd2843-6602-4e0e-b6cb-b04d990e7b7f">1,908,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash (used in)/provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTEtMS0xLTEzMzY2OA_8775e2bc-67a9-4872-b35f-f045569a0648">944,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTMtMS0xLTEzMzY2OA_12e3115d-3541-4240-99c2-0b4a4b1a7a10">385,112</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTUtMS0xLTEzMzY2OA_3e40233d-396c-4371-982f-9d64ca2d8926">1,487,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTEtMS0xLTEzMzY2OA_b0ab2408-ac8b-4a86-97d9-2eac65c9266a">169,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTMtMS0xLTEzMzY2OA_20b7710f-e472-4b10-b790-a1234c4b0142">532,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTUtMS0xLTEzMzY2OA_08efec1d-108d-42ef-9798-c496baa0ab26">762,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTEtMS0xLTE3ODM3NA_e1272ab0-5c25-4cca-a8f5-2ad095028c9c">1,541,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTMtMS0xLTE3ODM3NA_b9efdb82-5ce5-4ea6-ad5d-7b9c6b31866b">1,008,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6924ffcc56464af49725a154112a2c81_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTUtMS0xLTE3ODM3NA_6296c58e-e100-4443-96ac-31d50f5e20bb">246,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTEtMS0xLTE3ODM3NA_9a06ce8b-4fc6-4ea0-9fbf-ef9493ca7acb">1,710,751</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTMtMS0xLTE3ODM3NA_9f9e4703-f6f3-431b-b38e-943922ac0849">1,541,048</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTUtMS0xLTE3ODM3NA_e09bf596-c8c0-4f26-becf-60ab4e870f4e">1,008,680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4Xzc5NDA_543b6359-2076-465b-9c56-6edc6ea482f3" continuedAt="ied829fd72cbf4e748d09945e99ecd5c6" escape="true">Organization and Purpose </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ied829fd72cbf4e748d09945e99ecd5c6" continuedAt="i9ee2d2e4eda149eeaaff1b32317e4fc4"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the IPO of our Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#8217; Class A ordinary shares (the &#8220;RP Holdings Class A Interests&#8221;) and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity, and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;), and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is responsible for our management, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#8220;Management Agreement&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer (defined below) and before the consummation of the IPO, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to RPI 2019 ICAV. Prior to the Exchange Offer, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Old RPI.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Offer&#8221;) to facilitate the IPO. Through the Exchange Offer, investors which represented <ix:nonFraction unitRef="number" contextRef="i280e643fdef0483689f89d2627e67117_D20200211-20200211" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NDY_46d34583-7f95-4f0f-b270-6f3f77527bf9">82</ix:nonFraction>% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The Exchange Offer together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own indirectly an <ix:nonFraction unitRef="number" contextRef="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MjY_c85cc9f6-8d63-4cd8-955e-a48b51d1cbf0">82</ix:nonFraction>% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;). We are entitled to <ix:nonFraction unitRef="number" contextRef="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MzE_0bd40d35-6134-4f9f-a44e-74d969ef793a">82</ix:nonFraction>% of the economics of Old RPI&#8217;s wholly-owned subsidiar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, an Irish private limited company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and <ix:nonFraction unitRef="number" contextRef="i955ef8f092f6410b8368691a366b3ccd_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MzY_be7bfdbf-8964-4581-9ed1-3301b2374565">66</ix:nonFraction>% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining <ix:nonFraction unitRef="number" contextRef="ia00f566083814766b799de815b74eb68_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NDE_7750d863-54d3-43a8-a053-1d675656a86d">34</ix:nonFraction>% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of the Exchange Offer until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships could participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9ee2d2e4eda149eeaaff1b32317e4fc4"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer, the Legacy Investors Partnerships and RPI Intermediate FT entered into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit facilities in the amount of $<ix:nonFraction unitRef="usd" contextRef="id6272e7fd11d44329684f5f26db3b0e5_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NTE_3c8bcf9d-ebaa-452e-aa6e-ad49450121fc">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ieabc44fc792946909b8b90c908c11b2a_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NjU_08928fff-d3e6-40f5-b090-b9d618e543ba">6.0</ix:nonFraction>&#160;billion, respectively, the proceeds of which were used to repay the $<ix:nonFraction unitRef="usd" contextRef="i12ff36e2c24f4dfba76ba7b4b27451b6_D20200211-20200211" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1Nzk_1151967d-400a-4844-9bba-90ab0617741d">6.3</ix:nonFraction>&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the senior credit facilities, RPI Intermediate FT repaid $<ix:nonFraction unitRef="usd" contextRef="i0abe73d17656428c858e609114abb39a_D20200211-20200211" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1OTM_674d478f-c485-4c40-a70b-bcba70d71212">5.2</ix:nonFraction>&#160;billion, its pro rata portion of RPIFT&#8217;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#8220;RPRX&#8221;, in which we issued <ix:nonFraction unitRef="shares" contextRef="i9572c0d747ab4d80a3666c92eef2f3e7_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MDc_75d89ffa-bfcc-4c86-b95b-c3c9e4fefecb">89,334</ix:nonFraction>&#160;thousand Class A ordinary shares at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic92461c4b3514d22afb54b7350b5a973_I20200618" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MjQ_649c8fce-ad7d-49c5-b8bf-11bfab0ff199">28.00</ix:nonFraction> per Class A ordinary share, of which <ix:nonFraction unitRef="shares" contextRef="idec997943fd44095835407fd6f299a6d_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MzI_7d293379-d1e5-476e-8bc1-49cade2273eb">71,652</ix:nonFraction>&#160;thousand Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="id7d4834e0547457480186ed9fe6cfbed_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2NDk_d5fbf66d-5e1b-4d30-91d3-f4c9454d5c27">17,682</ix:nonFraction>&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire <ix:nonFraction unitRef="number" contextRef="idf5b5a5cdfc4467896657cf7dc34567d_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzE2NDkyNjc0NDUwMjE1_b1d1abe5-5c26-4892-aa3f-b7c352b0101a">100</ix:nonFraction>% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, according to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of <ix:nonFraction unitRef="shares" contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2NzI_6afc4df9-04bd-43f9-b55a-e1e64ffc4ade">294,176</ix:nonFraction>&#160;thousand RP Holdings Class B Interests into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7cdeed76822f459e89ec58e43a1d83ea_D20200618-20200618" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2OTA_8f4434cc-722a-4286-be7b-d87efa566c05">294,176</ix:nonFraction>&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned <ix:nonFraction unitRef="shares" contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA3MDg_c241862a-3337-4462-9bd5-b8b9f1be1abb">294,176</ix:nonFraction>&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held <ix:nonFraction unitRef="shares" contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618" decimals="INF" name="rprx:SaleOfStockNumberOfSharesNotConverted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA3MjY_c27073ad-c774-41d8-8bcd-ae3a91fe51fa">241,207</ix:nonFraction>&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a <ix:nonFraction unitRef="number" contextRef="ic6c853fcbec74369a6114e07a900dfc8_I20200618" decimals="INF" name="rprx:CommonStockExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzUxMTI3MjkwNzQwNzQ2_ffc50781-ba4c-44d5-b8a2-ac4a853e0e0f">one</ix:nonFraction>-for-one basis for Class A ordinary shares of Royalty Pharma plc. Refer to Note 12&#8211;Shareholders&#8217; Equity for additional information.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ5_b94d4ba5-e67f-4d7d-b1e7-32449f6ebe75" continuedAt="idb22e5b85f2a4e2e83ec50276a584026" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idb22e5b85f2a4e2e83ec50276a584026" continuedAt="ia31351d0747e475d9891ae9699580be1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ1_97939cc6-2a40-4578-baf0-cf9e81846646" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQx_ea526279-b6e1-4e22-83a1-90e2de06c6a2" escape="true">The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU2_802f6d00-6cfd-4650-a961-858955016926" continuedAt="i0d561f75370545cba8cd1ee7dc1286c4" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the date of the Exchange Offer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we became an indirect owner of an <ix:nonFraction unitRef="number" contextRef="ie00852d0b4174efbaafedf7b99cbfe00_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDgw_037e5aac-30aa-4cec-90b4-67bcb9b08483">82</ix:nonFraction>% economic interest in RPI ICAV, which previously was owned directly by Old RPI.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia31351d0747e475d9891ae9699580be1" continuedAt="i5a4e66b9c31a4e3fb9fe0fa43cec16bf"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0d561f75370545cba8cd1ee7dc1286c4" continuedAt="i080b216ddae44fc0bdda66ae82e3e4d7">We report <ix:nonFraction unitRef="noncontrolling_interest" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:NumberOfNoncontrollingInterestsCreated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1MjE_450c6781-7355-430d-b8c1-6b74e38e9685">four</ix:nonFraction> non-controlling interests: (1) the Legacy Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="i9e6a1451ee4f45f286b64a9a27bc35ec_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1MjM_6025954b-e934-4cb7-af0e-dcf6be8c9c75">18</ix:nonFraction>% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the &#8220;legacy non-controlling interests&#8221;). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). The Continuing Investors Partnerships are referred to as the &#8220;continuing non-controlling interests.&#8221; Income will not be allocated to EPA Holdings until certain performance conditions are met.</ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i080b216ddae44fc0bdda66ae82e3e4d7">All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM5_d29c0385-6c6d-4d7b-b03b-a136ecb45e89" escape="true">Certain prior period amounts have been reclassified to conform to the current period presentation.</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU5_8026698b-ed37-400a-98bb-7d73d23306ea" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank of America, US Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Scotiabank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for <ix:nonFraction unitRef="number" contextRef="i6036429cbf7d478bb21d142552f11fd3_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4NDIwMDU_fbd5212e-9468-4b98-8efd-c4d665f4cc20">31</ix:nonFraction>% and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i50014516371a4a1d80e1b25e358497c7_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1NTg_e355c619-17e6-4ab8-a455-7deb4466b15f">32</ix:nonFraction>% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUx_d37b6b85-73c5-4d5d-9965-35e48176d460" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions. As such, we concluded that we operate as <ix:nonFraction unitRef="segment" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDg5_a29c54b2-eb76-41f1-8f8b-170a934d2e6a">one</ix:nonFraction> single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="rprx:RoyaltyAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDMz_1aca5241-0602-4a22-8128-1ace733157d4" continuedAt="id6a48ed766b24f64bbcb7b88db1f793d" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective and passive in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i5a4e66b9c31a4e3fb9fe0fa43cec16bf" continuedAt="i671b1d5c13824975a30bdb57502b980e"><div style="text-indent:22.5pt"><ix:continuation id="id6a48ed766b24f64bbcb7b88db1f793d"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible royalty assets. The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FinanceLoansAndLeasesReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUy_66e95f7e-f1ee-43f1-9b14-abdcfafd2720" continuedAt="ia4ef2e2c7f6c488086839868e359c8e8" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure our financial royalty assets at amortized cost requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available sell-side equity research analyst consensus sales estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products. Based o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i671b1d5c13824975a30bdb57502b980e" continuedAt="i34a16e03121649f997cde7d05bf8c6be"><ix:continuation id="ia4ef2e2c7f6c488086839868e359c8e8" continuedAt="i8ec44c8fbe1e4b5b8e076b13cdb75afc"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i34a16e03121649f997cde7d05bf8c6be" continuedAt="if064e22b55b043a4a8ce444870a32427"><ix:continuation id="i8ec44c8fbe1e4b5b8e076b13cdb75afc" continuedAt="i058e241d2a91402ba0c41c13a1536e72"><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheets, are accompanied by corresponding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> income or expense. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUw_a9c5f772-b8ab-4799-a7a9-10d99b4c2fe6" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets. Any subsequent provision for credit losses is recorded as part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="i058e241d2a91402ba0c41c13a1536e72"><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status. In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, clinical trial results</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and approval status. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized if, based on available information, it is prob</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="if064e22b55b043a4a8ce444870a32427" continuedAt="i8f36a8c899b94a0da5952282b5b12f76"><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM0_634c6b1c-c370-4666-881a-0a3f7ea1b17f" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of Januvia and Janumet (&#8220;DPP-IV&#8221;) products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved. We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments and Fair value measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM2_ee8ac652-379d-4bf6-a120-7c43617163e5" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets. Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU4_588ba653-d1fd-4216-b591-a8e79c4faa7f" continuedAt="ic4b707042adb4f2b9bff407e9c75a241" escape="true">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value</ix:nonNumeric></span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4b707042adb4f2b9bff407e9c75a241">.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i8f36a8c899b94a0da5952282b5b12f76" continuedAt="i18f64503acf6408883fd65f2e9f39a07"><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM3_1ff29d55-6fc4-48c2-b594-3550918ac0a7" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity securities primarily consist of investments in publicly traded equity securities. The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Investments classified as available for sale debt securities are recorded at fair value. We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings. For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AOCI&#8221;) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows. A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ3_0d94a78f-7b67-48fc-b15d-87a45aa01d6c" escape="true">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings.</ix:nonNumeric> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQy_817b56ad-0b9a-48eb-bf52-5ab9d104fc7a" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQz_8772c956-c99f-400d-91db-1d8dd16444b5" continuedAt="icda420ae7318488b81150bfaa3cd875f" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. If these conditions are not met, we may record the funded amounts as a financial royalty asset. We may  fund R&amp;D upfront or over time as the underlying products undergo clinical trials.</span></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i18f64503acf6408883fd65f2e9f39a07" continuedAt="i1543d4d1bc944942958a0de9798cb85f"><div style="text-indent:22.5pt"><ix:continuation id="icda420ae7318488b81150bfaa3cd875f"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f contractual criteria for pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oducts arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDY1_ac987d6e-1549-4952-a07e-7e27e95fe6e6" escape="true"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years presented in the consolidated financial statements</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time. Income from these funding arrangements are subject to U.S. taxation and we record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to this income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16&#8211;Related Party Transactions that will be subject to U.S. taxation when we begin to recognize revenue</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, we will record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with respect to revenue from the MSCI transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, applies to U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the U.K. CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material tax charges to arise under the U.K. CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K. income taxes related to this matter</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other taxation matters</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S. withholding taxes on U.S.-source royalty payments.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i1543d4d1bc944942958a0de9798cb85f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQw_bb2bc913-6b7a-42cd-8dc1-adfbd302b38e" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a <ix:nonFraction unitRef="number" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:CommonStockExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDcy_df50ef5d-4b4c-4a0b-b2d1-7f29046b49ab">one</ix:nonFraction>-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information have been presented for any period prior to that date.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_121"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzY2NTc_8a5a5b4b-4248-4aeb-885d-28906d29e869" continuedAt="icb74594a3e84438588ace52ec72d19c4" escape="true">Available for Sale Debt Securities </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="icb74594a3e84438588ace52ec72d19c4" continuedAt="i145db98438344b7895047d27f3b598d5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cytokinetics Commercial Launch Funding </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products. During 2022, we amended the funding agreement to increase the required draw amount, extend the draw period and modify the return for the second and third tranches. As part of the funding agreement, we agreed to provide capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) of up to $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDgxNTA_830a4d7b-f1f8-43d0-a6e3-3311647ceb4a">300</ix:nonFraction>&#160;million, which is comprised of <ix:nonFraction unitRef="tranche" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="INF" name="rprx:LongTermFundingPartnershipNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzODk4_e1708230-4829-43e8-a300-582f629b36f2">five</ix:nonFraction> tranches, including an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipInitialPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDgxMTA_1d82f175-eb2f-45f9-aa24-76879d61b615">50</ix:nonFraction>&#160;million that was funded upon closing. Cytokinetics is required to draw $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipCovenantRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzUyMzU_260bdcc8-0e65-46b6-bfe8-7781b2e45be1">50</ix:nonFraction>&#160;million if a certain contingency is met and has the option to draw the remaining $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzU0MDY_6d672792-cd46-4fde-8e2a-ca2319fe6aec">200</ix:nonFraction>&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#8220;Cytokinetics Funding Commitments&#8221;). Each tranche has an interest-free and payment-free period of <ix:nonFraction unitRef="tranche" contextRef="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107" decimals="INF" name="rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1Nzc0NTY_0834ae34-9914-420c-8602-9611363eed19">six</ix:nonFraction> calendar quarters, followed by <ix:nonFraction unitRef="tranche" contextRef="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107" decimals="INF" name="rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1Nzc0NDg_40c2ce31-db2f-4733-864b-240eec2550ef">34</ix:nonFraction> calendar quarters of installment re-payments totaling <ix:nonFraction unitRef="number" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="INF" name="rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzU2MDQ_c3f9c235-dd85-42b5-9ada-11d1c702b896">1.9</ix:nonFraction> times the amount drawn, except for the second and third tranches, which each total <ix:nonFraction unitRef="number" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="INF" name="rprx:LongTermFundingPartnershipTotalAmountDrawn" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyNzEz_a2c16114-d52d-4a21-b910-6293674f5d66">2.0</ix:nonFraction> times the amount drawn. As of December 31, 2022, we expect $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-6" name="rprx:LongTermFundingPartnershipExpectedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyOTU5_f0b1ee8d-71c4-416a-961f-6267643bec51">125</ix:nonFraction>&#160;million of the optional $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyOTQ1_176c5789-f1e4-40c5-95b4-ded15ded7a79">200</ix:nonFraction>&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2022 on the consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i145db98438344b7895047d27f3b598d5" continuedAt="ic77c192498484e63a93830d4142bfb08"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $<ix:nonFraction unitRef="usd" contextRef="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzkwMzY_82c3233a-46e4-4242-86b5-374e11f1245c">350</ix:nonFraction>&#160;million of capital (the &#8220;Development Funding Bonds&#8221;), of which MorphoSys was required to draw a minimum of $<ix:nonFraction unitRef="usd" contextRef="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MDU_42ecdb57-25a0-4cbf-b006-22014c14821a">150</ix:nonFraction>&#160;million. Our commitment to fund at least $<ix:nonFraction unitRef="usd" contextRef="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MTk_1106bc50-532c-4e5a-9ad1-4c2dcf05b094">150</ix:nonFraction>&#160;million of the Development Funding Bonds was recognized as the Development Funding Bond Forward as of December 31, 2021. In September 2022, we funded $<ix:nonFraction unitRef="usd" contextRef="ia5062756e7634788ade2313173101917_D20220901-20220930" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MzM_0895792d-5b42-4a15-8391-94ec43677f15">300</ix:nonFraction>&#160;million of the Development Funding Bonds, which represents additional funding of $<ix:nonFraction unitRef="usd" contextRef="i5b27d2843a794aa78e16c71951dd44e8_D20220901-20220930" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4NDc_eb3409c3-1526-4bf2-837a-eb5300387a39">150</ix:nonFraction>&#160;million above the minimum funding commitment (&#8220;Additional Funding&#8221;) and the Development Funding Bond Forward was settled at the same time. We expect to receive a return of <ix:nonFraction unitRef="number" contextRef="ic197bc2dabd546778e0292339fc66971_D20220101-20221231" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzOTI0_760f1fe5-4295-4e49-b294-162702cbf1d6">2.2</ix:nonFraction> times the amount funded on the Development Funding Bonds payable on a quarterly basis over <ix:nonNumeric contextRef="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2Mzk1ODk_c60844b2-4582-4000-b517-078ad3a1c639">nine years</ix:nonNumeric>, with the first payment beginning in the fourth quarter of 2024. As of December 31, 2022, we have no remaining funding commitment under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the funded amount of the Development Funding Bonds and the Development Funding Bond Forward as it most accurately reflects the nature of the instruments. The funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The changes in the fair values of the funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="padding-left:4.5pt;text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, RPIFT purchased <ix:nonFraction unitRef="shares" contextRef="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIwOTQ_022942d7-bd41-4115-8908-f5261da8113a">2,495</ix:nonFraction> Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd (&#8220;Biohaven&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIxNjE_bab9f76f-a7c1-4240-9199-f90403150430">50,100</ix:nonFraction> per preferred share, for a total of $<ix:nonFraction unitRef="usd" contextRef="i298d7c29452d4bcdbaf7cd89d8fc8533_D20190405-20190405" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIyMDE_df77d104-3882-4e55-a639-304f2a8b9f59">125</ix:nonFraction>&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 resulted in a payment due to us of <ix:nonFraction unitRef="number" contextRef="ie0c3a6ae85e346a0a5e3381b803dd465_D20200201-20200229" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIzMzQ_074754f5-7ada-4b21-a826-857305271695">two</ix:nonFraction> times the original purchase price of the Series A Biohaven Preferred Shares beginning in the first quarter of 2021 through the fourth quarter of 2024. In the first quarter of 2021, we began receiving payments of $<ix:nonFraction unitRef="usd" contextRef="ida8d155decaa4354a46677a02d47d72b_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzODc1_036ef52f-3b90-4495-9f9e-666e190b4743">15.6</ix:nonFraction>&#160;million from the quarterly redemption of the Series A Biohaven Preferred Shares.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet as of December 31, 2021. The unrealized changes in the fair value of the Series A Biohaven Preferred Shares were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of comprehensive income. In 2022, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1NzU4NzA_fe95502e-f1f9-4b5a-8a8d-d41bda651a69">53.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1NzU5MDI_55da8bba-fbbd-4fbd-939a-0bb82aebd2a5">50.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzU0OTc1NTgyMTAzMTQ_d4c0f53e-8d5c-454b-af7c-a6953512986a">20.6</ix:nonFraction> million of unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire <ix:nonFraction unitRef="shares" contextRef="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM0NDM_88396530-c934-4933-8303-6cd83043a9a7">3,992</ix:nonFraction> shares of Series B Biohaven Preferred Shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM1MDY_e12d0f57-36a2-4618-9566-ed51269dda1d">50,100</ix:nonFraction> per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;), for a total of $<ix:nonFraction unitRef="usd" contextRef="i69adb70664a447e79c77ca4463c73f8c_D20200807-20200807" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM1ODk_bbdad245-ce5e-49c1-99b0-63bd86f64450">200</ix:nonFraction>&#160;million payable on a quarterly basis between the first quarter of 2021 and the fourth quarter of 2024. Our commitment to purchase the Series B Biohaven Preferred Shares was recognized as the Series B Forwards. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheet as of December 31, 2021. We believe the fair value option most accurately reflects the nature of these instruments. The changes in fair value of the Series B Biohaven Preferred Shares and Series B Forwards were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations. In 2022, 2021 and 2020, we recognized gains of $<ix:nonFraction unitRef="usd" contextRef="i8c0d89f6c512426b935355784dc5eca8_D20220101-20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1ODI0NzM_11f191c5-cd7f-4546-a11a-ef48715ca150">122.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i8926e1456d5b484da7113982a2cc6f8b_D20210101-20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1ODI0ODk_e1f1ffe7-dfb2-4aa1-8dab-5e6cd8e657c2">13.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b454c53374c471884c05778788c7dae_D20200101-20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3Njg3Njk_740146e3-e5e1-4660-a680-1145a1fd784b">18.6</ix:nonFraction>&#160;million, respectively, related to Series B Biohaven Preferred Shares within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic77c192498484e63a93830d4142bfb08"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, Pfizer Inc. (&#8220;Pfizer&#8221;) acquired Biohaven, which was a change of control event that accelerated the issuance of all unissued Series B Biohaven Preferred Shares and the redemption of all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. We purchased all remaining unissued Series B Biohaven Preferred Shares simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares at a price equal to approximately <ix:nonFraction unitRef="number" contextRef="ie2d8cbe5699f4354a0a0fb8aa7ac335c_D20221003-20221003" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDc4MjE4_c932c4de-9a70-4f03-b72c-9ed4c6366fbe">1.8</ix:nonFraction> times the original purchase price. The Series A Biohaven Preferred Shares were redeemed at a price equal to <ix:nonFraction unitRef="number" contextRef="ib5453ca3d1fa434f832ded0a6cbd1d30_D20221003-20221003" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc1MTMwMzA_871eca29-590e-4345-8ef0-882060138678">two</ix:nonFraction> times the original purchase price. As of December 31, 2022, we no longer hold any Series A Biohaven Preferred Shares or Series B Biohaven Preferred Shares.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzY2NTg_7946059b-7046-4651-a577-3956ed92084b" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized (Losses)/Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMS0xLTEtMTMzNjY4_f61cd4f9-b1b6-4b6e-9abf-fc3b957f3898">359,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMy0xLTEtMTMzNjY4_d818444c-b2d1-4ecc-a08e-896d806bee31">131,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItNS0xLTEtMTMzNjY4_346334c4-0128-428a-9210-1c5cb574e0e8">227,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItNy0xLTEtMTMzNjY4_8c9cf9ab-3d20-4d70-ac5c-93abcd2f9eb5">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItOS0xLTEtMTMzNjY4_39cfa9a0-8da8-4ac3-8613-a2d518ce8e60">226,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTItMS0xLTE3ODIwMg_99929733-c7fb-4ce2-8b69-568048b00e7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTQtMS0xLTE3ODIwOQ_f0358c4d-4785-4c2d-87cb-520787d9ee60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTEtMS0xLTEzMzY2OA_73984bd2-4f0f-47c4-9a98-5446bc351ee0">227,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMS0xLTEtMTMzNjY4_826a2387-e8fd-4365-81da-294e196db8f3">9,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMy0xLTEtMTMzNjY4_8927401e-5c16-4d65-822c-b0b8c94cb13f">6,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtNS0xLTEtMTMzNjY4_35f09435-423e-496a-9030-3a8f316685df">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtNy0xLTEtMTMzNjY4_3b3f951e-ceaf-45c6-baaa-0520c9edcda8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtOS0xLTEtMTMzNjY4_5047783e-9d1b-4f31-9b1e-ed72fce31925"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTItMS0xLTE3ODIwMg_b61e282b-5cd0-4378-ab74-679fbb635fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTQtMS0xLTE3ODIwOQ_59e71478-1533-4de0-b07c-beb38f9a26e6">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia387ad8558934defb6159f7305efa385_I20221231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTEtMS0xLTEzMzY2OA_feb53c89-50d2-44fb-964c-63d27fcd413b">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMS0xLTEtMTMzNjY4_c31d52ef-b007-452e-b82e-0a8086e2fc49">350,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMy0xLTEtMTMzNjY4_384a2eb1-f6c4-4128-b2ba-4a76cabacdea">124,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtNS0xLTEtMTMzNjY4_2cae6741-89dd-4927-a682-7ed8d2a1b5a7">225,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtNy0xLTEtMTMzNjY4_dd4f8f48-ea7a-4fd4-bebc-f61d05d62695">1,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtOS0xLTEtMTMzNjY4_2cd61bcd-4539-4350-9a3b-8996cec6542c">226,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTItMS0xLTE3ODIwMg_a45bf2aa-7dd3-4c9c-a29b-3a51f6a66c84">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTQtMS0xLTE3ODIwOQ_b8a2cb89-8773-4544-b025-d0eef4e00f0c">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTEtMS0xLTEzMzY2OA_1e02c333-3aa7-4434-8ada-b98ae5bb0d6a">225,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMS0xLTEtMTMzNjY4_eb80899b-3c91-4660-9a8b-5c74666872a3">204,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMy0xLTEtMTMzNjY4_9a31a9c5-bee8-4ad4-90a1-b9f889776ac2">49,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtNS0xLTEtMTMzNjY4_fb3f96fe-3805-4988-88e0-fe82c8524e0b">253,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtNy0xLTEtMTMzNjY4_f88375bb-dbe9-4929-af5e-6c4518c134bf">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtOS0xLTEtMTMzNjY4_582685f3-1592-4a52-9606-fa2a0968f83c">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTItMS0xLTE3ODIwMg_5f5b4248-a7f6-4513-a91d-32d18d179619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTQtMS0xLTE3ODIwOQ_6c414781-fe05-44a8-b79e-67fa0ee48ee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTEtMS0xLTEzMzY2OA_44799a7d-fd90-4317-b1b8-0f21498d2a1c">253,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMS0xLTEtMTMzNjY4_b37d042e-c359-4d89-9048-0d1f68688e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMy0xLTEtMTMzNjY4_9deab51a-5545-42cc-b242-029d1afd6d9f">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktNS0xLTEtMTMzNjY4_438885e9-3825-4219-b2e0-f4c71b818101">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktNy0xLTEtMTMzNjY4_4d3220fa-55de-4184-a178-7869d74c6dc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktOS0xLTEtMTMzNjY4_f61d135b-63a9-4c5f-87aa-b496f5077c45">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTItMS0xLTE3ODIwMg_f37a0899-58c3-4b30-ae16-08d36ae95d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTQtMS0xLTE3ODIwOQ_d17cd37f-8496-4b7f-8a84-ede7e0d46f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808aa487867047a1aeeed484938b9306_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTEtMS0xLTEzMzY2OA_b73a913d-bd74-4dc1-9e36-fe677cc1fa92">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTEtMS0xLTEzMzY2OA_f6083136-24af-438f-a336-482967324465">204,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTMtMS0xLTEzMzY2OA_d3aeb2ac-8e2b-4807-84a8-7a1ed8e05b44">65,891</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTUtMS0xLTEzMzY2OA_a80669fb-cf32-42f0-b864-b2072aed97bf">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTctMS0xLTEzMzY2OA_530c5817-bf10-48ee-b285-73f3de0d38a0">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTktMS0xLTEzMzY2OA_0d011e2e-4896-4ba1-a274-c27e49308b15">204,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTEyLTEtMS0xNzgyMDI_b6f31dc6-dd55-4ad2-8754-a4b193423fb8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTE0LTEtMS0xNzgyMDk_43be3bc7-8d5d-4bd7-b1a9-c06ce5ca46bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTExLTEtMS0xMzM2Njg_9e3c8bbc-4bab-484e-b6a4-2d3c04122c25">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTM_cc26c9c8-ebd7-4a9e-95aa-2860dd1c2157" continuedAt="id551fd688ebd44cfbb61270d603f71ae" escape="true">Derivative Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id551fd688ebd44cfbb61270d603f71ae" continuedAt="i74810c83a37240878730391884b7131c"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven, which included the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Upon a change of control event, we have the option to cause Biohaven to accelerate the payment of zavegepant milestone payments, if triggered, in a lump sum amount (&#8220;Milestone Acceleration Option&#8221;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. On October 3, 2022, Pfizer acquired Biohaven and we elected to accelerate the zavegepant success-based milestone payments, if triggered, in a lump sum amount. As of December 31, 2022, the fair value of the Milestone Acceleration Option was $<ix:nonFraction unitRef="usd" contextRef="ie4bf194cfc2e4ae29733f8ea9a9e30c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzMyOTg1MzQ5MTMwMjc_f82c1976-ab98-4835-90a6-7b408efc146e">96.6</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQzOTgwNDY1NDQwODM_41ff434a-9288-45e7-8529-80573daaeebe">86.2</ix:nonFraction> million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and $<ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQzOTgwNDY1NDQxMTU_a756c44e-1e64-43c4-86eb-76af4aeeb773">10.5</ix:nonFraction> million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i74810c83a37240878730391884b7131c" continuedAt="i6eff7bb6e88f44c8a68582e9d1d0ba81"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury rate lock contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i83621d3576df4e908ddd466a0e61f733_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzgwOQ_32a8df15-cb48-4344-9b4b-f8cdbb8ccb27">600.0</ix:nonFraction>&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#8211;Borrowings). The treasury rate lock contracts had collateral requirements and were not designated as hedge instruments. We paid $<ix:nonFraction unitRef="usd" contextRef="iec09d9a909cb4c17866b5eb148734cbb_D20210701-20210731" decimals="-5" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzEzMTY_359b8c11-0aef-46ea-93ba-00887ed94084">16.1</ix:nonFraction>&#160;million in July 2021 to terminate our treasury rate lock contracts in connection with the issuance of the 2021 Notes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $<ix:nonFraction unitRef="usd" contextRef="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229" decimals="-5" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzE1MzI_e95a8e0d-81a3-4bfa-98d8-2616f0fdc054">35.4</ix:nonFraction>&#160;million to terminate these swaps and reclaimed $<ix:nonFraction unitRef="usd" contextRef="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229" decimals="-5" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzE1NzQ_bdca007b-11b7-46fb-94a6-4cbf2723860b">45.3</ix:nonFraction>&#160;million of collateral that was held by the respective counterparties. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#8220;Epizyme&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i68d67c1c36ac474584018997072ac0ba_I20191130" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIwODU_67478d5f-eaed-402b-b5aa-5f510f1c8691">100.0</ix:nonFraction>&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idf0a219828db455db7c7f67f043e8346_D20191101-20191130" decimals="-5" name="rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIxNjY_740dda09-a477-4adf-b341-cb7a52f63050">100.0</ix:nonFraction>&#160;million in exchange for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="id15fe3c8a0254d78944bd1d10ea2a29a_I20191130" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIyNDk_856b14f1-0c0f-4e48-9ed5-6560bb4fe76a">2.5</ix:nonFraction>&#160;million shares of Epizyme common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b09b987997c4801be4424e787583ad3_I20191130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIyODY_5b4bfe13-e84c-4d4b-a519-d1b49cb6304e">20</ix:nonFraction> per share over a <ix:nonNumeric contextRef="i3b09b987997c4801be4424e787583ad3_I20191130" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTI_1f263840-d190-4901-9450-1ad5cb838bca">three-year</ix:nonNumeric> term and (3) Epizyme&#8217;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#8220;Eisai&#8221;). In addition, Epizyme had an <ix:nonNumeric contextRef="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130" name="rprx:OptionIndexedToIssuersEquityTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI0NDA_2d656d7b-6aaf-4002-bff7-7f61dc6e824d">18</ix:nonNumeric> month put option to sell an additional $<ix:nonFraction unitRef="usd" contextRef="ie250c596f2414ce2a10252ee5fe6b000_I20191130" decimals="-5" name="rprx:OptionIndexedToIssuersEquityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI0ODI_98a70e80-365b-4def-b7d2-0651dcc56dbe">50.0</ix:nonFraction>&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $<ix:nonFraction unitRef="usdPerShare" contextRef="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130" decimals="INF" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI1NTU_4b7ae913-5174-4d29-ab69-a47933718ed9">20</ix:nonFraction> per share. We recorded the put option as a forward purchase contract as of December 31, 2019. The exercise of the put option was settled in February 2020. As of December 31, 2021, the fair value of the warrant was immaterial. The warrant remained unexercised and was terminated upon Ipsen&#8217;s acquisition of Epizyme in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTE_60ec5ece-e115-40e6-8148-f819dae4e0ff" continuedAt="i0f87c37b6367432f955185bc21fa6901" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.549%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtMS0xLTEtMTMzNjY4_f857c9db-d469-414b-8612-7704ec912517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ee900d9be64dff809bae93067b329b_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtMy0xLTEtMTMzNjY4_b53d0aa5-c1e2-473a-8cab-a2ce3baf72cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtNS0xLTEtMTMzNjY4_a37368bd-77cb-426d-8ef8-f81e926a47d4">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtMS0xLTEtMTMzNjY4_e17f19f2-af67-45b4-a0ee-0644ec3d2ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ee900d9be64dff809bae93067b329b_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtMy0xLTEtMTMzNjY4_cec4c35d-bd42-4caf-87df-e1663dc84f97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtNS0xLTEtMTMzNjY4_5951428a-424b-4d69-9882-1451b55bf0d4">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b84d20eec148e8a629524fec68a0a9_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtMS0xLTEtMTMzNjY4_eac81b18-71e4-42f5-8118-a4f55d9cfdff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i584e4daf7e194c5892cde63718b1c7ca_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtMy0xLTEtMTMzNjY4_4deb9d8a-e69d-4991-96e5-017bb13224f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ab4d2a31844b79b2cc049b2d2d82a3_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtNS0xLTEtMTMzNjY4_e9354b58-f867-4261-aae1-cf4b309a5cde">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5401a91f4148caa202184655267c97_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTEtMS0xLTEzMzY2OA_9f5703cd-a540-451d-84f1-0a1a1360f9d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf13c3669b9445de801580639f1dcd01_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTMtMS0xLTEzMzY2OA_18c89d3a-f4bc-4e4c-9e88-716ca436b2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377698d44a004b60a93b6e026bb496b0_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTUtMS0xLTEzMzY2OA_42008f0c-8e45-4993-a576-d72bac80d287">6,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51deee71524e45f2b92578b1b7a69a43_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTEtMS0xLTEzMzY2OA_e99795c2-71ec-4fa8-9e39-c1b42d2bb881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78355224105441eeb9b89315786e6bb1_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTMtMS0xLTEzMzY2OA_a13c1175-3ecb-4f19-b31a-9492b39e940c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da8d7006a174307ad5d37753b978bd4_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTUtMS0xLTEzMzY2OA_620cd609-c26d-48cb-99d9-b0be2d1bfc80">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of other instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18b06181b4d43fbb3e315553e743a9c_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTEtMS0xLTEzMzY2OA_77040af1-2de3-4d20-a8e4-08fbfaf023ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6913761eb9d476a89d786eb84437c8f_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTMtMS0xLTEzMzY2OA_43c4f217-7b61-4da8-b36c-e49410260b3a">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bde215a2f7d41c19e08a08fda54ecec_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTUtMS0xLTEzMzY2OA_3c8209e2-f00d-4ad3-b6d6-9da6f9862367">25,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b208c40e457458888bdd3417e87cc6c_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTEtMS0xLTEzMzY2OA_b3ddf8f6-4ba7-4eaf-a1e8-ebf6bdee6a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a25c9fbeac4e028b27a42ea86ea95b_D20210101-20211231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTMtMS0xLTEzMzY2OA_656f14b0-c697-4588-8761-a59f89450a2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib489dd79da964d4f9415ec89293c3ae7_D20200101-20201231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTUtMS0xLTEzMzY2OA_66b5d7e0-c5f1-4583-b9af-3b873be3dfe0">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81792be75c1c4c2d9399629e922cab13_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTEtMS0xLTEzMzY2OA_6be033d2-ac9b-420b-b3d7-b6f26b7d463f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb080182b0d4caaa2be643121414d08_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTMtMS0xLTEzMzY2OA_0b44338c-b890-4fe8-a0a0-8ca650d601ab">16,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f43d56301b49e996fc395673d519ca_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTUtMS0xLTEzMzY2OA_809627c3-bf8a-49a8-88ea-bc67edb20b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone Acceleration Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b7ceeaef8dc42f28a13e4f9c0bb24d5_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTEtMS0xLTIzMjkyMw_bff47904-1f16-4d71-ba24-fc86a39766bf">96,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c740405d5a64a9b80be8f8b658e7edb_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTMtMS0xLTIzMjkyMw_8e15664f-3b82-44ac-8714-d3d0bdc05f22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09689e7a29b04e63b1743e322c38e197_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTUtMS0xLTIzMjk0Ng_9a3e91cc-aaa8-4e15-9153-fef9dd911c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><ix:continuation id="i6eff7bb6e88f44c8a68582e9d1d0ba81" continuedAt="ia000addcd0c14091a61b6a907307c08c"><ix:continuation id="i0f87c37b6367432f955185bc21fa6901" continuedAt="i15b294e2cf8743518505bc7db6c6fc75"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ia000addcd0c14091a61b6a907307c08c"><ix:continuation id="i15b294e2cf8743518505bc7db6c6fc75"> were released into earnings.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzkz_465c66e4-053e-4b1b-a487-74ca72c2fb1e" continuedAt="i89f11274ffad4fcd9824b01041b838a8" escape="true">Fair Value Measurements and Financial Instruments </ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i89f11274ffad4fcd9824b01041b838a8" continuedAt="ic422489071a6439ab6f8c8f2111c84dc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk2_002c9116-d947-49b9-a8fa-c8dbb34812e2" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fb45740e6145a5b10b66dd36b462b3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMS0xLTEtMTMzNjY4_532ae545-26c6-4089-9acb-8b3fa565b2a4">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib406778ea8824af6aae3c5dfb2e1610f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMy0xLTEtMTMzNjY4_5c0c2481-daf8-468f-ba99-79bda4c049d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a21bed221044a0890c2c913d788b8a8_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtNS0xLTEtMTMzNjY4_e666efbb-d9b3-4065-b910-be2cf956eca7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186084ca8b944fd98cdadde833e23388_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtNy0xLTEtMTMzNjY4_3e770ad7-a639-4c0d-bdaa-5d6a4786aa0f">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796975e015ca44e1a9105072f8fc8ba5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtOS0xLTEtMTMzNjY4_b7793d3d-468a-45e5-9825-48182bef5fe7">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1873077ea3a4449b93ac140b1258d597_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTEtMS0xLTEzMzY2OA_1f39cfbe-23fd-4ec4-a71e-0a111ab96944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4a77eb1b3c42f690d02b5f7c117bb3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTMtMS0xLTEzMzY2OA_553c5a4a-cd83-4fc9-adff-011cf422abb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4228e1020e84d28a5d3606eb13fba5a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTUtMS0xLTEzMzY2OA_6bd53fb2-1142-42a1-934a-18cb0d69a046">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce834481aa64cca87e9f3cc25a312ba_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMS0xLTEtMTMzNjY4_c9554988-9c67-4041-aba7-6717467ba8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba512b3b31444ed910800ea1536abc0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMy0xLTEtMTMzNjY4_673c71c5-ff1f-4f37-b78b-a92f82dfff4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29550347abe146f89941dfcd98915c01_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctNS0xLTEtMTMzNjY4_1dee2800-3107-46e1-8f3e-aa135710eeb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd2992133f24f0f9d76c8ca5fe08441_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctNy0xLTEtMTMzNjY4_becd2c3a-0d8f-461b-b56b-a72d6606a631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfec8d4041469bb92dd0165296ed5d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctOS0xLTEtMTMzNjY4_50a34ff1-536c-44c2-9386-260d8be5bfa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1f65e37bdc4ae98f2ef6443c0e36d2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTEtMS0xLTEzMzY2OA_9e331579-7e9e-42e8-90ca-52681b9ba332">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb596f160574fde859a997dd3688a51_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTMtMS0xLTEzMzY2OA_8e64a64d-7afd-459f-ada4-e27cc7cbc2f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1505389d35a4fe697a3107d3e1a4e20_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTUtMS0xLTEzMzY2OA_a468b601-be04-40be-ae80-f4ef96574953">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3ab05ebb3f4cefb671b072e85ae362_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMS0xLTEtMTMzNjY4_6923308c-19a9-41c5-84e7-0271930cce09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0a251553004651bae3fe39fca66f0c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMy0xLTEtMTMzNjY4_5fe55600-4835-45da-a407-3c43166f86b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2611175ae914a0cb275393ef07b82b6_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtNS0xLTEtMTMzNjY4_28332683-cc4f-4c7b-b452-9247ac5b9c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3e7cecd2194bba94c9ea68302d6da5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtNy0xLTEtMTMzNjY4_56a15a99-99ec-477d-923d-a83be27c4aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fb97cbac8b416db2ba868db73a9261_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtOS0xLTEtMTMzNjY4_d5520d6a-c402-4025-8518-9bf8efded1a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63036932758473e8e19c69328045159_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTEtMS0xLTEzMzY2OA_5cd1b7a8-08de-4256-86aa-93b052f0c6a0">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b041c7b1fd843f4801f45f69864a734_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTMtMS0xLTEzMzY2OA_9f79f32c-ebef-4e7b-84df-516b14e6fe99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513ac86b5f644e0abbd6fd515bf19a93_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTUtMS0xLTEzMzY2OA_76e351cd-360d-4864-9f6a-e1cbdaa13e11">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia930877a154f4ea397b7a9ed77275162_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTEtMS0xLTEzMzY2OA_2df49ebc-3629-4d59-95f4-eb68e58cea54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd6c9fd69b64ac3ada61bea9f9a809e_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTMtMS0xLTEzMzY2OA_7b456de0-6b7f-4ce3-9d55-ac9687a2f729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6606a8ffd244eb8b5538e380fb0155d_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTUtMS0xLTEzMzY2OA_904f23cf-4fec-47a7-8569-2dc2e9bc14a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2ed614ee654625b83a27f5186d6d46_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTctMS0xLTEzMzY2OA_32e9bd9d-069c-4882-9afa-930c50ad5ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf13afac5c747a58a510a05b6306845_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTktMS0xLTEzMzY2OA_16c699d7-4339-49d9-8c1a-b08ce1450de1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib747f5c2a7ac44d2adede24f51ea0ed2_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTExLTEtMS0xMzM2Njg_4167c1dc-bbe1-4468-8c7b-60ba4e80756f">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4e09328663481a88570d82f2b0b2da_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTEzLTEtMS0xMzM2Njg_90cd377f-f224-4c8a-8e3f-7472d3f4c2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f44f16ba8447af88c5f94ba782e24e_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTE1LTEtMS0xMzM2Njg_b72470cd-9995-4729-84fe-ac953f1f52e6">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886a32de12484bc3a8fa2095f96ce3aa_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEtMS0xLTEzMzY2OA_64b66b17-7b1b-4359-8fe9-34bab748af48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b749d46341641ce864db1980ea0eadd_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTMtMS0xLTEzMzY2OA_7c696830-e9fa-473d-9ff3-7390868e9acb">11,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d1f95532784cb4b004e23c96a53c2b_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTUtMS0xLTEzMzY2OA_43af00d9-8832-48ef-a0a0-280239148167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7913fe2f2f1f4f17975329f9e86b47f7_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTctMS0xLTEzMzY2OA_4f87b2fd-e715-4b5d-b002-ac47cbabe408">11,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8167718861cf4cc097ec7bc1722c4abe_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTktMS0xLTEzMzY2OA_c937066f-c654-4842-983d-f5805d2d00a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie34968ddaef047e5aee9da6ed328c6a2_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTExLTEtMS0xMzM2Njg_858f1c68-4215-4d22-ade3-261e10b05914">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc45285d96740488e652d34212bd6bf_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEzLTEtMS0xMzM2Njg_c85f2614-14d1-4139-99b9-8cad9aae1b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6ca2229ea245549c7358f77e0511f3_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTE1LTEtMS0xMzM2Njg_4f8caeb4-c215-476e-adfa-102b74eb7fa7">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6b624b7369483aab919710178f1675_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTEtMS0xLTEzMzY2OA_ff69ed42-46c5-4f95-9912-0a99ba788bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea5eb15f1b3454786bccad98927ed9b_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTMtMS0xLTEzMzY2OA_7bf58aaf-d044-479c-a65f-587a475ab2a7">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a230a360ef4bd6bdd4b1fde0b5e287_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTUtMS0xLTEzMzY2OA_9520e968-100e-4c16-a345-c2a061061773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bf206b0fe441d9a604aa40decf5e98_I20221231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTctMS0xLTEzMzY2OA_03dafea9-9186-4b86-8bda-c3a7e88a695d">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie196b18bfc6e42cdbb8fc1c9cf933b38_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTktMS0xLTE2MTQ4MA_c20e2f13-540a-4295-b18e-8bcb436fa0a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671467da1004443aadefa5fc4adc8a66_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTExLTEtMS0xNjE0ODA_e4acc287-8e4e-4370-9b75-cd278c032ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d09b91ce0940f8bf8d043a117aa8b4_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEzLTEtMS0xNjE0ODA_a625bf74-e2c9-4c5d-99a0-c8c92ce89e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9965e6b7e930491083134897c58109bd_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTE1LTEtMS0xNjE0ODA_0d098a5f-24ef-415a-a488-688173f234cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db25f68b5f64a1b83cb921118b07a8b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTEtMS0xLTEzMzY2OA_8fca8308-b376-445c-92a9-db99bd8aba29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de25f5e6375404c800880744168d22f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTMtMS0xLTEzMzY2OA_d70c5da7-318a-4959-8b6f-5193a892a04e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3db62c54fe54935bfbb368cd4dcd185_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTUtMS0xLTEzMzY2OA_13321129-a330-4175-a0b0-7d1691f0af16">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311eff96434042c48fc1a0da1a969d9c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTctMS0xLTEzMzY2OA_a596553d-6241-49c1-86f2-58c5ef30ab47">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89a50ad7a634d438a6aea813c2e2267_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTktMS0xLTE2MTQ4MA_98e807a0-5fd0-467b-9422-be2deb3865e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4aabe1887bb4026b0b128e258134f11_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTExLTEtMS0xNjE0ODA_b8e026bc-0fb7-4d1f-88bc-c4a6723840b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTEzLTEtMS0xNjE0ODA_ed1819cf-6e97-4b00-9946-e8c45929733b">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d1415d925c4be3a6b3679f2f242c45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTE1LTEtMS0xNjE0ODA_e6f7c314-2e1c-47ea-8850-b32f8af8c6ba">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTEtMS0xLTEzMzY2OA_76341c49-6c89-4c60-9f62-210c2ba48ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTMtMS0xLTEzMzY2OA_a2a92bb5-98c6-46c4-bc3a-4c792c274f3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTUtMS0xLTEzMzY2OA_6a506b69-2828-49ed-a820-c4e886c78360">86,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTctMS0xLTEzMzY2OA_1e6527a6-0fe9-4f07-bfec-13926fc599fa">86,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTktMS0xLTEzMzY2OA_6bf19c6d-9d83-4d0c-8367-d8d80869666a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTExLTEtMS0xMzM2Njg_a2ca4678-3260-4453-bb03-5d114c5c14b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTEzLTEtMS0xMzM2Njg_0c1ecd73-a24b-4392-a980-5162cf407550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTE1LTEtMS0xMzM2Njg_63d7e232-bf9e-4d9c-9665-846003e1f5a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTEtMS0xLTEzMzY2OA_d12d7af9-3bdf-453c-b570-c1eec2c61b5d">5,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTMtMS0xLTEzMzY2OA_49a74228-f0fe-418a-a64a-57b0b958bfc2">24,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTUtMS0xLTEzMzY2OA_dbb5e92e-e75a-4245-9eca-85dab0f91f04">87,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTctMS0xLTEzMzY2OA_72d7093a-ca44-44f0-a86b-a6f0f8c59054">116,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTktMS0xLTEzMzY2OA_12bebc1d-9089-43f2-8336-47c032aed7bf">598,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTExLTEtMS0xMzM2Njg_eb24e9a2-9612-4340-b98b-ac1ffcc5a903">636,823</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTEzLTEtMS0xMzM2Njg_0192c31c-d157-418d-9ab1-1053fed7854d">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTE1LTEtMS0xMzM2Njg_3f07d779-a843-42c9-a736-60965cc5a571">1,301,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTEtMS0xLTE2MTQwNA_d76595e0-2d2e-427c-80d9-9ce36e445870">103,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTMtMS0xLTE2MTQwNA_3c4e91a7-1f00-4b40-bc81-2ed205a31f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTUtMS0xLTE2MTQwNA_aaa4c893-8a4c-4a96-a22d-5770b64aa892">8,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTctMS0xLTE2MTQwNA_f90cbaef-fda7-473d-9f42-e7f6ba59e830">112,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTktMS0xLTE2MTUwOQ_b121ae3c-8a5c-4a02-a597-6e468c160ef4">226,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTExLTEtMS0xNjE1MDk_128ce806-dbe6-4605-827c-d509dd87e034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTEzLTEtMS0xNjE1MDk_e88018cd-0f13-4af5-a368-4747d7a05166">43,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTE1LTEtMS0xNjE1MDk_930d04e4-9bf5-4f1b-9d8f-32244d683ac6">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db25f68b5f64a1b83cb921118b07a8b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTEtMS0xLTE2MTQwNA_2056f1d0-11ff-404c-b89f-d1270702a519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de25f5e6375404c800880744168d22f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTMtMS0xLTE2MTQwNA_a51021ac-1c32-4af9-9a76-82b958c550e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3db62c54fe54935bfbb368cd4dcd185_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTUtMS0xLTE2MTQwNA_7f1aca09-b196-4007-bd5c-4985693790aa">226,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311eff96434042c48fc1a0da1a969d9c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTctMS0xLTE2MTQwNA_4aebd9f6-7f8e-4593-b39b-38822d92e73f">226,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89a50ad7a634d438a6aea813c2e2267_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTktMS0xLTE2MTQ4MA_937b3479-8cf4-4194-b04a-d18bdea40c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4aabe1887bb4026b0b128e258134f11_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTExLTEtMS0xNjE0ODA_267b7c7e-f85c-4728-83b4-6295399b7581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTEzLTEtMS0xNjE0ODA_52ce2463-66f4-4ae4-968f-1c8656d476ba">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d1415d925c4be3a6b3679f2f242c45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTE1LTEtMS0xNjE0ODA_d628bbeb-2228-4b15-8d49-a5286b260c54">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4355b2c313964e16a9cc70955cb99e95_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTEtMS0xLTE2MTQwNA_5b9d7fdc-ec35-4624-93c8-60e41d646e40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87bec58187049c0b4315cc2e7e75220_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTMtMS0xLTE2MTQwNA_2c8c4c21-8a09-4b0a-a7a7-0132f4822868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b1de3d1e04b99b1569a7a6cca90fb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTUtMS0xLTE2MTQwNA_b3ecce17-cc1b-44ee-98ba-3099d48b2554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40c65086ad44d44b48a424f98b6eba8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTctMS0xLTE2MTQwNA_60639c3e-2130-4f2b-9586-9861b8ae8206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief66559de8974b67ad08f5c7e106bc13_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTktMS0xLTE2MTQ4MA_832e1aae-f88f-4f97-8015-75b41ac03dd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0284f5e21ce642a7876ab339f755553c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTExLTEtMS0xNjE0ODA_84441ebe-5887-4663-8692-89e570820ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70136bdb09f640f6a595ebcc3b848490_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTEzLTEtMS0xNjE0ODA_964ee98b-1e94-4978-b921-5ef1c5506956">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18426df2a74c460381450590d12af14e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTE1LTEtMS0xNjE0ODA_b6247a24-89fe-4db7-aa0e-1e5c242cce8d">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTEtMS0xLTE2MTQwNA_b6ef26d1-3710-4dc5-bd3b-29ce23084aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTMtMS0xLTE2MTQwNA_c4ec1ee6-bedd-493e-a1f2-819e3efb8091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTUtMS0xLTE2MTQwNA_21159d1e-fd1a-4fad-b5c4-5409936b52cd">10,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTctMS0xLTE2MTQwNA_bb29a88e-8096-4a69-bea5-204fe53c6636">10,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTktMS0xLTE2MTQ4MA_4d3ac494-bef8-4438-9a87-6dc042a68f98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTExLTEtMS0xNjE0ODA_12b2cce2-6fa7-4f60-8c18-1796a823fa97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTEzLTEtMS0xNjE0ODA_e5c3fe70-7628-4cae-b2e1-93dd5c6bc3f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTE1LTEtMS0xNjE0ODA_fcd0dfe6-0b2a-482a-9d78-5753ec8484cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386b4142f4104da8bbeb674cc226ccf2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTEtMS0xLTE2MTQwNA_a8bc367a-37eb-485b-bc50-b16fe0cc3d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c35e8641845417891560b40c078c58b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTMtMS0xLTIyNzQwNQ_2b7bdeb9-ee74-4d0b-949e-59ea2ccb7bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b89ba5713246ecb69cbe5915280e12_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTUtMS0xLTE2MTQwNA_e8e4df2f-c3dc-4bb7-b066-686c9c7b1945">14,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic244222348804b5795bfab47417210e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTctMS0xLTE2MTQwNA_5b2224bc-b934-4c9d-a386-87cb70ecc537">14,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffc8574733247448667f38369095447_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTktMS0xLTE2MTQ4MA_fba69417-29e8-48f3-8971-abafc8fe9859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b7ad3a58f94ab791be7207d0fe8590_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTExLTEtMS0xNjE0ODA_bc85f3a4-7a4c-4831-84f6-daf5545d6e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if339554672b642ae891f1ba2a6cbf38c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTEzLTEtMS0xNjE0ODA_41a2da28-e496-4447-8c14-416216f6affc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b55421b8464ed6a1a539d99d821dba_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTE1LTEtMS0xNjE0ODA_ba07fb27-2df4-4400-81bb-ba057c858e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTEtMS0xLTE2MTQwNA_8ba88f33-0adc-4d56-be59-a52054cffc15">103,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTMtMS0xLTE2MTQwNA_0c299a62-4a85-484c-a8c0-4196c89fcdc5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTUtMS0xLTE2MTQwNA_c2736331-4c7c-4801-bab5-e5663bebccd8">259,732</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTctMS0xLTE2MTQwNA_3aa6b53a-4eae-4e39-823f-86baf73e5457">363,608</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTktMS0xLTE2MTUwOQ_6c468137-5363-48e5-b677-703fd6880cef">226,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTExLTEtMS0xNjE1MDk_e58aa6ed-e927-4f8f-8543-6bec81f335aa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTEzLTEtMS0xNjE1MDk_cec3b441-079d-4261-b412-2d2ca4201ab2">247,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTE1LTEtMS0xNjE1MDk_fcb32fd1-314e-4c1c-bf2b-74d72eb9008e">474,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84360bddd1754c6aa91800aaa849b568_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTEtMS0xLTE2MTQwNA_3d7ef6f2-ffc9-4dba-9756-a182bcb4a466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ee4838df9e479ca3a26e0b99bd5d60_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTMtMS0xLTE2MTQwNA_80814f84-76dd-47dd-b329-2add5d84d4a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85817d340b744538889a7450f9dbd2e0_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTUtMS0xLTE2MTQwNA_9a9767ab-fcfd-4f8f-8f6a-df9222344dd5">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07a9073c101943dcb449f3c807e6fabc_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTctMS0xLTE2MTQwNA_ce442b0f-66ea-4f18-b3b4-c97120b6f763">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2169911e4a4795a6d397f381a2d74e_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTktMS0xLTE2MTUwOQ_8f5963fb-f452-43f8-a2c6-b6cbcea00af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8693ab100ea8484492349f889e6977b6_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTExLTEtMS0xNjE1MDk_59dae278-01b9-45ff-a174-55d2cd9b8e46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8240f1e3dadf4870b07c601e66065543_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTEzLTEtMS0xNjE1MDk_1d060163-fe0c-4182-8b5e-ae6fe694333e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6203b19a65da4c90ac16749d22ed023f_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTE1LTEtMS0xNjE1MDk_d7688e7b-b25c-4697-a0fe-f16e88ee7bb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTEtMS0xLTE2MTQwNA_80f2d1a1-3a44-4c7b-8423-3324cb15d7c1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTMtMS0xLTE2MTQwNA_5cee8d8e-196c-43d7-b817-fa8b523ddc0d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTUtMS0xLTE2MTQwNA_a91b5654-a1d8-4bd7-aeb0-a5c6c4f4a74c">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231" decimals="-3" sign="-" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTctMS0xLTE2MTQwNA_d1dbec48-c988-4b48-8ea6-046acde7b365">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTktMS0xLTE2MTUxOA_7d7304ee-2f52-4704-abee-647cbdaff3a9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTExLTEtMS0xNjE1MTg_710362f0-cc2c-4ec2-b198-c3978fa30132">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTEzLTEtMS0xNjE1MTg_e584aedb-27fc-435e-b942-d3d2a4c6839f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231" decimals="-3" name="rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTE1LTEtMS0xNjE1MTg_cc37a97e-13a5-43b8-a5b1-9fd0bf52f8cc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of December 31, 2022, amounts reflect the <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTk3MDY_8cf178d4-8e65-4ee0-a9a9-9df1d17ac491"><ix:nonNumeric contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" name="rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTk3MDY_c2c678c1-e1d6-40ad-b03c-fa61cf22f98b">fair value</ix:nonNumeric></ix:nonNumeric> of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds. As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761">Milestone Acceleration Option</span></span>.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the consolidated balance sheet. See Note 9&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments.</span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 and 2021, we recognized losses of $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzI3NDA_ec9c4e5d-9cb2-46c5-834a-9cc8b6f44b32">39.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzI3NTQ_6cddeda8-61ec-449a-ba85-8b61d2b416e1">41.4</ix:nonFraction>&#160;million, respectively, on equity securities still held as of December 31, 2022. There were <ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY2MDA5MTg_f126de01-dfb2-464d-8859-8f442ed83024">no</ix:nonFraction> gains or losses in 2020 associated with the equity securities still held as of December 31, 2022.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic422489071a6439ab6f8c8f2111c84dc" continuedAt="ib95b6d470971460ea5557ec35775ebda"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk1_7b35a12c-603f-4dff-9479-312643807a99" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0796e20c9d41059187f605c28f22c8_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMS0xLTEtMTc4MjQ4_9284bbaf-fce6-49a5-abb0-df883a75cd0b">43,013</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0371a080d9412b814cd70dc8e5ad90_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMy0xLTEtMTc4MjQ4_7e775434-e40d-46d2-8a27-7e48d08b344f">253,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6e062894f1415ba03737996d595769_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItNS0xLTEtMTc4MjQ4_8fa4b96c-2d8c-4e47-933f-cfe0d59a3814">16,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806d566ae63e4dd1bb3b094e2720d64b_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItNy0xLTEtMTc4MjQ4_0cd67ffb-0e97-40f0-83c8-5302d929219b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf58ad8accb4f42904d7cca513f316e_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItOS0xLTEtMTc4MjQ4_31ec5170-5e32-4218-abd3-9157d96d2331">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9ad39844434b80bc9e6f439efedad1_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTEtMS0xLTE3ODI0OA_3a6a2507-a69a-43ee-a712-019a410089af">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd997478ad974d568fbddf3f973a46e7_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTMtMS0xLTI0NzczMA_295d749a-e5c5-47e0-840b-76a0de07e491">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99e011b5e4c43d9b3b72a4b809c2f49_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTMtMS0xLTE3ODMwNQ_cd7ccb1b-be2c-4ea2-bf83-98d31f63f7d4">214,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41f6ecb8c944a33bdde5a9125f24870_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTUtMS0xLTE3ODMwNQ_2f3694ef-0289-4d73-88d9-782e431a99e1">18,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMS0xLTEtMTc4MjQ4_07aaccbd-ddd8-419f-b701-f082779979be">28,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMy0xLTEtMTc4MjQ4_6941e347-d8ad-44fa-8214-bccffafd5242">479,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTEtMS0xLTE3ODI0OA_ab13dbf9-d157-4e88-979d-36ba8401bc00">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTMtMS0xLTI0NzczMA_dff365eb-4e85-4325-84bc-09716b7af761">35,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTMtMS0xLTE3ODMwNQ_52a2c3eb-0678-417d-ac83-94b609bc4414">70,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzQtMy0xLTEtMTc4MjQ4_f1033b17-cc24-4442-b8d9-89899ff2b75b">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzQtNy0xLTEtMTc4MjQ4_6d836d00-34c5-4ada-af8a-626d1288b775">9,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzUtMS0xLTEtMTc4MjQ4_0814925e-cf9a-4e7a-9b7d-480a3ebedbd6">22,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzUtMTMtMS0xLTI0NzczMA_410d0b6a-1281-4e05-8cb6-b600d62ece16">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a0bb5b28394f50af0be743d1778ecc_D20220101-20221231" decimals="-3" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzYtOS0xLTEtMTc4MjQ4_abe09fa9-3e7c-4e69-a442-00f9461ac254">96,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzctMy0xLTEtMTc4MjQ4_9046d3a0-e925-422f-908e-56dea46dd07f">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzctMTMtMS0xLTE3ODMwNQ_bf923c37-a1f6-4e3f-a2c0-a32bf2fec68e">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on available for sale debt securities included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMy0xLTEtMTc4MjQ4_89743965-a1ce-429d-88ce-3e7692a6991d">67,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtNS0xLTEtMTc4MjQ4_2d77f594-4494-4920-9f6d-e9c01868b106">62,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtNy0xLTEtMTc4MjQ4_5b348d55-b705-4440-b41f-bc37905b0dcf">6,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMTMtMS0xLTE3ODMwNQ_44a459e5-387c-4b99-9e11-4361af40aa09">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47c45e714054471849ababb1fb4798c_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMTUtMS0xLTE3ODMwNQ_f3cc6be8-de38-4ff1-a8fb-10fdfd76cdb6">16,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzktMTEtMS0xLTE3ODI0OA_a8ee2af0-ca08-467f-96e8-4676aef0f39e">6,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTMtMS0xLTE3ODI0OA_4aedcaf8-9c94-467e-9aee-297da6c85bab">79,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTUtMS0xLTE3ODI0OA_a0fb6f30-c4f4-4850-b93e-5b1f1c8866aa">79,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTEzLTEtMS0xNzgzMDU_4c163e92-07e2-4c2c-8056-d7349271f5aa">18,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia47c45e714054471849ababb1fb4798c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTE1LTEtMS0xNzgzMDU_49aa71d1-ee7a-4f71-a34d-f14b1af38605">18,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer out of Level 3 (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzExLTEtMS0xLTE3ODI0OA_15c05d0f-7339-4318-81eb-33c067f4f53e">40,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEyLTMtMS0xLTE3ODI0OA_9dbd41d1-b294-4391-a365-0461bc2bf5f0">542,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEyLTEzLTEtMS0xNzgzMDU_a1ea3eaf-9f9a-4b2c-a391-10898b097efb">62,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e61aeea53b148b68f5668ae4c89ca1f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEtMS0xLTE3ODI0OA_a37d468a-59f0-468d-bab2-1f47772ae879">8,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf0e3d7700c4f61bcb0877b468b7e92_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTMtMS0xLTE3ODI0OA_2124feef-9bd8-4e6c-a612-ba381520fc3c">227,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8413cab6c79345889a6dcd08bb93b8a9_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTUtMS0xLTE3ODI0OA_eed2994c-e0e2-42c3-9b4f-028c2d0d9604">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bc4135d264f4850ac652f81ebdd7653_I20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTctMS0xLTE3ODI0OA_9fd76604-9f9e-4022-af6c-2b90f6225ee2">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8dafb087fc4a46989b1599f69c7c66_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTktMS0xLTE3ODI0OA_ae615612-d113-43e3-9e0a-9678e9546972">96,610</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12caaaf5dc4b4f7bb3868430bd3b390e_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTExLTEtMS0xNzgyNDg_42f315e9-4ff6-4404-8056-f8972ec3f9fc">14,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0796e20c9d41059187f605c28f22c8_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEzLTEtMS0yNDc3MzA_c6499a99-b515-4e4c-aaf2-a1b950ab4e06">43,013</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0371a080d9412b814cd70dc8e5ad90_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEzLTEtMS0xNzgzMDU_8b9a717e-bbfe-4259-9b8e-3fbef11d4ec3">253,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6e062894f1415ba03737996d595769_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTE1LTEtMS0xNzgzMDU_6b7e9b4d-e8da-4be3-871a-d4fbbbe3e8a9">16,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Following Pfizer&#8217;s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition. Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $<ix:nonFraction unitRef="usd" contextRef="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNTQ0ODcyMTM2NDg0_80cad03a-8dab-457f-a7e8-481ee2395338">150</ix:nonFraction>&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares. Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the expiration of the transfer restriction on BioCryst common stock.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ib95b6d470971460ea5557ec35775ebda" continuedAt="id8b1adc973eb4cde865ddca1cfad6daf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApiJect Investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value as of December 31, 2022 of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (&#8220;ApiJect&#8221;), a private company, in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cytokinetics Commercial Launch Funding &amp; Funding Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#8217;s assumed cost of debt, which would impact Cytokinetics&#8217; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of <ix:nonFraction unitRef="number" contextRef="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzU0OTc1NTgxNzgxNzg_3d383faa-82fd-4c95-b47a-37178c340c2e">30</ix:nonFraction>% and an assumed risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzU0OTc1NTgxNzgxODU_f069c7a2-5d46-4830-a432-4dca937122f4">13.5</ix:nonFraction>%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we purchased <ix:nonFraction unitRef="shares" contextRef="i3c4a1403d54240dea67d826b88016777_D20211101-20211130" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzEwOTk1MTE2NDgzNjY_f9cdedda-fe6c-4266-87aa-9b5b083b3b12">3,846</ix:nonFraction>&#160;thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;). As part of the transaction, we were restricted from selling the BioCryst common stock for <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzEwOTk1MTE2NDg2NjU_404ec3ba-aed5-46b3-ba71-1e535098ba43">six months</ix:nonNumeric> following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#8217;s common stock, which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the second quarter of 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds &amp; Forward</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the Development Funding Bonds and the Development Funding Bond Forward as of December 31, 2022 and 2021 were based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair values could be significantly higher or lower.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="id8b1adc973eb4cde865ddca1cfad6daf" continuedAt="i06385b612a4d4898be5174dac9b3c5a2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Series A Biohaven Preferred Shares</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares were redeemed following Pfizer&#8217;s acquisition of Biohaven in October 2022. The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which results in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a <ix:nonNumeric contextRef="i7c629d986ffc48cfa2eb9caa4dd6242b_D20220101-20221231" name="rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk4_3de19a00-e6e3-4d4c-812c-e3176288eddd">four-year</ix:nonNumeric> time period and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="idb876c0578a24141af7bab85dbf86a2d_D20210101-20211231" decimals="4" name="rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzM4NDgyOTA3NDI2MTE_0ebe5625-05e4-44ae-9e85-2831a9049c20">9.5</ix:nonFraction>% as of December 31, 2021 could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares &amp; Forwards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All remaining unissued Series B Biohaven Preferred Shares were purchased simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The fair value of each of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 was based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the &#8220;with-and-without&#8221; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer&#8217;s cost of debt and management&#8217;s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower. The fair value associated with this instrument was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i06385b612a4d4898be5174dac9b3c5a2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts&#8217; consensus sales forecasts. These projected future royalty payments by asset, along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzky_23b79d9f-3f82-41b1-9642-6294b76f75bf" continuedAt="iffef1812a57b4bcfa8414455d1b861fb" escape="true">The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><ix:continuation id="iffef1812a57b4bcfa8414455d1b861fb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc4b8074b244545ab8c7b941208037b_I20221231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItMS0xLTEtMTMzNjY4_c731c657-b7f4-4d3a-9752-2269f10086b9">17,314,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892ba36fbecd4c5c828c453e8b75d851_I20221231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItMy0xLTEtMTMzNjY4_0e440844-a7d7-4b45-add3-a660abc9a134">13,493,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94aede0a88af4f98b9e9b7e04739e350_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItNS0xLTEtMTMzNjY4_536faabd-13ab-407b-bd94-b47a3a669b98">19,047,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac2696acac7403eabc89c247ae97720_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItNy0xLTEtMTMzNjY4_594f621d-0252-4bf8-9031-e95cfae7f2b9">13,718,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:FinancingReceivablesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI5NDA_d9b04bad-77e5-4174-a73e-ba307719088d" continuedAt="i3d067708dfb14635b41e59a365ff0949" escape="true">Financial Royalty Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3d067708dfb14635b41e59a365ff0949" continuedAt="i662f7740fa0a43ea81080dcb99aaf21e"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI5NDI_4560c851-dc23-40b4-b29d-d3e23a55a42d" continuedAt="i079d49e6f7e14bf6968906c372cc4b7c" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItNC0xLTEtMTMzNjY4_8bac0137-6867-4f2c-8d43-6eb5ff25c5e0">5,333,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItNi0xLTEtMTMzNjY4_2a601ce5-c480-4579-a8a4-3c459f771d65">10,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItOC0xLTEtMTMzNjY4_2e7bc2e2-24f3-49f8-9f80-95f6724636df">5,322,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtNC0xLTEtMTMzNjY4_bfd3a33d-cbb6-4f65-912d-b571e2a411a2">1,683,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtNi0xLTEtMTMzNjY4_1bce0a8f-c5a5-4342-8040-ea20aa556907">212,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtOC0xLTEtMTMzNjY4_9510ae4a-c3ca-4fd1-94a5-6ed20e363cd3">1,471,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtNC0xLTEtMTMzNjY4_950cb928-0246-47b0-90c9-a47fab3198e7">1,284,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtNi0xLTEtMTMzNjY4_bad8c103-2a34-4902-95a8-67aae961bfe0">24,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtOC0xLTEtMTMzNjY4_1082f07f-341b-4a93-93a9-1af153625fdf">1,259,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtNC0xLTEtMTMzNjY4_70888515-d580-44de-8c9c-928688e674e5">894,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtNi0xLTEtMTMzNjY4_687481ce-057e-48c2-9414-50ac846451d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtOC0xLTEtMTMzNjY4_c1e16e86-46a6-452a-81a5-87d8d0fe12cf">894,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtNC0xLTEtMTMzNjY4_f9c70cf4-2787-4baf-b3bd-64f33737731a">1,436,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtNi0xLTEtMTMzNjY4_9680b5c8-52e4-4736-b3b1-74fad4bb6626">660,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtOC0xLTEtMTMzNjY4_6f949588-1829-420f-a521-5200187be927">776,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663288bef185415e913cccac3fdce980_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctNC0xLTEtMTMzNjY4_65011949-6049-4bf0-a6e3-99b6bb37e3af">1,009,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i663288bef185415e913cccac3fdce980_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctNi0xLTEtMTMzNjY4_4f76e86a-0fa3-4f7e-a3c3-cd442834241a">235,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663288bef185415e913cccac3fdce980_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctOC0xLTEtMTMzNjY4_36269408-2368-4ed0-b63c-750b52d4bd76">773,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtNC0xLTEtMTMzNjY4_6d2c0ce4-5cb0-4c86-b63e-c3ae94f272e2">5,134,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtNi0xLTEtMTMzNjY4_8414a085-1cff-4016-b519-9fbd6ac1850b">1,332,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtOC0xLTEtMTMzNjY4_611e652a-fe47-4e33-93ba-339129f110bf">3,802,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktNC0xLTEtMTMzNjY4_88bfcbd6-cd25-4070-b4ac-1829e6e6e6c3">16,776,307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktNi0xLTEtMTMzNjY4_af9dcc5e-7b56-45ba-9406-33a2d92ac581">2,476,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktOC0xLTEtMTMzNjY4_491223ff-b089-46b9-a8b7-953170635b0e">14,299,847</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzEwLTgtMS0xLTEzMzY2OA_5101990e-c223-4b06-aea7-f426772b6081">115,422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzExLTgtMS0xLTEzMzY2OA_c10dadfb-c77c-4ff5-ac94-161a0d335c67">14,184,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i662f7740fa0a43ea81080dcb99aaf21e"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="ia5208a4b0fa34da2ad818a6631d4834a_D20221001-20221231" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzEzMTk0MTM5NTQ1NTU1_296683f4-8dda-4ac2-bc0d-a7ddbc611067">160.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia3cf7b243e4b44089454ec775107f6b1_D20221001-20221231" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzM4NDgyOTA3MTAyODk_ef9994d7-3725-4f9a-b500-4b4753cef4d4">273.6</ix:nonFraction>&#160;million of non-cash impairment charges for otilimab and gantenerumab, respectively, both unapproved financial royalty assets held at cost. The impairment charges were recorded as a result of GSK plc&#8217;s announcement that it has decided not to progress with regulatory submissions for otilimab and Roche&#8217;s statement that it would discontinue clinical trials of gantenerumab. Included in the total financial royalty assets balance of $<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-8" name="us-gaap:NotesReceivableNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzQzOTgwNDY1MjYxNDE_0271fa54-b713-46b0-90ad-c5ba6cf11d69">14.2</ix:nonFraction> billion as of December 31, 2022, is $<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-5" name="rprx:UnapprovedFinancialAssetsHeldAtCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzM4NDgyOTA3MTExMTA_aae19281-f608-46af-89ad-2d5e682271f1">533.8</ix:nonFraction>&#160;million related to unapproved financial assets held at cost: zavegepant, seltorexant and olpasiran. Additionally, during the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i4429291ceec343fd99325883de8cd9b9_D20221001-20221231" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzYwNDczMTM5Njk5MzQ_35bbc93c-fc2c-4e70-aebb-0a564f952c3f">182.1</ix:nonFraction>&#160;million due to the uncertainty of Gavreto&#8217;s commercial outlook. These impairment charges were recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial royalty asset impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i079d49e6f7e14bf6968906c372cc4b7c"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItNC0xLTEtMTMzNjY4_db8844c1-ae12-41a6-ad24-917e32a15639">5,335,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItNi0xLTEtMTMzNjY4_045e02b2-c5a8-4bc8-9634-c679736ffdb1">48,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItOC0xLTEtMTMzNjY4_d2d8b02d-9a5a-404e-bc0b-c16c31ebe1bf">5,287,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154af41306544e04b3092509a83bb96f_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtNC0xLTEtMTMzNjY4_d5fc0406-b999-4c0e-ba1c-75d1188b9e39">1,846,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i154af41306544e04b3092509a83bb96f_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtNi0xLTEtMTMzNjY4_53361dbb-e6fa-49a9-9492-65b02f794faa">16,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154af41306544e04b3092509a83bb96f_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtOC0xLTEtMTMzNjY4_4f4c753a-ea35-4d9d-8c93-ff66e907a50f">1,829,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtNC0xLTEtMTMzNjY4_be1c7be1-a439-467a-9b80-294e4a9e1053">1,438,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtNi0xLTEtMTMzNjY4_d133077a-fdaa-4b91-b9c6-880d82ee96d2">236,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtOC0xLTEtMTMzNjY4_38de0cfb-25b3-47db-96ed-8264e6abe9cf">1,201,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtNC0xLTEtMTMzNjY4_83ce5b8b-250a-4225-8017-21dcdbad8810">1,100,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtNi0xLTEtMTMzNjY4_7ef25e9a-0b85-4a02-b3b5-09faf9ac5999">172,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtOC0xLTEtMTMzNjY4_740568f7-a41f-4f68-add6-a0c04f33278c">927,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtNC0xLTEtMTMzNjY4_af414e83-620d-47a1-a4a0-140de43f73b7">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtNi0xLTEtMTMzNjY4_c5b1fe43-47ae-45d8-8d61-3cd0edd2acb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtOC0xLTEtMTMzNjY4_1dd24815-cd80-4a00-8105-9b78358d9977">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctNC0xLTEtMTMzNjY4_c76c8436-5d63-410a-951c-0275294832d2">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctNi0xLTEtMTMzNjY4_99d6adf5-575e-4bae-b957-73b71964bb26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctOC0xLTEtMTMzNjY4_da818333-9fd9-4dc2-86d2-4adaa1dedff2">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtNC0xLTEtMTMzNjY4_0ffa911e-3112-4822-8adb-95fc594a7b8f">4,697,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtNi0xLTEtMTMzNjY4_b26c1106-8a20-4ab2-9564-816876a4ba47">909,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtOC0xLTEtMTMzNjY4_3c4005fc-1d35-4788-a6e7-948b4d713886">3,787,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktNC0xLTEtMTMzNjY4_aed92430-7663-4da8-97bb-02af01729181">16,027,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktNi0xLTEtMTMzNjY4_3a658daf-e9db-4fc5-a14b-ee868a70b9d7">1,384,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktOC0xLTEtMTMzNjY4_92bad12a-5120-469c-a5c8-cdf25a19d27a">14,643,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzEwLTgtMS0xLTEzMzY2OA_ed3d9ec6-9d53-4d51-a611-7e8095517347">310,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzExLTgtMS0xLTEzMzY2OA_2ddec4c4-8f39-481a-b3e6-c4e51c0cc65a">14,332,596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $<ix:nonFraction unitRef="usd" contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231" decimals="-8" name="rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI3MDQ_07f4bc26-eb28-499a-8da2-efdf86e6dc29">1.3</ix:nonFraction>&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzI3NDA_fe1d8439-4831-433b-a589-2f1e18d6fe00" continuedAt="ia24fcc13c0164a819fc82b8c461c2b16" escape="true">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia24fcc13c0164a819fc82b8c461c2b16" continuedAt="idf4d879a470745c88bc55bc2e6d84f11"><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated using sell-side equity research analysts&#8217; </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consensus sales forecasts,</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the write-off of cumulative allowance at the end of a royalty asset&#8217;s life which only impacts the consolidated balance sheets, and</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="idf4d879a470745c88bc55bc2e6d84f11"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzI3Mzk_1ad8072b-7e1c-478a-98d6-eaac5be5ebd6" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6924ffcc56464af49725a154112a2c81_I20191231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEtMS0xLTEtMTMzNjY4_f9af9d60-592d-4a80-b7fc-500e044265cd">868,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2485d51e396d457d82d53b0d720876f9_I20191231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzItMS0xLTEtMTMzNjY4_28403238-0bdc-4865-83dc-a790893d0232">192,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzMtMS0xLTEtMTMzNjY4_bde5e576-c0de-4337-b33d-c1d018364afc">645,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzQtMS0xLTEtMTMzNjY4_54d0d7dd-c0ad-4f6b-91a5-92e5f1cd3d4f">570,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzUtMS0xLTEtMTMzNjY4_d224f1fb-74cc-47d5-87a1-73416e72918a">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzYtMS0xLTEtMTMzNjY4_1fe6916e-c788-4685-8f86-76c20bae7436">25,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzctMS0xLTEtMTMzNjY4_9a5c4e36-1aed-42f7-8aba-64460c51e1f1">156,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzgtMS0xLTEtMTMzNjY4_d4422804-d0a3-4a22-8438-0cf038ad692d">1,263,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEwLTEtMS0xLTEzMzY2OA_9f9deaa3-8785-4517-9bb5-6d4bb604cef9">912,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzExLTEtMS0xLTEzMzY2OA_eb7f0696-1668-4577-a4a5-66b147186158">446,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEyLTEtMS0xLTEzMzY2OA_c2352907-a3be-433c-864c-7155a9ceb1bf">21,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE0LTEtMS0xLTEzMzY2OA_609c023f-7b85-48db-8b7c-b73363500bff">12,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE1LTEtMS0xLTEzMzY2OA_2869ba2b-59b3-46be-a3f7-516fc21e1e8a">1,694,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE3LTEtMS0xLTEzMzY2OA_2dd340d6-5779-418f-99a6-43a1444ea3c4">1,394,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE4LTEtMS0xLTEzMzY2OA_e1d1ed2b-053f-4542-be76-03302479f98c">296,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE5LTEtMS0xLTEzMzY2OA_940fb2d2-5394-4725-9854-9e8eab5f1a82">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIwLTEtMS0xLTIyNDA4MQ_33dda8eb-60b1-4f08-b380-9b427915617c">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIwLTEtMS0xLTE3ODAzNw_7a2fcb24-5e6d-4a96-aa5b-3df81647c02a">193,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIxLTEtMS0xLTE3ODAzNw_a6d4807f-e90f-456a-b88a-fb4c98dfcdd9">2,591,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-5" name="rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzE2NDkyNjc0NDI5MzIz_cced7c04-3c61-4c26-8079-e7d17e331737">90.2</ix:nonFraction>&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik. For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">by increases in the value of zavegepant. For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzEyNTM_4649b5ee-6103-47e2-85f5-4e1cb4315995" continuedAt="i9352a4c545e34a01a63ace6a75e51dfe" escape="true">Intangible Royalty Assets, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9352a4c545e34a01a63ace6a75e51dfe" continuedAt="i5ab52e5a740c49779bb9135a827b7d9d"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the first quarter of 2022. Our royalties on the other DPP-IV products have also substantially ended. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzEyNTQ_e46e4620-19f7-48c3-b426-82525bdff292" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItMS0xLTEtMTMzNjY4_65d90586-7162-45e3-b617-5848883e0b9f">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItMy0xLTEtMTMzNjY4_c198fabc-8f18-4648-b70a-67604fa5d11d">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItNS0xLTEtMTMzNjY4_69d5105a-e776-4a4a-886c-70d08752b108">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtMS0xLTEtMTMzNjY4_1f8fce33-ec10-4b1b-8bec-ba7476f8e600">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtMy0xLTEtMTMzNjY4_f6cfbcbf-277b-4372-b3e2-560419d72828">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtNS0xLTEtMTMzNjY4_d23ff188-a80d-47df-81d8-d816ec6fb896">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ab52e5a740c49779bb9135a827b7d9d">Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for <ix:nonFraction unitRef="number" contextRef="ib252428d952a4cf3902a48bd039d459d_D20220101-20221231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzU0OTc1NTgxNDExODI_e34c7780-ecc6-4852-b235-77176481454c">90</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i153bc6bd9c0047408ceded26b5f9e59a_D20210101-20211231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzE2NDkyNjc0NDE5NjUw_501e0a3e-8837-449a-bd63-2b3d63056f6e">86</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icc9b2898f14b4fc8b46de629cd65f242_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzE2NDkyNjc0NDE5NjU1_48e39d72-929a-4ded-be38-bc72a5f7e459">97</ix:nonFraction>% of revenues from intangible royalty assets in 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzQxMjA_04a4eb75-18fe-4acc-bfe2-ef33c64ce3cb" continuedAt="i38fce66449e744819677f0b94ea0c460" escape="true">Non-Consolidated Affiliates</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i38fce66449e744819677f0b94ea0c460" continuedAt="ib5689ab5d9c04582a45efc15cffdc0c7"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2022 and the change in fair value was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for 2022. The fair value of the revenue participation right was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 and the change in fair value was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-operating expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for 2022. No amounts were due from ApiJect as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $<ix:nonFraction unitRef="usd" contextRef="i0fbcaa672be248e197fc3072f0903674_I20200211" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3Nw_7e56752e-45f3-44dd-87b9-6509ba2bb652">303.7</ix:nonFraction>&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. We recorded income allocations of $<ix:nonFraction unitRef="usd" contextRef="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE3MzU_3ece9f6c-0832-4588-8a7c-51df087fec61">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE3NDI_e43b21cc-89f5-4edd-a9c5-25bce839e4c3">8.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTU2_0e2cd2a4-3c63-46dd-b587-8ef423784bd3">62.0</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2022, 2021 and 2020, respectively. We collected cash receipts from the Legacy SLP Interest of $<ix:nonFraction unitRef="usd" contextRef="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE4MzQ_1bcd9591-33d5-4293-8b24-94d95a8d805c">25.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE4NDE_50cb89b2-2d4d-4e04-9772-51202154b52b">21.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTI2_1a76cbb6-f57e-408e-9a78-866b24e70fa3">22.7</ix:nonFraction>&#160;million during 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (&#8220;Avillion I&#8221;) and BAv Financing II, LP and its related entities (&#8220;Avillion II&#8221; and, together with Avillion I, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. We recorded loss allocations from the Avillion Entities of $<ix:nonFraction unitRef="usd" contextRef="i7d8076ed02354170b8e1aef0696b1dd1_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzIyNTI_92b35944-0996-4563-a154-438d06d55734">12.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="icb803d1f20cc4fce8c2f9ab745affbd7_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzIyNTY_b32f74b7-f566-486b-aa9a-35c8a8ee3235">28.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i850f55de08b348c6896f173a3de0636e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTQx_380456a6-1172-4b9f-9422-ec296bf20446">17.6</ix:nonFraction>&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in losses/(earnings) of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $<ix:nonFraction unitRef="usd" contextRef="ia14cea8f163049d485a56b89150c4bc2_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_31b82f27-e7af-4418-bbae-7e4c43d776d7"><ix:nonFraction unitRef="usd" contextRef="i80c12de839c544f5bb19445f982348c5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_6054a959-f7d3-45a0-8aa1-7182f44362eb"><ix:nonFraction unitRef="usd" contextRef="i91fcca9afda04cc6ba4981ca2685afe6_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_b668dd58-866d-4046-9e2d-c4c06c29af07">13.4</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million in each of 2022, 2021 and 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $<ix:nonFraction unitRef="usd" contextRef="i8b06f23fa444477b8d31b04cd8b75199_I20220630" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzEwOTk1MTE2MzUzNjc_711246f5-0fde-4170-8e8e-b813d75bb722">150.0</ix:nonFraction>&#160;million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $<ix:nonFraction unitRef="usd" contextRef="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131" decimals="-6" name="rprx:ProceedsFromExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDMzOTQ4_caef913a-9302-4759-9f56-278951d7c61f">80</ix:nonFraction>&#160;million to Avillion II to exercise an option to commercialize Airsupra in the United States. We expect to receive our pro rata portion of the exercise fee of approximately $<ix:nonFraction unitRef="usd" contextRef="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131" decimals="-6" name="rprx:ProceedsFromExerciseFeeProRataAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzQzOTgwNDY1MjkyMDM_94582d24-8922-487f-b1ab-be2c90c89391">35</ix:nonFraction>&#160;million, subject to any holdback for expenses, in 2023. </span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ib5689ab5d9c04582a45efc15cffdc0c7">Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of December 31, 2022 and 2021, RPIFT had unfunded commitments related to the Avillion Entities of $<ix:nonFraction unitRef="usd" contextRef="i84614dd16a8241bc9bb8d393780ce7a1_I20221231" decimals="-5" sign="-" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzM4ODc_cbdfd52a-709e-4a42-9da8-334b8fa2d7af">28.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if8da099dd6c543afb79c83d2662bba53_I20211231" decimals="-5" sign="-" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzM4OTQ_0f2f8405-2921-4e38-8653-016449fb6ea9">11.2</ix:nonFraction>&#160;million, respectively.</ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzE4Mzg_a4c01cce-bade-43e2-ba4d-818ea9a41e39" continuedAt="ia8912c20d5f140a687138ecbda1ead74" escape="true">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia8912c20d5f140a687138ecbda1ead74" continuedAt="ic783e6d272b64bc09251ab6828edfc0e"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. It includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4MzM_14b85120-6393-4519-8258-5faa2163eafc">177.1</ix:nonFraction>&#160;million in 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, primarily related to upfront and milestone development-stage funding payments of $<ix:nonFraction unitRef="usd" contextRef="i44ef2537a2d647a4b5b8a82e00bf960a_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDM0ODQ_b0b58e77-1782-4a99-9522-52fc0283bebb">100.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i10ff8205a3ec46f18544e77a5fe83eab_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzM4NDgyOTA3MDQyNzA_958e0525-1676-4a14-97ed-fdb1819f1768">25.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i61ecf49a29ae4381b6950b4facb564aa_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzM4NDgyOTA3MDk3OTE_df8d31f6-3d85-40f2-8638-81e7cae9dd01">50.0</ix:nonFraction>&#160;million to acquire royalties on development-stage products from Cytokinetics, Theravance Biopharma, Inc., and MSD International Business GmbH, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4NTA_8347596c-b062-4a73-b1c6-5705379c0f6b">200.1</ix:nonFraction>&#160;million in 2021, comprised of $<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-5" name="rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzEwOTk1MTE2NDE3MTA_a97277a3-f875-4c53-a9d7-815b2a93a32c">193.2</ix:nonFraction>&#160;million in upfront R&amp;D funding expense and $<ix:nonFraction unitRef="usd" contextRef="i3edb74e20d194d1cb5aaf64169b64925_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4NTg_dfb8519b-b980-440d-85b4-47cb3846078f">6.9</ix:nonFraction>&#160;million in ongoing R&amp;D funding expense, primarily under our co-funding agreement with Sanofi. The upfront R&amp;D funding expense included $<ix:nonFraction unitRef="usd" contextRef="i3ffdc417e74646e7a3d9fc1fea36076e_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNTIzNDE_3db62543-bdcc-4ea4-92ea-e049f8f6b772">103.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDI5OTE_20a0d94a-3b5c-425e-b27f-a457d55f7933">90.0</ix:nonFraction>&#160;million in exchange for an incremental royalty on a development-stage product from BioCryst and future royalties on two development-stage products from MorphoSys, respectively. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic783e6d272b64bc09251ab6828edfc0e">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzQzOTgwNDY1MjM4Mzk_aa90e1c9-7d03-4e40-b8fb-cebb6e042c4b">26.3</ix:nonFraction>&#160;million in 2020, comprised of $<ix:nonFraction unitRef="usd" contextRef="ib41d6ba411fa44fe8f54e00c9719be69_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzE2NDkyNjc0NDI1Njky_b5c70f70-9e97-4c68-9f37-b19b8b28fb8d">20.5</ix:nonFraction>&#160;million in ongoing R&amp;D funding expense, primarily under our co-funding agreement with Sanofi, and $<ix:nonFraction unitRef="usd" contextRef="i93638517e843430abd0622cd117849fc_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzEyOTk_0ee90a20-e405-4d8a-9cf9-7ad5c125c49f">5.8</ix:nonFraction>&#160;million in upfront R&amp;D funding expense for a royalty on a development-stage product that we acquired from BioCryst.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTI_fa560971-b1ff-4252-9649-0a47f07c2de5" continuedAt="idf0bef36dd1d4bc6b36454832503b479" escape="true">Borrowings</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idf0bef36dd1d4bc6b36454832503b479" continuedAt="i3e385131645e4914b61a2ede3ec2cd09"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTQ_98a9e4b6-186f-4af0-8d75-a560c9dd0ba3" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfNA_6612fb10-4f91-487a-812e-5bded4c95841">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfOA_eb2b2441-fbbd-4f30-b432-0d632efd9e81">0.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i8faa4e13bd38491daf38566f6eebb9b9_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfMjI_460f6dd9-1545-462c-9a42-066eb14355db">99.322</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItNi0xLTEtMTMzNjY4_8ffbdc8c-ea09-4822-a1c6-6eeb2cb0fb48">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa254b18546f40f685306a6288911d2c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItOC0xLTEtMTMzNjY4_3244aff7-ae50-482b-86da-d0db7359add4">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i506d480262374d17bc6c2d61664062dd_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfNA_05ef2d37-31dc-4684-8a70-4f45d81c71b5">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i506d480262374d17bc6c2d61664062dd_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfOA_e17aca86-f48a-49df-8abc-5f90d431edb5">1.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i8198214b15354bb4a8f445cec4dbc5e2_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfMjI_099a3d07-01eb-4cac-b70e-07fd4e5786fa">98.875</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506d480262374d17bc6c2d61664062dd_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtNi0xLTEtMTMzNjY4_d590866d-e1d3-4ac3-ba7c-35e6036a5acf">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026f9953369d49eea32d8638a01cd4ca_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtOC0xLTEtMTMzNjY4_09c2f24d-4edc-459f-920a-2abe63320f8e">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i320c72757fa545478705ae929cf21624_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfNA_18fdc13c-9cfe-476a-9735-e5b6dba71323">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i320c72757fa545478705ae929cf21624_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfOA_a3a7f5a5-ed61-42cd-83e4-6297fae42788">1.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ic03ffc7bd4c74c5ca68cf23404563dd7_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfMjI_78c17c7b-6343-4714-a315-1364dc05f7a0">98.284</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320c72757fa545478705ae929cf21624_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtNi0xLTEtMTMzNjY4_c57e3666-2e78-42cc-ba83-5a15c8bb5994">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36467572e76c44bab1b0c5564c2c4f5f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtOC0xLTEtMTMzNjY4_331d78b5-19fe-4cc1-8cd4-a5a8cee5cdae">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfNA_3aa66144-ad3e-48ae-906b-2636a4b2f9e2">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfOA_090879c0-411e-445b-b335-abcf971db8c8">2.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ie13d0bca9e81479fac36370bd642690c_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfMjI_4d3f164d-3010-4eea-adfb-de960d26830a">97.760</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtNi0xLTEtMTMzNjY4_2eb72870-63a6-4bda-9441-d1a2a5402609">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0acbd3d4d824163a23c1f2c06b0d15a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtOC0xLTEtMTMzNjY4_a3376cd0-a7d6-4377-8c0d-191edf498b05">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfNA_18e025dd-2aee-476d-9d22-fd9247575598">600,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfOA_2009f755-3fb9-4ed8-8e04-b133b550b944">2.15</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i5aad990d21894f778fa32056c3d7f296_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfMjI_013e8aad-5543-441e-9e95-daed88c7ede3">98.263</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtNi0xLTEtMTMzNjY4_4bd60090-8fb7-4ea5-8a9d-b99f2b9aa470">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6788ce3a13ed48968ef184ebb77330c2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtOC0xLTEtMTMzNjY4_b0e04a0b-3816-4e70-a639-5495b8a9cbc5">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfNA_571f90e8-41c1-4f94-beb6-81237ee1b672">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfOA_0cc8a4ea-6ca9-49b9-b339-57ab35453011">3.30</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i838c7cff011e48c7b534f0f3eedaa181_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfMjI_d9785364-7184-4f9a-891c-29d8145acf30">95.556</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctNi0xLTEtMTMzNjY4_c2373e42-64a7-41f9-84bc-2180c4400508">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd566c8dcd3c4e5b9f6aec7f920d2ee9_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctOC0xLTEtMTMzNjY4_e50efe61-9e77-4e0a-9766-45abff3b15be">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfNA_76588c22-5847-4232-81c2-b02d913e5a1a">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfOA_ae5682b5-7eb8-489d-b3c3-2f120ba6854a">3.55</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i149da048776c4462b194bf3e704f0d93_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfMjI_89d50c0e-15da-4c78-9cef-762b7bbd2458">95.306</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtNi0xLTEtMTMzNjY4_bfff8f20-00c5-4104-94b0-2b3491f01012">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cdc999f38464531a986434571af11df_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtOC0xLTEtMTMzNjY4_dc58c7a4-b9bd-4482-a6b6-bc98b9947427">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ief8928daca3b419895b3307d21daa429_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfNA_f54e5b6a-4207-4473-8cdf-967f3679bacc">700,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="ief8928daca3b419895b3307d21daa429_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfOA_5a99e745-549c-4ffc-98c2-ec1948ab1cf8">3.35</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ifa5d9597c55743f0b0ea434a2f05583e_D20220101-20221231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfMjI_b644c93f-f5a2-4189-bd4b-bc9354170521">97.565</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8928daca3b419895b3307d21daa429_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktNi0xLTEtMTMzNjY4_84c12686-d7c2-4f37-a02b-502c13951507">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b0dac23f424541b08adeb45318f282_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktOC0xLTEtMTMzNjY4_2417dd9f-dade-4c99-94a2-116efc93602e">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzExLTYtMS0xLTEzMzY2OA_9982074b-35f3-40ca-9147-45247f92ba58">183,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzExLTgtMS0xLTEzMzY2OA_b84a351a-15ab-41cb-9102-167725e8dee7">203,930</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzEyLTYtMS0xLTEzMzY2OA_aa512bfc-03a9-44d4-8062-f0cc225451dc">7,116,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzEyLTgtMS0xLTEzMzY2OA_81b80c93-5929-4752-a069-76dbc61f321d">7,096,070</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE2LTYtMS0xLTEzMzY2OA_853164e6-b423-4d7d-b174-247564eb5912">997,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE2LTgtMS0xLTEzMzY2OA_b6680eaf-6159-403c-9841-3a1f692dd144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE3LTYtMS0xLTE4NzQ1Mw_346a6b11-92b8-434d-b73c-cac5460e651b">6,118,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE3LTgtMS0xLTE4NzQ1Ng_d0a7f222-7469-4719-b461-579ae2517c37">7,096,070</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 26, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="i9df2b8b2b611422b93e15b5384fee55a_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0OA_59ea1d8a-aeb4-4d5d-89dc-96b773b325e2">1.3</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $<ix:nonFraction unitRef="usd" contextRef="i81df3e9523394784bee4f0ab4f95754b_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzIwOQ_172f0072-a2ea-4c68-afbc-4ec8b731fe48">600.0</ix:nonFraction>&#160;million principal amount of notes due September 2031 and $<ix:nonFraction unitRef="usd" contextRef="i841ed43575b4462d8d7e171a31c3a0ea_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzI2MQ_2f4cbccf-e746-4132-8ec6-7655cc09c27c">700.0</ix:nonFraction>&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="i9df2b8b2b611422b93e15b5384fee55a_I20210726" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNDM_52fab0c6-12e3-4cb4-bfac-4aeba74c0040">27.5</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i841ed43575b4462d8d7e171a31c3a0ea_I20210726" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNTE_d15876b6-e59d-46be-82b2-aaa31d7d97d2">12.3</ix:nonFraction>&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i384458f232644f91aa9aeae55e9bf165_I20221231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzc1Ng_ad25559c-fea1-41af-a2aa-8eb9632bd728">2.80</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i384458f232644f91aa9aeae55e9bf165_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzc2Mw_9a5a7c6a-adbe-4b27-90eb-2e8185ab7a70">3.06</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i3e385131645e4914b61a2ede3ec2cd09" continuedAt="i9d48dfe112d44b51b95c1299e7ee0757"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzgxNA_8f728783-221d-4a2e-ac8d-ac9207f45fa0">6.0</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNjc_42e136c6-efdb-41c6-8b0e-d33c2381e69b">149.0</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNTk_03f8fa4e-f459-4150-b1f5-909869ca7847">40.4</ix:nonFraction>&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0Nzc_232a71f2-cc86-4ba8-8bf5-018bfb35ddff">2.13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0ODQ_ba668793-6e31-4ec1-8f11-9d6d4b6a7f8a">2.50</ix:nonFraction>%, respectively.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="ib6668080e1a943078f97f24224e6214b_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE4MzQ_6e144621-38c5-49bc-90b9-07a504506fc3">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i87ec196b42b349799568466b38b36d11_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzI1MzU_a3ab05d1-21bf-423a-b59b-e94ed88c0ff3">101</ix:nonFraction>% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as of December 31, 2022, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022 and 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $<ix:nonFraction unitRef="usd" contextRef="i3ef9b1f654c54a45a6014f3846682ac2_I20221231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwMjQ_8ba3a8ff-e8df-48a7-ba16-7f58ab5a1bdc">5.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="if2e5ff3a9e2243d18e1771b08d510e30_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzMwNDY_486b1007-0684-4ad9-afe8-5f6309fd84df">7.2</ix:nonFraction>&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the &#8220;Credit Agreement&#8221;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a <ix:nonNumeric contextRef="if3f37019f75444bfb079f9eae44011a7_D20221031-20221031" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTY_427e46d4-9ce1-4b68-a7e5-64ddee78e4e1">five-year</ix:nonNumeric> unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="i0477a1e950d844878b385b517d204739_I20221031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzM1MTQ_4652c375-a084-4cbb-9c9e-cfc7322eaea3">1.5</ix:nonFraction>&#160;billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2021, there were <ix:nonFraction unitRef="usd" contextRef="ibc82c34f1b1841fb9acad0573bb9c2af_I20211231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUxMTI3MjkwNzA4ODM1_3151c003-0fe7-418e-8fb8-c5771bd49435"><ix:nonFraction unitRef="usd" contextRef="i0913b22937e94ce69dadc8d8ef64f99d_I20221231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUxMTI3MjkwNzA4ODM1_6ce3c8f2-569c-46f7-8616-849fe1a20820">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i7ded29aec73342379a32b7f0d37ce932_D20221031-20221031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwMDg_16790aa2-1b86-4e42-8a12-f06eb69d444b"><ix:nonFraction unitRef="number" contextRef="i2b646b86d4204e5ab0e00d75294a4677_D20221031-20221031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwMDg_4a78268a-0945-4a8b-b348-cafdc3019ea6">0.5</ix:nonFraction></ix:nonFraction>% and (3) Term SOFR plus <ix:nonFraction unitRef="number" contextRef="ifa789f47637b468b8e0a81f1258d7822_D20221031-20221031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwNTQ_48e84c81-a592-4ba0-a9e4-54a65f070b4d">1</ix:nonFraction>% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below <ix:nonFraction unitRef="number" contextRef="id28f0ac392314518bd09f5981a109a33_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQ3MDk_c4ed4d0f-aaf0-4cfc-bb74-d429242fdcac">4.00</ix:nonFraction> to 1.00 (or at or below <ix:nonFraction unitRef="number" contextRef="id28f0ac392314518bd09f5981a109a33_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQ3MzY_97728005-4b4d-46c0-a12c-011cc96250fb">4.50</ix:nonFraction> to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above <ix:nonFraction unitRef="number" contextRef="id28f0ac392314518bd09f5981a109a33_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUwMjA_5bf0672e-e017-450b-82af-cd8fc7e294f8">2.50</ix:nonFraction> to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings was in compliance with these covenants. </span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9d48dfe112d44b51b95c1299e7ee0757" continuedAt="ia93b4571fb6a4e7da1111f2467a534a2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#8211;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $<ix:nonFraction unitRef="usd" contextRef="ida442f1cecf14df5945065908673a6d0_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU5OTM_6ad6c368-a304-4834-a185-3e4bb83cbead">3.20</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i7f70bcb4de984b258954aedd1f27e7db_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzYwMDA_0046a315-5f74-44f1-aafe-952fa6bc91b5">2.84</ix:nonFraction>&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i9c86a83a372f42caa003779427589736_D20200901-20200930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE2NDkyNjc0NDI4NDMx_716547ec-9373-4dfb-83a7-f15399284c72">25.1</ix:nonFraction>&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="if0b4057d220b45ad8565474419d30930_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE2NDkyNjc0NDI4NDQ2_bb069cc6-3267-48d1-9bcd-50597b94fb1b">5.4</ix:nonFraction>&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTg_161c224a-0d48-44d1-90cc-070a3900c369" continuedAt="i68c4c8049437422c882bc325d6ce4f4f" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzItMi0xLTEtMTMzNjY4_0587856d-2464-47c6-8d50-8611622250b6">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzMtMi0xLTEtMTMzNjY4_521ec292-b696-4a84-9a86-290142fb42f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzQtMi0xLTEtMTMzNjY4_d660d20e-759e-43e1-a3f0-ae1e42e6fe85">1,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzUtMi0xLTEtMTMzNjY4_5c60d71c-5e39-40b5-a00f-80137ad1fea4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzYtMi0xLTEtMTMzNjY4_258c9b5c-b651-4921-92e3-36ad6e7e354d">1,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzctMi0xLTEtMTMzNjY4_fc92affa-ce31-433a-bcc2-50ca62f23aa0">4,300,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzgtMi0xLTEtMTMzNjY4_03967741-1822-4213-95da-a0861301b5a5">7,300,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ia93b4571fb6a4e7da1111f2467a534a2" continuedAt="i4aaf1bdc951248d797ced937321df1c7"><ix:continuation id="i68c4c8049437422c882bc325d6ce4f4f" continuedAt="ie5c95ac5a3654d0bb63ddbe305ce1b11">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="i4aaf1bdc951248d797ced937321df1c7"><ix:continuation id="ie5c95ac5a3654d0bb63ddbe305ce1b11">Excludes unamortized debt discount and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzY5OTM_826c44ea-5bda-4822-83eb-763aa1400dc2">183.7</ix:nonFraction> million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDY_443645bd-f689-4246-b52b-ff4df2d224b4" continuedAt="if015da3ec16843f69d2d88880df3d750" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if015da3ec16843f69d2d88880df3d750" continuedAt="ia3187473a1e341b0a6afd80e21a7d3d5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1&#8211;Organization and Purpose, we have <ix:nonFraction unitRef="class" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:NumberOfClassesOfVotingStock" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE0Mw_0f59be4c-0951-4027-91c7-000124543306">two</ix:nonFraction> classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has <ix:nonFraction unitRef="vote" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:CommonStockVotingRightsNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQzOTgwNDY1MjU0MTk_4bddc898-97ad-4155-91f9-1380f691e0f0">one</ix:nonFraction> vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of December 31, 2022, we have <ix:nonFraction unitRef="shares" contextRef="iabe3448245414e18a4b4313799d4a486_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzM4NDgyOTA3MDQ1NTI_b71b4b48-205f-4524-a60f-7995f75e1b5f">443,166</ix:nonFraction>&#160;thousand Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzM4NDgyOTA3MDQ1ODQ_5ac7b390-b80e-4805-8cd1-94503d48970f">164,058</ix:nonFraction>&#160;thousand Class B ordinary shares outstanding.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a <ix:nonFraction unitRef="shares" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:CommonStockQuarterlyConversionBasis" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQzOTgwNDY1MjU0Mjc_4d50abf2-ec24-4d93-917a-193dbace4728">one</ix:nonFraction>-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2022, we have <ix:nonFraction unitRef="shares" contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzEzMTk0MTM5NTQ0MjM2_1b7d2a6d-00e3-4428-8a1c-796b8fdfd216">371,325</ix:nonFraction> thousand deferred shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue <ix:nonFraction unitRef="shares" contextRef="i4a118afd54f1420497a8451111036378_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE0NTI_2123f768-79a3-462c-a7ea-c2777455cea8">50</ix:nonFraction> thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights.The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="iebf80945d01e4cda8265a7a35cb92256_D20220101-20221231" decimals="INF" name="rprx:RedeemableStockRedemptionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE5Mjc_7eeb169e-d343-4ff0-bb2d-60d6eb50105c">1</ix:nonFraction> each.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia3187473a1e341b0a6afd80e21a7d3d5" continuedAt="i03887022c2ff448c86c2ce941865649e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDc_69194b85-ea72-4474-866b-0b04108e1e97" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balance of our <ix:nonFraction unitRef="noncontrolling_interest" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="INF" name="rprx:NumberOfNoncontrollingInterests" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_5ad9e0c6-ebe7-40fc-adf6-b37408958d6d"><ix:nonFraction unitRef="noncontrolling_interest" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="INF" name="rprx:NumberOfNoncontrollingInterests" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_8bb6e858-52b4-4d18-8056-fc37736fc018"><ix:nonFraction unitRef="noncontrolling_interest" contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231" decimals="INF" name="rprx:NumberOfNoncontrollingInterests" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_c195a293-f759-43f0-9b14-177b45482183">four</ix:nonFraction></ix:nonFraction></ix:nonFraction> non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands): </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id583806a07ed4cd8bfd78850b5f779a6_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMS0xLTEtMjg1MjUw_6529489b-355a-4ed7-a2f5-b1e2488d1257">35,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cc65a06afd46199b75bfd37257d1bd_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMy0xLTEtMjg1MjUw_ce8dc61c-2e8f-4757-b111-3547087285e5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0509ce4690e4e7589a22610857ffc76_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNS0xLTEtMjg1MjUw_914047c2-caa0-48e2-b73b-2b03b208a257">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d596cf933ba4342a229fa9b82d58290_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNy0xLTEtMjg1MjUw_269a8529-2d52-4e65-aa94-58061f67be4c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtOS0xLTEtMjg1MjUw_7218116c-4d76-4c28-b839-696a5e8b1599">35,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMS0xLTEtMjg1MjUw_0ca1ef50-2207-4649-b8fe-61002982fc50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMy0xLTEtMjg1MjUw_0f245608-1910-496f-8fbb-c43674f4268a">1,165,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNS0xLTEtMjg1MjUw_c2517d8e-c3f7-430c-8e8a-9792979904da">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNy0xLTEtMjg1MjUw_62fb1fe1-2ecd-4596-bdbd-6a8611a209b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItOS0xLTEtMjg1MjUw_b5d94738-b894-4468-8f48-a058f26b69c8">1,174,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMS0xLTEtMjg1MjUw_d61b2ab4-4353-429d-b708-3e41d28dcaa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMy0xLTEtMjg1MjUw_cadeba4a-21ee-474b-9b6b-d4053502d940">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNS0xLTEtMjg1MjUw_b19403f6-6b66-4f57-a5d4-4bc1d5426454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNy0xLTEtMjg1MjUw_331e5654-770b-409f-a244-0e1fb8c6d92a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtOS0xLTEtMjg1MjUw_5a9e68e1-8c71-456b-b9dd-c66c673d6426">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMS0xLTEtMjg1MjUw_50cfd469-62be-4bd1-b4da-27748907df24">112,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMy0xLTEtMjg1MjUw_2a90053e-aa4d-42af-9ac1-6b7916ad09e5">594,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNS0xLTEtMjg1MjUw_6b8c3c9a-10d4-48fa-832f-0bdaf1816caa">85,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNy0xLTEtMjg1MjUw_ce33ba62-11a0-46d7-a48a-2d50befde775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtOS0xLTEtMjg1MjUw_1cc7255e-1118-4f45-aa95-421749a0c280">792,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcd0fcdf8b845239f1f57b6fe825b41_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMS0xLTEtMjg1MjUw_1064f22f-f880-4d0d-a2e6-ffaab7b0f639">42,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2009985eb36743ad88c72d8e11fbaea0_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMy0xLTEtMjg1MjUw_98568b65-155a-417f-828f-cfdda038ce43">102,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e55b25dde154b019f47eae3a218e41e_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNS0xLTEtMjg1MjUw_f18cd469-0a85-446c-8554-86987439ab81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e9d4812c374bfb90bd218fd00ab822_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNy0xLTEtMjg1MjUw_fd84907a-527a-4536-aa92-054393ea93d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtOS0xLTEtMjg1MjUw_49f8fc76-8d0b-442c-b91c-8f1bff78a48e">145,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtMS0xLTEtMjg1MjUw_75800d06-ed1d-47d5-adf9-e9f8de8bb5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtMy0xLTEtMjg1MjUw_ca07f5bc-a1f9-4e0f-8465-eb529bbb3309">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtNS0xLTEtMjg1MjUw_34ba323d-c824-43b0-aeef-34bc9d40b0ac">2,433,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtNy0xLTEtMjg1MjUw_7524090f-cca8-4f41-bfff-4d7a591ff7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtOS0xLTEtMjg1MjUw_146e2a75-35e8-44d8-a0ca-1e72a6f018f1">2,433,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMS0xLTEtMjg1MjUw_99aeb9ff-80e4-4d1d-86d5-b1d76c2ca8a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMy0xLTEtMjg1MjUw_f9654781-406c-442b-b299-9ea1beb4b5c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNS0xLTEtMjg1MjUw_d5065afc-8f97-4594-9a52-c00d9be17ed9">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNy0xLTEtMjg1MjUw_aa367a68-4f8c-4a6e-8626-b877b0aaa57b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctOS0xLTEtMjg1MjUw_1ddeb289-678e-4f4f-9beb-7921611fe033">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMS0xLTEtMjg1MjUw_a4f9d7c2-763a-4bf1-93f8-aab76324ede4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMy0xLTEtMjg1MjUw_6af9a94a-46a8-4de8-b0ba-fdfa06267aa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNS0xLTEtMjg1MjUw_38475caa-b069-4b02-a3b7-f225f145fd41">309,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNy0xLTEtMjg1MjUw_63965a9a-bd66-4530-9d9f-db9ca23e03a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtOS0xLTEtMjg1MjUw_34c00c8a-eeaa-4891-ae93-668442d76ec9">309,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f9625cef1e4423ba1d7b313528b32b_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMS0xLTEtMjg1MjUw_70a2fd82-f0c2-4cdc-abac-a530ef2f63b5">46,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3b4d885275470faa50792d4a4bce70_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMy0xLTEtMjg1MjUw_c2cedd63-f1e8-425f-80e9-3d3bb924c994">218,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1895d5cab12548d4b8aa19c4ea3f7bc4_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNS0xLTEtMjg1MjUw_ebc5d987-c312-4e66-812f-00d8c10c7869">316,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475cdd9f0f940c2b84d9176875725f0_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNy0xLTEtMjg1MjUw_a89794a0-dd5e-4757-8311-2a98f712d1f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida16729ea6c0450498d0894c41753058_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktOS0xLTEtMjg1MjUw_0281b65b-6a4d-41c4-bdd2-af20f60c1eb4">581,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTEtMS0xLTI4NTI1MA_ff8de986-04b3-4818-8e7d-9782e5649a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTMtMS0xLTI4NTI1MA_f9ed4c57-fd43-4e9b-8d17-b55711af54e4">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTUtMS0xLTI4NTI1MA_0eba59b8-ff4c-4347-adfd-d4c6387390c1">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTctMS0xLTI4NTI1MA_80d64af9-4530-42c3-b681-f0f49e596d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTktMS0xLTI4NTI1MA_83b8ac55-9705-4dce-942a-37774b1ff2dc">22,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTEtMS0xLTI4NTI1MA_2e0e7f6b-7782-42fc-ad8d-47855eda1722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTMtMS0xLTI4NTI1MA_c2154653-fea1-4d30-bc10-f93e75640667">3,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTUtMS0xLTI4NTI1MA_08d9039b-02f9-457d-aa6a-b610e94224e8">6,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTctMS0xLTI4NTI1MA_fcf65437-18fe-49b0-b25f-2557c69f29d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTktMS0xLTI4NTI1MA_26326512-37e3-4584-a8b4-9b62ebd81206">9,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4c363df47947bbb51883fe4178ece5_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMS0xLTEtMTMzNjY4_d5b8bfd2-4297-4469-a9ec-47939bcd32d1">12,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82fdaebc451745f9b2bb4e66ff3dc751_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMy0xLTEtMTMzNjY4_9b572c29-944f-49fc-a5cc-4b518d206b3d">1,939,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e0662e7e53b4956bd13f22f2295afdb_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNS0xLTEtMTMzNjY4_a7e07ac5-54ea-4ac8-94ec-72f33ff074cb">3,125,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e9ab43b7524668a5566f0c037e8e3a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNy0xLTEtMTMzNjY4_4bd03482-7d8f-4d66-82ac-00d1d31c2580">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtOS0xLTEtMTMzNjY4_d00288b1-e1b9-4c80-b353-9859ced493c4">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMS0xLTEtMTMzNjY4_552ddbc4-9a58-4394-934e-0c39755bb5e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMy0xLTEtMTMzNjY4_b0cc73aa-3b35-4808-96c1-91ebcb73b620">35,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNS0xLTEtMTMzNjY4_a0506833-6864-4263-9a22-dcba1f9e76c2">13,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNy0xLTEtMTMzNjY4_933230f9-d4bd-4dfa-ae29-8d695cf0a70d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItOS0xLTEtMTMzNjY4_ba485c82-4f5d-48af-bee2-60eb10fd243c">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMS0xLTEtMTMzNjY4_432172ee-ed6c-47c1-be3b-b309f7e4bb6b">56,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMy0xLTEtMTMzNjY4_dbf1440e-6654-4713-9127-da4e735570b0">425,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNS0xLTEtMTMzNjY4_c201235e-c490-4b8c-ad3f-1591f9b02e18">133,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNy0xLTEtMTMzNjY4_6f5b8764-da2c-4ca5-aa71-4cfa7e9f118e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtOS0xLTEtMTMzNjY4_08c6a858-cf3e-4c9c-8b38-aea994ba55f4">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMS0xLTEtMTMzNjY4_930c16a8-dc61-4aad-b786-3cf5640c78c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMy0xLTEtMTMzNjY4_25fda4d3-cb43-4201-b9a3-fc74512bc2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNS0xLTEtMTMzNjY4_1e56624b-bad3-431d-a283-92f82e55e17d">642,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNy0xLTEtMTMzNjY4_fb4e3fba-385c-4d3e-b038-dc5f92478093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtOS0xLTEtMTMzNjY4_e56b0ea5-fad3-4345-959c-a8af42649bb8">642,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMS0xLTEtMTMzNjY4_620f2ea9-c31b-4f56-8dba-d4df1742028f">57,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMy0xLTEtMTMzNjY4_f9665126-f6b8-4b63-8262-3e4457d32823">266,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNS0xLTEtMTMzNjY4_6105fb81-2d7a-4574-82af-7292b3436aa5">297,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNy0xLTEtMTMzNjY4_8d42c12b-8686-479a-b852-bca61249ab38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtOS0xLTEtMTMzNjY4_ca8d62f8-b3ce-499b-a7e2-4633540fee9d">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMS0xLTEtMTMzNjY4_20d9eceb-efda-4efe-ae8d-f1923e0e9c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMy0xLTEtMTMzNjY4_10b279a3-a5e4-4c7d-82fb-bc3a3274521a">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNS0xLTEtMTMzNjY4_ce3791b7-2383-4a33-8bd4-818b85a29f8f">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNy0xLTEtMTMzNjY4_68e8ad17-201e-4be8-a3ca-5cb3682ed408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctOS0xLTEtMTMzNjY4_b5763a4f-4ae7-4ed9-b80b-484110b22a35">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMS0xLTEtMTMzNjY4_b483c5ea-32fb-49c1-8936-4b10fa496b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMy0xLTEtMTMzNjY4_6434dbf8-b026-428f-b300-e05ac92ee9f7">8,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNS0xLTEtMTMzNjY4_6f3ba615-a2d9-47a5-861f-232c08b3bf00">13,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNy0xLTEtMTMzNjY4_994fc834-2bff-4eb4-a1de-365f3e383894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtOS0xLTEtMTMzNjY4_e4db84a4-5cea-4b16-9109-53db040a5b01">22,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdd18cadc3747e1bea0a4efcb970f3a_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMS0xLTEtMTMzNjY4_d5acef6a-eb3b-40b0-8d34-b04364f97c27">13,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5dd6dc7e594c9f91e9eccb9dce463b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMy0xLTEtMTMzNjY4_76453746-edae-4d02-9e78-cc09077dfd65">1,809,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0835b7194744e4c9e4f528591ea0b3b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNS0xLTEtMTMzNjY4_48d6fa61-bd1b-4efb-86f9-de2df8b656af">2,649,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf340aa855a942858168f3ecce184356_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNy0xLTEtMTMzNjY4_4bbc4838-3c00-4746-b86a-014f9ef2bff9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktOS0xLTEtMTMzNjY4_48de6705-cdd5-440a-b55d-e347b64d7ef6">4,471,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTEtMS0xLTIyOTg5NA_c83337fc-e54b-4e19-a5ce-95e8e42983e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTMtMS0xLTIyOTg5NA_76771ee6-737f-4e86-81dc-b65c79e49377">6,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTUtMS0xLTIyOTg5NA_8a38af44-8216-4d40-a22c-fdfa2a8d00e8">5,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTctMS0xLTIyOTg5NA_61e965de-064d-4c0d-b1b2-c3bbd21fe39a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTktMS0xLTIyOTg5NA_e24add2b-36be-4dd8-8780-9eb586ea4515">11,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTEtMS0xLTIyOTg5NA_de38a747-59ec-4e14-a2c8-4c511640fd45">24,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTMtMS0xLTIyOTg5NA_ef6ea43b-7112-4b45-879f-e844031fff96">435,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTUtMS0xLTIyOTg5NA_816efcb0-c98e-4951-a18d-c372b8b5053f">144,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTctMS0xLTIyOTg5NA_dd85349e-b358-4f68-b9af-f0ab61572bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTktMS0xLTIyOTg5NA_51e3f24c-44d3-4ebc-a2c9-c861da744e2a">604,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTEtMS0xLTIyOTg5NA_63071955-780d-48c1-ae7f-a27986d7fff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTMtMS0xLTIyOTg5NA_831d6ea9-5123-442a-b845-9314a44a70a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTUtMS0xLTIyOTg5NA_0ac1ad85-b023-41c5-8711-afb630b1c37b">157,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTctMS0xLTIyOTg5NA_de0d469c-ad15-4598-bc0e-b4de783142de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTktMS0xLTIyOTg5NA_3e19c500-ffa9-4ddf-a85d-5839885652a9">157,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTEtMS0xLTIyOTg5NA_d18d187b-e792-42ab-8fab-a660bd8f0057">10,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTMtMS0xLTIyOTg5NA_2e94c9b7-c21b-4970-99a9-8c98bf981e2d">152,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTUtMS0xLTIyOTg5NA_d79f1676-9d6c-412a-8cdf-f1c569047494">23,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTctMS0xLTIyOTg5NA_12414e67-3e15-4ab8-85be-635d79d7e8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTktMS0xLTIyOTg5NA_331f9712-f67d-425a-b2d0-f70b42eb5a8b">187,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTEtMS0xLTIyOTg5NA_5d11a33e-5399-48cd-892a-9347e01eb758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTMtMS0xLTIyOTg5NA_6b86e911-2e63-4d0d-a1b7-b50e32b36b7b">4,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTUtMS0xLTIyOTg5NA_21f79a7a-0a93-4f4c-bc32-263d9a220590">5,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTctMS0xLTIyOTg5NA_34867070-2ac4-4d88-9a3c-fcfce8f82559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTktMS0xLTIyOTg5NA_329030f9-787a-4ffb-871b-1c032ada4281">9,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTEtMS0xLTIyOTg5NA_c1498810-42a5-4189-8f62-fa55df61aead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTMtMS0xLTIyOTg5NA_36aca99d-2287-433b-96ee-b20fd8135b33">9,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTUtMS0xLTIyOTg5NA_a896e40f-1259-46fd-b836-753eaa05f2ab">12,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTctMS0xLTIyOTg5NA_78a83a2a-8e8b-4918-b765-f98336b58e0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTktMS0xLTIyOTg5NA_e394fda7-8ed0-4063-8a04-2c91e2f3362b">21,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic272076b47ca427798a7eb4b50714520_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTEtMS0xLTIyOTg5NA_4832aba4-0d41-4ad4-a02e-cd603657ab4e">597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie580dc2708034fd4b6b4cfd3e17819c2_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTMtMS0xLTIyOTg5NA_b4969d60-ae0b-46db-929a-0b8339b4d42e">1,527,887</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife94ebe41b0c47e3ba05d415807efda4_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTUtMS0xLTIyOTg5NA_dd7fad8a-abaf-4feb-9d53-c39e7ed51586">2,369,933</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida148d60e093484bb7aecaf26959ca76_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTctMS0xLTIyOTg5NA_0c112dbc-bed5-4f89-85c2-3d3f1bf058e8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1fc390f90a425883695c27f2ee9af6_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTktMS0xLTIyOTg5NA_beaf22d2-1ff3-45b2-a35a-53545fc28c9b">3,897,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Continuing Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="i03743a114d964d26b43b9ebb04e7dd8e_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzExNTQ0ODcyMTAxNzA2_ca32691f-1572-4e7d-8024-1f0b91b4be12">27</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ia73f9519d5db426a8cec4e56bf77101b_I20211231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU3NjE_6a43f1a4-bc56-4d59-ae06-b97844690d22">29</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1e1f278076d844b99be68cf3e9873d75_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNTM1NTY_f6f30d9e-8ce9-4d08-95d8-4ca19aa300d8">36</ix:nonFraction>% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and <ix:nonFraction unitRef="number" contextRef="ief164fe055724316addcd160fcd29535_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzExNTQ0ODcyMTAxNjk4_8911474b-28f0-4011-b964-c8589f5e7bef">73</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i3f6b542ff447402ab303deafe356aa4d_I20211231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU3NjY_fbc6a44f-8335-4666-9886-d40ad9d6d7ae">71</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i89cd3ad806e748eb9957406a9dba417e_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNTM1NjM_a172a0e1-8702-4e8d-988b-86198fc1581d">64</ix:nonFraction>% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i03887022c2ff448c86c2ce941865649e" continuedAt="idc5efa375b3f4de99e8d1b6a50a97fc2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest Held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. During 2022, we declared and paid four quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i858eae6f03ab4f6095837812fe2050e8_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_54721b09-28f0-4a5c-a4aa-5ce31f23612c"><ix:nonFraction unitRef="usdPerShare" contextRef="i05f6894c03c244809fd48ceb945f3ef4_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_706f11f9-2f13-4d15-9b80-82472cd090c5"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a476c779a0f4059929c8b1c13bcb11c_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_cabf657c-25bd-4be8-a62e-aeb65ec9b561"><ix:nonFraction unitRef="usdPerShare" contextRef="ib698c75befc449c9b5e6d1b50a9022ff_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_f94414ce-fa75-4af4-9ed7-5b34581e675f">0.19</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per Class A ordinary share for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3ODI_b1f405d1-6862-43c0-8f1e-94b02dfca489">333.3</ix:nonFraction>&#160;million to holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby <ix:nonFraction unitRef="shares" contextRef="i33f144445f0e4c28a6b92715967d2981_I20200615" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ5OTM_abd69e26-ffda-4371-9a41-696c911201ef">800</ix:nonFraction> thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="i7f8140079fb2406ca4822f6e2dbf5f31_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU5NzM_b23e8c5f-7a0e-410f-97f6-e3d2c72c7c6c">565</ix:nonFraction>&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:continuation id="idc5efa375b3f4de99e8d1b6a50a97fc2" continuedAt="i08a10f713b194c46ad24aa97178d39a2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU1MzM_6d62696a-b765-4b8f-a648-c7d10e6b81bb">one year</ix:nonNumeric> as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08a10f713b194c46ad24aa97178d39a2"> in the consolidated statements of operations. In 2022, 2021 and 2020, respectively, we did not recognize material share-based compensation expense. As of December 31, 2022, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $<ix:nonFraction unitRef="usd" contextRef="ie3e504b2ac6f44869467d497b88bcd64_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYxNTU_1928067b-bf4b-4aa7-9910-b8e6f75f3460">1.0</ix:nonFraction>&#160;million, which we expect to recognize in the next <ix:nonNumeric contextRef="i048f1daf85ab40479caf539c7b2a985f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDA_67dac199-4739-485a-a4e8-a33884b43cd4">six months</ix:nonNumeric>.</ix:continuation> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_157"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90ZXh0cmVnaW9uOjFhMzU3YWIxOTExZDQwMDNhMDI4YmE5Mjc1ZTA1ODIwXzMyNzU_d5f17a23-4213-4207-a0c9-ec7313912c73" continuedAt="i876752ff75944c72a5d938ae9d831285" escape="true">Earnings per Share</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i876752ff75944c72a5d938ae9d831285" continuedAt="i14e2b126cb8740dd8ec2ba669b719167">For 2022, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for 2022, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i14e2b126cb8740dd8ec2ba669b719167"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90ZXh0cmVnaW9uOjFhMzU3YWIxOTExZDQwMDNhMDI4YmE5Mjc1ZTA1ODIwXzMyNzc_1d733a05-4f33-4782-8810-e79212d68c48" continuedAt="i653de8ea5f3e4afa80253675771a9fe0" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzMtMy0xLTEtMTMzNjY4_817e1988-30be-4d12-a81d-6ec2fe43538f">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzMtMy0xLTEtMTg3NDk4_e4dce6bf-77c6-439d-8a18-69f0aaa0ca2c">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34aa33e8820445b893a30e990847995_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzQtMy0xLTEtMTMzNjY4_c857f3d9-6ace-44be-a174-6b176c6cab68">23,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a8a06b5b3141b6b061529bf42fe3a2_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzQtMy0xLTEtMTg3NDk4_712f2218-2a1f-47da-8638-83daa78edeca">297,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bfaf7eb7d04751af4ffb41e99d27d2_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzUtMy0xLTEtMTMzNjY4_14595e01-f5e7-473b-85b9-e6c0edf31bd5">163,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79bf03ace46488f877dae1dc4f250f5_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzUtMy0xLTEtMTg3NDk4_a01bbcfa-2077-4ee6-9416-d1043e142c3c">324,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTMzNjY4_2efb44e0-c2aa-4dc6-bc26-5d74569691c5"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTMzNjY4_504fe481-b728-4c69-bf23-a49591a4be53">42,832</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTg3NDk4_20647a63-a484-496d-b331-8b80358f25d0"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTg3NDk4_bc2eb36c-c6cc-447d-86a1-77b41fcceb7d">619,728</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzExLTMtMS0xLTEzMzY2OA_73847c67-fa0d-4e8d-94da-2dfd5e5b5679">437,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzExLTMtMS0xLTE4NzQ5OA_59bfcdab-4c71-4fb2-9302-1274a298f2df">414,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE0LTMtMS0xLTEzMzY2OA_f142df63-cd80-4e1f-b62f-7108e0f3b7fb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE0LTMtMS0xLTE4NzQ5OA_8d91b956-a4de-4587-a5b2-545c0f0f0bbd">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE1LTMtMS0xLTEzMzY2OA_cbcfafd8-765b-447c-814f-c23b5e56be72">437,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE1LTMtMS0xLTE4NzQ5OA_47504af9-d615-4e6c-8a37-962b8318c0c0">414,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE3LTMtMS0xLTEzMzY2OA_db328196-3236-436f-ab79-35526545d523">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE3LTMtMS0xLTE4NzQ5OA_9b72d9dd-7af4-4d54-a582-fcccd2af796b">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE4LTMtMS0xLTEzMzY2OA_4463de77-e5a0-422f-a187-6e7c038b0fb7">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE4LTMtMS0xLTE4NzQ5OA_9fd53a65-32fd-4379-8c02-7df9dabc9591">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i653de8ea5f3e4afa80253675771a9fe0"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzMtMi0xLTEtMjI3ODA1_b8db784d-3b14-4359-9249-854784a90c32">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:NetIncomeLossAttributableToParentPriorToOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzQtMi0xLTEtMjI3ODA1_0bbef4f2-4ad4-450c-bc00-ad681beaf736">479,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15818908d4464f36813ed35be63cb421_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzUtMi0xLTEtMjI3ODA1_3a7fbddf-ad25-45c3-b3cd-edccf591110e">316,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b423fa12d043fb86870ee9477f4152_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzYtMi0xLTEtMjI3ODA1_d6a5323d-6883-4b24-aa28-6fb88722f1bc">409,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzctMi0xLTEtMjI3ODA1_2a75dc63-17b9-4ab5-8485-209eec5fd159"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzctMi0xLTEtMjI3ODA1_2fb7729a-53eb-4a20-93c9-652ba0b34a76">495,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzEwLTItMS0xLTIyNzgwNQ_ed0919b8-9218-4026-a6ff-1b318a66a801">375,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzExLTItMS0xLTIyNzgwNQ_39e48a9e-f26b-4aae-9718-c676dc962f33">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzEyLTItMS0xLTIyNzgwNQ_e475bebd-26bb-4e91-9c98-686f997a5fdb">375,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzE0LTItMS0xLTIyNzgwNQ_b6935e31-148f-49b0-be24-4fb8b7a097c1">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzE1LTItMS0xLTIyNzgwNQ_8e0a4001-4a80-46f8-b934-a29b2a94984c">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Royalty Pharma plc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzI0NQ_1fafac7f-ca2b-4f7a-8b3c-d0ddd9ce9115" continuedAt="i726e1e30e8f64831a880ba356eb17a58" escape="true">Indirect Cash Flow</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i726e1e30e8f64831a880ba356eb17a58"><ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzI0Ng_fdc7beb9-ea31-4207-873a-91024a1a2dd0" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtMS0xLTEtMTMzNjY4_16961a1a-5fb4-4ddd-a98a-a37f79fbf547">230,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtMy0xLTEtMTMzNjY4_2939c1e5-504d-411d-9a46-d0f18f68e29c">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtNS0xLTEtMTMzNjY4_90d301ff-53c4-4ea4-905c-efdb88f56f3d">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtMS0xLTEtMTMzNjY4_d9dced2c-1ef8-4b7c-bc1c-657008b8f23d">2,125,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtMy0xLTEtMTMzNjY4_d6a29fb3-59a7-4ae8-bdec-487e5c1cc72f">2,065,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtNS0xLTEtMTMzNjY4_ed10d54d-3bc8-487c-a8f2-29cb8d465ede">1,959,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtMS0xLTEtMTMzNjY4_f495b2d9-8a62-499a-9b63-52bd57f463b3">904,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtMy0xLTEtMTMzNjY4_9416df88-1038-46be-8f1b-7139d7654262">452,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForOtherCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtNS0xLTEtMTMzNjY4_010dd28a-6840-4d27-afc1-5410890254e9">230,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctMS0xLTEtMTMzNjY4_1d99d9c5-3bda-4ba4-9c86-f272288359b0">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctMy0xLTEtMTMzNjY4_bf2119f2-638b-4bfb-a608-196086503ddd">22,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctNS0xLTEtMTMzNjY4_c2e948fb-d7d7-4105-9656-5dd40ee9353e">23,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtMS0xLTEtMTMzNjY4_02b718e9-22f9-4dac-91bd-f2a2cbf25639">21,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtMy0xLTEtMTMzNjY4_732fd7ae-98d4-4850-b64d-aa3e84f372fb">20,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtNS0xLTEtMTMzNjY4_3de570c1-30da-4b7b-82fd-ea627fe29ac2">11,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTEtMS0xLTEzMzY2OA_754a6842-e51e-4134-9e48-e46daaa37b4a">96,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTMtMS0xLTEzMzY2OA_30af7806-3a9f-4ee8-a562-7f8da2f6a977">21,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTUtMS0xLTEzMzY2OA_9e6c3fc6-3d05-40e7-bded-32a76f031666">42,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTEtMS0xLTEzMzY2OA_1fef2e14-9716-47dc-a2a9-101ddafa82d4">33,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTMtMS0xLTEzMzY2OA_c4eb6c4a-9473-48c6-b52c-f494f0c272a5">48,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTUtMS0xLTEzMzY2OA_2df42805-21a7-4755-9956-8e0465683239">247,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTEtMS0xLTEzMzY2OA_e25b6876-6b12-4bad-814e-a390165acc8e">8,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTMtMS0xLTEzMzY2OA_13057d60-2cda-4130-8e57-49f55eecc732">19,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTUtMS0xLTEzMzY2OA_e719f474-d624-4879-9cd7-bf3b6508946f">44,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTEtMS0xLTEzMzY2OA_9bb4dcff-1a21-4b8f-9d72-3dd9eab3f8e7">39,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTMtMS0xLTEzMzY2OA_1cb03d5b-fa0a-41f5-ab9d-94edc64f985c">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTUtMS0xLTEzMzY2OA_8a3456c7-d8e0-4929-aa10-685dd8dc8727">42,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTEtMS0xLTEzMzY2OA_147f45f3-f75f-4948-bb24-ff20fbe6bcec">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTMtMS0xLTEzMzY2OA_5a75d59c-1316-45bc-a9a0-6ff741c26732">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTUtMS0xLTEzMzY2OA_9900f37e-9d37-4944-ba50-e286e18dcf8f">30,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTEtMS0xLTEzMzY2OA_b0351c77-031d-42f3-956a-718c32941f49">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTMtMS0xLTEzMzY2OA_23e8550a-d361-4149-b1d0-3f801e6f5ceb">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTUtMS0xLTEzMzY2OA_85c0220f-73d5-4689-9ca2-0896e211dea3">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTEtMS0xLTEzMzY2OA_8bf15a37-8381-409f-a391-7f31508775f3">53,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTMtMS0xLTEzMzY2OA_296eafff-e534-456f-94dc-5d944701b8dc">50,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTUtMS0xLTEzMzY2OA_8540cf96-420b-4a14-9a23-4dcfd7fb8540">20,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTEtMS0xLTEzMzY2OA_95431997-cb74-49aa-99d6-75addffebd6a">6,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTMtMS0xLTEzMzY2OA_2c93209c-eeb2-471a-887c-b58d01c0a7f0">17,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTUtMS0xLTEzMzY2OA_a7fc6423-ecb9-41ba-a6f1-d8ab5b7bc73c">18,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTEtMS0xLTEzMzY2OA_f4d98028-d8da-4323-bf44-62693d0206e6">615,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTMtMS0xLTEzMzY2OA_2e8d2d14-db64-44bf-a0cb-fe9544dd4cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTUtMS0xLTEzMzY2OA_74775fc7-512b-44c9-b350-51aae7f97266">65,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTEtMS0xLTEzMzY2OA_ff41e5dc-99df-4043-963c-7b94f2f9486d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTMtMS0xLTEzMzY2OA_bb5b58f0-227d-496c-8f5f-60880cb895bb">16,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTUtMS0xLTEzMzY2OA_a7f82beb-c505-457c-bdc7-b0fcfeb3a21a">34,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTEtMS0xLTEzMzY2OA_05239b8c-a437-41c6-8e5d-1eba26f0123f">11,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTMtMS0xLTEzMzY2OA_74d62584-5c11-4279-89d7-aa6548e6e6bb">4,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTUtMS0xLTEzMzY2OA_39b24041-05c2-4b43-80a5-54a62869d3bb">9,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTEtMS0xLTEzMzY2OA_ea6fcccf-1576-4e12-8b76-c5c493bed5ae">2,507,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTMtMS0xLTEzMzY2OA_846199a4-c5b8-4c16-8009-7c362aa59169">2,315,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTUtMS0xLTEzMzY2OA_40ed7836-b1d1-435b-8b0d-92df7dde00cc">2,121,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTEtMS0xLTEzMzY2OA_c8a8050e-efbe-4887-84f8-090059bec7a8">36,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTMtMS0xLTEzMzY2OA_ee98c1c4-72d5-4dd9-a7d0-d87fa5c0d41f">20,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTUtMS0xLTEzMzY2OA_bc863640-9872-4083-9695-559289af528d">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTEtMS0xLTEzMzY2OA_e5accdc9-1477-40d4-9056-e34ba2238b87">4,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTMtMS0xLTEzMzY2OA_47e42515-4e18-45e4-a6df-20ed7206ae6e">9,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTUtMS0xLTEzMzY2OA_bf9f2427-37d9-43cd-bea0-f1c25257f051">770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTEtMS0xLTEzMzY2OA_eac3dbec-1b0c-4fea-8355-ce253fe8ff5d">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTMtMS0xLTEzMzY2OA_9259737d-4488-44e9-ba31-bef20071e3a8">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTUtMS0xLTEzMzY2OA_24dcaa53-e783-44a5-a00b-1ae75860f8a3">34,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTEtMS0xLTEzMzY2OA_6bbbc1ba-2090-4acb-aad7-fd370a345ea4">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTMtMS0xLTEzMzY2OA_7ef12c91-e9eb-48e4-824a-41569c82c4f0">4,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTUtMS0xLTEzMzY2OA_e2eb74fd-0bac-489c-bd5f-49349c2f3f8b">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTEtMS0xLTEzMzY2OA_c33c071f-2490-4cb1-9227-0c09705f0413">3,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTMtMS0xLTEzMzY2OA_754106bc-4145-41e0-a1f3-1396515c5a07">15,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTUtMS0xLTEzMzY2OA_be18512c-f138-4268-b4e7-d6c36290cc6a">42,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTEtMS0xLTEzMzY2OA_25b296ce-57f1-4851-9fb2-021d5b7f4a3f">2,143,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTMtMS0xLTEzMzY2OA_e6a931e5-b009-4cb2-8bf8-6c5ff4d1093e">2,017,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTUtMS0xLTEzMzY2OA_9d96528f-cf7e-4a9b-83c1-fcd7721914ee">2,034,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItMS0xLTEtMTMzNjY4_8734f033-4376-4b1c-965a-c6bed2482d8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItMy0xLTEtMTMzNjY4_99bd69da-2a55-4ac4-8c66-9897d83cdef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItNS0xLTEtMTMzNjY4_65347438-7e81-4080-b836-31e9872d2ed1">303,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtMS0xLTEtMTMzNjY4_a5f8acf5-7e80-49d6-934c-def1f7078409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtMy0xLTEtMTMzNjY4_fe0f5c75-0efa-47eb-8da1-497bceeb58be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtNS0xLTEtMTMzNjY4_2a3c1e70-919f-4e41-8211-27c2aa5f4fa2">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtMS0xLTEtMTMzNjY4_e7f4a154-94af-455b-a62e-5980c75e0770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtMy0xLTEtMTMzNjY4_5c44dcdd-7a93-4a7f-baaa-d2b945f92008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtNS0xLTEtMTMzNjY4_b863bb3b-e916-44fc-934a-7ee2e4f8e188">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interests (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtMS0xLTEtMTMzNjY4_d359979d-7bde-4125-b3bf-adb12c820b08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtMy0xLTEtMTMzNjY4_3b073522-51ef-481d-9417-704a720f015e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtNS0xLTEtMTMzNjY4_11022676-c24f-4573-a372-54eb8e528dac">1,103,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payable - Erleada (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtMS0xLTEtMTMzNjY4_3bf79e75-8b9b-4456-97d0-3c74f19c35b3">12,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtMy0xLTEtMTMzNjY4_112829cf-fbba-49ab-9321-98d9669fe475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtNS0xLTEtMTMzNjY4_2eae08b5-2f84-48d1-abdb-e00a68846832">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $<ix:nonFraction unitRef="usd" contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231" decimals="-5" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzE2NDkyNjc0NDQ0NjE_5182d2c3-8e90-429e-9021-b542be93054c">110.0</ix:nonFraction>&#160;million following the June 2020 FDA approval of additional indications of Tazverik. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzQ4MTQ_5abe30ca-6d8d-49db-8c0f-c0dabfe16069" continuedAt="ia6554e14fdd041be91ae9471c14df3e6" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia6554e14fdd041be91ae9471c14df3e6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitments</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various funding commitments as of December 31, 2022 and 2021. See Note 3&#8211;Available for Sale Debt Securities for discussion of the respective arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-6" name="rprx:LongTermFundingCommitmentAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM0ODEw_5f413be8-1a0f-430f-a7b7-6934a36c7705">250</ix:nonFraction>&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipCovenantRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzM4NDgyOTA3MTI4NTI_260bdcc8-0e65-46b6-bfe8-7781b2e45be1">50</ix:nonFraction>&#160;million if a certain contingency is met and has the option to draw the remaining $<ix:nonFraction unitRef="usd" contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzM4NDgyOTA3MTI4NTY_6d672792-cd46-4fde-8e2a-ca2319fe6aec">200</ix:nonFraction>&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of December 31, 2022, we expect $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-6" name="rprx:LongTermFundingPartnershipExpectedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM1MDQ3_5d707790-ee71-45c4-bf1a-160bf0b3e30f">125</ix:nonFraction>&#160;million of the optional $<ix:nonFraction unitRef="usd" contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM1MDYx_ad3a968e-89d5-42e7-8a64-2fe3dbc73b68">200</ix:nonFraction>&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 9&#8211;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 16&#8211;Related Party Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our consolidated balance sheets as of December 31, 2022 and 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_166"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzcyNDE_1e062601-6fbd-4797-b351-4c285ddc2a8d" continuedAt="i42db50b9f97642b8846e59e5587343e6" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i42db50b9f97642b8846e59e5587343e6" continuedAt="i62b0a119e5cc4e03b41fc66e5c965f72"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1&#8211;Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to <ix:nonFraction unitRef="number" contextRef="i799427d0838947d38f9dbd8016b9306e_I20221231" decimals="INF" name="rprx:RelatedPartyTransactionRateAdjustedCashReceipts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzg3Mw_af1b2fc3-2956-4e97-8500-d74db5fe5778">6.5</ix:nonFraction>% of the cash receipts from royalty investments for such quarter and <ix:nonFraction unitRef="number" contextRef="i799427d0838947d38f9dbd8016b9306e_I20221231" decimals="INF" name="rprx:RelatedPartyTransactionRateValueOfSecurityInvestments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzk3NA_01c592cf-5c5a-4643-8732-840d6ce96d9b">0.25</ix:nonFraction>% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $<ix:nonFraction unitRef="usd" contextRef="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231" decimals="-6" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzEzMDU_49e6bccd-4eae-4e54-aa4f-b73ef4777ec4">1</ix:nonFraction>&#160;million per quarter and <ix:nonFraction unitRef="number" contextRef="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231" decimals="INF" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzEzMjQ_c9df3de7-be85-494c-b710-e35b03ddd26c">0.3125</ix:nonFraction>% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i62b0a119e5cc4e03b41fc66e5c965f72" continuedAt="ib73847f74eb040069b6fa09b93129e7e"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the date of the Exchange Offer, the Manager received operating and personnel payments payable in equal quarterly installments that increased by <ix:nonFraction unitRef="number" contextRef="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231" decimals="INF" name="rprx:RelatedPartyTransactionAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzE2MjM_1b4bcdfd-4958-4c38-97f6-9fcd90ca5450">5</ix:nonFraction>% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager or its affiliates receive an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, total operating and personnel payments incurred were $<ix:nonFraction unitRef="usd" contextRef="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzExNTQ0ODcyMTAzNDA1_03483ab0-ebe4-4455-bb51-63a04195fd45">188.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="icbc155b4bacf429796772ce27e94cbda_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzIxODg_7bdfe52d-c58a-4f8d-b5f8-a4b115d5cffb">145.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic382ad4d1e4b4ca887dcde3037d6a744_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzIxOTU_65041854-5513-41bd-bfc5-cdc81cc61da4">112.5</ix:nonFraction>&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Legacy Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPI ICAV and RPSFT&#8217;s non-controlling interest in RPCT. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzcyNDI_79d47572-110d-4031-8688-78cff16cf62a" continuedAt="ib3a988624a5d489bb3bffda7ddba4b28" escape="true">The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands): </ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><ix:continuation id="ib3a988624a5d489bb3bffda7ddba4b28"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32472808f32c48669cdcdb6fb300ef19_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzEtMS0xLTEtMTMzNjY4_9c87f96a-b952-4169-92d6-090b1051c2b2">87,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ab9056722446e7a354e96a0a2398a7_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzEtMy0xLTEtMTMzNjY4_67ed456d-2077-49ee-911c-fc62b8846034">92,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a8232720454e84ab4193b8ecf8a19a_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzItMS0xLTEtMTMzNjY4_64691e17-3088-4155-8b98-03daedf7baef">7,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7d2cfb65f04eeb990ed450281e3d84_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzItMy0xLTEtMTMzNjY4_d1ae8add-2c73-4c68-96da-4a1f3f2a930c">15,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to legacy non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzMtMS0xLTEtMTMzNjY4_02b7cc7c-dc9c-4bea-93cc-6b3d04098038">94,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzMtMy0xLTEtMTMzNjY4_351d2569-ae43-4360-b823-4d3b1ced9f4f">107,934</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2017, RPI Acquisitions </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(Ireland), Limited (&#8220;RPI Acquisitions&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of <ix:nonFraction unitRef="number" contextRef="if80e60d8ab83494c9238a91d2d655393_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQzMTQ_242a274c-ca3e-4711-89a5-fc81574a708f">50</ix:nonFraction>% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting <ix:nonFraction unitRef="number" contextRef="ieb555ed4cafa441b8b4640b8ea55f77e_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQzOTk_93f5db91-48ab-4cdc-a8a8-8766b768a5b8">50</ix:nonFraction>% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the financial royalty asset of $<ix:nonFraction unitRef="usd" contextRef="iac904b7432ab421db7ac86aa4c7b05f0_I20221231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU0OTc1NTgxNTA1NDk_a0843c5b-0b6a-4d6b-9328-9c20d4ea8c31">103.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iab860d9e81b6417c8a8c4038bbe057ae_I20211231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQ5MzY_8b34738b-340c-4234-bd69-ac62635f35b7">130.9</ix:nonFraction>&#160;million, respectively, on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of <ix:nonNumeric contextRef="i8a92b3734ca649b4894cb7e1fc75d883_D20210416-20210416" name="rprx:RelatedPartyTransactionInitialTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzUzNTg_5fcc5457-2d90-479f-b930-3c86254adeab">seven years</ix:nonNumeric> to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. <ix:nonFraction unitRef="usd" contextRef="ief9bfddb245a424897b5627ca71545ef_I20221231" decimals="INF" name="us-gaap:DueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU2MDI_67f04eb3-b552-4160-a6b9-b64754a435f3"><ix:nonFraction unitRef="usd" contextRef="ib71576f7e90f47a7ac7433ab13a80a52_I20211231" decimals="INF" name="us-gaap:DueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU2MDI_c21f97cc-373e-4ce2-9a27-c574044a2b1e">No</ix:nonFraction></ix:nonFraction> amounts were due from MSCI as of December 31, 2022 and 2021. The financial impact associated with this transaction has not been material to date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, we reimbursed Pablo Legorreta approximately $<ix:nonFraction unitRef="usd" contextRef="i26d178fad8c34db685697ae7ed68e651_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4NDg_fa05b348-8a1f-45f6-864b-16da25757857">1.0</ix:nonFraction>&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns <ix:nonFraction unitRef="shares" contextRef="i75854c27514042c189af622ae1d3b9b3_D20220101-20221231" decimals="INF" name="rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzYzNTU_ecb2a4d7-3846-4f11-b991-b8605b69ed75">27,210</ix:nonFraction> limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $<ix:nonFraction unitRef="usd" contextRef="i393ab282388f413799453b142053e5c2_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA3NzE_5c29b835-651f-43fd-9414-c505e4288b36">4.3</ix:nonFraction>&#160;million was recorded as treasury interests, of which $<ix:nonFraction unitRef="usd" contextRef="if58be7d678254e86aa0bb99632dcf71b_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4MTU_85ca57a3-6b80-4b28-b592-36b9498681ab">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id61936b93228428ab0a7f8fc0e01f96c_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4MDM_7b39dfef-ad7e-4de9-bae5-0c4a82ad277b">1.6</ix:nonFraction>&#160;million were held by non-controlling interests as of December 31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib73847f74eb040069b6fa09b93129e7e">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_175"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzg3OQ_0accc549-d643-45c6-a07c-4cec4f498bb0" continuedAt="ieb8f5503220d467c930a12ad9504a307" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ieb8f5503220d467c930a12ad9504a307">In January 2023, we acquired an interest in Ionis Pharmaceuticals, Inc.&#8217;s royalty in Biogen&#8217;s Spinraza (nusinersen) and Novartis&#8217; pelacarsen, a development-stage product, for up to $<ix:nonFraction unitRef="usd" contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNTgz_0749ce57-6e6e-487c-9b03-42d785876cd2">1.125</ix:nonFraction>&#160;billion, including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131" decimals="-6" name="rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNTk5_427a5bd0-4ca1-433f-9ed5-2c0c00f655d9">500</ix:nonFraction>&#160;million and up to $<ix:nonFraction unitRef="usd" contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131" decimals="-6" name="rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNjEz_43e46d10-1b1f-4684-884a-dfb6d0f413c0">625</ix:nonFraction>&#160;million in additional pelacarsen milestone payments.</ix:continuation></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s Report on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control-Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> independent registered public accounting firm, Ernst &amp; Young LLP, has issued an audit report on our internal control over financial reporting as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Their report is included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal controls over financial reporting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">identified in management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the fourth quarter of 2022 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_965"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. &#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. &#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. &#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. &#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSACTIONS, AND DIRECTORS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEPENDENCE</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i7624980bc44b4db29e5ea00d25f439ff_205"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_208"></div><div style="text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">15(a)(1) Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following documents are filed as part of this Form 10-K: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Reports of Independent Registered Public Accounting Firm</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Consolidated Balance Sheets as of December 31, 2022 and 2021 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Consolidated Statements of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Consolidated Statements of Shareholders&#8217; Equity for the years ended December 31, 2022, 2021 and 2020 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:14.5pt">Notes to the Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">15(a)(2) Financial Statement Schedules. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">15(a)(3) Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit Description</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Filing Date/<br/>Period End Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Filed or Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex31.htm">Articles of Association of Royalty Pharma plc</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312522256763/d341793dex32.htm">Articles of Association of Royalty Pharma Holdings Ltd</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/30/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex41.htm">Form of Class A Ordinary Share Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20221231ex42.htm">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex101.htm">Amended and Restated Management and Services Agreement dated October 3, 2022, among the Company and RP Management, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">11/08/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex101.htm">Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Ltd, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex104.htm">Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex105.htm">Form of Deed of Indemnity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex106.htm">Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex107.htm">Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex108.htm">Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.8#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex109.htm">Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Incorporated, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1010.htm">Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1011.htm">Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1012.htm">Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1013.htm">Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">Amended and Restated Management and Services Agreement dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">October 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">, among Royalty Pharma </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">Holdings L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm">td</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex102.htm"> and RP Management, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">11/08/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000180276822000045/rprx-20220930ex103.htm">Second Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">11/08/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex1015.htm">Form of Independent Director Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0401.htm">Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0402.htm">First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0409.htm">Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs  &amp; Co LLC, J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.19#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520286894/d66211dex101.htm">Amendment No. 2 to the Amended and Restated Purchase and Sale Agreement, dated October 30, 2020, by and among RPI Finance Trust, RPI 2019 Intermediate Finance Trust and Cystic Fibrosis Foundation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">11/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001802768/000119312521224416/d61746dex42.htm">Second Supplemental Indenture, dated as of July 26, 2021, Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">7/26/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20221231ex211.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20221231ex231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Power of Attorney (reference is made to the signature page hereto)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20221231ex311.htm">Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20221231ex312.htm">Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20221231ex32.htm">Certifications of Chief Executive Office and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presentation Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8224; &#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"># &#160;&#160;&#160;&#160;Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_211"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. &#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i7624980bc44b4db29e5ea00d25f439ff_214"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROYALTY PHARMA PLC</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Pablo Legorreta</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pablo Legorreta</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrance Coyne</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrance Coyne</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">POWER OF ATTORNEY</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Terrance Coyne and George Lloyd, and each of them,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Pablo Legorreta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Chairman of the Board, Director &amp; Chief Executive Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer and Royalty Pharma plc&#8217;s authorized representative in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pablo Legorreta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrance Coyne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President &amp; Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial Officer and Principal Accounting Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrance Coyne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bonnie Bassler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonnie Bassler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Errol De Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Errol De Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Catherine Engelbert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catherine Engelbert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Henry Fernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Henry Fernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. Germano Giuliani</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. Germano Giuliani</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Hodgson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Hodgson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ted Love</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ted Love</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rory Riggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rory Riggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>rprx-20221231ex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iead7f229432745b7bbceb460d3fd2e32_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED UNDER SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Royalty Pharma plc (&#8220;Royalty Pharma&#8221; or the &#8220;Company&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934&#58; our Class&#160;A ordinary shares,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">par value $0.0001 per share, which are listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;RPRX.&#8221; </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description is a summary of our share capital as specified in our Articles of Association. This summary does not purport to be complete and the statements in this summary are qualified in their entirety by reference to, and are subject to, the detailed provisions of our Articles of Association and the U.K. Companies Act. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Structure </font></div><div style="margin-top:6pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued Share Capital </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of voting shares&#58; Class&#160;A and Class&#160;B, each of which has one vote per share. The Class&#160;A ordinary shares and Class&#160;B shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. We also have in issue 50,000 Class&#160;R redeemable shares, which do not entitle the holder to voting or dividend rights, and deferred shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class&#160;R redeemable shares was to ensure we had sufficient sterling denominated share capital at the time we re-registered as a public limited company, as required by the U.K. Companies Act. The Class&#160;R redeemable shares may be redeemed at some future point in order to leave the Company with only U.S. dollar denominated share capital. Any such redemption would be at nominal value. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has been granted authority from our shareholders to allot and issue new Class&#160;A ordinary shares and other shares, and to grant rights to subscribe for or to convert any security into new Class&#160;A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000, for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May&#160;31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. This authority is in addition to authorities to allot and issue new Class&#160;A ordinary shares in exchange for Royalty Pharma Holdings Ltd Class&#160;B ordinary shares or the depositary receipts that represent them. The rights and restrictions to which the Class&#160;A ordinary shares are subject are prescribed by our Articles of Association. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;A Ordinary Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;A ordinary shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable, the holders of Class&#160;A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the board of directors out of funds legally available therefor. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights upon liquidation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of liquidation, dissolution or winding up of Royalty Pharma the holders of Class&#160;A ordinary shares are entitled to share ratably in all assets remaining after payment of liabilities. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;B Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares do not have any rights to receive dividends. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights upon liquidation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of Royalty Pharma, following the prior payment of the nominal capital paid up or credited as paid up on each Class&#160;A ordinary share as well as an amount of $10,000,000 on each Class&#160;A ordinary share upon such liquidation, dissolution or winding up. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, the Company may only pay dividends out of profits available for that purpose. The Company&#8217;s profits available for distribution are its accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of the Company&#8217;s distributable reserves is a cumulative calculation. The Company may be profitable in a single financial year but unable to pay a dividend if our accumulated, realized profits of that year do not offset all previous years&#8217; accumulated, realized losses. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may only make a distribution if the amount of its net assets is not less than the aggregate of its called-up share capital and undistributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association authorize our board of directors to approve interim dividends without shareholder approval to the extent that the approval of such dividends appears justified by profits. Our board of directors may also recommend a final dividend to be approved and declared by the shareholders at an annual general meeting and may direct that the payment be made by distribution of assets, shares or cash. No dividend may exceed the amount recommended by the board of directors. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association also permit a scrip dividend scheme under which the board of directors may offer any holders of Class&#160;A ordinary shares the right to elect to receive Class&#160;A ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part determined by the board of directors) of all or any dividend subject to certain terms and conditions set out in our Articles of Association. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entitlement to a dividend lapses if unclaimed for 12 years. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Articles of Association, each holder of Class&#160;A ordinary shares or Class&#160;B shares is entitled to one vote for each share that he or she holds as of the record date for the meeting. Neither English law nor any of our constituent documents places limitations on the right of nonresident or foreign owners to vote or hold ordinary shares. The voting at a general meeting must be taken by poll. Subject to any relevant special rights or restrictions attached to any shares, on a poll taken at a general meeting, each qualifying shareholder present in person or by proxy (or, in the case of a corporation, a corporate representative) and entitled to vote on the resolution has one vote for every Class&#160;A ordinary share or Class&#160;B share held by such shareholder. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ordinary resolution must be approved by a simple majority, and a special resolution approved by at least 75%, of shareholders attending and voting, whether in person or by proxy. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment to our Articles of Association </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, shareholders may amend the articles of association of a company by special resolution. However, certain provisions of our Articles of Association require a higher threshold of shareholder approval or satisfaction of other procedures before such provision or provisions can be varied. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The article in our Articles of Association which requires voting at a general meeting to be taken on a poll may only be removed, amended or varied by resolution of the shareholders passed unanimously. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Winding Up </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a voluntary winding up of the Company, the liquidator may, with the sanction of a special resolution of the Company and any other sanction required by law, subject to the U.K. Insolvency Act of 1986, after effectively applying the Company&#8217;s property to satisfy the Company&#8217;s liabilities, divide among the holders of Class&#160;A ordinary shares of the Company the whole or any part of the assets of the Company, whether they consist of property of the same kind or not, and vest the whole or any part of the assets in trustees upon such trusts for the benefit of the holders of Class&#160;A ordinary shares of the Company as the liquidator, with such sanction, may determine. No shareholder of the Company shall be compelled to accept any assets upon which there is a liability. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a return of capital on a liquidation, reduction of capital or otherwise, the surplus assets of the Company available for distribution among the holders of Class&#160;A ordinary shares shall be applied pro rata (rounded to the nearest whole number). </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rights of Pre-Emption on New Issues of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.K. Companies Act, the allotment of &#8220;equity securities&#8221; (except pursuant to an employees&#8217; share scheme and as bonus shares) that are to be paid for wholly in cash must be offered first to the existing holders of ordinary shares in proportion to the respective nominal amounts (i.e., par values) of their holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association otherwise provide disapplication from this requirement (which disapplication can be for a maximum of five years after which shareholders&#8217; approval would be required to renew the disapplication). &#8220;Equity securities&#8221; means ordinary shares or rights to subscribe for, or convert securities into, ordinary shares where ordinary shares means shares other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution. In relation to the Company, &#8220;equity securities&#8221; will therefore include the Class&#160;A ordinary shares, and all rights to subscribe for or convert securities into such shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has been granted authority from our shareholders to allot and issue new Class&#160;A ordinary shares and other shares and to grant rights to subscribe for or to convert any security into new Class&#160;A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May&#160;31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure of Ownership Interests in Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;793 of the U.K. Companies Act gives us the power to require persons whom we know have, or whom we have reasonable cause to believe have, or within the previous three years have had, an interest in any shares of the Company to disclose specified information regarding those shares. Failure to provide the information requested within the prescribed period (or knowingly or recklessly providing false information after the date the notice is sent) can result in criminal or civil sanctions being imposed against the person in default. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Articles of Association, if any of our shareholders, or any other person appearing to be interested in the shares of the Company held by such shareholder, has been duly served with a notice under section 793 and fails to give us the information required by such notice or has made a statement which is false or inadequate in a material particular, then our board of directors may, in its absolute discretion at any time by notice, withdraw voting rights and place restrictions on the rights to receive dividends and refuse to register a transfer of such shares. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alteration of Share Capital&#47;Share Repurchases </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of the U.K. Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time, among other things&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;increase our share capital by allotting and issuing new shares in accordance with our Articles of Association and any relevant shareholder resolution&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than the existing shares&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;redenominate our share capital or any class of share capital </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not consolidate, divide, subdivide or redenominate any class of voting shares without consolidating, dividing, subdividing or redenominating (as the case may be) the other classes of voting shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">English law prohibits us from purchasing our own shares unless such purchase has been approved by our shareholders. Shareholders may approve two different types of such share purchases&#58; &#8220;on-market&#8221; share purchases or &#8220;off-market&#8221; share purchases. &#8220;On-market&#8221; purchases may only be made on a &#8220;recognised investment exchange,&#8221; which does not include Nasdaq, which is the only exchange on which the Company&#8217;s shares are traded. In order to purchase our own shares, as a Company listed on Nasdaq, we must therefore obtain the approval of our shareholders for an &#8220;off-market purchase&#8221; (on the basis of a specific purchase agreement with a financial intermediary) to acquire shares that are traded on Nasdaq. This requires our shareholders to pass an ordinary resolution approving an &#8220;off-market purchase,&#8221; where such approval may be for a maximum period of five years. In relation to an &#8220;off-market purchase,&#8221; we may not acquire our own shares until the terms of the contract pursuant to which the purchase(s) are to be made have been authorized by our shareholders. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer and Registration of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association allow shareholders to transfer all or any of their shares by instrument of transfer in writing in any usual form or in any other form which our board of directors may approve. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The instrument of transfer must be executed by or on behalf of the transferor and (in the case of a transfer of a share that is not fully paid) by or on behalf of the transferee. Our Articles of Association also permit transfer of shares in uncertificated form by means of a relevant electronic system. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not charge a fee for registering the transfer of a share. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may, in its absolute discretion, refuse to register a transfer of shares in certificated form if it is not fully paid (provided that the refusal does not prevent dealings in the shares from taking place on an open and proper basis) or is with respect to a share on which we have a lien and sums in respect of which the lien exists are payable and are not paid within 14 clear days after due notice has been sent. If our board of directors refuses to register a transfer of a share, it shall notify the transferor of the refusal and the reasons for it as soon as practicable and in any event within two months after the date on which the instrument of transfer was lodged with us (in the case of a transfer of a share in certificated form) or the instructions to the relevant system received. Any instrument of transfer which our board of directors refuses to register shall (except in the case of fraud) be returned to the person lodging it when notice of the refusal is sent. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computershare Trust Company, N.A. acts as our transfer agent and registrar. The share register reflects only registered owners of our Class&#160;A ordinary shares, Class&#160;B shares, Class&#160;R redeemable shares and deferred shares. Registration in the Company&#8217;s share register is determinative of ownership of shares of the Company. A shareholder who holds shares beneficially is not the holder of record of such shares. Instead, the clearance service or depositary (for example, Cede&#160;&#38; Co, as nominee for the Depository Trust Company, or DTC, or GTU Ops, Inc., as nominee for Computershare Trust Company, N.A.) or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who holds such shares beneficially through a clearance service or depositary or other nominee will not be registered in the Company&#8217;s official share register, as the depositary or other nominee will remain the record holder of any such shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company notifies one or both of the parties to a share transfer that it believes stamp duty or stamp duty reserve tax is required to be paid in connection with a transfer of shares of the Company, if the parties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the transfer have an instrument of transfer duly stamped to the extent required and then provide such instrument of transfer to the Company&#8217;s share registrar, the buyer will be registered as the legal owner of the relevant shares on the official share register, subject to our rights with respect to the disclosure of interests in our shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeover Provisions </font></div><div style="margin-top:6pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Takeover Bids </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), we do not currently envisage that the City Code on Takeovers and Mergers (the &#8220;Takeover Code&#8221;) will apply to an offer for the Company. It is possible that in the future circumstances could change that may cause the Takeover Code to apply to us. The Takeover Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the Takeover Code contains certain rules in respect of mandatory offers. Under Rule 9 of the Takeover Code, if a person&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;acquires an interest in shares that, when taken together with shares in which such person is already interested and in which persons acting in concert with such person are interested, carries 30% or more of the voting rights of shares&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;who, together with persons acting in concert with such person, is interested in shares that in the aggregate carry not less than 30% of the voting rights but is not interested in shares carrying more than 50% of such voting rights and such person, or any person acting in concert with such person, acquires an additional interest in shares that increases the percentage of shares carrying voting rights in which that person is interested, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the acquirer, and, depending on the circumstances, its concert parties, would be required (except with the consent of the Takeover Panel) to make a cash offer for the outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, an offeror for the Company that has acquired (i)&#160;not less than 90% in value of&#59; and (ii)&#160;not less than 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for the Company is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i)&#160;approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting&#59; and (ii)&#160;approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting. </font></div><div style="margin-top:18pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Issues in the Context of an Acquisition </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association provide the board of directors with the power to establish a rights plan and to grant rights to subscribe for our shares pursuant to a rights plan where, in the opinion of the board of directors, acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so would improve the likelihood that&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an acquisition process is conducted in an orderly manner&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;all our shareholders are treated equally and fairly and in a similar manner&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an optimum price is achieved for our Class&#160;A ordinary shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the board of directors would have time to gather relevant information and pursue appropriate strategies&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the success of Royalty Pharma would be promoted for the benefit of our shareholders as a whole&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the long term interests of Royalty Pharma, our shareholders and business would be safeguarded&#59; and&#47;or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Royalty Pharma would not suffer serious economic harm. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association further provide that the board of directors may, in accordance with the terms of a rights plan, determine to (i)&#160;allot shares pursuant to the exercise of rights or (ii)&#160;exchange rights for our shares, where in the opinion of the board of directors acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so is necessary in order to prevent&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the use of abusive tactics by any person in connection with such acquisition&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;unequal treatment of shareholders&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an acquisition which would undervalue Royalty Pharma&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;harm to the prospects of the success of Royalty Pharma for the benefit of its shareholder as a whole&#59; and&#47;or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;serious economic harm to the prospects of Royalty Pharma, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or where to do so is otherwise necessary to safeguard the long term interests of Royalty Pharma, our shareholders and our business. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeover Code, the board of a public company incorporated under the laws of England and Wales is constrained from implementing such defensive measures. However, as discussed above, these measures are included in our Articles of Association as the Takeover Code is not expected to apply to us and these measures are included commonly in the constitution of U.S. companies. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions will apply for so long as we are not subject to the Takeover Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>rprx-20221231ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibe6b98e7f0ad4ace9fa3390dceecbdf3_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SUBSIDIARIES OF THE REGISTRANT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a list of subsidiaries of Royalty Pharma plc, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as of December 31, 2022&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.292%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Legal Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Royalty Pharma Holdings Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Royalty Pharma Investments 2019 ICAV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RPI 2019 Intermediate Finance Trust</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Royalty Pharma Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RPI Acquisitions (Ireland) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RPI Finance Trust</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Royalty Pharma Collection Trust</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RP IP HoldCo (Ireland) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Royalty Pharma Investments ICAV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ireland</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>rprx-20221231ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if9ce3875b52c44e59e7bd5e00eb7da00_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 23.1</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Consent&#160;of Independent Registered Public Accounting Firm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We&#160;consent&#160;to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.75pt">Registration Statement (Form S-8 No. 333-239193) pertaining to the Royalty Pharma plc 2020 Independent Director Equity Incentive Plan&#59; and</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Registration Statement (Form S-4 No. 333-257188) of Royalty Pharma plc&#59; and </font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Registration Statement (Form S-3ASR No. 333-257883) of Royalty Pharma plc&#59; </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of our reports dated February 15, 2023, with respect to the consolidated financial statements of Royalty Pharma plc and the effectiveness of internal control over financial reporting of Royalty Pharma plc, included in this Annual Report (Form 10-K) of Royalty Pharma plc for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">New York, New York</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">February 15, 2023</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>rprx-20221231ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7441d319fe134d4ea1eb57a4ccf2cf9c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Pablo Legorreta, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; February 15, 2023</font></div><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.454%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>rprx-20221231ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id68e90251741493fa31407413176739e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Terrance Coyne, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; February 15, 2023</font></div><div><font><br></font></div><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.454%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>rprx-20221231ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if53ec825b38b4778b767a02db7ad4320_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Royalty Pharma plc (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;February 15, 2023</font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>rprx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rprx="http://royaltypharma.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://royaltypharma.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://royaltypharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://royaltypharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurpose" roleURI="http://royaltypharma.com/role/OrganizationandPurpose">
        <link:definition>0000010 - Disclosure - Organization and Purpose</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecurities" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities">
        <link:definition>0000012 - Disclosure - Available for Sale Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://royaltypharma.com/role/DerivativeInstruments">
        <link:definition>0000013 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstruments" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments">
        <link:definition>0000014 - Disclosure - Fair Value Measurements and Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssets" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssets">
        <link:definition>0000015 - Disclosure - Financial Royalty Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets">
        <link:definition>0000016 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNet" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet">
        <link:definition>0000017 - Disclosure - Intangible Royalty Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliates" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates">
        <link:definition>0000018 - Disclosure - Non-Consolidated Affiliates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpense" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense">
        <link:definition>0000019 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://royaltypharma.com/role/Borrowings">
        <link:definition>0000020 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://royaltypharma.com/role/ShareholdersEquity">
        <link:definition>0000021 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://royaltypharma.com/role/EarningsperShare">
        <link:definition>0000022 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlow" roleURI="http://royaltypharma.com/role/IndirectCashFlow">
        <link:definition>0000023 - Disclosure - Indirect Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://royaltypharma.com/role/CommitmentsandContingencies">
        <link:definition>0000024 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://royaltypharma.com/role/RelatedPartyTransactions">
        <link:definition>0000025 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://royaltypharma.com/role/SubsequentEvents">
        <link:definition>0000026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesTables" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables">
        <link:definition>0000028 - Disclosure - Available for Sale Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsTables">
        <link:definition>0000029 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsTables" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables">
        <link:definition>0000030 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsTables" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables">
        <link:definition>0000031 - Disclosure - Financial Royalty Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables">
        <link:definition>0000032 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetTables" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables">
        <link:definition>0000033 - Disclosure - Intangible Royalty Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://royaltypharma.com/role/BorrowingsTables">
        <link:definition>0000034 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://royaltypharma.com/role/ShareholdersEquityTables">
        <link:definition>0000035 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://royaltypharma.com/role/EarningsperShareTables">
        <link:definition>0000036 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowTables" roleURI="http://royaltypharma.com/role/IndirectCashFlowTables">
        <link:definition>0000037 - Disclosure - Indirect Cash Flow (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables">
        <link:definition>0000038 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurposeDetails" roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails">
        <link:definition>0000039 - Disclosure - Organization and Purpose (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesNarrativeDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails">
        <link:definition>0000041 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>0000042 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsNarrativeDetails" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails">
        <link:definition>0000043 - Disclosure - Derivative Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails">
        <link:definition>0000044 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
        <link:definition>0000047 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
        <link:definition>0000048 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails">
        <link:definition>0000049 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsNarrativeDetails" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails">
        <link:definition>0000050 - Disclosure - Financial Royalty Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails">
        <link:definition>0000051 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
        <link:definition>0000052 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetNarrativeDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails">
        <link:definition>0000053 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliatesDetails" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails">
        <link:definition>0000054 - Disclosure - Non-Consolidated Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpenseDetails" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails">
        <link:definition>0000055 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails">
        <link:definition>0000056 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails_1" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1">
        <link:definition>0000056 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000057 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofRepaymentsofDebtbyYearDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
        <link:definition>0000058 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>0000059 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquitySummaryofNoncontrollingInterestsDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
        <link:definition>0000060 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://royaltypharma.com/role/EarningsperShareDetails">
        <link:definition>0000061 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowDetails" roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails">
        <link:definition>0000062 - Disclosure - Indirect Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000064 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://royaltypharma.com/role/SubsequentEventsDetails">
        <link:definition>0000065 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rprx_SeniorUnsecuredRevolvingCreditFacilityMember" abstract="true" name="SeniorUnsecuredRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" abstract="false" name="PaymentsToNoncontrollingInterestsRoyaltyReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" abstract="true" name="ThreePointThreeZeroPercentSeniorNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInFinancialRoyaltyAssets" abstract="false" name="IncreaseDecreaseInFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IntangibleRoyaltyAssetsMember" abstract="true" name="IntangibleRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyAssetsPolicyPolicyTextBlock" abstract="false" name="RoyaltyAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" abstract="false" name="StockIssuedDuringPeriodSharesIssuedToPartnerships" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" abstract="true" name="RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OptionIndexedToIssuersEquityTerm" abstract="false" name="OptionIndexedToIssuersEquityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_ContinuingInvestorsPartnershipMember" abstract="true" name="ContinuingInvestorsPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancialRoyaltyAssetsMember" abstract="true" name="FinancialRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForMilestones" abstract="false" name="PaymentsForMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_MilestoneAccelerationOptionMember" abstract="true" name="MilestoneAccelerationOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" abstract="true" name="OnePointTwoZeroPercentSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PabloLegorretaMember" abstract="true" name="PabloLegorretaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" abstract="false" name="DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rprx_PaymentsToNoncontrollingInterestsOther" abstract="false" name="PaymentsToNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" abstract="false" name="DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_RochesMember" abstract="true" name="RochesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" abstract="false" name="FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_XtandiMember" abstract="true" name="XtandiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssignmentAgreementFundingObligationsMember" abstract="true" name="AssignmentAgreementFundingObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" abstract="false" name="CollaborativeArrangementRightsAndObligationsPeriodOfReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_TheNotesMember" abstract="true" name="TheNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RPIFTSeniorSecuredCreditFacilitiesMember" abstract="true" name="RPIFTSeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IPOSharesFromCompanyMember" abstract="true" name="IPOSharesFromCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" abstract="false" name="StockholdersEquityValueEffectOfExchangeAndReallocation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateAdjustedCashReceipts" abstract="false" name="RelatedPartyTransactionRateAdjustedCashReceipts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_NumberOfNoncontrollingInterests" abstract="false" name="NumberOfNoncontrollingInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionInitialTerm" abstract="false" name="RelatedPartyTransactionInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_DebtInstrumentIssuanceAsAPercentOfPar" abstract="false" name="DebtInstrumentIssuanceAsAPercentOfPar" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" abstract="true" name="OnePointSevenFivePercentSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesSharesIssued" abstract="false" name="DeferredSharesSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" abstract="false" name="RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_PaymentsForCollateralPostedOnDerivativeInstruments" abstract="false" name="PaymentsForCollateralPostedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RedeemableStockRedemptionPricePerShare" abstract="false" name="RedeemableStockRedemptionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_CytokineticsCommercialLaunchFundingMember" abstract="true" name="CytokineticsCommercialLaunchFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionAnnualIncreasePercentage" abstract="false" name="RelatedPartyTransactionAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_RoyaltyPharmaCollectionTrustMember" abstract="true" name="RoyaltyPharmaCollectionTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NoncontrollingInterestTransfersOfInterests" abstract="false" name="NoncontrollingInterestTransfersOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" abstract="true" name="LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToAcquireEquitySecuritiesFNNI" abstract="false" name="PaymentsToAcquireEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EvrysdiMember" abstract="true" name="EvrysdiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipCovenantRequiredAmount" abstract="false" name="LongTermFundingPartnershipCovenantRequiredAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipNumberOfTranches" abstract="false" name="LongTermFundingPartnershipNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodValueIssuedForRegistration" abstract="false" name="StockIssuedDuringPeriodValueIssuedForRegistration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" abstract="true" name="RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" abstract="true" name="TwoPointTwoZeroPercentSeniorNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CytokineticsMember" abstract="true" name="CytokineticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSalePricePerShare" abstract="false" name="DebtSecuritiesAvailableForSalePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_TheravanceBiopharmaMember" abstract="true" name="TheravanceBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssignmentAgreementBenefitOfPaymentStreamMember" abstract="true" name="AssignmentAgreementBenefitOfPaymentStreamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToTerminateDerivativeInstruments" abstract="false" name="PaymentsToTerminateDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FundingAgreementsWithSanofiMember" abstract="true" name="FundingAgreementsWithSanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingCommitmentAmountOutstanding" abstract="false" name="LongTermFundingCommitmentAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesSharesOutstanding" abstract="false" name="DeferredSharesSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_AvillionIIMember" abstract="true" name="AvillionIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesParOrStatedValuePerShare" abstract="false" name="DeferredSharesParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_DPPIVPatentsMember" abstract="true" name="DPPIVPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_SaleOfStockNumberOfSharesNotConverted" abstract="false" name="SaleOfStockNumberOfSharesNotConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsMember" abstract="true" name="LegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForOngoingDevelopmentStageFunding" abstract="false" name="PaymentsForOngoingDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipExpectedPayment" abstract="false" name="LongTermFundingPartnershipExpectedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RoyaltyInvestmentsMember" abstract="true" name="RoyaltyInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" abstract="false" name="PaymentsToAcquireEquityInvestmentsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ClassBHoldersMember" abstract="true" name="ClassBHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForUpfrontDevelopmentStageFunding" abstract="false" name="PaymentsForUpfrontDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TrelegyMember" abstract="true" name="TrelegyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" abstract="false" name="RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesValueIssued" abstract="false" name="DeferredSharesValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DerivativeAssetMember" abstract="true" name="DerivativeAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AccruedRoyaltyReceivable" abstract="false" name="AccruedRoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OtilimabMember" abstract="true" name="OtilimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DevelopmentFundBondMember" abstract="true" name="DevelopmentFundBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_UnitHoldersAndShareholdersContributionsMember" abstract="true" name="UnitHoldersAndShareholdersContributionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_GainLossOnDerivativeFinancialInstruments" abstract="false" name="GainLossOnDerivativeFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipTotalAmountDrawn" abstract="false" name="LongTermFundingPartnershipTotalAmountDrawn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" abstract="false" name="IncreaseDecreaseInOtherRoyaltyIncomeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureNoncurrent" abstract="false" name="AssetsFairValueDisclosureNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IndividualLicenseesConcentrationRiskMember" abstract="true" name="IndividualLicenseesConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FundingAgreementWithBioCrystMember" abstract="true" name="FundingAgreementWithBioCrystMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RepaymentsOfLongTermDebtScheduledPayments" abstract="false" name="RepaymentsOfLongTermDebtScheduledPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OperatingAndPersonnelPaymentsMember" abstract="true" name="OperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForDistributionsToShareholdersAndUnitholders" abstract="false" name="PaymentsForDistributionsToShareholdersAndUnitholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" abstract="false" name="LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TreasuryRateLockContractsMember" abstract="true" name="TreasuryRateLockContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_EpizymeIncMember" abstract="true" name="EpizymeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_NetIncomeLossAttributableToParentPriorToOffering" abstract="false" name="NetIncomeLossAttributableToParentPriorToOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SettlementsWithEquityMethodInvestments" abstract="false" name="SettlementsWithEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_NumberOfNoncontrollingInterestsCreated" abstract="false" name="NumberOfNoncontrollingInterestsCreated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" abstract="false" name="ProceedsFromCollateralReceivedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" abstract="false" name="IncreaseDecreaseInCashCollectionsOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" abstract="true" name="RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ImbruvicaMember" abstract="true" name="ImbruvicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RPHoldingsMember" abstract="true" name="RPHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CommonStockVotingRightsNumberOfVotes" abstract="false" name="CommonStockVotingRightsNumberOfVotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_CysticFibrosisFranchiseMember" abstract="true" name="CysticFibrosisFranchiseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" abstract="true" name="ThreePointThreeFivePercentSeniorNotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" abstract="true" name="RoyaltyDistributionPayableToRPSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" abstract="true" name="TwoPointOneFivePercentSeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FormerOperatingAndPersonnelPaymentsMember" abstract="true" name="FormerOperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromExerciseFeeProRataAmount" abstract="false" name="ProceedsFromExerciseFeeProRataAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_GantenerumabMember" abstract="true" name="GantenerumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ExchangeOfferTransactionMember" abstract="true" name="ExchangeOfferTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyPharmaInvestmentsOldRPIMember" abstract="true" name="RoyaltyPharmaInvestmentsOldRPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" abstract="false" name="FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" abstract="false" name="PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_BioCrystPharmaceuticalsIncMember" abstract="true" name="BioCrystPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionEntitiesMember" abstract="true" name="AvillionEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rprx_EpizymeCommonStockWarrantMember" abstract="true" name="EpizymeCommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_MilestoneAccelerationMember" abstract="true" name="MilestoneAccelerationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_OptionIndexedToIssuersEquityValue" abstract="false" name="OptionIndexedToIssuersEquityValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SeniorNotesDue2031Member" abstract="true" name="SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" abstract="false" name="ProceedsFromNoncontrollingInterestsResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SeniorNotesDue2051Member" abstract="true" name="SeniorNotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRPSFTMember" abstract="true" name="LegacyInvestorsPartnershipsAndRPSFTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" abstract="true" name="ThreePointFiveFivePercentSeniorNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OvernightBankFundingRateMember" abstract="true" name="OvernightBankFundingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAmount" abstract="false" name="LongTermFundingPartnershipAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IPOContinuingInvestorsPartnershipsMember" abstract="true" name="IPOContinuingInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" abstract="false" name="FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OtherFinancialRoyaltyAssetMember" abstract="true" name="OtherFinancialRoyaltyAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" abstract="false" name="InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForOperatingCostsAndProfessionalServices" abstract="false" name="PaymentsForOperatingCostsAndProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CommonStockQuarterlyConversionBasis" abstract="false" name="CommonStockQuarterlyConversionBasis" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_PaymentOfDividendsToShareholders" abstract="false" name="PaymentOfDividendsToShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PointSevenFivePercentSeniorNotesDue2023Member" abstract="true" name="PointSevenFivePercentSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AccruedPurchaseObligationEquityInvestment" abstract="false" name="AccruedPurchaseObligationEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" abstract="false" name="ProceedsFromIssuanceOfEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" abstract="false" name="IncreaseDecreaseInAccruedRoyaltyReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OtherRoyaltyIncomeReceivableCurrent" abstract="false" name="OtherRoyaltyIncomeReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FundingCommitmentsMember" abstract="true" name="FundingCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IPOSharesFromSellingShareholdersMember" abstract="true" name="IPOSharesFromSellingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CytokineticsFundingCommitmentMember" abstract="true" name="CytokineticsFundingCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_UnapprovedFinancialAssetsHeldAtCosts" abstract="false" name="UnapprovedFinancialAssetsHeldAtCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EquityMethodInvestmentsUnfundedCommitments" abstract="false" name="EquityMethodInvestmentsUnfundedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsOther" abstract="false" name="ProceedsFromNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" abstract="true" name="AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyIncomeOtherMember" abstract="true" name="RoyaltyIncomeOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" abstract="false" name="RelatedPartyTransactionRateValueOfSecurityInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_FinancingReceivablesFairValueDisclosure" abstract="false" name="FinancingReceivablesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RPI2019IntermediateFinanceMember" abstract="true" name="RPI2019IntermediateFinanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PurchasingAndDonatingVentilatorsMember" abstract="true" name="PurchasingAndDonatingVentilatorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OldCreditFacilityMember" abstract="true" name="OldCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_MilestonePaymentAccruedButNotPaid" abstract="false" name="MilestonePaymentAccruedButNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" abstract="false" name="FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" abstract="false" name="LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" abstract="false" name="CollaborativeArrangementRightsAndObligationsPaymentOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_AgreementWithMSCIMember" abstract="true" name="AgreementWithMSCIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" abstract="false" name="LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_NumberOfClassesOfVotingStock" abstract="false" name="NumberOfClassesOfVotingStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" abstract="false" name="FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EPAHoldingsMember" abstract="true" name="EPAHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" abstract="false" name="DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_TysabriMember" abstract="true" name="TysabriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionIMember" abstract="true" name="AvillionIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" abstract="false" name="FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromExerciseFee" abstract="false" name="ProceedsFromExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" abstract="false" name="StockholdersEquitySharesEffectOfExchangeAndReallocation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_MorphoSysMember" abstract="true" name="MorphoSysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_MerckToFundMember" abstract="true" name="MerckToFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ClassRRedeemableStockMember" abstract="true" name="ClassRRedeemableStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" abstract="false" name="LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInitialPayment" abstract="false" name="LongTermFundingPartnershipInitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SaleOfStockNumberOfSharesAvailableToConvert" abstract="false" name="SaleOfStockNumberOfSharesAvailableToConvert" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedForRegistration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_MerckAssetPhaseIIClinicalTrialMember" abstract="true" name="MerckAssetPhaseIIClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" abstract="false" name="ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" abstract="false" name="StockIssuedDuringPeriodValueIssuedToPartnerships" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureCurrent" abstract="false" name="AssetsFairValueDisclosureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RoyalPharmacySelectFinanceTrustMember" abstract="true" name="RoyalPharmacySelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>rprx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_606531c9-6b7b-4b16-b6bc-ff01a3273d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_CommonStockValue_606531c9-6b7b-4b16-b6bc-ff01a3273d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_68abe492-eedb-452a-9b3a-f99032e0d27c" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_rprx_DeferredSharesValueIssued_68abe492-eedb-452a-9b3a-f99032e0d27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_891902a6-ff86-449b-bfc8-be1b2d03847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_891902a6-ff86-449b-bfc8-be1b2d03847b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d097edbf-f37a-4f7f-ba1c-dadee509332c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d097edbf-f37a-4f7f-ba1c-dadee509332c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_84e15d04-cc0e-4d05-9064-7bb6c608041b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_MinorityInterest_84e15d04-cc0e-4d05-9064-7bb6c608041b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95e8e578-5170-406e-82f3-4ce3b03b7d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95e8e578-5170-406e-82f3-4ce3b03b7d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e8368d19-a7c4-4d12-af56-a7cfe652bd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccc717fb-fcfb-46bd-bb35-9f34716fa8d3" xlink:to="loc_us-gaap_TreasuryStockValue_e8368d19-a7c4-4d12-af56-a7cfe652bd5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2f2ca38-3a89-45dc-ab34-ac796fcf335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2e335661-f51d-43af-83bd-891bff06fa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2f2ca38-3a89-45dc-ab34-ac796fcf335d" xlink:to="loc_us-gaap_Liabilities_2e335661-f51d-43af-83bd-891bff06fa2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1d25fd6b-0915-45ed-97d8-515db4315e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2f2ca38-3a89-45dc-ab34-ac796fcf335d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1d25fd6b-0915-45ed-97d8-515db4315e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20b4a08b-8a16-4de7-a8bc-f12d4c9c97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2f2ca38-3a89-45dc-ab34-ac796fcf335d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20b4a08b-8a16-4de7-a8bc-f12d4c9c97f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_493b9563-e0f7-4c64-849b-ec7ae23d4796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_713e1472-2cc7-47f5-8759-f74e9f722010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_493b9563-e0f7-4c64-849b-ec7ae23d4796" xlink:to="loc_us-gaap_LiabilitiesCurrent_713e1472-2cc7-47f5-8759-f74e9f722010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7b809ffe-5c31-479c-b5d0-a1e683c81411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_493b9563-e0f7-4c64-849b-ec7ae23d4796" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7b809ffe-5c31-479c-b5d0-a1e683c81411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0ed96d32-7c28-4004-afab-acaed729437f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_493b9563-e0f7-4c64-849b-ec7ae23d4796" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0ed96d32-7c28-4004-afab-acaed729437f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae290d03-fd17-4964-9c32-86b46ea27390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae290d03-fd17-4964-9c32-86b46ea27390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_eb89d859-d0fd-4df5-ae1e-1078361fdb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_eb89d859-d0fd-4df5-ae1e-1078361fdb1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_0fc08f8d-34c2-4e87-aa14-f5a8e7f4175a" xlink:href="rprx-20221231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_rprx_AccruedRoyaltyReceivable_0fc08f8d-34c2-4e87-aa14-f5a8e7f4175a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c5fc4a05-e08c-4c24-b22c-2e44648d5855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c5fc4a05-e08c-4c24-b22c-2e44648d5855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_47e4afb7-fab9-4510-a965-e374723bef5c" xlink:href="rprx-20221231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_47e4afb7-fab9-4510-a965-e374723bef5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cf0036c-9086-4ae8-b67a-cc9c5d17154c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cf0036c-9086-4ae8-b67a-cc9c5d17154c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_15841217-a28f-4f5b-be1c-5daa803c3404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3155a471-66bc-4675-81ab-81c06e953021" xlink:to="loc_us-gaap_TradingSecuritiesDebt_15841217-a28f-4f5b-be1c-5daa803c3404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e0a4bac9-6f78-4c4d-9cb0-196e17d0c530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e0a4bac9-6f78-4c4d-9cb0-196e17d0c530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f058e1d7-48a2-4e20-9ded-343cf882897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f058e1d7-48a2-4e20-9ded-343cf882897f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2ac1cba9-0178-4c1b-b8fd-c3e0f23572e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:to="loc_us-gaap_InterestPayableCurrent_2ac1cba9-0178-4c1b-b8fd-c3e0f23572e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d500fd15-1a04-4c1c-8552-608e2a9ae4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:to="loc_us-gaap_LongTermDebtCurrent_d500fd15-1a04-4c1c-8552-608e2a9ae4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2de83e1d-af74-4475-b3d8-62ae1d0876bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f140b832-a413-4c21-9496-65c9931e03cb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2de83e1d-af74-4475-b3d8-62ae1d0876bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_67ded3e1-d973-4c89-9c77-86e33b8d4eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_AssetsCurrent_67ded3e1-d973-4c89-9c77-86e33b8d4eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e07e60c9-a9c6-4836-a498-0801c07618cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e07e60c9-a9c6-4836-a498-0801c07618cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df5047a8-5582-4481-b28f-b5f4218b776e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df5047a8-5582-4481-b28f-b5f4218b776e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2699a3ee-24ae-4687-8ce7-2423dc038ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2699a3ee-24ae-4687-8ce7-2423dc038ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fed0c4c3-84a6-4b11-b5ab-a0736aabd6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_fed0c4c3-84a6-4b11-b5ab-a0736aabd6d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_904c35a3-6399-4c15-9647-41a8405f57ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_EquityMethodInvestments_904c35a3-6399-4c15-9647-41a8405f57ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4d21a5fa-b2ad-4667-8844-96aff7e4ed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_15d336ce-ae48-4725-af1a-642a28cf67f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4d21a5fa-b2ad-4667-8844-96aff7e4ed8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_836476e9-481c-468b-ba71-082d645934ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24fb2146-d84a-4dde-a568-1d296827b255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_836476e9-481c-468b-ba71-082d645934ed" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24fb2146-d84a-4dde-a568-1d296827b255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17a91bee-91b4-4d73-88b5-5df91803e052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_836476e9-481c-468b-ba71-082d645934ed" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17a91bee-91b4-4d73-88b5-5df91803e052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_752634a1-ceee-4f86-9f25-cbf41068bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_38f433e9-55d9-46ee-8d53-0f69e5446d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_752634a1-ceee-4f86-9f25-cbf41068bad6" xlink:to="loc_us-gaap_Revenues_38f433e9-55d9-46ee-8d53-0f69e5446d72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ee427a3-5074-433b-9460-9b5d848e6331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_752634a1-ceee-4f86-9f25-cbf41068bad6" xlink:to="loc_us-gaap_CostsAndExpenses_1ee427a3-5074-433b-9460-9b5d848e6331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_662be524-850e-4b8b-8634-7d16c08f4c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed0e465b-4ef6-4eca-9bbd-30dfb7ed7da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_662be524-850e-4b8b-8634-7d16c08f4c62" xlink:to="loc_us-gaap_ProfitLoss_ed0e465b-4ef6-4eca-9bbd-30dfb7ed7da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_876316a2-cacb-47cf-a189-cf057fcb8edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_662be524-850e-4b8b-8634-7d16c08f4c62" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_876316a2-cacb-47cf-a189-cf057fcb8edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0a94816-69de-440f-84c7-0fbef4353430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0a94816-69de-440f-84c7-0fbef4353430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fe59587a-9eba-4bec-85cd-33ba0eda47a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_InterestExpense_fe59587a-9eba-4bec-85cd-33ba0eda47a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_59bd6fd3-e151-4334-beeb-7ecc97de0831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_59bd6fd3-e151-4334-beeb-7ecc97de0831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_943f3543-3202-473f-a161-d96695456275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_943f3543-3202-473f-a161-d96695456275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_5c69ea8d-1114-4a7c-8e03-41060c43a7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_InvestmentIncomeNet_5c69ea8d-1114-4a7c-8e03-41060c43a7d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f5a94bc7-1c2c-4ae3-b1ce-efe85fa10247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f5a94bc7-1c2c-4ae3-b1ce-efe85fa10247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_8917a7d7-c167-48fd-b5c6-890fe59c8759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_34f4ec48-37de-422c-a38e-356e35194df2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_8917a7d7-c167-48fd-b5c6-890fe59c8759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_91ae550f-7cea-4cad-add1-28022fb4766d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_91ae550f-7cea-4cad-add1-28022fb4766d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_29bd989d-a171-487c-a586-de58c0735cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_29bd989d-a171-487c-a586-de58c0735cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_35b26497-c4ee-4179-a90d-083a905e91c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_35b26497-c4ee-4179-a90d-083a905e91c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64cc364e-f745-429a-b384-414ffef75a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64cc364e-f745-429a-b384-414ffef75a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c613a7c0-d7ae-4c26-b752-2e3dc40f61e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_176ad3a0-c111-46fa-af44-892f59628984" xlink:to="loc_us-gaap_AssetImpairmentCharges_c613a7c0-d7ae-4c26-b752-2e3dc40f61e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_350eaffb-30c1-4fc6-a5af-953e44be1ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8a073d1-5cf5-4e6f-9693-c0f735cffac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_350eaffb-30c1-4fc6-a5af-953e44be1ab0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d8a073d1-5cf5-4e6f-9693-c0f735cffac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3eab490d-a4b7-47c2-b97d-b78420425e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_350eaffb-30c1-4fc6-a5af-953e44be1ab0" xlink:to="loc_us-gaap_OperatingIncomeLoss_3eab490d-a4b7-47c2-b97d-b78420425e5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9858dce8-00f2-4adb-b442-b36790cfe60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e8e23558-c3b6-4710-ae97-b266363e8439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9858dce8-00f2-4adb-b442-b36790cfe60d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e8e23558-c3b6-4710-ae97-b266363e8439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_9c3cccc0-b3b4-470b-aecc-c9f5947e187f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9858dce8-00f2-4adb-b442-b36790cfe60d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_9c3cccc0-b3b4-470b-aecc-c9f5947e187f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34c8b29b-de8c-4308-a142-3f5cbd9e2d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_21c8ad8d-1211-4013-9604-08f09b02b366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34c8b29b-de8c-4308-a142-3f5cbd9e2d74" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_21c8ad8d-1211-4013-9604-08f09b02b366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13f7740e-9f74-4888-9dd7-1fcff505d505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34c8b29b-de8c-4308-a142-3f5cbd9e2d74" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_13f7740e-9f74-4888-9dd7-1fcff505d505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_885e21dd-d47f-4f82-88c9-d3932a043de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_34c8b29b-de8c-4308-a142-3f5cbd9e2d74" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_885e21dd-d47f-4f82-88c9-d3932a043de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_24e8e488-042a-4430-99f5-07aa450b001f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9bd88e03-290d-4322-bdff-ea232b8e398c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_24e8e488-042a-4430-99f5-07aa450b001f" xlink:to="loc_us-gaap_ProfitLoss_9bd88e03-290d-4322-bdff-ea232b8e398c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dc5b0226-85ff-40fb-bb7b-edb359988485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_24e8e488-042a-4430-99f5-07aa450b001f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dc5b0226-85ff-40fb-bb7b-edb359988485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_639498ec-8b19-4559-8f98-150afc01ba04" xlink:href="rprx-20221231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_639498ec-8b19-4559-8f98-150afc01ba04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_953882b5-41aa-4c5f-86c9-5869b6888abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_953882b5-41aa-4c5f-86c9-5869b6888abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_12b9a05a-07e8-4253-8991-09ea8bc155e5" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_12b9a05a-07e8-4253-8991-09ea8bc155e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_6f07c9b3-17e7-4c7d-a6bd-6c9aa34bc742" xlink:href="rprx-20221231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_6f07c9b3-17e7-4c7d-a6bd-6c9aa34bc742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_610655dd-bfcd-4d69-8948-c7f7ade1c0c8" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_610655dd-bfcd-4d69-8948-c7f7ade1c0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_0b0f7f78-e6b5-4d5e-9ff2-a3b50dab805a" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_0b0f7f78-e6b5-4d5e-9ff2-a3b50dab805a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_32ae8924-e9bc-41e0-8ac8-566d5c4421cf" xlink:href="rprx-20221231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_32ae8924-e9bc-41e0-8ac8-566d5c4421cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9153528e-5981-409f-8429-f22d22051a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9153528e-5981-409f-8429-f22d22051a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b5dc584f-faa4-4e37-81c9-7538ac580475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b5dc584f-faa4-4e37-81c9-7538ac580475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_41da6e9b-6878-4b35-9f26-c63e6c018e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_41da6e9b-6878-4b35-9f26-c63e6c018e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_bb0cd252-505b-42b2-82e1-0271bb49cd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_bb0cd252-505b-42b2-82e1-0271bb49cd6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_747d415f-038d-4124-9906-1b1ffe70299a" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8803167-7566-4b71-b5cf-16ee3e9eb3ac" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_747d415f-038d-4124-9906-1b1ffe70299a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_d6630a26-0db3-44bf-b47c-e6365a85763e" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_d6630a26-0db3-44bf-b47c-e6365a85763e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_10c6cb2b-6140-48dd-b934-0b5c99e4c111" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_10c6cb2b-6140-48dd-b934-0b5c99e4c111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_3535945e-91a2-4fbe-936d-fda128a47122" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_3535945e-91a2-4fbe-936d-fda128a47122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_befede93-32b1-40b7-9f37-2b5e9e7f8ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_befede93-32b1-40b7-9f37-2b5e9e7f8ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_6957ed2f-ac50-4247-9895-45de7a625396" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_6957ed2f-ac50-4247-9895-45de7a625396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_611c62f5-5047-4597-9d6e-0f9c0a257281" xlink:href="rprx-20221231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_611c62f5-5047-4597-9d6e-0f9c0a257281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_293a00fa-0eda-45cc-9bc6-4285ef298d6b" xlink:href="rprx-20221231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_293a00fa-0eda-45cc-9bc6-4285ef298d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_f691579e-9630-4b9c-9421-b8076df80bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_f691579e-9630-4b9c-9421-b8076df80bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_4318d393-9a11-4c50-8e07-a9aba84c52e2" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_4318d393-9a11-4c50-8e07-a9aba84c52e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_eea754f5-ab99-4614-86bd-13ff11113701" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_eea754f5-ab99-4614-86bd-13ff11113701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fc74d974-b385-43af-956d-0ac74911bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_us-gaap_InterestPaidNet_fc74d974-b385-43af-956d-0ac74911bff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_d5e276e0-3800-48aa-aa09-c3280d1af76d" xlink:href="rprx-20221231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39714b2-2191-4377-8a74-c16153cd5fbd" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_d5e276e0-3800-48aa-aa09-c3280d1af76d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6091a74f-91e3-425f-a942-d83b1117869c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08e9b277-5a0e-4148-9e96-409b68c991e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6091a74f-91e3-425f-a942-d83b1117869c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08e9b277-5a0e-4148-9e96-409b68c991e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f9a165a-3e38-48e2-b8e5-c3337bc7322c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6091a74f-91e3-425f-a942-d83b1117869c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f9a165a-3e38-48e2-b8e5-c3337bc7322c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2821577-f9b1-4014-858e-73d380fe2d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6091a74f-91e3-425f-a942-d83b1117869c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2821577-f9b1-4014-858e-73d380fe2d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4421f969-1d74-42d5-a39d-006a35b8129c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4421f969-1d74-42d5-a39d-006a35b8129c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e70a439-da58-40c9-bfe4-4d3ffc9ea943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e70a439-da58-40c9-bfe4-4d3ffc9ea943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_c0e7adda-7461-4581-b8dc-a0a0c3bf072b" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_c0e7adda-7461-4581-b8dc-a0a0c3bf072b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e7974853-0bb3-4f0b-b7c2-1aa98dc394f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e7974853-0bb3-4f0b-b7c2-1aa98dc394f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d2151f60-1123-464c-a40f-a6215d349a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d2151f60-1123-464c-a40f-a6215d349a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f68b25a6-c877-44ec-bf9c-6377849b64fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f68b25a6-c877-44ec-bf9c-6377849b64fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c8867c46-33dc-44ae-bd16-150282c133bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c8867c46-33dc-44ae-bd16-150282c133bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_3ec1b51e-66a7-47db-841e-16a1f45c2409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_3ec1b51e-66a7-47db-841e-16a1f45c2409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_8b08fa64-8278-4b96-96e1-2ad9a91a01ee" xlink:href="rprx-20221231.xsd#rprx_PaymentsForMilestones"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_rprx_PaymentsForMilestones_8b08fa64-8278-4b96-96e1-2ad9a91a01ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_ec778e63-5132-4678-b75a-6561f3d77823" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_ec778e63-5132-4678-b75a-6561f3d77823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_7a80813e-8681-4037-ae12-7ee61a6c0178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6527bfb5-2f24-4ef0-8cb7-4f5d2437c5cd" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_7a80813e-8681-4037-ae12-7ee61a6c0178" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_26f29110-35ec-4c0b-9303-012026820950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a0183f4d-7172-40e5-b951-b9eec301fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_26f29110-35ec-4c0b-9303-012026820950" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a0183f4d-7172-40e5-b951-b9eec301fae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73c1fba4-01e3-4f4b-b5fd-1387f3f42fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_26f29110-35ec-4c0b-9303-012026820950" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73c1fba4-01e3-4f4b-b5fd-1387f3f42fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f65ca997-4f14-4df2-a300-5e5964ece937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_26f29110-35ec-4c0b-9303-012026820950" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f65ca997-4f14-4df2-a300-5e5964ece937" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_58f2c1c1-f608-47ea-8750-6173741f224c" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ffd4610e-bcf6-45bb-b639-7de02f7da815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_58f2c1c1-f608-47ea-8750-6173741f224c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ffd4610e-bcf6-45bb-b639-7de02f7da815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_7d0f9b6a-2553-437e-a226-eb76ce35823a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_58f2c1c1-f608-47ea-8750-6173741f224c" xlink:to="loc_us-gaap_TradingSecuritiesDebt_7d0f9b6a-2553-437e-a226-eb76ce35823a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f61e1a19-47c8-467c-9c3b-2332b5ae2be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_58f2c1c1-f608-47ea-8750-6173741f224c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f61e1a19-47c8-467c-9c3b-2332b5ae2be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_9fe9ad47-bc25-4b5d-b8b0-513b389f1f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_58f2c1c1-f608-47ea-8750-6173741f224c" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_9fe9ad47-bc25-4b5d-b8b0-513b389f1f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_36a71ea2-4603-4ac0-a7fd-fb478889156c" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2a130677-bc6b-43d8-8e6f-91d66a3cacef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_36a71ea2-4603-4ac0-a7fd-fb478889156c" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2a130677-bc6b-43d8-8e6f-91d66a3cacef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cc9b9454-6bf7-4c99-a85f-3aac2bde185b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_36a71ea2-4603-4ac0-a7fd-fb478889156c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cc9b9454-6bf7-4c99-a85f-3aac2bde185b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8e189d4b-6928-4b54-ba36-fa5b4b99f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_36a71ea2-4603-4ac0-a7fd-fb478889156c" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8e189d4b-6928-4b54-ba36-fa5b4b99f0c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_fc393bf7-67bc-4bdd-9bf9-491f89876ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_01304ee8-b1b7-4b69-bd0b-6eecedbca065" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_fc393bf7-67bc-4bdd-9bf9-491f89876ae2" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_01304ee8-b1b7-4b69-bd0b-6eecedbca065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_c84ee6e6-a182-4f9b-b8a8-9b305d2395d5" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_fc393bf7-67bc-4bdd-9bf9-491f89876ae2" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_c84ee6e6-a182-4f9b-b8a8-9b305d2395d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_eda44b9f-e668-433b-9de9-4bceb47756a9" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_0e002c01-d6b9-4549-85a9-ff8f9fc03d5f" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_eda44b9f-e668-433b-9de9-4bceb47756a9" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_0e002c01-d6b9-4549-85a9-ff8f9fc03d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_fab45935-124e-4be9-a991-6d0ba14a6fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_eda44b9f-e668-433b-9de9-4bceb47756a9" xlink:to="loc_us-gaap_NotesReceivableGross_fab45935-124e-4be9-a991-6d0ba14a6fde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_102cf336-f019-4164-a4cb-ddb354bc900c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1feb0cda-9ca2-493c-8473-042c8cf0fd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_102cf336-f019-4164-a4cb-ddb354bc900c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1feb0cda-9ca2-493c-8473-042c8cf0fd59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6592d11d-27bc-4d43-8359-ce89391e3f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_102cf336-f019-4164-a4cb-ddb354bc900c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6592d11d-27bc-4d43-8359-ce89391e3f29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bd381d71-8366-4778-bba2-657d9fbb555d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8eb849d7-15d5-4176-baed-14b303edc2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bd381d71-8366-4778-bba2-657d9fbb555d" xlink:to="loc_us-gaap_LongTermDebtCurrent_8eb849d7-15d5-4176-baed-14b303edc2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_92bf21d8-515c-4b6e-ab76-1a0240438ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bd381d71-8366-4778-bba2-657d9fbb555d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_92bf21d8-515c-4b6e-ab76-1a0240438ac5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_064a556f-e21f-482d-88f9-688070bd99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bd4787cc-55e9-4a0f-8683-66cbe94ba207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_064a556f-e21f-482d-88f9-688070bd99c5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bd4787cc-55e9-4a0f-8683-66cbe94ba207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_be77c3c4-8fa2-4848-9098-ddc7f81720fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_064a556f-e21f-482d-88f9-688070bd99c5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_be77c3c4-8fa2-4848-9098-ddc7f81720fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60c7a535-423f-4dc7-a81b-ac24ab232814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60c7a535-423f-4dc7-a81b-ac24ab232814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2ae1429-9319-46ab-9721-d3f617fab3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2ae1429-9319-46ab-9721-d3f617fab3cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_447d06b3-a9d0-4c51-b19d-1c407fae10db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_447d06b3-a9d0-4c51-b19d-1c407fae10db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7180c8c3-c4b7-4c8f-96b1-df092cca4dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7180c8c3-c4b7-4c8f-96b1-df092cca4dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_949ca96a-410c-4458-b5d8-37a764e7e388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_949ca96a-410c-4458-b5d8-37a764e7e388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4fb0fe2d-02eb-4e8d-99bd-03ee9df33f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0815c694-b236-4579-825f-6fe603808e63" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4fb0fe2d-02eb-4e8d-99bd-03ee9df33f53" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4955481c-f98c-4d3e-8bbb-9302b0cd2c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3533ca06-bc71-4eb7-a1bc-0b1f5da19ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4955481c-f98c-4d3e-8bbb-9302b0cd2c47" xlink:to="loc_us-gaap_ProfitLoss_3533ca06-bc71-4eb7-a1bc-0b1f5da19ecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e64d0929-e310-408a-b3de-ab697b4a70ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4955481c-f98c-4d3e-8bbb-9302b0cd2c47" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e64d0929-e310-408a-b3de-ab697b4a70ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_b3c29143-346d-4853-9ca5-3d747df8ad9b" xlink:href="rprx-20221231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4955481c-f98c-4d3e-8bbb-9302b0cd2c47" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_b3c29143-346d-4853-9ca5-3d747df8ad9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8a2f7293-74d0-4551-b34a-dd1ee13bd396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_68855b8b-e475-4c0f-a40d-4849f01ee5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8a2f7293-74d0-4551-b34a-dd1ee13bd396" xlink:to="loc_us-gaap_ProfitLoss_68855b8b-e475-4c0f-a40d-4849f01ee5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_5b188b0a-207d-4213-9822-4698aec759be" xlink:href="rprx-20221231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8a2f7293-74d0-4551-b34a-dd1ee13bd396" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_5b188b0a-207d-4213-9822-4698aec759be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6abcb18b-8d7a-473b-9773-42a62a87c1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8a2f7293-74d0-4551-b34a-dd1ee13bd396" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6abcb18b-8d7a-473b-9773-42a62a87c1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da628b53-63dc-40f7-b7fa-dd8f2d134374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7064a152-75dd-4f8d-819f-30bbac1982dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da628b53-63dc-40f7-b7fa-dd8f2d134374" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7064a152-75dd-4f8d-819f-30bbac1982dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f8562b28-7ee4-4aaa-ad66-b26e057487e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da628b53-63dc-40f7-b7fa-dd8f2d134374" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f8562b28-7ee4-4aaa-ad66-b26e057487e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IndirectCashFlowDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8eac3fb1-1343-470a-8f6f-ff7bf7b04b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8eac3fb1-1343-470a-8f6f-ff7bf7b04b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a604ef9-86d0-4816-aece-9916adeb437e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8a604ef9-86d0-4816-aece-9916adeb437e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_081734b7-4c7e-4d16-a362-0bc3041f05f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_ShareBasedCompensation_081734b7-4c7e-4d16-a362-0bc3041f05f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2407befb-2cf2-4b35-b797-71b2f2a72bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_ProfitLoss_2407befb-2cf2-4b35-b797-71b2f2a72bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_965a2bbd-bdba-4d4b-bb7d-7fbcb0083c18" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_965a2bbd-bdba-4d4b-bb7d-7fbcb0083c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e275ac16-28ca-4f13-9c38-87242392dfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e275ac16-28ca-4f13-9c38-87242392dfab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_8477833a-c8a6-40f8-a272-7ee6d27b836e" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_8477833a-c8a6-40f8-a272-7ee6d27b836e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_e7d7029c-011a-404a-9459-d42aa5642a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_e7d7029c-011a-404a-9459-d42aa5642a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c66558fa-42cf-48e8-b50a-fdfc793881da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c66558fa-42cf-48e8-b50a-fdfc793881da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0bf0de55-2648-407c-93f4-686ba2440427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0bf0de55-2648-407c-93f4-686ba2440427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_28156958-2839-443f-a85d-6bee41d1d384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_28156958-2839-443f-a85d-6bee41d1d384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfec4965-69e1-4da0-aeb6-59b971364b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bfec4965-69e1-4da0-aeb6-59b971364b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4db21786-cf9f-47be-aeb3-94603ba7f7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4db21786-cf9f-47be-aeb3-94603ba7f7aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_81846152-7a8f-47a4-b67b-f4761bd9a187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_81846152-7a8f-47a4-b67b-f4761bd9a187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_c0cb115c-e8d8-4e76-b4ba-b5272580f88d" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_c0cb115c-e8d8-4e76-b4ba-b5272580f88d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_f0fbb6fd-3f1a-474a-8645-800720328d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_f0fbb6fd-3f1a-474a-8645-800720328d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_dae22ab7-50f3-40e8-942d-8a133bd44dee" xlink:href="rprx-20221231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_dae22ab7-50f3-40e8-942d-8a133bd44dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_89299e4b-e87d-4a08-b9a7-699a2a1980f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_89299e4b-e87d-4a08-b9a7-699a2a1980f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_bc46cbf9-9841-4949-a761-6ab86ae6d024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_AssetImpairmentCharges_bc46cbf9-9841-4949-a761-6ab86ae6d024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments_b41cc071-2225-41a0-ba26-4e02392438cb" xlink:href="rprx-20221231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_GainLossOnDerivativeFinancialInstruments_b41cc071-2225-41a0-ba26-4e02392438cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_66ea86d6-897d-4f92-8021-9f9a4057c198" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_66ea86d6-897d-4f92-8021-9f9a4057c198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_62339a00-a187-4b39-acbd-062bca695af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bae09ce-7fee-4033-8039-c646983bfff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_62339a00-a187-4b39-acbd-062bca695af1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>rprx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20221231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended" id="ic2e9c4a5423d4507bace9d0ad560a091_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ad58b5ba-6714-4c3b-ac56-7680993d4a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentType_ad58b5ba-6714-4c3b-ac56-7680993d4a2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_29c7039a-def5-4626-80b3-05cb9a4c4a7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentAnnualReport_29c7039a-def5-4626-80b3-05cb9a4c4a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9c7cd6aa-d6f8-44ec-9864-4d5070a94045" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentPeriodEndDate_9c7cd6aa-d6f8-44ec-9864-4d5070a94045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8e1b9357-c61e-4b69-8783-ca00508a7ca2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_CurrentFiscalYearEndDate_8e1b9357-c61e-4b69-8783-ca00508a7ca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d2116109-92ce-4a2c-a6c7-f55a73f9959c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentTransitionReport_d2116109-92ce-4a2c-a6c7-f55a73f9959c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a636b3af-f411-4d5e-bd6d-14354f7466bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityFileNumber_a636b3af-f411-4d5e-bd6d-14354f7466bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee5f5b0a-6fbd-456e-9c6a-dc9a3568e8af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityRegistrantName_ee5f5b0a-6fbd-456e-9c6a-dc9a3568e8af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3e2054ef-4c97-4921-984d-10d1d36f3c0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3e2054ef-4c97-4921-984d-10d1d36f3c0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_811ed640-7c97-491f-bde2-8e1bfdfc113a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityTaxIdentificationNumber_811ed640-7c97-491f-bde2-8e1bfdfc113a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_18af6996-54d0-4617-b87e-33e02b8bcda6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressAddressLine1_18af6996-54d0-4617-b87e-33e02b8bcda6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_81a06bf2-268c-45c2-8960-2b63baddd0ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressCityOrTown_81a06bf2-268c-45c2-8960-2b63baddd0ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d16a9964-05b6-4e60-8dcc-63b37cdffbb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressStateOrProvince_d16a9964-05b6-4e60-8dcc-63b37cdffbb8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_27f31bc6-2005-43fe-ab9f-ce4f3341cce7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressPostalZipCode_27f31bc6-2005-43fe-ab9f-ce4f3341cce7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0f945ed0-6f0f-447d-872e-d44eadfffa16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_CityAreaCode_0f945ed0-6f0f-447d-872e-d44eadfffa16" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fee89ae8-c5c3-48f8-9e85-f8f4c4062d37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_LocalPhoneNumber_fee89ae8-c5c3-48f8-9e85-f8f4c4062d37" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b6ab76fb-54b3-4917-86cb-22ed356c1a5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_Security12bTitle_b6ab76fb-54b3-4917-86cb-22ed356c1a5a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_da347ab4-2c71-4215-bf4e-f77219acac94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_TradingSymbol_da347ab4-2c71-4215-bf4e-f77219acac94" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7440debc-add9-4314-9322-eec48b4ac279" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_SecurityExchangeName_7440debc-add9-4314-9322-eec48b4ac279" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cb785e26-ad61-4c61-83c1-187f296e04fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cb785e26-ad61-4c61-83c1-187f296e04fc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b8b36308-e11d-4e8b-9d88-7842bb964cc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityVoluntaryFilers_b8b36308-e11d-4e8b-9d88-7842bb964cc1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7153c7f0-bf58-45e8-bb04-533081243655" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCurrentReportingStatus_7153c7f0-bf58-45e8-bb04-533081243655" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9efa88ed-8bf5-4a30-88d1-b5924f4cb727" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityInteractiveDataCurrent_9efa88ed-8bf5-4a30-88d1-b5924f4cb727" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_98e80be1-5b06-4d8c-a83b-90fc723c8f39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityFilerCategory_98e80be1-5b06-4d8c-a83b-90fc723c8f39" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_83a343c8-1d49-40fd-90d0-d801fffa2534" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntitySmallBusiness_83a343c8-1d49-40fd-90d0-d801fffa2534" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_30ed4ce9-9d8f-4ea2-bc11-a389977f2f82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityEmergingGrowthCompany_30ed4ce9-9d8f-4ea2-bc11-a389977f2f82" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a33ec7ba-e1f6-45de-84d7-f0334f254bf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a33ec7ba-e1f6-45de-84d7-f0334f254bf8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_27722b96-94ce-417b-927c-dd8b9ca6238c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityShellCompany_27722b96-94ce-417b-927c-dd8b9ca6238c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_138e3758-03b5-487c-ba87-d266a886e026" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityPublicFloat_138e3758-03b5-487c-ba87-d266a886e026" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c18ec499-839d-493a-b5ab-515fb48d32de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c18ec499-839d-493a-b5ab-515fb48d32de" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9fe9b423-eecd-4f84-95d7-66e556af3d2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9fe9b423-eecd-4f84-95d7-66e556af3d2d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c50f9597-0287-4a24-af34-ce369cf33aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCentralIndexKey_c50f9597-0287-4a24-af34-ce369cf33aa8" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8ec7c441-9ca4-4646-a7e3-741e2f74be86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentFiscalYearFocus_8ec7c441-9ca4-4646-a7e3-741e2f74be86" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f103627b-1de5-4661-ae1d-c8e9cb6a471e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f103627b-1de5-4661-ae1d-c8e9cb6a471e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eefdd009-f98a-40fa-bc7c-3ee75aa22f6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_AmendmentFlag_eefdd009-f98a-40fa-bc7c-3ee75aa22f6c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d8d388a-ea9a-410c-8dd7-758d4000e539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:to="loc_us-gaap_ClassOfStockDomain_1d8d388a-ea9a-410c-8dd7-758d4000e539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:to="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_30343a94-04fd-4b5c-bb53-d9d5880154f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:to="loc_us-gaap_CommonClassAMember_30343a94-04fd-4b5c-bb53-d9d5880154f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8333c56f-0536-4bcf-bb3c-f9946b59d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:to="loc_us-gaap_CommonClassBMember_8333c56f-0536-4bcf-bb3c-f9946b59d26a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ie3f76b0bb1ab41d59d497b6f5f8ee199_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:to="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_369edc16-04ff-4963-a494-087b8d77dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_369edc16-04ff-4963-a494-087b8d77dafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_c67fb6de-1a26-4a87-97eb-3ad0cc096855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_TradingSecuritiesDebt_c67fb6de-1a26-4a87-97eb-3ad0cc096855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1554e3f2-b904-474f-a8ad-525db1c46e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1554e3f2-b904-474f-a8ad-525db1c46e3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_8f599d06-36da-4c63-9021-666bdf65178f" xlink:href="rprx-20221231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_rprx_AccruedRoyaltyReceivable_8f599d06-36da-4c63-9021-666bdf65178f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_546c84d0-fa46-4f91-93e6-cce883b8d52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_546c84d0-fa46-4f91-93e6-cce883b8d52e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_12c00b88-6d8a-47b5-9e30-891b9536b592" xlink:href="rprx-20221231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_12c00b88-6d8a-47b5-9e30-891b9536b592" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0b988595-5247-40ed-bec0-65e1f668bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_OtherAssetsCurrent_0b988595-5247-40ed-bec0-65e1f668bfea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c3a3f3bd-8334-4991-acfe-bce89ffc263b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_AssetsCurrent_c3a3f3bd-8334-4991-acfe-bce89ffc263b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a09761f4-e072-4f00-ad76-a9acebeac095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a09761f4-e072-4f00-ad76-a9acebeac095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5482fa6-b903-4788-a467-c7b8dd4158b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5482fa6-b903-4788-a467-c7b8dd4158b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2cbd94cf-7f42-4411-9a79-592784972578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2cbd94cf-7f42-4411-9a79-592784972578" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_408be613-2973-4c7b-8e69-248bdcd7d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_408be613-2973-4c7b-8e69-248bdcd7d1b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a1c45b55-bc49-4a93-8f80-52995faaf330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_EquityMethodInvestments_a1c45b55-bc49-4a93-8f80-52995faaf330" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_462039d9-4919-4b5f-a004-f218c0e40e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_462039d9-4919-4b5f-a004-f218c0e40e34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cf388b41-8c3b-4651-83e6-246e9545049a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_Assets_cf388b41-8c3b-4651-83e6-246e9545049a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e84d183d-74f4-4c67-a40d-f0091a983798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e84d183d-74f4-4c67-a40d-f0091a983798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_19fc0ec8-17e1-446b-91b7-b595738ebeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_19fc0ec8-17e1-446b-91b7-b595738ebeaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b6d4ef6c-d239-408e-b0e6-c513e94cf4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_InterestPayableCurrent_b6d4ef6c-d239-408e-b0e6-c513e94cf4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f725d4dd-92d4-4ae2-bee2-ff054b0e5cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_LongTermDebtCurrent_f725d4dd-92d4-4ae2-bee2-ff054b0e5cc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_edddf76b-5aad-4713-99af-801b08f8657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_edddf76b-5aad-4713-99af-801b08f8657b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63842f65-e82d-4ac6-ae1d-f1467b424626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_LiabilitiesCurrent_63842f65-e82d-4ac6-ae1d-f1467b424626" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ab3b4ba8-2f49-4a6f-a50b-a3f77d50f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ab3b4ba8-2f49-4a6f-a50b-a3f77d50f7bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0778433-5733-431e-8c53-827fd9201f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0778433-5733-431e-8c53-827fd9201f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e0c9d0fb-36d1-447f-88f9-d87ca2d54b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_Liabilities_e0c9d0fb-36d1-447f-88f9-d87ca2d54b24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_757bf09a-610f-4af3-8c3a-944ea6bc2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_757bf09a-610f-4af3-8c3a-944ea6bc2006" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_df6ebece-a9d6-4bda-9ae6-905fd783018d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_CommonStockValue_df6ebece-a9d6-4bda-9ae6-905fd783018d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_6364c992-e6fd-49a8-a9f1-96ac0f666757" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_rprx_DeferredSharesValueIssued_6364c992-e6fd-49a8-a9f1-96ac0f666757" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_68a798de-a29a-4bf2-a766-3c2ee0d6200f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_68a798de-a29a-4bf2-a766-3c2ee0d6200f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6315302-a33c-4367-a11f-8aa958715940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6315302-a33c-4367-a11f-8aa958715940" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_89fefe9e-ee17-4ff7-9ee5-4959b7742af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_MinorityInterest_89fefe9e-ee17-4ff7-9ee5-4959b7742af7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e4bf5d2-998d-46c4-a7af-39390fc9db97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e4bf5d2-998d-46c4-a7af-39390fc9db97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_60698fbd-7d42-4578-b162-706f94934415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_TreasuryStockValue_60698fbd-7d42-4578-b162-706f94934415" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2effff3f-f36b-41ae-b253-5d1b9ab83958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2effff3f-f36b-41ae-b253-5d1b9ab83958" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_883e338e-ba41-4ac8-98b3-14328a3b1136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_883e338e-ba41-4ac8-98b3-14328a3b1136" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:to="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f9082907-8b40-44c3-b903-14284bfe0984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:to="loc_us-gaap_ClassOfStockDomain_f9082907-8b40-44c3-b903-14284bfe0984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:to="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21f55636-ca98-4c43-991d-4e3e79c18415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_us-gaap_CommonClassAMember_21f55636-ca98-4c43-991d-4e3e79c18415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_afb26d93-866b-40b6-a907-59c5bc0cb084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_us-gaap_CommonClassBMember_afb26d93-866b-40b6-a907-59c5bc0cb084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_873cce19-ddef-4547-ad8a-c9d0821b079f" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_rprx_ClassRRedeemableStockMember_873cce19-ddef-4547-ad8a-c9d0821b079f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="iaaac3cd6192144729b8437d1fd591355_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_992d0b23-6fe1-4df8-987f-83fa02a7338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_992d0b23-6fe1-4df8-987f-83fa02a7338c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d563ccd6-92a2-4c8b-a9c0-82591eedecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_d563ccd6-92a2-4c8b-a9c0-82591eedecb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b430ba8a-65e1-4145-903e-dee4d6dd8e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b430ba8a-65e1-4145-903e-dee4d6dd8e1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_983605e6-bc2e-43a6-84d8-3f109cc80e5a" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_983605e6-bc2e-43a6-84d8-3f109cc80e5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_487b5add-b551-428b-a411-fa4909913423" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesSharesIssued_487b5add-b551-428b-a411-fa4909913423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_b86bbc86-d312-4d49-9d50-6e43dd81da18" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_b86bbc86-d312-4d49-9d50-6e43dd81da18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6ea69bce-4e36-4c9d-98fa-effc4f1013c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:to="loc_us-gaap_ClassOfStockDomain_6ea69bce-4e36-4c9d-98fa-effc4f1013c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:to="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_fd56fa69-edc9-4f9f-bf4b-6d6fed847006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_us-gaap_CommonClassAMember_fd56fa69-edc9-4f9f-bf4b-6d6fed847006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_70835b9a-f01e-48a1-a801-61f051762113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_us-gaap_CommonClassBMember_70835b9a-f01e-48a1-a801-61f051762113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_a3f2180c-2c1b-4cb8-a4b9-e5b627437363" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_rprx_ClassRRedeemableStockMember_a3f2180c-2c1b-4cb8-a4b9-e5b627437363" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i3c49b330235c42b5af3a9c19ed450453_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c7fe5c3-6fc8-4f65-9a56-55d93f07849f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_Revenues_4c7fe5c3-6fc8-4f65-9a56-55d93f07849f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_4ca16385-53f7-4260-8ca7-1aa6c5c69909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_4ca16385-53f7-4260-8ca7-1aa6c5c69909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e99ce8bf-c107-4955-9fa4-a3fb7ed21c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e99ce8bf-c107-4955-9fa4-a3fb7ed21c6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_62b1a213-bc92-4510-a92b-7982e2c80b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_62b1a213-bc92-4510-a92b-7982e2c80b30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a8cb5f8f-428c-41d3-a9bc-de4e6b6bae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a8cb5f8f-428c-41d3-a9bc-de4e6b6bae81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_468e0dde-118f-4118-9b8b-eb69f9ba08b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_AssetImpairmentCharges_468e0dde-118f-4118-9b8b-eb69f9ba08b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_67c53e01-e856-4ecb-b9ae-b6711e419283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_CostsAndExpenses_67c53e01-e856-4ecb-b9ae-b6711e419283" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e6482290-824d-46e4-8b25-f3ee7d8468d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OperatingIncomeLoss_e6482290-824d-46e4-8b25-f3ee7d8468d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e96c5665-5e0e-4efe-a3ae-89d7b2fa2809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e96c5665-5e0e-4efe-a3ae-89d7b2fa2809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fef3a046-b6ff-45fc-a397-27cdf4397f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_InterestExpense_fef3a046-b6ff-45fc-a397-27cdf4397f37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f9f32fea-207e-4043-8c58-cb22df4651a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f9f32fea-207e-4043-8c58-cb22df4651a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5df8c490-5b6c-4111-b83f-b80423ed00fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5df8c490-5b6c-4111-b83f-b80423ed00fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_334aaedf-2a0f-4e08-8762-7347cf728c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_334aaedf-2a0f-4e08-8762-7347cf728c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_93793291-e765-482b-ac46-724e0335d29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_InvestmentIncomeNet_93793291-e765-482b-ac46-724e0335d29f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bbea907e-e7d1-46b7-98f6-8926f549f7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bbea907e-e7d1-46b7-98f6-8926f549f7de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ff43a0a2-306f-4db5-b380-5bf916f35105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ff43a0a2-306f-4db5-b380-5bf916f35105" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e02a76c3-0ce0-4a26-bf87-6a4fcb02e125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e02a76c3-0ce0-4a26-bf87-6a4fcb02e125" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_90dcf6fe-696b-4e37-81b3-c3e11bb5e101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_90dcf6fe-696b-4e37-81b3-c3e11bb5e101" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e689b577-665a-43e1-aee3-be1f59cd76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_ProfitLoss_e689b577-665a-43e1-aee3-be1f59cd76a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d96b3a3-743f-4404-bc33-6dc9435b6687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d96b3a3-743f-4404-bc33-6dc9435b6687" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4be9a613-66d0-42e3-80a0-da75155be5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_NetIncomeLoss_4be9a613-66d0-42e3-80a0-da75155be5fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_363498e1-f033-4d4c-85f1-d56142dbdee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:to="loc_us-gaap_EarningsPerShareBasic_363498e1-f033-4d4c-85f1-d56142dbdee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ef37a8f7-e6cf-4757-8709-eaaa8f5393b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ef37a8f7-e6cf-4757-8709-eaaa8f5393b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57075729-be35-41a1-869a-215815d60f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57075729-be35-41a1-869a-215815d60f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24effcdc-fe28-4671-966e-f4d48184fe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24effcdc-fe28-4671-966e-f4d48184fe3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:to="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:to="loc_srt_ProductsAndServicesDomain_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:to="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_a0291240-6a52-4b53-815b-eca1d987e69d" xlink:href="rprx-20221231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_a0291240-6a52-4b53-815b-eca1d987e69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_c505cad1-9312-49f6-8a07-002ebb8500e4" xlink:href="rprx-20221231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_c505cad1-9312-49f6-8a07-002ebb8500e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_e0fa1c92-7bbe-4d6a-a099-4155c5407291" xlink:href="rprx-20221231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_e0fa1c92-7bbe-4d6a-a099-4155c5407291" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="ibd52d8b4400c489eaf67e82c4a2d5a4f_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d0921975-abfd-4522-bf9e-fc285195580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_SharesOutstanding_d0921975-abfd-4522-bf9e-fc285195580d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab73555e-0ca8-4b5f-a747-75e78aef6f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab73555e-0ca8-4b5f-a747-75e78aef6f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_44a36961-3b9b-4abf-9e3e-cc3af24801db" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_44a36961-3b9b-4abf-9e3e-cc3af24801db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_341a3d3f-4673-4df6-a58a-de121746bf90" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_341a3d3f-4673-4df6-a58a-de121746bf90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8f006f25-4d90-4ec5-b09b-5775d0bbd363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8f006f25-4d90-4ec5-b09b-5775d0bbd363" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_32288e54-ac66-42cb-ad06-66367c9612dc" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_32288e54-ac66-42cb-ad06-66367c9612dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_f038756d-3881-4f12-85f2-a536f5343381" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_f038756d-3881-4f12-85f2-a536f5343381" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6960f3bd-1af6-4aca-a1d1-5e26282b7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_ProfitLoss_6960f3bd-1af6-4aca-a1d1-5e26282b7e6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_73e37db8-4999-442c-bfd9-69e0db829ca8" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_73e37db8-4999-442c-bfd9-69e0db829ca8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_c4dc34ff-f815-4bfe-b012-c34d831959db" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_c4dc34ff-f815-4bfe-b012-c34d831959db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_536eb604-021b-4057-a862-0223926fa8a9" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_536eb604-021b-4057-a862-0223926fa8a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_03dc9122-aa07-4c01-93a4-9313c5bda833" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_03dc9122-aa07-4c01-93a4-9313c5bda833" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f842b02f-96fd-4a66-a1f0-9a7e57ab17b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f842b02f-96fd-4a66-a1f0-9a7e57ab17b7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9f2ac735-f0ca-4bd1-b04a-1f4465fc4126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9f2ac735-f0ca-4bd1-b04a-1f4465fc4126" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_912ffb07-59b5-41a0-98f1-53f49987f694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_912ffb07-59b5-41a0-98f1-53f49987f694" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_160819ad-95af-40cc-9e55-0c7af05ff0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_160819ad-95af-40cc-9e55-0c7af05ff0e7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_58cbe87f-0a5e-474c-9bb4-85a26d26b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_58cbe87f-0a5e-474c-9bb4-85a26d26b5a9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_698cf223-e4f0-469a-ad67-ce2eb09be3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityOther_698cf223-e4f0-469a-ad67-ce2eb09be3f3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_9512fc2e-349c-4594-8f14-42c3b0768e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_DividendsCash_9512fc2e-349c-4594-8f14-42c3b0768e85" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_088cff7e-087b-4d66-8fa7-9daa77cfb324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_088cff7e-087b-4d66-8fa7-9daa77cfb324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28f4fc43-0802-402e-a880-ffe6bd395298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28f4fc43-0802-402e-a880-ffe6bd395298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e882f168-e32b-4177-90c0-a75033af0811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e882f168-e32b-4177-90c0-a75033af0811" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c842ea15-5b0c-4f93-9aee-270b0ee4a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af1331e-d8aa-405a-b02b-09818b284ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_67bca06a-abce-46a1-9216-88ace6145adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_67bca06a-abce-46a1-9216-88ace6145adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:to="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6a39a35-56e2-438e-88f5-71c340b04475_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:to="loc_us-gaap_EquityComponentDomain_b6a39a35-56e2-438e-88f5-71c340b04475_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:to="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e0090a9-9123-4a8e-9eb4-664864f8a845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_CommonStockMember_3e0090a9-9123-4a8e-9eb4-664864f8a845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_f77b7808-095e-4d62-b1d2-104a30b37b91" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_rprx_DeferredSharesMember_f77b7808-095e-4d62-b1d2-104a30b37b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9d293117-ebd3-498a-855e-d3cc9a658eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9d293117-ebd3-498a-855e-d3cc9a658eec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember_49de5569-8c81-4b84-80c7-306a19802c25" xlink:href="rprx-20221231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_rprx_UnitHoldersAndShareholdersContributionsMember_49de5569-8c81-4b84-80c7-306a19802c25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2793d5c6-4f17-4978-916c-e1eac6ad67f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_RetainedEarningsMember_2793d5c6-4f17-4978-916c-e1eac6ad67f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df417d4-eee3-4a36-b8d3-77c05306bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df417d4-eee3-4a36-b8d3-77c05306bec5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3ff3a495-90ef-4191-aed7-4f150b7a7831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3ff3a495-90ef-4191-aed7-4f150b7a7831" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_174cbb67-1f6d-4ec1-b967-9082b74d2356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_TreasuryStockMember_174cbb67-1f6d-4ec1-b967-9082b74d2356" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50121009-553d-4960-b75a-7b1d8b51d6ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:to="loc_us-gaap_ClassOfStockDomain_50121009-553d-4960-b75a-7b1d8b51d6ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:to="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_68a7a747-e7fc-48c2-8ed4-1c3d12a9b432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_us-gaap_CommonClassAMember_68a7a747-e7fc-48c2-8ed4-1c3d12a9b432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3e1095b5-5f4c-4f01-b588-91fb6ef107ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_us-gaap_CommonClassBMember_3e1095b5-5f4c-4f01-b588-91fb6ef107ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_ed1cc712-73b0-4950-a9d0-cdc8fac9fbae" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_rprx_ClassRRedeemableStockMember_ed1cc712-73b0-4950-a9d0-cdc8fac9fbae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_36292a0a-87bf-4351-b0a8-5afc8cb5026a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_36292a0a-87bf-4351-b0a8-5afc8cb5026a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c3fad65-3f04-4e6c-8328-a18320178f54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c3fad65-3f04-4e6c-8328-a18320178f54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#OrganizationandPurposeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended" id="ib91ae27023a34e96a13bffc6da3dace2_OrganizationandPurposeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_b3789c34-9265-4aab-ab14-372e7848a128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_b3789c34-9265-4aab-ab14-372e7848a128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c2ef0175-c30f-4403-a7f8-5c9c3605a249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c2ef0175-c30f-4403-a7f8-5c9c3605a249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f65af50c-885d-4f93-8cb0-2fce1aa59bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f65af50c-885d-4f93-8cb0-2fce1aa59bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_377ff047-25ae-4b07-b59c-dda047c50ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_377ff047-25ae-4b07-b59c-dda047c50ebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_01426c20-319d-45e4-9962-8f9d916bacf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_01426c20-319d-45e4-9962-8f9d916bacf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8a46a557-a247-4876-9e4d-a9ee5f51175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8a46a557-a247-4876-9e4d-a9ee5f51175c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a523c14f-8e4c-41a5-a8c0-493229221cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a523c14f-8e4c-41a5-a8c0-493229221cef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8fa9a965-417d-4c0e-8144-2976f4fc5b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8fa9a965-417d-4c0e-8144-2976f4fc5b3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_f64c2a29-2adc-4c93-9ef9-5f99d18c3fa4" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_f64c2a29-2adc-4c93-9ef9-5f99d18c3fa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted_be02da21-1718-4bc7-afa2-753c07c417da" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_SaleOfStockNumberOfSharesNotConverted_be02da21-1718-4bc7-afa2-753c07c417da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_f578287e-f508-4110-8eff-36c29b788875" xlink:href="rprx-20221231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_CommonStockExchangeRatio_f578287e-f508-4110-8eff-36c29b788875" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a61a7266-8cbd-4030-bf14-780e66ff2425_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a61a7266-8cbd-4030-bf14-780e66ff2425_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_a475c933-3c7f-4871-90c5-a099fec98602" xlink:href="rprx-20221231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_ExchangeOfferTransactionMember_a475c933-3c7f-4871-90c5-a099fec98602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9800c5f9-5d69-44b4-96fc-1262e1036316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_us-gaap_IPOMember_9800c5f9-5d69-44b4-96fc-1262e1036316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember_09bcca0f-f288-4c63-b24c-27dc32868d1c" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOSharesFromCompanyMember_09bcca0f-f288-4c63-b24c-27dc32868d1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember_3e7cbf01-112f-4adc-9907-060636681247" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOSharesFromSellingShareholdersMember_3e7cbf01-112f-4adc-9907-060636681247" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_f512f18b-b6fa-48ac-8488-6df94d23a4fc" xlink:href="rprx-20221231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_f512f18b-b6fa-48ac-8488-6df94d23a4fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff14ce36-1fea-4344-b518-b755cfc749cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:to="loc_us-gaap_ClassOfStockDomain_ff14ce36-1fea-4344-b518-b755cfc749cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:to="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_04d7511b-5210-4191-a570-abc2d9a44127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:to="loc_us-gaap_CommonClassAMember_04d7511b-5210-4191-a570-abc2d9a44127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c8fcc950-080a-4916-a11d-f2947e01b838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:to="loc_us-gaap_CommonClassBMember_c8fcc950-080a-4916-a11d-f2947e01b838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e71dce06-e469-49b3-9c87-6f815d01083d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:to="loc_dei_EntityDomain_e71dce06-e469-49b3-9c87-6f815d01083d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:to="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_6e01c577-4da7-4a2d-807c-6fe31c0e05fe" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_6e01c577-4da7-4a2d-807c-6fe31c0e05fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_810d9734-c3ab-4012-be46-e4897bb2c6e3" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_810d9734-c3ab-4012-be46-e4897bb2c6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_29f6e8d1-363f-4b92-859c-244dff6028dd" xlink:href="rprx-20221231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_29f6e8d1-363f-4b92-859c-244dff6028dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6c26b47a-ca04-4c81-85b5-e55da367d9a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:to="loc_srt_OwnershipDomain_6c26b47a-ca04-4c81-85b5-e55da367d9a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:to="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_307c3909-e001-454b-ab7b-f1f2eff81987" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_307c3909-e001-454b-ab7b-f1f2eff81987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_f83ad6f2-8b2e-4c6e-9e93-a8d7328a0aba" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_f83ad6f2-8b2e-4c6e-9e93-a8d7328a0aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_12a08610-427f-4b7f-a840-189187323bd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_12a08610-427f-4b7f-a840-189187323bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fe3ffbae-7cda-4f33-8352-cf6a7a4cecaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:to="loc_us-gaap_SecuredDebtMember_fe3ffbae-7cda-4f33-8352-cf6a7a4cecaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_b980a50f-6a62-40e5-8900-843b168c802e" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_b980a50f-6a62-40e5-8900-843b168c802e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_afd98865-2d91-4775-9492-26cd7345f45f" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_afd98865-2d91-4775-9492-26cd7345f45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember_2d66be1d-6f8c-4ac2-bd13-4fbb9d9382e1" xlink:href="rprx-20221231.xsd#rprx_OldCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_OldCreditFacilityMember_2d66be1d-6f8c-4ac2-bd13-4fbb9d9382e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_cea4745e-05ea-4588-ac73-5082a15fb933" xlink:href="rprx-20221231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_cea4745e-05ea-4588-ac73-5082a15fb933" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="id236d99a21ab4acb8137932cc07c5ce4_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f1baf176-1711-43df-9162-096c4e728274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f1baf176-1711-43df-9162-096c4e728274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated_918ea1e0-7f94-4a07-8bc8-241c9c6922e0" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_rprx_NumberOfNoncontrollingInterestsCreated_918ea1e0-7f94-4a07-8bc8-241c9c6922e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3ad1ef7e-25c5-4f9f-82f2-283526f95960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3ad1ef7e-25c5-4f9f-82f2-283526f95960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_089ac386-be3e-44b5-b922-6d0ae10fc443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_NumberOfReportableSegments_089ac386-be3e-44b5-b922-6d0ae10fc443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_4f733151-523b-4ce0-9790-667663c0add8" xlink:href="rprx-20221231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_rprx_CommonStockExchangeRatio_4f733151-523b-4ce0-9790-667663c0add8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cac9161b-575d-4e0e-89ac-5a1ddf44016b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:to="loc_dei_EntityDomain_cac9161b-575d-4e0e-89ac-5a1ddf44016b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:to="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_81ec2a55-8b8f-4439-b12d-da20aed23644" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_81ec2a55-8b8f-4439-b12d-da20aed23644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9a8126fb-e341-4fc9-9c80-38cdbd6437e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9a8126fb-e341-4fc9-9c80-38cdbd6437e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_789a7944-1fa9-43ea-8172-4499ea0de4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_789a7944-1fa9-43ea-8172-4499ea0de4c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7155d7c6-bedd-40a1-b1e4-50e72cf90df3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7155d7c6-bedd-40a1-b1e4-50e72cf90df3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_e5bc8021-b3c7-4d66-bd14-d3faca859abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:to="loc_us-gaap_FinanceReceivablesMember_e5bc8021-b3c7-4d66-bd14-d3faca859abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4c090153-4ccf-4fba-9716-4bafde3e605e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:to="loc_srt_OwnershipDomain_4c090153-4ccf-4fba-9716-4bafde3e605e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:to="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e4433d30-2bee-4b50-9b4b-99b6f36cc4bb" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e4433d30-2bee-4b50-9b4b-99b6f36cc4bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_28f32c17-b6e2-4c32-aec4-92c2b8bc45e7" xlink:href="rprx-20221231.xsd#rprx_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:to="loc_rprx_VertexMember_28f32c17-b6e2-4c32-aec4-92c2b8bc45e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended" id="i5bcb42164bda4da685280fa05dd591c0_AvailableforSaleDebtSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_08ceed8d-590c-48ab-8969-bb7539bc02b1" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_08ceed8d-590c-48ab-8969-bb7539bc02b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_233268a4-587e-4176-9f00-4b97ab1892b7" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_233268a4-587e-4176-9f00-4b97ab1892b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_5f8661fc-ad53-49ca-b807-62168e9799e1" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_5f8661fc-ad53-49ca-b807-62168e9799e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_decb220f-2499-4482-bbdc-92640a7d3765" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_decb220f-2499-4482-bbdc-92640a7d3765" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_50384dfe-79b2-444a-bb88-7e6d90a1d698" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_50384dfe-79b2-444a-bb88-7e6d90a1d698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_76955043-6b0c-4bd5-a1db-50e677fc3ffe" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_76955043-6b0c-4bd5-a1db-50e677fc3ffe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_e25ce3d3-e336-4502-9f1c-b70acb7f0c07" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_e25ce3d3-e336-4502-9f1c-b70acb7f0c07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_81fe55d5-2a6a-416a-8e59-b9dd56aef735" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_81fe55d5-2a6a-416a-8e59-b9dd56aef735" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn_98cd5da2-59de-4c63-b5cb-af68e315e502" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipTotalAmountDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn_98cd5da2-59de-4c63-b5cb-af68e315e502" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_71b30464-dd90-4e56-9b85-812ff46aeec4" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_71b30464-dd90-4e56-9b85-812ff46aeec4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_69024642-c887-4469-8c42-1b20fe484562" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_69024642-c887-4469-8c42-1b20fe484562" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_929530c7-bcfc-4a0b-b568-b59a98d7a363" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_929530c7-bcfc-4a0b-b568-b59a98d7a363" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_39a0ace6-213f-442c-b85e-cbe75bfc319a" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_39a0ace6-213f-442c-b85e-cbe75bfc319a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_e16fda78-0e0d-4ad2-98f3-d0d42b956d44" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_e16fda78-0e0d-4ad2-98f3-d0d42b956d44" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_eece696a-98de-4834-9285-b061f348ba38" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_eece696a-98de-4834-9285-b061f348ba38" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_2a3ea9db-2e08-42f8-aefc-69e27c06c7cc" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_2a3ea9db-2e08-42f8-aefc-69e27c06c7cc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e1615f4-c828-4bc6-8c40-e41173660390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e1615f4-c828-4bc6-8c40-e41173660390" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7288fb99-e57d-41a6-9e6a-70b3dbbd4304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7288fb99-e57d-41a6-9e6a-70b3dbbd4304" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2cdce91d-b913-4a73-8e5b-7b92b0c04d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2cdce91d-b913-4a73-8e5b-7b92b0c04d3b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_d344b3cc-594e-4305-9824-405992b54d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_d344b3cc-594e-4305-9824-405992b54d10" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4584877-83ba-40ad-9fae-210ff72380cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4584877-83ba-40ad-9fae-210ff72380cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f24e46a2-f26c-4adb-a998-98796341bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:to="loc_us-gaap_PreferredStockMember_f24e46a2-f26c-4adb-a998-98796341bdd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_f30da36c-2f47-498f-8639-999bf0e95b03_default" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_f30da36c-2f47-498f-8639-999bf0e95b03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_f773d15d-2a5c-4637-ad00-9c3ca186aa5b" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_f773d15d-2a5c-4637-ad00-9c3ca186aa5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_7cb83fd8-eee8-4379-ac0b-7ef435707d92" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_7cb83fd8-eee8-4379-ac0b-7ef435707d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b822ccc-936f-4952-9b65-daaccba57fa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:to="loc_us-gaap_ClassOfStockDomain_0b822ccc-936f-4952-9b65-daaccba57fa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:to="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_81e7b401-0d6b-41bd-865c-066a62a430f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_81e7b401-0d6b-41bd-865c-066a62a430f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c0cac913-e5f8-4d12-b448-99dc891ee4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c0cac913-e5f8-4d12-b448-99dc891ee4c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2265bd0d-f5b4-4345-8b30-2ad8faa955c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2265bd0d-f5b4-4345-8b30-2ad8faa955c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_0207fb9f-27e7-4d65-8098-144667541c48" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:to="loc_rprx_MorphoSysMember_0207fb9f-27e7-4d65-8098-144667541c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundBondMember_eeab6c73-4433-47da-a36c-66209b7aa694" xlink:href="rprx-20221231.xsd#rprx_DevelopmentFundBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:to="loc_rprx_DevelopmentFundBondMember_eeab6c73-4433-47da-a36c-66209b7aa694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_49ce6f90-baea-4450-aec6-528de9e5fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_49ce6f90-baea-4450-aec6-528de9e5fb5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i33e88ee5709d4c088e5a70d002da3814_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0597eb44-2c73-463c-bf11-5dddb6a1b32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0597eb44-2c73-463c-bf11-5dddb6a1b32a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4779151b-4c41-4518-aad9-497f2969b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4779151b-4c41-4518-aad9-497f2969b6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c846d6a-aee7-4a15-b365-40196fcff3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c846d6a-aee7-4a15-b365-40196fcff3d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d86d69f9-f964-4dda-88eb-c4b472996470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d86d69f9-f964-4dda-88eb-c4b472996470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b2644c4-0549-45e5-a1b3-8f4bc4f02051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b2644c4-0549-45e5-a1b3-8f4bc4f02051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_85c515e8-b9f0-4090-98bb-6c68965113dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_85c515e8-b9f0-4090-98bb-6c68965113dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_3dfc8fae-0466-4812-b3ab-577ba69b93bd" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_3dfc8fae-0466-4812-b3ab-577ba69b93bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_c85e9843-9713-410f-88dc-ad79ef6a8dd2" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_c85e9843-9713-410f-88dc-ad79ef6a8dd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e0d4b57-d0d0-4964-81ad-eec37fad45dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e0d4b57-d0d0-4964-81ad-eec37fad45dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9d264925-73ae-4a9f-9f2c-1aba222877db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_us-gaap_PreferredStockMember_9d264925-73ae-4a9f-9f2c-1aba222877db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_afd42195-0e9b-45d2-bd22-1ee4b1fb462f" xlink:href="rprx-20221231.xsd#rprx_FundingCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_rprx_FundingCommitmentsMember_afd42195-0e9b-45d2-bd22-1ee4b1fb462f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_6cc987bd-ef14-40eb-88b6-cdffd1c15e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_us-gaap_ForwardContractsMember_6cc987bd-ef14-40eb-88b6-cdffd1c15e5e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended" id="i414c78ce143b4b1c8e0af678b1e83f22_DerivativeInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_923bd609-a246-4b41-b4e4-53882eb7fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_923bd609-a246-4b41-b4e4-53882eb7fdb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4e9b46d9-aa12-4c7a-856f-63f51e63dcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4e9b46d9-aa12-4c7a-856f-63f51e63dcdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_46433375-8218-4894-adf2-eba5c44ee183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_46433375-8218-4894-adf2-eba5c44ee183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1e907b8f-e829-4e47-93b3-f50acd38dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1e907b8f-e829-4e47-93b3-f50acd38dc20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_fa5da6c7-bef3-4641-a692-edc996b51872" xlink:href="rprx-20221231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_fa5da6c7-bef3-4641-a692-edc996b51872" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_64df07a6-d109-4e5a-9874-76553ce01424" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_64df07a6-d109-4e5a-9874-76553ce01424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4c20a4d7-0cec-4251-8487-48ab2997f9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4c20a4d7-0cec-4251-8487-48ab2997f9ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_5442031b-8089-42e8-b187-0d56df99ce08" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_5442031b-8089-42e8-b187-0d56df99ce08" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f9cf1b9f-e111-46a5-8dd7-2abfc02990af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f9cf1b9f-e111-46a5-8dd7-2abfc02990af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ddb8297-bdcf-4948-aa3a-e8d098705323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ddb8297-bdcf-4948-aa3a-e8d098705323" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f93378ab-5072-4a9b-9cf5-3e73d3b8c145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f93378ab-5072-4a9b-9cf5-3e73d3b8c145" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm_89e374db-ec5c-4005-8727-78b6b3ca6a01" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_OptionIndexedToIssuersEquityTerm_89e374db-ec5c-4005-8727-78b6b3ca6a01" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue_a44b0e90-f026-4217-b3d8-635a26c60897" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_OptionIndexedToIssuersEquityValue_a44b0e90-f026-4217-b3d8-635a26c60897" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_2600e325-8df2-4959-99c1-dc5a8649bed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_2600e325-8df2-4959-99c1-dc5a8649bed1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_daab98c0-a542-4d8d-87ec-98f4974a2711_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_daab98c0-a542-4d8d-87ec-98f4974a2711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_0295125b-835e-4d73-b100-cb9764949b53" xlink:href="rprx-20221231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:to="loc_rprx_TreasuryRateLockContractsMember_0295125b-835e-4d73-b100-cb9764949b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_231ffe60-06a1-419b-88eb-a0498d4ce9a6" xlink:href="rprx-20221231.xsd#rprx_EpizymeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:to="loc_rprx_EpizymeIncMember_231ffe60-06a1-419b-88eb-a0498d4ce9a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b6422f54-ee91-4658-857b-6b6eb51fb856_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_b6422f54-ee91-4658-857b-6b6eb51fb856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_d6f71362-dd71-4cd1-a9de-6b921f467578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:to="loc_us-gaap_PutOptionMember_d6f71362-dd71-4cd1-a9de-6b921f467578" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_52eb631b-e1a6-4ff0-a9cc-3f1343112add_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_52eb631b-e1a6-4ff0-a9cc-3f1343112add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember_96b900ff-b69c-472b-bd98-3f0b74f1cd78" xlink:href="rprx-20221231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:to="loc_rprx_EpizymeCommonStockWarrantMember_96b900ff-b69c-472b-bd98-3f0b74f1cd78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55ed2964-1661-4df4-b6c4-df09227c2cf4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55ed2964-1661-4df4-b6c4-df09227c2cf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0a15f5ae-b729-43ce-8251-a037587d1490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:to="loc_us-gaap_PreferredStockMember_0a15f5ae-b729-43ce-8251-a037587d1490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f9215b-e4d6-41dc-bfbf-79a63e97cc56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f9215b-e4d6-41dc-bfbf-79a63e97cc56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_56f511bf-606c-4211-a697-4bda7e3863fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_56f511bf-606c-4211-a697-4bda7e3863fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_42eef684-4d85-42d8-aaac-d31f5959fc1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_42eef684-4d85-42d8-aaac-d31f5959fc1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0db6684d-59d4-4027-90b3-8c709795bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0db6684d-59d4-4027-90b3-8c709795bfb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f07b293-8384-4c47-9b83-2c54684439b1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f07b293-8384-4c47-9b83-2c54684439b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_e266067a-4157-4e56-94e4-2c76b52769c1" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:to="loc_rprx_MilestoneAccelerationMember_e266067a-4157-4e56-94e4-2c76b52769c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="extended" id="i0a18e3edd4d64b6091621d1bdd868de9_DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0f1438a7-0731-4e8e-a79c-7932adfacb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0f1438a7-0731-4e8e-a79c-7932adfacb8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_aac556c8-5bea-44cb-9d73-20e7abdba01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_aac556c8-5bea-44cb-9d73-20e7abdba01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7db38466-cd8e-47e2-9b3b-090a0ec4a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7db38466-cd8e-47e2-9b3b-090a0ec4a17e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_c34ca6d4-7e71-49e8-a5a0-63608fa8d666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_c34ca6d4-7e71-49e8-a5a0-63608fa8d666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7bf201c-761c-417f-a17f-13e86b791509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7bf201c-761c-417f-a17f-13e86b791509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_beed149f-8148-41a0-bcb1-d5fdcd1d3472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_InterestRateSwapMember_beed149f-8148-41a0-bcb1-d5fdcd1d3472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a0169282-6fc9-4018-a362-b9fd819d401b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_WarrantMember_a0169282-6fc9-4018-a362-b9fd819d401b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_46e17706-5003-4095-8c10-362396646846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_ForwardContractsMember_46e17706-5003-4095-8c10-362396646846" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_f84dff81-cc6d-4ad0-8fb6-64d62bd419b4" xlink:href="rprx-20221231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_rprx_TreasuryRateLockContractsMember_f84dff81-cc6d-4ad0-8fb6-64d62bd419b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationOptionMember_9eec6335-e138-457a-a6dc-f0397433a981" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_rprx_MilestoneAccelerationOptionMember_9eec6335-e138-457a-a6dc-f0397433a981" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa0a815b-6630-45f5-a6db-5572e4678f3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa0a815b-6630-45f5-a6db-5572e4678f3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_57070a32-994a-4b14-8a02-c05fb2d084cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_57070a32-994a-4b14-8a02-c05fb2d084cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_ff39fe72-e918-4956-b835-65daca4d06b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:to="loc_us-gaap_InterestExpenseMember_ff39fe72-e918-4956-b835-65daca4d06b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_81d54e87-a839-449e-85d5-b42cc428cff7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:to="loc_us-gaap_HedgingDesignationDomain_81d54e87-a839-449e-85d5-b42cc428cff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:to="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18875d0c-4fa7-45d4-a47c-6e7bfa87a743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18875d0c-4fa7-45d4-a47c-6e7bfa87a743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_22b39725-a25c-4664-893a-0ab97ad56f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:to="loc_us-gaap_NondesignatedMember_22b39725-a25c-4664-893a-0ab97ad56f59" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended" id="i83d0434adadf42f4a0e121ccf2061fda_FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc93b196-064f-4243-b2c6-29b560b1ebdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc93b196-064f-4243-b2c6-29b560b1ebdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_e49ccf3d-840e-43ac-8c32-82ac6e89452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_TradingSecuritiesDebt_e49ccf3d-840e-43ac-8c32-82ac6e89452f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b4d53fa7-e1c6-4a1d-b741-2866b3f6fdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b4d53fa7-e1c6-4a1d-b741-2866b3f6fdf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_276bf3d8-cefc-4dbc-9575-186c2e244942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_276bf3d8-cefc-4dbc-9575-186c2e244942" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_6c114106-43bc-4c68-8f9a-54fa639ee661" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_6c114106-43bc-4c68-8f9a-54fa639ee661" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_011d2deb-a6b4-4e73-9813-503b4624a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_011d2deb-a6b4-4e73-9813-503b4624a0be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5684bc6c-9d28-4c91-a556-d9db4bdd1c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5684bc6c-9d28-4c91-a556-d9db4bdd1c44" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_dde0ad17-4ed9-4322-a77e-8d7148051fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_dde0ad17-4ed9-4322-a77e-8d7148051fcc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_948ce7d4-34e3-4955-8af0-e3ebe8aef30c" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_948ce7d4-34e3-4955-8af0-e3ebe8aef30c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_dbabc287-5fe9-48bd-97c5-9fce0b59b4f0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_dbabc287-5fe9-48bd-97c5-9fce0b59b4f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_1a402228-c3dc-45ef-80b6-3c2ac3df842b" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_1a402228-c3dc-45ef-80b6-3c2ac3df842b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_51d2bf91-3b51-4f11-93af-8cca5d05b497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_51d2bf91-3b51-4f11-93af-8cca5d05b497" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_876c3752-afdb-47e2-873a-36bc10a67f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_876c3752-afdb-47e2-873a-36bc10a67f6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb363009-b06a-4aa5-a0bd-26385c6a354d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb363009-b06a-4aa5-a0bd-26385c6a354d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_281bf472-f4d7-4b9b-ab8b-51cb79f66489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_MoneyMarketFundsMember_281bf472-f4d7-4b9b-ab8b-51cb79f66489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5c7a3037-8e82-442c-847d-e412f05f9522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_CommercialPaperMember_5c7a3037-8e82-442c-847d-e412f05f9522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d1a0fd88-7476-43c6-b063-0e179ef1e040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d1a0fd88-7476-43c6-b063-0e179ef1e040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4990846a-3fc4-48bf-a52e-43fa799c01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_CommercialPaperMember_4990846a-3fc4-48bf-a52e-43fa799c01e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cecdd1a3-5fcf-446c-88d6-ac5a38602965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cecdd1a3-5fcf-446c-88d6-ac5a38602965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_8750a524-7c50-4c35-b579-e80ac004b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_8750a524-7c50-4c35-b579-e80ac004b53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4ff51cec-1351-45e9-b0a1-64f9f2192411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_DebtSecuritiesMember_4ff51cec-1351-45e9-b0a1-64f9f2192411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_1d825580-cc0c-43cd-ad71-c4444ab9410e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_ForwardContractsMember_1d825580-cc0c-43cd-ad71-c4444ab9410e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3db2e0af-48fb-4659-ab53-59648c09c3d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3db2e0af-48fb-4659-ab53-59648c09c3d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_817fdc8a-4726-4844-81cc-bb116883bdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_817fdc8a-4726-4844-81cc-bb116883bdcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f16085b6-c96a-4bb0-86f9-d499714193aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f16085b6-c96a-4bb0-86f9-d499714193aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d5a78df5-f0d5-41cd-8323-29e97655561b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d5a78df5-f0d5-41cd-8323-29e97655561b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ec60579-a69b-41f6-8a26-10e1466f4b84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ec60579-a69b-41f6-8a26-10e1466f4b84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_30f4f81a-ced3-4c12-ac70-c3a9144853c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_30f4f81a-ced3-4c12-ac70-c3a9144853c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1f4f9bea-a8cd-4335-a049-9cea6fadb954_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1f4f9bea-a8cd-4335-a049-9cea6fadb954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember_182ea4ba-6e26-42c0-9cae-ecf3da5f120a" xlink:href="rprx-20221231.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:to="loc_rprx_RoyaltyInvestmentsMember_182ea4ba-6e26-42c0-9cae-ecf3da5f120a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember_500f3507-b1c1-482f-b10c-20ba909d7659" xlink:href="rprx-20221231.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:to="loc_rprx_CytokineticsFundingCommitmentMember_500f3507-b1c1-482f-b10c-20ba909d7659" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ie7094440e8674e1693c3cef6ed6686e5_FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_bb7d9c95-7864-4756-8015-16bc2cc6c0c1" xlink:href="rprx-20221231.xsd#rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_bb7d9c95-7864-4756-8015-16bc2cc6c0c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_ed4735fe-4a06-4358-9fed-63fa206410bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_ed4735fe-4a06-4358-9fed-63fa206410bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_113b5be3-6034-49a6-9663-5383d630838d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_113b5be3-6034-49a6-9663-5383d630838d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fab29c34-67c6-4bba-a5f7-47df0854170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fab29c34-67c6-4bba-a5f7-47df0854170b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_f7f180a0-46d1-44e8-89ff-03e9f7faefa0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_f7f180a0-46d1-44e8-89ff-03e9f7faefa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_47604773-3b05-4ed2-809c-a39b525cd0cb" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_47604773-3b05-4ed2-809c-a39b525cd0cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_612640fd-7be1-4585-bab0-22fafb2558b0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_612640fd-7be1-4585-bab0-22fafb2558b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_22ca028d-8c36-4766-935c-5560a86c08a5" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_22ca028d-8c36-4766-935c-5560a86c08a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember_88edb555-ff73-4795-a8e4-500a67528853" xlink:href="rprx-20221231.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:to="loc_rprx_CytokineticsCommercialLaunchFundingMember_88edb555-ff73-4795-a8e4-500a67528853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_43018af1-b73f-4a67-9b02-f01168385369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:to="loc_us-gaap_PreferredStockMember_43018af1-b73f-4a67-9b02-f01168385369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66782b57-e106-4319-8c6d-04079961cd30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66782b57-e106-4319-8c6d-04079961cd30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_dd96a819-5f77-46fd-82cb-6bb10e3f4890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_dd96a819-5f77-46fd-82cb-6bb10e3f4890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_92bca047-df63-4dd2-aa5d-8d07667c3ebe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:to="loc_us-gaap_ClassOfStockDomain_92bca047-df63-4dd2-aa5d-8d07667c3ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:to="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5b2a8775-1e2a-4234-bfd8-e57eeefed4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5b2a8775-1e2a-4234-bfd8-e57eeefed4d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5e103ad2-ea8c-4155-b66b-fadbea948c14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5e103ad2-ea8c-4155-b66b-fadbea948c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ba847ce9-d3b5-445f-83b7-697f478db84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:to="loc_us-gaap_EquitySecuritiesMember_ba847ce9-d3b5-445f-83b7-697f478db84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3831919e-7976-44ec-84a1-c87d3e96e660_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3831919e-7976-44ec-84a1-c87d3e96e660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_132ad235-e0b4-4d54-a271-46ccec90c661" xlink:href="rprx-20221231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_132ad235-e0b4-4d54-a271-46ccec90c661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_d307b406-c455-4b63-919f-d9301cf618d4" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:to="loc_rprx_MorphoSysMember_d307b406-c455-4b63-919f-d9301cf618d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i3b1d0a54265b4645bf20b7b727dd3419_FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a16456ac-95d1-4e47-9708-1d38801fcca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a16456ac-95d1-4e47-9708-1d38801fcca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0fe41133-1d30-47f6-a274-7e515b19c98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0fe41133-1d30-47f6-a274-7e515b19c98b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_ebe19866-bb8b-4dd2-8687-75e380873f4d" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_ebe19866-bb8b-4dd2-8687-75e380873f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c22461d5-bad5-4ed4-8259-69f2fa5b3aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c22461d5-bad5-4ed4-8259-69f2fa5b3aed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_70c4e9a2-7d1a-4093-9c69-bf708f833a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_70c4e9a2-7d1a-4093-9c69-bf708f833a51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_caf28e96-b3ea-44b0-8ce3-a51567ab65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_caf28e96-b3ea-44b0-8ce3-a51567ab65f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_e22e91fb-0812-4ed9-84ba-2ba079b8b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_e22e91fb-0812-4ed9-84ba-2ba079b8b9dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_a0d3842b-e619-4272-afd2-dac8cb2e0aba" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_a0d3842b-e619-4272-afd2-dac8cb2e0aba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_c5072f0f-0c93-4e71-8f6d-c47a05118bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_c5072f0f-0c93-4e71-8f6d-c47a05118bc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_9855891a-1580-4405-a790-7a2996a5d019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_9855891a-1580-4405-a790-7a2996a5d019" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_480b82c7-d506-47a6-b338-11b4ec263a05" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_480b82c7-d506-47a6-b338-11b4ec263a05" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_deeed763-ab45-483a-9b96-b2bab5d4cfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_8b9d7630-fc0e-4ffe-beea-f43188ac85d9" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_8b9d7630-fc0e-4ffe-beea-f43188ac85d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a6636c58-c0a4-489e-8b69-714651af7a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a6636c58-c0a4-489e-8b69-714651af7a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b868b525-3f94-4047-a7a0-96a450162bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_EquitySecuritiesMember_b868b525-3f94-4047-a7a0-96a450162bd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9c159f55-2c4e-45ea-a6bc-629ddcea8237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9c159f55-2c4e-45ea-a6bc-629ddcea8237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_99a891d5-67ec-4cc3-b618-9d8984bd005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_ForwardContractsMember_99a891d5-67ec-4cc3-b618-9d8984bd005c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_36b8ddc5-e226-4747-b4e1-86a3b6087bf6" xlink:href="rprx-20221231.xsd#rprx_FundingCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_rprx_FundingCommitmentsMember_36b8ddc5-e226-4747-b4e1-86a3b6087bf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember_cd2f43c8-e554-41c9-9fff-a420ba6f336a" xlink:href="rprx-20221231.xsd#rprx_DerivativeAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_rprx_DerivativeAssetMember_cd2f43c8-e554-41c9-9fff-a420ba6f336a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_dbbaba7d-82e4-4f45-b4c5-c4e8b2756577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_RoyaltyMember_dbbaba7d-82e4-4f45-b4c5-c4e8b2756577" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a52e8a6-887c-42e5-ade2-b8df373eb90b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a52e8a6-887c-42e5-ade2-b8df373eb90b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74136735-8173-4993-b25b-23bd5e3af2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74136735-8173-4993-b25b-23bd5e3af2a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f174daf1-725b-49ff-bafb-b3cfe7940111_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f174daf1-725b-49ff-bafb-b3cfe7940111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ae6db391-dbe9-4a30-a5ee-3b1c6a9adf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ae6db391-dbe9-4a30-a5ee-3b1c6a9adf79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b968a7b-4da2-4710-8c86-56765361f1dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b968a7b-4da2-4710-8c86-56765361f1dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_bd8817e6-72ca-46ce-96ef-37ed3b1cd482" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:to="loc_rprx_MorphoSysMember_bd8817e6-72ca-46ce-96ef-37ed3b1cd482" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended" id="i1cc96c7d81274fe7826d01e3d86eb5b0_FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ae652895-b0ee-4cde-87f1-8a328b62e43c" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ae652895-b0ee-4cde-87f1-8a328b62e43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23ac72b8-7870-43e1-975f-c2cad15c7ca6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23ac72b8-7870-43e1-975f-c2cad15c7ca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b21c0332-e8ea-47de-a5f7-bdeb182e1242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b21c0332-e8ea-47de-a5f7-bdeb182e1242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69bea700-7f65-4542-b604-5e21c3a439cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_69bea700-7f65-4542-b604-5e21c3a439cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_edbf54ca-e217-4238-9262-5ce5d390b507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_edbf54ca-e217-4238-9262-5ce5d390b507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0f2e8413-b113-4f42-8686-78516611fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0f2e8413-b113-4f42-8686-78516611fd0e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="extended" id="idd41370425ff4e32bab69e4e6690f21e_FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_e8ff30d2-8600-4900-a046-be2477726d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_us-gaap_NotesReceivableGross_e8ff30d2-8600-4900-a046-be2477726d0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_d68dcc5a-6a1b-4bd0-96f6-f311b35fd310" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_d68dcc5a-6a1b-4bd0-96f6-f311b35fd310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_fd7148ec-9305-4e73-978f-3f179ad3ebe9" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_fd7148ec-9305-4e73-978f-3f179ad3ebe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_6dd2d02b-7b0b-4ef5-b05f-7e4c2f31e851" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_6dd2d02b-7b0b-4ef5-b05f-7e4c2f31e851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_28a0b9f6-a9ba-407c-863f-973bc75da764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_us-gaap_NotesReceivableNet_28a0b9f6-a9ba-407c-863f-973bc75da764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_0c8e6490-2fef-4cc3-9905-83d5a8ade6ca" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_0c8e6490-2fef-4cc3-9905-83d5a8ade6ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:to="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:to="loc_srt_NameOfMajorCustomerDomain_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:to="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_f4e1a3dc-6e7c-4587-90f0-553fc4d94e8b" xlink:href="rprx-20221231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_f4e1a3dc-6e7c-4587-90f0-553fc4d94e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_0dc04fbf-14dc-49de-8902-239dab7ac1e6" xlink:href="rprx-20221231.xsd#rprx_TysabriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TysabriMember_0dc04fbf-14dc-49de-8902-239dab7ac1e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TrelegyMember_f694ab14-37ca-4dec-ae91-eb96a3290589" xlink:href="rprx-20221231.xsd#rprx_TrelegyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TrelegyMember_f694ab14-37ca-4dec-ae91-eb96a3290589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_6c4004ae-175b-4ac3-815c-d50134d1fc88" xlink:href="rprx-20221231.xsd#rprx_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TremfyaMember_6c4004ae-175b-4ac3-815c-d50134d1fc88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_13a672e5-5d79-44cf-a250-c3c8f73357e6" xlink:href="rprx-20221231.xsd#rprx_ImbruvicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_ImbruvicaMember_13a672e5-5d79-44cf-a250-c3c8f73357e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_32d89805-080c-4ecd-b124-8f9ea2cff4bd" xlink:href="rprx-20221231.xsd#rprx_XtandiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_XtandiMember_32d89805-080c-4ecd-b124-8f9ea2cff4bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_460940a2-16ee-470f-b3b8-c326d9d6b703" xlink:href="rprx-20221231.xsd#rprx_EvrysdiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_EvrysdiMember_460940a2-16ee-470f-b3b8-c326d9d6b703" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_b6604814-ab41-48b3-8ff7-1323f572863f" xlink:href="rprx-20221231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_b6604814-ab41-48b3-8ff7-1323f572863f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtilimabMember_3086bba3-b9c2-48dc-916a-774470a973f9" xlink:href="rprx-20221231.xsd#rprx_OtilimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_OtilimabMember_3086bba3-b9c2-48dc-916a-774470a973f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GantenerumabMember_aad3cab4-e3cb-4690-ae9d-3bd9119ebeec" xlink:href="rprx-20221231.xsd#rprx_GantenerumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_GantenerumabMember_aad3cab4-e3cb-4690-ae9d-3bd9119ebeec" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" xlink:type="extended" id="id233a2e5fe13432e89ad0548468da3f7_FinancialRoyaltyAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_cd4c8cbb-7f5c-41bf-83a4-ddfd6d65f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_cd4c8cbb-7f5c-41bf-83a4-ddfd6d65f36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_406f7eec-1a97-42de-bd4a-3ce3f56ef1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_us-gaap_NotesReceivableNet_406f7eec-1a97-42de-bd4a-3ce3f56ef1ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts_45e71bd0-78f0-4c50-b077-09b5bbaeede1" xlink:href="rprx-20221231.xsd#rprx_UnapprovedFinancialAssetsHeldAtCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts_45e71bd0-78f0-4c50-b077-09b5bbaeede1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:to="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1dd27b2c-0d8c-425c-9348-e83368466dc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_1dd27b2c-0d8c-425c-9348-e83368466dc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtilimabMember_71b1f83e-ea7c-46a9-ad9d-8057ac6fca09" xlink:href="rprx-20221231.xsd#rprx_OtilimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_OtilimabMember_71b1f83e-ea7c-46a9-ad9d-8057ac6fca09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GantenerumabMember_706cb44f-8125-4f13-bf48-6f6b12b13b38" xlink:href="rprx-20221231.xsd#rprx_GantenerumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_GantenerumabMember_706cb44f-8125-4f13-bf48-6f6b12b13b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RochesMember_8a05feb6-df88-4d7e-95c4-6ac097a0a4d8" xlink:href="rprx-20221231.xsd#rprx_RochesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_RochesMember_8a05feb6-df88-4d7e-95c4-6ac097a0a4d8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="extended" id="ifdda802b065147c3b708606c29c8d69e_CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_a4dcbeec-acb8-4280-b380-64bbd35060cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_a4dcbeec-acb8-4280-b380-64bbd35060cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_7dc34703-d0a9-460a-b155-59b57422a31b" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_7dc34703-d0a9-460a-b155-59b57422a31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_c2859f7c-f25a-4a1b-a3df-c111f29f8d44" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_c2859f7c-f25a-4a1b-a3df-c111f29f8d44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_4dfb8f2c-0777-4631-b3fe-5a171616b5d9" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_4dfb8f2c-0777-4631-b3fe-5a171616b5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_7b40f64e-b211-4860-b533-80a0875f8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_7b40f64e-b211-4860-b533-80a0875f8b7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_0fc022a7-e6a9-4fcb-a8be-d2f224f528cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_0fc022a7-e6a9-4fcb-a8be-d2f224f528cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_0d24fbdf-f4f2-48e6-9332-8860984d197a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_229c5533-a728-4194-93b3-9d29889fbd24" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_229c5533-a728-4194-93b3-9d29889fbd24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1080ae95-9954-4790-a54a-573591b6c931" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1080ae95-9954-4790-a54a-573591b6c931" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended" id="i495be910fdb444d084a01a74f0fb7e0d_IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94db19db-4258-4e36-9057-6f90075305e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94db19db-4258-4e36-9057-6f90075305e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_561420f7-1617-4816-bb64-b0456d309ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_561420f7-1617-4816-bb64-b0456d309ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42c52b28-8254-4ec1-a719-6dcdd7afb949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42c52b28-8254-4ec1-a719-6dcdd7afb949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4994b839-414b-4970-994c-26f13a239ce7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4994b839-414b-4970-994c-26f13a239ce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_fd35a96d-9bb4-4300-8507-1a169b6ca7ba" xlink:href="rprx-20221231.xsd#rprx_DPPIVPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:to="loc_rprx_DPPIVPatentsMember_fd35a96d-9bb4-4300-8507-1a169b6ca7ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended" id="i5ba9b9089f784a588fbe7d66058987b5_IntangibleRoyaltyAssetsNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1522d987-cbd4-453b-9fd3-1396bc99e5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1522d987-cbd4-453b-9fd3-1396bc99e5f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_c7bbfbb7-2fb9-40be-9f30-9c46eefa71a5" xlink:href="rprx-20221231.xsd#rprx_DPPIVPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:to="loc_rprx_DPPIVPatentsMember_c7bbfbb7-2fb9-40be-9f30-9c46eefa71a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee493110-8465-44f1-a15c-e02625d1865c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee493110-8465-44f1-a15c-e02625d1865c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1c545004-d1fa-42f1-b7ff-36ad3959fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:to="loc_us-gaap_SalesRevenueNetMember_1c545004-d1fa-42f1-b7ff-36ad3959fc3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_37898448-dab2-48ec-8c25-afaed2a99f29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_37898448-dab2-48ec-8c25-afaed2a99f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_731361ee-4f79-4317-abad-0f1acbed534d" xlink:href="rprx-20221231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_731361ee-4f79-4317-abad-0f1acbed534d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended" id="i8b68fa6ee7194415b9df68ae9f1272e8_NonConsolidatedAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_391eba09-1134-453d-881d-064e035be055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_EquityMethodInvestments_391eba09-1134-453d-881d-064e035be055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb69a166-0a33-4966-9df5-5fb5c4f46fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb69a166-0a33-4966-9df5-5fb5c4f46fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_928c231d-7319-4b08-9d91-ba305c623225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_928c231d-7319-4b08-9d91-ba305c623225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_0f21131b-7779-40e5-9582-ca785768d0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_OtherCommitment_0f21131b-7779-40e5-9582-ca785768d0ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFee_ce98a589-ecfb-4f98-8877-6b9903a94a75" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_ProceedsFromExerciseFee_ce98a589-ecfb-4f98-8877-6b9903a94a75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFeeProRataAmount_500a0295-99c3-4307-af24-92461e16ede2" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFeeProRataAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_ProceedsFromExerciseFeeProRataAmount_500a0295-99c3-4307-af24-92461e16ede2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_807808e2-a0e3-4352-aeb3-6603e7c6f4c8" xlink:href="rprx-20221231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_807808e2-a0e3-4352-aeb3-6603e7c6f4c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_73906b14-bdec-4542-a6f4-d2e04f59be77_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_73906b14-bdec-4542-a6f4-d2e04f59be77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_7eac9f12-aed6-466c-8e7a-3711979afb44" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_7eac9f12-aed6-466c-8e7a-3711979afb44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_49c6bb41-b152-4b9d-91ee-0e8f4a577d3c" xlink:href="rprx-20221231.xsd#rprx_AvillionEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionEntitiesMember_49c6bb41-b152-4b9d-91ee-0e8f4a577d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_0f1bf211-6a5a-4b51-8d12-cc237bad6c77" xlink:href="rprx-20221231.xsd#rprx_AvillionIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionIMember_0f1bf211-6a5a-4b51-8d12-cc237bad6c77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_830cf47d-286c-4f10-902f-28f1a2918de2" xlink:href="rprx-20221231.xsd#rprx_AvillionIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionIIMember_830cf47d-286c-4f10-902f-28f1a2918de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_921a1c0e-7a21-48bb-9891-267d34c53961_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:to="loc_us-gaap_OtherCommitmentsDomain_921a1c0e-7a21-48bb-9891-267d34c53961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:to="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_48786f23-c442-4b77-8302-8467ac1de663" xlink:href="rprx-20221231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_48786f23-c442-4b77-8302-8467ac1de663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_138805f4-75b2-4c0b-91b0-977df4027980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:to="loc_us-gaap_SubsequentEventMember_138805f4-75b2-4c0b-91b0-977df4027980" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended" id="i95e6a8cb04ab4da3b820297aa90a5709_ResearchDevelopmentRDFundingExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48021ecc-9981-46d4-b827-7fceaaf07cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_48021ecc-9981-46d4-b827-7fceaaf07cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_af2f7816-955e-4149-9ab8-171d160d2694" xlink:href="rprx-20221231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:to="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_af2f7816-955e-4149-9ab8-171d160d2694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:to="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b41956b9-14bc-495a-b067-8e9b6d73d4ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b41956b9-14bc-495a-b067-8e9b6d73d4ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember_d068ff16-0244-446f-9a4e-0810638fcc52" xlink:href="rprx-20221231.xsd#rprx_CytokineticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_CytokineticsMember_d068ff16-0244-446f-9a4e-0810638fcc52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheravanceBiopharmaMember_9b7722ab-3841-4c59-9cd2-443e8a09dd34" xlink:href="rprx-20221231.xsd#rprx_TheravanceBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_TheravanceBiopharmaMember_9b7722ab-3841-4c59-9cd2-443e8a09dd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember_bac5d899-29ed-41f2-85f4-2975df7ed3e0" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_FundingAgreementsWithSanofiMember_bac5d899-29ed-41f2-85f4-2975df7ed3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_4fc922bb-9015-46e4-87fe-4061010190e7" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_MorphoSysMember_4fc922bb-9015-46e4-87fe-4061010190e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember_01a8f2ff-d5d7-4b1c-8b1b-9b55f768f669" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_FundingAgreementWithBioCrystMember_01a8f2ff-d5d7-4b1c-8b1b-9b55f768f669" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckToFundMember_c8dbff60-cdc9-462f-b267-985c05dc1dac" xlink:href="rprx-20221231.xsd#rprx_MerckToFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:to="loc_rprx_MerckToFundMember_c8dbff60-cdc9-462f-b267-985c05dc1dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_09feacaa-8e33-49bc-9e9c-11b921547f39" xlink:href="rprx-20221231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_09feacaa-8e33-49bc-9e9c-11b921547f39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended" id="ic6ebb6702fdb4eda90151157b228e79e_BorrowingsScheduleofBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db4e7189-1594-4c40-865e-1df3abd95ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db4e7189-1594-4c40-865e-1df3abd95ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff898174-8c74-4584-86a0-ec694656232d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff898174-8c74-4584-86a0-ec694656232d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_99769b3a-b6e2-44e0-aa71-d929bb60aaeb" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_99769b3a-b6e2-44e0-aa71-d929bb60aaeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d0c5c108-a782-4609-b343-6ad6742a948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d0c5c108-a782-4609-b343-6ad6742a948c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_08100232-2810-44c9-a491-6f2cfdacf899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebt_08100232-2810-44c9-a491-6f2cfdacf899" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_152b3135-ce90-4498-966d-b2e96a60988a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebtCurrent_152b3135-ce90-4498-966d-b2e96a60988a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1effb3d7-1504-4918-a4f4-33c1dd53f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1effb3d7-1504-4918-a4f4-33c1dd53f5b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_696659f3-5564-4a79-9fa9-7d25c429af89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_696659f3-5564-4a79-9fa9-7d25c429af89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0c977626-93f1-4743-9fcb-5418783f07ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:to="loc_us-gaap_UnsecuredDebtMember_0c977626-93f1-4743-9fcb-5418783f07ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:to="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f33c2cc9-b7a6-41a1-90ca-8177d029e65c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f33c2cc9-b7a6-41a1-90ca-8177d029e65c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_2e88075f-045c-4f99-a36d-de86146a2f59" xlink:href="rprx-20221231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_2e88075f-045c-4f99-a36d-de86146a2f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_a186621a-d621-4bc6-8076-d2638c9cc4af" xlink:href="rprx-20221231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_a186621a-d621-4bc6-8076-d2638c9cc4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e7a5d57b-bed5-4f44-a143-498bb9db461a" xlink:href="rprx-20221231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e7a5d57b-bed5-4f44-a143-498bb9db461a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_4437526c-dd1f-4c92-8237-38c26af23ff8" xlink:href="rprx-20221231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_4437526c-dd1f-4c92-8237-38c26af23ff8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_29057940-edfb-4fbb-b868-9b9fc72a88db" xlink:href="rprx-20221231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_29057940-edfb-4fbb-b868-9b9fc72a88db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_8fa549e3-ccd7-420b-a776-eae8246ff28a" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_8fa549e3-ccd7-420b-a776-eae8246ff28a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_558fba9e-90a5-44db-bb43-4999d2b6aa93" xlink:href="rprx-20221231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_558fba9e-90a5-44db-bb43-4999d2b6aa93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_b07ebe3d-cfa3-4f32-8df4-1b31523c6fa6" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_b07ebe3d-cfa3-4f32-8df4-1b31523c6fa6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i22a659240e4f4198a8a935c9698580f8_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2475b108-3953-400d-9dcf-4ad633cabe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2475b108-3953-400d-9dcf-4ad633cabe2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b120018-73be-41a4-ba8e-b86d2bc8eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b120018-73be-41a4-ba8e-b86d2bc8eaa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_054c34c9-355d-40e7-967a-49ef67b4f7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_054c34c9-355d-40e7-967a-49ef67b4f7b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_8390cade-f262-48a1-91d0-6f88b5dd7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_8390cade-f262-48a1-91d0-6f88b5dd7a86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1f571583-74cb-4b66-a99c-c27491c4009e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1f571583-74cb-4b66-a99c-c27491c4009e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0a3ddde0-f86c-4456-b085-926fbc1cb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0a3ddde0-f86c-4456-b085-926fbc1cb04d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c466e106-35e3-48e4-9dc3-a62f6fb7b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LongTermDebtFairValue_c466e106-35e3-48e4-9dc3-a62f6fb7b1d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d092991e-81ca-4b95-964b-1b3ad829d4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentTerm_d092991e-81ca-4b95-964b-1b3ad829d4b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b482c0d2-e981-44fa-ba60-bb7ff9f586a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b482c0d2-e981-44fa-ba60-bb7ff9f586a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_57b93231-d8d8-4090-80b0-19348821e742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LongTermDebt_57b93231-d8d8-4090-80b0-19348821e742" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e05c7de5-6566-4367-936a-1f973dc234af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e05c7de5-6566-4367-936a-1f973dc234af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_01aa453f-9f20-45c6-982a-90fc4143d2bf" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_01aa453f-9f20-45c6-982a-90fc4143d2bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_aca0fb7b-dc59-4762-ba5e-001eb831ff8c" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_aca0fb7b-dc59-4762-ba5e-001eb831ff8c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_3a4ebaaa-a537-4fc5-b161-778ca7c3ff58" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_3a4ebaaa-a537-4fc5-b161-778ca7c3ff58" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad9be7c1-6820-44b8-8614-891f9406f104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad9be7c1-6820-44b8-8614-891f9406f104" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_add45bbb-d5af-4915-89ca-a1c58cd81d07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_add45bbb-d5af-4915-89ca-a1c58cd81d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_854703d2-7338-4b33-86f9-6bff014a33f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_SeniorNotesMember_854703d2-7338-4b33-86f9-6bff014a33f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_99e9557f-2bbf-4204-92a9-c1f71e84a92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_UnsecuredDebtMember_99e9557f-2bbf-4204-92a9-c1f71e84a92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b76c7b2c-c461-4a3b-92bf-90f81ed1732c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_SecuredDebtMember_b76c7b2c-c461-4a3b-92bf-90f81ed1732c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ed65e8c-625f-42b8-8fba-b973cee6a099_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ed65e8c-625f-42b8-8fba-b973cee6a099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_88a26db8-21ac-40d3-89c9-92702409dad2" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorNotesDue2031Member_88a26db8-21ac-40d3-89c9-92702409dad2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_79248f0a-4053-432d-888d-19a554a80a86" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorNotesDue2051Member_79248f0a-4053-432d-888d-19a554a80a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_e1714bee-4623-49b7-b971-839a1b8ce293" xlink:href="rprx-20221231.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_TheNotesMember_e1714bee-4623-49b7-b971-839a1b8ce293" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_153a92b3-72b4-4b55-8e80-6ab5e4c53943" xlink:href="rprx-20221231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_153a92b3-72b4-4b55-8e80-6ab5e4c53943" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_7bf7afb6-5c98-4441-a048-45878eb9c6ea" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_7bf7afb6-5c98-4441-a048-45878eb9c6ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_77837a32-84cc-4713-864d-169c4062dfbd" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_77837a32-84cc-4713-864d-169c4062dfbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_57653f8e-7ecd-454e-bc1a-3db07e83c344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:to="loc_us-gaap_VariableRateDomain_57653f8e-7ecd-454e-bc1a-3db07e83c344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:to="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_67515c5f-70fe-4a71-aa9a-a7964f884207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_67515c5f-70fe-4a71-aa9a-a7964f884207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_56db7508-a6e2-4813-97c5-199c78300dbd" xlink:href="rprx-20221231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_rprx_OvernightBankFundingRateMember_56db7508-a6e2-4813-97c5-199c78300dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da017c0e-77eb-46ca-a0e8-40c3c6a3dc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da017c0e-77eb-46ca-a0e8-40c3c6a3dc38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_278c1c56-9c8e-495e-8d50-fdbaa4baacc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_278c1c56-9c8e-495e-8d50-fdbaa4baacc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5bc99bdf-932d-4520-93fb-d7a19b8f75a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5bc99bdf-932d-4520-93fb-d7a19b8f75a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_182b950b-375a-49de-9461-bf2ffe6329c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_182b950b-375a-49de-9461-bf2ffe6329c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fefa27a8-b94a-4dc2-b036-fddb73153fdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:to="loc_us-gaap_CreditFacilityDomain_fefa27a8-b94a-4dc2-b036-fddb73153fdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:to="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_22a485b3-3f7d-468a-ae1c-dd7b1c3e3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_22a485b3-3f7d-468a-ae1c-dd7b1c3e3ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83eb1200-8a08-4992-bc63-b87cd2e4edc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83eb1200-8a08-4992-bc63-b87cd2e4edc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5148191-6634-4bd3-8612-5186cb1c3920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5148191-6634-4bd3-8612-5186cb1c3920" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended" id="id6c739cbe2f84e82b4bdb5c999e41ca6_BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_47224800-f0c0-4ebc-babf-43e16ca018f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_47224800-f0c0-4ebc-babf-43e16ca018f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bbbd049b-92fe-45de-b718-b4ef16d9d556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bbbd049b-92fe-45de-b718-b4ef16d9d556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_57fedebc-0d73-4db4-aa3b-a25e916dc70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_57fedebc-0d73-4db4-aa3b-a25e916dc70d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_57749668-dd3f-4071-8af8-d0f2067e58bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_57749668-dd3f-4071-8af8-d0f2067e58bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e9c41b58-224d-43ef-b3b4-2c108be004d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e9c41b58-224d-43ef-b3b4-2c108be004d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f938c488-d0fd-4cda-bdb1-028e90137082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f938c488-d0fd-4cda-bdb1-028e90137082" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_cf8955ed-9a9a-468f-84ec-75de8d383e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_cf8955ed-9a9a-468f-84ec-75de8d383e17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_588b7f4d-58e8-4f0f-9e4c-c081e2cdc15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_588b7f4d-58e8-4f0f-9e4c-c081e2cdc15d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c769f555-0d21-490a-9d37-9b67a64e48f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:to="loc_us-gaap_UnsecuredDebtMember_c769f555-0d21-490a-9d37-9b67a64e48f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:to="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_68807ba0-4001-4b66-92ff-fcae5e0894f2" xlink:href="rprx-20221231.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:to="loc_rprx_TheNotesMember_68807ba0-4001-4b66-92ff-fcae5e0894f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i9f7e56be5ba248879a8a959ccc21b28e_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_28944a81-160a-4193-9800-57621149894d" xlink:href="rprx-20221231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_28944a81-160a-4193-9800-57621149894d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes_655c7f6b-5293-4099-9033-e2c2d3f882d4" xlink:href="rprx-20221231.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_CommonStockVotingRightsNumberOfVotes_655c7f6b-5293-4099-9033-e2c2d3f882d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_042a3abd-23bb-439a-88d2-49db0ca6eac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_042a3abd-23bb-439a-88d2-49db0ca6eac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis_add828fe-816a-4f96-b14a-c0fb21b0bb8c" xlink:href="rprx-20221231.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_CommonStockQuarterlyConversionBasis_add828fe-816a-4f96-b14a-c0fb21b0bb8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_29a31d45-d702-44e5-ba69-c78eca68beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_SharesOutstanding_29a31d45-d702-44e5-ba69-c78eca68beea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_841ca228-e32e-40fd-be38-6723f9ec06c9" xlink:href="rprx-20221231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_841ca228-e32e-40fd-be38-6723f9ec06c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_12ea0fb8-441b-42d9-b4e3-c84d0048364a" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_12ea0fb8-441b-42d9-b4e3-c84d0048364a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c488b8ad-e7e2-4033-b1cc-57cd34048e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c488b8ad-e7e2-4033-b1cc-57cd34048e1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7f6537eb-f791-4835-81ad-9faa2d5eead5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_DividendsCommonStockCash_7f6537eb-f791-4835-81ad-9faa2d5eead5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c42d148d-4b37-4924-8072-98aeaf678c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c42d148d-4b37-4924-8072-98aeaf678c2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7ce0e936-926d-4591-b8a1-efa580d12b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7ce0e936-926d-4591-b8a1-efa580d12b09" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_d4282766-8681-4206-8ace-d28fb9ad2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_d4282766-8681-4206-8ace-d28fb9ad2d86" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36fc2c9a-3687-4e07-a028-a8847a453f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36fc2c9a-3687-4e07-a028-a8847a453f8c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf80bdd2-672b-4728-8a3c-bc8ca1545a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf80bdd2-672b-4728-8a3c-bc8ca1545a69" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_907d133b-4426-442b-8869-76114f8c1c80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:to="loc_us-gaap_ClassOfStockDomain_907d133b-4426-442b-8869-76114f8c1c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:to="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1f0c2b8e-cc52-4695-96fd-1d386089234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_us-gaap_CommonClassAMember_1f0c2b8e-cc52-4695-96fd-1d386089234d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_bf02484e-3526-4fbd-bc8a-b100ae6a37aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_us-gaap_CommonClassBMember_bf02484e-3526-4fbd-bc8a-b100ae6a37aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_428621b9-c09a-488a-9f80-fc4c165c3d93" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_rprx_ClassRRedeemableStockMember_428621b9-c09a-488a-9f80-fc4c165c3d93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e7dcec8-ca77-440e-a42c-00ded2fc369a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:to="loc_us-gaap_PlanNameDomain_1e7dcec8-ca77-440e-a42c-00ded2fc369a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:to="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_4942d11c-b1f8-40ae-8a5e-2408f1638d9e" xlink:href="rprx-20221231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_4942d11c-b1f8-40ae-8a5e-2408f1638d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_65735c17-76c3-473f-b0dd-b55a02318ff8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:to="loc_us-gaap_EquityComponentDomain_65735c17-76c3-473f-b0dd-b55a02318ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:to="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_7baa3b25-8758-4f78-a6c4-7aaf67ead27a" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:to="loc_rprx_DeferredSharesMember_7baa3b25-8758-4f78-a6c4-7aaf67ead27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fc5ba69-04da-4f65-8e55-b2194304f225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fc5ba69-04da-4f65-8e55-b2194304f225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_099f3c53-3dcd-4be3-9d78-dbc24e7e600e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_099f3c53-3dcd-4be3-9d78-dbc24e7e600e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended" id="i71f717b679b944da88c4c23d2a59b689_ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39725012-e85f-45ab-ad9d-f1e3a3787870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39725012-e85f-45ab-ad9d-f1e3a3787870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_75db0a73-b375-4b6e-90a3-3794bad4dc10" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_75db0a73-b375-4b6e-90a3-3794bad4dc10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_0ca45769-92c2-456a-ab81-e74e93e098ba" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_0ca45769-92c2-456a-ab81-e74e93e098ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9a277007-c419-470f-90dd-ae00bf008d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9a277007-c419-470f-90dd-ae00bf008d1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cf085170-d84f-43db-a75e-97efd3aec510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockholdersEquityOther_cf085170-d84f-43db-a75e-97efd3aec510" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d5a35a77-4e59-4fd2-b38d-1f683e14b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_ProfitLoss_d5a35a77-4e59-4fd2-b38d-1f683e14b3d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_10dffd82-182a-45ba-9833-2c10e8a6a801" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_10dffd82-182a-45ba-9833-2c10e8a6a801" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e02d5e57-144b-4140-8112-516be68e8b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e02d5e57-144b-4140-8112-516be68e8b01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dd39b2ae-a583-4efd-ae51-da6aaa39ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dd39b2ae-a583-4efd-ae51-da6aaa39ae77" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cedad2cd-d149-4178-8dc2-375c22ec33ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cedad2cd-d149-4178-8dc2-375c22ec33ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5636938f-f2dd-4e03-98ff-789878af5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3e9ef853-3697-4885-93c5-22e2d5e5d8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3e9ef853-3697-4885-93c5-22e2d5e5d8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5a06d196-c92f-42df-ab24-12877186e1b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:to="loc_us-gaap_EquityComponentDomain_5a06d196-c92f-42df-ab24-12877186e1b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:to="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_450821c5-400a-4902-9bde-c157d480426d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:to="loc_us-gaap_NoncontrollingInterestMember_450821c5-400a-4902-9bde-c157d480426d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25f21faf-e35d-4ebe-97ed-74ba1d971642_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:to="loc_dei_EntityDomain_25f21faf-e35d-4ebe-97ed-74ba1d971642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:to="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_95d04885-8f86-43f6-a5d3-ee9f303a59e2" xlink:href="rprx-20221231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_95d04885-8f86-43f6-a5d3-ee9f303a59e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_af18f348-70a9-4807-aefe-5f4638ebfd93" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_af18f348-70a9-4807-aefe-5f4638ebfd93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_7355781b-bc14-440a-89b9-e958baf4841d" xlink:href="rprx-20221231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_7355781b-bc14-440a-89b9-e958baf4841d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_a529b0bd-31d1-4afe-82b8-b0a65412f898" xlink:href="rprx-20221231.xsd#rprx_EPAHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_EPAHoldingsMember_a529b0bd-31d1-4afe-82b8-b0a65412f898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5282f58d-8343-412a-a927-4492fcaa07fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:to="loc_srt_OwnershipDomain_5282f58d-8343-412a-a927-4492fcaa07fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:to="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_1dffb363-a0b4-47d4-9390-e3d3add326d2" xlink:href="rprx-20221231.xsd#rprx_RPHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:to="loc_rprx_RPHoldingsMember_1dffb363-a0b4-47d4-9390-e3d3add326d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended" id="i724190e8dd7b4624b005308489d371fb_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a2aec5ba-bec4-476d-a42b-52ba6a92832c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_ProfitLoss_a2aec5ba-bec4-476d-a42b-52ba6a92832c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_1a1fce87-1099-435a-b425-ff064ccff4b4" xlink:href="rprx-20221231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_1a1fce87-1099-435a-b425-ff064ccff4b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4735954-7b97-4f38-99da-a7e117f213ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4735954-7b97-4f38-99da-a7e117f213ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8da4bfc4-debc-436d-994d-e332abd66b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8da4bfc4-debc-436d-994d-e332abd66b5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bb6912dd-f534-4540-a14b-f2b3f2c840be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bb6912dd-f534-4540-a14b-f2b3f2c840be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45be888a-a121-4b87-bbf8-3636600773fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45be888a-a121-4b87-bbf8-3636600773fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1d756b2e-619d-447b-b261-1aeeabec02de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1d756b2e-619d-447b-b261-1aeeabec02de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c438d97-8462-4da6-8831-faf4c81f77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c438d97-8462-4da6-8831-faf4c81f77a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f68609eb-fc28-49ad-82c7-44bf0406d532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_EarningsPerShareBasic_f68609eb-fc28-49ad-82c7-44bf0406d532" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6141db0c-dd49-4d57-9f27-f4e7b8c9b570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6141db0c-dd49-4d57-9f27-f4e7b8c9b570" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:to="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4a4ab53-78ab-44db-88c2-bf80bca62995_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4a4ab53-78ab-44db-88c2-bf80bca62995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_5cec8afc-aacb-429f-8181-81816a0d2d0d" xlink:href="rprx-20221231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_5cec8afc-aacb-429f-8181-81816a0d2d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_8dbc4312-e02c-4389-aa92-4194dc50f91c" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_8dbc4312-e02c-4389-aa92-4194dc50f91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_5b1f7fb3-a91a-4a71-a85f-dbb2f19f9995" xlink:href="rprx-20221231.xsd#rprx_ClassBHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_ClassBHoldersMember_5b1f7fb3-a91a-4a71-a85f-dbb2f19f9995" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i2130e1f0ac044b39b21111a5f5f5390d_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_44c9e18a-5899-4836-a184-bf5cd13150c2" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_44c9e18a-5899-4836-a184-bf5cd13150c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_787d649b-712b-462e-bd31-0b6f472618aa" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_787d649b-712b-462e-bd31-0b6f472618aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_1a76a17f-38d8-4a73-ac4f-124775c6ab28" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_1a76a17f-38d8-4a73-ac4f-124775c6ab28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_304240b3-6d9d-42a5-9845-047ad2850883" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_304240b3-6d9d-42a5-9845-047ad2850883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_440c835c-12b3-4549-ab49-db4439b607ca" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_440c835c-12b3-4549-ab49-db4439b607ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5d35aa24-b74c-41d6-9eea-02a6ebcc15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5d35aa24-b74c-41d6-9eea-02a6ebcc15cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_1c405af9-e768-4c75-9c9f-d3bcf0630d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_1c405af9-e768-4c75-9c9f-d3bcf0630d6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_b946ac8e-7682-4e60-b1ba-3fb6ddfa6c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_b946ac8e-7682-4e60-b1ba-3fb6ddfa6c3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_492bd265-939a-4032-b627-66422f6b5c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_NotesReceivableNet_492bd265-939a-4032-b627-66422f6b5c3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_052dfa89-7914-4db6-bf49-3c0eec789503" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_052dfa89-7914-4db6-bf49-3c0eec789503" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_64751f47-20f4-4d4b-83e4-492dbf2c7467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_DueFromRelatedParties_64751f47-20f4-4d4b-83e4-492dbf2c7467" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_98ad3882-d246-489a-b005-f33b4f4f5db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_98ad3882-d246-489a-b005-f33b4f4f5db6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_4f6ca899-b61e-406d-ad93-579da07107d7" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_4f6ca899-b61e-406d-ad93-579da07107d7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_51fdf6bc-6206-40f1-b463-828cd9bd908e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_51fdf6bc-6206-40f1-b463-828cd9bd908e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3fe23926-8923-416c-a89d-75923423a06c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:to="loc_us-gaap_RelatedPartyDomain_3fe23926-8923-416c-a89d-75923423a06c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:to="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_185df403-bb2f-4e02-b143-cded23d44c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_srt_ManagementMember_185df403-bb2f-4e02-b143-cded23d44c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c14ffe12-6886-491d-b30a-e83f1285a475" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_srt_AffiliatedEntityMember_c14ffe12-6886-491d-b30a-e83f1285a475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember_24820c99-b8ba-456c-b8a3-2145f3482866" xlink:href="rprx-20221231.xsd#rprx_PabloLegorretaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_rprx_PabloLegorretaMember_24820c99-b8ba-456c-b8a3-2145f3482866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f5f35483-20e2-4a8d-8fcf-7dbfd109f821_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f5f35483-20e2-4a8d-8fcf-7dbfd109f821_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_7f1c2b89-8b86-4e12-938d-09423e4e627d" xlink:href="rprx-20221231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_7f1c2b89-8b86-4e12-938d-09423e4e627d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_f76006f9-66f0-433d-9535-9b8fc43e689a" xlink:href="rprx-20221231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_f76006f9-66f0-433d-9535-9b8fc43e689a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_c8c0f5d4-9cfd-4452-a6a4-6a9060fc038f" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_c8c0f5d4-9cfd-4452-a6a4-6a9060fc038f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_a6363409-300a-42dc-9463-0013211c448e" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_a6363409-300a-42dc-9463-0013211c448e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_01bd278f-83a2-42c4-a5a9-88063f5510a9" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_01bd278f-83a2-42c4-a5a9-88063f5510a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_8504c6dd-0d80-4f6b-a886-94d229dd4022" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_8504c6dd-0d80-4f6b-a886-94d229dd4022" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_6163a780-979a-4373-8a8f-d988544924e7" xlink:href="rprx-20221231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AgreementWithMSCIMember_6163a780-979a-4373-8a8f-d988544924e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember_2b04a6a7-fe71-4e6b-802b-2d0b0dc0894c" xlink:href="rprx-20221231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_PurchasingAndDonatingVentilatorsMember_2b04a6a7-fe71-4e6b-802b-2d0b0dc0894c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_102a75b5-0543-4e59-95cb-f24de5fddde7" xlink:href="rprx-20221231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_102a75b5-0543-4e59-95cb-f24de5fddde7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_17fa1e18-a420-4d77-826b-5459ea28b8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:to="loc_us-gaap_EquityComponentDomain_17fa1e18-a420-4d77-826b-5459ea28b8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:to="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e250ea2e-e346-434e-86a9-709c6c991aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:to="loc_us-gaap_TreasuryStockMember_e250ea2e-e346-434e-86a9-709c6c991aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7bff9e32-d880-455e-abe0-3ba6cd765fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7bff9e32-d880-455e-abe0-3ba6cd765fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caf19977-1c3b-4656-a982-7e892908a90c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caf19977-1c3b-4656-a982-7e892908a90c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_108cc3ed-ad46-466b-a956-85585f31897c" xlink:href="rprx-20221231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:to="loc_rprx_BristolMyersSquibbMember_108cc3ed-ad46-466b-a956-85585f31897c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="i8a597e0003c14c33a8770f4edbedea3f_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_b24059cc-8c13-426e-afdc-6896ba482172" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_b24059cc-8c13-426e-afdc-6896ba482172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e1eb4590-649f-40a1-bfea-d3ee29ac5327" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e1eb4590-649f-40a1-bfea-d3ee29ac5327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7ea5038-efc6-4edc-ae57-e92b0314ac63" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7ea5038-efc6-4edc-ae57-e92b0314ac63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87249ed9-497c-4f3b-844e-ef4ef2b28e89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87249ed9-497c-4f3b-844e-ef4ef2b28e89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7efa609f-13ec-4436-9605-b74c809327cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:to="loc_us-gaap_SubsequentEventMember_7efa609f-13ec-4436-9605-b74c809327cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>rprx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_77243f6b-7d0b-42af-9f29-092bfe5ff3c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForMilestones_fb9638e1-87fb-4de1-a53b-1a8922b46236_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_label_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_documentation_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones" xlink:href="rprx-20221231.xsd#rprx_PaymentsForMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForMilestones" xlink:to="lab_rprx_PaymentsForMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a04e96b7-1cf0-42fc-92cf-3d2df7633c1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a47e98f8-4164-485a-b35d-0ffd8ac77310_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3b81592a-c62e-4fe9-a4e0-234a72ad525f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9f116901-4212-4300-ac22-f9e0319c6b4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_80471124-0fb7-49e3-a7d3-56a6b2689046_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0cf50a25-860d-459e-aee4-7cbb5a9d8fd8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_2885a8c4-8f8b-4db9-9884-6567cb59e04b_terseLabel_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:href="rprx-20221231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:to="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPHoldingsMember_9855afde-88ff-461c-9e10-24e78cdb860b_terseLabel_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_label_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings [Member]</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_documentation_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember" xlink:href="rprx-20221231.xsd#rprx_RPHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPHoldingsMember" xlink:to="lab_rprx_RPHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_ba6fe6b6-8b3c-4607-9dee-68364b9dfe35_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051</link:label>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:to="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_c6566df8-372b-4a50-a4fe-be54448b6635_terseLabel_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_1ac13445-4415-4328-b3fd-86f755479f95_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPCT</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:to="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_3f82583d-cac3-4865-873a-ec611cc55f97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Of Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_505987f2-9146-4482-90b6-8f0c8ce3aac1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_124f12a0-0dad-41cf-a699-21d1e4932192_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_72cbe9f8-3f35-4d96-b8b6-dc7b445d1390_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests - other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_b2e96ff8-cd22-4c8e-9585-580cfb74b19f_terseLabel_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_label_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction [Member]</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_documentation_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember" xlink:href="rprx-20221231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ExchangeOfferTransactionMember" xlink:to="lab_rprx_ExchangeOfferTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_155ec6d9-13f8-4978-9022-eff93ace5184_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_4a7e2219-988d-46b7-9949-0d19e2df3139_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old RPI</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI) [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:to="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_5391bfb6-97c1-4911-9cca-a4212135be5f_terseLabel_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange by continuing investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (in shares)</link:label>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_label_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</link:label>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_documentation_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:to="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_4ff3c471-6d76-4ef7-b5cb-b92e17f5a908_terseLabel_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:href="rprx-20221231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:to="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_0a19e654-5a5c-46b4-bcc4-c01ab7058ae7_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in quarterly installment payments (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Increase, Percentage</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:to="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5ba5f4f6-9ae1-4b4d-b6a6-6eb6128ba80f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments and Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_742b2478-8fa4-4d66-be2b-c3d2330a8d00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense/(income)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c685c26b-98f3-485f-bde5-7ce573c1bf25_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TheNotesMember_505e2528-ca42-4830-baf5-72e4ad770c6d_terseLabel_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:label id="lab_rprx_TheNotesMember_label_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes [Member]</link:label>
    <link:label id="lab_rprx_TheNotesMember_documentation_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember" xlink:href="rprx-20221231.xsd#rprx_TheNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TheNotesMember" xlink:to="lab_rprx_TheNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_7dd92432-9e15-441c-aea1-f72ff17cd32f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_7273138b-8f56-4a0e-94df-04758109fd96_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required amount to be drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Covenant, Required Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Covenant, Required Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:to="lab_rprx_LongTermFundingPartnershipCovenantRequiredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_bd51599d-1913-4933-af94-2722b59c3f92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a11d2ed-0bcf-4d45-9a90-9761e37f890c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c82c227f-2176-45c7-969e-fc5ede54b68d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_68e9a684-d2f4-42bb-8329-3fa566c4ff0f_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class B ordinary shares to Continuing Investors Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued To Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued To Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:to="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ef59d0c8-671f-43b8-b968-271bfe5abb2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9dceace3-be58-4a4b-9061-a54215f5b7ac_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e6702fa0-6688-4b81-a443-1f0855023872_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivatives and Reclassifications</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_886d8d88-a3af-4d95-9df2-5a25b6b4be77_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:to="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AuditInformationAbstract_label_en-US" xlink:label="lab_rprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_rprx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_rprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AuditInformationAbstract" xlink:href="rprx-20221231.xsd#rprx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AuditInformationAbstract" xlink:to="lab_rprx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_72d304d2-f0cc-4890-b0d7-4770531fe576_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon occurrence of a change of control triggering event</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_4a630996-fec4-4a12-9f0a-f9d7c7ffbaa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_95069255-51a6-4a33-a62c-bbff7a698284_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DevelopmentFundBondMember_d5c5d17c-b34c-4dbf-ad00-ad914c097f14_terseLabel_en-US" xlink:label="lab_rprx_DevelopmentFundBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development fund bond</link:label>
    <link:label id="lab_rprx_DevelopmentFundBondMember_label_en-US" xlink:label="lab_rprx_DevelopmentFundBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development fund bond [Member]</link:label>
    <link:label id="lab_rprx_DevelopmentFundBondMember_documentation_en-US" xlink:label="lab_rprx_DevelopmentFundBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development fund bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundBondMember" xlink:href="rprx-20221231.xsd#rprx_DevelopmentFundBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DevelopmentFundBondMember" xlink:to="lab_rprx_DevelopmentFundBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_19d48087-b314-4cf2-927a-ec522a421b7e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EpizymeIncMember_8d101078-9c3e-45cc-9e2e-188898124c1d_terseLabel_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment In Epizyme Inc.</link:label>
    <link:label id="lab_rprx_EpizymeIncMember_label_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Inc. [Member]</link:label>
    <link:label id="lab_rprx_EpizymeIncMember_documentation_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember" xlink:href="rprx-20221231.xsd#rprx_EpizymeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EpizymeIncMember" xlink:to="lab_rprx_EpizymeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_33d158d1-6f4c-4b1c-bd00-6a63c6b6acb4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_32ee8234-8415-4d41-b425-889f64efe6ac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of financial royalty assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Finance Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_2e29fef3-1d11-4e47-a70c-e0173eadd4ee_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_205d57b9-8df7-4a5a-b1e1-d9579d85d2b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_bd209773-16ab-40c1-bf01-d992aa593fae_terseLabel_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of interests</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_label_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Transfers Of Interests</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_documentation_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Transfers Of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NoncontrollingInterestTransfersOfInterests" xlink:to="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_1def52d5-fddc-47ca-b605-19316d61f2e5_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_3e02286a-f471-456a-a122-07d52d735e6e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_bb6e6f5a-e977-400f-9d09-f91358bfe844_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Repayments of Debt by Year</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e14a7f5e-ec10-4fe1-952f-afbf1cf6ceb8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_5cc83372-f4ed-443f-8e7f-5f1af30850ed_terseLabel_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic fibrosis franchise</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_label_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise [Member]</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_documentation_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember" xlink:href="rprx-20221231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CysticFibrosisFranchiseMember" xlink:to="lab_rprx_CysticFibrosisFranchiseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_356c1695-598f-41f2-997f-be1289ad2ada_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_987d1ad6-aea6-4224-bb25-dcc790090e05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_570dc919-5d7d-4e91-ba98-51218998313b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_7d749b3e-b1fc-44ec-9727-c1e22c57aa04_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:to="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eac2cf2a-96e7-43aa-858a-632b90dffbac_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6a69d803-d3f2-4946-8bb0-5f62671aa3b9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_ee3cc058-9b95-41e9-8514-e87fc9bc3007_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_42122e2b-d60c-4d9e-912c-298cd3b74767_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_d1d0657c-a3ae-42ee-81ca-4a8a5f92bae7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_e771a2ad-69de-4871-9467-8eff957241cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_b4ad3e5c-f9c0-41a8-8eec-cd128b330dd3_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_a532669d-fe5c-4122-994b-5ab1da574cc9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party, rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cc9c7eee-71d1-43c6-9d10-c1cf6408b89e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_f06f6877-4d9a-4f69-90e7-161a0c9c99cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_a9615074-501d-45f9-9561-2342c2aea36c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_437615cc-69db-4f21-a646-ac078b5cbbf4_terseLabel_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT</link:label>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_label_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance [Member]</link:label>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_documentation_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember" xlink:href="rprx-20221231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPI2019IntermediateFinanceMember" xlink:to="lab_rprx_RPI2019IntermediateFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0078ef87-cb89-45b4-b6cf-d2e5f2a83074_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9e96a06a-dd19-46d2-b012-126587275332_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_13779842-80d8-4d21-ac9d-62fb240dcc26_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio following qualifying material acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_c047f4ea-6389-49b3-8e86-7af75bf75dc9_terseLabel_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment and premium paid</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_label_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Upfront Payment and Premium Paid</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_documentation_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Upfront Payment and Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:href="rprx-20221231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:to="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_1695e46d-5d89-4ef4-94a1-73add37e0a91_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, number of tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:to="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_116df692-924a-458d-ad0f-c7082c1eb106_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbd1c17f-1de0-4da5-abf3-5f5fa013428c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5661b882-8f72-4883-8cb8-53989c0927ba_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_98ae6821-59c3-4b2e-aa7d-a435162eef05_negatedTerseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_3e91483e-3d0e-4259-a372-180275cc5f25_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period One</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_7420fba6-ee17-40db-8c77-c6e9a67d5d4a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_01e4a43b-a1a5-4163-b750-7f66cf642c3f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b5fb9abb-2496-4c97-a089-cbaaddc18dd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2a1ab1ab-4ff3-458f-abaa-95aeb6062342_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_24d0f0a9-352f-4d30-82d5-f2841da951cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIIMember_f5665676-ccc6-421d-9c25-107acf31eb37_terseLabel_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:label id="lab_rprx_AvillionIIMember_label_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II [Member]</link:label>
    <link:label id="lab_rprx_AvillionIIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember" xlink:href="rprx-20221231.xsd#rprx_AvillionIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIIMember" xlink:to="lab_rprx_AvillionIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d34efe60-f6a2-4a66-a297-ff5f787a4d94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2d8d239a-5f7c-4db2-ac3c-034df523618e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d3149300-73d4-4c4a-88a4-574a61d3d601_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_31dc69d9-e2f3-41cb-bbac-6b311f848202_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_cd241fa8-9131-4635-aaac-e3be20f3e237_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bf894be-1120-4d8b-a04f-d6c8286753d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_1ee707de-5a3c-4108-aa6d-d33d680132f8_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_3280a704-c097-4b49-8444-de9016050e93_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_e3b739f3-0e9b-44bc-bc33-31076137bb0d_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, weighted average cost of capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_5af92f04-c4a4-46c3-acd3-0c62a14b145b_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest free and payment free period, calendar quarters, tranche two</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche Two</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:to="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_17ce713e-9fa2-4100-9417-591e6275f772_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for equity investment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Investments, Upfront Payment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Investments, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:to="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_31ba904b-8b38-42cb-9647-f63e46e2ebcd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_36e37e8a-2265-45c2-9ad1-c463a10d4486_terseLabel_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember" xlink:href="rprx-20221231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_A2020EquityIncentivePlanMember" xlink:to="lab_rprx_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1798407a-13e0-40a2-9a30-1447128672a4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_5153b875-a1ac-44a1-8114-4f6fcde8af5f_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0a6139aa-2364-4d8d-baa6-d00e5188e134_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_83074579-b52c-4150-b6e4-c4429c3e7af7_terseLabel_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury rate lock contracts</link:label>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_label_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Contracts [Member]</link:label>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_documentation_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember" xlink:href="rprx-20221231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TreasuryRateLockContractsMember" xlink:to="lab_rprx_TreasuryRateLockContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_903398d5-e5cf-45fb-b390-50e7104a552a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_cbd135b2-a743-4a07-b17a-bbf9e4c1c08a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e49a935f-12d5-45f8-b354-fcac13dd24dd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsMember_4668d19b-f4b6-4884-88f2-e153786f606f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_244aab0e-7913-4667-a264-5f35c80438cf_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_135dde49-b1b6-43db-a0bf-ea1499f0ba1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_19229d78-5854-4417-aaa7-75af3f9b0d35_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_56f5172d-6f89-4ac4-b059-ddd74a367e2f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6103e0a9-56a2-487f-8223-758eaea78055_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_5f377996-beb6-4897-a50c-a68fdb27dfe6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_18696aca-5081-4af7-bc7c-8dd08e0cb3e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f9f18c9d-d6de-4954-aa51-e39be5c23c22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loss reclassified from accumulated other comprehensive income into net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TheravanceBiopharmaMember_38978db9-c4d1-48bc-a432-4cc09c629752_terseLabel_en-US" xlink:label="lab_rprx_TheravanceBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theravance Biopharma</link:label>
    <link:label id="lab_rprx_TheravanceBiopharmaMember_label_en-US" xlink:label="lab_rprx_TheravanceBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theravance Biopharma [Member]</link:label>
    <link:label id="lab_rprx_TheravanceBiopharmaMember_documentation_en-US" xlink:label="lab_rprx_TheravanceBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theravance Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheravanceBiopharmaMember" xlink:href="rprx-20221231.xsd#rprx_TheravanceBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TheravanceBiopharmaMember" xlink:to="lab_rprx_TheravanceBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e7a8dbfe-b017-493a-8c04-339381b4cf81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e26c366d-dbe1-4043-b44b-be5750ffa226_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares sold in IPO, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3d6916ee-7a96-4253-82bd-c0a57d70b5d7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5533fc4a-df85-4fcc-a738-e7f59862f299_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_218cddc6-1ddf-4bec-8875-b8dac50f6205_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_996b49be-3cd5-4eae-be66-919310c26dcf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f93be455-4033-4feb-86db-f55d0da9ad7b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_bf8506cc-9bdf-41e7-b6fd-a186b0e5a65d_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate royalty amount when patents cease</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_label_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:to="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e2e1842-786a-45cf-a0b0-52886a879e93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9de0904d-f7a9-4f2c-bfd5-c4914f25c15e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_12bfa64c-9534-45bb-968a-66a0a12fc4e2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7d2aa6d4-635d-4c7b-ad37-13e650856747_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offering, ownership percentage</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e3d1d8f4-6ec5-405f-b7db-a9b95ffed6c0_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0a22e7a2-d8dc-4d13-b88a-5e975f18efac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_907ced60-2688-40f1-a829-70b09e679fc2_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2031Member" xlink:to="lab_rprx_SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a7268a40-8cae-4e25-9695-4d0c92f64262_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b789fb9c-3c3b-40c4-82ad-ed8c8c4b8b37_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_440ef8dc-55d2-4c9b-a93c-3ab530f1a5a4_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b4806f32-9d23-4fb5-8b35-3e2b0ea433a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_cbd02de6-7359-4a35-b623-b7dcd61673da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0a6d07fd-b968-4b0b-b5e4-bf5a5e664814_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b6d1b7be-321c-4d60-8152-81849c238e86_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_84314281-36ab-4c54-a093-7fd6efbb9f9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_6c215090-6438-46ea-b5b1-1aeef0c3ebcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in operating assets:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtilimabMember_fe4d7a8f-68f6-4626-a549-8768065d70c9_terseLabel_en-US" xlink:label="lab_rprx_OtilimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otilimab</link:label>
    <link:label id="lab_rprx_OtilimabMember_label_en-US" xlink:label="lab_rprx_OtilimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otilimab [Member]</link:label>
    <link:label id="lab_rprx_OtilimabMember_documentation_en-US" xlink:label="lab_rprx_OtilimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otilimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtilimabMember" xlink:href="rprx-20221231.xsd#rprx_OtilimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtilimabMember" xlink:to="lab_rprx_OtilimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9b2407d1-013c-4ad8-9705-cb79810f3ff7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5a64dd82-bf18-42c4-bd3e-997129cd073b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_493224a7-0037-4018-9a61-3e686efadac3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on available for sale debt securities included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_c32b032f-6f38-4380-bcff-c56fc23f350b_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_50d34ded-62fb-4de8-b809-711c464613fb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_b77d79a1-d285-45b7-abb2-8aaa70f1327b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_a8e0d3b1-3d8a-40f6-8b59-67d2029cd71e_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_9adcc39c-2497-486a-88a6-f445155d0d00_terseLabel_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Shares</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_label_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock [Member]</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_documentation_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassRRedeemableStockMember" xlink:to="lab_rprx_ClassRRedeemableStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_59cbf898-7d6e-4616-9d5a-19a091a24eab_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_68354410-40fe-41dd-9676-9cdb0b43f853_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_c108ff95-59e2-4a31-9abd-e5c3c857ffe2_terseLabel_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchase obligation - Tazverik</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_label_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Equity Investment</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_documentation_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationEquityInvestment" xlink:href="rprx-20221231.xsd#rprx_AccruedPurchaseObligationEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedPurchaseObligationEquityInvestment" xlink:to="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_3f5926bd-136f-4a9c-bbf1-682b28b88eda_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:to="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_eb1589ae-ebe0-4d9d-8803-33e15123cd1a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_9c88ea3c-0d05-4cd4-b5f3-98eb1b554447_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option, selling price, maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_72db82dc-97ce-4fa6-b935-dceda078f561_terseLabel_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_label_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate [Member]</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_documentation_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember" xlink:href="rprx-20221231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OvernightBankFundingRateMember" xlink:to="lab_rprx_OvernightBankFundingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e770ebc6-7b7a-41d6-afb3-8734d5353832_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_2b838187-975f-450f-b3a4-5e6f328470ff_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to legacy non-controlling interests - royalty receipts</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_label_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Royalty Receipts</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_documentation_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Royalty Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:to="lab_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_df194f5d-bfda-4c6c-9fad-514af094da3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_cc0cc9a1-0c74-4a38-94c5-2410507707c2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_3d1e5fdd-1a26-48b3-8ac6-fa262980ca91_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f335a3e5-7bd2-4981-8a5f-4922a30ffd9a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3182fe34-e006-4f85-ae03-a5bafa1b7c5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_28f0829d-c19e-42ef-a964-5851a885f0bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5caff71f-56b4-4992-be4f-aaededc4ed2c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in)/provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_91022c12-47f8-4642-aa74-49a8199657af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of outstanding Notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_233ded72-c475-4097-8648-354f2bbb9be4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_76463d11-48e8-4efb-9be9-3122e8ac85fc_terseLabel_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable" xlink:href="rprx-20221231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedRoyaltyReceivable" xlink:to="lab_rprx_AccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_a015e0c7-93bf-42d5-a83a-7d07eb6a129f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_45c255dc-95d3-4274-9de0-90046332712f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_f7b92286-614e-447e-98c6-15338c9836f7_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_f17c2a7f-1d78-4e63-b4f4-9ae50064c366_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e62d4e4c-0f6d-4381-b667-ecf73f9afb0a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_444cb7cf-621f-43a4-8e93-2d1a4a6855c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_284b35df-47df-4e14-a759-63d0b3901d97_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_38fc5e74-21e7-4ef1-af87-6959e41187d4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6a902760-ed50-4eb0-99ef-803e7fb23ecc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_36620694-414c-4123-8d43-e37efe9caf20_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_c1fe26b4-eaf0-4561-82c0-aa7912002c55_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromExerciseFee_09f8e920-ac57-4e2f-a337-0d10ee52cd13_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds exercise fee</link:label>
    <link:label id="lab_rprx_ProceedsFromExerciseFee_label_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Fee</link:label>
    <link:label id="lab_rprx_ProceedsFromExerciseFee_documentation_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFee" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromExerciseFee" xlink:to="lab_rprx_ProceedsFromExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_01343760-058b-4354-8d35-2cb44a2b6f7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Marketable securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e110cd7a-b55d-47a4-b431-55cf7dcd5f3c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d737c402-19bb-4954-b3a7-d7dcc41eba0f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acbeab61-14fa-4691-bed9-a9ebcae76f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_54119372-057e-458e-9083-01ea2547179e_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding</link:label>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_label_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsCommercialLaunchFundingMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Commercial Launch Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember" xlink:href="rprx-20221231.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsCommercialLaunchFundingMember" xlink:to="lab_rprx_CytokineticsCommercialLaunchFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3040e2fb-6ba7-4d77-8ee0-d71a4f3908ef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase additional shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fab5fbb4-de5c-41d1-bf7c-7087f0d685e2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share based compensation expense, period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e65c5521-ab6a-4964-9678-84a39ab2f651_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_c4c63043-b6ba-4c08-baa8-d657d8fd9050_terseLabel_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnerships</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_label_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership [Member]</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_documentation_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:href="rprx-20221231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:to="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3c86edf3-3a75-44e8-9c27-4c63339d54a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Royalty Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_582bc009-b069-49c2-8c0c-29f952fc9ad2_terseLabel_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_label_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial [Member]</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_documentation_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:href="rprx-20221231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:to="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_9ae9126a-a918-4c00-8599-38296f5b81ce_terseLabel_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares converted (in shares)</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_label_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Not Converted</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_documentation_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Not Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:to="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_0c0c8f5e-6a5e-4322-8f83-78bcb0dda8f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of other financial assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ff9bf7c1-30cf-4cb1-a01f-829bc7e84c8f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_7d60b8c8-5b2b-43fd-a283-3b809d79f1b6_verboseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_e59e2c1d-a03a-4ce8-b7f6-65860c0cf028_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt" xlink:to="lab_us-gaap_TradingSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_46e27579-28e5-4b68-97cb-bdbe56967662_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Writeoff related to financial royalty asset</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Financial Royalty Asset, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_6a8a70a0-717d-4f1b-adf7-246267229566_negatedTerseLabel_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income accretion</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_label_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_documentation_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:href="rprx-20221231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:to="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_026bb910-5d89-4450-aa6e-9c4d9175fe64_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_781ec71a-702f-4f5b-a6c3-c667fe53dbc8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares sold in IPO, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_938b0da5-0578-4793-b004-960e7a143034_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_cfe554ad-a40b-4d50-ac70-f144a710bb31_terseLabel_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant</link:label>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_label_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant [Member]</link:label>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_documentation_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember" xlink:href="rprx-20221231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EpizymeCommonStockWarrantMember" xlink:to="lab_rprx_EpizymeCommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ccfd6430-4417-426b-88aa-b4120c78136f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_384c3e58-d739-4803-882c-57df78f92dfa_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:to="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_dac1c00c-e46c-4feb-bdf7-38ccf3f3f76f_terseLabel_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember" xlink:href="rprx-20221231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancialRoyaltyAssetsMember" xlink:to="lab_rprx_FinancialRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a421dc51-818f-4bce-8439-6f414d28025c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_afbc45b9-da88-431f-8a98-8dfa8402c901_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, expected payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership Expected Payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipExpectedPayment_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership Expected Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipExpectedPayment" xlink:to="lab_rprx_LongTermFundingPartnershipExpectedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EvrysdiMember_3e2f312d-4ccf-46cb-b5ae-f90c08cf5276_terseLabel_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:label id="lab_rprx_EvrysdiMember_label_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi [Member]</link:label>
    <link:label id="lab_rprx_EvrysdiMember_documentation_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember" xlink:href="rprx-20221231.xsd#rprx_EvrysdiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EvrysdiMember" xlink:to="lab_rprx_EvrysdiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesMember_ce02e08a-77ed-49e2-b828-bdadf58c4a48_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_8e1d9ae4-866d-4632-931f-44880a4a21df_verboseLabel_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_label_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_documentation_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesMember" xlink:to="lab_rprx_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ea4e4a0a-66fe-47ca-8e48-c7d86c64ac00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_e3f13a90-775b-43e2-b1f5-5ac8bc56e7fe_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial share issuance upon registration of Royalty Pharma plc</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Registration</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:to="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70a231f1-1084-4a77-bc40-c07e0f7865b6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_348c78db-e390-4ab3-aa31-3dc8140ee50b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b559ef8-ef5f-425c-ad96-1af2679b1d99_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7c621d44-6133-4214-bf18-939c9b514146_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_a066757f-5cdd-47d2-ae90-e2e39c67680c_terseLabel_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:href="rprx-20221231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abffc3ec-4172-41a3-aa03-d176ec1ee3a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_3e8b7abb-5f70-484b-b133-8187972fcec6_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Multiple</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_51a48411-6702-4afd-8b8b-f23be8755868_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_5869fed7-56b6-48ff-b7eb-53b7e2f10194_terseLabel_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of noncontrolling interests created</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_label_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Noncontrolling Interests Created</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_documentation_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Noncontrolling Interests Created</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfNoncontrollingInterestsCreated" xlink:to="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_64412549-b5cc-4615-b247-e4d6ec1e5f35_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_df243c54-df3b-48ff-a27c-1605884243ef_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_6c3b23f0-54e3-4f6a-8a93-f9cd5a60e392_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty at Fair Value</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f883a710-4797-4499-92a8-c96a8a0c304f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_39f208a3-e024-4fc2-b830-049e7bd09a54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_c063170f-7b2e-4fe5-a807-2490a85f13ff_terseLabel_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</link:label>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_label_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Value, Effect Of Exchange And Reallocation</link:label>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_documentation_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Value, Effect Of Exchange And Reallocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:to="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_3af5e05a-2818-42b3-9690-4b8e9e0c539d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b360e411-b0dc-40c9-9dd1-e84fbbff369a_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_92444021-dda1-487c-a6ea-42c190d454e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_06f952c3-2023-44f6-898a-14937cbb628e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_32aaf5ff-6c34-4387-96be-3e0dca27ca19_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_1532e81e-5c87-445b-9625-112b3f80fc33_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_fcc90986-2d2c-41f6-87be-c7ad24d577fa_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount calculated for operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_895ac22d-6b18-4eb0-8f04-db2a3295d775_terseLabel_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration List</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_label_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk [Member]</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_documentation_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:href="rprx-20221231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:to="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_26954837-8811-4065-b534-71dbd7bb3449_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development funding expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_63ea296b-8843-463d-bd94-8598ed4802fa_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_d858b8f5-7a5f-4a8f-9853-813d30ad7a18_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding commitment, outstanding</link:label>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_label_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Commitment, Amount Outstanding</link:label>
    <link:label id="lab_rprx_LongTermFundingCommitmentAmountOutstanding_documentation_en-US" xlink:label="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Commitment, Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingCommitmentAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:to="lab_rprx_LongTermFundingCommitmentAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_94988296-2db7-4469-88d9-168c3c1a9b3e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage following IPO</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4caf9178-8c0c-4091-8def-04508cbe7cd9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_b34df805-7772-44ff-8d2b-09836efe9443_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0a43bd67-59cc-4707-8bfc-60f2f0672c8f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsMember_00e9c9d1-a3f9-4e9e-985b-67ecb0dbb186_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics</link:label>
    <link:label id="lab_rprx_CytokineticsMember_label_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember" xlink:href="rprx-20221231.xsd#rprx_CytokineticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsMember" xlink:to="lab_rprx_CytokineticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ef4c9e09-0a97-41e6-9f1e-97a3aa3174ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TrelegyMember_12a50ea0-9233-4954-bb11-55b5265a00da_terseLabel_en-US" xlink:label="lab_rprx_TrelegyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trelegy</link:label>
    <link:label id="lab_rprx_TrelegyMember_label_en-US" xlink:label="lab_rprx_TrelegyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trelegy [Member]</link:label>
    <link:label id="lab_rprx_TrelegyMember_documentation_en-US" xlink:label="lab_rprx_TrelegyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trelegy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TrelegyMember" xlink:href="rprx-20221231.xsd#rprx_TrelegyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TrelegyMember" xlink:to="lab_rprx_TrelegyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8f0d7a64-9994-4b8a-87a0-6c8462403f3c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_6256e3fb-1632-4ef7-9ec5-5366c37907e5_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral received</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:to="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9eb75d7d-74ac-4f8f-87ae-e2b0cd430b55_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_becd4dcd-9ebd-4017-aa81-d96306345b78_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total distributions payable to legacy non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3cda38f4-dad3-490e-8844-47ec56af02c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d629b84f-9daf-4913-bd0a-2de604c595ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual licensees exceeding 10% or more of revenue (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8b4d573f-cdbc-4fa9-b2b0-46ffc22a6917_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income and other revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_3c2d4ff5-0c3b-4b46-9635-769162bf9ef3_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:to="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ebdf6d4b-c482-4b74-aae3-928543dced77_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0be5b298-1c5c-4ac7-af27-aa19f21b1d00_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_e2a7e39b-e240-43d2-999a-cfa295ef4cc2_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_56621e36-089f-43e0-aa99-4895a2698805_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average coupon rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_2d78add7-c4df-4e51-8528-0f43693dbd78_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum commitment to fund collaborative arrangement</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_06027a1f-1c87-44ad-a980-9a5036ae52b8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_79332dac-29db-4789-a751-810772231d5b_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest free and payment free period, calendar quarters, tranche one</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche One</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:to="lab_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_9b348efb-50b5-41f1-9206-71c1c19549ec_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of contribution of investments in Legacy Investors Partnerships</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_8dd185b4-5120-473b-b2ff-66ce12812216_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in operating liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_d98132b9-983d-4891-995d-4460282b726a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_4486cfa8-7ef4-4ce2-834b-692eccfa19dd_negatedTerseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-operating expense</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Nonoperating Expense</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b2236c32-7b10-473b-9b17-0d6dc118e179_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7365e859-b386-4162-9e07-70cd412b9b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_faddb5c7-2409-4319-b408-96736dbba07a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8f4346ba-69fc-426e-9913-02e084b5af1a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_eaf2bdc6-1907-48ae-93f1-a4712d3c2f0b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_696628fd-89ee-42a0-8f74-7c31274d5fec_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on selling common stock, period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_cd8df7a3-61d8-41d3-82b4-d3cc0b2c487b_terseLabel_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_label_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:href="rprx-20221231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:to="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_fb58be19-c677-45ae-a6b8-fff945727ff1_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased (in shares)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4dc287a5-f396-4f38-ae35-2d6699ec7314_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ae94f6d7-5cce-4a75-b62d-484558bfadc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e8f7cfd9-c0c6-4911-b541-1385b98fe09b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DPPIVPatentsMember_7b738903-2f91-4add-8d0f-8cdaaffc5f42_terseLabel_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV patents</link:label>
    <link:label id="lab_rprx_DPPIVPatentsMember_label_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Patents [Member]</link:label>
    <link:label id="lab_rprx_DPPIVPatentsMember_documentation_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember" xlink:href="rprx-20221231.xsd#rprx_DPPIVPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DPPIVPatentsMember" xlink:to="lab_rprx_DPPIVPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_5116c46e-7ff7-4f39-8c6d-885fb05d0fcc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to continuing non-controlling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6fe66b2e-ea27-4140-98a8-bec81b4ee108_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f25d784a-0075-42bc-9261-a449fbed1846_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_71430fc7-bf2e-4aad-894b-d1d360a554e2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_61f570bb-5593-4f28-9aa2-decb93c9c030_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_37e440aa-1feb-45fe-bd48-9ade91dede88_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_884a510c-0965-4b51-99e1-30c9d0106bfd_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_31b55864-ab38-4640-b168-aa48438a09b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_b7754c1b-20b3-4a6a-adf0-635f0018b666_totalLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and non-current financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_84661d92-0d56-430e-9c33-8b80889bcd65_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty asset, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_67abce2d-b666-4714-8a96-204b062af946_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockExchangeRatio_41bce062-46db-4274-9d16-7600e85113ba_terseLabel_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_label_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio" xlink:href="rprx-20221231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockExchangeRatio" xlink:to="lab_rprx_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5602ed9a-3250-4b6b-bbb3-49d5b9763ebe_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b999200d-6122-4e0a-a8a1-d449a3538b51_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76a676a4-0eb6-4814-b3bc-578914434dd6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_bf795526-e88a-4d74-84be-8f6c9237f8ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionEntitiesMember_c45d6bc8-e55a-400b-926b-4b12dd4a7941_terseLabel_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_label_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities [Member]</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_documentation_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember" xlink:href="rprx-20221231.xsd#rprx_AvillionEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionEntitiesMember" xlink:to="lab_rprx_AvillionEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6a14e6d1-47c2-4a0d-86c3-811dcad2d5ed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_854e327f-1033-4dc8-ab28-5ae39f1c6a50_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7c1bf08d-b0a2-4a82-a0ea-18d2cae22a63_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_109071c4-9822-4825-a68d-95be43affffe_terseLabel_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:href="rprx-20221231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:to="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn_c19858e0-7788-4b52-9014-751aa2d7c53f_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, total amount drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Total Amount Drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Total Amount Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipTotalAmountDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:to="lab_rprx_LongTermFundingPartnershipTotalAmountDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_08d9fb5c-9461-4eab-8579-ed29b5604b5e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4355015e-9987-4130-98cd-9b8ce871d630_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_62c47c12-4c85-404f-9496-373fd3ff7598_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared and paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_984702df-06b7-4a5e-8191-6b95de89c934_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued as a percent of par value (as a percent)</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_label_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:to="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_cebf104d-c41c-4049-a538-0d8bda29ab34_terseLabel_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_label_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_documentation_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:href="rprx-20221231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:to="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_51465ff8-6a6c-4501-8787-2060dc003aa8_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development-stage funding payments - upfront and milestone</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:href="rprx-20221231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd547ca6-53db-4bd7-8969-183961e77772_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d4cd6c7-c966-4959-877a-0e1450f4d082_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation and related issuances of Class A ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PabloLegorretaMember_44f7bc48-0f4e-4778-89c2-0547a5d6e113_terseLabel_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta</link:label>
    <link:label id="lab_rprx_PabloLegorretaMember_label_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta [Member]</link:label>
    <link:label id="lab_rprx_PabloLegorretaMember_documentation_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember" xlink:href="rprx-20221231.xsd#rprx_PabloLegorretaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PabloLegorretaMember" xlink:to="lab_rprx_PabloLegorretaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_db04b42e-e495-4210-ba26-1317010fa640_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1f65380c-94ba-4d03-bba9-985705449cb4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_133b9edc-2ae8-408e-b559-be159d95d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ea238a46-7427-4c1f-8e97-e2900c806128_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes and Other taxation matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_cd6dc3d4-147c-471a-8d73-e2d71314ac6b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from intangible royalty assets and Milestone payments</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_c6a926bb-f00f-4dfc-afb7-36ca8fb41b46_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated coverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromExerciseFeeProRataAmount_e438ca47-6a05-40ba-b3a4-e73aa89a4221_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise fee, pro rata amount</link:label>
    <link:label id="lab_rprx_ProceedsFromExerciseFeeProRataAmount_label_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Fee, Pro Rata Amount</link:label>
    <link:label id="lab_rprx_ProceedsFromExerciseFeeProRataAmount_documentation_en-US" xlink:label="lab_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Fee, Pro Rata Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFeeProRataAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:to="lab_rprx_ProceedsFromExerciseFeeProRataAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_927d5564-260d-4fee-8141-ba74bd0e5358_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_389f5a87-a685-4e0f-9af1-172d83dbf9bc_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent for calculating operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a9c64449-ea57-4756-a9bd-34ebc95b1cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_645a15cc-b9a0-404e-8478-076f7efd4a6a_terseLabel_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting rights, number of shares</link:label>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_label_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:label id="lab_rprx_CommonStockVotingRightsNumberOfVotes_documentation_en-US" xlink:label="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes" xlink:href="rprx-20221231.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockVotingRightsNumberOfVotes" xlink:to="lab_rprx_CommonStockVotingRightsNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d213ca7a-6fce-4e74-9504-09b85ddcf268_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c9d870fd-a6a7-4f78-8477-8ca595ec0fe5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_ac2861d1-b1cd-46d3-a826-d869eff6ae10_terseLabel_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_label_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_documentation_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:to="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_f9cb9786-811f-4a79-9413-9c750c61ac63_terseLabel_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unitholders&#8217;/ Shareholders&#8217; Contributions</link:label>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_label_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Holders' and Shareholders' Contributions [Member]</link:label>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_documentation_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Holders' and Shareholders' Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:href="rprx-20221231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:to="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_f8a39c76-e36b-413d-9e29-8cbc2b44e989_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2051Member" xlink:to="lab_rprx_SeniorNotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_e757bee5-cadf-4ba3-b874-4da37c150c7a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_d49c297b-fd80-4db4-b4fc-7d08a61adf70_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a20e0c3b-a281-4cca-91f9-8a4853c38591_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_e686305b-f5f3-4102-a2eb-f2d442c86311_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_94539eda-6c61-4792-8a62-fea0c2ae3362_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, additional payments, aggregate amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39ceff4e-a79b-4518-b726-d7dd9e87b178_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_bfee4749-f97f-4e3c-bbd2-2192dd89479b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_af39d99d-ed8d-4cf4-9ca7-274c383a32c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_6aea36e7-c5e1-406c-b002-77b6ddcbba9a_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_25c32e77-1fba-40a6-89c2-900b814d102a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7c450728-3e7d-4091-84e9-31034123f79c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_5f6fa129-93ac-429a-a76e-960da6a7c5db_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_71085848-f6a3-4dca-aefd-267b68d37be9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingCommitmentsMember_b9a97524-ac07-489e-a845-e1068c57077e_terseLabel_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments</link:label>
    <link:label id="lab_rprx_FundingCommitmentsMember_label_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments [Member]</link:label>
    <link:label id="lab_rprx_FundingCommitmentsMember_documentation_en-US" xlink:label="lab_rprx_FundingCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember" xlink:href="rprx-20221231.xsd#rprx_FundingCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingCommitmentsMember" xlink:to="lab_rprx_FundingCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_6c8f06fe-7e0c-4e07-a082-570afa5bcc7b_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of cumulative allowance</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Change In Present Value, Write-off Cumulative Allowance</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Change In Present Value, Write-off Cumulative Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6154540f-384d-4e86-afde-6a9b85291a7a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67c8caaa-e4b0-470c-8a78-25a53b4821f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3ea3e468-95e9-47b2-a2d1-fa339b252170_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_945b6dba-2fc5-4b00-8c1e-a3d2a542ef1a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_09a2fe49-573b-4df8-a151-cc213f6ee5d7_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_274dc8c0-1a3c-455f-b097-eb2ab9148726_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses/(income), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_103f78da-4f27-41ea-b273-dd75976eaebc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_75ab21a8-31ec-41f0-b3ab-90b931733da5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c560b6b-0c31-45ad-baa7-9510bf2b6e73_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_ae299c47-9458-4750-bccd-9846898f1020_negatedLabel_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to shareholders/unitholders</link:label>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_label_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Distributions To Shareholders and Unitholders</link:label>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_documentation_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Distributions To Shareholders and Unitholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:href="rprx-20221231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:to="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_a341ed59-fa70-471f-ba5d-d12b42294559_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_label_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:to="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OldCreditFacilityMember_13c5005c-306f-4ab7-ab6e-5143bdab03c4_terseLabel_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility</link:label>
    <link:label id="lab_rprx_OldCreditFacilityMember_label_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility [Member]</link:label>
    <link:label id="lab_rprx_OldCreditFacilityMember_documentation_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember" xlink:href="rprx-20221231.xsd#rprx_OldCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OldCreditFacilityMember" xlink:to="lab_rprx_OldCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_149d5982-4cb8-4ea8-a414-20d49fa345ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Losses)/Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_fb33fb67-c453-4600-a1ef-a8d18f3f2d5c_terseLabel_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable stock, redemption price (in pound per share)</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_label_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_documentation_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:href="rprx-20221231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:to="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_ec47fe9a-f21e-4f57-ab01-b7d915aeb71b_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_85c3d820-b60b-4824-b859-82c3dfba434c_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f8d6e8f4-66cd-40f3-904c-3fa37560b1a3_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_81d4a24d-934f-486b-87e0-906d50d7959e_terseLabel_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, unfunded commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_label_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_documentation_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:href="rprx-20221231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:to="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_36d94681-37a9-4f56-b098-496a8e505da8_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_label_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_documentation_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders" xlink:href="rprx-20221231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentOfDividendsToShareholders" xlink:to="lab_rprx_PaymentOfDividendsToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9542ab5a-2a9f-46cb-9fda-5f9136d2d5a7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_48b91fc1-b4a8-48ea-b6cf-2af5ca3b4fe9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_73804839-9465-4578-9068-750cd537f5f8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d95bd675-c182-432e-bedf-c85846511911_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_bc58de31-86dd-41f3-ada4-31f1524306f3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_2a7c2abb-0f24-4126-85d8-fcb33d75f7af_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_15c616db-d805-4dc7-aa68-46cd4bc57324_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3d42bfc1-cc63-430e-b00b-154fbe253277_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RochesMember_b4cb47c7-c576-48d6-8505-b3517c618ab2_terseLabel_en-US" xlink:label="lab_rprx_RochesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche&#8217;s</link:label>
    <link:label id="lab_rprx_RochesMember_label_en-US" xlink:label="lab_rprx_RochesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche&#8217;s [Member]</link:label>
    <link:label id="lab_rprx_RochesMember_documentation_en-US" xlink:label="lab_rprx_RochesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche&#8217;s</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RochesMember" xlink:href="rprx-20221231.xsd#rprx_RochesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RochesMember" xlink:to="lab_rprx_RochesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_25f751e9-a618-42b9-a6d5-81252190a55c_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:to="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_45c75b6e-21d1-48d1-ae8f-2a1c69fad777_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, noncurrent, statement of financial position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_89371934-16a0-4b99-9d9c-c5675ab1135e_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_657e10fb-cf9c-410a-b03d-30218a286f8b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and personnel payments incurred</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_62fccc60-c768-44ad-95f9-295101f3ee67_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from legacy non-controlling interests - R&amp;D</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b5c6b3a-359b-452e-a055-8d289a70422f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3e5a1eca-c231-4881-8964-6d33b789130d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_feffe50b-ca88-4a0a-98fd-b4ae7d1c2648_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_a53871af-d613-40c2-b417-7640f0378b43_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_2a6c1593-fd96-4bf7-b17d-9fc7f02c406b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b299cc17-89cb-42ce-98c3-ca617e7fbba5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cfa50c00-32ee-4bfa-8f11-76e2e57e69fe_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_08518f4e-cbb0-4169-8092-fe75b36eec09_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_c0765470-b2bd-4159-af0a-18311a419fcd_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments</link:label>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_label_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyInvestmentsMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyInvestmentsMember" xlink:to="lab_rprx_RoyaltyInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MilestoneAccelerationMember_59f49e42-35e8-426e-a124-53a46fe3d2d8_terseLabel_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationMember_label_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration [Member]</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationMember_documentation_en-US" xlink:label="lab_rprx_MilestoneAccelerationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MilestoneAccelerationMember" xlink:to="lab_rprx_MilestoneAccelerationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BristolMyersSquibbMember_187e5e4d-2ede-452f-990b-dc98dcd32b08_terseLabel_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_label_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember" xlink:href="rprx-20221231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BristolMyersSquibbMember" xlink:to="lab_rprx_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80071dda-c79b-49cf-b5f1-70e5323970a7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66cd42c1-bdef-450a-8430-018c50a0af20_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_a7d49134-2048-41d4-ade9-9d64018e7696_terseLabel_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from intangible royalty assets</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:href="rprx-20221231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:to="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MerckToFundMember_1625dd0e-dbc6-4191-b04c-7e6dd587ef61_terseLabel_en-US" xlink:label="lab_rprx_MerckToFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck to Fund</link:label>
    <link:label id="lab_rprx_MerckToFundMember_label_en-US" xlink:label="lab_rprx_MerckToFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck to Fund [Member]</link:label>
    <link:label id="lab_rprx_MerckToFundMember_documentation_en-US" xlink:label="lab_rprx_MerckToFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck to Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckToFundMember" xlink:href="rprx-20221231.xsd#rprx_MerckToFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MerckToFundMember" xlink:to="lab_rprx_MerckToFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_32b084a5-5211-4dd3-bdfd-4e402ce2f840_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination payments on derivative instruments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_dcaa9169-3cab-4b19-991d-5b5a112d0bb9_verboseLabel_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap termination payments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_label_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Derivative Instruments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments" xlink:href="rprx-20221231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToTerminateDerivativeInstruments" xlink:to="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_ef38c678-d10d-4501-acc8-dbe9e7092366_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on initial recognition</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60f95562-e5c1-4baa-94df-455f728fb635_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_c75bc2ee-f2f1-4787-8d52-3bdce88e31db_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_65d51b78-6e45-427b-a3a3-c6d15b3376f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_d4e4bedb-d89e-4efb-b9f2-c52f9e5f8b00_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0ff32396-a09a-45d5-bc3b-6c69b93f9dd5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b7ab9387-7eb8-4d44-8f98-ea040741e4b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_10172733-c6e5-455d-ba6d-99e054bc4f89_terseLabel_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option, term (in months)</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_label_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Term</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_documentation_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OptionIndexedToIssuersEquityTerm" xlink:to="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_16af22ab-6513-45d5-8e7f-0a833f64b185_terseLabel_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Continuing Investors Partnerships Interests</link:label>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Continuing Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Continuing Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:href="rprx-20221231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:to="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_51c45cd6-c52b-48ac-83f0-be832f57eb1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_029dfd05-fe5c-414e-8995-58d4d7ff78b4_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MorphoSysMember_d3ff9e1f-a6de-40f0-a3df-ed9178e2ecd6_terseLabel_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:label id="lab_rprx_MorphoSysMember_label_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys [Member]</link:label>
    <link:label id="lab_rprx_MorphoSysMember_documentation_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MorphoSysMember" xlink:to="lab_rprx_MorphoSysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ce9fb621-4d74-401a-b215-72d84ad79e4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9ad97f49-9ca2-4814-9155-d0056047567d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_bee1901d-c885-4a38-9fe7-e8b654504717_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_c1af00e0-8a37-488b-82e1-51ce9632e6cf_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_19255d32-5ff5-4928-994c-2d3d65e536fa_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassBHoldersMember_abdb41c1-e0b7-4bf3-bfd0-06752a0409eb_terseLabel_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_label_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders [Member]</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_documentation_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember" xlink:href="rprx-20221231.xsd#rprx_ClassBHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassBHoldersMember" xlink:to="lab_rprx_ClassBHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_d14983ed-0b42-45bf-9a48-8ad6dd26f542_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_31706ffd-8521-4c7c-84b1-314c4b618bc1_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_c3a5007e-8edc-4947-b16f-14808cf68deb_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_d8317eeb-c851-4d4f-8403-7f8160a1ff9a_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment repayments, percentage of amount drawn</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:to="lab_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ada5eaeb-79b8-42b1-994b-0e7fd14e4585_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_0e073c1e-1b70-4d0b-a40d-721cf8065ff5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward purchase contract</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives and Commodity Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_c2cf9a86-7ce0-4a49-92c9-1da9438295de_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_746dac61-5b85-4059-8083-9bc3316fcbcb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_607569d7-06de-4eef-aeca-ddcce9674f1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_6cb9575d-1977-4b67-a852-59924adb18b4_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_97ca4e7d-bfbf-4104-826c-041e84401652_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f58aefde-be0d-4859-acca-b6ccc410eb50_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cd7ced02-cb82-424e-8e72-8c800e15f11e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8621a991-a5da-46c3-a344-8b31b695bd55_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8792f35f-bcc9-4fc1-9085-abd7a8b9aded_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3993299c-1211-4649-a002-93235e04ca69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_788bf359-db11-4ff1-b0e4-542026eb0123_terseLabel_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option to sell additional common stock</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_label_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed To Issuers Equity, Value</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_documentation_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed To Issuers Equity, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OptionIndexedToIssuersEquityValue" xlink:to="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e6920a70-aeb2-4962-9df2-1be1b90c18b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5d73a3c5-4309-4449-9e76-a0e69021a3d8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_071a1ed7-6347-4430-b152-cc07bef1d5c6_terseLabel_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock conversion basis</link:label>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_label_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Quarterly Conversion Basis</link:label>
    <link:label id="lab_rprx_CommonStockQuarterlyConversionBasis_documentation_en-US" xlink:label="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Quarterly Conversion Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis" xlink:href="rprx-20221231.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockQuarterlyConversionBasis" xlink:to="lab_rprx_CommonStockQuarterlyConversionBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_49c21517-c2ea-4301-80c7-33e3b6f26536_terseLabel_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of noncontrolling interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_label_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_documentation_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfNoncontrollingInterests" xlink:to="lab_rprx_NumberOfNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1b81f6cb-b5b1-4932-ad8f-0adce77048f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_cbf74aee-7a5c-4ba6-96d2-06a9904d24d2_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, liabilities current</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Current</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7f1fcf4b-f171-4f7e-90d0-18e8283fd7c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_67bb9e4e-6447-4141-bb5a-993535f1167c_terseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collected on financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:to="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIMember_4c89b890-e6b4-44a6-8808-fb600f2f4b49_terseLabel_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:label id="lab_rprx_AvillionIMember_label_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I [Member]</link:label>
    <link:label id="lab_rprx_AvillionIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember" xlink:href="rprx-20221231.xsd#rprx_AvillionIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIMember" xlink:to="lab_rprx_AvillionIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e94cf133-1ddf-45ad-b87b-480578dac4aa_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_303ca4d4-51f5-46cb-81bd-f6bde8809c3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_8717e478-e62d-47e8-94b5-ebf0ff7b0531_terseLabel_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_label_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset [Member]</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_documentation_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:href="rprx-20221231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:to="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2f4a4e4d-2751-4b9c-a94f-082251c6960f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EPAHoldingsMember_34521ce8-c993-4bee-918e-278273501d53_terseLabel_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_label_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings [Member]</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_documentation_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember" xlink:href="rprx-20221231.xsd#rprx_EPAHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EPAHoldingsMember" xlink:to="lab_rprx_EPAHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_7d5e99fd-e662-4452-b32a-e8e994afedcd_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from intangible royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_467dece2-f6b1-4ddc-ac54-06cc9992ffda_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss)/income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8c937027-3b1f-4470-a0bf-ff1a90403b7c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Royalty Pharma plc</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_108f49c5-6345-4fd3-97ff-3d0ee71cd391_negatedTerseLabel_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled repayments of long-term debt</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_label_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long-term Debt, Scheduled Payments</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_documentation_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long-term Debt, Scheduled Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:href="rprx-20221231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:to="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_982991cd-0a71-4106-836d-1ad09bd24cfb_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire royalty interests, additional milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_71fa8098-1f0f-401e-bba1-ee49b75b66f8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Losses)/Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_927416de-95d2-4577-a0f2-86f7b0bd7e14_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_GantenerumabMember_b3dbf695-c1af-492b-8521-7cdcf7b3f60d_terseLabel_en-US" xlink:label="lab_rprx_GantenerumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gantenerumab</link:label>
    <link:label id="lab_rprx_GantenerumabMember_label_en-US" xlink:label="lab_rprx_GantenerumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gantenerumab [Member]</link:label>
    <link:label id="lab_rprx_GantenerumabMember_documentation_en-US" xlink:label="lab_rprx_GantenerumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gantenerumab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GantenerumabMember" xlink:href="rprx-20221231.xsd#rprx_GantenerumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_GantenerumabMember" xlink:to="lab_rprx_GantenerumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1fd88ca0-9b81-43c1-903c-2c70fc34316c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_4bd99655-a290-48ba-8be2-ca140e028315_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_label_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember" xlink:href="rprx-20221231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyIncomeOtherMember" xlink:to="lab_rprx_RoyaltyIncomeOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c6ed0072-6bbc-40fd-bf9b-a7a8583a88a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_90178bcd-5f1e-4f2a-b9ee-b418c58f1436_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_ec9bda3f-a108-48e7-934c-9e4e438797ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_725e28f9-ea7a-42fe-b697-c26d1d628499_terseLabel_en-US" xlink:label="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="rprx-20221231.xsd#rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_fadad837-48e0-43bd-89a4-6d3d0eefa91e_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty assets</link:label>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Assets, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:href="rprx-20221231.xsd#rprx_RoyaltyAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:to="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_65eb84c5-a11f-446c-9705-47a90c9d1017_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_c1161efb-1b99-4a1f-ad53-626e22001d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bc99d6bd-1475-4f4d-a558-5254aa2e7199_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cbe252e9-d411-436e-b83b-13f054e8d1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount and loan issuance costs on long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_265dd853-2a18-4949-81bb-12aad601b4b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_34997942-8ec2-4a1e-ab4a-868bf453524b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_a7a1cbad-9d95-4ab4-a1d8-f36b3b1a8d4a_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79067d0e-0f72-4441-bf14-e74c9db92e9c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_99e0cb94-2892-4c10-b0b2-db4d3f804a7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_2d9ce3c8-1fa5-4d88-b214-5bf43defe4cb_terseLabel_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst</link:label>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_label_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst [Member]</link:label>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_documentation_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingAgreementWithBioCrystMember" xlink:to="lab_rprx_FundingAgreementWithBioCrystMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41057f83-4a01-4fdc-a465-0b6804faafdc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_cddd1f3c-cbfe-4e9c-8dc8-1a76bb26336f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect Cash Flow</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DerivativeAssetMember_df73198b-f3c7-48d1-86ea-9c67a61e85ad_terseLabel_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_rprx_DerivativeAssetMember_label_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Member]</link:label>
    <link:label id="lab_rprx_DerivativeAssetMember_documentation_en-US" xlink:label="lab_rprx_DerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember" xlink:href="rprx-20221231.xsd#rprx_DerivativeAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DerivativeAssetMember" xlink:to="lab_rprx_DerivativeAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MilestoneAccelerationOptionMember_083a6d47-c5a5-4ad3-b288-689c0c83baba_terseLabel_en-US" xlink:label="lab_rprx_MilestoneAccelerationOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration Option</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationOptionMember_label_en-US" xlink:label="lab_rprx_MilestoneAccelerationOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration Option [Member]</link:label>
    <link:label id="lab_rprx_MilestoneAccelerationOptionMember_documentation_en-US" xlink:label="lab_rprx_MilestoneAccelerationOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Acceleration Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationOptionMember" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MilestoneAccelerationOptionMember" xlink:to="lab_rprx_MilestoneAccelerationOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_92a0c053-53f6-4e7f-9be3-b4486fe621fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_77c5a64e-9cba-479b-be0c-1360ab343a54_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of outstanding debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_a90631c3-45a9-4f1e-9098-419f0abf221f_terseLabel_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of Epizyme forward purchase contract (Note 4)</link:label>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_label_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements With Equity Method Investments</link:label>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_documentation_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements With Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SettlementsWithEquityMethodInvestments" xlink:href="rprx-20221231.xsd#rprx_SettlementsWithEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SettlementsWithEquityMethodInvestments" xlink:to="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_d034fb87-122d-44bd-841a-436be77ff762_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Purchased [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsPurchasedMember" xlink:to="lab_us-gaap_FederalFundsPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_932da2a9-6f9d-48b6-aae6-e5a6dc4eb1f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01471e4c-8bfb-4262-a655-e49ad32760a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_7fda81d4-b30e-4646-b650-59fc8b46c8dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_7b084549-9b43-4b1e-ae8c-e0b47a93e33c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0c5611e7-8eaf-4789-bde0-8727ad341bc4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_93874f61-b061-4e4d-b3c0-8869841e7652_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-operating expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_74995ce1-8b67-4303-bfd5-81ff504fd4ac_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_28259c37-93fd-43c4-b958-dd693eeabd15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_ddb72f51-2788-4435-95e5-f6e0b1966683_terseLabel_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company</link:label>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_label_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company [Member]</link:label>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_documentation_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOSharesFromCompanyMember" xlink:to="lab_rprx_IPOSharesFromCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_0ef1e49a-f0ad-400a-ae3e-2bae0bcad953_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_0b82a17a-83ec-4619-95e2-05bfdf1b3874_terseLabel_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators</link:label>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_label_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators [Member]</link:label>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_documentation_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember" xlink:href="rprx-20221231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PurchasingAndDonatingVentilatorsMember" xlink:to="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_XtandiMember_2b04fe31-9f94-4419-905e-ba56f546e79f_terseLabel_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:label id="lab_rprx_XtandiMember_label_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:label id="lab_rprx_XtandiMember_documentation_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember" xlink:href="rprx-20221231.xsd#rprx_XtandiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_XtandiMember" xlink:to="lab_rprx_XtandiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_fefe667a-6543-4541-84df-f1ef9d55b573_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_8ef35c98-9da7-444d-ab9b-879a45bb8db1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_508d0fcd-b32d-4b09-94e9-7a2bf9dff028_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_0a0c2a00-6bfe-4e97-9380-d7c3ad223636_totalLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value, before cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_3db7e3f7-d7c7-469f-8967-f7b180a64354_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:to="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_5384f620-c041-460a-9372-f559b4063009_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6864773-56bf-4310-bb6c-ae81252c5e7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_79f8d84a-52b1-456c-b9ac-f8be8509ef70_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses)/gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a3969e10-63b8-4985-b065-96203d0c158c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d7692887-3da7-4624-ba29-f205b6bcfa6a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_53d0d4a8-894d-4f25-8d77-a258072d8853_terseLabel_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to Continuing Investors Partnerships prior to the IPO</link:label>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_label_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Prior To Offering</link:label>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_documentation_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Prior To Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:href="rprx-20221231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:to="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_bbd72251-bf6b-41de-a900-fffc908043fc_terseLabel_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt by contributions from non-controlling interest</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_label_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_documentation_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:href="rprx-20221231.xsd#rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:to="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8a9cf41e-fe0a-4d23-89ff-0e48cff8d6d0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_edbc4e07-0ff8-479b-8d08-2851f1c4f4a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_9784c878-6dee-410e-9e1c-d41b5ea01aa9_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from financial royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8abf8622-3d72-4287-909a-6223719bd27a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_10d5dc3e-ac20-4685-9fc6-554b230cdfa2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_7e66b891-a5ec-435a-93c7-fa466066e34e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d863984d-3fec-4f0f-9902-f0bc560ef72a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_5e689352-5326-412c-b152-0efc400771b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_cf60b30b-03df-4282-85d9-7e9918b9a356_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible royalty assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a69389aa-815e-4c97-a9b9-c6a1fba0eb42_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_ce5c04ce-0645-4c66-9837-0ffa5fe6709e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, current, statement of financial position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_b46db42c-f5c6-4aed-9f09-493e92e3fa93_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5b6d0ed9-2477-4258-a899-8a8ea38247c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d73398ef-a282-48fd-b2db-ab6473d667f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8df402b8-a117-46ad-848e-54f89805d830_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1ada63fc-8ac6-462f-9bd1-8ae7b2f5f85c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesValueIssued_6bea899c-b596-4635-88e7-9bc675b761c3_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred shares, $0.000001 par value, 371,325 and 361,170 issued and outstanding, respectively</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesValueIssued" xlink:to="lab_rprx_DeferredSharesValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9a12a3e1-9b81-49d0-8f04-8f1d3fc3bb09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_5a8113ed-8f38-439e-bdbc-c819f4e392b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_VertexMember_3f548c35-6416-4769-83e9-c5dca0f262d7_terseLabel_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_rprx_VertexMember_label_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_rprx_VertexMember_documentation_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember" xlink:href="rprx-20221231.xsd#rprx_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_VertexMember" xlink:to="lab_rprx_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_7e60b7d2-1a7c-4748-8f6f-142456078269_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_e7edad25-f108-4882-b08f-eefb70d35a66_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Manager</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_504c8b79-3fbd-4c46-aa35-16ec258251df_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial share issuance upon registration of Royalty Pharma plc (in shares)</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Registration</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:to="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_05949719-ee7b-4d12-9f5f-9ae728d418ed_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_460195f5-91f8-45d9-8382-13c2c0f2d418_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Purpose</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_3c5ec360-9b98-4f95-9d7c-abfa52032e4f_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period Two</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e44e536c-bc3c-4cb5-bf94-6c30b76a7bc7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest (percentage)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7a39c9f5-20cd-4e10-8fcd-bba8c07b5d4f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_452bc685-aa13-443d-b631-20801e9d20c9_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses, net</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts_fb7dcacd-40da-45b1-b323-8ced741f6ca8_terseLabel_en-US" xlink:label="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved financial assets held at costs</link:label>
    <link:label id="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts_label_en-US" xlink:label="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved Financial Assets Held At Costs</link:label>
    <link:label id="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts_documentation_en-US" xlink:label="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved Financial Assets Held At Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:href="rprx-20221231.xsd#rprx_UnapprovedFinancialAssetsHeldAtCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:to="lab_rprx_UnapprovedFinancialAssetsHeldAtCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_22bf753b-13fc-4d82-a439-1a3d10c8c5bf_terseLabel_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities</link:label>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:href="rprx-20221231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:to="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ce39167c-7298-42fa-bece-a0904ccfeb64_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0e7cec51-3333-4561-9405-a75e81d70954_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_dd9c9ed8-e90c-4669-9817-051fd84fd6bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_f1868be7-f7ad-49e5-aec2-453242982fd5_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instrument, noncurrent</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_915e6c4c-ea2e-45d2-995e-926ffb377943_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_07957874-557a-44f3-9ec6-58427e66edbb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation and related issuance of Class A ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_42745ee6-c138-43ae-af1f-4c64b5d0e956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs and other</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_38918bb0-857d-47fb-94ac-d971d394f131_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_af0da8e3-3294-44ec-b403-fba8a4680742_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesOutstanding" xlink:to="lab_rprx_DeferredSharesSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_720535f3-dda2-4765-b507-7086a13a529d_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class B ordinary shares to continuing investors partnerships (in shares)</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued To Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued To Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:to="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_35cd776b-5200-4a51-8261-3714e4636032_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_a8731de7-01a8-41b1-bd10-604ec202f7ec_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_33628cf4-195d-4cea-b45e-169a276f4991_terseLabel_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_label_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_documentation_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:to="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7058741e-6ded-4bdf-bf8b-46d52bab482f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_86d4be6b-2616-4162-abfe-c0386785f299_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e3c465c0-22e0-4fff-8f72-9373a4c4acf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54407650-1fc5-4a0a-b8b7-d6f408104899_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_4bf73e00-1bde-4ccd-9724-30c305dae1d7_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForOtherCreditLosses_fe36f87f-eaa0-4f69-9a4f-8f149352d692_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_us-gaap_ProvisionForOtherCreditLosses_label_en-US" xlink:label="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Other Credit Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForOtherCreditLosses" xlink:to="lab_us-gaap_ProvisionForOtherCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_b6b22464-bc47-44ed-8c93-5ead364f7e55_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:to="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cc1f4d61-9c23-4ab8-8f4d-e367dfb4d94a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_fb4af246-7dde-4fc2-8e02-8fd90ee907ac_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_3c7e7ee1-2d00-4d2e-9975-d22adea9257a_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b0003a2a-94df-408d-a7d8-1de779ed5291_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c2090226-35e6-485e-86ac-c3e5fb9a2fc4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b6f636e-85fc-422f-94ee-7aa2dcd1fd20_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_72498cc1-31e6-46a1-96eb-d913e3cb35d5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_e2e92c6a-cf60-4810-a54b-ef743ff58014_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TysabriMember_fdabaf04-1601-4146-8576-c41a26385167_terseLabel_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:label id="lab_rprx_TysabriMember_label_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri [Member]</link:label>
    <link:label id="lab_rprx_TysabriMember_documentation_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember" xlink:href="rprx-20221231.xsd#rprx_TysabriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TysabriMember" xlink:to="lab_rprx_TysabriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_492c181e-66ad-418e-93b2-d00ffe02ee53_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development-stage funding payments - ongoing</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_fddb9292-b4a8-4ce8-b864-40b844d6707d_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, initial payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:to="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0941c45e-cdea-496b-afd2-9c503c9464f0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_4f6a9cd6-2ccd-4098-8711-8a67a43be3c7_verboseLabel_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available to convert (in shares)</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_label_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Available To Convert</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_documentation_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Available To Convert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:to="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_bccaf07e-7b7b-477a-854c-cc0a9147cee5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_15fa86dd-7807-4e1a-9e81-29c7f5eec249_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_402c2360-7e82-4385-b244-5219f5689a7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_9286f178-fbdc-483b-ac6f-3f725799fb2c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_e7220bbb-05e7-427a-b603-b18088a7a088_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ba7bc0df-116a-4314-9adc-a14cfe20f989_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_e040c210-3cb3-4f4f-9a3d-12639a2f3d0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities included in other comprehensive losses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_50ccbbf7-edd3-43fd-b1b3-67a6d6cb1da5_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for changes in expected cash flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_56d7a5cd-2339-40f3-942b-70893eb319fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_85986fba-4a31-4bb7-8b1b-94e5e2f2fcd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_11098eb3-a5c6-44ee-b588-7dd76f19535b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c8dea7e2-3a9b-46aa-b95c-ec41aec00318_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_bb3a12cf-e8d1-431d-a87d-915ee5480f88_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8e31db93-2f12-4265-afe6-863a6bc47301_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b4309eb4-a5f2-4460-9af6-477cfb5aea8c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_67c126a6-7a6f-4aed-8c8c-e5b18424f8ca_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_744d363e-34f8-4dc2-a163-d84dd074fe13_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_3acc27a8-bbb4-49f7-982f-4be5c197dad8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments, current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ec586bb8-a951-4361-8e8a-050ddd2f2e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-adjusted discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_91dcb69a-4123-4218-aeaf-5ab46c0828e8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesTextBlock" xlink:to="lab_us-gaap_FinancingReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7bd92352-0669-42b6-8f3a-8bb1e8bf9483_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_65bf8236-31d1-4c5f-8396-1b38ccbbe6e2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_429db539-0a9e-4d8d-8d88-0ed323214ed8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_0f2be312-17da-40ff-810f-fc4d7ac104e2_terseLabel_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_label_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:href="rprx-20221231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:to="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_25e3785c-4305-4f00-9fda-80b7efd9f54b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b0c99e1e-802c-465c-a1af-ef704178ce16_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_682e2309-43eb-45dc-a271-7e5c72f1032b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_1e844d76-a568-4f10-8145-564d590fac8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_d6e1c315-1f89-4bd4-bc2b-a2e50868bafc_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, issued (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesIssued" xlink:to="lab_rprx_DeferredSharesSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e5fe0289-7597-4855-85f8-b92390624431_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Dilutive effect of unvested RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_a62f6983-b56f-4223-8d9c-d87aba32553b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of forwards</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_383e28d5-6bc8-46f2-9f55-803140895fe5_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_d006e825-d688-4916-83fc-0a640ea62f93_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of limited partnership interest acquired (in shares)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:to="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7cf50688-92a7-4779-a98a-d08a761083f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_794188fb-b88e-452d-aa9d-868b859a3ada_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the applicable par call date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0b268bb4-e604-400c-84a2-7da429112685_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_f62514fc-f33c-479e-b712-594ba44c397c_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty cash collections</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_9c516e73-f882-4d13-bf7d-11a7fad468e8_negatedTerseLabel_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of derivative financial instruments</link:label>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_label_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Derivative Financial Instruments</link:label>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Derivative Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments" xlink:href="rprx-20221231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_GainLossOnDerivativeFinancialInstruments" xlink:to="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_b7249b16-0db2-4551-a70f-d5d487722fe8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_b32e8876-8bdf-4459-bc46-44e8ac169305_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_e3e04ae3-9c68-421d-a611-29c1bda7e1eb_terseLabel_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payable - Erleada</link:label>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_label_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Accrued But Not Paid</link:label>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_documentation_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Accrued But Not Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestonePaymentAccruedButNotPaid" xlink:href="rprx-20221231.xsd#rprx_MilestonePaymentAccruedButNotPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MilestonePaymentAccruedButNotPaid" xlink:to="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e467a9f-1312-4fba-b621-90f920ee96dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc610d3f-1e3d-4b55-bec7-e1a6eb7ee431_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3d7bca38-7c87-4101-b311-51a48f122fea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cae54ba7-62e0-49db-96c8-5732684be663_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b86847b2-b608-48a5-9322-db53523e3994_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_730a45f2-81eb-4d3b-a080-838ad6984b2b_terseLabel_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_label_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:href="rprx-20221231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:to="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5e002973-8aea-47de-b80b-ae97e90f574f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_cf61c674-7d97-4d68-a5cb-5607f0c5e915_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_82bc3e0d-31df-471d-a33b-97292202e4b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7c32860c-88b7-46ae-845d-0868115d03c0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_7f1a4afb-83a2-4965-804f-501c8e03177e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ebb4a594-f658-4120-a6e3-ba69baa3bc7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_8bd4b7bb-5a16-4f00-828c-64149f49efc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_36abbb79-524e-4bc9-ad2f-05e7ebac45bf_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:to="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_bdb9040c-4af4-4062-bdea-aaad75a908a8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_8ec67efd-990d-4308-9407-4ad201708073_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_b4c6186b-0db2-4ff8-8c8a-fa57e10b59b9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_7a57931f-eb12-40d0-b9cf-198716f456d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses, net</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_4d969782-77e9-4e28-9731-ca99820585e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impairment charges</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_9d4934e2-c45d-4b0e-84b9-a4f61c94340a_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5d0fffed-49fc-4cb8-82ac-ef0d61d1455d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AgreementWithMSCIMember_43144dbc-c53e-43c0-813d-3715e91a191d_terseLabel_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_label_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI [Member]</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_documentation_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember" xlink:href="rprx-20221231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AgreementWithMSCIMember" xlink:to="lab_rprx_AgreementWithMSCIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_401e85bf-67eb-4295-ada7-f1a5c81d6185_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_80ed38bd-25ad-434e-8227-a766de2d315c_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control event, period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Change In Control Event, Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Change In Control Event, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_492be987-d84c-4488-ad3c-af8c40bc467d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_dd07bff3-1161-4420-95a5-ee974874987d_terseLabel_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_label_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_documentation_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:href="rprx-20221231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:to="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_ae7b7bea-547d-456d-8848-580f9ac9188d_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to legacy non-controlling interests - other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:to="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_71a02e82-8dd3-4592-90b3-f3c1fa981bed_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f9819d2e-15ff-4ae5-8a1a-b12dfc778e9c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ImbruvicaMember_417f1556-f4d5-474e-849c-48ab025916d1_terseLabel_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_label_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica [Member]</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_documentation_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember" xlink:href="rprx-20221231.xsd#rprx_ImbruvicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ImbruvicaMember" xlink:to="lab_rprx_ImbruvicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_43670539-74c5-45cd-aadf-341e2fca0077_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a7b6538d-6fb6-41c3-9cc0-c987d50d8cda_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_adaed259-d800-41ad-9f38-f506e32e38a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d9e0cdb0-8e0e-4a6a-b4a7-6d7382592d7b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_b894f9ea-8b1f-44db-98ed-de3c0c1c80cd_terseLabel_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Commitment</link:label>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_label_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Funding Commitment [Member]</link:label>
    <link:label id="lab_rprx_CytokineticsFundingCommitmentMember_documentation_en-US" xlink:label="lab_rprx_CytokineticsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cytokinetics Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember" xlink:href="rprx-20221231.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CytokineticsFundingCommitmentMember" xlink:to="lab_rprx_CytokineticsFundingCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_755f5276-ddd7-4f8d-b590-202cecafd320_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_19d305ed-2b36-469a-950e-91f28e4593ca_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid to CEO</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_85676b7a-371d-4002-96f1-e86585592e5d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_4f91a14a-e9b3-4c29-bf49-671cc24603fd_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, liabilities noncurrent</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Noncurrent</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e810eb93-6367-4494-a78e-5687ca1c327c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a006469a-d777-4ce8-8ed2-52e2275b652b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_19a8cf6b-34ac-42cf-8ba9-9d8dac777e90_terseLabel_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of voting shares</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_label_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_documentation_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock" xlink:href="rprx-20221231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfClassesOfVotingStock" xlink:to="lab_rprx_NumberOfClassesOfVotingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_694b4249-5d6d-4ed6-a8db-257009dfc489_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_c09861b6-f671-4012-be7c-8470ec132e7b_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity securities</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:to="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_b6799ac2-8fd4-43aa-9626-132c1ac8413e_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_162c3fe3-02b1-458f-af21-b42e6eb6c1a0_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_c82d8507-cc6b-4b05-ae3d-badcebbebb81_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of credit loss allowance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_a7240eeb-e709-4b40-8c92-578561dd5525_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral posted</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:href="rprx-20221231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:to="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_0f9d085f-b9c4-4bdb-b646-4ff7c36a2e33_terseLabel_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders</link:label>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_label_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders [Member]</link:label>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_documentation_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOSharesFromSellingShareholdersMember" xlink:to="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_0c8326df-58ab-4caf-b864-4ec541fd703e_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of security investment (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:to="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_c62f7a7e-f740-4562-86c0-0ca0f083f578_terseLabel_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_label_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate [Member]</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_documentation_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:href="rprx-20221231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:to="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7030ebbc-cad4-4629-aeef-3f905d27b0c5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_fdf1d442-5d7a-401c-8319-d68d7a964fca_terseLabel_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:href="rprx-20221231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_16dd6a90-540c-4904-9ca6-3035abd88b54_terseLabel_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_label_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:href="rprx-20221231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:to="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6c153a01-0fb8-4dca-9831-5d85335d6425_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f9cb4504-9dae-42cc-8506-91b2a69198e9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f1cfa08e-ea8a-4547-bfcb-b5b917906a21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e4e1d0e2-873a-47e9-abca-6475418d9236_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development funding expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_e8bf13c1-176c-4bf0-a5f0-b8036fb508cc_terseLabel_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_label_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_documentation_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:href="rprx-20221231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:to="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bcb423ac-9edc-4fca-a0ab-1845079e0e76_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_187bd81b-e8b7-4412-bee4-dffa83adcb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_58ce722d-a12f-4055-8271-fb6a527a576f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for current expected credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_d96e4db8-0350-48ac-a660-6e3956ea76a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8295745d-cdfe-494a-b1e6-879809ae872d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_8240c410-ab31-47e3-b2e1-8adfdf493c6f_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:to="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0ad2ecff-d9dd-48dc-802d-b8fbab40e0a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TremfyaMember_897b2f87-b7e6-431d-9c78-a38fef28d1df_terseLabel_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_rprx_TremfyaMember_label_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_rprx_TremfyaMember_documentation_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember" xlink:href="rprx-20221231.xsd#rprx_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TremfyaMember" xlink:to="lab_rprx_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_b391f4bf-6ae7-4d48-82c5-1245dff8f02b_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities and Available for sale debt securities</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:to="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6e4203d9-55fb-4d4a-bd63-e0672bd0571a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2184e5ab-f8ea-420f-be30-92630311621b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_5894ee98-ccdd-483c-b00d-542ba5500ddc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_ac3dda04-5d0d-4f03-90ae-274b4108cbf8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) on equity securities still held</link:label>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_423affee-2bf5-4c7c-b5cc-c9f182bdc301_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8578864d-4be6-40e5-8be4-772f9833a633_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_89f1bee6-2d5f-43d2-a551-eb7fa69b92b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_e9785e9a-cefe-499c-9807-df023db20ec0_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_d8058a4f-8af9-4daf-8d77-49b54703c551_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_bb36bf2b-21b5-4001-baae-91222e5d6b52_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1d82a11a-95b0-4a86-a21c-bd44e68c1eef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemption of preferred shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_8945c555-dcd7-40fe-a5a0-a5e9e8358514_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42013f34-ab67-4c94-85dc-2a8e80fea1b7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_8ac598dd-378e-4461-8431-9beb41f80882_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions payable to legacy non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_3838f1eb-589a-4e4c-a5b4-c7db5ff32737_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_6a5ee9ab-3ead-43da-8258-75d337112f90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_e2fe30a7-afde-462a-bdc9-3d0a68354ea5_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_44214213-5fbf-4a32-a7cf-9144e892f647_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c3fddaf3-ca14-487f-a922-3a277c5d448e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_91e5e614-4f78-41ac-8559-d3162be7ee90_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Schedule of Non-cash Investing/Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_27598ff5-2a48-4247-a85a-487bed194f43_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:to="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_53b43531-6b9a-4d66-8942-e743e8a34153_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b77b2570-d563-4b91-90b4-1df4b240464d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_6e16c04a-d870-4bc4-9de6-d6258701e1bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c29c0e42-68ad-487d-a998-401d5b426e59_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ee91f2f8-479d-491c-975f-d0aaffd02ed3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b93c9c9c-dbde-4599-932e-ad5db54f9f4e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Consolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_bcd46579-e8d7-4290-b386-e41889f19985_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for operating and professional costs</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_label_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_documentation_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:to="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c11b7b0d-03d2-4d78-94b4-6c9941f65467_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in losses/(earnings) of equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4aabcfbb-da5b-4537-a6ac-598f8829eb2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b508e310-3b8e-4c21-90ee-d884d2b241f0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty asset impairment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_9636320f-832a-4710-8302-19a6889309e1_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:to="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_c19e41ce-5374-4370-8867-879be3878dc1_terseLabel_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_label_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi [Member]</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_documentation_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingAgreementsWithSanofiMember" xlink:to="lab_rprx_FundingAgreementsWithSanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b316f18-08fe-48cf-b04d-bd4ca59e1842_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_432a8d01-1e8a-4a26-9ed2-fdde7c204eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; Development ("R&amp;D") Funding Expense</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ed4a8550-4622-4135-b08b-48d698ee898f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_329d16ba-dfde-4461-89bc-2dd4be141cd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting standards update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>rprx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f9f2204-c4f9-43df-95d4-9be4c65fda10,g:426ba86b-f05a-4fc5-9002-9bda7f4510d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b70784ee-5790-4ba4-a45c-00e00f5b42cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b70784ee-5790-4ba4-a45c-00e00f5b42cc" xlink:to="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d8d388a-ea9a-410c-8dd7-758d4000e539" xlink:to="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_30343a94-04fd-4b5c-bb53-d9d5880154f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:to="loc_us-gaap_CommonClassAMember_30343a94-04fd-4b5c-bb53-d9d5880154f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8333c56f-0536-4bcf-bb3c-f9946b59d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_490d74e2-db1f-44ac-8c91-dcde89d7865c" xlink:to="loc_us-gaap_CommonClassBMember_8333c56f-0536-4bcf-bb3c-f9946b59d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_06aab77c-7e75-4418-8f05-0a944601febe" xlink:to="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ad58b5ba-6714-4c3b-ac56-7680993d4a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentType_ad58b5ba-6714-4c3b-ac56-7680993d4a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_29c7039a-def5-4626-80b3-05cb9a4c4a7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentAnnualReport_29c7039a-def5-4626-80b3-05cb9a4c4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9c7cd6aa-d6f8-44ec-9864-4d5070a94045" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentPeriodEndDate_9c7cd6aa-d6f8-44ec-9864-4d5070a94045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8e1b9357-c61e-4b69-8783-ca00508a7ca2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_CurrentFiscalYearEndDate_8e1b9357-c61e-4b69-8783-ca00508a7ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d2116109-92ce-4a2c-a6c7-f55a73f9959c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentTransitionReport_d2116109-92ce-4a2c-a6c7-f55a73f9959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a636b3af-f411-4d5e-bd6d-14354f7466bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityFileNumber_a636b3af-f411-4d5e-bd6d-14354f7466bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee5f5b0a-6fbd-456e-9c6a-dc9a3568e8af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityRegistrantName_ee5f5b0a-6fbd-456e-9c6a-dc9a3568e8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3e2054ef-4c97-4921-984d-10d1d36f3c0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3e2054ef-4c97-4921-984d-10d1d36f3c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_811ed640-7c97-491f-bde2-8e1bfdfc113a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityTaxIdentificationNumber_811ed640-7c97-491f-bde2-8e1bfdfc113a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_18af6996-54d0-4617-b87e-33e02b8bcda6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressAddressLine1_18af6996-54d0-4617-b87e-33e02b8bcda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_81a06bf2-268c-45c2-8960-2b63baddd0ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressCityOrTown_81a06bf2-268c-45c2-8960-2b63baddd0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d16a9964-05b6-4e60-8dcc-63b37cdffbb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressStateOrProvince_d16a9964-05b6-4e60-8dcc-63b37cdffbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_27f31bc6-2005-43fe-ab9f-ce4f3341cce7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityAddressPostalZipCode_27f31bc6-2005-43fe-ab9f-ce4f3341cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0f945ed0-6f0f-447d-872e-d44eadfffa16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_CityAreaCode_0f945ed0-6f0f-447d-872e-d44eadfffa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fee89ae8-c5c3-48f8-9e85-f8f4c4062d37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_LocalPhoneNumber_fee89ae8-c5c3-48f8-9e85-f8f4c4062d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b6ab76fb-54b3-4917-86cb-22ed356c1a5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_Security12bTitle_b6ab76fb-54b3-4917-86cb-22ed356c1a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_da347ab4-2c71-4215-bf4e-f77219acac94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_TradingSymbol_da347ab4-2c71-4215-bf4e-f77219acac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7440debc-add9-4314-9322-eec48b4ac279" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_SecurityExchangeName_7440debc-add9-4314-9322-eec48b4ac279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cb785e26-ad61-4c61-83c1-187f296e04fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cb785e26-ad61-4c61-83c1-187f296e04fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b8b36308-e11d-4e8b-9d88-7842bb964cc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityVoluntaryFilers_b8b36308-e11d-4e8b-9d88-7842bb964cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7153c7f0-bf58-45e8-bb04-533081243655" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCurrentReportingStatus_7153c7f0-bf58-45e8-bb04-533081243655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9efa88ed-8bf5-4a30-88d1-b5924f4cb727" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityInteractiveDataCurrent_9efa88ed-8bf5-4a30-88d1-b5924f4cb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_98e80be1-5b06-4d8c-a83b-90fc723c8f39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityFilerCategory_98e80be1-5b06-4d8c-a83b-90fc723c8f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_83a343c8-1d49-40fd-90d0-d801fffa2534" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntitySmallBusiness_83a343c8-1d49-40fd-90d0-d801fffa2534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_30ed4ce9-9d8f-4ea2-bc11-a389977f2f82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityEmergingGrowthCompany_30ed4ce9-9d8f-4ea2-bc11-a389977f2f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a33ec7ba-e1f6-45de-84d7-f0334f254bf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a33ec7ba-e1f6-45de-84d7-f0334f254bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_27722b96-94ce-417b-927c-dd8b9ca6238c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityShellCompany_27722b96-94ce-417b-927c-dd8b9ca6238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_138e3758-03b5-487c-ba87-d266a886e026" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityPublicFloat_138e3758-03b5-487c-ba87-d266a886e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c18ec499-839d-493a-b5ab-515fb48d32de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c18ec499-839d-493a-b5ab-515fb48d32de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9fe9b423-eecd-4f84-95d7-66e556af3d2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_9fe9b423-eecd-4f84-95d7-66e556af3d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c50f9597-0287-4a24-af34-ce369cf33aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_EntityCentralIndexKey_c50f9597-0287-4a24-af34-ce369cf33aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8ec7c441-9ca4-4646-a7e3-741e2f74be86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentFiscalYearFocus_8ec7c441-9ca4-4646-a7e3-741e2f74be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f103627b-1de5-4661-ae1d-c8e9cb6a471e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f103627b-1de5-4661-ae1d-c8e9cb6a471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eefdd009-f98a-40fa-bc7c-3ee75aa22f6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7828d3c2-4234-42f4-ab26-a73557ba3b13" xlink:to="loc_dei_AmendmentFlag_eefdd009-f98a-40fa-bc7c-3ee75aa22f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AuditInformation" xlink:type="simple" xlink:href="rprx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AuditInformationAbstract_41b29483-d32a-412a-9fb8-225efb9968e3" xlink:href="rprx-20221231.xsd#rprx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f53443d7-6202-4e6f-ae2e-cc94aa2ff3e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_41b29483-d32a-412a-9fb8-225efb9968e3" xlink:to="loc_dei_AuditorFirmId_f53443d7-6202-4e6f-ae2e-cc94aa2ff3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_393c922d-cc88-4593-a697-f7e51ba49b84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_41b29483-d32a-412a-9fb8-225efb9968e3" xlink:to="loc_dei_AuditorName_393c922d-cc88-4593-a697-f7e51ba49b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2d7ad62e-5d6f-46cd-9279-f47e2c78711f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_41b29483-d32a-412a-9fb8-225efb9968e3" xlink:to="loc_dei_AuditorLocation_2d7ad62e-5d6f-46cd-9279-f47e2c78711f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1fbe0b81-cb10-4424-9c87-9b4a7349e114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1fbe0b81-cb10-4424-9c87-9b4a7349e114" xlink:to="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f9082907-8b40-44c3-b903-14284bfe0984" xlink:to="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21f55636-ca98-4c43-991d-4e3e79c18415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_us-gaap_CommonClassAMember_21f55636-ca98-4c43-991d-4e3e79c18415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_afb26d93-866b-40b6-a907-59c5bc0cb084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_us-gaap_CommonClassBMember_afb26d93-866b-40b6-a907-59c5bc0cb084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_873cce19-ddef-4547-ad8a-c9d0821b079f" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66a8fff1-8b69-4178-a8ef-141eaddcd7e5" xlink:to="loc_rprx_ClassRRedeemableStockMember_873cce19-ddef-4547-ad8a-c9d0821b079f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43e50dd1-7e88-4a6a-afd4-5a65268ecaef" xlink:to="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:to="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_369edc16-04ff-4963-a494-087b8d77dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_369edc16-04ff-4963-a494-087b8d77dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_c67fb6de-1a26-4a87-97eb-3ad0cc096855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_TradingSecuritiesDebt_c67fb6de-1a26-4a87-97eb-3ad0cc096855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1554e3f2-b904-474f-a8ad-525db1c46e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1554e3f2-b904-474f-a8ad-525db1c46e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_8f599d06-36da-4c63-9021-666bdf65178f" xlink:href="rprx-20221231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_rprx_AccruedRoyaltyReceivable_8f599d06-36da-4c63-9021-666bdf65178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_546c84d0-fa46-4f91-93e6-cce883b8d52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_546c84d0-fa46-4f91-93e6-cce883b8d52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_12c00b88-6d8a-47b5-9e30-891b9536b592" xlink:href="rprx-20221231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_12c00b88-6d8a-47b5-9e30-891b9536b592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0b988595-5247-40ed-bec0-65e1f668bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_OtherAssetsCurrent_0b988595-5247-40ed-bec0-65e1f668bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c3a3f3bd-8334-4991-acfe-bce89ffc263b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c25964cb-5dc8-4483-9607-17371ba34168" xlink:to="loc_us-gaap_AssetsCurrent_c3a3f3bd-8334-4991-acfe-bce89ffc263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a09761f4-e072-4f00-ad76-a9acebeac095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a09761f4-e072-4f00-ad76-a9acebeac095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5482fa6-b903-4788-a467-c7b8dd4158b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5482fa6-b903-4788-a467-c7b8dd4158b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2cbd94cf-7f42-4411-9a79-592784972578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_2cbd94cf-7f42-4411-9a79-592784972578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_408be613-2973-4c7b-8e69-248bdcd7d1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_408be613-2973-4c7b-8e69-248bdcd7d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a1c45b55-bc49-4a93-8f80-52995faaf330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_EquityMethodInvestments_a1c45b55-bc49-4a93-8f80-52995faaf330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_462039d9-4919-4b5f-a004-f218c0e40e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_462039d9-4919-4b5f-a004-f218c0e40e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cf388b41-8c3b-4651-83e6-246e9545049a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_857c3e33-c468-4014-8af1-16aa4ac9316e" xlink:to="loc_us-gaap_Assets_cf388b41-8c3b-4651-83e6-246e9545049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f048e032-f048-4da7-8bf3-f4c01ea73fcc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e84d183d-74f4-4c67-a40d-f0091a983798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e84d183d-74f4-4c67-a40d-f0091a983798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_19fc0ec8-17e1-446b-91b7-b595738ebeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_19fc0ec8-17e1-446b-91b7-b595738ebeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b6d4ef6c-d239-408e-b0e6-c513e94cf4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_InterestPayableCurrent_b6d4ef6c-d239-408e-b0e6-c513e94cf4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f725d4dd-92d4-4ae2-bee2-ff054b0e5cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_LongTermDebtCurrent_f725d4dd-92d4-4ae2-bee2-ff054b0e5cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_edddf76b-5aad-4713-99af-801b08f8657b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_edddf76b-5aad-4713-99af-801b08f8657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63842f65-e82d-4ac6-ae1d-f1467b424626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7ead7ea-216e-4c94-a7b1-5e76c7e8fd09" xlink:to="loc_us-gaap_LiabilitiesCurrent_63842f65-e82d-4ac6-ae1d-f1467b424626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ab3b4ba8-2f49-4a6f-a50b-a3f77d50f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ab3b4ba8-2f49-4a6f-a50b-a3f77d50f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0778433-5733-431e-8c53-827fd9201f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0778433-5733-431e-8c53-827fd9201f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e0c9d0fb-36d1-447f-88f9-d87ca2d54b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_Liabilities_e0c9d0fb-36d1-447f-88f9-d87ca2d54b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_757bf09a-610f-4af3-8c3a-944ea6bc2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_757bf09a-610f-4af3-8c3a-944ea6bc2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_df6ebece-a9d6-4bda-9ae6-905fd783018d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_CommonStockValue_df6ebece-a9d6-4bda-9ae6-905fd783018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_6364c992-e6fd-49a8-a9f1-96ac0f666757" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_rprx_DeferredSharesValueIssued_6364c992-e6fd-49a8-a9f1-96ac0f666757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_68a798de-a29a-4bf2-a766-3c2ee0d6200f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_68a798de-a29a-4bf2-a766-3c2ee0d6200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6315302-a33c-4367-a11f-8aa958715940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6315302-a33c-4367-a11f-8aa958715940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_89fefe9e-ee17-4ff7-9ee5-4959b7742af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_MinorityInterest_89fefe9e-ee17-4ff7-9ee5-4959b7742af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e4bf5d2-998d-46c4-a7af-39390fc9db97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e4bf5d2-998d-46c4-a7af-39390fc9db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_60698fbd-7d42-4578-b162-706f94934415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_TreasuryStockValue_60698fbd-7d42-4578-b162-706f94934415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2effff3f-f36b-41ae-b253-5d1b9ab83958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2789b54f-e0b3-4476-ad00-d44505fe35eb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2effff3f-f36b-41ae-b253-5d1b9ab83958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_883e338e-ba41-4ac8-98b3-14328a3b1136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb574b66-8726-4b37-89a8-b5eee62bd2eb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_883e338e-ba41-4ac8-98b3-14328a3b1136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c2541061-1bcd-460e-af6e-0576537332c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c2541061-1bcd-460e-af6e-0576537332c3" xlink:to="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ea69bce-4e36-4c9d-98fa-effc4f1013c7" xlink:to="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_fd56fa69-edc9-4f9f-bf4b-6d6fed847006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_us-gaap_CommonClassAMember_fd56fa69-edc9-4f9f-bf4b-6d6fed847006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_70835b9a-f01e-48a1-a801-61f051762113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_us-gaap_CommonClassBMember_70835b9a-f01e-48a1-a801-61f051762113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_a3f2180c-2c1b-4cb8-a4b9-e5b627437363" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_256c5a36-d929-4956-a866-836c642f7712" xlink:to="loc_rprx_ClassRRedeemableStockMember_a3f2180c-2c1b-4cb8-a4b9-e5b627437363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b6d964b9-abba-4754-bfed-b1a26658c37b" xlink:to="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_992d0b23-6fe1-4df8-987f-83fa02a7338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_992d0b23-6fe1-4df8-987f-83fa02a7338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d563ccd6-92a2-4c8b-a9c0-82591eedecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_d563ccd6-92a2-4c8b-a9c0-82591eedecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b430ba8a-65e1-4145-903e-dee4d6dd8e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b430ba8a-65e1-4145-903e-dee4d6dd8e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_983605e6-bc2e-43a6-84d8-3f109cc80e5a" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_983605e6-bc2e-43a6-84d8-3f109cc80e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_487b5add-b551-428b-a411-fa4909913423" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesSharesIssued_487b5add-b551-428b-a411-fa4909913423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_b86bbc86-d312-4d49-9d50-6e43dd81da18" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f09ded1-b827-442d-bb31-54a750fc26cc" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_b86bbc86-d312-4d49-9d50-6e43dd81da18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b68601f3-db65-4928-aa77-68628ebb7f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b68601f3-db65-4928-aa77-68628ebb7f9c" xlink:to="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:to="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d0faa7c4-4c19-4b70-be16-e2e56b51d8e4" xlink:to="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_a0291240-6a52-4b53-815b-eca1d987e69d" xlink:href="rprx-20221231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_a0291240-6a52-4b53-815b-eca1d987e69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_c505cad1-9312-49f6-8a07-002ebb8500e4" xlink:href="rprx-20221231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_c505cad1-9312-49f6-8a07-002ebb8500e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_e0fa1c92-7bbe-4d6a-a099-4155c5407291" xlink:href="rprx-20221231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58733e19-9631-49d7-9b0c-45d6ee568c66" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_e0fa1c92-7bbe-4d6a-a099-4155c5407291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1510384b-7f6a-4dfc-a94f-5a5f98996cee" xlink:to="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c7fe5c3-6fc8-4f65-9a56-55d93f07849f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_Revenues_4c7fe5c3-6fc8-4f65-9a56-55d93f07849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_4ca16385-53f7-4260-8ca7-1aa6c5c69909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_4ca16385-53f7-4260-8ca7-1aa6c5c69909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e99ce8bf-c107-4955-9fa4-a3fb7ed21c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e99ce8bf-c107-4955-9fa4-a3fb7ed21c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_62b1a213-bc92-4510-a92b-7982e2c80b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_62b1a213-bc92-4510-a92b-7982e2c80b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a8cb5f8f-428c-41d3-a9bc-de4e6b6bae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a8cb5f8f-428c-41d3-a9bc-de4e6b6bae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_468e0dde-118f-4118-9b8b-eb69f9ba08b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_AssetImpairmentCharges_468e0dde-118f-4118-9b8b-eb69f9ba08b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_67c53e01-e856-4ecb-b9ae-b6711e419283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ea7072d0-bd61-481e-9df7-dc577b8f1f11" xlink:to="loc_us-gaap_CostsAndExpenses_67c53e01-e856-4ecb-b9ae-b6711e419283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e6482290-824d-46e4-8b25-f3ee7d8468d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OperatingIncomeLoss_e6482290-824d-46e4-8b25-f3ee7d8468d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e96c5665-5e0e-4efe-a3ae-89d7b2fa2809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e96c5665-5e0e-4efe-a3ae-89d7b2fa2809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fef3a046-b6ff-45fc-a397-27cdf4397f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_InterestExpense_fef3a046-b6ff-45fc-a397-27cdf4397f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f9f32fea-207e-4043-8c58-cb22df4651a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_f9f32fea-207e-4043-8c58-cb22df4651a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5df8c490-5b6c-4111-b83f-b80423ed00fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5df8c490-5b6c-4111-b83f-b80423ed00fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_334aaedf-2a0f-4e08-8762-7347cf728c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_334aaedf-2a0f-4e08-8762-7347cf728c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_93793291-e765-482b-ac46-724e0335d29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_InvestmentIncomeNet_93793291-e765-482b-ac46-724e0335d29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bbea907e-e7d1-46b7-98f6-8926f549f7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bbea907e-e7d1-46b7-98f6-8926f549f7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ff43a0a2-306f-4db5-b380-5bf916f35105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9b6742f3-37a8-4ff2-85b6-7b4b581e2916" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ff43a0a2-306f-4db5-b380-5bf916f35105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e02a76c3-0ce0-4a26-bf87-6a4fcb02e125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e02a76c3-0ce0-4a26-bf87-6a4fcb02e125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_90dcf6fe-696b-4e37-81b3-c3e11bb5e101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_90dcf6fe-696b-4e37-81b3-c3e11bb5e101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e689b577-665a-43e1-aee3-be1f59cd76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_ProfitLoss_e689b577-665a-43e1-aee3-be1f59cd76a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d96b3a3-743f-4404-bc33-6dc9435b6687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d96b3a3-743f-4404-bc33-6dc9435b6687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4be9a613-66d0-42e3-80a0-da75155be5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_NetIncomeLoss_4be9a613-66d0-42e3-80a0-da75155be5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_363498e1-f033-4d4c-85f1-d56142dbdee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:to="loc_us-gaap_EarningsPerShareBasic_363498e1-f033-4d4c-85f1-d56142dbdee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ef37a8f7-e6cf-4757-8709-eaaa8f5393b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_81e75e52-c7ba-4f81-a417-29a6b69bc7cd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ef37a8f7-e6cf-4757-8709-eaaa8f5393b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce75ea7-4af3-4692-877d-334a7bafb891" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57075729-be35-41a1-869a-215815d60f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57075729-be35-41a1-869a-215815d60f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24effcdc-fe28-4671-966e-f4d48184fe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7aa1c79e-b2bb-4f10-a48e-ac6b4085cc97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24effcdc-fe28-4671-966e-f4d48184fe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a208457b-3bb6-4a4c-9984-be540cca354b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:to="loc_us-gaap_ProfitLoss_a208457b-3bb6-4a4c-9984-be540cca354b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_e6a2c397-c766-4b41-81d4-aa6991f070cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_e6a2c397-c766-4b41-81d4-aa6991f070cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_160f326e-8a24-4778-ac52-ddf19c2dc6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_160f326e-8a24-4778-ac52-ddf19c2dc6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b9ef170c-849e-41d6-9b78-c7113084e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b9ef170c-849e-41d6-9b78-c7113084e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08220abc-1c4e-424c-a0ad-a618ee9837ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4e0a87c-8159-4412-8ddd-860822105093" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08220abc-1c4e-424c-a0ad-a618ee9837ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a6ff60ac-873c-4e89-b74c-f15dedf7d734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a6ff60ac-873c-4e89-b74c-f15dedf7d734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_c420198c-1c0d-4b60-9af4-df1832fa5040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_c420198c-1c0d-4b60-9af4-df1832fa5040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f4625d05-92f0-4335-8c8e-5ca92353ad38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97a41511-43d9-4f2f-8ad5-ddf55776ee48" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f4625d05-92f0-4335-8c8e-5ca92353ad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_04eac932-417a-46d1-ad94-9e70c946c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_04eac932-417a-46d1-ad94-9e70c946c598" xlink:to="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b6a39a35-56e2-438e-88f5-71c340b04475" xlink:to="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3e0090a9-9123-4a8e-9eb4-664864f8a845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_CommonStockMember_3e0090a9-9123-4a8e-9eb4-664864f8a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_f77b7808-095e-4d62-b1d2-104a30b37b91" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_rprx_DeferredSharesMember_f77b7808-095e-4d62-b1d2-104a30b37b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9d293117-ebd3-498a-855e-d3cc9a658eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9d293117-ebd3-498a-855e-d3cc9a658eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember_49de5569-8c81-4b84-80c7-306a19802c25" xlink:href="rprx-20221231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_rprx_UnitHoldersAndShareholdersContributionsMember_49de5569-8c81-4b84-80c7-306a19802c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2793d5c6-4f17-4978-916c-e1eac6ad67f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_RetainedEarningsMember_2793d5c6-4f17-4978-916c-e1eac6ad67f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df417d4-eee3-4a36-b8d3-77c05306bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6df417d4-eee3-4a36-b8d3-77c05306bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3ff3a495-90ef-4191-aed7-4f150b7a7831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3ff3a495-90ef-4191-aed7-4f150b7a7831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_174cbb67-1f6d-4ec1-b967-9082b74d2356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21b02c8f-2139-4e34-9b66-e85c704a40aa" xlink:to="loc_us-gaap_TreasuryStockMember_174cbb67-1f6d-4ec1-b967-9082b74d2356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50121009-553d-4960-b75a-7b1d8b51d6ad" xlink:to="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_68a7a747-e7fc-48c2-8ed4-1c3d12a9b432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_us-gaap_CommonClassAMember_68a7a747-e7fc-48c2-8ed4-1c3d12a9b432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3e1095b5-5f4c-4f01-b588-91fb6ef107ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_us-gaap_CommonClassBMember_3e1095b5-5f4c-4f01-b588-91fb6ef107ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_ed1cc712-73b0-4950-a9d0-cdc8fac9fbae" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af13b057-3fea-4c21-8231-7adb848759cc" xlink:to="loc_rprx_ClassRRedeemableStockMember_ed1cc712-73b0-4950-a9d0-cdc8fac9fbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_36292a0a-87bf-4351-b0a8-5afc8cb5026a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c3fad65-3f04-4e6c-8328-a18320178f54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa99dfbe-c382-420a-beac-e8a695ef3280" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3c3fad65-3f04-4e6c-8328-a18320178f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_913d5ab7-db87-4a72-b7bf-9cad2bf4341c" xlink:to="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d0921975-abfd-4522-bf9e-fc285195580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_SharesOutstanding_d0921975-abfd-4522-bf9e-fc285195580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab73555e-0ca8-4b5f-a747-75e78aef6f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab73555e-0ca8-4b5f-a747-75e78aef6f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_44a36961-3b9b-4abf-9e3e-cc3af24801db" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_44a36961-3b9b-4abf-9e3e-cc3af24801db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_341a3d3f-4673-4df6-a58a-de121746bf90" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_341a3d3f-4673-4df6-a58a-de121746bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8f006f25-4d90-4ec5-b09b-5775d0bbd363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8f006f25-4d90-4ec5-b09b-5775d0bbd363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_32288e54-ac66-42cb-ad06-66367c9612dc" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_32288e54-ac66-42cb-ad06-66367c9612dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_f038756d-3881-4f12-85f2-a536f5343381" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_f038756d-3881-4f12-85f2-a536f5343381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6960f3bd-1af6-4aca-a1d1-5e26282b7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_ProfitLoss_6960f3bd-1af6-4aca-a1d1-5e26282b7e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_73e37db8-4999-442c-bfd9-69e0db829ca8" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_73e37db8-4999-442c-bfd9-69e0db829ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_c4dc34ff-f815-4bfe-b012-c34d831959db" xlink:href="rprx-20221231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_c4dc34ff-f815-4bfe-b012-c34d831959db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_536eb604-021b-4057-a862-0223926fa8a9" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_536eb604-021b-4057-a862-0223926fa8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_03dc9122-aa07-4c01-93a4-9313c5bda833" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_03dc9122-aa07-4c01-93a4-9313c5bda833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f842b02f-96fd-4a66-a1f0-9a7e57ab17b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f842b02f-96fd-4a66-a1f0-9a7e57ab17b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9f2ac735-f0ca-4bd1-b04a-1f4465fc4126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9f2ac735-f0ca-4bd1-b04a-1f4465fc4126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_912ffb07-59b5-41a0-98f1-53f49987f694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_912ffb07-59b5-41a0-98f1-53f49987f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_160819ad-95af-40cc-9e55-0c7af05ff0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_160819ad-95af-40cc-9e55-0c7af05ff0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_58cbe87f-0a5e-474c-9bb4-85a26d26b5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_58cbe87f-0a5e-474c-9bb4-85a26d26b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_698cf223-e4f0-469a-ad67-ce2eb09be3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityOther_698cf223-e4f0-469a-ad67-ce2eb09be3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_9512fc2e-349c-4594-8f14-42c3b0768e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_DividendsCash_9512fc2e-349c-4594-8f14-42c3b0768e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_088cff7e-087b-4d66-8fa7-9daa77cfb324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_088cff7e-087b-4d66-8fa7-9daa77cfb324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28f4fc43-0802-402e-a880-ffe6bd395298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28f4fc43-0802-402e-a880-ffe6bd395298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e882f168-e32b-4177-90c0-a75033af0811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a44ceba0-72d1-4604-a4b3-b2e12f122930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e882f168-e32b-4177-90c0-a75033af0811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c842ea15-5b0c-4f93-9aee-270b0ee4a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_SharesOutstanding_c842ea15-5b0c-4f93-9aee-270b0ee4a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af1331e-d8aa-405a-b02b-09818b284ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_52f0ecee-12d8-4d0d-9781-27f4a1077b09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3af1331e-d8aa-405a-b02b-09818b284ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_67bca06a-abce-46a1-9216-88ace6145adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_188a31c8-ce4c-4f74-ab2c-c224f3e99f49" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_67bca06a-abce-46a1-9216-88ace6145adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c9b5af3e-5070-49b1-adc0-da8e42652024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_70f601ea-23d5-4518-aca4-40333ab7727d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c9b5af3e-5070-49b1-adc0-da8e42652024" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_70f601ea-23d5-4518-aca4-40333ab7727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_50501571-dc15-4fd3-807f-9bc04bc3d789" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_50501571-dc15-4fd3-807f-9bc04bc3d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_d0c9b3c8-0549-42f1-b2fb-51fcd3e9ebb6" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_d0c9b3c8-0549-42f1-b2fb-51fcd3e9ebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_9e146430-573b-4c19-a37a-6cdf5b3a1df6" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_9e146430-573b-4c19-a37a-6cdf5b3a1df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_56f45152-e871-4b52-b094-cdf1e78ec817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_56f45152-e871-4b52-b094-cdf1e78ec817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_aada12d3-5fb4-462f-918f-cc90a8f9096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_aada12d3-5fb4-462f-918f-cc90a8f9096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_6ea3009a-ba5e-4f16-b3a2-fe9c5825873d" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_6ea3009a-ba5e-4f16-b3a2-fe9c5825873d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_ef56346b-79a7-4e3c-b357-07c81e79d465" xlink:href="rprx-20221231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_ef56346b-79a7-4e3c-b357-07c81e79d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_030d2944-903b-495a-acca-b9caaf8f0ad4" xlink:href="rprx-20221231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_030d2944-903b-495a-acca-b9caaf8f0ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_14c37676-5aa6-4d3b-a74c-42f111b58e95" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_14c37676-5aa6-4d3b-a74c-42f111b58e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_1d69ef9c-4435-4790-867b-89a9605beef4" xlink:href="rprx-20221231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_1d69ef9c-4435-4790-867b-89a9605beef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_23269737-3dce-42cd-b732-2cfda53d7ec8" xlink:href="rprx-20221231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_23269737-3dce-42cd-b732-2cfda53d7ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5d6e8d4b-06b6-4b4e-ad6a-c1c3363b53db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_us-gaap_InterestPaidNet_5d6e8d4b-06b6-4b4e-ad6a-c1c3363b53db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ee8760-9523-482d-8fad-ed82161b7314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_840b32ad-1a10-4459-8cde-1ba3199b4a10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ee8760-9523-482d-8fad-ed82161b7314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_80975ea8-f81a-427c-b41b-055359416cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_80975ea8-f81a-427c-b41b-055359416cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_0eff4885-f7ee-4d17-8d5c-d416bf9e1c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_0eff4885-f7ee-4d17-8d5c-d416bf9e1c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_c0edbf2e-0223-4ff5-9e96-5d34f2a2c657" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_c0edbf2e-0223-4ff5-9e96-5d34f2a2c657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_5b4bcac9-7c92-4b26-8045-2dd7036e1341" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_5b4bcac9-7c92-4b26-8045-2dd7036e1341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3be4ed53-3c63-4191-a56a-07ecd04ad5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3be4ed53-3c63-4191-a56a-07ecd04ad5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f4007a85-d47a-4ac5-949c-d861d0985128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f4007a85-d47a-4ac5-949c-d861d0985128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_394e4ba4-e805-43bb-98ba-255f6041924f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_394e4ba4-e805-43bb-98ba-255f6041924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_04ecb96c-56c0-4ab0-ac02-e12efd1e99e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_04ecb96c-56c0-4ab0-ac02-e12efd1e99e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_3f436837-fbfb-467a-84ae-dc4b3e9a1803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_3f436837-fbfb-467a-84ae-dc4b3e9a1803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_3046e40c-a692-4879-80fd-c44659d57935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_3046e40c-a692-4879-80fd-c44659d57935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_b8ba37c1-e9b4-4b9e-b3ae-814bce2c71eb" xlink:href="rprx-20221231.xsd#rprx_PaymentsForMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_rprx_PaymentsForMilestones_b8ba37c1-e9b4-4b9e-b3ae-814bce2c71eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9edd3050-2496-41fe-b094-03f483a6f164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0b9457e-7aa1-4033-b979-0ab6b40dffcd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9edd3050-2496-41fe-b094-03f483a6f164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_44d7b731-48db-4fce-9999-143962d0d790" xlink:href="rprx-20221231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_44d7b731-48db-4fce-9999-143962d0d790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_0eca5ecc-72cb-4aac-aad9-dd18e8890740" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts_0eca5ecc-72cb-4aac-aad9-dd18e8890740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_067588cb-6df6-4f82-bb70-91913076e122" xlink:href="rprx-20221231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_067588cb-6df6-4f82-bb70-91913076e122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_7b3f1a25-c2b0-4ce5-a9a5-d5724341de32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_7b3f1a25-c2b0-4ce5-a9a5-d5724341de32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_834ef3c3-5f9c-4ca9-b0ec-7559caee3a4c" xlink:href="rprx-20221231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_834ef3c3-5f9c-4ca9-b0ec-7559caee3a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_02a47ca9-146c-44a3-b49f-b54ed34d4e19" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_02a47ca9-146c-44a3-b49f-b54ed34d4e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_d58960c8-f186-42ae-900e-66f1332725bc" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_d58960c8-f186-42ae-900e-66f1332725bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_85ce181e-9bd8-4c92-8b43-7f4959ce3422" xlink:href="rprx-20221231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_85ce181e-9bd8-4c92-8b43-7f4959ce3422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9a62a7ed-f79c-465c-b7b2-33bdb9f60491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9a62a7ed-f79c-465c-b7b2-33bdb9f60491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9dd546f4-f72a-45ff-a6e3-8c4fff38f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9dd546f4-f72a-45ff-a6e3-8c4fff38f9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b05747b0-398e-4923-8df9-2277753c2d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b05747b0-398e-4923-8df9-2277753c2d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7d664874-becf-4cbb-a242-a5a6c6fbee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7d664874-becf-4cbb-a242-a5a6c6fbee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1afb4b1d-912e-46c2-b7ba-0d914a859b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d4f8db5a-459f-4fad-859d-2befe753fd4d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1afb4b1d-912e-46c2-b7ba-0d914a859b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f68c8cb8-01e1-4678-b5b5-23bba7809626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f68c8cb8-01e1-4678-b5b5-23bba7809626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c66d385a-156f-42ec-a1a6-0935fb25576e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c66d385a-156f-42ec-a1a6-0935fb25576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4386935b-9232-4a19-92d0-c956fe93a159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_96043d44-1951-402f-b2f3-005655cacc5e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4386935b-9232-4a19-92d0-c956fe93a159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="simple" xlink:href="rprx-20221231.xsd#OrganizationandPurpose"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c61eeddb-3e5d-480e-88b2-90f5023a894b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c90db637-3519-48fc-b5dc-ae21c008454c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c61eeddb-3e5d-480e-88b2-90f5023a894b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c90db637-3519-48fc-b5dc-ae21c008454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rprx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d5ea32c-d116-4f71-8031-61bcdfef60e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9250105e-63eb-4324-a910-8fa9442a1d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d5ea32c-d116-4f71-8031-61bcdfef60e6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9250105e-63eb-4324-a910-8fa9442a1d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecurities"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d1561c4-68f9-4478-8b8e-037092320da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b1ce9c78-d395-41a4-bc77-bf2711f2e361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d1561c4-68f9-4478-8b8e-037092320da5" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b1ce9c78-d395-41a4-bc77-bf2711f2e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3ffa312d-f194-4147-a49f-cb00df2cd333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4266271c-f0cc-4901-81b9-c3de05dee01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3ffa312d-f194-4147-a49f-cb00df2cd333" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4266271c-f0cc-4901-81b9-c3de05dee01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstruments"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4eb8aac6-ab3c-4a70-ba80-91db4f3ca7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4eabb25c-cf51-4d67-962b-ef86879d9be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4eb8aac6-ab3c-4a70-ba80-91db4f3ca7b7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4eabb25c-cf51-4d67-962b-ef86879d9be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssets" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_644b8b04-3ac9-4f98-b77a-eec1ec529a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock_ade12780-ecc6-4c34-b13f-dba95f83cbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_644b8b04-3ac9-4f98-b77a-eec1ec529a62" xlink:to="loc_us-gaap_FinancingReceivablesTextBlock_ade12780-ecc6-4c34-b13f-dba95f83cbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="simple" xlink:href="rprx-20221231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_570a3928-2bf1-437f-868c-ab71d663a0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_1a39e87a-45a9-4705-a355-9c6d144ff472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_570a3928-2bf1-437f-868c-ab71d663a0ea" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_1a39e87a-45a9-4705-a355-9c6d144ff472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNet"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff2f2b8-da74-48e0-9f5e-5317bc14f4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a72d7d4f-0d68-4e2e-bfe3-3cd1733c6ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bff2f2b8-da74-48e0-9f5e-5317bc14f4df" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a72d7d4f-0d68-4e2e-bfe3-3cd1733c6ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="simple" xlink:href="rprx-20221231.xsd#NonConsolidatedAffiliates"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3695725a-b850-4105-9567-3257f85a572d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b2308e22-6c0e-434e-bd3a-81dafbba5a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3695725a-b850-4105-9567-3257f85a572d" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b2308e22-6c0e-434e-bd3a-81dafbba5a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="simple" xlink:href="rprx-20221231.xsd#ResearchDevelopmentRDFundingExpense"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a8833351-1577-46ac-876b-890e9c23efcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6cd0b9ed-8187-4e68-ac8d-47a88770c023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a8833351-1577-46ac-876b-890e9c23efcd" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6cd0b9ed-8187-4e68-ac8d-47a88770c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/Borrowings" xlink:type="simple" xlink:href="rprx-20221231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97a8dbbd-d978-40b1-9e7d-760d1ae0b763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e8179e90-de71-4d25-9bfc-3c9ca77d801d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97a8dbbd-d978-40b1-9e7d-760d1ae0b763" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e8179e90-de71-4d25-9bfc-3c9ca77d801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_209cf895-a0cf-40b6-a535-e4bd6d2f55dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_a0af9908-ae7b-4992-a32c-cd4cebad3149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_209cf895-a0cf-40b6-a535-e4bd6d2f55dc" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_a0af9908-ae7b-4992-a32c-cd4cebad3149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShare" xlink:type="simple" xlink:href="rprx-20221231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6ab0e4ad-4474-414b-8b93-3af0a26d26a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bda47d72-c6db-4a7d-bfd5-bf446f37e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6ab0e4ad-4474-414b-8b93-3af0a26d26a4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bda47d72-c6db-4a7d-bfd5-bf446f37e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="simple" xlink:href="rprx-20221231.xsd#IndirectCashFlow"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_2f0ac7e4-2cdb-4218-92b7-e65ec8e418dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_2cc329cf-978f-4f98-a164-264a0a9d8164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_2f0ac7e4-2cdb-4218-92b7-e65ec8e418dd" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_2cc329cf-978f-4f98-a164-264a0a9d8164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rprx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a75d3f3f-acab-49a7-9932-5787139495f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a87b80e3-7695-4bf8-814e-0b9a8c5c3645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a75d3f3f-acab-49a7-9932-5787139495f8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a87b80e3-7695-4bf8-814e-0b9a8c5c3645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rprx-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b636a24a-88e1-47db-9bc8-02b5a12e47bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cefd20c8-36ed-49ad-8f29-41246abfb0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b636a24a-88e1-47db-9bc8-02b5a12e47bc" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cefd20c8-36ed-49ad-8f29-41246abfb0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="rprx-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bb0f5b87-6687-4ce2-afa0-ef1648912488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f53d37ce-7e70-466f-b373-5a34a24d97b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bb0f5b87-6687-4ce2-afa0-ef1648912488" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f53d37ce-7e70-466f-b373-5a34a24d97b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rprx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_79f92f3e-f0b8-490f-9580-1cbefcf29116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_79f92f3e-f0b8-490f-9580-1cbefcf29116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e81b85ae-eebf-4ad9-90d0-1b07831a11f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_UseOfEstimates_e81b85ae-eebf-4ad9-90d0-1b07831a11f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4a166fbc-a17b-452a-b6ac-cae2aaebd95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4a166fbc-a17b-452a-b6ac-cae2aaebd95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b5298d23-4012-4154-a3f5-4e9404b6d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b5298d23-4012-4154-a3f5-4e9404b6d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e52a7d05-8b6e-430e-b9ae-a8660a9f68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e52a7d05-8b6e-430e-b9ae-a8660a9f68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a02ce6df-7c77-470c-bb38-c1f3ac48e3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a02ce6df-7c77-470c-bb38-c1f3ac48e3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock_4b48dc4f-eee6-41d4-a1df-13fae14ffd3a" xlink:href="rprx-20221231.xsd#rprx_RoyaltyAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock_4b48dc4f-eee6-41d4-a1df-13fae14ffd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_ac4629c7-8745-4aa5-8c11-e53326418417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_ac4629c7-8745-4aa5-8c11-e53326418417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_22897eef-60b5-4f5a-afe3-71d81262ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_22897eef-60b5-4f5a-afe3-71d81262ead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8abcf895-b70c-4060-a35f-d5a1e9e08869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8abcf895-b70c-4060-a35f-d5a1e9e08869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e1cb1f2e-0be4-4507-9a82-0b52462cc94b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e1cb1f2e-0be4-4507-9a82-0b52462cc94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_425f84d1-c66c-4b74-9755-c09d1042e251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_425f84d1-c66c-4b74-9755-c09d1042e251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_178d66be-6eee-4ce2-9764-266ef861516a" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_178d66be-6eee-4ce2-9764-266ef861516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_7b15ddea-0de2-47f3-9366-8a74503294e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_7b15ddea-0de2-47f3-9366-8a74503294e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_875faee4-3d31-4e1f-a732-bd63076a1d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_875faee4-3d31-4e1f-a732-bd63076a1d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_720d513d-ad1f-4d78-9807-c39611e12891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_720d513d-ad1f-4d78-9807-c39611e12891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4603806a-bc31-4ef6-8334-bdadc29a7123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4603806a-bc31-4ef6-8334-bdadc29a7123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5d50644b-8159-44a3-afe7-d1bdb85eb9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51f4826e-1783-477f-98ee-e5f3ec0df800" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5d50644b-8159-44a3-afe7-d1bdb85eb9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ad1e1527-fb65-43ea-9ca9-185ae8da5ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d3bdbca2-72bd-43df-bef9-1ce71e8a573b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ad1e1527-fb65-43ea-9ca9-185ae8da5ca8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d3bdbca2-72bd-43df-bef9-1ce71e8a573b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8e7012a-752b-4215-b985-d9d3a0efb409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fc9e4f6a-778f-4e31-80ae-50d0d1800d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8e7012a-752b-4215-b985-d9d3a0efb409" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fc9e4f6a-778f-4e31-80ae-50d0d1800d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d48a0517-f5d4-4830-978b-f149d17d23d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7a3af082-9110-44c2-8f18-b3186ef07d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d48a0517-f5d4-4830-978b-f149d17d23d0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7a3af082-9110-44c2-8f18-b3186ef07d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b313f4bc-7fd4-42cd-898f-0c5d9b6f8831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d48a0517-f5d4-4830-978b-f149d17d23d0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b313f4bc-7fd4-42cd-898f-0c5d9b6f8831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_84437e8a-4651-4cab-88c8-af8a15c3a538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d48a0517-f5d4-4830-978b-f149d17d23d0" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_84437e8a-4651-4cab-88c8-af8a15c3a538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_8b3e1a4b-b1c8-43bb-b80c-fccab57afcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e3646dba-ea97-4bf9-9bed-79725ca465fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8b3e1a4b-b1c8-43bb-b80c-fccab57afcad" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e3646dba-ea97-4bf9-9bed-79725ca465fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_dc3dac5e-19f6-4bff-b4ae-f5fb56e4c836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_bb05eef6-20eb-443c-96f7-b9e92005c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_dc3dac5e-19f6-4bff-b4ae-f5fb56e4c836" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_bb05eef6-20eb-443c-96f7-b9e92005c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5a26b7b-0c28-4c4b-92f8-10c3f45fb0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e33cce6b-c39e-47db-b592-c90909e5cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5a26b7b-0c28-4c4b-92f8-10c3f45fb0ec" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e33cce6b-c39e-47db-b592-c90909e5cbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9b10282-d2a4-4280-bcbd-39d67e827cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9c7e0a53-5ce1-4530-a7fb-4d02804a9058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9b10282-d2a4-4280-bcbd-39d67e827cf5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9c7e0a53-5ce1-4530-a7fb-4d02804a9058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7a66eebf-8505-43e8-9346-b3b47277da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9b10282-d2a4-4280-bcbd-39d67e827cf5" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7a66eebf-8505-43e8-9346-b3b47277da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f1ad26eb-f88e-49f7-876c-e89ea63bfffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_8df62dd5-12ce-433c-a15b-6bfbc22f3721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f1ad26eb-f88e-49f7-876c-e89ea63bfffd" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_8df62dd5-12ce-433c-a15b-6bfbc22f3721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fe3db158-a9c7-4544-8e8a-315c7947e832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dd36bc34-1653-4c9d-b80a-a42d4fe11385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe3db158-a9c7-4544-8e8a-315c7947e832" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dd36bc34-1653-4c9d-b80a-a42d4fe11385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#IndirectCashFlowTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0694b9c8-62f9-4845-b281-1c8e3ad32513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a75255f6-fb45-410e-8326-16c692cf3cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0694b9c8-62f9-4845-b281-1c8e3ad32513" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a75255f6-fb45-410e-8326-16c692cf3cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="rprx-20221231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5f57af66-a547-44d8-b115-aacd342783ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_793d1232-b5d6-4dcc-ab3d-df5d9ee8eced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5f57af66-a547-44d8-b115-aacd342783ec" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_793d1232-b5d6-4dcc-ab3d-df5d9ee8eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#OrganizationandPurposeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a2db0ac-7003-48e1-9e25-90101652ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a2db0ac-7003-48e1-9e25-90101652ee9d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a61a7266-8cbd-4030-bf14-780e66ff2425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_a475c933-3c7f-4871-90c5-a099fec98602" xlink:href="rprx-20221231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_ExchangeOfferTransactionMember_a475c933-3c7f-4871-90c5-a099fec98602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9800c5f9-5d69-44b4-96fc-1262e1036316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_us-gaap_IPOMember_9800c5f9-5d69-44b4-96fc-1262e1036316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember_09bcca0f-f288-4c63-b24c-27dc32868d1c" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOSharesFromCompanyMember_09bcca0f-f288-4c63-b24c-27dc32868d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember_3e7cbf01-112f-4adc-9907-060636681247" xlink:href="rprx-20221231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOSharesFromSellingShareholdersMember_3e7cbf01-112f-4adc-9907-060636681247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_f512f18b-b6fa-48ac-8488-6df94d23a4fc" xlink:href="rprx-20221231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0c1ca981-3235-49aa-84c0-33be6ecc7da1" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_f512f18b-b6fa-48ac-8488-6df94d23a4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ff14ce36-1fea-4344-b518-b755cfc749cb" xlink:to="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_04d7511b-5210-4191-a570-abc2d9a44127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:to="loc_us-gaap_CommonClassAMember_04d7511b-5210-4191-a570-abc2d9a44127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c8fcc950-080a-4916-a11d-f2947e01b838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d9497741-4935-4c3c-be4a-aca8bb3d662a" xlink:to="loc_us-gaap_CommonClassBMember_c8fcc950-080a-4916-a11d-f2947e01b838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e71dce06-e469-49b3-9c87-6f815d01083d" xlink:to="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_6e01c577-4da7-4a2d-807c-6fe31c0e05fe" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_6e01c577-4da7-4a2d-807c-6fe31c0e05fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_810d9734-c3ab-4012-be46-e4897bb2c6e3" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_810d9734-c3ab-4012-be46-e4897bb2c6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_29f6e8d1-363f-4b92-859c-244dff6028dd" xlink:href="rprx-20221231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cf1780cf-faf8-4ece-9e93-c6f424aff3a6" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_29f6e8d1-363f-4b92-859c-244dff6028dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6c26b47a-ca04-4c81-85b5-e55da367d9a9" xlink:to="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_307c3909-e001-454b-ab7b-f1f2eff81987" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_307c3909-e001-454b-ab7b-f1f2eff81987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_f83ad6f2-8b2e-4c6e-9e93-a8d7328a0aba" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2b46982e-f2c9-4124-bbc6-ceb036b00571" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_f83ad6f2-8b2e-4c6e-9e93-a8d7328a0aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_12a08610-427f-4b7f-a840-189187323bd4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fe3ffbae-7cda-4f33-8352-cf6a7a4cecaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4a2141b8-66b3-47ac-89c5-cfcf9df97e2a" xlink:to="loc_us-gaap_SecuredDebtMember_fe3ffbae-7cda-4f33-8352-cf6a7a4cecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39291fbe-d0d4-4e4a-acbc-71b0e4eca9ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_b980a50f-6a62-40e5-8900-843b168c802e" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_b980a50f-6a62-40e5-8900-843b168c802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_afd98865-2d91-4775-9492-26cd7345f45f" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_afd98865-2d91-4775-9492-26cd7345f45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember_2d66be1d-6f8c-4ac2-bd13-4fbb9d9382e1" xlink:href="rprx-20221231.xsd#rprx_OldCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_OldCreditFacilityMember_2d66be1d-6f8c-4ac2-bd13-4fbb9d9382e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_cea4745e-05ea-4588-ac73-5082a15fb933" xlink:href="rprx-20221231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff567356-f293-4388-84c4-f11b30f70a5b" xlink:to="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_cea4745e-05ea-4588-ac73-5082a15fb933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d99e8e9-6839-4765-b764-c94e7e50b3e2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_b3789c34-9265-4aab-ab14-372e7848a128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_b3789c34-9265-4aab-ab14-372e7848a128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c2ef0175-c30f-4403-a7f8-5c9c3605a249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_c2ef0175-c30f-4403-a7f8-5c9c3605a249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f65af50c-885d-4f93-8cb0-2fce1aa59bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f65af50c-885d-4f93-8cb0-2fce1aa59bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_377ff047-25ae-4b07-b59c-dda047c50ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_377ff047-25ae-4b07-b59c-dda047c50ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_01426c20-319d-45e4-9962-8f9d916bacf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_01426c20-319d-45e4-9962-8f9d916bacf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8a46a557-a247-4876-9e4d-a9ee5f51175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8a46a557-a247-4876-9e4d-a9ee5f51175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a523c14f-8e4c-41a5-a8c0-493229221cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a523c14f-8e4c-41a5-a8c0-493229221cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8fa9a965-417d-4c0e-8144-2976f4fc5b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8fa9a965-417d-4c0e-8144-2976f4fc5b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_f64c2a29-2adc-4c93-9ef9-5f99d18c3fa4" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_f64c2a29-2adc-4c93-9ef9-5f99d18c3fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted_be02da21-1718-4bc7-afa2-753c07c417da" xlink:href="rprx-20221231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_SaleOfStockNumberOfSharesNotConverted_be02da21-1718-4bc7-afa2-753c07c417da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_f578287e-f508-4110-8eff-36c29b788875" xlink:href="rprx-20221231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_c0fb5e6f-39f1-4aeb-93fc-5ea4de0935fa" xlink:to="loc_rprx_CommonStockExchangeRatio_f578287e-f508-4110-8eff-36c29b788875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5cbedec2-ea7d-40be-bd6b-d74b794e20cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5cbedec2-ea7d-40be-bd6b-d74b794e20cc" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cac9161b-575d-4e0e-89ac-5a1ddf44016b" xlink:to="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_81ec2a55-8b8f-4439-b12d-da20aed23644" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3c3acbac-5892-460a-b61f-4f281cfe586f" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_81ec2a55-8b8f-4439-b12d-da20aed23644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a8126fb-e341-4fc9-9c80-38cdbd6437e1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_789a7944-1fa9-43ea-8172-4499ea0de4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_46b7ab47-4a9d-44cc-b1ed-2c4a55f01d8d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_789a7944-1fa9-43ea-8172-4499ea0de4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7155d7c6-bedd-40a1-b1e4-50e72cf90df3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_e5bc8021-b3c7-4d66-bd14-d3faca859abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ea82364-3763-4ebb-9cf4-606d14966166" xlink:to="loc_us-gaap_FinanceReceivablesMember_e5bc8021-b3c7-4d66-bd14-d3faca859abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4c090153-4ccf-4fba-9716-4bafde3e605e" xlink:to="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e4433d30-2bee-4b50-9b4b-99b6f36cc4bb" xlink:href="rprx-20221231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f70f955c-968e-44f9-a122-bb976f9f73ba" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e4433d30-2bee-4b50-9b4b-99b6f36cc4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2bc2f649-6bcb-43e1-bf32-f0d7c2dcd7ce" xlink:to="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_28f32c17-b6e2-4c32-aec4-92c2b8bc45e7" xlink:href="rprx-20221231.xsd#rprx_VertexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee5bf2be-94f7-4d05-856c-a415a3e678a1" xlink:to="loc_rprx_VertexMember_28f32c17-b6e2-4c32-aec4-92c2b8bc45e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e7b95ff-744b-4976-b2d6-848eb4936879" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f1baf176-1711-43df-9162-096c4e728274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f1baf176-1711-43df-9162-096c4e728274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated_918ea1e0-7f94-4a07-8bc8-241c9c6922e0" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_rprx_NumberOfNoncontrollingInterestsCreated_918ea1e0-7f94-4a07-8bc8-241c9c6922e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3ad1ef7e-25c5-4f9f-82f2-283526f95960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3ad1ef7e-25c5-4f9f-82f2-283526f95960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_089ac386-be3e-44b5-b922-6d0ae10fc443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_us-gaap_NumberOfReportableSegments_089ac386-be3e-44b5-b922-6d0ae10fc443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_4f733151-523b-4ce0-9790-667663c0add8" xlink:href="rprx-20221231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_632ba790-cd80-4164-968c-3c28b554004f" xlink:to="loc_rprx_CommonStockExchangeRatio_4f733151-523b-4ce0-9790-667663c0add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c20ff78b-d803-4ab0-b016-89cc4764735b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c20ff78b-d803-4ab0-b016-89cc4764735b" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4584877-83ba-40ad-9fae-210ff72380cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_f24e46a2-f26c-4adb-a998-98796341bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0eb941b-336c-458c-930f-a239fb980e0a" xlink:to="loc_us-gaap_PreferredStockMember_f24e46a2-f26c-4adb-a998-98796341bdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_f30da36c-2f47-498f-8639-999bf0e95b03" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_f773d15d-2a5c-4637-ad00-9c3ca186aa5b" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_f773d15d-2a5c-4637-ad00-9c3ca186aa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_7cb83fd8-eee8-4379-ac0b-7ef435707d92" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_b390218c-4a3e-462d-8799-b6483e42eb9c" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_7cb83fd8-eee8-4379-ac0b-7ef435707d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b822ccc-936f-4952-9b65-daaccba57fa2" xlink:to="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_81e7b401-0d6b-41bd-865c-066a62a430f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_81e7b401-0d6b-41bd-865c-066a62a430f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c0cac913-e5f8-4d12-b448-99dc891ee4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_881aa028-8dc2-41f9-a87e-4d6a316bf46d" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c0cac913-e5f8-4d12-b448-99dc891ee4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2265bd0d-f5b4-4345-8b30-2ad8faa955c7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_0207fb9f-27e7-4d65-8098-144667541c48" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:to="loc_rprx_MorphoSysMember_0207fb9f-27e7-4d65-8098-144667541c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundBondMember_eeab6c73-4433-47da-a36c-66209b7aa694" xlink:href="rprx-20221231.xsd#rprx_DevelopmentFundBondMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de8c0e1f-9460-4eeb-a7d4-68f6fc2a00a2" xlink:to="loc_rprx_DevelopmentFundBondMember_eeab6c73-4433-47da-a36c-66209b7aa694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d9d18d9-d4ea-4118-a073-cfa4272ef3b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_49ce6f90-baea-4450-aec6-528de9e5fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ce8c198-48bb-45b0-be65-577a57216e34" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_49ce6f90-baea-4450-aec6-528de9e5fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_51ee7ab5-15ec-457f-9173-36b2d1b6e260" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_08ceed8d-590c-48ab-8969-bb7539bc02b1" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_08ceed8d-590c-48ab-8969-bb7539bc02b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_233268a4-587e-4176-9f00-4b97ab1892b7" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_233268a4-587e-4176-9f00-4b97ab1892b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_5f8661fc-ad53-49ca-b807-62168e9799e1" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_5f8661fc-ad53-49ca-b807-62168e9799e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_decb220f-2499-4482-bbdc-92640a7d3765" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_decb220f-2499-4482-bbdc-92640a7d3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_50384dfe-79b2-444a-bb88-7e6d90a1d698" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_50384dfe-79b2-444a-bb88-7e6d90a1d698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_76955043-6b0c-4bd5-a1db-50e677fc3ffe" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne_76955043-6b0c-4bd5-a1db-50e677fc3ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_e25ce3d3-e336-4502-9f1c-b70acb7f0c07" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo_e25ce3d3-e336-4502-9f1c-b70acb7f0c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_81fe55d5-2a6a-416a-8e59-b9dd56aef735" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple_81fe55d5-2a6a-416a-8e59-b9dd56aef735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn_98cd5da2-59de-4c63-b5cb-af68e315e502" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipTotalAmountDrawn"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipTotalAmountDrawn_98cd5da2-59de-4c63-b5cb-af68e315e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_71b30464-dd90-4e56-9b85-812ff46aeec4" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_71b30464-dd90-4e56-9b85-812ff46aeec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_69024642-c887-4469-8c42-1b20fe484562" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_69024642-c887-4469-8c42-1b20fe484562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_929530c7-bcfc-4a0b-b568-b59a98d7a363" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_929530c7-bcfc-4a0b-b568-b59a98d7a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_39a0ace6-213f-442c-b85e-cbe75bfc319a" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple_39a0ace6-213f-442c-b85e-cbe75bfc319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_e16fda78-0e0d-4ad2-98f3-d0d42b956d44" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_e16fda78-0e0d-4ad2-98f3-d0d42b956d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_eece696a-98de-4834-9285-b061f348ba38" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_eece696a-98de-4834-9285-b061f348ba38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_2a3ea9db-2e08-42f8-aefc-69e27c06c7cc" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_2a3ea9db-2e08-42f8-aefc-69e27c06c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e1615f4-c828-4bc6-8c40-e41173660390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8e1615f4-c828-4bc6-8c40-e41173660390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7288fb99-e57d-41a6-9e6a-70b3dbbd4304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7288fb99-e57d-41a6-9e6a-70b3dbbd4304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2cdce91d-b913-4a73-8e5b-7b92b0c04d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2cdce91d-b913-4a73-8e5b-7b92b0c04d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_d344b3cc-594e-4305-9824-405992b54d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_cf741e10-36c0-4657-a4a2-f8bd907a7993" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_d344b3cc-594e-4305-9824-405992b54d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cef46b0f-735d-4606-8d89-52860bdfbd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cef46b0f-735d-4606-8d89-52860bdfbd25" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4e0d4b57-d0d0-4964-81ad-eec37fad45dd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9d264925-73ae-4a9f-9f2c-1aba222877db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_us-gaap_PreferredStockMember_9d264925-73ae-4a9f-9f2c-1aba222877db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_afd42195-0e9b-45d2-bd22-1ee4b1fb462f" xlink:href="rprx-20221231.xsd#rprx_FundingCommitmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_rprx_FundingCommitmentsMember_afd42195-0e9b-45d2-bd22-1ee4b1fb462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_6cc987bd-ef14-40eb-88b6-cdffd1c15e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57bde48f-445c-4cca-9e51-dc7834d86512" xlink:to="loc_us-gaap_ForwardContractsMember_6cc987bd-ef14-40eb-88b6-cdffd1c15e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_40e81814-4551-451a-8888-6e573617e85b" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0597eb44-2c73-463c-bf11-5dddb6a1b32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0597eb44-2c73-463c-bf11-5dddb6a1b32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4779151b-4c41-4518-aad9-497f2969b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4779151b-4c41-4518-aad9-497f2969b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c846d6a-aee7-4a15-b365-40196fcff3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c846d6a-aee7-4a15-b365-40196fcff3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d86d69f9-f964-4dda-88eb-c4b472996470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d86d69f9-f964-4dda-88eb-c4b472996470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b2644c4-0549-45e5-a1b3-8f4bc4f02051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b2644c4-0549-45e5-a1b3-8f4bc4f02051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_85c515e8-b9f0-4090-98bb-6c68965113dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_85c515e8-b9f0-4090-98bb-6c68965113dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_3dfc8fae-0466-4812-b3ab-577ba69b93bd" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_3dfc8fae-0466-4812-b3ab-577ba69b93bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_c85e9843-9713-410f-88dc-ad79ef6a8dd2" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7901091d-3b92-4ef4-a04f-f35fd0b833c8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_c85e9843-9713-410f-88dc-ad79ef6a8dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1aed29f5-fa58-4f01-ba08-82d5f75dfb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1aed29f5-fa58-4f01-ba08-82d5f75dfb3c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_daab98c0-a542-4d8d-87ec-98f4974a2711" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_0295125b-835e-4d73-b100-cb9764949b53" xlink:href="rprx-20221231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb5335f9-602c-4014-bb0d-3a83fba2e7ec" xlink:to="loc_rprx_TreasuryRateLockContractsMember_0295125b-835e-4d73-b100-cb9764949b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21aa436f-3ea2-461a-8ce5-3d8fa2d378d0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_231ffe60-06a1-419b-88eb-a0498d4ce9a6" xlink:href="rprx-20221231.xsd#rprx_EpizymeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eb2633c2-e7be-4f8d-9872-a44133739429" xlink:to="loc_rprx_EpizymeIncMember_231ffe60-06a1-419b-88eb-a0498d4ce9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_b6422f54-ee91-4658-857b-6b6eb51fb856" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_d6f71362-dd71-4cd1-a9de-6b921f467578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d0e423f0-a099-4254-bade-b9c545c0dcc6" xlink:to="loc_us-gaap_PutOptionMember_d6f71362-dd71-4cd1-a9de-6b921f467578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_52eb631b-e1a6-4ff0-a9cc-3f1343112add" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember_96b900ff-b69c-472b-bd98-3f0b74f1cd78" xlink:href="rprx-20221231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4de0d23e-9289-439a-aec9-35b9f1f089b8" xlink:to="loc_rprx_EpizymeCommonStockWarrantMember_96b900ff-b69c-472b-bd98-3f0b74f1cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55ed2964-1661-4df4-b6c4-df09227c2cf4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0a15f5ae-b729-43ce-8251-a037587d1490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9aaef549-5d71-4bf8-95fd-943e3af27054" xlink:to="loc_us-gaap_PreferredStockMember_0a15f5ae-b729-43ce-8251-a037587d1490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_91f9215b-e4d6-41dc-bfbf-79a63e97cc56" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_56f511bf-606c-4211-a697-4bda7e3863fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_02e55554-643c-43be-9e2d-d9fb0635784f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_56f511bf-606c-4211-a697-4bda7e3863fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42eef684-4d85-42d8-aaac-d31f5959fc1e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0db6684d-59d4-4027-90b3-8c709795bfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a57f7d1-70cd-4e97-8cdc-6e5f978025aa" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0db6684d-59d4-4027-90b3-8c709795bfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3f07b293-8384-4c47-9b83-2c54684439b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationMember_e266067a-4157-4e56-94e4-2c76b52769c1" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81a8652b-9e41-40a4-b0a0-714d40b72971" xlink:to="loc_rprx_MilestoneAccelerationMember_e266067a-4157-4e56-94e4-2c76b52769c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_46e09d08-6d1f-4c9e-ab03-d0a51cc88bb7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_923bd609-a246-4b41-b4e4-53882eb7fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_923bd609-a246-4b41-b4e4-53882eb7fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4e9b46d9-aa12-4c7a-856f-63f51e63dcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4e9b46d9-aa12-4c7a-856f-63f51e63dcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_46433375-8218-4894-adf2-eba5c44ee183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_46433375-8218-4894-adf2-eba5c44ee183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1e907b8f-e829-4e47-93b3-f50acd38dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1e907b8f-e829-4e47-93b3-f50acd38dc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_fa5da6c7-bef3-4641-a692-edc996b51872" xlink:href="rprx-20221231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_fa5da6c7-bef3-4641-a692-edc996b51872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_64df07a6-d109-4e5a-9874-76553ce01424" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_64df07a6-d109-4e5a-9874-76553ce01424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4c20a4d7-0cec-4251-8487-48ab2997f9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4c20a4d7-0cec-4251-8487-48ab2997f9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_5442031b-8089-42e8-b187-0d56df99ce08" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_5442031b-8089-42e8-b187-0d56df99ce08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f9cf1b9f-e111-46a5-8dd7-2abfc02990af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f9cf1b9f-e111-46a5-8dd7-2abfc02990af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ddb8297-bdcf-4948-aa3a-e8d098705323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9ddb8297-bdcf-4948-aa3a-e8d098705323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f93378ab-5072-4a9b-9cf5-3e73d3b8c145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f93378ab-5072-4a9b-9cf5-3e73d3b8c145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm_89e374db-ec5c-4005-8727-78b6b3ca6a01" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_OptionIndexedToIssuersEquityTerm_89e374db-ec5c-4005-8727-78b6b3ca6a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue_a44b0e90-f026-4217-b3d8-635a26c60897" xlink:href="rprx-20221231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_rprx_OptionIndexedToIssuersEquityValue_a44b0e90-f026-4217-b3d8-635a26c60897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_2600e325-8df2-4959-99c1-dc5a8649bed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_64b71298-dfb0-4ab1-87ec-8fa20a3eed0d" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_2600e325-8df2-4959-99c1-dc5a8649bed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6f255798-7c5c-419d-87ac-a3934cc86cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6f255798-7c5c-419d-87ac-a3934cc86cd5" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c7bf201c-761c-417f-a17f-13e86b791509" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_beed149f-8148-41a0-bcb1-d5fdcd1d3472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_InterestRateSwapMember_beed149f-8148-41a0-bcb1-d5fdcd1d3472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a0169282-6fc9-4018-a362-b9fd819d401b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_WarrantMember_a0169282-6fc9-4018-a362-b9fd819d401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_46e17706-5003-4095-8c10-362396646846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_us-gaap_ForwardContractsMember_46e17706-5003-4095-8c10-362396646846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_f84dff81-cc6d-4ad0-8fb6-64d62bd419b4" xlink:href="rprx-20221231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_rprx_TreasuryRateLockContractsMember_f84dff81-cc6d-4ad0-8fb6-64d62bd419b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestoneAccelerationOptionMember_9eec6335-e138-457a-a6dc-f0397433a981" xlink:href="rprx-20221231.xsd#rprx_MilestoneAccelerationOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fb17e08b-64af-4349-a27f-925812d4ee98" xlink:to="loc_rprx_MilestoneAccelerationOptionMember_9eec6335-e138-457a-a6dc-f0397433a981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa0a815b-6630-45f5-a6db-5572e4678f3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_57070a32-994a-4b14-8a02-c05fb2d084cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_57070a32-994a-4b14-8a02-c05fb2d084cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_ff39fe72-e918-4956-b835-65daca4d06b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_85ec5027-868e-4f3e-a108-5d496ecac883" xlink:to="loc_us-gaap_InterestExpenseMember_ff39fe72-e918-4956-b835-65daca4d06b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_81d54e87-a839-449e-85d5-b42cc428cff7" xlink:to="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18875d0c-4fa7-45d4-a47c-6e7bfa87a743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_18875d0c-4fa7-45d4-a47c-6e7bfa87a743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_22b39725-a25c-4664-893a-0ab97ad56f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bae0efba-fb5c-4dd3-bfb6-c4b24b8184fe" xlink:to="loc_us-gaap_NondesignatedMember_22b39725-a25c-4664-893a-0ab97ad56f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_22a9eee6-dc6f-45e1-9765-7f9f8fde3661" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0f1438a7-0731-4e8e-a79c-7932adfacb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0f1438a7-0731-4e8e-a79c-7932adfacb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_aac556c8-5bea-44cb-9d73-20e7abdba01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_aac556c8-5bea-44cb-9d73-20e7abdba01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7db38466-cd8e-47e2-9b3b-090a0ec4a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7db38466-cd8e-47e2-9b3b-090a0ec4a17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_c34ca6d4-7e71-49e8-a5a0-63608fa8d666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d682bc3a-64c0-407f-93c4-7555cde281ec" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_c34ca6d4-7e71-49e8-a5a0-63608fa8d666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb259253-e85c-4201-8945-3dd464531836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb259253-e85c-4201-8945-3dd464531836" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cb363009-b06a-4aa5-a0bd-26385c6a354d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_281bf472-f4d7-4b9b-ab8b-51cb79f66489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_MoneyMarketFundsMember_281bf472-f4d7-4b9b-ab8b-51cb79f66489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5c7a3037-8e82-442c-847d-e412f05f9522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_CommercialPaperMember_5c7a3037-8e82-442c-847d-e412f05f9522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d1a0fd88-7476-43c6-b063-0e179ef1e040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8a78e111-b624-49d3-b9e0-a835c0818789" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d1a0fd88-7476-43c6-b063-0e179ef1e040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7cc18425-6ec9-48ef-9fb8-96cdf18b4a9e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4990846a-3fc4-48bf-a52e-43fa799c01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_CommercialPaperMember_4990846a-3fc4-48bf-a52e-43fa799c01e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cecdd1a3-5fcf-446c-88d6-ac5a38602965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cecdd1a3-5fcf-446c-88d6-ac5a38602965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_8750a524-7c50-4c35-b579-e80ac004b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_8750a524-7c50-4c35-b579-e80ac004b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4ff51cec-1351-45e9-b0a1-64f9f2192411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_DebtSecuritiesMember_4ff51cec-1351-45e9-b0a1-64f9f2192411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_1d825580-cc0c-43cd-ad71-c4444ab9410e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc15f36-61cc-47c0-bdd3-fd5ba7fe331d" xlink:to="loc_us-gaap_ForwardContractsMember_1d825580-cc0c-43cd-ad71-c4444ab9410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3db2e0af-48fb-4659-ab53-59648c09c3d6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_817fdc8a-4726-4844-81cc-bb116883bdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_817fdc8a-4726-4844-81cc-bb116883bdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f16085b6-c96a-4bb0-86f9-d499714193aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f16085b6-c96a-4bb0-86f9-d499714193aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d5a78df5-f0d5-41cd-8323-29e97655561b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63a53827-873a-4112-b924-32f569a8317b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d5a78df5-f0d5-41cd-8323-29e97655561b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ec60579-a69b-41f6-8a26-10e1466f4b84" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_30f4f81a-ced3-4c12-ac70-c3a9144853c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_17a80e0e-12a5-46e2-8f12-fe6bcf9e8f1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_30f4f81a-ced3-4c12-ac70-c3a9144853c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1f4f9bea-a8cd-4335-a049-9cea6fadb954" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyInvestmentsMember_182ea4ba-6e26-42c0-9cae-ecf3da5f120a" xlink:href="rprx-20221231.xsd#rprx_RoyaltyInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:to="loc_rprx_RoyaltyInvestmentsMember_182ea4ba-6e26-42c0-9cae-ecf3da5f120a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsFundingCommitmentMember_500f3507-b1c1-482f-b10c-20ba909d7659" xlink:href="rprx-20221231.xsd#rprx_CytokineticsFundingCommitmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_788bf6e6-03b0-4f21-af80-15be9f1257b9" xlink:to="loc_rprx_CytokineticsFundingCommitmentMember_500f3507-b1c1-482f-b10c-20ba909d7659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8284c169-3aa0-47cd-8787-af5f9b32efdd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc93b196-064f-4243-b2c6-29b560b1ebdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fc93b196-064f-4243-b2c6-29b560b1ebdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_e49ccf3d-840e-43ac-8c32-82ac6e89452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_TradingSecuritiesDebt_e49ccf3d-840e-43ac-8c32-82ac6e89452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b4d53fa7-e1c6-4a1d-b741-2866b3f6fdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b4d53fa7-e1c6-4a1d-b741-2866b3f6fdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_276bf3d8-cefc-4dbc-9575-186c2e244942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_276bf3d8-cefc-4dbc-9575-186c2e244942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_6c114106-43bc-4c68-8f9a-54fa639ee661" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_6c114106-43bc-4c68-8f9a-54fa639ee661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_011d2deb-a6b4-4e73-9813-503b4624a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_011d2deb-a6b4-4e73-9813-503b4624a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5684bc6c-9d28-4c91-a556-d9db4bdd1c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5684bc6c-9d28-4c91-a556-d9db4bdd1c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_dde0ad17-4ed9-4322-a77e-8d7148051fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_dde0ad17-4ed9-4322-a77e-8d7148051fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_948ce7d4-34e3-4955-8af0-e3ebe8aef30c" xlink:href="rprx-20221231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a75d495d-e432-46d0-921d-47bab7d88e40" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_948ce7d4-34e3-4955-8af0-e3ebe8aef30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_dbabc287-5fe9-48bd-97c5-9fce0b59b4f0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent_dbabc287-5fe9-48bd-97c5-9fce0b59b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_1a402228-c3dc-45ef-80b6-3c2ac3df842b" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2b1c177b-4c87-4674-9297-6df350a5b523" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent_1a402228-c3dc-45ef-80b6-3c2ac3df842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_51d2bf91-3b51-4f11-93af-8cca5d05b497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_51d2bf91-3b51-4f11-93af-8cca5d05b497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_876c3752-afdb-47e2-873a-36bc10a67f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9923df2a-14ea-4c07-b069-56372e7bbe73" xlink:to="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_876c3752-afdb-47e2-873a-36bc10a67f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_233e8e84-4971-4297-8a17-cce0d8f6a15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_233e8e84-4971-4297-8a17-cce0d8f6a15c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aa8ab184-ed79-4a29-b43b-ab0dd04d8f37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsCommercialLaunchFundingMember_88edb555-ff73-4795-a8e4-500a67528853" xlink:href="rprx-20221231.xsd#rprx_CytokineticsCommercialLaunchFundingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:to="loc_rprx_CytokineticsCommercialLaunchFundingMember_88edb555-ff73-4795-a8e4-500a67528853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_43018af1-b73f-4a67-9b02-f01168385369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad2d1872-1734-4e56-aab3-c110954e2c4b" xlink:to="loc_us-gaap_PreferredStockMember_43018af1-b73f-4a67-9b02-f01168385369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66782b57-e106-4319-8c6d-04079961cd30" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_dd96a819-5f77-46fd-82cb-6bb10e3f4890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82e028ea-e807-4d14-97cf-c4da62352759" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_dd96a819-5f77-46fd-82cb-6bb10e3f4890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92bca047-df63-4dd2-aa5d-8d07667c3ebe" xlink:to="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5b2a8775-1e2a-4234-bfd8-e57eeefed4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_38730b91-1bf9-4eba-9c18-4e4acf7bf681" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5b2a8775-1e2a-4234-bfd8-e57eeefed4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e103ad2-ea8c-4155-b66b-fadbea948c14" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ba847ce9-d3b5-445f-83b7-697f478db84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1a9f764c-cc61-4244-86fb-7fcbdfead09a" xlink:to="loc_us-gaap_EquitySecuritiesMember_ba847ce9-d3b5-445f-83b7-697f478db84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3831919e-7976-44ec-84a1-c87d3e96e660" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_132ad235-e0b4-4d54-a271-46ccec90c661" xlink:href="rprx-20221231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_132ad235-e0b4-4d54-a271-46ccec90c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_d307b406-c455-4b63-919f-d9301cf618d4" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e0d968f-9a1a-42d7-b96d-7e6c2d5418ca" xlink:to="loc_rprx_MorphoSysMember_d307b406-c455-4b63-919f-d9301cf618d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f70c050d-fa9e-41dd-b79d-8fbd294399ef" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_bb7d9c95-7864-4756-8015-16bc2cc6c0c1" xlink:href="rprx-20221231.xsd#rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_bb7d9c95-7864-4756-8015-16bc2cc6c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_ed4735fe-4a06-4358-9fed-63fa206410bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_ed4735fe-4a06-4358-9fed-63fa206410bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_113b5be3-6034-49a6-9663-5383d630838d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_113b5be3-6034-49a6-9663-5383d630838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fab29c34-67c6-4bba-a5f7-47df0854170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fab29c34-67c6-4bba-a5f7-47df0854170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_f7f180a0-46d1-44e8-89ff-03e9f7faefa0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_f7f180a0-46d1-44e8-89ff-03e9f7faefa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_47604773-3b05-4ed2-809c-a39b525cd0cb" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_47604773-3b05-4ed2-809c-a39b525cd0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_612640fd-7be1-4585-bab0-22fafb2558b0" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_612640fd-7be1-4585-bab0-22fafb2558b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_22ca028d-8c36-4766-935c-5560a86c08a5" xlink:href="rprx-20221231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_384308e2-3688-4926-bd66-7e168b4fc3ad" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_22ca028d-8c36-4766-935c-5560a86c08a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23a117aa-869a-49d4-828c-f8aa35356afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23a117aa-869a-49d4-828c-f8aa35356afe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a6636c58-c0a4-489e-8b69-714651af7a89" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b868b525-3f94-4047-a7a0-96a450162bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_EquitySecuritiesMember_b868b525-3f94-4047-a7a0-96a450162bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9c159f55-2c4e-45ea-a6bc-629ddcea8237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9c159f55-2c4e-45ea-a6bc-629ddcea8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_99a891d5-67ec-4cc3-b618-9d8984bd005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_ForwardContractsMember_99a891d5-67ec-4cc3-b618-9d8984bd005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingCommitmentsMember_36b8ddc5-e226-4747-b4e1-86a3b6087bf6" xlink:href="rprx-20221231.xsd#rprx_FundingCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_rprx_FundingCommitmentsMember_36b8ddc5-e226-4747-b4e1-86a3b6087bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DerivativeAssetMember_cd2f43c8-e554-41c9-9fff-a420ba6f336a" xlink:href="rprx-20221231.xsd#rprx_DerivativeAssetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_rprx_DerivativeAssetMember_cd2f43c8-e554-41c9-9fff-a420ba6f336a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_dbbaba7d-82e4-4f45-b4c5-c4e8b2756577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_de33c08f-0f85-4a81-9b7a-971c3336c680" xlink:to="loc_us-gaap_RoyaltyMember_dbbaba7d-82e4-4f45-b4c5-c4e8b2756577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a52e8a6-887c-42e5-ade2-b8df373eb90b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74136735-8173-4993-b25b-23bd5e3af2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58cf7b6e-295c-413c-adb9-e516e14253f2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74136735-8173-4993-b25b-23bd5e3af2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f174daf1-725b-49ff-bafb-b3cfe7940111" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ae6db391-dbe9-4a30-a5ee-3b1c6a9adf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_917905fa-6541-4a39-a9e3-40a2e3f5c373" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ae6db391-dbe9-4a30-a5ee-3b1c6a9adf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1b968a7b-4da2-4710-8c86-56765361f1dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_bd8817e6-72ca-46ce-96ef-37ed3b1cd482" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c557f952-123d-4ae0-8785-e8f73dddd3b3" xlink:to="loc_rprx_MorphoSysMember_bd8817e6-72ca-46ce-96ef-37ed3b1cd482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f2c72761-6724-40ab-b6fe-5534985aaffe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a16456ac-95d1-4e47-9708-1d38801fcca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a16456ac-95d1-4e47-9708-1d38801fcca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0fe41133-1d30-47f6-a274-7e515b19c98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0fe41133-1d30-47f6-a274-7e515b19c98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_ebe19866-bb8b-4dd2-8687-75e380873f4d" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition_ebe19866-bb8b-4dd2-8687-75e380873f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c22461d5-bad5-4ed4-8259-69f2fa5b3aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c22461d5-bad5-4ed4-8259-69f2fa5b3aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_70c4e9a2-7d1a-4093-9c69-bf708f833a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_70c4e9a2-7d1a-4093-9c69-bf708f833a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_caf28e96-b3ea-44b0-8ce3-a51567ab65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_caf28e96-b3ea-44b0-8ce3-a51567ab65f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_e22e91fb-0812-4ed9-84ba-2ba079b8b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_e22e91fb-0812-4ed9-84ba-2ba079b8b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_a0d3842b-e619-4272-afd2-dac8cb2e0aba" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense_a0d3842b-e619-4272-afd2-dac8cb2e0aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_c5072f0f-0c93-4e71-8f6d-c47a05118bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_c5072f0f-0c93-4e71-8f6d-c47a05118bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_9855891a-1580-4405-a790-7a2996a5d019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_9855891a-1580-4405-a790-7a2996a5d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_480b82c7-d506-47a6-b338-11b4ec263a05" xlink:href="rprx-20221231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_480b82c7-d506-47a6-b338-11b4ec263a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_deeed763-ab45-483a-9b96-b2bab5d4cfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3d52fb80-ca1e-4475-8e12-fa9f26c9fca4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_deeed763-ab45-483a-9b96-b2bab5d4cfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_8b9d7630-fc0e-4ffe-beea-f43188ac85d9" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3b60d8a1-d441-4a1a-9934-e07508df8d99" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_8b9d7630-fc0e-4ffe-beea-f43188ac85d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e31dd730-6031-419e-b6c6-66e722f62820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e31dd730-6031-419e-b6c6-66e722f62820" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23ac72b8-7870-43e1-975f-c2cad15c7ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b21c0332-e8ea-47de-a5f7-bdeb182e1242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbeed101-9558-4360-a7fe-257e939ff056" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b21c0332-e8ea-47de-a5f7-bdeb182e1242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_69bea700-7f65-4542-b604-5e21c3a439cf" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_561abd7f-d59a-46a8-8ac1-d9ae7034a79b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_edbf54ca-e217-4238-9262-5ce5d390b507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_edbf54ca-e217-4238-9262-5ce5d390b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0f2e8413-b113-4f42-8686-78516611fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2c795c4-b6d4-4cd8-95c4-2bc7cb5e57c8" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0f2e8413-b113-4f42-8686-78516611fd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c80abb74-ac3a-4073-88cf-8a49e756549b" xlink:to="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ae652895-b0ee-4cde-87f1-8a328b62e43c" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_52dd7fdb-c42d-4062-bcd6-1b7659e7e685" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ae652895-b0ee-4cde-87f1-8a328b62e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_9152942a-09a2-4eed-aa55-706dd86374ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9152942a-09a2-4eed-aa55-706dd86374ec" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:to="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e2a71e2f-fcf2-481a-bbcc-bd45d49d3d42" xlink:to="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_f4e1a3dc-6e7c-4587-90f0-553fc4d94e8b" xlink:href="rprx-20221231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_f4e1a3dc-6e7c-4587-90f0-553fc4d94e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_0dc04fbf-14dc-49de-8902-239dab7ac1e6" xlink:href="rprx-20221231.xsd#rprx_TysabriMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TysabriMember_0dc04fbf-14dc-49de-8902-239dab7ac1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TrelegyMember_f694ab14-37ca-4dec-ae91-eb96a3290589" xlink:href="rprx-20221231.xsd#rprx_TrelegyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TrelegyMember_f694ab14-37ca-4dec-ae91-eb96a3290589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_6c4004ae-175b-4ac3-815c-d50134d1fc88" xlink:href="rprx-20221231.xsd#rprx_TremfyaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_TremfyaMember_6c4004ae-175b-4ac3-815c-d50134d1fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_13a672e5-5d79-44cf-a250-c3c8f73357e6" xlink:href="rprx-20221231.xsd#rprx_ImbruvicaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_ImbruvicaMember_13a672e5-5d79-44cf-a250-c3c8f73357e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_32d89805-080c-4ecd-b124-8f9ea2cff4bd" xlink:href="rprx-20221231.xsd#rprx_XtandiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_XtandiMember_32d89805-080c-4ecd-b124-8f9ea2cff4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_460940a2-16ee-470f-b3b8-c326d9d6b703" xlink:href="rprx-20221231.xsd#rprx_EvrysdiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_EvrysdiMember_460940a2-16ee-470f-b3b8-c326d9d6b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_b6604814-ab41-48b3-8ff7-1323f572863f" xlink:href="rprx-20221231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_b6604814-ab41-48b3-8ff7-1323f572863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtilimabMember_3086bba3-b9c2-48dc-916a-774470a973f9" xlink:href="rprx-20221231.xsd#rprx_OtilimabMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_OtilimabMember_3086bba3-b9c2-48dc-916a-774470a973f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GantenerumabMember_aad3cab4-e3cb-4690-ae9d-3bd9119ebeec" xlink:href="rprx-20221231.xsd#rprx_GantenerumabMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85797af4-e071-444c-817a-5006290c89a4" xlink:to="loc_rprx_GantenerumabMember_aad3cab4-e3cb-4690-ae9d-3bd9119ebeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_37c6e3f0-f819-4b2d-bc15-c28af765769f" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_e8ff30d2-8600-4900-a046-be2477726d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_us-gaap_NotesReceivableGross_e8ff30d2-8600-4900-a046-be2477726d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_d68dcc5a-6a1b-4bd0-96f6-f311b35fd310" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_d68dcc5a-6a1b-4bd0-96f6-f311b35fd310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_fd7148ec-9305-4e73-978f-3f179ad3ebe9" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_fd7148ec-9305-4e73-978f-3f179ad3ebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_6dd2d02b-7b0b-4ef5-b05f-7e4c2f31e851" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_6dd2d02b-7b0b-4ef5-b05f-7e4c2f31e851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_28a0b9f6-a9ba-407c-863f-973bc75da764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_us-gaap_NotesReceivableNet_28a0b9f6-a9ba-407c-863f-973bc75da764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_0c8e6490-2fef-4cc3-9905-83d5a8ade6ca" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d709a51c-1de2-477e-83b8-d6ed7a1c8901" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_0c8e6490-2fef-4cc3-9905-83d5a8ade6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#FinancialRoyaltyAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_a46398f5-6281-47aa-9e96-689bda45cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_a46398f5-6281-47aa-9e96-689bda45cd47" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:to="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1dd27b2c-0d8c-425c-9348-e83368466dc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtilimabMember_71b1f83e-ea7c-46a9-ad9d-8057ac6fca09" xlink:href="rprx-20221231.xsd#rprx_OtilimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_OtilimabMember_71b1f83e-ea7c-46a9-ad9d-8057ac6fca09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GantenerumabMember_706cb44f-8125-4f13-bf48-6f6b12b13b38" xlink:href="rprx-20221231.xsd#rprx_GantenerumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_GantenerumabMember_706cb44f-8125-4f13-bf48-6f6b12b13b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RochesMember_8a05feb6-df88-4d7e-95c4-6ac097a0a4d8" xlink:href="rprx-20221231.xsd#rprx_RochesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a46fd429-75ef-47e2-abc9-7e8988b7223c" xlink:to="loc_rprx_RochesMember_8a05feb6-df88-4d7e-95c4-6ac097a0a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0eca9c25-a13b-4f55-92aa-cbc3c2b36199" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_cd4c8cbb-7f5c-41bf-83a4-ddfd6d65f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_cd4c8cbb-7f5c-41bf-83a4-ddfd6d65f36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_406f7eec-1a97-42de-bd4a-3ce3f56ef1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_us-gaap_NotesReceivableNet_406f7eec-1a97-42de-bd4a-3ce3f56ef1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts_45e71bd0-78f0-4c50-b077-09b5bbaeede1" xlink:href="rprx-20221231.xsd#rprx_UnapprovedFinancialAssetsHeldAtCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_fe5032a4-2be4-4e17-9369-16b4938b220c" xlink:to="loc_rprx_UnapprovedFinancialAssetsHeldAtCosts_45e71bd0-78f0-4c50-b077-09b5bbaeede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_fa82f27f-25b7-4111-aa5d-1e0aedc68ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_fa82f27f-25b7-4111-aa5d-1e0aedc68ab5" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_4e22ec4a-1883-496b-a8ee-e9ea2fadb4a6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1080ae95-9954-4790-a54a-573591b6c931" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_28f9fbb9-c5a2-411d-ad94-2be10b109802" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1080ae95-9954-4790-a54a-573591b6c931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_78972cf5-1e2a-4198-b005-e805b570fe12" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_a4dcbeec-acb8-4280-b380-64bbd35060cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_a4dcbeec-acb8-4280-b380-64bbd35060cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_7dc34703-d0a9-460a-b155-59b57422a31b" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_7dc34703-d0a9-460a-b155-59b57422a31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_c2859f7c-f25a-4a1b-a3df-c111f29f8d44" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_c2859f7c-f25a-4a1b-a3df-c111f29f8d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_4dfb8f2c-0777-4631-b3fe-5a171616b5d9" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance_4dfb8f2c-0777-4631-b3fe-5a171616b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_7b40f64e-b211-4860-b533-80a0875f8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_7b40f64e-b211-4860-b533-80a0875f8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_0fc022a7-e6a9-4fcb-a8be-d2f224f528cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_0fc022a7-e6a9-4fcb-a8be-d2f224f528cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_0d24fbdf-f4f2-48e6-9332-8860984d197a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_0d24fbdf-f4f2-48e6-9332-8860984d197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_229c5533-a728-4194-93b3-9d29889fbd24" xlink:href="rprx-20221231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_364bb4b9-c837-43c4-9c70-71de42dd18a3" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_229c5533-a728-4194-93b3-9d29889fbd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75ae3a75-fc45-4332-a9ec-be2cb31f8185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75ae3a75-fc45-4332-a9ec-be2cb31f8185" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4994b839-414b-4970-994c-26f13a239ce7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_fd35a96d-9bb4-4300-8507-1a169b6ca7ba" xlink:href="rprx-20221231.xsd#rprx_DPPIVPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9e4123b7-5b07-4be1-b328-862a2d7fb67a" xlink:to="loc_rprx_DPPIVPatentsMember_fd35a96d-9bb4-4300-8507-1a169b6ca7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7e47fd9f-143c-4c8d-a93d-dbe1e073da08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94db19db-4258-4e36-9057-6f90075305e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94db19db-4258-4e36-9057-6f90075305e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_561420f7-1617-4816-bb64-b0456d309ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_561420f7-1617-4816-bb64-b0456d309ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42c52b28-8254-4ec1-a719-6dcdd7afb949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cf003ada-3f81-4ce2-ba94-8a9f48ddb722" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42c52b28-8254-4ec1-a719-6dcdd7afb949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5064577d-a5ec-4040-8396-09d46377b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5064577d-a5ec-4040-8396-09d46377b715" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12d95d2d-60e0-4b74-9d0e-f2aa4fd3ed1b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_c7bbfbb7-2fb9-40be-9f30-9c46eefa71a5" xlink:href="rprx-20221231.xsd#rprx_DPPIVPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2948334-0005-4909-8482-d48c36f18932" xlink:to="loc_rprx_DPPIVPatentsMember_c7bbfbb7-2fb9-40be-9f30-9c46eefa71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ee493110-8465-44f1-a15c-e02625d1865c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1c545004-d1fa-42f1-b7ff-36ad3959fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9ebaa7e-8337-4ae8-afd3-472552f76ded" xlink:to="loc_us-gaap_SalesRevenueNetMember_1c545004-d1fa-42f1-b7ff-36ad3959fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37898448-dab2-48ec-8c25-afaed2a99f29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_731361ee-4f79-4317-abad-0f1acbed534d" xlink:href="rprx-20221231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ae9e0f6-3d14-4609-80b8-619a47de9fe3" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_731361ee-4f79-4317-abad-0f1acbed534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e6fd6589-e666-4ecd-ab39-d035b26e8570" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1522d987-cbd4-453b-9fd3-1396bc99e5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_568fdc7e-11f0-4123-9e87-a332fbb2ace5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1522d987-cbd4-453b-9fd3-1396bc99e5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b5afaf6c-e996-4f37-b44f-9c0e50f07509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b5afaf6c-e996-4f37-b44f-9c0e50f07509" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73906b14-bdec-4542-a6f4-d2e04f59be77" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_7eac9f12-aed6-466c-8e7a-3711979afb44" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_7eac9f12-aed6-466c-8e7a-3711979afb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_49c6bb41-b152-4b9d-91ee-0e8f4a577d3c" xlink:href="rprx-20221231.xsd#rprx_AvillionEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionEntitiesMember_49c6bb41-b152-4b9d-91ee-0e8f4a577d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_0f1bf211-6a5a-4b51-8d12-cc237bad6c77" xlink:href="rprx-20221231.xsd#rprx_AvillionIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionIMember_0f1bf211-6a5a-4b51-8d12-cc237bad6c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_830cf47d-286c-4f10-902f-28f1a2918de2" xlink:href="rprx-20221231.xsd#rprx_AvillionIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09546131-176b-432d-94e7-de030efda47e" xlink:to="loc_rprx_AvillionIIMember_830cf47d-286c-4f10-902f-28f1a2918de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_921a1c0e-7a21-48bb-9891-267d34c53961" xlink:to="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_48786f23-c442-4b77-8302-8467ac1de663" xlink:href="rprx-20221231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_d6413b75-7026-4f95-9d32-30b32c51b35e" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_48786f23-c442-4b77-8302-8467ac1de663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bfe3b6f3-fb1c-453d-a222-fdcf9458cc78" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_138805f4-75b2-4c0b-91b0-977df4027980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a2a5e817-a51e-41b7-9997-1707cc811c4f" xlink:to="loc_us-gaap_SubsequentEventMember_138805f4-75b2-4c0b-91b0-977df4027980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_01f9900e-e122-4dd2-b0a0-8b067d15a19a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_391eba09-1134-453d-881d-064e035be055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_EquityMethodInvestments_391eba09-1134-453d-881d-064e035be055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb69a166-0a33-4966-9df5-5fb5c4f46fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb69a166-0a33-4966-9df5-5fb5c4f46fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_928c231d-7319-4b08-9d91-ba305c623225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_928c231d-7319-4b08-9d91-ba305c623225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_0f21131b-7779-40e5-9582-ca785768d0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_us-gaap_OtherCommitment_0f21131b-7779-40e5-9582-ca785768d0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFee_ce98a589-ecfb-4f98-8877-6b9903a94a75" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_ProceedsFromExerciseFee_ce98a589-ecfb-4f98-8877-6b9903a94a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromExerciseFeeProRataAmount_500a0295-99c3-4307-af24-92461e16ede2" xlink:href="rprx-20221231.xsd#rprx_ProceedsFromExerciseFeeProRataAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_ProceedsFromExerciseFeeProRataAmount_500a0295-99c3-4307-af24-92461e16ede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_807808e2-a0e3-4352-aeb3-6603e7c6f4c8" xlink:href="rprx-20221231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_808e5436-fc98-4e21-bdf0-ccc55f731a29" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_807808e2-a0e3-4352-aeb3-6603e7c6f4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_46066842-4da3-41e7-93c6-aabb6b62bbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_46066842-4da3-41e7-93c6-aabb6b62bbbc" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:to="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b41956b9-14bc-495a-b067-8e9b6d73d4ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CytokineticsMember_d068ff16-0244-446f-9a4e-0810638fcc52" xlink:href="rprx-20221231.xsd#rprx_CytokineticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_CytokineticsMember_d068ff16-0244-446f-9a4e-0810638fcc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheravanceBiopharmaMember_9b7722ab-3841-4c59-9cd2-443e8a09dd34" xlink:href="rprx-20221231.xsd#rprx_TheravanceBiopharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_TheravanceBiopharmaMember_9b7722ab-3841-4c59-9cd2-443e8a09dd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember_bac5d899-29ed-41f2-85f4-2975df7ed3e0" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_FundingAgreementsWithSanofiMember_bac5d899-29ed-41f2-85f4-2975df7ed3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_4fc922bb-9015-46e4-87fe-4061010190e7" xlink:href="rprx-20221231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_MorphoSysMember_4fc922bb-9015-46e4-87fe-4061010190e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember_01a8f2ff-d5d7-4b1c-8b1b-9b55f768f669" xlink:href="rprx-20221231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6af806e-3d5f-4522-853c-289be95ecc76" xlink:to="loc_rprx_FundingAgreementWithBioCrystMember_01a8f2ff-d5d7-4b1c-8b1b-9b55f768f669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d58396ff-97a7-4bdb-a3ed-a8d2911c87a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckToFundMember_c8dbff60-cdc9-462f-b267-985c05dc1dac" xlink:href="rprx-20221231.xsd#rprx_MerckToFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:to="loc_rprx_MerckToFundMember_c8dbff60-cdc9-462f-b267-985c05dc1dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_09feacaa-8e33-49bc-9e9c-11b921547f39" xlink:href="rprx-20221231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14cb5412-222a-446c-afc0-3508743c8c3f" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_09feacaa-8e33-49bc-9e9c-11b921547f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_c676aa56-e886-4f06-bc51-380d203ab92b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48021ecc-9981-46d4-b827-7fceaaf07cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_48021ecc-9981-46d4-b827-7fceaaf07cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_af2f7816-955e-4149-9ab8-171d160d2694" xlink:href="rprx-20221231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a7d70aef-e13c-4918-ac8d-f0d493debe0e" xlink:to="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_af2f7816-955e-4149-9ab8-171d160d2694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_df2b5604-be5e-4862-9d9a-e98ebbcc1805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_df2b5604-be5e-4862-9d9a-e98ebbcc1805" xlink:to="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_696659f3-5564-4a79-9fa9-7d25c429af89" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0c977626-93f1-4743-9fcb-5418783f07ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_91e7e6f1-dd51-4205-b17b-8f4f42716b49" xlink:to="loc_us-gaap_UnsecuredDebtMember_0c977626-93f1-4743-9fcb-5418783f07ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:to="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f33c2cc9-b7a6-41a1-90ca-8177d029e65c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_2e88075f-045c-4f99-a36d-de86146a2f59" xlink:href="rprx-20221231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_2e88075f-045c-4f99-a36d-de86146a2f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_a186621a-d621-4bc6-8076-d2638c9cc4af" xlink:href="rprx-20221231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_a186621a-d621-4bc6-8076-d2638c9cc4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e7a5d57b-bed5-4f44-a143-498bb9db461a" xlink:href="rprx-20221231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e7a5d57b-bed5-4f44-a143-498bb9db461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_4437526c-dd1f-4c92-8237-38c26af23ff8" xlink:href="rprx-20221231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_4437526c-dd1f-4c92-8237-38c26af23ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_29057940-edfb-4fbb-b868-9b9fc72a88db" xlink:href="rprx-20221231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_29057940-edfb-4fbb-b868-9b9fc72a88db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_8fa549e3-ccd7-420b-a776-eae8246ff28a" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_8fa549e3-ccd7-420b-a776-eae8246ff28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_558fba9e-90a5-44db-bb43-4999d2b6aa93" xlink:href="rprx-20221231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_558fba9e-90a5-44db-bb43-4999d2b6aa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_b07ebe3d-cfa3-4f32-8df4-1b31523c6fa6" xlink:href="rprx-20221231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b672a9cc-379f-4f8e-8f36-77569f0a566b" xlink:to="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_b07ebe3d-cfa3-4f32-8df4-1b31523c6fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b469b619-49bb-49aa-ab7d-86182af58322" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db4e7189-1594-4c40-865e-1df3abd95ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db4e7189-1594-4c40-865e-1df3abd95ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff898174-8c74-4584-86a0-ec694656232d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff898174-8c74-4584-86a0-ec694656232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_99769b3a-b6e2-44e0-aa71-d929bb60aaeb" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_99769b3a-b6e2-44e0-aa71-d929bb60aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d0c5c108-a782-4609-b343-6ad6742a948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d0c5c108-a782-4609-b343-6ad6742a948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_08100232-2810-44c9-a491-6f2cfdacf899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebt_08100232-2810-44c9-a491-6f2cfdacf899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_152b3135-ce90-4498-966d-b2e96a60988a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebtCurrent_152b3135-ce90-4498-966d-b2e96a60988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1effb3d7-1504-4918-a4f4-33c1dd53f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0405013e-aa5a-4538-bcac-ea2434c91338" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1effb3d7-1504-4918-a4f4-33c1dd53f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4d701818-e9ea-4ec5-bb60-b3a110919aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4d701818-e9ea-4ec5-bb60-b3a110919aa4" xlink:to="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_add45bbb-d5af-4915-89ca-a1c58cd81d07" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_854703d2-7338-4b33-86f9-6bff014a33f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_SeniorNotesMember_854703d2-7338-4b33-86f9-6bff014a33f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_99e9557f-2bbf-4204-92a9-c1f71e84a92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_UnsecuredDebtMember_99e9557f-2bbf-4204-92a9-c1f71e84a92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b76c7b2c-c461-4a3b-92bf-90f81ed1732c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32292c85-7b71-4728-a0a3-1ba6daad17c6" xlink:to="loc_us-gaap_SecuredDebtMember_b76c7b2c-c461-4a3b-92bf-90f81ed1732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0ed65e8c-625f-42b8-8fba-b973cee6a099" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_88a26db8-21ac-40d3-89c9-92702409dad2" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorNotesDue2031Member_88a26db8-21ac-40d3-89c9-92702409dad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_79248f0a-4053-432d-888d-19a554a80a86" xlink:href="rprx-20221231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorNotesDue2051Member_79248f0a-4053-432d-888d-19a554a80a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_e1714bee-4623-49b7-b971-839a1b8ce293" xlink:href="rprx-20221231.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_TheNotesMember_e1714bee-4623-49b7-b971-839a1b8ce293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_153a92b3-72b4-4b55-8e80-6ab5e4c53943" xlink:href="rprx-20221231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_153a92b3-72b4-4b55-8e80-6ab5e4c53943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_7bf7afb6-5c98-4441-a048-45878eb9c6ea" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_7bf7afb6-5c98-4441-a048-45878eb9c6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_77837a32-84cc-4713-864d-169c4062dfbd" xlink:href="rprx-20221231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c2db7d32-4074-4bba-a5c0-c0c4f97a2dd5" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_77837a32-84cc-4713-864d-169c4062dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_57653f8e-7ecd-454e-bc1a-3db07e83c344" xlink:to="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_67515c5f-70fe-4a71-aa9a-a7964f884207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_67515c5f-70fe-4a71-aa9a-a7964f884207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_56db7508-a6e2-4813-97c5-199c78300dbd" xlink:href="rprx-20221231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_rprx_OvernightBankFundingRateMember_56db7508-a6e2-4813-97c5-199c78300dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da017c0e-77eb-46ca-a0e8-40c3c6a3dc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_38ca94b1-dc51-483c-a1b1-0dc3273ebdd8" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da017c0e-77eb-46ca-a0e8-40c3c6a3dc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_278c1c56-9c8e-495e-8d50-fdbaa4baacc9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5bc99bdf-932d-4520-93fb-d7a19b8f75a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5bc99bdf-932d-4520-93fb-d7a19b8f75a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_182b950b-375a-49de-9461-bf2ffe6329c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_26cfe05a-d409-46be-b79b-baca7f7a543f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_182b950b-375a-49de-9461-bf2ffe6329c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fefa27a8-b94a-4dc2-b036-fddb73153fdb" xlink:to="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_22a485b3-3f7d-468a-ae1c-dd7b1c3e3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a0376320-874b-465c-ad41-f9540c4b8ecc" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_22a485b3-3f7d-468a-ae1c-dd7b1c3e3ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83eb1200-8a08-4992-bc63-b87cd2e4edc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5148191-6634-4bd3-8612-5186cb1c3920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8b175ab-6d63-4c39-9521-6f2aceea4906" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5148191-6634-4bd3-8612-5186cb1c3920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07c6bf35-9f93-484a-80ee-9f93c6a84239" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2475b108-3953-400d-9dcf-4ad633cabe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2475b108-3953-400d-9dcf-4ad633cabe2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b120018-73be-41a4-ba8e-b86d2bc8eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b120018-73be-41a4-ba8e-b86d2bc8eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_054c34c9-355d-40e7-967a-49ef67b4f7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_054c34c9-355d-40e7-967a-49ef67b4f7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_8390cade-f262-48a1-91d0-6f88b5dd7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_8390cade-f262-48a1-91d0-6f88b5dd7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1f571583-74cb-4b66-a99c-c27491c4009e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1f571583-74cb-4b66-a99c-c27491c4009e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0a3ddde0-f86c-4456-b085-926fbc1cb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0a3ddde0-f86c-4456-b085-926fbc1cb04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c466e106-35e3-48e4-9dc3-a62f6fb7b1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LongTermDebtFairValue_c466e106-35e3-48e4-9dc3-a62f6fb7b1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d092991e-81ca-4b95-964b-1b3ad829d4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentTerm_d092991e-81ca-4b95-964b-1b3ad829d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b482c0d2-e981-44fa-ba60-bb7ff9f586a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b482c0d2-e981-44fa-ba60-bb7ff9f586a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_57b93231-d8d8-4090-80b0-19348821e742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_LongTermDebt_57b93231-d8d8-4090-80b0-19348821e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e05c7de5-6566-4367-936a-1f973dc234af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e05c7de5-6566-4367-936a-1f973dc234af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_01aa453f-9f20-45c6-982a-90fc4143d2bf" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_01aa453f-9f20-45c6-982a-90fc4143d2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_aca0fb7b-dc59-4762-ba5e-001eb831ff8c" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_aca0fb7b-dc59-4762-ba5e-001eb831ff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_3a4ebaaa-a537-4fc5-b161-778ca7c3ff58" xlink:href="rprx-20221231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_3a4ebaaa-a537-4fc5-b161-778ca7c3ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad9be7c1-6820-44b8-8614-891f9406f104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e73d5f68-9da1-4e23-bf24-08a17eba9711" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ad9be7c1-6820-44b8-8614-891f9406f104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_70322576-b1e6-423c-aae1-24c9953530ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_70322576-b1e6-423c-aae1-24c9953530ef" xlink:to="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_82eee2cd-07b1-48fd-a45b-8b47ec1b7e5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c769f555-0d21-490a-9d37-9b67a64e48f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_220d7446-fb05-4b34-9bc2-605acaecccad" xlink:to="loc_us-gaap_UnsecuredDebtMember_c769f555-0d21-490a-9d37-9b67a64e48f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:to="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5497c9b7-2ee6-4fd8-8fb1-7d958f48cc01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_68807ba0-4001-4b66-92ff-fcae5e0894f2" xlink:href="rprx-20221231.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62ac3b03-a1a8-47ac-a513-517af07a5ac1" xlink:to="loc_rprx_TheNotesMember_68807ba0-4001-4b66-92ff-fcae5e0894f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ceaa2e36-9d0c-4de5-9fd2-70cc27c5e548" xlink:to="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_47224800-f0c0-4ebc-babf-43e16ca018f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_47224800-f0c0-4ebc-babf-43e16ca018f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bbbd049b-92fe-45de-b718-b4ef16d9d556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bbbd049b-92fe-45de-b718-b4ef16d9d556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_57fedebc-0d73-4db4-aa3b-a25e916dc70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_57fedebc-0d73-4db4-aa3b-a25e916dc70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_57749668-dd3f-4071-8af8-d0f2067e58bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_57749668-dd3f-4071-8af8-d0f2067e58bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e9c41b58-224d-43ef-b3b4-2c108be004d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e9c41b58-224d-43ef-b3b4-2c108be004d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f938c488-d0fd-4cda-bdb1-028e90137082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f938c488-d0fd-4cda-bdb1-028e90137082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_cf8955ed-9a9a-468f-84ec-75de8d383e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_cf8955ed-9a9a-468f-84ec-75de8d383e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_588b7f4d-58e8-4f0f-9e4c-c081e2cdc15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_62dff12f-8fdd-4aad-97d5-1ac48ee8f35f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_588b7f4d-58e8-4f0f-9e4c-c081e2cdc15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4c8abfd0-3339-4946-844c-abe2a13dde51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c8abfd0-3339-4946-844c-abe2a13dde51" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_907d133b-4426-442b-8869-76114f8c1c80" xlink:to="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1f0c2b8e-cc52-4695-96fd-1d386089234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_us-gaap_CommonClassAMember_1f0c2b8e-cc52-4695-96fd-1d386089234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_bf02484e-3526-4fbd-bc8a-b100ae6a37aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_us-gaap_CommonClassBMember_bf02484e-3526-4fbd-bc8a-b100ae6a37aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_428621b9-c09a-488a-9f80-fc4c165c3d93" xlink:href="rprx-20221231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cf453fd-aa34-4e1c-bdb0-ee8fd9774b09" xlink:to="loc_rprx_ClassRRedeemableStockMember_428621b9-c09a-488a-9f80-fc4c165c3d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1e7dcec8-ca77-440e-a42c-00ded2fc369a" xlink:to="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_4942d11c-b1f8-40ae-8a5e-2408f1638d9e" xlink:href="rprx-20221231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f2009177-ab16-47d9-ae5e-a2af5d4ea58c" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_4942d11c-b1f8-40ae-8a5e-2408f1638d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65735c17-76c3-473f-b0dd-b55a02318ff8" xlink:to="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_7baa3b25-8758-4f78-a6c4-7aaf67ead27a" xlink:href="rprx-20221231.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7806c088-685c-4393-a88a-aca3b040e801" xlink:to="loc_rprx_DeferredSharesMember_7baa3b25-8758-4f78-a6c4-7aaf67ead27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8fc5ba69-04da-4f65-8e55-b2194304f225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_099f3c53-3dcd-4be3-9d78-dbc24e7e600e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679d382c-66e9-4bc5-87c5-2b01256aa171" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_099f3c53-3dcd-4be3-9d78-dbc24e7e600e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2121efc4-0e63-4dc1-aa60-93ba97e0a338" xlink:to="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_28944a81-160a-4193-9800-57621149894d" xlink:href="rprx-20221231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_28944a81-160a-4193-9800-57621149894d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockVotingRightsNumberOfVotes_655c7f6b-5293-4099-9033-e2c2d3f882d4" xlink:href="rprx-20221231.xsd#rprx_CommonStockVotingRightsNumberOfVotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_CommonStockVotingRightsNumberOfVotes_655c7f6b-5293-4099-9033-e2c2d3f882d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_042a3abd-23bb-439a-88d2-49db0ca6eac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_042a3abd-23bb-439a-88d2-49db0ca6eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockQuarterlyConversionBasis_add828fe-816a-4f96-b14a-c0fb21b0bb8c" xlink:href="rprx-20221231.xsd#rprx_CommonStockQuarterlyConversionBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_CommonStockQuarterlyConversionBasis_add828fe-816a-4f96-b14a-c0fb21b0bb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_29a31d45-d702-44e5-ba69-c78eca68beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_SharesOutstanding_29a31d45-d702-44e5-ba69-c78eca68beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_841ca228-e32e-40fd-be38-6723f9ec06c9" xlink:href="rprx-20221231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_841ca228-e32e-40fd-be38-6723f9ec06c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_12ea0fb8-441b-42d9-b4e3-c84d0048364a" xlink:href="rprx-20221231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_12ea0fb8-441b-42d9-b4e3-c84d0048364a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c488b8ad-e7e2-4033-b1cc-57cd34048e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c488b8ad-e7e2-4033-b1cc-57cd34048e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7f6537eb-f791-4835-81ad-9faa2d5eead5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_DividendsCommonStockCash_7f6537eb-f791-4835-81ad-9faa2d5eead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c42d148d-4b37-4924-8072-98aeaf678c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_c42d148d-4b37-4924-8072-98aeaf678c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7ce0e936-926d-4591-b8a1-efa580d12b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7ce0e936-926d-4591-b8a1-efa580d12b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_d4282766-8681-4206-8ace-d28fb9ad2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_d4282766-8681-4206-8ace-d28fb9ad2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36fc2c9a-3687-4e07-a028-a8847a453f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36fc2c9a-3687-4e07-a028-a8847a453f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf80bdd2-672b-4728-8a3c-bc8ca1545a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_82c10f9b-d3ec-4ca7-9a7c-3b5d5b14f974" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf80bdd2-672b-4728-8a3c-bc8ca1545a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_090ef363-005d-44a7-bad7-4f7eced9dd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_090ef363-005d-44a7-bad7-4f7eced9dd28" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a06d196-c92f-42df-ab24-12877186e1b2" xlink:to="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_450821c5-400a-4902-9bde-c157d480426d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05e96653-1cef-443e-b322-1b6040986e04" xlink:to="loc_us-gaap_NoncontrollingInterestMember_450821c5-400a-4902-9bde-c157d480426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_25f21faf-e35d-4ebe-97ed-74ba1d971642" xlink:to="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_95d04885-8f86-43f6-a5d3-ee9f303a59e2" xlink:href="rprx-20221231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_95d04885-8f86-43f6-a5d3-ee9f303a59e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_af18f348-70a9-4807-aefe-5f4638ebfd93" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_af18f348-70a9-4807-aefe-5f4638ebfd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_7355781b-bc14-440a-89b9-e958baf4841d" xlink:href="rprx-20221231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_7355781b-bc14-440a-89b9-e958baf4841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_a529b0bd-31d1-4afe-82b8-b0a65412f898" xlink:href="rprx-20221231.xsd#rprx_EPAHoldingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4806496-74ac-4118-9653-55a2fe808687" xlink:to="loc_rprx_EPAHoldingsMember_a529b0bd-31d1-4afe-82b8-b0a65412f898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5282f58d-8343-412a-a927-4492fcaa07fe" xlink:to="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_1dffb363-a0b4-47d4-9390-e3d3add326d2" xlink:href="rprx-20221231.xsd#rprx_RPHoldingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7799e4f4-388b-48ce-a153-9b90f64a7f6d" xlink:to="loc_rprx_RPHoldingsMember_1dffb363-a0b4-47d4-9390-e3d3add326d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3a944dd8-c4d6-40da-a519-f18e972a0555" xlink:to="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39725012-e85f-45ab-ad9d-f1e3a3787870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_39725012-e85f-45ab-ad9d-f1e3a3787870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_75db0a73-b375-4b6e-90a3-3794bad4dc10" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_75db0a73-b375-4b6e-90a3-3794bad4dc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_0ca45769-92c2-456a-ab81-e74e93e098ba" xlink:href="rprx-20221231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_0ca45769-92c2-456a-ab81-e74e93e098ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9a277007-c419-470f-90dd-ae00bf008d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9a277007-c419-470f-90dd-ae00bf008d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_cf085170-d84f-43db-a75e-97efd3aec510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockholdersEquityOther_cf085170-d84f-43db-a75e-97efd3aec510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d5a35a77-4e59-4fd2-b38d-1f683e14b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_ProfitLoss_d5a35a77-4e59-4fd2-b38d-1f683e14b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_10dffd82-182a-45ba-9833-2c10e8a6a801" xlink:href="rprx-20221231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_10dffd82-182a-45ba-9833-2c10e8a6a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e02d5e57-144b-4140-8112-516be68e8b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e02d5e57-144b-4140-8112-516be68e8b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dd39b2ae-a583-4efd-ae51-da6aaa39ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dd39b2ae-a583-4efd-ae51-da6aaa39ae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cedad2cd-d149-4178-8dc2-375c22ec33ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cedad2cd-d149-4178-8dc2-375c22ec33ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5636938f-f2dd-4e03-98ff-789878af5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_6e6d3443-4c87-459a-927e-6e7f14fa1395" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5636938f-f2dd-4e03-98ff-789878af5afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3e9ef853-3697-4885-93c5-22e2d5e5d8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0f1c5b8f-f224-403f-b270-b6f9d635e844" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3e9ef853-3697-4885-93c5-22e2d5e5d8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70de2c5b-be32-4663-90b6-c55805692bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70de2c5b-be32-4663-90b6-c55805692bba" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:to="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c4a4ab53-78ab-44db-88c2-bf80bca62995" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_5cec8afc-aacb-429f-8181-81816a0d2d0d" xlink:href="rprx-20221231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_5cec8afc-aacb-429f-8181-81816a0d2d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_8dbc4312-e02c-4389-aa92-4194dc50f91c" xlink:href="rprx-20221231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_8dbc4312-e02c-4389-aa92-4194dc50f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_5b1f7fb3-a91a-4a71-a85f-dbb2f19f9995" xlink:href="rprx-20221231.xsd#rprx_ClassBHoldersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71908a2e-8963-4931-9bc8-a178306996d0" xlink:to="loc_rprx_ClassBHoldersMember_5b1f7fb3-a91a-4a71-a85f-dbb2f19f9995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_f248c029-ce5f-46d9-b5f6-4f6921fcae41" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_237d786d-80b3-42ab-a1c2-26cecd25728b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a2aec5ba-bec4-476d-a42b-52ba6a92832c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_ProfitLoss_a2aec5ba-bec4-476d-a42b-52ba6a92832c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_1a1fce87-1099-435a-b425-ff064ccff4b4" xlink:href="rprx-20221231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_1a1fce87-1099-435a-b425-ff064ccff4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4735954-7b97-4f38-99da-a7e117f213ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4735954-7b97-4f38-99da-a7e117f213ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8da4bfc4-debc-436d-994d-e332abd66b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8da4bfc4-debc-436d-994d-e332abd66b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bb6912dd-f534-4540-a14b-f2b3f2c840be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a2030a55-aa28-45d5-8a55-364994fccf5d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bb6912dd-f534-4540-a14b-f2b3f2c840be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_15efcb19-409a-4d6c-b2fa-7e7fc3fc793a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45be888a-a121-4b87-bbf8-3636600773fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45be888a-a121-4b87-bbf8-3636600773fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1d756b2e-619d-447b-b261-1aeeabec02de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1d756b2e-619d-447b-b261-1aeeabec02de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c438d97-8462-4da6-8831-faf4c81f77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c438d97-8462-4da6-8831-faf4c81f77a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f68609eb-fc28-49ad-82c7-44bf0406d532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_EarningsPerShareBasic_f68609eb-fc28-49ad-82c7-44bf0406d532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6141db0c-dd49-4d57-9f27-f4e7b8c9b570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_96917be2-f367-4110-aac2-5b0dc98a9d56" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6141db0c-dd49-4d57-9f27-f4e7b8c9b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#IndirectCashFlowDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2f3b088e-54cc-414e-ab3e-e56ef2f5e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_ProfitLoss_2f3b088e-54cc-414e-ab3e-e56ef2f5e3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_5d5d5271-dda1-45e2-8c7a-52758e80352f" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_5d5d5271-dda1-45e2-8c7a-52758e80352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForOtherCreditLosses_967e06b4-1063-4ec9-9879-e50ea8fcee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_ProvisionForOtherCreditLosses_967e06b4-1063-4ec9-9879-e50ea8fcee5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9e75ec29-a504-44f3-9f6a-4d8a2afdc244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9e75ec29-a504-44f3-9f6a-4d8a2afdc244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d0f7e5d-0eb5-4bd6-8f70-fa795224b961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d0f7e5d-0eb5-4bd6-8f70-fa795224b961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_85fa5bdc-baa7-4d48-93ee-a35f44dfd6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_85fa5bdc-baa7-4d48-93ee-a35f44dfd6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_23ccee4e-06ef-4691-80f6-a5c083b81389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_23ccee4e-06ef-4691-80f6-a5c083b81389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_72c8baa9-2526-4693-9676-3f01dc38b4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_72c8baa9-2526-4693-9676-3f01dc38b4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5f0d8ea6-6683-4ed7-86db-d183252421b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5f0d8ea6-6683-4ed7-86db-d183252421b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03e6f67f-31b8-469e-a2d3-8fe79e790c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03e6f67f-31b8-469e-a2d3-8fe79e790c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_af2517ed-2409-412a-b119-c793d9608256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_ShareBasedCompensation_af2517ed-2409-412a-b119-c793d9608256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_dfc2e5da-02af-434b-935c-b3cce1f01ea8" xlink:href="rprx-20221231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_dfc2e5da-02af-434b-935c-b3cce1f01ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_36714d26-df13-4c45-8426-62c5ece8c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_36714d26-df13-4c45-8426-62c5ece8c3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b0919c84-74b3-4247-b579-f50a315cc718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_AssetImpairmentCharges_b0919c84-74b3-4247-b579-f50a315cc718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments_54934bd7-983b-49ec-86ba-8d853c49a9e7" xlink:href="rprx-20221231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_rprx_GainLossOnDerivativeFinancialInstruments_54934bd7-983b-49ec-86ba-8d853c49a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_70a6d8e2-02d3-46bc-a4ff-f9cf20e4161d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e01fdce2-d245-417f-9277-3990e1636af4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_70a6d8e2-02d3-46bc-a4ff-f9cf20e4161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_392c0129-306d-41db-af42-aa0fb1ff216c" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_392c0129-306d-41db-af42-aa0fb1ff216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_a7fa2fab-1607-4a1e-bd55-c56b325be5cd" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_a7fa2fab-1607-4a1e-bd55-c56b325be5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_6ae3a568-3b1b-4040-8bef-fc1329c4c01d" xlink:href="rprx-20221231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_6ae3a568-3b1b-4040-8bef-fc1329c4c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_a2d12eef-e7bd-4aa5-9928-3d495abc7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_cb0bd43d-4c7d-482a-8ef6-c73c755a6d0d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_a2d12eef-e7bd-4aa5-9928-3d495abc7e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_516a5d14-6df9-44f8-8a31-79e02b10d77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_516a5d14-6df9-44f8-8a31-79e02b10d77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d688abfd-c2ba-4448-80bc-15b00ac7ef70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_516a5d14-6df9-44f8-8a31-79e02b10d77a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d688abfd-c2ba-4448-80bc-15b00ac7ef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_4b7d2568-5aa0-41c0-a6ec-e906b3ec7df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_516a5d14-6df9-44f8-8a31-79e02b10d77a" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_4b7d2568-5aa0-41c0-a6ec-e906b3ec7df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_841bdecc-3be4-43fe-afd5-9957eac0884b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_841bdecc-3be4-43fe-afd5-9957eac0884b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_25ea4e22-83e5-4364-960f-284203211b10" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_e8d67876-fffe-4972-b773-095202595c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_e8d67876-fffe-4972-b773-095202595c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SettlementsWithEquityMethodInvestments_1e3eb4cf-6beb-49eb-bc49-335e3301d44d" xlink:href="rprx-20221231.xsd#rprx_SettlementsWithEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:to="loc_rprx_SettlementsWithEquityMethodInvestments_1e3eb4cf-6beb-49eb-bc49-335e3301d44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationEquityInvestment_3263bded-152a-4508-88d7-b6c82e8c331f" xlink:href="rprx-20221231.xsd#rprx_AccruedPurchaseObligationEquityInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:to="loc_rprx_AccruedPurchaseObligationEquityInvestment_3263bded-152a-4508-88d7-b6c82e8c331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_64028b6d-3b66-4d17-a2f6-745471b46862" xlink:href="rprx-20221231.xsd#rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:to="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_64028b6d-3b66-4d17-a2f6-745471b46862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestonePaymentAccruedButNotPaid_f480fd12-8b5a-4821-a2db-20f2f7ec4f74" xlink:href="rprx-20221231.xsd#rprx_MilestonePaymentAccruedButNotPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_844e50b3-9eb8-450a-9b97-a19d6cdfd607" xlink:to="loc_rprx_MilestonePaymentAccruedButNotPaid_f480fd12-8b5a-4821-a2db-20f2f7ec4f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b5e76ee-2d04-4507-a129-7e0cb7dc3a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingCommitmentAmountOutstanding_ecac916e-0daa-46cc-8cf8-dc146c35fcb9" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingCommitmentAmountOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b5e76ee-2d04-4507-a129-7e0cb7dc3a4a" xlink:to="loc_rprx_LongTermFundingCommitmentAmountOutstanding_ecac916e-0daa-46cc-8cf8-dc146c35fcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_18173c10-e832-44d8-b1a9-53b02d66dd78" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipCovenantRequiredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b5e76ee-2d04-4507-a129-7e0cb7dc3a4a" xlink:to="loc_rprx_LongTermFundingPartnershipCovenantRequiredAmount_18173c10-e832-44d8-b1a9-53b02d66dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_fd91f944-ab75-4160-b2b3-9557620b2a46" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b5e76ee-2d04-4507-a129-7e0cb7dc3a4a" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_fd91f944-ab75-4160-b2b3-9557620b2a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipExpectedPayment_a2540bd5-e74f-4e7d-bc8d-fc27851151b6" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipExpectedPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b5e76ee-2d04-4507-a129-7e0cb7dc3a4a" xlink:to="loc_rprx_LongTermFundingPartnershipExpectedPayment_a2540bd5-e74f-4e7d-bc8d-fc27851151b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c14c2ae2-a7ef-4d21-a87c-902bdf1ab429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c14c2ae2-a7ef-4d21-a87c-902bdf1ab429" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3fe23926-8923-416c-a89d-75923423a06c" xlink:to="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_185df403-bb2f-4e02-b143-cded23d44c29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_srt_ManagementMember_185df403-bb2f-4e02-b143-cded23d44c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c14ffe12-6886-491d-b30a-e83f1285a475" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_srt_AffiliatedEntityMember_c14ffe12-6886-491d-b30a-e83f1285a475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember_24820c99-b8ba-456c-b8a3-2145f3482866" xlink:href="rprx-20221231.xsd#rprx_PabloLegorretaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3e9274ca-c857-47ed-8cbf-74f8ee15794b" xlink:to="loc_rprx_PabloLegorretaMember_24820c99-b8ba-456c-b8a3-2145f3482866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f5f35483-20e2-4a8d-8fcf-7dbfd109f821" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_7f1c2b89-8b86-4e12-938d-09423e4e627d" xlink:href="rprx-20221231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_7f1c2b89-8b86-4e12-938d-09423e4e627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_f76006f9-66f0-433d-9535-9b8fc43e689a" xlink:href="rprx-20221231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_f76006f9-66f0-433d-9535-9b8fc43e689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_c8c0f5d4-9cfd-4452-a6a4-6a9060fc038f" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_c8c0f5d4-9cfd-4452-a6a4-6a9060fc038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_a6363409-300a-42dc-9463-0013211c448e" xlink:href="rprx-20221231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_a6363409-300a-42dc-9463-0013211c448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_01bd278f-83a2-42c4-a5a9-88063f5510a9" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_01bd278f-83a2-42c4-a5a9-88063f5510a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_8504c6dd-0d80-4f6b-a886-94d229dd4022" xlink:href="rprx-20221231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_8504c6dd-0d80-4f6b-a886-94d229dd4022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_6163a780-979a-4373-8a8f-d988544924e7" xlink:href="rprx-20221231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AgreementWithMSCIMember_6163a780-979a-4373-8a8f-d988544924e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember_2b04a6a7-fe71-4e6b-802b-2d0b0dc0894c" xlink:href="rprx-20221231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_PurchasingAndDonatingVentilatorsMember_2b04a6a7-fe71-4e6b-802b-2d0b0dc0894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_102a75b5-0543-4e59-95cb-f24de5fddde7" xlink:href="rprx-20221231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3e8421e4-11c8-4758-abba-ab121c923204" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_102a75b5-0543-4e59-95cb-f24de5fddde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fa1e18-a420-4d77-826b-5459ea28b8c2" xlink:to="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e250ea2e-e346-434e-86a9-709c6c991aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:to="loc_us-gaap_TreasuryStockMember_e250ea2e-e346-434e-86a9-709c6c991aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7bff9e32-d880-455e-abe0-3ba6cd765fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_660812e4-fc21-4726-aee2-a713217a959b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7bff9e32-d880-455e-abe0-3ba6cd765fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_caf19977-1c3b-4656-a982-7e892908a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_108cc3ed-ad46-466b-a956-85585f31897c" xlink:href="rprx-20221231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_670db12a-e3f6-4428-a0ac-6a020fd9d389" xlink:to="loc_rprx_BristolMyersSquibbMember_108cc3ed-ad46-466b-a956-85585f31897c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df2018d6-b23e-4eae-b910-9b61d468f61b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_44c9e18a-5899-4836-a184-bf5cd13150c2" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_44c9e18a-5899-4836-a184-bf5cd13150c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_787d649b-712b-462e-bd31-0b6f472618aa" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_787d649b-712b-462e-bd31-0b6f472618aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_1a76a17f-38d8-4a73-ac4f-124775c6ab28" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_1a76a17f-38d8-4a73-ac4f-124775c6ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_304240b3-6d9d-42a5-9845-047ad2850883" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_304240b3-6d9d-42a5-9845-047ad2850883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_440c835c-12b3-4549-ab49-db4439b607ca" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_440c835c-12b3-4549-ab49-db4439b607ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5d35aa24-b74c-41d6-9eea-02a6ebcc15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5d35aa24-b74c-41d6-9eea-02a6ebcc15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_1c405af9-e768-4c75-9c9f-d3bcf0630d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_1c405af9-e768-4c75-9c9f-d3bcf0630d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_b946ac8e-7682-4e60-b1ba-3fb6ddfa6c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_b946ac8e-7682-4e60-b1ba-3fb6ddfa6c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_492bd265-939a-4032-b627-66422f6b5c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_NotesReceivableNet_492bd265-939a-4032-b627-66422f6b5c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_052dfa89-7914-4db6-bf49-3c0eec789503" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_052dfa89-7914-4db6-bf49-3c0eec789503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_64751f47-20f4-4d4b-83e4-492dbf2c7467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_DueFromRelatedParties_64751f47-20f4-4d4b-83e4-492dbf2c7467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_98ad3882-d246-489a-b005-f33b4f4f5db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_98ad3882-d246-489a-b005-f33b4f4f5db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_4f6ca899-b61e-406d-ad93-579da07107d7" xlink:href="rprx-20221231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_4f6ca899-b61e-406d-ad93-579da07107d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_51fdf6bc-6206-40f1-b463-828cd9bd908e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_96dd3b49-3b47-4cfc-a56d-47603dc43787" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_51fdf6bc-6206-40f1-b463-828cd9bd908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_372f90da-8483-4ccb-8162-1b5b09c9bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_372f90da-8483-4ccb-8162-1b5b09c9bba1" xlink:to="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_87249ed9-497c-4f3b-844e-ef4ef2b28e89" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7efa609f-13ec-4436-9605-b74c809327cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b5178d4c-8434-4f0a-bb7f-23e95272bfc5" xlink:to="loc_us-gaap_SubsequentEventMember_7efa609f-13ec-4436-9605-b74c809327cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d31ae2ab-c9bc-4f38-a115-2a1a4dcbe5ed" xlink:to="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_b24059cc-8c13-426e-afdc-6896ba482172" xlink:href="rprx-20221231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_b24059cc-8c13-426e-afdc-6896ba482172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e1eb4590-649f-40a1-bfea-d3ee29ac5327" xlink:href="rprx-20221231.xsd#rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment_e1eb4590-649f-40a1-bfea-d3ee29ac5327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7ea5038-efc6-4edc-ae57-e92b0314ac63" xlink:href="rprx-20221231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e12ac637-cd15-45e4-9f27-d286c230daf9" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_a7ea5038-efc6-4edc-ae57-e92b0314ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>rprx-20221231_g1.jpg
<TEXT>
begin 644 rprx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<V$@4FEN
M86QD:0    60 P "    %   $*:0!  "    %   $+J2D0 "     S(R  "2
MD@ "     S(R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5J* +-%5J* +-%5J* +-%5JFB^Z?K0 ^BBB@ HHJ"3_6&@">BJU% %FBJU%
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M-RD9Z'J,CFKU?-'@1+[P;\,O!7CBWUS53IO]I20:K82W;&TB@DFDBWK%T&"
MW?YFS]/5_A7>ZAXA37O%5[>7,MGJNHNNF6\DS-'%;1$HK(I.%+$,3@<X!YH
MLZY\8_ GAO6KG2-:UW[-?6K!9HOL<[[20".50@\$=#71^'O$FD>*]'CU7P]?
M1WUG(2HD0$8(Z@J0"I]B >1ZUXH^I>-M'^*/Q.U'P)9Z5?"U-G+>6]\LK2R
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M/$>E>&XK.36KK[,E]=I96Y\MWWS/G:OR@XSM/)P/>O%[NX\00^"/"&AWNO\
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M7CO9;<!I8_*>)@#WVNH)'N.!QZUPGQ1_MO\ X71X!_X1;[!_:ODW_D?VEO\
M(_U7S;MGS?=W8QWQVKGO#NOZO=:]XY\9^)/LUIXO\-Z3+9#2+:V*1B-09%G+
M,S&0%@>G&T*<X9: /H&BOG;X=:MX]@\4>&]0U"XOIK'6XGDG74_$5M<)=J4W
M;K>W^5XRI.2J[B <'&*UO 3ZIXAT;3/'^L?$>\TJ[N=5:.;3[J=?L#(&9?LR
MPEE =E (.21UP3\U 'N=9>G>(]*U76M4TBPNO-OM):-;V+RW7RC("4Y( ;(!
MZ$^]?.E[XI^(6J:KK?B;3+F\@CT_5WMH7F\06UKI\"HP BEM9<;F(S\Q89+
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M&G3ZOKO@/3-+M_$NJ*8[B;49)C;RH[ R;D4D G&<A>O7J:[BB@#EOAOX,C\
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MAP3A2,G!7'.#U KH** .3TGX7^#="T74=)TK1([>TU-#'>+YTC/*A&-N\L6
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M+7T_6G44 -\M?3]:/+7T_6G44 -\M?3]:/+7T_6G44 -\M?3]:/+7T_6G44
M-\M?3]:/+7T_6G44 -\M?3]:/+7T_6G44 -\M?3]:/+7T_6G44 -\M?3]:!&
MH/ IU% !1110 4$ C!HHH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^
MGZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M
M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^G
MZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.
MHH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZ
MT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.H
MH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT
M>6OI^M.HH ;Y:^GZTH4*.*6B@ HHHH *:44G)%.HH ;Y:^GZT>6OI^M.HH ;
MY:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6O
MI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y
M:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI
M^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:
M^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^
MM.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^GZT>6OI^M.HH ;Y:^
MGZT>6OI^M.HH ;Y:^GZT>6OI^M.HH :(U!X%.HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=,O;=+.S6\D2"+=9PLY**0'R3G#94') !))[F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ@ #'/.*2[\"WNL6NN2:_K$%QJ.J:5+I4,UK9&&&TA=3DB-I'+,6())?G:H
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M82500 1@Y0<848QMQG%6XSW1*E'9F3X?_P"1FTS_ *_(O_0Q7G.N?\C#J/\
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M!C*$<8.?3%;8\1:(==.B#6+ ZL.38?:D\\?+N_U>=WW?FZ=.:\VO?#6K:/\
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M/Y<^M>345$J<)_$AIM;'USX3^+OA7Q8R0079L;UN!:WF$9CZ*<X;Z Y]A7<
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M7$;VL5I:7<5O,IE4%PJ1>85P=O+/A1EBHR O/G6I6?\ 9^JW=EY@E^S3O%O
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M#C>O.=I['O\ 2N4R+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y'\6_%GG3#P]8R?NXR'NR#]YNJI^'4^^/2O1/%6O1^&
M_#ESJ+X,BKMA0_QR'[H_J?8&OF^XGENKF6XN',DLKEW<]68G)-=V$I<SYWT.
M;$3LN5$=6;+4K[39&?3KVXM'<89H)60L/0X-5J*]/<X30;Q!K+W4=R^KWS3Q
M@JDIN7+(#U .<C-03ZE?7-ZEY<WMQ+=(05GDE9G4CD88G(Q5:BERH=V6;74[
M^RNGN;*]N+>>0$/+%*R,P)R<D')Y -5J**8@HHHH **** "BBB@ KB_$7_(T
M:I_U^3?^AFNTKB_$7_(T:I_U^3?^AFI>YO2ZF=1113-@HHHH **** "BBB@
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MDN'M82?+%Q)O903G /IFM6L7:^A 4444@"BBB@ HHHH **** "BBB@ HHHH
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M>64,TCKC8LC/<N3C:B[#C/)Q0!Z5=7EM8Q+)>W$-NC2+&K2N$!=B%503W)(
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MNBH[>XCNK6*X@=9(Y5#HRG(((SD5)7B'2%%%% !1110 4444 %%%% !1110
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M[1XGM;)3E;6WR1Z,YR?T"UT8:/-51E6E:#//****]D\T**** "BBB@ HHHH
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M% '.Z3X/33]4@U'4-9U36[JU@,%J^HM$?LZMC<5$<:99L*"S;FP.",G,>E>
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MD<8(/N*VC)2V,W%K<;1115$G._$/_DI&O_\ 7_+_ .A&N<KH_B'_ ,E(U_\
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MQY-C-=.#]ZYFVHP_W$ (_P"^S7NW]NZO_P!!2]_\"'_QH_MW5O\ H)WG_?\
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MH5_SLC23_KG*C?IG-:=%/FD'*C&DTK4(N7LK@#U\LX_.H;Q8K^,0ZW9I> #
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M+V=L]O?QVBB1Y56X#@X,>1\W(Z],5J>'_B;J^H_$]/".H:;91F.)Q<W%O*S
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M3Q2 CHK/NO$>@V/%QJ\#MC(2V!F)_%?E_6L2Z^(^FQ<6&F7%P<?>N91& ?\
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MVQB(R&G3=],C/Z5,GRQ;&E=V/:E^Z/I2T45\4>Z%%%% !1110 4444 %%%%
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MU:^_(+'V4ULN[2.SNQ9F.2Q.23ZUQ59<T^7M^?\ 7YBD[*W<2BBBI,0HHHH
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M* "BBB@ HHHH A:RM7D,CVT+.>K&,$G\:FZ=***5DMAMM[C1$BR-(J*';[S
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MZ<G^8KDQD^2A)_+[S:C'FJ)'=T445\F>P%%%% !1110 4444 %%%% !1110
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M;_@>7F"A=7N>545WFMZ%);:!+:Z/+;I#F6ZNHU<[[GRVP0IQ@QQ9*C+ L0[
M'BN#K>C55571,H\H4445L2%%%% !0 2<#DT5T?@RP6349-4N4#6^F@2!6'#R
MG_5K^8W'V4U%2:A%R&C?-I_8^E6VD#B2+][=8[S,.1_P$87ZAO6H*<[M+(SR
M,6=B2S$\DGO3:X8II:F,G=W"BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****
M "K%A:/?ZA!:Q_>FD"9],GK5>NU^'>D^;>2ZG*ORPCRXB?[Q')_+C\:PQ%54
M:3F:4X<\U$]!@A2WMXX8QM2-0J@=@*?117Q^Y[04444 %%%% !1110 4444
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MS3N09[@=PS#[J_[*\>I-:TZ<JCT)E)1W+#1Z=X>/^FB+4]24_P#'JK9@@/\
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MGZ?<:G=>1:J,A2[NYVI&HZLS'@*/4U]$^)/#MIXFT>2QO1@GYHI0.8W[,/\
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MD%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\#$XZ=;W5HCT*6'C#5ZL****\\Z0HHHH **** "BBB@ HHHH **** "BBB@
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M5K*^USAQF*GAE%QAS7=M[:O;H>PE@JEF( '4DU0DURP1BL<CW#C^&VC:4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8+C/'7BMZN&MR^T?+L=M+FY%S;A11161J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ",H92K $$8((ZU2@T/2;6Y^TVV
MEV4,^<^;';HK?F!FKU%-2:V$TGN%%%%(84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>rprx-20221231_g2.jpg
<TEXT>
begin 644 rprx-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<V$@4FEN
M86QD:0    60 P "    %   $*:0!  "    %   $+J2D0 "     SDP  "2
MD@ "     SDP  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<%Y(5-CJ5GF.WN P)4,CNQC8\*!N;+9[8)].FFBMX6EN)$BC099W8*%'N30
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFW;03N4$A><C&3TSQG%0^)/B1I>A^*++PM91MJ?B*^_U5C%(J",;2V9'/"#
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ME3_DJ>I?]@67_P!'P5[=XX^-NB?#[6AIOB'1-<5I%+0S0Q0/',O]Y3YH/7U
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M+)!\8;:6%VCDCTV!D=#@J0\A!![&OI_PW?P>+_ FD:CJ%M#*FHV4%S+#(@=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6""(V_BQCY@"%<<?, ,=0:^KS\4O"UU+86OA_4H==O\ 4'18+/3Y!)( W5W
M_P!6JKEFW8( Z9XJWXI^'/A+QI*DOB;0[>]F1=JSY:.7;U WH0Q'MG')]:F\
M+> _#'@J&2/PQH\%AYHQ)(I9Y'&<X+L2Q&3T)H Z"L7QG_R(>O\ _8-N?_13
M5M5#>V<&H6%Q97B>9;W,312IDC<C#!&1R.#VH ^//V:98X_C-;+(ZJTEG.J
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M3W%G&Z7,*2 O"QE? =>JY'(SU'(KI->^'7A'Q+I%KIFL:#:2V=F"+6*)3"(
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M5N?$NA07EPH $ZN\4A S@%D*DCGH3BKWACP9X=\&V;6WAG2H+"-SERF6=_\
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M_M)X+"=ERMTF5D4AL8SMCY]&&*^FK:V@L[6*ULX8X+>%!'%%$@5(U P%4#@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D==^%?@GQ+K0U?6_#
MUM<WV<M-N=/,. /G"D!^ /O UU<,,5M;QP6\:10Q*$CCC4*J*!@  = !VI]%
M !1110 4444 %%%% !7'ZI\)O NL^(#K6I^&[2>_9B[R'<%D8]2Z [6/N0>>
M:["B@!%544*@"JHP !@ 4M%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!5U+3++6=-GT_5;6*[L[A=DL,R[E<>X_6L+PQ\-_"/@R[ENO#6AP65
MQ,"&FW-(^#C*AG)(' X&!73T4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !115'6M6MM"T.\U2^;;!:1-*Y]<#I^/2A:Z 4K;Q9IMUXTO/"
M\)D.H6=LMS+P-@4D<9SG/S*>G1A6W7Q[H_C+4=$^*@\3:DLL=P;QY+R$@AMC
MDATP?0'@=L#TK[ CD26-9(G5T<!E93D,#T(-;UJ7L[$QE<R?$7BK2/"EHEUK
MT\UM;N2/.6UEE13P/F9%(7.1C.,]NAJKX:\>^&O%]S-;^'=2^V2P('D7R)(]
MJDXS\ZC-4_BK_P DKU__ *]3_P"A"O)?V;/^1DUK_KT3_P!#IQIQE2<^J$VU
M*QZMJ7Q9\&:/J$ECJNJS6=U$</%-I]PK#T.#'T/8]ZZNPOK?4].MK^QD\VVN
MHEFA?:1N1@"IP>1D$=:^;_VC?^2BV'_8*C_]&RU[SX$_Y)UX<_[!5K_Z*6BI
M3C&G&2Z@FV[&Y(XBC9V#$*"2%4L>/0#D_05Q^H?%CP=I%U]FU74KFQGVAO*N
M=-NHVP>APT8.*[*OGS]I51_:^@M@9,$P)Q_M+4T81G/E8Y-I7/1_^%V?#[_H
M8/\ R2N/_C==%HGC'P[XD<IH>L6MY(%W&)),.!Z[3S^E>>?L[PQ7'PUU&*XC
M26-M5D#(ZA@?W474&N"^-/@^/P3XKLM9\-JVGV]Z2Z"VS&+>9,9V$'Y<Y! &
M,8..G&OLJ;FZ:NF3S.USZ:HKS_X/^.I?&OA(C47WZII["*Y?@>8#DH^!TR 0
M?=37=W-U!9V[W%Y/'!"@R\DKA57ZD\"N:47&7*RT[JY+15#3=>TC6=_]CZK9
M7_E_?^RW"2[?KM)Q5^E9K<845E7WBGP_IDY@U+7=-LYAUCN+R.-OR)K0MKJ"
M\MTN+.>.>%QE)(G#*WT(X-%F!S6N?$OPIX:U$V.NZC-97 &0LEC/AATRK!,,
M/<$BMO1-;T_Q'H\&JZ-<?:;*XW>7+L9-VUBIX8 CD$=*\6_:9_YEG_M[_P#:
M-=Y\$_\ DCNB?]M__2B2MY4XJDIKJ0F^:QWE%9DWB;0K?4?[/N-:TZ*]R%^S
M/=HLF?3:3FK\5Q#.T@@ECD,3^7($8'8V =IQT."#CW%8699)1112 **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(['_D<;?\
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MNL'\GKF?VC?^2BV'_8*C_P#1LM3#3$M('\![3HG_ "173O\ L7XO_2<5X-\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  8Q?_%4?\)WX1_Z&K1/_!C%_P#%4?\ "">$?^A5T3_P71?_ !-'_"">$?\
MH5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\ @QB_
M^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z
M&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\31_P
M@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-6B?^
M#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&H?\
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M$?\ H5=$_P#!=%_\31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\
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M  8Q?_%4?\)WX1_Z&K1/_!C%_P#%4?\ "">$?^A5T3_P71?_ !-'_"">$?\
MH5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\ @QB_
M^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z
M&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\31_P
M@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-6B?^
M#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&H?\
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M$?\ H5=$_P#!=%_\31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\
M@QB_^*H_X3OPC_T-6B?^#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0
MJZ)_X+HO_B:/W?F&H?\ "=^$?^AJT3_P8Q?_ !5'_"=^$?\ H:M$_P#!C%_\
M51_P@GA'_H5=$_\ !=%_\31_P@GA'_H5=$_\%T7_ ,31^[\PU#_A._"/_0U:
M)_X,8O\ XJC_ (3OPC_T-6B?^#&+_P"*H_X03PC_ -"KHG_@NB_^)H_X03PC
M_P!"KHG_ (+HO_B:/W?F&H?\)WX1_P"AJT3_ ,&,7_Q5'_"=^$?^AJT3_P &
M,7_Q5'_"">$?^A5T3_P71?\ Q-'_  @GA'_H5=$_\%T7_P 31^[\PU#_ (3O
MPC_T-6B?^#&+_P"*H_X3OPC_ -#5HG_@QB_^*H_X03PC_P!"KHG_ (+HO_B:
M/^$$\(_]"KHG_@NB_P#B:/W?F&H?\)WX1_Z&K1/_  8Q?_%4?\)WX1_Z&K1/
M_!C%_P#%4?\ "">$?^A5T3_P71?_ !-'_"">$?\ H5=$_P#!=%_\31^[\PU#
M_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\ @QB_^*H_X03PC_T*NB?^"Z+_
M .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z&K1/_!C%_P#%4?\ "=^$
M?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\31_P@GA'_H5=$_\ !=%_\31^
M[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-6B?^#&+_ .*H_P"$$\(_]"KH
MG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&H?\ "=^$?^AJT3_P8Q?_ !5'
M_"=^$?\ H:M$_P#!C%_\51_P@GA'_H5=$_\ !=%_\31_P@GA'_H5=$_\%T7_
M ,31^[\PU#_A._"/_0U:)_X,8O\ XJC_ (3OPC_T-6B?^#&+_P"*H_X03PC_
M -"KHG_@NB_^)H_X03PC_P!"KHG_ (+HO_B:/W?F&H?\)WX1_P"AJT3_ ,&,
M7_Q5'_"=^$?^AJT3_P &,7_Q5'_"">$?^A5T3_P71?\ Q-'_  @GA'_H5=$_
M\%T7_P 31^[\PU#_ (3OPC_T-6B?^#&+_P"*H_X3OPC_ -#5HG_@QB_^*H_X
M03PC_P!"KHG_ (+HO_B:/^$$\(_]"KHG_@NB_P#B:/W?F&H?\)WX1_Z&K1/_
M  8Q?_%4?\)WX1_Z&K1/_!C%_P#%4?\ "">$?^A5T3_P71?_ !-'_"">$?\
MH5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\ @QB_
M^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z
M&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\31_P
M@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-6B?^
M#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&H?\
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M"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z&K1/_!C%_P#%4?\
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M$?\ H5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\
M@QB_^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)W
MX1_Z&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\
M31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-
M6B?^#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&
MH?\ "=^$?^AJT3_P8Q?_ !5'_"=^$?\ H:M$_P#!C%_\51_P@GA'_H5=$_\
M!=%_\31_P@GA'_H5=$_\%T7_ ,31^[\PU#_A._"/_0U:)_X,8O\ XJC_ (3O
MPC_T-6B?^#&+_P"*H_X03PC_ -"KHG_@NB_^)H_X03PC_P!"KHG_ (+HO_B:
M/W?F&H?\)WX1_P"AJT3_ ,&,7_Q5'_"=^$?^AJT3_P &,7_Q5'_"">$?^A5T
M3_P71?\ Q-'_  @GA'_H5=$_\%T7_P 31^[\PU#_ (3OPC_T-6B?^#&+_P"*
MH_X3OPC_ -#5HG_@QB_^*H_X03PC_P!"KHG_ (+HO_B:/^$$\(_]"KHG_@NB
M_P#B:/W?F&H?\)WX1_Z&K1/_  8Q?_%4?\)WX1_Z&K1/_!C%_P#%4?\ "">$
M?^A5T3_P71?_ !-'_"">$?\ H5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&
M+_XJC_A._"/_ $-6B?\ @QB_^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KH
MG_@NB_\ B:/W?F&H?\)WX1_Z&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'
M_"">$?\ H5=$_P#!=%_\31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6
MB?\ @QB_^*H_X3OPC_T-6B?^#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(
M_P#0JZ)_X+HO_B:/W?F&H?\ "=^$?^AJT3_P8Q?_ !5'_"=^$?\ H:M$_P#!
MC%_\51_P@GA'_H5=$_\ !=%_\31_P@GA'_H5=$_\%T7_ ,31^[\PU#_A._"/
M_0U:)_X,8O\ XJC_ (3OPC_T-6B?^#&+_P"*H_X03PC_ -"KHG_@NB_^)H_X
M03PC_P!"KHG_ (+HO_B:/W?F&H?\)WX1_P"AJT3_ ,&,7_Q5'_"=^$?^AJT3
M_P &,7_Q5'_"">$?^A5T3_P71?\ Q-'_  @GA'_H5=$_\%T7_P 31^[\PU#_
M (3OPC_T-6B?^#&+_P"*H_X3OPC_ -#5HG_@QB_^*H_X03PC_P!"KHG_ (+H
MO_B:/^$$\(_]"KHG_@NB_P#B:/W?F&H?\)WX1_Z&K1/_  8Q?_%4?\)WX1_Z
M&K1/_!C%_P#%4?\ "">$?^A5T3_P71?_ !-'_"">$?\ H5=$_P#!=%_\31^[
M\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\ @QB_^*H_X03PC_T*NB?^
M"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z&K1/_!C%_P#%4?\
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M$?\ H5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\
M@QB_^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)W
MX1_Z&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\
M31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-
M6B?^#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&
MH?\ "=^$?^AJT3_P8Q?_ !5'_"=^$?\ H:M$_P#!C%_\51_P@GA'_H5=$_\
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M"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)WX1_Z&K1/_!C%_P#%4?\
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M$?\ H5=$_P#!=%_\31^[\PU#_A._"/\ T-6B?^#&+_XJC_A._"/_ $-6B?\
M@QB_^*H_X03PC_T*NB?^"Z+_ .)H_P"$$\(_]"KHG_@NB_\ B:/W?F&H?\)W
MX1_Z&K1/_!C%_P#%4?\ "=^$?^AJT3_P8Q?_ !5'_"">$?\ H5=$_P#!=%_\
M31_P@GA'_H5=$_\ !=%_\31^[\PU#_A._"/_ $-6B?\ @QB_^*H_X3OPC_T-
M6B?^#&+_ .*H_P"$$\(_]"KHG_@NB_\ B:/^$$\(_P#0JZ)_X+HO_B:/W?F&
MH?\ "=^$?^AJT3_P8Q?_ !5'_"=^$?\ H:M$_P#!C%_\51_P@GA'_H5=$_\
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M ZBF^8G]Y?SH\Q/[R_G0 ZBF^8G]Y?SH\Q/[R_G0 ZBF^8G]Y?SIU !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !3H_\ 6+]13:='_K%^HH NT444 %%%% %:Y_U@^E0U-<_ZP?2H: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *OU0J_0 4444 %%
M%% !6#X(TNZT7P=8Z?J"".XA\S>H8,!F1F'(]B*WJRO#.M_\)%X=M=5^S_9O
MM&_]UOW[=KE>N!GIGI3UL+J:M%%%(84444 %5)_]<U6ZJ3_ZYJ (Z*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT?\ K%^HIM.C_P!8OU%
M%VBBB@ HHHH K7/^L'TJ&IKG_6#Z5#0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5^J%7Z "BBB@ HHHH *R?"^BMX=\-VNEO.)V@WYD"
M[0VYV;I^-:U87@O5KK7/"%EJ-^5-Q-YF\HN!Q(RCCZ 4];"ZF[1112&%%%%
M!52?_7-5NJD_^N:@".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *='_ *Q?J*;3H_\ 6+]10!=HHHH **** *US_K!]*AJ:Y_U@^E0T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %VBBB@ HHHH K7/
M^L'TJ&IKG_6#Z5#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5^J%7Z "BBB@ HHHH *K:=!96UA'#I:0QVJY\M8,;!R2<8XZYJS7+?#9
M&3X>Z:KJ58>;D$8/^M>GT%U.IHHHI#"BBB@ JI/_ *YJMU4G_P!<U $=%%%
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MDV_COX?"VGO1*DTMG*RQ_O$7&X9(4JP7##(.3GG)( -'PYH7C2T^/VH>((M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^HIM.C_ -8OU% %VBBB
M@ HHHH K7/\ K!]*AJ:Y_P!8/I4- !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD:M&)QU4U&PQE%*01UXI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "G1_ZQ?J*;3H_]8OU% %VBBB@ HHHH K7/^L'TJ&IKG_6#Z5#0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 44K 1QEYF6)!U9S@5GW&O6%OD1E[AO]D87\S0!H=>E*4*KN?"*.I8XKFKCQ
M'>2Y6 );K_L#)_,UF2SS3MNGE>0^K,30!UDVJZ=;_?N?,;^[$-WZ]*I2^)H5
M_P"/>T9O>1\?H*YRB@#6E\27[_ZKRX1_L)_CFJ<FIWTO^LNYB/0.0/TJK10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X[XEKK&H>#M4T30O#]WJ<^H6;PI-'/;QQ1EOE^8R2*W YX4CH,^G"_
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M>7<-F)S_ +,G0?0X_&O0R, 'J",@CH:X90E!VDC1-/82BBBH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.C
M_P!8OU%-IT?^L7ZB@"[1110 4444 5KG_6#Z5#4US_K!]*AH **** "BBB@
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MC_A65<W4UW,9+B1G8^O;Z>E0T *S,[%G)9CU).<TE%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y3\?_ /D>-,_[ \/_ *')7JU>4_'_ /Y'C3/^
MP/#_ .AR5U87^(1/8\MHHHKUC **** "BBB@ HHHH **** "BBB@ HHHH **
M** .H\'_ !#\0>"KC.DW9>U8YDLI_GB?\/X3[C!KZ"\%?%KP_P",O+M9'_LO
M56P/LL[?+(?]A^A^AP?:OE6CITK"I0A4]2E)H^XRI4X(P:2OG+P'\;]4T#RM
M/\3"35=-&%64G,\ ]B?O#V//OVKW_1=;TSQ'I<>HZ'>1W=JX^\I^9#_=8=5/
ML:\RI1E3>ILI)EZBBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "K]4*OT %%%% !1110 5SO@&_NM3\#V%W?S-/
M<2>9OD?J<2,!^@%=%573-,M-'TZ*PTV+R;:+.Q-Q;&22>22>I-/H+J6J***0
MPHHHH *J3_ZYJMU4G_US4 1T444 %%%% !1110 4444 %%%% !1110 4444
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4Z/_ %B_44VG1_ZQ?J* +M%%% !1110!6N?]8/I4-37/^L'TJ&@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *)'C@A,UPXCB7JQ[_2H;V]@
MTV$/<?,[?<B'5O\  5RM]J$^H3;YVX'W4'1?I0!=U/79+K=#:YAM_;[S_7_"
MLBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRGX__
M /(\:9_V!X?_ $.2O5J\I^/_ /R/&F?]@>'_ -#DKJPO\0B>QY;1117K& 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6SX9\5ZQX0U07^A7;02
M<"1#RDJ_W67N/U';%8U%)I-68'U9X!^*6D>.8Q:N%T_6%7YK1V^67U,9[_3J
M/?K7;D8.#7P]%+)!,DL+M'(C!D=#@J1T(/8U[U\-_C<EZ8='\;2K'-@)!J9X
M#GL)?0_[73UQUKSJV&<?>@;1GT9[-12D8QT((R".A%)7":!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5?JA5^@ HHHH ***
M* "N5^&?_).],_[:_P#HUZZJJNF75C>:=%/I3Q/:/GRVB&%."0<?B#3Z"ZEJ
MBBBD,**** "JD_\ KFJW52?_ %S4 1T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI6H0WVFW,EM=0MNCEB;#*:YZU"-37J5&31]LT5YG\-_C%9^*VBTKQ#Y5CK!
M6.4?+%='V_NO[=#V]*]-(*G!&#7E3A*#M(W33V$HHHJ!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3H_]8OU%-IT?^L7ZB@"[111
M0 4444 5KG_6#Z5#4US_ *P?2H: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,S6=(;65BMY;RZM[,;C/':S&)YN,!2Z_,J\DG:5)('.,
M@_.OCGP?=^$?C1I5G\)I+Z/5+N(74\(E>58LR%=\C-G*'G=O)]^HKZ:FB6>"
M2%RX612I*.48 C'# @@^X.17RS\9_AC/\.]0L_%WAO4[UX9;D!Y)YB\\$_+*
MP?J0=IY/((ZG/ !] >.K#Q+K6GV^C^%+X:2;QF^UZI@E[:(#I& 0=[$C!R,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC8_W3V].G3&/>64JQ!ZUXU2FZ<K,Z$[H2BBBLQA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4Z/_ %B_44VG1_ZQ?J* +M%%% !1110!6N?]8/I4
M-37/^L'TJ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA+HSTNBBBN U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "OHKX,_$S^W;6/PSKT^=2@3%G/(>;A /N$]V
M_,>X.?G6I;6ZGL;N*ZM)6AGA<21R(<,C Y!!K*K352-F.+LS[=Z45Q_PU\>P
M^//#@DF*1ZM: +>0KQN])%'H?T.1Z9["O&E%Q=F="=PHHHJ1A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !3H_]8OU%-IT?^L7ZB@"[1110 4444 5KG_6
M#Z5#4US_ *P?2H: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "G*I9@!3:S]<U#[%:>1$V)YA
MR0>47_Z] &9KNIB[F%O;M_H\1Z_WV]:R*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRGX__ /(\:9_V
M!X?_ $.2O5J\I^/_ /R/&F?]@>'_ -#DKJPO\0B>QY;1117K& 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;TK5+
MO1=6MM2TV4PW5K()(W'8C^8[$=Q52BC<#[&\&>++3QKX7@U>SVI*?DNH <F&
M4=1].X/H16Y7RC\+_'4G@CQ4DLSL=+NR(KV,<_+V<#U4G/TR.]?5P9'19(G6
M2-U#(ZG(93R"#7CUZ7LY:;'1&5T%%%%<Y04444 %%%% !1110 4444 %%%%
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MIM.C_P!8OU% %VBBB@ HHHH K7/^L'TJ&IKG_6#Z5#0 4444 %%%% !1110
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MYU5]K7+?NK.(G[\I'''H.I]A71JI=@!WKY9^+WC?_A+_ !>\5G)NTO3B8+4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-!(T4L;!T=&(96!R"".A%>Y^!/BQ:^(UBT;QK+';:@ $MM4.%67_ &9>P/\
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MBBB@ IT?^L7ZBFTZ/_6+]10!=HHHH **** *US_K!]*AJ:Y_U@^E0T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!'=W(L;&6Y/WE&$'JQZ5Q1)9B6.23DD]ZW/$UUF:*S4\1#<_P#O
M'_ZW\ZPJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O*?C__ ,CQIG_8'A_]#DKU:O*?C_\
M\CQIG_8'A_\ 0Y*ZL+_$(GL>6T445ZQ@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[)^SYXI^R:S=
M^&;I\17X\^VR>DRCD?\  E'_ (X*\;JWI>I7&CZM:ZC8OLN+6598V]U.?RK.
MI#G@XC3L[GVO1572]4M]<T:RU6S_ -1>P+,@S]W(R0?<'BK5>&]-#I"BBB@
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MK Y!!Z&O)Q5/EG==3>#NA****Y2PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^
MHIM.C_UB_44 7:*** "BBB@"M<_ZP?2H:FN?]8/I4- !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4H98U:6
M3A(U+-]!250UZX^SZ3Y8.&N&V_\  1R: .8N)VN;F2:3[TC%C4=%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7E/Q__P"1XTS_ + \/_H<E>K5Y3\?_P#D>-,_[ \/_H<E
M=6%_B$3V/+:***]8P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /HG]G[Q)_:'A>\T"=\S:;)Y
MT )_Y9.>0/HV3_P(5ZS7RE\)/$'_  COQ*TV:1MMO=-]CGSTVR<#/L&VG\*^
MKF&UB/0UY.*ARU+]S>#NA****Y2PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *OU0J_0
M 4444 %%%% !6'X-U>YU[PE9ZE?",3S;]PC7"\2,HX^@%;E9^AZ-;^']%@TR
MS>5X8-VUI2"QW,6.< #J?2GI874T****0PHHHH *J3_ZYJMU4G_US4 1T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ%<V)AS4_0N#LSZ,HHHKR#<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M"ZEFBBBD,**** "JD_\ KFJW52?_ %S4 1T444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?,7^^/YU'4EO_P ?,7^^/YT >%_&;_DKVN?[\7_HE*X>NX^,W_)7M<_WXO\
MT2E</7N4_@CZ',]PHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8L+M[#4K:\B_UEO*LJ
M_52"/Y5]M>:DZ)-$<QRJ'4^H(R*^':^PO &H?VI\-_#]V3N8V21,?5D^0G\U
MK@QBT3-*9T%%%%><;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN/C-_P E>US_ 'XO_1*5P]>Y3^"/H<SW"BBBM!!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MU#\#KO[5\*+2/.?LEU-#],MO_P#9Z^7J^AOV=;HOX1UFTSQ#>K*!_OH!_P"R
M5RXI7IEPW/7****\DW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %VB
MBB@ HHHH K7/^L'TJ&IKG_6#Z5#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 56U5MFAW9]E'YL*LU2ULXT.;W=1
M^M ')4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7E/Q_P#^1XTS_L#P_P#H<E>K
M5Y3\?_\ D>-,_P"P/#_Z')75A?XA$]CRVBBBO6, HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ]3_ &?)_*^)$\>?]=ITJ?\ CR-_[+7T?7S#\"Y"GQ:T]1_RTAG4_P#?
MMC_2OIZO*Q?\0VI[!1117(:!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5^J%7Z "BBB@ HHH
MH *S?#VBQ^'M!M]+AE:9(-V'<8)W,6_K6E7/>!-1NM5\$V%[J$QGN)?,WR$
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M]FZ?_D9+<G[RV\@'T,@/\Q7AE>Q_LY2$>)M:C[-8AL?1Q_C6&(UI,J'Q'O\
M1117C'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %.C_UB_44VG1_ZQ?J* +M%%% !1110!6N
M?]8/I4-37/\ K!]*AH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *H:]_R!&_ZZK5^J&O_P#($/\ UU7^5 '*4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%3VME<7LFRVB9SW(Z#ZF@""O*?C__ ,CQIG_8
M'A_]#DKV^TL]*M[B1;^\25K>,RW 1L1P*.27?MTZ?TKYL^)GC"/QKXSEO[6)
M8K*WC%K:#!!:)22&;W)8G'88';-=N%A)5+M&<Y)K0Y&BBBO3,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH [WX)OM^,&B_[7GC_R!)7U+7RO\%EW?&#0Q[S'_P @25]4
MUY>,_B+T-J>PE%%%<9H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %7ZH5?H **** "BBB@ JK
MIFF6FCZ=%8:;%Y-M%G8FXMC))/))/4FK5<M\-G9_A[IK.Q9CYN23D_ZUZ?07
M4ZFBBBD,**** "JD_P#KFJW52?\ US4 1T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >-_M'-C1/#Z^L\Q_1?
M\:\!KWS]H]<Z1X=;TFG'Z)_A7@=>OAOX2.>?Q!111722%%%% !1110 4444
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M]#FGT%U.EHHHI#"BBB@ JI/_ *YJMU4G_P!<U $=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C_[1BY\-Z&_
MI=2#\U'^%?/M?1O[0\&_P#IL^/\ 5ZD$_P"^HW/_ ++7SE7KX7^$C"?Q!111
M720%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[Y^SA!MT?Q#<
M8_UDT$>?]T.?_9J\#KZ5^ %G]G^&L\Y'S76H2,#_ +*HJ_S!KFQ3M29</B/3
M:***\@W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% %VBBB@ HHHH K7
M/^L'TJ&IKG_6#Z5#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIKSL34YW[);=?\O\SKH0M[[^1D$EF)8DDG))[TE%%8G2%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OK+X361L/A/H<;##2QR3GW
MWR,P_0BODX L0 ,D\ #O7VOI5@-*T+3M. P+.TB@P/\ 94#^E<.,?NI&E/<M
M4445YIL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %.C_UB_44VG1_ZQ?J* +M%%% !1110!6N
M?]8/I4-37/\ K!]*AH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,'Q/%BXMYO[\>T_4'_Z]8==5X@A\W1Q(
M.L,@/X'C^>*Y6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***<B/*X
M2-2['HJC)- #:='&\T@2)&=CT51DFKTEC:Z9$)M=NUME(RL*_-(_T%8]]XR=
M(VM]!MQ8Q'@RGYI6_'M^OUKJH86K6^%:=S*I6A#<UYK2TTJ,2Z[=K!D96WC^
M:1OP[5C7_C*;RVM]#@%A >#(.97^K=OP_.N;DD>:1I)G:1V.69CDD_6FU[E#
M+Z5+66K."IB9RT6B'.[22,\C%W8Y9F.233:**]$Y0HHHH **** "K>EZ;/JV
MI16=L/GD/+8X4=R?854 R<#DTSQ_XB_X0/PI_8UDY37]8BS<.I^:TM_[OLS<
MC\^F!7/7J^SCIN]C6E3YY>1Q_P 6/&<&L7T/AW09 =$TIB Z_P#+S/R&DSW'
M) ^I/0C'G5%%>?%65CO"BBBF 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4MK;
M27EY#;0+NEFD6-!ZL3@?SJ*NT^$>D_VQ\4M&B9<QV\ING]O+!8?^/!1^-3*7
M+%L%JSZJMK1+"RMK*'_5VL*0I]%4 ?RJ2E8[F)]325X)U!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M074LT444AA1110 54G_US5;JI/\ ZYJ (Z*** "BBB@ HHHH **** "BBB@
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M%_\  _,[:,.5<SW(****S-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH U?#&BR>(_%6FZ1%G-Y<+&Q'\*Y^9OP7)_"OLT1QPHD,"!(HE"(HZ*H&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?.?[0&@?V?XW@U>),0ZK
M&8@<>:F%;]-A_$UY37U-\9_#W]O?#:ZFBC+W.EL+N/'78.)!]-I)_P" BOEF
MO7PT^:FO(PFK,****Z2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[/X3>'_P#A(OB5ID$B;K>U?[7/GIMCY&?8MM'XUQE?0?[/7ATVGA_4
M?$,ZX>^D%M;Y_P">:<L1[%CC_@%8UY\E-LJ*NSV!FW,3ZFDHHKQ3H"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IT?\ K%^HIM.C_P!8OU% %VBBB@ HHHH K7/^L'TJ
M&IKG_6#Z5#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K]4*OT %%%% !1110
M5SW@33KK2?!-A9:A"8+B+S-\9()&9&(Z>Q%=#67X;UI?$7A^VU1(# L^[$9;
M<5VN5Z_A3UL+J:E%%%(84444 %5)_P#7-5NJD_\ KFH CHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8/I4- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/H+J=)1112&%%%% !52?_7-5NJD_^N:@".BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FKZ3::
M_HEYI&HKNMKR(QOZJ>S#W!P1]*^._$6A7GAGQ#>:1J*[9[60H3C <=58>Q&"
M/K7V?7DWQW\%'5]$C\3:?%F[T]=EV%'+P=F]RI_0GTKKPM7EERO9F<U=7/G:
MBBBO5,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )+:WFN[J*VMHVEFF<1Q
MHHY9B< #\:^O_ WA2'P7X/M-(CVM<8\V[D'_ "TF8<_@. /8"O)/@'X)^U:A
M)XLU&+_1[0F*R##[\N,,_P!%!Q]3[5[V3D\UYN*JW?(C:$>HE%%%<)H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4Z/_6+]13:='_K%^HH NT444 %%%% %:Y_
MU@^E0U-<_P"L'TJ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM"-M0HHHKC- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J_5"K] !1110
M 4444 %5M.TZUTFPCLM/A$%O%G9&"2!DDGK[DU9KE?AG_P D[TS_ +:_^C7I
M]!=3JJ***0PHHHH *J3_ .N:K=5)_P#7-0!'1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1A65
MDD17C<%71AD,#U!%%% 'RE\4O [>"?%CQ6ZL=,O,S63GLO=/JI./I@]ZXJOL
M/QMX0M?&_A>;2;DK'./WEI<$9\F4=#]#T/L?I7R-J6G76D:G<:?J$+0W-M(8
MY8V'0C^GO7KX>K[2-GNC"4;,JT445TD!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6YX.
M\+W?C'Q1:Z/8_*96W2R]HHQ]YC]!^9('>L5$:214C4L['"JHR2?2OJCX5> E
M\$>&?,O4']L:@H>Y)',*]H@?;J??Z"L*]7V<;]2HQNSL-.TZTT;2K73--C\J
MTM(Q%$OL.Y]2>I/<U8HHKQMSH"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "G1_P"L7ZBFTZ/_ %B_44 7:*** "BBB@"M<_ZP?2H:FN?]8/I4- !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5^J%7Z "BBB@ HHHH *K:=>6=_81W.FR1RVSYV/']TX)!_4&K-<W\/[.YT_
MP+I]K?0203Q^9NCD7#+F5B./H13Z"ZG24444AA1110 54G_US5;JI/\ ZYJ
M(Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O*_C7\/#XATT^)-'B+:G9QXN8D'-Q$/XA
MZLOZCZ"O5*56*L".M73FX2YD)JZL?#E%>M_&GX;?V%?/XDT2+&EW<G^D1(.+
M:4_R5CT]#QW%>25[4)J<>9'.U9V"BBBK$%%%% !1110 4444 %%%% !1110
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M4**** "BBB@ HHHH *OU0J_0 4444 %%%% !6?H>LV_B#18-3LTE2&?=M64
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M#UKR)\SV$Y)M+L#B1?0^C#N/QKDJ]>,E)71SO0****H HHHH **** "BBB@
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M3ZSJ":?O\R*W\]E%P<^@/"#]:]OK*M25*7+>Y4)<RO8****Q+"BBB@ HHHH
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M9_,&O,/AAI/P]\4-#8:U;S6VK*.%>XQ'<X]..O\ LU]&V-C;:980V5C"L%O
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M2+B'391YL,KXQ$_<=>A_I2Q$J6(I<\7K'ONT%-3A.SV9N?'7_DE-]_UVA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+'D^Y-/H+J7****0PHHHH *J3_ZYJMU4G_US4 1T444 %%%% !1110 4444
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M5NJD_P#KFH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %!
MQTKDO'/PWT7QW;,]V@L]45<17\2_-QT#C^(?J.Q%=9151DXNZ$U<^0/%_@37
M/!-_Y&LVI\AF(ANX_FBF^A['V.#7.5]NWEI;:C8RV6HVT5U:RC;)#,H96'T-
M>)>.?@(ZF2_\#.94Y9M-F?YE_P"N;G[WT//N:]&EBE+2>C,I0ML>'T5->6=S
MI]Y):7UO+;7$3;9(I4*LA]"#TJ&NTS"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIR
M(TDBI&I=V("JHR2?0"@!M:OA[PSJ_BK4A8Z%9274W!8J,+&/[S-T4?6O1O _
MP*U/5S%?>+"^E6!PPM\?Z1*/3'\'X\^W>O>M&T73/#NF)I^AV4=G;)_"@Y<^
MK-U8^YKDJXF,-(ZLN,&]SC/ 'PBTGP;Y5_J7EZGK*\B4C]U ?]A3U/\ M'GT
MQ7H))8Y)R:2BO,E.4W>1LDEL%%%%2,**** "BBB@ HHHH **** "C(JCKDCQ
M>']0DB8HZ6TC*P."#M/-?*&@:KXU\3:U'I>E:Y?/<RYVA[ME''OFNO#X5UXN
M5[6,:E7D:5MSZ]R*,BOG7_A7WQ<_Z"L__@Q:JNI>#?BSI>GRWDVH7DL<2EG$
M-^S, .IQFM5@X-V]HB?;2_E9]*45\Z?!OX@^()_&T&D:IJ-Q?6=TK+MG?>48
M#@@GD?2O0?CGJ=]I7@6*;3;N:TE-TJEX7*DC!XR*SGA)0K*DWN5&JG!S1Z51
M7G?P0U&]U3X=BXU&ZFNIOM<B^9,Y9L +QDUZ+BN>I!TYN#Z&D9<T4Q,T5\^?
M&'Q!K&G?%.VM;#4[NV@,<),44S*IR>> :^@8CF%">3M%:5:+IPC-OXB8SYI-
M=AU%%>&?%?QGK&L>,K7PAX-N)DGB?$KV[E2\A'W<CL._O4T:+K2Y4.<U!7/<
MZ*\.^#?CS48?$-WX2\5W,TEP9&\A[ARS+(O#1Y/TR/H?6O<:*U&5&?*PA-35
MT%&16%XVN)K7P-K$]M*\4L=H[(Z'!4XZ@U\[^!+/QKX]GNXM/\47=N;559C+
M<OSG/O[5K1PWM8.;E9(F=3EDHI7N?4N117AW_"J?B+_T.<G_ ($2?XUR\6M>
M,_ OQ/M-&U'7KB\Q/%YL;3,\<B/CC!]C6D<)&=^2:;)=9Q^*)],T45\W_%WQ
M;KVA?%.4:7JMU;QPQQ.L2RG9GGJO0UAAZ#KSY4[%U)J"NSZ0HKD_AYXZM/'/
MAY+J,K'>Q +=6X/*-ZCV-;NN:U9>'M&N-3U.416\"[F/<GL![FLI4Y1GR-:E
M*2:N7Z*^5+[XF:_XE\?6]W%?W5E9RW4:16L4Q553<.#CJ3WKZIC.8USZ"MZ^
M&E02YNI%.HJE[#J**\%^)GC#6_$_CZ#PKX(NIT:UW+(UO*5\V3&6&1V4#'US
M44*+K2LM/,J<U!7/>J*\5^"7CZ[N;ZZ\+>)+F26\5F>WDN')8D<-'D^G4?C7
MM5*M1E1GR2"$U.-T%%%%8EA1110 4444 %%%% !3H_\ 6+]13:='_K%^HH N
MT444 %%%% %:Y_U@^E0U-<_ZP?2H: "BBB@ HHHH **** "BBB@ HHHH ***
M* /F?]J?79WU_1?#ZDK;PVIO6 /#L[,@S]!&V/\ >->U?"FQ@T[X2^&H;4@H
MVGQ3'']^0>8__CS&N(_:#^&U[XNT:UUO0+>2ZU+304DMHQEIH3R=HZLRGD#N
M"V.< WO@1XYT_5? MGX>O;B.UUK2<VLEI,VR1U4_*RJ3D@ A3Z$'@ C(!Z/K
MVBVOB/P_?:/J&_[-?0-!(8R RAAC*D@C(ZC(/(KS[XI_%*Y\+>(-&\+>'1;_
M -L:K+&'GN$+I:QN^Q6V@C<Q.>,\!>1R*[76_%-KI,\=E:Q/J6J32(D=A:D-
M( Q^^_\ SS0#DLV!]20*\-^.F@W6D?%WP]XPGC8Z.TMLL\X&1"\<F2#Z97!&
M>N&]* .P^('CC7?A)J>AW-[JDWB+2=09X[N*[@ACGC*[?FB:)$7HWW6!Z=><
MK)\<?&.M^&?!.E>(_!^N26J75S'#L%O#)'*CQNX?YT)!^0=P,'I7,_M)!O$5
M[X2T+0E_M#4;F2:2*"W(8E6";3[ \G/3 )S@5+\?],_L+X$^&-&>59'L;NUM
MMP/W_+MI%)_3]: (-1\8?$T_ RR\<0^(;2U\H 31I91/+<*TQC\QF*[%Y*X5
M5Z<DYXK0@\=^/O%?P7G\6Z9J&GZ))IL,C3,EL)GO&C/S$!\K&-OLQ)S]T5EZ
MA=6__#%<2^?%N=(HE&\99Q> E1ZG )QZ TO@*[MQ^R5XA4SQ;HXKM'&\95F'
MR@^A.1@=\B@#L_@YXXUCXC_#^]_M2[-KJEI*;<WUM&FYLJ&638RE,\D8QCCH
M*\_\ >._B?XN^(&H^&8O$ULPMXY?,N[C3X?W*QRJID5%4;F/W=I.,.3V!K9_
M9693X7UY01N%Y&2,\@%/_K&N:^ ]Q%!\>O$?G2*GF6]TBECC+&ZBP/QH ZSP
ME\3/%&@_&*Y\ ^/K^#5C)*(K>^B@2(JS('CR% &&4C(P2&/4BMZ\^(>I>)/C
M$W@/PQ<C3K:R1GU#4A"LLI*@92,-E5P6"EF4\]L#YO/]7TM_%_[7L8TS=)!I
M=Q;SW4R#*Q^0BL02.GS )SW.*P]3M;#P-^TK>S>-].M[O1=1O)IR]Y:B6,QS
MDLKJ#D'8Q )Y^ZW&: /8/!/Q#U&\^(VO^ ]:N([F\T_<UEJ!A"><JXR)$4@%
MAN!^7:#AN%XKQEX/$VH_M."PE\3L-8BNGAAU3[&K+$!$QPL+$J%P2,9[D]:^
MAO"Z^ )=6\SP5I^AR7*1$R7>DVL6(5/\+2(/E)_NYR<$XP*\)GGAT3]KZ2[U
MF:*PMEO6D:>Y<1H%: [6+'C!R* .M^,7B;QW\-])T"2R\92W=Q="6*Z=M-MD
M61EP0ZKL)7AL$9(XSQ6I\2=4\17?[-]CKMOK7V62;2[2340EN/,NS-Y2D!P0
M(QEV) 4Y!QP.O-_M.7]OJ?AGPI?63L]O<23R1.R,FY2J8.& //TKI?&$,EY^
MR';I:H9F71-.<A.<!#"SG\ I)^AH QOV=-*U]_"L>IP>*!:Z)#?3"?2381L)
M3L7+><3N7J#Q_=]ZW_!GQ!U3XK>,];MM%U231="TL+Y$EK!&UQ<[BP#,9D95
M4[2=NP'D#/!SD?L]:II5Q\,Y?#<M_&-1OKJY MH_GD1#&N791G:O!&YL G S
MD@5E?L\V,_@_Q]XI\.>(0+/45@C81N<!U1FRRD]1A@0?3F@#M?A]\4+W4?B%
MK'@3Q.T,VH:?-*MI?PQ^6+I4;!#IG ?'S<<8!';)XKQ%\2_&WAWX^CPM;:U+
MJ&G?;K:)+66WMT:42JC",R",$#+XW=0.>347PTT.X\2?M):[XJL49M(TZ]NR
M+K'R2NX:-54]\ARWL ,XR,Y'BN:)/VQ(9'D14&I6(+%@ #Y,0Z_7B@#UWPYJ
M'Q&B^+^HZ5XCC2[\._9?-@O(;010JQP0%;)).2RE22?E#8 Z^DT44 %%%% !
M1110 4444 %%%% !6?KOA_2?$^GFRU^PBO8>=I<8>,^JL.5/TK0HIIM.Z ^?
M_&/P!U&Q\R[\'S_VE;#)^R2D+.@]CT?]#[&O(KJUN+&ZDMKV"2WGC.UXI4*L
MI]"#R*^W@<=*QO$?A+0?%MOY7B#38KEE&$G'RRQ_1QS^'2NVGBVM)ZF;IKH?
M&M%>R^*OV?-0M=]SX0O!J,/7[)<$),/8-PK?^.UY-J>DZAHMXUIJUE/93KUC
MGC*'ZC/4>]=T*D)_"S)IK<IT445H(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***[?PK\)/%7BH)-#9?8+)N?M5[
MF-2/55^\WX#'O4RE&*NV"39Q%==X1^&?B3QDRR:=9^19$_->W.4B ]CU;\ :
M]Q\*?!3PQX<,=QJ*G6[U>=]RN(5/M'W_ .!$UZ)GY0H 55&%4#  ^E<53%K:
M!HJ?<X/P7\(?#OA#9<SH-7U->?M-PGR1G_83H/J<GW%=XS%CECFDHK@E.4W>
M3-4DM@HHHJ1A1110 4444 %%%% !1110 4444 %<E\4_^27ZY_U[_P!176UR
M7Q3_ .27ZY_U[_U%:T?XL?5$S^%GS[\)/&.E^#/$EQ>ZSYPAD@*+Y2;CG->Q
M?\+]\&^M]_WX'^->1?!WPII/BWQ/<VFMPM-#';EU56V\YKVK_A2/@?\ Z!TO
M_?XUZ^,^K>U_>7OY''1]IR>[:QR7CCXV>&]9\&:CIFEQW<MQ>1&)=\855SW)
MS7,_L\Q2/XYNY%4E([0[CZ9(Q7J?_"D? _\ T#I?^_QKJ/#OA/1?"ML\&AV,
M=L)#EV'+/]37/+$4(494Z2>O<T5.<IJ4NAY-^TC_ ,>NB?[TG]*YKPQX!^(F
MJ>&+&]T76Q!831EH8OM;+M&XC& ..<UWGQS\*ZUXFM]*&A:?)>&%G,@CQ\N<
M8KM?AUIUWI'P]TBPU&%H+J"$K)&W53N)_K5+$>RPL>6S=Q.GS57?8\D_X5E\
M5?\ H81_X&O_ (5QFBZ?J6E?&K3[+6Y_/OHM0C$TF\MN/U/6OK.O!M3\#^))
MOCPNM1:5,VG?V@DOV@8V[1C)JL/BG/F4[+1^0JE&UG'N>\UYS\9?''_"*>%&
ML[&3;J6H@Q1XZQICYG_H/<UZ*[;$9L$[1G &2:\$E\"^)_B!\4QJ/BO39K'2
M$?(5R,>4IX0>[?UKBPL8.?/4>BU]3>JY<MH[LR_A'XS\'^"M-N;G6)KAM4NV
MP^R#<$0=!GWZUS.O^)-,TSXF#Q)X(FD$+2B?RW0IM8_?7Z'D_C7T)_PJ;P7_
M - 2'\S6;XB^#?AF^\/W<&DZ=':7K1DP2J3\K#D?GTKNCB\/[1S=]='V,'2J
M<J6FAV'AO7[3Q/X?M=6L&W17" D=T;NI^AKE/C9_R2O4?]Z/_P!"%<M\&=+\
M8^$M4N-)UO2+B/2KC++*2"L4@[_0C^E=M\5M(O\ 7/AY?6&DVSW-U(R;8TZG
M#<UQ\D:6)23TNC:[E3=UJ>(?#/5?B#I^CW2>!]*AO;5ILRM(JG:^!QRZ]L5;
MN?C;\0+?47TVYM["WNU?RFCDMRA5NG4O@?4\5Z3\#_#>K^&O#=_;ZY926<LE
MUO19,<C:!FM#XD?"[3_&]FUS;A;75XU_=W '$F.BO[>_:NR>(H.NU.*:[F*I
MS]FG%ZGGWP]^'WB^[^(T/BGQ+ MLGFM<R2,Z$S,1QM"DC!KWZO$?AW+\1O!U
MPNEZOH-W?Z0'VY#!FA'JASR/:O;4;<@;!&1G!&"*X\9*4JFK372QM1243YQT
MW1;+Q#^T!KNF:G$);>X\Y6'=3M&"/0BJEI<ZS\#?B \-PLESI5P?F'03Q]F'
M;</\]:[7PWX0UZS^/6H:W<Z;+'ITK2%+@XVG(&*]#\:>"]-\;Z&=/U+,;*=T
M-P@!:)O4?X5USQ,8S4):Q:5S%4VTVM'<\6LXM3^.7Q!:ZN?,M_#]BPQ&>BK_
M '1VWMW]*S[:U@L?VD%M;2)8H(;Y4CC48"J(P *^A/"_AJP\):!!I6F+B*(?
M,Y'S2,>K&O'V\$>(_P#A?C:W_94W]FF^\S[1QMV[,9HI8B,I3BM(J+2_KN.5
M-I)[NY[O7E_QN\<?\([X;_LBPEVW^I*5)4\QQ="?QZ5Z;-(8H))%1I"BE@B]
M6P.@]Z\$T_X?^)?'/Q/?6/&^FRVFGAO,*2$89!]V,<UQX6,.?GJ/2/XFU5RM
M:/4J?";QOX+\$^'9O[3EF;4[QR9F2 L%0<*F?3J?QKC[OQ-8>'?B=_PD'@N:
M1K/S?-$3IL.&^_&?8\X^H]*^A_\ A4W@O_H"0_F:QO%OP9\.W_AB\BT+3X[3
M453?;R*3RPYVGZ]/QKMABL/[1R=_>WOL8.E4Y4M-#O=$UBTU[1;;4]/D$D%P
M@=2#T]0?<5>KQ_X+6/B[PS)/HOB#2;F'39,R0RM@B)^X^A_G7L%>97IJG4<8
MNZ.F$G*-V%%%%8EA1110 4444 %%%% !5^J%7Z "BBB@ HHHH *YGX=6\UKX
M!TZ&YBDAE7S=R2*58?O7/0UTU4M'U:UUS2H=1L"QMYMVPNN#PQ4\?4&GT%U+
MM%%%(84444 %5)_]<U6ZJ3_ZYJ (Z*** "BBB@ HHHH **** "BBB@ HHHH
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MX9()HSAXY4*LI]"#R*BKI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4ET:[BLX[V:>2%D1#$%!)!')SQ6U_P *1\#_ /0.E_[_ !H_X4CX'_Z!TO\
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MJ'@CP1IW@;138Z<6FDD;?-<.H#2'^@'I6RQD.3G:_>+2_P"I'L7>R?NG@'Q
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M/"NU],TJ.:Y7_EZO/WLF?49X4_[H%=2S,WWCFFT5RRDY.[9IL%%%%2 4444
M%%%% !1110 4444 %%%% !1110 4444 %8?C319_$7@W4=)M'1)KJ+8C/T!S
MWK<HJHR<9*2Z":NK'DWPL^%FK>"/$-Q?:E<V\L<D'E@1$YSFO6:**NK5E6ES
M2W)A!05D%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5?JA5^@ HHHH **** "L
M'P1I=UHO@ZQT_4$$=Q#YF]0P8#,C,.1[$5O5E>&=;_X2+P[:ZK]G^S?:-_[K
M?OV[7*]<#/3/2GK874U:***0PHHHH *J3_ZYJMU4G_US4 1T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2@XZ<4E% &
M=KGAS1?$MOY.OZ7;WR@85W7#K_NN/F'X&O*O$?[/%I/OF\)ZJUN_46M]\R_A
M(.1^(/UKV:BM859P^%B<4]SY&\0?#;Q9X9W/J>C3F!?^7BW'FQX]2RYQ^.*Y
M:ON179?NDBN=USP#X4\2%GU?0[9YFZSP@Q2$^I9<$_CFNN&,_F1FZ?8^/:*^
M@-:_9VTR?<_A[6Y[5NHAO(Q(OTW+@C\C7!:M\#O&VF;F@L8=1C7^.SG#?^.M
MAOTKIC7IRZD.+1YY15[4M$U71I-FK:;=V39QBX@://YCFJ-;WOL2%%%% !11
M10 4444 %%%% !1110 4444 %%%6;+3KW4IO)TZSN+N7^Y!$SM^0% %:BN[T
MGX,>.-5PW]D?8HS_ !WLBQ8_X#][]*[S1?V<XEVOXDUXM_>AT^/_ -G?_P")
MK&5>G'=E*+9X16]H'@CQ)XG8?V)H]S<QDX\[;LC'_ VPOZU]-:)\,/!OA\J]
MGHD-Q,O(FO29FSZX;@'Z 5UFX[0HX4# 4< "N:>,7V46J?<\*\.?L[S,4F\6
M:LD*]3:V(W,?8NPP/P!^M>K^'?!7AOPH@_L+28(90.;F0>9*?^!MDCZ#BMRB
MN.=:<]V6HI"DECDG-)116104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %75+5[W2+NUB(#S0O&I/0$@BO'OA]\'-;\*>,[75KZ[M9(80VY8R<G(
MKVNBMZ=>=.+C'9D2IQDTWT"BBBL"PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%
M^HIM.C_UB_44 7:*** "BBB@"M<_ZP?2H:FN?]8/I4- !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-6U2VT
M31KS5-0<I:V4#SRL!DA5!)P.YXZ5\W> TO?CQ\59]<\6JDFC:.H=-.R3&FXG
MRX\=\E2S$_>VXQC@>G_M"7,MO\&=36'=B::"-RO9?,4_ED ?C7G_ .SWX/T#
MQ7\/M?@UVQAO#+=^5^\ +1#RAADS]UOF;##F@#Z+CC2*-8XD5$0!551@*!T
M%?+7BS69O$G[6&F0O*WV?3=6M;:!2/NB-U9A^+[N?<>E.^!GB[5_#OQ3;P7<
M7,DVF7$TUN89F+>1)&K$,O'&=FTC@<Y[5D"UFM/VL/+N"Q=O$?F#=_=>3>OX
M;6% '8_M5;K>\\)W4,CQS 76UE;!4J82"#U!R:[?Q)K-[XF_9@N=6@/F7=UH
MZ/.8N>1@3?A@/GT&:XG]J_\ YE/_ +?/_:%>H_"*PV_!;P_:7\*NDUD2\<B9
M5TD9F (/4%6'L<T >(>$?*_X9%\8^?\ =_M48Z_>_P!%V]/?%>E_LY37%O\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5?JA5^@ HHHH ****
M"J.BZ1;:#H\&FV)D,$&[:9#EN6+'GZDU>KFOA[=7%[X#TZXO)Y;B9_-W22N6
M9L2N!DGGH,4^@NITM%%%(84444 %5)_]<U6ZJ3_ZYJ (Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHW+W/VAUVEW!D)*$AQC:0 5Z<G/T-;SQW5M%<0-OBE0.C8(RI&0>: )****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT?^L7ZBFTZ/\ UB_44 7:
M*** "BBB@"M<_P"L'TJ&IKG_ %@^E0T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY)R(%'W(%Y.%4<=?09( KG_CW\-M0\=>'[*]T("74-*,A%MP#/&^W< ?[PV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J_5"
MK] !1110 4444 %5=,U.TUC3HK_39?.MI<['VE<X)!X(!Z@U:KGO FG76D^"
M;"RU"$P7$7F;XR02,R,1T]B*?074Z&BBBD,**** "JD_^N:K=5)_]<U $=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z/_ %B_44VG1_ZQ
M?J* +M%%% !1110!6N?]8/I4-37/^L'TJ&@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "K]4*OT %%%% !1110 5F^'M:C\0Z#;ZI#$T*3
M[L(YR1M8K_2M*L;PEHTWA_PO::9<R1RRP;]SQYVG<[-W^M/2PNILT444AA11
M10 54G_US5;JI/\ ZYJ (Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ IT?^L7ZBFTZ/_6+]10!=HHHH **** *US_K!]*AJ:Y_U@^E0T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5?JA5^@ HHHH **
M** "L7PAK-QX@\*6>IWB1)-/OW+$"%&UV48R2>@]:VJSM T:'P_H=OIEM))+
M%!NVO)C<=S%NWUIZ6%U-&BBBD,**** "JD_^N:K=5)_]<U $=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4Z/\ UB_44VG1_P"L7ZB@"[11
M10 4444 5KG_ %@^E0U-<_ZP?2H: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *OU0J_0 4444 %%%% !7.^ ;^ZU/P/87=_,T]Q)YF^1^
MIQ(P'Z 5T55M.TZUTFPCLM/A$%O%G9&"2!DDGK[DT^@NI9HHHI#"BBB@ JI/
M_KFJW52?_7-0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J &T4[RW_NM^5'EO\
MW6_*@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J &T4[RW_NM^5'
MEO\ W6_*@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J &T4[RW_N
MM^5'EO\ W6_*@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J &T4[
MRW_NM^5'EO\ W6_*@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J
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M@!M%.\M_[K?E1Y;_ -UORH ;13O+?^ZWY4>6_P#=;\J &T4[RW_NM^5'EO\
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M/+?^ZWY4 -HIWEO_ '6_*CRW_NM^5 #:*=Y;_P!UORH\M_[K?E0 VBG>6_\
M=;\J/+?^ZWY4 -HIWEO_ '6_*CRW_NM^5 #:*=Y;_P!UORH\M_[K?E0 VBG>
M6_\ =;\J/+?^ZWY4 -HIWEO_ '6_*CRW_NM^5 #:*=Y;_P!UORH\M_[K?E0
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M/+?^ZWY4 -HIWEO_ '6_*CRW_NM^5 #:*=Y;_P!UORH\M_[K?E0 VBG>6_\
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M_)G_ .PH_P"%F_\ 4)_\F?\ ["CZAB?Y?Q7^8?6*7<[RBN#_ .%F_P#4)_\
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MF_\ 4)_\F?\ ["CZAB?Y?Q7^8?6*7<[RBN#_ .%F_P#4)_\ )G_["C_A9O\
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M_P!0G_R9_P#L*/\ A9O_ %"?_)G_ .PH^H8G^7\5_F'UBEW.\HK@_P#A9O\
MU"?_ "9_^PH_X6;_ -0G_P F?_L*/J&)_E_%?YA]8I=SO**X/_A9O_4)_P#)
MG_["C_A9O_4)_P#)G_["CZAB?Y?Q7^8?6*7<[RBN#_X6;_U"?_)G_P"PH_X6
M;_U"?_)G_P"PH^H8G^7\5_F'UBEW.\HK@_\ A9O_ %"?_)G_ .PH_P"%F_\
M4)_\F?\ ["CZAB?Y?Q7^8?6*7<[RBN#_ .%F_P#4)_\ )G_["C_A9O\ U"?_
M "9_^PH^H8G^7\5_F'UBEW.\HK@_^%F_]0G_ ,F?_L*/^%F_]0G_ ,F?_L*/
MJ&)_E_%?YA]8I=SO**X/_A9O_4)_\F?_ +"C_A9O_4)_\F?_ +"CZAB?Y?Q7
M^8?6*7<[RBN#_P"%F_\ 4)_\F?\ ["C_ (6;_P!0G_R9_P#L*/J&)_E_%?YA
M]8I=SO**X/\ X6;_ -0G_P F?_L*/^%F_P#4)_\ )G_["CZAB?Y?Q7^8?6*7
M<[RBN#_X6;_U"?\ R9_^PH_X6;_U"?\ R9_^PH^H8G^7\5_F'UBEW.\HK@_^
M%F_]0G_R9_\ L*/^%F_]0G_R9_\ L*/J&)_E_%?YA]8I=SO**X/_ (6;_P!0
MG_R9_P#L*/\ A9O_ %"?_)G_ .PH^H8G^7\5_F'UBEW.\HK@_P#A9O\ U"?_
M "9_^PH_X6;_ -0G_P F?_L*/J&)_E_%?YA]8I=SO**X/_A9O_4)_P#)G_["
MC_A9O_4)_P#)G_["CZAB?Y?Q7^8?6*7<[RBN#_X6;_U"?_)G_P"PH_X6;_U"
M?_)G_P"PH^H8G^7\5_F'UBEW.\HK@_\ A9O_ %"?_)G_ .PKO*PJX>I1M[16
MN7"I&?PL****P- HHHH *YOX?V=SI_@73[6^@D@GC\S='(N&7,K$<?0BNDK/
MT/6;?Q!HL&IV:2I#/NVK* &&UBIS@D=1ZT^@NIH4444AA1110 445R6M^.O[
M&UB>P_L[SO*V_/Y^W.5!Z;3ZUK2HSK2Y8*[(G.,%>1UM%<'_ ,+-_P"H3_Y,
M_P#V%'_"S?\ J$_^3/\ ]A73]0Q/\OXK_,S^L4NYWE%<'_PLW_J$_P#DS_\
M84?\+-_ZA/\ Y,__ &%'U#$_R_BO\P^L4NYWE%<'_P +-_ZA/_DS_P#84?\
M"S?^H3_Y,_\ V%'U#$_R_BO\P^L4NYWE%<'_ ,+-_P"H3_Y,_P#V%'_"S?\
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M5P?_  LW_J$_^3/_ -A1_P +-_ZA/_DS_P#84?4,3_+^*_S#ZQ2[G>45P?\
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M?4,3_+^*_P P^L4NYWE%<'_PLW_J$_\ DS_]A1_PLW_J$_\ DS_]A1]0Q/\
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M*_S#ZQ2[G>45P?\ PLW_ *A/_DS_ /84?\+-_P"H3_Y,_P#V%'U#$_R_BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]_VS_P#1:UZW7DGC;_D<;[_MG_Z+6O5RO^,_3]4<F+^!>I@T445]$>8%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5_0O^1BTW_K[B_]#%4*OZ%_
MR,6F_P#7W%_Z&*SJ? _0J/Q(]JHHHKXP]P**** /,_B/_P C%!_UZ+_Z&]<E
M76_$?_D8H/\ KT7_ -#>N2KZW!_[O'T/'K?Q&%%%%=1B%%%% !1110 4444
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M8Q,EQ/D[Y99&]RS,3^I-=493=1K3E7]=S)J*BNXRGPQ-/,L:% S="[A!^))
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MX$2*ZUIK2ZMK>>%HF?$L*N01CH2,_ATH\?6EM9Z]#'9V\4"&V5BL2!03N;G
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M5ML1F_TD=!G^%A5^:&2W^'KPS(4DCTXJRGJ"$Z5R*;]C3UUYC9Q7M):=#C_
M4<%WJTUI=VMM<1&$R#S858@@@<$C/?I6QX@;P_H6O6[3:9'*\D2@PK&JQQIN
M;+XQ\S=L>U9'PZ_Y&63_ *]F_P#0EIWQ'_Y&*#_KT7_T-Z[9QY\;R-Z6,(NU
M#F\S=\3^'-$MX4U.:'[/% 0)8;9 OG#LO' Y[^F?:I[#3-&\2^&A+%I<%F90
MR@H@W(P.,A@ 3S4OCS_D4Y_]]/\ T(4> _\ D4X/]]__ $(UP<\_JJJ<SNG;
M<Z.6/M>6VECB_!_AZ/7M0E-T6^S6X!=5."Q)X'TX.:UM,;3]6\6WFES:;:+9
MA72)4A"L"IQNW 9Y&>]6?AK<H;2]MNCJZR?4$8_I^M8_B5O$&F:[,@O;\0S2
MEK<I,^U@3PHP>HZ8KOG*57$3IMVTT_S.=)1IQE]YC:[IAT?6KBRRS)&V49NI
M4C(_G6?5O4A=+?NNH3M/<* '9I"Y!Q]TD]QT([$&GZ19VE[>E-0O19P(A=I"
M,DX_A ]3^/T->C&7+33D[Z',U>5D6M*\4:II"A+>?S(0,"&;YD'T]/PKK(-#
MLO$MHUQ>Z/+H\VW_ %R$*K'UVG'\OQK';7]$T3Y?#NG+<3KC%Y=#)!XY Z^O
M3;6%J>MZAK$FZ_N7D7.5C!PB]>@Z=^O6N.5*=67-!<GGU^Y?J;J:@K2=_+_@
MFOI.I0^$_$DB1W27]FZA))(1^.?J/8GK7>7-KIWB?19?(E!CNE4&:(#=\IR
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MW4;&T'!SC-:7N96A?\E/;_KYN/\ T%ZZG68%?QQH+$9)$V<_[*Y%<WH5N_\
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M!*QO"/\ R/\ >_\ ;;_T.A_'7!?#3(O&>E1GQ79V.F6T4)GA0!(T"KN+L,G
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M^N\'_H*5VIOZY473E_R,7_!B_,Z/XC_\B[!_U]K_ .@/5KPE_P B';_[DO\
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M5;9=F?;.21^!K HHJX4X4U:"L3*4I.[9T6F^-]6TRS2V3R9XXP%3SD)*@#
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M&;<[R*Q9C[_-C\JPJ*'1IN'(UH"G)/FOJ;T/BNX@UF75([&R%U*NUFVO@>I
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M$,2I2C&2MS*Z*E2LFT]CEJ***ZS$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O>:\&KWFO#S;['S_0[\']KY!1117B'>%%%
M% !5+1]6M=<TJ'4; L;>;=L+K@\,5/'U!J[7/^!M,N]'\&6-AJ47DW,7F;TW
M!L9D8CD$CH13Z"ZG04444AA1110 5Y)XV_Y'&^_[9_\ HM:];KR3QM_R.-]_
MVS_]%K7JY7_&?I^J.3%_ O4P:***^B/,"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BNPM?$DVA^";.*R %S<
M/)B1AD( W7'KS73^"M4O-7T6:?4)O.E6X9 VT+@;5.. /4UP5<5.G%S<-$[;
M_P# .F%&,FHWU]#RBBNUU3QEJNF>*+F(2+-:Q2E1"R*/E_W@,Y]ZQ?%\R7'B
MFYGB.Z.1(G4^H,2D5M3JSG)*4;)J^]^WDNYG*$4G9F)115BQL;C4KR.ULXS)
M*YX [>Y]!70VDKLS2OHBO172^+=&AT.VTNVB"F3RW,L@'+MD?H,X'M7-5%*H
MJL.>.Q4HN#LPHHK>\&7$T/BBTCBE=$E8B158@.-IZCO3J2Y(.7845S22,&BN
M]^)O_,,_[:_^R5P59X>M[:FJEK7*J0Y).(45Z?X!O[N_T><WMQ).8YMJM(VX
M@8!ZGDUDZ]XNU32O%-U;QO'+:QE0(9(QCE5)Y'/KWKGCBIRJRI1CJO/_ (!J
MZ,5!3;W\O^"<-17I]SH>E>+=%2_LX5MKB5"RR(N,-T(8=^1C/Y5YG-$\$[PR
MKMDC8JR^A!P16U#$1K75K-;HSJ4W"W9C****Z3(**** "BO4/A]<S7'AMQ/*
M\GE3F--QSM4*N /;FO.=4_Y#%Y_UW?\ ]"-<M+$.I5E3:MRFTZ?+!2ON5:**
M*ZC$**** "BM70QHYNHQJ\=S*S2!0D9 3!P,D]?7IBNV\:V5M8>#S#9P)#&)
MD^5!CUKDJ8E4ZD:=MS:-)RBY7V/-**GLVMDNE>]1Y(ER3&AQO/8$]@>YZUVO
MAGQB\VJPZ<--MH+:5BL8ME*E.IY['WZ>OM5UJLZ<6XQO;SL3",9.S=C@Z*Z_
MXAVEG;:I;26RHDTJ$S(O'3 4X]^?RKD*NC556FII;BG'DDXA1116I 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5_0
MO^1BTW_K[B_]#%4*OZ%_R,6F_P#7W%_Z&*SJ? _0J/Q(]JHHHKXP]P**** /
M,_B/_P C%!_UZ+_Z&]<E76_$?_D8H/\ KT7_ -#>N2KZW!_[O'T/'K?Q&%%%
M%=1B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &]X)_Y'&Q_[:?\ HMJZSXD?\@&V_P"OD?\ H+5R?@G_ )'&Q_[:?^BVKK/B
M1_R ;;_KY'_H+5X^(_WZGZ?YG;3_ -WE_78X;0M)?6M7BLT;8K99WQG:HZG_
M #ZUT'BHVGAV[M+#3+"U(6,2R-/"LK29)&"6R>QZ8Z\5!\/)DB\2NKL%,ENR
M+DXR=RG _ &G?$7_ )&2+_KV7_T)JWG*4\6J;V2(BDJ+DM[EGQ9X7M(-*36-
M+40QX4RPY)7YCP1GIR0,=/IWVOA_=?:-#D06\,(AD"9B4@O\H^9LGDU:UV=+
M;P'+YIVEK58P#QDD 8K-^&W_ "![O_KO_P"RBO/E.53!RY];/0Z%%1K*W5'/
M>+-7\S4[^Q_L^P7$N/M"P8F."#][-:5YHEEH_@E-0LVMIKIA&S2RJLH;)P50
M-QU/IT'Y<_XFC=O$VI.J,528[F X7/K731^';?PMX>EU:\A6[OXU4HKC*1,2
M ..^"1D^W&*[)\L*=-)[VT[[&$;RE)M?/L6VT'3]9\'1W<EE#:71M_,$D$83
MD#.<# (/]:Y+P9_R-]C_ +S_ /H#5Z+HMQ+=^$H9[AS)+)"S,Q[GFO.O!G_(
MWV/^\_\ Z U94)R=.M%]+_J7424H-'0_$W_F&?\ ;7_V2N"KO?B;_P PS_MK
M_P"R5P5=F _W:/S_ #9CB/XK.T^&O_(4O?\ KB/_ $*I/B7_ ,?>G_[C_P Q
M4?PU_P"0I>_]<1_Z%4GQ+_X^]/\ ]Q_YBN3_ )F/]=C7_F&_KN0?#>9UUJZ@
M'W'M]Y^H8 ?^A&KWQ+A!BT^?/(9TQCKG!_I3?AO8.#=W[KA2!$A(Z\Y/]*H?
M$+4TN]8AM(B&%HA#'T=L9'Y 46YLPO'IO]P]L-KU+0T&U\/>$6U2[MH[J_=5
M*K,NY(]Q QMZ'&>_>D31K;Q!X)_M".VB@OX%?FVB"B3;V*CC)'IW_*NG\1^;
M=^%99=-2.=BB2HIC6167(/ 8$'CG^5<!IWB'Q!(PL]+D1=V3Y4-M$H]SPN!]
M:FC*K6@ZB=I)]7T[>@YJ$)*+6EB[X'T*PU::>;4&63R"I2#=C/J6'<=/US6E
MX7M[?4=3U2PO[&QN(K=B$ECME7'S$<$#.#CC)S[UD^$/"J:XSW5XY%I$^W8I
MP9&X.,]A@CWYKI_#FH>=XFU"PMHEMK*R4QQ0HN.0V"Q]23_GK3Q4W>IRN]DO
MEZ"I1TC=?\$X?Q1I<.CZ_-:VQ)BP'4'^$'G&>^*]&U7_ )$2;_KR'_H-<7\0
MO^1G'_7!/YFNTU7_ )$2;_KR'_H-37DY0H2>_P#PQ5-)2FD<UX-\/07>AW-^
M\,,]TQ9+=9UW1J0."1]?TJF4B_L[5+75]*@MM4M[??'(D80,N0"<#Y<^X]3[
MY;X;URY\-V<<UQ'YVG7<C#"?>1UP"?3D$<=\=J[/4K?3O%/AV22%DE78S12@
M<HP'YCW%.K4G3K-SUBWH^UNG^:%",90M'==#@?!EM877B)8]3",GEDQI)]UG
MR, COQGBKOCZRTZRU*W73XHX9&0F:.(  =-O Z=ZP-)TFZUF_6TLE!<C<68X
M51ZGVYJ36M#O-"NE@O0IWKN1XR2K?0D#G_ZU=[C'ZRI<^MMCG3?LK<OS,ZKV
MG:SJ.DL3I]W)"&ZJ.5/OM/&?>J-='I.@Z:VFQ:EK>J1P0R;BENG^L< D']0>
M@/;FMJTH1C[ZNO2YG!2;]TNQ^*-+UK;%XCTE&E8A1<6R_-U^N<?B?I3]3\ -
M':M=Z7=;HMH8172^6X&.A)QSGL0*A;Q9I^DJT7AG2TB)&/M,_+D_3.?U_"N>
MU#5K_59 VH74DQ'0$X4?0#@5QTZ57FO3]R/9Z_AT^\WE.%K2U?\ 74IUZSXR
M_P"1)N_]V/\ ]#6O)J]9\9?\B3=_[L?_ *&M3C?XU'U_5#H?!/T_S/*[:![J
MZBMX\;Y7"+GIDG KU/Q,T&D>#GMU23R=J0!8G"G'U(/8'L:\PTZ=;;5+6>3[
MD4R.V/0,#7I?CM?.\(R21D,JNCY'(()Q_6EC;NO2B]KCH:4YM;G/P>#+'6-!
M6^T.YG64Y_=7!4C(_AR ,?7FKWPVB"6VH,RXD\Q%;/48!X_4U8^'#?\ %/W(
M/071/_CBU7\&:A$WBC6K>,Y2XE::(J?EP'/3ZAA^5<]:=24*M)NZ5OS-(1BI
M0DNID:K_ ,E2C_Z_(/\ V2NC^(D7F>&T?.#'<*?KP1_6N=U;CXI1Y_Y_+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@/0'M]0,US+,68LQ)).23WI**TITH4E:"L3*<I;LZ?0O&]WH]F+2:%;N%/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#$T?\ "N-7_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\
MQ-'_  KC5_\ GYLO^^W_ /B:/KF'_F0>QJ=CDJ*ZW_A7&K_\_-E_WV__ ,31
M_P *XU?_ )^;+_OM_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\
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M_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\ "N-7_P"?FR_[[?\
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M_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\ Q-'_  KC5_\
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M_P#$T?\ "N-7_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\
MQ-'_  KC5_\ GYLO^^W_ /B:/KF'_F0>QJ=CDJ*ZW_A7&K_\_-E_WV__ ,31
M_P *XU?_ )^;+_OM_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\
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M_P#$T?\ "N-7_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\
MQ-'_  KC5_\ GYLO^^W_ /B:/KF'_F0>QJ=CDJ*ZW_A7&K_\_-E_WV__ ,31
M_P *XU?_ )^;+_OM_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\
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M_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\ "N-7_P"?FR_[[?\
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M_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\ Q-'_  KC5_\
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M_P#$T?\ "N-7_P"?FR_[[?\ ^)H^N8?^9![&IV.2HKK?^%<:O_S\V7_?;_\
MQ-'_  KC5_\ GYLO^^W_ /B:/KF'_F0>QJ=CDJ*ZW_A7&K_\_-E_WV__ ,31
M_P *XU?_ )^;+_OM_P#XFCZYA_YD'L:G8Y*BNM_X5QJ__/S9?]]O_P#$T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>rprx-20221231_g3.jpg
<TEXT>
begin 644 rprx-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<V$@4FEN
M86QD:0    60 P "    %   $*:0!  "    %   $+J2D0 "     S0Y  "2
MD@ "     S0Y  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(S.C Q.C(W(#$Q.C(V.C$Q #(P,C,Z,#$Z
M,C<@,3$Z,C8Z,3$   !, &D <P!A "  4@!I &X 80!L &0 :0   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 Q+3(W5#$Q.C(V.C$Q+C0X
M-SPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y,:7-A(%)I;F%L9&D\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@$$ DY P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO-V^+-K
M_P +X7P&IM_LWV,AIR#O^V??$8;.W;Y?MG<<9XP?2* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***XSXE^-M3^'_ (;DUZUT*#5M/MRHN<WY
M@DCW,%4A?+8,,D#J#STQD@ [.BO-OA'\7/\ A:G]K_\ $D_LK^S?)_Y>_/\
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M.>8Q(Q]"X5B![[3]* )Z*\.\;?M"ZKX!\32:)KO@B$W"(LBR0:P6CD1NC*3
M#C((Y Y!K0TGXQ^--;\,P^(=+^%=Q>:5-N*36VLQR2,%8JV(A'O)!4C&.<>]
M 'L-%>7^#/C]X0\7:FNF3-/HNH.^R.'4 %61O[H<'&<\ '!)QCDXKU"@ HHH
MH **** "BBN#^*'Q!U3X<:0FL1>'H-6TS<L<LG]HF"6-V)Q\GE,"O Y#9R>F
M!F@#O**X#X3?%#_A:&DW][_9']E_8YUAV?:?.WY7.<[%Q7?T %%%% !1110
M4444 %%%% !17GOQ0^)&K_#:P75&\-VVIZ4\JPB9=3,4JN5)^:,PD <$ AC[
MXJ?X4?$O_A9_A^\U/^R?[+^RW7V?ROM/G;OD5LYVKC[V,8[4 =W1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?V?]H>1?L_G>;MV.5^]M7.<9Z4 =31110 4444 %%%% !1110 4444 %%%%
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MM1>NH)^>5V9!D=#M5>#_ +;5ZY>6,%M^S'/:QH!%'X38@#C)%KG)QWSR?4T
M=OI.OZ5KFB1ZQI-_!=:?(I=;E'^4 =<YZ8P<YZ8YKYJ^.?QSM?$=A)X6\'2L
M]@[8O;X97S\'_5I_L<9)[]!QU3]E7Q+/;>*M4\-R,3:WEM]JC!;A94(!P/=6
MY_W!^'*_M'?\ELU/_KA;_P#HI: /ISP1\3O"'C&9-)\-ZO\ ;+ZWM!-+%]FF
MCVHNU2<N@!Y8#@]ZT+WQUI4'B";0=.2XUC68(_-FL;!59XEXQO9V5$SN'#,#
MS6YIW_(+M?\ KBG_ *"*^=/A]\//%_PZ^*EWXI\::G9Z=H<?G&]U&2]1(K\R
M A1MR"#O96PP'*\<XH ]3T+XS>&M9\8R>%KN#4=$UE)#$+;5(4CWN/X5978$
MGMS\W;.1GK_$/_(LZI_UYR_^@&OBOXU:O!K'QCU?5=-:803K;20/)$\3%?LT
M6&VL PSU&0."#7VEKLBR^$]1DC.4>RE93CJ"AH ^2_V9_P#DL</_ %XS_P A
M7V/7QQ^S/_R6.'_KQG_D*^QZ .4^)GC#_A!/A[J>NQHLES"@CMD;D-*Y"KD=
MP"=Q'H#7RS\#M"/CWXT0W6O2M>_9%?5+DSL6:=U90N3GG]XZ$]<@$=#7M/[4
ML<S_  GM&A#%(]6B:7!X"^7*.?;<5_'%><_LHRH/B%K$1/SMI98#'4"6//\
M,4 ?5U9/BCPY8^+?#-]HFJQ+);W<10EESL;^%Q[J<$?2M:B@#+T6V_L'PE86
MNHS0I_9]C''/-OQ&OEQ@,V3CY>"<G'%<W-\4],?0KO7-%T?6=<TFSSYM[I]N
MFPA20Q02.C.%(.2H([].:=\7O#.L^,/AGJ.B^'9(UO+@QG9(VT2JKABF[MG
M_+!X)KSOX>6][\+OACJ6A>/+Y(-3U+SFT[1HIOM,ZJ8V!(2/=A258DCY1U8@
MDT >H>!?B-X=^(FG2W7AVY<O 0)[:==DL)(R,KD\=1D$C(//%2^,?'NC>"8K
M,:H9Y[R_F$%G86:"2XN7)QA%R.Y R2!D@=2*^7/V:)A%\9($+E?-LIT '\7
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MENM(^']GI5G)Y8U>X*3L"0QC0!BHQV)*YSVK5_9MM8K?X+V4D2!6N+J>20@
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MW[V<DDL8;,(BC.SGL?,;([]^E>2?!JX^P_M Z1Y3>4C7<\.%'!#(Z[<>G(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC8^*]<N=1U_55*F!M2E1H[<K]W9&B(HQG@$$ \]>:V/B/_R2SQ7_ -@6\_\
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M(P1M]^-[0?V=O F@^((]6BAOKQX7$D-O=SAXHF!R" %!;GLQ(KIO'WPU\/\
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MEM](@&!!:W<MOOX(.]HV5GSDDAB03R>0* /EO]F?_DL</_7C/_(5]CUY]8?
MSX>Z7?1WNF:)/9W41)CGM]4NXW0XQPPE!'!(KT&@# \<^%H?&G@C5- G*H;R
M K%(PR(Y!RC?@P!^F:^0/ FIWGP=^,MN?%-G);?9G:VO4(R5C<8\Q<9W <,,
M?> P.M?;U8'BGP-X;\:6PA\2Z1;WI12L<K+MEC!_NN,,/7&<4 ;5I=V]_9Q7
M5C<17-M,H>*:%PZ2*>A##@CW%8'C+QMIW@W3XVN0UWJ5TWEV&F6YS/>2'@*J
M]<9(RV,#ZX!Y*P^ VBZ.Q70?%/B[2+=FW-;6&K>5&W)/("9[XZUUGAKX?^'/
M"=U->Z58EM0N!B;4+J5I[B0<<&1R2!P.!@<#B@#"^,WCN]\!?#1]3T]1%J5W
M*EI;L0'$,C*S%L$$-@(V,\9Q]*\L^ Z6%]X.\:>+-;OTN=>F$L$D]U)F1(C$
M#G<3_&S8_P"  5[[XJ\*Z5XS\/S:-K\#36<S*Q".48,IR"".AKD/!WP)\$>#
M+];^TLY]1O8SF*?49!*8_<* JY]]N1V- 'SI^SFRK\;M+#, 6AN H)ZGRF/\
M@:^F?%%OX7\?ZU?^ /$ML&GAM8K^!MX60AF=2\9Z@J5 /J''49K%TG]G7P#I
M'B)-6CM;RY\MQ)%9W4XD@0CIQC+<\X8D?AQ72:]\,]!\0^,(/$]XU]#JUM#'
M#;SVMR8?*",[9&WJ3O(.[(P ,#G(!\E?$?X9ZM\,_&UI8VER]S'=.)-,NXCL
MD8A@ ./NNK$<CU!'H/ICX^"1?@%KHG8-(%M0[#H3]IBS6Y:_#;3!XIM?$6MZ
MAJ.OZG91^7:2ZD\16W]U2-$7=_M$$]\\#&IXI\&Z)XTL4LO$=O/=6J$GR$O)
MH4<Y!^98W4/@J"-V<=L9- 'A/[(W_,W?]N7_ +7KS#QC_P G%:C_ -C!_P"U
MA7U=X?\ A+X-\*7DEUX<TVYTZ:6-HY&@U.Z =2",$>9@XR2#U!P1@@&LZ3X"
M_#B:[>ZF\/R27#N9&F;4KHNSDY+$^;DG/.: /1**@L[2.QLXK6!IFCB7:K3S
MO,Y'N[DLQ]R2:+RTCOK.6UG:98Y5VLT$[PN![.A#*?<$&@#Y&_:@8-\7(P""
M5TR$$ ]#N<_UKW'X"WMK9_ '0[B[N88(8?M/F22R!53_ $F3J3P.H_.KM[\"
MOAWJ5[+>:CH4UW=3-NDGGU.[=W/J6,N2:B7]G[X8HX8>&!E3D9OKDC\C)S0!
MX!\8-?N/BW\68M-\&V[ZG'9QFUM?(&?/()9W!SC;G/S<# !KZ/\ A[\.X/!?
MPR7PT90UQ<QR/>W"#[\L@P2!G^$;5'J%![UT6@^%]#\+VKV_AW2;338Y#F06
M\04R$9QN/5L9.,]*U: /AOX=:U)\+OC-;OK>8DL[F2QOP%SA3E"><' .&SUP
M/PK[+U/Q;H>DZ+#JESJ,$EM<A?LI@<2&Z+$!1$%^^26&,>OI7.>._@YX2^(-
MV+W6;:>WU#8$-Y92".1E'0-D%6XXR03CC/ J+P/\$_!_@+4!J&F6]Q>7Z_ZN
MZOY%D>+J#M 55!P<9QGWH X+]K'_ )%+0/\ K^?_ -%UT?[-#*WP:MPK E;V
M<, >AR#_ %%<Y^UC_P BEH'_ %_/_P"BZO\ [/F@I??!^&XM+Z[TN\DN)XI+
MJR*;W0-P"'5E."<@E<CG! )! /)/$^G2>,OVJ+K3K)!<>=K*12!&VX2(*)3D
M_P!U8W)^AQ7N'[2O_)&;G_K\@_\ 0JZ?P1\*_#?@.YN;W2TN;S4[HMY^I:A+
MYL\@)R1G  R>N ">,YQ5_P 5?#_PYXU,?_"36EQ>QQJ L(OYXHA@DY\M'"EN
M?O8ST&>!0!Y+^R=_R*6O_P#7\G_HNO.?"6B2^"_VJ;/2[_<!#J<BQ.P \Q)$
M?RV_$,O\J^EO#'PM\(>#-1-]X8TV?3YF&'$>H7#)(,$#>C2%6QN.-P.#R.:L
M>*_A]X?\8W%G>:O;2)J%@P:SO[:4Q3V[!@P*L.N",@$$ Y(H \C_ &LYXU\-
M^'8"X$KW<KJG<JJ $_@67\Z[/]GOPU<>&OA'9_;8FAN-2F>_:-CR%<*J'VRB
M*<>_/-:\WPIT?5/$=MK?BJ_U+Q)=6:@6T>IM%Y,/?(BBC1"3QG(.<#TK?\6>
M*=-\%^%[S7M::06EHH++$NYW)8*JJ,C))(') [D@<T >'?M4>#/-L=.\8642
M[H&^QWQ5>2K<QN>.@.Y22?XE%=)^S=#JU_X(&MZ[++*JQKINF^8>!;0LQR/^
M!N4SZ1*.U;&M>,-"^)?P5U&;2$FD&K!M-MK:YC*R"[;B,$+G[I*N2"0 "3T-
M=WX;T.W\,^&--T2S8O#86R0*[#!?:,%C[D\GZT >+_M6Z!/>^$]%UR$%H]-N
M9(9E ^ZLP7#'V#1@?5A4O[,?CBQO?!A\)7=S'%J.GS.UM"[*IFA<ESM[L0Q?
M/H"OX>WWME;:C8S6=_!'<6UPACEAE4,KJ1@@@]17DEU^S!X!GU'[3$^K6T6X
M-]DBNE,>,_=RR%\=OO9]Z /3K'Q'I>IZU>:7IURMS<6*(UR8OF2(OG:I8<;L
M*3MZ@8)ZBOC_ , 6I^'O[2-AI^J.D8L-1ELVDF.U2KH\:OGT(<$?45]@>'?#
M>D^$]%ATGP_91V=G%R$0<L>[,>K,<=3S7-^._A#X3^(<\=UK=K-#?1KL%Y9R
M>7(5P<*<@JP&<C()&/3((!QO[4E[;P_"^TM))56XN-1C:*/NX56W'Z#(_,50
M_90FC;P/K<(<&5-1#LO< QJ ?QVG\J[:Z^"GA?4="73=7GU;4VWHTE[>WS2W
M$@0,%3>?NH-V=JA02!GI6QX7^&7@[P;.MQX>T*WMKI5*BY<M+*,\'#N21GVQ
M0!U=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*:5XIMOLVM"\DMRC1O#!J$]O'(K=0ZQNH<?[V?UKC_^&?/AC_T+/_D_<_\
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M\/\ CK3$L?$VGK=QQ,7A<,4>)B,95E((^G0X&0<4 <#^TS/'%\'9$D<*TU]
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M/J$HD$)X(VJ HX(R"03[T ?,WP,8+\;?#A8@#SY!DGN8G KW?]JO_DEFF_\
M8:B_]$3UM)^SKX!'BAM9DM;N4-*9?L,DX-ONW;ON[=Q';:6(QVKJ?$_PU\+>
M,I(V\2V$]ZL( CA-_<1Q1X&,K&CA0<=P,T >>?LJ?\DLU+_L-2_^B(*]MKE?
M"OPU\+>";J2?PO83V#2C$B+?W#QOZ%D9RI([$C(SQ754 >1^)_B+8^!?VA+>
MTUR86^EZOH5O&\Y7B*5+B?RV8]DP[@GW!/ )KUKY)HOX7C=?J&!_F*YW6/A_
MX8\0Z_)K&OZ1;ZE=/9K9*+N,2)'&&=LJ"/E8ES\W7@8QSGF/^%&:%;!H=#\0
M>*=$T]AAM.T[5W2!@2<Y#!CSDYYH \4OO!UIJ7[6?]E^%(T%E;:A#>7"0*%2
MW"!'F'H/FR..A8"O0?VKE8_#W1V .T:H 3C@'RI/\#7J?A#P'X;\"V+VWAG3
M([3S<>=,27EE(_O.V21U..@R< 9JYXF\,:3XPT&;1_$%HMU:3<X/#(PZ,IZJ
MP]1].A- 'D_[-FJV.G_!Z1[RZCB']KM#@G)WR>6J+@<Y8D #OFN:_:7^).KV
M&L1>#M&N9+.U:U6:^DB.&F+-\J9QD* N3@\[L'@<^E^#?@3X,\$ZZNL:?%>7
ME[&Q:![Z8.("1CY0JJ.AZG)%7?B!\'_#'Q(N[>\UP7D%Y;Q>2MS9S!&*;BP4
MA@RD9+=L\F@#QSXLZ9HFA?LR^$=/T*:WD26]M[EI(V&ZX=K>4R2$9)^\<>W"
M]A73_LHL#X"UE01N&IY(SR!Y2?X&NV_X4?X%3PC<>'8-),-M<NDDLZ2GSV=2
M=IWG/3)XZ<GBK7@'X1^%OAS)+/H<$\UY,FQ[R\</+MSG:, !1TS@#.!G.* /
MEWXR_N?V@]8:;]V%O+=B6XP/+C.?ICFOL^+4K.?4);&"X22YAB2:2-#G8CE@
MA)Z<[&QZX-<7X\^#/A/XAWR7^L17-K?JH1KJQD6-Y%'0-N5@<=,D9QQG@5O>
M#? ^A> M%.F>'+0P1._F2R.Y>29\8W,Q^G08 ["@#X_\0HNF?M)7CW+[(T\3
M>>[,,;5:XWY^F#7I7[5^LV5Q-H6D02B2\M#)-<*G(B#A=@;T)VD@>@S7J?CW
MX)^$_B%JR:IJPO;2_"A))[&94,RCA0P96''J #ZDX&)F^"7P_D\/V>BS: LE
MG9R-+&/M,J.TC !G9E8%B=HZ\#&!@<4 8O[/4XA^!-C*,.89+EBH/<2,<>U8
MWB[X8>'?C;X4M_&?A:1+#6;RV5PX(,<K@<Q3 ?Q _*7'(QW %>G^%O OA[P7
M9SVGANSEM+6<Y>W>[FFCSW(21V )[D 9P,]*PM ^$6E>$M/-KX3UO7-'$@7S
MV@N8Y/.8+M+E98W0,>Y55Z#&,4 >(_LP6>JV/Q4UJTD\R&*VL9([V$M\OF+*
MH4$#@L#OP?3=SSS]65S_ (/\$Z+X'TV6ST*!P;B0RW%S._F37#_WG<\GK].3
MZFN@H \0_:C\.7&J?#^QUBU#.-)NB9D Z1R *6_!@@_X$?2MG]FZ=)O@K8(A
MRT-S<(_L?,+?R85ZG-#%<V\D%Q&DL,JE)(Y%#*ZD8((/4$=JX>V^$NE:187^
MG^%M9UKP[I^H$M<6FGW$90L5VEE,L;LA('5&'0>@P ?-/PLT"3Q;^T##/9*9
MK*SU&34I9E/RJB2%D/XOL&/?TS7K?[5W_)/]'_["@_\ 13UZOX0\$:!X%TDZ
M?X;L5M8W;=+(3NDE/8LQY.,\=AVJCXG^%_A+QE??:_$VGW%_(,;5?4;E8TX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX[G#;B>@R!R<XP?B+KOBZU^%K:UX4;3;:5=/-U>7%PS[XEV!OW*;6!;[WWB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXRL^GS*.2,-L)4Y]B :\._92\4SR#6/"MQ(&AB47ULI/S)DA) /;)0^Q)]:
M.MN-87XG_'"X\)R#S?#'AJ(S7MN0K1WMVK!0D@YW(I/W#_$C9SQB;]H?0A)\
M*M5U5=2U"'[&MNL=G#/LMR#,J'<@'S<.>I[#%<U\"XYHOC?\14N0PE%S+OW=
M<_:'Y]_K7<_M!_\ )"?$/_;M_P"E,5 %?]G/_DB.E?\ 7:X_]'-6?XNU,?"C
MXK:-JEGNA\.^)Y#;:G:)Q%#< C%PHZ*2&RVW[VUB<DUH?LY_\D1TK_KM<?\
MHYJY+]J_Y_#'AZ)/FD>^?:@Y+?)C@?B/SH ]^HJ*U61;.%9\^8(U#Y.3G'/-
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7F_Q3UC5-55/ '@T!]:UB$F[G.0EA9G*M*[#INY
M4#KUQSC/5>-/$-UX8\*W6HZ;H][K-ZHV6]G90-*SR'IN"@D*.I/I[XKY!EA^
M,DFLZAJL.G^,K2[U&7S;IK.UNH!(PX&0@ P!P!V% 'U=X5\,Z#\*? B6<4H2
MVMQONKQX_GGD8@;B%&222% Y.-HYKRC]K33I)=!\-ZF ?+M[F:W8]LR*K#_T
M4:X;P1H/Q.\1?$+P]:^,8/%DVDPZA'=3#54N&MQY7S_-YOR\XQSZX')KZ;\>
M^#K3QYX*O] O6$9N$W03[0QAE7E''X\'&"02,C- '$?LU?\ )&;;_K\G_P#0
MJ^>OA38MJ/Q_T:%.JZE)-UQQ&'D/Z+7N7PI77?A;X/U;PYX@T#4)[^&[>>P;
M3[.6YBO-Z* /,1=J?,O5RO![8-.^!7P?O_!]Q<^)O%J(NM7:E(8$D#?9T8Y8
MMCY=S''0D >Y( ![77P]\+/^2^Z+_P!A-_\ V:OLC7O$UKX>C!N+'5KR1D+I
M%IVF3W1;';<B%5/^\17R%X&\.^+= ^*&E>(=1\%>(Q:P7WG3!-+G9E4DY(^3
MG&<^^* /M:L/QAXJM/!WAN?5;U'F92([:VB!,ES,W"1* "<L>.G'7M5_3=6M
M]5L6N[6.\CC5BI6ZLIK>3C_8D56(]\<U\K_%'6?B;XU\;1ZCHWACQ5IMAIK,
MNF"'3IXI4R,-(65<AFQZ\# ]20#V3X6_#>]TO5;WQOXW,<_BK5V,CQJH*V*-
M_P LU//S8PI(/ &T9Y)]'T_4K35;9KC3YA/"LTD)=00-\;E' SUPRD9''%?%
MS+\;74JX\?LK#!!%Z017UI\-M#?PW\,_#^E3P&WG@L8S/$5 *2L-[@X[[F;/
MK0!LZW+J,&@:A+H<$=SJ<=K(UG#*<)),%)16Y'!; /(^HKR#_A*/VAO^A$\/
M_P#?]/\ Y*KVVB@#Q+_A*/VAO^A$\/\ _?\ 3_Y*K;\':]\9+WQ99V_C3PGH
M^GZ(^_[3<VTJM(F$8K@"=NKA1]T\'MUKU*B@ I&944LY"JHR23@ 4M>(?M >
M(?%UU8-X2\'>'-:NH;E =0OK;3Y)(V0CB)&"D'/\1'L.YH E_L"7XW^/+;7]
M20IX'T60KIT3J?\ B:2 C=(58?ZLE0.1R!@=6QZ^NH6::HNE)(HNA;^>(%4_
M+&&VYZ8 SP!WP<=#7Q9##\:K:WC@MX_'L4,2A(XXUO55% P  .@ [5[E^SIH
M/B2VA\0ZYXU@U1=3O98;=)-61Q,R1J3D&3Y]OS@>GRCTX /#+73I=)_:7M+&
M92K0^*X@,]U^U J?Q!!_&O:?VKO^2?Z/_P!A0?\ HIZ=\8OA-J=[XRT_QYX-
MLDO;VUFADO-/!"-.8V!5U/<X&#GG &,T_P"+FD:W\7QH>A>%-+OK>SAF>YO;
M[5;*6SCA.W:J@2*'<\MG:".1SUP 3_LM6#VWPMO+J3_E[U.1DP?X51%_/(;]
M*[;XD>++W0]+@TCPS ;SQ-K):#3K=1]S^_,QZ!4!SD\9QVS5^PT^Q^&WP[CL
MM)L;V]MM)MB([>UB,L]PV<G"CJS,23V&3T KY3\03_&'7/&5[XCBT3Q9IMW=
M+Y0%C9W,/EP@Y6(%5!*CWZGGK0!]*_#7X>Z;\+/"4_VFXCGOI0;C4]1<8R0,
MD GG8O.,^I/&<#M[6ZBO;.&ZMF+0SQK)&Q4J2K#(.#R.#T/-?%D&B_%_Q'=V
M^CZU'XVDL+V>.&<78NC$%+CEM_RX'7+<#&:^HOB9XFU?PCX.*^$-!OM3U2<&
M"TCL;)IDML#[[A00 !T'<X'3- '.?$MM2^(^M?\ "N?#$GDVD;)+X@U+!VVR
M<,D([,[<-@'L,X&['>:58:'X$\.Z9HUF%M+17CM+9=N6ED;N=HY9CEB<>I.!
M7QU:6'QBL!,-/LO&]FL\S3RK;0W<2O(QRSD* ,GN:[_X-Z#\0-6^+&F7WCR#
MQ))9:5%-<1/K23&-7*; %,O&[+ \<_+GM0!]1UYU\?%E;X&^(A!G=L@)P<?*
M+B,M^F:]%K(\6:$GB?P?JNB2$*+^UDA5B2-C%3M;CT.#^% 'A_[)7_((\3?]
M=[?_ -!>OH>OFC]E>YETSQ-XK\/7\;PW@CCD:&0D-&T3NC@KZYD4'Z"O7?BK
MXMU?PYX8FM_"^A:MJVL7L3) UC9RRI;YX,CLHX(SD#J3CMS0!R-K_P )_P"*
M/B#JOC;P1_PCATU5;1K%M7:<^9#$^9)$\H8(:4-R3_"!C@$\)\>/!WC[4=#B
M\5^,(_"X32U$#OHWGB5TD<!0_F#!56/'(QO/7->P_!S4U3P'I&@3Z)K.DWNG
MV86:._TR:!&8'#%9&78<L<XSG!SC@XW?'ES8#PE?V&IZ??ZA'?VLL(M[*PFN
M6<[.F8T;8<D89L<\YXH \2_96\9$?VGX0O)1C/VVR4Y)])5STQPA XY+'G/'
MJ?QR_P"2)^)/^N"?^C4KY;\&>'OB!X-\9Z9K]IX,\0-)8S!V3^RYOG0@JZ_=
M[J6'XU]4>.+>Y^('P9U>#1;&]@NKVV_=6E];M;S;U<-L*OC!.W /3G.<4 >0
M?LD_\A3Q1_UQMO\ T*2OIJOD'X#^*[OP'XGUG2Y_#.K:CJ6H1QQ0VEM#M=)5
MW$"0-C8I#$ECT S@BOKFU^T"SA^W&(W/EKYQA!"%\?-M!YQG.,T 2UY3\1?^
M$C\6^/-*\/\ @K^S&?PZT>LWK:DTGDB;)%O&WE@MG&]\=\ Y&!GT/Q#K0\/Z
M'/J)L+_46B'R6NGVS3S2MV 51^IP!7E'P@\2ZO\ VYX@N/&7A;Q!INIZ]J22
MI,^DW!A6/8$CC+[3M"XQEL  YSUP ,\>^#OBUXY\(W&CZW'X'>#<LZ-:_:_.
M1TY!C+ @,1E>G1B.]>(_ CQD?!_Q2LC<2B.PU,?8KK=D@;C\C8'<.%YYP"WK
MFOM.^O8M.L9+NX6=XXAEEM[=YW/..$0%F_ &OBOX@^!M?U/XAZW?>&?!GB :
M7<W;RP'^R;A0P/)(!0$ MD@8& <4 ?37QWO)K'X(>(Y;9MKM%%"3_LO,B,/^
M^6->8?LE7T>WQ/8-Q+FWF7K\R_O%/Y';^?M7I'ARZNOB?\*;KP_XNTC5=(U.
M6Q^S7;7]A)$K28PLT98 -\P#8SP>#QU^<-&N/%/P#^)(N=3TV4Q M#*C$K%>
M0D]58<$\9'7!'(ZB@#[*CT/28=8?5HM+LH]2D38]ZMN@F9?0OC<1P.,]J^/?
MVCM1N+[XV:E;SD&.P@M[>''9#$LIS_P*1J^D?"OC_4?B#>65SX<T.^TS0HV+
MW=[JT*QM.-OR1P*K-NR2"7/  P,D\>3_ +2WPUU*XUJ/QCHEK<7L,T0BOTB7
M>8"@PKX'.TKP3T!7GK0![WXOC6+X?:Y'&,(FEW"J/0")J^7/V7O^2N3?]@N;
M_P!#CKUB#XN6_C+X07D6C65Y?:T^E2Q7BFW=8+9Q"?,D>8C;@#+  ECP,#.:
M\G_9>_Y*Y-_V"YO_ $..@#T']K'_ )%+0/\ K^?_ -%UI?LX?\D/OO\ K\N?
M_1:5?_:/\):GXH^',$NBVK7=QIMVMP\$:%I'C*LK;  22"5)'H">U>=? [QG
MJP^'>I>#_#>AWEWJTUQ*\5\(Q]DM4=%!>5LYW+M8A0/FX% '(_LX_P#);-,_
MZX7'_HIJ]C_:K_Y)9IO_ &&HO_1$]>4_!?P]XE\)?%;3-4USPGX@M[%5ECEF
M_LFX;R]T; $@(21G _'/:O5OVE(;_P 0>$K'0=!T76-2O8]02ZD^R:;-)&L8
MBD7_ %@7:3EQP"3USB@"+]EZVCO/@_K%M-DQS:M/&^#@X-O"#_.OG_QOX(\0
M_"WQ?Y,S3P>7)YEAJ5NS*)%S\K*XQM<=QU!]L$^__LZPZIH7@C5?#VKZ)K6F
M:C+=RW4#76G311NK1(HQ(5"A@4/!(ZC&><7/"GC[PYXX^%<&F?%6-;"1K=(Y
M9-64PQWGR'9/%*V 68 M\IR#G'&#0!'\!/BR_CF6[TOQ#%!_PD-O;(1>I&%:
M\@1B &P.J-(3CH?,) 'S5Y'^TQ_R6.;_ *\8/Y&N]_9Q^'UWIOBG5_%+PSQZ
M28Y+/3'N4,<EPAD!\S;@'&U ,],L<=..-^-^B>(/&?Q*FU7P[X6\17-E]FBB
M65M&N8]Q4'. R XY[B@#W[QI_P F^ZK_ -@ _P#HFO$?V4/^1\UK_L&_^U4K
MW"6.?QG\$;[3;"ROK.^FTEK,6VHVCVT@F\D *1(!D9(&X97KSP:^<_@IXAN_
MAO\ $6_M=5\.:O=WMS:M;+96EOF=7#J>48CY?E.3V]Z /?\ ]H/_ )(3XA_[
M=O\ TIBKS;]D;_F;O^W+_P!KUW?QHFU74O@S<:(VCW]WKVI16[-;:78S7$4;
MK+&[@R*I4 ;2!D@G@X].(_9ILM7\):IKECXC\.Z[I[:H+?[/--I<XBS'YF0S
M[<+]\8)P.#STR ><Z-<277[4L<TIR[^)W)]OWYX^E>S_ +5?_)+--_[#47_H
MB>N6^)/P\U7PE\;-.\>:/I\]YHTVI0WEX+.$R/;L'!EW*H)PP#'=ZD@\XSJ?
M'K7K3XB:/HOA7P%-%XBOY;P7CKISB81*L;J-S#Y5SO/!((V\XH O?LIWEQ-\
M/]6M92[0V^HDQ;CD+NC7('IR,X]_>O&O "J_[25@'4,/[:E.",\AG(KZ?^&G
M@^/X6_#6.PO#)/<*6NKYK6%YBTK  A$12S8"J!@$G%?-WA+P_P")M'^,UGXC
MO?!_B0:='J;SNZZ1.66-F;G;MSP&R1U^M '8_M;?\A3PO_UQN?\ T*.O6_@;
M_P D3\-_]<'_ /1KUY5^TEIVL>+M=T6+PWX=UW4!8P2>?+%I4_E@R;" &V<G
M YQTSCKD#U+X(-<0?"O2]*U#3M1TZ]T]&CGAOK*2 Y,C$%2Z@,,'MG'?% '$
M_M7[/^$$T7.WS/[2^7UQY3Y_I^E:OP(TB#7_ -GE-)U>/S;*]>Z@9>,[&<@X
M/8YR0>H-<Q^UA>M+!X7T>W3S9YIIIMB E\@(J@ =<EF_*O9/AQX;/A'X<:)H
MCC;+;6H,X!) E<EY,9[;V:@#F_A9:W_@O3Y/ 7B0N'MIY?[)NQG9>6[9?"L!
MPZY;*DY';(&:NW_P3\!:KJ!O]4TFZO;PXS<W&K7<DAQT^9I2>.U=[10!AWU]
MI_@OPZFXWMPBMY5O"TLUW<7$K$E8PS%G8DYZG  [*..6^$G@6]\.6NJ>(/$J
MK_PD?B&X-U>*&#"!2Q98@>G&XYQQG Z**]%HH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQ-XBL/"GAV[UG57
M*V]LN<*"6D8G"HH'4LQ 'UKSWX;_  ^U"X\57?Q&\>PJNOZCS:V!&X:?$0 H
MYZ/M 'L,YY)QY;\8M;^(OC3Q;$OA_P +^)[/2=)FW6+Q:;.DCRC@S[@N0?[O
M/ ]"37'?\7O_ .J@?^3M 'U/\0##XF^%OBVSTJ3[1+#:W$#! 1^]C3<4!(Y.
M<#CC.1G(./GS]E3_ )*GJ7_8%E_]'P5[_P#"#P_/X?\ A+HNGZE;/%=R0M/=
M1SIB3?*[.0XZY 8#!YXP>E><Z)\.-0^%'QN?Q!8:?/?^%K^.:-GLH&FEL0^&
M"F&-2S . HV@_*<G&* //?VH?^2N0_\ 8+A_]#DKZ>^']@^E_#?PY92_ZR#3
M+=7YS\WEKG!],YKR/5?AIJ7Q7^-1\1ZUI\]CX4LQ%%&MXA@GO50%B!&1O52Y
M.2P4[3QST]TU"_ATRPDN[E+AXH\;EMK:2XD.2!Q'&K,>O8' YZ"@#Y)_:A_Y
M*Y#_ -@N'_T.2OIOX<?\DL\*?]@6S_\ 1"5\T_''3/$/CKXCMJ?A_P (>));
M*&UCMEF?2+A/-*EB6 *9 ^;'(!XZ5]!?"W7!/X)T+1KO2]8T[4+'388)H[[2
M[B% 8T5"1(R!#G&0-V?;B@#MV944LY"JHR23@ 5XM_8$OQO\>6VOZDA3P/HL
MA73HG4_\320$;I"K#_5DJ!R.0,#JV(OV@/$/BZZL&\)>#O#FM74-R@.H7UMI
M\DD;(1Q$C!2#G^(CV'<UXA##\:K:WC@MX_'L4,2A(XXUO55% P  .@ [4 ?:
M:ZA9IJBZ4DBBZ%OYX@53\L8;;GI@#/ '?!QT-6Z\3_9TT'Q);0^(=<\:P:HN
MIWLL-NDFK(XF9(U)R#)\^WYP/3Y1Z<>V4 >6^,=>^,EEXLO+?P7X3T?4-$39
M]FN;F55D?**6R#.O1RP^Z.!WZUB?\)1^T-_T(GA__O\ I_\ )5>VT4 >)?\
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M\8QFO+/V>?&-]HNGZEX3T_P_?W>K7=[YD<WE?Z/:\*CM.<@J$P#@<MG;P2*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-VY" 6/ X4]:^S:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IZMJMIHFE3:AJ,ACMX0,E5+,Q)"JJJ.69F(4*.22 .M7** /(_#?@?4/&GQ
M*'Q'\;Z>UA';QHFBZ1<#,L"J25DE'\+9)8+R0S=MHSZY110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7$?%3X:V7Q*\*FQE9+?4;8F2PNV7/E.<94]]K8 /T
M!YP*[>B@#D? WB2^OK*/1/%=M)8^)K*+%S$Z'9=*I"^?"^-LB'<I..5+8('&
M>NHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \G^(L6
MJ_%*9O _AJ*2#2$N%.LZU*A$(\M^8(O^>CAU^;!PI4 D<X]'T#0M/\,Z!9Z-
MHT M[*SC\N)!^9)/<DDDGN236C10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 C':I/H,U#]I_P!C]:ED_P!6WT-4J +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/
MUH^T_P"Q^M5Z* +'VG_8_6C[3_L?K5>B@"Q]I_V/UH^T_P"Q^M5Z* +'VG_8
M_6C[3_L?K5>B@"Q]I_V/UI\4OF9XQCWJI5BV_B_"@">BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[;$+8SBG5'/\ ZEJ
M&?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
ML?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +
M'VG_ &/UH^T_['ZU7HH L?:?]C]:/M/^Q^M5Z* +'VG_ &/UH^T_['ZU7HH
MN1R>8N<8YQ3ZBMO]6?K4M !1110 4444 -D_U;?0U2J[)_JV^AJE0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5BV_B_"J]6+;^+\* )Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.
M?_4M4E1S_P"I:@"I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %JV_U9^M2U%;?ZL_6I: "BBB@ HHHH ;)_JV^AJE5V3_5M]#5*@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K%M_%^%5ZL6W\7
MX4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4<_\ J6J2HY_]2U %2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** +5M_JS]:EJ*V_P!6?K4M !1110 4444 -D_U;?0U2J[)_JV^
MAJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5BV_B_"J
M]6+;^+\* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J.?_4M4E1S_ .I:@"I1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>)?%3XG>/OAMJ=N@@\/ZA978=XI!9SJT85@,/^]Q_$.0>>>!7MM<?XBT33
M_$?C%-(UFW6YLKK1;A)8F[CSX""#V((!![$ T +\-?B!8_$3PG'J5MMBO(<1
M7UMT,4N,G R3L/53^'4'&?8ZIX]D^(D^@7EUX>-E:VL-X]S'83!Y(W=UVA3.
M0K9C;DD@=>>E?/UU!X@_9]^*@DMF-Q8R@A'9/DO+8L"5/HXXSCH<=CS]!>$O
M$.G>*OB%=:SHTWG6EUX>LF0G[RG[1=95AV8'((]10!WU%>3ZG\2K_7?C-;^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M169JOB70M"DCCUS6M.TUY06C6\NTA+@=P&(S0!IT5SO_  L/P5_T-^@_^#.'
M_P"*K<M;RVO[=9[&XBN86^[)"X=3^(XH FHHHH **** "BBB@ HK#O/&WA73
MKR2TU#Q-H]K<Q';)#/?Q(Z'T*ELBMR@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **K:AJ5CI-H;K5;VWLK=3@S7,JQH/Q8@5%9Z[I.HZ<^H:?JEE=6
M4:EGN8+A'C4#.26!P ,'\J +U%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 58MOXOPJO5BV_B_"@">BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *CG_ -2U25'/_J6H J4444 %%%% !1110 44
M44 %%%9&I>+O#>C7AM-8\0:587(4,8;J]CB< ]#M9@<4 :]%<\OQ!\&.X5/%
MVA,S'  U*$DG_OJMZ&:.XA66"1)8V&5=&!!'L10 ^BBB@ HHHH **** "BL.
M/QMX5EOUL8O$VCO=O*(5MUOXC(TA. @7=G=GC'7-;E !1110 4444 %%%% !
M1110 4444 %%%% !1110 452U36]*T2%9M:U.STZ)CA7N[A8E)]BQ'K3[?5-
M/N[&.]M;ZVFM92JQSQS*R.6("@,#@Y) 'KD4 6J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD+G6M.3XQ6&FO>0B[.CSGR
MC( P)FA*C&<Y(#$#T4FNOKGY? '@Z:5Y9O">AR2.Q9W?3826)ZDG;R: (O'O
M@C3?'_A:;2-3!5L^9;3J<-!* 0&'J.2".X)]C7D_[/'AS4O"7C3QAHNM0B*[
MM8[8-M.58$N0RGN"""/UP>*]\50BA4 55&  , "F"WA%TUR(8Q.R"-I=HW%0
M20N>N 23CW- 'SGINBS>"OVM//U@&&SUBXNKBTNGXCD\U&;&?4,VW'7..Q!H
M^(.BS^.?VG-.L-%!G73X[8W\J<K;JCEWR>@.&  /\1 KZ%U+2--UFU^S:QI]
MK?P9SY5U"LJY^C CM3=+T32M$A:'1=,L].B8Y9+2W6)2?<*!ZT ?-G[2D,D/
MQ8T&\E4I;-81()6X4E9Y"PS[!E)^HKZ1TC7--U^UDN=&NX[VVCE,7GPY,;L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M())(^TB+(JET/9ER#ZUX;^T7KMPOQ+\+Z1,Z_P!GVT<5ZT4DOEQN[3,I+G!
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_U+5)4<_\
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M]^"N3Z*/2O0_"7B*'XG3:!JRQQFWTJV6\N5491;]U:/8.>#&OF-@@G$L9X-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMPI"G<VW;]XY&#P."#S70?"7X>>)_AMH.LVEY>:;>K.S36L-NKDF3: "SMM
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M@L_H0 <<5M_$+Q+?:?;VOA_PP=WB36F,5EC:1;H.9)WST55SCKDX&#536?!
MT3X':KX7\-(\\PT^8*6&Z2YD8%G)ZY9CG ]P!@"@"NGQL\++:?;EM=230TO/
ML"ZO]F7[,9,9P &\S;COLQQ7HD<B2QK)$ZNC@,K*<A@>A!KY'N+N)_V5[:P#
M?Z4GB(PF'^/=M9L8Z]#WKZ8^'^GWND_#G0+#50RW=O80QRHW6,A1\A_W1\OX
M4 =%16#XJ\+?\)3:P0?V[K6C>2Y?S-(O/L[R9&,,<'(]JSO#?P^_X1S6!?\
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M &B(O!MSXDEO]*6]6(B:SMU=T:/> 62,<C.,C'3M7/\ PC95_:<U@,0"TU^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK;R.%4YX QVFJ:[IFBB$:I>Q0/<-L@B)S).W'RQH,LYY'"@F@"_17.:-X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXMKF ^JX<#^1_2M:U\1:+>8\C4HE8_PS9C/ZURSPM:'Q19M&K"6S-"BG*A=
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M&!A ?J2.V3V9^'\NO?!VU\&>*C!!-;VD5LL]C*TBJT2@)(-RJ<_+RN.Y&>]
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M_B_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *CG_P!2U25'/_J6H J4444 %%%% !1110 4444 %?)WB:%[C]K7R8;F
M6U=]5ME6>$*7C.Q.0'#+GZ@CVKZKO&NDLY6L(89[D+^[CFE,2,?0L%8@>^TU
MX/?_  <\>WOQ8'C@7'A^.5;^.[%K]LF(VH5PF[R/[JXSCWQ0!Z)+\(O#NHZ]
M'K'B>;4/$EY$,1G59E:-/FW8$:*B8Y/RD;?:L3]H[_DCUS_U]P?^A5Z=8O=R
M64;:E!#;W1'[R.WF,J*<]G*J3Q_LBN)^+W@_7/'7A!-"T$Z?&))EEGFO9W38
M%Y 551LYR<DD8QWSP <1\)/ &B^,?@!'I^L)*%OKMY6GA;$L9CD(7:3D #YN
M,8^=N,DFN7MY7_X:OTC1R&6PT0K86$#G(BACMCMY/))/S9///TKV'X2^%-?\
M$>#UT#7_ .S9$MY'>">RN)'+AV+$,K1KC!/4$YST&,FCXS^%TVI>/--\<>%+
MBWM-<LY%,\5UN$-VJC:-S*"5.WY<X/&/3D \T_:&U2[T#XO>&=7THLE[:VB/
M&4X9L3/\ON#DC'<$CO2?&G5+B^_:"\,:7.V;2REM/+B/(W23 NWX@*/^ BO1
M;GX8:AXM^)EGXL\<O8I!IL:I9Z78S/,A*L75I'=$S\S$D!><+DXR*7XM_"23
MQ]<6.L:)?1V&N6 "1R39\N1 Q8 D D$,200#U/'H <5^U7#%]A\-S^6GFF6=
M#)M&[;A#C/IGM6]XW5G_ &0;8(I8_P!C:8< 9X#0$U6\:_"3Q[\0]/T<>)?$
M.CK<67F+(EK#(L:@@#>.,N[%1G.P+S@5W4/@.ZO/A._@KQ!J<-POV1;.&ZM+
M8Q%(T51&2I=MS J"3\H/3 ZD \D\"_\ )I/BC_KK<?RCJU\!=3FT7X'^,M4M
M<>?8O<7$>>FY+8,/U%7-)^#OQ"T[X=ZKX.&O:'#IUW(TR&))&DD) &QG*@(A
M*J3A6/49 KJ?@[\.M?\  .C:IHWB(Z7=65[)YJO:3R,VXJ%965D48('4'/L<
M\ ''?LY0VOB;PEXQL=8/VI]0G O0QP[I*C DGKR=_/KFO3=#\":7\//AYJ^D
M:)+=302I/<N]VZLY<Q!>JJHQA!VK@]+^"WBOP%XVDU?X;Z[IRV,VY9+/51)C
MRSR%.P'?@\@Y4\#GDUZWI^E7ATF>'7[[[;=7B%;@PJ8XD!&-D2$G:HR>22QZ
MD]  #P/]E/\ Y"7B;_KC;_SDKZ2KQCX<_!_Q5\/O$6H_8=>TW^R;UHP\X@9K
MHQH2<!3\B$Y()._@Y S7L] 'QIXKBG\+_M(37>IY18]?2_627A3$TPD4Y/8#
MC.<<&OLNN#^)7PET7XDP12WDLECJ=NA2"^A4,=O)V.I^\N23C(().",G,GAJ
MR^(>@:?#IFHG0M=M[95BAO9+R:VN'0 #,B^5(&8<\YYXSSDT =Q7B?C"STK0
M/CW8>(+77;Z]U^]5(H?#MLH!?Y-@W2D[8XC@,003G)'MZ9I^A:A+KD6L^(-1
M\ZX@C>.WL[0%+:$,>7P22[D<;B< $@ <D^<ZK\'?$LGQN_X3?1M=L(HFE68?
M;(GE>,[-A38,!EV\#YU/;C&: .'\ &9/VL]1$RQQ2O<7GG)"Q*;BK%@#@9&[
MG)'O4'[2D:S?&#1HI!E'TR!6&>H-Q-7?:9\'/$NC?&K_ (3&SUW3Y[665Y9S
M<PMYK&12'4(N%[G!W<<9!P<P?%/X1>+/'OQ M]<L9M&MK6S@C@B2:ZEWR*KL
M^YL1$*27(P">G6@#AOVF+>#3/'6AG3X(;;R].78(HPH&V5]HP!C ]*ZO]JC5
M[JVT'0-)B<K;WL\TTP!QN,00*#ZC]X3CU ]*L?%7X1^-/B5XBM=11]!T^.VM
M%@6(WLTC$Y+,<^2.,M@<=!GO@=W\0/A\?B5X'AT_6'BT_586$T4MNYEBCEP0
M1DJI9"#Z ]#VY ..^*UM W[+VG[H8SY%KI[0Y0?NSA%ROH=K$<=B1WJ/X1?\
MFRZI_P!<;_\ ] :DN_A7\1]9^&$?A#6?$.BK!9^4EJMNDA,J(PP)9"HX11\H
M5<DXRW'._P"%?AWXF\(?#+4O"\&H:7J?VI)4A61)+?RO,!#,9!OW 9R%V#_>
MH \\_9ANC8Z7XWNT4,T$-M(%/0E5G./TJ?\ 9@NIM1\2>+;^^D,UW<+#++,W
MWG9GD9C^)YKK?@O\,/$_PTO]3759-)NK34EBWR6US*9(C'OQA6B 8'?SR,8[
M]*J:5\'O%/@;Q[=:K\.]8TN'2K[*2VVI1NQB0G. %'S;3DK\R]@<\D@'!^$(
M8K?]L*6*WC2*-=1O@J(H4#]Q+T KT#XRZ=HEGXW\.>)]2\2WUE?V96.UTFRB
M$DMV1)GY#N C)W;69L@@ =L&IHGP0\4Z5\3YO&(\3:>UV+N:9'FM'E\T2*58
MN@9 I(=OE5L#CFK_ ,2_@]KWB[XCZ;XGT+6;2V^RI&"EV')A:-BRE  0P)))
M!V\YZYX //=>EO7_ &K]'GU"UCL;R:YLVFAAEW[,HHVE\#<=N >W7&16U^U?
M_P RG_V^?^T*Z#Q)\&O%6I?%/3O&5AX@TV2XBDAEG-S;.BH\>,!(U)RA Z%P
MW7YNXZ#XQ_"VY^)6CZ<+"^AMM1TYG,9G#"*0.%W XR5Y12#@]QWH ROB1K%W
MHW[,]K)I\K0RW-A9VQD4X*HZKNQ]5!7Z$US?@_0/$/C;]FFW\-:)::/#;718
M&\N-2D$BLET9#NB6 @9VX'S]"#[5Z39>!=2U7X=7'ACQSJ-O<QSVD-JD6G1%
M([<1@;75GRS/N ))PORKA1SGD_ GPV^(_P /II],T;Q#H4^ASRER;NWE>2(]
M-Z1@J-Q 7*F3'\R 5_''PU\6W_P'T;1FNDO];T*7SW2VE9A.B^8JA"RABZHR
MXZ=& SQ7/_#[XK-XC\7Z'H?Q+MGBUC3KO&GZ@L7ER&9U,?E3)C^+=C( Y"Y'
M4U[-KOA[7+F/17T/6DAN]-N&GEGO(O-^T@HP*,JX #%NV-HZ#@"N7N?AA>^)
MOB=IGBWQ/#I=B=+$;K'ILKR/>2H<J\C,B;0I"X'S<<9P* /4**** "BBB@ H
MHHH **** "BBB@ HHHH ***4*6Z F@!**9<SV]C'YE]=06J?WIY0@_6N>OOB
M)X5T_(;4_M+C^"UC+Y_X%]W]:N-.<_A5R7)+=G245YU=_&;38\_8=&N9O0SR
MK'_+=6+=?&76),BRTZQMQZLK2,/QR!^E=$<'6?0S=:"ZGL&,]*4(QZ*?RKP>
MX^)_BV<G&J>4I_AC@C&/QVY_6LV?QIXEN,^9KE\,_P!R=D_EBM5@*G5HCZQ'
ML?1?E/\ W32^3)_=_6OF275]2G.9M0NI#ZO.Q_K5=KF=_OS2-]7)K3^SW_-^
M OK'D?4?DOW 'XT>2YZ#/XUX)X#.9/$6?^@%=?R6O%E=D^XQ7Z'%9/!^\X\V
MWD:1JW5['W)Y,G]VD\MQ_"?RKXBCU"]A;,5W/&1W65A_6M&#Q?XEM<?9O$.J
MPX_N7L@_D:/J;[C]H?915AU!'X4E?)5K\4_&]FP,/B2];'_/9A+_ .A@UNVG
MQ[\;VV/M$]E>_P#7>U49_P"^-M0\'/HQ^T1],45X1I_[1]ZN!JWAVUF]6M9V
MBQ^!#?SKJ-/_ &@/"-UA;ZUU*P;N3&LB#\0<_I63P]5="N>)Z?17/Z5X^\(Z
MWM&F^(K%G;I'-)Y+G_@+X)KHMC%0R_,I&05.016+BUNBAM%%%( HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "K%M_%^%5ZL6W\7X4 3T444
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MBB@ HHHH **** "BBB@ HHHH *[/X1?\E9T'_KLW_HMJXRNS^$7_ "5G0?\
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MF,RD =  R@@>P% '1Z]:_#O6?C]IVK7'BF[M=9BO+:-M)ETVX!DN491%\[*
MBG"=L'KGFL7]JN-!K'AN0(HD:"=6?') 9,#/H,G\S5#XA_\ )VVD?]A+3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^=K4)T9<LT>E"I&:O$2LKQ5I<^N>#=9TFT:-)[^PGMHFE)"AGC9020"<9/.
M:U:*Q+/-/@M\.=7^'.BZE9ZW<64\EW<+*ALW=@ %QSN5>:3XM^#?%GQ!T/\
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ME0=UK$].C7533J6J***X3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH *[/X1?\E9T'_KLW_HMJXRNS^$7_ "5G0?\ KLW_ *+:HJ?
M_0:W/3M2_P"0K=_]=G_]"-5JLZE_R%;O_KL__H1JM7L0^%'EO<****H04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5:T[4;G2[Q+JRD,<
MB_DP]".XJK12:4E9C3:=T>M:)K=MK]GYL&([A!^^@SRON/45H5X[8WUQIUXE
MU9R&.5#P1W]CZBO4="UR#7[+S8L1W,8_?0YZ>X]J^;QF"=%\\/A_(].A7Y_=
MEN:-%%%>:=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 58MOXOPJO5BV_
MB_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *CG_ -2U25'/_J6H J4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2@%C@<F@ L<#DUXU\7?BR-/6?PUX5N/]*.4O;V,_P"J]8T/][U/
M;H.>FE.G*I*R$VDBQ\4?C'%HRSZ%X2F674.8[F^0Y6W]53U?W[?7I\]R2/+(
MTDK,[N2S,QR6)ZDFFT5Z].E&FK(YW)L****U$==\.O&[^#->+7$?VC2;X"&_
MMS_$G]X?[2Y)'KR.,Y'KFLZ8EA-%-9RK<:?=H)K2X0Y61#R.?7FOG6O5OA-X
MP@FA_P"$*\02!;.Y<MIURQ_X]IS_  _[K$_F?]K((3=*7.MNO^?R(J0YXVZG
M1458OK*?3KV6UNTV2QG##^H]JKUZR::NCS]@HHHIB"BBB@ HHHH **** "I[
M&Z-EJ%O=*,F&59,>N#G%044FDU9CV,_XD:>+#QU?&/\ U5T5N4([AQDG_OK=
M7+5W_P 0(?MOAGP_JX'S+&UE*?\ </R_IN-<!7G4K\EGTT^XZI[W"BBBM" H
MHHH ZOP%]_Q%_P!@&Z_DM>*U[5X"^_XB_P"P#=?R6O%:Y'_$E\CJA\""BBBJ
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#I?!/C
MG5O VL"[TR3S+=R!<6CG]W.OOZ'T/;Z9%?4_ACQ1I?C#0X]5T67=&>)86^_
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M;NIKYG&X1T)<T?A9ZE"M[16>Y/1117GG2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 58MOXOPJO5BV_B_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *CG_P!2U25'/_J6H J4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %*!DX'6DKS_XK?$F+P5I1T_3)%?7;M/D Y^RH?XS
M[^@_'MS4(.<N5";LC&^,/Q1_L&&3PYX<N/\ B9R#%W<QG_CV4_P*?[Y]>P]^
MGSL22<GDTZ662:9Y9G:21V+.[G)8GDDGN:;7LTJ:IQLCGE*["BBBM1!1110
M4444 >]>"O$@^(GAK[#>-GQ+I40VL3S>P#O[N._X'N<-((.",$5XIH^K7FA:
MQ:ZIIDQANK6021N/7T/J",@CN"17OOVVS\8^'(O%6BQ>5O.S4;4')MYNY_W3
MU!]Q[@:X>I[.7LWL]O\ +_(YZU/F7,C-HHHKTCC"BBB@ HHHH **** "BBB@
M#5>'^U/AOK=EC,EFZ7L?X<-^2@_G7F->K>$'C.O?9)P/)OH9+:3/HP_Q %>7
MWEK)97T]K-Q)!(T;_53@_P J\]KEJR7?7^ON.E:P3(:***H04444 =7X"^_X
MB_[ -U_):\5KVKP%]_Q%_P!@&Z_DM>*UR/\ B2^1U0^!!1115%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =%X*\9ZEX(U
M]-1TUM\;86YMF/R3IZ'W]#V/X@_5_A_7M/\ %&@V^KZ/)OMIQRI^]$W=&'8B
MOBZNR^''Q!N_ FO"3YIM,N2%O+;/WA_?7_:'Z]/IRXBA[176Y<96/K"BH;*]
MM=2T^"_TZ=;BTN4$D4J'(8'^OM4U>2;A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %JV_U9^M2U%;?ZL_6I: "BBB@ HHHH ;)_JV^AJE5V3_5M]#5*@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K.\0:_8>%] N=8U9]MO;KPH/S
M2OV1?4DUHY559I&5$4%F9C@*!U)-?+GQ:^(#>-/$/V>P<C1[!BELH/\ K6[R
MD>_;T'U-;T:3J2MT)E*R.;\6^*M0\9>(I]6U1OGD^6.)3\L*#HB^P_4Y/>L2
MBBO8225D<X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *[/X1?\E9T'_KLW_HMJXRNS^$7_)6=!_Z[-_Z+:HJ? _0:
MW/3M2_Y"MW_UV?\ ]"-5JLZE_P A6[_Z[/\ ^A&JU>Q#X4>6]PHHHJA!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;7AG7
MWT/4,R$M:3?+,@]/[P]Q6+145(1J1<9;,J,G%W1[4K))&DL+B2*10R.IX8&B
MN'\$>(/*D&DWLF(I#_H[-_ _]WZ'^?UKN2""0>HKY/$4)4*G*SV*=15(W0E%
M%%<YH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5BV_B_"J]6+;^+\* )Z*** "BBB@
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MM3^/(?MW@_0-54#=!OL92.V.4'Y _G7'B%:<9?+]?T-Z>L6CS^BBBI&%%%%
M'5^ OO\ B+_L W7\EKQ6O:O 7W_$7_8!NOY+7BM<C_B2^1U0^!!1115%!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'J?P:^) \,ZC_86MS'^R+QQY<C'BUE/\7LI[^G7UKZ09=K8-?#E?1/P1^(1U
MO3QX7UB8MJ%HA-G(YYFB'\&?5?Y?0UY^*H_;C\S6$NC/6:***\\U"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH M6W^K/UJ6HK;_ %9^M2T %%%% !1110 V3_5M
M]#5*KLG^K;Z&J5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8?C/Q7;>"O"
MMSK%R%>5?W=K"QQYTI^Z/IU)]@::3D[(#SKX[>//[.L?^$2TJ7%S<H'U!UZI
M&>5C^K=3[8]:^?JLZAJ%SJNI7%_?RM-<W,ADED;JS$Y-5J]JE35./*CFD[L*
M***U$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %=G\(O^2LZ#_P!=F_\ 1;5QE=G\(O\ DK.@_P#79O\ T6U14^!^
M@UN>G:E_R%;O_KL__H1JM5G4O^0K=_\ 79__ $(U6KV(?"CRWN%%%%4(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS*I+H%%%%>@9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 2V]O)MOM6)MHL'E8\?O&_(X^K"JA%SDHH3=E<\)^)OB]O&7C:ZO8F)L8/\
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MAJ%MJVEVNI6+;[:\A6:,^S#.#[UY>*I\LN9=3:#NK$]%%%<9H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 6K;_5GZU+45M_JS]:EH **** "BBB@!LG^K;Z&J579/]6WT-4J
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M:K5[$/A1Y;W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,J7_P!JH_X::_ZE+_RI?_:J\2^SQ?W?U-'V>+^[^IH^JP[!SL]M_P"&FO\
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MKPO[/%_=_4T?9XO[OZFCZK#L'.SW3_AJ3_J3_P#RI_\ VJC_ (:D_P"I/_\
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M3>A+EJ(](HI2,$@]J2OE3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% !1110 4^&5X)XYHSAXV#*?0@Y%,HHW
M]ICG2ZMX;F/[D\:R+]",TM8?@R[^U^%HD8Y:VD:(_3J/YX_"MROC:T/9U'#L
M>W"7-%,****R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XL\;_ /)2
MO$/_ &%[G_T<U4*O^-_^2E>(?^PO<_\ HYJH5[=+X3F>X4445J(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%PZI_NY^7],5P37+6:[Z_I_D=,=8+R-GP%]_Q%_V ;K^2UXK7M7@+[_B+_L
MW7\EKQ6N5_Q)?(Z8? @HHHJB@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ._9\U7[7X%O\
M37;+V%YN4>B2+D?^/*]?.->N?L[ZD8/&FH:<S82\L2P'JZ,"/T9JY\3'FI,J
M#U/H:BBBO'.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"U;?ZL_6I:BMO]6?K4M !1110 4444 -D_
MU;?0U2J[)_JV^AJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG6G\S67PH^J]2TVU\8^")+.^BW0ZC9@X(&Y"RY5AGC<#@CW%?.?P#8K\5+<
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M#@UA_L[W=Q=> K\7,\DPCU)PGF,6VY1&.,^I)/U)/>KGQ_\ ^27/_P!?D/\
M6LW]G#_D1-2_["3?^BHZS27U=OS*^V>8_'2V2#XLZ@Z9S/%#(P/8^6%X_P"^
M17G=>D_'K_DJMS_U[0_^@UYM7H4?X<?0QEN%%%%:B"BBB@ HHHH *I7'^O;\
M/Y5=JE<?Z]OP_E43V&C[OHHHKPCI"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N(^,E^;#X3ZKM.U[IHK=3]7!/\ XZ#7;UY-^T1>^5X+
MTJQ!P;B^,I'J$0C^;BM:*O42)EL?.U%%%>V<X4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;'A;Q+?\ A'Q%
M;:OI;XEA;YXR?EE0_>1O8C\N#U K'HI-)JS ^C+T6&KZ3;>)?#V3IM]]^,CF
MVE_BC8=N?P].,9RZ\_\ AGXZ7PIJLMEJY>70=1'EWD0&?+/:51UR.^.H]2!7
MJ&LZ4VE7WEJXFMY%$EO.IRLJ'H0177AJK_ARWZ>:_P" <E:G;WEL4 2K J2"
M#D$=JC^*-N'UZSU:-<)J=G'*?]\#:1^ VT^KOBB'^T?AE9W(&9-+O&B8_P"Q
M(,Y_/:*>(5G&?R^__@V)I;-&)X"^_P"(O^P#=?R6O%:]J\!??\1?]@&Z_DM>
M*UQ/^)+Y'7#X$%%%%44%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %=E\)=1_LSXJZ'*3A99_L
MY]_,4H/U85QM7-(O/[/UJQO0<&VN(Y<^FU@?Z5,ES1:!:,^UV&&(]#24^7_6
MG'0\TRO!.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"U;?ZL_6I:BMO]6?K4M !1110 4444 -D_U;
M?0U2J[)_JV^AJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y3^T/<^7X#TVV!P9M1#GW"QL
M/_9A7SG7NO[2%SB'PY:C_IXE;_QP#^M>%5Z^%5J2,)_$%%%%=) 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5V?PB_P"2LZ#_ -=F_P#1;5QE=G\(O^2LZ#_UV;_T6U14^!^@
MUN>G:E_R%;O_ *[/_P"A&JU6=2_Y"MW_ -=G_P#0C5:O8A\*/+>X44450@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KU7PM+YWA*P;NJLA_!B/Y5Y57I?@=]_A11_P \[AU_
M0'^M>7F:O13\SKPK_>&_1117SAZ84444 %%%% !1110 4444 %%%% !1110
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MX?RJ)[#1]WT445X1TA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +:?^BEIS]I&._4%9L@\*_#3P#XI6;2-.\67MSK\4+2&2.#9;D@XRJLN6 )
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/3O OQ7_ +"\%:OX:UQ9KBUEM)4L'C +1.ZD%#D_=).<]N>N>/,:**B,%%MK
MJ.[844458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^H/@9G_A5-MG_ )^YL?G7H5<#
M\$5V_"6P/]Z><_\ CY']*[ZO$K?Q)>IT1V"BBBLB@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6W^K/UJ6H
MK;_5GZU+0 4444 %%%% #9/]6WT-4JNR?ZMOH:I4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M > ?M&QX\3:++_>L2OY.?\:\<KW/]I&WX\-W0'5;B-C]#&1_,UX97LX?6DCG
MG\04445N2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &EX>UV]\,^(+35]-?9<6L@8#/#
MCNI]B,@_6O>]4-GJVGVGB71?^0?J:[RF<F&7^.,^^<_KVKYRKTOX0^+(;*_F
M\*ZW*1I6KL!&Y/%O<?PO^. #_P ![9H4G3E[1?/T)G'GCRG6T58O[*;3K^:T
MNEVRQ-M;'0^A'L1S5>O6335T><]- HHHIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]#^'ZXT"Z;
MUN<?^.BO/*]+\#Q^7X44_P#/2X=OT _I7G9D[8?YHZL+_$-^BBBOF3U KQ2^
M_:(^Q:A<6O\ PB^_R)6CW?VAC=@D9QY?M7M=?/.H_ 'Q3>:I=7,5_I 2:9Y%
M#32Y +$C/[OWKHH*DV_:$2YNAJ?\-(_]2K_Y4?\ [51_PTC_ -2K_P"5'_[5
M6%_PSSXK_P"@AHW_ '_E_P#C='_#//BO_H(:-_W_ )?_ (W75RX7^KD7F;O_
M  TC_P!2K_Y4?_M5'_#2/_4J_P#E1_\ M587_#//BO\ Z"&C?]_Y?_C='_#/
M/BO_ *"&C?\ ?^7_ .-T<N%_JX7F;O\ PTC_ -2K_P"5'_[51_PTC_U*O_E1
M_P#M587_  SSXK_Z"&C?]_Y?_C='_#//BO\ Z"&C?]_Y?_C='+A?ZN%YF[_P
MTC_U*O\ Y4?_ +51_P -(_\ 4J_^5'_[56%_PSSXK_Z"&C?]_P"7_P"-T?\
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M/4 _2LY0]^*2T0T]&8FJ>-;.T\&'PGX.@N;;3IY3-?75V5\^\;C PN0BC:.
M3G'7KNW?ASXZ\(>"_#^JVE[_ &W=76KQ+'<&&UA5(@%883,N6Y=OF.,\<#OY
M;16CIQ<>47,[W.V\%ZSX3\+>.$UJ>YUFXMK.0M:QI91*\F4(^<F7"X)(XSG&
M>.E+X\UOPMXN\:2ZW:7.KVD=XR_:(I+&)S'MC"Y7$PW9*C@XQDG/:N(HHY%S
M<U]0OI8]5\<>.O!OBCP/I>AV UVWET>$1VCS6T+++MC" /B3C.T<@<=<'I4G
M@OXOV%EX3;PSX[TM]7TQ$$<)CC1V5!T4JQ ."!@YR/P%>345/L8\O*/F=[G?
M>)O&GAE-)N-*^'OAQM(@O%VW5[<2%[B1,@F,$LQ5#M7(W<\C'7.OX5\<^#/#
M_P .]4\,W)UV>350YGN([2%1&60+A093D#'4]?:O*J*;I1:L+F9Z!\.?$WA;
MP1XJEUB[FU>]\M'BMXX[&-,JP7YV)FX/WAMY'0Y["O=>+='T_P"*L7B[P[]O
MFB>^:\GMKV!$9=[9=5978'.YL$@8XZ]:X>BG[-7NPN>@_$3QGX5\2W%S?>']
M#N(=2U$)]LNKU@?+V[>(E#$ G: 6X. 1CYC7GU%%5&*BK(3=PHHHJ@"BBB@
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M^H*^;_V@X/*^)$,F/]?IT3_^/.O_ ++77A'^\,ZFQY;1117JF(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?5GP<A,/P
MAT7/60SO_P"1GQ7;5S7PW@^S_"_P]'C&;-7_ .^B6_K72UX51WFWYG2M@HHH
MJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!:MO]6?K4M16W^K/UJ6@ HHHH **** &R?ZMOH:I5=D_U;?0U
M2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \E_:)MC)X+TFZ SY-^8R?3=&Q_P#9:^=Z^IOC
M79?;/A-J#@9-I-#./^^PA_1C7RS7K81WIF$]PHHHKJ("BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ H!P<BBB@#W_ ,-:\/'W@9;J5MVN:*@BO,GF>'^&7ZCO^/J*@KR;
MP5XJN?!OBJUU>U!=$.RXA_Y[1'[R_P!1[@5[;K=G;(]OJ.E.)=+U&,3VL@[
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MG1X-2_M&%8LROM\O&[V.5.[E>,X'/%<;0F[M-""BBBJ **** "BBB@ HHHH
M**** "J5Q_KV_#^57:I7'^O;\/Y5$]AH^[Z***\(Z0HHHH **** "BBB@ HH
MHH **** (KI&DLYD099HV 'J2*\2\(_L_?<NO&-W[_8K5OT:3^B_G7N5%:0J
M2@FH]1-)[E'2-$TW0;%;/1K*&S@7^")<9/J3U)]SS5ZBBH;;W&%%%%( HHHH
M *\$_:.M-NN:%>X_UUH\.?\ <?/_ +/7O=>0_M%VGF>%=%O<?ZB\>'/^^F[_
M -DKHPSM51$_A/GNBBBO8, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJUIEH;_ %:TLUZW$Z1#'^TP']: /LCP]:?V?X3T
M:RQ@V]A!$?J$ K0I\N!(0HP!P .U,KP&[NYU!1112 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +5M_JS]:E
MJ*V_U9^M2T %%%% !1110 V3_5M]#5*KLG^K;Z&J5 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &+XTT\ZKX!UZR49>2QE*#U95W+^H%?&]?<B ,^UP"K<$'N#7Q3KFGG2/$&
MH:<P(-I<R0<_[+$?TKT<'+1HRJ%&BBBN\R"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *];^$'B6/4+6;P/JTH6.X8S:9*W_+*;J4SZ-_//<UY)3X)I;:XCGMW:
M.6)@Z.IP58'((_&IDK[;AZGO,\$EM<203H4DC8JZGL14=7[/6(_'7@^#Q) %
M&H6VVWU6) !AP.) /0C'\NQJA7IT:OM87Z]3SZD.25@HHHK8S"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@">
MR@^U7]O;C_EK*J?F<5[-+_K3CH.*\N\'6OVKQ59@CY8F,K>VT9'ZXKT\G+$^
MIKP,UE><8]D>CA%[K8E%%%>.=H4444 %%%% !1110 4444 %%%% !1110 44
M44 ?%GC?_DI7B'_L+W/_ *.:J%7_ !O_ ,E*\0_]A>Y_]'-5"O;I?"<SW"BB
MBM1!1110!ZS\*/B3I>D:3/X3\90K-H]T_P"ZD>,.D6[[RN.ZDX(('!S^&WXI
M^!%EJ5DVK_#F_CN()%+QV;3!T?T$<N?_ $(_C7FMWX4?_A5^F^)[.W++]LFM
M[V123M^[Y9(Z ?>&>.2/45%X*\9Z]X0UJ*709I9!+(HDL>62YR<;2O\ >[ C
MD=JYG!W<Z;LR[]&)!K^O>%/%QO+NWC35[*)+8+>VJDPB-%1,*1P0B* W7'.>
M<UZ9\?\ Q!+I_BR'3DL-,F2XTI<SW%E'),FYY5^20C<N,9&.AYJA^T;'8KXP
MTQX %OI++-R /X=Q"$]B?OCUP!VQ3?VB+:>?XC:<(())"^EH$"(3N(EE) QU
MP"#4IJ<H2MT8;)HQM(D\*^'OA2-:1=,U/Q1=7)A%K?*)OLR;NODGCHH.XC^+
M&>U=%/HEEXJ^!-_XAU#P[::-JUA)F"XL[06ZW,8V$-M  *D.1GGE<^U4$T&+
MP!\)-.\76UC!?:WJDB^7=3Q^;'IZ,"R,BGC?\J_,1P3@>^]H.HZKJ_[./BS4
M-<N+FYFN+J5TFN"3O7$0^7/&W<&&!P""*F3^TNXT<E\-/!VGWWAC7_%^LV\=
M_#HT3M;V+N0LLJIOS)CG;]WCODYZ<Z7PMN](\=>)+K0/%7A_29(;B)IK=[2R
M2V>)E(.P/$%;;C/))/&,G)IGP?O]6TRT\2V=]ICW7A^.T,FIVY4^<"R$*$7J
M2X!&#@8&<C'.3X9\6>%/ FKWFL>'DU?4;QH3%9PW\,4*0AB-S,RNQ8X'&%7N
M.^14N:3DNO02LK$.K:#IWB+XFQ>$_#&C1:*\-Y+9RRBZEN!)L8@R?/R,!2<#
M\ZW[ZSU3PYKTNG>'OAB-0TNS<P>?J&CR7,EYM.#+YFWC=R1MP ".*Y_X6ZR6
M^-6EZIJ]P#+=7,QEE?"[I94=>W RSC\Z7XM>"M3\,>,K^]GB>73M0N7GM[H)
M\I+DL8R>S#D>X&?I3^-0;Z!TN;OQJ^'VF^'8K#Q!H-N;*UU!RDUFP($4A7<-
MH/W01NRO&,# QP/):VK_ ,-76E>'+34]3\RUEO9V2WM98BK21J!NER>@R0!D
M<\XZ&L6M::M&U[DO<['X9:3;7GB=]5U9<Z7H<#:A=%A\K;.40GIEFQQSG!&*
M]$^$'C%/%6L^)?#OB1O,C\0-+=)&S_>++MDC#9S]S;C'0(>F*YO^TS\-/AW8
M6']GV-UJOB$B^O8+^W\U%MEXA5D./XLL.#@Y]JR],^+%YI>IP7MMX:\-020O
MG?;:8D4F.A"N.5)!(S[UC.+J)V7H4M#EO$NA7'AGQ-?Z->'=+9S&/>!C>O56
MQDXRI!Q[UU/@OPE9CPCJOC?Q%!]HTW3/W=M9L2JW<Y( #$<[ 67..O/. 0>N
M^/6BP:I9:-XYT@F2TOH$BE.W'!&^)R,<$@D')XPHJ?P)9'QK^SSK7AO3=BZE
M:SEUC# M*=RRID'&-VUD!)_AS[4.JW34OO#EUL8G@+7O"WBN]O-%\=:3X?TV
MUDMR]M>P0I9M&X(^7S!CJ#G+'^'!SG%8O@OP1IFN>)M;GO;IY/#6@K)/<7,9
MPT\:EMBC'(W!2<@= 1P2*YG3_"VN:GK8TFUTN[-[O5)(F@8&+=T+C'RC'.3V
MYKV'X2:?:W_A#QUX3L;V&XN':6*&X3@3(R-&L@'=<C/7^+MGDJ6@FXL%KN<)
MI'C?3YM?M;.;P=H/]D2S+";<6@:98RV ?//SEP,?-GDCIS6K\9=-L/!GC_2X
M?#FGV=K##I:$1/;),CDR2J6=9 P=L8Y;)X'H*X?2]&U*#QK9Z5-8SI?QW:*]
MNR$.I# G(],<YZ8YZ5Z!^T;_ ,E%L/\ L%1_^C9:;251)=F'V2S\7[#21\/?
M".KZ;HNGZ9/J,2SS?8[9(\[HE;&5 R 35CPI#8>(/@3XFU+4]&TAK^R$T<-U
M%IT,4B@1JP.54<@D\]:;\6%9O@QX!D4$HMI"I8#@'[.G&?7@_D:M^ M/N[3]
MG'Q5+<V\D270GFA++CS$\I1N'ME3S[5E?]TO7]1]3"^!FG^'-<\22Z=JV@1W
MUREL]P+BYEWQC#J-HBVXZ,.23T/KBL+PWX:T_P 1?&TZ%>)Y=A)J%R&BA^0;
M(][A!CH#L XZ \5N?L[?\E)N?^P;+_Z,CKE?L6JW_P 4]0B\/2-'J27MW/;L
MC%6S'ODP".Y"D#U)K77GDK]!=$=3<^(8M!^(8TCQ;X'T&VTT7:J8_L"QO'#N
MP)%D'WQCDYR&P1QVYW0CH#_%)K:^TI-2LKK5?(MXXKCRH41I2H;"@[A@C !
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5UWPJT[^U/BEH,!7(2Y$Y_[9@R?^RUR->L?L\Z
M<;CQU>7[+E+*Q;!]'=@!^FZLJLN6FV..K/HMCEB?4TE%%>(=(4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %JV_U9^M2U%;?ZL_6I: "BBB@ HHHH ;)_JV^AJE5V3_5M]#5*@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.T^'=MFXOKPC[D8B4_[QR?\ T$5VU8?@NT^R^%HW(P]S(TISZ=!_+]:W*^4Q
ML^?$2?R^X]BA'EIH****XS8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "GQG;(I]Z910!\=>-M)_L+QUK.G!=J07<@C'^P3E?\
MQTBL*O5?V@M'-EX]@U-5_=ZE:JQ;UD3Y"/\ OD)^=>55[E.7-!,YI*S"BBBM
M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@#XL\;_\ )2O$/_87N?\ T<U4*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@#XL\;_\E*\0_P#87N?_ $<U4*O^-_\ DI7B'_L+W/\
MZ.:J%>W2^$YGN%%%%:B"BBB@ HHHH *[CX-_\E8TG_<N?_2>2N'KNO@Q&\GQ
M7TORT9ML=P6VC.!]GD'\R!^-9U?@EZ#CNC;^$/Q'M]%9_"WBGRY=!ORRA[@[
MDMRPY!!R/+8]>P)R>]4_'7PZF\#^.K"6R2231;R[C:UG/(0[L^43Z@=">H^A
MKS:O=?A9XXL_%VDIX&\9_O9%PUA=R,-S%3E5RW\:_P )[CCMSE4BZ;YX_/\
MS*6NC.+^(FES:W\==0TNU_UUY?10J<9P65!GZ#K6Q\0-<G^&^N6_A;P+-_9L
M-A CW-Q&JF>YF8;LR/CD8VX7@<],;0*WB?6U\.?M(3ZM+M\FVU"(REE)Q&45
M7.!SD*21[^M6OC]HI'B:R\360CFT[5;9 MS#DJ[J."6Z<IMQSR%/I4QU<(O:
MWXAT;-/[!;?%GX17FNWELL/B30U=7NK>$*;L(@;#*.N5_)AQP<&[\'/%>I^)
MO".M>$)M3:*^ALBNESA]KQ+L*  C!PAV$'KSUX%9?PWU4^$/@MXFUF]_<"^D
M-O8;\@SR^65^7N0">H_NMZ5YWX"\2?\ ")>.-,U=RWD0R[;@+U,3#:_'? )(
M'J!2Y')2BNFP[V:9W'P3\0:YI?Q&.AW<UR]G*)Q=PRR$I;NH+&0Y. =RA2>^
M[OQ65\2K#Q$?C7):2WTTU]-=1?V9-YA7RT=\Q*A'W=I..,?,">^:Z/XMPV?@
MK4-5ET>Y4:CXHE68M"X#6]LN&?D8(\R7)SR"$(ZBNCUO5M/U+P)H_P 5)'":
MSI]C);(L8&)+E\Q@$'^%&,C@#G!SSW7-[RJ);Z?,+:6/,/BMXPO?$'B:32C=
MS2Z;I#?9H5<_ZR1!L>5N?F)8-@GL1TR:X.BGPPRW-Q'!;QO+-*P2.-%+,[$X
M  '4D]JZXQ48V1FW=G<^ @/#WA[7?&DS*DUI$;#2\[=QNI1C>N3U1.<8.0WL
M:[;X(ZA;^)O!^N^ ]6D"QR1-);D$;PKC#X!_NMM8>['-8/BSQ;K?P[_LWP=X
M9U V7]EVBF_>)0WFW4GSORPY49&.!U/X9^@?&?Q=9^(;&?5M9ENK%)E^TPR1
MKAHR<-T&<X)(]P*YI1E4BVEOM^A::3.&U33;K1M6NM-OT\NYM)6AE7L&4X.#
MW'H>]>W>"=3TR\^ _B&ZO]"LXH+24Q20V*F)KF,"-MKR$ELDG!;)('TK)_:$
M\+_9->L_$UE&OV344$4SH./.49!)_P!I.G^X:G^'EI-??L[^,(+9"\AGD8*!
MDG;'&QQ[X!HG)3IQEYH$K.QH?#OXM)XDUN+PEKF@Z9!I=XK0VL-K#MCCX)V,
MK$@@CC@#D].>,?3]%L_!'[0$6@KI%G=V5S<H;:2\0R-%&X##9DX!5A@,1N^4
M\\UQ7POTFXUCXF:)';*V+:Z2[E?;D(D3!R2>P. ,GN178W/B*#Q-^TS87EE*
MLUI%>QV\$B-D.J#!(/<%MQ&.,$?6E*"C)J.UAIW6II^-OB0O@3XH:HN@:%8R
M7S.GVV]NU+/(ICCQ''@C8H &>N3SCBI?B99Z3XS^%NG_ !#TZQCM[N-D^U)@
M_.I?8R,1C.).C<$CTSQP_P ;;2>U^+6JO/&56X6*6)O[Z^6JY'XJP_"NDUV\
M;PS^S?I>@7ZB/4-7F\[[.S8>.'S3('(]#M3KC[WJ,4E%)0E'?0+[IF];ZQI_
M_#.(U:[T2Q 2XXM((=L,LBS$1EQG)7."1GG!'>L&Q\03_'#Q%H/A_5-)MK2&
MQ#SW=S:G#&,+C"Y^XI.T8&>2#VJ8*6_9,8@<+>9/_@1C^M<Y\#M?MM!^)4(O
MG6.+4+=[,2,<!68JR_FR!?\ @5"C[LI+=-A?5(?XC^)6M:)XON[#PI)%I&DZ
M9</;V]C;QKY;JC$%G&/F+$$G/KU[UM_$#0].UOX>:7\2_#MLNF7DCH;V.V'E
MKOWE3(N.C"08SWSGKUXSXI^'+KPY\1-5CN(BL%W</=6T@4A71VW8'KMSM/N*
M[+Q!J1\-_LX:-X<OX_+U'5I#*+=CAD@$QE#D>_R  X^\?[I%4TER.'47>YT7
M@[Q7K?CGX*ZWIMIJ5T/$6F1X6X5LRS1_>7YN/F8*Z9SG@$GFO,_A5?7.C^(K
MS6TO9;6RTJRDNKI5;"W&!MCB;L=SLH /X8/(/A#XJ/A;XAV3RMBSOB+.X&<
M!R-K=<<-@D^FZNA^+6G:?X&MKCP[H;J/[:O3J%U&N/W42_ZJ( #A0S2$?0>]
M'*HR=-+?^F%[JY0\"Z==?$WQY>ZOXJF>]M]/MVNIUD?"/C[D.20$7.3Z84],
MYK:\->*_%UKXGM1JVI^'ET"241W.GQZIIXMXH"<$*@D) 4'( Y.T YJG\ ]3
ML(O$>J:+J4HB75[3R8R3C>P)^4'U(8X^E8/B/X1^+-%\1/86>D7>HVTDF+:Z
MMHS(CH3P6(X0^N['?MS1+E<W"7R#6UT=-JGP\\/>(OC3::=X2O;671KN'[9=
MFRG25+?:QWHNUOE!^0 =O,X&!@9'B3XEZSHGBJ\TSPHT.DZ-IUR\$%C!$ACD
M",5)?C+;CDD$]_QK:^%D5EX&^+=II6IW*+?W6FFVNE+@I#=/('6(,.,[%13R
M?G+ $UR7Q-\&ZKH'CZ_1[.9[?4+MI;*5$++*)&)" CJP)QCKQG&"*(V<^66J
MMH#VNCT+XT:@NJ_"'PGJ"V\=L+IXIO)B&%C+0DE1[#/%>#U[O\3-(U*7X'^#
MK>+3[IY[=(?.B6!BT6("#N&,C\:\(J\/;DLN[%+<****Z"0HHHH **** "J5
MQ_KV_#^57:I7'^O;\/Y5$]AH^[Z***\(Z0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 4'!!':OF#XW^'_P"Q?B1<W,2;;?5$%W&>
MVX\./KN!/_ A7T]7F_QS\-_VUX &I0INN='D\W(')B; <?A\K?\  :Z,-/EJ
M+S(FKH^9:***]@P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHKHO ?AMO%?C?3=)VDPRRAIR.T2_,_Z CZD4FTE=@?1OPDT#_A'OAGIR2)
MLN+[-[-D8/S_ '1_WP%KLZ5MH.$ 55&% &  *2O"E)RDY,Z5H@HHHJ1A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 6K;_5GZU+45M_JS]:EH **** "BBB@!LG^K;Z&J579/]6WT-4J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!RMM8$=J^4?BWX8_X1?XAWL4,>VSO#]KML
M#C:_) ^C;A],5]65YW\;?"G_  D/@5M1MH]U[HY,XP.6A/\ K!^& W_ 373A
MJG)/7J1-71\PT445ZY@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'IWP@\5PP74WA'6Y=NFZJP^SR,>+>X_A(]FX'UQ[UV-[9S:??2VERNV6)MK#
M^H]N]> ABK!E)!!R".U>_P#A_71X_P#!"ZA(V[7-(40WX)^::/\ AEQ_/Z'V
MJZ-3V4]=G^?_  3&M#FC=;HKT445ZAPA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !112@%F"J"23@ =Z .N^'^F>;?S:E*N4MEVQY[N?\
M!_,5W=4]&TT:/HMO9<>8!OE([N>O^'X5<KY+%UO;5G);=#V*,.2"04445RFP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q9XW_ .2E>(?^PO<_
M^CFJA5_QO_R4KQ#_ -A>Y_\ 1S50KVZ7PG,]PHHHK404444 %%%% !71>'_'
M?B#PK"8] NK>S)R&D6Q@:1AG."[(6(]B>*YVBDTFK,#1UG7;[7[K[3J7V9IB
MS,TD%G% 7+')+>6J[CGN<FJ,4LD$R2P.T<D;!D=#AE(Y!!'0TRBBR2L@+FK:
MM>Z[JL^I:K/]HN[@@RRE0NX@ =  .@%:^C?$#Q/H&DG2],U,I8EBWV>:".9
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MT_"O/Q]?V5+E6[.G#T^>=WLB\2223U-)117S!ZH4444 %%%% !1110 4444
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MCK?_ '_B_P#C5'UJ(<C/G+[4GHWY4?:D]&_*OHW_ (9P\(_]!'6_^_\ %_\
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MZU$.1GS3]J3T;\J/M2>C?E7TM_PS1X._Z"6N?]_X?_C5'_#-'@[_ *"6N?\
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M"/\ T$=;_P"_\7_QJCZU$.1GSE]J3T;\J/M2>C?E7T;_ ,,X>$?^@CK?_?\
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MRY7LT:GM(7ZG/*-F%%%%;DA1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\8^%+[P9XEN-)U 9V'=#,!\LT9^ZP_KZ$$5A5[*::NCG"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !4MK:SWUY#:VD333S.(XXT&2[$X 'XU%7OGP+^'WV2W7Q=K$(\Z5
M2-.B<<HIX,OX]![9/<5G5J*G'F8XJ[L=]\._!<7@7PG'8':VH7&)KZ53G+X^
MZ#_=4<#\3WKJ*7K25XLI.3NSH6@4445(PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6
MW^K/UJ6HK;_5GZU+0 4444 %%%% #9/]6WT-4JNR?ZMOH:I4 %%%% !1110
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MRQ^)G30H^T=WL68XXX(8X+=!'#$NU$'84M%%?,MMN[/5"BBBD 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %6+;^+\*KU8MOXOPH GHHHH **** "BBB@ HHHH ****
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M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC>*1HY49'0E65A@J1U!%-KZ.^+'PG7Q+'+K_ (;A":NHW7%LHP+L#^(?[?\
M/Z]?G-T:.1DD4HZDAE88(/H:]BE5C4C='/*+3&T445J(**** "BBB@ HHHH
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M4R(/[OJ.W4<=/0P^(^Q(RG'JCQ"BBBO0,@HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "K%M_%^%5ZL6W\7X4 3T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !4<_\ J6J2HY_]2U %2BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$.9)6YDF;^\Q[G]!VK5KR:]=U'9;&\8V"BBBN8L**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2@XZ4E% '%?$#X7Z5X[A-PA6PUA%Q'=JORR^BR#N/?J/?I7S-XA\.:
MIX6U:33M;M'MITZ9Y60?WE/0CWK[.K+\1>&M(\6Z4=/U^T6XB',;CB2$_P!Y
M6[']#WS751Q#IZ/8B4+GQC17?^/_ (2ZOX+9[RVW:CHY.1=1K\T0])%[?7H?
M;I7 5ZD91FKQ,&F@HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BK
M6G:;>ZO?Q66F6LMU<S-M2*)=S'_/K7T#\/\ X(V6A^5J7BX1W^HJ0T=F#NAA
M/^U_?;]/KUK*I5C36HU%LX7X;_!R\\4K%JWB#S+'1\AD7&);H?[/HO\ M?EZ
MCZ*L+"STG3XK#2K6.TM(1B.&)< ?XGW-668L<L:;7E5:TJCU-XQ2"BBBL2@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +5M_JS]:EJ*V_U9
M^M2T %%%% !1110 V3_5M]#5*KLG^K;Z&J5 !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4-M>6MZLC6=S#<+%(T,ABD#!'4X93CHP/!'
M45E^+M;DT#PM>7MI$9[XKY5E HR9KASMB3'NQ&?09/:O"/V:O&$T'B/6/"VK
MRE);UVO8EE&UC.O$JX/.XJ <8_Y9M0!](T5!?7D6GV,UW<B4Q0J7?RH7E; ]
M$0%C] #7$VOQO^'=X)S!XEB @C\QS);31_+N5>-R#)RPX&3C)Z D '>T5SGA
M7X@>%_&K3KX9U>*]DMQF2/8\;J/7:X!(YZ@8K/U+XN>"M&U]]%U75Y+34$E$
M30S6-PO). =QCP5/9LX(Y!QS0!V=%<79?&#P%J.N)I%GXDMI+R23RT&R0([9
MP )"NPY/3!Y[5K^*?&>A>"[2&Z\2W4MG;S,429;665 P[%D5@I/8'&<'&<&@
M#=HKCY/BOX(AT"TUF;Q!!'8WC,MN[QR*TA5MK80KNP">3C'?I6UJGBG0]%TB
M'5-4U2WMK.X"^1*[_P"NW#*A .6)'. "<4 :U%8>F^,]"U75?[,M[QX=1*[U
MLKVVEM9W7KN6.559AP>0".#Z&LC7OBYX)\,:Q+I>O:O)97L6"T3V-P>#T((C
M((]P2* .SHK"U7QGHNB>'XM;U26[M].E4-YQT^X.P'H74(6C'^\!UJU/XBTJ
MT\/C6[^\6QTXH'\Z\5H, ],JX# GL",GTH TZ*PM(\:^']<OQ8Z??YNVC\Y+
M>>&2"22/M(BR*I=#V9<@^M3>(O%>A^$[-+GQ#J4-E'(VV,-EGE/HB*"S'D=
M>M $=]XT\+:9>R6>I>)='L[J(XD@N+^*-T.,\J6R."*V8Y$EC62)U=' 964Y
M# ]"#7S!^TOK5CK-]X=>PDDW11W"RPSP/!+$28\;HY KKD<C(&1R.*^D= _Y
M%O3/^O2+_P! % &A1110 4444 %%%% !1110 4JL5.5.#244 >>^._@[HWB[
MS+W2_+TG5VY,B+^YF/\ MJ.A_P!H?B#7SQXD\)ZUX2U VFNV,ELQ)V2=8Y!Z
MJPX/\_6OLFJ^HZ?9:QI[V.KVD-[:2?>AF7</J/0^XKJI8F4-'JB)03/B6BO;
M_&GP E0O>^!Y_.3J=/N'PZ_[CG@_1L?4UXSJ&G7FE7LEGJ=K-:7,9P\4R%6'
MX&O2A4C47NLQ<6MRM1116@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^U>E2Q49Z2T9C*#6QY'13Y89+>9XIXVBD0X9'4@J?0@]*9760%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M I]%<,ZDIN\F:I);!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBL*Z\<>$[&[EM;[Q1HUM<0L4DAFU")'1AU!4MD'VK=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *<KLO0_A3:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH M6W^K/UJ6HK;_5GZU+0 4444 %%%% #9/]6WT-4JNR?ZMOH:I4 %%%%
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MZ]O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]UY)9Y+AUVF5V.2=N3M'8#T Y)R3T=%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,K#((.017SQ\1O@-%;^#]4\4W7B2_P!0U^"%KN\EN0OE7! RP50,IQP!D@8
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M<]JZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZL_6I: "BBB@ HHHH ;)_JV^AJE5V3_5M]#5*@ HHHH **** "BBB@ HHHH
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MSX4*J)N+$!0#Z'!QZK7(^&?"E_;^*=4\4>*)K>XU:Z8P6B6\CO%96@(VQJ6
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M&8ZC9:5%JRQD0K!>2/;R/MZL3$&0;L\ -@=S0!R'Q6O;W7;-? /AF-)]6UA
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MO)?YFNRKCOAOHWB3PSX6LM!\10Z4T=A#Y<5U8W4CM)SP"CQKC@]0QY'05V-
M'RS\2H8KC]J_3(+B-)8I+_34>-U#*ZDQ@@@]01VK5_:ELX+'5?"VI6:""[>.
M>,RQ#:V(S$4Y'/!=L>E=;XR^#>N>(/BH_C33-5L+:2U>VGLK>=';S)(MO$A
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M_C7''9?M!Z$;.*.';'9,-B #(E(''L !] *^I*\+\?\ PC\;>-/B);^)HI-
MM%M5A6*W:\F8D1MN^8^2.I)Z#IBO<+=IVM8FNXXXIR@,J12%U5L<@,0"P!Z$
M@9]!TH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** +5M_JS]:EJ*V_P!6?K4M !1110 4444 -D_U;?0U2J[)
M_JV^AJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5BV_
MB_"J]6+;^+\* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J.?_4M4E1S_ .I:@"I1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% %JV_U9^M2U%;?ZL_6I: "BBB@ HHHH ;)_JV^A
MJE5V3_5M]#5*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"K%M_%^%5ZL6W\7X4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4<_P#J6J2HY_\ 4M0!4HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"U;?ZL_6I:BMO]6?K4M !1110 4444 -
MD_U;?0U2J[)_JV^AJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5BV_B_"J]6+;^+\* )Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J.?_ %+5)4<_^I:@"I1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %JV_P!6?K4M16W^K/UJ6@ HHHH
M**** &R?ZMOH:I5=D_U;?0U2H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JQ;?Q?A5>K%M_%^% $]%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5'/_J6J2HY_P#4M0!4HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"U;?ZL_6I:BMO]6?K4M !
M1110 4444 -D_P!6WT-4JO/S&V/0U3\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?
ME0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*
MCRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIW
MEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"Z
MWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UO
MRH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*
M=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\
MNM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=
M;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 V
MBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_
M +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\
MW6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4
M-HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M
M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_
M -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5
M #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/
M+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6
M_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?
ME0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*
MCRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIW
MEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UORH\M_P"Z
MWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*=Y;_ -UO
MRH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\ NM^5 #:*
M=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=;\J/+?\
MNM^5 #:*=Y;_ -UORH\M_P"ZWY4 -HIWEO\ W6_*CRW_ +K?E0 VBG>6_P#=
M;\J/+?\ NM^5 #:L6W\7X5#Y;_W6_*I[=2N[<".G44 34444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>rprx-20221231_g4.jpg
<TEXT>
begin 644 rprx-20221231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'H0: +5%>0?L>?M\_L@_M^>%-:\;?L@?'#3?&VF>'=8;2]9N+&VN(#;7(7<
M4N(XW*,.4D4&-P"59L''K] !1110 45Q?[0W[1/P5_91^$&K_'S]H?X@V?A;
MP?H1MQJ^NZ@DC0VWGW$=O%N$:LWS32QH, \N.W-> ^+_ /@N=_P2F^'UCINJ
M>/?VO=+T2VUF!IM'N-7\/:I;1WT:XW/"TEJ!*HW+DKD#</6@#ZRHKP7X9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^%O\ P>;_ +?7Q3^&_A#X>?\ !/[X7^(+K2M/\=Z?/KWC
MR2TF,;ZC91S""TLBPZPM*D\DB]&,478$']@/V*_V3_A?^Q!^R[X+_9A^$?AV
MTT_2O"FAP6LK6D 0WUV$7[1>2D#YY9I=\CL>26/; K\R/^#L[_@DE\;?VVOA
M?X-_:Z_9>\%WGB;Q7\-K.ZT_Q)X7TN$RWNH:/*PE2:VC7YII()1(3$H+NMPQ
M4$QX;ZN_X)^?\%Q/V#/VF?V5_#GCOXK_ +5'@7P%XYTW1(;?XB>$/'GBBUT>
M_P!)U2&-4NLQ7;QL\)E#,DJ@J58 [6#(H!ZS9?L^_LV_L+?%[X]_\%#IKRP\
M+:1XV\':1J7Q(6"R$<*2Z(NJRSZFVS[\LL%XBNJJ"S6H;YGD:OC2V_X.#?CC
MJG["6K_\%:=(_8ZT5_@!H_CU=!DTF;QC*OBJ;3C>167]JA!;FT4_:9D3[*9#
MW_? #<?H+]LF]US_ (*J_P#!.#X_?"#]F?P?K::?KO@J>P\ >+-7MC8VWBZ]
M$;3$6:3;9#:%XXH5NW58YC*[1[XT$C_D)H?Q:\&Z/_P:3>)_V$[_ %!(/C(W
MQ4C\+/\ "^4%?$!U/_A*K;4A -/_ ./@M]G0G[G52.HQ0!^I/_!4+_@N%9?L
M+_L&_#+_ (*(_ ;X-:7\4O ?Q*U.QM+);KQ5+I%U"M[8SWEO*%%I.#A;:5)$
M8HR/M&#\VWQ?]I[_ (..?VAOV/+OX!_&/]H+_@GS!HGP@^.6F175A?0>.A>>
M(+:/RK22:<VD< C4!;M)(H2Y>6/&\P2%HD^1_P#@MU\$O$7[&?\ P;%_LO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6Z).<DRA=^>3W[UOT44 4=#\,^&_#$4\'AKP_8Z<ES<-<7*6-HD(EE;[TC!
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MI)&6!V,/[PP:O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2QV@VQR!^=)]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XT ;%%5]-CU&*U":I<1RR[CEXDVC';BK% !1110 4444 %>'_M
M:_LW?&_XQ6^IZG\$?CG8^'KC4O"$^B7_ (?\2:"U_I=\3)YL%P3%-%-;SQL7
M42*SJ4E8-&Q"E?<** /E+Q=_P3+\0ZE\"_$'PC^'7[6?B'P=J?CWXC77C7XF
M^*=)\+Z9<R^(]0G$2M;&VO(IK>*Q\N"WA-N4D,D-ND<KR;IC+T/A#]@?Q+XD
M^&_Q!^%'[:G[67C#X\:'\0?#HT.ZTWQ5HNE:5;Z?9,LHF$$.DVULGFR&1#Y[
M!I$,$>QEP<_1E% 'C'PK_8TT;P=\6-+^.7Q/^)NM?$#Q5X=\%/X3\,ZKXAM[
M:/\ L_3))(I+E]D$:K)=W+06_GSD .($")$I</@?#7_@FW\&/AK<^!M!M?%.
MOZCX*^%OB2ZU[X9> -0>V.G>'KZ9;A$=&2%9ITMDN[E+9)9'6%9?XC'"T?T-
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4455U?6]&\/V9U#7=5M[.!>#-<S*BY],D]?:HJ5*=
M*#G-I);MZ)?,J,93DHQ5VRU15?2=6TW7=-AU?1[Q+BVN$WPS1G*L/6K%.$X5
M8*<'=/5-:II]4*490DXR5F@HHHJA!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKU?FPHHHKU3C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7.=T[ K;0W7FY5VNO,B$*Q>6X!]UT444 %%%% !1110 4444 %%%% !1110
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M[M6YM;W6BBBI.L**X^R^.?PZU/XQS? O3-:%QKUKI3WUY%%@I JO&OELV?\
M6$2!MHY"C)QQG-_:3^/NA_L[>!+7QGK,:RFZUJULXH">61Y 9F&.<K"LK#_:
M"@]:]"CE68U\72PT:;YZEG%6LVGL_1[W[:GG5LVRZAA*N*E57LZ5U)IW2:W3
MMU6UM[Z;GH5%-BEBGB6>&171U#(ZG(8'H0>].KS]CT=PHHHH **** "BBB@
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M+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBJFN:[I'AK2IM:UR_CMK6W0M+
M+(< #T]SZ <FHJ5*=&FZE1I12NV]$DNK?8J$)3DHQ5V]D4O^$'TC_GYO?_ M
MJ/\ A!](_P"?F]_\"VIG@KXA^$?B#8M?>%M66?R\">%E*R1$] RGD=#ST..#
M6W66%Q6&QV'C7P\U.$MI1::?HT56HU</4=.K%QDMTU9F/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M6Q1709F/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6
MQ10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M
M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L5$]_
M91WT>FR748N)8FDCA+?,R*5#,!Z LOYBIE*,%>3M_P '8:3>QF?\(/I'_/S>
M_P#@6U'_  @^D?\ /S>_^!;58T_Q9X;U76;KP]IVLP2WUE_Q]6JM\\?U'Y?G
M6A44JU&O'FI24E=JZ:>J=FM.J>C[,J=.I3=III[Z^>QC_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6?XR^,/@7P%J+:3XFU":"?[,)HU6T=A*"2-JD#!;V]Q[
MUO:)K>E>(]*@UO1+U+BUN8]\,T9X8?T(Z$=01BN:AF>78G%SPM*M&52'Q14D
MY1UMJMUKW_4UJ83%4J,:TX-0ELVG9^C*/_"#Z1_S\WO_ (%M1_P@^D?\_-[_
M .!;5L45W'.8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_
M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MS5BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#L[OY?E%@0I5B!M(/>?'K3OBIK'PFUG2?@O=6]OXCNK<16-S<W)B\H%@'9&
M.'V;MI. &P<C%=A17#6S.G/%4*].A"+IJ":LW&;C]J2;U<OM=_F=]#*ZD,)7
MH5<1.?M93:;:4H*?V8M+11UY>WR/G7]C7]C7QC\#/&.K_%CXL>+K76/$6L6K
M1$V[R3&,R2"25WED +NQ5<G'][DYKZ*HHJ,XSC'9YCGB\6TY-):*R26B22V2
M+R;)L!D. CA,)%J";>K;;;=VVWNV%%%%>8>H%%%% !1110 4444 %%%% !11
M10 4444 %%%% !6?XLT"'Q5X9U#PW<2;%OK.2'S-N=A92 V.^#@_A6A165:C
M3Q%&5*HKQDFFNZ>C1=.<Z4U.+LT[KU1\N?M9_LF6?Q<UKPSHFCZV]GXNLO#;
MPZ=J[H$@U)K?#+#(!EHV'S,) 3C=R#P1S_\ P32^%FL>$?'_ (R\0?$S3KVW
M\4X-H(K^)C((Q*&GD9SD,7D\O!S\VQB,@YKZG\:_#SPWX^%I_;Z7&ZQE9[>2
MVN&B=2PPPW+S@@"J/@/P7J>A^*?$7B?6O+,FI7<<=D$E+[;6) L>2>0QR<CU
M'4]:ZL/QAQEE^5OAU*,\).<5";NY4Z,8<TH/1;U(I)RE)M2\M?%K\&<+XK/(
MY_K'$1C)RBOAG4;Y8SM?=0;;22U1U5%%%9'KG-:!X'O_  _\0M9\46FI1_V=
MK$4;RV/EG<MP@"^8#TP1G/J3[5XI_P %%YOBG<^ [72?A_X@O].@6&6[NDL)
MS&;X189XF( 8%4S( & ;!&&.W'TA6/XV\$:-X]TJ+2M9,JB"[CN()H" \;H<
M@@D$<C(/'0FN/!?6N'I0Q.5)<].JJJC+6,KSYYPUORJ:<DFOA;YE:PLQH4,]
MPM3"XV34:D'3YHZ2C[O+&2M:[B[.S^)*SO<\@_96_;!\-_$[X%)XF\=:S"FO
M:)MM=;MHV!FG(*JEPL?4A]RYP,!MX'2L2+X<_%/X9_M6W7Q(/Q@.I6OB6^2U
MTSPU=327$\-E*Z2R;E<A8$C9&5=N>/3FN&^$7[&]YX%_;2URPMM)/_".Z?'#
MJFG7#C]V+6:4E8 >[!HWCQW6-CD9&?K*]\#Z+?\ CBQ\>SQ_Z98V4MO%QU#D
M8/U +C_MH:]SC#%YE@\ZQV'X?<88;$1HI.45=1JVG5Y'K9QBXQCLXR4END?/
M<*82EF.2X.MGJ;Q&'G4VDTI2IWA!S6EU)IN6Z::>S:/F_P .?'GXMZ)_P4=U
M/X0>,_$Q;0=2C,&GZ:@_T>)!:_:('7=R'/*L1]YF(Z!<?5-? W[7ESXO^#_[
M5WAOXS>)2]Y_9.HVQGN((55KF!)FE3.,*&:)FCQQCROQKZ$_:)^+?QR\1?#+
M0O%_['?V/6(]2O8H]0D@MEGN(%E5&B(#-L5?FQ(2"4W Y4!B/I,31P/$^"RK
M&X'EHJM#V4N>T%&M1<HU%.U[2]WSNDFFUJ>'EV.Q7#V*S;!XWGK2HU/:Q4;S
MDZ-51E!P3M>*OY6O9V>AYY^VM\'?B3\4?VD/"VO>(/",\GP]T6WB_M"_6>-D
MVAVFN05#;D+JJ1#(&2%QG-?2_ARRTKQIIF@^.-7\,?8[RVMS+86[2D_91(FT
MC P#E<=1Q[$5'X@\&WOQ$\(Z9I7C.1;.426UQJ]E8R>9#*Z@,\.Y@"T>[H<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0M/([$%E4<#!*X.#C&<<XJGI4B?'[P;/)K%C<V&D2ZJKV"JP#WEO$5/[P'.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:LJ3CRN"46O-;O[[_(****]@X0HHHH *I>(/#VC>*M)ET+Q!8)<VD^/-A<D
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M3]K'2M-^)OP2\9_#G2/$]S;ZM8Z%)J#6MC,4>01H9%B?C#(^ I7_ &A7#?\
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7?W+5^1Q3J0I1YIM):;Z;NR^]Z+S+UI:6MA:QV5E;I##"@2**-0JHH&  !T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/RC/T57A'[&G[&5O^S$^M:WK^LVNK:SJ,OD6M];1,HBLEP0N&Y5G;EADCY$
M)P2?6_$'Q'\%^&&O(]8UR..2PCCDO(D1G:)9&"H2%!P"2/ID9QD5S\88WA?
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M]HEI>I&VZ-+NV60*?4!@<56OO _@O4YA<:EX0TNXD5%17GT^-R% P%R5Z <
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M490EK:497WNE:46G>.MDXOJ*OAZ5*C"<97;;4EI=-6\]4T]'W3[#J*Y3Q_\
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MCEB*D$KN5AGJIYP>^#VP3J5S-OX,U*P^*UQXXT^XA6RO]*6#4(&8[VG1ODD
MQ@X3Y>35^T\=^$KV]U*Q@UR#=HY4:C([[8X2V>"Y^7(P<\\=#7I8+'584W#'
MM0GSSC'9*<4W*+BF_P#GWK+LU)['+7P\)23PR<H\L6^MF[)I_P#;VWJC'^'>
MMZAXX3Q/!XA>.ZLH/$%SI]M!)"NTP(%!4X'S Y/7-;OB/P=X6\76L=EXET&V
MO8XCF)9X@=A_V3U'X4[PWX=T'PY920^';81PW5R]TY$K.'DDY9LL3U_*M"C+
M\OE_9D:&/M5DT^:_O)WDVE[RU2OI=:!B<2OK;J8>\$MK:-:)=-F[:G/?#CP7
M=^ M+NO#QU(W%BE^[Z4C$EH(& /EDGKAB_KQCZ!?&WP[T;QCX<U#P^-MC_:D
ML3WMS;0KOE*,I&X]^% Y[5T%%:+)\N66_4'"]+E<>5WTBTTTGNERMQ5GHM"7
MCL5]:^LJ5IW3OYJSOVW5_74155%"*  !@ =JX;Q7X2^)OC'Q5!I6HZM:6GAJ
M*\6Z\W3972[?8 4C8G@?/\V5]/4"NZHJLRRRAFE%4:LI**:;47;F2^S+O%]5
MU%A<74PE1S@DW;1M7MYKS71E;4M'TK5[>2UU33X9TFA:&594!W1MC*GV.!Q[
M4:/<Z/<:>BZ#<V\EK"/*C^RR*R)M^7:-O QC&.V*LUQEM\-K[PGX]M_$?@*X
M%OIU])(=>TR6=O*8D966-<'#[NHZ'V&:C&U,1A*].K1HJ:DU&;7QI-I*2T]Z
M,6VY*Z:6JO:S="-*M3E"=3E:5XW^%M+5>3?33?1VW.SHKA3JGC3P_P#&V.TU
MR\6XT?7K1XM,C@1L6SP@/\X[$AGY[Y'3&!W57E^8PS#VJ4'&5.;@T][JS3])
M1:DO)BQ.%EAN1\R:E%237GHUZIII^@4445Z)RA1110 4444 %%%>+?M1_MM>
M#/V:_$.F_#FQ\"ZWXS\9ZKH\VLV_A7P]+:Q31:5!=VEI/?32W4L444:S7MO&
MH+%Y'DPJE5D= #VFBO-O#?[3.@>(/@GKGQIN?AMXQT[_ (1N>_MM9\*W>C+)
MJ\-S:2,DD*Q6\DD<I) 9)(Y&B=&5P^P[JY[P7^WO\ O$_P"P=8?\%%]?U"^\
M-_#J\\#+XLEEUJ!1=6M@8O,"O'"SAIB,*(T9RSL%7<2,@'M5%>,?#+]LW0/%
M/Q:B^!?Q6^'&L_#OQ5J'@H^+M#TOQ-=6K"^TE)%BN&\R"5TCN+9Y(1<0D_()
MXV5Y%+,O*?#/_@I7\./B$WPV\87O@/5-&\ ?&;79]'^%7C>^N8_+U>[2.>6W
M$T ^>T2]AMIY;1F+&14 D6"22.-@#Z2HHHH **** /FS]F+_ (GG[4?C?Q&?
MF4?;MA]-]XNW_P =4BOI.OFO]A.2*?5/&7B[49DB0"W,DLK *H9IG8DG@ ;1
MFOH:_P#$FA:7?V.F7^I1Q3ZDS+8HV?WI5=QP>G3UK\Z\-JU&'"4,34DH^UJ5
M):NVLJCBM^[22[O1'GY+3J5,&I13=W)_=>_W)7?D)XIT6/Q)X9U'P],!LO[&
M:W;/3#H5_K7S)^RU\8]/^%?PZ\5VFKQE[BVO(I;"R+8,T[HZD'^Z!Y2[CV'J
M< _3NM^(]%\.Z%-XEU>_2*R@B\R2?[PV]L8ZYR,8ZY%?$G[:EMIW[/WCJQ\0
MZ#ID=_H_BV7[8MJTK1NL:LK31 XR@;>-I(X#$8.VNKB'(.)\]XFP'^K48U,8
ME4ARN25HU(NTY7VC%QD[O2^FNIAF^*P>2PAFN/O&A3YE)I.[;6D5H]7)Q6SM
M>]K':_#;X,7WBCX5>-?C%XUMVEO9;:XN=*E+?ZQXP\LLF/X@S?+_ ,!;VKT/
M]F&S@^(_P U+PM%J]S91G598?,M&VO&"D4C*,]B68'U!->':A_P5(TF>UUCP
MI8_!X0^'I?#XL]%M8[H+-%.8RC"0C*^5AL *,C8.N["^H_\ !-_Q!<ZQX UJ
M&[\L2?:+:Y98L[1YD;#C//\ RSJ,;X1YIX?9QEOU^DE#$4ZM&I+F7-4G*+JR
MORN^B35V]-%=V/+X=XXRC,,7' Y55YXQ;GJG>+BW9IM)/FOVU23:5D>T_#9/
MB1::>=#^(-E9R?9(A'!J,%R6:Z R,NI'!P <YY]*L>(Y-$^'/AG5_%FC^&XE
ME6W,LR65H T[*N%W;1D@=SV&3ZU\N_M#^,_BO\)_VUCX]T3QA.-(_LFT$FE&
MY+130A2#"T?  W[W!Z@MD$9KW3]J[PW\3/B-^SSK6@?!>\A_M'4;5?E+E7N;
M4\R11-D!7=?E^;@@L.,@C[#+\%D>(QM/)<'F,:E6$(<U22YG0E5YE:3LE*5-
M+WM;VLI.[9ZRXGK8CZYB'A))T92_=Q=O:J.J<=[*;6BMH]EL>=^%_BQ\,-?^
M#.D:KK/QLM--T4>([J/Q-<7%Z8KB6\#,XABVYRC9WY!Y#!O4#WKP)I?AC1_"
M&GV?@QT?2S;+)92QON$J/\X?=WW;LY]Z^(?A+_P3 ^(=Y\2(M/\ B[?1VWAN
MULH+JYFT^X!>ZE=,M;)UVE&!5G(Z %?O<?:OPO\ AIX6^$'@BR^'W@N*XCTV
MP#"W2ZNFF<;F+'YF/J3P, =A7TF:\%\#<*R@\GQ,J];EC'F=FHTU%)14KW3O
M%2DDM6VW9H\_A_BCC3B)3>;X6-"DFVDFU)SN[RY;6M9M)WT2TNF<'??LD>'+
M[]J*']J)_%UZM_#MQI8@3R3BU^S?>^]T^;ZUZS<VT%Y;R6ES$'CE0I(C=&4C
M!'Y5QW[0WC&_\!_!W6_$FDWK6]W' D=K,GWEDDD5 1[C<3^%?.'PX_; ^*'@
MI[W_ (2PSZ_]LMT-A'>R[/*<-]X$+DJ06R!U('/6O@.+/$[!91FV&P.:2D^6
MFE&22:A!.2BG;WGJFEHWKJ;P_LG)*]2G3AR^UDZDVKN\I;MW;WMLM#Z%T#]E
MG]G;PQ]K_L/X.Z%";VT>VN2;,.7B<89,MG (ZXQFNE\ _#_P=\+_  I:>"?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17D?[1'[2>J
M_!OQ-IGA;P_X:@U*YOK4S2)+(P9<N40*%ZDE6_*O/;7]K/XY>&?$&F^(/B7X
M-%IX?U"X8"$::\3-&,!C&SG)*Y!YZ^V<CXC,_$'AS*LPG@ZTIN4&E-J#<87M
MK*6UM5>U]=+7//K9GA:-5TY-W6^FB]6?3U%5]*U73M<TRWUG2+Q+BUNH5EMY
MXSE71AD$?A6)X/\ BCX4\<^)-<\,>'[SS9]!N$ANV!&UBP.2OJ RLI]U^E?7
M3QN$ISIPE-7J:0U^*R<M.^B;]#M=2":3>^WGU.CHJ%M1L%U!=):]B%T\+3);
MEQO,:D*7QUP"RC/J14U="E&5[/8NZ"BBBF 4444 %%%% !0 % 50  . ***
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M>E;7PG_:,T;1?V9D\7>(K@2WNA+_ &=]G+X:YF4?N5'?E-N3_LN>U>[@^/\
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M?E /<<5Z5/Q9X9=)2J0JQ=DY+D?NW[N]K=4^J7R-5G>$<;M-?+8^E?L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&DOO'_A?3_ C?$>>_SI*V O!.BY+1%0
MPP.Y.0,>IQ6-\,/CQ\.OB]=W6G^#M2F>XLXUDEAN8#&Q0G&Y0>H!P#Z9'K7W
MTLVRN&*IX:5:*J5%>$;J\EW2ZK0]-UZ*FH.2N]EW-K[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V**]$U,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V*
M* ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V*
M* ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V*
M* ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_QI'M?&D:EWUVR55&23;$
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M_H-V7_@,?\:/L7C?_H-V7_@,?\:V*1W2-#)(X55&69C@ >M>SL=!D?8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-87AGX_?#?QC\1)?AMX9U?[9=0VKS&Z
MB ,#LI ,:-GYV ).1Q@'DUVM<>"S#!9C3E4PM13C%N+<7=76ZNNQG3JTZJO!
MW6QC_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%06VJ:9>W,UE9ZC!--
M;$"XBBF5FB)SC< <KG!Z^E=3E&+2;WV-+HSOL7C?_H-V7_@,?\:/L7C?_H-V
M7_@,?\:V**H#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
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M5&4O:<S]Q<SC&-KRDKWY==_)]B,7CZ.#E%33=[[=+=6?57V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C7CGCO]MGP1??#F]?P+/>VNOS6ZI:0W-I_J78@,
MV[E25&2,]3BO.M#\7_M#_!"STGXP:SJEQJ.D>)&66Y@O+EI1(#D@/N_U;L@W
M*R]L=<%:\?'^)>1X7%1AAHRKTU%2J5*?O1IQ;Y4Y=;WM=:-)WUV.>KFV'A-*
M'O*UVUT6Q]4?8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C5GPMXETKQCX<LO%
M.AS&2TO[=9H&88.UAG!'8CH1ZBJ/Q#\?:#\._#-UKNLZE;PR):S26D$TH5KB
M1(V?8H/WCQT%?=U,;A*6$^M2FO9VYN:^EMT[^?3N>DZD(T^=O3N?+'CQ_BA\
M3OVB]:U#X>7+SZIX=5C!+:.$*I;D1MLSP<N3\O\ %N(YSBK'B']K[X@^)/AD
MWA9KUH=<N;@V]S<6MJ$+08^\I'W78_*0!ZD8R,=S^P=X:GFT[Q#\1M1!>:^O
M%M8Y7ZG:/,D/XET_%:]9_P"%'_"0Z_\ \)1_P@&G?;_M?VG[3Y//G;MV_&<9
MW<]*_$LDX9XFSC*99I@<8Z,L:ZCJ1E>W+*7NN*6TN5/7LTDT?/X?"8NO1=:G
M/E]I>Z?9O2WF>%:5^PGXK_L.QUBW\>QV.KM&LD\+0MB%B,E0ZG.1G&>YS5/Q
M1X=_:[^!FBW=O!XCNM7T>:V>*2XM96NA K C< X\R(@'.X?*#WKZKHK["IX8
MY%1HVRZI4PU2UN>$Y:Z6O)-V=^J5K^1W/*,-&/[IN#[IO\3PK]F#X$WOAWX>
MIXCU.ST]KO7HEFDCO[/S2D'6-,-P,C#GZC/05RWC#]B?Q]%XBDA\#>(K1-&U
M2Y7[9 9WC^SIG=\R=)54_=&<YQ[M7T\  , 45WUO#[AS%9+A\NK4]**TE'W9
M-OXKM=)Z\R\]-D:2RS"SP\:4E\/79^?W]3YO\/?L,:[I_B6RN]>\;66H:99S
M;A:R6\G[Q1R%*DD %L9&>1FJ7QQ^!OBKX0ZU8?&7X56%O$FF,K75O80MB$@G
M]X4).48':V.WL21].T5C6\-^&EED\+A(>RFY*4:B;E.$HVY6I2;=E;X;KKL]
M2995A/8N$%9[I[M/YGQ[XY\7?M<KX*O)_&MGJ8T?Q"@\S=9)^Z4D?* @W0!@
M,;6QD$\$G->U_ _X"WOPW\")ITT.FF]U.W5M8^TVGFER1GRCG@JN<8Z$@GO7
MJY (P116N1\#T,IS1X[$8F>)GR<L?:^\X7;<[/\ O-Z:*RNKNY6'RZ-&M[2<
MW-VLKZV[_>8D>F>,H46.+5K!51=J*MI@*/0>@X%)=:/XMOK=K2]U+3YHG&'B
MEL]RM]0>#6Y17W#C%QLUH>C9'&ZO\+5UO2;K1+_3]$-O>0-#.L>F*A*GT(P0
M>A!'0@'M7S[X3\4^*_V0_B=J'@'Q'>2-HMZ/.298/,#K@^7,BY')QL8#N.^T
M5]:5A^,?AKX#^(#0-XS\+6FHM:AA;M<1Y*!L9 (]<#\J^/XDX9K9A4H8W+)1
MI8JB[QDU[KB_BA*VKBU_P+7;.#%X.55QJ46HSCL^ENJ9\_>)_P!N:]N=)O;/
MPSI]Q'<R0LEG<SV\:[6/&\@,<$#)'7D"M']G']G#7+BUM_B_XOU)9K_4[:1H
M+6_0R$1RJ5\UR3EF9"<>@;UZ>R:E\%?A+JVCQZ!>_#O2?LD3!HHXK-8RA'<,
M@!'OSSWS73HB1H(XT"JHPJ@8 'I7F8'A'-\7G,,=Q!B(XA4E^[C&/+&,F[N3
MCLVK)1;O?=I61E3P->>(53$R4K;*UDGW/DVTTWX_?LAZM?SZ7H2:AH5W*#+<
M1QF6%U4G:Q(^:%L'!W#!_P!K KUGX)?'^;XUI-9:?JEOI^IVZ[Y=.N8<ED_O
MHP/S $X/ (].17K77K7SS\>_@9XT\$^.XOCC\#+#;-"3-?V-H@+))R&=8_XT
M=20RCG.3@Y..&KE6=<!PC7RRI*O@HR]^@TI2A%N[E3DM7RMWY=NKOJUE*CB,
MM2E1;E33UCU2[I_H>W?8O&__ $&[+_P&/^-9EGX@UN^\57O@VV\3637^GVL-
MQ<Q?9C\J2EPO?D_)D^FY?6O"_P!G3]HKQ/'\5[ZQ^+FK/##XBC26"2\!BCMY
M0,QA0W"1LAVCU(7GJ:Y?P7^T%'I?[3=Y\3]4O'32M4NY+:[;:3MM#A8S@9)V
MA(V.!GY3CK2GXI9/+#X2O#W55K.G-2T<(K[3[?%"7:S:W0/.*#C"2TO*SOT7
M?\F?1?BOXHZ5X&U0:+XM^)NC6%T8A*()X6#;"2 >/H:W-+G\3:UIL&L:3XHT
MZXM;F)9;>>* E9$(R&!STQ7S0WARP_:H_:4\0+:ZJXTV.RE:TNXA\H6)%AB8
M C[ID(?'!(STK)USQQ\=?@)H&H? ;7&C2WO+8BSD3YS''(WS- XQE6^=<$9!
M)Q@UQ_\ $3,5AJE;%XG#7P2E4A3J0NVY0>G-K9*?1]^Z3M']KS@Y3G#]W=I-
M=UW]3Z5\1?$>P\(ZR/#_ (H^)VAV%X;;[0(+I=A,?/.2<=C@=3C@5QO@+]J2
MQ^(GQ&'@'1-36-9HV^QZA=6FQ+B1>=BKG(RN2"<$XQ@'&>%^'?[%GC#Q8]UJ
M'Q=UFYL<V4(T]H;A9I2Q4</NS@(H"[>.>AP.=[XL_L@3Z+H>BZU\#HV&KZ+@
MS[[@)+=L#O68,<*) V>.!@@#[H!TJ<0>)&*HK,*6!5.C!\SIN[JSAS).*3V=
MKRO97TM?9MXK-9Q]K&G:*UM]IKL>P^(M3\0>%-#NO$>O>)["WL[*!I;B5K8\
M*!GUY/8#J2<5\S>._C+\4?VEM9L?!/P]TZZ1+8F[$$++&[R1Y(D9@<*%XV\_
M>8=\5T>F?LW_ !]^.-TOB#XV>-)M.@)S%:3 22 ?[,*$1Q?S]17O?PZ^&GA3
MX8>&[7PYX:T]%%O#L>Z>-?.G).69V Y)/..@X X K?%4^)^/&J,J<\'@7\7-
M;VM75.UMZ:MWO_V\G95-8O,O=:=.GUO\3_R_K<^>K3]J?]HSPQ9#1_$7P^DG
MN;-=D]Q<Z;*CMM[O@8SZD8!ZU4MM:^/G[8>HOI%C=KI?A^V*B[*L5@4XZ,0
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MX]<KZ;'J,5J$U2XCEEW'+Q)M&.W%6*** "BBB@ HHHH **** "BBB@ HHHH
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M'3H15).ZC9<M[\U[;?%KZFL:%&-/V:BN7MT[A1117I&H4444 %%%% !1110
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M-O4]C#8>&%HJG'H%%%%>N;A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $&J:7IVMZ=-I&KV45S:W$9CG@F0,KJ
M>H(/6OE?]I/]GS7O GBPZ]\)M'NTTG5+"475MI^[%ML3=*C8/^K95W8/4AAZ
M"OJ^D=$D0QR(&5AAE89!'I7RW%7"F7\58'V-;W9IIQFDN:/=)]FKIK;KNCCQ
MN"I8VGRRT?1]4?(7@+]K;XO>'-#TZQT_PY#J.DZ!8);W^ZW=MR;B$9Y5_P!6
M0H"#/!P20<\=!\>?VJO#/Q-^$$7A;PE;7,.HZM<HFI64B$M;QHP; 8##[F"@
M8[9R!TKZ \!_#3P9\-_#[>&?"FCI#:R.SSA_F:9FZER?O<<8Z <5S_A[]F3X
M+>&O$;^*=/\ !T;W1N?/@$\K/';MG(\M"=H /(R#CMBOAX\(<?T\H6 681G"
MK#DJ*:?[M62_=R2N_=]UIV6[W=UYRP.9JA[/VJ:DK._3T^6A1^#G[//A3P;X
M?\+ZUK&B1KXATBSD:6Y3@F28,65_[^S>54]L<5Z9117ZAE>58')\)'#X6"C%
M);+>T5&[[NT4F_(]BC1IT(*$%9?\"P4445Z)J%0QZ=I\5[)J45C"MS*BI+<+
M$ [J.@+=2!DX'O4U%)QC*UUL%D<UJ'PF\$:OX_\ ^%CZMI*W.H+IHLHQ, T:
M)ER6"_WB'*Y]!@8YKYQ\ ^.+G]D7XN:_X5\4:+?3:->2%8&C7#,BL3%,N[ <
M;&(.#U/7Y<5]9USWQ,^&7A7XK^&)?"_BJSWQM\UO<1X$EO)V=#V/Z$<&OB>)
M.%:N+]GC<IE&CBJ4I3B[*TW-6DI_XDDKZVM]WGXO!.=JE"T9Q;:\[[W]3Y\M
M/VE?VH_%5E>^-/"'@^.71;>Y?F+3#*L2C!V%@=S84C)'UXKO_@_^V/X4^(NM
M6WA;Q%I!T:\FMV(N);E3;O(HR5!."N1DC/IC).,^J>$O"NA^"/#EIX5\.68@
ML[*$1PQCJ?5B>[$Y)/<DFO-OCY^RUX<^*BGQ%H#KINKV]G(L:P1*L5V_WD$G
MH<Y&[KAN<X%>(\DX[R/#0QF%QKQ-1).I2G;EEUDJ<GK'K;O]T3F^KYEAX*I"
MISOK%]?1]#UB*6*>)9H9%='4,CJ<A@>A![BH=0U?2=)56U75+>V#DA#<3JF[
M'7&3S7R9\-/C_P#'_2O#MO\ "#P/X3-[J&ES/&9)+1YIH8@<>4RY 4*=PRW0
M8'&*TY?@_P#M#?M%>.;=_C!;3Z/9VEDZI=-:J$C[@)&&^9F8C)R.%Z\ 55/Q
M)_M+"065X&K5KRY5;E<:<9/XDZCT7+KK:WHAK-O:P7L:;E)V]+]=?(3]H>SU
M#XZ_M*V_PU\.WB8LM/\ (CESF,.(FG=L_BJY_P!D5A_!K]E;XD>/=%F\6VGB
M+^P#'<O;P><D@DEVDK(05(( 8;?<AO3GTW]F']G/Q9\*/B3K.L^,(89$@L5M
M]+O(7W).)&RS =5($8!! QO[CFO=T1(UVQH%&2< 8Y/)KQ,E\/Z?$N(GG.>4
MYPJU*E1NG=II748*ZL_=Y96:MS)I[+7GP^6+%R=?$)IMO3\ONU]3YAU_]AOQ
MJ^@:AK=W\0!JFK0PAK&V\ICY^WDH7=L@D9 &,9QDUI?L(>$+UK[Q)X_UF.4W
M/FBP62?._?GS)@V><Y\O.><YKZ-JMIVD:7I!N#IEA%!]JN6N+GREQYDK !G/
MN<#)[U]/A/#?),LS_#9C@DXJGS<T6W+FDTU&5VV[J[_#:VO9#*</1Q,*M/2U
M]-[]F6:***_1#U HHHH **** .'\9_L\?"WX@>-%\<^+M&EN[H6R0F W#)"V
MTDAF"X);!QR<8 XKH-:\!^%=>\%S?#Z\TB)=)EM/LPM85"K&@'R[/[I7 (/8
M@&MBBO.IY/E5*564*$$ZM^=\JO.^_,]W?LS)4**<FHKWM]-_4\5\2?L,?"C5
M(;6/0-1U'2W@CVS.LHF^T?[3!^C?[N![5ZA\/? VC_#?P=8^"]"!-O8P[?,<
M#=*Y)+.V.[,2?QK:HKCRWAG(,GQ<L3@L/&G.2Y6XJVFFEMELKV2N]69TL)AJ
M$W.G!)OL%%%%>Z=)D^.?!NC_ ! \)WO@[7D8VM]$$EV'#+@A@1[@@'\*TK.S
MM=/M(K"Q@6*&"-8X8D& BJ,  >@ J2BL5AZ"KNNHKG:46^MDVTK]DVW\R>6/
M-S6U"BBBMB@HHHH **** "BBB@#C=+^!/P_TKXH7OQ8ATS?J5X 55P#'!)C#
MRH.SMQD^N2/O&NRHHKDP> P67QE'#4U!2DY.RM>4G=M^;_X&Q$*=.DFH*UW?
MYF;XM\)>'O'.@7'ACQ1IJ7=E<IMDB?MZ,".58'D$<BK6DZ5IVA:9;Z-I%FEO
M:VL*Q6\$0PJ(HP /PJQ16JP]!5W74%SM6YK*]EJE?>UW>P^6/-S6U(+#3=.T
MN)K?3+""VC>1I'2"((&=CEF( Y)/)/>IZ**UC&,(J,59%))*R"@  8 Q]***
M8!1110 4444 %%%% !7#>!OV=_AEX#\27/C#3]):YU2XNY9TN[QMYM][$[8U
MP H&<9QNQWKN:*XL3EV QE:G6KTHSE3;<6U?E;ZJ^ST6NYG.E3J24I*[6WD%
M%%%=IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9H8;
MB%[>XB62.12KHZY# \$$'J*<  , 444K*]P"BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $%EI6F::\TNG:=! US*9;AH854RN>
MK-@?,?<\U/114QC&"M%60DDM@HHHJAA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?+7_!6/QK\??AI\$_"'Q(^$O@KQAXD\):%\1;&\
M^,V@?#NYEBU^[\*+;W(G-D8'29C'<FTEDCA=9)(HI$W!&?/'?\$Z_%>G7O\
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MO#4;F.36(0RG# GH:3_A,?#'_0:@_P"^JN'3[ G)LH23U)C%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I
M_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]
MG:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X
M3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I
M_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]
MG:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X
M3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD5J_MC>*_P!G_3OAWIWPW_:F^'EOX@\ ^/M7/A_Q"=6T5KS2[%&M;BX2:_\
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MKX'_ /0W>.__  KYZ/\ AW5\#_\ H;O'?_A7ST >]45X+_P[J^!__0W>._\
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MAN\=_P#A7ST >]45X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\]
M'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+_P .ZO@?
M_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\ P[J^!_\ T-WCO_PK
MYZ/^'=7P/_Z&[QW_ .%?/0![U17@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\
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M5\#_ /H;O'?_ (5\] 'O5%>"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
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MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\] 'O5%>"_\.ZO@?\ ]#=X[_\
M"OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U? _\
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M17@O_#NKX'_]#=X[_P#"OGH_X=U? _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\
M0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C
M_AW5\#_^AN\=_P#A7ST >]45X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[
MQW_X5\] 'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+
M_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\ P[J^!_\
MT-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/0![U17@O_#NKX'_ /0W>.__  KYZ/\
MAW5\#_\ H;O'?_A7ST >]45X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^
M%?/0![U17@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\] 'O5%>"
M_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\] 'O5%>"_\.ZO@?\ ]#=X
M[_\ "OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U?
M _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\
MA7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST >]45X+_P
M[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\] 'O5%>"_\.ZO@?_T-WCO_
M ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+_P .ZO@?_P!#=X[_ /"OGH_X=U?
M_P#Z&[QW_P"%?/0![U17@O\ P[J^!_\ T-WCO_PKYZ/^'=7P/_Z&[QW_ .%?
M/0![U17@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\ H;O'?_A7ST >]45X+_P[
MJ^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/0![U17@O_  [J^!__ $-WCO\
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MX;FT'4-&^+/B2UO[*&PG!%S%'#:VMNG[Y=JNSASM0!2H+;@#P#]J*SMOAO\
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M:8UKXD^*],UGX33ZG-X9TS2)+$6,S7]J;2Y-PLUK)))NA)4;9$V]1@\UZW0
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M"7AK3O"FER7#VNF6,-I;/=W#32M'&@12\CDL[8498DDG)/)H O4444 %%%%
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MBC2H/@I<QZ!#!;:MHVN%+?1K]X!S<""[%W'?E2%5+-V01 @UTG@W_@B]\%/
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M[2/Q=U/P3HD]Q/X%^&/B3Q5!=Z'X5DEWX-JAMA-*L0D<0QW,LT<1.X*7574
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M11Z/H7@YM.O_  ??:5H#ZM&(9OM$IOX9;>VFB<RA&$@5UV*WECJ/V>/VA_\
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M7OVQ_P#A57Q$U#P%_P *Y^W_ &#R?]+_ +7\KS-\*2?=\EL8WXZGIGVKFO\
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M_C[XX\?_  D^+GPZN=;\0>!_'?BV\\0S^"[B*+4'2>VO;Z26YAA)LHOW<LK
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M[;R*&26*5"5=&4@A@2"#0!IT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWPUD^(%]_P (YIUY>(4EO+33U81)<+D-')()#"R1M'L,:;;WB_\ X(@_L?\
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MFWX9_$CQU8Z=%J'[6OA"XU6V.O?8KJ+2A#J,=S=JZ.LL,:!\&=2OEL5.X'%
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M\0OC/^P!_8?B9VT_7/VJ_#WV/6-#OP&,,US:;+BWGC) .U@Z2*3V85[9KO\
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M'(_$5Y'<36%C#$D4-JLB1HSQHJ *9-S\XW$!0 #\W?\ @@AJ7CW]@/\ ;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6]T/1=2E$^HZ/:W#A=H>>W5R!Z9(Z<G\ZM44 -@@AMH5M[:%8XT7"(B@!1Z
M#I3J** "BBB@ HHHH **** "N+^._P "/ G[0G@2;P1XWLO5["_B4>=938P)
M$)_5>C#@^W:45OA<5B,%B(UZ$G&<7=-;IG/BL+AL=AIX?$04H25FGLT<7\"/
M@1X$_9[\"0^"/!%EZ/?W\JCSKV;&#(Y'Z+T4<#W[2BBC%8K$8W$2KUY.4Y.[
M;W;#"X7#8'#0P^'@HPBK)+9(****P.@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "L#XC?#GP_\ $SP^VA:[&593NM;J,?/ _P#>'J/4="/P(WZ*YL9@
M\+F&%GAL3!3A-6:>S7]?<:T*];#5HU:4N64=4T?)OCOX ?$;P/<N3HTFHV8)
MV7NGQF0$>K*/F3\1CT)KCOL5YY_V7[)+YO\ SS\L[ORK[CHK\4S#P.RROB'/
M!XN5.#^S**G;R3YHNWK=]VS[[#>(.+ITN6O14WW3Y?PL_P +'R;X$^ 'Q&\<
M7*$:-)IUF2-][J$9C 'JJGYG_ 8]2*^D_AS\.?#_ ,,_#ZZ%H499F.ZZNI!\
M\[_WCZ#T'0#\2=^BON.$?#W).$9.M1O4K-6YY6NEU44M(I]=WYVT/GLZXFS#
M.ER3M&"^ROU?7\O(****^\/G0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JM?:-H^INLFI:5;7#*,*T\"N0/;(JS10 RVM;:S@6VL[=(H
MT&$CC0*J_0#I3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701096061056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Royalty Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1535773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 East 59th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">883-0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary shares, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for the 2023 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2022. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001802768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,166,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,057,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701095434512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701097743200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,710,751<span></span>
</td>
<td class="nump">$ 1,541,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">24,421<span></span>
</td>
<td class="nump">581,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Financial royalty assets</a></td>
<td class="nump">691,319<span></span>
</td>
<td class="nump">614,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="nump">16,830<span></span>
</td>
<td class="nump">53,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_OtherRoyaltyIncomeReceivableCurrent', window );">Other royalty income receivable</a></td>
<td class="nump">19,767<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">90,520<span></span>
</td>
<td class="nump">6,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,554,908<span></span>
</td>
<td class="nump">2,878,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Financial royalty assets, net</a></td>
<td class="nump">13,493,106<span></span>
</td>
<td class="nump">13,718,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible royalty assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">112,348<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">397,175<span></span>
</td>
<td class="nump">435,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">29,629<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,813,466<span></span>
</td>
<td class="nump">17,515,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Distributions payable to legacy non-controlling interests</a></td>
<td class="nump">94,803<span></span>
</td>
<td class="nump">107,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,906<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">54,162<span></span>
</td>
<td class="nump">57,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">997,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,166,783<span></span>
</td>
<td class="nump">171,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">6,118,810<span></span>
</td>
<td class="nump">7,096,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,288,093<span></span>
</td>
<td class="nump">7,267,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DeferredSharesValueIssued', window );">Deferred shares, $0.000001 par value, 371,325 and 361,170 issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,666,160<span></span>
</td>
<td class="nump">3,507,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,964,689<span></span>
</td>
<td class="nump">2,255,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">3,897,223<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury interests</a></td>
<td class="num">(2,806)<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">9,525,373<span></span>
</td>
<td class="nump">10,248,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">16,813,466<span></span>
</td>
<td class="nump">17,515,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Value, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherRoyaltyIncomeReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Royalty Income Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherRoyaltyIncomeReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701092237104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DeferredSharesParOrStatedValuePerShare', window );">Deferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DeferredSharesSharesIssued', window );">Deferred stock, issued (in shares)</a></td>
<td class="nump">371,325<span></span>
</td>
<td class="nump">371,325<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DeferredSharesSharesOutstanding', window );">Deferred stock, outstanding (in shares)</a></td>
<td class="nump">371,325<span></span>
</td>
<td class="nump">371,325<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">443,166<span></span>
</td>
<td class="nump">443,166<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">443,166<span></span>
</td>
<td class="nump">443,166<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">164,058<span></span>
</td>
<td class="nump">164,058<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">164,058<span></span>
</td>
<td class="nump">164,058<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Par or Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701095313680">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,237,215<span></span>
</td>
<td class="nump">$ 2,289,463<span></span>
</td>
<td class="nump">$ 2,122,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">904,244<span></span>
</td>
<td class="nump">452,842<span></span>
</td>
<td class="nump">230,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,106<span></span>
</td>
<td class="nump">200,084<span></span>
</td>
<td class="nump">26,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">22,996<span></span>
</td>
<td class="nump">23,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,303<span></span>
</td>
<td class="nump">182,826<span></span>
</td>
<td class="nump">181,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Financial royalty asset impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">615,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,930,150<span></span>
</td>
<td class="nump">858,748<span></span>
</td>
<td class="nump">526,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">307,065<span></span>
</td>
<td class="nump">1,430,715<span></span>
</td>
<td class="nump">1,595,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other expense/(income)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in losses/(earnings) of equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,973<span></span>
</td>
<td class="nump">19,490<span></span>
</td>
<td class="num">(44,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187,961<span></span>
</td>
<td class="nump">166,142<span></span>
</td>
<td class="nump">157,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">(Gains)/losses on derivative financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96,610)<span></span>
</td>
<td class="nump">21,532<span></span>
</td>
<td class="nump">42,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses/(gains) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,442<span></span>
</td>
<td class="nump">48,066<span></span>
</td>
<td class="num">(247,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Losses/(gains) on available for sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,815<span></span>
</td>
<td class="num">(17,859)<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,335)<span></span>
</td>
<td class="num">(53,535)<span></span>
</td>
<td class="num">(28,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">5,678<span></span>
</td>
<td class="nump">32,821<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses/(income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,001<span></span>
</td>
<td class="nump">189,514<span></span>
</td>
<td class="num">(106,555)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Consolidated net income before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,064<span></span>
</td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,064<span></span>
</td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187,232<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="nump">726,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Royalty Pharma plc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 42,832<span></span>
</td>
<td class="nump">$ 619,728<span></span>
</td>
<td class="nump">$ 975,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per Class A ordinary share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average Class A ordinary shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">437,963<span></span>
</td>
<td class="nump">414,794<span></span>
</td>
<td class="nump">375,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">437,972<span></span>
</td>
<td class="nump">414,802<span></span>
</td>
<td class="nump">375,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember', window );">Income from financial royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,125,096<span></span>
</td>
<td class="nump">$ 2,065,083<span></span>
</td>
<td class="nump">$ 1,959,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember', window );">Revenue from intangible royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,484<span></span>
</td>
<td class="nump">171,248<span></span>
</td>
<td class="nump">143,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember', window );">Other royalty income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74,635<span></span>
</td>
<td class="nump">$ 53,132<span></span>
</td>
<td class="nump">$ 18,996<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;). See Note 13&#8211;Earnings per Share.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701092208096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 230,064<span></span>
</td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Changes in other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">83,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(53,432)<span></span>
</td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss)/income</a></td>
<td class="num">(29,432)<span></span>
</td>
<td class="num">(39,296)<span></span>
</td>
<td class="nump">66,635<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">200,632<span></span>
</td>
<td class="nump">1,201,905<span></span>
</td>
<td class="nump">1,768,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to non-controlling interests</a></td>
<td class="nump">175,418<span></span>
</td>
<td class="nump">604,323<span></span>
</td>
<td class="nump">739,787<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Royalty Pharma plc</a></td>
<td class="nump">$ 25,214<span></span>
</td>
<td class="nump">$ 597,582<span></span>
</td>
<td class="nump">$ 1,028,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089406416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Class R Redeemable Shares</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Ordinary Shares</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B Ordinary Shares</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class R Redeemable Shares</div>
</th>
<th class="th"><div>Deferred Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Unitholders&#8217;/ Shareholders&#8217; Contributions</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Non-Controlling Interests</div></th>
<th class="th"><div>Treasury Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 6,141,438<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,282,516<span></span>
</td>
<td class="nump">$ 2,825,212<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="nump">$ 35,883<span></span>
</td>
<td class="num">$ (4,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">1,482,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,037,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(1,105,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration', window );">Initial share issuance upon registration of Royalty Pharma plc (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodValueIssuedForRegistration', window );">Initial share issuance upon registration of Royalty Pharma plc</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,701,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships', window );">Issuance of Class B ordinary shares to continuing investors partnerships (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships', window );">Issuance of Class B ordinary shares to Continuing Investors Partnerships</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation', window );">Effect of exchange by continuing investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,176,000<span></span>
</td>
<td class="num">(294,176,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,762<span></span>
</td>
<td class="num">(2,553,001)<span></span>
</td>
<td class="num">(1,261,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,022)<span></span>
</td>
<td class="nump">2,433,098<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="nump">1,908,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation and related issuance of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,231,000<span></span>
</td>
<td class="num">(22,231,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(112,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">4,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">83,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,617<span></span>
</td>
<td class="nump">22,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(20,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,921)<span></span>
</td>
<td class="num">(9,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,135,000<span></span>
</td>
<td class="nump">218,976,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">316,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">9,895,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,865,964<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,920,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
<td class="num">(2,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">48,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(614,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,241,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation and related issuance of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,763,000<span></span>
</td>
<td class="num">(44,763,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,242<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(285,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(50,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,481)<span></span>
</td>
<td class="num">(22,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,963,000<span></span>
</td>
<td class="nump">174,213,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">361,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">10,248,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,507,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,491<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">11,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(604,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(604,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">230,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation and related issuance of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">2,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,155,000<span></span>
</td>
<td class="num">(10,155,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(157,494)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(333,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,262<span></span>
</td>
<td class="nump">9,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(53,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,880)<span></span>
</td>
<td class="num">(21,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">443,166,000<span></span>
</td>
<td class="nump">164,058,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">371,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,525,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,666,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,964,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,897,223<span></span>
</td>
<td class="num">$ (2,806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestTransfersOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Transfers Of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestTransfersOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued For Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodSharesIssuedForRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued To Partnerships</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodValueIssuedForRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued For Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodValueIssuedForRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued To Partnerships</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodValueIssuedToPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Value, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquityValueEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701095432336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share)</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089242832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables', window );">Cash collections from financial royalty assets</a></td>
<td class="nump">$ 2,507,236<span></span>
</td>
<td class="nump">$ 2,315,854<span></span>
</td>
<td class="nump">$ 2,121,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets', window );">Cash collections from intangible royalty assets</a></td>
<td class="nump">72,943<span></span>
</td>
<td class="nump">151,158<span></span>
</td>
<td class="nump">143,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables', window );">Other royalty cash collections</a></td>
<td class="nump">69,891<span></span>
</td>
<td class="nump">44,123<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="nump">39,142<span></span>
</td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="nump">24,982<span></span>
</td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">7,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments', window );">Derivative collateral received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,660<span></span>
</td>
<td class="nump">45,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments', window );">Derivative collateral posted</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,660)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Termination payments on derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,093)<span></span>
</td>
<td class="num">(35,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForOngoingDevelopmentStageFunding', window );">Development-stage funding payments - ongoing</a></td>
<td class="num">(2,106)<span></span>
</td>
<td class="num">(6,876)<span></span>
</td>
<td class="num">(20,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForUpfrontDevelopmentStageFunding', window );">Development-stage funding payments - upfront and milestone</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="num">(193,208)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForOperatingCostsAndProfessionalServices', window );">Payments for operating and professional costs</a></td>
<td class="num">(222,969)<span></span>
</td>
<td class="num">(184,511)<span></span>
</td>
<td class="num">(179,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(170,139)<span></span>
</td>
<td class="num">(130,430)<span></span>
</td>
<td class="num">(103,196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">2,143,980<span></span>
</td>
<td class="nump">2,017,536<span></span>
</td>
<td class="nump">2,034,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">15,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investments in equity method investees</a></td>
<td class="num">(9,896)<span></span>
</td>
<td class="num">(34,855)<span></span>
</td>
<td class="num">(40,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI', window );">Purchases of equity securities</a></td>
<td class="num">(87,785)<span></span>
</td>
<td class="num">(135,134)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI', window );">Proceeds from equity securities</a></td>
<td class="nump">211,158<span></span>
</td>
<td class="nump">115,957<span></span>
</td>
<td class="nump">384,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available for sale debt securities</a></td>
<td class="num">(479,559)<span></span>
</td>
<td class="num">(70,441)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from available for sale debt securities</a></td>
<td class="nump">542,044<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(234,869)<span></span>
</td>
<td class="num">(1,196,579)<span></span>
</td>
<td class="num">(1,705,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">792,341<span></span>
</td>
<td class="nump">1,597,851<span></span>
</td>
<td class="nump">815,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireFinanceReceivables', window );">Acquisitions of financial royalty assets</a></td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="num">(2,191,502)<span></span>
</td>
<td class="num">(2,182,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Acquisitions of other financial assets</a></td>
<td class="num">(21,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForMilestones', window );">Milestone payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,029,421)<span></span>
</td>
<td class="num">(1,870,280)<span></span>
</td>
<td class="num">(2,759,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsForDistributionsToShareholdersAndUnitholders', window );">Distributions to shareholders/unitholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(285,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts', window );">Distributions to legacy non-controlling interests - royalty receipts</a></td>
<td class="num">(441,963)<span></span>
</td>
<td class="num">(479,604)<span></span>
</td>
<td class="num">(543,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToNoncontrollingInterestsOther', window );">Distributions to legacy non-controlling interests - other</a></td>
<td class="num">(31,301)<span></span>
</td>
<td class="num">(20,367)<span></span>
</td>
<td class="num">(67,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to continuing non-controlling interests</a></td>
<td class="num">(144,115)<span></span>
</td>
<td class="num">(133,433)<span></span>
</td>
<td class="num">(113,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentOfDividendsToShareholders', window );">Dividends to shareholders</a></td>
<td class="num">(333,322)<span></span>
</td>
<td class="num">(285,184)<span></span>
</td>
<td class="num">(112,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment', window );">Contributions from legacy non-controlling interests - R&amp;D</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">8,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsOther', window );">Contributions from non-controlling interests - other</a></td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">36,874<span></span>
</td>
<td class="nump">58,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RepaymentsOfLongTermDebtScheduledPayments', window );">Scheduled repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(94,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,116,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,272,533<span></span>
</td>
<td class="nump">11,891,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs and other</a></td>
<td class="num">(1,347)<span></span>
</td>
<td class="num">(13,046)<span></span>
</td>
<td class="num">(46,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,908,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="num">(944,856)<span></span>
</td>
<td class="nump">385,112<span></span>
</td>
<td class="nump">1,487,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">169,703<span></span>
</td>
<td class="nump">532,368<span></span>
</td>
<td class="nump">762,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">1,541,048<span></span>
</td>
<td class="nump">1,008,680<span></span>
</td>
<td class="nump">246,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 1,710,751<span></span>
</td>
<td class="nump">$ 1,541,048<span></span>
</td>
<td class="nump">$ 1,008,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentOfDividendsToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Dividends To Shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentOfDividendsToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Collateral Posted On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForCollateralPostedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForDistributionsToShareholdersAndUnitholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Distributions To Shareholders and Unitholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForDistributionsToShareholdersAndUnitholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOngoingDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Ongoing Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOngoingDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOperatingCostsAndProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Operating Costs and Professional Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOperatingCostsAndProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForUpfrontDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Upfront Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForUpfrontDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Noncontrolling Interests, Royalty Receipts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToTerminateDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Terminate Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToTerminateDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collateral Received On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RepaymentsOfLongTermDebtScheduledPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long-term Debt, Scheduled Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RepaymentsOfLongTermDebtScheduledPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701181144976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Purpose<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Purpose</a></td>
<td class="text">Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the IPO of our Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#8217; Class A ordinary shares (the &#8220;RP Holdings Class A Interests&#8221;) and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity, and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;), and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is responsible for our management, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#8220;Management Agreement&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer (defined below) and before the consummation of the IPO, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to RPI 2019 ICAV. Prior to the Exchange Offer, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Old RPI.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Offer&#8221;) to facilitate the IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The Exchange Offer together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;). We are entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, an Irish private limited company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of the Exchange Offer until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships could participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer, the Legacy Investors Partnerships and RPI Intermediate FT entered into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit facilities in the amount of $1.3&#160;billion and $6.0&#160;billion, respectively, the proceeds of which were used to repay the $6.3&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the senior credit facilities, RPI Intermediate FT repaid $5.2&#160;billion, its pro rata portion of RPIFT&#8217;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#8220;RPRX&#8221;, in which we issued 89,334&#160;thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652&#160;thousand Class A ordinary shares and 17,682&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire 100% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, according to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176&#160;thousand RP Holdings Class B Interests into an aggregate of 294,176&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc. Refer to Note 12&#8211;Shareholders&#8217; Equity for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701181149280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the date of the Exchange Offer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we became an indirect owner of an 82% economic interest in RPI ICAV, which previously was owned directly by Old RPI.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report four non-controlling interests: (1) the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the &#8220;legacy non-controlling interests&#8221;). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). The Continuing Investors Partnerships are referred to as the &#8220;continuing non-controlling interests.&#8221; Income will not be allocated to EPA Holdings until certain performance conditions are met.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank of America, US Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Scotiabank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective and passive in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible royalty assets. The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure our financial royalty assets at amortized cost requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available sell-side equity research analyst consensus sales estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products. Based o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.</span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheets, are accompanied by corresponding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> income or expense. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets. Any subsequent provision for credit losses is recorded as part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status. In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, clinical trial results</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and approval status. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized if, based on available information, it is prob</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of Januvia and Janumet (&#8220;DPP-IV&#8221;) products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved. We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments and Fair value measurements</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets. Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity securities primarily consist of investments in publicly traded equity securities. The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Investments classified as available for sale debt securities are recorded at fair value. We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings. For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AOCI&#8221;) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows. A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. If these conditions are not met, we may record the funded amounts as a financial royalty asset. We may  fund R&amp;D upfront or over time as the underlying products undergo clinical trials.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f contractual criteria for pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oducts arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years presented in the consolidated financial statements</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time. Income from these funding arrangements are subject to U.S. taxation and we record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to this income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16&#8211;Related Party Transactions that will be subject to U.S. taxation when we begin to recognize revenue</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, we will record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with respect to revenue from the MSCI transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, applies to U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the U.K. CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material tax charges to arise under the U.K. CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K. income taxes related to this matter</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other taxation matters</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S. withholding taxes on U.S.-source royalty payments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information have been presented for any period prior to that date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701181144976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available for Sale Debt Securities</a></td>
<td class="text">Available for Sale Debt Securities <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cytokinetics Commercial Launch Funding </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products. During 2022, we amended the funding agreement to increase the required draw amount, extend the draw period and modify the return for the second and third tranches. As part of the funding agreement, we agreed to provide capital (&#8220;Cytokinetics Commercial Launch Funding&#8221;) of up to $300&#160;million, which is comprised of five tranches, including an initial tranche of $50&#160;million that was funded upon closing. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#8220;Cytokinetics Funding Commitments&#8221;). Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn, except for the second and third tranches, which each total 2.0 times the amount drawn. As of December 31, 2022, we expect $125&#160;million of the optional $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2022 on the consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#8220;Development Funding Bonds&#8221;), of which MorphoSys was required to draw a minimum of $150&#160;million. Our commitment to fund at least $150&#160;million of the Development Funding Bonds was recognized as the Development Funding Bond Forward as of December 31, 2021. In September 2022, we funded $300&#160;million of the Development Funding Bonds, which represents additional funding of $150&#160;million above the minimum funding commitment (&#8220;Additional Funding&#8221;) and the Development Funding Bond Forward was settled at the same time. We expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning in the fourth quarter of 2024. As of December 31, 2022, we have no remaining funding commitment under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the funded amount of the Development Funding Bonds and the Development Funding Bond Forward as it most accurately reflects the nature of the instruments. The funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. The changes in the fair values of the funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="padding-left:4.5pt;text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, RPIFT purchased 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd (&#8220;Biohaven&#8221;) at a price of $50,100 per preferred share, for a total of $125&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares beginning in the first quarter of 2021 through the fourth quarter of 2024. In the first quarter of 2021, we began receiving payments of $15.6&#160;million from the quarterly redemption of the Series A Biohaven Preferred Shares.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares were classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet as of December 31, 2021. The unrealized changes in the fair value of the Series A Biohaven Preferred Shares were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of comprehensive income. In 2022, 2021 and 2020, $53.4 million, $50.9 million and $20.6 million of unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;), for a total of $200&#160;million payable on a quarterly basis between the first quarter of 2021 and the fourth quarter of 2024. Our commitment to purchase the Series B Biohaven Preferred Shares was recognized as the Series B Forwards. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheet as of December 31, 2021. We believe the fair value option most accurately reflects the nature of these instruments. The changes in fair value of the Series B Biohaven Preferred Shares and Series B Forwards were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations. In 2022, 2021 and 2020, we recognized gains of $122.5&#160;million, $13.5&#160;million and $18.6&#160;million, respectively, related to Series B Biohaven Preferred Shares within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, Pfizer Inc. (&#8220;Pfizer&#8221;) acquired Biohaven, which was a change of control event that accelerated the issuance of all unissued Series B Biohaven Preferred Shares and the redemption of all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. We purchased all remaining unissued Series B Biohaven Preferred Shares simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original purchase price. The Series A Biohaven Preferred Shares were redeemed at a price equal to two times the original purchase price. As of December 31, 2022, we no longer hold any Series A Biohaven Preferred Shares or Series B Biohaven Preferred Shares.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized (Losses)/Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">350,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(124,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099383728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven, which included the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Upon a change of control event, we have the option to cause Biohaven to accelerate the payment of zavegepant milestone payments, if triggered, in a lump sum amount (&#8220;Milestone Acceleration Option&#8221;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. On October 3, 2022, Pfizer acquired Biohaven and we elected to accelerate the zavegepant success-based milestone payments, if triggered, in a lump sum amount. As of December 31, 2022, the fair value of the Milestone Acceleration Option was $96.6&#160;million, of which $86.2 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and $10.5 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury rate lock contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#8211;Borrowings). The treasury rate lock contracts had collateral requirements and were not designated as hedge instruments. We paid $16.1&#160;million in July 2021 to terminate our treasury rate lock contracts in connection with the issuance of the 2021 Notes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4&#160;million to terminate these swaps and reclaimed $45.3&#160;million of collateral that was held by the respective counterparties. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#8220;Epizyme&#8221;) of $100.0&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0&#160;million in exchange for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5&#160;million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme&#8217;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#8220;Eisai&#8221;). In addition, Epizyme had an 18 month put option to sell an additional $50.0&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. We recorded the put option as a forward purchase contract as of December 31, 2019. The exercise of the put option was settled in February 2020. As of December 31, 2021, the fair value of the warrant was immaterial. The warrant remained unexercised and was terminated upon Ipsen&#8217;s acquisition of Epizyme in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.549%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of other instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone Acceleration Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099340720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Financial Instruments <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">259,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of December 31, 2022, amounts reflect the fair value of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds. As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761">Milestone Acceleration Option</span></span>.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the consolidated balance sheet. See Note 9&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 and 2021, we recognized losses of $39.1&#160;million and $41.4&#160;million, respectively, on equity securities still held as of December 31, 2022. There were no gains or losses in 2020 associated with the equity securities still held as of December 31, 2022.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on available for sale debt securities included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer out of Level 3 (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Following Pfizer&#8217;s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition. Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares. Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the expiration of the transfer restriction on BioCryst common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApiJect Investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value as of December 31, 2022 of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (&#8220;ApiJect&#8221;), a private company, in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cytokinetics Commercial Launch Funding &amp; Funding Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#8217;s assumed cost of debt, which would impact Cytokinetics&#8217; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 13.5%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we purchased 3,846&#160;thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;). As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#8217;s common stock, which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the second quarter of 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds &amp; Forward</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of the Development Funding Bonds and the Development Funding Bond Forward as of December 31, 2022 and 2021 were based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair values could be significantly higher or lower.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Series A Biohaven Preferred Shares</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares were redeemed following Pfizer&#8217;s acquisition of Biohaven in October 2022. The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which results in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate of 9.5% as of December 31, 2021 could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares &amp; Forwards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All remaining unissued Series B Biohaven Preferred Shares were purchased simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares following Pfizer&#8217;s acquisition of Biohaven in October 2022. The fair value of each of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 was based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the &#8220;with-and-without&#8221; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer&#8217;s cost of debt and management&#8217;s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower. The fair value associated with this instrument was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts&#8217; consensus sales forecasts. These projected future royalty payments by asset, along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,314,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,493,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099221952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Financial Royalty Assets</a></td>
<td class="text">Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,333,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,908)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,683,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,471,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,284,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,259,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(660,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,134,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,332,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,776,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,476,460)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,299,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,422)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,184,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, we recorded $160.1&#160;million and $273.6&#160;million of non-cash impairment charges for otilimab and gantenerumab, respectively, both unapproved financial royalty assets held at cost. The impairment charges were recorded as a result of GSK plc&#8217;s announcement that it has decided not to progress with regulatory submissions for otilimab and Roche&#8217;s statement that it would discontinue clinical trials of gantenerumab. Included in the total financial royalty assets balance of $14.2 billion as of December 31, 2022, is $533.8&#160;million related to unapproved financial assets held at cost: zavegepant, seltorexant and olpasiran. Additionally, during the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $182.1&#160;million due to the uncertainty of Gavreto&#8217;s commercial outlook. These impairment charges were recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial royalty asset impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196816<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099223952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</a></td>
<td class="text">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated using sell-side equity research analysts&#8217; </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consensus sales forecasts,</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the write-off of cumulative allowance at the end of a royalty asset&#8217;s life which only impacts the consolidated balance sheets, and</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,394,679)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,591,882)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $90.2&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik. For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">by increases in the value of zavegepant. For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701100768784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Royalty Assets, Net</a></td>
<td class="text">Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the first quarter of 2022. Our royalties on the other DPP-IV products have also substantially ended. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90%, 86% and 97% of revenues from intangible royalty assets in 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099342384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Non-Consolidated Affiliates</a></td>
<td class="text">Non-Consolidated Affiliates<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2022 and the change in fair value was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for 2022. The fair value of the revenue participation right was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 and the change in fair value was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other non-operating expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for 2022. No amounts were due from ApiJect as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. We recorded income allocations of $3.0&#160;million, $8.9&#160;million and $62.0&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2022, 2021 and 2020, respectively. We collected cash receipts from the Legacy SLP Interest of $25.7&#160;million, $21.0&#160;million and $22.7&#160;million during 2022, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (&#8220;Avillion I&#8221;) and BAv Financing II, LP and its related entities (&#8220;Avillion II&#8221; and, together with Avillion I, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. We recorded loss allocations from the Avillion Entities of $12.0&#160;million, $28.4&#160;million and $17.6&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in losses/(earnings) of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million in each of 2022, 2021 and 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $150.0&#160;million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80&#160;million to Avillion II to exercise an option to commercialize Airsupra in the United States. We expect to receive our pro rata portion of the exercise fee of approximately $35&#160;million, subject to any holdback for expenses, in 2023. </span></div>Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of December 31, 2022 and 2021, RPIFT had unfunded commitments related to the Avillion Entities of $28.8&#160;million and $11.2&#160;million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099280112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research &amp; Development ("R&amp;D") Funding Expense</a></td>
<td class="text">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. It includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized R&amp;D funding expense of $177.1&#160;million in 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, primarily related to upfront and milestone development-stage funding payments of $100.0&#160;million, $25.0&#160;million and $50.0&#160;million to acquire royalties on development-stage products from Cytokinetics, Theravance Biopharma, Inc., and MSD International Business GmbH, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $200.1&#160;million in 2021, comprised of $193.2&#160;million in upfront R&amp;D funding expense and $6.9&#160;million in ongoing R&amp;D funding expense, primarily under our co-funding agreement with Sanofi. The upfront R&amp;D funding expense included $103.2&#160;million and $90.0&#160;million in exchange for an incremental royalty on a development-stage product from BioCryst and future royalties on two development-stage products from MorphoSys, respectively. </span></div>We recognized R&amp;D funding expense of $26.3&#160;million in 2020, comprised of $20.5&#160;million in ongoing R&amp;D funding expense, primarily under our co-funding agreement with Sanofi, and $5.8&#160;million in upfront R&amp;D funding expense for a royalty on a development-stage product that we acquired from BioCryst.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701100768784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,116,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,118,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13% and 2.50%, respectively.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as of December 31, 2022, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022 and 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.7&#160;billion and $7.2&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the &#8220;Credit Agreement&#8221;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2021, there were no outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds rate plus 0.5% and (3) Term SOFR plus 1% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings was in compliance with these covenants. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#8211;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20&#160;billion and $2.84&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,300,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $183.7 million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099443776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1&#8211;Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of December 31, 2022, we have 443,166&#160;thousand Class A ordinary shares and 164,058&#160;thousand Class B ordinary shares outstanding.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2022, we have 371,325 thousand deferred shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights.The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;1 each.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands): </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(435,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(604,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,527,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,369,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,897,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Continuing Investors Partnerships&#8217; ownership of approximately 27%, 29% and 36% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and 73%, 71% and 64% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest Held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. During 2022, we declared and paid four quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $333.3&#160;million to holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2022, approximately 565&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the consolidated statements of operations. In 2022, 2021 and 2020, respectively, we did not recognize material share-based compensation expense. As of December 31, 2022, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0&#160;million, which we expect to recognize in the next six months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099165552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per ShareFor 2022, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for 2022, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.194%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Royalty Pharma plc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099286224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Indirect Cash Flow</a></td>
<td class="text">Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,125,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,315,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,121,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,143,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interests (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,103,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payable - Erleada (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $110.0&#160;million following the June 2020 FDA approval of additional indications of Tazverik. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099342384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitments</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various funding commitments as of December 31, 2022 and 2021. See Note 3&#8211;Available for Sale Debt Securities for discussion of the respective arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, $250&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of December 31, 2022, we expect $125&#160;million of the optional $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 9&#8211;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 16&#8211;Related Party Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our consolidated balance sheets as of December 31, 2022 and 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099342384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1&#8211;Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the date of the Exchange Offer, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager or its affiliates receive an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, total operating and personnel payments incurred were $188.4&#160;million, $145.2&#160;million and $112.5&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Legacy Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPI ICAV and RPSFT&#8217;s non-controlling interest in RPCT. The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to legacy non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In November 2017, RPI Acquisitions </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(Ireland), Limited (&#8220;RPI Acquisitions&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the financial royalty asset of $103.4&#160;million and $130.9&#160;million, respectively, on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. No amounts were due from MSCI as of December 31, 2022 and 2021. The financial impact associated with this transaction has not been material to date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, we reimbursed Pablo Legorreta approximately $1.0&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million was recorded as treasury interests, of which $1.5&#160;million and $1.6&#160;million were held by non-controlling interests as of December 31, 2022 and 2021, respectively.</span></div>Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701095488448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn January 2023, we acquired an interest in Ionis Pharmaceuticals, Inc.&#8217;s royalty in Biogen&#8217;s Spinraza (nusinersen) and Novartis&#8217; pelacarsen, a development-stage product, for up to $1.125&#160;billion, including an upfront payment of $500&#160;million and up to $625&#160;million in additional pelacarsen milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701095274288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of preparation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the date of the Exchange Offer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we became an indirect owner of an 82% economic interest in RPI ICAV, which previously was owned directly by Old RPI.</span></div>We report four non-controlling interests: (1) the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the &#8220;legacy non-controlling interests&#8221;). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP&#8217;s (&#8220;EPA Holdings&#8221;) ownership of the RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). The Continuing Investors Partnerships are referred to as the &#8220;continuing non-controlling interests.&#8221; Income will not be allocated to EPA Holdings until certain performance conditions are met.All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">Certain prior period amounts have been reclassified to conform to the current period presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bank of America, US Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Scotiabank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RoyaltyAssetsPolicyPolicyTextBlock', window );">Royalty assets</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective and passive in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible royalty assets. The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Financial royalty assets, net</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure our financial royalty assets at amortized cost requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available sell-side equity research analyst consensus sales estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products. Based o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.</span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheets, are accompanied by corresponding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> income or expense. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status. In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, clinical trial results</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and approval status. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized if, based on available information, it is prob</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for current expected credit losses</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets. Any subsequent provision for credit losses is recorded as part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue from intangible royalty assets and Milestone payments</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of Januvia and Janumet (&#8220;DPP-IV&#8221;) products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved. We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments and Fair value measurements</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets. Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents and Marketable securities</a></td>
<td class="text">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock', window );">Equity securities and Available for sale debt securities</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity securities primarily consist of investments in publicly traded equity securities. The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Investments classified as available for sale debt securities are recorded at fair value. We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings. For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AOCI&#8221;) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows. A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Investments in non-consolidated affiliates</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses/(gains) on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of equity method investees</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development funding expense</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. If these conditions are not met, we may record the funded amounts as a financial royalty asset. We may  fund R&amp;D upfront or over time as the underlying products undergo clinical trials.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f contractual criteria for pr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oducts arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes and Other taxation matters</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years presented in the consolidated financial statements</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time. Income from these funding arrangements are subject to U.S. taxation and we record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to this income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16&#8211;Related Party Transactions that will be subject to U.S. taxation when we begin to recognize revenue</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At that time, we will record a provision for U.S. income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with respect to revenue from the MSCI transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, applies to U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the U.K. CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material tax charges to arise under the U.K. CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K. income taxes related to this matter</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other taxation matters</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S. withholding taxes on U.S.-source royalty payments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information have been presented for any period prior to that date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RoyaltyAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Assets, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RoyaltyAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (b,d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099286224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Debt Securities</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized (Losses)/Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">350,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(124,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099230128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivatives and Reclassifications</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.549%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of other instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone Acceleration Option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099666720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instruments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">259,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">As of December 31, 2022, amounts reflect the fair value of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds. As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761">Milestone Acceleration Option</span></span>.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on the consolidated balance sheet. See Note 9&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Instruments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forwards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities included in other comprehensive losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Losses)/gains on available for sale debt securities included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer out of Level 3 (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemptions (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,500)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96,610</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Following Pfizer&#8217;s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition. Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares. Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the expiration of the transfer restriction on BioCryst common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</a></td>
<td class="text">The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,314,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,493,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2E<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498357-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099415376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Financial Royalty Assets, Net</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,333,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,908)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,683,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,471,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trelegy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029-2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,284,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,259,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(660,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(235,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,134,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,332,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,776,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,476,460)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,299,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,422)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,184,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current and non-current financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099253840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,394,679)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,591,882)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $90.2&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik. For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">by increases in the value of zavegepant. For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099221952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Royalty Interests</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701100826768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Borrowings</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,116,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(997,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,118,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Repayments of Debt by Year</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,300,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $183.7 million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099437680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Balance Of Non-controlling Interests</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands): </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(435,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(604,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(597)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,527,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,369,933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,897,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Continuing Investors Partnerships&#8217; ownership of approximately 27%, 29% and 36% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and 73%, 71% and 64% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099537456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.194%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Royalty Pharma plc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099443776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,125,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,315,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,121,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,143,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interests (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,103,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payable - Erleada (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $110.0&#160;million following the June 2020 FDA approval of additional indications of Tazverik. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701099393216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text">The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to legacy non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701087401440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Purpose (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,116,196,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | Old Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember', window );">Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember', window );">RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember', window );">RPSFT | RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember', window );">RPI Intermediate FT | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember', window );">RPI Intermediate FT | Senior Secured Debt | RPIFT Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Ownership percentage following IPO</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Exchange offering, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">89,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember', window );">IPO - Shares From Company | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">71,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember', window );">IPO - Shares From Selling Shareholders | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">17,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember', window );">Public Stock Offering - Continuing Investors Partnerships Interests | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_SaleOfStockNumberOfSharesAvailableToConvert', window );">Number of shares available to convert (in shares) | shares</a></td>
<td class="nump">294,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember', window );">Public Stock Offering - Continuing Investors Partnerships Interests | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_SaleOfStockNumberOfSharesAvailableToConvert', window );">Number of shares available to convert (in shares) | shares</a></td>
<td class="nump">294,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_SaleOfStockNumberOfSharesNotConverted', window );">Number of shares converted (in shares) | shares</a></td>
<td class="nump">241,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SaleOfStockNumberOfSharesAvailableToConvert">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Available To Convert</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SaleOfStockNumberOfSharesAvailableToConvert</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SaleOfStockNumberOfSharesNotConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Not Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SaleOfStockNumberOfSharesNotConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OldCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OldCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIFTSeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIFTSeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701087279088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>noncontrolling_interest </div>
<div>segment</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NumberOfNoncontrollingInterestsCreated', window );">Number of noncontrolling interests created | noncontrolling_interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember', window );">Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Current portion of Financial royalty assets | Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfNoncontrollingInterestsCreated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Noncontrolling Interests Created</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfNoncontrollingInterestsCreated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701090853104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th">
<div>Jan. 07, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 05, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAmount', window );">Long term funding partnership, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipNumberOfTranches', window );">Long term funding partnership, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount', window );">Required amount to be drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, additional payments, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne', window );">Interest free and payment free period, calendar quarters, tranche one | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo', window );">Interest free and payment free period, calendar quarters, tranche two | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple', window );">Installment repayments, percentage of amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipTotalAmountDrawn', window );">Long term funding partnership, total amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipExpectedPayment', window );">Long term funding partnership, expected payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,559<span></span>
</td>
<td class="nump">$ 70,441<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,432<span></span>
</td>
<td class="nump">50,896<span></span>
</td>
<td class="nump">20,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Realized gain on available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,815)<span></span>
</td>
<td class="nump">17,859<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital', window );">Payment of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn', window );">Period of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_DevelopmentFundBondMember', window );">Development fund bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from redemption of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Realized gain on available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 18,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period One | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period Two | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period Two | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple', window );">Redemption price, percentage</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSalePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSalePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Price, Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Covenant, Required Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipCovenantRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipExpectedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership Expected Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipExpectedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipTotalAmountDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Total Amount Drawn</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipTotalAmountDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_DevelopmentFundBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_DevelopmentFundBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089978960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 204,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="num">(124,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">225,100<span></span>
</td>
<td class="nump">270,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">359,400<span></span>
</td>
<td class="nump">204,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="num">(131,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">227,600<span></span>
</td>
<td class="nump">253,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember', window );">Funding Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rprx_FundingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701091941456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Swap termination payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,093<span></span>
</td>
<td class="nump">$ 35,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments', window );">Derivative collateral received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,660<span></span>
</td>
<td class="nump">$ 45,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Milestone Acceleration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized (Losses)/Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember', window );">Epizyme Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment', window );">Upfront payment for equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc. | Epizyme Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc. | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_OptionIndexedToIssuersEquityTerm', window );">Put option, term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_OptionIndexedToIssuersEquityValue', window );">Put option to sell additional common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Put option, selling price, maximum (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember', window );">Treasury rate lock contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Swap termination payments</a></td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OptionIndexedToIssuersEquityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option Indexed to Issuer's Equity, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OptionIndexedToIssuersEquityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OptionIndexedToIssuersEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option Indexed To Issuers Equity, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OptionIndexedToIssuersEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Equity Investments, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToTerminateDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Terminate Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToTerminateDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collateral Received On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MilestoneAccelerationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701094690464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Summary of Derivatives and Reclassifications (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Gain (Loss) on Derivative Instruments | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of loss reclassified from accumulated other comprehensive income into net income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Gain (Loss) on Derivative Instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Interest expense | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Interest expense | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant | Gain (Loss) on Derivative Instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">25,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forwards | Gain (Loss) on Derivative Instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts', window );">Forward purchase contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember', window );">Treasury rate lock contracts | Gain (Loss) on Derivative Instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,093<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_MilestoneAccelerationOptionMember', window );">Milestone Acceleration Option | Gain (Loss) on Derivative Instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="num">$ (96,610)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GainLossOnDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GainLossOnDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_MilestoneAccelerationOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rprx_MilestoneAccelerationOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701088887984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">$ 24,421<span></span>
</td>
<td class="nump">$ 581,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">112,348<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">204,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative asset, current, statement of financial position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative asset, noncurrent, statement of financial position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="nump">$ 86,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">116,939<span></span>
</td>
<td class="nump">1,301,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">112,348<span></span>
</td>
<td class="nump">269,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative instrument, noncurrent</a></td>
<td class="nump">10,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">363,608<span></span>
</td>
<td class="nump">474,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">103,876<span></span>
</td>
<td class="nump">226,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative instrument, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">103,876<span></span>
</td>
<td class="nump">226,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">24,421<span></span>
</td>
<td class="nump">636,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative instrument, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative instruments, current</a></td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="nump">87,450<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">8,472<span></span>
</td>
<td class="nump">43,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative instrument, noncurrent</a></td>
<td class="nump">10,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">259,732<span></span>
</td>
<td class="nump">247,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Royalty Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">11,501<span></span>
</td>
<td class="nump">374,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">11,501<span></span>
</td>
<td class="nump">374,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">226,300<span></span>
</td>
<td class="nump">187,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent', window );">Available for sale debt securities, liabilities current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent', window );">Available for sale debt securities, liabilities noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">598,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=rprx_RoyaltyInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=rprx_RoyaltyInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=rprx_CytokineticsFundingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=rprx_CytokineticsFundingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701097664992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">fair value<span></span>
</td>
<td class="text">fair value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Unrealized (loss) on equity securities still held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39.1)<span></span>
</td>
<td class="num">$ (41.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod', window );">Restrictions on selling common stock, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | BioCryst Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember', window );">Cytokinetics Commercial Launch Funding | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Interest rate volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-adjusted discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod', window );">Change in control event, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital', window );">Preferred shares, weighted average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Change In Control Event, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rprx_CytokineticsCommercialLaunchFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701087768976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,013<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,785<span></span>
</td>
<td class="nump">35,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Losses)/gains on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,634)<span></span>
</td>
<td class="nump">7,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,472<span></span>
</td>
<td class="nump">43,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember', window );">Debt Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,700<span></span>
</td>
<td class="nump">214,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,559<span></span>
</td>
<td class="nump">70,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition', window );">Gains/(losses) on initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Unrealized gains on available for sale debt securities included in other comprehensive losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Losses/(gains) on available for sale debt securities included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,800)<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,585<span></span>
</td>
<td class="nump">18,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions', window );">Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542,044)<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,600<span></span>
</td>
<td class="nump">253,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Losses/(gains) on available for sale debt securities included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,885<span></span>
</td>
<td class="nump">16,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,585)<span></span>
</td>
<td class="num">(18,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember', window );">Funding Commitments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition', window );">Gains/(losses) on initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Losses/(gains) on available for sale debt securities included in earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember', window );">Derivative Instruments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gains on derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,610<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember', window );">Royalty at Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense', window );">Other non-operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Nonoperating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rprx_FundingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rprx_DerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701101231616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 17,314,094<span></span>
</td>
<td class="nump">$ 19,047,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 13,493,106<span></span>
</td>
<td class="nump">$ 13,718,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089212144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Royalty Assets - Summary of Financial Royalty Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 16,776,307<span></span>
</td>
<td class="nump">$ 16,027,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(2,476,460)<span></span>
</td>
<td class="num">(1,384,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">14,299,847<span></span>
</td>
<td class="nump">14,643,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal', window );">Cumulative allowance for credit losses</a></td>
<td class="num">(115,422)<span></span>
</td>
<td class="num">(310,804)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Total current and non-current financial royalty assets, net</a></td>
<td class="nump">14,184,425<span></span>
</td>
<td class="nump">14,332,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember', window );">Cystic fibrosis franchise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,333,535<span></span>
</td>
<td class="nump">5,335,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(10,908)<span></span>
</td>
<td class="num">(48,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">5,322,627<span></span>
</td>
<td class="nump">5,287,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TysabriMember', window );">Tysabri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,683,441<span></span>
</td>
<td class="nump">1,846,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(212,283)<span></span>
</td>
<td class="num">(16,617)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,471,158<span></span>
</td>
<td class="nump">1,829,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TrelegyMember', window );">Trelegy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,284,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(24,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,259,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TremfyaMember', window );">Tremfya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">894,160<span></span>
</td>
<td class="nump">881,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">894,160<span></span>
</td>
<td class="nump">881,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember', window );">Imbruvica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,436,969<span></span>
</td>
<td class="nump">1,438,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(660,703)<span></span>
</td>
<td class="num">(236,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">776,266<span></span>
</td>
<td class="nump">1,201,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_XtandiMember', window );">Xtandi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,009,168<span></span>
</td>
<td class="nump">1,100,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(235,625)<span></span>
</td>
<td class="num">(172,101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">773,543<span></span>
</td>
<td class="nump">927,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_EvrysdiMember', window );">Evrysdi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents', window );">Aggregate royalty amount when patents cease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,134,980<span></span>
</td>
<td class="nump">4,697,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(1,332,815)<span></span>
</td>
<td class="num">(909,916)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">$ 3,802,165<span></span>
</td>
<td class="nump">$ 3,787,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TrelegyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TrelegyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_ImbruvicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_XtandiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_XtandiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_EvrysdiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_EvrysdiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701100580928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financial royalty asset, net</a></td>
<td class="nump">$ 14,184,425<span></span>
</td>
<td class="nump">$ 14,332,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_UnapprovedFinancialAssetsHeldAtCosts', window );">Unapproved financial assets held at costs</a></td>
<td class="nump">533,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_OtilimabMember', window );">Otilimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Non-cash impairment charges</a></td>
<td class="nump">160,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_GantenerumabMember', window );">Gantenerumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Non-cash impairment charges</a></td>
<td class="nump">273,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_RochesMember', window );">Roche&#8217;s</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Non-cash impairment charges</a></td>
<td class="nump">$ 182,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_UnapprovedFinancialAssetsHeldAtCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unapproved Financial Assets Held At Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_UnapprovedFinancialAssetsHeldAtCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_OtilimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_OtilimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_GantenerumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_GantenerumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_RochesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_RochesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701087254960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Beginning balance</a></td>
<td class="num">$ (1,694,945)<span></span>
</td>
<td class="num">$ (1,263,824)<span></span>
</td>
<td class="num">$ (868,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense', window );">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="num">(1,394,679)<span></span>
</td>
<td class="num">(912,710)<span></span>
</td>
<td class="num">(645,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense', window );">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="nump">296,637<span></span>
</td>
<td class="nump">446,955<span></span>
</td>
<td class="nump">570,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance', window );">Write-off of cumulative allowance</a></td>
<td class="nump">5,723<span></span>
</td>
<td class="nump">21,721<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs', window );">Write-off of credit loss allowance</a></td>
<td class="nump">1,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Provision for credit losses, net</a></td>
<td class="nump">193,798<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
<td class="num">(156,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Ending balance</a></td>
<td class="num">$ (2,591,882)<span></span>
</td>
<td class="num">$ (1,694,945)<span></span>
</td>
<td class="num">(1,263,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff', window );">Writeoff related to financial royalty asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Financial Royalty Asset, Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable Change In Present Value, Write-off Cumulative Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of financing receivable, charged against allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701096177536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 606,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember', window );">DPP-IV patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701096063520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember', window );">DPP-IV patents | Revenue Benchmark | Individual Licensees Concentration List</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Individual licensees exceeding 10% or more of revenue (as a percent)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701094700016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397,175<span></span>
</td>
<td class="nump">$ 435,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,973)<span></span>
</td>
<td class="num">(19,490)<span></span>
</td>
<td class="nump">$ 44,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">15,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember', window );">Avillion Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="num">(28,400)<span></span>
</td>
<td class="num">(17,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_EquityMethodInvestmentsUnfundedCommitments', window );">Equity method investment, unfunded commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,800)<span></span>
</td>
<td class="num">(11,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember', window );">Avillion I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember', window );">Avillion II | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromExerciseFee', window );">Proceeds exercise fee</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ProceedsFromExerciseFeeProRataAmount', window );">Exercise fee, pro rata amount</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember', window );">Avillion II | Merck Asset - Phase II Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_EquityMethodInvestmentsUnfundedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Unfunded Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_EquityMethodInvestmentsUnfundedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromExerciseFeeProRataAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise Fee, Pro Rata Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromExerciseFeeProRataAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701097660576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">$ 177,106<span></span>
</td>
<td class="nump">$ 200,084<span></span>
</td>
<td class="nump">$ 26,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid', window );">Upfront payment and premium paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rprx_MerckToFundMember', window );">Merck to Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_CytokineticsMember', window );">Cytokinetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_TheravanceBiopharmaMember', window );">Theravance Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember', window );">Funding Agreements With Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | BioCryst Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember', window );">Funding Agreement With BioCryst</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Upfront Payment and Premium Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rprx_MerckToFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rprx_MerckToFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_CytokineticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_CytokineticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_TheravanceBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_TheravanceBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701090868640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">$ (183,678,000)<span></span>
</td>
<td class="num">$ (203,930,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt carrying value</a></td>
<td class="nump">7,116,322,000<span></span>
</td>
<td class="nump">7,096,070,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(997,512,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">6,118,810,000<span></span>
</td>
<td class="nump">7,096,070,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">99.322%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.284%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point One Five percent Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.263%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.556%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.306%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Five Percent Senior Notes Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.565%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance As A Percent Of Par</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentIssuanceAsAPercentOfPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFivePercentSeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFivePercentSeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701090375568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 18, 2020</div></th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,678,000<span></span>
</td>
<td class="nump">$ 203,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,116,322,000<span></span>
</td>
<td class="nump">7,096,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,000<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="nump">$ 30,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of outstanding Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000,000<span></span>
</td>
<td class="nump">7,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Prior to the applicable par call date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio', window );">Maximum consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition', window );">Maximum consolidated leverage ratio following qualifying material acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio', window );">Minimum consolidated coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,840,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701097695328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of Repayments of Debt by Year (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="nump">$ 183,678<span></span>
</td>
<td class="nump">$ 203,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701088776848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>vote </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>vote </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>vote </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>noncontrolling_interest </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>noncontrolling_interest </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NumberOfClassesOfVotingStock', window );">Number of classes of voting shares | class</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CommonStockVotingRightsNumberOfVotes', window );">Voting rights, number of shares | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CommonStockQuarterlyConversionBasis', window );">Common stock conversion basis</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NumberOfNoncontrollingInterests', window );">Number of noncontrolling interests | noncontrolling_interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared and paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (333.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share based compensation expense, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember', window );">Deferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">371,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,325,000<span></span>
</td>
<td class="nump">371,325,000<span></span>
</td>
<td class="nump">361,170,000<span></span>
</td>
<td class="nump">316,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">443,166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,166,000<span></span>
</td>
<td class="nump">443,166,000<span></span>
</td>
<td class="nump">432,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,000<span></span>
</td>
<td class="nump">565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">164,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,058,000<span></span>
</td>
<td class="nump">164,058,000<span></span>
</td>
<td class="nump">174,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RedeemableStockRedemptionPricePerShare', window );">Redeemable stock, redemption price (in pound per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockQuarterlyConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Quarterly Conversion Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockQuarterlyConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfClassesOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Classes Of Voting Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfClassesOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RedeemableStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Stock, Redemption Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RedeemableStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089678688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,141,438<span></span>
</td>
<td class="nump">$ 10,248,545<span></span>
</td>
<td class="nump">$ 9,895,815<span></span>
</td>
<td class="nump">$ 6,141,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="nump">1,482,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(604,248)<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="num">(1,105,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">624,885<span></span>
</td>
<td class="nump">230,064<span></span>
</td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,908,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">83,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,432)<span></span>
</td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">9,895,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,525,373<span></span>
</td>
<td class="nump">10,248,545<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="nump">4,471,951<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,596<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="nump">1,174,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(604,248)<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="num">(792,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,494)<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">581,871<span></span>
</td>
<td class="nump">145,043<span></span>
</td>
<td class="nump">187,232<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,738<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
<td class="nump">22,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,552)<span></span>
</td>
<td class="num">(22,415)<span></span>
</td>
<td class="num">(9,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 5,077,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,897,223<span></span>
</td>
<td class="nump">$ 4,471,951<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | RPSFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="nump">$ 13,528<span></span>
</td>
<td class="nump">$ 12,436<span></span>
</td>
<td class="nump">$ 35,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,687)<span></span>
</td>
<td class="num">(56,490)<span></span>
</td>
<td class="num">(112,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 46,741<span></span>
</td>
<td class="nump">42,151<span></span>
</td>
<td class="nump">10,562<span></span>
</td>
<td class="nump">57,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">12,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="nump">13,528<span></span>
</td>
<td class="nump">12,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,809,269<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,343<span></span>
</td>
<td class="nump">35,148<span></span>
</td>
<td class="nump">1,165,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(435,446)<span></span>
</td>
<td class="num">(425,050)<span></span>
</td>
<td class="num">(594,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">218,137<span></span>
</td>
<td class="nump">102,892<span></span>
</td>
<td class="nump">152,895<span></span>
</td>
<td class="nump">266,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,218<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,392)<span></span>
</td>
<td class="num">(8,946)<span></span>
</td>
<td class="num">(3,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">1,939,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,527,887<span></span>
</td>
<td class="nump">1,809,269<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | Continuing Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,649,154<span></span>
</td>
<td class="nump">3,125,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,253<span></span>
</td>
<td class="nump">13,391<span></span>
</td>
<td class="nump">9,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,115)<span></span>
</td>
<td class="num">(133,433)<span></span>
</td>
<td class="num">(85,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,494)<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">316,993<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,775<span></span>
</td>
<td class="nump">297,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,520<span></span>
</td>
<td class="nump">3,227<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,160)<span></span>
</td>
<td class="num">(13,469)<span></span>
</td>
<td class="num">(6,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 3,125,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,369,933<span></span>
</td>
<td class="nump">$ 2,649,154<span></span>
</td>
<td class="nump">$ 3,125,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | Continuing Investors Partnerships | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests | EPA Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestTransfersOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Transfers Of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestTransfersOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Value, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquityValueEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RPHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RPHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_EPAHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_EPAHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701091917840">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">$ 624,885<span></span>
</td>
<td class="nump">$ 230,064<span></span>
</td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_NetIncomeLossAttributableToParentPriorToOffering', window );">Less: net income attributable to Continuing Investors Partnerships prior to the IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,232<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="nump">726,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Royalty Pharma plc - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,832<span></span>
</td>
<td class="nump">619,728<span></span>
</td>
<td class="nump">495,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Royalty Pharma plc - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,832<span></span>
</td>
<td class="nump">$ 619,728<span></span>
</td>
<td class="nump">$ 495,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average Class A ordinary shares outstanding - basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,963<span></span>
</td>
<td class="nump">414,794<span></span>
</td>
<td class="nump">375,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Add: Dilutive effect of unvested RSUs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Class A ordinary shares outstanding - diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,972<span></span>
</td>
<td class="nump">414,802<span></span>
</td>
<td class="nump">375,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per Class A ordinary share - basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Class A ordinary share - diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_ContinuingInvestorsPartnershipMember', window );">Continuing Investors Partnerships</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,775<span></span>
</td>
<td class="nump">$ 297,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember', window );">Legacy Investors Partnerships and RPSFT</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,457<span></span>
</td>
<td class="nump">$ 324,152<span></span>
</td>
<td class="nump">$ 409,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember', window );">Class B Holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,993<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;). See Note 13&#8211;Earnings per Share.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NetIncomeLossAttributableToParentPriorToOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) Attributable to Parent, Prior To Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NetIncomeLossAttributableToParentPriorToOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_ContinuingInvestorsPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_ContinuingInvestorsPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_ClassBHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701088848496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">$ 624,885<span></span>
</td>
<td class="nump">$ 230,064<span></span>
</td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets', window );">Income from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,125,096)<span></span>
</td>
<td class="num">(2,065,083)<span></span>
</td>
<td class="num">(1,959,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,244<span></span>
</td>
<td class="nump">452,842<span></span>
</td>
<td class="nump">230,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">22,996<span></span>
</td>
<td class="nump">23,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,356<span></span>
</td>
<td class="nump">20,162<span></span>
</td>
<td class="nump">11,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gains)/losses on derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,610)<span></span>
</td>
<td class="nump">21,532<span></span>
</td>
<td class="nump">42,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses/(gains) on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,442<span></span>
</td>
<td class="nump">48,066<span></span>
</td>
<td class="num">(247,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in losses/(earnings) of equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,973<span></span>
</td>
<td class="nump">19,490<span></span>
</td>
<td class="num">(44,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,142<span></span>
</td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">30,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss', window );">Interest income accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,432)<span></span>
</td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Losses/(gains) on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="num">(17,859)<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Financial royalty asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_GainLossOnDerivativeFinancialInstruments', window );">Termination of derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,093)<span></span>
</td>
<td class="num">(34,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,098<span></span>
</td>
<td class="nump">4,461<span></span>
</td>
<td class="nump">9,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease/(increase) in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables', window );">Cash collected on financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,507,236<span></span>
</td>
<td class="nump">2,315,854<span></span>
</td>
<td class="nump">2,121,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,456<span></span>
</td>
<td class="num">(20,131)<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable', window );">Other royalty income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,744)<span></span>
</td>
<td class="num">(9,012)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">34,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
<td class="num">(4,586)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,534)<span></span>
</td>
<td class="nump">15,550<span></span>
</td>
<td class="nump">42,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143,980<span></span>
</td>
<td class="nump">2,017,536<span></span>
</td>
<td class="nump">2,034,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Schedule of Non-cash Investing/Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Receipt of contribution of investments in Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">303,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_SettlementsWithEquityMethodInvestments', window );">Settlement of Epizyme forward purchase contract (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_AccruedPurchaseObligationEquityInvestment', window );">Accrued purchase obligation - Tazverik</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash', window );">Repayments of long-term debt by contributions from non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,103,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_MilestonePaymentAccruedButNotPaid', window );">Milestone payable - Erleada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedPurchaseObligationEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase Obligation, Equity Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedPurchaseObligationEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_GainLossOnDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Derivative Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_GainLossOnDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInAccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Collections On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Royalty Income Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_MilestonePaymentAccruedButNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Accrued But Not Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_MilestonePaymentAccruedButNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SettlementsWithEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlements With Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SettlementsWithEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701100505520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingCommitmentAmountOutstanding', window );">Funding commitment, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount', window );">Required amount to be drawn</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, additional payments, aggregate amount</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipExpectedPayment', window );">Long term funding partnership, expected payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingCommitmentAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Commitment, Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingCommitmentAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipCovenantRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Covenant, Required Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipCovenantRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipExpectedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership Expected Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipExpectedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701089483520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 08, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to legacy non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,803,000<span></span>
</td>
<td class="nump">$ 107,934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financial royalty asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,184,425,000<span></span>
</td>
<td class="nump">14,332,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember', window );">Agreement with MSCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionInitialTerm', window );">Initial term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Amounts due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts', window );">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments', window );">Quarterly payments to affiliates, percent of security investment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount', window );">Amount calculated for operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent', window );">Percent for calculating operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Former Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionAnnualIncreasePercentage', window );">Increase in quarterly installment payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Operating and personnel payments incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,400,000<span></span>
</td>
<td class="nump">145,200,000<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to legacy non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,522,000<span></span>
</td>
<td class="nump">92,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distributions payable to legacy non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,281,000<span></span>
</td>
<td class="nump">15,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financial royalty asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,400,000<span></span>
</td>
<td class="nump">130,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired', window );">Number of limited partnership interest acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember', window );">Pablo Legorreta | Purchasing And Donating Ventilators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount paid to CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Initial Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number of Partnership Interests Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Adjusted Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateAdjustedCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Value Of Security Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateValueOfSecurityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_PurchasingAndDonatingVentilatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_PurchasingAndDonatingVentilatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701091913168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, additional payments, aggregate amount</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, additional payments, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments', window );">Payments to acquire royalty interests, additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interest, Additional Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140701094924416">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ProfitLoss</td>
<td class="nump">$ 479,842,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ProfitLoss</td>
<td class="nump">$ 495,198,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>rprx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rprx="http://royaltypharma.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rprx-20221231.xsd" xlink:type="simple"/>
    <context id="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a353e18b5564d8c99b2d3b373d4a329_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic682e5b806304506930fd5fd21e6c21a_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="i1909231d99304e4a834f210d58e1fa93_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="icd27d5636b244ddd89fd2e8030b54641_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i192dc6dc29504992a09bfae83dcce963_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabe3448245414e18a4b4313799d4a486_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i158874ffe5c04ef4b93cee255fec0dfc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a118afd54f1420497a8451111036378_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd431f21346c42daa2c77e7ca72e959c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie92cf91b49d444b89c5ca4d63d6e997a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22b14c23fc6244f59ebfbae3ac633db6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dfb9308ae154def8f8c57d02cde386a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie008f8c9d7654553948cf5d03673f74b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa24c4f1c1cf4fa4a7afb95c44a5b6f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iccebf37c46634c398d67ec2e7c9899b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3db1d86622b54d0aa7386b802e458701_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if34a184452ef4fa88c4aa26700a19e27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5ad5247fc86440e9432a456ffbf26ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8885fde0c1284600a478a453d7f04c9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iedb811a285154e8abc06e48048183949_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b8405fbbc504757866319d871cfe818_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2626c942e9294d08899937a29e6df6d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21985f335d0445f5a86183ee1ff7f4b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07f248f1983243fd9644c279de47a32c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4bd0b8d23d7d46f28641ee528276a6bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e797a142c1d4e669b384c7cb83c9dee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6924ffcc56464af49725a154112a2c81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i209869199a674f339c33431cd676e2a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia13e806ca6da4fa5b16131baa358c469_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0fbcf597b512467294d0d8a431cff682_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2485d51e396d457d82d53b0d720876f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89cbf4efe96145bc9b29ae5fcb436732_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i6bd60620e8d7464586752970db0211e9_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fe5497d8e994e039ef92e85073e55a8_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida16729ea6c0450498d0894c41753058_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7ffbc7e40f849c79a2370de012b62a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i193b3040cd2347e7addc1373ea7a38fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i921629adeeab477cbc0cc2df2b75eef0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3be8c068c0e4210b0b20061ca476efd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49f8305cf2864dbda8cea2f22f63e356_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89ea0ca2684e4b76aaeb8cfe35fffb2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09e0f207870b4fc7922227f8a820157a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67d04637150e49448bad7423d2ea8dbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f1d98977d25401ab5199bd95b2ac683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b9169a4bf9c4e2692a023b17759e46f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06aaf4b76d2b48d6a71c3deedfa9f5d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84e1faf18b8b44d991d1d1a4c417f179_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i638daa38667341c8878e93ae45445868_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7af311935ef147839b589ff0401a4cc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7f5fba4c66c4d59b458232cfefd397b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i388294e0fecc48b7acef50ad301ac37c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ca490efe8f34a918c292b71f44885d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ebba7acc969439b987dcc2d0fba6673_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idec2f808579b4b78902a87ec4cc91f2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i852db36c0318454ea53dd42de40f5456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49f12c6f1519441d92c1fb354e0c1a55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i143cf5791aaf471fa5e1a7b574902892_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ec20854f553421a86396e564097af71_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id43eea863eed4e989a4af810e68237ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd8756959c734531850ee0869d7a395d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd4bbb534e9247e69a9f399be66e680d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabd19d54ace74630abbabeca7a180eb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2563f49c9d244ee28c8dcc79a588677d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia422b9c6dc3d49fa986c24ca134e7dfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie02e089bd28e49abaff42a3961b0d5db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i762c4b988d95468ca6e9ff58ce974d4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica1fc390f90a425883695c27f2ee9af6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia953612cc13a40389485402ddbb1c92a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i280e643fdef0483689f89d2627e67117_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i955ef8f092f6410b8368691a366b3ccd_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ia00f566083814766b799de815b74eb68_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="id6272e7fd11d44329684f5f26db3b0e5_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ieabc44fc792946909b8b90c908c11b2a_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i12ff36e2c24f4dfba76ba7b4b27451b6_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OldCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i0abe73d17656428c858e609114abb39a_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIFTSeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i9572c0d747ab4d80a3666c92eef2f3e7_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="ic92461c4b3514d22afb54b7350b5a973_I20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="idec997943fd44095835407fd6f299a6d_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="id7d4834e0547457480186ed9fe6cfbed_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromSellingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="idf5b5a5cdfc4467896657cf7dc34567d_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i7cdeed76822f459e89ec58e43a1d83ea_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="ic6c853fcbec74369a6114e07a900dfc8_I20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="ie00852d0b4174efbaafedf7b99cbfe00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e6a1451ee4f45f286b64a9a27bc35ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6036429cbf7d478bb21d142552f11fd3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i50014516371a4a1d80e1b25e358497c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5062756e7634788ade2313173101917_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:DevelopmentFundBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b27d2843a794aa78e16c71951dd44e8_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic197bc2dabd546778e0292339fc66971_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i298d7c29452d4bcdbaf7cd89d8fc8533_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="ie0c3a6ae85e346a0a5e3381b803dd465_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ida8d155decaa4354a46677a02d47d72b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i69adb70664a447e79c77ca4463c73f8c_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i8c0d89f6c512426b935355784dc5eca8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8926e1456d5b484da7113982a2cc6f8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b454c53374c471884c05778788c7dae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2d8cbe5699f4354a0a0fb8aa7ac335c_D20221003-20221003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="ib5453ca3d1fa434f832ded0a6cbd1d30_D20221003-20221003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia387ad8558934defb6159f7305efa385_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7cb276a5c674234b53a15b315d62a67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i808aa487867047a1aeeed484938b9306_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4bf194cfc2e4ae29733f8ea9a9e30c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MilestoneAccelerationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7aecdb813e34569b6db97dce91bbfab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83621d3576df4e908ddd466a0e61f733_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec09d9a909cb4c17866b5eb148734cbb_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i68d67c1c36ac474584018997072ac0ba_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="idf0a219828db455db7c7f67f043e8346_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="id15fe3c8a0254d78944bd1d10ea2a29a_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i3b09b987997c4801be4424e787583ad3_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ie250c596f2414ce2a10252ee5fe6b000_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if1ee900d9be64dff809bae93067b329b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97b84d20eec148e8a629524fec68a0a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i584e4daf7e194c5892cde63718b1c7ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43ab4d2a31844b79b2cc049b2d2d82a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee5401a91f4148caa202184655267c97_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf13c3669b9445de801580639f1dcd01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i377698d44a004b60a93b6e026bb496b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51deee71524e45f2b92578b1b7a69a43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78355224105441eeb9b89315786e6bb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8da8d7006a174307ad5d37753b978bd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia18b06181b4d43fbb3e315553e743a9c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6913761eb9d476a89d786eb84437c8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bde215a2f7d41c19e08a08fda54ecec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b208c40e457458888bdd3417e87cc6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72a25c9fbeac4e028b27a42ea86ea95b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib489dd79da964d4f9415ec89293c3ae7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81792be75c1c4c2d9399629e922cab13_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfb080182b0d4caaa2be643121414d08_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7f43d56301b49e996fc395673d519ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b7ceeaef8dc42f28a13e4f9c0bb24d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c740405d5a64a9b80be8f8b658e7edb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09689e7a29b04e63b1743e322c38e197_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:MilestoneAccelerationOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0fb45740e6145a5b10b66dd36b462b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib406778ea8824af6aae3c5dfb2e1610f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a21bed221044a0890c2c913d788b8a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i186084ca8b944fd98cdadde833e23388_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i796975e015ca44e1a9105072f8fc8ba5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1873077ea3a4449b93ac140b1258d597_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d4a77eb1b3c42f690d02b5f7c117bb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4228e1020e84d28a5d3606eb13fba5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ce834481aa64cca87e9f3cc25a312ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ba512b3b31444ed910800ea1536abc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29550347abe146f89941dfcd98915c01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6dd2992133f24f0f9d76c8ca5fe08441_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfdfec8d4041469bb92dd0165296ed5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d1f65e37bdc4ae98f2ef6443c0e36d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cb596f160574fde859a997dd3688a51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1505389d35a4fe697a3107d3e1a4e20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b3ab05ebb3f4cefb671b072e85ae362_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa0a251553004651bae3fe39fca66f0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2611175ae914a0cb275393ef07b82b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c3e7cecd2194bba94c9ea68302d6da5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2fb97cbac8b416db2ba868db73a9261_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib63036932758473e8e19c69328045159_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b041c7b1fd843f4801f45f69864a734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i513ac86b5f644e0abbd6fd515bf19a93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia930877a154f4ea397b7a9ed77275162_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd6c9fd69b64ac3ada61bea9f9a809e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6606a8ffd244eb8b5538e380fb0155d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b2ed614ee654625b83a27f5186d6d46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecf13afac5c747a58a510a05b6306845_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib747f5c2a7ac44d2adede24f51ea0ed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf4e09328663481a88570d82f2b0b2da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9f44f16ba8447af88c5f94ba782e24e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i886a32de12484bc3a8fa2095f96ce3aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b749d46341641ce864db1980ea0eadd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3d1f95532784cb4b004e23c96a53c2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7913fe2f2f1f4f17975329f9e86b47f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8167718861cf4cc097ec7bc1722c4abe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie34968ddaef047e5aee9da6ed328c6a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bc45285d96740488e652d34212bd6bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a6ca2229ea245549c7358f77e0511f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe6b624b7369483aab919710178f1675_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibea5eb15f1b3454786bccad98927ed9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94a230a360ef4bd6bdd4b1fde0b5e287_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2bf206b0fe441d9a604aa40decf5e98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie196b18bfc6e42cdbb8fc1c9cf933b38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i671467da1004443aadefa5fc4adc8a66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87d09b91ce0940f8bf8d043a117aa8b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9965e6b7e930491083134897c58109bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5db25f68b5f64a1b83cb921118b07a8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7de25f5e6375404c800880744168d22f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3db62c54fe54935bfbb368cd4dcd185_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i311eff96434042c48fc1a0da1a969d9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie89a50ad7a634d438a6aea813c2e2267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4aabe1887bb4026b0b128e258134f11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5d1415d925c4be3a6b3679f2f242c45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fb4e4e310ba440aacab956e88cdcd59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ef49f9006f64af4b44d5878e8dab385_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia96f43839fad463b8054251eb61aaf8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i568a2e5375d9455592a7ac8716ee21fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ec3afdb32d543f6a697d49c7789b2af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1f14546a2c04d92ab9cc2604c837de4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c890bd4904a4b3987af9a1db0691475_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4355b2c313964e16a9cc70955cb99e95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id87bec58187049c0b4315cc2e7e75220_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if30b1de3d1e04b99b1569a7a6cca90fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id40c65086ad44d44b48a424f98b6eba8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief66559de8974b67ad08f5c7e106bc13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0284f5e21ce642a7876ab339f755553c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70136bdb09f640f6a595ebcc3b848490_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18426df2a74c460381450590d12af14e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i386b4142f4104da8bbeb674cc226ccf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c35e8641845417891560b40c078c58b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6b89ba5713246ecb69cbe5915280e12_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic244222348804b5795bfab47417210e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ffc8574733247448667f38369095447_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14b7ad3a58f94ab791be7207d0fe8590_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if339554672b642ae891f1ba2a6cbf38c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66b55421b8464ed6a1a539d99d821dba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:RoyaltyInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84360bddd1754c6aa91800aaa849b568_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19ee4838df9e479ca3a26e0b99bd5d60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85817d340b744538889a7450f9dbd2e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07a9073c101943dcb449f3c807e6fabc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa2169911e4a4795a6d397f381a2d74e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8693ab100ea8484492349f889e6977b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8240f1e3dadf4870b07c601e66065543_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6203b19a65da4c90ac16749d22ed023f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">rprx:CytokineticsFundingCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e0796e20c9d41059187f605c28f22c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida0371a080d9412b814cd70dc8e5ad90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f6e062894f1415ba03737996d595769_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i806d566ae63e4dd1bb3b094e2720d64b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bf58ad8accb4f42904d7cca513f316e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e9ad39844434b80bc9e6f439efedad1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd997478ad974d568fbddf3f973a46e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie99e011b5e4c43d9b3b72a4b809c2f49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib41f6ecb8c944a33bdde5a9125f24870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42a0bb5b28394f50af0be743d1778ecc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia47c45e714054471849ababb1fb4798c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e61aeea53b148b68f5668ae4c89ca1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9bf0e3d7700c4f61bcb0877b468b7e92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8413cab6c79345889a6dcd08bb93b8a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bc4135d264f4850ac652f81ebdd7653_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:FundingCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc8dafb087fc4a46989b1599f69c7c66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rprx:DerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12caaaf5dc4b4f7bb3868430bd3b390e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:CytokineticsCommercialLaunchFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3c4a1403d54240dea67d826b88016777_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i7c629d986ffc48cfa2eb9caa4dd6242b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb876c0578a24141af7bab85dbf86a2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5dc4b8074b244545ab8c7b941208037b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i892ba36fbecd4c5c828c453e8b75d851_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94aede0a88af4f98b9e9b7e04739e350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idac2696acac7403eabc89c247ae97720_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i291d6a5f159947a298875759e6b12a1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i403646e7babf4420ba107143a3a7a49c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1eabb1130de844f0a07dc3f24ad506bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TrelegyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56dbca1ce972434cb58c60cd86493a5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i663288bef185415e913cccac3fdce980_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i338803206bb64a83b9b1b2ea2de4bb21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5208a4b0fa34da2ad818a6631d4834a_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtilimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3cf7b243e4b44089454ec775107f6b1_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:GantenerumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4429291ceec343fd99325883de8cd9b9_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:RochesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95c43f443bf14a7bbbc638ead341d873_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i154af41306544e04b3092509a83bb96f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9499567243fb4bb6a99f9c18d1a4b027_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d3fcb3410a948649edfbf04b196d762_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69d319ef128f4f8885c3dadade2065f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib252428d952a4cf3902a48bd039d459d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i153bc6bd9c0047408ceded26b5f9e59a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc9b2898f14b4fc8b46de629cd65f242_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fbcaa672be248e197fc3072f0903674_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d8076ed02354170b8e1aef0696b1dd1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb803d1f20cc4fce8c2f9ab745affbd7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i850f55de08b348c6896f173a3de0636e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia14cea8f163049d485a56b89150c4bc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80c12de839c544f5bb19445f982348c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91fcca9afda04cc6ba4981ca2685afe6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b06f23fa444477b8d31b04cd8b75199_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i84614dd16a8241bc9bb8d393780ce7a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8da099dd6c543afb79c83d2662bba53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44ef2537a2d647a4b5b8a82e00bf960a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:CytokineticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10ff8205a3ec46f18544e77a5fe83eab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:TheravanceBiopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61ecf49a29ae4381b6950b4facb564aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:MerckToFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3edb74e20d194d1cb5aaf64169b64925_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ffdc417e74646e7a3d9fc1fea36076e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib41d6ba411fa44fe8f54e00c9719be69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93638517e843430abd0622cd117849fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementWithBioCrystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86c83ded7cd649d49c712b21a4451c82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8faa4e13bd38491daf38566f6eebb9b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaa254b18546f40f685306a6288911d2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i506d480262374d17bc6c2d61664062dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8198214b15354bb4a8f445cec4dbc5e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i026f9953369d49eea32d8638a01cd4ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i320c72757fa545478705ae929cf21624_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic03ffc7bd4c74c5ca68cf23404563dd7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36467572e76c44bab1b0c5564c2c4f5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45e5e2ba7c2b48ad8d172dab75994092_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie13d0bca9e81479fac36370bd642690c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic0acbd3d4d824163a23c1f2c06b0d15a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5aad990d21894f778fa32056c3d7f296_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6788ce3a13ed48968ef184ebb77330c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6276f25d8444c9ab2361232593a04a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i838c7cff011e48c7b534f0f3eedaa181_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd566c8dcd3c4e5b9f6aec7f920d2ee9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba5ff526d64b44c38b351540afac0ce9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i149da048776c4462b194bf3e704f0d93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cdc999f38464531a986434571af11df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief8928daca3b419895b3307d21daa429_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa5d9597c55743f0b0ea434a2f05583e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90b0dac23f424541b08adeb45318f282_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9df2b8b2b611422b93e15b5384fee55a_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i81df3e9523394784bee4f0ab4f95754b_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i841ed43575b4462d8d7e171a31c3a0ea_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i384458f232644f91aa9aeae55e9bf165_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-02</instant>
        </period>
    </context>
    <context id="i8d165cc588cb42c7a715455ac1f644a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib6668080e1a943078f97f24224e6214b_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="i87ec196b42b349799568466b38b36d11_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="i3ef9b1f654c54a45a6014f3846682ac2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2e5ff3a9e2243d18e1771b08d510e30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3f37019f75444bfb079f9eae44011a7_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i0477a1e950d844878b385b517d204739_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ibc82c34f1b1841fb9acad0573bb9c2af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0913b22937e94ce69dadc8d8ef64f99d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ded29aec73342379a32b7f0d37ce932_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i2b646b86d4204e5ab0e00d75294a4677_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ifa789f47637b468b8e0a81f1258d7822_D20221031-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="id28f0ac392314518bd09f5981a109a33_I20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="ida442f1cecf14df5945065908673a6d0_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i7f70bcb4de984b258954aedd1f27e7db_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i9c86a83a372f42caa003779427589736_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0b4057d220b45ad8565474419d30930_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebf80945d01e4cda8265a7a35cb92256_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id583806a07ed4cd8bfd78850b5f779a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6cc65a06afd46199b75bfd37257d1bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0509ce4690e4e7589a22610857ffc76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d596cf933ba4342a229fa9b82d58290_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fcd0fcdf8b845239f1f57b6fe825b41_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i2009985eb36743ad88c72d8e11fbaea0_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i5e55b25dde154b019f47eae3a218e41e_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i19e9d4812c374bfb90bd218fd00ab822_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="ic3f9625cef1e4423ba1d7b313528b32b_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e3b4d885275470faa50792d4a4bce70_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1895d5cab12548d4b8aa19c4ea3f7bc4_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0475cdd9f0f940c2b84d9176875725f0_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c4c363df47947bbb51883fe4178ece5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82fdaebc451745f9b2bb4e66ff3dc751_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e0662e7e53b4956bd13f22f2295afdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8e9ab43b7524668a5566f0c037e8e3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cdd18cadc3747e1bea0a4efcb970f3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe5dd6dc7e594c9f91e9eccb9dce463b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0835b7194744e4c9e4f528591ea0b3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf340aa855a942858168f3ecce184356_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e16c6c7260e403881edc832b000788b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i070f49ed42d5461697cd16327dd87162_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic272076b47ca427798a7eb4b50714520_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie580dc2708034fd4b6b4cfd3e17819c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife94ebe41b0c47e3ba05d415807efda4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida148d60e093484bb7aecaf26959ca76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03743a114d964d26b43b9ebb04e7dd8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia73f9519d5db426a8cec4e56bf77101b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e1f278076d844b99be68cf3e9873d75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief164fe055724316addcd160fcd29535_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f6b542ff447402ab303deafe356aa4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89cd3ad806e748eb9957406a9dba417e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i858eae6f03ab4f6095837812fe2050e8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05f6894c03c244809fd48ceb945f3ef4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8a476c779a0f4059929c8b1c13bcb11c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib698c75befc449c9b5e6d1b50a9022ff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33f144445f0e4c28a6b92715967d2981_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i7f8140079fb2406ca4822f6e2dbf5f31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3e504b2ac6f44869467d497b88bcd64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i048f1daf85ab40479caf539c7b2a985f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia34aa33e8820445b893a30e990847995_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83a8a06b5b3141b6b061529bf42fe3a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2bfaf7eb7d04751af4ffb41e99d27d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia79bf03ace46488f877dae1dc4f250f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15818908d4464f36813ed35be63cb421_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0b423fa12d043fb86870ee9477f4152_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i799427d0838947d38f9dbd8016b9306e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbc155b4bacf429796772ce27e94cbda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic382ad4d1e4b4ca887dcde3037d6a744_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32472808f32c48669cdcdb6fb300ef19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51ab9056722446e7a354e96a0a2398a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40a8232720454e84ab4193b8ecf8a19a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d7d2cfb65f04eeb990ed450281e3d84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if80e60d8ab83494c9238a91d2d655393_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="ieb555ed4cafa441b8b4640b8ea55f77e_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="iac904b7432ab421db7ac86aa4c7b05f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab860d9e81b6417c8a8c4038bbe057ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a92b3734ca649b4894cb7e1fc75d883_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="ief9bfddb245a424897b5627ca71545ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib71576f7e90f47a7ac7433ab13a80a52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26d178fad8c34db685697ae7ed68e651_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:PurchasingAndDonatingVentilatorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rprx:PabloLegorretaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75854c27514042c189af622ae1d3b9b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i393ab282388f413799453b142053e5c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if58be7d678254e86aa0bb99632dcf71b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id61936b93228428ab0a7f8fc0e01f96c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="noncontrolling_interest">
        <measure>rprx:noncontrolling_interest</measure>
    </unit>
    <unit id="segment">
        <measure>rprx:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>rprx:tranche</measure>
    </unit>
    <unit id="class">
        <measure>rprx:class</measure>
    </unit>
    <unit id="vote">
        <measure>rprx:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8xLTEtMS0xLTEzMzY2OA_b83f6d66-7b9d-4ed4-ae70-8c85b7c822ba">0001802768</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8yLTEtMS0xLTEzMzY2OA_08dd9013-4a6c-4b31-8941-f424ec4c8662">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV8zLTEtMS0xLTEzMzY2OA_7554435e-0158-48aa-b12e-52f093589f3e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl80L2ZyYWc6NTNhOGEwMWI0M2VmNDU0NGIwMTc2NzljYzM1ZWEyZmEvdGFibGU6Yjg5MjBhYmJhOWM2NDkzY2I5ODU2MjVjMGNiZmY1NTkvdGFibGVyYW5nZTpiODkyMGFiYmE5YzY0OTNjYjk4NTYyNWMwY2JmZjU1OV80LTEtMS0xLTEzMzY2OA_316e939f-7920-4f90-9f76-9b07b8a301ee">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ia13e806ca6da4fa5b16131baa358c469_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTAtMS0xLTEzMzY2OA_88944e72-0e6d-43cf-9aca-c19425f17385">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentType
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU3_1734e219-5a00-4249-9c6c-d9d4171542bd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6OTEyMjUzZDU3ZTViNDM4OGFjMjEwNmJiOTU0YmQzNDMvdGFibGVyYW5nZTo5MTIyNTNkNTdlNWI0Mzg4YWMyMTA2YmI5NTRiZDM0M18wLTAtMS0xLTEzMzY2OA_cf607cd5-b86e-44ff-b0b8-6070163670c4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18xMjk_56f5a1f2-9385-444a-8b31-5cafc4e3c937">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18xMjk_028de732-1719-4813-b832-89b7c0fc14df">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6NThlMDk2YzRlMDUzNDExYWFmZjEyNjY5MzU2YjE0ODYvdGFibGVyYW5nZTo1OGUwOTZjNGUwNTM0MTFhYWZmMTI2NjkzNTZiMTQ4Nl8wLTAtMS0xLTEzMzY2OA_a6df59e3-78eb-43c5-9114-d59825b7ccdf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODUz_252fd5e6-2a9a-4a65-9245-07e0b56b3192">001-39329</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU4_903afd74-c79f-4d55-b5c7-b8127c0a147e">Royalty Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18wLTAtMS0xLTEzMzY2OA_19a11dfb-0df7-48f4-be93-2e38382212c4">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18wLTMtMS0xLTEzMzY2OA_1603e5cf-13e6-4115-85a1-3753f412662f">98-1535773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y18zLTAtMS0xLTEzMzY2OA_a06fc916-8955-45a0-b140-65d94ddc626f">110 East 59th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3XzQ_99fdf318-0891-45c5-bdc7-b676bc367d87">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3Xzg_faf6a6ae-8680-4728-8787-9d6b8f706810">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6YmI2NmVhN2Q4NDI4NDc1MTlhMDJkNWM3YjljZDBlNGMvdGFibGVyYW5nZTpiYjY2ZWE3ZDg0Mjg0NzUxOWEwMmQ1YzdiOWNkMGU0Y180LTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOmI4MTEyMzFkY2VmYzQwOWNiZmRkMTEyMjYwODk5N2Q3XzEx_f8974c9c-07a5-402c-bbb0-d99b0c24bbda">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYy_1c82012f-602d-47d4-a486-de30e3f3b630">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU1_d0137972-e216-4c67-9188-c655cfa8e3e5">883-0200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTAtMS0xLTEzMzY2OA_3b866200-79bf-4835-931c-06786a70eeb7">Class A ordinary shares, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTEtMS0xLTEzMzY2OA_a23bf11e-1b85-4333-8b50-384e6a214602">RPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6MmViYjFmMGEyZDYyNGNjYzhlNTY5Y2NlNzFmMzhiNTIvdGFibGVyYW5nZToyZWJiMWYwYTJkNjI0Y2NjOGU1NjljY2U3MWYzOGI1Ml8xLTItMS0xLTEzMzY2OA_a38f9c3f-bebf-435d-9d77-9107d33012df">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYz_7ab2ddc5-f40a-4446-a260-9f0323418764">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU0_bf8402ca-be32-42f4-845a-92f92173103e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU5_5264c862-6c2f-41b7-a3dc-9fba6a611674">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODU2_e48de55f-f03f-4898-be27-0828a8675398">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8wLTAtMS0xLTEzMzY2OA_11ebdae4-ba2c-414a-abae-34bd0b542a7f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8xLTMtMS0xLTEzMzY2OA_2e2ef32f-0389-4e9d-979b-d3e3ada797da">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGFibGU6M2NjZmMzZmNiNzA0NDFmMWE3NjdiYTk1ODI0YWVlOTIvdGFibGVyYW5nZTozY2NmYzNmY2I3MDQ0MWYxYTc2N2JhOTU4MjRhZWU5Ml8yLTMtMS0xLTEzMzY2OA_69a9f5ad-ba26-4404-a7a4-c02ee107b10c">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODYw_d3c7c164-9ae1-4e1a-bc2e-4514ee782aef">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMTMzNjA4MTM5NTYyNA_97c1ff52-d555-4c73-981b-b36f7a3336de">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i8a353e18b5564d8c99b2d3b373d4a329_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18yOTE5_28dd7fbc-2d35-4125-a62a-03f593d4a601"
      unitRef="usd">18500000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic682e5b806304506930fd5fd21e6c21a_I20230210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMTY0_1095bbc7-b4ac-4805-a4d2-437295a34078"
      unitRef="shares">443166030</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1909231d99304e4a834f210d58e1fa93_I20230210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zMjA3_afc38bb4-9ef4-4daa-aa25-195f1f55ef8a"
      unitRef="shares">164057651</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xL2ZyYWc6MTJmNDBjM2VkNTU1NGE0YTkxYzgwNGYwODk3NzhlNmMvdGV4dHJlZ2lvbjoxMmY0MGMzZWQ1NTU0YTRhOTFjODA0ZjA4OTc3OGU2Y18zODY2_a14d25ea-a743-4375-8eef-a1d86ccfa02a">Portions of the registrant&#x2019;s definitive proxy statement for the 2023 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2022. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85MS9mcmFnOjBiMjI4MWVjYjhiNzQyYTlhYTcyZDFiZGFjMmY0NmY3L3RhYmxlOjVlMGFkMWY5YjM3ODRhOGZiNWQwODI3YjQxYmVhMGMzL3RhYmxlcmFuZ2U6NWUwYWQxZjliMzc4NGE4ZmI1ZDA4MjdiNDFiZWEwYzNfMC0wLTEtMS0xMzM2NjgvdGV4dHJlZ2lvbjo1MWRkMjNkMjU1ZWY0ZTAyOTI1MjM4ZmFlZGU2ZTgyOV83Mg_97521820-2e79-41fd-b149-f9e17d1ad979">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5MA_45b51f95-b290-4a3c-96a0-e86fd79b8aff">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5MQ_28aa2426-64fc-433d-9376-168ac9473444">New York, New York</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY5Mg_d2633a45-1cb7-4f95-9b92-06c0d6379bfd">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85NC9mcmFnOjUxMDhmMzI4NGQyMjQxNzZiZDM5YzEyMTRiMmQwMmQ3L3RleHRyZWdpb246NTEwOGYzMjg0ZDIyNDE3NmJkMzljMTIxNGIyZDAyZDdfNzY4OQ_2ed13444-6a02-499f-ad0e-1df930afdb6a">New York, New York</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNC0xLTEtMS0xMzM2Njg_f5facb7c-3494-4e4d-8518-3d3846890182"
      unitRef="usd">1710751000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNC0zLTEtMS0xMzM2Njg_b3fa924c-4c12-457d-a25a-efdddfb9536f"
      unitRef="usd">1541048000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:TradingSecuritiesDebt
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNi0xLTEtMS0xMzM2Njg_0c73bbea-d075-4f73-87fe-6ce935498ccd"
      unitRef="usd">24421000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNi0zLTEtMS0xMzM2Njg_d28d87f2-aa76-4d85-b6a3-969c97a3b308"
      unitRef="usd">581872000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNy0xLTEtMS0xMzM2Njg_6fac4180-0842-4db8-9913-aeaedcf04d90"
      unitRef="usd">691319000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNy0zLTEtMS0xMzM2Njg_932d5589-aaf1-481c-9153-1b41098a8474"
      unitRef="usd">614351000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <rprx:AccruedRoyaltyReceivable
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfOC0xLTEtMS0xMzM2Njg_03564153-b3f1-41ed-ac31-965a48c4a118"
      unitRef="usd">16830000</rprx:AccruedRoyaltyReceivable>
    <rprx:AccruedRoyaltyReceivable
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfOC0zLTEtMS0xMzM2Njg_15453630-8516-4a9e-a995-0c10cba522c8"
      unitRef="usd">53286000</rprx:AccruedRoyaltyReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTAtMS0xLTEtMTMzNjY4_5e7b84d4-25a7-4bdd-865d-f8bdf6fd3a66"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTAtMy0xLTEtMTMzNjY4_03f97110-e39c-494b-a673-c10af1319828"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTItMS0xLTEtMTMzNjY4_ad1d3a48-617e-478b-9f42-d0eeee07cb48"
      unitRef="usd">19767000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTItMy0xLTEtMTMzNjY4_2de0600f-babd-44d3-9e55-d419342a1a33"
      unitRef="usd">15023000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTMtMS0xLTEtMTMzNjY4_ff9bfa4e-a773-4cc0-a30d-aff0569637b7"
      unitRef="usd">90520000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTMtMy0xLTEtMTMzNjY4_823c884e-f956-4086-976b-0b7144ea840a"
      unitRef="usd">6631000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTQtMS0xLTEtMTMzNjY4_4c4eb8a1-468a-4c6c-8a81-3ed556bef652"
      unitRef="usd">2554908000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTQtMy0xLTEtMTMzNjY4_c40b52e5-0cd6-4283-8dab-011cf64cfcc0"
      unitRef="usd">2878211000</us-gaap:AssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTYtMS0xLTEtMTMzNjY4_a7c5b01c-4ab8-4d7a-8d76-b7656fc725a8"
      unitRef="usd">13493106000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTYtMy0xLTEtMTMzNjY4_6c98f6fa-3a5e-4c1a-aeca-7ba7d926c7bf"
      unitRef="usd">13718245000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTctMS0xLTEtMTMzNjY4_66b1122e-22b9-478c-a489-aacedc85dc61"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTctMy0xLTEtMTMzNjY4_b578bec7-e1f4-4b3e-90dc-2e8d65e03693"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTgtMS0xLTEtMTMzNjY4_0c0dfbd5-69aa-4114-a6e3-d9d3e83d0833"
      unitRef="usd">112348000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTgtMy0xLTEtMTMzNjY4_ec102f72-a2db-4aa8-8705-7b0d4a0a193f"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTktMS0xLTEtMTMzNjY4_20d192db-c495-4b53-8b09-55a3beefdb4c"
      unitRef="usd">226300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMTktMy0xLTEtMTMzNjY4_1d0cf894-116f-42a2-9d08-7314f6b40391"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjEtMS0xLTEtMTMzNjY4_a10e8dc8-f8a3-42da-9a3c-f2644e575348"
      unitRef="usd">397175000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjEtMy0xLTEtMTMzNjY4_391799a3-10b9-407a-be21-632f92329848"
      unitRef="usd">435394000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjItMS0xLTEtMTMzNjY4_15d2b941-55dc-4f4d-95ba-3152f6fa4ac4"
      unitRef="usd">29629000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjItMy0xLTEtMTMzNjY4_39a1e39a-8747-4f7c-bd01-d24f68dfa93b"
      unitRef="usd">4145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjQtMS0xLTEtMTMzNjY4_03919e79-91b8-4da3-bee6-c0b92c930802"
      unitRef="usd">16813466000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjQtMy0xLTEtMTMzNjY4_62bbfed1-387e-4d9a-b139-b9dbf41aa794"
      unitRef="usd">17515865000</us-gaap:Assets>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjgtMS0xLTEtMTMzNjY4_72c51c49-eb0b-45ba-97d8-0b384b83f3a3"
      unitRef="usd">94803000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjgtMy0xLTEtMTMzNjY4_76cef67b-17c6-4be0-abc8-fcfa4e81132b"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjktMS0xLTEtMTMzNjY4_eb8120ad-ef16-4f53-90b5-0a075f4824d5"
      unitRef="usd">7906000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMjktMy0xLTEtMTMzNjY4_f76148c3-2c7e-4c9c-8aad-26b585b77ca9"
      unitRef="usd">5620000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzAtMS0xLTEtMTMzNjY4_77d47ef5-9700-4ca9-a52d-23c51c6ab055"
      unitRef="usd">54162000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzAtMy0xLTEtMTMzNjY4_57d119d1-4476-4f4b-ab6c-f19221944c1b"
      unitRef="usd">57696000</us-gaap:InterestPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzMtMS0xLTEtMTMzNjY4_f6cdbdbf-bb53-4698-9d1e-04d76194bacd"
      unitRef="usd">997512000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzMtMy0xLTEtMTMzNjY4_cac6c638-2c66-4d65-9a16-4605dcd2bd30"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzUtMS0xLTEtMTMzNjY4_f4cd8379-e563-4dd1-9204-935f7169ca2d"
      unitRef="usd">12400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzUtMy0xLTEtMTMzNjY4_2a6a88f6-60cf-4fda-ad04-d3fdda4da76f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzYtMS0xLTEtMTMzNjY4_43ef7bd2-e3a0-476a-a724-c1e4cc787af6"
      unitRef="usd">1166783000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzYtMy0xLTEtMTMzNjY4_853c6d6b-b93f-4570-9c2f-785efbaaa403"
      unitRef="usd">171250000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzgtMS0xLTEtMTMzNjY4_dd89248f-2395-49ee-a64b-fe1ec61cf8d6"
      unitRef="usd">6118810000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfMzgtMy0xLTEtMTMzNjY4_887c9111-e381-496e-9aad-c5480377f75c"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDAtMS0xLTEtMTMzNjY4_d713fe0f-173c-426c-acc6-df0ef800dea4"
      unitRef="usd">2500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDAtMy0xLTEtMTMzNjY4_e920607b-d791-4d3c-9d54-d1b6696247cc"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDItMS0xLTEtMTMzNjY4_b16fdc27-197e-46bf-b683-8a8c66c0c575"
      unitRef="usd">7288093000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDItMy0xLTEtMTMzNjY4_eb914729-c011-43cd-ba65-e6acd13ec2be"
      unitRef="usd">7267320000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDQtMS0xLTEtMTMzNjY4_be0ed706-27c7-496f-98b7-a885287dcedf"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDQtMy0xLTEtMTMzNjY4_2e2ff8ff-8b6d-4b40-b19c-753d175564f0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfMjk_be8b00db-c196-47cf-b6ef-4c33d8b3d3fc"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iabe3448245414e18a4b4313799d4a486_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfMjk_c9a9da05-a8c1-41fe-b343-fd197b1505e8"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iabe3448245414e18a4b4313799d4a486_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNDM_428463dc-c724-4adf-8e09-8ff538848777"
      unitRef="shares">443166000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iabe3448245414e18a4b4313799d4a486_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNDM_678aeeb9-3fc8-4616-9361-079643a33373"
      unitRef="shares">443166000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNTA_281b90c5-c675-40a3-81e7-208887a70648"
      unitRef="shares">432963000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MGFiMjVkYTIzNjU3NGI0NDg5Y2Q2MTI1MWViYzYxMzVfNTA_80f618f2-98e7-43e6-8639-4629a19207aa"
      unitRef="shares">432963000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iabe3448245414e18a4b4313799d4a486_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMS0xLTEtMTMzNjY4_abdc8129-21f5-469b-8461-45452f260fc0"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2c07f0b96ef34f73b7b9a86aeaefbcef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDctMy0xLTEtMTMzNjY4_e1d7ffb8-764b-40da-bb64-a7d62b46c07e"
      unitRef="usd">43000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfMjk_033a6e9e-71f8-4cba-afed-da1758e0d2a3"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfMjk_a378fd2d-dece-4d20-a38c-a87c338d58cc"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNDM_3e726c3b-17d2-4cc3-9f5b-06779b53be93"
      unitRef="shares">164058000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNDM_af12d1df-f20c-4e9e-8e97-a1b135f0c0b2"
      unitRef="shares">164058000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNTA_9bb75ace-6379-454d-b7cc-c422aa195b6c"
      unitRef="shares">174213000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MDFhMTgwMTNhNGVhNDY0MDg3MWViN2M3MjM0MmUyMzBfNTA_d871d1ff-9715-4947-a22d-78217f310ccd"
      unitRef="shares">174213000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMS0xLTEtMTMzNjY4_056be7ad-bc3f-4a32-8227-63d9255777a8"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i158874ffe5c04ef4b93cee255fec0dfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDgtMy0xLTEtMTMzNjY4_eccae1ac-c71c-46be-8990-6e7220417cb1"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4a118afd54f1420497a8451111036378_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfMzE_8b551814-1d25-4844-a96a-4aa35f2476c6"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfMzE_b2efa519-7e42-48e6-a125-4a16fec7b041"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4a118afd54f1420497a8451111036378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNDU_3801d3fe-eedb-474f-be42-e25b40098a20"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4a118afd54f1420497a8451111036378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNDU_b0d008d3-e69e-4971-8aa9-1ac8cc03b4ce"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNTI_781a6018-8cae-47f3-b0a4-a434cb4ac7f2"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU5YTY3ZDUwZTk4NDlhNDhhMzI5ZmRmMDIxZmEwZTdfNTI_ee3f9ff4-19fd-46bc-b5c5-07300c1d5875"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i4a118afd54f1420497a8451111036378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMS0xLTEtMTMzNjY4_83d6de46-e2c3-46c8-b4f4-0269b8c2647f"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idd431f21346c42daa2c77e7ca72e959c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNDktMy0xLTEtMTMzNjY4_89f622ef-1bfe-4672-b004-e4583bef3f2e"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMjE_6c655bfa-fb86-40a8-9dce-d07126f33db4"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMjE_aab22686-09d0-4976-8c38-c6dc2c4d223a"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMzU_b295dae5-446b-4dbb-bc81-cfa9e27f5402"
      unitRef="shares">371325000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesSharesIssued
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfMzU_c112a10c-e25a-4f39-bc12-4551bc2e8e4d"
      unitRef="shares">371325000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesSharesIssued
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfNDI_41ed4dcc-b00c-454a-8c55-ffa9fc0d7178"
      unitRef="shares">361170000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjhhMjFlMDExZDJhNGZkM2I1OTM3MGI0NmVlNWY5NzJfNDI_fef69477-a485-482a-88b3-7cefc3ea1b47"
      unitRef="shares">361170000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesValueIssued
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMS0xLTEtMTMzNjY4_6e392303-8222-459a-b0ae-30948d37145d"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <rprx:DeferredSharesValueIssued
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTAtMy0xLTEtMTMzNjY4_1fdaf359-f0b0-45e4-9f60-20f39a837975"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTEtMS0xLTEtMTMzNjY4_ef00e64d-d174-4549-9a00-1c0337eecbe9"
      unitRef="usd">3666160000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTEtMy0xLTEtMTMzNjY4_0c07e47b-ae87-4c17-9004-07ae2c8d9c68"
      unitRef="usd">3507533000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTItMS0xLTEtMTMzNjY4_cf829afb-8a50-4731-903e-e50064abbdb6"
      unitRef="usd">1964689000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTItMy0xLTEtMTMzNjY4_315c7d90-e8f6-4b30-9fac-c06a081fbd95"
      unitRef="usd">2255179000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MinorityInterest
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTMtMS0xLTEtMTMzNjY4_daa235ec-5320-40ba-ba73-8eb97ac724e1"
      unitRef="usd">3897223000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTMtMy0xLTEtMTMzNjY4_f24f0aaa-9160-42df-86fc-728c0e0e198b"
      unitRef="usd">4471951000</us-gaap:MinorityInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTQtMS0xLTEtMTMzNjY4_34befaa9-6a84-4028-af8f-f7fec3b3b533"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTQtMy0xLTEtMTMzNjY4_fec27380-3c34-4f4b-97bd-46f0e61c8ab8"
      unitRef="usd">16491000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTUtMS0xLTEtMTMzNjY4_a102153d-0756-4c3e-bcb0-ddb323b1e2aa"
      unitRef="usd">2806000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTUtMy0xLTEtMTMzNjY4_fa3707c4-b3c6-498f-aec3-58dd7456a7aa"
      unitRef="usd">2715000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTctMS0xLTEtMTMzNjY4_19cd6a98-187e-4ce2-a3df-6b56d879c69b"
      unitRef="usd">9525373000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTctMy0xLTEtMTMzNjY4_18f7616e-035b-4f33-bd86-1743628a457d"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTktMS0xLTEtMTMzNjY4_2c2ead79-2439-4c72-ac46-4c7f6919039a"
      unitRef="usd">16813466000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl85Ny9mcmFnOmJhN2IzMDYxMTI1NTQ0MjI5YzI1YzEyNmFhY2M4OWIxL3RhYmxlOjg2NWY4NWVmNmM0NTQzZmNhM2QzMmE5MDBkZjkwMzVmL3RhYmxlcmFuZ2U6ODY1Zjg1ZWY2YzQ1NDNmY2EzZDMyYTkwMGRmOTAzNWZfNTktMy0xLTEtMTMzNjY4_b6076bfb-8f8a-4d49-9ad9-cc6d12030ad2"
      unitRef="usd">17515865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ie92cf91b49d444b89c5ca4d63d6e997a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtMS0xLTEtMTMzNjY4_0021544c-b1f3-4298-be72-6a0bb91a0ef8"
      unitRef="usd">2125096000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22b14c23fc6244f59ebfbae3ac633db6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtMy0xLTEtMTMzNjY4_b4dfa867-a864-4362-928d-cd9812c312f6"
      unitRef="usd">2065083000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dfb9308ae154def8f8c57d02cde386a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMtNS0xLTEtMTMzNjY4_79ab3fb9-d148-491a-9a33-56cdedcbc6f8"
      unitRef="usd">1959975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie008f8c9d7654553948cf5d03673f74b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtMS0xLTEtMTMzNjY4_ea0df987-1ecc-4cec-b444-62ececb2bdb5"
      unitRef="usd">37484000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa24c4f1c1cf4fa4a7afb95c44a5b6f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtMy0xLTEtMTMzNjY4_df2d97c4-f286-4d0d-9f5e-9b2127f14995"
      unitRef="usd">171248000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccebf37c46634c398d67ec2e7c9899b7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQtNS0xLTEtMTMzNjY4_bbc146e0-1c0c-45c7-a89c-4fe52c48ee7f"
      unitRef="usd">143382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3db1d86622b54d0aa7386b802e458701_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtMS0xLTEtMTMzNjY4_2da0cadc-1eb8-4169-9401-10d032fa229a"
      unitRef="usd">74635000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if34a184452ef4fa88c4aa26700a19e27_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtMy0xLTEtMTMzNjY4_2f95c60e-809e-4d1e-bab7-2d79a745cb3d"
      unitRef="usd">53132000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5ad5247fc86440e9432a456ffbf26ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzUtNS0xLTEtMTMzNjY4_a3092614-38e6-4ef9-8cbe-85b22329a820"
      unitRef="usd">18996000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtMS0xLTEtMTMzNjY4_05c58905-0353-4857-bfa4-caa6ccb3cf5f"
      unitRef="usd">2237215000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtMy0xLTEtMTMzNjY4_0cda0a4a-c475-4352-a78c-b4c11c76726c"
      unitRef="usd">2289463000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzYtNS0xLTEtMTMzNjY4_ceb75dfd-8f78-4ceb-9390-c27276131f00"
      unitRef="usd">2122353000</us-gaap:Revenues>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktMS0xLTEtMTMzNjY4_025ddfd2-f087-4231-a9e3-f440c5271c70"
      unitRef="usd">904244000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktMy0xLTEtMTMzNjY4_44532908-b1f2-455d-aa98-8a6a22f06eab"
      unitRef="usd">452842000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzktNS0xLTEtMTMzNjY4_f6b6bc15-aaab-4431-baf6-287d18b5e111"
      unitRef="usd">230839000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTEtMS0xLTEzMzY2OA_7c97b3e3-be02-4485-8aeb-8e35d7f1f1c8"
      unitRef="usd">177106000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTMtMS0xLTEzMzY2OA_1a71c053-b340-46bf-a774-c47fd20f328e"
      unitRef="usd">200084000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEwLTUtMS0xLTEzMzY2OA_6d5331e8-fc16-4011-9974-e785ab58087c"
      unitRef="usd">26289000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTEtMS0xLTEzMzY2OA_a6cea9ac-1ad3-4ba6-96a5-faff5509e13f"
      unitRef="usd">5670000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTMtMS0xLTEzMzY2OA_28969b19-41ba-4ddd-b792-3c1d6d0d8ffb"
      unitRef="usd">22996000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzExLTUtMS0xLTEzMzY2OA_d35bfb76-1da2-45c2-8294-ec61f63d4a83"
      unitRef="usd">23058000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTEtMS0xLTEzMzY2OA_36694e76-c779-4133-bc7b-35581f5ea3b7"
      unitRef="usd">227303000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTMtMS0xLTEzMzY2OA_d6db8032-b647-4912-a516-8c9f00839113"
      unitRef="usd">182826000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEyLTUtMS0xLTEzMzY2OA_3f1024c2-6aef-4365-a25d-6f5bc00687bc"
      unitRef="usd">181715000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTEtMS0xLTEzMzY2OA_c3a89500-1b74-482d-ae3b-c9c612011839"
      unitRef="usd">615827000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTMtMS0xLTEzMzY2OA_b7762781-573c-448f-b0f5-0a0ca1ec101b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzEzLTUtMS0xLTEzMzY2OA_f558745b-b43d-4da2-a35a-18aef29344b9"
      unitRef="usd">65053000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTEtMS0xLTEzMzY2OA_68ba5276-9ca5-4851-a208-a5534b479fd5"
      unitRef="usd">1930150000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTMtMS0xLTEzMzY2OA_485ad893-e5f4-41e9-ae31-3362a6086f1d"
      unitRef="usd">858748000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE0LTUtMS0xLTEzMzY2OA_5ac9aea5-62b6-46c8-b5fb-5a1cd17708d8"
      unitRef="usd">526954000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTEtMS0xLTEzMzY2OA_e96526a0-900e-4040-aaa3-c57f10c490cb"
      unitRef="usd">307065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTMtMS0xLTEzMzY2OA_c4cea92d-a910-485d-a853-0d35c018544c"
      unitRef="usd">1430715000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE2LTUtMS0xLTEzMzY2OA_83e73dfd-ce66-4a00-a21b-ed88b49111bb"
      unitRef="usd">1595399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTEtMS0xLTEzMzY2OA_2bf46a31-7f1d-464f-8636-fd636d527bbf"
      unitRef="usd">-8973000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTMtMS0xLTEzMzY2OA_d7215ce3-5eb6-4663-ad33-994ea654b17a"
      unitRef="usd">-19490000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzE5LTUtMS0xLTEzMzY2OA_38530756-f098-43da-a012-afb4c4b9d717"
      unitRef="usd">44459000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTEtMS0xLTEzMzY2OA_48e81430-833a-4305-831a-390aa3cd349d"
      unitRef="usd">187961000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTMtMS0xLTEzMzY2OA_d18c5c54-e9ca-44d5-a2b4-13f7981dcfbc"
      unitRef="usd">166142000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIwLTUtMS0xLTEzMzY2OA_6d591215-2bd5-4a91-885f-8f70985d6672"
      unitRef="usd">157059000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTEtMS0xLTEzMzY2OA_05b0477f-af8c-41ab-b93b-17b11b5a0b66"
      unitRef="usd">96610000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTMtMS0xLTEzMzY2OA_3b8de12e-e380-48e0-a04d-99e2cd0ab0df"
      unitRef="usd">-21532000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIyLTUtMS0xLTEzMzY2OA_9ae301aa-874e-4efe-800f-a289d714de65"
      unitRef="usd">-42076000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTEtMS0xLTEzMzY2OA_d0ed15fa-360a-41b0-a076-be06c896342e"
      unitRef="usd">-33442000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTMtMS0xLTEzMzY2OA_60d19304-d8b3-4f53-94a1-70e2e980652e"
      unitRef="usd">-48066000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzIzLTUtMS0xLTEzMzY2OA_a3f8bef2-3656-4602-bbbf-dbce227156d4"
      unitRef="usd">247073000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTEtMS0xLTEzMzY2OA_8bb3ef57-3890-4e7b-a06d-f08df698533d"
      unitRef="usd">-6815000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTMtMS0xLTEzMzY2OA_4ed5a0d5-5394-4382-ab65-498da74f9816"
      unitRef="usd">17859000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI1LTUtMS0xLTEzMzY2OA_e4b7ae26-0563-4782-9848-18225f422ef9"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTEtMS0xLTEzMzY2OA_88e49814-eba4-4ab2-83a0-97d881566087"
      unitRef="usd">78335000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTMtMS0xLTEzMzY2OA_de9402b5-6ada-42f7-adb6-0fedde428ca5"
      unitRef="usd">53535000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI2LTUtMS0xLTEzMzY2OA_4ef5ebf4-628d-49e9-8b38-573e31d20058"
      unitRef="usd">28379000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTEtMS0xLTEzMzY2OA_e71c99ae-cf09-448f-a94e-815462f8b50f"
      unitRef="usd">-14755000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTMtMS0xLTEzMzY2OA_ddc994d4-5500-4658-9db0-ef35b220c825"
      unitRef="usd">-5678000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI3LTUtMS0xLTEzMzY2OA_3c3cac62-14a6-453e-9135-2d77c11b6357"
      unitRef="usd">-32821000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTEtMS0xLTEzMzY2OA_812af143-b89d-43e3-a1a8-87d9da27532b"
      unitRef="usd">-77001000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTMtMS0xLTEzMzY2OA_e586d9b5-1826-4043-a52b-93ec706619df"
      unitRef="usd">-189514000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI4LTUtMS0xLTEzMzY2OA_52bf9a10-9d20-4825-b50d-b1f283b8ad59"
      unitRef="usd">106555000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTEtMS0xLTEzMzY2OA_71681c85-6669-47b4-8bd8-65803454422f"
      unitRef="usd">230064000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTMtMS0xLTEzMzY2OA_2841a79e-c45e-4b34-8a26-154ffd30d7c5"
      unitRef="usd">1241201000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzI5LTUtMS0xLTEzMzY2OA_9b497956-598e-47af-abec-8e9bd40c7027"
      unitRef="usd">1701954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTEtMS0xLTEzMzY2OA_3bfb7ef9-5709-43d6-9639-2da07ada2677"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTMtMS0xLTEzMzY2OA_d42605c3-1860-476d-a8f4-58038caa38f6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMwLTUtMS0xLTEzMzY2OA_57efd025-a8c0-4bad-a5ef-421fe176bfe0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTEtMS0xLTEzMzY2OA_e79f9801-e762-47b6-9bf8-3c5eca5a36e8"
      unitRef="usd">230064000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTMtMS0xLTEzMzY2OA_485bbb14-b712-446e-b785-b131601863e2"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMxLTUtMS0xLTEzMzY2OA_eb13c7b2-73dc-4d14-922f-13bda93a4650"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTEtMS0xLTEzMzY2OA_7b3000eb-3a77-4c33-948d-6aa81f46f612"
      unitRef="usd">187232000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTMtMS0xLTEzMzY2OA_762acff6-0ea0-4f4d-8909-52d43669ce0c"
      unitRef="usd">621473000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzMzLTUtMS0xLTEzMzY2OA_d3546f6d-121d-4524-8eaa-d007b17a9449"
      unitRef="usd">726914000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTEtMS0xLTEzMzY2OA_8237052f-580b-4f98-bb99-455555ec5b08"
      unitRef="usd">42832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTMtMS0xLTEzMzY2OA_f1bb8ea3-8562-4577-b77a-d9d1b12b270d"
      unitRef="usd">619728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM1LTUtMS0xLTEzMzY2OA_731ce9c6-8fad-40ed-b06b-7583cad6f192"
      unitRef="usd">975040000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9"
      unitRef="shares">437963000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f"
      unitRef="shares">414794000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57"
      unitRef="shares">375444000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6"
      unitRef="shares">437972000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425"
      unitRef="shares">414802000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5"
      unitRef="shares">375455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItMS0xLTEtMTMzNjY4_e79f9801-e762-47b6-9bf8-3c5eca5a36e8"
      unitRef="usd">230064000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItMy0xLTEtMTMzNjY4_485bbb14-b712-446e-b785-b131601863e2"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzItNS0xLTEtMTMzNjY4_eb13c7b2-73dc-4d14-922f-13bda93a4650"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtMS0xLTEtMTMzNjY4_43d947b5-4474-4ab5-8699-cfdc9b9b8caa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtMy0xLTEtMTMzNjY4_50386616-3ac6-48b2-b63f-b8f99d144ab0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzQtNS0xLTEtMTMzNjY4_b6f13caf-b721-4f42-8554-ebed466cfb94"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtMS0xLTEtMTMzNjY4_0f6497eb-841e-4de8-979d-fb1580f9937f"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtMy0xLTEtMTMzNjY4_659924ae-6128-4590-be09-360273af7b1f"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzUtNS0xLTEtMTMzNjY4_e7886f70-22eb-4d6f-ba1e-59d210aed5f9"
      unitRef="usd">83120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtMS0xLTEtMTMzNjY4_4027acf5-b927-4994-a2fc-d04bdc7ec23f"
      unitRef="usd">53432000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtMy0xLTEtMTMzNjY4_1bf72636-5848-40f3-bd96-acc54903fa5e"
      unitRef="usd">50896000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzYtNS0xLTEtMTMzNjY4_e6c091e4-8890-497b-a5e6-397855f59f1e"
      unitRef="usd">20551000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctMS0xLTEtMTMzNjY4_84d7bb91-16ca-4fd9-948b-91affb53462f"
      unitRef="usd">-29432000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctMy0xLTEtMTMzNjY4_f4c151fa-3a81-4db8-b6a3-3b75ce4ca016"
      unitRef="usd">-39296000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzctNS0xLTEtMTMzNjY4_f833a058-14eb-46cc-9bdc-b924999cfc94"
      unitRef="usd">66635000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtMS0xLTEtMTMzNjY4_86c1a96c-288d-424b-9276-ebddb153ffaf"
      unitRef="usd">200632000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtMy0xLTEtMTMzNjY4_0a757ff5-9bcc-4f33-b67d-33a610ef555d"
      unitRef="usd">1201905000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzgtNS0xLTEtMTMzNjY4_751a38e9-7d1c-457e-8c41-450f926a23c0"
      unitRef="usd">1768589000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTEtMS0xLTEzMzY2OA_0b8b66cf-65b3-4e25-b8e5-937fa7ced3a9"
      unitRef="usd">175418000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTMtMS0xLTEzMzY2OA_08b56913-8882-4898-aa1b-0732904e5382"
      unitRef="usd">604323000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzEwLTUtMS0xLTEzMzY2OA_9c297fee-34b0-4c88-8cd7-aa65f03b9561"
      unitRef="usd">739787000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTEtMS0xLTEzMzY2OA_df6c79af-e770-4362-a526-a2ec0ec79181"
      unitRef="usd">25214000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTMtMS0xLTEzMzY2OA_7d23b16e-1c38-4949-b344-4a02e65fac0b"
      unitRef="usd">597582000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDMvZnJhZzpjMTFhZTY4MmM4ZDA0ZjU1YjIxMGRkNGQ2MTNiMDRmNC90YWJsZTo0OWY2MDMyMDRhNmE0YzQyODQ4NGQ1OGVkMDVkZjU2MC90YWJsZXJhbmdlOjQ5ZjYwMzIwNGE2YTRjNDI4NDg0ZDU4ZWQwNWRmNTYwXzExLTUtMS0xLTEzMzY2OA_89b8631b-8c96-4a4e-9ef8-34ef12c762fd"
      unitRef="usd">1028802000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i8885fde0c1284600a478a453d7f04c9e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMS0xLTEtMTMzNjY4_2f6d90c4-668b-4008-9145-463ccf4ab78d"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8885fde0c1284600a478a453d7f04c9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMi0xLTEtMTMzNjY4_27f125ff-8ec8-44ff-aa93-d791ea603422"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMy0xLTEtMTMzNjY4_4d93a0e6-0a61-4ec6-9c60-5e3c6f8502a4"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54c75a9f64ea4d219dc93f0ab3ab65db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNC0xLTEtMTMzNjY4_aef3056e-0e7d-4fb9-a5d0-c965673f662f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iedb811a285154e8abc06e48048183949_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNS0xLTEtMTMzNjY4_1dde1ec2-644b-4120-8eac-a93ae3d94114"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedb811a285154e8abc06e48048183949_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNi0xLTEtMTMzNjY4_f8c11674-1b6e-4314-8f76-90e280fec908"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4b8405fbbc504757866319d871cfe818_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktNy0xLTEtMTMzNjY4_85092397-3fb8-4414-80df-763ea67060ac"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b8405fbbc504757866319d871cfe818_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktOC0xLTEtMTMzNjY4_c26bb37d-496d-47ac-87b3-60c766cbcc46"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2626c942e9294d08899937a29e6df6d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktOS0xLTEtMTMzNjY4_f2e59bd7-470c-4d1e-9943-b3e6385cc85e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21985f335d0445f5a86183ee1ff7f4b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTAtMS0xLTEzMzY2OA_5608b933-8ecc-4119-adf2-3dc17832b38e"
      unitRef="usd">3282516000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07f248f1983243fd9644c279de47a32c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTEtMS0xLTEzMzY2OA_ed3555ea-ec97-4575-8f92-e62de6feaa2d"
      unitRef="usd">2825212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bd0b8d23d7d46f28641ee528276a6bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTItMS0xLTEzMzY2OA_b3dddc25-eab5-4e64-9e57-0c7160857cb0"
      unitRef="usd">2093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTMtMS0xLTEzMzY2OA_d59a0306-0072-4715-b41d-bb1e5d6729ca"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e797a142c1d4e669b384c7cb83c9dee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTQtMS0xLTEzMzY2OA_9939212c-c0cd-477c-a086-76cd373398a5"
      unitRef="usd">-4266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6924ffcc56464af49725a154112a2c81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzktMTUtMS0xLTEzMzY2OA_f3ef5d04-eadf-4036-8c52-61a11beb9540"
      unitRef="usd">6141438000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTEwLTEtMS0xMzM2Njg_1285d94c-729c-4601-a74a-69c7f8c5b706"
      unitRef="usd">307646000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTEzLTEtMS0xMzM2Njg_552c1152-934c-46c4-ad7e-34fe49efe242"
      unitRef="usd">1174676000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEwLTE1LTEtMS0xMzM2Njg_62450973-4b27-48bb-a6f1-1fbf39119773"
      unitRef="usd">1482322000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTEwLTEtMS0xMzM2Njg_a1fe50b4-3eb8-4f09-a4be-14ccc24733a7"
      unitRef="usd">-1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTEzLTEtMS0xMzM2Njg_aab486c9-fa36-4d1f-81f3-e7e28039c379"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzExLTE1LTEtMS0xMzM2Njg_496f0d0d-c1d5-462c-ab84-99fcc4b5d788"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fbcf597b512467294d0d8a431cff682_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTExLTEtMS0xMzM2Njg_161efeb8-cb84-4ee2-80a5-4f9e0b54acea"
      unitRef="usd">-192705000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2485d51e396d457d82d53b0d720876f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEyLTE1LTEtMS0xMzM2Njg_43d7dc36-3a91-4af5-b15d-2abea7622d55"
      unitRef="usd">-192705000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTExLTEtMS0xMzM2Njg_9512016b-ddfa-4921-b75a-c59ad1ef4aa4"
      unitRef="usd">313408000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTEzLTEtMS0xMzM2Njg_2a15107a-534a-4f92-881d-adc369bc41e8"
      unitRef="usd">792357000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzEzLTE1LTEtMS0xMzM2Njg_21db476a-3274-4b9a-8b66-8def53fc8430"
      unitRef="usd">1105765000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <rprx:StockIssuedDuringPeriodSharesIssuedForRegistration
      contextRef="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTUtMS0xLTEzMzY2OA_8e30b853-59eb-4884-b47e-d17105e4fb9c"
      unitRef="shares">50000</rprx:StockIssuedDuringPeriodSharesIssuedForRegistration>
    <rprx:StockIssuedDuringPeriodValueIssuedForRegistration
      contextRef="i7c0442c3f2cc42c788cbbfba7a5cb727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTYtMS0xLTEzMzY2OA_079b937e-f989-4b6f-9c50-3f8edd2b9ee7"
      unitRef="usd">63000</rprx:StockIssuedDuringPeriodValueIssuedForRegistration>
    <rprx:StockIssuedDuringPeriodValueIssuedForRegistration
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE0LTE1LTEtMS0xMzM2Njg_b0bdea5f-8941-415f-8391-f3769d80933a"
      unitRef="usd">63000</rprx:StockIssuedDuringPeriodValueIssuedForRegistration>
    <us-gaap:ProfitLoss
      contextRef="i89cbf4efe96145bc9b29ae5fcb436732_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTExLTEtMS0xMzM2Njg_0aa9d5b5-da39-4ab6-a3a0-e9fbfb129544"
      unitRef="usd">479842000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTEzLTEtMS0xMzM2Njg_d0256836-9d21-4b07-97a3-7ee3be690cad"
      unitRef="usd">145043000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6bd60620e8d7464586752970db0211e9_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE1LTE1LTEtMS0xMzM2Njg_e7e0a5bb-6925-4977-a4a4-1d5177966b4f"
      unitRef="usd">624885000</us-gaap:ProfitLoss>
    <rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships
      contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTMtMS0xLTEzMzY2OA_0d84c723-3f90-4d98-b491-ac0aee484e6f"
      unitRef="shares">535383000</rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships>
    <rprx:StockIssuedDuringPeriodValueIssuedToPartnerships
      contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTQtMS0xLTEzMzY2OA_d097c65b-a3a0-4eab-82ee-19be87e60e01"
      unitRef="usd">1000</rprx:StockIssuedDuringPeriodValueIssuedToPartnerships>
    <rprx:StockIssuedDuringPeriodValueIssuedToPartnerships
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE2LTE1LTEtMS0xMzM2Njg_f4032739-ea13-4167-8f34-75ed7b53bea6"
      unitRef="usd">1000</rprx:StockIssuedDuringPeriodValueIssuedToPartnerships>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEtMS0xLTEzMzY2OA_c637f824-bd95-4714-88e0-b043e741e951"
      unitRef="shares">294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTItMS0xLTEzMzY2OA_4afcd792-4162-436a-a190-8deac3a9367b"
      unitRef="usd">30000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTMtMS0xLTEzMzY2OA_5aae822e-a56a-4ffe-a03d-f798aa24a1e9"
      unitRef="shares">-294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTQtMS0xLTEzMzY2OA_dbbfc272-05df-43f6-9457-fb3e345caebf"
      unitRef="usd">-1000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTctMS0xLTEzMzY2OA_9b648b44-e7ea-463f-a866-837bcdee30ed"
      unitRef="shares">294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTktMS0xLTEzMzY2OA_9654ef7f-44f2-440d-a17a-cacc38243b27"
      unitRef="usd">1402762000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="iba2deda2d788474b90a4f1a3d85d5f55_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEwLTEtMS0xMzM2Njg_66200037-4d61-4685-b984-865acc10d865"
      unitRef="usd">-2553001000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTExLTEtMS0xMzM2Njg_959cf0e4-a9da-4f29-9d9f-0b27ad9bd365"
      unitRef="usd">-1261014000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEyLTEtMS0xMzM2Njg_45f0865e-3d7e-4f22-82c2-355e1f0fa457"
      unitRef="usd">-24022000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTEzLTEtMS0xMzM2Njg_0f79c7af-c61e-4985-a6dd-55d7a84faa0c"
      unitRef="usd">2433098000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTE0LTEtMS0xMzM2Njg_2f58fbe7-85da-4aed-92a6-67425c94a076"
      unitRef="usd">2147000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE3LTE1LTEtMS0xMzM2Njg_7862a1f8-bec4-4698-8a1e-3a89a670f399"
      unitRef="usd">-1000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTEtMS0xLTEzMzY2OA_7a98733f-1bc2-4cda-96d4-ce9dfc777dae"
      unitRef="shares">71652000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTItMS0xLTEzMzY2OA_9638b7dd-7eae-42d3-be04-97851b7a1281"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTktMS0xLTEzMzY2OA_d6d2599b-2834-4d1b-af2e-e46ac0110a73"
      unitRef="usd">1150383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTEzLTEtMS0xMzM2Njg_78a989d2-dac9-4760-a77a-758ae81ed72f"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzE4LTE1LTEtMS0xMzM2Njg_d9045d22-56e8-4ee3-b9a3-196a68156468"
      unitRef="usd">1908744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTEtMS0xLTEzMzY2OA_626fd311-1b9d-4a59-9013-4ad198475c6b"
      unitRef="shares">76000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTktMS0xLTEzMzY2OA_fa149ac5-bf76-48bf-bf92-6b9226ff0dad"
      unitRef="usd">5428000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIwLTE1LTEtMS0xMzM2Njg_e1b10c55-7dfd-43f0-a86f-6bb6216f1419"
      unitRef="usd">5428000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEtMS0xLTEzMzY2OA_77b7e72b-abac-4517-96d6-1e7a87271bff"
      unitRef="shares">-22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i5d3bfdfac217434c8def60fd36071c53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTItMS0xLTEzMzY2OA_03f97a84-05df-42c0-a688-13e9a90294d3"
      unitRef="usd">-2000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i696fc13ef442460a950b6f30ca8282ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTMtMS0xLTEzMzY2OA_2869a9b3-6809-4237-a8f3-1c79866890c5"
      unitRef="shares">22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i901a6984c417463cb00baa96fd850e9b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTctMS0xLTEzMzY2OA_c238f068-ee24-4cf7-a538-96ce9ae2fcb5"
      unitRef="shares">-22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ia8b53ad0e55544cdb69c2b60112fdb32_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTktMS0xLTEzMzY2OA_ffc551c9-9213-4af0-b368-fee02b5d54bb"
      unitRef="usd">-307391000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEyLTEtMS0xMzM2Njg_17cf0560-d767-4452-99d1-687611115883"
      unitRef="usd">-2562000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTEzLTEtMS0xMzM2Njg_0062a84b-b772-4e98-b66f-09346af206e3"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib581854bf97f4a278e568eb3acdfd76b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTE0LTEtMS0xMzM2Njg_c8f757aa-25f6-45a4-95ae-d5e6906558fb"
      unitRef="usd">198000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIxLTE1LTEtMS0xMzM2Njg_f4bd5a85-8ac3-43f0-be6c-db7ff6cbcac1"
      unitRef="usd">-191000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTAtMS0xLTEzMzY2OC90ZXh0cmVnaW9uOjIxNDc1OWM0NWNmYzRkYzZiNTViNTY3NzY2NzVmYWE3XzE1_71d8394e-a21f-444a-b2b8-68aa91dd878e"
      unitRef="usdPerShare">0.30</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="ibf3b6b56f8ea4e9aabe7c162dd951977_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTExLTEtMS0xMzM2Njg_5d61c20e-93ef-4739-9a6e-b29f6762bd98"
      unitRef="usd">112490000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIyLTE1LTEtMS0xMzM2Njg_4cc09c18-c5c7-4393-aa10-513e7653fe88"
      unitRef="usd">112490000</us-gaap:DividendsCash>
    <us-gaap:ProfitLoss
      contextRef="i4fe5497d8e994e039ef92e85073e55a8_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTExLTEtMS0xMzM2Njg_0dc3daad-e23f-4f57-9cd9-da28a4a96eab"
      unitRef="usd">495198000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida16729ea6c0450498d0894c41753058_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTEzLTEtMS0xMzM2Njg_8cf6ac84-fa2b-4ad7-bb68-129ea2b0103d"
      unitRef="usd">581871000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzIzLTE1LTEtMS0xMzM2Njg_57f1bd4c-0e13-4411-af14-ad83a5715a51"
      unitRef="usd">1077069000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI1LTEyLTEtMS0xMzM2Njg_fa8f306f-70ad-4a4a-a296-2d6eb2d440a4"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI1LTE1LTEtMS0xMzM2Njg_3b5276f7-23db-4b30-986e-a4171417a15f"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTEyLTEtMS0xMzM2Njg_788d2100-dd45-472a-bbd0-8d3e9c12a2a4"
      unitRef="usd">60617000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTEzLTEtMS0xMzM2Njg_55d847db-aadf-4584-aba2-a2d4c35d8301"
      unitRef="usd">22503000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI2LTE1LTEtMS0xMzM2Njg_b08620b8-7999-477b-a855-60d6aced0b39"
      unitRef="usd">83120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i2c1c79ab3a7e44188215ca5df9b760f8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTEyLTEtMS0xMzM2Njg_55228df1-9423-4ece-b91d-d2c4a4ef40a9"
      unitRef="usd">10921000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTEzLTEtMS0xMzM2Njg_98edca71-5323-4d59-be2f-74e40ab0151d"
      unitRef="usd">9630000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI3LTE1LTEtMS0xMzM2Njg_ff377aa0-0495-4cce-bdcc-634e618b77dc"
      unitRef="usd">20551000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEtMS0xLTEzMzY2OA_caff5455-1f57-4976-8c70-d2ca9bfb4d35"
      unitRef="shares">388135000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTItMS0xLTEzMzY2OA_6af9867a-30f7-4361-b295-c0a7eb63b99a"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTMtMS0xLTEzMzY2OA_05451fe5-9e1c-4007-8699-dac7a1a19fcd"
      unitRef="shares">218976000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTQtMS0xLTEzMzY2OA_f83f88b8-93f3-45a1-84eb-b5920967988a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTUtMS0xLTEzMzY2OA_6c2157d9-526f-43ab-9daa-72c0f04a858a"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTYtMS0xLTEzMzY2OA_a102d308-ea6d-4355-a5dc-3ba76a0c5e57"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTctMS0xLTEzMzY2OA_9ed89a76-0f9c-40cb-8c41-17af75749cd3"
      unitRef="shares">316407000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTgtMS0xLTEzMzY2OA_230449d4-31f1-4492-bb1d-f6f3bad92399"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49f8305cf2864dbda8cea2f22f63e356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTktMS0xLTEzMzY2OA_6e6c707b-3c9e-4241-9fd1-81c3ba1b12c0"
      unitRef="usd">2865964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89ea0ca2684e4b76aaeb8cfe35fffb2a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEwLTEtMS0xMzM2Njg_d3496272-a97a-468e-a96c-003457364c27"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTExLTEtMS0xMzM2Njg_bb8053ee-c8ea-40e0-b278-5e0c6bc7f973"
      unitRef="usd">1920635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09e0f207870b4fc7922227f8a820157a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEyLTEtMS0xMzM2Njg_3b92fa94-7445-42b2-a009-a105521ab68a"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTEzLTEtMS0xMzM2Njg_6462d61b-a041-460c-a5d3-1200b7e302e1"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f1d98977d25401ab5199bd95b2ac683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTE0LTEtMS0xMzM2Njg_7c92d5e0-9e40-4ec4-8759-3e3309d056b0"
      unitRef="usd">-2317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTphYzJiNTNiNmM5MmY0ZDcyOTQ1MWI4YTlmODFmMzMwOS90YWJsZXJhbmdlOmFjMmI1M2I2YzkyZjRkNzI5NDUxYjhhOWY4MWYzMzA5XzI5LTE1LTEtMS0xMzM2Njg_225a07f8-ac69-4c0f-ae0f-6bd1ff2e9baa"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMS0xLTEtMTMzNjY4_caff5455-1f57-4976-8c70-d2ca9bfb4d35"
      unitRef="shares">388135000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ffbc7e40f849c79a2370de012b62a7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMi0xLTEtMTMzNjY4_6af9867a-30f7-4361-b295-c0a7eb63b99a"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMy0xLTEtMTMzNjY4_05451fe5-9e1c-4007-8699-dac7a1a19fcd"
      unitRef="shares">218976000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i193b3040cd2347e7addc1373ea7a38fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNC0xLTEtMTMzNjY4_f83f88b8-93f3-45a1-84eb-b5920967988a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNS0xLTEtMTMzNjY4_6c2157d9-526f-43ab-9daa-72c0f04a858a"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i921629adeeab477cbc0cc2df2b75eef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNi0xLTEtMTMzNjY4_a102d308-ea6d-4355-a5dc-3ba76a0c5e57"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItNy0xLTEtMTMzNjY4_9ed89a76-0f9c-40cb-8c41-17af75749cd3"
      unitRef="shares">316407000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3be8c068c0e4210b0b20061ca476efd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItOC0xLTEtMTMzNjY4_230449d4-31f1-4492-bb1d-f6f3bad92399"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49f8305cf2864dbda8cea2f22f63e356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItOS0xLTEtMTMzNjY4_6e6c707b-3c9e-4241-9fd1-81c3ba1b12c0"
      unitRef="usd">2865964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ac0c49e2e974c0b84d4018e6f63c303_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTEtMS0xLTEzMzY2OA_bb8053ee-c8ea-40e0-b278-5e0c6bc7f973"
      unitRef="usd">1920635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09e0f207870b4fc7922227f8a820157a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTItMS0xLTEzMzY2OA_3b92fa94-7445-42b2-a009-a105521ab68a"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTMtMS0xLTEzMzY2OA_6462d61b-a041-460c-a5d3-1200b7e302e1"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f1d98977d25401ab5199bd95b2ac683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTQtMS0xLTEzMzY2OA_7c92d5e0-9e40-4ec4-8759-3e3309d056b0"
      unitRef="usd">-2317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzItMTUtMS0xLTEzMzY2OA_225a07f8-ac69-4c0f-ae0f-6bd1ff2e9baa"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzMtMTMtMS0xLTEzMzY2OA_58512f2d-6cab-484d-90bb-cf3c86424ad0"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzMtMTUtMS0xLTEzMzY2OA_04c0293a-905b-4d22-bf83-2e3ed5ca7921"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzQtMTMtMS0xLTEzMzY2OA_9e8d5ff7-bd18-460a-b471-7c315213cbca"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzQtMTUtMS0xLTEzMzY2OA_64a338c9-99b5-45be-af0d-a256ecb71791"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246M2E0Y2EyNmViYjAyNGU3MTkyMTJjNjc0ZTU3ODVjMTBfMTU_52190445-72dd-4d3c-88f2-8c9387d6d02a"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMTEtMS0xLTEzMzY2OA_7e44a916-fc26-41e4-a7f9-68f5c909a702"
      unitRef="usd">285184000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzUtMTUtMS0xLTEzMzY2OA_2a2dc9fa-063a-49e6-a1ac-e43116da0027"
      unitRef="usd">285184000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMS0xLTEtMTMzNjY4_a805b977-4677-4a0e-861b-b60d48754d86"
      unitRef="shares">-44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMi0xLTEtMTMzNjY4_ce6d3768-3208-4580-a6b7-8ee49c92d035"
      unitRef="usd">-4000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i06aaf4b76d2b48d6a71c3deedfa9f5d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMy0xLTEtMTMzNjY4_7e241194-0ae8-4379-9ee7-c9d6a8ab6dcc"
      unitRef="shares">44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i84e1faf18b8b44d991d1d1a4c417f179_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtNy0xLTEtMTMzNjY4_19f2788c-61dd-4954-9736-337b63195664"
      unitRef="shares">-44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i638daa38667341c8878e93ae45445868_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtOS0xLTEtMTMzNjY4_21391e9d-91ef-4a12-9acb-181b6e1e0cb1"
      unitRef="usd">-639126000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTItMS0xLTEzMzY2OA_819927b0-4109-4ff3-b6c2-ee58ffe995d7"
      unitRef="usd">-4242000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTMtMS0xLTEzMzY2OA_97f3bea1-f615-4a86-89c3-7edb0fcb6df9"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i7af311935ef147839b589ff0401a4cc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTQtMS0xLTEzMzY2OA_4f0ad4fc-eae0-43c0-aa38-0c952bc16ef9"
      unitRef="usd">398000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzYtMTUtMS0xLTEzMzY2OA_46338205-8306-4dc1-89f1-516195f629f6"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i44fbf5e550314083a9bb66cca9fd7dfe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctMS0xLTEtMTMzNjY4_996d9e8e-e99e-4d8b-bd3e-c1df5727d83d"
      unitRef="shares">65000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i638daa38667341c8878e93ae45445868_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctOS0xLTEtMTMzNjY4_96c52086-aa25-406f-bd2a-204cf4003fa1"
      unitRef="usd">2443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzctMTUtMS0xLTEzMzY2OA_5d037665-db9a-4223-9fd9-62c53eed548f"
      unitRef="usd">2443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i794034549b0041f6acfc891ce5e23edc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTEtMS0xLTEzMzY2OA_8d455da9-f2b8-4f05-8563-6a191f9721c9"
      unitRef="usd">619728000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTMtMS0xLTEzMzY2OA_09840526-69b8-4d55-a3f1-27a14752625c"
      unitRef="usd">621473000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzgtMTUtMS0xLTEzMzY2OA_ac69a0ff-e264-4f89-9302-b7c499d5d748"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTEyLTEtMS0xMzM2Njg_115c3312-2f12-4e9e-b0c9-272d1951f49e"
      unitRef="usd">6335000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTEzLTEtMS0xMzM2Njg_fe36128d-ed18-48c1-8acf-561152241847"
      unitRef="usd">5265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEwLTE1LTEtMS0xMzM2Njg_684cee1a-fa0c-4a13-a600-60b9248ae261"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id8d298a078e24a8cb076ce7b36f31c57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTEyLTEtMS0xMzM2Njg_5b0ead00-35b8-4555-9bc1-6798b5298d95"
      unitRef="usd">28481000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTEzLTEtMS0xMzM2Njg_b89f2955-1940-47d7-98ad-c22ca53772a1"
      unitRef="usd">22415000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzExLTE1LTEtMS0xMzM2Njg_86c0ee20-6b57-4207-a090-571b67543539"
      unitRef="usd">50896000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id7f5fba4c66c4d59b458232cfefd397b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEtMS0xLTEzMzY2OA_acbf6ecc-148b-4f41-93e6-3cab747b9116"
      unitRef="shares">432963000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7f5fba4c66c4d59b458232cfefd397b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTItMS0xLTEzMzY2OA_7898e690-c452-4bc8-adaa-5ed542e21ba5"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i388294e0fecc48b7acef50ad301ac37c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTMtMS0xLTEzMzY2OA_d778bfd2-6eb8-4b4d-b6b3-f11c9f3df485"
      unitRef="shares">174213000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i388294e0fecc48b7acef50ad301ac37c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTQtMS0xLTEzMzY2OA_19969b1a-5d4b-45c0-bda3-674eadca16f3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4ca490efe8f34a918c292b71f44885d9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTUtMS0xLTEzMzY2OA_47dceb0a-0458-4e2c-831e-197d73d732ed"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ca490efe8f34a918c292b71f44885d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTYtMS0xLTEzMzY2OA_5883613e-b631-425d-b1ea-60bfe300b87c"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i8ebba7acc969439b987dcc2d0fba6673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTctMS0xLTEzMzY2OA_02c86bc0-b9dc-4278-8f9a-87e4eb32f64c"
      unitRef="shares">361170000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ebba7acc969439b987dcc2d0fba6673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTgtMS0xLTEzMzY2OA_920910e2-8f00-4a97-8866-a7c1e38f91f9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idec2f808579b4b78902a87ec4cc91f2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTktMS0xLTEzMzY2OA_150b48c4-cdf7-430b-9c14-3bd1322f6372"
      unitRef="usd">3507533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i852db36c0318454ea53dd42de40f5456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTExLTEtMS0xMzM2Njg_f00241eb-64f7-4a03-9b40-7be1184d8f6b"
      unitRef="usd">2255179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49f12c6f1519441d92c1fb354e0c1a55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEyLTEtMS0xMzM2Njg_94d2dbab-17a1-4d6f-aafd-e984e52dba31"
      unitRef="usd">16491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTEzLTEtMS0xMzM2Njg_0803099c-8296-4588-85cb-201a8f9f79e8"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i143cf5791aaf471fa5e1a7b574902892_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTE0LTEtMS0xMzM2Njg_e28dd15c-96d9-4182-89f8-61a3da842c11"
      unitRef="usd">-2715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzEzLTE1LTEtMS0xMzM2Njg_e82ca9dd-7a7b-4f19-8639-e16738ab6b42"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE0LTEzLTEtMS0xODg4MTI_9215db52-c4b6-4d58-91ec-a933df51a975"
      unitRef="usd">11596000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE0LTE1LTEtMS0xODg4MTI_65dd6b0b-fc98-4668-bc22-be1522e0da7c"
      unitRef="usd">11596000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE1LTEzLTEtMS0xODg4MTI_7552f6b3-42a5-4491-ad1a-0c5675965c9f"
      unitRef="usd">604248000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE1LTE1LTEtMS0xODg4MTI_8d7d9d57-af13-4796-98e9-1d39bb1206ff"
      unitRef="usd">604248000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTAtMS0xLTE4ODgxMi90ZXh0cmVnaW9uOmZiZGQ4ZTJiNGYzMTQ3Yzk5YTdlZDkzOTI2ODZhOTcxXzU0OTc1NTgxMzg5MjM_42d6a16c-a901-4e37-8cf4-8f238211c16b"
      unitRef="usdPerShare">0.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTExLTEtMS0xODg4MTI_ffc9c5b1-8301-49ec-bf0d-1f7d5059e12c"
      unitRef="usd">333322000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE2LTE1LTEtMS0xODg4MTI_e0e01790-8744-4c65-8279-b59e79dab51d"
      unitRef="usd">333322000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEtMS0xLTE4ODgxMg_1a1c5e6c-0476-4a6c-b16c-2257bdd60f35"
      unitRef="shares">-10155000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTItMS0xLTE4ODgxMg_08935afa-e756-4c54-9378-b0967d9341c7"
      unitRef="usd">-1000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i9ec20854f553421a86396e564097af71_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTMtMS0xLTE4ODgxMg_f24bffb1-b61a-4c53-b70b-5e74633a7c88"
      unitRef="shares">10155000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="id43eea863eed4e989a4af810e68237ed_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTctMS0xLTE4ODgxMg_968da5b8-3b77-4177-9cd7-eb6e39830031"
      unitRef="shares">-10155000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTktMS0xLTE4ODgxMg_8c774dba-33ba-4913-83d3-356394c471c6"
      unitRef="usd">-156457000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEyLTEtMS0xODg4MTI_60661919-b762-493d-86c1-7a0966a0eb07"
      unitRef="usd">-1127000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTEzLTEtMS0xODg4MTI_e3d4f2e6-5a3d-4b9c-a65b-419bc818aad5"
      unitRef="usd">157494000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icd8756959c734531850ee0869d7a395d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTE0LTEtMS0xODg4MTI_ac7068ab-5542-4d8f-89dd-9e2cd561d5e2"
      unitRef="usd">91000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE3LTE1LTEtMS0xODg4MTI_fb393b44-946c-4ab6-a2d0-ced6a2d0c60c"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i76611d21cb2f4bd69765b8bb39071499_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTEtMS0xLTE4ODgxMg_eac933e3-f5ac-4465-a974-899e1990b6b6"
      unitRef="shares">48000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica13389fac0c4ba4b7bda25a5cba126b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTktMS0xLTE4ODgxMg_43317987-1848-4152-864e-c2a9c2a0b202"
      unitRef="usd">2170000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE4LTE1LTEtMS0xODg4MTI_f35adf1f-e8db-4dbb-b2d4-49dba4f329e1"
      unitRef="usd">2170000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="ic2a19f3033d147bcbec4f0b128eaf6dd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTExLTEtMS0xODg4MTI_627113a2-1002-4072-a7ef-12a20a0ed79a"
      unitRef="usd">42832000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTEzLTEtMS0xODg4MTI_e1715b49-1392-4059-9e4d-c11ae254320b"
      unitRef="usd">187232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzE5LTE1LTEtMS0xODg4MTI_992e1127-85f3-4765-a80f-aeffaa948f8b"
      unitRef="usd">230064000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTEyLTEtMS0xODg4MTI_ebd391a6-f9c5-4d1e-8153-ccee0d19c7e8"
      unitRef="usd">14262000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTEzLTEtMS0xODg4MTI_09b72629-f63a-4746-b0a6-b013bce622e8"
      unitRef="usd">9738000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIxLTE1LTEtMS0xODg4MTI_02e2a847-fc6e-409e-8698-25a928dac688"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ifa3ca88876a84592aadff9be8d3615ee_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTEyLTEtMS0xODg4MTI_d8c12338-4ca2-469d-bcd3-2774696fa557"
      unitRef="usd">31880000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTEzLTEtMS0xODg4MTI_4765ea44-3f77-4f7d-a46c-2acae2e46def"
      unitRef="usd">21552000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzIyLTE1LTEtMS0xODg4MTI_6160f5c8-86f2-40fa-9700-86b270fb08cd"
      unitRef="usd">53432000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ifd4bbb534e9247e69a9f399be66e680d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEtMS0xLTE4ODgxMg_0d30d78c-b72b-42da-b706-c65c8495c8f5"
      unitRef="shares">443166000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd4bbb534e9247e69a9f399be66e680d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTItMS0xLTE4ODgxMg_21548e65-5885-4fa0-bdcf-0da7341db919"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iabd19d54ace74630abbabeca7a180eb9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTMtMS0xLTE4ODgxMg_7405b6d5-e976-4ff8-a08b-8c23f30a3ffc"
      unitRef="shares">164058000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd19d54ace74630abbabeca7a180eb9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTQtMS0xLTE4ODgxMg_29c305c9-66cb-4c0a-bb2f-fa62481ebb1b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2563f49c9d244ee28c8dcc79a588677d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTUtMS0xLTE4ODgxMg_51482ffd-a2b5-41c2-b545-d4c51210bcbb"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2563f49c9d244ee28c8dcc79a588677d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTYtMS0xLTE4ODgxMg_a189c780-bca5-43d5-8ea8-16589aec3661"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTctMS0xLTE4ODgxMg_bc6cc020-45dc-4b21-bfae-71609d81b7ea"
      unitRef="shares">371325000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTgtMS0xLTE4ODgxMg_f6ce6eaa-ed39-45f3-8202-f15d42dde9ea"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia422b9c6dc3d49fa986c24ca134e7dfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTktMS0xLTE4ODgxMg_9e74939f-484c-4b68-87af-ea1529327c4a"
      unitRef="usd">3666160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie02e089bd28e49abaff42a3961b0d5db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTExLTEtMS0xODg4MTI_ef16486b-651b-4360-8c9b-097a4249545a"
      unitRef="usd">1964689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i762c4b988d95468ca6e9ff58ce974d4f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEyLTEtMS0xODg4MTI_c8da362a-7a30-4fc1-b794-1e66ee62899b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica1fc390f90a425883695c27f2ee9af6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTEzLTEtMS0xODg4MTI_109a80af-59e7-4162-8107-edd3ca42c3d5"
      unitRef="usd">3897223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia953612cc13a40389485402ddbb1c92a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTE0LTEtMS0xODg4MTI_4f05b525-0250-4ba2-9304-d173ac0d86b5"
      unitRef="usd">-2806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDYvZnJhZzo4ZmQ2YmJkN2ZkNGY0OGM0YmFhNzlmZjBlN2FiNWM3Yy90YWJsZTowODZlM2NkZTY2NWU0OGI2YmEyNDk2YWQ2MTViOThmZC90YWJsZXJhbmdlOjA4NmUzY2RlNjY1ZTQ4YjZiYTI0OTZhZDYxNWI5OGZkXzI0LTE1LTEtMS0xODg4MTI_42052544-5ea9-478c-8e9a-045b15e311bf"
      unitRef="usd">9525373000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtMS0xLTEtMTMzNjY4_a4b5462d-23b4-4a1f-acaf-58431013f538"
      unitRef="usd">2507236000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtMy0xLTEtMTMzNjY4_5fa0203d-6b1c-40aa-975a-2484c72b1119"
      unitRef="usd">2315854000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMtNS0xLTEtMTMzNjY4_c8140275-a088-42c8-9f1b-ef2b4504b899"
      unitRef="usd">2121923000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtMS0xLTEtMTMzNjY4_e0f82edf-b6d5-4847-8ef0-ef70245db15c"
      unitRef="usd">72943000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtMy0xLTEtMTMzNjY4_6725f5e6-e9a1-44ae-92f1-2b6235fc2826"
      unitRef="usd">151158000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQtNS0xLTEtMTMzNjY4_f3292716-2489-4fe0-95d5-3d5336d579e2"
      unitRef="usd">143753000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtMS0xLTEtMTMzNjY4_989aa86c-3d51-4f03-a02f-27fcd790d751"
      unitRef="usd">69891000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtMy0xLTEtMTMzNjY4_a23946cd-4178-4e0b-944e-c0496f1649b6"
      unitRef="usd">44123000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUtNS0xLTEtMTMzNjY4_7c4883b7-ea52-40b9-a58a-2dbe63a81736"
      unitRef="usd">18305000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtMS0xLTEtMTMzNjY4_a039c45f-a0b1-481c-9e1f-d2677e225579"
      unitRef="usd">39142000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtMy0xLTEtMTMzNjY4_758059c0-2b19-40da-99cb-4f854be213e5"
      unitRef="usd">34384000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzYtNS0xLTEtMTMzNjY4_5a12c893-fe10-4685-ac6c-8c5892291a1f"
      unitRef="usd">42334000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctMS0xLTEtMTMzNjY4_acbdbf1c-3af1-4878-9990-0bc9d3abd99e"
      unitRef="usd">24982000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctMy0xLTEtMTMzNjY4_b2c59d03-1a3d-42ae-a3a6-e615916309a5"
      unitRef="usd">3135000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzctNS0xLTEtMTMzNjY4_b8c98d87-c27a-4b4d-a0c0-16a849ee4b37"
      unitRef="usd">7704000</us-gaap:ProceedsFromInterestReceived>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtMS0xLTEtMTMzNjY4_7aff184e-ec10-4b53-ac3c-ea39bebc4b2f"
      unitRef="usd">0</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtMy0xLTEtMTMzNjY4_a669f371-388b-4cbf-ac86-1a5ddbbc184c"
      unitRef="usd">34660000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzgtNS0xLTEtMTMzNjY4_d1694eff-182b-4b3e-87e9-d755f78e62d8"
      unitRef="usd">45252000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktMS0xLTEtMTMzNjY4_1479a902-fb17-4f9e-ba49-bd29e9d899ae"
      unitRef="usd">0</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktMy0xLTEtMTMzNjY4_604f3496-2b3b-4fad-965a-fd19b1a3ccb8"
      unitRef="usd">34660000</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzktNS0xLTEtMTMzNjY4_16239da8-87df-4515-9e82-8895673b8f02"
      unitRef="usd">0</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTEtMS0xLTEzMzY2OA_8ba1dace-b704-4e84-921b-b1a006f5464c"
      unitRef="usd">0</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTMtMS0xLTEzMzY2OA_aae1feee-9fb6-412f-9feb-43e50d073bb7"
      unitRef="usd">16093000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEwLTUtMS0xLTEzMzY2OA_00898745-e06d-4dc2-b16b-f7b076ca5d13"
      unitRef="usd">35448000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTEtMS0xLTEzMzY2OA_63a2408c-34b2-4217-bc5d-c6a0b7ef1fe0"
      unitRef="usd">2106000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTMtMS0xLTEzMzY2OA_02dab5d5-4792-46b2-b08a-deb0a2ede144"
      unitRef="usd">6876000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzExLTUtMS0xLTEzMzY2OA_248ee991-875b-4fe8-9083-157bdbe0f83f"
      unitRef="usd">20479000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTEtMS0xLTEzMzY2OA_be98fddb-7fae-4a10-8c49-a6176bf93040"
      unitRef="usd">175000000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTMtMS0xLTEzMzY2OA_c2d1383d-eaff-4fde-b6cd-da103e3eb472"
      unitRef="usd">193208000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEyLTUtMS0xLTEzMzY2OA_c4574e53-acff-470d-a512-c4e49fb93b1b"
      unitRef="usd">5810000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTEtMS0xLTEzMzY2OA_0dda1b44-2b00-4ce3-80e4-f51ce6d55848"
      unitRef="usd">222969000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTMtMS0xLTEzMzY2OA_f3045c03-2b70-47ee-9237-e3da52ba249c"
      unitRef="usd">184511000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzEzLTUtMS0xLTEzMzY2OA_ec78d6a7-88de-44fe-ab9e-bc944e170dae"
      unitRef="usd">179709000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <us-gaap:InterestPaidNet
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTEtMS0xLTEzMzY2OA_ecebc471-03cb-4c36-9421-cead3bbae9f2"
      unitRef="usd">170139000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTMtMS0xLTEzMzY2OA_a95fa19e-114b-4006-9158-2da6b37fe5e7"
      unitRef="usd">130430000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE1LTUtMS0xLTEzMzY2OA_22d7ae09-1e9a-47a9-8768-a8837450aa33"
      unitRef="usd">103196000</us-gaap:InterestPaidNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTEtMS0xLTEzMzY2OA_e204bbce-549e-46cb-ad4b-3ab2e8ada84e"
      unitRef="usd">2143980000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTMtMS0xLTEzMzY2OA_1b2826ca-a123-45e1-b6f7-7672148b24b6"
      unitRef="usd">2017536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzE3LTUtMS0xLTEzMzY2OA_88772489-4420-4d88-ae25-db0a67c12e04"
      unitRef="usd">2034629000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTEtMS0xLTEzMzY2OA_a43b5d68-9bcb-4dde-89b9-dc4c0aa9c134"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTMtMS0xLTEzMzY2OA_4881fb95-e29b-41d5-a2ee-bb1167d326d7"
      unitRef="usd">523000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIwLTUtMS0xLTEzMzY2OA_1c2b93a2-7c36-46d8-b5e3-68a5614a070a"
      unitRef="usd">15084000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTEtMS0xLTEzMzY2OA_02f54d40-77a9-414b-a7ec-d7429475227b"
      unitRef="usd">9896000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTMtMS0xLTEzMzY2OA_b5375276-6c64-43ed-9730-88ee7711a4c1"
      unitRef="usd">34855000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIxLTUtMS0xLTEzMzY2OA_4104d3a9-64c8-4c60-acaa-c6c37ed24a44"
      unitRef="usd">40155000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTEtMS0xLTEzMzY2OA_d6c11972-3edc-4a12-a833-cea88217ec59"
      unitRef="usd">87785000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTMtMS0xLTEzMzY2OA_f17343c0-573d-41d0-85af-ff40782319a9"
      unitRef="usd">135134000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIyLTUtMS0xLTEzMzY2OA_36ed0b29-4d17-486c-b9e1-b40417891f7f"
      unitRef="usd">50000000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTEtMS0xLTEzMzY2OA_dde5b5f3-b848-405c-9ae1-cd505c5308cb"
      unitRef="usd">211158000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTMtMS0xLTEzMzY2OA_e5fc8681-8882-492b-88b9-73adaac3bfc7"
      unitRef="usd">115957000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzIzLTUtMS0xLTEzMzY2OA_039868b0-1d0d-4d63-9acf-9899c3d97f63"
      unitRef="usd">384840000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTEtMS0xLTEzMzY2OA_dad203df-4105-412d-812a-88e4b79036a0"
      unitRef="usd">479559000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTMtMS0xLTEzMzY2OA_f90a4651-2a64-4bea-b683-18a16be3e5f6"
      unitRef="usd">70441000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI0LTUtMS0xLTEzMzY2OA_86b4407a-e509-49d3-93e0-213f000b2b6f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTEtMS0xLTEzMzY2OA_b03d30e2-a93b-4b28-8306-fee7f7038073"
      unitRef="usd">542044000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTMtMS0xLTEzMzY2OA_da2507e2-97bd-4433-9fb2-e6bb80443f15"
      unitRef="usd">62500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI1LTUtMS0xLTEzMzY2OA_9654934b-0d42-4c38-8ede-153aced4935c"
      unitRef="usd">3000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTEtMS0xLTEzMzY2OA_cdd5854e-ec53-4d90-b7a4-f410ac66992c"
      unitRef="usd">234869000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTMtMS0xLTEzMzY2OA_4f5ebb00-5de9-4ca6-96f1-b9c3e048a7e1"
      unitRef="usd">1196579000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI2LTUtMS0xLTEzMzY2OA_c39aaf64-12c3-4030-8ff9-6bc57eacd05e"
      unitRef="usd">1705283000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTEtMS0xLTEzMzY2OA_e6a7c325-1951-4595-9693-9365b7167495"
      unitRef="usd">792341000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTMtMS0xLTEzMzY2OA_b07d7f54-4338-4a96-ab10-47558c975de2"
      unitRef="usd">1597851000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI3LTUtMS0xLTEzMzY2OA_39beb6d8-f9cb-4ee4-8720-2068d53dc55b"
      unitRef="usd">815440000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTEtMS0xLTEzMzY2OA_d9577a6d-1bee-4d09-b0fc-ca714bfba11d"
      unitRef="usd">1741640000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTMtMS0xLTEzMzY2OA_e7daa522-9253-4405-ab80-727d3223fc30"
      unitRef="usd">2191502000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzI5LTUtMS0xLTEzMzY2OA_12970e43-9107-4278-9a45-4fc8d99f05f2"
      unitRef="usd">2182246000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTEtMS0xLTEzMzY2OA_735a46a4-44ab-40cd-9b3c-e7b40b7b78d8"
      unitRef="usd">21215000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTMtMS0xLTEzMzY2OA_536d40ca-b913-47a2-bda5-d5ac3cbffa82"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMwLTUtMS0xLTEzMzY2OA_50f7b692-1916-42ab-b2d7-aec86afb0b02"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <rprx:PaymentsForMilestones
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTEtMS0xLTEzMzY2OA_059142c5-d26a-4411-9635-80e70c2a30d2"
      unitRef="usd">0</rprx:PaymentsForMilestones>
    <rprx:PaymentsForMilestones
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTMtMS0xLTEzMzY2OA_085158be-b1d3-4ee6-bf69-a172aa04dc9c"
      unitRef="usd">18600000</rprx:PaymentsForMilestones>
    <rprx:PaymentsForMilestones
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMxLTUtMS0xLTEzMzY2OA_46354eee-fa4d-4ae5-9a72-dcc02025c27b"
      unitRef="usd">0</rprx:PaymentsForMilestones>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTEtMS0xLTEzMzY2OA_80b1ae26-494f-468f-8ee2-4fbc78c49372"
      unitRef="usd">-1029421000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTMtMS0xLTEzMzY2OA_d863fea5-9938-40c1-bac6-830efb7e02a4"
      unitRef="usd">-1870280000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzMyLTUtMS0xLTEzMzY2OA_e5891ef0-d340-40a7-a8c5-46877979b09e"
      unitRef="usd">-2759320000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTEtMS0xLTEzMzY2OA_4c49ef5d-fbf8-4f6b-b20e-6488efe3ccf9"
      unitRef="usd">0</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTMtMS0xLTEzMzY2OA_8f7265ac-8331-4f6d-a695-04d6c4b9a100"
      unitRef="usd">0</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM1LTUtMS0xLTEzMzY2OA_43e5a923-5d80-44d0-a511-aed46b3729e6"
      unitRef="usd">285353000</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTEtMS0xLTEzMzY2OA_2830e177-43c7-4256-8a0e-d83143dee01e"
      unitRef="usd">441963000</rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts>
    <rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTMtMS0xLTEzMzY2OA_150f999d-f260-4400-9b4d-2de9e826c6d8"
      unitRef="usd">479604000</rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts>
    <rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM2LTUtMS0xLTEzMzY2OA_43307db6-b4d7-4ff0-a23a-2306e32fa4a0"
      unitRef="usd">543952000</rprx:PaymentsToNoncontrollingInterestsRoyaltyReceipts>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTEtMS0xLTIzNTE3NQ_5128f5c6-9c7e-48ad-8ec1-60c262a32b2e"
      unitRef="usd">31301000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTMtMS0xLTIzNTE3NQ_153ab701-3318-410c-bf9b-acbb6a8fe6de"
      unitRef="usd">20367000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTUtMS0xLTIzNTE3NQ_4c53f1f9-35bf-427e-a102-62416bfce332"
      unitRef="usd">67654000</rprx:PaymentsToNoncontrollingInterestsOther>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTEtMS0xLTEzMzY2OA_ace21dbf-8614-4561-8ed0-4ffe3bc942f5"
      unitRef="usd">144115000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTMtMS0xLTEzMzY2OA_00f99ee9-bbfa-453a-bd3a-d812439d6234"
      unitRef="usd">133433000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM3LTUtMS0xLTEzMzY2OA_b3095dce-2d99-4dae-b6ad-5cc57c591024"
      unitRef="usd">113481000</us-gaap:PaymentsToMinorityShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTEtMS0xLTEzMzY2OA_71c6d56d-1c03-45d0-a48b-272c7efe077a"
      unitRef="usd">333322000</rprx:PaymentOfDividendsToShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTMtMS0xLTEzMzY2OA_cb23f444-d703-4821-9ea5-3c5a36c15b49"
      unitRef="usd">285184000</rprx:PaymentOfDividendsToShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzM4LTUtMS0xLTEzMzY2OA_54c1bd45-6d20-45ca-a693-60905e714584"
      unitRef="usd">112490000</rprx:PaymentOfDividendsToShareholders>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTEtMS0xLTEzMzY2OA_20373b4a-d9fc-4f77-8738-b7277e81e820"
      unitRef="usd">1059000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTMtMS0xLTEzMzY2OA_c282e394-73db-4368-89c2-c51a7ce77b37"
      unitRef="usd">7339000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQwLTUtMS0xLTEzMzY2OA_2361b717-984f-485c-ab80-75ba66ebb75a"
      unitRef="usd">8482000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTEtMS0xLTEzMzY2OA_a612e264-92df-4770-9b80-a9c974976e1d"
      unitRef="usd">6133000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTMtMS0xLTEzMzY2OA_26b1edad-5f2a-4ec0-b3c8-c805da486490"
      unitRef="usd">36874000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQxLTUtMS0xLTEzMzY2OA_ff2e4a23-7b7f-4249-bb12-3220ad37bdf7"
      unitRef="usd">58957000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTEtMS0xLTEzMzY2OA_12908f57-513b-49b0-8de4-b550e4b28d61"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTMtMS0xLTEzMzY2OA_cb4e0f83-2a0d-4a44-9f84-5125e3bb1ad4"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQyLTUtMS0xLTEzMzY2OA_9e1596c2-8745-4b18-a4a7-3d80e90de839"
      unitRef="usd">94200000</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTEtMS0xLTEzMzY2OA_6bf829d8-c64e-4fe5-887a-52e9cb5cc278"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTMtMS0xLTEzMzY2OA_95dc9ca1-3ab2-4354-b7e9-a5baec7d5b0f"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQzLTUtMS0xLTEzMzY2OA_e4e603ed-7322-40d9-9f9e-20c85732d87b"
      unitRef="usd">11116196000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTEtMS0xLTEzMzY2OA_7e4e1125-54c1-468b-99a5-8eb3bdab8f90"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTMtMS0xLTEzMzY2OA_f7afa381-70a1-49d8-8746-31a0a1bc2974"
      unitRef="usd">1272533000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ0LTUtMS0xLTEzMzY2OA_02dbbc78-ee6e-4b98-bcd4-fcb7b81dc895"
      unitRef="usd">11891030000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTEtMS0xLTEzMzY2OA_e3624a50-7531-4b17-819b-80085ea7dd0b"
      unitRef="usd">1347000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTMtMS0xLTEzMzY2OA_408a53d5-384e-490b-a981-ca6a4abcf42e"
      unitRef="usd">13046000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ1LTUtMS0xLTEzMzY2OA_8713e3b0-0653-490f-9a06-a74d30c6a30a"
      unitRef="usd">46715000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTEtMS0xLTEzMzY2OA_e624e010-cdb4-48d4-a606-0bb5ac8c749c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTMtMS0xLTEzMzY2OA_ffc621c7-b249-4978-aa75-b612d1c08729"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ3LTUtMS0xLTEzMzY2OA_1ffd2843-6602-4e0e-b6cb-b04d990e7b7f"
      unitRef="usd">1908744000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTEtMS0xLTEzMzY2OA_8775e2bc-67a9-4872-b35f-f045569a0648"
      unitRef="usd">-944856000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTMtMS0xLTEzMzY2OA_12e3115d-3541-4240-99c2-0b4a4b1a7a10"
      unitRef="usd">385112000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzQ5LTUtMS0xLTEzMzY2OA_3e40233d-396c-4371-982f-9d64ca2d8926"
      unitRef="usd">1487172000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTEtMS0xLTEzMzY2OA_b0ab2408-ac8b-4a86-97d9-2eac65c9266a"
      unitRef="usd">169703000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTMtMS0xLTEzMzY2OA_20b7710f-e472-4b10-b790-a1234c4b0142"
      unitRef="usd">532368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUxLTUtMS0xLTEzMzY2OA_08efec1d-108d-42ef-9798-c496baa0ab26"
      unitRef="usd">762481000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTEtMS0xLTE3ODM3NA_e1272ab0-5c25-4cca-a8f5-2ad095028c9c"
      unitRef="usd">1541048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTMtMS0xLTE3ODM3NA_b9efdb82-5ce5-4ea6-ad5d-7b9c6b31866b"
      unitRef="usd">1008680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6924ffcc56464af49725a154112a2c81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzUzLTUtMS0xLTE3ODM3NA_6296c58e-e100-4443-96ac-31d50f5e20bb"
      unitRef="usd">246199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTEtMS0xLTE3ODM3NA_9a06ce8b-4fc6-4ea0-9fbf-ef9493ca7acb"
      unitRef="usd">1710751000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTMtMS0xLTE3ODM3NA_9f9e4703-f6f3-431b-b38e-943922ac0849"
      unitRef="usd">1541048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDkvZnJhZzo2NjI2OGI2ZTNkNjg0NzJiYTZkYTJkOTQ3YmFmNmYxZS90YWJsZToyNjU5MDk4MjU4MDE0OTgwYTlkMmI2ZDQ4YWU2ZDYwMS90YWJsZXJhbmdlOjI2NTkwOTgyNTgwMTQ5ODBhOWQyYjZkNDhhZTZkNjAxXzU0LTUtMS0xLTE3ODM3NA_e09bf596-c8c0-4f26-becf-60ab4e870f4e"
      unitRef="usd">1008680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4Xzc5NDA_543b6359-2076-465b-9c56-6edc6ea482f3">Organization and Purpose &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the IPO of our Class A ordinary shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We control Royalty Pharma Holdings Ltd (&#x201c;RP Holdings&#x201d;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings&#x2019; Class A ordinary shares (the &#x201c;RP Holdings Class A Interests&#x201d;) and RP Holdings&#x2019; Class B ordinary shares (the &#x201c;RP Holdings Class B Interests&#x201d;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#x201c;RPI 2019 ICAV&#x201d;), which is an Irish collective asset management entity, and is the successor to Royalty Pharma Investments, an Irish unit trust (&#x201c;Old RPI&#x201d;). RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#x201c;Continuing Investors Partnerships&#x201d;), and Royalty Pharma plc. Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the &#x201c;Legacy Investors Partnerships&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RP Management, LLC (the &#x201c;Manager&#x201d;), a Delaware limited liability company, is responsible for our management, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including our day-to-day operations, pursuant to advisory and management agreements (collectively, the &#x201c;Management Agreement&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer (defined below) and before the consummation of the IPO, &#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to RPI 2019 ICAV. Prior to the Exchange Offer, &#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Old RPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#x2014;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer Transactions &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consummated an exchange offer on February 11, 2020 (the &#x201c;Exchange Offer&#x201d;) to facilitate the IPO. Through the Exchange Offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The Exchange Offer together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#x201c;Exchange Offer Transactions.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#x201c;RPI Intermediate FT&#x201d;). We are entitled to 82% of the economics of Old RPI&#x2019;s wholly-owned subsidiar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; RPI Finance Trust, a Delaware statutory trust (&#x201c;RPIFT&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and, an Irish private limited company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#x201c;RPCT&#x201d;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#x201c;RPSFT&#x201d;), which is wholly owned by Royalty Pharma Select, an Irish unit trust.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the date of the Exchange Offer until the expiration of the Legacy Investors Partnerships&#x2019; investment period on June 30, 2020 (the &#x201c;Legacy Date&#x201d;), the Legacy Investors Partnerships could participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Exchange Offer, the Legacy Investors Partnerships and RPI Intermediate FT entered into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;senior &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;credit facilities in the amount of $1.3&#160;billion and $6.0&#160;billion, respectively, the proceeds of which were used to repay the $6.3&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the senior credit facilities, RPI Intermediate FT repaid $5.2&#160;billion, its pro rata portion of RPIFT&#x2019;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IPO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#x201c;RPRX&#x201d;, in which we issued 89,334&#160;thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652&#160;thousand Class A ordinary shares and 17,682&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire 100% of RP Holdings Class A Interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, according to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176&#160;thousand RP Holdings Class B Interests into an aggregate of 294,176&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc. Refer to Note 12&#x2013;Shareholders&#x2019; Equity for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="i280e643fdef0483689f89d2627e67117_D20200211-20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NDY_46d34583-7f95-4f0f-b270-6f3f77527bf9"
      unitRef="number">0.82</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MjY_c85cc9f6-8d63-4cd8-955e-a48b51d1cbf0"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i349c01ea378b45a6bbaa2138dcd0f70d_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MzE_0bd40d35-6134-4f9f-a44e-74d969ef793a"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i955ef8f092f6410b8368691a366b3ccd_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1MzY_be7bfdbf-8964-4581-9ed1-3301b2374565"
      unitRef="number">0.66</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ia00f566083814766b799de815b74eb68_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NDE_7750d863-54d3-43a8-a053-1d675656a86d"
      unitRef="number">0.34</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id6272e7fd11d44329684f5f26db3b0e5_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NTE_3c8bcf9d-ebaa-452e-aa6e-ad49450121fc"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieabc44fc792946909b8b90c908c11b2a_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1NjU_08928fff-d3e6-40f5-b090-b9d618e543ba"
      unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i12ff36e2c24f4dfba76ba7b4b27451b6_D20200211-20200211"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1Nzk_1151967d-400a-4844-9bba-90ab0617741d"
      unitRef="usd">6300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0abe73d17656428c858e609114abb39a_D20200211-20200211"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA1OTM_674d478f-c485-4c40-a70b-bcba70d71212"
      unitRef="usd">5200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9572c0d747ab4d80a3666c92eef2f3e7_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MDc_75d89ffa-bfcc-4c86-b95b-c3c9e4fefecb"
      unitRef="shares">89334000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic92461c4b3514d22afb54b7350b5a973_I20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MjQ_649c8fce-ad7d-49c5-b8bf-11bfab0ff199"
      unitRef="usdPerShare">28.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="idec997943fd44095835407fd6f299a6d_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2MzI_7d293379-d1e5-476e-8bc1-49cade2273eb"
      unitRef="shares">71652000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id7d4834e0547457480186ed9fe6cfbed_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2NDk_d5fbf66d-5e1b-4d30-91d3-f4c9454d5c27"
      unitRef="shares">17682000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="idf5b5a5cdfc4467896657cf7dc34567d_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzE2NDkyNjc0NDUwMjE1_b1d1abe5-5c26-4892-aa3f-b7c352b0101a"
      unitRef="number">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2NzI_6afc4df9-04bd-43f9-b55a-e1e64ffc4ade"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i7cdeed76822f459e89ec58e43a1d83ea_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA2OTA_8f4434cc-722a-4286-be7b-d87efa566c05"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA3MDg_c241862a-3337-4462-9bd5-b8b9f1be1abb"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesNotConverted
      contextRef="i5f69710f1a7e45d4ad7dce0663fb8bce_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzEwOTk1MTE2NjA3MjY_c27073ad-c774-41d8-8bcd-ae3a91fe51fa"
      unitRef="shares">241207000</rprx:SaleOfStockNumberOfSharesNotConverted>
    <rprx:CommonStockExchangeRatio
      contextRef="ic6c853fcbec74369a6114e07a900dfc8_I20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTUvZnJhZzo0NDJhYzBjYWI2Zjg0NGE5OGVmY2ExZjU2Y2UzMmQwOC90ZXh0cmVnaW9uOjQ0MmFjMGNhYjZmODQ0YTk4ZWZjYTFmNTZjZTMyZDA4XzUxMTI3MjkwNzQwNzQ2_ffc50781-ba4c-44d5-b8a2-ac4a853e0e0f"
      unitRef="number">1</rprx:CommonStockExchangeRatio>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ5_b94d4ba5-e67f-4d7d-b1e7-32449f6ebe75">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of preparation and use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following management&#x2019;s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI&#x2019;s assets and liabilities at the carrying value reflected on Old RPI&#x2019;s balance sheet as of the date of the Exchange Offer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we became an indirect owner of an 82% economic interest in RPI ICAV, which previously was owned directly by Old RPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report four non-controlling interests: (1) the Legacy Investors Partnerships&#x2019; ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the &#x201c;legacy non-controlling interests&#x201d;). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships&#x2019; ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP&#x2019;s (&#x201c;EPA Holdings&#x201d;) ownership of the RP Holdings&#x2019; Class C ordinary share (the &#x201c;RP Holdings Class C Special Interest&#x201d;). The Continuing Investors Partnerships are referred to as the &#x201c;continuing non-controlling interests.&#x201d; Income will not be allocated to EPA Holdings until certain performance conditions are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bank of America, US Bank&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Scotiabank&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp;amp; Johnson, Merck &amp;amp; Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective and passive in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible royalty assets. The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#x201c;ASC&#x201d;), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the carrying value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is presented net of the cumulative allowance for changes in expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of the prospective approach to measure our financial royalty assets at amortized cost requires management&#x2019;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Analyst coverage.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#x2019; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; available sell-side equity research analyst consensus sales estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#x2019; consensus sales forecasts to project future sales for products. Based o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#x2019;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial performance.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#x2019; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#x2019;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty duration. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#x2019;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#x2019; models. The most sensitive of these assumptions relates to management&#x2019;s estimate of the royalty duration in the final years of an asset&#x2019;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#x2019;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#x2019;s cumulative allowance, which reduces the net carrying value of the financial royalty asset&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; line item on the consolidated balance sheets, are accompanied by corresponding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provision&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; income or expense. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#x2019;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for current expected credit losses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2016-13&#x201d;) which requires earlier recognition of credit losses. We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets. Any subsequent provision for credit losses is recorded as part of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected future cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status. In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, clinical trial results&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and approval status. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is recognized if, based on available information, it is prob&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from intangible royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We earn royalties on sales by our licensees of Januvia and Janumet (&#x201c;DPP-IV&#x201d;) products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#x2019; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved. We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial instruments and Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets. Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity securities and Available for sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity securities primarily consist of investments in publicly traded equity securities. The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Investments classified as available for sale debt securities are recorded at fair value. We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings. For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;AOCI&#x201d;) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows. A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in non-consolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of operations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#x2019;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in losses/(earnings) of equity method investees&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of operations. The investment is reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#x201c;Avillion entities&#x201d;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development funding expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into transactions where we agree to fund a portion of the research and development (&#x201c;R&amp;amp;D&#x201d;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we account for the funded amounts as R&amp;amp;D expense when we have the ability to obtain the results of the R&amp;amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. If these conditions are not met, we may record the funded amounts as a financial royalty asset. We may  fund R&amp;amp;D upfront or over time as the underlying products undergo clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty payments owed to the Company on successfully commercialized products generated from R&amp;amp;D arrangements are recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f contractual criteria for pr&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;oducts arising out of our R&amp;amp;D arrangements are also recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#x201c;the Code&#x201d;) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years presented in the consolidated financial statements&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time. Income from these funding arrangements are subject to U.S. taxation and we record a provision for U.S. income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with respect to this income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16&#x2013;Related Party Transactions that will be subject to U.S. taxation when we begin to recognize revenue&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At that time, we will record a provision for U.S. income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with respect to revenue from the MSCI transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to the U.K.&#x2019;s &#x201c;controlled foreign companies&#x201d; rules (the &#x201c;U.K. CFC Rules&#x201d;). The U.K. CFC Rules, broadly, applies to U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#x201c;Controlled Foreign Company&#x201d;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the U.K. CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material tax charges to arise under the U.K. CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K. income taxes related to this matter&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other taxation matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S. withholding taxes on U.S.-source royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information have been presented for any period prior to that date.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ1_97939cc6-2a40-4578-baf0-cf9e81846646">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQx_ea526279-b6e1-4e22-83a1-90e2de06c6a2">The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU2_802f6d00-6cfd-4650-a961-858955016926">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following management&#x2019;s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI&#x2019;s assets and liabilities at the carrying value reflected on Old RPI&#x2019;s balance sheet as of the date of the Exchange Offer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we became an indirect owner of an 82% economic interest in RPI ICAV, which previously was owned directly by Old RPI.&lt;/span&gt;&lt;/div&gt;We report four non-controlling interests: (1) the Legacy Investors Partnerships&#x2019; ownership of approximately 18% in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the &#x201c;legacy non-controlling interests&#x201d;). The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO. Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships&#x2019; ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP&#x2019;s (&#x201c;EPA Holdings&#x201d;) ownership of the RP Holdings&#x2019; Class C ordinary share (the &#x201c;RP Holdings Class C Special Interest&#x201d;). The Continuing Investors Partnerships are referred to as the &#x201c;continuing non-controlling interests.&#x201d; Income will not be allocated to EPA Holdings until certain performance conditions are met.All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ie00852d0b4174efbaafedf7b99cbfe00_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDgw_037e5aac-30aa-4cec-90b4-67bcb9b08483"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <rprx:NumberOfNoncontrollingInterestsCreated
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1MjE_450c6781-7355-430d-b8c1-6b74e38e9685"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterestsCreated>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i9e6a1451ee4f45f286b64a9a27bc35ec_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1MjM_6025954b-e934-4cb7-af0e-dcf6be8c9c75"
      unitRef="number">0.18</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM5_d29c0385-6c6d-4d7b-b03b-a136ecb45e89">Certain prior period amounts have been reclassified to conform to the current period presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU5_8026698b-ed37-400a-98bb-7d73d23306ea">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bank of America, US Bank&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Scotiabank&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp;amp; Johnson, Merck &amp;amp; Co, Pfizer, Astellas, Novartis, and Gilead. As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32% of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6036429cbf7d478bb21d142552f11fd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4NDIwMDU_fbd5212e-9468-4b98-8efd-c4d665f4cc20"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50014516371a4a1d80e1b25e358497c7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzEwOTk1MTE4Mjg1NTg_e355c619-17e6-4ab8-a455-7deb4466b15f"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUx_d37b6b85-73c5-4d5d-9965-35e48176d460">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDg5_a29c54b2-eb76-41f1-8f8b-170a934d2e6a"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <rprx:RoyaltyAssetsPolicyPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDMz_1aca5241-0602-4a22-8128-1ace733157d4">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective and passive in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible royalty assets. The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</rprx:RoyaltyAssetsPolicyPolicyTextBlock>
    <us-gaap:FinanceLoansAndLeasesReceivablePolicy
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUy_66e95f7e-f1ee-43f1-9b14-abdcfafd2720">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#x201c;ASC&#x201d;), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the carrying value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is presented net of the cumulative allowance for changes in expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of the prospective approach to measure our financial royalty assets at amortized cost requires management&#x2019;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Analyst coverage.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#x2019; consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty. The statistical curves are modelled from a combination of historical trends &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; available sell-side equity research analyst consensus sales estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#x2019; consensus sales forecasts to project future sales for products. Based o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#x2019;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial performance.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#x2019; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#x2019;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty duration. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product&#x2019;s life cycle at which we acquire the royalty. Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#x2019; models. The most sensitive of these assumptions relates to management&#x2019;s estimate of the royalty duration in the final years of an asset&#x2019;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#x2019;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#x2019;s cumulative allowance, which reduces the net carrying value of the financial royalty asset&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; line item on the consolidated balance sheets, are accompanied by corresponding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provision&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; income or expense. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#x2019;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status. In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, clinical trial results&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and approval status. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is recognized if, based on available information, it is prob&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinanceLoansAndLeasesReceivablePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDUw_a9c5f772-b8ab-4799-a7a9-10d99b4c2fe6">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2016-13&#x201d;) which requires earlier recognition of credit losses. We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets. Any subsequent provision for credit losses is recorded as part of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected future cash flows from financial royalty assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM0_634c6b1c-c370-4666-881a-0a3f7ea1b17f">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We earn royalties on sales by our licensees of Januvia and Janumet (&#x201c;DPP-IV&#x201d;) products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#x2019; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved. We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM2_ee8ac652-379d-4bf6-a120-7c43617163e5">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets. Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDU4_588ba653-d1fd-4216-b591-a8e79c4faa7f">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDM3_1ff29d55-6fc4-48c2-b594-3550918ac0a7">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity securities primarily consist of investments in publicly traded equity securities. The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Investments classified as available for sale debt securities are recorded at fair value. We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings. For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;AOCI&#x201d;) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows. A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQ3_0d94a78f-7b67-48fc-b15d-87a45aa01d6c">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQy_817b56ad-0b9a-48eb-bf52-5ab9d104fc7a">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of operations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#x2019;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in losses/(earnings) of equity method investees&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of operations. The investment is reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#x201c;Avillion entities&#x201d;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQz_8772c956-c99f-400d-91db-1d8dd16444b5">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into transactions where we agree to fund a portion of the research and development (&#x201c;R&amp;amp;D&#x201d;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we account for the funded amounts as R&amp;amp;D expense when we have the ability to obtain the results of the R&amp;amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. If these conditions are not met, we may record the funded amounts as a financial royalty asset. We may  fund R&amp;amp;D upfront or over time as the underlying products undergo clinical trials.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty payments owed to the Company on successfully commercialized products generated from R&amp;amp;D arrangements are recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f contractual criteria for pr&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;oducts arising out of our R&amp;amp;D arrangements are also recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDY1_ac987d6e-1549-4952-a07e-7e27e95fe6e6">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#x201c;the Code&#x201d;) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years presented in the consolidated financial statements&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time. Income from these funding arrangements are subject to U.S. taxation and we record a provision for U.S. income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with respect to this income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16&#x2013;Related Party Transactions that will be subject to U.S. taxation when we begin to recognize revenue&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At that time, we will record a provision for U.S. income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with respect to revenue from the MSCI transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to the U.K.&#x2019;s &#x201c;controlled foreign companies&#x201d; rules (the &#x201c;U.K. CFC Rules&#x201d;). The U.K. CFC Rules, broadly, applies to U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#x201c;Controlled Foreign Company&#x201d;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the U.K. CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material tax charges to arise under the U.K. CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K. income taxes related to this matter&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other taxation matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S. withholding taxes on U.S.-source royalty payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzQzMDQw_bb2bc913-6b7a-42cd-8dc1-adfbd302b38e">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information have been presented for any period prior to that date.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <rprx:CommonStockExchangeRatio
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMTgvZnJhZzo1NWJjZjJkNWMwMGU0MjFjYjM5MzZhOGRkZjUzNGRkMS90ZXh0cmVnaW9uOjU1YmNmMmQ1YzAwZTQyMWNiMzkzNmE4ZGRmNTM0ZGQxXzE2NDkyNjc0NjI1NDcy_df50ef5d-4b4c-4a0b-b2d1-7f29046b49ab"
      unitRef="number">1</rprx:CommonStockExchangeRatio>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzY2NTc_8a5a5b4b-4248-4aeb-885d-28906d29e869">Available for Sale Debt Securities &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cytokinetics Commercial Launch Funding &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (&#x201c;Cytokinetics&#x201d;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products. During 2022, we amended the funding agreement to increase the required draw amount, extend the draw period and modify the return for the second and third tranches. As part of the funding agreement, we agreed to provide capital (&#x201c;Cytokinetics Commercial Launch Funding&#x201d;) of up to $300&#160;million, which is comprised of five tranches, including an initial tranche of $50&#160;million that was funded upon closing. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones (&#x201c;Cytokinetics Funding Commitments&#x201d;). Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn, except for the second and third tranches, which each total 2.0 times the amount drawn. As of December 31, 2022, we expect $125&#160;million of the optional $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of December 31, 2022 on the consolidated balance sheets. The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MorphoSys Development Funding Bonds&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#x201c;MorphoSys&#x201d;) to support its acquisition of Constellation Pharmaceuticals, Inc. which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#x201c;Development Funding Bonds&#x201d;), of which MorphoSys was required to draw a minimum of $150&#160;million. Our commitment to fund at least $150&#160;million of the Development Funding Bonds was recognized as the Development Funding Bond Forward as of December 31, 2021. In September 2022, we funded $300&#160;million of the Development Funding Bonds, which represents additional funding of $150&#160;million above the minimum funding commitment (&#x201c;Additional Funding&#x201d;) and the Development Funding Bond Forward was settled at the same time. We expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning in the fourth quarter of 2024. As of December 31, 2022, we have no remaining funding commitment under the Development Funding Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to account for the funded amount of the Development Funding Bonds and the Development Funding Bond Forward as it most accurately reflects the nature of the instruments. The funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. The changes in the fair values of the funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:4.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2019, RPIFT purchased 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd (&#x201c;Biohaven&#x201d;) at a price of $50,100 per preferred share, for a total of $125&#160;million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares beginning in the first quarter of 2021 through the fourth quarter of 2024. In the first quarter of 2021, we began receiving payments of $15.6&#160;million from the quarterly redemption of the Series A Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Biohaven Preferred Shares were classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet as of December 31, 2021. The unrealized changes in the fair value of the Series A Biohaven Preferred Shares were recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of comprehensive income. In 2022, 2021 and 2020, $53.4 million, $50.9 million and $20.6 million of unrealized gains were reclassified from other comprehensive income to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Biohaven Preferred Shares &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#x201c;Series B Biohaven Preferred Share Agreement&#x201d;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#x201c;Commercial Launch Preferred Equity&#x201d;), for a total of $200&#160;million payable on a quarterly basis between the first quarter of 2021 and the fourth quarter of 2024. Our commitment to purchase the Series B Biohaven Preferred Shares was recognized as the Series B Forwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which were recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheet as of December 31, 2021. We believe the fair value option most accurately reflects the nature of these instruments. The changes in fair value of the Series B Biohaven Preferred Shares and Series B Forwards were recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of operations. In 2022, 2021 and 2020, we recognized gains of $122.5&#160;million, $13.5&#160;million and $18.6&#160;million, respectively, related to Series B Biohaven Preferred Shares within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses/(gains) on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2022, Pfizer Inc. (&#x201c;Pfizer&#x201d;) acquired Biohaven, which was a change of control event that accelerated the issuance of all unissued Series B Biohaven Preferred Shares and the redemption of all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. We purchased all remaining unissued Series B Biohaven Preferred Shares simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original purchase price. The Series A Biohaven Preferred Shares were redeemed at a price equal to two times the original purchase price. As of December 31, 2022, we no longer hold any Series A Biohaven Preferred Shares or Series B Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses)/Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(124,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;There are no costs associated with the forwards.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <rprx:LongTermFundingPartnershipAmount
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDgxNTA_830a4d7b-f1f8-43d0-a6e3-3311647ceb4a"
      unitRef="usd">300000000</rprx:LongTermFundingPartnershipAmount>
    <rprx:LongTermFundingPartnershipNumberOfTranches
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzODk4_e1708230-4829-43e8-a300-582f629b36f2"
      unitRef="tranche">5</rprx:LongTermFundingPartnershipNumberOfTranches>
    <rprx:LongTermFundingPartnershipInitialPayment
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDgxMTA_1d82f175-eb2f-45f9-aa24-76879d61b615"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipInitialPayment>
    <rprx:LongTermFundingPartnershipCovenantRequiredAmount
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzUyMzU_260bdcc8-0e65-46b6-bfe8-7781b2e45be1"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipCovenantRequiredAmount>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzU0MDY_6d672792-cd46-4fde-8e2a-ca2319fe6aec"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne
      contextRef="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1Nzc0NTY_0834ae34-9914-420c-8602-9611363eed19"
      unitRef="tranche">6</rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne>
    <rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo
      contextRef="i8ddf32fa2b8b4d32bc52a4bde47a2d1e_I20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1Nzc0NDg_40c2ce31-db2f-4733-864b-240eec2550ef"
      unitRef="tranche">34</rprx:LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo>
    <rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzU2MDQ_c3f9c235-dd85-42b5-9ada-11d1c702b896"
      unitRef="number">1.9</rprx:LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple>
    <rprx:LongTermFundingPartnershipTotalAmountDrawn
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyNzEz_a2c16114-d52d-4a21-b910-6293674f5d66"
      unitRef="number">2.0</rprx:LongTermFundingPartnershipTotalAmountDrawn>
    <rprx:LongTermFundingPartnershipExpectedPayment
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyOTU5_f0b1ee8d-71c4-416a-961f-6267643bec51"
      unitRef="usd">125000000</rprx:LongTermFundingPartnershipExpectedPayment>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDgyOTQ1_176c5789-f1e4-40c5-95b4-ded15ded7a79"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital
      contextRef="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2MzkwMzY_82c3233a-46e4-4242-86b5-374e11f1245c"
      unitRef="usd">350000000</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="iee9e15a4496e41b997a6387918fda39c_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MDU_42ecdb57-25a0-4cbf-b006-22014c14821a"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MTk_1106bc50-532c-4e5a-9ad1-4c2dcf05b094"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="ia5062756e7634788ade2313173101917_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4MzM_0895792d-5b42-4a15-8391-94ec43677f15"
      unitRef="usd">300000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="i5b27d2843a794aa78e16c71951dd44e8_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3MzY4NDc_eb3409c3-1526-4bf2-837a-eb5300387a39"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ic197bc2dabd546778e0292339fc66971_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzOTI0_760f1fe5-4295-4e49-b294-162702cbf1d6"
      unitRef="number">2.2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn
      contextRef="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2Mzk1ODk_c60844b2-4582-4000-b517-078ad3a1c639">P9Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIwOTQ_022942d7-bd41-4115-8908-f5261da8113a"
      unitRef="shares">2495</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="i4cacd8f70f13441b95c9cc9016fab6c9_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIxNjE_bab9f76f-a7c1-4240-9199-f90403150430"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i298d7c29452d4bcdbaf7cd89d8fc8533_D20190405-20190405"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIyMDE_df77d104-3882-4e55-a639-304f2a8b9f59"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ie0c3a6ae85e346a0a5e3381b803dd465_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NTIzMzQ_074754f5-7ada-4b21-a826-857305271695"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ida8d155decaa4354a46677a02d47d72b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDYzODc1_036ef52f-3b90-4495-9f9e-666e190b4743"
      unitRef="usd">15600000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1NzU4NzA_fe95502e-f1f9-4b5a-8a8d-d41bda651a69"
      unitRef="usd">53400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1NzU5MDI_55da8bba-fbbd-4fbd-939a-0bb82aebd2a5"
      unitRef="usd">50900000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzU0OTc1NTgyMTAzMTQ_d4c0f53e-8d5c-454b-af7c-a6953512986a"
      unitRef="usd">20600000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM0NDM_88396530-c934-4933-8303-6cd83043a9a7"
      unitRef="shares">3992</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="i22e23f227041424798f8c0ceb6153a0d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM1MDY_e12d0f57-36a2-4618-9566-ed51269dda1d"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i69adb70664a447e79c77ca4463c73f8c_D20200807-20200807"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzEwOTk1MTE2NDM1ODk_bbdad245-ce5e-49c1-99b0-63bd86f64450"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="i8c0d89f6c512426b935355784dc5eca8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1ODI0NzM_11f191c5-cd7f-4546-a11a-ef48715ca150"
      unitRef="usd">122500000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="i8926e1456d5b484da7113982a2cc6f8b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzQzOTgwNDY1ODI0ODk_e1f1ffe7-dfb2-4aa1-8dab-5e6cd8e657c2"
      unitRef="usd">13500000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="i1b454c53374c471884c05778788c7dae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzM4NDgyOTA3Njg3Njk_740146e3-e5e1-4660-a680-1145a1fd784b"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ie2d8cbe5699f4354a0a0fb8aa7ac335c_D20221003-20221003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc0NDc4MjE4_c932c4de-9a70-4f03-b72c-9ed4c6366fbe"
      unitRef="number">1.8</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple
      contextRef="ib5453ca3d1fa434f832ded0a6cbd1d30_D20221003-20221003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzE2NDkyNjc1MTMwMzA_871eca29-590e-4345-8ef0-882060138678"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPriceMultiple>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90ZXh0cmVnaW9uOjRkNTUyNjg0OGRmZTRmNzViZGVlMTU2ODg2ZGUyODNjXzY2NTg_7946059b-7046-4651-a577-3956ed92084b">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized (Losses)/Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(124,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;amounts paid to purchase the instruments. These instruments were fully redeemed during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;There are no costs associated with the forwards.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMS0xLTEtMTMzNjY4_f61cd4f9-b1b6-4b6e-9abf-fc3b957f3898"
      unitRef="usd">359400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMy0xLTEtMTMzNjY4_d818444c-b2d1-4ecc-a08e-896d806bee31"
      unitRef="usd">131800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItNS0xLTEtMTMzNjY4_346334c4-0128-428a-9210-1c5cb574e0e8"
      unitRef="usd">227600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItNy0xLTEtMTMzNjY4_8c9cf9ab-3d20-4d70-ac5c-93abcd2f9eb5"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItOS0xLTEtMTMzNjY4_39cfa9a0-8da8-4ac3-8613-a2d518ce8e60"
      unitRef="usd">226300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTItMS0xLTE3ODIwMg_99929733-c7fb-4ce2-8b69-568048b00e7f"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTQtMS0xLTE3ODIwOQ_f0358c4d-4785-4c2d-87cb-520787d9ee60"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie37bf16a4f5e488c885dbb79612ad6a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzItMTEtMS0xLTEzMzY2OA_73984bd2-4f0f-47c4-9a98-5446bc351ee0"
      unitRef="usd">227600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMS0xLTEtMTMzNjY4_826a2387-e8fd-4365-81da-294e196db8f3"
      unitRef="usd">-9400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMy0xLTEtMTMzNjY4_8927401e-5c16-4d65-822c-b0b8c94cb13f"
      unitRef="usd">6900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtNS0xLTEtMTMzNjY4_35f09435-423e-496a-9030-3a8f316685df"
      unitRef="usd">-2500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtNy0xLTEtMTMzNjY4_3b3f951e-ceaf-45c6-baaa-0520c9edcda8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtOS0xLTEtMTMzNjY4_5047783e-9d1b-4f31-9b1e-ed72fce31925"
      unitRef="usd"
      xsi:nil="true"/>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTItMS0xLTE3ODIwMg_b61e282b-5cd0-4378-ab74-679fbb635fa6"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTQtMS0xLTE3ODIwOQ_59e71478-1533-4de0-b07c-beb38f9a26e6"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia387ad8558934defb6159f7305efa385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzQtMTEtMS0xLTEzMzY2OA_feb53c89-50d2-44fb-964c-63d27fcd413b"
      unitRef="usd">-2500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMS0xLTEtMTMzNjY4_c31d52ef-b007-452e-b82e-0a8086e2fc49"
      unitRef="usd">350000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMy0xLTEtMTMzNjY4_384a2eb1-f6c4-4128-b2ba-4a76cabacdea"
      unitRef="usd">124900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtNS0xLTEtMTMzNjY4_2cae6741-89dd-4927-a682-7ed8d2a1b5a7"
      unitRef="usd">225100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtNy0xLTEtMTMzNjY4_dd4f8f48-ea7a-4fd4-bebc-f61d05d62695"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtOS0xLTEtMTMzNjY4_2cd61bcd-4539-4350-9a3b-8996cec6542c"
      unitRef="usd">226300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTItMS0xLTE3ODIwMg_a45bf2aa-7dd3-4c9c-a29b-3a51f6a66c84"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTQtMS0xLTE3ODIwOQ_b8a2cb89-8773-4544-b025-d0eef4e00f0c"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzUtMTEtMS0xLTEzMzY2OA_1e02c333-3aa7-4434-8ada-b98ae5bb0d6a"
      unitRef="usd">225100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMS0xLTEtMTMzNjY4_eb80899b-3c91-4660-9a8b-5c74666872a3"
      unitRef="usd">204509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMy0xLTEtMTMzNjY4_9a31a9c5-bee8-4ad4-90a1-b9f889776ac2"
      unitRef="usd">49191000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtNS0xLTEtMTMzNjY4_fb3f96fe-3805-4988-88e0-fe82c8524e0b"
      unitRef="usd">253700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtNy0xLTEtMTMzNjY4_f88375bb-dbe9-4929-af5e-6c4518c134bf"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtOS0xLTEtMTMzNjY4_582685f3-1592-4a52-9606-fa2a0968f83c"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTItMS0xLTE3ODIwMg_5f5b4248-a7f6-4513-a91d-32d18d179619"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTQtMS0xLTE3ODIwOQ_6c414781-fe05-44a8-b79e-67fa0ee48ee4"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7cb276a5c674234b53a15b315d62a67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzgtMTEtMS0xLTEzMzY2OA_44799a7d-fd90-4317-b1b8-0f21498d2a1c"
      unitRef="usd">253700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMS0xLTEtMTMzNjY4_b37d042e-c359-4d89-9048-0d1f68688e52"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMy0xLTEtMTMzNjY4_9deab51a-5545-42cc-b242-029d1afd6d9f"
      unitRef="usd">16700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktNS0xLTEtMTMzNjY4_438885e9-3825-4219-b2e0-f4c71b818101"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktNy0xLTEtMTMzNjY4_4d3220fa-55de-4184-a178-7869d74c6dc9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktOS0xLTEtMTMzNjY4_f61d135b-63a9-4c5f-87aa-b496f5077c45"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTItMS0xLTE3ODIwMg_f37a0899-58c3-4b30-ae16-08d36ae95d0c"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTQtMS0xLTE3ODIwOQ_d17cd37f-8496-4b7f-8a84-ede7e0d46f30"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i808aa487867047a1aeeed484938b9306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzktMTEtMS0xLTEzMzY2OA_b73a913d-bd74-4dc1-9e36-fe677cc1fa92"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTEtMS0xLTEzMzY2OA_f6083136-24af-438f-a336-482967324465"
      unitRef="usd">204509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTMtMS0xLTEzMzY2OA_d3aeb2ac-8e2b-4807-84a8-7a1ed8e05b44"
      unitRef="usd">65891000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTUtMS0xLTEzMzY2OA_a80669fb-cf32-42f0-b864-b2072aed97bf"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTctMS0xLTEzMzY2OA_530c5817-bf10-48ee-b285-73f3de0d38a0"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTktMS0xLTEzMzY2OA_0d011e2e-4896-4ba1-a274-c27e49308b15"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTEyLTEtMS0xNzgyMDI_b6f31dc6-dd55-4ad2-8754-a4b193423fb8"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTE0LTEtMS0xNzgyMDk_43be3bc7-8d5d-4bd7-b1a9-c06ce5ca46bd"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjEvZnJhZzo0ZDU1MjY4NDhkZmU0Zjc1YmRlZTE1Njg4NmRlMjgzYy90YWJsZTpjYWFjNmZjZjgzYWY0ZTAwOTgyYTgwNGZkYmY0OGNjZi90YWJsZXJhbmdlOmNhYWM2ZmNmODNhZjRlMDA5ODJhODA0ZmRiZjQ4Y2NmXzEwLTExLTEtMS0xMzM2Njg_9e3c8bbc-4bab-484e-b6a4-2d3c04122c25"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTM_cc26c9c8-ebd7-4a9e-95aa-2860dd1c2157">Derivative Instruments&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 7, 2020, we entered into an expanded funding agreement with Biohaven, which included the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. Upon a change of control event, we have the option to cause Biohaven to accelerate the payment of zavegepant milestone payments, if triggered, in a lump sum amount (&#x201c;Milestone Acceleration Option&#x201d;). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven. On October 3, 2022, Pfizer acquired Biohaven and we elected to accelerate the zavegepant success-based milestone payments, if triggered, in a lump sum amount. As of December 31, 2022, the fair value of the Milestone Acceleration Option was $96.6&#160;million, of which $86.2 million was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and $10.5 million was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury rate lock contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#x2013;Borrowings). The treasury rate lock contracts had collateral requirements and were not designated as hedge instruments. We paid $16.1&#160;million in July 2021 to terminate our treasury rate lock contracts in connection with the issuance of the 2021 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4&#160;million to terminate these swaps and reclaimed $45.3&#160;million of collateral that was held by the respective counterparties. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Epizyme put option and warrant&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#x201c;Epizyme&#x201d;) of $100.0&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0&#160;million in exchange for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5&#160;million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme&#x2019;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#x201c;Eisai&#x201d;). In addition, Epizyme had an 18 month put option to sell an additional $50.0&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. We recorded the put option as a forward purchase contract as of December 31, 2019. The exercise of the put option was settled in February 2020. As of December 31, 2021, the fair value of the warrant was immaterial. The warrant remained unexercised and was terminated upon Ipsen&#x2019;s acquisition of Epizyme in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of derivatives and reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives in hedging relationships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount of loss reclassified from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of other instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury rate lock contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt; were released into earnings.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4bf194cfc2e4ae29733f8ea9a9e30c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzMyOTg1MzQ5MTMwMjc_f82c1976-ab98-4835-90a6-7b408efc146e"
      unitRef="usd">96600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQzOTgwNDY1NDQwODM_41ff434a-9288-45e7-8529-80573daaeebe"
      unitRef="usd">86200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQzOTgwNDY1NDQxMTU_a756c44e-1e64-43c4-86eb-76af4aeeb773"
      unitRef="usd">10500000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i83621d3576df4e908ddd466a0e61f733_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzgwOQ_32a8df15-cb48-4344-9b4b-f8cdbb8ccb27"
      unitRef="usd">600000000</us-gaap:DerivativeNotionalAmount>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="iec09d9a909cb4c17866b5eb148734cbb_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzEzMTY_359b8c11-0aef-46ea-93ba-00887ed94084"
      unitRef="usd">16100000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzE1MzI_e95a8e0d-81a3-4bfa-98d8-2616f0fdc054"
      unitRef="usd">35400000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i59c4f6d96d234dbabcb6a4bd19bf467e_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzE1NzQ_bdca007b-11b7-46fb-94a6-4cbf2723860b"
      unitRef="usd">45300000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i68d67c1c36ac474584018997072ac0ba_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIwODU_67478d5f-eaed-402b-b5aa-5f510f1c8691"
      unitRef="usd">100000000</us-gaap:EquitySecuritiesFvNi>
    <rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment
      contextRef="idf0a219828db455db7c7f67f043e8346_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIxNjY_740dda09-a477-4adf-b341-cb7a52f63050"
      unitRef="usd">100000000</rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id15fe3c8a0254d78944bd1d10ea2a29a_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIyNDk_856b14f1-0c0f-4e48-9ed5-6560bb4fe76a"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3b09b987997c4801be4424e787583ad3_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzIyODY_5b4bfe13-e84c-4d4b-a519-d1b49cb6304e"
      unitRef="usdPerShare">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i3b09b987997c4801be4424e787583ad3_I20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTI_1f263840-d190-4901-9450-1ad5cb838bca">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <rprx:OptionIndexedToIssuersEquityTerm
      contextRef="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI0NDA_2d656d7b-6aaf-4002-bff7-7f61dc6e824d">P18M</rprx:OptionIndexedToIssuersEquityTerm>
    <rprx:OptionIndexedToIssuersEquityValue
      contextRef="ie250c596f2414ce2a10252ee5fe6b000_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI0ODI_98a70e80-365b-4def-b7d2-0651dcc56dbe"
      unitRef="usd">50000000</rprx:OptionIndexedToIssuersEquityValue>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="i31142fb58ba14c8091c0f372f933b225_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzI1NTU_4b7ae913-5174-4d29-ab69-a47933718ed9"
      unitRef="usdPerShare">20</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90ZXh0cmVnaW9uOjU4ODQzOTI4NmQ3ZTQ5MTFhNzc5MWE1YTg4YzMzZjY5XzQwNTE_60ec5ece-e115-40e6-8148-f819dae4e0ff">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives in hedging relationships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount of loss reclassified from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value of other instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury rate lock contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt; were released into earnings.</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtMS0xLTEtMTMzNjY4_f857c9db-d469-414b-8612-7704ec912517"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if1ee900d9be64dff809bae93067b329b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtMy0xLTEtMTMzNjY4_b53d0aa5-c1e2-473a-8cab-a2ce3baf72cc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzQtNS0xLTEtMTMzNjY4_a37368bd-77cb-426d-8ef8-f81e926a47d4"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtMS0xLTEtMTMzNjY4_e17f19f2-af67-45b4-a0ee-0644ec3d2ad6"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if1ee900d9be64dff809bae93067b329b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtMy0xLTEtMTMzNjY4_cec4c35d-bd42-4caf-87df-e1663dc84f97"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i3fcea58ddf274f43b61690e3a8720cbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzUtNS0xLTEtMTMzNjY4_5951428a-424b-4d69-9882-1451b55bf0d4"
      unitRef="usd">-73000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i97b84d20eec148e8a629524fec68a0a9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtMS0xLTEtMTMzNjY4_eac81b18-71e4-42f5-8118-a4f55d9cfdff"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i584e4daf7e194c5892cde63718b1c7ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtMy0xLTEtMTMzNjY4_4deb9d8a-e69d-4991-96e5-017bb13224f3"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i43ab4d2a31844b79b2cc049b2d2d82a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzYtNS0xLTEtMTMzNjY4_e9354b58-f867-4261-aae1-cf4b309a5cde"
      unitRef="usd">114000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iee5401a91f4148caa202184655267c97_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTEtMS0xLTEzMzY2OA_9f5703cd-a540-451d-84f1-0a1a1360f9d3"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="icf13c3669b9445de801580639f1dcd01_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTMtMS0xLTEzMzY2OA_18c89d3a-f4bc-4e4c-9e88-716ca436b2d7"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i377698d44a004b60a93b6e026bb496b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzEwLTUtMS0xLTEzMzY2OA_42008f0c-8e45-4993-a576-d72bac80d287"
      unitRef="usd">6908000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i51deee71524e45f2b92578b1b7a69a43_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTEtMS0xLTEzMzY2OA_e99795c2-71ec-4fa8-9e39-c1b42d2bb881"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i78355224105441eeb9b89315786e6bb1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTMtMS0xLTEzMzY2OA_a13c1175-3ecb-4f19-b31a-9492b39e940c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8da8d7006a174307ad5d37753b978bd4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzExLTUtMS0xLTEzMzY2OA_620cd609-c26d-48cb-99d9-b0be2d1bfc80"
      unitRef="usd">408000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ia18b06181b4d43fbb3e315553e743a9c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTEtMS0xLTEzMzY2OA_77040af1-2de3-4d20-a8e4-08fbfaf023ba"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic6913761eb9d476a89d786eb84437c8f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTMtMS0xLTEzMzY2OA_43c4f217-7b61-4da8-b36c-e49410260b3a"
      unitRef="usd">5439000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1bde215a2f7d41c19e08a08fda54ecec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE0LTUtMS0xLTEzMzY2OA_3c8209e2-f00d-4ad3-b6d6-9da6f9862367"
      unitRef="usd">25375000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="i1b208c40e457458888bdd3417e87cc6c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTEtMS0xLTEzMzY2OA_b3ddf8f6-4ba7-4eaf-a1e8-ebf6bdee6a84"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="i72a25c9fbeac4e028b27a42ea86ea95b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTMtMS0xLTEzMzY2OA_656f14b0-c697-4588-8761-a59f89450a2c"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="ib489dd79da964d4f9415ec89293c3ae7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE3LTUtMS0xLTEzMzY2OA_66b5d7e0-c5f1-4583-b9af-3b873be3dfe0"
      unitRef="usd">5800000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i81792be75c1c4c2d9399629e922cab13_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTEtMS0xLTEzMzY2OA_6be033d2-ac9b-420b-b3d7-b6f26b7d463f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="idfb080182b0d4caaa2be643121414d08_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTMtMS0xLTEzMzY2OA_0b44338c-b890-4fe8-a0a0-8ca650d601ab"
      unitRef="usd">16093000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib7f43d56301b49e996fc395673d519ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzE5LTUtMS0xLTEzMzY2OA_809627c3-bf8a-49a8-88ea-bc67edb20b1f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0b7ceeaef8dc42f28a13e4f9c0bb24d5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTEtMS0xLTIzMjkyMw_bff47904-1f16-4d71-ba24-fc86a39766bf"
      unitRef="usd">-96610000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i3c740405d5a64a9b80be8f8b658e7edb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTMtMS0xLTIzMjkyMw_8e15664f-3b82-44ac-8714-d3d0bdc05f22"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i09689e7a29b04e63b1743e322c38e197_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMjcvZnJhZzo1ODg0MzkyODZkN2U0OTExYTc3OTFhNWE4OGMzM2Y2OS90YWJsZTo2YjNkOWQ0NjMxODY0ODAzODMwMDJmNDIxNzU4NjY5Yi90YWJsZXJhbmdlOjZiM2Q5ZDQ2MzE4NjQ4MDM4MzAwMmY0MjE3NTg2NjliXzIxLTUtMS0xLTIzMjk0Ng_9a3e91cc-aaa8-4e15-9153-fef9dd911c19"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzkz_465c66e4-053e-4b1b-a487-74ca72c2fb1e">Fair Value Measurements and Financial Instruments &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instruments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instruments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty at fair value (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;103,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;259,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;363,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;As of December 31, 2022, amounts reflect the fair value of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds. As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet. See Note 9&#x2013;Non-Consolidated Affiliates for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the fair value of the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For 2022 and 2021, we recognized losses of $39.1&#160;million and $41.4&#160;million, respectively, on equity securities still held as of December 31, 2022. There were no gains or losses in 2020 associated with the equity securities still held as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on initial recognition (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Losses)/gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities included in other comprehensive losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Losses)/gains on available for sale debt securities included in earnings (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer out of Level 3 (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Redemptions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;227,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;96,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Following Pfizer&#x2019;s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition. Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares. Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the expiration of the transfer restriction on BioCryst common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Inputs for Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApiJect Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value as of December 31, 2022 of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc. (&#x201c;ApiJect&#x201d;), a private company, in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 9&#x2013;Non-Consolidated Affiliates for additional discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cytokinetics Commercial Launch Funding &amp;amp; Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the Cytokinetics Funding Commitments as of December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty&#x2019;s assumed cost of debt, which would impact Cytokinetics&#x2019; decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 13.5%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioCryst Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2021, we purchased 3,846&#160;thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (&#x201c;BioCryst&#x201d;). As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst&#x2019;s common stock, which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the second quarter of 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;MorphoSys Development Funding Bonds &amp;amp; Forward&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of the Development Funding Bonds and the Development Funding Bond Forward as of December 31, 2022 and 2021 were based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs. Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair values could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Series A Biohaven Preferred Shares were redeemed following Pfizer&#x2019;s acquisition of Biohaven in October 2022. The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which results in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate of 9.5% as of December 31, 2021 could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Biohaven Preferred Shares &amp;amp; Forwards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All remaining unissued Series B Biohaven Preferred Shares were purchased simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares following Pfizer&#x2019;s acquisition of Biohaven in October 2022. The fair value of each of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 was based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the &#x201c;with-and-without&#x201d; methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer&#x2019;s cost of debt and management&#x2019;s estimated probabilities of achieving the success-based milestones. Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement. Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower. The fair value associated with this instrument was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts&#x2019; consensus sales forecasts. These projected future royalty payments by asset, along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,314,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,493,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk2_002c9116-d947-49b9-a8fa-c8dbb34812e2">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instruments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;116,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative instruments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty at fair value (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;103,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;259,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;363,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding commitments (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;As of December 31, 2022, amounts reflect the fair value of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds. As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_65e55891-f35a-452c-8fcf-7e90c7b45fb8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTY2ODM_72596dcc-e0d7-4842-a3be-ee0ddc095761"&gt;Milestone Acceleration Option&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet. See Note 9&#x2013;Non-Consolidated Affiliates for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the fair value of the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia0fb45740e6145a5b10b66dd36b462b3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMS0xLTEtMTMzNjY4_532ae545-26c6-4089-9acb-8b3fa565b2a4"
      unitRef="usd">5068000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib406778ea8824af6aae3c5dfb2e1610f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMy0xLTEtMTMzNjY4_5c0c2481-daf8-468f-ba99-79bda4c049d3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a21bed221044a0890c2c913d788b8a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtNS0xLTEtMTMzNjY4_e666efbb-d9b3-4065-b910-be2cf956eca7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i186084ca8b944fd98cdadde833e23388_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtNy0xLTEtMTMzNjY4_3e770ad7-a639-4c0d-bdaa-5d6a4786aa0f"
      unitRef="usd">5068000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i796975e015ca44e1a9105072f8fc8ba5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtOS0xLTEtMTMzNjY4_b7793d3d-468a-45e5-9825-48182bef5fe7"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1873077ea3a4449b93ac140b1258d597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTEtMS0xLTEzMzY2OA_1f39cfbe-23fd-4ec4-a71e-0a111ab96944"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d4a77eb1b3c42f690d02b5f7c117bb3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTMtMS0xLTEzMzY2OA_553c5a4a-cd83-4fc9-adff-011cf422abb0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic4228e1020e84d28a5d3606eb13fba5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzYtMTUtMS0xLTEzMzY2OA_6bd53fb2-1142-42a1-934a-18cb0d69a046"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ce834481aa64cca87e9f3cc25a312ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMS0xLTEtMTMzNjY4_c9554988-9c67-4041-aba7-6717467ba8e4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ba512b3b31444ed910800ea1536abc0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMy0xLTEtMTMzNjY4_673c71c5-ff1f-4f37-b78b-a92f82dfff4d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i29550347abe146f89941dfcd98915c01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctNS0xLTEtMTMzNjY4_1dee2800-3107-46e1-8f3e-aa135710eeb9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6dd2992133f24f0f9d76c8ca5fe08441_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctNy0xLTEtMTMzNjY4_becd2c3a-0d8f-461b-b56b-a72d6606a631"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfdfec8d4041469bb92dd0165296ed5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctOS0xLTEtMTMzNjY4_50a34ff1-536c-44c2-9386-260d8be5bfa9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d1f65e37bdc4ae98f2ef6443c0e36d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTEtMS0xLTEzMzY2OA_9e331579-7e9e-42e8-90ca-52681b9ba332"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2cb596f160574fde859a997dd3688a51_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTMtMS0xLTEzMzY2OA_8e64a64d-7afd-459f-ada4-e27cc7cbc2f0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia1505389d35a4fe697a3107d3e1a4e20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzctMTUtMS0xLTEzMzY2OA_a468b601-be04-40be-ae80-f4ef96574953"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b3ab05ebb3f4cefb671b072e85ae362_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMS0xLTEtMTMzNjY4_6923308c-19a9-41c5-84e7-0271930cce09"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa0a251553004651bae3fe39fca66f0c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMy0xLTEtMTMzNjY4_5fe55600-4835-45da-a407-3c43166f86b6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic2611175ae914a0cb275393ef07b82b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtNS0xLTEtMTMzNjY4_28332683-cc4f-4c7b-b452-9247ac5b9c2f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c3e7cecd2194bba94c9ea68302d6da5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtNy0xLTEtMTMzNjY4_56a15a99-99ec-477d-923d-a83be27c4aea"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2fb97cbac8b416db2ba868db73a9261_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtOS0xLTEtMTMzNjY4_d5520d6a-c402-4025-8518-9bf8efded1a9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib63036932758473e8e19c69328045159_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTEtMS0xLTEzMzY2OA_5cd1b7a8-08de-4256-86aa-93b052f0c6a0"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3b041c7b1fd843f4801f45f69864a734_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTMtMS0xLTEzMzY2OA_9f79f32c-ebef-4e7b-84df-516b14e6fe99"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i513ac86b5f644e0abbd6fd515bf19a93_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzgtMTUtMS0xLTEzMzY2OA_76e351cd-360d-4864-9f6a-e1cbdaa13e11"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ia930877a154f4ea397b7a9ed77275162_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTEtMS0xLTEzMzY2OA_2df49ebc-3629-4d59-95f4-eb68e58cea54"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i1bd6c9fd69b64ac3ada61bea9f9a809e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTMtMS0xLTEzMzY2OA_7b456de0-6b7f-4ce3-9d55-ac9687a2f729"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie6606a8ffd244eb8b5538e380fb0155d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTUtMS0xLTEzMzY2OA_904f23cf-4fec-47a7-8569-2dc2e9bc14a1"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i4b2ed614ee654625b83a27f5186d6d46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTctMS0xLTEzMzY2OA_32e9bd9d-069c-4882-9afa-930c50ad5ef4"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="iecf13afac5c747a58a510a05b6306845_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTktMS0xLTEzMzY2OA_16c699d7-4339-49d9-8c1a-b08ce1450de1"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ib747f5c2a7ac44d2adede24f51ea0ed2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTExLTEtMS0xMzM2Njg_4167c1dc-bbe1-4468-8c7b-60ba4e80756f"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ibf4e09328663481a88570d82f2b0b2da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTEzLTEtMS0xMzM2Njg_90cd377f-f224-4c8a-8e3f-7472d3f4c2ac"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie9f44f16ba8447af88c5f94ba782e24e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEyLTE1LTEtMS0xMzM2Njg_b72470cd-9995-4729-84fe-ac953f1f52e6"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i886a32de12484bc3a8fa2095f96ce3aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEtMS0xLTEzMzY2OA_64b66b17-7b1b-4359-8fe9-34bab748af48"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i0b749d46341641ce864db1980ea0eadd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTMtMS0xLTEzMzY2OA_7c696830-e9fa-473d-9ff3-7390868e9acb"
      unitRef="usd">11501000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="if3d1f95532784cb4b004e23c96a53c2b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTUtMS0xLTEzMzY2OA_43af00d9-8832-48ef-a0a0-280239148167"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i7913fe2f2f1f4f17975329f9e86b47f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTctMS0xLTEzMzY2OA_4f87b2fd-e715-4b5d-b002-ac47cbabe408"
      unitRef="usd">11501000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i8167718861cf4cc097ec7bc1722c4abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTktMS0xLTEzMzY2OA_c937066f-c654-4842-983d-f5805d2d00a9"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie34968ddaef047e5aee9da6ed328c6a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTExLTEtMS0xMzM2Njg_858f1c68-4215-4d22-ade3-261e10b05914"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i2bc45285d96740488e652d34212bd6bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEzLTEtMS0xMzM2Njg_c85f2614-14d1-4139-99b9-8cad9aae1b0d"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i2a6ca2229ea245549c7358f77e0511f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTE1LTEtMS0xMzM2Njg_4f8caeb4-c215-476e-adfa-102b74eb7fa7"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ibe6b624b7369483aab919710178f1675_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTEtMS0xLTEzMzY2OA_ff69ed42-46c5-4f95-9912-0a99ba788bd0"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ibea5eb15f1b3454786bccad98927ed9b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTMtMS0xLTEzMzY2OA_7bf58aaf-d044-479c-a65f-587a475ab2a7"
      unitRef="usd">12920000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i94a230a360ef4bd6bdd4b1fde0b5e287_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTUtMS0xLTEzMzY2OA_9520e968-100e-4c16-a345-c2a061061773"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie2bf206b0fe441d9a604aa40decf5e98_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE0LTctMS0xLTEzMzY2OA_03dafea9-9186-4b86-8bda-c3a7e88a695d"
      unitRef="usd">12920000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie196b18bfc6e42cdbb8fc1c9cf933b38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTktMS0xLTE2MTQ4MA_c20e2f13-540a-4295-b18e-8bcb436fa0a9"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i671467da1004443aadefa5fc4adc8a66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTExLTEtMS0xNjE0ODA_e4acc287-8e4e-4370-9b75-cd278c032ad4"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i87d09b91ce0940f8bf8d043a117aa8b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTEzLTEtMS0xNjE0ODA_a625bf74-e2c9-4c5d-99a0-c8c92ce89e95"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i9965e6b7e930491083134897c58109bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzEzLTE1LTEtMS0xNjE0ODA_0d098a5f-24ef-415a-a488-688173f234cb"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5db25f68b5f64a1b83cb921118b07a8b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTEtMS0xLTEzMzY2OA_8fca8308-b376-445c-92a9-db99bd8aba29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7de25f5e6375404c800880744168d22f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTMtMS0xLTEzMzY2OA_d70c5da7-318a-4959-8b6f-5193a892a04e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib3db62c54fe54935bfbb368cd4dcd185_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTUtMS0xLTEzMzY2OA_13321129-a330-4175-a0b0-7d1691f0af16"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i311eff96434042c48fc1a0da1a969d9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE2LTctMS0xLTEzMzY2OA_a596553d-6241-49c1-86f2-58c5ef30ab47"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie89a50ad7a634d438a6aea813c2e2267_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTktMS0xLTE2MTQ4MA_98e807a0-5fd0-467b-9422-be2deb3865e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic4aabe1887bb4026b0b128e258134f11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTExLTEtMS0xNjE0ODA_b8e026bc-0fb7-4d1f-88bc-c4a6723840b8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTEzLTEtMS0xNjE0ODA_ed1819cf-6e97-4b00-9946-e8c45929733b"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia5d1415d925c4be3a6b3679f2f242c45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE1LTE1LTEtMS0xNjE0ODA_e6f7c314-2e1c-47ea-8850-b32f8af8c6ba"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTEtMS0xLTEzMzY2OA_76341c49-6c89-4c60-9f62-210c2ba48ec9"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTMtMS0xLTEzMzY2OA_a2a92bb5-98c6-46c4-bc3a-4c792c274f3d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTUtMS0xLTEzMzY2OA_6a506b69-2828-49ed-a820-c4e886c78360"
      unitRef="usd">86150000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTctMS0xLTEzMzY2OA_1e6527a6-0fe9-4f07-bfec-13926fc599fa"
      unitRef="usd">86150000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTktMS0xLTEzMzY2OA_6bf19c6d-9d83-4d0c-8367-d8d80869666a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTExLTEtMS0xMzM2Njg_a2ca4678-3260-4453-bb03-5d114c5c14b4"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTEzLTEtMS0xMzM2Njg_0c1ecd73-a24b-4392-a980-5162cf407550"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzE4LTE1LTEtMS0xMzM2Njg_63d7e232-bf9e-4d9c-9665-846003e1f5a5"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTEtMS0xLTEzMzY2OA_d12d7af9-3bdf-453c-b570-c1eec2c61b5d"
      unitRef="usd">5068000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTMtMS0xLTEzMzY2OA_49a74228-f0fe-418a-a64a-57b0b958bfc2"
      unitRef="usd">24421000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTUtMS0xLTEzMzY2OA_dbb5e92e-e75a-4245-9eca-85dab0f91f04"
      unitRef="usd">87450000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTctMS0xLTEzMzY2OA_72d7093a-ca44-44f0-a86b-a6f0f8c59054"
      unitRef="usd">116939000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTktMS0xLTEzMzY2OA_12bebc1d-9089-43f2-8336-47c032aed7bf"
      unitRef="usd">598253000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTExLTEtMS0xMzM2Njg_eb24e9a2-9612-4340-b98b-ac1ffcc5a903"
      unitRef="usd">636823000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTEzLTEtMS0xMzM2Njg_0192c31c-d157-418d-9ab1-1053fed7854d"
      unitRef="usd">66000000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIwLTE1LTEtMS0xMzM2Njg_3f07d779-a843-42c9-a736-60965cc5a571"
      unitRef="usd">1301076000</rprx:AssetsFairValueDisclosureCurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTEtMS0xLTE2MTQwNA_d76595e0-2d2e-427c-80d9-9ce36e445870"
      unitRef="usd">103876000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTMtMS0xLTE2MTQwNA_3c4e91a7-1f00-4b40-bc81-2ed205a31f7c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTUtMS0xLTE2MTQwNA_aaa4c893-8a4c-4a96-a22d-5770b64aa892"
      unitRef="usd">8472000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIyLTctMS0xLTE2MTQwNA_f90cbaef-fda7-473d-9f42-e7f6ba59e830"
      unitRef="usd">112348000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTktMS0xLTE2MTUwOQ_b121ae3c-8a5c-4a02-a597-6e468c160ef4"
      unitRef="usd">226787000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTExLTEtMS0xNjE1MDk_128ce806-dbe6-4605-827c-d509dd87e034"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTEzLTEtMS0xNjE1MDk_e88018cd-0f13-4af5-a368-4747d7a05166"
      unitRef="usd">43013000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIxLTE1LTEtMS0xNjE1MDk_930d04e4-9bf5-4f1b-9d8f-32244d683ac6"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5db25f68b5f64a1b83cb921118b07a8b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTEtMS0xLTE2MTQwNA_2056f1d0-11ff-404c-b89f-d1270702a519"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7de25f5e6375404c800880744168d22f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTMtMS0xLTE2MTQwNA_a51021ac-1c32-4af9-9a76-82b958c550e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib3db62c54fe54935bfbb368cd4dcd185_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTUtMS0xLTE2MTQwNA_7f1aca09-b196-4007-bd5c-4985693790aa"
      unitRef="usd">226300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i311eff96434042c48fc1a0da1a969d9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTctMS0xLTE2MTQwNA_4aebd9f6-7f8e-4593-b39b-38822d92e73f"
      unitRef="usd">226300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie89a50ad7a634d438a6aea813c2e2267_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTktMS0xLTE2MTQ4MA_937b3479-8cf4-4194-b04a-d18bdea40c52"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic4aabe1887bb4026b0b128e258134f11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTExLTEtMS0xNjE0ODA_267b7c7e-f85c-4728-83b4-6295399b7581"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1824f03c9cf34bec8bf535f5626d5e1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTEzLTEtMS0xNjE0ODA_52ce2463-66f4-4ae4-968f-1c8656d476ba"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia5d1415d925c4be3a6b3679f2f242c45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzIzLTE1LTEtMS0xNjE0ODA_d628bbeb-2228-4b15-8d49-a5286b260c54"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4355b2c313964e16a9cc70955cb99e95_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTEtMS0xLTE2MTQwNA_5b9d7fdc-ec35-4624-93c8-60e41d646e40"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id87bec58187049c0b4315cc2e7e75220_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTMtMS0xLTE2MTQwNA_2c8c4c21-8a09-4b0a-a7a7-0132f4822868"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if30b1de3d1e04b99b1569a7a6cca90fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTUtMS0xLTE2MTQwNA_b3ecce17-cc1b-44ee-98ba-3099d48b2554"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id40c65086ad44d44b48a424f98b6eba8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI1LTctMS0xLTE2MTQwNA_60639c3e-2130-4f2b-9586-9861b8ae8206"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ief66559de8974b67ad08f5c7e106bc13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTktMS0xLTE2MTQ4MA_832e1aae-f88f-4f97-8015-75b41ac03dd9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0284f5e21ce642a7876ab339f755553c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTExLTEtMS0xNjE0ODA_84441ebe-5887-4663-8692-89e570820ffd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70136bdb09f640f6a595ebcc3b848490_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTEzLTEtMS0xNjE0ODA_964ee98b-1e94-4978-b921-5ef1c5506956"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i18426df2a74c460381450590d12af14e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI0LTE1LTEtMS0xNjE0ODA_b6247a24-89fe-4db7-aa0e-1e5c242cce8d"
      unitRef="usd">16700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTEtMS0xLTE2MTQwNA_b6ef26d1-3710-4dc5-bd3b-29ce23084aae"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTMtMS0xLTE2MTQwNA_c4ec1ee6-bedd-493e-a1f2-819e3efb8091"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTUtMS0xLTE2MTQwNA_21159d1e-fd1a-4fad-b5c4-5409936b52cd"
      unitRef="usd">10460000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTctMS0xLTE2MTQwNA_bb29a88e-8096-4a69-bea5-204fe53c6636"
      unitRef="usd">10460000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTktMS0xLTE2MTQ4MA_4d3ac494-bef8-4438-9a87-6dc042a68f98"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTExLTEtMS0xNjE0ODA_12b2cce2-6fa7-4f60-8c18-1796a823fa97"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTEzLTEtMS0xNjE0ODA_e5c3fe70-7628-4cae-b2e1-93dd5c6bc3f7"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI3LTE1LTEtMS0xNjE0ODA_fcd0dfe6-0b2a-482a-9d78-5753ec8484cb"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i386b4142f4104da8bbeb674cc226ccf2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTEtMS0xLTE2MTQwNA_a8bc367a-37eb-485b-bc50-b16fe0cc3d93"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5c35e8641845417891560b40c078c58b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTMtMS0xLTIyNzQwNQ_2b7bdeb9-ee74-4d0b-949e-59ea2ccb7bdf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if6b89ba5713246ecb69cbe5915280e12_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTUtMS0xLTE2MTQwNA_e8e4df2f-c3dc-4bb7-b066-686c9c7b1945"
      unitRef="usd">14500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic244222348804b5795bfab47417210e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTctMS0xLTE2MTQwNA_5b2224bc-b934-4c9d-a386-87cb70ecc537"
      unitRef="usd">14500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8ffc8574733247448667f38369095447_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTktMS0xLTE2MTQ4MA_fba69417-29e8-48f3-8971-abafc8fe9859"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i14b7ad3a58f94ab791be7207d0fe8590_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTExLTEtMS0xNjE0ODA_bc85f3a4-7a4c-4831-84f6-daf5545d6e39"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if339554672b642ae891f1ba2a6cbf38c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTEzLTEtMS0xNjE0ODA_41a2da28-e496-4447-8c14-416216f6affc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i66b55421b8464ed6a1a539d99d821dba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI4LTE1LTEtMS0xNjE0ODA_ba07fb27-2df4-4400-81bb-ba057c858e25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTEtMS0xLTE2MTQwNA_8ba88f33-0adc-4d56-be59-a52054cffc15"
      unitRef="usd">103876000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTMtMS0xLTE2MTQwNA_0c299a62-4a85-484c-a8c0-4196c89fcdc5"
      unitRef="usd">0</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTUtMS0xLTE2MTQwNA_c2736331-4c7c-4801-bab5-e5663bebccd8"
      unitRef="usd">259732000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzMwLTctMS0xLTE2MTQwNA_3aa6b53a-4eae-4e39-823f-86baf73e5457"
      unitRef="usd">363608000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTktMS0xLTE2MTUwOQ_6c468137-5363-48e5-b677-703fd6880cef"
      unitRef="usd">226787000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTExLTEtMS0xNjE1MDk_e58aa6ed-e927-4f8f-8543-6bec81f335aa"
      unitRef="usd">0</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTEzLTEtMS0xNjE1MDk_cec3b441-079d-4261-b412-2d2ca4201ab2"
      unitRef="usd">247413000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzI5LTE1LTEtMS0xNjE1MDk_fcb32fd1-314e-4c1c-bf2b-74d72eb9008e"
      unitRef="usd">474200000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i84360bddd1754c6aa91800aaa849b568_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTEtMS0xLTE2MTQwNA_3d7ef6f2-ffc9-4dba-9756-a182bcb4a466"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i19ee4838df9e479ca3a26e0b99bd5d60_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTMtMS0xLTE2MTQwNA_80814f84-76dd-47dd-b329-2add5d84d4a0"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i85817d340b744538889a7450f9dbd2e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTUtMS0xLTE2MTQwNA_9a9767ab-fcfd-4f8f-8f6a-df9222344dd5"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i07a9073c101943dcb449f3c807e6fabc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTctMS0xLTE2MTQwNA_ce442b0f-66ea-4f18-b3b4-c97120b6f763"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="ifa2169911e4a4795a6d397f381a2d74e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTktMS0xLTE2MTUwOQ_8f5963fb-f452-43f8-a2c6-b6cbcea00af9"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i8693ab100ea8484492349f889e6977b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTExLTEtMS0xNjE1MDk_59dae278-01b9-45ff-a174-55d2cd9b8e46"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i8240f1e3dadf4870b07c601e66065543_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTEzLTEtMS0xNjE1MDk_1d060163-fe0c-4182-8b5e-ae6fe694333e"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent
      contextRef="i6203b19a65da4c90ac16749d22ed023f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM4LTE1LTEtMS0xNjE1MDk_d7688e7b-b25c-4697-a0fe-f16e88ee7bb3"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityCurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i7fb4e4e310ba440aacab956e88cdcd59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTEtMS0xLTE2MTQwNA_80f2d1a1-3a44-4c7b-8423-3324cb15d7c1"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i5ef49f9006f64af4b44d5878e8dab385_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTMtMS0xLTE2MTQwNA_5cee8d8e-196c-43d7-b817-fa8b523ddc0d"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ic7aecdb813e34569b6db97dce91bbfab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTUtMS0xLTE2MTQwNA_a91b5654-a1d8-4bd7-aeb0-a5c6c4f4a74c"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ia96f43839fad463b8054251eb61aaf8d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTctMS0xLTE2MTQwNA_d1dbec48-c988-4b48-8ea6-046acde7b365"
      unitRef="usd">-2500000</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i568a2e5375d9455592a7ac8716ee21fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTktMS0xLTE2MTUxOA_7d7304ee-2f52-4704-abee-647cbdaff3a9"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i5ec3afdb32d543f6a697d49c7789b2af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTExLTEtMS0xNjE1MTg_710362f0-cc2c-4ec2-b198-c3978fa30132"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="ib1f14546a2c04d92ab9cc2604c837de4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTEzLTEtMS0xNjE1MTg_e584aedb-27fc-435e-b942-d3d2a4c6839f"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent
      contextRef="i9c890bd4904a4b3987af9a1db0691475_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo4MmFjYzc1ZGRkYzg0YjQwOGJiZDhiNjRkNTU4NTdiMC90YWJsZXJhbmdlOjgyYWNjNzVkZGRjODRiNDA4YmJkOGI2NGQ1NTg1N2IwXzM5LTE1LTEtMS0xNjE1MTg_cc37a97e-13a5-43b8-a5b1-9fd0bf52f8cc"
      unitRef="usd">0</rprx:DebtSecuritiesAvailableForSaleLiabilityNoncurrent>
    <rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTk3MDY_8cf178d4-8e65-4ee0-a9a9-9df1d17ac491">fair value</rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY1OTk3MDY_c2c678c1-e1d6-40ad-b03c-fa61cf22f98b">fair value</rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzI3NDA_ec9c4e5d-9cb2-46c5-834a-9cc8b6f44b32"
      unitRef="usd">39100000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzI3NTQ_6cddeda8-61ec-449a-ba85-8b61d2b416e1"
      unitRef="usd">41400000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzQzOTgwNDY2MDA5MTg_f126de01-dfb2-464d-8859-8f442ed83024"
      unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk1_7b35a12c-603f-4dff-9479-312643807a99">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funding Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on initial recognition (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Losses)/gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities included in other comprehensive losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Losses)/gains on available for sale debt securities included in earnings (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(79,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer out of Level 3 (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Redemptions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;227,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;96,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Following Pfizer&#x2019;s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition. Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $150&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares. Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the expiration of the transfer restriction on BioCryst common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i4e0796e20c9d41059187f605c28f22c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMS0xLTEtMTc4MjQ4_9284bbaf-fce6-49a5-abb0-df883a75cd0b"
      unitRef="usd">43013000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ida0371a080d9412b814cd70dc8e5ad90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMy0xLTEtMTc4MjQ4_7e775434-e40d-46d2-8a27-7e48d08b344f"
      unitRef="usd">253700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6f6e062894f1415ba03737996d595769_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItNS0xLTEtMTc4MjQ4_8fa4b96c-2d8c-4e47-933f-cfe0d59a3814"
      unitRef="usd">16700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i806d566ae63e4dd1bb3b094e2720d64b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItNy0xLTEtMTc4MjQ4_0cd67ffb-0e97-40f0-83c8-5302d929219b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i1bf58ad8accb4f42904d7cca513f316e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItOS0xLTEtMTc4MjQ4_31ec5170-5e32-4218-abd3-9157d96d2331"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i0e9ad39844434b80bc9e6f439efedad1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTEtMS0xLTE3ODI0OA_3a6a2507-a69a-43ee-a712-019a410089af"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ibd997478ad974d568fbddf3f973a46e7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTMtMS0xLTI0NzczMA_295d749a-e5c5-47e0-840b-76a0de07e491"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ie99e011b5e4c43d9b3b72a4b809c2f49_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTMtMS0xLTE3ODMwNQ_cd7ccb1b-be2c-4ea2-bf83-98d31f63f7d4"
      unitRef="usd">214400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ib41f6ecb8c944a33bdde5a9125f24870_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzItMTUtMS0xLTE3ODMwNQ_2f3694ef-0289-4d73-88d9-782e431a99e1"
      unitRef="usd">18600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMS0xLTEtMTc4MjQ4_07aaccbd-ddd8-419f-b701-f082779979be"
      unitRef="usd">28785000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMy0xLTEtMTc4MjQ4_6941e347-d8ad-44fa-8214-bccffafd5242"
      unitRef="usd">479559000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTEtMS0xLTE3ODI0OA_ab13dbf9-d157-4e88-979d-36ba8401bc00"
      unitRef="usd">21215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTMtMS0xLTI0NzczMA_dff365eb-4e85-4325-84bc-09716b7af761"
      unitRef="usd">35120000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzMtMTMtMS0xLTE3ODMwNQ_52a2c3eb-0678-417d-ac83-94b609bc4414"
      unitRef="usd">70441000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzQtMy0xLTEtMTc4MjQ4_f1033b17-cc24-4442-b8d9-89899ff2b75b"
      unitRef="usd">600000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition
      contextRef="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzQtNy0xLTEtMTc4MjQ4_6d836d00-34c5-4ada-af8a-626d1288b775"
      unitRef="usd">-9400000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzUtMS0xLTEtMTc4MjQ4_0814925e-cf9a-4e7a-9b7d-480a3ebedbd6"
      unitRef="usd">-22634000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6c78b818000549adb3693afbdfc1028e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzUtMTMtMS0xLTI0NzczMA_410d0b6a-1281-4e05-8cb6-b600d62ece16"
      unitRef="usd">7893000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i42a0bb5b28394f50af0be743d1778ecc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzYtOS0xLTEtMTc4MjQ4_abe09fa9-3e7c-4e69-a442-00f9461ac254"
      unitRef="usd">96610000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzctMy0xLTEtMTc4MjQ4_9046d3a0-e925-422f-908e-56dea46dd07f"
      unitRef="usd">24000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzctMTMtMS0xLTE3ODMwNQ_bf923c37-a1f6-4e3f-a2c0-a32bf2fec68e"
      unitRef="usd">11600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMy0xLTEtMTc4MjQ4_89743965-a1ce-429d-88ce-3e7692a6991d"
      unitRef="usd">-67800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtNS0xLTEtMTc4MjQ4_2d77f594-4494-4920-9f6d-e9c01868b106"
      unitRef="usd">62885000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i3b7d4633a1cd4e2c8adf586ee512d584_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtNy0xLTEtMTc4MjQ4_5b348d55-b705-4440-b41f-bc37905b0dcf"
      unitRef="usd">6900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMTMtMS0xLTE3ODMwNQ_44a459e5-387c-4b99-9e11-4361af40aa09"
      unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ia47c45e714054471849ababb1fb4798c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzgtMTUtMS0xLTE3ODMwNQ_f3cc6be8-de38-4ff1-a8fb-10fdfd76cdb6"
      unitRef="usd">16559000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense
      contextRef="i826c5290b6a34a8083f7b2c7841b91d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzktMTEtMS0xLTE3ODI0OA_a8ee2af0-ca08-467f-96e8-4676aef0f39e"
      unitRef="usd">6715000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTMtMS0xLTE3ODI0OA_4aedcaf8-9c94-467e-9aee-297da6c85bab"
      unitRef="usd">79585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ic7c844f1923e45e4a74450f8cf35cf8e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTUtMS0xLTE3ODI0OA_a0fb6f30-c4f4-4850-b93e-5b1f1c8866aa"
      unitRef="usd">-79585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTEzLTEtMS0xNzgzMDU_4c163e92-07e2-4c2c-8056-d7349271f5aa"
      unitRef="usd">18459000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ia47c45e714054471849ababb1fb4798c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEwLTE1LTEtMS0xNzgzMDU_49aa71d1-ee7a-4f71-a34d-f14b1af38605"
      unitRef="usd">-18459000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ic5592716bfd04e1f80a40974bdcc8e3b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzExLTEtMS0xLTE3ODI0OA_15c05d0f-7339-4318-81eb-33c067f4f53e"
      unitRef="usd">-40692000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="i7d5589bd3b804eff8edddefeec7ae281_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEyLTMtMS0xLTE3ODI0OA_9dbd41d1-b294-4391-a365-0461bc2bf5f0"
      unitRef="usd">-542044000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="ib9138a429d36435f80ba030dfe97874d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEyLTEzLTEtMS0xNzgzMDU_a1ea3eaf-9f9a-4b2c-a391-10898b097efb"
      unitRef="usd">-62500000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5e61aeea53b148b68f5668ae4c89ca1f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEtMS0xLTE3ODI0OA_a37d468a-59f0-468d-bab2-1f47772ae879"
      unitRef="usd">8472000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i9bf0e3d7700c4f61bcb0877b468b7e92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTMtMS0xLTE3ODI0OA_2124feef-9bd8-4e6c-a612-ba381520fc3c"
      unitRef="usd">227600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i8413cab6c79345889a6dcd08bb93b8a9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTUtMS0xLTE3ODI0OA_eed2994c-e0e2-42c3-9b4f-028c2d0d9604"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i2bc4135d264f4850ac652f81ebdd7653_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTctMS0xLTE3ODI0OA_9fd76604-9f9e-4022-af6c-2b90f6225ee2"
      unitRef="usd">-2500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ibc8dafb087fc4a46989b1599f69c7c66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTktMS0xLTE3ODI0OA_ae615612-d113-43e3-9e0a-9678e9546972"
      unitRef="usd">96610000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i12caaaf5dc4b4f7bb3868430bd3b390e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTExLTEtMS0xNzgyNDg_42f315e9-4ff6-4404-8056-f8972ec3f9fc"
      unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i4e0796e20c9d41059187f605c28f22c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEzLTEtMS0yNDc3MzA_c6499a99-b515-4e4c-aaf2-a1b950ab4e06"
      unitRef="usd">43013000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ida0371a080d9412b814cd70dc8e5ad90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTEzLTEtMS0xNzgzMDU_8b9a717e-bbfe-4259-9b8e-3fbef11d4ec3"
      unitRef="usd">253700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6f6e062894f1415ba03737996d595769_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTpjNmNhMTUxNDUyODE0ZTE2OGFhY2I2M2FjOTk4ZmEyNi90YWJsZXJhbmdlOmM2Y2ExNTE0NTI4MTRlMTY4YWFjYjYzYWM5OThmYTI2XzEzLTE1LTEtMS0xNzgzMDU_6b7e9b4d-e8da-4be3-871a-d4fbbbe3e8a9"
      unitRef="usd">16700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="i2b45e0b64ab94782aed6808aa37c04bd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNTQ0ODcyMTM2NDg0_80cad03a-8dab-457f-a7e8-481ee2395338"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzU0OTc1NTgxNzgxNzg_3d383faa-82fd-4c95-b47a-37178c340c2e"
      unitRef="number">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i20d225cb10804c378948a2986a8d9b5c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzU0OTc1NTgxNzgxODU_f069c7a2-5d46-4830-a432-4dca937122f4"
      unitRef="number">0.135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i3c4a1403d54240dea67d826b88016777_D20211101-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzEwOTk1MTE2NDgzNjY_f9cdedda-fe6c-4266-87aa-9b5b083b3b12"
      unitRef="shares">3846000</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzEwOTk1MTE2NDg2NjU_404ec3ba-aed5-46b3-ba71-1e535098ba43">P6M</rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod>
    <rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod
      contextRef="i7c629d986ffc48cfa2eb9caa4dd6242b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzk4_3de19a00-e6e3-4d4c-812c-e3176288eddd">P4Y</rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod>
    <rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital
      contextRef="idb876c0578a24141af7bab85dbf86a2d_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzM4NDgyOTA3NDI2MTE_0ebe5625-05e4-44ae-9e85-2831a9049c20"
      unitRef="number">0.095</rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90ZXh0cmVnaW9uOjM4NDA2YzJlOWIxNjRmYzRiOGQ5ODI2Y2E4NGEwOWEzXzExNzky_23b79d9f-3f82-41b1-9642-6294b76f75bf">The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,314,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,493,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i5dc4b8074b244545ab8c7b941208037b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItMS0xLTEtMTMzNjY4_c731c657-b7f4-4d3a-9752-2269f10086b9"
      unitRef="usd">17314094000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i892ba36fbecd4c5c828c453e8b75d851_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItMy0xLTEtMTMzNjY4_0e440844-a7d7-4b45-add3-a660abc9a134"
      unitRef="usd">13493106000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i94aede0a88af4f98b9e9b7e04739e350_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItNS0xLTEtMTMzNjY4_536faabd-13ab-407b-bd94-b47a3a669b98"
      unitRef="usd">19047183000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="idac2696acac7403eabc89c247ae97720_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzAvZnJhZzozODQwNmMyZTliMTY0ZmM0YjhkOTgyNmNhODRhMDlhMy90YWJsZTo5OWYyMzNmZDYxZDY0Yzk2YWY0ZjEwNDRlZDExZGMxYS90YWJsZXJhbmdlOjk5ZjIzM2ZkNjFkNjRjOTZhZjRmMTA0NGVkMTFkYzFhXzItNy0xLTEtMTMzNjY4_594f621d-0252-4bf8-9031-e95cfae7f2b9"
      unitRef="usd">13718245000</rprx:FinancingReceivablesFairValueDisclosure>
    <us-gaap:FinancingReceivablesTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI5NDA_d9b04bad-77e5-4174-a73e-ba307719088d">Financial Royalty Assets&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,333,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,322,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,683,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,471,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trelegy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029-2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,284,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,259,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,436,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(660,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(235,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,134,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,332,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,802,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,776,307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,476,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,299,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current and non-current financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,184,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, we recorded $160.1&#160;million and $273.6&#160;million of non-cash impairment charges for otilimab and gantenerumab, respectively, both unapproved financial royalty assets held at cost. The impairment charges were recorded as a result of GSK plc&#x2019;s announcement that it has decided not to progress with regulatory submissions for otilimab and Roche&#x2019;s statement that it would discontinue clinical trials of gantenerumab. Included in the total financial royalty assets balance of $14.2 billion as of December 31, 2022, is $533.8&#160;million related to unapproved financial assets held at cost: zavegepant, seltorexant and olpasiran. Additionally, during the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $182.1&#160;million due to the uncertainty of Gavreto&#x2019;s commercial outlook. These impairment charges were recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial royalty asset impairment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current and non-current financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI5NDI_4560c851-dc23-40b4-b29d-d3e23a55a42d">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,333,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,322,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,683,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,471,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trelegy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029-2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,284,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,259,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;894,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,436,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(660,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(235,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,134,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,332,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,802,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,776,307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,476,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,299,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current and non-current financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,184,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current and non-current financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt"&gt;Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableGross
      contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItNC0xLTEtMTMzNjY4_8bac0137-6867-4f2c-8d43-6eb5ff25c5e0"
      unitRef="usd">5333535000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItNi0xLTEtMTMzNjY4_2a601ce5-c480-4579-a8a4-3c459f771d65"
      unitRef="usd">10908000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i291d6a5f159947a298875759e6b12a1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzItOC0xLTEtMTMzNjY4_2e7bc2e2-24f3-49f8-9f80-95f6724636df"
      unitRef="usd">5322627000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtNC0xLTEtMTMzNjY4_bfd3a33d-cbb6-4f65-912d-b571e2a411a2"
      unitRef="usd">1683441000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtNi0xLTEtMTMzNjY4_1bce0a8f-c5a5-4342-8040-ea20aa556907"
      unitRef="usd">212283000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i403646e7babf4420ba107143a3a7a49c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzMtOC0xLTEtMTMzNjY4_9510ae4a-c3ca-4fd1-94a5-6ed20e363cd3"
      unitRef="usd">1471158000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtNC0xLTEtMTMzNjY4_950cb928-0246-47b0-90c9-a47fab3198e7"
      unitRef="usd">1284054000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtNi0xLTEtMTMzNjY4_bad8c103-2a34-4902-95a8-67aae961bfe0"
      unitRef="usd">24126000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i1eabb1130de844f0a07dc3f24ad506bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzQtOC0xLTEtMTMzNjY4_1082f07f-341b-4a93-93a9-1af153625fdf"
      unitRef="usd">1259928000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtNC0xLTEtMTMzNjY4_70888515-d580-44de-8c9c-928688e674e5"
      unitRef="usd">894160000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtNi0xLTEtMTMzNjY4_687481ce-057e-48c2-9414-50ac846451d7"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i1d8617601ee545eb9cc62625fd2f9ec5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzUtOC0xLTEtMTMzNjY4_c1e16e86-46a6-452a-81a5-87d8d0fe12cf"
      unitRef="usd">894160000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtNC0xLTEtMTMzNjY4_f9c70cf4-2787-4baf-b3bd-64f33737731a"
      unitRef="usd">1436969000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtNi0xLTEtMTMzNjY4_9680b5c8-52e4-4736-b3b1-74fad4bb6626"
      unitRef="usd">660703000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i56dbca1ce972434cb58c60cd86493a5f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzYtOC0xLTEtMTMzNjY4_6f949588-1829-420f-a521-5200187be927"
      unitRef="usd">776266000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i663288bef185415e913cccac3fdce980_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctNC0xLTEtMTMzNjY4_65011949-6049-4bf0-a6e3-99b6bb37e3af"
      unitRef="usd">1009168000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i663288bef185415e913cccac3fdce980_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctNi0xLTEtMTMzNjY4_4f76e86a-0fa3-4f7e-a3c3-cd442834241a"
      unitRef="usd">235625000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i663288bef185415e913cccac3fdce980_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzctOC0xLTEtMTMzNjY4_36269408-2368-4ed0-b63c-750b52d4bd76"
      unitRef="usd">773543000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtNC0xLTEtMTMzNjY4_6d2c0ce4-5cb0-4c86-b63e-c3ae94f272e2"
      unitRef="usd">5134980000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtNi0xLTEtMTMzNjY4_8414a085-1cff-4016-b519-9fbd6ac1850b"
      unitRef="usd">1332815000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i338803206bb64a83b9b1b2ea2de4bb21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzgtOC0xLTEtMTMzNjY4_611e652a-fe47-4e33-93ba-339129f110bf"
      unitRef="usd">3802165000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktNC0xLTEtMTMzNjY4_88bfcbd6-cd25-4070-b4ac-1829e6e6e6c3"
      unitRef="usd">16776307000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktNi0xLTEtMTMzNjY4_af9dcc5e-7b56-45ba-9406-33a2d92ac581"
      unitRef="usd">2476460000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzktOC0xLTEtMTMzNjY4_491223ff-b089-46b9-a8b7-953170635b0e"
      unitRef="usd">14299847000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzEwLTgtMS0xLTEzMzY2OA_5101990e-c223-4b06-aea7-f426772b6081"
      unitRef="usd">115422000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo3MDM5NjY4MDU4NTQ0ODYyYTA0OTM5M2Y5Nzk0OTY1Mi90YWJsZXJhbmdlOjcwMzk2NjgwNTg1NDQ4NjJhMDQ5MzkzZjk3OTQ5NjUyXzExLTgtMS0xLTEzMzY2OA_c10dadfb-c77c-4ff5-ac94-161a0d335c67"
      unitRef="usd">14184425000</us-gaap:NotesReceivableNet>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="ia5208a4b0fa34da2ad818a6631d4834a_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzEzMTk0MTM5NTQ1NTU1_296683f4-8dda-4ac2-bc0d-a7ddbc611067"
      unitRef="usd">160100000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="ia3cf7b243e4b44089454ec775107f6b1_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzM4NDgyOTA3MTAyODk_ef9994d7-3725-4f9a-b500-4b4753cef4d4"
      unitRef="usd">273600000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:NotesReceivableNet
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzQzOTgwNDY1MjYxNDE_0271fa54-b713-46b0-90ad-c5ba6cf11d69"
      unitRef="usd">14200000000</us-gaap:NotesReceivableNet>
    <rprx:UnapprovedFinancialAssetsHeldAtCosts
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzM4NDgyOTA3MTExMTA_aae19281-f608-46af-89ad-2d5e682271f1"
      unitRef="usd">533800000</rprx:UnapprovedFinancialAssetsHeldAtCosts>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i4429291ceec343fd99325883de8cd9b9_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzYwNDczMTM5Njk5MzQ_35bbc93c-fc2c-4e70-aebb-0a564f952c3f"
      unitRef="usd">182100000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:NotesReceivableGross
      contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItNC0xLTEtMTMzNjY4_db8844c1-ae12-41a6-ad24-917e32a15639"
      unitRef="usd">5335641000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItNi0xLTEtMTMzNjY4_045e02b2-c5a8-4bc8-9634-c679736ffdb1"
      unitRef="usd">48636000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i95c43f443bf14a7bbbc638ead341d873_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzItOC0xLTEtMTMzNjY4_d2d8b02d-9a5a-404e-bc0b-c16c31ebe1bf"
      unitRef="usd">5287005000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i154af41306544e04b3092509a83bb96f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtNC0xLTEtMTMzNjY4_d5fc0406-b999-4c0e-ba1c-75d1188b9e39"
      unitRef="usd">1846069000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i154af41306544e04b3092509a83bb96f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtNi0xLTEtMTMzNjY4_53361dbb-e6fa-49a9-9492-65b02f794faa"
      unitRef="usd">16617000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i154af41306544e04b3092509a83bb96f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzMtOC0xLTEtMTMzNjY4_4f4c753a-ea35-4d9d-8c93-ff66e907a50f"
      unitRef="usd">1829452000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtNC0xLTEtMTMzNjY4_be1c7be1-a439-467a-9b80-294e4a9e1053"
      unitRef="usd">1438730000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtNi0xLTEtMTMzNjY4_d133077a-fdaa-4b91-b9c6-880d82ee96d2"
      unitRef="usd">236871000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i21a5ffa26a4845dd941f2fb5539f7c4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzQtOC0xLTEtMTMzNjY4_38de0cfb-25b3-47db-96ed-8264e6abe9cf"
      unitRef="usd">1201859000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtNC0xLTEtMTMzNjY4_83ce5b8b-250a-4225-8017-21dcdbad8810"
      unitRef="usd">1100065000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtNi0xLTEtMTMzNjY4_7ef25e9a-0b85-4a02-b3b5-09faf9ac5999"
      unitRef="usd">172101000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="iefbe0b1fc7d543fc9f37ef14dfb56c12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzUtOC0xLTEtMTMzNjY4_740568f7-a41f-4f68-add6-a0c04f33278c"
      unitRef="usd">927964000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtNC0xLTEtMTMzNjY4_af414e83-620d-47a1-a4a0-140de43f73b7"
      unitRef="usd">881671000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtNi0xLTEtMTMzNjY4_c5b1fe43-47ae-45d8-8d61-3cd0edd2acb9"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9499567243fb4bb6a99f9c18d1a4b027_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzYtOC0xLTEtMTMzNjY4_1dd24815-cd80-4a00-8105-9b78358d9977"
      unitRef="usd">881671000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctNC0xLTEtMTMzNjY4_c76c8436-5d63-410a-951c-0275294832d2"
      unitRef="usd">727774000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctNi0xLTEtMTMzNjY4_99d6adf5-575e-4bae-b957-73b71964bb26"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzctOC0xLTEtMTMzNjY4_da818333-9fd9-4dc2-86d2-4adaa1dedff2"
      unitRef="usd">727774000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtNC0xLTEtMTMzNjY4_0ffa911e-3112-4822-8adb-95fc594a7b8f"
      unitRef="usd">4697591000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtNi0xLTEtMTMzNjY4_b26c1106-8a20-4ab2-9564-816876a4ba47"
      unitRef="usd">909916000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i69d319ef128f4f8885c3dadade2065f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzgtOC0xLTEtMTMzNjY4_3c4005fc-1d35-4788-a6e7-948b4d713886"
      unitRef="usd">3787675000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktNC0xLTEtMTMzNjY4_aed92430-7663-4da8-97bb-02af01729181"
      unitRef="usd">16027541000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktNi0xLTEtMTMzNjY4_3a658daf-e9db-4fc5-a14b-ee868a70b9d7"
      unitRef="usd">1384141000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzktOC0xLTEtMTMzNjY4_92bad12a-5120-469c-a5c8-cdf25a19d27a"
      unitRef="usd">14643400000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzEwLTgtMS0xLTEzMzY2OA_ed3d9ec6-9d53-4d51-a611-7e8095517347"
      unitRef="usd">310804000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90YWJsZTo0MzE3NGI4NmU4ODY0YTY2ODI2NzI0YTAxZGNiNWIxNi90YWJsZXJhbmdlOjQzMTc0Yjg2ZTg4NjRhNjY4MjY3MjRhMDFkY2I1YjE2XzExLTgtMS0xLTEzMzY2OA_2ddec4c4-8f39-481a-b3e6-c4e51c0cc65a"
      unitRef="usd">14332596000</us-gaap:NotesReceivableNet>
    <rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents
      contextRef="i0d3fcb3410a948649edfbf04b196d762_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzYvZnJhZzpjZmQ2YWJiNmUyYTQ0YjNhYjNlN2JlMzAwM2ViYjc2OC90ZXh0cmVnaW9uOmNmZDZhYmI2ZTJhNDRiM2FiM2U3YmUzMDAzZWJiNzY4XzI3MDQ_07f4bc26-eb28-499a-8da2-efdf86e6dc29"
      unitRef="usd">1300000000</rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzI3NDA_fe1d8439-4831-433b-a589-2f1e18d6fe00">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets and includes the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated using sell-side equity research analysts&#x2019; &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consensus sales forecasts,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the write-off of cumulative allowance at the end of a royalty asset&#x2019;s life which only impacts the consolidated balance sheets, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(868,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(192,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,263,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(912,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,394,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,591,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $90.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik. For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;by increases in the value of zavegepant. For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzI3Mzk_1ad8072b-7e1c-478a-98d6-eaac5be5ebd6">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(868,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(192,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,263,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(912,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,394,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for credit losses, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,591,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $90.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik. For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;by increases in the value of zavegepant. For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.&lt;/span&gt;&lt;/div&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i6924ffcc56464af49725a154112a2c81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEtMS0xLTEtMTMzNjY4_f9af9d60-592d-4a80-b7fc-500e044265cd"
      unitRef="usd">868418000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i2485d51e396d457d82d53b0d720876f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzItMS0xLTEtMTMzNjY4_28403238-0bdc-4865-83dc-a790893d0232"
      unitRef="usd">192705000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzMtMS0xLTEtMTMzNjY4_bde5e576-c0de-4337-b33d-c1d018364afc"
      unitRef="usd">645612000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzQtMS0xLTEtMTMzNjY4_54d0d7dd-c0ad-4f6b-91a5-92e5f1cd3d4f"
      unitRef="usd">570959000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzUtMS0xLTEtMTMzNjY4_d224f1fb-74cc-47d5-87a1-73416e72918a"
      unitRef="usd">2964000</rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzYtMS0xLTEtMTMzNjY4_1fe6916e-c788-4685-8f86-76c20bae7436"
      unitRef="usd">25174000</us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzctMS0xLTEtMTMzNjY4_9a5c4e36-1aed-42f7-8aba-64460c51e1f1"
      unitRef="usd">156186000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzgtMS0xLTEtMTMzNjY4_d4422804-d0a3-4a22-8438-0cf038ad692d"
      unitRef="usd">1263824000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEwLTEtMS0xLTEzMzY2OA_9f9deaa3-8785-4517-9bb5-6d4bb604cef9"
      unitRef="usd">912710000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzExLTEtMS0xLTEzMzY2OA_eb7f0696-1668-4577-a4a5-66b147186158"
      unitRef="usd">446955000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzEyLTEtMS0xLTEzMzY2OA_c2352907-a3be-433c-864c-7155a9ceb1bf"
      unitRef="usd">21721000</rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE0LTEtMS0xLTEzMzY2OA_609c023f-7b85-48db-8b7c-b73363500bff"
      unitRef="usd">-12913000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE1LTEtMS0xLTEzMzY2OA_2869ba2b-59b3-46be-a3f7-516fc21e1e8a"
      unitRef="usd">1694945000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE3LTEtMS0xLTEzMzY2OA_2dd340d6-5779-418f-99a6-43a1444ea3c4"
      unitRef="usd">1394679000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE4LTEtMS0xLTEzMzY2OA_e1d1ed2b-053f-4542-be76-03302479f98c"
      unitRef="usd">296637000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzE5LTEtMS0xLTEzMzY2OA_940fb2d2-5394-4725-9854-9e8eab5f1a82"
      unitRef="usd">5723000</rprx:FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIwLTEtMS0xLTIyNDA4MQ_33dda8eb-60b1-4f08-b380-9b427915617c"
      unitRef="usd">1584000</us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIwLTEtMS0xLTE3ODAzNw_7a2fcb24-5e6d-4a96-aa5b-3df81647c02a"
      unitRef="usd">-193798000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90YWJsZTpjNjFjNTZjOTc3Njc0ZjYxYWRkMzNkNDU3YWE4ZjZkZC90YWJsZXJhbmdlOmM2MWM1NmM5Nzc2NzRmNjFhZGQzM2Q0NTdhYThmNmRkXzIxLTEtMS0xLTE3ODAzNw_a6d4807f-e90f-456a-b88a-fb4c98dfcdd9"
      unitRef="usd">2591882000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMzkvZnJhZzpiNmIyNmI5NGZiNDk0ZDk5OThhMTFmOWZiNjcxZTJkZC90ZXh0cmVnaW9uOmI2YjI2Yjk0ZmI0OTRkOTk5OGExMWY5ZmI2NzFlMmRkXzE2NDkyNjc0NDI5MzIz_cced7c04-3c61-4c26-8079-e7d17e331737"
      unitRef="usd">90200000</rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzEyNTM_4649b5ee-6103-47e2-85f5-4e1cb4315995">Intangible Royalty Assets, Net&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the first quarter of 2022. Our royalties on the other DPP-IV products have also substantially ended. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90%, 86% and 97% of revenues from intangible royalty assets in 2022, 2021 and 2020, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzEyNTQ_e46e4620-19f7-48c3-b426-82525bdff292">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItMS0xLTEtMTMzNjY4_65d90586-7162-45e3-b617-5848883e0b9f"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItMy0xLTEtMTMzNjY4_c198fabc-8f18-4648-b70a-67604fa5d11d"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i71b6eb6811ec4585a35ba78cd19a5c8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzItNS0xLTEtMTMzNjY4_69d5105a-e776-4a4a-886c-70d08752b108"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtMS0xLTEtMTMzNjY4_1f8fce33-ec10-4b1b-8bec-ba7476f8e600"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtMy0xLTEtMTMzNjY4_f6cfbcbf-277b-4372-b3e2-560419d72828"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90YWJsZTo2NmQ1MmM0MGMwYzg0MjNiYWU5MGE1YWM3YTE5YzA5Mi90YWJsZXJhbmdlOjY2ZDUyYzQwYzBjODQyM2JhZTkwYTVhYzdhMTljMDkyXzQtNS0xLTEtMTMzNjY4_d23ff188-a80d-47df-81d8-d816ec6fb896"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib252428d952a4cf3902a48bd039d459d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzU0OTc1NTgxNDExODI_e34c7780-ecc6-4852-b235-77176481454c"
      unitRef="number">0.90</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i153bc6bd9c0047408ceded26b5f9e59a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzE2NDkyNjc0NDE5NjUw_501e0a3e-8837-449a-bd63-2b3d63056f6e"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc9b2898f14b4fc8b46de629cd65f242_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDIvZnJhZzo0MDgyYzE4MjAxOTI0Yzg5YjVkMTljODFkNGYzYWEyOS90ZXh0cmVnaW9uOjQwODJjMTgyMDE5MjRjODliNWQxOWM4MWQ0ZjNhYTI5XzE2NDkyNjc0NDE5NjU1_48e39d72-929a-4ded-be38-bc72a5f7e459"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzQxMjA_04a4eb75-18fe-4acc-bfe2-ef33c64ce3cb">Non-Consolidated Affiliates&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities over which we have elected the fair value option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ApiJect&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments. We are also required to purchase additional common stock from ApiJect if certain milestones are achieved. The fair value of our equity investment in ApiJect was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December 31, 2022 and the change in fair value was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gains)/losses on equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for 2022. The fair value of the revenue participation right was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022 and the change in fair value was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other non-operating expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for 2022. No amounts were due from ApiJect as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Legacy SLP Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#x201c;Legacy SLP Interest&#x201d;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#x2019;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#x2019;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. We recorded income allocations of $3.0&#160;million, $8.9&#160;million and $62.0&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in losses/(earnings) of equity method investees &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2022, 2021 and 2020, respectively. We collected cash receipts from the Legacy SLP Interest of $25.7&#160;million, $21.0&#160;million and $22.7&#160;million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Avillion Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our partnership interests in Avillion Financing I, LP and its related entities (&#x201c;Avillion I&#x201d;) and BAv Financing II, LP and its related entities (&#x201c;Avillion II&#x201d; and, together with Avillion I, the &#x201c;Avillion Entities&#x201d;) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. We recorded loss allocations from the Avillion Entities of $12.0&#160;million, $28.4&#160;million and $17.6&#160;million within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity in losses/(earnings) of equity method investees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#x2019;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million in each of 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $150.0&#160;million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023. Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments. In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $80&#160;million to Avillion II to exercise an option to commercialize Airsupra in the United States. We expect to receive our pro rata portion of the exercise fee of approximately $35&#160;million, subject to any holdback for expenses, in 2023. &lt;/span&gt;&lt;/div&gt;Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments. As of December 31, 2022 and 2021, RPIFT had unfunded commitments related to the Avillion Entities of $28.8&#160;million and $11.2&#160;million, respectively.</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i0fbcaa672be248e197fc3072f0903674_I20200211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3Nw_7e56752e-45f3-44dd-87b9-6509ba2bb652"
      unitRef="usd">303700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE3MzU_3ece9f6c-0832-4588-8a7c-51df087fec61"
      unitRef="usd">3000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE3NDI_e43b21cc-89f5-4edd-a9c5-25bce839e4c3"
      unitRef="usd">8900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTU2_0e2cd2a4-3c63-46dd-b587-8ef423784bd3"
      unitRef="usd">62000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ia2eaf3ac0c674a12acb478f730d652f8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE4MzQ_1bcd9591-33d5-4293-8b24-94d95a8d805c"
      unitRef="usd">25700000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="id0634ff0b1314484a75b37c5261a15a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE4NDE_50cb89b2-2d4d-4e04-9772-51202154b52b"
      unitRef="usd">21000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1a9c112b5dd847f39328c72d118bb8e2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTI2_1a76cbb6-f57e-408e-9a78-866b24e70fa3"
      unitRef="usd">22700000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7d8076ed02354170b8e1aef0696b1dd1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzIyNTI_92b35944-0996-4563-a154-438d06d55734"
      unitRef="usd">-12000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icb803d1f20cc4fce8c2f9ab745affbd7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzIyNTY_b32f74b7-f566-486b-aa9a-35c8a8ee3235"
      unitRef="usd">-28400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i850f55de08b348c6896f173a3de0636e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDI2MTQx_380456a6-1172-4b9f-9422-ec296bf20446"
      unitRef="usd">-17600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ia14cea8f163049d485a56b89150c4bc2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_31b82f27-e7af-4418-bbae-7e4c43d776d7"
      unitRef="usd">13400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i80c12de839c544f5bb19445f982348c5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_6054a959-f7d3-45a0-8aa1-7182f44362eb"
      unitRef="usd">13400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i91fcca9afda04cc6ba4981ca2685afe6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzI3MTg_b668dd58-866d-4046-9e2d-c4c06c29af07"
      unitRef="usd">13400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:OtherCommitment
      contextRef="i8b06f23fa444477b8d31b04cd8b75199_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzEwOTk1MTE2MzUzNjc_711246f5-0fde-4170-8e8e-b813d75bb722"
      unitRef="usd">150000000</us-gaap:OtherCommitment>
    <rprx:ProceedsFromExerciseFee
      contextRef="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzE2NDkyNjc0NDMzOTQ4_caef913a-9302-4759-9f56-278951d7c61f"
      unitRef="usd">80000000</rprx:ProceedsFromExerciseFee>
    <rprx:ProceedsFromExerciseFeeProRataAmount
      contextRef="ic63aa84bd1dc45e982967ed60412bc21_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzQzOTgwNDY1MjkyMDM_94582d24-8922-487f-b1ab-be2c90c89391"
      unitRef="usd">35000000</rprx:ProceedsFromExerciseFeeProRataAmount>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="i84614dd16a8241bc9bb8d393780ce7a1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzM4ODc_cbdfd52a-709e-4a42-9da8-334b8fa2d7af"
      unitRef="usd">-28800000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="if8da099dd6c543afb79c83d2662bba53_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDUvZnJhZzplYzNhNTkxNGNlY2U0NTkxYTBlY2ZhZTdjODk1ZTA5OS90ZXh0cmVnaW9uOmVjM2E1OTE0Y2VjZTQ1OTFhMGVjZmFlN2M4OTVlMDk5XzM4OTQ_0f2f8405-2921-4e38-8653-016449fb6ea9"
      unitRef="usd">-11200000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzE4Mzg_a4c01cce-bade-43e2-ba4d-818ea9a41e39">Research &amp;amp; Development (&#x201c;R&amp;amp;D&#x201d;) Funding Expense &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. It includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognized R&amp;amp;D funding expense of $177.1&#160;million in 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, primarily related to upfront and milestone development-stage funding payments of $100.0&#160;million, $25.0&#160;million and $50.0&#160;million to acquire royalties on development-stage products from Cytokinetics, Theravance Biopharma, Inc., and MSD International Business GmbH, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized R&amp;amp;D funding expense of $200.1&#160;million in 2021, comprised of $193.2&#160;million in upfront R&amp;amp;D funding expense and $6.9&#160;million in ongoing R&amp;amp;D funding expense, primarily under our co-funding agreement with Sanofi. The upfront R&amp;amp;D funding expense included $103.2&#160;million and $90.0&#160;million in exchange for an incremental royalty on a development-stage product from BioCryst and future royalties on two development-stage products from MorphoSys, respectively. &lt;/span&gt;&lt;/div&gt;We recognized R&amp;amp;D funding expense of $26.3&#160;million in 2020, comprised of $20.5&#160;million in ongoing R&amp;amp;D funding expense, primarily under our co-funding agreement with Sanofi, and $5.8&#160;million in upfront R&amp;amp;D funding expense for a royalty on a development-stage product that we acquired from BioCryst.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4MzM_14b85120-6393-4519-8258-5faa2163eafc"
      unitRef="usd">177100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i44ef2537a2d647a4b5b8a82e00bf960a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDM0ODQ_b0b58e77-1782-4a99-9522-52fc0283bebb"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i10ff8205a3ec46f18544e77a5fe83eab_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzM4NDgyOTA3MDQyNzA_958e0525-1676-4a14-97ed-fdb1819f1768"
      unitRef="usd">25000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61ecf49a29ae4381b6950b4facb564aa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzM4NDgyOTA3MDk3OTE_df8d31f6-3d85-40f2-8638-81e7cae9dd01"
      unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4NTA_8347596c-b062-4a73-b1c6-5705379c0f6b"
      unitRef="usd">200100000</us-gaap:ResearchAndDevelopmentExpense>
    <rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzEwOTk1MTE2NDE3MTA_a97277a3-f875-4c53-a9d7-815b2a93a32c"
      unitRef="usd">193200000</rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3edb74e20d194d1cb5aaf64169b64925_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDU4NTg_dfb8519b-b980-440d-85b4-47cb3846078f"
      unitRef="usd">6900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3ffdc417e74646e7a3d9fc1fea36076e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNTIzNDE_3db62543-bdcc-4ea4-92ea-e049f8f6b772"
      unitRef="usd">103200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9ff4aab128754f10b2751bd913443e32_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzU0OTc1NTgxNDI5OTE_20a0d94a-3b5c-425e-b27f-a457d55f7933"
      unitRef="usd">90000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzQzOTgwNDY1MjM4Mzk_aa90e1c9-7d03-4e40-b8fb-cebb6e042c4b"
      unitRef="usd">26300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib41d6ba411fa44fe8f54e00c9719be69_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzE2NDkyNjc0NDI1Njky_b5c70f70-9e97-4c68-9f37-b19b8b28fb8d"
      unitRef="usd">20500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i93638517e843430abd0622cd117849fc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNDgvZnJhZzpmNzZiMmYxZWRlMTU0MTUyODAyMDM3Mjk4ZmQ2MzQ5MC90ZXh0cmVnaW9uOmY3NmIyZjFlZGUxNTQxNTI4MDIwMzcyOThmZDYzNDkwXzEyOTk_0ee90a20-e405-4d8a-9cf9-7ad5c125c49f"
      unitRef="usd">5800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTI_fa560971-b1ff-4252-9649-0a47f07c2de5">Borrowings&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,116,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,096,070&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(997,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,118,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,096,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#x201c;2021 Notes&#x201d;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#x201c;2020 Notes&#x201d; and, together with the 2021 Notes, the &#x201c;Notes&#x201d;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13% and 2.50%, respectively.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as of December 31, 2022, we were in compliance with all applicable covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022 and 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.7&#160;billion and $7.2&#160;billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Senior Unsecured Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the &#x201c;Credit Agreement&#x201d;). The Credit Agreement amended and restated the prior credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Revolving Credit Facility has a maturity date of October 31, 2027. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2021, there were no outstanding borrowings under the Revolving Credit Facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#x2019;s prime rate, (2) the federal funds rate plus 0.5% and (3) Term SOFR plus 1% or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RP Holdings was in compliance with these covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#x2013;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20&#160;billion and $2.84&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1&#160;million as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other non-operating expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RPIFT Senior Secured Credit Facilities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4&#160;million as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other non-operating expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Principal Payments on the Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,300,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,300,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Excludes unamortized debt discount and issuance costs of $183.7 million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTQ_98a9e4b6-186f-4af0-8d75-a560c9dd0ba3">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,116,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,096,070&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(997,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,118,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,096,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfNA_6612fb10-4f91-487a-812e-5bded4c95841"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfOA_eb2b2441-fbbd-4f30-b432-0d632efd9e81"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i8faa4e13bd38491daf38566f6eebb9b9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWU1NjkxYzc5MDEzNGNiZjgxMzQ1ZWMxMjZkMmQ2NTZfMjI_460f6dd9-1545-462c-9a42-066eb14355db"
      unitRef="number">0.99322</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i86c83ded7cd649d49c712b21a4451c82_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItNi0xLTEtMTMzNjY4_8ffbdc8c-ea09-4822-a1c6-6eeb2cb0fb48"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaa254b18546f40f685306a6288911d2c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzItOC0xLTEtMTMzNjY4_3244aff7-ae50-482b-86da-d0db7359add4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i506d480262374d17bc6c2d61664062dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfNA_05ef2d37-31dc-4684-8a70-4f45d81c71b5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i506d480262374d17bc6c2d61664062dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfOA_e17aca86-f48a-49df-8abc-5f90d431edb5"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i8198214b15354bb4a8f445cec4dbc5e2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NmVhYTYwYjJjOTY2NDA5ZWIyMDc5YjU5NWIzYzI4NzJfMjI_099a3d07-01eb-4cac-b70e-07fd4e5786fa"
      unitRef="number">0.98875</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i506d480262374d17bc6c2d61664062dd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtNi0xLTEtMTMzNjY4_d590866d-e1d3-4ac3-ba7c-35e6036a5acf"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i026f9953369d49eea32d8638a01cd4ca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzMtOC0xLTEtMTMzNjY4_09c2f24d-4edc-459f-920a-2abe63320f8e"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i320c72757fa545478705ae929cf21624_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfNA_18fdc13c-9cfe-476a-9735-e5b6dba71323"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i320c72757fa545478705ae929cf21624_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfOA_a3a7f5a5-ed61-42cd-83e4-6297fae42788"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ic03ffc7bd4c74c5ca68cf23404563dd7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246YjNkZGVkNmQwODAwNDQ1N2FhYWQxM2ZhOTIzM2RkZmVfMjI_78c17c7b-6343-4714-a315-1364dc05f7a0"
      unitRef="number">0.98284</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i320c72757fa545478705ae929cf21624_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtNi0xLTEtMTMzNjY4_c57e3666-2e78-42cc-ba83-5a15c8bb5994"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i36467572e76c44bab1b0c5564c2c4f5f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzQtOC0xLTEtMTMzNjY4_331d78b5-19fe-4cc1-8cd4-a5a8cee5cdae"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfNA_3aa66144-ad3e-48ae-906b-2636a4b2f9e2"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfOA_090879c0-411e-445b-b335-abcf971db8c8"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ie13d0bca9e81479fac36370bd642690c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NzE2NDM0YmFkZDRkNGM4NmJlMzEwMzQ2OTM5YTI5NzFfMjI_4d3f164d-3010-4eea-adfb-de960d26830a"
      unitRef="number">0.97760</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i45e5e2ba7c2b48ad8d172dab75994092_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtNi0xLTEtMTMzNjY4_2eb72870-63a6-4bda-9441-d1a2a5402609"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic0acbd3d4d824163a23c1f2c06b0d15a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzUtOC0xLTEtMTMzNjY4_a3376cd0-a7d6-4377-8c0d-191edf498b05"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfNA_18e025dd-2aee-476d-9d22-fd9247575598"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfOA_2009f755-3fb9-4ed8-8e04-b133b550b944"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i5aad990d21894f778fa32056c3d7f296_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246NDg2ZDE1ZWFhMDRmNDg4YjkwYjU4NDQ3OGFjYmNhN2RfMjI_013e8aad-5543-441e-9e95-daed88c7ede3"
      unitRef="number">0.98263</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9e3b1f7f781f4552b2f27601b07a52ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtNi0xLTEtMTMzNjY4_4bd60090-8fb7-4ea5-8a9d-b99f2b9aa470"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6788ce3a13ed48968ef184ebb77330c2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzYtOC0xLTEtMTMzNjY4_b0e04a0b-3816-4e70-a639-5495b8a9cbc5"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfNA_571f90e8-41c1-4f94-beb6-81237ee1b672"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfOA_0cc8a4ea-6ca9-49b9-b339-57ab35453011"
      unitRef="number">0.0330</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i838c7cff011e48c7b534f0f3eedaa181_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctMC0xLTEtMTMzNjY4L3RleHRyZWdpb246ZjMyZWU0MTkyMmRjNDE1Mzg1ZTYxYThhMTIyYzQzMzFfMjI_d9785364-7184-4f9a-891c-29d8145acf30"
      unitRef="number">0.95556</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6276f25d8444c9ab2361232593a04a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctNi0xLTEtMTMzNjY4_c2373e42-64a7-41f9-84bc-2180c4400508"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifd566c8dcd3c4e5b9f6aec7f920d2ee9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzctOC0xLTEtMTMzNjY4_e50efe61-9e77-4e0a-9766-45abff3b15be"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfNA_76588c22-5847-4232-81c2-b02d913e5a1a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfOA_ae5682b5-7eb8-489d-b3c3-2f120ba6854a"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i149da048776c4462b194bf3e704f0d93_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtMC0xLTEtMTMzNjY4L3RleHRyZWdpb246MmRkODMyODg1ZDkwNDMyM2I2Y2U5NWEwMTk3NGMzMTFfMjI_89d50c0e-15da-4c78-9cef-762b7bbd2458"
      unitRef="number">0.95306</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba5ff526d64b44c38b351540afac0ce9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtNi0xLTEtMTMzNjY4_bfff8f20-00c5-4104-94b0-2b3491f01012"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1cdc999f38464531a986434571af11df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzgtOC0xLTEtMTMzNjY4_dc58c7a4-b9bd-4482-a6b6-bc98b9947427"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ief8928daca3b419895b3307d21daa429_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfNA_f54e5b6a-4207-4473-8cdf-967f3679bacc"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ief8928daca3b419895b3307d21daa429_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfOA_5a99e745-549c-4ffc-98c2-ec1948ab1cf8"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ifa5d9597c55743f0b0ea434a2f05583e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktMC0xLTEtMTMzNjY4L3RleHRyZWdpb246OWY5MDA1ZmVjNDcyNDQyM2E5YmFiNjM2NTBiYzg5NWNfMjI_b644c93f-f5a2-4189-bd4b-bc9354170521"
      unitRef="number">0.97565</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ief8928daca3b419895b3307d21daa429_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktNi0xLTEtMTMzNjY4_84c12686-d7c2-4f37-a02b-502c13951507"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90b0dac23f424541b08adeb45318f282_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzktOC0xLTEtMTMzNjY4_2417dd9f-dade-4c99-94a2-116efc93602e"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzExLTYtMS0xLTEzMzY2OA_9982074b-35f3-40ca-9147-45247f92ba58"
      unitRef="usd">183678000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzExLTgtMS0xLTEzMzY2OA_b84a351a-15ab-41cb-9102-167725e8dee7"
      unitRef="usd">203930000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzEyLTYtMS0xLTEzMzY2OA_aa512bfc-03a9-44d4-8062-f0cc225451dc"
      unitRef="usd">7116322000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzEyLTgtMS0xLTEzMzY2OA_81b80c93-5929-4752-a069-76dbc61f321d"
      unitRef="usd">7096070000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE2LTYtMS0xLTEzMzY2OA_853164e6-b423-4d7d-b174-247564eb5912"
      unitRef="usd">997512000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE2LTgtMS0xLTEzMzY2OA_b6680eaf-6159-403c-9841-3a1f692dd144"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE3LTYtMS0xLTE4NzQ1Mw_346a6b11-92b8-434d-b73c-cac5460e651b"
      unitRef="usd">6118810000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo1MTg3MDk1NTQ4NGE0NTZhYWMwZDc1Y2Q5NjBmYTBjYi90YWJsZXJhbmdlOjUxODcwOTU1NDg0YTQ1NmFhYzBkNzVjZDk2MGZhMGNiXzE3LTgtMS0xLTE4NzQ1Ng_d0a7f222-7469-4719-b461-579ae2517c37"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9df2b8b2b611422b93e15b5384fee55a_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0OA_59ea1d8a-aeb4-4d5d-89dc-96b773b325e2"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i81df3e9523394784bee4f0ab4f95754b_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzIwOQ_172f0072-a2ea-4c68-afbc-4ec8b731fe48"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i841ed43575b4462d8d7e171a31c3a0ea_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzI2MQ_2f4cbccf-e746-4132-8ec6-7655cc09c27c"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9df2b8b2b611422b93e15b5384fee55a_I20210726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNDM_52fab0c6-12e3-4cb4-bfac-4aeba74c0040"
      unitRef="usd">27500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i841ed43575b4462d8d7e171a31c3a0ea_I20210726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNTE_d15876b6-e59d-46be-82b2-aaa31d7d97d2"
      unitRef="usd">12300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i384458f232644f91aa9aeae55e9bf165_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzc1Ng_ad25559c-fea1-41af-a2aa-8eb9632bd728"
      unitRef="number">0.0280</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i384458f232644f91aa9aeae55e9bf165_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzc2Mw_9a5a7c6a-adbe-4b27-90eb-2e8185ab7a70"
      unitRef="number">0.0306</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzgxNA_8f728783-221d-4a2e-ac8d-ac9207f45fa0"
      unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNjc_42e136c6-efdb-41c6-8b0e-d33c2381e69b"
      unitRef="usd">149000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i22b9307cb7ec46f19ce7cf4ea087b100_I20200902"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwNTk_03f8fa4e-f459-4150-b1f5-909869ca7847"
      unitRef="usd">40400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0Nzc_232a71f2-cc86-4ba8-8bf5-018bfb35ddff"
      unitRef="number">0.0213</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE0ODQ_ba668793-6e31-4ec1-8f11-9d6d4b6a7f8a"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib6668080e1a943078f97f24224e6214b_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE4MzQ_6e144621-38c5-49bc-90b9-07a504506fc3"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i87ec196b42b349799568466b38b36d11_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzI1MzU_a3ab05d1-21bf-423a-b59b-e94ed88c0ff3"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3ef9b1f654c54a45a6014f3846682ac2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU0OTc1NTgxNDgwMjQ_8ba3a8ff-e8df-48a7-ba16-7f58ab5a1bdc"
      unitRef="usd">5700000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if2e5ff3a9e2243d18e1771b08d510e30_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzMwNDY_486b1007-0684-4ad9-afe8-5f6309fd84df"
      unitRef="usd">7200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentTerm
      contextRef="if3f37019f75444bfb079f9eae44011a7_D20221031-20221031"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTY_427e46d4-9ce1-4b68-a7e5-64ddee78e4e1">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0477a1e950d844878b385b517d204739_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzM1MTQ_4652c375-a084-4cbb-9c9e-cfc7322eaea3"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="ibc82c34f1b1841fb9acad0573bb9c2af_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUxMTI3MjkwNzA4ODM1_3151c003-0fe7-418e-8fb8-c5771bd49435"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0913b22937e94ce69dadc8d8ef64f99d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUxMTI3MjkwNzA4ODM1_6ce3c8f2-569c-46f7-8616-849fe1a20820"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7ded29aec73342379a32b7f0d37ce932_D20221031-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwMDg_16790aa2-1b86-4e42-8a12-f06eb69d444b"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2b646b86d4204e5ab0e00d75294a4677_D20221031-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwMDg_4a78268a-0945-4a8b-b348-cafdc3019ea6"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifa789f47637b468b8e0a81f1258d7822_D20221031-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQwNTQ_48e84c81-a592-4ba0-a9e4-54a65f070b4d"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio
      contextRef="id28f0ac392314518bd09f5981a109a33_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQ3MDk_c4ed4d0f-aaf0-4cfc-bb74-d429242fdcac"
      unitRef="number">4.00</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition
      contextRef="id28f0ac392314518bd09f5981a109a33_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzQ3MzY_97728005-4b4d-46c0-a12c-011cc96250fb"
      unitRef="number">4.50</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition>
    <rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio
      contextRef="id28f0ac392314518bd09f5981a109a33_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzUwMjA_5bf0672e-e017-450b-82af-cd8fc7e294f8"
      unitRef="number">2.50</rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ida442f1cecf14df5945065908673a6d0_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzU5OTM_6ad6c368-a304-4834-a185-3e4bb83cbead"
      unitRef="usd">3200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7f70bcb4de984b258954aedd1f27e7db_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzYwMDA_0046a315-5f74-44f1-aafe-952fa6bc91b5"
      unitRef="usd">2840000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9c86a83a372f42caa003779427589736_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE2NDkyNjc0NDI4NDMx_716547ec-9373-4dfb-83a7-f15399284c72"
      unitRef="usd">-25100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if0b4057d220b45ad8565474419d30930_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzE2NDkyNjc0NDI4NDQ2_bb069cc6-3267-48d1-9bcd-50597b94fb1b"
      unitRef="usd">-5400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzcxMTg_161c224a-0d48-44d1-90cc-070a3900c369">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,300,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,300,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Excludes unamortized debt discount and issuance costs of $183.7 million as of December 31, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzItMi0xLTEtMTMzNjY4_0587856d-2464-47c6-8d50-8611622250b6"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzMtMi0xLTEtMTMzNjY4_521ec292-b696-4a84-9a86-290142fb42f0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzQtMi0xLTEtMTMzNjY4_d660d20e-759e-43e1-a3f0-ae1e42e6fe85"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzUtMi0xLTEtMTMzNjY4_5c60d71c-5e39-40b5-a00f-80137ad1fea4"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzYtMi0xLTEtMTMzNjY4_258c9b5c-b651-4921-92e3-36ad6e7e354d"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzctMi0xLTEtMTMzNjY4_fc92affa-ce31-433a-bcc2-50ca62f23aa0"
      unitRef="usd">4300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8d165cc588cb42c7a715455ac1f644a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90YWJsZTo5NmMzZjliMzQ4ZGQ0ZjU1Yjc2MmI5MzJkNzI5NWUxOS90YWJsZXJhbmdlOjk2YzNmOWIzNDhkZDRmNTViNzYyYjkzMmQ3Mjk1ZTE5XzgtMi0xLTEtMTMzNjY4_03967741-1822-4213-95da-a0861301b5a5"
      unitRef="usd">7300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTEvZnJhZzplMWE1YjQ2ZDNmYTY0YzNiOGQyM2I2ZjE1YzhkZWVhZC90ZXh0cmVnaW9uOmUxYTViNDZkM2ZhNjRjM2I4ZDIzYjZmMTVjOGRlZWFkXzY5OTM_826c44ea-5bda-4822-83eb-763aa1400dc2"
      unitRef="usd">183700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDY_443645bd-f689-4246-b52b-ff4df2d224b4">Shareholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capital Structure&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the completion of our IPO as discussed in Note 1&#x2013;Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of December 31, 2022, we have 443,166&#160;thousand Class A ordinary shares and 164,058&#160;thousand Class B ordinary shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#x201c;Exchange Agreement&#x201d;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2022, we have 371,325 thousand deferred shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights.The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#xa3;1 each.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(594,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(792,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income prior to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuance of Class A ordinary shares sold in IPO, net of offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income subsequent to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(425,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(435,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(604,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,527,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,369,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,897,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 27%, 29% and 36% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and 73%, 71% and 64% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;RP Holdings Class C Special Interest Held by EPA Holdings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a &#x201c;Portfolio&#x201d;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#x201c;Equity Performance Awards&#x201d;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest. We do not &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met. Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. During 2022, we declared and paid four quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $333.3&#160;million to holders&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our Class A ordinary shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Independent Directors Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2022, approximately 565&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSU Activity and Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt; in the consolidated statements of operations. In 2022, 2021 and 2020, respectively, we did not recognize material share-based compensation expense. As of December 31, 2022, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0&#160;million, which we expect to recognize in the next six months.</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <rprx:NumberOfClassesOfVotingStock
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE0Mw_0f59be4c-0951-4027-91c7-000124543306"
      unitRef="class">2</rprx:NumberOfClassesOfVotingStock>
    <rprx:CommonStockVotingRightsNumberOfVotes
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQzOTgwNDY1MjU0MTk_4bddc898-97ad-4155-91f9-1380f691e0f0"
      unitRef="vote">1</rprx:CommonStockVotingRightsNumberOfVotes>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iabe3448245414e18a4b4313799d4a486_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzM4NDgyOTA3MDQ1NTI_b71b4b48-205f-4524-a60f-7995f75e1b5f"
      unitRef="shares">443166000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia31bf864aa8c4b788872a9ae3d5dc500_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzM4NDgyOTA3MDQ1ODQ_5ac7b390-b80e-4805-8cd1-94503d48970f"
      unitRef="shares">164058000</us-gaap:CommonStockSharesOutstanding>
    <rprx:CommonStockQuarterlyConversionBasis
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQzOTgwNDY1MjU0Mjc_4d50abf2-ec24-4d93-917a-193dbace4728"
      unitRef="shares">1</rprx:CommonStockQuarterlyConversionBasis>
    <us-gaap:SharesOutstanding
      contextRef="i76d3c2ccbb2e48b4bb1b655fce22c0fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzEzMTk0MTM5NTQ0MjM2_1b7d2a6d-00e3-4428-8a1c-796b8fdfd216"
      unitRef="shares">371325000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i4a118afd54f1420497a8451111036378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE0NTI_2123f768-79a3-462c-a7ea-c2777455cea8"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <rprx:RedeemableStockRedemptionPricePerShare
      contextRef="iebf80945d01e4cda8265a7a35cb92256_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzE5Mjc_7eeb169e-d343-4ff0-bb2d-60d6eb50105c"
      unitRef="gbpPerShare">1</rprx:RedeemableStockRedemptionPricePerShare>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDc_69194b85-ea72-4474-866b-0b04108e1e97">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(594,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(792,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income prior to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuance of Class A ordinary shares sold in IPO, net of offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income subsequent to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(425,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(435,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(604,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,527,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,369,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,897,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 27%, 29% and 36% in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively. Royalty Pharma plc owns the remaining and 73%, 71% and 64% of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <rprx:NumberOfNoncontrollingInterests
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_5ad9e0c6-ebe7-40fc-adf6-b37408958d6d"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterests>
    <rprx:NumberOfNoncontrollingInterests
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_8bb6e858-52b4-4d18-8056-fc37736fc018"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterests>
    <rprx:NumberOfNoncontrollingInterests
      contextRef="i8b9169a4bf9c4e2692a023b17759e46f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzIxOTc_c195a293-f759-43f0-9b14-177b45482183"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id583806a07ed4cd8bfd78850b5f779a6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMS0xLTEtMjg1MjUw_6529489b-355a-4ed7-a2f5-b1e2488d1257"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6cc65a06afd46199b75bfd37257d1bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMy0xLTEtMjg1MjUw_ce8dc61c-2e8f-4757-b111-3547087285e5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0509ce4690e4e7589a22610857ffc76_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNS0xLTEtMjg1MjUw_914047c2-caa0-48e2-b73b-2b03b208a257"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d596cf933ba4342a229fa9b82d58290_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNy0xLTEtMjg1MjUw_269a8529-2d52-4e65-aa94-58061f67be4c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f39a0b7c18043a28e9ffe389d1710f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtOS0xLTEtMjg1MjUw_7218116c-4d76-4c28-b839-696a5e8b1599"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMS0xLTEtMjg1MjUw_0ca1ef50-2207-4649-b8fe-61002982fc50"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMy0xLTEtMjg1MjUw_0f245608-1910-496f-8fbb-c43674f4268a"
      unitRef="usd">1165258000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNS0xLTEtMjg1MjUw_c2517d8e-c3f7-430c-8e8a-9792979904da"
      unitRef="usd">9418000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNy0xLTEtMjg1MjUw_62fb1fe1-2ecd-4596-bdbd-6a8611a209b3"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItOS0xLTEtMjg1MjUw_b5d94738-b894-4468-8f48-a058f26b69c8"
      unitRef="usd">1174676000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMS0xLTEtMjg1MjUw_d61b2ab4-4353-429d-b708-3e41d28dcaa9"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMy0xLTEtMjg1MjUw_cadeba4a-21ee-474b-9b6b-d4053502d940"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNS0xLTEtMjg1MjUw_b19403f6-6b66-4f57-a5d4-4bc1d5426454"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNy0xLTEtMjg1MjUw_331e5654-770b-409f-a244-0e1fb8c6d92a"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtOS0xLTEtMjg1MjUw_5a9e68e1-8c71-456b-b9dd-c66c673d6426"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMS0xLTEtMjg1MjUw_50cfd469-62be-4bd1-b4da-27748907df24"
      unitRef="usd">112339000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMy0xLTEtMjg1MjUw_2a90053e-aa4d-42af-9ac1-6b7916ad09e5"
      unitRef="usd">594592000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNS0xLTEtMjg1MjUw_6b8c3c9a-10d4-48fa-832f-0bdaf1816caa"
      unitRef="usd">85426000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNy0xLTEtMjg1MjUw_ce33ba62-11a0-46d7-a48a-2d50befde775"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtOS0xLTEtMjg1MjUw_1cc7255e-1118-4f45-aa95-421749a0c280"
      unitRef="usd">792357000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i5fcd0fcdf8b845239f1f57b6fe825b41_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMS0xLTEtMjg1MjUw_1064f22f-f880-4d0d-a2e6-ffaab7b0f639"
      unitRef="usd">42151000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2009985eb36743ad88c72d8e11fbaea0_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMy0xLTEtMjg1MjUw_98568b65-155a-417f-828f-cfdda038ce43"
      unitRef="usd">102892000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e55b25dde154b019f47eae3a218e41e_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNS0xLTEtMjg1MjUw_f18cd469-0a85-446c-8554-86987439ab81"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19e9d4812c374bfb90bd218fd00ab822_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNy0xLTEtMjg1MjUw_fd84907a-527a-4536-aa92-054393ea93d7"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i155073e088c24e3fb6763b85cd7c0862_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtOS0xLTEtMjg1MjUw_49f8fc76-8d0b-442c-b91c-8f1bff78a48e"
      unitRef="usd">145043000</us-gaap:ProfitLoss>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtMS0xLTEtMjg1MjUw_75800d06-ed1d-47d5-adf9-e9f8de8bb5b9"
      unitRef="usd">0</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtMy0xLTEtMjg1MjUw_ca07f5bc-a1f9-4e0f-8465-eb529bbb3309"
      unitRef="usd">-750000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtNS0xLTEtMjg1MjUw_34ba323d-c824-43b0-aeef-34bc9d40b0ac"
      unitRef="usd">2433848000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtNy0xLTEtMjg1MjUw_7524090f-cca8-4f41-bfff-4d7a591ff7a1"
      unitRef="usd">0</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzYtOS0xLTEtMjg1MjUw_146e2a75-35e8-44d8-a0ca-1e72a6f018f1"
      unitRef="usd">2433098000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMS0xLTEtMjg1MjUw_99aeb9ff-80e4-4d1d-86d5-b1d76c2ca8a1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMy0xLTEtMjg1MjUw_f9654781-406c-442b-b299-9ea1beb4b5c0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNS0xLTEtMjg1MjUw_d5065afc-8f97-4594-9a52-c00d9be17ed9"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNy0xLTEtMjg1MjUw_aa367a68-4f8c-4a6e-8626-b877b0aaa57b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctOS0xLTEtMjg1MjUw_1ddeb289-678e-4f4f-9beb-7921611fe033"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityOther
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMS0xLTEtMjg1MjUw_a4f9d7c2-763a-4bf1-93f8-aab76324ede4"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMy0xLTEtMjg1MjUw_6af9a94a-46a8-4de8-b0ba-fdfa06267aa8"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNS0xLTEtMjg1MjUw_38475caa-b069-4b02-a3b7-f225f145fd41"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNy0xLTEtMjg1MjUw_63965a9a-bd66-4530-9d9f-db9ca23e03a1"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtOS0xLTEtMjg1MjUw_34c00c8a-eeaa-4891-ae93-668442d76ec9"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="ic3f9625cef1e4423ba1d7b313528b32b_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMS0xLTEtMjg1MjUw_70a2fd82-f0c2-4cdc-abac-a530ef2f63b5"
      unitRef="usd">46741000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e3b4d885275470faa50792d4a4bce70_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMy0xLTEtMjg1MjUw_c2cedd63-f1e8-425f-80e9-3d3bb924c994"
      unitRef="usd">218137000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1895d5cab12548d4b8aa19c4ea3f7bc4_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNS0xLTEtMjg1MjUw_ebc5d987-c312-4e66-812f-00d8c10c7869"
      unitRef="usd">316993000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0475cdd9f0f940c2b84d9176875725f0_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNy0xLTEtMjg1MjUw_a89794a0-dd5e-4757-8311-2a98f712d1f1"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida16729ea6c0450498d0894c41753058_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktOS0xLTEtMjg1MjUw_0281b65b-6a4d-41c4-bdd2-af20f60c1eb4"
      unitRef="usd">581871000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTEtMS0xLTI4NTI1MA_ff8de986-04b3-4818-8e7d-9782e5649a09"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTMtMS0xLTI4NTI1MA_f9ed4c57-fd43-4e9b-8d17-b55711af54e4"
      unitRef="usd">15015000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTUtMS0xLTI4NTI1MA_0eba59b8-ff4c-4347-adfd-d4c6387390c1"
      unitRef="usd">7488000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTctMS0xLTI4NTI1MA_80d64af9-4530-42c3-b681-f0f49e596d3a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTktMS0xLTI4NTI1MA_83b8ac55-9705-4dce-942a-37774b1ff2dc"
      unitRef="usd">22503000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4300f4dd73534bc4aa48a624102af47c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTEtMS0xLTI4NTI1MA_2e0e7f6b-7782-42fc-ad8d-47855eda1722"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ib292b0c7b1664545977cf9e9aade2819_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTMtMS0xLTI4NTI1MA_c2154653-fea1-4d30-bc10-f93e75640667"
      unitRef="usd">3612000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ibfffca86213b4155ad7153b7a5b3d07a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTUtMS0xLTI4NTI1MA_08d9039b-02f9-457d-aa6a-b610e94224e8"
      unitRef="usd">6018000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i7c9134a84c124d0984a8a67f1ca1a9af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTctMS0xLTI4NTI1MA_fcf65437-18fe-49b0-b25f-2557c69f29d5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i209869199a674f339c33431cd676e2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTktMS0xLTI4NTI1MA_26326512-37e3-4584-a8b4-9b62ebd81206"
      unitRef="usd">9630000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c4c363df47947bbb51883fe4178ece5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMS0xLTEtMTMzNjY4_d5b8bfd2-4297-4469-a9ec-47939bcd32d1"
      unitRef="usd">12436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82fdaebc451745f9b2bb4e66ff3dc751_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtMy0xLTEtMTMzNjY4_9b572c29-944f-49fc-a5cc-4b518d206b3d"
      unitRef="usd">1939509000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e0662e7e53b4956bd13f22f2295afdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNS0xLTEtMTMzNjY4_a7e07ac5-54ea-4ac8-94ec-72f33ff074cb"
      unitRef="usd">3125091000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8e9ab43b7524668a5566f0c037e8e3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtNy0xLTEtMTMzNjY4_4bd03482-7d8f-4d66-82ac-00d1d31c2580"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67d04637150e49448bad7423d2ea8dbf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEtOS0xLTEtMTMzNjY4_d00288b1-e1b9-4c80-b353-9859ced493c4"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMS0xLTEtMTMzNjY4_552ddbc4-9a58-4394-934e-0c39755bb5e5"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItMy0xLTEtMTMzNjY4_b0cc73aa-3b35-4808-96c1-91ebcb73b620"
      unitRef="usd">35148000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNS0xLTEtMTMzNjY4_a0506833-6864-4263-9a22-dcba1f9e76c2"
      unitRef="usd">13391000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItNy0xLTEtMTMzNjY4_933230f9-d4bd-4dfa-ae29-8d695cf0a70d"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzItOS0xLTEtMTMzNjY4_ba485c82-4f5d-48af-bee2-60eb10fd243c"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMS0xLTEtMTMzNjY4_432172ee-ed6c-47c1-be3b-b309f7e4bb6b"
      unitRef="usd">56490000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtMy0xLTEtMTMzNjY4_dbf1440e-6654-4713-9127-da4e735570b0"
      unitRef="usd">425050000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNS0xLTEtMTMzNjY4_c201235e-c490-4b8c-ad3f-1591f9b02e18"
      unitRef="usd">133433000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtNy0xLTEtMTMzNjY4_6f5b8764-da2c-4ca5-aa71-4cfa7e9f118e"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzMtOS0xLTEtMTMzNjY4_08c6a858-cf3e-4c9c-8b38-aea994ba55f4"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMS0xLTEtMTMzNjY4_930c16a8-dc61-4aad-b786-3cf5640c78c2"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtMy0xLTEtMTMzNjY4_25fda4d3-cb43-4201-b9a3-fc74512bc2ee"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNS0xLTEtMTMzNjY4_1e56624b-bad3-431d-a283-92f82e55e17d"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtNy0xLTEtMTMzNjY4_fb4e3fba-385c-4d3e-b038-dc5f92478093"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzQtOS0xLTEtMTMzNjY4_e56b0ea5-fad3-4345-959c-a8af42649bb8"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMS0xLTEtMTMzNjY4_620f2ea9-c31b-4f56-8dba-d4df1742028f"
      unitRef="usd">57582000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtMy0xLTEtMTMzNjY4_f9665126-f6b8-4b63-8262-3e4457d32823"
      unitRef="usd">266570000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNS0xLTEtMTMzNjY4_6105fb81-2d7a-4574-82af-7292b3436aa5"
      unitRef="usd">297321000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtNy0xLTEtMTMzNjY4_8d42c12b-8686-479a-b852-bca61249ab38"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzUtOS0xLTEtMTMzNjY4_ca8d62f8-b3ce-499b-a7e2-4633540fee9d"
      unitRef="usd">621473000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMS0xLTEtMTMzNjY4_20d9eceb-efda-4efe-ae8d-f1923e0e9c93"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctMy0xLTEtMTMzNjY4_10b279a3-a5e4-4c7d-82fb-bc3a3274521a"
      unitRef="usd">2038000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNS0xLTEtMTMzNjY4_ce3791b7-2383-4a33-8bd4-818b85a29f8f"
      unitRef="usd">3227000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctNy0xLTEtMTMzNjY4_68e8ad17-201e-4be8-a3ca-5cb3682ed408"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzctOS0xLTEtMTMzNjY4_b5763a4f-4ae7-4ed9-b80b-484110b22a35"
      unitRef="usd">5265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ieedaec8cae48469cbe6534dd010fc31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMS0xLTEtMTMzNjY4_b483c5ea-32fb-49c1-8936-4b10fa496b05"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icdbc8aff5d8e4c8ba8a42e0630e5fa83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtMy0xLTEtMTMzNjY4_6434dbf8-b026-428f-b300-e05ac92ee9f7"
      unitRef="usd">8946000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ida4d052f271740ddb62eb9f5e94cfebf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNS0xLTEtMTMzNjY4_6f3ba615-a2d9-47a5-861f-232c08b3bf00"
      unitRef="usd">13469000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i154d8fd83a344b10958cc3bbe85829d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtNy0xLTEtMTMzNjY4_994fc834-2bff-4eb4-a1de-365f3e383894"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i96b97b44916543e78fc5245c8b709f2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzgtOS0xLTEtMTMzNjY4_e4db84a4-5cea-4b16-9109-53db040a5b01"
      unitRef="usd">22415000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cdd18cadc3747e1bea0a4efcb970f3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMS0xLTEtMTMzNjY4_d5acef6a-eb3b-40b0-8d34-b04364f97c27"
      unitRef="usd">13528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe5dd6dc7e594c9f91e9eccb9dce463b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktMy0xLTEtMTMzNjY4_76453746-edae-4d02-9e78-cc09077dfd65"
      unitRef="usd">1809269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0835b7194744e4c9e4f528591ea0b3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNS0xLTEtMTMzNjY4_48d6fa61-bd1b-4efb-86f9-de2df8b656af"
      unitRef="usd">2649154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf340aa855a942858168f3ecce184356_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktNy0xLTEtMTMzNjY4_4bbc4838-3c00-4746-b86a-014f9ef2bff9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48be734bf52f43b58b94e9c5cf13e1ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzktOS0xLTEtMTMzNjY4_48de6705-cdd5-440a-b55d-e347b64d7ef6"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTEtMS0xLTIyOTg5NA_c83337fc-e54b-4e19-a5ce-95e8e42983e2"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTMtMS0xLTIyOTg5NA_76771ee6-737f-4e86-81dc-b65c79e49377"
      unitRef="usd">6343000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTUtMS0xLTIyOTg5NA_8a38af44-8216-4d40-a22c-fdfa2a8d00e8"
      unitRef="usd">5253000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTctMS0xLTIyOTg5NA_61e965de-064d-4c0d-b1b2-c3bbd21fe39a"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzExLTktMS0xLTIyOTg5NA_e24add2b-36be-4dd8-8780-9eb586ea4515"
      unitRef="usd">11596000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTEtMS0xLTIyOTg5NA_de38a747-59ec-4e14-a2c8-4c511640fd45"
      unitRef="usd">24687000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTMtMS0xLTIyOTg5NA_ef6ea43b-7112-4b45-879f-e844031fff96"
      unitRef="usd">435446000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTUtMS0xLTIyOTg5NA_816efcb0-c98e-4951-a18d-c372b8b5053f"
      unitRef="usd">144115000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTctMS0xLTIyOTg5NA_dd85349e-b358-4f68-b9af-f0ab61572bca"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEyLTktMS0xLTIyOTg5NA_51e3f24c-44d3-4ebc-a2c9-c861da744e2a"
      unitRef="usd">604248000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTEtMS0xLTIyOTg5NA_63071955-780d-48c1-ae7f-a27986d7fff5"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTMtMS0xLTIyOTg5NA_831d6ea9-5123-442a-b845-9314a44a70a3"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTUtMS0xLTIyOTg5NA_0ac1ad85-b023-41c5-8711-afb630b1c37b"
      unitRef="usd">157494000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTctMS0xLTIyOTg5NA_de0d469c-ad15-4598-bc0e-b4de783142de"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzEzLTktMS0xLTIyOTg5NA_3e19c500-ffa9-4ddf-a85d-5839885652a9"
      unitRef="usd">157494000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTEtMS0xLTIyOTg5NA_d18d187b-e792-42ab-8fab-a660bd8f0057"
      unitRef="usd">10562000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTMtMS0xLTIyOTg5NA_2e94c9b7-c21b-4970-99a9-8c98bf981e2d"
      unitRef="usd">152895000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTUtMS0xLTIyOTg5NA_d79f1676-9d6c-412a-8cdf-f1c569047494"
      unitRef="usd">23775000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTctMS0xLTIyOTg5NA_12414e67-3e15-4ab8-85be-635d79d7e8ae"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE0LTktMS0xLTIyOTg5NA_331f9712-f67d-425a-b2d0-f70b42eb5a8b"
      unitRef="usd">187232000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTEtMS0xLTIyOTg5NA_5d11a33e-5399-48cd-892a-9347e01eb758"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTMtMS0xLTIyOTg5NA_6b86e911-2e63-4d0d-a1b7-b50e32b36b7b"
      unitRef="usd">4218000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTUtMS0xLTIyOTg5NA_21f79a7a-0a93-4f4c-bc32-263d9a220590"
      unitRef="usd">5520000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTctMS0xLTIyOTg5NA_34867070-2ac4-4d88-9a3c-fcfce8f82559"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE2LTktMS0xLTIyOTg5NA_329030f9-787a-4ffb-871b-1c032ada4281"
      unitRef="usd">9738000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5e16c6c7260e403881edc832b000788b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTEtMS0xLTIyOTg5NA_c1498810-42a5-4189-8f62-fa55df61aead"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia1632e81dc72459783936e15eb36e43a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTMtMS0xLTIyOTg5NA_36aca99d-2287-433b-96ee-b20fd8135b33"
      unitRef="usd">9392000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i5d8f52c1136b47f6b216a657c786806c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTUtMS0xLTIyOTg5NA_a896e40f-1259-46fd-b836-753eaa05f2ab"
      unitRef="usd">12160000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i070f49ed42d5461697cd16327dd87162_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTctMS0xLTIyOTg5NA_78a83a2a-8e8b-4918-b765-f98336b58e0e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1f652567236b4dc3a92c5c8e1c654fdb_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE3LTktMS0xLTIyOTg5NA_e394fda7-8ed0-4063-8a04-2c91e2f3362b"
      unitRef="usd">21552000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic272076b47ca427798a7eb4b50714520_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTEtMS0xLTIyOTg5NA_4832aba4-0d41-4ad4-a02e-cd603657ab4e"
      unitRef="usd">-597000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie580dc2708034fd4b6b4cfd3e17819c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTMtMS0xLTIyOTg5NA_b4969d60-ae0b-46db-929a-0b8339b4d42e"
      unitRef="usd">1527887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife94ebe41b0c47e3ba05d415807efda4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTUtMS0xLTIyOTg5NA_dd7fad8a-abaf-4feb-9d53-c39e7ed51586"
      unitRef="usd">2369933000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida148d60e093484bb7aecaf26959ca76_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTctMS0xLTIyOTg5NA_0c112dbc-bed5-4f89-85c2-3d3f1bf058e8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica1fc390f90a425883695c27f2ee9af6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90YWJsZTo1MmQ5OThmNjdlMGY0MGIzYTRlOTI2N2YwZjgxMmFhYy90YWJsZXJhbmdlOjUyZDk5OGY2N2UwZjQwYjNhNGU5MjY3ZjBmODEyYWFjXzE4LTktMS0xLTIyOTg5NA_beaf22d2-1ff3-45b2-a35a-53545fc28c9b"
      unitRef="usd">3897223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i03743a114d964d26b43b9ebb04e7dd8e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzExNTQ0ODcyMTAxNzA2_ca32691f-1572-4e7d-8024-1f0b91b4be12"
      unitRef="number">0.27</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ia73f9519d5db426a8cec4e56bf77101b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU3NjE_6a43f1a4-bc56-4d59-ae06-b97844690d22"
      unitRef="number">0.29</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i1e1f278076d844b99be68cf3e9873d75_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNTM1NTY_f6f30d9e-8ce9-4d08-95d8-4ca19aa300d8"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ief164fe055724316addcd160fcd29535_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzExNTQ0ODcyMTAxNjk4_8911474b-28f0-4011-b964-c8589f5e7bef"
      unitRef="number">0.73</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i3f6b542ff447402ab303deafe356aa4d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU3NjY_fbc6a44f-8335-4666-9886-d40ad9d6d7ae"
      unitRef="number">0.71</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i89cd3ad806e748eb9957406a9dba417e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNTM1NjM_a172a0e1-8702-4e8d-988b-86198fc1581d"
      unitRef="number">0.64</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i858eae6f03ab4f6095837812fe2050e8_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_54721b09-28f0-4a5c-a4aa-5ce31f23612c"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i05f6894c03c244809fd48ceb945f3ef4_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_706f11f9-2f13-4d15-9b80-82472cd090c5"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i8a476c779a0f4059929c8b1c13bcb11c_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_cabf657c-25bd-4be8-a62e-aeb65ec9b561"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ib698c75befc449c9b5e6d1b50a9022ff_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3MjU_f94414ce-fa75-4af4-9ed7-5b34581e675f"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ3ODI_b1f405d1-6862-43c0-8f1e-94b02dfca489"
      unitRef="usd">333300000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="i33f144445f0e4c28a6b92715967d2981_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzQ5OTM_abd69e26-ffda-4371-9a41-696c911201ef"
      unitRef="shares">800000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7f8140079fb2406ca4822f6e2dbf5f31_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU0OTc1NTgxNDU5NzM_b23e8c5f-7a0e-410f-97f6-e3d2c72c7c6c"
      unitRef="shares">565000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzU1MzM_6d62696a-b765-4b8f-a648-c7d10e6b81bb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie3e504b2ac6f44869467d497b88bcd64_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYxNTU_1928067b-bf4b-4aa7-9910-b8e6f75f3460"
      unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i048f1daf85ab40479caf539c7b2a985f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTQvZnJhZzo2MjRiNTZkYTEzYmM0OGUzOTdlZmVjZjgzYmUzZWM1YS90ZXh0cmVnaW9uOjYyNGI1NmRhMTNiYzQ4ZTM5N2VmZWNmODNiZTNlYzVhXzYyMDA_67dac199-4739-485a-a4e8-a33884b43cd4">P6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90ZXh0cmVnaW9uOjFhMzU3YWIxOTExZDQwMDNhMDI4YmE5Mjc1ZTA1ODIwXzMyNzU_d5f17a23-4213-4207-a0c9-ec7313912c73">Earnings per ShareFor 2022, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for 2022, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Royalty Pharma plc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90ZXh0cmVnaW9uOjFhMzU3YWIxOTExZDQwMDNhMDI4YmE5Mjc1ZTA1ODIwXzMyNzc_1d733a05-4f33-4782-8810-e79212d68c48">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Royalty Pharma plc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzMtMy0xLTEtMTMzNjY4_817e1988-30be-4d12-a81d-6ec2fe43538f"
      unitRef="usd">230064000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzMtMy0xLTEtMTg3NDk4_e4dce6bf-77c6-439d-8a18-69f0aaa0ca2c"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia34aa33e8820445b893a30e990847995_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzQtMy0xLTEtMTMzNjY4_c857f3d9-6ace-44be-a174-6b176c6cab68"
      unitRef="usd">23775000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i83a8a06b5b3141b6b061529bf42fe3a2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzQtMy0xLTEtMTg3NDk4_712f2218-2a1f-47da-8638-83daa78edeca"
      unitRef="usd">297321000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if2bfaf7eb7d04751af4ffb41e99d27d2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzUtMy0xLTEtMTMzNjY4_14595e01-f5e7-473b-85b9-e6c0edf31bd5"
      unitRef="usd">163457000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia79bf03ace46488f877dae1dc4f250f5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzUtMy0xLTEtMTg3NDk4_a01bbcfa-2077-4ee6-9416-d1043e142c3c"
      unitRef="usd">324152000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTMzNjY4_2efb44e0-c2aa-4dc6-bc26-5d74569691c5"
      unitRef="usd">42832000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTMzNjY4_504fe481-b728-4c69-bf23-a49591a4be53"
      unitRef="usd">42832000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTg3NDk4_20647a63-a484-496d-b331-8b80358f25d0"
      unitRef="usd">619728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzgtMy0xLTEtMTg3NDk4_bc2eb36c-c6cc-447d-86a1-77b41fcceb7d"
      unitRef="usd">619728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzExLTMtMS0xLTEzMzY2OA_73847c67-fa0d-4e8d-94da-2dfd5e5b5679"
      unitRef="shares">437963000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzExLTMtMS0xLTE4NzQ5OA_59bfcdab-4c71-4fb2-9302-1274a298f2df"
      unitRef="shares">414794000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE0LTMtMS0xLTEzMzY2OA_f142df63-cd80-4e1f-b62f-7108e0f3b7fb"
      unitRef="shares">9000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE0LTMtMS0xLTE4NzQ5OA_8d91b956-a4de-4587-a5b2-545c0f0f0bbd"
      unitRef="shares">8000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE1LTMtMS0xLTEzMzY2OA_cbcfafd8-765b-447c-814f-c23b5e56be72"
      unitRef="shares">437972000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE1LTMtMS0xLTE4NzQ5OA_47504af9-d615-4e6c-8a37-962b8318c0c0"
      unitRef="shares">414802000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE3LTMtMS0xLTEzMzY2OA_db328196-3236-436f-ab79-35526545d523"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE3LTMtMS0xLTE4NzQ5OA_9b72d9dd-7af4-4d54-a582-fcccd2af796b"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE4LTMtMS0xLTEzMzY2OA_4463de77-e5a0-422f-a187-6e7c038b0fb7"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo0ZTVkYmZkOGU1OGM0NmE2YWVhOTNlMjNhNjE2YWRkYi90YWJsZXJhbmdlOjRlNWRiZmQ4ZTU4YzQ2YTZhZWE5M2UyM2E2MTZhZGRiXzE4LTMtMS0xLTE4NzQ5OA_9fd53a65-32fd-4379-8c02-7df9dabc9591"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzMtMi0xLTEtMjI3ODA1_b8db784d-3b14-4359-9249-854784a90c32"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <rprx:NetIncomeLossAttributableToParentPriorToOffering
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzQtMi0xLTEtMjI3ODA1_0bbef4f2-4ad4-450c-bc00-ad681beaf736"
      unitRef="usd">479842000</rprx:NetIncomeLossAttributableToParentPriorToOffering>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i15818908d4464f36813ed35be63cb421_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzUtMi0xLTEtMjI3ODA1_3a7fbddf-ad25-45c3-b3cd-edccf591110e"
      unitRef="usd">316993000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic0b423fa12d043fb86870ee9477f4152_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzYtMi0xLTEtMjI3ODA1_d6a5323d-6883-4b24-aa28-6fb88722f1bc"
      unitRef="usd">409921000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzctMi0xLTEtMjI3ODA1_2a75dc63-17b9-4ab5-8485-209eec5fd159"
      unitRef="usd">495198000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzctMi0xLTEtMjI3ODA1_2fb7729a-53eb-4a20-93c9-652ba0b34a76"
      unitRef="usd">495198000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzEwLTItMS0xLTIyNzgwNQ_ed0919b8-9218-4026-a6ff-1b318a66a801"
      unitRef="shares">375444000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzExLTItMS0xLTIyNzgwNQ_39e48a9e-f26b-4aae-9718-c676dc962f33"
      unitRef="shares">11000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzEyLTItMS0xLTIyNzgwNQ_e475bebd-26bb-4e91-9c98-686f997a5fdb"
      unitRef="shares">375455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzE0LTItMS0xLTIyNzgwNQ_b6935e31-148f-49b0-be24-4fb8b7a097c1"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNTcvZnJhZzoxYTM1N2FiMTkxMWQ0MDAzYTAyOGJhOTI3NWUwNTgyMC90YWJsZTo4YTE5Y2UxMTg3M2Q0Y2M2ODZiZGQ3MTJlNmM5OGYwYy90YWJsZXJhbmdlOjhhMTljZTExODczZDRjYzY4NmJkZDcxMmU2Yzk4ZjBjXzE1LTItMS0xLTIyNzgwNQ_8e0a4001-4a80-46f8-b934-a29b2a94984c"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzI0NQ_1fafac7f-ca2b-4f7a-8b3c-d0ddd9ce9115">Indirect Cash Flow&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,125,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,065,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,959,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;904,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in losses/(earnings) of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination of derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,507,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,315,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,121,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Increase/(decrease) in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,143,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,017,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,034,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash investing and financing activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental Schedule of Non-cash Investing/Financing Activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of Epizyme forward purchase contract (Note 4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase obligation - Tazverik (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayments of long-term debt by contributions from non-controlling interests (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,103,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payable - Erleada (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $110.0&#160;million following the June 2020 FDA approval of additional indications of Tazverik. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the pro rata portion of RPIFT&#x2019;s outstanding debt repaid by the Legacy Investors Partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzI0Ng_fdc7beb9-ea31-4207-873a-91024a1a2dd0">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,125,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,065,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,959,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;904,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in losses/(earnings) of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Termination of derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,507,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,315,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,121,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Increase/(decrease) in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,143,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,017,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,034,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash investing and financing activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental Schedule of Non-cash Investing/Financing Activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of Epizyme forward purchase contract (Note 4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase obligation - Tazverik (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayments of long-term debt by contributions from non-controlling interests (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,103,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payable - Erleada (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $110.0&#160;million following the June 2020 FDA approval of additional indications of Tazverik. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the pro rata portion of RPIFT&#x2019;s outstanding debt repaid by the Legacy Investors Partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtMS0xLTEtMTMzNjY4_16961a1a-5fb4-4ddd-a98a-a37f79fbf547"
      unitRef="usd">230064000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtMy0xLTEtMTMzNjY4_2939c1e5-504d-411d-9a46-d0f18f68e29c"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMtNS0xLTEtMTMzNjY4_90d301ff-53c4-4ea4-905c-efdb88f56f3d"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtMS0xLTEtMTMzNjY4_d9dced2c-1ef8-4b7c-bc1c-657008b8f23d"
      unitRef="usd">2125096000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtMy0xLTEtMTMzNjY4_d6a29fb3-59a7-4ae8-bdec-487e5c1cc72f"
      unitRef="usd">2065083000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzUtNS0xLTEtMTMzNjY4_ed10d54d-3bc8-487c-a8f2-29cb8d465ede"
      unitRef="usd">1959975000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtMS0xLTEtMTMzNjY4_f495b2d9-8a62-499a-9b63-52bd57f463b3"
      unitRef="usd">904244000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtMy0xLTEtMTMzNjY4_9416df88-1038-46be-8f1b-7139d7654262"
      unitRef="usd">452842000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzYtNS0xLTEtMTMzNjY4_010dd28a-6840-4d27-afc1-5410890254e9"
      unitRef="usd">230839000</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctMS0xLTEtMTMzNjY4_1d99d9c5-3bda-4ba4-9c86-f272288359b0"
      unitRef="usd">5670000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctMy0xLTEtMTMzNjY4_bf2119f2-638b-4bfb-a608-196086503ddd"
      unitRef="usd">22996000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzctNS0xLTEtMTMzNjY4_c2e948fb-d7d7-4105-9656-5dd40ee9353e"
      unitRef="usd">23058000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtMS0xLTEtMTMzNjY4_02b718e9-22f9-4dac-91bd-f2a2cbf25639"
      unitRef="usd">21356000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtMy0xLTEtMTMzNjY4_732fd7ae-98d4-4850-b64d-aa3e84f372fb"
      unitRef="usd">20162000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzgtNS0xLTEtMTMzNjY4_3de570c1-30da-4b7b-82fd-ea627fe29ac2"
      unitRef="usd">11715000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTEtMS0xLTEzMzY2OA_754a6842-e51e-4134-9e48-e46daaa37b4a"
      unitRef="usd">96610000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTMtMS0xLTEzMzY2OA_30af7806-3a9f-4ee8-a562-7f8da2f6a977"
      unitRef="usd">-21532000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEwLTUtMS0xLTEzMzY2OA_9e6c3fc6-3d05-40e7-bded-32a76f031666"
      unitRef="usd">-42076000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTEtMS0xLTEzMzY2OA_1fef2e14-9716-47dc-a2a9-101ddafa82d4"
      unitRef="usd">-33442000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTMtMS0xLTEzMzY2OA_c4eb6c4a-9473-48c6-b52c-f494f0c272a5"
      unitRef="usd">-48066000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzExLTUtMS0xLTEzMzY2OA_2df42805-21a7-4755-9956-8e0465683239"
      unitRef="usd">247073000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTEtMS0xLTEzMzY2OA_e25b6876-6b12-4bad-814e-a390165acc8e"
      unitRef="usd">-8973000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTMtMS0xLTEzMzY2OA_13057d60-2cda-4130-8e57-49f55eecc732"
      unitRef="usd">-19490000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzEyLTUtMS0xLTEzMzY2OA_e719f474-d624-4879-9cd7-bf3b6508946f"
      unitRef="usd">44459000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTEtMS0xLTEzMzY2OA_9bb4dcff-1a21-4b8f-9d72-3dd9eab3f8e7"
      unitRef="usd">39142000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTMtMS0xLTEzMzY2OA_1cb03d5b-fa0a-41f5-ab9d-94edc64f985c"
      unitRef="usd">34384000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE1LTUtMS0xLTEzMzY2OA_8a3456c7-d8e0-4929-aa10-685dd8dc8727"
      unitRef="usd">42334000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTEtMS0xLTEzMzY2OA_147f45f3-f75f-4948-bb24-ff20fbe6bcec"
      unitRef="usd">-419000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTMtMS0xLTEzMzY2OA_5a75d59c-1316-45bc-a9a0-6ff741c26732"
      unitRef="usd">-358000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE3LTUtMS0xLTEzMzY2OA_9900f37e-9d37-4944-ba50-e286e18dcf8f"
      unitRef="usd">-30272000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTEtMS0xLTEzMzY2OA_b0351c77-031d-42f3-956a-718c32941f49"
      unitRef="usd">2170000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTMtMS0xLTEzMzY2OA_23e8550a-d361-4149-b1d0-3f801e6f5ceb"
      unitRef="usd">2443000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzE5LTUtMS0xLTEzMzY2OA_85c0220f-73d5-4689-9ca2-0896e211dea3"
      unitRef="usd">5428000</us-gaap:ShareBasedCompensation>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTEtMS0xLTEzMzY2OA_8bf15a37-8381-409f-a391-7f31508775f3"
      unitRef="usd">53432000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTMtMS0xLTEzMzY2OA_296eafff-e534-456f-94dc-5d944701b8dc"
      unitRef="usd">50896000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIwLTUtMS0xLTEzMzY2OA_8540cf96-420b-4a14-9a23-4dcfd7fb8540"
      unitRef="usd">20551000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTEtMS0xLTEzMzY2OA_95431997-cb74-49aa-99d6-75addffebd6a"
      unitRef="usd">-6815000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTMtMS0xLTEzMzY2OA_2c93209c-eeb2-471a-887c-b58d01c0a7f0"
      unitRef="usd">17859000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIxLTUtMS0xLTEzMzY2OA_a7fc6423-ecb9-41ba-a6f1-d8ab5b7bc73c"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTEtMS0xLTEzMzY2OA_f4d98028-d8da-4323-bf44-62693d0206e6"
      unitRef="usd">615827000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTMtMS0xLTEzMzY2OA_2e8d2d14-db64-44bf-a0cb-fe9544dd4cb9"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIyLTUtMS0xLTEzMzY2OA_74775fc7-512b-44c9-b350-51aae7f97266"
      unitRef="usd">65053000</us-gaap:AssetImpairmentCharges>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTEtMS0xLTEzMzY2OA_ff41e5dc-99df-4043-963c-7b94f2f9486d"
      unitRef="usd">0</rprx:GainLossOnDerivativeFinancialInstruments>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTMtMS0xLTEzMzY2OA_bb5b58f0-227d-496c-8f5f-60880cb895bb"
      unitRef="usd">16093000</rprx:GainLossOnDerivativeFinancialInstruments>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzIzLTUtMS0xLTEzMzY2OA_a7f82beb-c505-457c-bdc7-b0fcfeb3a21a"
      unitRef="usd">34952000</rprx:GainLossOnDerivativeFinancialInstruments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTEtMS0xLTEzMzY2OA_05239b8c-a437-41c6-8e5d-1eba26f0123f"
      unitRef="usd">-11098000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTMtMS0xLTEzMzY2OA_74d62584-5c11-4279-89d7-aa6548e6e6bb"
      unitRef="usd">-4461000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI0LTUtMS0xLTEzMzY2OA_39b24041-05c2-4b43-80a5-54a62869d3bb"
      unitRef="usd">-9621000</us-gaap:OtherNoncashIncomeExpense>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTEtMS0xLTEzMzY2OA_ea6fcccf-1576-4e12-8b76-c5c493bed5ae"
      unitRef="usd">2507236000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTMtMS0xLTEzMzY2OA_846199a4-c5b8-4c16-8009-7c362aa59169"
      unitRef="usd">2315854000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI2LTUtMS0xLTEzMzY2OA_40ed7836-b1d1-435b-8b0d-92df7dde00cc"
      unitRef="usd">2121923000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTEtMS0xLTEzMzY2OA_c8a8050e-efbe-4887-84f8-090059bec7a8"
      unitRef="usd">-36456000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTMtMS0xLTEzMzY2OA_ee98c1c4-72d5-4dd9-a7d0-d87fa5c0d41f"
      unitRef="usd">20131000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzI4LTUtMS0xLTEzMzY2OA_bc863640-9872-4083-9695-559289af528d"
      unitRef="usd">-370000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTEtMS0xLTEzMzY2OA_e5accdc9-1477-40d4-9056-e34ba2238b87"
      unitRef="usd">4744000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTMtMS0xLTEzMzY2OA_47e42515-4e18-45e4-a6df-20ed7206ae6e"
      unitRef="usd">9012000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMwLTUtMS0xLTEzMzY2OA_bf9f2427-37d9-43cd-bea0-f1c25257f051"
      unitRef="usd">770000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTEtMS0xLTEzMzY2OA_eac3dbec-1b0c-4fea-8355-ce253fe8ff5d"
      unitRef="usd">-2198000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTMtMS0xLTEzMzY2OA_9259737d-4488-44e9-ba31-bef20071e3a8"
      unitRef="usd">-1857000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMxLTUtMS0xLTEzMzY2OA_24dcaa53-e783-44a5-a00b-1ae75860f8a3"
      unitRef="usd">-34986000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTEtMS0xLTEzMzY2OA_6bbbc1ba-2090-4acb-aad7-fd370a345ea4"
      unitRef="usd">2286000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTMtMS0xLTEzMzY2OA_7ef12c91-e9eb-48e4-824a-41569c82c4f0"
      unitRef="usd">-4586000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzMzLTUtMS0xLTEzMzY2OA_e2eb74fd-0bac-489c-bd5f-49349c2f3f8b"
      unitRef="usd">-766000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTEtMS0xLTEzMzY2OA_c33c071f-2490-4cb1-9227-0c09705f0413"
      unitRef="usd">-3534000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTMtMS0xLTEzMzY2OA_754106bc-4145-41e0-a1f3-1396515c5a07"
      unitRef="usd">15550000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM0LTUtMS0xLTEzMzY2OA_be18512c-f138-4268-b4e7-d6c36290cc6a"
      unitRef="usd">42146000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTEtMS0xLTEzMzY2OA_25b296ce-57f1-4851-9fb2-021d5b7f4a3f"
      unitRef="usd">2143980000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTMtMS0xLTEzMzY2OA_e6a931e5-b009-4cb2-8bf8-6c5ff4d1093e"
      unitRef="usd">2017536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxMmU4MzU1MjEwNTM0YmIzYWU5ZWNkOTczN2JlYWQ3Mi90YWJsZXJhbmdlOjEyZTgzNTUyMTA1MzRiYjNhZTllY2Q5NzM3YmVhZDcyXzM3LTUtMS0xLTEzMzY2OA_9d96528f-cf7e-4a9b-83c1-fcd7721914ee"
      unitRef="usd">2034629000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItMS0xLTEtMTMzNjY4_8734f033-4376-4b1c-965a-c6bed2482d8a"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItMy0xLTEtMTMzNjY4_99bd69da-2a55-4ac4-8c66-9897d83cdef9"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzItNS0xLTEtMTMzNjY4_65347438-7e81-4080-b836-31e9872d2ed1"
      unitRef="usd">303679000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtMS0xLTEtMTMzNjY4_a5f8acf5-7e80-49d6-934c-def1f7078409"
      unitRef="usd">0</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtMy0xLTEtMTMzNjY4_fe0f5c75-0efa-47eb-8da1-497bceeb58be"
      unitRef="usd">0</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzMtNS0xLTEtMTMzNjY4_2a3c1e70-919f-4e41-8211-27c2aa5f4fa2"
      unitRef="usd">5700000</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtMS0xLTEtMTMzNjY4_e7f4a154-94af-455b-a62e-5980c75e0770"
      unitRef="usd">0</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtMy0xLTEtMTMzNjY4_5c44dcdd-7a93-4a7f-baaa-d2b945f92008"
      unitRef="usd">0</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzQtNS0xLTEtMTMzNjY4_b863bb3b-e916-44fc-934a-7ee2e4f8e188"
      unitRef="usd">110000000</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtMS0xLTEtMTMzNjY4_d359979d-7bde-4125-b3bf-adb12c820b08"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtMy0xLTEtMTMzNjY4_3b073522-51ef-481d-9417-704a720f015e"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzUtNS0xLTEtMTMzNjY4_11022676-c24f-4573-a372-54eb8e528dac"
      unitRef="usd">1103774000</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtMS0xLTEtMTMzNjY4_3bf79e75-8b9b-4456-97d0-3c74f19c35b3"
      unitRef="usd">12400000</rprx:MilestonePaymentAccruedButNotPaid>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="i4b44fae948f24f0d91006a467051ea02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtMy0xLTEtMTMzNjY4_112829cf-fbba-49ab-9321-98d9669fe475"
      unitRef="usd">0</rprx:MilestonePaymentAccruedButNotPaid>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90YWJsZToxYzQxYTEwMmVmYTc0YWMwYmFjNjkyNGVjOGM3NGM2Yy90YWJsZXJhbmdlOjFjNDFhMTAyZWZhNzRhYzBiYWM2OTI0ZWM4Yzc0YzZjXzYtNS0xLTEtMTMzNjY4_2eae08b5-2f84-48d1-abdb-e00a68846832"
      unitRef="usd">18600000</rprx:MilestonePaymentAccruedButNotPaid>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjAvZnJhZzo0YmZjNDE3ODM5N2E0YmI0ODNkMzE0ZTcyYmE0YTgzMi90ZXh0cmVnaW9uOjRiZmM0MTc4Mzk3YTRiYjQ4M2QzMTRlNzJiYTRhODMyXzE2NDkyNjc0NDQ0NjE_5182d2c3-8e90-429e-9021-b542be93054c"
      unitRef="usd">110000000</rprx:AccruedPurchaseObligationEquityInvestment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzQ4MTQ_5abe30ca-6d8d-49db-8c0f-c0dabfe16069">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have various funding commitments as of December 31, 2022 and 2021. See Note 3&#x2013;Available for Sale Debt Securities for discussion of the respective arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cytokinetics Commercial Launch Funding&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022, $250&#160;million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50&#160;million if a certain contingency is met and has the option to draw the remaining $200&#160;million upon the occurrence of certain regulatory and clinical development milestones. As of December 31, 2022, we expect $125&#160;million of the optional $200&#160;million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 9&#x2013;Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 16&#x2013;Related Party Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our consolidated balance sheets as of December 31, 2022 and 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rprx:LongTermFundingCommitmentAmountOutstanding
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM0ODEw_5f413be8-1a0f-430f-a7b7-6934a36c7705"
      unitRef="usd">250000000</rprx:LongTermFundingCommitmentAmountOutstanding>
    <rprx:LongTermFundingPartnershipCovenantRequiredAmount
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzM4NDgyOTA3MTI4NTI_260bdcc8-0e65-46b6-bfe8-7781b2e45be1"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipCovenantRequiredAmount>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzM4NDgyOTA3MTI4NTY_6d672792-cd46-4fde-8e2a-ca2319fe6aec"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:LongTermFundingPartnershipExpectedPayment
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM1MDQ3_5d707790-ee71-45c4-bf1a-160bf0b3e30f"
      unitRef="usd">125000000</rprx:LongTermFundingPartnershipExpectedPayment>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjkvZnJhZzphYTk0YTI2YzA0YTY0MDgzOTI4ZWI1YzMxZjI1YmU1MC90ZXh0cmVnaW9uOmFhOTRhMjZjMDRhNjQwODM5MjhlYjVjMzFmMjViZTUwXzE2NDkyNjc0NDM1MDYx_ad3a968e-89d5-42e7-8a64-2fe3dbc73b68"
      unitRef="usd">200000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzcyNDE_1e062601-6fbd-4797-b351-4c285ddc2a8d">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Manager&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Manager is the investment manager of Royalty Pharma plc and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Exchange Offer Transactions (discussed in Note 1&#x2013;Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (&#x201c;Operating and Personnel Payments&#x201d;) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. Additionally, we also pay certain costs and expenses of the Manager. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the date of the Exchange Offer, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Manager or its affiliates receive an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, total operating and personnel payments incurred were $188.4&#160;million, $145.2&#160;million and $112.5&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distributions Payable to Legacy Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#x2019; non-controlling interest in Old RPI and RPI ICAV and RPSFT&#x2019;s non-controlling interest in RPCT. The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distributions payable to legacy non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;94,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;107,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition from Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In November 2017, RPI Acquisitions &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(Ireland), Limited (&#x201c;RPI Acquisitions&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#x201c;BMS&#x201d;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#x201c;Purchase Agreement&#x201d;). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#x201c;Assignment Agreement&#x201d;) with a wholly owned subsidiary of BioPharma Credit PLC (&#x201c;BPCR&#x201d;), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the financial royalty asset of $103.4&#160;million and $130.9&#160;million, respectively, on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#x201c;MSCI&#x201d;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes. In return, we will receive a percentage of MSCI&#x2019;s revenues from those indexes. No amounts were due from MSCI as of December 31, 2022 and 2021. The financial impact associated with this transaction has not been material to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During 2020, we reimbursed Pablo Legorreta approximately $1.0&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV. Refer to Note 9&#x2013;Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million was recorded as treasury interests, of which $1.5&#160;million and $1.6&#160;million were held by non-controlling interests as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#x2019; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <rprx:RelatedPartyTransactionRateAdjustedCashReceipts
      contextRef="i799427d0838947d38f9dbd8016b9306e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzg3Mw_af1b2fc3-2956-4e97-8500-d74db5fe5778"
      unitRef="number">0.065</rprx:RelatedPartyTransactionRateAdjustedCashReceipts>
    <rprx:RelatedPartyTransactionRateValueOfSecurityInvestments
      contextRef="i799427d0838947d38f9dbd8016b9306e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzk3NA_01c592cf-5c5a-4643-8732-840d6ce96d9b"
      unitRef="number">0.0025</rprx:RelatedPartyTransactionRateValueOfSecurityInvestments>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount
      contextRef="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzEzMDU_49e6bccd-4eae-4e54-aa4f-b73ef4777ec4"
      unitRef="usd">1000000</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent
      contextRef="i1424cd772f48470692bdb5bcdc4fac61_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzEzMjQ_c9df3de7-be85-494c-b710-e35b03ddd26c"
      unitRef="number">0.003125</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent>
    <rprx:RelatedPartyTransactionAnnualIncreasePercentage
      contextRef="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzE2MjM_1b4bcdfd-4958-4c38-97f6-9fcd90ca5450"
      unitRef="number">0.05</rprx:RelatedPartyTransactionAnnualIncreasePercentage>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i31228dd6ef774882b79ae22ffc514f1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzExNTQ0ODcyMTAzNDA1_03483ab0-ebe4-4455-bb51-63a04195fd45"
      unitRef="usd">188400000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="icbc155b4bacf429796772ce27e94cbda_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzIxODg_7bdfe52d-c58a-4f8d-b5f8-a4b115d5cffb"
      unitRef="usd">145200000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="ic382ad4d1e4b4ca887dcde3037d6a744_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzIxOTU_65041854-5513-41bd-bfc5-cdc81cc61da4"
      unitRef="usd">112500000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzcyNDI_79d47572-110d-4031-8688-78cff16cf62a">The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distributions payable to legacy non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;94,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;107,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i32472808f32c48669cdcdb6fb300ef19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzEtMS0xLTEtMTMzNjY4_9c87f96a-b952-4169-92d6-090b1051c2b2"
      unitRef="usd">87522000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i51ab9056722446e7a354e96a0a2398a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzEtMy0xLTEtMTMzNjY4_67ed456d-2077-49ee-911c-fc62b8846034"
      unitRef="usd">92608000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i40a8232720454e84ab4193b8ecf8a19a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzItMS0xLTEtMTMzNjY4_64691e17-3088-4155-8b98-03daedf7baef"
      unitRef="usd">7281000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i0d7d2cfb65f04eeb990ed450281e3d84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzItMy0xLTEtMTMzNjY4_d1ae8add-2c73-4c68-96da-4a1f3f2a930c"
      unitRef="usd">15326000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="icd27d5636b244ddd89fd2e8030b54641_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzMtMS0xLTEtMTMzNjY4_02b7cc7c-dc9c-4bea-93cc-6b3d04098038"
      unitRef="usd">94803000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i192dc6dc29504992a09bfae83dcce963_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90YWJsZTozOGVkNjAxOWJiMmQ0ZTJhYjY3YWE5ZmI4ZDczNWQyNS90YWJsZXJhbmdlOjM4ZWQ2MDE5YmIyZDRlMmFiNjdhYTlmYjhkNzM1ZDI1XzMtMy0xLTEtMTMzNjY4_351d2569-ae43-4360-b823-4d3b1ced9f4f"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="if80e60d8ab83494c9238a91d2d655393_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQzMTQ_242a274c-ca3e-4711-89a5-fc81574a708f"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ieb555ed4cafa441b8b4640b8ea55f77e_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQzOTk_93f5db91-48ab-4cdc-a8a8-8766b768a5b8"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:NotesReceivableNet
      contextRef="iac904b7432ab421db7ac86aa4c7b05f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU0OTc1NTgxNTA1NDk_a0843c5b-0b6a-4d6b-9328-9c20d4ea8c31"
      unitRef="usd">103400000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="iab860d9e81b6417c8a8c4038bbe057ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzQ5MzY_8b34738b-340c-4234-bd69-ac62635f35b7"
      unitRef="usd">130900000</us-gaap:NotesReceivableNet>
    <rprx:RelatedPartyTransactionInitialTerm
      contextRef="i8a92b3734ca649b4894cb7e1fc75d883_D20210416-20210416"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzUzNTg_5fcc5457-2d90-479f-b930-3c86254adeab">P7Y</rprx:RelatedPartyTransactionInitialTerm>
    <us-gaap:DueFromRelatedParties
      contextRef="ief9bfddb245a424897b5627ca71545ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU2MDI_67f04eb3-b552-4160-a6b9-b64754a435f3"
      unitRef="usd">0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="ib71576f7e90f47a7ac7433ab13a80a52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzU2MDI_c21f97cc-373e-4ce2-9a27-c574044a2b1e"
      unitRef="usd">0</us-gaap:DueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i26d178fad8c34db685697ae7ed68e651_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4NDg_fa05b348-8a1f-45f6-864b-16da25757857"
      unitRef="usd">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired
      contextRef="i75854c27514042c189af622ae1d3b9b3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzYzNTU_ecb2a4d7-3846-4f11-b991-b8605b69ed75"
      unitRef="shares">27210</rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i393ab282388f413799453b142053e5c2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA3NzE_5c29b835-651f-43fd-9414-c505e4288b36"
      unitRef="usd">4300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if58be7d678254e86aa0bb99632dcf71b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4MTU_85ca57a3-6b80-4b28-b592-36b9498681ab"
      unitRef="usd">1500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id61936b93228428ab0a7f8fc0e01f96c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNjYvZnJhZzo1Y2E0Mzg5MzExMTc0YzM0OGY3MDA1MjQ5MzJiNzg3ZS90ZXh0cmVnaW9uOjVjYTQzODkzMTExNzRjMzQ4ZjcwMDUyNDkzMmI3ODdlXzM4NDgyOTA3MTA4MDM_7b39dfef-ad7e-4de9-bae5-0c4a82ad277b"
      unitRef="usd">1600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzg3OQ_0accc549-d643-45c6-a07c-4cec4f498bb0">Subsequent EventsIn January 2023, we acquired an interest in Ionis Pharmaceuticals, Inc.&#x2019;s royalty in Biogen&#x2019;s Spinraza (nusinersen) and Novartis&#x2019; pelacarsen, a development-stage product, for up to $1.125&#160;billion, including an upfront payment of $500&#160;million and up to $625&#160;million in additional pelacarsen milestone payments.</us-gaap:SubsequentEventsTextBlock>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNTgz_0749ce57-6e6e-487c-9b03-42d785876cd2"
      unitRef="usd">1125000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNTk5_427a5bd0-4ca1-433f-9ed5-2c0c00f655d9"
      unitRef="usd">500000000</rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments
      contextRef="iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xNzUvZnJhZzo2YWNhMWE1OGZlNTA0ODk5YjQ2MjBiNjMwMzE2N2EwZi90ZXh0cmVnaW9uOjZhY2ExYTU4ZmU1MDQ4OTliNDYyMGI2MzAzMTY3YTBmXzE2NDkyNjc0NDIzNjEz_43e46d10-1b1f-4684-884a-dfb6d0f413c0"
      unitRef="usd">625000000</rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#x201c;IPO&#x201d;). See Note 13&#x2013;Earnings per Share.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTUtMS0xLTEzMzY2OA_699f3cd8-ff85-4078-a094-cc14991fe216"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTUtMS0xLTEzMzY2OA_457dbd69-c3a1-499e-840a-8fd7a6551ef5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTEtMS0xLTEzMzY2OA_6124b2f3-09b5-499d-ae03-9da5e9273e6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTEtMS0xLTEzMzY2OA_59b31689-7827-4dbe-a295-52772efa5364"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTUtMS0xLTEzMzY2OA_bab80993-7bcf-4cae-9f51-a99270067b57"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTUtMS0xLTEzMzY2OA_16ea2ebc-9973-4938-8662-733fafe1d190"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTMtMS0xLTEzMzY2OA_c2f8e4eb-11cc-4be8-800b-fcc05d2c2425"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzM5LTMtMS0xLTEzMzY2OA_486e5dfe-585e-4a69-a58d-5816610a7474"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQwLTMtMS0xLTEzMzY2OA_b2931561-885e-4970-9d8a-34c2de5c0521"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTMtMS0xLTEzMzY2OA_62895b61-e17e-43c9-840a-eff6ce98707f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQzLTEtMS0xLTEzMzY2OA_1922bbf5-726b-4b3c-b648-0036d93955a6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90YWJsZTpmYmY5MzgwYzcxNDQ0YjU4ODNlZWFjNmVmN2I1Y2ZmNy90YWJsZXJhbmdlOmZiZjkzODBjNzE0NDRiNTg4M2VlYWM2ZWY3YjVjZmY3XzQyLTEtMS0xLTEzMzY2OA_b66728ac-743a-4133-bdae-b8a28e62a9a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc2MjQ5ODBiYzQ0YjRkYjI5ZTVlYTAwZDI1ZjQzOWZmL3NlYzo3NjI0OTgwYmM0NGI0ZGIyOWU1ZWEwMGQyNWY0MzlmZl8xMDAvZnJhZzo0Yzg4Yjk1NjRjMDI0NzM4YjE1NTJiZGZhZTI3NmM4ZC90ZXh0cmVnaW9uOjRjODhiOTU2NGMwMjQ3MzhiMTU1MmJkZmFlMjc2YzhkXzE2NDkyNjc0NDE4MDkw_a752cb7c-8682-4f53-9747-e1af4ef7b2ba"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MU/-HR-._:)==.QATD)=P0:,\&)X@"N+L%[_E((X"QE9-@),'..\"[+H[N'F
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M0BI]@JU/[C]1Z:@6&QKK4M\3(N.QV[4<2YU_&'4)IM2JM$J?8.N3_*^! (M
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M]6&MH9W# +BE 7 ;32DL-Y"KZ6K8"9G:&J:/:[T,X1P^P"U]@-MH#F&1K,+
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MPV+99U?9CJ#;]$.D%16"1NGFAF PV/(".+^F5!QVY V*C]]N_P=02P,$%
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M=$#3OW/;?U#RT+V%>B^5DOON<B<*(&8M@-\W4JKG#_H&PYO/-_\'4$L#!!0
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MK1X:06!=><0'?>39P,*&Q)?>9(!G"?6J8*9.'M5BTQ350; PGF & M98[@9
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MB_"AM=T>/E=#,YA)[0 [3>'H:'CT>L!L^ 0<?GA3TF?7B?'>%/0X%P"<+&Z
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M>%^MUAU^\>35RVV^,A],]^OVUL*G)V&6LMJ8QE5MDUFS_/'LZN+Y3]_B\_3
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M\'UK778+Q"#8<P()A4_<^79KVWL2Y[#ZQ0_?:.0BU/WVZ<.CR\= )B 3@7)
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M\.0T))7G39PP22FS3/#/P2:)*B_K'L4L_T"^$SY6]BHK02'G<&!00!O>74?
M3PV*%%QHE#<K,H.&,I<CU6R(4>1I_$F4*[ MX!B,H:$\XRCC_989HZZ6(<;%
M TB48EH-87>.R2>1I7/EKPWU<@,#K^IN3>&&? K-0*[&I02K20_CCH"L_9;
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MM"EBVQ"13J:&> M$YD_=&(+K/2A832OLYV\Q^^NWF*U@;I?$[F,Y7]4W?A%
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MUJJY^S@3/!.:)N#[B5(V/M &]=N E_\#4$L#!!0    ( &I(3U;],/)LV D
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M3B9KR/VXFMU'L_V3:7\:C0XVP?WCFH@+;I3UV+@53DQDU#OII2#F]><(7K\
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M"LBJ#5Z:1V"E329J44.=JE!;*80T47:RH?K%K<G_ST06KPOMUP$27"R8_%%
M&YQGX:I?K;4-*H%@+NF<9+,5H&[Z[F4NS$N=P*IJ>6Z0MM4[@ OT9J4^;LV!
M0I=+R5QUYU-SB?!XG>QHW:@--OG]<^N-2I/F1],P!XA.2K2,5RAPL4U@P!I4
M>]!C+<,^*9_X^G'*G!RH3M@T^'3:21<7/.98\Y\'0>!I.RN='<U[S)&;ENB
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M4O$ )D?8N19JK7E7;1UN CP*WK*E0+FH)CV-GAAQG)(]Y(U0VV7..2F&I.Z
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M_7F6S(8OCKL'JSKW 1L\V:K&_:P$+X4F >RO%!(V/I"!Z7\T;O\-4$L#!!0
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MB=]EP=CS)Z-[+>I>WJD-G&"D)_XX]/QIV#V0R6! F?2](!QZTV#T=/F(?"P
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M=,,<G!L*,OPP"T5Z.]OO4_WH5SC@'P]SZSWAQNP!$T61M._SAS8[!H5]>WZ
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M%RSC\\'3?Q3Z'\QVK!S_0HO'YS$#KU_.A"SIT!CGP:HL<V8?L,![M18O7;7
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M'1FB%@OO#-TXU/@B% ?GR$HT;QH@>TQZGLNV 8&]9WDV:C@ _"FP]=V #P>
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M(2.ZX=*F\#2A1?CU&T'-\<6A1L*$&;#-3""&P)8;[.EF$4;V#IRC,&JQ*Y<
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M5@TAOW%LZL@U/VP#5]&Y^]3SNFHZGVMW>.=1)-[?\A12YU>T=ZB^U_D=@%P
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M:@Z?8(/ 1_&C>8P;G*<-]8>M _3H7AIDGWY_!N23E^]PSJQW%/\=OB'-2,-
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MM;:/*X$R6],&K"^4JKL/=$'_:Y-W_P%02P,$%     @ :DA/5FDA=T)Q!0
M%0\  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULK5=M;]LV$/XK!Z\8
M6D"U]>;8RA(#29JB'=K.2-H5P[ /M'2RB%*B2E)QO5^_(R793F:G[I8/B262
M]]QSQ[M'Y-E*JB^Z0#3PK125/A\4QM2GHY%."RR9'LH:*YK)I2J9H5>U'.E:
M(<N<42E&H>^?C$K&J\'LS(W-U>Q,-D;P"N<*=%.63*TO4<C5^2 8] ,W?%D8
M.S":G=5LB;=H/M5S16^C#4K&2ZPTEQ4HS,\'%\'I96S7NP6_<USIG6>PD2RD
M_&)?WF;G ]\20H&IL0B,?N[P"H6P0$3C:X<YV+BTAKO//?IK%SO%LF :KZ3X
MS#-3G ^F \@P9XTP-W+U!KMXQA8OE4*[_[!JUT;^ -)&&UEVQL2@Y%7[R[YU
M>=@QF!XR"#N#T/%N'3F6KYAALS,E5Z#L:D*S#RY49TWD>&4WY=8HFN5D9V;7
M3%6\6FJH4<%MP12>C0SAVME1VF%<MACA 8P@A/>R,H6&ZRK#[#[ B AM6(4]
MJ\OP4<17F XA"CP(_3!\!"_:1!DYO.A[4<[[*.'/BX4VBHKBKWT!MW#Q?CC;
M**>Z9BF>#Z@3-*H[',Q^_BDX\7]YA&R\(1L_AG[DEOPH!M6PRZ;+:0"LRNR#
M[\&58%K#)4B5\8KZ$K1=KB&E+24(K(Q8 ]>Z80N!8"1<SR_@C129PU\AY1+O
MF&B8P<S!NJ$,#2JJ5QJKI+%F!;M#FE]#QD5C6Q%X23DT0[C(,FY;E FQ/LR'
M5XX%/G394,TI, 7AY2^)]!TJ.URB*60&)%M02T-1<":VKC'/21;T7K[$=6&9
M&OYRLSX_E#W[1+Y)2J3JJ7U+14-] +F2I2.6RK)N#',R)/.6!<WC[B9U4=)T
MFX"+!PD8PL?"\A DHV0$QFZ'!DVZ3:Y-00I)P:=<<.?'(5G?55.B8D:J-M@,
M*TEAM@.-;L--F4@;0=FT L?3=N$^DONI'<H./*<]HUUH-(UHSR8&:[.-%E@I
MF\KH%Z?P![GIY .H^;%<T*)> %K4#WT@<$7A2<$SM_T5)8!7E&&$9Q!&ON>?
MQ/04>&%,?WX [U#K4_BP7<:,47S1F+Z>KURA-S:I;ZEZM$O-G"E3H=(%KS7!
M>I/)&,)DXD7A$8CO<,G2]2$TFYZ;^>WKCQ"<1%X\GD 4QEXP#A^#O)%K)LP:
MYI2XDD$M4GBY9[>>01QZTRBDAY,@\2;AE-*YV7'X[#Y2MD^I2^B;>V!#J7@:
MHPT!VZ3T?N)HXB4G$<1![$V2V+;M*;RZWU&VZAH7-CFYN?VD(8'I?W7;!^4<
M3T+G>.J'<'U$2?:DGX$_#'Q;$,,X.=)RF\Q=V[GBE$':"MM5;^>_><164>O4
MW)"RT+>D24U#]O8D9!6SZE2@J3CU@+ BQ2L2&<J-'E)*:-^86/^-62L170MV
M$G&OZWJS5LR0>&0T\8!.U]U;%2N8<7-D22<4DC.PDDE)7LE&M*I,,E<BLX[R
M1O18) JJ5P]MM6NGV7)*%&F,BY<&Z'!F8_G8ZY_G +ZC(?<DPP?[(FW"6%T+
MGKIZMY,6J8VUU=%?FPJI8;S6BK@^E D2XU7!4RN$[J-,U'9!2(K:Z172IRB[
M5VH'RG'H9.F *OE'"5+@3?S 2\;Q4\C0O[;\>? "XDGB3>/P*?!UL]#XM:',
M[3J)*.E)$CV=ZL5^XB56T)]"[9*Q%R1/*'+19.S%\;'B%@3_5]N<O_'X!S4M
M&$;'RN V5\[(ELP-YO929#GK']P%674'FIV"WTJ!31!=%U5[ AGN.PN/=JXJ
MU#Y+=R&SATTZ"+2WELWHYLYWT5YUMLO;"^-[II:<#CH"<S+UAY/Q %1["6M?
MC*S=Q6<A#5VCW&-!]U94=@'-YY(.AMV+=;"Y"<_^ 5!+ P04    " !J2$]6
M O1W)O8&  "R#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RU5VUO
M&S<2_BL#-2AD8&WM^XMC&W 2N^=#DQIQ[@Z'PWV@=BF)EWTKR;7C_/H^PUUM
MU<9V>\#=!TG<%>?AS#//#,FSATY_-CLI+7UIZM:<+W;6]J>KE2EWLA'FI.ME
MBW\VG6Z$Q:/>KDROI:B<45.O0M]/5XU0[>+BS+V[U1=GW6!KU<I;369H&J$?
MW\BZ>SA?!(O]BX]JN[/\8G5QUHNMO)/V;_VMQM-J1JE4(UNCNI:TW)PO+H/3
M-S'/=Q/^KN2#.1@31[+NNL_\<%.=+WQV2-:RM(P@\',OW\JZ9B"X\?.$N9B7
M9,/#\1[]VL6.6-;"R+==_0]5V=WY(E]0)3=BJ.W'[N$O<HHG8;RRJXW[IH=Q
M;APMJ!R,[9K)&!XTJAU_Q9>)AP.#W'_&()P,0N?WN)#S\IVPXN),=P^D>3;0
M>.!"==9P3K6<E#NK\:^"G;VX:2NEP1"]%69'U\C1V<H"E_]=E1/&FQ$C? 8C
M".E]U]J=H:NVDM5O 59P:/8JW'OU)GP1\9TL3R@*/ K],'P!+YJCC!Q>] S>
MW=#WM826K*A_C92NQG>&_G6Y-E9#(?]^*OH1.WX:FZOFU/2BE.<+E(61^EXN
M+K[_+DC]UR]X'L^>QR^A_\G\_+<8=%G]!]H:@[<=JJOLVE+5DO!KNEI5PLJ*
M6C0%U99=(WD2/Y6,T.ON7B'1M'XD= <MK&JW8WTIJZ0AH>54Y>HK3^/2IZ5J
MR>ZZP8BV,D<G]$\I]*080KYELY9ZSCE_!?SECTYO&&&CN^;)!4_I[3-NOZ(P
M\CT_C3$*O##&QP_<./,#KTCB_R\3IW0S&CG7-ZH5P(8$=?<H:OM(PAB)=9>A
M%X2)YQ?I$8_]%.,\PIA=++PB2X[HEI=RK1"=F,J=:+=@&IS*+SUR"Q_*/5'F
M#Y8K_!A4Q!0GH9?'H:,HCPJZ;#IMU5?AVF6W ;C%*FH-,B;+Q$LSG\+0*XH4
M9IZ?Y-]857)MJ5*F[(;6$I)-RI@!GC"E!B!AX$4)S'TO2$,*D(H@H>4/V$#,
MT:KNL)(A0%52JWO!/?L@$LRQ>ABSM2Q2+PW\(P9,HI!B,)>E]*-#6"VW#I"1
MY,^#0O1&EH,>!1I%7HS XQQ<IZ \SF *PJ_&F6"UGE @TA8Y9:#-'JB1T#'"
M:N^EL1)P.5(445!X<>'3,HZ]."F.Z)V"KVH],#%32IX#B HO@#]1[$5YS(%$
M4>P"<>Y_854-RNPX[IGB."@H O](7IB%=+=#U1WS!@4E= TV;3.F!-KBG"'@
M"/F+PQR:M!*=:E:T*$LMW=QE F*B$,I+((E1CKZ7),'1$[2*>Z%JP>I@11J!
M@7/L@.?4RSFW0>;ES,@RR+W41\:NGY8FJ:872KLPTR#Q\C"C[[_+PR!\35P3
M242?I,8N>""V/Q#)WGP9I*@OKBF07"0(\2>[0\.!_/PB)Z0L#:CP4G0=-",<
M;XQ<H6.-HR-6Q$%]NV(X'3L3-N!ZK#\NS>=*+O02/_/""++W(HX,G8>+'@4>
M1G2)! Q V!NA"4F$Q=1&*<24NC0$$=(0(9>CY_O)4Q(/;):QE\4Q0BT\/^!D
M9IF_CQ>IT4SO[%> Z /XD['ZBCSECC6%7\DGPZ^56*MZZF]PG>O<4"\>W>)<
M\&**AUM3R^4<>B&0X5>2LZ:R%-^S"O>6RPAE#+=!3Y+X7 5!G-*'/[WKO.)H
MX@A!^&[L0W8)&'=C!)>&!7WHVF.'-M:>0X##4][^E[O8;XX<=SA+5P-BA&1G
M%V[V+JRNY^4O#[:.W^V#'SG!O:M_;$US9QD;-2.YLH%[/\JM*!\G^ [>W0IM
M6ZG-3O7HFA\Z*PG%^&JNC<-1Y$?H\07A-&Y']WF!JUY]?6Q<H3\(75$_:.Q
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M.YX;[B PJ7D"_M]T**CI@1>8K^D7OP!02P,$%     @ :DA/5B<0 V%B!@
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MT#++? O)$'$!8PX#PFJ/.<SVA6FIK>BB'%=_YHCPK03)D,=^/:"23C6@\"4
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M$T*U%%4(QK"ECR  YQP45%)^2=JDHB#K6R@T#*&0P *P,J'P4Z0WL$Z(J$O
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M<L1"YZ[=H9ML:/UT*#W>SZ=:.Y(>F43E<,TUQP)4^V86S$,*FPMC($LG\7P
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MHF%OZB\/4"'PWZ*IAQ'V9Y<7#Q[#F^'QER^V(+;>@OZ-&?&%6\*K9Z<__O"
M\T3T0UMM<4A,86FK#?VY=BF0*CX OR\K.!GY@!/LJOH++>_E_P!02P,$%
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M[] T&(=.Z(UVYE\&SP.R%"],YIC0VA(TE'QGZKN'IH?&V0OEJ5$*U$JBP%^
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MUH7@4QYZ30CQ"M"2?-R4F:MS#/T><C(6FQC2$=>5&D>[XO9]E/.R&=\N<+L
M[L_J->WVT[YUNT_HG@?JG4-H)DH4"P LHMOM"@J;S"\EHBQ2"&GP;_7K_5J+
MKU#S-8\[*?LC+?-XU6@/"_QA(@]8*T5A\F>]XTY +1P<*L;G,OT,<0#JG)$[
M+E;TA>7D$38PB=CB>441C2%KU;*[P\L&)G:>[&'JP&F?."!9#16=S.(8.@5)
MC92_%V; J#Y"0)22B'G*EV83K!!&6V8EC2'!0:TR+[JB'>'9B':,[!&]8T0_
ML5A(-%>%K'Z'/;*.2V&15@PT1<H3**H) +(4$#Y4<>P?!L A([\)S<C4N*'W
M[C?P]OOVAMEB 1YO"C(&($T2(R/X3P)XN538JPU,N#VQU.P ]O?KON.(M3#W
MFZ ='(''HP8>CXZ"V0TD=BI$5W<Y">KCJ4&F=XA,'?(E%W.$Z";#?,B+4AN=
M0A.$0H-L^_#T<1803UNH9.!_;M2.O7 ;51O#K&B^Q.Q?F2F; Z6DD[2;3 ON
MT$I$EZC2&KXNFJ:M4T>VH/2_&)6V"]N#IX^\].K*_;Q565OSIBKN,6J[SK6;
MRE:5:K4Q;SCKKO)D:A/+G"UYGN/AE;>M4::+&C=@/0I,W;VH"_"YB1FV0H4,
M[=8)5#*7/);0KE!5@0I_ D5M!.5KZHQ&T\.@UW-\0*/!R/$ 6XZAF(<;[/H+
M!>,-^]!_ M5+=%6>@\!@5&BFQ#+G-C^UP$'4*MG]*?)W/B+I?[3G#)=X+)[&
M=N!9'^I.%.Q!#8?&L3.9!CN__E*?D&S\8+_'GJ(_C9S(.PU3ON22T12"+"&-
M=/0TB.!YG)88 ! WPF11"$@(X!5^C@*>K64VQ@P-PCT;^GE.QUX[^G\CA^#;
MZ.M='-J/QHB-+TGD.Q-P2$#H1UBLNH[(^*RM&YAA1&%J(L01^U: [.Q\IX*P
M\O; KGI\9EJGYF,3ANBB0=(M%\,( L;[=CSM>A".(7#?M^,E^2QIKJ# 0DG5
M[12)Y:D/K6PTW8.NWSH^L81EA2W5[9ZB/PI]QPW?$#']: N);N4TAN"@D\UL
MCX1 >FP<:C_TK"+EHD;VQ[(@2O"^^?KSN(# D8;F^)UJ@QIDI($QB#1B+;!,
M6'SZ"L6NRHD)H2EF+?P^C"3+G"M5LG,0G"ES0 I2'H.8 THU1H-GV:B=%'1M
M4X9!)' :F%MI:FO/_Q-/UC)"9>=H)E!;; $D<H(K4I$O?]),9@;"&5R]E,QZ
M/4(!:>(7(!("MBXB@A\I8).7QORT**2 DT#\[T!3!VH(X/4*EM-4B0XVKU+<
M@=IC/L=T,Y+L(KZ$+T"!#!T8'*1/+P_@P-D&0]9\G^HRC,GZ\\L*:NL2]K:@
M:-6SV(8#B5W@1X^,IZE%IY D9UO-B 5?BNQ\CGP#>G<V:QI80D\ ]WKE !^V
MNKL=BW01XC_;\#G?T^TUXIW$\B:O;RM]2PJJM>3SLN5"N_K4*XB&5W K<#RL
M'V!EA3G"I"8TQ7FFVK@]*--@WAUE'V7LE#DK/H&WFLVRP+10+3W5RNVV3U!]
M>=6<5D;1=7$#<8 ]>\<%?R#SO5PK;;Y_P!S:V_CKL5XJ:GJIZ,Q>JG4W@MR8
MQLJX0OVI9HU=Y*;3ZH#Z?1W4T8/WWZ!@6P6"\\QHJ1VOR$B=BF)(H6O4;#>6
MVQ]Q6KZ^ :*R;D>JVXX#%P]XE&F*P*=VVKN_>WO1TO=]+4;5RD*@G7Q]0!;[
M%NK]V D #[C3$">!$TX#QW/QFYTW!=@R=KQ)8-^, 4[YX8CL<Z%AZ^(1\LK2
M7*\J<#V(+7L'V?S:W.#.[,7E9KF]_OU$Y1+1;\H6L-4=C*&MEO9*U4ZT*,PU
MYEQH+3+SN&(4^@A< .\70NAZ@@<T]]JW_P-02P,$%     @ :DA/5A^>^)#8
M!@  NA,  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL[5AK;]PV%OTK
MQ#0H;$#UZ/UP; ..D^P&?1F.VRZPV \<Z<Y(B"0J)#7._/N>2VG&3FJ[W<5^
M6&#SQ1:I^SB\K\/1V9W2'TQ-9,6GKNW-^:*V=CA=+DU94R?-B1JHQYNUTIVT
M6.K-T@R:9.64NG89^GZZ[&33+R[.W-ZUOCA3HVV;GJZU,&/72;U[1:VZ.U\$
MB_W&3;.I+6\L+\X&N:'W9'\9KC56RX.5JNFH-XWJA:;U^>(R.'T5L[P3^+6A
M._/@6?!)5DI]X,6[ZGSA,R!JJ;1L0>+?EJZH;=D08'R<;2X.+EGQX?/>^EMW
M=IQE)0U=J?:WIK+U^2)?B(K6<FSMC;K[.\WG2=A>J5KC_HJ[23:&QW(T5G6S
M,M9=TT__Y:<Y#@\4<O\)A7!6"!WNR9%#^5I:>7&FU9W0+ UK_.".ZK0!KNDY
M*>^MQML&>O;B;=/+OFQD*V[43K9V)RZ-(6O$T:U<M62.SY86;EAX6<XF7TTF
MPR=,!J'X4?6V-N)-7U'UN8$E\!U AGN0K\)G+;ZF\D1$@2="/PR?L1<=#ATY
M>]$3]FZHI&;KSB?^>;DR5J,X_O7822<[\>-VN&%.S2!+.E^@(PSI+2TNOOTF
M2/V7SZ",#RCCYZQ?O)_Z1*BU>"I+GOB)[&.XG[=\6Y/8:&6,**76NZ;?B*UL
M1_)0<=W82FX4(5LT++R20.N+LI;]!N%J>D&?!K0455 VM5A#"CCH4]F.AO4
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MN+G_+VMC=*A''._=#$I4&W?_T9#:-=I>$OJW_15KU=XL'J:W][./3&TXE;/
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M#GNL^N%!(Q>H-WY<&;K92MJFI]O==B).FT'PYMZ,TUNF-UP:$+@F:'1Y-0A
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M88XO9&6\ *[/M7:;#V^@>W.?_@M02P,$%     @ :DA/5MDP(1LD!   =0L
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M@72$U8*,=EIJ43_M$H%K2D^6O&"6GZ "<)'+"N$,HCCP@WY"J]"/$OH+0OB
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M%@(3FC;@][5"08U?Z(#IYG[^)U!+ P04    " !J2$]6G:?\HJT"   K!@
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M4VIPV^]ZH.K15!M&EFX<K*2AX>*6&4US5#: WJ^E- ?#%FC^'^+?4$L#!!0
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M&M] ]C(%&H,T$_#Y2@B]NS$.ZB\<X7]02P,$%     @ :DA/5O@K73/7#0
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M@VHNJGFHYJ-:0&G-X-?=(%U_Y;U@'2T&H9J!:B:J6:AFHYJ#:BZJ>:CFHUI
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MOD1"6P.:_I G,_>&X4>IKON=$O!M!'YJ2IB('JG./;I*I1(9U%1)=(SNBD9
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MUFZHM,GS(5!.CC=EL+@DA2Y4VF0_!73)\=*.>5RJ7D9-PND1%(58G''.DH4
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MX6G0:E+(\+!(^$*( H9?AK/JTE(D:0:S7D OC, ,4 *SS+W[A-,)V_OJ!=T
MXF"F8PXV"=;,H->$RDS, X $Y]&E94K2#&:_>%[*,8 $F&7N;2><0-C>5R\
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M5.*>.#MYP]<\AAY\@RLAQ^H9X^/]DN'^/>*9$1&+<47&.-IN$M9)/E182EA
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M7,&#'J"^7TE9/+W1"]@_SFK^%U!+ P04    " !J2$]6T*[>V=D"  !?"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6S-5EU/VS 4_2M7&9J8U)'/
MML#:2$"'A@03HH,]3'MPD]O6PHDSVVGIO]]UVD8MA,*D/NREC>-[3NXY/H[3
MFTOUJ*>(!IXRD>N^,S6F.'5=G4PQ8_I(%IC3S%BJC!D:JHFK"X4LK4"9< //
MZ[@9X[D3]ZI[MRKNR=((GN.M EUF&5.+<Q1RWG=\9WWCCD^FQMYPXU[!)CA$
M<U_<*AJY-4O*,\PUESDH'/>=,__THFOKJX('CG.]<0U6R4C*1SNX2ON.9QM"
M@8FQ#(S^9GB!0E@B:N//BM.I'VF!F]=K]LM*.VD9,8T74OSDJ9GVG6,'4ARS
M4I@[.?^&*SUMRY=(H:M?F*]J/0>24AN9K<#40<;SY3][6OFP ?"C5P#!"A"\
M%Q"N &$E=-E9)6O #(M[2LY!V6IBLQ>5-Q6:U/#<KN+0*)KEA#/Q)>,*'I@H
M$6Z0Z5(A+9'1P/(4+GG.\H0S 5>Y-JI<SGR&(44I+06"',-7;3B9B51=,VDX
M)V-3H%6ZQAD*"(F@* E[.$##N-"?B.5^.(##@T]P #R''U-9:GJF[KF&5-G>
MW&2EX'RI('A%P0"3(PC]%@1>$#3 +]X/][?A+GE9&QK4A@857_2FH4U2=F+M
MCCW5!4NP[]"6U*AFZ,0?/_@=[TN3L#V1;<D,:YEAQ1Z^G9L!UXF0-CHM.-.:
MWCPV/-><C;C@9M&"[]*LPY4",QM)@5_7Q M7!C/]N\FO<)]^[8ELRZ^H]BO:
M'8MZ+RFY8,(L@%FK= MR-$W*EW3=BLZ^BF>QWPW]R#N)>NYL4U5#X8D7=?WC
ML"[<ZKA==]S>V?$=%E+9C?WB[=#4[DZN?UVH/9%MR>[4LCO_0[ [^_1K3V1;
M?G5KO[K[#7;W95[#Z"3TO<ZS8#<54JR#J/TLV.[&\6<_/6Z8FO!<@\ Q0;VC
M+N5)+8_SY<#(HCH11]+0^5I=3ND+")4MH/FQE&8]L(=L_4T5_P502P,$%
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M?O.]TX,7'LBHTC?JU/=-4T93LFQSOQ-Y:-;U1-80.:Y$CE_U.H[[#$Q/9(W
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M6Y1V@WF_$B:)RHDU4#7+\U]02P,$%     @ :DA/5H&3VN5S!   &A(  !D
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M.76$;+P,X<2;AJ[KAM".AB "[V@A%AS\4B0DZ09P9%.-=/1-^C4R1KPE\07
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MT+PZ7) H(:PL(.\_4IG--B=E \UNY]G_4$L#!!0    ( &I(3U;*$IH"<@T
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M6MAHAM(E!_;3/OE+OJYYY_N:]='V^V39[9-9]N)+!)I4HYJ#:BZJ>:CFHUJ
M:F&C*=5O=JO_KTB@)VT"/=&ON/ZQG,&3\ZI-4N&ME_-"?*P7I X,'_2'-[B-
MT$0;U5Q4\U#-1[4 U4)4BRA-;;<VT9Y,T?!A@L;9J.:@FHMJ'JKYJ!:@6HAJ
M$:6I[=&FWA-]ZGT1%TDABLJ.Y_52[_NX.A&IEVD\?M9!<^%'-2_KO?:CP9^N
M_Q_;3]]T12-J5'-1S4,U']4"5 M1+:(TM0W:B'HR<+7WH$G9K]6IR[+^^!!Q
M$2\_;^9F]89_:G:&9M^HYJ":BVH>JOFH%J!:B&H1I:E]UV;?$W;Y^ 1=/HYJ
M#JJYJ.:AFH]J :J%J!91FM(>=AN+V_I8_,=F9PW^XNQ,?Q!#VP#57%3S4,U'
MM0#50E2+*$UM@S82MP>N,Q\T.[MJMFEG:5ZRC)>S[13MU=6OWL>?=GX>+N?R
MJ[AZB%=_:@ZG?S9#7Z10S4$U%]4\5/-1+4"U$-4B2E.[LTW\;78!NXU&_:CF
MH)J+:AZJ^:@6H%J(:A&EJ>W17A5@ZZ\*^,$Y7,_J\W%G/=2E_A@&=P&:Y:.:
MAVH^J@6H%J):1&EJ%[29OZW/_)L9VY4ZC_OX(:Q>.>KKW:M)5=T.WF_BR9;J
M?"N1A7@C?LNKZ=N=%._>]'Y'N/Y0!K_ H!<*H)J+:AZJ^:@6H%J(:A&EJ:W5
M7E!@LTO:;?0" %1S4,U%-0_5?%0+4"U$M8C2U/9H+P"PD>\(URN#NP+-_5'-
M134/U7Q4"U M1+6HT7;7+%C=#[14:[Y-]6WZ@]OUX.#R1_-^N_MQYJ9M]"SN
M<M']>JCFHUJ :B&J192F%G^;Y=OZ+/\O.=6X>.94 XWK4<U!-1?5/%3S42U
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MGL;%QQ4-0LJ$ -^_3-/\]8LPL'LUT>S_4$L#!!0    ( &I(3U;P_[0GH0X
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M?CH3BJJV4=E25+8,E4UAL8UKK%4^D2_I2A)4=P"5+45ERU#9%!;;N%=H-X'
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MD1^#=7X?1P$@BP6'Y'4G[]X,$=+.KN??RB=X=MH'MQB#KX3Q9O2B$,*SPVN
M?=%D&NQ=-.29;UG>(<U 4$1M>R]F5[J[IWI5WLYLE4_@: H%Y2X<S43EE\@8
M><@0UIB\IKQN.:B[M+U(^\6GRRC-0(P7O'M:W^8C@6[OIFY?&%F75R/O"6,D
M*1]7V.>+=&' ZQ>$1ZEZ*1K8W1 >_P-02P,$%     @ :DA/5FL,SWJ1"0
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M)_(U2W5/95)R]9%D7-F$<=+:"H.$T0HVV#W?H3<*0[]_J(WMV"#P^^>#0W5
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M+W=O<FMS:&5E=',O<VAE970V-2YX;6S%E]%.VS 4AE_%RM $$B-MVJ:4M9&
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MUN>Q* ORLJ%X;DO4!ZYTP6MO4_T- \(,T,_GG*MUPP2HOXJ"OU!+ P04
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M:-N?'Z[L!07:;;#O%TKA=N)Z8'OEI;\ 4$L#!!0    ( &I(3U;*'JM6? ,
M )L8   -    >&PO<W1Y;&5S+GAM;-U9[6[:,!1]E2A=IU::&D+:0%9 VI J
M3=JF2NV/_:L,<<"2XV2.Z6"OLS?9D\W7#N&COHSVQPH+*K%]?,X]MJ\3K/8J
MM>#T;DJI\N8Y%U7?GRI5O@^":CRE.:DNBI(*C62%S(G253D)JE)2DE9 RGG0
M;K7B("=,^(.>F.4WN:J\<3$3JN^'8=/FV=NG5+?&E[YG]89%2OO^P]G;[[-"
M7;_Q[/WDW<E)ZZ+U<'Z]C9S5T+D?.(6O]A!&93'1>"^WYMIAV5Q8B,Z^(78'
MP.2[;OG?OY!Y:8#=$Y/LYWJ79T2ZT]J4-MU/M9 EGF*TT$$SB?27Q.FTG<2U
MD%#!R)&;O,G&Z9<(?8M?"P3U'AOTLD*LMEKDVP8=@>34>R2\[P\)9R/)@)61
MG/&%;6Y#P[C@A?24WN,Z9 @MU4\+A[8&V[_6R9DHI(EM(]CO4=U]"UC6P"#C
MO#'8]FW#H%<2I:@4-[IB.IO&)Y!7E^\7I78XD601MJ_\%<'<=)!1(5,J5X\<
M?]DTZ'&:@1W))E.XJZ(, %2JR'4A9612"&(\+!EU0<N.*>=W\&S\EFUHS[.U
MM3-9*IJB-E07K8RM@/ZZFM5>E^V^2-<KV6.A/L[T<(2IP\ZBMY)F;&[J\ZPQ
M@*F'N#HI2[[XP-E$Y-0.?N^ @QY9\KQI(=E/'0U29:P;J/2]1RH5&Z^W_)"D
MO*=SM4RG>89[;A^AYW\[SQ,JJ"1\W;3._4.>Y1<[KG]+O(9G\UC9=NPT&74.
MWV/]V^G03<;'8/(HEKM[#":3(S#9>;6GYG-,AL=@LGT,)J/#-QD=Q;XYS#=W
M4/\Z7SL";!P FE8/#EI]_RL<W?@JJ#>:,:Z8J&M3EJ94/#D':'E%1IQNZNO^
M*<W(C*O[!NS[J_(7FK)9GC2];F$BZEZK\F<87A@WISP=BXF4SFDZK*MR,C)%
M3Q=TU/H"PC9R8RXW@G$LYD8 P^)@#C".96%Q_J?Q=-'Q6 SSUG4B793313F6
MY4*&YH/%<7,2?;E'FB11%,?8C Z'3@=#;-[B&/[<:I@W8&!Q(-+SYAI?;3Q#
M=N<!MJ:[,@0;*9Z)V$CQN0;$/6_ 2!+W:F-Q@(&M I8[$-\=!W+*S8DB6%7,
M&[:#<21), 1RT9VC<8S,3@P?]_I@NR2*DL2- .9V$$48 KL11S 'X %#HLB\
M![?>1\'R/16L_ATQ^ -02P,$%     @ :DA/5I>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !J2$]6CG8)ME(%
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M=@*]'?5V KT=]78"O0/U#@*] _4. KT#]0X"O0/U#@*] _4. KUC\K&20.]
MO8- [T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*]
M,^J="?3.DY]-OE/O.GX>2KWV?*WQ^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+
M4$L#!!0    ( &I(3U:E?PYQ[@$  ) F   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &I(3U8P'*QXP@@   @W   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !J2$]6S,_*OS<"  "Z!0  &               @($&$0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ :DA/5L6&,P)J!P  N20
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M965T-RYX;6Q02P$"% ,4    " !J2$]60X>%M>P"  "A"@  &
M    @('6/P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M:DA/5BP].<EP"0  !2T  !@              ("!^$(  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &I(3U86;X?;: H  ),?   9
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M970Q-"YX;6Q02P$"% ,4    " !J2$]6H"=>F;D(  #=&   &0
M    @($-J   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M &I(3U9+CWS[Z 4  ,$2   9              " @?VP  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ :DA/5G4VR&\& P  (P<  !D
M             ("!'+<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !J2$]6E;):"04)  !H&   &0              @(%9N@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &I(3U:;=99UYP,
M /()   9              " @97#  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ :DA/5N=>'\1]#0  ."<  !D              ("!
ML\<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !J2$]6
MSI8[1X<,  !Y(@  &0              @(%GU0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &I(3U9I(7="<04  !4/   9
M      " @27B  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ :DA/5@+T=R;V!@  L@\  !D              ("!S><  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !J2$]6)Q #86(&  #?#@
M&0              @('Z[@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( &I(3U8B=79[UPD  'L:   9              " @9/U  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ :DA/5LG4XQN^
M @  ] 4  !D              ("!H?\  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !J2$]65#-WL80K  #(E@  &0
M@(&6 @$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &I(
M3U9'LH-M2P0  +T*   9              " @5$N 0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ :DA/5O7J%HM\!   U0L  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( &I(3U:02MV6"00  (@*   9
M  " @690 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M:DA/5J.L7WX(!@  ?P\  !D              ("!IE0! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !J2$]6V3 A&R0$  !U"P  &0
M            @('E6@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( &I(3U9AHZH#!P<  ,4/   9              " @4!? 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ :DA/5IVG_**M @
M*P8  !D              ("!?F8! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !J2$]6H3V)FC@*   T=P  &0              @(%B
M:0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &I(3U:W
M;-]&X0,  .T0   9              " @=%S 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ :DA/5O@K73/7#0  =\0  !D
M     ("!Z7<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &I(3U94\^#+YP4  'PD   9              "
M@<*I 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ :DA/
M5JVE3*S8"   VDH  !D              ("!X*\! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !J2$]6T*[>V=D"  !?"0  &0
M        @('ON $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( &I(3U8+I<KKM08  -PL   9              " @?^[ 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ :DA/5I-QQ/.! P  . \
M !D              ("!Z\(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !J2$]6@9/:Y7,$   :$@  &0              @(&CQ@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &I(3U:C3%9]
MZ@(  ! +   9              " @4W+ 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ :DA/5L:=W7'4 @  .0@  !D
M ("!;LX! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !J
M2$]62\(7S#4&  !]-0  &0              @(%YT0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &I(3U8[-$N3^P0  )4C   9
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M970U.2YX;6Q02P$"% ,4    " !J2$]6\/^T)Z$.  !?BP  &0
M    @(&0_@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M &I(3U:R7)5,Z08  "TL   9              " @6@- @!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ :DA/5FL,SWJ1"0  UC@  !D
M             ("!B!0" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " !J2$]6B-4RZ.,"  !<"   &0              @(%0'@( >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &I(3U:Q+C6?, D
M (Q4   9              " @6HA @!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ :DA/5JCQ!68X P  (0T  !D              ("!
MT2H" 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !J2$]6
M@X#0>HP"  #^!@  &0              @(% +@( >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( &I(3U;*'JM6? ,  )L8   -
M      "  0,Q @!X;"]S='EL97,N>&UL4$L! A0#%     @ :DA/5I>*NQS
M    $P(   L              ( !JC0" %]R96QS+RYR96QS4$L! A0#%
M  @ :DA/5HYV";92!0   "P   \              ( !DS4" 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( &I(3U8>WYE>' (  #TG   :
M  "  1([ @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M &I(3U:E?PYQ[@$  ) F   3              "  68] @!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !* $H /10  (4_ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>462</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>147</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization and Purpose</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurpose</Role>
      <ShortName>Organization and Purpose</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Available for Sale Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</Role>
      <ShortName>Available for Sale Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements and Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financial Royalty Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssets</Role>
      <ShortName>Financial Royalty Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Intangible Royalty Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</Role>
      <ShortName>Intangible Royalty Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Non-Consolidated Affiliates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliates</Role>
      <ShortName>Non-Consolidated Affiliates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Indirect Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlow</Role>
      <ShortName>Indirect Cash Flow</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Available for Sale Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables</Role>
      <ShortName>Available for Sale Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/DerivativeInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Financial Royalty Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsTables</Role>
      <ShortName>Financial Royalty Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FinancialRoyaltyAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Intangible Royalty Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables</Role>
      <ShortName>Intangible Royalty Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/Borrowings</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ShareholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsperShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Indirect Cash Flow (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowTables</Role>
      <ShortName>Indirect Cash Flow (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlow</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Organization and Purpose (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurposeDetails</Role>
      <ShortName>Organization and Purpose (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/OrganizationandPurpose</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Available for Sale Debt Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Derivative Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails</Role>
      <ShortName>Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails</Role>
      <ShortName>Financial Royalty Assets - Summary of Financial Royalty Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Financial Royalty Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails</Role>
      <ShortName>Financial Royalty Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Non-Consolidated Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails</Role>
      <ShortName>Non-Consolidated Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/NonConsolidatedAffiliates</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Borrowings - Schedule of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails</Role>
      <ShortName>Borrowings - Schedule of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails</Role>
      <ShortName>Borrowings - Schedule of Repayments of Debt by Year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsperShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Indirect Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowDetails</Role>
      <ShortName>Indirect Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlowTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="rprx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - rprx-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - rprx-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis has a value of -9400000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis fact are: Context: ia387ad8558934defb6159f7305efa385_I20221231, Unit: usd, Rule Element Id: 3685. rprx-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:AvailableForSaleSecuritiesDebtSecurities has a value of -2500000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:AvailableForSaleSecuritiesDebtSecurities fact are: Context: ia387ad8558934defb6159f7305efa385_I20221231, Unit: usd, Rule Element Id: 5877. rprx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="rprx-20221231.htm">rprx-20221231.htm</File>
    <File>rprx-20221231.xsd</File>
    <File>rprx-20221231_cal.xml</File>
    <File>rprx-20221231_def.xml</File>
    <File>rprx-20221231_lab.xml</File>
    <File>rprx-20221231_pre.xml</File>
    <File>rprx-20221231ex211.htm</File>
    <File>rprx-20221231ex231.htm</File>
    <File>rprx-20221231ex311.htm</File>
    <File>rprx-20221231ex312.htm</File>
    <File>rprx-20221231ex32.htm</File>
    <File>rprx-20221231ex42.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rprx-20221231_g1.jpg</File>
    <File>rprx-20221231_g2.jpg</File>
    <File>rprx-20221231_g3.jpg</File>
    <File>rprx-20221231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1087">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rprx-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 38,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1087,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 462,
   "dts": {
    "calculationLink": {
     "local": [
      "rprx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rprx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rprx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rprx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rprx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rprx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 690,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 7
   },
   "keyCustom": 113,
   "keyStandard": 274,
   "memberCustom": 88,
   "memberStandard": 50,
   "nsprefix": "rprx",
   "nsuri": "http://royaltypharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://royaltypharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Organization and Purpose",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://royaltypharma.com/role/OrganizationandPurpose",
     "shortName": "Organization and Purpose",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Available for Sale Debt Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities",
     "shortName": "Available for Sale Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Derivative Instruments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://royaltypharma.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value Measurements and Financial Instruments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments",
     "shortName": "Fair Value Measurements and Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Financial Royalty Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssets",
     "shortName": "Financial Royalty Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Intangible Royalty Assets, Net",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet",
     "shortName": "Intangible Royalty Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Non-Consolidated Affiliates",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates",
     "shortName": "Non-Consolidated Affiliates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Research & Development (\"R&D\") Funding Expense",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense",
     "shortName": "Research & Development (\"R&D\") Funding Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://royaltypharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://royaltypharma.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://royaltypharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Earnings per Share",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://royaltypharma.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Indirect Cash Flow",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://royaltypharma.com/role/IndirectCashFlow",
     "shortName": "Indirect Cash Flow",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://royaltypharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://royaltypharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Available for Sale Debt Securities (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables",
     "shortName": "Available for Sale Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Derivative Instruments (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Financial Royalty Assets (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables",
     "shortName": "Financial Royalty Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Intangible Royalty Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables",
     "shortName": "Intangible Royalty Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://royaltypharma.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://royaltypharma.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Earnings per Share (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://royaltypharma.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Indirect Cash Flow (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://royaltypharma.com/role/IndirectCashFlowTables",
     "shortName": "Indirect Cash Flow (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Related Party Transactions (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Organization and Purpose (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails",
     "shortName": "Organization and Purpose (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i12ff36e2c24f4dfba76ba7b4b27451b6_D20200211-20200211",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "rprx:DeferredSharesParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "rprx:DeferredSharesParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfNoncontrollingInterestsCreated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "noncontrolling_interest",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfNoncontrollingInterestsCreated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "noncontrolling_interest",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Available for Sale Debt Securities - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
     "shortName": "Available for Sale Debt Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i192dc6dc29504992a09bfae83dcce963_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Derivative Instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
     "shortName": "Derivative Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i83621d3576df4e908ddd466a0e61f733_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
     "shortName": "Derivative Instruments - Summary of Derivatives and Reclassifications (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i2eadc88e319645deb8fc2371d70fb154_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ia96f43839fad463b8054251eb61aaf8d_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:AssetsFairValueDisclosureCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rprx:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i9ff4aab128754f10b2751bd913443e32_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd997478ad974d568fbddf3f973a46e7_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i5dc4b8074b244545ab8c7b941208037b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i5dc4b8074b244545ab8c7b941208037b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails",
     "shortName": "Financial Royalty Assets - Summary of Financial Royalty Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Financial Royalty Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
     "shortName": "Financial Royalty Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "rprx:UnapprovedFinancialAssetsHeldAtCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i192dc6dc29504992a09bfae83dcce963_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i6924ffcc56464af49725a154112a2c81_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i192dc6dc29504992a09bfae83dcce963_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails",
     "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i192dc6dc29504992a09bfae83dcce963_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ib252428d952a4cf3902a48bd039d459d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
     "shortName": "Intangible Royalty Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ib252428d952a4cf3902a48bd039d459d_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Non-Consolidated Affiliates (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
     "shortName": "Non-Consolidated Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i0fbcaa672be248e197fc3072f0903674_I20200211",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails",
     "shortName": "Research & Development (\"R&D\") Funding Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i4b44fae948f24f0d91006a467051ea02_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Borrowings - Schedule of Borrowings (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
     "shortName": "Borrowings - Schedule of Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i86c83ded7cd649d49c712b21a4451c82_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Borrowings - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i9df2b8b2b611422b93e15b5384fee55a_I20210726",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
     "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i8d165cc588cb42c7a715455ac1f644a1_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfClassesOfVotingStock",
      "reportCount": 1,
      "unitRef": "class",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i192dc6dc29504992a09bfae83dcce963_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "rprx:NumberOfNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "noncontrolling_interest",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i6924ffcc56464af49725a154112a2c81_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
     "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ida16729ea6c0450498d0894c41753058_D20200618-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://royaltypharma.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icfee70051e8f42e9a54d73cf2ec58304_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:NetIncomeLossAttributableToParentPriorToOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i45828e14489e4f4fbb5d0f3ab4faa55f_D20200618-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Indirect Cash Flow (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://royaltypharma.com/role/IndirectCashFlowDetails",
     "shortName": "Indirect Cash Flow (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingCommitmentAmountOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingCommitmentAmountOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "icd27d5636b244ddd89fd2e8030b54641_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i285488d1ca814ef9a03bdaabeea843a8_D20220107-20220107",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://royaltypharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "iacedbc9a96424070a3ba755f2467ddb6_D20230101-20230131",
      "decimals": "-6",
      "lang": "en-US",
      "name": "rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i8885fde0c1284600a478a453d7f04c9e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i8885fde0c1284600a478a453d7f04c9e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i8a476c779a0f4059929c8b1c13bcb11c_D20221001-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "ibd80829e2c144cf0a250eea11c8be41e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20221231.htm",
      "contextRef": "i89cbf4efe96145bc9b29ae5fcb436732_D20200101-20200617",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - rprx-20221231.htm",
     "menuCat": "Cover",
     "order": "66",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - rprx-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 147,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rprx_A2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2020EquityIncentivePlanMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AccruedPurchaseObligationEquityInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase Obligation, Equity Investment",
        "label": "Accrued Purchase Obligation, Equity Investment",
        "terseLabel": "Accrued purchase obligation - Tazverik"
       }
      }
     },
     "localname": "AccruedPurchaseObligationEquityInvestment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalty Receivable",
        "label": "Accrued Royalty Receivable",
        "terseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "AccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Of Limited Partnership Interests In Affiliate",
        "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]",
        "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate"
       }
      }
     },
     "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AgreementWithMSCIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with MSCI",
        "label": "Agreement with MSCI [Member]",
        "terseLabel": "Agreement with MSCI"
       }
      }
     },
     "localname": "AgreementWithMSCIMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssetsFairValueDisclosureCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Current",
        "label": "Assets, Fair Value Disclosure, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureCurrent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssetsFairValueDisclosureNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Noncurrent",
        "label": "Assets, Fair Value Disclosure, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureNoncurrent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Benefit of Payment Stream",
        "label": "Assignment Agreement - Benefit of Payment Stream [Member]",
        "terseLabel": "Assignment Agreement - Benefit of Payment Stream"
       }
      }
     },
     "localname": "AssignmentAgreementBenefitOfPaymentStreamMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssignmentAgreementFundingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Funding Obligations",
        "label": "Assignment Agreement - Funding Obligations [Member]",
        "terseLabel": "Assignment Agreement - Funding Obligations"
       }
      }
     },
     "localname": "AssignmentAgreementFundingObligationsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://royaltypharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rprx_AvillionEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion Entities",
        "label": "Avillion Entities [Member]",
        "terseLabel": "Avillion Entities"
       }
      }
     },
     "localname": "AvillionEntitiesMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion II",
        "label": "Avillion II [Member]",
        "terseLabel": "Avillion II"
       }
      }
     },
     "localname": "AvillionIIMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion I",
        "label": "Avillion I [Member]",
        "terseLabel": "Avillion I"
       }
      }
     },
     "localname": "AvillionIMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BioCrystPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioCryst Pharmaceuticals, Inc.",
        "label": "BioCryst Pharmaceuticals, Inc. [Member]",
        "terseLabel": "BioCryst Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "BioCrystPharmaceuticalsIncMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Bristol-Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassBHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Holders",
        "label": "Class B Holders [Member]",
        "terseLabel": "Class B Holders"
       }
      }
     },
     "localname": "ClassBHoldersMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassRRedeemableStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class R Redeemable Stock",
        "label": "Class R Redeemable Stock [Member]",
        "terseLabel": "Class R Redeemable Shares"
       }
      }
     },
     "localname": "ClassRRedeemableStockMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "terseLabel": "Maximum commitment to fund collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "terseLabel": "Payment of capital"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "label": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "terseLabel": "Period of return"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Exchange Ratio",
        "label": "Common Stock, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_CommonStockQuarterlyConversionBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Quarterly Conversion Basis",
        "label": "Common Stock, Quarterly Conversion Basis",
        "terseLabel": "Common stock conversion basis"
       }
      }
     },
     "localname": "CommonStockQuarterlyConversionBasis",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_CommonStockVotingRightsNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights, Number Of Votes",
        "label": "Common Stock, Voting Rights, Number Of Votes",
        "terseLabel": "Voting rights, number of shares"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_ContinuingInvestorsPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing Investors Partnership",
        "label": "Continuing Investors Partnership [Member]",
        "terseLabel": "Continuing Investors Partnerships"
       }
      }
     },
     "localname": "ContinuingInvestorsPartnershipMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CysticFibrosisFranchiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystic Fibrosis Franchise",
        "label": "Cystic Fibrosis Franchise [Member]",
        "terseLabel": "Cystic fibrosis franchise"
       }
      }
     },
     "localname": "CysticFibrosisFranchiseMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsCommercialLaunchFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics Commercial Launch Funding",
        "label": "Cytokinetics Commercial Launch Funding [Member]",
        "terseLabel": "Cytokinetics Commercial Launch Funding"
       }
      }
     },
     "localname": "CytokineticsCommercialLaunchFundingMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsFundingCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics Funding Commitment",
        "label": "Cytokinetics Funding Commitment [Member]",
        "terseLabel": "Funding Commitment"
       }
      }
     },
     "localname": "CytokineticsFundingCommitmentMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CytokineticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytokinetics",
        "label": "Cytokinetics [Member]",
        "terseLabel": "Cytokinetics"
       }
      }
     },
     "localname": "CytokineticsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DPPIVPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DPP-IV Patents",
        "label": "DPP-IV Patents [Member]",
        "terseLabel": "DPP-IV patents"
       }
      }
     },
     "localname": "DPPIVPatentsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "terseLabel": "Maximum consolidated leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "terseLabel": "Minimum consolidated coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentIssuanceAsAPercentOfPar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Issuance As A Percent Of Par",
        "label": "Debt Instrument, Issuance As A Percent Of Par",
        "terseLabel": "Debt issued as a percent of par value (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceAsAPercentOfPar",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Change In Control Event, Period",
        "label": "Debt Securities, Available-For-Sale, Change In Control Event, Period",
        "terseLabel": "Change in control event, period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleChangeInControlEventPeriod",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Liability, Current",
        "label": "Debt Securities, Available For Sale, Liability, Current",
        "terseLabel": "Available for sale debt securities, liabilities current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleLiabilityCurrent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Liability, Noncurrent",
        "label": "Debt Securities, Available For Sale, Liability, Noncurrent",
        "terseLabel": "Available for sale debt securities, liabilities noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleLiabilityNoncurrent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "terseLabel": "Number of shares purchased (in shares)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Policy",
        "label": "Debt Securities, Available For Sale, Policy [Policy Text Block]",
        "terseLabel": "Equity securities and Available for sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePolicyPolicyTextBlock",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rprx_DebtSecuritiesAvailableForSalePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Price Per Share",
        "label": "Debt Securities, Available-For-Sale, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePricePerShare",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]",
        "terseLabel": "Redemption, Period One"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]",
        "terseLabel": "Redemption, Period Two"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Multiple",
        "label": "Debt Securities, Available-For-Sale, Redemption Price, Multiple",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPriceMultiple",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Restriction Period",
        "label": "Debt Securities, Available-For-Sale, Restriction Period",
        "terseLabel": "Restrictions on selling common stock, period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRestrictionPeriod",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "terseLabel": "Preferred shares, weighted average cost of capital"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DeferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "terseLabel": "Deferred Shares",
        "verboseLabel": "Deferred Shares"
       }
      }
     },
     "localname": "DeferredSharesMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DeferredSharesParOrStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Par or Stated Value Per Share",
        "label": "Deferred Shares, Par or Stated Value Per Share",
        "terseLabel": "Deferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "DeferredSharesParOrStatedValuePerShare",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DeferredSharesSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Issued",
        "label": "Deferred Shares, Shares, Issued",
        "terseLabel": "Deferred stock, issued (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesIssued",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Outstanding",
        "label": "Deferred Shares, Shares, Outstanding",
        "terseLabel": "Deferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesOutstanding",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesValueIssued": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Value, Issued",
        "label": "Deferred Shares, Value, Issued",
        "terseLabel": "Deferred shares, $0.000001 par value, 371,325 and 361,170 issued and outstanding, respectively"
       }
      }
     },
     "localname": "DeferredSharesValueIssued",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DerivativeAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Asset",
        "label": "Derivative Asset [Member]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeAssetMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DevelopmentFundBondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development fund bond",
        "label": "Development fund bond [Member]",
        "terseLabel": "Development fund bond"
       }
      }
     },
     "localname": "DevelopmentFundBondMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EPAHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EPA Holdings",
        "label": "EPA Holdings [Member]",
        "terseLabel": "EPA Holdings"
       }
      }
     },
     "localname": "EPAHoldingsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EpizymeCommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epizyme Common Stock Warrant",
        "label": "Epizyme Common Stock Warrant [Member]",
        "terseLabel": "Epizyme Common Stock Warrant"
       }
      }
     },
     "localname": "EpizymeCommonStockWarrantMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EpizymeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epizyme Inc.",
        "label": "Epizyme Inc. [Member]",
        "terseLabel": "Equity Investment In Epizyme Inc."
       }
      }
     },
     "localname": "EpizymeIncMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EquityMethodInvestmentsUnfundedCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Unfunded Commitments",
        "label": "Equity Method Investments, Unfunded Commitments",
        "terseLabel": "Equity method investment, unfunded commitments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsUnfundedCommitments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_EvrysdiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evrysdi",
        "label": "Evrysdi [Member]",
        "terseLabel": "Evrysdi"
       }
      }
     },
     "localname": "EvrysdiMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ExchangeOfferTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer Transaction",
        "label": "Exchange Offer Transaction [Member]",
        "terseLabel": "Exchange Offer Transaction"
       }
      }
     },
     "localname": "ExchangeOfferTransactionMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "label": "Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "terseLabel": "Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition",
        "terseLabel": "Gains/(losses) on initial recognition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Nonoperating Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Nonoperating Expense",
        "negatedTerseLabel": "Other non-operating expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherNonoperatingExpense",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "terseLabel": "Redemption"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancialRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Royalty Assets",
        "label": "Financial Royalty Assets [Member]",
        "terseLabel": "Income from financial royalty assets"
       }
      }
     },
     "localname": "FinancialRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails": {
       "order": 1.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "negatedLabel": "Cumulative allowance for changes in expected cash flows"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "negatedLabel": "Cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Financial Royalty Asset, Writeoff",
        "label": "Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff",
        "terseLabel": "Writeoff related to financial royalty asset"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable Change In Present Value, Write-off Cumulative Allowance",
        "label": "Financing Receivable Change In Present Value, Write-off Cumulative Allowance",
        "terseLabel": "Write-off of cumulative allowance"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "terseLabel": "Aggregate royalty amount when patents cease"
       }
      }
     },
     "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "totalLabel": "Net carrying value, before cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, Fair Value Disclosure",
        "label": "Financing Receivables, Fair Value Disclosure",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "FinancingReceivablesFairValueDisclosure",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FormerOperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Operating and Personnel Payments",
        "label": "Former Operating and Personnel Payments [Member]",
        "terseLabel": "Former Operating and Personnel Payments"
       }
      }
     },
     "localname": "FormerOperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingAgreementWithBioCrystMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreement With BioCryst",
        "label": "Funding Agreement With BioCryst [Member]",
        "terseLabel": "Funding Agreement With BioCryst"
       }
      }
     },
     "localname": "FundingAgreementWithBioCrystMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingAgreementsWithSanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreements With Sanofi",
        "label": "Funding Agreements With Sanofi [Member]",
        "terseLabel": "Funding Agreements With Sanofi"
       }
      }
     },
     "localname": "FundingAgreementsWithSanofiMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Commitments",
        "label": "Funding Commitments [Member]",
        "terseLabel": "Funding Commitments"
       }
      }
     },
     "localname": "FundingCommitmentsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_GainLossOnDerivativeFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Derivative Financial Instruments",
        "label": "Gain (Loss) On Derivative Financial Instruments",
        "negatedTerseLabel": "Termination of derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeFinancialInstruments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_GantenerumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gantenerumab",
        "label": "Gantenerumab [Member]",
        "terseLabel": "Gantenerumab"
       }
      }
     },
     "localname": "GantenerumabMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IPOContinuingInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Continuing Investors Partnerships",
        "label": "IPO - Continuing Investors Partnerships [Member]",
        "terseLabel": "Public Stock Offering - Continuing Investors Partnerships Interests"
       }
      }
     },
     "localname": "IPOContinuingInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IPOSharesFromCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Shares From Company",
        "label": "IPO - Shares From Company [Member]",
        "terseLabel": "IPO - Shares From Company"
       }
      }
     },
     "localname": "IPOSharesFromCompanyMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IPOSharesFromSellingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Shares From Selling Shareholders",
        "label": "IPO - Shares From Selling Shareholders [Member]",
        "terseLabel": "IPO - Shares From Selling Shareholders"
       }
      }
     },
     "localname": "IPOSharesFromSellingShareholdersMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ImbruvicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imbruvica",
        "label": "Imbruvica [Member]",
        "terseLabel": "Imbruvica"
       }
      }
     },
     "localname": "ImbruvicaMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Royalty Receivable",
        "label": "Increase (Decrease) In Accrued Royalty Receivable",
        "negatedTerseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "label": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "terseLabel": "Cash collected on financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Financial Royalty Assets",
        "label": "Increase (Decrease) In Financial Royalty Assets",
        "negatedTerseLabel": "Income from financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancialRoyaltyAssets",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Other Royalty Income Receivable",
        "label": "Increase (Decrease) In Other Royalty Income Receivable",
        "negatedTerseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IndividualLicenseesConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Licensees Concentration Risk",
        "label": "Individual Licensees Concentration Risk [Member]",
        "terseLabel": "Individual Licensees Concentration List"
       }
      }
     },
     "localname": "IndividualLicenseesConcentrationRiskMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IntangibleRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Royalty Assets",
        "label": "Intangible Royalty Assets [Member]",
        "terseLabel": "Revenue from intangible royalty assets"
       }
      }
     },
     "localname": "IntangibleRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "negatedTerseLabel": "Interest income accretion"
       }
      }
     },
     "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and RPSFT",
        "label": "Legacy Investors Partnerships and RPSFT [Member]",
        "terseLabel": "Legacy Investors Partnerships and RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRPSFTMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust",
        "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships",
        "label": "Legacy Investors Partnerships [Member]",
        "terseLabel": "Legacy Investors Partnerships"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LongTermFundingCommitmentAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Commitment, Amount Outstanding",
        "label": "Long Term Funding Commitment, Amount Outstanding",
        "terseLabel": "Funding commitment, outstanding"
       }
      }
     },
     "localname": "LongTermFundingCommitmentAmountOutstanding",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "terseLabel": "Long term funding partnership, additional payments, aggregate amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Amount",
        "label": "Long Term Funding Partnership, Amount",
        "terseLabel": "Long term funding partnership, amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAmount",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipCovenantRequiredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Covenant, Required Amount",
        "label": "Long Term Funding Partnership, Covenant, Required Amount",
        "terseLabel": "Required amount to be drawn"
       }
      }
     },
     "localname": "LongTermFundingPartnershipCovenantRequiredAmount",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipExpectedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership Expected Payment",
        "label": "Long Term Funding Partnership Expected Payment",
        "terseLabel": "Long term funding partnership, expected payment"
       }
      }
     },
     "localname": "LongTermFundingPartnershipExpectedPayment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipInitialPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Initial Payment",
        "label": "Long Term Funding Partnership, Initial Payment",
        "terseLabel": "Long term funding partnership, initial payment"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInitialPayment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple",
        "label": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple",
        "terseLabel": "Installment repayments, percentage of amount drawn"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche One",
        "label": "Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche One",
        "terseLabel": "Interest free and payment free period, calendar quarters, tranche one"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheOne",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche Two",
        "label": "Long Term Funding Partnership, Interest Free And Payment Free Period, Number Of Calendar Quarters, Tranche Two",
        "terseLabel": "Interest free and payment free period, calendar quarters, tranche two"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInterestFreeAndPaymentFreePeriodNumberOfCalendarQuartersTrancheTwo",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermFundingPartnershipNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Number of Tranches",
        "label": "Long Term Funding Partnership, Number of Tranches",
        "terseLabel": "Long term funding partnership, number of tranches"
       }
      }
     },
     "localname": "LongTermFundingPartnershipNumberOfTranches",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermFundingPartnershipTotalAmountDrawn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Total Amount Drawn",
        "label": "Long Term Funding Partnership, Total Amount Drawn",
        "terseLabel": "Long term funding partnership, total amount drawn"
       }
      }
     },
     "localname": "LongTermFundingPartnershipTotalAmountDrawn",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_MerckAssetPhaseIIClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Asset - Phase II Clinical Trial",
        "label": "Merck Asset - Phase II Clinical Trial [Member]",
        "terseLabel": "Merck Asset - Phase II Clinical Trial"
       }
      }
     },
     "localname": "MerckAssetPhaseIIClinicalTrialMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MerckToFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck to Fund",
        "label": "Merck to Fund [Member]",
        "terseLabel": "Merck to Fund"
       }
      }
     },
     "localname": "MerckToFundMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MilestoneAccelerationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Acceleration",
        "label": "Milestone Acceleration [Member]",
        "terseLabel": "Milestone Acceleration"
       }
      }
     },
     "localname": "MilestoneAccelerationMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MilestoneAccelerationOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Acceleration Option",
        "label": "Milestone Acceleration Option [Member]",
        "terseLabel": "Milestone Acceleration Option"
       }
      }
     },
     "localname": "MilestoneAccelerationOptionMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MilestonePaymentAccruedButNotPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Accrued But Not Paid",
        "label": "Milestone Payment Accrued But Not Paid",
        "terseLabel": "Milestone payable - Erleada"
       }
      }
     },
     "localname": "MilestonePaymentAccruedButNotPaid",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_MorphoSysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MorphoSys",
        "label": "MorphoSys [Member]",
        "terseLabel": "MorphoSys"
       }
      }
     },
     "localname": "MorphoSysMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_NetIncomeLossAttributableToParentPriorToOffering": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss) Attributable to Parent, Prior To Offering",
        "label": "Net Income (Loss) Attributable to Parent, Prior To Offering",
        "terseLabel": "Less: net income attributable to Continuing Investors Partnerships prior to the IPO"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentPriorToOffering",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NoncontrollingInterestIncreaseFromContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase from Contributions",
        "label": "Noncontrolling Interest, Increase from Contributions",
        "terseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NoncontrollingInterestTransfersOfInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Transfers Of Interests",
        "label": "Noncontrolling Interest, Transfers Of Interests",
        "terseLabel": "Transfer of interests"
       }
      }
     },
     "localname": "NoncontrollingInterestTransfersOfInterests",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NumberOfClassesOfVotingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Classes Of Voting Stock",
        "label": "Number Of Classes Of Voting Stock",
        "terseLabel": "Number of classes of voting shares"
       }
      }
     },
     "localname": "NumberOfClassesOfVotingStock",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_NumberOfNoncontrollingInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Noncontrolling Interests",
        "label": "Number of Noncontrolling Interests",
        "terseLabel": "Number of noncontrolling interests"
       }
      }
     },
     "localname": "NumberOfNoncontrollingInterests",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_NumberOfNoncontrollingInterestsCreated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Noncontrolling Interests Created",
        "label": "Number Of Noncontrolling Interests Created",
        "terseLabel": "Number of noncontrolling interests created"
       }
      }
     },
     "localname": "NumberOfNoncontrollingInterestsCreated",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_OldCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Old Credit Facility",
        "label": "Old Credit Facility [Member]",
        "terseLabel": "Old Credit Facility"
       }
      }
     },
     "localname": "OldCreditFacilityMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Seven Five Percent Senior Notes Due 2027",
        "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]",
        "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027"
       }
      }
     },
     "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Zero Percent Senior Notes Due 2025",
        "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]",
        "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025"
       }
      }
     },
     "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Personnel Payments",
        "label": "Operating and Personnel Payments [Member]",
        "terseLabel": "Operating and Personnel Payments"
       }
      }
     },
     "localname": "OperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OptionIndexedToIssuersEquityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Indexed to Issuer's Equity, Term",
        "label": "Option Indexed to Issuer's Equity, Term",
        "terseLabel": "Put option, term (in months)"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTerm",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_OptionIndexedToIssuersEquityValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Indexed To Issuers Equity, Value",
        "label": "Option Indexed To Issuers Equity, Value",
        "terseLabel": "Put option to sell additional common stock"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityValue",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtherFinancialRoyaltyAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Royalty Asset",
        "label": "Other Financial Royalty Asset [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFinancialRoyaltyAssetMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OtherRoyaltyIncomeReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Royalty Income Receivable, Current",
        "label": "Other Royalty Income Receivable, Current",
        "terseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "OtherRoyaltyIncomeReceivableCurrent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtilimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otilimab",
        "label": "Otilimab [Member]",
        "terseLabel": "Otilimab"
       }
      }
     },
     "localname": "OtilimabMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OvernightBankFundingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overnight Bank Funding Rate",
        "label": "Overnight Bank Funding Rate [Member]",
        "terseLabel": "Overnight Bank Funding Rate"
       }
      }
     },
     "localname": "OvernightBankFundingRateMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PabloLegorretaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pablo Legorreta",
        "label": "Pablo Legorreta [Member]",
        "terseLabel": "Pablo Legorreta"
       }
      }
     },
     "localname": "PabloLegorretaMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PaymentOfDividendsToShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Dividends To Shareholders",
        "label": "Payment Of Dividends To Shareholders",
        "negatedTerseLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentOfDividendsToShareholders",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Collateral Posted On Derivative Instruments",
        "label": "Payments For Collateral Posted On Derivative Instruments",
        "negatedTerseLabel": "Derivative collateral posted"
       }
      }
     },
     "localname": "PaymentsForCollateralPostedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForDistributionsToShareholdersAndUnitholders": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Distributions To Shareholders and Unitholders",
        "label": "Payments For Distributions To Shareholders and Unitholders",
        "negatedLabel": "Distributions to shareholders/unitholders"
       }
      }
     },
     "localname": "PaymentsForDistributionsToShareholdersAndUnitholders",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Milestones",
        "label": "Payments For Milestones",
        "negatedTerseLabel": "Milestone payments"
       }
      }
     },
     "localname": "PaymentsForMilestones",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOngoingDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Ongoing Development Stage Funding",
        "label": "Payments For Ongoing Development Stage Funding",
        "negatedTerseLabel": "Development-stage funding payments - ongoing"
       }
      }
     },
     "localname": "PaymentsForOngoingDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOperatingCostsAndProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Operating Costs and Professional Services",
        "label": "Payments For Operating Costs and Professional Services",
        "negatedTerseLabel": "Payments for operating and professional costs"
       }
      }
     },
     "localname": "PaymentsForOperatingCostsAndProfessionalServices",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForUpfrontDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Upfront Development Stage Funding",
        "label": "Payments For Upfront Development Stage Funding",
        "negatedTerseLabel": "Development-stage funding payments - upfront and milestone"
       }
      }
     },
     "localname": "PaymentsForUpfrontDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Equity Investments, Upfront Payment",
        "label": "Payments to Acquire Equity Investments, Upfront Payment",
        "terseLabel": "Upfront payment for equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityInvestmentsUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities, FN-NI",
        "label": "Payments To Acquire Equity Securities, FN-NI",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "terseLabel": "Payments to acquire royalty interests, additional milestone payments"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Noncontrolling Interests, Other",
        "label": "Payments To Noncontrolling Interests, Other",
        "negatedTerseLabel": "Distributions to legacy non-controlling interests - other"
       }
      }
     },
     "localname": "PaymentsToNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToNoncontrollingInterestsRoyaltyReceipts": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Noncontrolling Interests, Royalty Receipts",
        "label": "Payments To Noncontrolling Interests, Royalty Receipts",
        "negatedTerseLabel": "Distributions to legacy non-controlling interests - royalty receipts"
       }
      }
     },
     "localname": "PaymentsToNoncontrollingInterestsRoyaltyReceipts",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToTerminateDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Terminate Derivative Instruments",
        "label": "Payments To Terminate Derivative Instruments",
        "negatedTerseLabel": "Termination payments on derivative instruments",
        "verboseLabel": "Swap termination payments"
       }
      }
     },
     "localname": "PaymentsToTerminateDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PointSevenFivePercentSeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Point Seven Five Percent Senior Notes Due 2023",
        "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]",
        "terseLabel": "Point Seven Five Percent Senior Notes Due 2023"
       }
      }
     },
     "localname": "PointSevenFivePercentSeniorNotesDue2023Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "terseLabel": "Other royalty cash collections"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "terseLabel": "Cash collections from financial royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "terseLabel": "Cash collections from intangible royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collateral Received On Derivative Instruments",
        "label": "Proceeds From Collateral Received On Derivative Instruments",
        "terseLabel": "Derivative collateral received"
       }
      }
     },
     "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Exercise Fee",
        "label": "Proceeds From Exercise Fee",
        "terseLabel": "Proceeds exercise fee"
       }
      }
     },
     "localname": "ProceedsFromExerciseFee",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromExerciseFeeProRataAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Exercise Fee, Pro Rata Amount",
        "label": "Proceeds From Exercise Fee, Pro Rata Amount",
        "terseLabel": "Exercise fee, pro rata amount"
       }
      }
     },
     "localname": "ProceedsFromExerciseFeeProRataAmount",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "label": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "terseLabel": "Proceeds from equity securities"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Other",
        "label": "Proceeds From Noncontrolling Interests, Other",
        "terseLabel": "Contributions from non-controlling interests - other"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Research And Development",
        "label": "Proceeds From Noncontrolling Interests, Research And Development",
        "terseLabel": "Contributions from legacy non-controlling interests - R&amp;D"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PurchasingAndDonatingVentilatorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchasing And Donating Ventilators",
        "label": "Purchasing And Donating Ventilators [Member]",
        "terseLabel": "Purchasing And Donating Ventilators"
       }
      }
     },
     "localname": "PurchasingAndDonatingVentilatorsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RP Holdings",
        "label": "RP Holdings [Member]",
        "terseLabel": "RP Holdings"
       }
      }
     },
     "localname": "RPHoldingsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPI2019IntermediateFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI 2019 Intermediate Finance",
        "label": "RPI 2019 Intermediate Finance [Member]",
        "terseLabel": "RPI Intermediate FT"
       }
      }
     },
     "localname": "RPI2019IntermediateFinanceMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIFTSeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPIFT Senior Secured Credit Facilities",
        "label": "RPIFT Senior Secured Credit Facilities [Member]",
        "terseLabel": "RPIFT Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "RPIFTSeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1",
        "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]",
        "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1"
       }
      }
     },
     "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1",
        "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]",
        "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1"
       }
      }
     },
     "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RedeemableStockRedemptionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Stock, Redemption Price Per Share",
        "label": "Redeemable Stock, Redemption Price Per Share",
        "terseLabel": "Redeemable stock, redemption price (in pound per share)"
       }
      }
     },
     "localname": "RedeemableStockRedemptionPricePerShare",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_RelatedPartyTransactionAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Annual Increase, Percentage",
        "label": "Related Party Transaction, Annual Increase, Percentage",
        "terseLabel": "Increase in quarterly installment payments (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualIncreasePercentage",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Initial Term",
        "label": "Related Party Transaction, Initial Term",
        "terseLabel": "Initial term"
       }
      }
     },
     "localname": "RelatedPartyTransactionInitialTerm",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Number of Partnership Interests Acquired",
        "label": "Related Party Transaction, Number of Partnership Interests Acquired",
        "terseLabel": "Number of limited partnership interest acquired (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "terseLabel": "Amount calculated for operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "terseLabel": "Percent for calculating operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "label": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateAdjustedCashReceipts",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Value Of Security Investments",
        "label": "Related Party Transaction, Rate, Value Of Security Investments",
        "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash",
        "label": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash",
        "terseLabel": "Repayments of long-term debt by contributions from non-controlling interest"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RepaymentsOfLongTermDebtScheduledPayments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Long-term Debt, Scheduled Payments",
        "label": "Repayments Of Long-term Debt, Scheduled Payments",
        "negatedTerseLabel": "Scheduled repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtScheduledPayments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Upfront Payment and Premium Paid",
        "label": "Research and Development Expense, Upfront Payment and Premium Paid",
        "terseLabel": "Upfront payment and premium paid"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RochesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche\u2019s",
        "label": "Roche\u2019s [Member]",
        "terseLabel": "Roche\u2019s"
       }
      }
     },
     "localname": "RochesMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyalPharmacySelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharmacy Select Finance Trust",
        "label": "Royal Pharmacy Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "RoyalPharmacySelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Assets, Policy",
        "label": "Royalty Assets, Policy [Policy Text Block]",
        "terseLabel": "Royalty assets"
       }
      }
     },
     "localname": "RoyaltyAssetsPolicyPolicyTextBlock",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships",
        "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]",
        "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to RP Select Finance Trust",
        "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]",
        "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyIncomeOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Income, Other",
        "label": "Royalty Income, Other [Member]",
        "terseLabel": "Other royalty income"
       }
      }
     },
     "localname": "RoyaltyIncomeOtherMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Investments",
        "label": "Royalty Investments [Member]",
        "terseLabel": "Royalty Investments"
       }
      }
     },
     "localname": "RoyaltyInvestmentsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaCollectionTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Collection Trust",
        "label": "Royalty Pharma Collection Trust [Member]",
        "terseLabel": "RPCT"
       }
      }
     },
     "localname": "RoyaltyPharmaCollectionTrustMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaInvestmentsOldRPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Investments (Old RPI)",
        "label": "Royalty Pharma Investments (Old RPI) [Member]",
        "terseLabel": "Old RPI"
       }
      }
     },
     "localname": "RoyaltyPharmaInvestmentsOldRPIMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SaleOfStockNumberOfSharesAvailableToConvert": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Number of Shares Available To Convert",
        "label": "Sale of Stock, Number of Shares Available To Convert",
        "verboseLabel": "Number of shares available to convert (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesAvailableToConvert",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_SaleOfStockNumberOfSharesNotConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Shares Not Converted",
        "label": "Sale Of Stock, Number Of Shares Not Converted",
        "terseLabel": "Number of shares converted (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesNotConverted",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_SeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2031",
        "label": "Senior Notes Due 2031 [Member]",
        "terseLabel": "Senior Notes Due 2031"
       }
      }
     },
     "localname": "SeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorNotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2051",
        "label": "Senior Notes Due 2051 [Member]",
        "terseLabel": "Senior Notes Due 2051"
       }
      }
     },
     "localname": "SeniorNotesDue2051Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Revolving Credit Facility",
        "label": "Senior Unsecured Revolving Credit Facility [Member]",
        "terseLabel": "Senior Unsecured Revolving Credit Facility"
       }
      }
     },
     "localname": "SeniorUnsecuredRevolvingCreditFacilityMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SettlementsWithEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlements With Equity Method Investments",
        "label": "Settlements With Equity Method Investments",
        "terseLabel": "Settlement of Epizyme forward purchase contract (Note 4)"
       }
      }
     },
     "localname": "SettlementsWithEquityMethodInvestments",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockIssuedDuringPeriodSharesIssuedForRegistration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued For Registration",
        "label": "Stock Issued During Period, Shares, Issued For Registration",
        "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForRegistration",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued To Partnerships",
        "label": "Stock Issued During Period, Shares, Issued To Partnerships",
        "terseLabel": "Issuance of Class B ordinary shares to continuing investors partnerships (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedToPartnerships",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockIssuedDuringPeriodValueIssuedForRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Issued For Registration",
        "label": "Stock Issued During Period, Value, Issued For Registration",
        "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForRegistration",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockIssuedDuringPeriodValueIssuedToPartnerships": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Issued To Partnerships",
        "label": "Stock Issued During Period, Value, Issued To Partnerships",
        "terseLabel": "Issuance of Class B ordinary shares to Continuing Investors Partnerships"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedToPartnerships",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation",
        "label": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation",
        "terseLabel": "Effect of exchange by continuing investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (in shares)"
       }
      }
     },
     "localname": "StockholdersEquitySharesEffectOfExchangeAndReallocation",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockholdersEquityValueEffectOfExchangeAndReallocation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation",
        "label": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation",
        "terseLabel": "Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity"
       }
      }
     },
     "localname": "StockholdersEquityValueEffectOfExchangeAndReallocation",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_TheNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Notes",
        "label": "The Notes [Member]",
        "terseLabel": "The Notes"
       }
      }
     },
     "localname": "TheNotesMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TheravanceBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Theravance Biopharma",
        "label": "Theravance Biopharma [Member]",
        "terseLabel": "Theravance Biopharma"
       }
      }
     },
     "localname": "TheravanceBiopharmaMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Five Five Percent Senior Notes Due 2050",
        "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]",
        "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050"
       }
      }
     },
     "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Five Percent Senior Notes Due 2051",
        "label": "Three Point Three Five Percent Senior Notes Due 2051 [Member]",
        "terseLabel": "Three Point Three Five Percent Senior Notes Due 2051"
       }
      }
     },
     "localname": "ThreePointThreeFivePercentSeniorNotesDue2051Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Zero Percent Senior Notes Due 2040",
        "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]",
        "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040"
       }
      }
     },
     "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TreasuryRateLockContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Rate Lock Contracts",
        "label": "Treasury Rate Lock Contracts [Member]",
        "terseLabel": "Treasury rate lock contracts"
       }
      }
     },
     "localname": "TreasuryRateLockContractsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TrelegyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trelegy",
        "label": "Trelegy [Member]",
        "terseLabel": "Trelegy"
       }
      }
     },
     "localname": "TrelegyMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointOneFivePercentSeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Five percent Senior Notes Due 2031",
        "label": "Two Point One Five percent Senior Notes Due 2031 [Member]",
        "terseLabel": "Two Point One Five percent Senior Notes Due 2031"
       }
      }
     },
     "localname": "TwoPointOneFivePercentSeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Senior Notes Due 2030",
        "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]",
        "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TysabriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tysabri",
        "label": "Tysabri [Member]",
        "terseLabel": "Tysabri"
       }
      }
     },
     "localname": "TysabriMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_UnapprovedFinancialAssetsHeldAtCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unapproved Financial Assets Held At Costs",
        "label": "Unapproved Financial Assets Held At Costs",
        "terseLabel": "Unapproved financial assets held at costs"
       }
      }
     },
     "localname": "UnapprovedFinancialAssetsHeldAtCosts",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_UnitHoldersAndShareholdersContributionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unit Holders' and Shareholders' Contributions",
        "label": "Unit Holders' and Shareholders' Contributions [Member]",
        "terseLabel": "Unitholders\u2019/ Shareholders\u2019 Contributions"
       }
      }
     },
     "localname": "UnitHoldersAndShareholdersContributionsMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_XtandiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi",
        "label": "Xtandi [Member]",
        "terseLabel": "Xtandi"
       }
      }
     },
     "localname": "XtandiMember",
     "nsuri": "http://royaltypharma.com/20221231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r683",
      "r781",
      "r818",
      "r819",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r273",
      "r274",
      "r427",
      "r457",
      "r692",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r218",
      "r280",
      "r287",
      "r293",
      "r369",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r534",
      "r537",
      "r539",
      "r540",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r218",
      "r280",
      "r287",
      "r293",
      "r369",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r534",
      "r537",
      "r539",
      "r540",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r218",
      "r280",
      "r287",
      "r293",
      "r369",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r534",
      "r537",
      "r539",
      "r540",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r347",
      "r711",
      "r778",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r761",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "The Manager"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r347",
      "r711",
      "r778",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r345",
      "r629",
      "r710",
      "r722",
      "r771",
      "r772",
      "r778",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r345",
      "r629",
      "r710",
      "r722",
      "r771",
      "r772",
      "r778",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r273",
      "r274",
      "r427",
      "r457",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r281",
      "r282",
      "r283",
      "r356",
      "r357",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r516",
      "r517",
      "r518",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r575",
      "r576",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting standards update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r236",
      "r655",
      "r669",
      "r673"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r721"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r499",
      "r500",
      "r501",
      "r753",
      "r754",
      "r755",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r78",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r446",
      "r578",
      "r707",
      "r708",
      "r747"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r54",
      "r92",
      "r96"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r137",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r54",
      "r97"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Financial royalty asset impairment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r181",
      "r202",
      "r228",
      "r271",
      "r329",
      "r339",
      "r343",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r520",
      "r524",
      "r558",
      "r721",
      "r774",
      "r775",
      "r822"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r222",
      "r239",
      "r271",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r520",
      "r524",
      "r558",
      "r721",
      "r774",
      "r775",
      "r822"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized (Losses)/Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized (Losses)/Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r360",
      "r397"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r85",
      "r359",
      "r397",
      "r647"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r84",
      "r397"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r84",
      "r225",
      "r397"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r515",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r515",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r56",
      "r224",
      "r690"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents and Marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r51",
      "r56",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r51",
      "r172"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Schedule of Non-cash Investing/Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Indirect Cash Flow"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlow"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r271",
      "r297",
      "r301",
      "r308",
      "r310",
      "r317",
      "r318",
      "r364",
      "r413",
      "r416",
      "r417",
      "r418",
      "r422",
      "r423",
      "r455",
      "r456",
      "r458",
      "r459",
      "r461",
      "r558",
      "r684",
      "r736",
      "r748",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r120",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase additional shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r188",
      "r207"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r411",
      "r412",
      "r682",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Ordinary Shares"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Ordinary Shares"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r753",
      "r754",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r721"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r30",
      "r248",
      "r250",
      "r259",
      "r652",
      "r658"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Royalty Pharma plc"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r143",
      "r248",
      "r250",
      "r258",
      "r651",
      "r657"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r170",
      "r171",
      "r347",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r170",
      "r171",
      "r347",
      "r674",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r170",
      "r171",
      "r347",
      "r681",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r199",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r70",
      "r71",
      "r170",
      "r171",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)",
        "verboseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r170",
      "r171",
      "r347",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Investments in non-consolidated affiliates"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses, net"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r383",
      "r385",
      "r387",
      "r388",
      "r389",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Allowance for current expected credit losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r377",
      "r386",
      "r387",
      "r391",
      "r392",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r69",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r270",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r440",
      "r447",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r182",
      "r183",
      "r200",
      "r276",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r579",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r183",
      "r200",
      "r451"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r174",
      "r176",
      "r424",
      "r579",
      "r705",
      "r706"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt issued, amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r15",
      "r174",
      "r454",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r15",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r16",
      "r276",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r579",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to the applicable par call date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Upon occurrence of a change of control triggering event"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r16",
      "r111",
      "r114",
      "r115",
      "r116",
      "r173",
      "r174",
      "r176",
      "r198",
      "r276",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r579",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r175",
      "r436",
      "r452",
      "r705",
      "r706"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt discount and issuance costs",
        "terseLabel": "Unamortized discount and loan issuance costs on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Gain (Loss)",
        "negatedTerseLabel": "Losses/(gains) on available for sale debt securities",
        "terseLabel": "Realized gain on available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Losses/(gains) on available for sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average coupon rate (as a percent)"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as current.",
        "label": "Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative asset, current, statement of financial position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as noncurrent.",
        "label": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative asset, noncurrent, statement of financial position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 4.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative instruments, current"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Derivative financial instruments",
        "verboseLabel": "Derivative instrument, noncurrent"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r811"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r154",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r151",
      "r812"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivatives not designated as hedging instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r155",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r117",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Dividends declared and paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r186",
      "r208",
      "r234",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r593",
      "r751"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Amounts due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r9",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r593",
      "r751"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Distributions payable to legacy non-controlling interests"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r17",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r593",
      "r751"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Total distributions payable to legacy non-controlling interests"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r260",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r294",
      "r297",
      "r308",
      "r309",
      "r310",
      "r314",
      "r540",
      "r541",
      "r653",
      "r659",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per Class A ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r260",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r297",
      "r308",
      "r309",
      "r310",
      "r314",
      "r540",
      "r541",
      "r653",
      "r659",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share based compensation expense, period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r110",
      "r218",
      "r252",
      "r253",
      "r254",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r316",
      "r369",
      "r463",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r539",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r589",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r33",
      "r50",
      "r54",
      "r209"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Distributions from equity method investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r221",
      "r271",
      "r364",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r221",
      "r271",
      "r364",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r90",
      "r330",
      "r738"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Non-Consolidated Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r229",
      "r555",
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r766"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "(Losses)/gains on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r660",
      "r766"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Losses/(gains) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r89",
      "r201",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r438",
      "r557",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized (loss) on equity securities still held"
       }
      }
     },
     "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r543",
      "r544",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r438",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r544",
      "r602",
      "r603",
      "r604",
      "r705",
      "r706",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r161",
      "r165",
      "r438",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r546",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r438",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r438",
      "r464",
      "r469",
      "r544",
      "r602",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r438",
      "r464",
      "r469",
      "r544",
      "r603",
      "r705",
      "r706",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r438",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r544",
      "r604",
      "r705",
      "r706",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Losses/(gains) on available for sale debt securities included in earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Unrealized gains on available for sale debt securities included in other comprehensive losses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "terseLabel": "Settlement of forwards"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r438",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r602",
      "r603",
      "r604",
      "r705",
      "r706",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r551",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial instruments and Fair value measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsPurchasedMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.",
        "label": "Federal Funds Purchased [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsPurchasedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLoansAndLeasesReceivablePolicy": {
     "auth_ref": [
      "r75",
      "r79",
      "r80",
      "r81",
      "r350",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for financing receivable.",
        "label": "Financing Receivable [Policy Text Block]",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "FinanceLoansAndLeasesReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Current portion of Financial royalty assets"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r377",
      "r382",
      "r383",
      "r384",
      "r391",
      "r401",
      "r402",
      "r403",
      "r449",
      "r460",
      "r530",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r703",
      "r763",
      "r764",
      "r765",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r76",
      "r237",
      "r375",
      "r378",
      "r381",
      "r686",
      "r688",
      "r689",
      "r825"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Allowance for Credit Loss [Line Items]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": {
     "auth_ref": [
      "r77",
      "r380",
      "r701"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-off of credit loss allowance"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "auth_ref": [
      "r352",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financing receivable.",
        "label": "Financing Receivables [Text Block]",
        "terseLabel": "Financial Royalty Assets"
       }
      }
     },
     "localname": "FinancingReceivablesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r226",
      "r406"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r630",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r95",
      "r634"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r95",
      "r630"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Value",
        "verboseLabel": "Intangible royalty assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forwards"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing gain (loss) on derivative instruments.",
        "label": "Gain (Loss) on Derivative Instruments [Member]",
        "terseLabel": "Gain (Loss) on Derivative Instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "(Gains)/losses on derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gains on derivative financial instruments"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r54",
      "r102",
      "r103"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r147",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r32",
      "r179",
      "r191",
      "r211",
      "r329",
      "r338",
      "r342",
      "r344",
      "r654",
      "r700"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Consolidated net income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r33",
      "r54",
      "r90",
      "r190",
      "r209",
      "r327"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in losses/(earnings) of equity method investees",
        "terseLabel": "Income (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r272",
      "r291",
      "r292",
      "r328",
      "r504",
      "r513",
      "r514",
      "r661"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r251",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes and Other taxation matters"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Decrease/(increase) in operating assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase/(decrease) in operating liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r746"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r310",
      "r471"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Add: Dilutive effect of unvested RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Royalty Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r175",
      "r193",
      "r255",
      "r326",
      "r577"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r263",
      "r267",
      "r268"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r37",
      "r39"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r180",
      "r194",
      "r212",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available for Sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r271",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r521",
      "r524",
      "r525",
      "r558",
      "r699",
      "r774",
      "r822",
      "r823"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r185",
      "r206",
      "r721",
      "r750",
      "r767",
      "r817"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r223",
      "r271",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r521",
      "r524",
      "r525",
      "r558",
      "r721",
      "r774",
      "r822",
      "r823"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r183",
      "r203",
      "r437",
      "r453",
      "r705",
      "r706"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Amount outstanding",
        "totalLabel": "Total debt carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value of outstanding Notes"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r100",
      "r276",
      "r776"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r100",
      "r276",
      "r442"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r100",
      "r276",
      "r442"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r100",
      "r276",
      "r442"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r100",
      "r276",
      "r442"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r100",
      "r276",
      "r442"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r16",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r24",
      "r184",
      "r205",
      "r271",
      "r364",
      "r413",
      "r416",
      "r417",
      "r418",
      "r422",
      "r423",
      "r558"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest (percentage)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in)/provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r51",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r55",
      "r192",
      "r210",
      "r221",
      "r246",
      "r249",
      "r254",
      "r271",
      "r281",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r306",
      "r329",
      "r338",
      "r342",
      "r344",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r541",
      "r558",
      "r700",
      "r774"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Royalty Pharma plc"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r142",
      "r246",
      "r249",
      "r291",
      "r292",
      "r743"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net income attributable to non-controlling interest",
        "verboseLabel": "Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r307",
      "r310",
      "r329",
      "r338",
      "r342",
      "r344",
      "r700"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r310"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r64",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r293",
      "r314",
      "r356",
      "r357",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r499",
      "r500",
      "r501",
      "r509",
      "r510",
      "r511",
      "r512",
      "r516",
      "r517",
      "r518",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r575",
      "r576",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r631",
      "r632",
      "r633",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Receipt of contribution of investments in Legacy Investors Partnerships"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r130",
      "r463",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other expenses/(income), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r348",
      "r349",
      "r648"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Financial royalty assets"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r235",
      "r351",
      "r383",
      "r390",
      "r686",
      "r687",
      "r701",
      "r702",
      "r768",
      "r837"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails": {
       "order": 2.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r348",
      "r390"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Financial royalty asset, net",
        "totalLabel": "Total current and non-current financial royalty assets, net"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r329",
      "r338",
      "r342",
      "r344",
      "r700"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "auth_ref": [
      "r105",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.",
        "label": "Option Indexed to Issuer's Equity, Strike Price",
        "terseLabel": "Put option, selling price, maximum (in dollars per share)"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r106",
      "r156",
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Purpose"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurpose"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r747",
      "r770"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Non-cash impairment charges"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r238",
      "r721"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r243",
      "r244",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of loss reclassified from accumulated other comprehensive income into net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": {
     "auth_ref": [
      "r241",
      "r527"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax",
        "terseLabel": "Reclassification of loss on interest rate swaps"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r110",
      "r247",
      "r250",
      "r257",
      "r567",
      "r572",
      "r573",
      "r650",
      "r656",
      "r741",
      "r742"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive (loss)/income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Changes in other comprehensive income/(loss):",
        "verboseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r133",
      "r136",
      "r247",
      "r250"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r26",
      "r29",
      "r88",
      "r245"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassification of unrealized gains on available for sale debt securities",
        "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities",
        "terseLabel": "Reclassification of unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other expense/(income)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r721"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other non-operating expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs and other"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r42",
      "r83",
      "r261"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of available for sale debt securities",
        "verboseLabel": "Purchase of available for sale debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireFinanceReceivables": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.",
        "label": "Payments to Acquire Finance Receivables",
        "negatedLabel": "Acquisitions of financial royalty assets"
       }
      }
     },
     "localname": "PaymentsToAcquireFinanceReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Acquisitions of other financial assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to continuing non-controlling interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Shares",
        "verboseLabel": "Debt securities"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r265",
      "r744"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distributions from equity method investees"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r745"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r83",
      "r261",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from redemption of preferred shares"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r41",
      "r83",
      "r261"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from available for sale debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r221",
      "r246",
      "r249",
      "r264",
      "r271",
      "r281",
      "r291",
      "r292",
      "r329",
      "r338",
      "r342",
      "r344",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r519",
      "r522",
      "r523",
      "r541",
      "r558",
      "r654",
      "r700",
      "r718",
      "r719",
      "r743",
      "r774"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Consolidated net income",
        "verboseLabel": "Consolidated net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/EarningsperShareDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "auth_ref": [
      "r379",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses, net"
       }
      }
     },
     "localname": "ProvisionForLoanLossesExpensed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "auth_ref": [
      "r53",
      "r189"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions.",
        "label": "Provision for Other Credit Losses",
        "terseLabel": "Provision for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "ProvisionForOtherCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Put Option"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r470",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r178",
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount paid to CEO"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r215",
      "r592",
      "r593",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Related party, rate (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Operating and personnel payments incurred"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r470",
      "r592",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r590",
      "r591",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayments of long-term debt",
        "verboseLabel": "Repayments of outstanding debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r125",
      "r213",
      "r824"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development funding expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development funding expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research &amp; Development (\"R&amp;D\") Funding Expense"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r117",
      "r204",
      "r668",
      "r673",
      "r721"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r218",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r369",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r539",
      "r664",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue from intangible royalty assets and Milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r256",
      "r271",
      "r324",
      "r325",
      "r337",
      "r340",
      "r341",
      "r345",
      "r346",
      "r347",
      "r364",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r558",
      "r654",
      "r774"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total income and other revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty at Fair Value"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Ownership percentage following IPO"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Exchange offering, ownership percentage"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r347",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of Financial Royalty Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r16",
      "r111",
      "r114",
      "r115",
      "r116",
      "r173",
      "r174",
      "r176",
      "r198",
      "r705",
      "r707",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r149",
      "r152",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Summary of Derivatives and Reclassifications"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r65",
      "r68",
      "r297",
      "r301",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r91",
      "r221",
      "r271",
      "r364",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": {
     "auth_ref": [
      "r689",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Royalty Interests"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Repayments of Debt by Year"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r231",
      "r232",
      "r233",
      "r317",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r709",
      "r736",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Balance Of Non-controlling Interests"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r739",
      "r740",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Debt Securities",
        "verboseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r739",
      "r740",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Shares"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Interest rate volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-adjusted discount rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares, outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r271",
      "r297",
      "r301",
      "r308",
      "r310",
      "r317",
      "r318",
      "r364",
      "r413",
      "r416",
      "r417",
      "r418",
      "r422",
      "r423",
      "r455",
      "r456",
      "r458",
      "r459",
      "r461",
      "r558",
      "r684",
      "r736",
      "r748",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r110",
      "r218",
      "r252",
      "r253",
      "r254",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r292",
      "r316",
      "r369",
      "r463",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r539",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r589",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r316",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r110",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class A ordinary shares sold in IPO, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r110",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share based compensation and related issuance of Class A ordinary shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r110",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class A ordinary shares sold in IPO, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r117",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized under plan (in shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r130",
      "r131",
      "r141",
      "r218",
      "r219",
      "r253",
      "r277",
      "r278",
      "r279",
      "r282",
      "r290",
      "r369",
      "r463",
      "r499",
      "r500",
      "r501",
      "r511",
      "r512",
      "r539",
      "r567",
      "r568",
      "r573",
      "r589",
      "r665",
      "r666",
      "r750",
      "r767",
      "r817"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other exchanges"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "negatedTerseLabel": "Other exchanges (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r574",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r574",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r574",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r574",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r82",
      "r229",
      "r359",
      "r691"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r449",
      "r460",
      "r530",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r763",
      "r764",
      "r765",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r21",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Interests"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r21",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury interests"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r110",
      "r117",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Treasury interests"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "(Gains)/losses on derivative financial instruments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives and Commodity Contracts",
        "terseLabel": "Forward purchase contract"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivativesAndCommodityContracts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r319",
      "r320",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r296",
      "r310"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r294",
      "r310"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average Class A ordinary shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196816",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498357-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r727": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r728": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r729": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r731": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r732": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r733": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r734": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r735": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b,d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001802768-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001802768-23-000007-xbrl.zip
M4$L#!!0    ( &M(3U8)V@7TP0L% )5%-@ 1    <G!R>"TR,#(R,3(S,2YH
M=&WLO>U[$T?2+O[]_!7YY??U>-,OU2^5:S?G(A#RL">\++#)DB_/5=5=#4IL
MB4>2">:O/]6R#9@0($&V9N1APV)K1J/1W'=7W=5=7?7W__/RZ/"+%[)<S1;S
M?WQI_V:^_.+_?//W_^_@X#_?/OSABUN+<GPD\_47-Y=":ZE?_#9;/_OBIRJK
M7[]HR\71%S\MEK_.7M#!P>8]-Q?/3Y:SI\_67SCC_#L'EU_;ALTY P<%&AZ
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M/I#EHVYL7S_T.GNA#^OM4^^=ZOS%\EU;_8DN^7?O[R_>DOGB2(.+]USV4UW
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M:7< 7-DC6;D]X@HV@&8C4P:5"BWG$AH"4\I.+:],Q-T]<8?"E9PC>5?%.LC
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MV,X:&4%N[W6F]%!8E%LK.21(7@UC L@QIN:SCV@P (Q@T^%U9M$>R=<MAN_
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M4 AO+U7,/)NMQF('=0S%OA%5U6L#<(;)FF3!DZ=$@ .N9/I!4!Z?K(B7LY&
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MY>;R-(<W(C9=SJ)2;8XS.X[6@G.,7FS@H#JFB83S%4>37!PG0=X"YI(1,>G
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MO4,@$VT:&H$FZ;0M4IEX8-,62-47L3 '81\3>*HYE^1J%FL;D]"[*Q)#)-7
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MC6-[X_=_GOB=V<OX[[\<3;7?S5K"2Y]0+A4TID-$#Q'IU$&+:%RB3BD1H&:
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M?AJ&E/F[$U%A"-^,\*(2P"QDS%D:2RG()2V$:]2Y$E"X"9T%%M JGW!*,H_
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M19S_WY;L3-.!8Z9[?8Q3,M&C.BD'<I 6LGA]2\+UPZON>A&%T='9GOE=<X+
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ME(KEX05F:<S>"R(,J2]C-KJ $?:%CV@!^%G"XF%4)$^9**\*3^)K,!\>9P9
M$@.B9ND ;CZ%Q^'8X5%V%YE4P2[\)NC(_*MFAP5KQ?5& Z2%Z P3FZIH6+,L
M=M1C2^M(,:!;C#O'N(,KUI>A?:0IOM%'G.1W<==6Z ^/.G8 L!& C@")V7V[
M/P>*R.F11*](7")YA17=A1P#$E!^L'>S$7'V>/7 =BL:GI0#FJ5ESN$*#K1
M!L5NZIC $/L2DU0E;E_:[HI?!2%H=X"O:,']2^D^$;M](*__ 5F%BV87@/C
MK5[ TJ<S<0&I";\N1--Q2A E?EP"0%0HDXE(G"+M2&20(O-F=*)(AY&?OYV[
M7:$%RJCRO=6M2@\4PIJL.D\@JRTF+C$XL]Z]G,3V;NQL5"'DYR2F-1:%DA>E
MPSX!ZN#3DJG+R$B"TN>UL#A1OD;ZXE/D+%DZ(C%>X+O-C3S6C2!Y(UX48_0O
MW,C)<2NPMR-]_KPCO<%'!"GCWV6"BOV"?"%.?:2_>1DQI5JP?]8/J&2,@_C_
ME%%&-W?V:'<V3LP:XL5X%3MN;H; "XU000:1CM6@"Y _IT.\6QF88X_.QT!4
M.0(0FRLY$(4([.M4T-Z(W6H0S!ANQLOP++Y;?8-\+DSC*-W P^/B<"-+<^DC
M'E5ZKU?F,$P.0E :T'AS[H]V[DRP%K03P!RT;1^..2Q1.*8LQXP+WYQOC<90
ML\*ES74\U76@,I(A4>*ZW&!(BX@IJ'#T-.D5_8T8\7AG+_1+9@NH3"*H185Q
MY/-.(Q4CXF5/D60)88*]Q()A0,6.(V0:FXMY*OFN?>ZH=(\=.^/K!1 F8=O(
M*,M<Z,,40-$*D-T3%#2 E8>4=9PA\>:J'O>J:!A2;@OV1>E@%.O(#5"S7I3S
M#)):'L//*Y?3._QT<Q>/>1>+&1%10:U-\S3.Z36SS2U@:V)T+V$W*48$/$QZ
M>4,AOW1/NVW' ;ZQ=\,A@[55C7CCIS="/3O=VZE4L^[2.IL6,^!LQT4_+7M,
M_Q?N 78D;5MUY>!9Q&;*C*49)3E0+5!3,<]*$$1ABFU&Y;93H'(X90JSP^C$
MATN L7A^%H'AA-6S<]^\M;5]QDQ /U,QW=@LS <4XVDT?H(&\,8 DL_/#%JY
M4/E(RV@O3,NS%[<(D H[*QKB/3Q ]'+2^@30?HN='MA4WHAI_&A^9AH?.H'8
MLFL%)&4&>I#!$,;C&$<4!N&@*QVD&<4"-1TIH1';Z#4Z #)^4^R#(<URI'^H
MZS#--Q_",4:"O54MB/DI^B-AGQ\,8PH2"9L_;*[];F]*5_K*[>O<DIND4E!R
ML;(<!LS>O-@X$G.SLV6QU]@K=Y]XD3+!"7_GBG.49NT1F4EES-$ WV?T*D(X
M:X/7- E8-'1 WWHHW5CZP(E-#,1CQT!H38*(]-]_J9;R;OKO.2>SP"JWT<DT
M9VW6?1R$+6W:A;$H^%O3X/^,Y\K$(NY)ZLX]V'E_?_ARNG^X=WKZ0/_-RVSR
MZ K3]F"L1Y!5C)>15=@^!*M (A]C8 (HN5XY0@UKEHNC]F)P40(D>\+BAD+.
M:IBJG*170M3WLS3/V=#3(U7>=9 1(^9?Q:"6%(;!X8"WJZYK=9"+]LD52E$T
MD88P*,42'D)@JDQ3 ];3KH.ACC'Q6/P=1I&@("I6@Z(N\_@2GP1T$/GP!0^3
MX6$#* F0S.]+(.8,(U 6^?Y <)"!E\FH-**V6?0S)M;E _38XA.#*)!],L3]
M%=3O\W@''@:11%P!JHZH%Z<>FJC'CZ%^E#%MME=T0@Q S,/SK2W.>+3-X7/O
M$LKM!?JDN*]B2$9MJ2U@>?B@^Z;\M(IT*./U2]R/!>,-&CF@OHZZ-6NU;)1=
MR) ):WQ6X7_,6\N!&08I R* 7]W$30UHQN++*I]81[R'0_X%$B"]J6<ZRZ)+
M8&:D(_U!XA%&4':DH^R2#+R(Y\>.!@&]A \_1&F/)LU[HYQX6=21MCWOKX@+
MF;^G_02EK/^2P?!=]5O]QO[ R\HK.'=X)R\H0(OHQ! "PF3U8W\7Z 'H2)].
M_V@MDH(6.^I(AP!/61'EXAOLX@#7B:N?&.6PA%WZTM'N6>>>9<'8@W $(YRD
M?I_6'^]=9:.<K2/"RV@]CJ;PJQ$7YU5M(5<& R_$TC:""CR:CYP2"#G]!I*X
MTE?_*C??@-Z8(+(.X6P2E'X1^<;0P$]E-CWZ>\0J?0!'-EV!_%*@'%"U:O4Q
M 6VASSL0T4IS1$%9Q-'4 -B97%FU'.&^@[>CG!&%!F;K ) TBWJ@O<0M6M&=
MP7[OH]NK0N^/T*!,&)&3*<8%1:A,C;M9@+*@GED1%H_54"KXD;6)QB %;B&,
M;FB<ABO"'V%A<-I^7CTV'[[:5"'&T(7ZZJ,0AAOY,5YN#I)B!"O%0"&/9%F$
M/ #6!0O/1H)0)_@P9U%8#KND(G2, 6)>>CF&&?'0GXS"%%S=X&6V82BV*R1;
M#"L$\,-VXI@R0U85C A<(AX)\&VA'3.W= 2M9)M$IDIX-&:&VBXL!TV1#:=A
M@5FM$2HSR FC$;NUE]J',Q8 S@8(HQM8.ZRW1!M.F57=MC@3Q-_8&RUV4ME
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M9ZM-WP)_5AM[MBM]I>*<X%GXVAP?"MYAFVK'P?#L@+:K"I %3=^) ,Q*7..
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M>L5@'AX\6H>N"O?&$#,I\<D(@\ER#$8J,4BMJ:L<\R4Q&H>!1/<N<HJFD:I
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M$MV2NN"#:"HG*M(WQ6([E4^SY6K XM(UA-T76+.DA0*/*W'WT33&9:D]L-/
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M&UB&<5X/K&6XDB5HA.J^$Y:;9AQ^*?)8IY>;DCW;*%S3IB&C#[J]P[;RC9O
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M,0TJ(IE$M?Y8DP9/\L;NC>(..$[^=?_;G[LXW$6I^%.E!JDV)@'\3Z/V\O
M=FO1XH W51/9*?];@[RJ\NFK/?<5-2CSM*Z6?\4[@\C<JXO[/F^]O=L.7)^8
M^0X;YI'WOQ-;DCI38[T[*+2ZV%4C&.PKE5ZI>?G#3\&<IDEF'OX2;;KFW'F&
M?_\_@P*^U_+6^[=Q7]ZF17J'*%3S2I>OPA%YTQ+QL8NRXE7OV B0)(MAXU[M
MXF_N>_.:XV[?NQW':/*7O_UUL"HGW>,#7(4W-=>LEE$YR:^RJ-"S0I?8>RZO
MBTB753(E(A%%4@O+O8=U4>#?X9,Y2&'P*K&(%?]Z-0'74MF+?P5W&>O6P ^A
M,K5T'NDL[L#'DN$DFJIY%.L9_ 8E!+4A ($>5046M,$0ZK0J._##N$Z)%2%2
MLUF17ZH4?CN$J19JB&T>D!Q[2K^:3G4QQ"_'KN06_N"F ".<*2R9B_0U<2V@
M *,"W&C'C0E$6%J#>#+?B\V7\$7P3?BYQ/5Z$>5%E,."%-$(AI(7)0E#?,2E
M@N$.YM%8Y^-"S2;S;O0%/@=+!UL^T,@5KLH2%AX,_Q+65/%B.W>=5HX&J7E1
MX6<]A+%TU_#(]Y_:D8>]"$D,</'Q+(]RT#W4M-JKML0CS_7<<SSK_M%3XT)K
M[ME(_#I\B. +<%@+[*5A#L0@>&*AL?Z;[IP]0BK^5UU6_"P8D1H.\R+&\P%G
MH:)G\D%GLGAXBWOW.IZ)_:=V)@S^/"F1F9\[R+R.YEH53;E81E^*Y )TJK*W
MLD6LX,Y[];EDYG"S%:_#"@@8/%(HE^Q'QSJ#20U!4E8%R(TUW-N#I[:W?VH6
MJ#.XB2B'U25=K)^3?#91Q51UHO?9L!L=HWW-*BZ0#K#MN,WX-WV]&Q*:1&1;
M1?^L85OW]SK(DG5">[_"PUJ?]$8/]70 /^SW\&G[>^MXNP^?V@GX[(,+ C=L
M"+['5S1/LF00S9B9PQ+;_)$E>+O/*[(1#&':N9Y5O$?8/5V:?V1\,*:JN-"5
M^RP^952G;*6$!V(]+_?14]O:7T'9LOBES96^O^T[*!85L=GM'W:B0>T;7F*P
M#K%B54S9,2C9,1JW[@[/5!*C$J^I3S,(;'!;]YV7O89;^O*I;2G(:[3!4"%6
MJ:;5)MO_FNQQ\"(.]JUP72C)" @/F>ZP=_2W: 26EIR-=92HQT]MCY;;2XN.
MI/.DPNNX:#7A+IFF:G<UH4+#:0WW^.1I[G'B!"<)Q2ML4374R:5NE8\L%#%,
M>+1W;'MF)2-V<R=PD<%_!DV;P%;#IQ;L'>ZF14X1M2-<Y9VP^S\>NW:FZ[CY
M'AWS(^_^47??2N'AO^L$Q2L,*,&()]QDU)[O\PSN_2<RGH>ZIDA\R58TY?=>
MOBZC'?RIO_>:/DL_]UZ_L)H6'@+F-US9_UU&AD0;?_E/E=48/ '+:G\ME6GO
MR03XS#Y^] P<?Q/MLI/5@UWG"HI.\.:R-])Z[^P7VR[]P<M#>^GSHM$GC\-]
M)*\ST=XDO>G&#SFN.*1(HJ&XPEYXZQGAZ#V9L)=_H1MF59^]5'M'X>8VMQ>M
MZSG'I>"3O1Y;5(>W@(8"=NE.@UKZ@-^Z\'QAF5[+W7XR 2VSVX9E$DRJ*<8N
MHXL,K3(%<OL+[,E:+O*3B2R913XMJT+]#QB>0X66L'^UC 0;U/,<W,P"GU1R
MA+B#YI"^QFP%6+$=N#]U&DO* R\!&-$IN#6>8;R6N_5DHD!FMSZ[$"XJ'\I>
M,9-^&*:#WQGB=+9:KQ8EIW5 ,'X 2BPO$DQU7X$/4DZ2&<Q675"DX?12M.'[
M]VNYBT\FX+.J76KTF&=J_IY?*MCK\G^#KVJJ I^'M?ED8C=W-#*\?6@S,[ Z
MK-+H* H-1W_O%H-C+>_6DXGJW+![1WNT>Q_R8C;)S^=V!RM7/;&XA4$0[A"!
M2_"DE_2@Y[)W3R9:<[O!=_;I_>Y>?^]DU77>[QXNK#3][H?E<* F3DJ^V'^Y
ML$-+<;U_ 7Z*L$-+H1AW0V)$I]G<3^5+QB&V>!KKXE!86@!I>!%"8 WB U0,
MWG>)H6TU&E%Z$#XR2C(854)8/_":;5I9L#'X_'RFY6W=Z%SKZ$&.Y(K+*O&>
MSTEY$;UC0(R$?4@U5WH:]4X[D?]WBO>VC?G1S\BH+@B6D61XG9;8X#?>A@?;
M!'KBJZ12:3)< 2GW+KD&0?Z))7-T6J!H%LS*W2;4>KT//+'P5Q\XA/$0*!3N
M,=@(F+V]!+U21BHJZ^D4#3N\(G23K@FDP6N@O#5X=<=%^/O_X3=:%&D1ZP+/
M:*IFI7YE?GAMZJB3C,9-7WH-0P*MN"O0T\/%(AA:6OZS(#%/CKO] YRLJ0J0
M%PM.LTLX30.P#O]VW#T\Z"_]\UZWM_RK-SUVOWNT?_^//8*#U#]:Z;&WU$C<
M$3G.JWW?)_ADI5*(=S4'0[U+N0)F?HTF2&";&24(8)):/>#L_DJ<]FJ31V#"
M%X3L/5 )WO'A=]3@[7=[+?+'+\)[PM05ZS&,I;4MHC1P'^"$1V6>)G&$1^$)
M59HVC_BB!NX'M5S1>0VS*\O=GRDN]B$!MZZ"M2I;3M&C+]=?NU+W5P1V;RL!
M3_AAN?^W?_17^-FKG3#R((Y>/X@(764$H:O=.R"I^\/?S6GG*/#4G'87 *'
M1Z][PH51)X>8Z=2EP %A5>-(36&'"0?Z8_]PK[LL2XIHT60$^M,KH6JKB5@U
M?+G=W._=7-JR@Y>'_I:!&TN;W;[)E.]Q^V<A$J.D*%MW$QWF:3(N%$*=,!D_
MG"3Z<N7JC^T>W[K'[[TZ13_PS*6,X*DLO[%2SU$5R7A,V,/!W";[\%UH;5$%
MT_:2/N &OE58KF7O)N%$[#TQD!:34%544*-3#);!7]-Z.L,0@=GYYK8\$[:0
MU?;7!O8CKU-E9%S3G_,L_AX;;DT7Y?>\PEN;PI@&J?[+Y[^US[Y3.GPR(IV!
M^B#80P!YO]OWY/N/^WN> 1:*^ZW(OC^1[:KE'.!K_PBS&Z4>UI0=^7>MBHJR
M5Z$I36HXQZ"\^0AN:G^O?W _POO)\7RMMM-G\RJ_@-_"H,KHS%5 _Z;J#/2C
M2/%GPFZWFJ?]*%3"6X']G;*!R4E&E"#%7.P$17...2XP0D+YW)$*?<(7D ?U
MH^\_F^\;,2YI6?YD*#OZ6^'^@!HW=(C%>8H+=04[J*^'>D90!?HCB'^P,RFY
M74V2(K9GP'!%:+3VZ3P@S<R2QVZ]X_O:S,]:\'6XKA3O"&Y8 N:4=7F'! ,:
MZVQ(Q6!373&<?R9^L'D$02SU%+Y"5[J_UWBB>9[O-\-S+"^(1^KA_+Z2X$KP
MSNU-OE_/&EE;X! 0[8G(TXG"S'JOOSN%YTYX7V?PVAQAL$/M#H39,<:JV-W<
M;MH#;MK^P6UFM,AEUH:I F4XJ$MX>%E&L9J;&UI2(,49V:,\3?,KJMN8:%]]
MFKB8I?]!6<YBFL_+<KM\*9/7$T;[/16PGRG-_'@CJN7;*&SPOJ9Z3.'GLBKJ
M[R"VZ;AX&X+3O)K.58ANA".#C,$EG#?T0&^8RW7_YM'#'34NWK.BAUM8A';4
M&_C",_"*"3.YYC"W/S7RBVDD.+-3HDO)]XFPVHFA$9/*B&A@N&U,>:Z#HOK^
MDWDF8C%%3GQ0&1R-0A[';!FD&1*8FRJ<UL"@&KV->,67O\]PG^&S5)3"8S &
ME-54]4TW.V%,'5YI59%DHH)3?#A?/K FL5BGSGBFZE+!4/ K,C9F79$7@2+2
MG6"UD#]"UH7%2%DB1TM24O$(:$WZIITY_-Z3:4N6W1$3&/#[H)[K(EA=&[G"
M9ZC,;A(/EVN0#.,,D@.3D'6085PP9!OI>$A@%'E)53/ V E5<PAH(B">;QZC
MD=RPG3A??,Q 5ZC8AVI&P-*OB/V?P%FORW!M\)M97N&W:0-@@1*\(LF(S?5\
MP'DP6,'1*!DFJ)G<5M/"W["Q^+3L$HMY+&^.2Y/+V,P2T@S<22#SIAMA 4-:
MFET3G2(D?;FH$EE-K#OVO[YXA.VV=<RYP4+GI)ICCGY08=875"F%@JA'+/[.
M>SBJTV2(;(&8RO<GVHW>CVYZ'WI/' _)!)?.Q;0T"I[-5"O4JU>Z;4O,:??2
MD7+F8<CC(K\B5*RYR3>0$]KR-V;&(5>O#EZQ. M[I,E]"T_^)$_CFV2%DSIH
M/\PJ?VOO+JG71<)_\04!K8! F>D:#%29E#94,E3E)!J!36[I.&_8@<0(E2MM
M+A:M+=X03\2)%/1%'=_ZQ4?#<H'U5I"KKZ()3 )\#/N]2Q;B!=S4&,D^+_/T
M$@^_^18_-=79&&\ER(-L;@9K01$>CV>:C.A4RNF>@7F9<.G%;24<F<:3/LT+
M;V'I",NC"HW6,!9PHE6'@@(^CB1>_E0&<*]@@^$O<#AUD:&7X^0UZ(DI;I/8
MHU,5TTG5UTE)G*CFDYU()W1CX7$^>RHK :,"88_\1P]0FLI%E\]UHU,N$O&W
MJ2,3*(=(G-")QC">(A-<0\/_5F*9P^,G&F8T&9*"R4%&P19.T'G U<=2Y!*,
M6 0=J:QR)2ELF8-[6(<VA.B67;*ID8K)?D8.J-L!.HMP2?"<E";R5W/EK"'"
M+&N2E/; 6P<VKL6)N>W4&YF%PN8YBXTS[ZQ:!EK:*^.OBZ%A?!@Z$26CFXC-
M4+EC9VAO6PHBVB9^>-C=>[R9/V00IG=K8QH:0D3_]YCU5IJW&BX;;.?K[;:M
MR;:5:J0K-I9+5/&\C7@-1TFJM_NX+OLX*Q+4N$X/4N9J=Z8*XAPP]DBAD^F@
M!K5-03K2MF#G;K=Y7;:9&:IPGRM6E$:/6OO-&"RAM;/=X77988V!"C5DD:RO
M*87"K#"\Q<:7=XY)\I79*I'\I]+C^7:OUV6OQ2"6X +(Y^W6W6'K'G/GX#)F
M-7HY=4'R&*5NRG<V!H^[2 9T;;?[N2Y7,0A52)BB@>XB$POCOEM[:6VV54+J
M24I!G1&2-Q%!0ED9@F8.<"6Y))2V>[LV>XMQXC35#!P .W>FT=>!'RKM[&)]
M#=>W3"YA_[<[NRX[6Q5:$28#I&^67PJ!$052-69L*?:=$]$A_.LK)R8RK6,*
MTRKG]. )V&[Z>FRZB?RFB9'7PU0ETU53;>$.KDO0_)/)$N#!M<FQB<*4A$V3
M,^<U)1]M7L+R3$KJ^;M32+ZELT0U=L(<4YXMII<HH^N;4O#OA:1/-WKO:E,[
MF'NY*?GLR)I3[-!W">+=SP@A/"NOBZ')UY.\0&D .TSS8.<X2 -71 1#F?1%
MQ,/B^O,2PX@PX^-!0AB.8;UPWAU9?LJIJX5TXH+'AYG+&$5:4DYP]V!G*_P=
M(@4(1NY@&_S=CLE[T[*;;!0!"TPSIU;T0-L^+Q E4H\+K_[8GC++]>95G7-X
M"9Z6S%3:\1/_E'WD;ABT*)A$3U._TZ+'*V=N.P'V>!TIHP9[-THJFU=>Z3(D
M69"\M+A 5WM;TX&J"X(),0 $#K5*"IK5<((8%! Y[YAPK>/GA+_]CI+F$@R(
M[!76 %,=-F(FY?G3&CX;ZVF><2B'OY)2T8F*+^&PJS%=B,@$B3J,^(![0OG6
M*D>,HZPGA?0YNH\]!0M*5>817DXZRN+.>'@BNAHY;J [UG#G)$4WJM,N F_F
M;N!Q48\9&'2ED9>P1(0$'V1[Q1A'A1])8F(4I*//=>JSR;Q,X"T('9G!/;5G
MT ]>PXG+"\2H8!!;%S[.:/%C?+@04  K J<+%HSAIJ7VF[*8R\"LB7S"2AUT
MZI3<\P(5XFP%B=V1"%TFH'4");0^S0>^=.Y(L7COJ>3-PZ:^W&)3_WZ6%[.<
MQ,UGT!]PL!(1(.L/5$6QP_4%*-4KQAOB+;H)\T7R*DJU8M D8SQ(%QI7!&18
MD9=E"/RPJ"*4R6FJ!KBF^ 02]_)E(AE%?:Z&H"*G((E\!"6V%RZU*D"D3/*2
MX(6E[>='&5FOE5\Y52F#:I"=>JAF.!3P?"<959OZ4+?<SF:<Y@.T!9;86@18
M9%$&FG$Z0,YEY;6B#2ADI12.N9E+5*SP(FL\,%M-G(!>1/%G&JSDLUUJF&4;
M'DZ5%<!V!:VU9(9ME4DWPDJ#$CZE0%3*.05E""-$3MM1:I!!=9:@Y!5DB2]E
MHVD.>HAF.@!G4E]Z/+LZNTR*7$S73E3F)(MQC=FF)8-MY^WY/U[89$O')E'9
M>"+;<&B8>M%R17/5#!BL@S3/QKO4?O%2I347JN"[>1/@>320Z2S-YYI02SAA
MV"^-^*%0_1&IO_DU;$<J6+J)3F>X;'7))1!@/"'++=4H&'0L^0$A"'0-+CP]
ML8ULMET$_,/NVO.%71&!\93PT'AN&6H./C0>5=QQ!$5&&BPEO.G8^CQ61<Q&
MVP@KS94@<H4(>@B&!IA9<-$R;:[.%,.E>%H9%V_AZD1-K6=UY;KEH<D[+@B3
MC (+[AL]/2FG8-V E4TWD"]4CJ2J^@I',TEF<K.1QAWK (Q*\NX=/&]<*'P.
M"M!!#E\D8[;$Q2#O(1_4Y!";M7"W$0PRM#9*$3-LEEO1$-PC'!S)?+A"/$7V
MNW:-, K@:_@\7F&8BYZRL+=6(2XR7$9;]4T(TG)(UGKI8*AK?3CO>"7/^'RM
M]91O,SN,7J$^[CJ?I<X2N=!S<],,\M'Z1ZB%Z&J!W%;HU)"2*K6^P*^(AX&.
MUBY11&"K'E@ PN!>Y<7%+%7H TK9!NO"<G7UP0<7B^NT9\#HCCWFZ!.:R@@?
MR9T:G#4.@H;,BLV,K=)JRJ]U]!;E*XSZP/5K]%OL]SO18=]V4\4G@E096DED
MZCYHO<")Y4L8DNGL[Z_V?9")5!B,424>ZIJC<^]X$\_)NEGK&=]8&OUG<(ZE
M]*88@Z'[51(*>+6D!YR*XP(O(T/1*9?@PIWFMWE=8>0$ZV]F=1$X!)1IFG'X
MC.(8$<'9&Q;6:7!0<QBQD CM#.9\:UXTPUU8OEPJZ>E@ @VDXC4&4<"FA=/=
MW^OU^2\#C>U)<:I&75E/(W0D L>C&_V, 92BPNB(<5DX)!+Z)V8 4A 2VRHH
ME@98DT\CJ$ONUF+Z%I#.JX@XU+HX.U2B?:UP*AV:\]F\1&KN=\D W"NP+]Y9
M^^0%FP<SL'%5AA[0;$Z[5_I[1T)J A=:4^U 3K00M%+7O$&F_H-ZOE#\B:9A
MW+S2Q%I<.-F Z<3V,#FH3*K][/ZWZ?>.,;YI.]%*@Q'%28G]O#MHZ5#=B68N
MP))>YQ5"T( IXB7=+-VG\)_H][A/<Z%9P3(ZJ2I>?#*QG"DUA$/X%1Z)[<!(
M:E(0F^)[/$DC,7GE7)F<.=$JOLP)F88R?,:K-<4:&$),R*XZF[(,T:@Z^DW7
M%W 25?0?L.>OH]_FTQGH&Q6A(-)H,?YN;-$/8"0DJ#;/AZGFLV _]%L] _WX
MV;SO-&5;MQ-]T' V\'D+?Z.1?H+G8)_GZ Q_57B'Z_[LK\<)X+PUSN(:.' W
M:B2\XAPQR,50$?PCVE(8\>9B453AI,U=+-0=:)&TO^17V$&6)%:<4UY"*IW@
MP+,IE<V=FTU)"@I$R%M,?%EQ1[W%<72C3W51UIB DDIES^_PB $HO$F\3Y2=
MPL!N)O $UDBD2!(JBYW5 U#=^ H6PSNHO[1<4Q:1TM7F@WO7J7F7;6ILB0O$
MVND$A=2P9EQZZB0#+5Y,.:A*TF58%45A#!32K>6.ZW6T3I=9F_[23%0<O3QT
MIZ(;_9ZS%\RZT!T7E+6VH3SG,LC0P+@3]5K">,ZEH>/%D^6V$LQ@L$*8=\@>
ME,5XE#<P&P_C6#Q9 A14Q/,5C*F$/Y=<?#5_ &MV\Q($QT\J0; &7L4O-3P4
M="R9A<_7N?A9#Q7F%"7((V(91H?1*G0I61O$'=-SS.DAOK&LP*XRE,<EZH2T
M$PUJ-LO!<A?6_:B>2>3<>JX8Q,5[OZ@926%:<4!(J#1U3$HBT*F'.A7+=Z,_
M;/UJFT()A2-/2&CNI'J_$5FGC+,8SVQP8\P04][&F_&X%M =(K(= G9T@I (
M8B)H_C@>NP38Z@[;IK+"LA.2"2Y9$*&>,(OL/!<FH#+9%&^F"^P;A4F+I=JC
M"$Q%BSOML-( A'L()OLS1S!!*UF3I]"7B;XJO>$V=;G[14[U\OPZL]+&TF[J
M#8IXHF$-[AIG30PYA[_Q/N$V#I(*>K.2#8(S\2QL**5E^&S>8*I:.0,G.+R8
MG9B!F>X(!&3+925!G29YX9M2LKLM>Q,>5G.HR]8%L'M##I0!$=4#C(=7C')P
M=R4I&+@"GZ2!<"JE V*##_$GSO>])P8#MO+  3^)WI^=_F>T8_H.?GIOKCY,
MR/W2?=3::V1^@8F 9%?@75UJ\*4Q.V8JV&$<RU^-YREZ#^[E!&T/I,?#&+@9
MQ4?P<]U(7L!'4DJ)X9F\HIMDH!R#^9)=O4_XW>/X1__P\6B?+;2?UOVMG_&#
M8X.T,^6:V[H??9EL0S(4H6W2IH1\:>#R@[<-4C%55R888E8+,5$J23$>(2Q$
M<&>\.%';5PQ]@[RAEFB-<S0D<,PL;W 0AUJC.G#N'#Z$0F-%@N,*D(6#/"8I
MAHU&O[799UM?38HT>4FTVR:)*XQZ';T'%6%LKR!JI.E,#2O3DMW$R5"'(;('
MUA&I.%2!;L 2Y$]>!%0F-N^$^*]K0YI037*\QH9GX2^_<NUV,PD84@CLWRY+
M=*W7Q6IQT81(+,O]$Y.496UP?JU'ALF';+Q69XJ(Z-%BB_,9LY;PIT6AQTG)
MT$2&3/ 1*SFH0,:/$V,=BS\D <_>&0>YI1ZX"BR7\+MN9$VH&J:;\D(\7P7F
MB1H@IXXAT:>;'7ZC\SWH-K:3VJ(WJ+$1<EII=]G:KA=10UK>LP#:X6W&HN,]
M3"E +QPT(L/$U:<X;FDR>(ZQZAP!E082:VG.6 30Q!H/;3S L)T8K#.>!5X)
M2H:70C?#L>Z6CCYB^S@,;R/D7-0S.7C-@?]I%]BM 4HZGB<1XYHU;HZ9+@"8
MQV@K/95FQ#?: 7]TS[N>Z43V+=I=IR"FS\%DK=<^@/HG@QL8QHN7K&Y 3,$]
MBT1=D?8G(+ <),1ZX>D1:B[&0\L2.:*C&Q81P;2,!YLST);L:K(Y!HBM1= 3
MC,)@C-O?A%IY5A>@[)QK=]/&)2.0%(.2?1:O20Z:_-,9%QCL)"\$58]D4WD:
ME^A"ZQ0=F8K*#S1>-)V-T65'8/049 <YI045EM%@D$V+/N%_0!(_/@LE3XJJ
M@@MM_X&/ ILG9OXQ0S25<.AY)^$1YE<<._3?:9CMO+7RO@RBFN*(DG-'NX!,
MJ.A@SV;!^4\XLDJZ&!@'?L=4Q]&?:9F=B>6_AN#,2/66@"E5ON!R #@5Z.YA
MVT<Z/<0,UW' @$*/&'(NY%K@]-"POL \UCS5?MLM%)E*_((YTJVDZ'JN?MH>
MZK!UA%W34W=7QH*I%H=T#V]<T*\=NN(W76ES_3MF;"U+9>(V/K6>07.!6Y_$
M"7R0B>$69@#/!S5<RJ@]7]C2QQKN^'R0)F/?9K,Q?\J61XT0&V%:N:P"S32-
MK\DPXVM@JVY@CEFRS.W\"D8%@$?#!MK^SO#%SN&+G=,7*TA"N7@=H; 6D\_,
MY/SM&>)]1E+2 [.HC)WE1'4;BRE*:31GA8&7-YR4?ZJ1M?WP\&]&M!A@8&;<
M,3A3N 5QH484J+!%3PAKG7'F&^E42Z]ZQN?F]I??KCR7/=UA\3N._J@31 Y=
M;+9-8J&T>DM]07 K_C_,N8^(KOR4IFEP4; 0<:Y9I=)"42BGT+'64UI#__(A
M<?*N4,CBSE )6^44'09_84ZTM=5\1D>;>QI@S8I47F'\+/CV<Y:E6"@(:[O+
MP0 X<QB@Z42L<$[K,0:[>ON8S.OM=8R)BLR<&AWD7'*?[O2#?)W6Z9BMG:QQ
M&>2.A^RO G#W+T)NLGDMU5_>S;;@=\;"2Q2[<5!M0]W%D@2Y3_2\NF33;K'>
MW<LSVF<QSZ\.".H+?=N1%BMO4?J0##?"B6S^YHXX>DP3I/"6,EP>WR&]><["
MF?E=0Z=;&OSZZ(4Q42C+4 Z+9*!))^97;1CX;<[TKCG3DXW/F=X&16 BV4+R
M&[X-LV@C+#<*R#[RXB*%<7J0!P%C'N#8.43'4M_.2B?W!O5BI_=BYXQNST]Y
MT;Q *U@CW>A+;O!K33-3U#H[@CQ&S TM&1^3BJ.<)Q.5'!RN)9J 0<#>G$WJ
M":EQZ&F\:W$I_4^PCJ"2'#%<6GTM8RTX=2]!FQO\)GBS]R_2'S3(J?I7CE42
MN^#QZ7B)94A>^@3\+?8>%I;&+Z[%S^))D3;MP8;U7D3-/7RYFD5I:.9O'>[R
M0^HX\+D.N^5S5B)WO+.XW%ZUB;[:8^BWM-:NXJRP3L(-P^\L6+)4DFXL62(G
M@$%K++Z.,-S;L:X$Z[+6%9>9OR,R$ONZN00^Y)"%H[+&J#*202(I=/01**#L
M/*QCGY,B]<\;_\$+@QA&ZZ ;A9?#MY=3LM+!WK+ZI5R,,/@7VK;,D+M&=Z]D
MU-/MX1H;G*Q3O1@7]ZTS"JZ36G_6]NW(&JA$_5#:4T^_']48RN:L0$EP9FR5
MA'SW#<,UCWRB?EMPM&"G+>:2&]D"Y*YCUG(,?6<4'L*MD0?:>VE3ZPNO(*'1
ML*0E1X*UCS@(JHJ,5_"R%L*!JUIX8H[>LJXV)EDZS-W"?*R\5T3QAZCP7&@M
MP/U$-ZUTA;%WMW7#+(D-EYJPNY *+F9CB$0%'>%D"/>'D:Y7E*L86(1/;*0B
MAX.Q-0AYMQ;[*65[4QU[(5Y*69F[G-%=Q_"XH&0C1E'3]80/[8CS3&].DPL<
MHF/;H*E1N,M+,Y-\&(&+5E JR*!009WBNE;JFB'_AHYB!0LAIQF653ZC/7$I
M"HL(-AL?S@?\\"25 XN(#PE4XJD9%XJ3*4:8FGMFAX-56LMLJF!-L>B"Y@P+
M"[M&@>@ZD[6B<\=Z-GR5W4L:";FK,6BY2TWM*1,4VBC*@]1/,L6+XLR@)6K=
MP?))EHOP;62JL9<9TEOJ3I.EQ92D^(<6&4U&(_@(K:M1)MZ7A@9,Q#5P7H$S
M)]BFZD)3D'XJ19LP!,8>R^%ES$*8@2H]\U?2'7@Q,-CFI,V_G5 A3%SF4@-W
M,9.O9)@W7LLPWC['T9ZE<,^CTXAB<BBZJ1JO=8UFBDK1L$8[IA-K"'W$+%GR
MJ'O4CX_-0/'>X3">K\[_&(:HHBM5<MD,Z^W>R<F127[C'2?!* O4)J;?9N-4
M2;OB/YE6(8O>Z4%1XQ$Y(J#[GJT04F34F69K)#W-2;1<3H87R5H<.7,0<;>I
M@&VI84S\PL\NH]^JV(/"V=\;()J4<]D7-K&3;#&D^9#MA"KJ]?:BMV2EV^C"
MO6[=$9Z'6_>N)8 #.N?5[CY]N]&$'7T9?, /?Z\FCTI5? [V%O*&X?/^.R\N
MX*?_CGI[5/Y@]KX"'V<VP4B$U'W!YN_T>_T7T?'Q_NX>MD>F+7M/2%(X'+ .
MQ%UV=775%=.'S9LNG"O^[)4>T*>,S>^!K.A8*4X&HR&1"-J):F/,+]&YLYZV
MNP$">H$_G69939 ^)KS/T.&:PLQV?^4!J#$*\!$YX13R;[<"X$EGYV?1[SE6
M8IY.D2!*^6>O?]B+?DLJ# *_ \E?1F\*V/E.]&>2(AE_A2GF-W >KA0JR][)
M\=[Q]R"=^/1@5U+06DM$U"'^OP>4R*<V!7231%X?L=L7L5O040%QFR"UC90$
M(PI0Z/<$)(4&X,PK[Q+WHHQZ&!NC ]T[W(EM$.7<>>#@S##$YY3U=N]D_X"B
M"&JJN69?7!/_@QT6S6;1D>*"@=8,^NJ8W $;= A>+!V&*_>O6A5-JFI6OOKI
MIX5+B8,H<S9Q/ 27,;>(V@,CL:AW"-U>Y*8^'I>+C52+!L*UZWB+A[9;E=MT
M"P.U<1VQQ3I>]9+("X)APBA1?,!<NN/\4M!7N7Q:MLK/!_H"!(PVQ5G.VL?9
M-QK\T< =7LX"TG%@X1Q)06*6Q5_GI<N,DZ&6AP*P&J8YY9,=^M,'E 9U#HG;
MPPF;E#"$2DB Y 64MC90+ZJCMGVO);]5<EA*49H<9X.V-R%)J0:="PEA+4<@
M1ZD;.@DNMBH&0U"D"%I#\>>W+P[$\U 3-M40I%3B[D2?P#A 10VR%FY7UN9D
M&,7_Z=W[,PL]MUE_</# T*7R"-/\[QY./MM%\N(OZMH77%T36_NR5 OE307$
M@D">7G)F&%=20BLW:I]6M368NX=X.HSWS2.<M!\BQ\=,[X_/OY72_K8B.2*Q
MQ"0S7*0@9FM"!=JOYUGZK9#;C4M:]?>6)ZUPN$G\?W](7A[U#T"[#X8'!X.#
M>- _T8=:[>W%_</1P?[):/3_>B<_;!)](*V<@.OACO6.]EXO_N_G]^>_1N].
MS[Y\_'Q^#Q9$_TE5.[X)\\?,P2"0&X$*2WS=0*!L$#'$X?YW7AM]@(0.V&N8
M0AK8DXWM!:<"? FF!@@J\S"["((8:]*%KE1L07LZP7>[-&O2.!@!3+"(>+$B
MW4:&WX!>K+FT"_7+::;2.5(Y@.1^9Z'@9P$4_+.#@G^T4'";&1%?)0 =.E!Y
M&:HS4SU%(*0V_\NQ$>W* 1K1_[V^1\KU.QZG[D,3L-]Q/*<>VIP!X42.)B><
M[%W4<X+,@A-[D6&FBDLK\\(>?A>E0UA4E$RMG60S@TS"W+@5=Q<)3RJN=5[#
M1 M*U_F51P_D1SW@>?Z&NK.P:[U/)R-BRF,A=X*2V)OODR-9&M"[<H:8A9*.
M&6_!@E:$-QG!E-/G6FR36#<93_1O^$FN-//5.E0^?*9!?_:R4;A7/YN]^K8#
M"4=[#$:+&'W':"FBRY*-=U,]JE[M'\%O_$.[VSN^B^8^1?GP8&TU'OFRA$O5
MD^O,T$ ^8:TDQ:W-"CCAJ%VV]?6#;MFCBYEUVU6TF6!05]QCOO*XW9A8=+M=
M3VZ[O(9A/GT!!J0-?W)9)Y5/A^MRE8*5V6[KD]K6T&KUJ!5HOQTMB=_UA'*P
M7D\(,)^Q(F>I7 ;7#2R2.$B!&YYP*=YL>5S+ERV.G?]B"=BW9^I)G2E7Z2N[
MC"R;'L--NQ*W(>KM;CZIW<0;)VUB4N0.Q+NYA+#/8&1BC2@6O,NO'[<;[6,9
MZ>O3!>_[SH4'TK%GPS1M,/P<AM'U@>_UAN^&Z7//E9S&'Z+@@71[XYT)L:=Y
M76$DU22-!-1BT?--AB]/27<X$9Q(I<8XIXB%U]&.")2P6\A"0_9.V"1:FI%)
M#_?M(7G 0[*DF;.QYQ=ULF&HV5R5_)C;90%E='LQ_D%%XI1>U@8F,4H1CNK1
M_2;9B+=U<S?MR=I1X%\Q%5*#O=*04K:P4=*>(C1X2A2]9</Y?DSSRF:TA)Y0
MQ9=)B<(?6UML!?D#GB7%Q<Z$:;'.%L):TF38Z%"Z2#8I3*D.E[[=JL>)FTD%
MCE<@@,$0[J,KN1O*F&,C)4R.JY19M?T.4MO->_#-*\MZ*CQAA*:2VL:%WGG;
MG?@+M:>RV4>O(8>X/=N->. KX;OWF:*2P=M=B&7IU*>1]/WH=4#BTDE3Y_4T
MT\";<-2("M[;E[#ZS@$EFE#<1B7/HCAX2@?/%*]]-,5KYUP'MSUUCW3J+G/<
M(-]>X^"4XR:ZH>9PJWH>6!XX[#@*:D:W8Z4?EEJDZNKIWO4O4K^]O=B/:;EH
M@<Z-A'&87*Y*72/7>E)Z!/A4_ >_-Y!]@MENZP)L74#O29%9/5(#!6:(#.GS
MM]?[$:^W:2XPBLX^_N?[-[N]$UM7*-0F>5W1@:1FCMC9SM0 4"Z[EA9E6:7&
M]"_I2UEV# V$AZ%]LJKF'D"L_EGK];O]1ZDM:9_OS\OAGZH(^G9XN-$5,?/!
M5->A@/?&!9$%$/K:-+\RK1MM=P+#GN_#T*D$-@"BH^'+_X4#Q1TZD#H6&0FH
M 6JLIT3"8A%;)CR N=Z1=$=ALG^J*HTJ*COM@,$VO.#.#61@.R+<CE7/4IEN
MTMLNY6"113"ZW!#)YJ@_=3G4] SS>/=<K#;T&.F\OK*VDRW%U(ODDJEWA""7
MFS/!$W.A2E854<[:IA$=_[$>=1<7_CJQA/\RHBD:I_D =PM>29V(#>54Q)T*
MI6AU)60<[C&N-#/QJ.'$6S7L9V9WG-+]; 5AOV8UTA5QPFG<36RS)"6N)3Z=
M6D5(IQ?#N4+'14;0L=V4D:5%1E5H*JKMT-?B0EW15L>:=A\9CYB+HXBPW=;8
ME *CW\ZE"AW#Z&L;J3G,@AQE;B!,C4&&*)Z)\\G4!7>D[,L^1;X4@X2<8Z$Y
M=J@S88-,JV*7* Y=_81T J5]YVK2*U 8S;OSP.QK3TSH?EF 9].R8A4(8K@C
M(0DK%?9-4%P*GE34 TAN\$R5W(,%61S3U/8Q,8]!@FW#K2VL>IZ(\<B'L?MT
M27F1$$'^#252:RGN_]1>BQRS9+0)04H"Q1&S=U%#;\-<[\C<[9*&78%;]L."
MNP/*0W][//5AGDI[[;8-*9W=YTL0$;KC:"K%0DO32%C 45L(F- 60#4IV&M[
MMMBV,Z>+7;=B3(W@Y7F432,,U,A#)QK&8]O+YA('!\_EUCA,OB.20@Z:Q2U3
MVW@]5M(LW(AX2E.T5ER=A1HMO$V^NF56/AOG9"Z[9*9,!:>,!,<1Z,D9U;@C
MN]U45Y,\IA&(6!.8E5G30G$+(-,%8&G4GM>4!:[?T3TLW+CI^[RVJ">HQ6!"
M7<XFU,D'\=O8G _/QT*=@'^21AI-%W>8=I!?H_$[/&#@%A/YNSEA+X1DS^-1
MR NOF9!GJ-  O"OQ5@CEKG30&*YE<+  <R<,#=:.>3#@Y7"J,8];%_P*)<3U
MW-7QDOS'.2@AM*E&5C:*768;SXE!T*PXMBD*V0?#0$=:$)5C4@SK:<F]!19:
M7GG)3&-!-Q1QNSCPUX.%/^%52"BU"_O-TI6G#:B[=T:_O6PB]&Q\@SVHX'CF
MBH_J8.4*4IWJ+6O;5D-B.[GAL9[KRA0*>B!4BUXU7<I]8&L-LM5C#B8[>4 T
MKH@48'?!LJ:^>W,J[8)UC$Z45,#\$C@>[+Q^=N\X!3$R='PQ'W[Y?&KX8OAI
M;VML<P O=H]M?.?M!^\KGX+SQ4.@;\(,WVA&G#6^_^G#&_L YYBTK .N/9&S
M2LM4YD-R%9F%1^5I?VO87 =$1%UQ2UFR*M%B899J(PO-$[Q,C/DZ[MR,:5[R
M\ U,,JVOU726,FW0/^M,(^5?C]OG#(4(EC3]A[R83?+S.=.<%HD,::&"E'6H
M\%C "4?JG<SS-. ,CI&4%'1 /54#ZD&+;?EVU72>YDF\.]"50F*C?)A2.A/_
M.,ACH3N]8FL9=@O<EWW_.)/J.$V_PGV8>DZP1*?PE'[.AQ/P@\[K0:G_73.I
M  SG=]@1$A3[>T1XV._P)YD50AJU(&DJ:6DL C?"O>&LHZ3QYR:<6+A>__A\
M^N:/TR]OH_>T/N_?P\-K[$'JMU\.OHO&BLYA9]BU!/4'HUT^/;BZ=%FG6M,Q
M2 HQ:.>1SN)9GK#!6 H/B!TY^YQZ4:DQ@7-LYJ^(BI;[>!'= A.<VL:2/_9?
M[G>/<,-3IM@*BN2<XVB[>1--)/QO/DSHDS3+8 6NB&R,S^ &\'B3&$0Q)N+K
M _R $N9&R6**"/#>K2+;PVJ',@P==(0;%/EFL$<76.L7U,*Z48W0,3P+$3L#
M3+=&?T">+87<6_2)BBQH"GI-<X]M 2G-+K2>&5Y=X8*GH1JYY6ERV"B=E:;C
M;TLAA4]DS.QQI;WC?&%A,'.&/X$H!VLQQ;Z$S#@"+P:C;>HQO-G(C3,E@PF7
M;%*X9J(QFZD)AXE&!;UY..](WP+#:&T8T@UELI/6Y$"-EKU\1#$<EJCP.O(.
M9_G,Q<](Y))T,GTE7%RI\5P6YF'@R]A&\\#\7<E2$ X6YE\F:R-.T(/%&;MG
MX+(/J4T:.<?#6L(?#C0X$A([VVV>T(*A/8Y&!BFP%49FO5:5!1O ,3&GK C^
M4K"@PFYT4VZ*M>WE<P_IS_Z32G\^/;'?",>:8^WJ%TJ]>F"[X7]B\$+['7]M
MI,CW3<E,L/*Q$UA3+%,:96D>*[ZY8?ARC!;3XZ9\Z5,U[\AE8R=\F&-#NA$9
MJAI!J1G%F<(&C#R<!9NJB#[_!YBHK]_8_$,W I7)*M&LAK=V"=;GT:M=T5RC
MVD\9UXB#_,3(BV%^@ING&!FD9M"D<BB@32:O:>6R2N4@!U%&@;P*!V=L-'D6
M96B,N20Q%R_HT$15>R\*O09S%M1P0IQQ;@OQ@]3Y73B5"SWPE9,7=>)0#,_!
MEDY0;X:F^.2(5&>!=\D.LSW,]WQM.4O%N7BAV_>)O&Q*]W1\6X"N)=R 0<V<
M>VK&]1$4OH#3G^6W?TD5!<8]V>T2#WRJ8H:&<[J/I(4NIJ7O3!*@7SJ%V O6
M(F/(2*,C92@'G;3 ')*P#*$]YXZ9XOP@'YQN]%M.S9#(*)&.442)PM;,_=)Y
M/=]3]^<$N8JO]$)W7MQU<3!9$E/GD&22<W!U)9?!NIHVX,-6',H7RE7Z$64^
MD]7-01]IDV6-/SHB'!@!SP![<'6D"="JH915U&3'"[*LI%:_)0#3$L)9+HDW
M*^3[T6>T(<1!F&5SS2&6<.>T;:ESD@8H@'9'H"<;\8W0I'%O#5N?W<"UTFD0
M$BZALWSF864FCV[F-J1IF&]>)ED&4H)2,?1AVI/V#2$1M!BC2/S2;>X;-5$N
M@R,H-<I$UEJ,9569D!*FS"<Z0_$78[^MCOR$VLN0-V#ZL&U$!))@RQO<K3K
MI[AI&5V()R35Z,FZ7E&@@LHA&%%UJCF/)CVU2?I9$A@&2)CF205SQ<##$O<Q
MKP\?=6MI]+OK1N\$-#28MQC29(XG1<R9488$>*%!OSNV>-[^D#H\FGG[2/+"
M'PA)P0R;#Y5%/?/SG^S<PD<FR0P[UU=7F(VOK0':'*/)@Y+_P WM.;[DV5*<
MD7;$&2%+!N$2FRZ+G)I5@F-XV"PW(EEFMBF>")9G;44@/[.^H)X!;,;BH3!
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M_4V^D86GH0A.$SB*,6X%Y2$[MB!",K"-S(O?5Z6<<-;& WK9D!)5LYC\#1O
M<]M^8J#GN1C\@JRET)S+&MC'4*6'\%O3,Y=%SNA4!9^V;.I+JBV^52CW'U$H
MG]+-> ,ZA\G8>X:,G7K5Y!6Y(W#QP!KV6^!((K7.#$ :%H^(K2LT[TD@(9'X
MCR^[^__QOWI'>Z\'3%&^&'SD2SS#%?^QUST,/DV>E;4["XT&L[3/GB95<R_<
M8+Q/LOD,QX0/E"^V/]M/B9']3CYEY#68[M=(V$AVY^=/T2_<O;LT6)(!V *)
M*FS%D*DJ _&)C.K"PMJ^4G0AI-F#1PS5D236F(S?P@4Y.D:#\1Z49*[RW&]X
M"\>1Z21S 3G>G<"2QT<R*X\\N&-%^< A+#L!QR5VFU.9"SS(O2"=NR1)%V3M
MPU"Q5WOG"M;(WO'*]BGL0F/F5CQ&EP<RB6=+Q&=.*C6DT:J<)X]T)RGY=#HH
MR>%H6QACHP=E=U)ZV7$(?E/M!2=WR,H2*6A,2MV<";AV)C183C _H C^R/D"
M06AYI&5>.ZZ%#/P-V'!;)N9+!PHF4!6A%*3+IOFWRBA6;Z[^+,BKP'D:B"\-
M1&I)*:@.^^V3G%+E1 ,5UB[[_=? \1E>I-C0@9S+G,.IWN:8&]D\HTX]^KQO
MV0IZ8TMMWIJ3/5S#G.P3,^D^^G(XS$L$V.D.'G*-EJ_EA"1O(!M))W*LM%Q/
M-U22'\MF;MGH<):.AT9@G,3:X<J2G?&QU)BPDLWW2[!)3YYIV[$2 4YU9L&T
M^#L2)#YM'3N'_^+^(]9]'&B%5)U8O4/?".:RV'W4:Z0C]L8TC\D29Z_4-3TA
MXB$1[K^!;0U_?8_/'JCL N/A5+K^&1?,-&;Z[?W/'S\[7U> <U(X;)A'Z4-"
M:2-Q-@9GT@]#+:?/\ 'A$\[%I/F(&H4Z(+VSA"K! ,X_OO/>'W SU4&[#70*
M#< T4R8"X;+^IG4A87IB@R$#V\>GM\0 )*Y<8^P8YA,_1[H&3K77F\G3DWXI
MM>W"X?$,=*,OMU8XL!65$LCI@0L;O(:Z]US/\*CBX,RT>+$] 3 /9W/"6++&
MM#J-#/$?W?,N6/QIJEPBQ_!6&-DIWYPS%85K==IL6XR;C(W3.M&9RF"5529/
M[D0_X_4'XV^&,?Y.= Z^ -HT</QI%_^I8,DP:3O7S*28$^8Q&PK\F\%>TBC(
MC2?AF^7-H2$JEK81:,K.A:E:?4%SMO!W%\56J1.K_ JBL$ S#='?5D"Z!]&:
MFM2>S4LP,60^SC#6Y,BLZ>#FCF=,"(NMX4S?M85!]!LOP@X67Y5*(PF/>;*:
MN%=8;Z=1TT%0@U08H_SF?U=YD<97&$3G!M-H/IIJ2\?YQ/E-AAUZ;2=\)K2%
MM18!:5J0H^^(_9]*:[P;TY16-\V)V,F=9GBD?XHC;CZMO#"HDH+,8"\"+@SR
M3+P^A7,1ZJ[CD6GP$\O'2$W9D*>G;?W+-G<@!;3P6PY<,"0^;+0=A ((D+V7
M+CLR5<,BAT.3Y=C5G#OC^E%4KJE!9\ 0ER'U'<[B<UV6B=K]XP(S9+#G>#=M
MN_29Z9/.7.?BLH*'1>%_-)J12@ UI[!S$]&;LZ866O#:J*^W6\:T-P+#VSHZ
MKL2&YPPTJC&']U!XPNRL/3EANB-\%B*7@J;!S/C=\4CV;!C<:!(77!Z#MXW.
MZ',)@KY?()AMSWNW]8QQ8D,88P?U?*%3M 2W+?&PZ1,S(EZ!1L$S2,_Y5TF
M&6)$@UCQF*S88'%1 WF')%BQ])_?MIXJ^\\6OF:?QQ>;***I*#M@=T9"3JT[
M0Q+<$0>.\H CKPL6;Z4SPTGO7F4"F,ZFM&]S>*T6PCWE==D.ME\NM_\. PQS
M!\?T,F;BP3A''&8@E2N?\MEF^!<>ZA$>ARTT+(^1D#U=T&'%SGTD("70*1B"
MN"V"PC07C6:GKJB1G7)^(GL)UM8P+3H1L5XS8^[<JC@;;_+;N)(PLSR(QJ O
MO' UNFV4FF9X ^FF.!\:I@Y0&RW=@EJ\)W'78E4INT9"Z($70RH*A:J2-%=8
MK65[%[#MSVU7NM$;"ST(V,4DN6%H7AG$$(9(%\Y1@^$COS)BGB)QKM?>\Q#.
M7H6/6'Z+E9VV5;FLU*YUW/QN.$R[8B&0WE]X!_'0FK(2[J08Q Y])@J;8I1F
MGR/3VFL]I6T0,J(&D4'.>HH&/!SJ7:PM=9TDV4J0?Z!0@H-K$[*>G!2;F.K/
MS$;)G]HWJH5CC[1A"Z^PGQZW[,U+M488%I QK-1*VQ]>HV.<LXNXM:8_)$Z[
M+%L15P+$4T$T&M6IF4I;Q.%?P[-*Q)S..1J/-,U#XBBT_<7\7PAHV *IEC:Z
ML\4"';;!Y<A;"NM@/PC&UBRG2VW$1VQWM%S_5<=CVQ.(!59'XHH"/"I%JPPT
M^;.-ZB;6!> 05;N^/ATZXUD$M,>IMR!.O69YE"]P,_?WW*>2DZC'HF@0F0OZ
M;8B!L4HJL%?J<^7!S8*&1K#@Z.H+SBW$6-D>P7Z++MN59;$)2X5QFF8?8>DE
M,)MA4*>EYR$5:S/X6E9,<O+>Q,.[X@YY65E4=1%TQ\A-*Q,*0WA]]:P^!Y<S
MTS97XA [==G@:7-J=<G9H;]E'4_IWD7-VJ)3PA*0OU2Y^T#I'Z'A#KG:;3[3
MB7^6^KR@_",2'Y'[:. DDP1[-Y,#X591:-])R'";(ANX0!;M/":+E=_CMT,+
MZ"[;"@/O4@[X7$P$<A8N] W'UVB.N/;ZVC3()VVO&3;#TCGSSDLS&<Z>P@%P
M3/Y$4-"D8E<,\/?;-?DU.T'^19DF\1$9EV3<D,GG-R'U&Q:8)],I:P2K&BV7
M@Z93U.H+=AW6GJ#8ML_\>IHK[Q?+Q5V0G!MPZM@D7%CP$;PE==&7/S(R#LXK
M$M0FN_"/T]-/+KN F?84N?U&""@M%QI&&._ TKW[S&K^9Z@KKE8EI3@4A>R*
MBA!N&&Z1R(WH:HMY;CDU4PWV1.SAOV$RI^=GT?'^X>[^'NNT)8<-[3F00%B>
M+BK6&&SFW5:F6?>C%/%J0W]4XX"?39.1K9?F,L!FY,IP>G!&#*=-CEJ'D@GB
MK<WJ M1Z&40-D=&%"&$L0WV>62,#$?<R:IQ/L]NEN_+VF@>TO_-M];.7:3]:
MPTS[HU<_+^@1.(;(65U@P0LI%3C4R,Y9<B-.MJDQ6$#7G\L-Y%J:/$;S4BEW
M7-^CM7M!!IWOQUKK\?OTVI5K]F:PVCH;5\268 $]XI. 9*K8'^LX28%!;\I3
MD_1-AJ!IQAH[B<\F='U]W\58-=PYS40QY>FD22D%RNW50/7%SG)>--[746GA
M\?'ED@OKU"5ORR7C#-%@D[C^?'<PWY4?T1U/A$23/57KGRM#=TZDXSZMD"H7
MG<HH-BELZV!X&]5A BFV0T9)459!?UV5:F?.XX-WY62XCM8= 9O+V7#NAYP2
MM$8&26YIPFQZS"(3^ "7!*VR_6W,$2X%=]8P[>"RD%+ P<H]:%Z.4@PCZH:H
MBC21MO08.XVD)-BUX!+GK<;P 3@3.HM8R%^2P9[I,>L[SWLKY2Y3-907EFC)
M!(\1/4J>^$C646Y&ZWTP,6EP 9/8'B#Y'L8#*L&>!1E4=+?F!BJ=6A/#>YMK
M$CI'!SM-X?K[\5?S A^,2']K]#\%@P33=2*7,*J1%,-Z2LS&-.;P4?[DVP^A
ME1846?:6@9Q=&]I0!58^I)X$:IPM$UT).N]XR _N;^3:KN(PX$>Z]BZ$@!*;
MBB=KS@$AKQ+F^^%NEPX"8_JVTM:TYXTZ7J,KD/7#^3 U79!,225)Y-QL\YJ&
M$]^/.,-M%87X3K+G*O2@KC2GOG/4EAUBO'M@GTH<NC;/ZM$=*W2M'W3G[NA;
M?T /99'!O+"^4<)\^M_I^2SW=AK],3@ @J-!9VT)@$44Y&6.5S+E0%"=S1"U
M-ZRXH\1:WJM%OQ<7H</>:>CKF&WP_5.\9]*-4)5-L*++.AG"3L/H6DWJ\I;=
M-L6J2+U@/SI4#FCD]7 )Q]<8U$1=,HQAGFB$]ED'4)*9I9ZBETC5">6-1\O6
M3;0<+2\TP*<,-G \#R;1_A'ATA$_^B9)A'89)2V6S-SB-:Q':SE(O\T/7_:>
M99ZY'UV?@>H4ZE=:]XXK7/2"!BUEA YWQAJ;SPRV-6=[T$0S, [-@+3,(;KB
MZ!))7X?#0HOH%8YO$=OF?7:!>5U-KLTM@UVR%=9C/6_^:2@$*0>.##-X1,">
M*<9ZL?TA64C<8=Z/A=P@:9<<>6]+2HR7^?V_YUP]S<9M/N**O05UL8(\/I]B
M88KH;A)(6*"QB]ZIJ7NUM L$D2DK6SQ"5<%9"5+*HN\D%TE'!)LEHYHAIH.\
M2+YB/DEEOH&!:"AD=\ #9A=V8<ZF.9B<8/&&/>H';\FI[1,_A>\P@6XM"2Z5
MSW(JB9:,G2ZZ 71XA2TK@%9@9@$'V-_K'7ARG2,!0U@0L']'R0!N72+XT0E5
ME;F[',APM?R*_ PV<):Q[<NA 034Q;9J&#88!G'8"?8K@RGLDD6WL NC%3;3
M0/L84>U@GW8[J/:^%,@^0].L2&L>S@P;UB8IDF63,UU(WS)&R$YK$8D*X3NL
M3&F-3#-M]E*PI]Q I?1W=CF2<OF:?332""Y1P05*O3VS8EPAZTF^FV:E%BX[
MM0NW"5"[L+Z7J=PCS3&%[_[X\F"_VX^F4FL)7X9].^KX'5<+%.3\A)E6%^W+
M@X_J=??W(E.U.9A'YQAFYXK2/:PH[;WT&9UN7JP_/0%%J4TCG?X3?"M]#18!
M1NM1_0\,"Q9&!M0,Q-&7(KE0(Z3Q@>E\'%8Y#@%>?]*Y%Y'A6@]RW5UJ6LJE
M*&:1;"C&)CUTP4UIAT3CK*NZH,N; 6DS!Q>]8&;KDJ1@F.>A,]6V*<8-7GKU
MV;7R3ITJO?-FT#09[QU. GXX-LBR0D^)]@_.!6Q]SVU]ZU@X%X*68<V]V_@B
M#>;V]7C$6DZ]B8*.&F_A89TLML=S)0[WI"/:]*;='W,^V3@*LN B:P1&ZX#)
MJ^O==H7;XO[::!-869C=2ERW3>, T>>X0R&;8L\EN?N1)LF$,QSL-,@>%_2T
MP 8"#]P?7^YZ&HN.)-]@&]@3< @'Z9+HPRZ"QIRHRO8/#2(S=NN+"]7KKX1^
MD0+B? 8K?ND^8(63=;'$##HZ^5MH. I!S\RQQ!+\C(E@%M@,6HI;FK/V(*PL
MI:2W.QE$<'%=[H*"@'ZMG&E1T8U.L[#T@!B=DMRD@T1<.]?-UDC@2MAU%.Q)
M<X1;PN<'37F^7,.4YQ.3QG\2^9GV<8ND>L@5H:YP02\8K$<BJ5*"=F:&#]>!
M-S<>S'J*64:-,LGJHDJR$Z:(2$6I*\H=!6QW;@VHMF<7W 7*LGBKV*P(8*$<
M%FAYF^$]D5FG79DC^9>VNS6WFF93BFD]A*[6(Y[V2++YF87%E9:-J?B^",7+
M,\N9(E9R".G/C,L5Q)1G*HEO9_PN#4C5Y7<L4-,4)RAN!L'H>(H("JUEQY9C
ML#U/B3_DYK/U)B$/-TW!4.152#@GCT9%&6SF@.MY:LX+R%O0[1>U:O8E[-?)
M(X07_"N$%)IVG>KYL&;_O+RBJE%RZG.(>J=[;07%#22J5/9#MS^=N[E*U0V8
M(TF,Q"2&><!1K^)34XO7(#P5+Z9/K6?R]IQO9-Z> 5Y#BKP9C\?6S=\*A??[
MX2[>Y98J69?K"^-?&&C'2#;:#E(LXRBS>?Z#.;'B4\LR*C*HPI(@<+P*6TS<
M' -U56L=QU3%FA-Y!N%BL[/2+$M\.&,\V]+;9O$0)9OGEH?<?*X;G36^62[X
M*)2=J(1]K Q0!.@HYH7A,(^9_U+F*HAQ?P XM\N<4NP6VF^#"J=L2895!KSF
MY5 +]ICA%/AJ6TSND.=#PQDQT<B].B0AC<SV<QN18J,U+$H2PY4SXZ:VU&L=
M*V4Z)E[D/M,L_>)-M<#K(*R\GM+@S#OB[>4*HB^-@2U@?ML=*R@,O;W?_2U-
M3_>/FCIC_Q$7YT%[GJXRA'!Q>B>X$C9R@_[7Z^U"/]A"EVJDA4V'8WHL18A[
M)-7;E7^XE:<$<%BXEA3Q+D/#P @7&\#2,T^Y8H8[G&PWYN$VQI1W)8CB,Q@E
MQR!%M-],31UJSNV>/*@^ #MG.)<"6&H@P0%Y5__&O02;Q7J&@6F[.P^W.XYN
M3<^H^\?KK6WTD*OME9UVI.:4:<D]-MGM>7^X'0C<-P=#]I4Y:7>,?VU5]0-N
MA$1J+4R> GN[%'HT]3$A/'V[&P^X&^V@?5?&),K;EAR\CK9JX@'-6$3X2ANH
M++_T&RUIS)U0< \#BTD&__K*R%HD\V:6)FO5TJYM]^D!_4!3GV($V3!5R71-
M0VV?'$]7X<+#3&D5@@R8L="F^QTREI,XWQVO]K7Q$F7060AHMT2HG8/!W#'M
M_D4B[):!:1!6.7%@MP&:4&5+GL(E\R1;2*SJMA-D4$0CC6J9<)GN.=YB. V&
MEBW/0BP)@_IHO*WIA,9>\7808*S.O*0J$2ZZQ>"=E*VB)B%J(3FRX"80K90C
MO:7.0?@[S)#$A;K*')2#OVOZ.-1<)COW.G1YU7[+601; N+N,5P,*/_P>YE9
ML(<E[S=^OW3PZ/@X%TIV,$N,7J01(;24@Y@$_09X'?')W$"TLF6!*UT<T_38
M)S#D[I<&U4:M@3''(N7-VB^?,J#V;B0-(CM^ANO;[[.T0J1$M^P5EGV:YJ+F
M^=+K=,KM\BI)H' B5\67<-B58'%-+*##Q*QP3ZA)0P5'KS#K2?%,#FWZ.1V\
MG'24Q3SWDOAT-7+N@6F.-=PY20*,ZK2+?9/F;N!Q48\YB7J%;0V"WL+FBMEZ
M'N2I]8DRD&^)^E(F_S][[]K<-I)EB_X5QISI"3L"\O6CGE-Q/JAMN4K3Y;+'
M4DW=CALW3H D**%- FP E,S^]2?WVH_<"8"4_*BRZ=+$B=-ED002B<R=^['V
M6CGUM*W#/DU;1"4/&%8<F().*1^HLJG*,MK_6N3Q"3,25A>!Q+JHW:#]FI&(
M[[AR^K1)5^T.5-3Z%M8]DT1,5)VZPUC]OABK[^XP5A_<<CE:-F;)E=%"*'8U
M*:]0T40PE":1=8B.VZG!*(M13"A3Q3#*,_8M@LR"$-V1A1UM\G**2J)<4.DV
M=P0Y2NA'%5P4J_>&##+YM]C=&O4-6,_(D?RWO?Z=;N2R=$;7'>GWB0Q\_I8#
M(,'%3R&OK2BZQ,,2B)9SIS+%B''[$'L"\V)6SH5;?!8.72CE!=^)T!&U"?>-
M$>BF:TS #CL&(P:[MUQ5+4M7;0+^V[0WPDU8O%;A%XV(-/*Y?7V9>&/A"RP_
M?%TW;WAX$<7%'\W#&8!1V, !9<'L"W1./#J6S<*C%)FYBG2,T^EZJ_D*!QJV
M(U.X5MM(_KPAZ1!A#^AQ#SIY<?6VXG)1NBFW&DUR@@D76.VZ9:U=\LC'E,F'
M>K+<24H4DG7C"7QQDQH0:5+DD"&/T5G8(+7;PHL)4"[875 NDRMS,O=[L8:S
MX%O<KTF&264K*N)=Y Y1)[%!KPSB#HY1#Q)4>3/W<L+^O#Z_C%V\0YJH:#)2
M]1P6VTR(9_'.L*ZD',24/[-M-,/@@1>R#)V>2(CJ6D!4TN% @VWN.K@V2FH%
M8IK6K2S5E(\U+G^A1$U.O,:Z*HNWY 7S<9#L(/;*KDJ*O!?NE%@#0^7T'2QZ
MBTM==$'C>"S<-ZT#,D#AT2_[7-^N!708%P',E$F\D^C$S/]!D45ZGC'T2;L[
MFX0IR5_"VOI4O*TYT&;FW_8P]-;5308%6&4#$^)"F'W8**PW7@S-K5=>>F:E
M1E>-;8J-2,C,(:TW1FB>7LE(S#/E_;V)J3S&1N<.%>:)0Q>W/+M74(!4P8%I
MX1,=0#!NAPQ2@[.I=Q+]#C[GY\9]<IZ^P,4^28B<_"UCH<P /FVXOY8ZC]N2
MS*%V;*J,[NTX?L?(?5TBT"^40S0'/\9)H[D1Q>5HS843S68:6QX<4D6LX!0?
M92[E3!DL^*%L0+HT,"3J*=,MH-P4Q/ZM>%[XC_62]=F$\@*>,]-V%[&%F'W-
M-;65&>66=UL[4J^'"6257!DP(X/#S*S2JDE/#A/]_)9)&LDBURY?ZM68_9Q8
M'M4_7;E3I#F/7OJ\#D] IELRR"-NN<S_N^T2>97Z<HOD,6!SRV0<176A2;PP
MDTH$9F*\E&#>=*"+0&*0//.9=C7VD\GLNPQHHIV J&.?2GG91ZY!$@^;%G[F
M?)C RFZ3P>HE]LO%K>U8#!>CC&#LWI3UU8IV%G&5%W( NVX#)7[AXY%Y?HSR
M77O#35LA4CV8BDFDX!ADA%..@=VT-\.N;MJ+?OS*7/1E]-;\+!H +C(:]7'"
MC"--T'+OOX2,&2VZ357" T6N6;4$N!02UL)ZTRD[>P-N@;$2PH%C\V^8Q-L[
M6]/"36!2;NGO6@M[TM:25"(*-[8*DP4HO?P24UZIM[L</$OFC$ X?W))%IGG
M//[^.<:-$S)(&9!'?BF<DTLBLA(2RQF=@4(L(N:#R3>Y>Z=UMM:H+9G3VNA/
M,V^P58E!I-TPRB1W%H=,U:K!\UM_3TD%QIKK0_UL!MZ"W=V7:]*KF_J>E4 2
M$6U)8$*7SF($NK23Z,C0-\IS*&<'B(J*&+D0&8B1<6I.HHNT(BZ\[H6W16SR
M5)WP3:4A>;"9<VM;XOKN-LE^239O#,C:$T]1OZ#-N<"HS)N<<H)X8=UZ%?O!
M:^%H@A)T.!WBMKDKJ[BRRO<'6%;YU"6$Z/\,;2%VQB(OEW(XHKO7@QD<4DRC
M-MNLS)9H\;?N.'/EZ+JBYRGANM/X,)N@9^J#R<BQHWQ43#/8.WIZ2CX]6D[H
MC[T5QS$JWS+?3FN5^=Y<L-,)<AFQ$JKZQ/6,-9T8+GU*WOK2@.\LOL8$S;WO
MTW/V-GMT(MB5K7)2,@[/+.D7FVCQ+Y4 $89F5J\Q\V2%TW@MS%9!M?D=A+U@
M1I]=5LIJ1\H[PB0T_A;-LS0<@;/QSJ39?=U1(S1X7JZ%WC_1%@IA$/W2-$![
MK['ZV 7J- 13QMUYL<C!JU1A-H=/EX^=HOX-V60UX</Y0.E0#EQW>H(>(/50
M$I?>"AJF:\H]KE'?(W5,AL?)OA,=!S/_(;SV-I%W&V82PV)X@TYARAO.W(=M
MNO,IE@A3'U/?DK&5\YG*D%4O@L?WF1F@DK;.Y'KNKFZ=YQ<Y>>S)<CU,1YNL
ML\=[A/-XHYS*98\[S3R?/4Y$JR4F#2'#6&BEEHH>\6Q:WLPOZU:*D;_#KON"
MTJ EL9)?L:YP8DOV)".$O@DB )$0R?:"M'['DK#4-RD!>*"K>M3*"F!19U +
MR6Q;FJ)N+G)D/WAY/[W,U_3K1X]HWLZ)P$#^FV8-(LY/ZWD!L&;PN3E') [*
M7_/J3;-9=^$E\7>@#?C/#2*KWO6_U4OV?C2Y1_)G*L =?AO.J##H^U(M8^^%
M7_H\O,*M,#$4\R1*-7$@$2<G,84]1PKENCA23-V*+EUYX2B?%05]D^%BFPK@
MC4'9ENYF\H?,2XQD:LP9+25S#GQCG(!X Y'%1=C4%C.03#,4.K'"^K(MQ,?9
MH2P;-#CBZZ3$L($OE>IQYZBM_K?HQ-S)>.ET 4'0 K+P^1PU'*J.0R]*Z4-3
MV@LB%@%,A)/)B="L>UF<?2#51;G9" F^3 A>NR'S/5.+S#7-*^%-$8#Z"3%T
M2I@/$>Z-"V/4K@O-B1Z+]E+6*)NZ.EN^"=8@)QK,,)JM1,,BG5,9C\7XL4H>
M@XI^$Y=_V7H.3[<\",?8[90,-F-8+,7U:(I_&'GH<-$+9%&.)Z[Q]IV R!.2
M US.V78&"AFIDF,<UJA<D*WLM5HG7MT\F)Q)FDG6^4YT)2X<FYERAG7RG=\4
MN_'. ^CE9MD#8-Z=L2-'QZ^5*\D0.FNU[A)Z,'K[CE"[Y]1XEX8ZSD1M5VA#
MPU1+T$&[E5]$<A-@NH2J3.['2^<#<^2?G':)-0Y4'4?)4TQTN*.2@M/U$Q[?
M,&]U,&B\P>=-,,2:"4NZO8=Q7UB^5#4)3B740RTW.*]G&TTG8WK;Q&Z&1\TO
M)#Y6PQD1>G[Q(WCWU%BMX)\%1Y1C#.&W=5,5VY0R#=X)E7=:$2Y#<X"(7IMJ
M>1YG)Y%9YA*/$"03O]'<*PR3Y%F8NR:\+C&U;->,[PG)8)@HT31WVD,&\E^!
MS0Z$ZB6H?F-45[9,5 VRH)B1SP?O$BO6 CO-\) !VJQ6ELYVV@>8O00 03D!
MCD04\F' 2DW[Y%5RC5341F!+>934]CS6;)HGZTV(MF>:?<TB$;8<:/(X\KG%
MV?*S]C)O"JF4/YB\T$S-YGVLR.6F47]]O>EDU=]D6L##7%AY<Q.S82^PF&-F
M@%8T'^.1+6_+C'Q(@H5UP0S(<1/0#5Q=SZ)FR18-K%JO>>7WLF:?6<7OW*<$
M;T*'.QACE*+>^LR+(_@:IWG)Y!61,DD3I0,U;*<N%FY6*PC$6U@-:Y)J8P'C
M$>\5">T.\8P)KF 8UB7'93ARZ^H(_V#_C'3XM,"WKQ-,I\K1?"7UP,QP&)3,
MS1OD['9T_MO%DH9T/KTZ<??9'%\(R6#RNJ60U._G23H8[<8)+9S6ULOH'W-V
M'24Z1R.T7H8I?W!7W='JSI.'=]6=]VH0252<LQVR>V:94C1W45W28IS[U>SI
M,_2DG37A<M56A#>72_:W4)A?]3L\2(]Y<T$07Z(DSR:O@ADL@1;_*_T/SE*4
MN.F4RJ_Q#*?50O;M:Q.A.PY#5$WJT]?'3I*:I5R4OCTA(F\V%\X(:[W'[]M[
MY7W(T2@$=LK3=HTF#/S>X:<(_+I!-7^+O,S45:+<E)76?CJSIH6R80-#RG\$
M.BN.^ 37-D529RFI#$-=T*@#+?+61#AQ9(C2DXWVAS#X,/H7Q%M*QN85V<!G
MA"5B[4E^!FY5#5Y#X\#V(;0_JA='ZWKVIC 7!ETGZS4ESRP+8N4/O&'5R3)3
M"1?48FG%%8U,FS!Q/GKX%W3KDJR1/3>[T7+%BWQ-5S4&A#FR>NC@S#54H"O)
MP\)LPJ+BE0A_,02XXM$:7)\PE\$C)QK[-<EK[QRG 30>/_R+_9RFAVD6PH3[
M&4^"(BU/2C!#OWQ6T'&A^:2?<"[@.C]MPFTG9T5SA26BZ_JGG\YT7=,SZ>5M
M*=$[T&H0SY^NJ> AI^O@K[B/S%)TOVU')(/7<PIYG"@?LV>[YI7&?=!^Y615
MW@$]U<#["L^B40;4E,-JU,)7R]D@UF7F=GYRPOG<9$_*8TGF83&$IR1D2_A/
M38K#[V6B:#Q4],/#PZR HC1.:B78N)(MW5G_[P(55;=#@@TD:5@&W<!WUVFE
M2_,_RKD=[".9+[@ZK[AA.$Q?0JYR3+FJ.6*^IW3-8X)AQJRU!CJR4I[J;4^"
M$51[&"9T%MR7/!I%^H4LH..G9ABA/%-4N2+OG];5!;FA]%PO( ?S^.&CA^P#
MN=9H2M;_ _8['&&:\W,>C6Y434KQ1,'](M2\"QD15ZD]!7!R8QW4^5LM;ESF
M?=U18;B4FDA4@.(WNR *>4G!J0ARCUD]PEV[6X8#GCN=+R5VR1,+@^/?!PJB
MAKPHR.-?DG!NV:H($.IF:2Y:0,'(@:X+PNNZM 5P6W/*8L/,*O2+(8F@SXBH
MIXA;D+^$X] ,:5@!AQDVO(1UP.;1&46C&\V"G]HQS@[T03(#LT[SGA3N2*25
MY#7R%4GC:6.*;NXP'N1R2/6VDLXVU/0%'>#"QIZ3E6G_C=7XM 53I:G51>G!
MM1OE'3!S8^T4D^EFSKD0QM;S/#@E9VQ*A#;!J5*U[!4=C%&1.9B#65.R=!(?
M)]*ORQTL V]RDG=Z$EF[B[P+48LQ'PAKD\3;ZTUKI3,#,/",B*Y]W0NV]F.Q
MN3#BG*TX-=1?'$8G39(5KR5NHCSJZB/.=T&M#/F55BAC_$MDQ<VBD>ED-R&-
MYQ8%2B'Y,EB-7UQWKBDZ"G)J/M'6J;; ._ \XG)Q:=CZ+++_GSPO?='4UTS<
M#R\NS:Q(1=CUSR:K5_A8Y#?8MM%I9*-9H&@[2Y@V8(!%2R,#WO*R%%8C]I%4
M#(0=A>&&H<(SXT/G)B32#Y)J%PT@O4<_)#J4"W:(L,;<@A::&\)B;:LPV3/1
MX< Z[=>@I"&[T=9(:T<C+ZO#R<']E<D0;#=-(>K'!VDXZX"]NK$#71B=+,4=
MB>EI04]C&DQTAX^BS%LM;J(UN/BD2FH&]&)1[ 4!*O^7G>O< []+CH!+<Z4T
M0^/IEP3C;7T;BJ/V4=Z;\%7NOB%PFCH'PV3>3F4UE4E(X6MX=4;0I!@GYB7P
MJ?.TS^LP-_3+76=(1AYBT="QP(ZF)0739M*37[/)?^4T<IJZIV%?YAGCT8*I
MN\K1WC::I>CYJ_1K'YI7I!HB]1."(3#((OX@<Z014->^R!O([[RU+:0G]>#8
MVG%FP4BX7B5<NS;:B[1_:D\312]G[9Y**UA'*RWOS\5!R,U'.M"%E(17J]S;
MTU0W+BK&Z6$ 9\;YBH[9DBI_F:@<1_R ^C+><1O[-24H&%C'I@5PH_<_LHT=
MP$P)UW#VPOT/KBRS1^U'GM\5L=B6LE.IT4"RWLEX=Q,3A74%&0\OYK:Z%%8,
M)_Q+ MCU%K%R?U@J0N=/)HVMS9ZW8: F=XSG3O9,\I9TU.97@,N09+T/T=@S
M@(?\H_-K#&\DKR497:MX-R)Y9+16S[V/YX.F9+*8CS$X.GM?80F1:>=&/?+R
MRCEZ5B7%%"_*\!V71M)Q9+Z-3[-1KKI_ZYP"5X:W*IH)U34.VKCCLJ>=Z<--
M9$D(>EC$Y 9V"@5RT7';]S))W3AG)83AIDEC97DK?9W.(0R_LQZ\.\:XWZGX
M]>@ BU^?&WSL;(0\Y]: @)'^>B4GZK1E:"0_4LTMV?&/35.V<TU'",DFL"5Y
ML^HUIA_BN2-0BUFP&@UW(PGSYK[LS6*4HO<*7BJR;K''A6N+E7KLB6&4H@&,
M$: T$<$YM\A,*H+!2(;GXEK[NI#7 0WV^(:9U(#707A-X6$Q[ Z-]_1CID5+
M6#+"?U$4[GP.?P,QU(H+IKQ^$X*799JD4CM>5DJ)8N7$IR__Y_39T:/O@_D.
M+WM5SMP1)W\A/K4>0NKYL^-()E%4#+ESW]GQT.1"R_%D&3HL=O=3DCG4M3UR
MF>T'W7>0(11J/7DF49H?N;O> ^^^35^\RYF'K?AFJ&I?3\E3HI=)\V;7DBRL
MNU!<>KB0X/[S-H:#\MN#W<HW,0Y:5]*H8=1<C3+0@ E<4(Y7]1O^BZY\[6</
MPZZT;'B].UN_APQ R>9<.HQY=F]$9/=D@(5Y\0O!39\#?A^K8'WE&89F[K32
MYF22 T0H?V$'=2\^G*$SV:10MRG)>RXXH38[V)Q5?]Z\Z[ S*5.&U;-="_6"
M]!DK\8\(V%J)!,5BT!X2RV*3W<"=Y0>#/0-<+S*5<W?\:*(J=DN8):L7F6R4
MA#4(&7-I>R'+M\N7$9(<-PA';C:2V0/L3R^:(/]&%D\THJBR_^1JF"<O@L7_
M;=!$8;Q%<D0*=(]%>#6.H /;F"XI!3[=:F^W+%J5PLWGEP4WI/8)L-S<REX@
M^#I;L764G/,;A/@JET)G ;AZ"[/I-P7=E+?2<#QH%2YIA1PK*X8BYNLFWDCY
M&.T/F4"U*> +MZ+7T>LXTFZ<F\R!)Z7O$I*5?D!H5<QB/K* F6E(N^<3 5RP
M[ +.I'VLAVDG^BE)!Q]*II*)G+356:']BCIA$ SE5B(O5"08,ZIWYVODLS?Y
MA10M<89!5VRZ6;Z9-/EU9(K:M!&]TK-G_@PU1I;>+M8-[)!,W*5GMKX=279C
M&#H$"966R^'TI#^3J<C!J(!4AZZPGC'"7M6-'T87!;VEU"( F!_KL/1?)+OY
ME?"4"3 F*<&B.K A[G^*Q+@+5=A:Y/'9?V!5'M(>H7&FH=W.<KF16!2MZ]77
M%9%/VA7-4 3,O"F"398SPYMZF_;^:N-*(:T*M#P<5]O$5(3O7];7!;'N04.(
M(">R+,Q<1L=NR $8%YPSB/N%!S3#HPLYDOK^X4FCP_+97NT0&6*Z<F$F%=-+
M14E %7:[#X=I6,D!$]-'[<,)$J97Y8U65M/5:"AW&9S=LDW'NS[+I-RWE-(L
M]<.NPJ-0B6X/GL@B%)<:C@5?[ND5/IBTPS]V$K\#I>$'-Z$>YMHX7E)#\L5E
M2K'(Q1L#TDP+&&XAE^4YZE,,Y;O>?M+$OF,99FX1:CJ&^.]Y4?KWG^0:6T]O
MG:E_A_W]\:57%)>(OFD4-A*?:]R?^\"E\;F9T]\*N-4Q,J/5(9E$^$9:ND6E
MA_O?]=@+CK24H@1 I_PVU2WK/H>XO5[2(T2Z<.;/BU%N=%]ZW+?PB116!=0J
M(XJ940!@'5GH:"*]H&\W(B76MAM0V73,X;<KH5XLVX);&>0KUW5#Q=JDU\\+
MI.GPHW 8M7*82$%MR,AU"LZ61UKDNGU3!UJ*@E[-NA7]JT%V2IAWRFI!/R/>
M^[+UR**$5?>JK)?<##9&T>79E5P,$9Y?%W=F&D^4NXL]GXH-%;/42IMVQHN_
M 'I;%[]@6!I>_=RYFBS_$-UO1 3,TS=YPB;X_/%D4D+^2IC>&6*60-3"-+7U
MC7@S]D_3" HF_ZJ\J E)M-S:\Q69;6U[-'NLN>3]\$ /)B?25,U1>W)YI:)Y
M]\LB?MH:@];4\TK?E3A=B?/Q 98X/[EWK(:KCDWV(0B(%'X<?.T2JXQ6/"8G
MK:$AT_.QM30F,X"CJ"GL.,$Y;6/D' E*+Z/K'8:THNU \2*WCO6X#,81ZI;G
MBB2)T03A"SL/"*LBI7&Y,@PZ/L/8O8%-OFF"]:@,<NAX IRY=,,04IDX ;U?
M[3:EO;..RFG..F9:JO+8I23H,_32\.3JDS'O2,E!?(G)I(++*/T +4DBT2$
M!LF,#W P(MD!'CNE'9EY J;J>4D]PQ\;::+EI_.XO_QZC51#FZRMB\:+1<N2
ML;-CKT<-<"1ML,DON/$5;X1G7*:SU_&3^3Q<\$"I/=&BSG![=.C($^H.E*H(
M7]9PSSB@) )!6PE[WGT.8:^<^X&#>#!Y$38;@:^4ID3Z*^&-:0EN.'%Z"J>9
M6Z&G#Q\XZNU..$AX)CF"I8B9V4CE.DUAFYI2G:#OTF5WF)ZR>@UN$I*%=^/J
M5]HK\@&O*_*!,(.<XNTX&Y#X$/PQ7AAX<SGL)0=(27K#UU?*;Q5^5^04UX@=
M$SN1V0K4558[ 9Y^?EI6YYI=7:4W7Z5^Z_C=_2(V75B"0-]XUYY(%NNW8<BZ
M=6]C7*9;3]6MV5RG0.UW%\\JE:G$51?6E7!U#C!TK6JJ11<]O1?JQ!2AE9S;
M3'%!&G%XRLMR/;"K-(S4LF83I22G*M-E. >*ZB*F[\&NA@F36]?4ME#L.0SS
M:5/G<T'$V 7;22HT#(I/HGYRH&:F8U:B>@[:V%8R%W$!6'PDI0_?ORR65/IR
MT5Z*OQUM6;GQ#6+UR6HMK1./_[S1KJV^[70O&NW*#.#I.49F4[7MBW,]FR07
M/G+&6@O_!UOE0[1X5%?@!=,X\*BL0.&>;I)9',Z@,DK=F!Y3.1CZLN,,CU[6
M[8,]W$\L!^ZGQ[PI#Z25NLB&:R38^I!C&!1#]CI8D9=0W:HAV[2NK,LV> _>
MQ>T47HRCV=U$"8JY>D4Q(=KG,?2[E]E33=8_B)7PE!GB6^&E,#DD"2V&&IS.
M4# '9:?"F)0V0-:#!\V0BG+-211=?>V&[/$4S <=@\G\:3,%N^4(&;(GDXM!
M#/,+9$+.Y9BYK!(9V>D,-SV#M)PRGED9;'>J TN$!VZ\GK?*'QQ<.TB2.$RI
ME2P?J+W2?;$>OU<C-"\2_W'>3O+TO")M)\1Z3$_N^,,P8)\\,^"B,T>8-= L
MRY2M(4,-^JHN$4QIHI(1!TFR4MKKV6'C5*7G'MB;M)1#-UR'.]'2,&EA-(SG
M[OWW0N7H^B1>-OP3G/N2=EC1]FLF54&/CGO5 ]2+BA;W:H=<U]>,=*H7+8[4
MV +=,3*/0!4OBGO0HSX7N<AU.P"0<(*YH/Q(V:[P^F;I]&^J\I_$B%SD'6#.
M_@W?+!QMD8>9EJ2WUCE@P/7!$B63J[E2OUJ,TEMG$:"Q&@+@I/*DMY*_3)"Q
M("Y)W#9QY*AI)WS$6AL%F*1^$QIBQL#H V23TB!&82*]CJ2W\!VF@*QU,F";
MS?&ENX?1>N !6/LT_S4NC'TWT/3S(5H:'_Q&4G<"N\DB8DAU[U591QD%6J9.
MF?%A2+01Y16,4-<FP6GDBDW?:^3U8=]L5?2<[+[.7SX9AP[L<T*9VBIJ5O0?
M;(2SM4=\O4M5;BBJ$?9&6WA.;.LP[A..*W39W=56:K^IT7;>M3Q!=*>\^AKQ
MI!)NR](\-SN,Y,ZJ<TCP)^'R?Y=M=J1(B"'MMAH=]];HL;U A13N99,GJR,S
M)*QH"<V=(L[42,?GCM/1%E9MJ*_T34*#)>>4C;#T !JRKS0X0%A6KJO5D*PC
MDCBCOHK5[&VY1I;WWD7;=XA+[MKY_IA:UY,#K'5]9C'#L\@A3IYG0SS=+87I
MO/ 2*5?;"0-R9!=G)\EV5T]S()Z!JMCNVLHA'N;GEST]Y^31]S5+<C"1QA+)
M*\DF;ZKZ^N@R&*PD![;5DT=!^)*287,6T]^.ML4/2FM 8^\.402%C5'0/NG-
MB'=2-L1@Q1:<*\RYR-43]#0_DGGJKCRCH/K!>J\(TPYO+[C4M;"^Q1*?28-F
MDV*U7M;;0IL<B9=J"9IZSA,9)#=)C(/JG2U^'*><-&A/D%4=GRF9"_:TS;=B
M#1):A0*+65K:',G1(F^<VHR;4O%G^&B_SK=IPA>]K;?>7>GI\RX'W[A7\N5D
M1_!,E13O-^2#M-NV*U96 D&C9-'X%0)>?T1N%&I-H-!#RYI7SI :8US\*ZPF
M[32QK+?#%/$!7\@'EMIRE<YL/*VYQX/9W4R2DH%_%L#Q3VZQ=R\-&)-EO9D?
M<5S*7T"21(EFQU</[\/:] K*R&"EOJ14VJ-Q2P,T3>1*=<^9-%CZJ\VR$JD+
M2M_F*ZJ7]!N;K.B(A[HJFPWD".=Y1]K'^K5L,MM.BT8>,>^Z?$8-N8DR/9OI
M;%)1FH283\H67,ITLH3[A6^UJ[ ;\D8.IR6!QU>;2FO@C#H,*ZS!*I0R!*4C
M"J?9[K#F(T/"149&I>FE=4X6ZU02"H3/O?+9E'H6WD":BI*.^$U;)/.F5PPO
M+2YO%W8G=8V1S>T*63V8A[;G&XD]TTK)EO<W4VY?01[G5E_L^6G6P>YR@KU#
M2C#54LV+ Z8LX;#M#SUV[J$&9L\FU$^#C([U3GDQ4A-@WML7ZFU@!5))RJ7Y
M,EZ^'M,Y3SS4Y""N=SYREI1#C9Y[P U%=K&8&^CHYI?VL4J6 XTSR8C:BN5\
M_+O%K#=;_,^U9^@S\A->I@HO1(#.K9_EC*I4M/CFK29^O#@.5PK?%/Q'2-PT
MLTN4YGI:M=-M3TC-$0^?5!=$&0W.?G%CK9:7D%S@E/!"\(=X\OX*VEGWS)DU
MGM35,L&MS(O9$HAS?0<9S[;/"$FN22>>WT0[N:?ISIPX[3KG,%..3/+]1+_I
M82GRVX5R:X:+$JO(?;T"DV:W+ME/7_6C>4 TY3=\!^=X.,(V*^YESY0T4UFY
MV]&^; "9!)O>\;E)R(Z24=OARGR)Z;:7,&M(B@!;X5]B)]&4A3&.#H)L>O$^
M8[@.IT7X+B5A^72($ >\(\\\RV8-XPIG'7%VA^.-@4+1[M%VLX?!7(;7$QPP
MSBF'0X9'3Y%1L'@SZ46%<Z$U#:$Y7Q;JGY-@A+-R6^ISH@+VIM)5Q_H'NN;V
M;/&21[CW56K_@B2F<T#->,9P;SNH]KV+$,Q:<5::%(!/J#!OD&],WKD,K%+!
MLMBI'QO'N\%,YQ<7U+3783*7Q?QHLY:'UA>59&.3]R&812%)&*X<3N@G@S22
MF]$CCYUH&3WQRKF!D[>B8SU,&W@6'5YZ;)3H]#70^*9A%;!KV/3" CH3W!$@
M@JN>;\?)KN;:QERNW#D&\R/]EO62O:W@5,JFA#M0YPUH#[C<BDQ++',PZEPV
MIVP2H8P7/])D!@5VX\=#6V_I1J.$-RX& )LMTDB.]\A.7![BTV58&Y-C$LP(
M%PR>H-AN4-SBL[^.?A:L )S9&4N7\+V!6MAKX_UQ(,3I[@1[,"$/XIB@,X)N
M.I:" <R]!BX,*A_,K2?\&KXME8]U;D><EQ$3C2#(O>SUFBP<$5>7BU*2@Z./
MR(57?D0VQ"-#!9/CLD5C&SG*U7SP0J>Z'L7)ED.<Z3J\[X3%$OY?16M:R?A7
M!0H_((1/'@6W+M[2Z>U-A8TCNL3#81^FD;@)A(" S1PC#1S_N0D1$&7:$X1Q
M)@Y68]3Z0O5IEY(]TOM:/.[FI"PM-.O8U._M&;N^1R]RLLC%TD1V4B<?0?7%
MZL*I-I!Z2TUD;DDH;4%+R^$@-$.*"Q(K@KR1P&B8)R2E&A9.0B>[:8*2C*0,
MWWVGZ(@@&PU(I/7\3(@P.!^D:#MI)J[(.<UN'0'XR5ILEHM2FB@W:=I)4TXR
M#-HQ92?=\NA,RH@A=>)4%8A>R-\XD[<P&$RY\H#]JF_QG5G8"N1PQTI1+>WA
M>LFU+5 ([B0YEK<[SBHF>B@*8JQF"=W#W/_'B<V_OK1NXK;O[_&!Q"A_ 4<(
M-/02R<$V_ ]5D3#7EQ#_,MS0!1JW5+Z)V "XB4L\A-2OI#)>..^H'T)A]<E-
MPQ>P.ADF$5YBOE4K[BYSSPY4X=,M6;I)DMOJO-^_$4CXYRM_?W57_O[09,_I
M OD&B!)2O79%K/,":6&2U&#C5MK>0R:)MQ>:1(B![31^XZE\XYB[-1]]_]7#
MS.=Y$G/)Z3\<BF5'AI/9E"@M'C8$&\>9:*#T3B8<;*2WS,D^ YGK>_FX,_OX
M5N9I\OO<_'U?ZV>1U_RDY\5O'#YP_$U/N>G-0@CW:"F))KOP_$35*1#MO??Z
M!Y(-=/-;UQVM$=8M=QJD@3@$,1C%OCV'A,.T93_';[SB+8F3(]L%65)TFM'A
M%PY3Y+Z*Y0(17ZZ=645U 8VD=0B_\J:D-$M4YFE9,>>",_WV!3D#8R%G(0\E
MBA?V#WC:32X <:VL!+?R!_H$VJ-AB/4U9S/]355BW$U6_#6EXN W"<B0PR/Z
MRU=1<]/PAR4R*9U!;2;W#$!*'V.>G3*$NPV7RX)[6E)U]#X\=_(ZJ#A9:Q/;
M-&]+RQ. .V3!@#\YV4^?'F-8YQ\",/C4&TRR>;2,:&N%970%N.MM%]+OM8XX
M[]9G<]*LWV!('^&.R++Z&S*!YK[=JCL[T[&-3)4BBH@C&QC1QK"S(CZ1,ZGV
MR!-(R""CCMU;O(<0B(GBJPNA)L+Y2EI4W"#;=#V92.Y9,\DO*@]>4IF/\B0O
M>P.;F)Q?6]OS*<W+F;3P/;DWNW_OZ_OWCN_?PLC)EH*'[#O )=MQ=O*4:%H7
M"X/KMISATK8#'MJ6Q5OI!I1X688 H)M\_?5?U#"(20AS(_2/1+%*E<XFN)"T
MO&:S8JVXZW!25O07EB'EJ(1;5B..P4^QS2Y30;W#!--[EJQ')CQ!C+_(E(-R
MK[TY>4NCIBG_[Q!*EPO #X\/&&AXRDW61]+.LBRHFP3(CK B1!S\T9,,@K29
M0=5)QYH0$[50&-B:(;.TVBPOQ*OLTX;PUNB!PY3"DY5E\"MJ]F%L=PUXNOTF
M+@VW,3A0ITJ?D\SKKP&P=B[*V4Z@*%]/(1PCS2=1SMFNI0T''O;7W+A2Q/\9
M;EZ80$=+VP[>3)2Y4>!>,J5^>CSYR/YG%HVE#QHZ]E+RYV^B_CNEZ$B=<0J>
MBF5]?9A[Y;Q6_83^>2BV2;,43*6VT__E>AOM+)RE,04=SJJB98]RK4JE8I53
M9^?YB%OKOY%9%6B'GV>U,FV'V^.L1>0.]]Z@!W"ZM:K*47 S084[=F@A-K@,
M3AX[-H/)4&]0OTNK7Z2FDM7TZ#Z-(_G3M[<[[!3\>^-P=Q^JV)>H4GC>Z/'5
MGD4K%*UB:@9;=[)NVGB.9I.B9*R6&C1L=O9?]@P_&QS J+[J 8R#7C.7$\KB
M9>;EL)T8G7%Y\G,%^DAE,+4;.)[['@L;$TU^-[Q-'&Y%<!,]I>Q]CIZ6_IJ-
M<A9[IFA_Y@"7!"-UF#;F=&$'*J'8B+-'5E "-YS7ZPZ !>3UF^W@H*TG2JO
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M@_1"JG*46.<_23R!_ [K-CC,#D2!TUE(1W#_O@.[V; T3>,J2*MP[K" BZA
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MD@ZV'F[^G16DK*=&F'443C<C8US/57.(70)7["*H-+$MB#P0-W<YLRORF[!
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MA:<MT:;<QL2=]+63ZF+)V;'YY+=\Z3B>&#\,YMTK--ELN/.'B4*PLI2T./S
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M<E"-Q#L68<2!,ZLQSRV6+^=O:7YA>XK!<?5?FZJ8/'["U.?!R8?TQ3X3S9M
M<B3.H,VA^?P;-)21O6ZAD=FOZ'>2,4]U, CK6WAEXK$H;2C>+8I%#-?15"@?
M./."%%N+X?AIU_HN& GE7!J;14D^0._^,PNDSP>;9$S,TIR'$47+R%XT4&%T
M(!&2<;Q@WE--/5?:SFJ=M)ZG/N)RM6%,,9/*=Y3"?O<PVN]I[CM(BT#OS+V<
M%+&IU91=K^P>07X05S=%>&^"_P@&60P&BVRZ8FO]QKVQ_\JK#<V>.#H/"5;J
M5!(>\E^SL0&)D[ZD&K@T.U^40'C+Y5&^@8F78I$AM4/037X8@$$6S)_\J@M@
M6LSR51$](?7&>(R/&-YQPX4U6*<K:\A1(^4;+BA(\2;<Y;INWNB,J\P\1)>F
M17==%'OU5=,WX0M15&CI)(-KE7KRF4D7EI"VV>0JN)+$,R!-!AF.80\"H[M(
M_7^K8*Y," 8E!EQPA@02]7/7$"S0>B/"B"1! (@6=*:6[:KUW0J)K_]+W>53
MZH>-B: ;7R2@&8K7;3> 5S30KB/1]T+UGT14,)QS-=6%9J1+#F(8.63"TS2T
M&";DR2UU\\OE+VIJYMQQ293ZPG""IW-E.#K^A;PQ4].3GX_^8EW4ZV7Q[N__
MP>2I O]&]PL5#[P,<GA$OW?$4S(AX(Q>VJHV?*"J!:X*6C 5%RJ5'BS*$/ZT
M">9H\H*_5 S4DA]#;22L>\)D"DZJ;^5WE',Q?PMR(E=UVZEVL.0>PL,X$KQL
M<LE)A7Y.09N-!#NSTNXIT?6E.XLRC^ Q;MKE!E75XB.0L>$2\" BPA+PW["
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M/9@\WS3D#9([D7&(]>C)0\E5]KGA.$3\\?'#_X<&-CFME)?SN2%;X,61EH7
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M_"FA-A>2-=4]PSDH!Z%*1>OX?3K$8,(X'GGQ7"*6^@^$,'M$UUCJO6'IR7/
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M,VF*JE($Z*&;;OUH#GX]O-*'&4XM,HU5#E)T1X*R]_C)N"R3DL=AKL3C-MI
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M-0EVQZ?F@0C7[%P1.W@'WR2I(EOZ?.3_D%X)*Y$;+J&<8R#R)+4EAH9_'@5
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MYOQQ)T00.%&6PIM#I*_\S)$HU#_>+B& G#E<CF#!,37B.7D#\QO^)_,3G^8
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MRX NP-7EUP_7FVV\F/-T!_".4"B?)@SP#G2["09=.L"MESNZ]WFGZ1JMND/
M1&XD.?SN_'3,^ZT"3BJXI4A678J QUK("AOJMM"1K?HQO0@'CT(X)SA6F!VF
M.RQY@BPE=(.F%&7Q0?P"TT6G]\7EE\,\1[HQ?5!I4*8@1;M6;(#L4A FV60B
MC,SAW7#1[4JAT0WDUP%+E [SD7/XH1]FN 'K2A7B2L['*$!-!VD0-.Z;,>Z]
M'Q>%C_VS\P#8O//6>-83)<>10Q6%5/ODU_+#BSC5BC?@A9(_AF,1WDC2$>",
M(_6[OA/%\)R(9TY" >N'$&C^B$C0-SMY-\90O ?R:YC"TF!W5DP9(X\8R-+3
MYH@#TO#":1\DC=(U7XM E_'G8?[P2AY]N-O8;9 R]?ZR;RC/=?ZX- D96L6S
M?Z#5O(476O,%)LOS$EDZ+ZQ3F*?X<^<K&(7H(]24;]3*PSP&-)WL[44G*DS(
M3P.5Q<+Q0.<]QW O90S7?H)XOT[_3L1>SF9]8!+K;&ACR5C1';^U,"-B:0,*
M348W(:R++A-LDXHKIS&L'5W0(%;OQI(CN]$@\&]8U [@.=PM#_@GF6DXGC^9
MPB.**>+WF%84#;5YN)"_EDS(]1:,[&+QHO7ZIF*F9,$*5LRQ6O64YL>>DTTQ
M02Y),AH<N?-"SES8WXF8:?V#SUHX4R"DR/.'[/07WBT-"1-33A.60^LM7V\5
M4#M&GD-X29+@9'"&A8E@;E<XP[&1E@8RE".?AN*KC@/!'O$9\V'.].&EX@<>
M:91PY-I/<3!XZX1(!:>=!33K,;\,;(_A>,W3^Y=TO(@,_F$&K#Q$>0FF'VX#
MS@"5@QB?6')%(OM\,[A>@3.4<2I@1Z?6SU'&^NR-H60BS&=2RHB9@WHS:M-#
MF(\:#3=XXGM'H'PTDWE6M3_\B)1H3/!C HMS5U64NZJ*#-_5UKF;F^9LIY^S
MC53PXI"FA6I+'@[*LT >GLD_OZ2&WN*DABWD)U2=7ZO=:#\F<6_HB><J1"V%
M@' C,O1C>2O#3%8X9E>N:1\N^CHK]^U$/ SGQCXQ^)%^AC*DBI=9Y^FQ[\XU
M_U9/W(!4B<G?!*,F* EH#! '*)9&68#OF<@8Q_+_,K:Z2;/*D_BTWG-%72/>
M.:.,/>PBCE$>$S]Q:55"&63X+2D5*L,+!\[3"FG-^8J 3\$P/@J,XI*LE,"I
M()$:<]X()BL;:<0R"LP[K^%\BI)4.QQX+/1@$V=$H>>/?%:I\DU4;T+K-K--
M9_4F?#3?2-B;E ,IM-HI#GE+VD(H,+.1,L']$%U]0TG>5"/3*.,:_>5FC:3;
M>)',4W<G42QM5Z&>1%2RZ5%<9!CK"&9:8PL"F%<&C\ 407JD,_*UJ$7/6 >P
M-B2Q-YVW8$TCMG.\=W?O7Y9";3MVZ9986NZRV]4P3GI-OB"D)-5RX/.)?GX)
M+6MRYR3J8CHCDPE%:@J$CN0'K%6&"4_Q%JXR-B(>8AZ^C*>8:(U:[H?YH!_I
M%&H*H(^AR2Z&]!RQ GC@!H02)E<#(89.J_FKOCCI*EX5LO(:2F<F14R33,;H
M5U')VQP,&@#WN'N]8;#M'W_GAXUV0/5J0"F!F";RM?[CC09)\4,Z;WKH#;#/
M&Y"C2J7 >'6I7(U(DK_.)6RCR5)6 0"H-ZNO&_15J?B.OVMW&IW6Z<*OFXW6
M/;_KG-[OR663[78;IYW%7^_69$'"G_8Z^S39X[6&/6 @I15+VP!@84L_/9O[
M:47E-IL;<UPEFFZG2OE_@/LFSGNJF[$=\X6:X35/9O=7:Z+D*,S60"ZY!W7L
MS28\[/+7K@K?X8U![6<=.)N52WT^^]7:A$^L AS8;#-V#7SN&TQ%_M@V'-)!
M;.7Y(MR";4.E_P1B2R7VQ1-<W>H=[AS_%#3(@X%_;&T#?JU)Z:%(J5.3TL_(
MP/V#6>T/!M_\^_'BY]F3ZF(RB+-;F,Q^]J3:VLUJ=9\2T'-'&$A-%BO)XDG[
M"^\(61RPXZ\&G-_Z+ZMA]W8,%6!!(3/^OPLKPKTH_K;O-5M?EL06,1N>06Y4
MUC*7_OAA#M,"TXVEF"1<$S'SL1@%LP2 "D*=)C?!V#=5A%-8,I$3#*0%$<Q:
MUW5[#OQ.3+ 8#',+A_@$!9(Y;6TT4L%M$R1E(!M*# .F.LPPUKGHMPANYF2)
MBBY*F#O&53F)"U]F(&=4DEB.OW*K)A#X(VG2H>PM<G0:D<ZP\T.? N0VCMDT
M]H<4@2\&>/VDD$Z9EJ9/L\;L!)EF<9C/Q<S;GA1-1B>JP<!F3_*!0TK:D()@
MC*CL#O&2*,F0,R2FT\!G/"Z[*+,/@ZED<SAW.,( R,N3.O$3CU/$6'(7BF"6
MI";U%Q.^9)AD":'F)0XLG'+X.72<33D3#(M%+?S!@4@0O&?I1JC9<&A9_A"3
M:2!=3*Z__]PT55#" Z*,29X#DS.<+! B4Q0='$UZP9U1F:UJ&-I8E?@(NS>&
M>R=CDSB#B(+9(('9X@WCHTB65;CO>;K#-Q'[* N !/AP55&.N@4Z':><"+&<
M_>9<PB+<Q1PCAV92B0+J IDRH=?.B]9+1Y@:(OLF VF^:+^T[T,5$YG/@YE2
M^>109J0!F@0+5]&59V58<2;4SU,RS+3S$IZ[02X0Q3.%MR<HJ]-:'=:?#%5*
M)W./0 I.EPWAU.?XO(O]3\P.Z+1B=;<]Q\MBDZ]E,\L7LG'3<'4."65%\>^0
M#;RD:_*B5]A9@^@(7Z58E7BC<L#^S1L^AP6'/YP#V4H8X&\A]7##3%6  Q3[
MG;-9>#/A?:L/$:MX$B4AAK,AUAK/IO@+S,J2XGM"DLV9$LX<IJ'X"$'&Y 8O
M&\5\_9'YS:P<-9X!['GH<=:\WNHPC2D]FW*_,#L<A*U,Z3A=Q6HX]8HSOX2I
M1$IT$@SSJ8$(*-^9TL5TJGGYZLT)P$+ZF@;A7'U[\P0O7*Z/."[ 301GZ.'2
M)N*[M$4$RJ,DR1B,%(\)#2]\!FZ(&&*9CZMN,C,1/ (N)]!,Y=8PFS B,3B
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MDW87.?WA4 9D2\(P7Z;<Z8\46\/H8'H<Y21EED*0EI9*]P'4V@0$)5D#,.U
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M<F_37*LX\F1P.]NZU+.3K7X#U5AXI>Q*%'B:9S)2BO:O49HR+V.A($-0!01
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M+4$G^;"09$&7GFHC(](HQE2F@]T^CZPG3$@5U@:V/79#5+BO*KDLYU*8)UV
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M,2O8(R>W8EMSCJ%T#";+S9B;9LQU-7?+;N)"<((JIJE!%TU-AR,LGFK,PUP
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MVM-=0R6OD>\8HF9P0)/3"/+74#\8Q?+4 +1L8$5'O.UY&ML\^HJ(HQ\S!&8
M)C!,LQCS%S#'#8'Z_!"3_MQ"@QAT/!UY ALX>-3@U9JC+K[G?(B1'W-,.IIB
MG#10OV<.;2.+)9J)8*:HVE<&-)]$F #NQS J N?B0D4),W!N103W0-//@"2=
MOA/**2@YI'NPXY1.W?A[U/X5)T3A;@.7O7E>0AV>>EIF=W;6:6X].E5"8%G(
M[$!P1UE .H/.NV!/B>7&Q&;.O*Q<-<:$#^0WH 42*R)N:;R7"A2$.0H.UY_
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M>72T]JB[_($/OU[35V6.%LS\V%)Z=%=9!TF,_Z$I-N_63 $MU,X/)-?4ZZT
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M\SLG4F]VQ,PC@6+<V0O?^+UG))5M9P>>1@-$J(X7_7Z[U161,,V^D?7"53.
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M3&SZ0KDL8VQ7\1+-^!#?@!:-<C;(>9,Q=GI!C-$TDJ>T-2Q8,7Z5;X'TC;@
MO..]6(8>^"K4*3<;,-)7\%N\2D2P9*31^&(!J\&)R?8"\45^A_*;QE$<1[?,
M!\=PBBH8[!GT:\!WX,ET)655+J+T;DE?W](VQNC717,^IHQE<8I=H">[JX4S
M;R;N)31^<I&4]Y,!F9[%0MI+DX%L)I3*S$>M8F/\%3_7<MFVI,17Z^H K<A
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M/R]#QNGV;*<WJ)6F; P9 S_NP'9'O5KAI[%D=K)D[F[7<&E%X2S"7QD-0LY
M5[JVT]XWM::Q9)[-=[*'@WIAI[%E'DW@9$OPJ62E)&P!V]B%[-[BYTAUZJ!G
MMVL6'6AL'@,_HX[MMH>UPD]C\^P4.KY/W]XS4*FNZ]JC_JA62K4Q>0R),^S:
M/<>I%7X:HV<7S-VOM]P9*-'[Q8L;(^?91$[?;H_V#1DW-L[A$?<8_9+.[.[J
MHMMUP/Y9=S(;TZ<&N!F,['Z[6Q?</*D0>MCBQ_+DZ=E^U8F/&^:@7ZC!AGOG
M;>_6R>0$,UUW/'@=I-BF'-C!<&2[H\[1Y<#NW#VGMEG@#=<<+]<X[M >=88-
MUYQ71=L3]5.JVPYK84;55MXU57#G41W45,$U57#G0.=-%5S]HKDU8(.F"JZ.
M5E&-@DM-%5Q3!7>:^&FJX$[BCO&N*CCKC*X2FS*X>N.G*8,[1F.G*8-KRN#J
MC9^F#.Y839FF#*XI@SM&[#1E<,=IRS1E<$T9W&G@IRF#.U*;YQF*4HY3IS;1
MFWKCYUY%*8W1<WC$';0HY3C5Z_Y%*8WI4]^BE",V>^I70%(+25Q[V^^.HI1W
M;SY\>WMUGVJ4G5-@3RWC;+^#UT%\;<I%Z_7[=L?M'D\NVEZ@/Z3UW7#-J7(-
M6&/=KMUU!PW7'*0:Q=FK&J5NL[/KO\-:V$^UE7=/5HVR:R2F5M#86_H?B8P_
MPFJ4FD4?&SH_#CH_NFJ4,PCCUH -GJ@:Y1%MG6=>HQ9648VB2G6H1CG.RZO[
M5:/43+V?,'[N58UR!EJI]L+G.:I1CO.>JFFR66_\[%^-TMPCUOS)<['XFC:C
MSY#1T1A_]<WH:"R_PV/M QEV(G^5A]NL/G VUW%[PI;%Q<@>COIUR4]J;#X#
M,YVN/>SUZH*:QMK9!6G7:-$47<P=[)TO_^4MEJ_?GIF9X]CM7C-*IJ[8&=B=
M3KVPTY@Z^S<3?Q]$MP]O)#Z.TC1:E%-&SB]#[1&A4@?&WW3EZW9ZMGM,29^/
MAY<Z]^=LF/'\F-&Q>X..W>V,&F8\M.WP<XHWU?"WSV]^^3/\H;XAMWR)?/3*
M&2KFXJ'/PO35)?[FL8EG>!?B7/(@G9=/0C:[O/UU 2K#5I^@H&>;D&>4SIGU
M>^;%X @%&.SUV6))M<;1E#[["N^%[5Q9;W@T]VY8:'V.V93%\*3U=>Z!]X3!
M'+?M.M3_ 'YPZ0?\K@=D&&#2)3QKK)Q7,4\M+PBL*$N3U!-M%?3K< WYCS?K
MKYR" Q?=XA<^3P$:,=V=#5XG\,K?,YYP=0*]:=CCITD:C5DLMQ@S:PDKP3Y@
M52^QGA9)M. KG@*G3'8@FGTS- Y&83_]@J7HB&O 8,HT6BGY=@HH2EKY%>[Q
M\*Q;-Y[]!A FT6>-&7H3R1Q 2W#'[UL<0$_$P;S)W/)T ICF1)_';)):0301
MC02(D#)X-O_Z77A<0R,(;]J14D)"G0"0 F^9L%?JA]=*F/.0SDI?>KWPXAD/
ME6;J+=>U"9*"^/CU+??3.2K"5IN4H7(AY9OEQRWZJ*0:Q6==@&-[L/'C=LNY
MYV>=8?=>W[QSLZ.=EKW#G]Z2L3A!P1>7@2[@_=1,5VUE@5J*P@FGN%R>PKA#
M N,>^8%'!9"O!4[4D83$N@Z\).%3+GBY *'[!EAVM@7O\EF>&&"[Z]%[93H>
M.EWV6-"PPSU?L<[F841ZO^JC>I'B;K>?=9D>4 \0/S.9W2_/OUYD]AB9/H>6
M@O5"P%9PO^>A!T;+J<NZ/?L]'ZL4(Z?F !#\5%F96I>(Q#J2#^,<TSY GB7U
M"=8404/R\X8=$CPOBUYZG3)]SU(=/R@5I='#C1Y^1&-P6ZW-L6KLVOH=&R^J
MY%J]+KQL&8F;BE<Q"ZB3:Q[I_--/A6_).&D[_XHW3J(@2S=_92VV]=C@<MH[
M!=,'W9).,OZ<Z[XQ2V_&+L<Q\[Y?>E/8["LON/56R4\_%\ZTX*%:?.#"V\MG
M%R?\Y<_C&+Y7\=:CN'SHU.WRX5,6@]8"P,0),'68</B)+N[T1=["\QDZFTFV
M7$9QJG,I#7,60V[^6C?U91SYV02;M80^][T4'DPXG,J+<3DO25AJ7NDE>%.7
MSEDB^K G=(W'?BS9!&_QX!LS%M)]HVKV$H5> '99FL4AA5WPAF.:P3]9R[K"
MJT<Y*V)]9VM]WO$JI;K3^RY?AGW&#&$C;AL5@-2#>(8PP4[.-"^'AY-HP>@U
M^$U "K:P >&)#WBS60PV1$H0KXLE[.[5=N>0]Y5(5W&,;;.]U"HU6 2B %P!
MII(L2.WRIW"V)9).(LD(Z <P<TEXJ2;O,AVL7Z+57QQUZR:._L,V2"' + +<
MBD!>Y53W&S!X:MW $Q)U@':Z_6<Q(&V!CQR'N#(ITUN $84I'+ L+C4'HVHV
M1P)%9H6_@R AY@-0;##Y;%K]ZH:#_Q&%UKLPI9/;M$E8-%.;K. 6?1EE6V!=
MTC?"*,V_!5LO<U;%]?$F78ULP?V__,0'?;<[&K;'DVYWW/7'[HCUF-=N^VYO
MVNV,IM/_';1_6EOQZ>R;M6LZIU<*['\"._6&P[I[GM8TV23+NVZK]_@\?[?-
M1F?Z)-4BUV<3FNE6QHJ10[B@/@\_!9(#0J%T!-"HEV"_+9!7$J1TNKU$.AQG
M";PH25JT2VZ 3:H+H.\$'IPP_ :X";?IG/@0OUR.4=MD:P1T/XH[E8_?\G0.
M.R6R_\&%F8Y:=QH!D9,^C:93X-)4*/T)'ETP>WXPS% 2?"ZE!680P<&2%.R<
M^#NP./LQ"> P("I6+0O$$;OQ@@S9&# %W.*M\ !JQX6,)#*/LI"K%WDHRF S
M690!OWH)%W:&D!$(4_DQZ?J%]YT5Q8L4$5$,4M*+5_!T%B=L'>"P1SH$0!S<
M$I[,T0H!H@)C9F:E,2HP "PL@U_E2']\N@(0V>IHI+Y#)3T$:1@@@S]\<=G@
M"7VGX.=-@ I(!L;>DH$C.D%AX8E3IO"3(*Y%Y(.)@4O17L5;R-99(FW XOF*
M\,6=!'...B5E?=@QP"3%IQ%$4X3NA"U!<'FI5WJS$-MBXW1$*6(1WDL@TKDG
M *V!8.<6H=@E.75D[@'!P<<@C@&#")[Y:AQSO\ "^(6Q))88GU'(@\60J$'/
MS$*Z\P_3G+0UC=$K@ [$]J(4,0A,.96_F2"D94H<I?V(+VS)S3)%4:>O!=&Q
M"+ /E)+HVM:MPBD@X@7L2.31CJ720^U&$&<[XQ'(9 Z?6S<1NNP!:E9"AV;&
M-$)Q*!2TXD24G 7&)=9?,0_O^B_Q;\G\ON!T7"<+ES'S^40D6:6<+!58+RP(
MSZ)(H?,2S9.%E" =!"O@EV40K> ()A$I$T)E>=W.60A&@I=DF&<)3!=;"[ U
MN-@>V"<\\N'TZ P25V*F&>P86$EJ?,^: P;P=3R9\"4BQ=?R0PC5"4LD8\(W
MR6+ \Z7"4?  \"%?9 N >I@!#(U3 O>Q9!X%?@7)'AME@NX@UX@2^=!T(@P3
M(HP3&[8HX8(R^V1.;N E B2,:(@T!^),$N!JR<J+I3(?-U=%*"2M"Z)9T#U
MY\E+L#'#$(AB@L(\AC/B'LB*E:02LVF >FGA_2 \&0]9B&>16%/X*D6>B#Z
MK.\\2 LL2V'!:I(MOUOXEQZ(STV'(J\Y7(&@&R=@^]+YDR2:<"(TBKG#[I#
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MKH.DLZP98H-9KVUZ0WF]S6A$%TUGC+(8=-#OX._##O$=^=PI$"=T'HRF3<6
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M]8^DQFQX;Q <H!YNU'+=^V[H()L=/$OQWI&6_[Q% QM$U0=IF)]Q)=1'=(?
MA#UC$&SPN1N(E#W_0]3+/0\8JA-+OHI^7__2_;XHE-:4RS4[?-P=/E+F)V4O
M#>K-4B\<&]:G_ZQV:]#[$S@(HMF>EUJC4:OCNG^BN0I>O);,]4A)L8<4M]5
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M7GBCKQI_B<8,B9C+0591S&3M.<X?852LC8(RYI+R8 -^H6V8[E=8O0$XNC3
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M1\(#*J0!*J,8..C#_Z"PAD;/DFH*+BIDE]:>I6II3+4T/XHTSZI(V'G((<R
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M9?DY(B%GT"UJ[KX'4RWR%1^7?;S[NK-=VS^K@*3#>?T"6N@RXQC@2FM $:)
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M#&&%(06*L$P@KJS&00=">!E,8[4+J[)"O-2R]E\)<:T&W5U^9]4@K+F6,N.
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MFD@+M!26$.F8C/4(R6N]:K_UG<"K=O$\C[,8W8S$"\PMB3TR'0Z(9@E0&3,
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MM"R]HESQK6+!-ZP].SGKQ/!N,(/:MCVLH6EYT+2@/:S-)%8Z,T!J%BP?05"
M)N*!9Q!RJHUQAJ^MHZ;BM,FEJI#M4_LNJJEBU"+]P"(]JVT0Q*QP"@(O,PZH
M(1"H+%: 0ZZA1)EQBJVMXR9FK(E$E43Z9;DS=GI=$"6PW^N$#P\;[2",?3\8
MWDWK> E6T+*TCE:[V^NWAQ?;Q8K7@+0\0&K-ZQ@QJYLP;P$C..@8T&A@M"!
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M0A9R0[3='>KN83N&6*ZW1&LBC])V@S#"D7*",\H8453:C#E(N""9H*:VW2J
M30N(>+R&+E-2 .2MC05>P8H+QC?@V(>?#3;.L-@_L4DEK1!51\W#LUSQS32F
MEF;((IO13%,M=+BPF*54,\.SVM2IB/C.FCHNPT[%(OD,QP[A#CJ@,N:!,@%B
M18:HBHS"2*!8^E3+[[.5WS!'DY%P$#@GU!(E'1?>8B^LDDH949L&E9#?.=/
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M4^[#3Y(!@T@0[&""$(\?,%12R_\3E/^E6RJU_*]*_N>ISH*@6V$P$,190%U
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M8D8)L^SHTX%_7?[PQK4'IQU]\;K=32-+7WISHON'00P+'&.G<YIE&DS^\5A
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M=^WM__SOR^W223UL[;4N=X[WZ<-V0[^M?%2<9*6&N1<&<W7C]Z<"<Q<S,/?
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M0C 1?&* VC//FS;.F(1W8'4TH7H<U&&C]<X&(4P($\*$,"%,"!/"A# AW+K
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M?GAID=B>]< 5:/"!<Q#%8"S1>1&SSE+E%!>.[7WR_ANOGP)T*PT'S/9-MAD
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MH$26,5?EIR)GC>/'>/1:ABA,;F1-^=D#OB1GZT[EK[K([TKZKO3>Y\0^YN&
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M$":$"6%"^-8BO-)#79NW%XL$^Z)$X8OB2B4!-L20(Q0>A'09BTEIX6#?IVA
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MIH*U#$3]XF.R+ >3E7>*\\E(3_)DB0!O&<*+I/M1*.5\P<@C!(1@0T*I4<>
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M@;8CX<G8I&"T>!:HW.N.CADBHD^!L^\LYS%P]GUR=L?C\'PM).)TLI@#9T?
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MVZ?).-J5V0<#&^^HLS!HXWM@X.Y<1%"]P+8&R(AIPH0)"1>Q3[12<%I^J.Q
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MA@'Z3;DY$YF%>[H9+0G/2\,H\I(@H2P& HHYUR:AH8R9D5&R35IZ"VZ;JX<
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MCZ-7?X2?)6>:21$2$\4I89@KD=3$)/ 9XVEDP+ /UU&@@<Y\$\HD3'W!C&_
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M(M5^['L=Z&%F4A].)$XCQ1(XGR@)./QE@I"KQ"2/NQ+W8()#"DY.06YL\$?
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MQ;4>N*^YO8E^(XQ$43_[C4(%3]%#?'#9<VBQ#1M'I>)*QY&YY6HK:!P)7%Z
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M=EYG657?G_^NW);AY7D5'BB"+OWVR4E5(CI7 BTTP>)<<^W#FJZ/..D*4A5
MW)1:@O--/!Y5EG35,6]HOVY0UF0YJ"/[];GG([^A![M?+@\^>PSC) >['\FQ
M]4:K(","+<P@;@1%H*)%I")5T8@4Y8*FS8\M)EW"304651'@=@GZDVCB5A%5
MZW6S?"B2^\JP2I&0,W*#=FB#S*@+D^9+RXIUY?FV8004R>K65A'$&+:'8%\#
MP!2^\^X)&*AA*MI6RO\<X2O.O67A[W(IL#RNJ::Q'[I%1^#W.;D$%(6#JA)/
M\=7V^^RH XC+H9FZ4\3K'CRL]DB66F.(8Y=DM_(Y%8%;7R@51_TBI?RR=L(4
MV%C'?VR=G526A!UW.KPH(Z'U+ M7RUW.=-+CJNZ)G-L:MCKV8E*_UN5RUJW0
MBZ6[J1YR/5  ]Y-1NW!@;K=^K36GP@U;D4)%!E6 *F]5)VM4XXX"M;/I+J<$
MZY3/U6U-90%4_BL[T[VWV-[V%):6;MBJ_&(1\ZV[69;TUZW+9)=EVZN=OBPR
MPB91MT6I2Q,7V22):3-$X?-+FZDUE6L::#XFF[M_5K&*LLADS@OMYY!"]OX7
M]X:^O>AF*J_CP#EZVZ]:6%<MM?LE"XVO*!L#9/H S=UE\['4R[*E O/+"#-I
M U#Z8Q<.L0PPE#P)[RFH%\BVZB>94\7CZI3>7A)^X!L7?JA6YR@/^]['=N-(
M9M$!4&BPR7; =FMGG%A0Y>P6?LL"HW+"3G>:P$HBV'__>J\5RO84H.F1HN9^
MV9FTA+:#'HA<(JL*^W]6Y=7? 9-<@J";"OJ5&%]U:%Q*MW7@Q<63=K?NX%AF
M%5<=81X4)K\I)?/>A[53G7G-\+$U;H1YW[S_  T9IWE_(W=B:TYEN-;'*.L!
M!4=-!?">J>@MT[4!"7I%L*]HD#($Q;A([.YU8F$SY(4L2J/62M2'[?^W72I:
M]NLX@Q5P+8<=B^_RY^.;?.F^W:I5RVNH Q<#S9_W^E7"(MQ8::L7O7XG7&3-
M-L-2UMB!@XK\Q"Q5BW,XVTO?5J>OKO"NPL]X7JBUL'OY(:%(*BCK"50L"F [
M!#5A5()HKAI>T1;<51Q9J%I7N^*PQUFN'YOKP,$OL#2+GGO]@2G[:BH%.F><
M?@63JNJ67L1KKVGHDZ>-6\'":T>#RMO]KO7/7B?K*97FO?CRJ<OJ^_9 M!#3
MVGN]\^\MF%21[CD]L+*_S/71U>9*/^;2 O5=6;N?%2_SBU\0S,I&P?^[Q2@H
MVG?,3W5V3?(.K'CKDE7:#,GWXV#J!Z+1V.$\13DUWHQ/)54F?GU*L\REAP=U
M)ZQ?F?VM_BCW:)K.@2_HZ/7;UZT_\U?7$^"O?[?5<OV>#5E#J[.]:SI>@C?C
MELMP1Z?*&1[V3JJ4YTQS=<N!$@( >@? _%O7#PK8XC#V4A2]-IO7DS5X6ZU!
M%2L;.S[&^:=3ZP6$7>%T.80\T&HPY4IX0+23.'7L[OK2C!?$9>=)?9XM'UFH
MYC>\/"\SU,L'38'W./8P#NTMF\'6.%L<1E>>+"@/^:8RTV8,H&4WZS&]9*[.
M&>D53)4GD>J&=N.E'1]B&(>J<II1=KW;UDDA__+$@0FH^-]31W_+2J)Y_-?@
MLO73>)GAECV8XNFUS2OKNAS"T_-MMUQ<5S,IY,FDVG2%\=.NN<(&]NUS6U=)
MF8*KG[?J_D=UNZ2E2UV?Y1C3W$2B_S5.U*\ OJJV'*[7;YHAC^OB,8^T.MM0
MS*R:T76J+PWL\:X4IC/\768'%L<'IWM<EJW0<@G6'''K%(,N2:U@TDQC-U#O
M+/Q_RP KPWZR,.N*KZD.6(7!"G.!MSVL;+GG*A?WZJ58')(I@X-CL[9<Y(>J
M<'WO._C7 OT:K,P40^')SG1_6L)#K?O6@)WJ.'Q]:*EL6]GMCDIGVMAS7*C=
M6]<T\9*LMRKU<#"5F5LVC07V\O$F]W"E*M?',>!U,3N_NP5_E%R<?2(3SWT>
M?&&D% 7Y)YQ6)1EDQ_]VZ[?Z=/%6R6#YINP8.LO05LC Z?5@^'^/<Q2J!(2M
M<CV*XE63S\8UFJ^I*.7SKZGJL[&3XB;XKNQCG4%A?-YJ&JG>;Z.]C WCA9V:
M[5:9EUI?GET-]>>5QWYJ4%E7*+9_9MM+="U>5&[-.'9>3_*6(Q\+<SB?<9JF
M:-(TFS3-)DUSP9\-3M-<*>UR4[28-W4!C_-8%<C8F/22>FCO8O]]'MASSS(I
MSIE='#M'@;0(0](IBSCU >G@";(AN< P=4S'[\HL^5'(\RN87GY2069,@.-,
MBS?OWH]]#=G+8#N^JL<*&E;A5,MZQU0E&5#!"[.]U.1ZV:8MG::M<B YQ_!O
MT-Q.0*,9G;GRY,[KPM>X QH9/"X?$:]\KKVIQHI5>&R28K?=VFUG'2*T8)";
M-KAI7T+^]/;'E9&[PK\ZR>";?D=]]&WJA'[("Y S0J8J;9W:4-[;'@Q&,3Q
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M\G8P(C!G.!_4WR(+7+M%H<+S_K5:T5ME3<+J7-:Z!4.,#LH#AP@:N//!V:2
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MI1>OY);Y?DV[X?AG+-,;8_I'L/=\VIM(V' F$*<L=RB2%AG,,&(6A#B14HL
M[$VWQ%.5Y?=\K/)) L<&J IK98@U08)O!XQ9?8 YEHP ?<!'F]N7>(F<M19A
M0;$W,?A@]9V%"!XW;LP^XWZXYNN@_;+;[E25%>\@7:GAD+4X9"XC26"NE 9I
M:@)QB(,81<8!P\2@:/*1$4-%IJ@9UF@4UTV4/TTBS0/:HO.)-+!]D6KJP!H-
M&'&F-+).<2252<Y)T&:M? [2YTFR]8/8HW>1A-)8I=_+Z'.9*,)$13BP-Q&,
M(=AAC!Q6'KGHF$[&4AGED[9+&PYO/$Y/@[?GTC=2=()Y;9# .8>#)X>,Y!Y)
M%JA*/G#"W$;Q]I,J&71#Q;T5ZMFOFS:SM#[3)B?3+5ZBM9/I5IS[AB#VXDFO
M =@>N#<(R:2CG(>0NQ '&C5FV DN.6EJ#VT^7G^8C_9[1H*@,8'^A17B\"-R
M&O["5F,M(TV>FUQ["&_A!7A]+[TV5U,VOBW/;S6FW?!$Y09U'S?JKJ,G_R#8
M;8HH/0 6SP5?-+<T.H*2]!SQ7*G$46<1MTIZ"RP1HLV]X_G"=(RUBR@U6-A@
MX8-/>@.@L/$4_ BTF\M-H=Y&J3A!VH2 N*$J][VG2,6@ [7$":OR,0^Q11K-
M\WG4B6K O 'S>P+SIK;4?6#Z7!G0P)-.7*-H%>BM*? <TO&@T)* 19!4FJ6U
MI1I$;_3G!G*?$.0V\?3[0=VYE#3J@R3.@Q(MF$&<"8R,90X4:R-]]%)PZI<7
MR6IPM\'=!G<W&'>;),4']-'.)RE:+ERBUB(5 D/<&X\L-0XQ*TB25DJO^?(D
MQ09M&[1MT'8S(V9-[N@&XN]<[JC3EGJG#=)* ?X*SI'#5*" 8TP\8IRP__[\
ML@;]&O3;E$EOL(W?H-W=HMU<-BV)F'K&&*B75B'.&4?:!HN<T38*YW"0MHF2
MK9?I6X^B'B\MT'23VIMN?@/69H0_I,# 4UJ 9H3-")]HH^;%>MO.H-5+K=WH
MXYF+_18C6RW0OLC2TH(_*'&C><9&),,\QFDVSWA$SW@&Q5MWKQ]?:_W$ONL$
MX8:Y0+ZWZONB&6Z(H^.[*W\$Y1U5T@HO%:>,.\$L$8Z1G&5DI2H<':0YCK;)
M#H^3^>-HT6FL38ZF>4,0ES*G,NA<$$3!+U(K:MF+5Q3S+8'-TZL TH!5 U9-
M1=U'A6"S*;#&,F*-%\C%F#L6!HX,M@0YD[0V"JC TQ>ON-DBAC0 U@#8LP:P
M)JST(S!J[NA5RE4^98J(:2P0-UHCK2-&*6KJM: \XERB1; M]:3K?M^/\[[!
MP 8#FQ-+&PJ%L^H:*&5,">=0<-'D4Z@&V20BDI[G!M,$]CDW0) +RY\\>B1L
MH*J!JN:DS\:BU7SQ:4VE%HDA(@P%XU)09"260&_48B-UTLR_>$6T>IJ*6P-7
M#5PU!V0V"J(6') 123A.N496)8E C6+(&A(0HX'H0')G7O.$JW@W(-6 U'>"
MU#)]JL&I[\"IN8,D8.+E&N0$I9B]8-QJY)0!TT\EBV/D&OYO<*K!J0V8V@;;
M?HW%=[<P-7<"A'-EC%4!I6!R4Q2BD"-.(YPHX:8HE>8WT5G_I!)\E_0.[_4O
M;#\,6C_Q;VL8OF#*CZ/5PQJ I+&VEFNEI<)<66)CC(%K;IAVAF'Y8S*U&M7I
M&S'IRWR2EF,J8$XC\DP8Q(,VR&"P]W @26JI=13TSA2GQ:BP$442&\[^(9S=
MI#4] ,_/I36%:)T@%@G!<SMA[Y&CG"),32 V!1E,>O&*R+M00AJ6?W8LWU@7
M/X*KYQ*!.--:BV@0TS1S-3' U3D1B'L%-@;1!)-GP-7W?,"K 8T?"QI-C.>.
M86-6&>"!48I35@9"1)QHCBQ1&L$.FZ"XE\'?781G@W&C8>P?R]A-GLG],/A<
MGDFNUTV8<$@R"Q:^%PEI92URW,@DL%*>BV>@%S3\_7W\W21F/* %/Y^8D9BR
M^70E$MHSQ!W#R$8B$=:!21N-"+ER7B.V&[9N4ADVFK/G4AD"43XP!5(:!#1P
M=O[)@E8>0U01!RX3PPUG-YS=N.<VF['G@O].@0).6$ .[&K$@R?(1"91BA*4
M<$^2-70#%?$G57KF![54OW[@L)S:K*OQ65;RO<.%V1"<_^XRO\30D+ULU C,
MC<F'/URR4;, BV4D:ZK?;#[>O[GX?1[OD\2:$0!XRFU"G.F$+(-?N:9&*D8Y
MEV)Y_9O'4^[W[GAZP[-H&SAOX'Q3X+Q)I'D(C-^?Q?C ;'34>J0C=8#L6('9
M;C4">RT&';%PG+]X)<667E AJ('X!N(;B-^0%=D B&\\,S\&Q3_,HKC56$J3
M'/*)4<1IPLAIR9&C6%$;@U&Y< A5>(L_ZL8<3P;&'[CJ4R,E&BFQ<5*BJ3%U
M+\+"SPH+P; 7.I_<2P2C?+(8Y(062+'$0L2!:8N75IEJ9$6C\C=@OB$KLL%@
MWF1'WA>>?YG%<QPP(9%&@/(BW\(29*GBR%,5N6%8.U*YZ1OEOP'T#8*O!M ?
M$-";=-@'C;5>UO'6@ZN3R_W=O6,G$R.PHR@$(7*I?HJT$AQ9[HAAG++D]/*L
MN0;%&Q1O4'Q#5F1#4;S)?KX/(,?7@?S+,6<N,N<5TD$$4,=#+I%D#?)8^BB\
MY=*%!L@;(&^ O 'R)J2Z,3C^M<;Q_:M]"N,Y-I%Y[9S/'I6<&<,C<M)R1 /S
MF!-*/15-3/7.$O3_,<Q4#_^&]M^O_AO^JD=<O:&,?S)98VB[&T"3>8F(+L#\
M3M=9W[;.-*_S3^3G>]GE5=[^R[55T=NR6(6CTPBH-!BV[&#0\^V<7->Z: ]/
M6T/X(L&>P^^O+X>]+_ TV(Y!ZW7O["SVX<I.ZW<[ZOK3UENX"I[;ZL?4B7XX
M*&^U[7[K;]L9Q1:@8/[D?-3WIW806P%>LMT:O[B7BJ]WX]^QTSL_@QT:/_'7
M7C<,X+GG_3B S\LGVS,@1?BY'-SVF&@?#Q'01T4$UW:_WIE,!>WA6;$I,_MS
MV\X_P@UC&[MA^=1.7N+W\&AXXT[KUW;OU/X=NZUWP(X13+?0>G]J87^FM\G6
M!R.*ATSQXLSC?EWM<7#'ZIOZ,%M8@\:Y!2DT[$U(,L^VW1T,^Z."F(NU&%S[
MJ'41^QD*.YU+F'2(\0P6(8!.!6P "AI]C 3--Y"@89&!L%K=7D&*@\4"J2I8
M.[/FE29U !O6;_OR]ZQJM[LC6ZI6Q67E+:[_CU?S6U;HO$I2;C1VGG/'@Z,F
MBF@Q#E0DSDQ*QX2J%PLV>DIW^3P:#-OI\J[WE>#;K(]B8_EVZ[^OK<5UB\,%
MC37,BGK"N4_84H%CM(2 UAHYB<>[F: QP03E'TK3X[JQL0M/_1L6]>^X-V&1
MG6[X9PPGL*L[H,K^7=H>[8'O] :C?CR"]__:Z?DO#VY9^-JR((>[)_#YE\O#
MW4]?#N@'>,:;KQ^//#L\>GMZ\-<;?OA;UND_TL/W!G_ZSRGV9__NVK_,Z/#S
M!WZX"V,XV@/KXP_VZ>@/L9_ON?)B_Z\W!*P,_O%J_^K3YX_B/U=_7!P<[1][
M3Z4W7J.8'3O<FHB,L!91+7$(Q%,B5&D: KW&L),-M" $22&7HG4A;Y5S$F@/
M!XE94L3&%ZT(]MIYIKW^*+YX-=F6UM2^S#/&#-DOYXD9#JIV[M9179^%XII@
MKYEEBG*LE58,,T.TYDX1ELM^SW%1!8X J^+NT7&.BQ;#XU^QE85>Z[0]&/;Z
MV08!Z(>GVA/ HD)@G)V#S98UUWSF!-B^57I)_64K?@6YTCV)K3X@5\MV XB2
M(6 ;"-?BDWY[\ 6> >;4R2EH2?UV;P2J;+MKNX5*/25WMN 7WQD5ZE:8;.^T
M9!J,0/VV((#[T0*G79:OR*Q6;$0V+(O'3 ]@<&'/)]\6(YR;1 6SD\NV6X>C
M?NL<;#CXMCW($G24];GQL& LP_SXDVJUX()30(0(ZP&+F*=0O&@T!#R8&5#\
M>E[ 1'$%W'?6[K;/8+=:?_<Z\.SLAH8[6MX.3ENIT[L *=$>Y">F?N^LU8-Q
MC9\ =R]8[853S-]LMV"GS^QERW8&O9;U_S-JPT-ZL,/]Q5L"&V>'A93R'1!/
M[=0&@H#UGUJ'XIFA!V)LV(IY+'E$O64;6.A;?5OL<3Y_?1Y]/N"4+P,-!6:5
M'[A4OU@J=I8)N0<05\437[:'\#I_LP C EAOO]V!S>MU8VO'^]B)_1)]#L_S
M/_>S$ ^,.,6T#[NMG=$)#+VEMK)2B;= ZRSI)X:2@F!00.>V,,A39879DWY6
M1\%B+C2D6EF'FT_;@ PE?E28=:M*W]JIG[:5&2F_H[@Q3!GF@'A7<.])A($,
M2X8M3(?:)="^*O<+KCL8]8?1MPYWCS+WCF$Q4WR_=VD[64<HG@ @YN-@@!RH
MXP&XOR* K*M?%I4)>G\#%PUAN;=;'\[AX;95/0O>4B!4K].",>9Q7U3(G4?5
M*V@F3\7;#%;C>>?%K(FKO!3>M&!ZXZ'4WV<L3<"O[9.3O"\966$PG='9.4SB
MK'),M'[*<1J*?[F1E(MKR"\_E[;7C9=FO,V;?^9BR)NY$$J*=2UWO?"13'3G
M*7/\ J JX](9?-'/T'8.XJ>?UR/?,XBPF*'U/R/;S[ %:Y%UP$Q+F5824',?
MQM&%.?I,DX!>&6L+>BR@<]"NM[Y>:9 :, D_[#FXE6U5SZL?5<)MF.Q+)H9,
M]=F)%,.";9K:FR5$L]9.;;=V!GFXN]'GQ84ADGJ,LWZ,TD5U\S;EU?VO-=S_
MD;M$#&A1GD9N(S6*L:2C-: @,NQ)X?ZG<^Y_\8"'9N6ST^#W+V%L9/\J7[-_
M >\_3AJL)Z,DLLYHQ#43R& KD7*@X<8$EI4$?=S(;;FDG@T0:P=^V\I457+L
M.E3CE8T^.$U89%Q(XV1P1@4?#7$N6;<JU4P,AIW!( XG)RF>[5;GZTXN#G8_
MDH/=/RX.=_>/.4E@]W.+#-6PU2(JI 4U2&.A6+ V1@=;K>4VG=OJ5K7+!2KT
M 5G[H?)C !+=B^]E!95KB>Y1Z+M5FD>6''$XN.<1WCB>0@YL DM,)[\T7)&Y
MXNO^T8=CJX3TG$=$HN2(,\^1EM$A)6WBF2>48B]>$;PM'C]7;  W5#$4H/@B
MA%KH=,YVP#@%E>TTPO 6.$/GG)^W6CRW6$K5F 2'08-96JAZ+_NQM%5_N6B'
MX6F= #%U5Q49QI-;K(-9C(;+;YDRY7QA_SR0#XA@/;.L4W^?]B<N_I.('*A4
M7Y!-,-J7MG-A+P<O_G%M4F?M;OUT1>'UFS/YQ6[D/P\_[OQ^]+'U[I\[?^[O
MM-[]_GH5T_M!AWP \/>^=738.OKGF];KPX/WA[_O[>X<O=EMO=T[V#EXO;?S
M>^O]$7RP_^;@Z/T21^B/)K+6X_RSAAMY"?1,Q[Z6W+;\RQL<U+<ZG&<<U#*F
MI)R34>O$N==6:J%I-($$[*PF2]ES@_QF!24=W> !?KINL[UNZU\C,,=SGMR\
MQ^PFKWCI,.OV,NGD,IA5>'B8BV)FS]HZ^J=FDI+ A)(A\6BP#B%P*2V.DB0P
MZLL\/BP97E7_/*C&M5,,J['-%ZNF)[ER-*-6AT0$\HZ#C<8X1\9QAY(&D\!I
MGYL)OW@E,=Y>5E^VUDESZ*&(\<R&>#HC/RQ!)KN\BF]SZE&_<YDIQ<6N/SVS
M_2\SH8=%X>M,!RW87." GVS.8.H76F9H#_QHD!U9V?0),0&A9QHN+FT14B1^
MDU]^[?7[O0MXYZ!R&]Y(X*>V2'7.GI\^4'@_%NZV,NQ0>MJ*8/L0WC< !"@&
M"F,JHS;7,B+^BF7:Q%K.+8]-,-9@ _OBB=)2.A$=X8#(W#M71)H)5F6D&7Y8
M9IP5IQ7>55Z]H]Y1[(,R!8-=&(=N.&4QI[RYVC_Z>,R$ 88@!&$;$^(R6F28
MLPACK54,!@0FS[68M^>KMEWGE':&W<YE2<X9:.M-*:)Q-U)E#N3UNMU8$M"8
M,=J#P:BP:"I/ZX11EF?7S$NO7[[5NME@P;XW%[Q]VO+\;73]D>U?5E&P/]_M
MO3V:$!A 5*<#5#8<#&T9 IL/;B\ELC=U#.HP)4#=HSZ,M*3O;P0Y83Q/,A@9
M*./!6>=SMK<+Q+C$I2K3:3#\5X <_$!- W+W!W)D_VKO.!IA=<0!:6)SCY@$
M(*>#1E02F7 *'@L .2:V^>WJP 37AD528$E=67CVH^_8=DX$?$!ZZ?=\C&'P
MMM\[>ST6]']&'X%>PF&W(9ZUB.?@ZH]C%[S%6#E$B%,@(9-#AEN)0&-)5%&F
M)78O7G&QS6XAGB(R/=:]BJR1BT*YZH26NRS0"$#K/"/4W]FW-\HH=F[[.6)7
M9I  %,VDD-CNY4*T&XS< )2[[+RO(KG7,'1,Q7E<4YJFZ_T=U\HM>6+2M1 X
M;\[;5X"ZK?/1L,X7*'1CVP?A,/Q^/\>#IK'M90/B[S*T#9AB:FEZ9D,L,@K
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MBH.*ODQ@N)MUN=\CYN_]:0RC#E@V"T,8^=S*[[W!8*_[?@C4D3\[3&_KXYH
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M<RRF>)1-]F<.$O088^H-(1(%PQ7BQAED=;+(Z^ <XYK02&>9?B4N_=%* QC
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M]CQ'DC1#Q][+2)"!.3KV4 K.^ 345"V\\B N9*T9>L2E$WT(U.H4M ],<QX
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MF'N"8%?*6&4-)/%@T1.6Y4BHHR288'E(QB8K*X)7'\'6*IF4U\D*"I91(Y@
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M&RJZ'P6ZI_*)G+1*2A&)XL!0>P=&C,J<2!-DRH(Z#[JB>]71G8QUI2>(=DI
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MI=$FF>B\F#_(7"%\UQ">RA-QW%GNO206S=M2"@I(:5B%8-:6!ZXABUI<\@E
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M.G-WL5S:Y;)JDW#'R8N:KKS(DW<PHUB/B#IEE3G).5@"T3MBM53$,<-]\.!
MJ67L@;;H7?BG#FMF4P(C3,PV@;;!"<=5HMY:'V54M,)ZF6$]52#&4,,@&R!:
MQ4A XQ]><$LXKF$9#41PM,+ZD<+ZV4W4M31,1P'4:P IC#'6:9 TV^@C3S_
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MWDN^^\]7^^_Y:[[-7WW:W?L,?QV^/-GI7#H3?+A= DW?=O9>TIV]U["]]^8
MGPGO_WSUZ?VG]]_?_[DM=_?V#]_OO>;__?YZ4FEMN+T7 .<#/EANP'N720Y)
M$;!.$N<])3$;(YR6(5*_M@&B39EXQ.>!;X3I!V[X5DFYDO*8E*.C0C-'#8T6
M&/>&08B:QF"2=-'22LHK0<HGETA9)ZTE"" ):"2@(B?&<4UT A.I\0(@KVUP
M*=IZ1B'ARLJ5E2LKWR$KJZP25=Q8R R8](6DA;9615E.8MK*RJO RCN73663
M'?C2 XE'4ZI9@B96B$Q"3A0E[P1JY[4-IBHI5U*NI'S?I&PHTJ]2+BF1($;F
MO?#40N*:TZC +P<IKUPYLWODX\M6,@U1Z9P]H<EJ C138D0P1 K*H^66,^M7
MH999)>1*R,ORTC<@9.:S-"X:%X*'#-Q2B#H$)YG(@JEK^W)40EYR0MZ];" +
MEH)DFA*9!"? F2'.1T$LDSJB=\2%6(F.SY60*R$ORTO?@)#13')16 ,  KRA
M/MA4VM'9E%-TD55"?N2$O#TN]HND+':W\/TV/PBGRF$_39RRCH!(B3C-.*',
M.L 59*Q;B<+ME9(K)2_+2]^H_H^U&C2:R?B_*)7)/L8LLM7"@4JZH>3IPAJ5
MDA\/)6^/*?DUW?D>OF]O?N!61EU*PB09) &=*#% /='*T9BH3DU1XTK)E9(K
M)3\ )2=K$V7,RP0!1+1>>,U=L9=MX!GL<E!R#>XMBI>+J;S]=>>/#Z'L3GGF
MB4]-LSK'B<]&$&NB8%F)K".L;7 &;:CQO<K+E9?OV50&!&$*W@0+X(1 0SE)
M9QF7F8/1M/+R:O#RN\N\S+-0%E(FE!M+2@5"8DRT1!N>0#"'^AKM96;:JM+R
M7$V);G(,YE*;N:7BT=G3_OMQ/^R[4K[P7"NC*9W$;_;.,S7( [+I[%>_26E/
M*2W73/D<*226#75 K08?0S!)^.L*#]\EK9Y*L%+KXJAU>_KH!]6NQ&8CB3$:
M LQFXC4*/%/#M;966Y_0X#5M;>05=6IOVH]MB3ID5BH84X&.I3.+CP)=7%2S
MV21<#RFG%+1+W+!*!:M'!9=3J=# 8DF )M&X2$JM<6+0TR4^A)Q=CI(#7]L
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M1PV-%ACWAD&(FL9@DG31TLKX*\;XI^<8C+=.,YV(]SD1X-(2ZTTB(ON4&8N
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MR87 FQR,DP]<>&VCS41DPPDPSXA5P(GB%KQ664L_E62'+)>9074GM0<?LC.
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MJ6 D61FR2SKSQN$5;<U,F\/T.?8EI;YFT_+O3;QZ5I;Q760?-PM0*P[64!\
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M04G]:;3CQ\/EI2XD2M:.<D_@E&TJ419(77X,;^-P^*)V90:XO38#W!=,7NL
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MMGNU_/A\K@56]<>#8C1Y D'4O\>HT'JM"\^&+RPF<<,S.K71 !YT7.!,RUX
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MTLR-!/DWE;U]W-@^.M^_V.&-DZVO>ZU=O']Q)/9/_CIMM#HG>]MO3IM_[%^
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M5>%D^-(?=\+$P'<QYD_;8?; HPCK@)7/5CS5ZK[-@H5A..^?FKMO^XG:E]N
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MY$P3)XW CB?KG9#<5OCPPPGBE.VU=@Y#RNDV22(6M$ <)XJTS$X%$I6WT82
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MAF:0 54<$2)C M5,8AK+R,>W^)%">WC6L>=YL?';K%]=^;U7_NC$L"< PD^
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MKH$/'?O?^NUA/F\#T#'X*7!]:P^/ ;HJCR(+'GC$]B@_870*3RX!-\OG@DO
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M&G4ZY?UZH^%@"!]GQV<^-E7%F7*J8:<'NE5Y2?"-?KX2)F8\/Y/9\?"C/2S
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MOWUT5(:#BO@UCLMXA]ZW[A%8ESA9&5C+? 5\+\-E)7 .+-"W7B7"8) F81R
M&Y#52;AJ8NTR\(Y7J!@-QB&E41_&,P!_HM,IP*R=VOY$J=J3AY20/(?#UV2=
M*O?NDL X<T]798R0FDOI<J]>&0AI0/<NDM_([H\/AY99AT4@B!*7$*?,(B>,
M0]'P&, +P"F5H$N6@ZX] HM[5$;RK@2_$YD*$^19CARMH@TJT3UKU2%B<I>G
M3(KV,^]QG?91N6DSF"&(8\T#3<W1WK/QW(%2A7+GN R8'HULW\)$PM0"#KQ[
M4_P;%!T@ M3> @WMEE@/UP&0P"6#D1NT0]OVS\I0M2VIZ3E<EWSZK H]3&BR
M[P$:V6S_SJ/'XX%EQW-!SO_2,@'C?X%G*:BYPQFUI:U^%7T5+V:DRF4L788J
MQ-*M7K5=!FVJ2 M GSV%7_DJ\#YYZR=LG+873U.YKI6+E84P6; !)4N:6)U9
M7ZB2!* W\/>_P&YU"@JS>PI7%-]@&6X>+F4Q&4>2%-P+;KFP$A->-H66FEI/
MEQRVUC\[LO<'O,K?^4V:_;>KA$KAW0ZU ]NA4T)1![ <VBKD+)%():&M$Y:X
M7'E6;*I+-N.NFRV?:!1@E*R)X)2Q0'0D2N4.3D$0'!E><F*S6?[;+/_NM[U7
M'P^YEGD_0B$,_ QQ&PRR*6HDDF38I*!Y2!M;:K->]NG"DL^%K.[(@"\ZKO>@
M!P\Q6W3P\%W\VNM\S2#YLB+G?U1[K&=/^3#BS)8M$3-1NS(GJG0V@7+ P$!A
M8;P5-<Q\,'=BAK],9FSJSO2S']D=3@XL9/N21OURVWQR"P"5?3_L73!GL[O]
MX]G?GMSK?.,^AZ;F/UT\LG$( M9W?F15P"^;R'.>U9KC9."N]?K]'M"0UL6)
MZ%V8+SW-8"G?%:SHUW8>28XZVHGC-3Z0.X><+#&%B4E*<,Y=<EB99**-G&-"
MK*I:&(.<CEL8XPRA/_.K,GQ>0$R0"/\BC/K?>OTPB-UG!Y/^^^X!P"15D<O
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M'=COC;.P$JKQNJ(9)=W8X7L'.V1W^S#EBII&2X2Y8XAKH(,ZJH",TC0*F7N
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M1;.Y=9N+_[FC=U\3*%_\TM=!<A\"T=X&SQ17D;AHL>4Q>0!XG)@]W+EI21L
M\,XH3]B;7K^$[6%5MSI'Z)?5K6[0>G5H_:4>X@W"^IBD11$\-L2QPT@'H',
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M)L=O7[TU7#LMD5,$?#B<<B0X44AF*:8J4]C:]")Y+1O*)"X+? *]EK8H&.M
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M)'Y"!7_+!SB]]"#69+E]MG5C^B-PUL;^67\B)NKJQ@=+25XBS*NSV2V/YDR
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M)&74Q#SKZF6B VB\$ZC ]SJ=WG'([@7*^6<$KG,XTN3MYGJBCL+H Z OH*M
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M!V(G6#?'Q2"6EC@++#<,!![K3'J#01$^$UBI8E8WKC/22A=1K$1XB$&47P%
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M\4._Z/7',8R8K:Y4POD@T?D03[^:Q'R5_S"8H!J"]BFC&F=QE9 E!UTU56P
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M?0X=YU=50K4/2DLWM2)MG8N%?D#M:A O]2V/H(IRN 2IJ5'="B6DY<S8&J&
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M<L(C09X2*70N-BM$0E%[!#6-LJ @E>W8JM&: &']-M+>NW8:$WJ5JMQPPGC
M/@> (+F"OE/:V)TT:^30<>#'N WQE&H'3H'0!/3&)-'QOM 6#>_B37MG=;F8
MT/,)-(#>HR5E#(2AO7_U94WH1?MQ7T]%ZL3+$)U)>O ?AZLROGIV@X3<V'6J
MOMGI4>:.47ZR#QE>B'J;UV=M/L:.2+LT?XCX'!['#\$'DX@Y*WZ_K>/<:.3V
M[-HT!456HF*4RYBPJ"5*#UD*,]TC;TYV,0-&/-;7[VD0U&I'GP C1#VO$<M#
ML=]#]%VT>"[)CR^UC,AU/,V%1R(^%G84_C:&SW^T^"VTB8O;9T"YC DS "0-
M+PG_;KAD2/R8Q$"/%SY>QJE.VCNEQ<*$/E]3W@8:!TL-&>-2):+-\7(5!D/B
M%MH=R]?8FZ(P8J11</=A^?RB.U\AH3S+[+3E4B9 .9V,)#86J;U&D=Z$WHXF
MXWCCC]6C]<8F$B=E&X4)/1)VPU),G4@"<.MYR G'WNV3(];\(4__9,/6Z23M
M:3-#=F!GK&[9X#":PI=#]U]1D-R&E;HKM?D<V@?7Q<64*KL-)Z7FHX6,[C@.
M1@P5+!$[\ ;T8#_%[M(T/FI.^>YZD)VHD;?)"F>36SGM2^Y6YOE#,K?R'>6:
M-\C!/R/;QQY/?O, A1@HW4,'EHH MZXL7Z%F$]W>(QZ58_NM=G\5TN?7<<H
M<N<$E]=A,$QLB&,/.J (?R.U$9[YU$8Z R$D=[ *-%E)OU>SM:KS,4&CN$$>
M8K GQVI/T0'9 FXSR7$FI;I9I7YNI3M<P?^4;6]B36$MW=V+YW/;F0IN';'3
M00-M?T*Y C,FM>E$53Q$RJR,512S#%_"='2/[84(/YSR0PWWQU_9 0YF(33_
M%^2['PD#_1?_B=R?859Q"]0LA/ZOQ4HV JUIC6Z?0D0"'J1QCX,09GL2:8K<
M.]]>-IN\OG8[CB60(6_M(8,JXQ9]H>V+;F=V)JR]O'EHS5LA#F([,:"3[%WW
MQH5)C?RXNZRH1$6)WX;T,X8)BIV :]"P.8*Z<V]'Q%DE]B])/($Z S/ K=TV
MAH1$//U@[+=)5 10?76WGV8^1BA5B6%^(F+W^7:!1*OG#,[.,J^'G-($?.M/
MRP(A4(\"OAY+#]X:+(S=2>_1TG:V=2$^_/1<0G.&.)BQ\P8IB,)!6)L@*[D7
M.]$,D_NPV<9U]^'#2,$'WDIMK(3</K)M('/U[!0R ;5[2I;\.)YL+@7Q2^T9
M4Q3K^<,U?]ZF$4!]1J8:E)I[DAZ'DAC-YD5/A\61E%5URV-#G*[0V..O0=.<
MHB7F796;VO4X&3NAYPRMO:TD-&NGD D3.MDQ;O@8)X$RL+;R5LUIRUZCI*]T
M96K"N,"Q2"%*\%)V+T63BPD]+YXIU$\?)O5 $ANH=)#4XF'&:7*^0LQ^Y(O=
M%:;Q#6&I-[Z)P 08:X)"KA!!'A:F<J'_S4(XZJVU8TO:V9C0]UR_Y7H!J/ A
MZF:9E#,P=DM-M*$,M> 3#E<SFU!/HC<K$)J \8[6E[M08XUW'(6!B/4BS:92
M'18:;HBO'/M:=9VH]%U*]\Q^E^$CU,\=BR/)^E0I9X)PED<7M+0Q$W;U6#M7
MV#[5R(\:(Z*Z<=Y,)J-?)] Z(KOA5%?2!+2X3C+VQ'FJ'-X-2N8U!5V;A2W>
M/$7JY_;;=3Z._$6.' 5GXI@LX=BP+*08GG%#=K+,J[@C91R,W?6;;2'ILP9)
M+SM84RH<3+4I9:\#<)%=R]>EYO(F"?:.L;;0VH\;CU$2RI#59V2LF%_SET"O
M?HGC3"7'[+JB)N$*RTTR[GLL6#(.QB(Y9_#54A)$O5/(!/3RC+UC+UTRN=6C
M=&>.QWS7N^3XMW:P:O'1'H:]L;B75=R"T5I1*2Y1F'LX2VT&(AA'%GA26]@$
M81\Z#M3M%C-JB;MTC5@U$W2'ZJ@JPSC$/E[;"TE YDXI$[ I+/E\M;^BQ)7)
M62.!"?WY2'"8[-9#XA;3,)?6OO8^:C(QH=]I_%TQ\K'N<='&.:?.P-A-H?GL
M,:>A[<=FN1MF?VGVBNJP>-Y,B-7D8R+S0'88X;&7"DNM+AMCP8_SW63AJWE>
M5:[,1+#SMQQME&@-W7IX?NQ'[$:V?X\=_N81XHL4]W3&,$QQ\%F6SDV=@PE+
MW?#B[.(L/7SR9O*K#3#4$DNOA,J$GNWZ3KCKY K3:[:51::I4)K0PZ:#2?J:
M26H=:KL)J<S!V+6JFB^4H#1AJ$0U42(U >F"=:$8BA+,:5&?@EYP92OYI&*J
MT&!F+/Y[7$8\Q@7'9[ZZV*QS#5U7W*W,LND&PR6L<$M^Z[EKA*,"3U,-TW.N
MH45LRV]]WU/GLSB,0-]E>1]D9"8L%[<;_"?  5NS)"RW4LZ$UF>JXX,8ZFP+
M_DCH(D!,Z,XCLHG" '1IT*W$RZ-<M2I=JQ)J:'YKIGDY/%9UQBZ8'U 8'T7X
M"748QAM '-((4QN*3J");$['GH=8F\U;GY&IB\$,A:&?1]C$FNT#@MW/+;AD
MFMW.BN3FBD1[DHAK6/3:W.ZJY,^=:F+"J(.0F^1_26^YQB?R#E=FNW$S=0Y4
MC1<\"4I^1RL8DYH4;CH)W17YF3I G=)9#X^1(WMH5([LT7K!HD?L2&)T*\5,
M:/MTPDW3_(TZ&4R[Y4QH/8^2I$2$._U*^3DVSFN3+L>_\KC\EMPX*L3/O61?
M;X&G<X<7C(*6=2?D'P=(%L[?2F0"=#OO?+1D%'DC64&Z<#)A!-JNUDPGNK=)
MNW(S820.> (1_@90PVAJV>*!8B1H=EE\E;I-W='32TUCTC9M+F434).+$2)'
M0>-@>YA.-1B8T-^BKG[[Q)-+!.@.EDU&IW9H2^Q?:L2F"OG/L#DC@N#\(0NI
MJ"MI GAIIDIA1RADR9 8MR14)O2LE.6@8"H8^RX<##12:332FM#+*P:[,O4?
MMK!"S/Z(\$(BA\WE3>A-S:$U<Q PO%P*4U>\*, B"7L@3EXA\9+K%CH9TG4Y
M&^I7;[^#FB7&4H@NZ,#)U(C$O=X_E&Q9!^%MZHY6"9[/ FQB@V/NE<J> Y)Z
MPO?B:>I I4$+\1[A(&#O0*>E?B$YG0D+<7K=\):$"LG-FTJ;T).2);EL).5?
MQ:((;<YMR_FKD9)G-0_!VE3QUDL/",>S0V8;++ S08247U>)WPV!N9Q>(>-2
M<0<EM?02?=ZF[L)ZJ ^?<' 8^8DY'4!TW/"=B]<\+6B<^KECZLXD%J!@%?YD
M\X3I$KN;E,R$R5'[*F"'AP1-ZE-AQ-.3;GM,4S/!LP8LM3V4*@R3G9Y832@-
M/0[I6AC-MB4658R&"( I"I#-G!4<.PI77I24%DV.INHJNEX=LWTWDMR=D]G=
M?*_DGT4&)O0W]['=B9L\S2XV61HU?48F]%]RBBC<<BD=);3B10Y:AZG+P/@1
M,<+][%<V^9S$T_)04DF<NH3*!!%I"1+N'%ULN!UJ-!FW/X,N,4FHTYL <)UU
M.GF#<@);,I2-[WLEX5[!G%Y':V%1?,R/BU,>*A_8/G]^3.*8/E)UQL9@B@6N
M]NU3V45H&9T)TI,[J.*0X0\\6MKA^4"PAYW$C;%[9BZ?J--+M2T1AP>LPU@Y
M*:9&2LWYUY2_2T-<V$,]% 3"3CU#[!$[;1NN-B-CQZ1PMOUG!.LG8OXVSO?%
MNR!"5%3.Q<VTSQT&EV U]F[X[5)$W)W;6C*06PB-!?57GJWMJ7WQ*Y<Q8:%3
M>R7LLKU;FDQ,Z'<Y)8S,TEY7UH1>),E2TK?D\^<A=_-SR=*MJ' P=N85CV+I
M\WZ@0FD]:Z'!PE3]ONYH.?1@@SBF9Z5K#8::.JNW0+03&.FP^$M,*34_["&-
M)W]]NTE+'I5K2<B0$JVATZ>2#EL6EMM8WH3=M?0 ^PP)BWY1&=5XOKV%VH2>
M%A^4J&"B_A9%(ZD)??Q([,V&45A-,NM#'#'"'[,<AN(HV3@IU8@-G94-%WP_
M$@_P@ETYGWV-_==A86KHA(*;3JR]^_CY$@:F[DN%-\O'WCT&S.*@R]TW@T%G
M\3QQ=T9BZM^#H0EK0FF;%=@IIGNNE#>A-WH1/3>"[6&B@U)>)HQ"0RPQ=T )
M$_S82_JU5<F5T)';49]74'SVM$YEKLESIW7:JZ4W=-N;3D879^=O2_?5XRN5
MTCON$CH3Q#RQV,3!\3>4"'OXKU $)BKWRTDL=HK4)O1T[)<3"T@R?C<6-Z$O
MN]'XB6G@*N*OHT]LW)RT1('25*U#/2 W=XFZ_XKBQ13D,R^0N$53/^D!0H"U
M:S15NVV.2TB5L#N&$/>5Q?+#/\6;=YI"X1HV=N+:+'$KI=D[YE^:@S2/6^ES
M>[%$EIP%9;%\\##AI2@19YZ 7N76\B!S7%W;&QRVB.9^3$V=XC)UD<=U.[F^
MV/&^7 V?(R5B3HE4SE3%O*L/LVO9JV--Q4W8GHXVG\>D6<\\;J7/O8AD;>2!
M'2@0F6JX)9 [\*49RNJ)GKM+PPCVL1'Q*%O'%S"33C2*?&/Y8[ULIGJ+1#%J
M*W7IU$=M'2@T3+$28UU&BE>=9>X/73:FZF.WDZ%:KJZ:@B9L!>TX?$)<74'N
M,$XES.W?<M5G'Y;'?>E9T:(RWP;V@DD>P=TI9 *6V4NGB@^BFM1VQ=7S$P@5
MSYU2LW3NNS"WLC95(6]( J2;-,C<#@I=*'&E)G$ZPMMZZWG("7D$=7QID-_/
M038 YB2-;$J*VY7?<[_.^D#99D5G6\DV4REFPN1^ $'[/*=<\Y>TOEK0A/8+
M_7S*O2%HS=LBA$CA4<DF$A/Z=, 4>_F[4B,">[[(-DR7!+=.Q*]6O[&:=-N!
M&%19WQ?VHNPME,+#5 ^1'^)-2W#:(5@_[]M7;3T0&'=_I7B7@;%;7].SX9E*
M#4?(^/EP_:?'ZW@\]Q8GFAF_V'D3\2D>FW_B!L??PR%BBI8\G:K"-J_)ZKF[
M+S8_L:!->(SV:'3M8\)3',T9B*O"QBFE-6'?J;\BG]@]RL]+BQL_:(VC=:O+
M; ^.QD[]>O$M/&DK'K/(;F3JSH,61L9NESH>%<7WSO=A::KH-#YT*+/(R0E-
M#0#AT5I)4KAMIPS=<N*ONG+^> K=#)P5G!Q^^N;?4$L#!!0    ( &M(3U89
M.YSBW2<  &N- 0 5    <G!R>"TR,#(R,3(S,5]C86PN>&ULY7U9<UO)L>:[
M?X6FYW6R5?O28?N&6FK=JPBUJ)#4]ITG1"U9(FZ# .< U.)?/UD =X$D0-0!
M#VF'+9DDQ/-5Y7=RJZS,O_['MZ/)LR_8S<>SZ=]^XC^SGY[A-,WR>/KY;S_]
M\>DUN)_^X^]_^<M?_Q? ?__ZX>VS5[-T<H33Q;.7'88%YF=?QXO#9__,./_S
M6>EF1\_^.>O^''\) ']?_J.7L^/OW?CSX>*98$)>_VGW"R^^",$4)%4\*)D+
M>)T5^(@J&5URX.S_?/Y%"1.#,Q$*TP%421H\8X(^EH,M2G.6_?*73L;3/W^I
M?\0PQV>TN.E\^>7??CI<+(Y_>?[\Z]>O/W^+W>3G6??YN6!,/C_[]$^G'__V
MP^>_RN6GN??^^?*GYQ^=C]=]D'XM?_[?O[_]F [Q*,!X.E^$::H/F(]_F2^_
M^7:6PF*YYW?B>G;C)^I7</8QJ-\"+D#RG[_-\T]__\NS9ZOMZ&83_(#E6?W[
MCP]OSA_9S;Z'R>+[\6'HCL+/:7;TO'[B^<O9=#Z;C',5[Z]A4I%_/$1<S G_
M\O?1/\&__30?'QU/\.Q[AQV6O_W4'7??"(<07*Q0_.^;?]GS"X I3-+)9+D?
M;^GKTU]9P33"BM\6.,VXVI2SITYFZ<J')E4DL^[L7TY"Q,GRNZ.3.7P.X7CT
M<3%+?Q[.)IG>E]_^W\EX\?W--$U.ZLOR?M95^"\6BVX<3Q8A3O#3[-V,7J7I
M@I#2;_S\9KK #N>+44K)<EN(S(G^4"9FB%$2HXM4EIL27)97][5NPIQV82G^
M$N9QR8%36,_KAC_'R6)^]IVE");;WQ;Y2F;WW[^7LZ.CV72)Y1]A<H(CPXR6
M/'DPT=).1&X@FIB@%,:#%%9F;1KOQ'4,5]=TB8DONO1LUM&&D5K\Z=E7K$KL
M5$.N (4N7:'HC^_GZ2>>ST^.CI:_$\8+/#K[]U5=/CB_%K.&(EKQ@%9]7Z)4
M_3%ZA06[#O-'>M=QOD3Q9CX_P3PRCCZJO #$3%BT"&0 9(#B/9,"618VW:60
M;G_$)FP03Y\-#>6P,R?.MN-%SN.ZZ#!Y'\;YS?1E.!XOPF3D//=,!$.,= :4
M\A%B20XB\B@RDT[9V%B'W !E$_+(IT^>E@)KQIX/N CC*>;?0C>E!<Y?)/)C
MJW@P$\_':;P89>8M\;E D;;ZF+9 ##Q!#AE1,R^E2(V)=#>J33BE_GTXU5B,
MS>CU^W@ZZY8;<KI(IY#K7..:Q!!49C5@,0ILC"89YICBK;72=0R;4$?_^U!G
M)Q&ULV(7A#U8'&)'_M9QAX<XG8^_(.W)[ C?SN;S=[@X*)_"MY'7Z%!;!YI;
M!HH9!">*!)501B:C;>\A;PEQ$YJ9?Q^:]2G@9BS\U&&8GW3?+_GYZ*1QF7L(
M-BEZ&[B 4+2I7Q8T6L2L2V.B_8AB$R[9"R[!4R?3CG)JQI>WXQ#'$_+F</YB
MFG_<F!&*(E*0#F1PGB*"G"!$J2 DZPTM7$J=&[/G+DP-USP22 LPAD/1/(.2
MH8"3)$AR92,%PB1$@?TM;T@IBJ9,N$[W^VYY,Y[7[,=X4?/;=74OZ6VF-QFG
MJ0+B6>B2303FN::%809O<]7;.D<EN4;/>\A5W0!G2(F*7CG12B3-.-+(+ @6
M56 N@@N<HN",%H*K>34NLDH^>5L>0Q+X8;,<O3+O 03=A\$>*2^CUT8"LF+)
MKZ00Q]6D"R8;4,BL:"OV9;QV6LG+DZXC/3"R7")75H @UPJ4+1J<U1Z*5>B+
M%8)QUM^"3E$,U"AO)>U;[.]]]KH=>V?3SY^P.WJ%<5'?JC,LT3%?"H).DA,6
MGR!2  ^!HW$R.:YX:PN\'LE C>]NLM]]SYO)?QDX7UK8)3P,LS=9"K!). J7
M&>GR$B(I](#9"J^D;1VFWHQFH*9P)QXTVOMV";/Y'!?GZHA\.ATH; 93SR"5
ML:2..$%P/#&#7DLF6JN *P!V#C#"_+"ZL?17=2F^A,G2L5V\#%WWG;R&58Q/
M0O(L,PDE<Y*?)_GY1/ON3%0&@[#2MS9P&P$;DLV[/R]^B#":RZ09^=_-%DO/
M]NTL3.<?,"&A(U_S'2[.%H[1^>S((&=6*$S.9)\#<@3.K).&EQQYZ\3+G:"&
M9![;T:2M+-J42KQ(J3O!_&%5''4!:L1*8JZX#%(E 0H=!1V!*R@Z.+1%<:O#
M1I42-SUA2*9O=QFWV\QV=N]+&$_JXU_/NH^DDCXBF>&E1:X>VL579\M.NB2*
M,S79?$?+3D)!%"*!0*6,<ED[K5M;QNT@#NDHNYU:Z%-.;93$TJ,[9?7J .J"
MVV>HE$452K1 _ES-DW#R\+TAD-)2\"<C%KU99=4&#QO2N70CU=%ZB]M&4E<7
MR5.AG3()/*OE-P$=1&,#I.23)M^&:]6ZS.5'%$,Z-&ZG"W;<[8;'NZ%F*:^J
MHA'73G%!SFL0KH J.M:2JP0ZA^"83%(QU?R$=PV0+0]Y'XGL=]_S/I*_9RLK
M7+'H*%P)BM?: L'!4PP#1B?O)4>"TKH<Z:Z4Z?;K>G6"GV8?<%E;\3YTE]>'
M+*@8:I5RL8[6IS)%9Y$!]P:YS2R1[!JO[V8T0PJ3=^3"=98W$D'+<JK9"47K
M[\/W:FLI/#OUXM>MFVF'/%/P[D)UXP4#G[%Z]3(5YX3SS5.'6\ ;4M#<F#1]
M":D9B\[.ZDX!GF$1(?$4@P?&EXSFI+P=1?9)(BM":DL^>V/"K$<RI&"[,3<:
M;'TOQTYG0+)FK&2N@0>F*I $%* ),,RA"#Z@PN:5/S_"&%+HW)@ NVYZ;X=.
MYU3,Z"2I) C%$AA%3F&4V8$1@;[+G#6Q=8;U!BA#"IP;LZ#%YC<^<B+?/4N*
MW!"(;Z2#K-"$@@<P2I WGXJQQ?5RUM3VR,Q8LI^TAY"]K6)QGOPR:\$9E#*Z
MK##N\<AL"(=&6TGV!V?FWIN[AU.A2X>UR"P:1NYX\,F0-R4-O9?> 7.,HEEK
M.*US;P=#PRR=:,"&YJ)H1I+7XRFM_NWX"V;RL<+T\[BZWLL5$[I1+IHI&QQH
M[<C/5HY#K"F*J(L2W$5K36N_YG9$0_)Q&Q"CX?8WH\2JB/$B0_7Z'^_>7**I
M,-X'B0A"!01E'*FQA):^%#(G)EV(MC$E;D<T)*^W 24:;O_>3QDOX2R865))
M@E/!U(8 1%U=JX"8E2:$F$UNG6K;'N607.463D>_8FJL87['Q>&,U-X7BNN7
MA?LCSPB)#A*,]+X&=!J\4184#TXQ7;0-K=//-T 9WL%3 YVRVX;W<=AXB8@J
M"QYT"63@0B:]9DBO.:4(3RC%4BB?72\5F]>!#._8:2?)[[[9U^3^U^?7-^8M
M?=VDB]3'!?VY).:L'!QCM_SM.[>3NN&W-N\KM0GZ1@VFWG>S,E[4^\$CBA(4
M.8'T\CI>SR)=A!@LIZ!!9*.TER3+QJ_-Q=-W3ZB?W7-^3=Q?7=HZ&4\_7VS?
MKUAFW>E]Z$_A&\Y_^[;H KV&XVGHOK^A#9_?=)]&E2BX,I#)LH'*F5X?;1SP
M++QQPD;1O-"IQ^4,*3MR3_;]F-(?AO ;'@^= OWMVS%.Y_@K3I$V:L1M\#R2
MQTY_UJO8EIPM%S7H7#QW3"+3HA<F_@!ERZQ*O_?FF])HMUUOY]JLN%N9>$;N
MD=7"2!4X)"0TJC8S\H5,>(I%<49K#;GUO;HU,'9OC/0%IR<X'TE7E)0D*ZTS
M"<S0FES6$E@Q'K52)MO6;#Y[]I"4X*Z2_K%CT3WVM^&%]OGRWO3I.T0N)Z(2
ME@(#S>J!BI01O#(,?-2D4AT:*=O?8K^*85#*JK6X=]KP=B<$N+BT'F-$1"T4
M.%T;'<5Z%YD6"#9S4RO;53*MW^PK '9=S26#@IFA,CJ"PF+HCU0[#\8,DN42
M+6:;0VOG[R:O^&'5U/TE?)VQ]]S=?KBZT8UZ9XWD)@A((1%6FPH$[CRDPK0M
M*3K,K;-)6X,<E))K1Y9^A=7PA'0ZNZK83_7Q2*I"O%8.I*780=6;%T$Z!*D-
M2LV]RJ6Y+KP)3-LH^Z948&;!D_MMP/BZ8L4*.)4L^1T1R2/14C4OC=T(V*"T
M:1.^W!X(MY!/\XK'LV46U%X[2_H>(\75$6O%52+-+V-@F(.RS>WJ-0C#4I@]
M\>'^F]Y,\O\9QM-*R8/I*^S&7VB)M2WA?-$MQSK4P^GW'2["MY'V,9N2)2#7
MO#JN"BCJCF Q)4^+9ZYYI+ IMB'5"O1#E5ZDU%\AP9=WXS^F'8;)^%^8S["/
MO))%:B5!DJ3)],MJ^DVME3+&:Z6-L*V5RF;(AE18T ]_>I!00]MS9OQ6ZZWU
M,#H9C\%EX)Q3E!PLJ4)D$FJ\S9*2P38?B;$&QI"J!OHR0;OM?=NSXIO76#0Y
M19&\()YH>2J@A,@3 A9TN@3.A&I=BW0[HB'5#?1#C882:<:2J]4MUZM@UB@T
MY[DEOEI(W-0[1"5#)'Z#\ZQZ6ZGV+FO,FVTQ#JD.H1\F]2JU'E/CUH0L R,4
MG%PI4P*$HA2A$$5[(YQWK:][W9X:OU>F],NXCG*CO5YU'^\PKY)[M$#/ VI-
M\:5-2/%&"AE"SAR$(UPE*FM,#R4%-P,:4@9@)S:L2:DV$D/#^2=SI%]3&UV]
MPB\XF1U7)^#L;1<417CG"0BWM%A'+D#0SD!&[1*SDJ+2UFKS5D!#NB70E!GM
MQ-"N!/BH-K/]UW(K#LKU8O61U%$8Y4DWJWH8QFV]QL R4&!)?]<.RZEYN>^M
MB(84_#?E1D-!M,L6X93<@TF]LIV/QM/Q?-$M<Q%GC#4J)6D4UGZPFMP$'R!*
M1U$$5Z5@L3HT3R[? 6E(L7U3>K041=NKDF^.CL.XJXKLY6'H/M,ZD^$4-B8&
MV=:[#$D8B%8+$"AS4JP8CKW<.?P!R9 B^K;*8O>-;UP?UT_!G]0,0RD1)$N\
M#OXU9!)#'1(L4:F(/,1^3Z]ZK/9L>:Z97;W805ZD3H7>?C2T1<9+2*Q4OZ&4
MT-Q,[Y0KV9=?/Q1N_GAQM(4D>ZUOE!BBJAY&4+&V?D\"HK<4FENG!%-"8_.)
M4'?6-SYL*#!4,NTJO8>Y";)F,MI50+M="5GWZWN]&W+G>AI=$EGSG(MI<DZ[
MG- !8T6 "CE"5(I$+XWUK$X(8ZU3/+? :3".Z:9??:]1+.A02*T=)!D-O1.U
M!2=21$6!E9%&HE.R=9JC\1*&9%I;\7#-Q*<'DWK;\ZT[9C]NLPB?9*+_,-K!
M>NO!LDB+2 F2IU!!6>2NG[D7[98PJ *?OKC[D&+?*W='4B47A8^0L?:QELQ!
MX+1+LN@4LT>1;>O3DNVGT;9=^T4ISF_?JA["7#\XFZY.T^NH3GR%J[]?%!+@
MB_P_)_/ST75UTP1/+N1ZU"YJQ,^X)-^>*6"N,!^9((HUOS+4YX*&9(Z:LW:;
M=WN_U.C]3;\XH_VOV:3:VXMZM$L'N]UX3C]Z15^20:8-F.7S?>:R6*L8@E_V
M;7/.@<_9 B\4P&JF,_UO3T3?=2U#"D ?C.-[)<1>#-D'3),PGX_+.*VD>?Y&
MUMC^Q<'+-Z?U"@?E4G^5L^4XIU'PG"$K6_MZ.P'.)0]9>BD"4S)CZW1;;XO9
M\D"MY_MX#ZG%]\>)EA.+FP9+0E&X1*\G,"4"*-I;\.1K K,A*,TB8[QUG-%K
MB+S3;4,?LUN60M;17\0S04% +@4P""FB0^E=ZU$9P[QM^) LN^6^XC;RV6]T
ME),FGTT8<)KP*%8HAHPV N8HM??.*;<O_^?FZ.BAZVJ&PZGF,GV@C'J8'[Z>
MS+XV;:UT\4O[S9ZOQ]XH9UZG]-$#EH5Y]-M^_?['O#;F?#V>AFDB%KU(%+NM
MAJ=&YYBL=:A6F]HXS];&>:D -X@2/4896BO]S='M- CL??B^W&QR8E[5\I'Z
M2M5#JT^SCR0D/!UU3O'H']/QXO2KD9%>>5>OID5>QU9I#ZYX!URS4!+C,5R?
M&G3#9+#[/'U+&]C[+>H^.'1ED%CO(FIF!L^0?IK]/I[.NGK;Z!+"D=?2.1%U
M[3A8BUQU 6?(&=;.^&@H_ NQM1]Y.Z)!I9][IE(/,FHSBO "T'HC/E\:XA$7
MT0>F ]EN=*"$EN"\Y\#J/:68N-:HM](YMS]O4 'P/K5,0S$TY<=!>36NJY_F
M:XIO9 JSR4<)W&*=;&XS!!,S$&U#D/5^DA+;,./&)VU91OID.-%FZQNQH9LE
MQ+PLMKF!J.OKZ4>&,Z-USA!+JI.8#5E$KQPD6VS(R!-+;C.:W!?"D I/]T*?
MO<AJ;[Q:*4 *&HNMT^S05"N9=4U?%P%!1LURB(YM.$5[TR<.ZI;I,%BSO23:
MD.0#'I]:R8-R>4;5QW2(^612QQ^N?CR2(J#S0@'Z.C64(P,7D@/:BZR34H)?
MG[1R TLV?N265T@?OW'J1Q@-+]>MAS?R7$LM'(+VKA[J^MK;1W@H0F0AF.9!
MMRZ2N G+)IQQ3X0S3>72+F*^I.S>S.<GM%2\ABOJG+13!4H("A1*6V</>UJ[
M)!9KQU3SCBEWH]J$.?YI&*6>1-4\Z4)>.F$X0[:\6#12/ =#6@^,JR,SH]2U
M:ZF!9"2:Q+A#UKJSW2UP-LK<L2>F;UJ)IU>5\V9*"PV3]R=Q,DX'I6"MUAC%
MR%(66H!FM?^GB *<0(KUA>4Q*I^R"7O0/&O!;<2E/39>?2@-M+OD]I3%^[ Z
M^EG.PSLF[EMEL^*Z )..0CQ.[IGWS "/G%9AF?!^PSAJRR=OQ)RGDO7M7S8M
M>_ZNVXGS>TR7=T)ZRQ616G!?&]S5X9K!JMHJAIRXE'5I/GYW<W3-TA#U>2])
M4IB6QSWU6RM!T4-68R4Q'UPPY6+2Y'R4C9$LD"5A.4I0*A:(RB:*E*71P6E+
M!F;K),7]\0RI;*4GFMV8PMB3%-MGP38#_D-+"LZ225&03\,5 ^5J$L]+!2S6
MD<^HZKWVGJAWGZX@^ZIL&2;M=I+>7BBW3/5M^L)(BN"]JGE '@2H$NG_29.A
MY,"%"\IRL>%)4#M00VI-,P 2]B;/?N*C4P_I#.<H8L&,OC9'C35)%"U%;!3F
MBZC) [/%!6P>4-^"9TB-;7HF5W/Q]*"^B.IA41OR7/!Z;:OFD?':8A8%0M*D
M9H4BG,YK4#JC#49HZ<WVBFK3QS^"<\C^5%(O,FH;0[^>=1<PW\_FBUM <IZ,
M*!KJZ'""Y@ED-@BL^$2NH[;";>AM;?WL+<\E'R2,;DNC?L73.@]3L])D5!>X
M'IKP,C!6 M2I @0M)? Q&2*ZTUB$=]G$K9ASUQ,?PP%E+WQI*HJ>QW*?%_H<
M7*TU'17CN;:>'#"*24%%3QB5X! =LR87QV+S^4K;(=SR+/,QLVL/(FQNT ZF
MGV?U'NA%D<_'1?B,KT^F]4['2$GNZITX\*'>=*X6UR&S$'R(P='7XKI??;<=
MN_V16YY@/AUUU%88[8ERMN:SUHCU;A?.:^?D,/F(W9=QHEU #%8K,JPAUEGV
MABMPM?"0RU(X_4=:MK7?L]&3'\499F^\:2Z;YL.KWH=QO6 ^*LFJ[&E]43KR
MV>6R:YK)P +]P',>2_.9;M<@;'M"^:B9TD(,S57)'\>T#V00;U!S6:.P!AE(
MQVJN,P0(@7E(4CB6>2CV>NO[NW7([8]\%$>/?2F/AM)H=U.^)BCI?]63^A(F
M%>D'K#Y3HJ"N_H!TW-5O7/KDJIO%]58NY_=4?_N6#L/T,WX@O_^W4C M1H9Y
M3MM&[P!'62]/%+*I2D!V,I)BM,[XUM<(][O"/9X!,X<^"B*B#G5B*5<./'I3
M"_>B<<G3%K<NH[SO&? #W],?+L?73)+M0_Q]ERBL8J^K^&PAY]GH !*E(W6&
M@N(LU*3.I+0Q62G$GFX,KT$WI(/1QT_/7<7?-SW7U1(EX037]/H4OSPHJ3ZZ
M=@A69K*_!46^7GWU8!?:'WB:QZ.GYZ[B?PCM:;2PL40-HHA:2%T8N%1;5A>=
M!;F?2:<]%7C=J3UW.V#>+H7W 1<GW?2@O S'XT68C.K5E>*-!YYK S61*>:6
MGJ(K9H+4T7'1W)]L!GY(+E)/S+SMZ'I_@N^AN\.+1.@[O#[%[Z+_V?(VA$/+
M@I(><M!D UGR$ L2W"Q+21Y)L;6>W[HEQ,?0_Z$Y"7N48NLCS%.$/PPN?O?N
MS2@QM"'G %89,F':U8.,G""PP)*,A5FQ[?GE+8][#.T@6C&E)R'T4J"U:KQX
M!X71>JN<EL!BK:,M+$*LLR]X")[02D_?ZM%,;H+Q$11R]6D-FXNQ/Z/W>^C^
MQ&77N0MXHTS>-"^& 2?= LHH>@44(]_=T ^R5#XH[-O4K0.V9:77HU9;_4FL
M-\U%L>/O85$A?3\H:V$6XZ+0P4!R%*TIA8FLKT]@I+5.^6A4:5UVL37(1]"@
MHF_=U5:0_2FO]5''?)2<,S8I U*2]58J(,3,3>T6)YQ(7,K8G&8;8GL,96.]
MJ[ 6<NN/5:L,$UZIW,?$H^8(QH0Z:2Q'<(J^Y";PHG02BK6>JK0!K,?0[Z)W
M+NTHK>:G]+^/"<)B-B4<+C)7@E'@Q/(^O#?@#7(0(?O@>6 <-[RVN.[7/X:*
MKUYBN/MO<OL[$A>=,]8&E)C('**1H+D4Y)81PFAU *,-+S+3#X7<C $;/W/;
MBJ['3XM^Q-&??5G>&;ML]FQPS'&)X,RR58^T$) +L(B&A]HYP[J^K<MU4(^B
MW*MWX[*3J/IMD'Z>72BK[,*R5]@YW3_6C>V^S\KM'WM%COUX<J]>ZDV?WZ3M
M>G\[TJA#^_6$T-4GOSBJDP#^5<=JS1>_AOEX/A*F",\Y ZDIP%*)1?"226"<
M1&&<8%ZWSO1MBW%7[7C'\U(Z.:ILP/R?W6P^OYC15,<6K"81U[D%9.6=+"J#
MY984.T,-T6M.?R FR7@)S6<5-0$^I%/#7MEY7=/N7^S-[/E]H==Q8A?0K4R\
MQ*!HMVIE1%$1HBZUJMS90FL2)?.!,/8*\$&=,3X*RMY?[KU1]NI)Q)6TGD[!
M^^HM\7HFNFP_RQAHU-XH"K&]M#VS\B9L0ZJB>E#>-1%>O[[IZS#N_A$F)_@[
MAOE)MYI_$Z;YM'8K3"Y=%SWK;SLKY__JO\;8$;3#[SNXIZTA-/%0>]V7'9W4
M92R]:IMS_L!7XWF:S"K2ER==5SN9:U=$XHE#,<R!LAC 6<W <"NMXD4(E>X2
MS49/:G$5XL7T>@7CFN>-2LG*<(804S&@="2-;*0'FY&)8G-PO'5#VHW!#<$_
M;$^,ZQJN'UDULYZ?NE#+6Z\=W]O,BH\F@-!:UCM$"*%.3L-H34*IG9"M2X[7
M AE"\7O_%-E=!GMWILZ670Q''NK4*IM<33HF\$E&$%**J .*B*T'HF\)<0BN
M5?\4ZE-NS<AUT5%CM1=G8'Q!'[*RI/B$!A5UAN@BJXGL*)TOO.C6%3DW0!E"
M:5?_9&DAAS:G33<NLS:_/44E3; <:T\Y0T&%"HE!L!14EJBL<\YS;7;TRBX>
MUJ91RZ6#F7^\>W-I*2)PR8RM&VPBJ?3LP*&I%TBR,4&FD+#U4+W;$0W?!;LG
M$=:W7VDBF+W;VDLX4_+1*ZW Q%)G>'D/P>D",H0D8D;N=.O:G^U1#M]I:T2J
MG@78F]V]A,?1$WU6$8P7M<" D,4@#92@HXK>%Y9:Y\1N1C-\5ZT1<1H)I.<\
MUUG>YK3C_ KJ^4GC^A_ODM3:Y7EM,EC-5MQJZO5L<=9WMZJ959,6Z675'<;6
M^5@Q9_"QD!_O>7'>6=.^J>V/*';R^=9T#WXQF<R^UM*6VJZQPSQ>U*.PEZLS
MA_J6Y/\Y614IU$S*^0=^^W:,TSEQ^@MV\S 9,3+B"M%!Y+4F(AH/,3-ZE9">
ME&,*S&PV=K8WB,.:A[T;NZ[4*0U#J&V"DG7MK5^4!78WK&AY+WS^9EJ1GUTL
M?TV?K"6_A-R@@<!=[8GM(P54P=&>2J:SD%[G>Q/R?I"&X)OMB7][D-G0^(8Y
M*'(2"J QY#Q(&<%GI.V+"<DML=H$_Y!\Z\U2W+PE#!D3B7'()M)&:.7!Z>"A
M%%=\24QFO=EPSP9@!J']'Y!R][08;83;KC7&5;6U+(@8E1"5]E(#%PII\;0#
MH8Y:-V2J E?!E-PZA;D.QQ#4^P (UDQ4_498%Q-=KD049 @OSL=_^,SY(+ =
M0JTV#VX2<_6P!XV"+Z(P$?QM'3MP??1.=54X:9XB:V3.ZC$*-PJ"2A%RCE(3
M.3UCK?NYW(YH5[UVRV^_5/]U6O^S%/6(%ZS#"P/X5!,A7B9PRDI@2B27"BM9
MM[XYMCW*05C='DAU7=GU++]F]O,6G"L%;;07F?,,8AD$9"7!2>TAH?.R]MHJ
M8H^L&HQ=?5@*;2^:?FWGK[.NFWTE!^-2+=G%]W:PC9O]XB:V[QYK:&3;KD["
MSM+Q;#F)LLXJM?7B6"1]8+3-OL2HM6[=P.WF\>2[K>7E>18].N6S!4[1.KT$
MUD ,F($KBN(EYB12ZX:S:V ,X71U9XE?UQ&[;G<S.W(9R*4#%"]B$3P[T%S7
M%))!")$ \<"$8FHYW+U'T0_K&+17Z=]STP=@%T:\-\M OWI_MN'Z.OJP#LRH
MH+6A^%OP LJ)#,X5#\8Y9EG,WO?Z/NU^]AT7%X7G?TS#V?V%>J@[.YDNWG=X
M-#XY>C'-RX^>WK%>#LVH[E3,RCJ;$FA=DPZ!E7H[5H(Q*:)7]-ZP]@?D.T$>
M5+QS;RK]>&2^/SDV++RX#/IU2$CA%V$=1;0VR:3 E1IXN=H1G7E'3GJRQ7$K
M6&E=7WT3EL&:J79LN>?&[]]0?<#CTTOZLU*7$+__7PQ=XV#F]H?T9KRV6%LC
M,W:5!"]#UWVOW1161&"./!7C%40AZV4+Z\'5#MZFH&'2L=I)H]<W\"J>EL[P
M:7>SY<CFLST_*.^[\32-C^LUK'>TP9^^XN0+_CZ;+@XIK&?)!BW)=1>27C5Z
M%R X'B$DH0)MD'"\SW!I:\!#"JR:L>PV5[M?D?82DMT)N;[^G[[.1ED$Y$IX
M\+(FK$R(X*W@D&4QW)809?/^\??!.20[.0S.W4> #T@UX@Z.E+*9F2@A^,SJ
MN$0.D?L,/"E&4)&SYJ-1[X=T"+6P Z3;UD)\.,*]GIUT(\L=2RY)2*I6KR57
MP)M([T9A7J042#&WOO%Q+Z!#N/@T/+IM+<('9-OX"XZ\\BEX$T!Q5EN,:@=1
M9P?2!FL46I2N=:^U>P'=LM7UOPO;MA7A0[!M6<1SCE:5N)Q !$Q@!(4N@_>1
MOI2(/A<IBVX=1=T7ZY Z7P^!<_<79+]YD=]"-ZV9@V/L/M*/<(?LQTV_JDF.
M8R.<K>Z!(-&%GHRU5N[\UMFGV<O9T=%L^G$Q2W\>SB9$X7GMR)-&RFNM'$]0
MO*O']+6E8XS+MCRB%GR(I%HGK;>$V* [?UF5#HZDEK+> H"8+"?JDI$./"9@
MD1>= _?8/'Z\>/J0,A%]LF1-4_W[['_+^727UKI83=]:+;<>2\ZF"]HZ^L>?
MSTH%1VA4)H?- TI.00-S :+,]9S2>!M5L"ST,.1S.Y"#ZC^W3SKU*\XVUS1N
MP?@^U%-P,JVS[M/LH!3LZI3L*)/P7$F0RF183L,AWTZ#S)8"V.)"]IM-O=KV
MR4,;@-4[C?J73T^*Z[;M>#6>G"PPCUP0Q0HOP:J:[= UVR%5@)PY(I<Q2]^Z
MQ<[6(!N:<^.<UM%%0&5U[298ZK"?*A_E2^UWKYOW#GWLYOP^3+G%H&\C@0=2
MK3IRYR(+)$M+P 2G5]>)>A??NX#):A\W&S[1AVH=H(7>A2']2^@!O4(38B*D
M$5RV 92MMXNLK=.<@Q'!V<1S#\.+VWN% S3G+;12OP)MQKM_+K<>\XLOV(7/
M^.[D*&)W4$YW8)D>F!^<+.:+,*V-_D:9L+A(_H99CH)BQ4*TI6Z)*R)SJ:1M
M?=Z^)<2>=N2'YZQ\/EMK?;@68'4F95%<!L=] <EB#(F3XFC^%FX%<$AN09]<
MN_[Z]2?%9J\>J8=5J^$P.55!2W!7=<7R>P02\^D0E!==5R^<KL:>%*>-B,+5
M.2<*5 @!0C8&HC#(M%7.8NNW<7?40RI'V"<E]RSOOB\ YW&':7%VVWFG*[WK
M?U6C2[H;X&R7ZUXW#>G@F+AU?1I2#,A\0K %L<XKDN"8])!,]3)E+*6T/GW:
M'%WS5I)?WHVOSEU8!FL.0Y(E<JBO#?D[Y'&[8@J48B/]EZG8_ 1N,V2#*D/O
MB51W=IG<76;-#&5]^KP^GG3Q]+=O==4GX_EA58D'RX)<<M0-4U@\.%,==<<-
M4*2&X#TW(6.L+:@;4^E.4$.+M_?!HK:2:D:@"Z-*AK?VZ%K=(6>.6[FJC+&T
MTCK1-D@C@,4DF>*%Z=+ZMO9Z)$.JF-L34QJ(I-TDR(L$HE#,1BP11"H"5)2:
M_#MOP?(HB@A6Q.9%EMNE</=5R;8G&MQSZ]OD;I<..5'P%:[^?C-]D5)W@OFT
M5\M%^YV1-SJ(&#,0B%"[!T2(T69:<DR1,2<3=W?YN5L^<\M*LT=M/_H41S,U
ML1PZ6G-WM!&KU-YIP\<1"JM#(ETE7 IUS%,]CI,.G!5*2"]R":VUQHU@MBP6
M>]2T:2N9OI1*W8&7L\F$HE#:,7*,UG48&[EZFUW* (E<I)I9<!"$74VPS<)&
M)\UFYT+W!+ );^S3,#Y[DU,SU;.*SG['Q>$L7XP]?C6NVS/-\X/NU7B^RB)5
MY".TV3+A$S#.B?5,!?!*>\A*A* -_:E;%PQMAW 3LKFG0;8]B+!E1OKTP*H.
M;5^/>#Y*QFCM"J$B3XU"N-K@6+, )9=DO72.Y]8WP#<"M@FI_!.S?.TEUFY&
MR*5V;0?E>E.N$8N%9=0:A%&.5EW'.,FBP#C:#Z&(\:+Y2--;$6V4]6-/2RDU
ME%'+:/S+>$Z 7L^ZI6-WT6N55BL<U\9K1PX=K5$I6>H4D@PF(BJ>>9:N]8G7
MK8 V8LT>ZZ[V%+0WDE!/RN;<<5OV4*E]54X[K<Q'L6!2%#Z"\<@I<@P, D8#
MVD=ON30JJM9#*#;%MA&5]M;A_B$44".YM3VAOYZ16.)Y'[XOVWY/\VF.XNTX
MQ/%DM2$J1\&M,Y"*)W-K(U:L%'G6>3LQV&)##P[2/9!NQ+@GEGC>@TQ[Y-]*
MW:Y:UYT::<>=,LO:E> JLJ @&ANA*&MXS#YPU]J1V@371MQ23\\=;RNPOG)2
M2UCG+<EK#'$INYI8BKQV0T27R>W#VA-3Q4 Q@[!".U:<NU;3MG$JZK;G;L28
M)Y[Q;B:7'G706<'JJ;Y<#K]A)493,LA2LQ56!7!&:=H&9@63PF7!>M=!/^+:
MB%'[NCG]8"IH1WFU4D%GZ8@5K0D%,7L2YO-Q&:=3_^_Z5,JKLRC/BU!R0"%"
MM*!9D;0]Z,@,UQY[@4L9LU(9-TV5-P.U$=7LTU)>#R/19IKMQ_*F@^G%>$NR
MTUYXCRJ2NJWW0 )S$'VP%('X( +WI'!;IQKN@+01R=P3(5D?8FJ7;ZBNW)NC
MXS#NEGTP#D/WF;#$I$RJ4]^\4Q2E>N4AD%,')D1G IK,1&O*K$>R$5/\T[)\
M#632QM:MX^GY!-:+YBD$3?&4F.4@1)U:SP.#&(0AUX[5PVDE7=KLFO6F3]RH
M)I$]$072GRSZBLK6C^D=&8/!F6S ^:KABA>T>,'!%Q\4T[9>4+EG/+;^B1O1
MY*E40/<GBZ;-N"^\INL^U;D79824/C!6YW_6>;.T\)!J)R0C8@K&ZU!:WS_?
M#-E&?'IJM= ]"&W#*SVGWZ]_1.+RW__R_P%02P,$%     @ :TA/5E+_O^EF
MJ@  S&$' !4   !R<')X+3(P,C(Q,C,Q7V1E9BYX;6SLO5N76S>2+OC>O\+C
M\SI1QOU2JZO/DF6[6^O8ED92=9V9%RY< A)/,4DUR92E_O43()/*&YFYR8W-
MS&2Z5K<LI2CB0T0 B  BOOC7__GE;/+=9YPOQK/IW[[G?V'??X?3-,OCZ8>_
M??_W][^ ^_Y__MN__,N__E\ __O'M[]^]],LG9_A=/G=RSF&)>;O_A@O/W[W
MCXR+?WY7YK.S[_XQF_]S_#D _-OJ'[V<??HZ'W_XN/Q.,"%O_NW\K[SX(@13
MD%3QH&0NX'56X".J9'3)@;/_^\-?E3 Q.!.A,!U E:3!,R;H8SG8HC1GV:^^
M=#*>_O.O]9<8%O@=36ZZ6/WQ;]]_7"X__?6''_[XXX^_?(GSR5]F\P\_",;D
M#YM/?W_Q\2^W/O^'7'V:>^]_6/WMMX\NQML^2%_+?_C?O_WZ+GW$LP#CZ6(9
MINER !H^+[_]PZMH] _KOZ2/+L9_7:S^_:^S%)8K]=P[A>]V?J+^"38?@_HC
MX (D_\N71?[^W_[EN^_6D@OS-)]-\"V6[RY^^_>WKVXC'4^7/^3QV0\7G_DA
M3":$>/4-RZ^?\&_?+\9GGR:X^=G'.9:=Z#=3KJ!TA?,_ZK?]T!O31P(R3^<1
M@7Z*TVK@#3%N^_;^F+]]%V0LX7RR;(CX]G<WQ3L["^.6 K[UU0W0KKX(SO L
MXKPEU&O?>P7G!N1-A//9US"A@3^&^5GX2YJ=_;#"]W+VN0NN^:?Y%QI<""[6
MZ_=_K/_AE8%)P^/IN&X:O](?+_YU'>, "/AEB=.,^?OOQOEOWX^30)]4T$K(
MK#2S,23TF86L#0O,\]'Z*RJ6#9K)+%W[QDG=T&;?AIF$B)/53T<9QZ/-"?-J
M6F:$[6(2^&J)9XN1=<)EF030\(I^*0I"% :"E5H3%AFYO*W%Q<8J%IC^\F'V
M^0<:YX<JP?J;E2C7>KQG]+6$^\WJ/7UV1,)R4<< QG*:19(10M(&K'',>Y)K
M$+')+.IHUU%?6L:+^0;_Q?HX< '54W\ [2UG#82WU@S!__Z[V3SC_&_?LQ9*
M?#&=GH?)6_PTFR]'PB?+I ]U6]6@#,W'L2B!Z11]4+16;&BBS*NCGI!2#Q;F
M;>7R%LI]@_/Q+/\\S3^1?SLB/"F;0(!,<: 4)O#.T#PS[7TL>,64;J+=:\.>
MD'H/%^=M_8H^^GUY/I\3GE_&BQ0F_R^&^0:30QZ]U!:2X0@J&@_..@DIT '/
M7+ IB%XJWC7R"6BYB5!O*UHV.6KG@1S(.L^+S24+S@UG'KQ(A"F(!,$D"T5K
MFF?Q7OO4YMB],?()*+J)4&\K6O51],_3Y7CY]9?Q!'\_K^(8!2--E*% 49S7
M/04A9I.!*ZE5L<J8F'LI^.:()Z#87D*\K5#=7Z%O\<-XL20[6_X>SG"$J(N.
MC/R]$C,H;1!\,G2")!^D-@Y=* V4>GW4DU%L#V'>5J[IK]Q7TS2;T\:QFN2[
M)1T5+V?GT^7\Z\M9QI%$P;3"0FZ]MZ"\X.0>*+(]EGF6ILC$^NW0'4"<C.K;
MB?JV)=C^EO ^?'F5:>;C,E[?;U[L/XYSS$8QL&M@O-#^@P*J1U%R29S+?O'4
MG<.?C/9;B/>VWEU_O;_(>8Z+Q<5_ZG3YB-.V8[PWH%5F%/9Q"]%9!"F1B>AB
MRL$TT/F6H4]&WWW%>EO7OIFN7])O7\_?S_Z8DOD%9F(1((Q+= #1=)TW#$0T
M,H:<,TLM5O>M@4]-SP>*=,N=2:\;L6N85F?,Z_F;^>SS>)IPE+D)9'T*F(X&
M%!(FEU,"@B5MRJ7$Z-KI^L;HIZ;P/L+=HO5>5V77@+V9+99A\O^-/ZW<"F&+
MY#&9U>L(*%F0YNH+)%1%2L530MM.Y]?&/C6-'R[8+?KN=W560<TQK("PXI5&
M.D],8>0]*IO!68&0E<) =E<"[W=67QWM!'1ZL/"V:+'7O5C-(YB\^3B;;B+]
M@NA\0 =))PG*%0<>G8;BBDJ*&9%EO[5Z<\03T&8O(6[1:*\+L'>8SN=D7ES$
M]^/E!$?1A&@IM">'+\KJW%MP)D40 C.%]XD'W<^[NCGB"6BTEQ"W:+37#=C[
M>:BI5^^^GL799)2#5#9$!2)93E/B&F)1",5:P7U((7G52YW7ACL!71XNOBV*
M['7;M;&JG[^DCV'Z 5>W;U8IEC$F(*^\)KMQ!5X* 8A)N:A"$M8W69Y71ST!
MM?86YA;M-KC!^@=.)O]K2B'8.PP+.A'RJ\7BG(Z$%*W36.>5#=E=HE^<3!RX
MLT5X@TR5%K>8.X8_ 7VW$^\6Q3>XPOK/V>1\N@SSU;/)?#&*+DHCF0/D/%,L
MYB+X[!Q8IT2,%*2EQ!LH_,:P)Z/H/N+<HN &]U87S]KK)\YZH%#P?4[3Y%HF
M6Q@=(]H!.?(.8F0*M"2T7"AI=+]DD+M&/QEU-Q#NEM20!M=8KZ9+G(>T''_&
MG\(R7. <>2S!.:1(+=:<I" 9.)<Y1.V%(B<_6M'B2F/[Z">C]0;"W:+U!M=8
MJTWG95CBA]G\Z\@[="PB!QV9 94=^1=.T@;$2K)")E=D/Q=MRZ GH^/#1;E%
MM;UNK-9XWIV%R>3'\P5-;[$8.4GQ  T+/"MR&%G)!"4SR([Q>O,BM.P736T9
M]&14>[@HMZBVUS76&L_/9SC_0(?'O\]G?RP_OIR=?0K3KR/),*N$OOH+A3R'
M(" FSB%(Y[TE]["X?JE\=PQ^,JKN+]HM*N]US_4JE?F+\SRF3[Q8+G&Q7,WW
METGX, I28J(ID:]8:)/1&<&I;*$P*5416L72[XUI]]@GH/!&@MVB[P9Y8.\^
M4@"X,3]AK1#D^X-7-<V06SI'A$V0LXL^!2.D:Q%37QWS!/3;4Y!;]-H@!>S-
M>9R,TR^365B.N'0H+?G[3$9R_QP!B<%9R,(8\@LIF!<M$C^N#'DR6CU4C%N4
MVN NC,SKK&:9S=(_WWT,<UR\/E_6JM=Z'3M*W&%2WH.3G@)Z+P/Y]R&"YKI$
M13(0>4OMW?YQ\QT83D;MS02]Q0YZ78UMYKRXS#O$_./7MUB0(KV$[_'+\D?Z
M\#]'OJ"/-/EZ54LHBU.UYMN",:BU"45FT2]-NS.4$["*8<2^Q3A:7*L1SGF8
MO)IF_/*_\.LH:5:\]A:8H,U*!4%S+C3[A-+X5*0,H46"T(UA3T#I_<6YI>:F
M26GD9270+_03BA3)B4Q*<2#?@F9H5)T<2K"*HRA6173]#O@= Y^ DEN(=(N:
MFQ1)KC&M:_O6J IGT@CR)GG&6KEI*#1$GB$Y]"F:H"SO=\;O'/KD5'VH6+<H
MN]<EV@N"E%>P:D"(6')FS$/Q+M0['_(MR!!!(EH=@A#%](O K@UW DH]7'Q;
M%-FD(O+*]-Z'.,$1,R%$2R@L@0#:4QRXPC342EQE&"\8VRS:FR,W5.\5[IDC
MKM1>HMQ6N?[=FE7DKVDR6V#^V_?+^3E>_G V79(?]_,$Z]A_^WZ!'\YN/0YU
MMXGS!7P(X=-HE5-<O^CE)"P6K\LJJGCQ9;P8\4S2<62H&#Q9*V<)7"9?D6+,
MK!ACJ.]\!BEA$5?*NAAI;1TX62XV/[DTDWO!-+25.SB![K6= ]0\&T+<#6D/
M-L"NXOEIM5MV0C2Z05+4R!!NHVEY&.QB6+K4?V-US0:1]7&L0'F6K4(!.?*:
MKAP(6?(<<LKH?+;.Z+O._,>L_6M\50^H_'U$/(325]=)*UPO?EMY2"/)I)*T
MG0%3)8.*.D&,6D+V63O'N%;EKI#M(*7?0G$\_Z^5;FZJNI]@&S(7;4'TXP4B
M)Z5,VA1@6AI"E HADHE\5*],U#X+<U>^>$]5_WAZJCY$L#M7];_^<$,BY+[^
MLP>[W'0QFXSSZGXP3"HAY;N/B,O%=1Q=&>=V?5D;%KI.4&\PTZ$LUD06(P]1
M\4Q"5MY&4W1QB-S[T>ZO;>1&7X87A2F'3 JHOP&5@ZT)3A**2HQC)49)K0_.
MVRCZ;A@O%@L2SHM8^2/2<N2T31*EA*0,S8EQ!2X4#IQ<8EHO7G)S5[!XR)RN
M(SC^1M%3LS<WBAX"'> \6*.Y2,3[!BH)73-L(^B<*D.7D^ -L\"MM)SB8L7-
M77?RAVOY!I#C*[N/=K8JNH]HAW#UPN+CBVFN__GYO\['G\.D/AN]6+X,\_G7
M\?3#?X;).8ZD\9@3-]5)H8/0&PE!59_%V>BRM3F4YBY!%V /90^]E'C346BN
M@0',9%-#M:ZY&>/B)XPT;6-+-!F!!T$.34TN\!8CR)!92LP;=V?J^R%FL17(
M*9A!?PDWI$;<@/I]ML0%&>>OLS!=O,6$9)YQ@K_C<I.JS;56Y&,)B)XI4%85
M""YDT$*3TTR[),K6Y_^]H$[!'-I*OB&98G7[1R]2FI]C?KOVU"_AC5S1WF=F
M0)H<:AD639D)#J82Q!6CN77EOC#BSA&>LF[;B:XA9^*W:7X.XTD%\LML_H[.
MH.L;T>6?-N:GE4FN,@B5H&AG*A06>XD&4D+G))U)6C1W_/>#^)1-Y1A::<C3
MN++LU\N/.+^PZYIW=(:7UOUMTQ*)L>@<F%P?/&W4X+&6]W@>O9;U%D1TVA\Z
M#/:4]3^(0!MR-VYFO()X;=HC%KUSVFLZB)2E$ DS1$P,C*Y)XX;B8FP=*]Q&
M\91UWTBV#?D9M\YQE&201<8,3M;7<D][34@%(=)>XTM)PLB[&A;TOA0X!1T?
M+M&&-(SW^YR_SZ;I F-@WAI>%""S@DX8QB!D:R#XD#!BH*"D=<S7!=>3OAEJ
M+O@!0L%?JD#QU_%GS*^FRS#],":$:QD0SE'2RHD23(U&))U#="*1!V(AU>N)
MK+AV\:XBNT/,XFY$3]H@&@J[8>BW05>OJ99?+YW/7_[S]U=7#%6DF+U*!6Q1
MHF;#D \:K ?R1*Q3W@IM6U\6WXWH29M"0V$_8-1X!;%B+J+A$H2W9+QDL^#0
M>!#*Q9RRS3S>Q8LR9.!X(B8SL%(:QHW7C?PW7'Z<T8;W&1?+5?7**/"D=-2:
M/*!:4AZ\!%<<(_?7>UU"*%*R0;:26U">M$&T$.^PP>-54S2"25_9NSSW-2&F
M0&!,01'<)884]-S)R- S?CR1+:"_: <+'T>I2.>BXN!JFS9E=*7J0D-[C4&O
ME6;*M[X@6(_\I#5Z@/ &"!%_'8<XGJQ.#XI75KE2'V<3^N[%>H_Y-M48M571
MF,ID6W.=I 7G@X.H$=&(F 6VOASHBNW)9XP,HH0!'HVOX+QY9U(L4O"* 029
M?.TVHB#8R$&C-<FB*YFU+B78C>;X!C&,!G>;21_Q#V 8/YWC^]E;G-2<NS=A
M?O4! YW*W,D,5I7:R).BVJ!8IF7"/ _>2>M;!X^[T3RH8?32V6P0@0]@"B]2
MJOV'%F_"UQJQT&JX>""]+8D1]X6\E$HP99%3K&LB>!YMI8735KIZ"=;<<>@.
M[V2,92B5#' IN>(/I'#F NH&531983$)LI"5B<PA1%9?03676&]+5&Y]&;D=
MR<G81 -!#W 1^>ML^N$]SL_JM<8&4K%"9Y4S>)%I/PLH("+]4@K3BL#IE%J'
MCUM@G(SB^XIX@#O'56R[92_"G'--]@<=0@9EN03O0P''>&2N.*-MZY!C!Y23
MT7X+40]P7;@%D9%.B6(TH!.$*"2SID0H7!D;E:A=PP</*$Y&[ST%/,!=X=5]
MZ.JC:)1110J(1%G=8)H"0;,(019KLV;%QN;7#%N1G&H,V5_L [A]-[>E*\@R
ML]8I*8'<3UD;0""XI"4X84OV@O%BY,"'P,D;12/Q#^$07H(:(4L^LQ)K/FT-
M32P=3ZYXR*ZVF<_DJ8CFCN#E\">J^D,%/( ;6 MLQ^N'K%H^,YO6M@$X316:
M)?^C,!_ \-I1+119[\L#^-I1S<0D&!NB6GT'G!.UA58*&,!!O&/&PCH?M2J
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M-[=NO@=5T0!W)3=;&WQ#>@G_QZ]OPIQ^.TH"*;ZWFG9U1LZ 8A*"+>0,))J
M83J(YGWN]H!W4G8TE%H&N%CM!/7Z._#Z(Z-BR(W4C(YLI_.Z0)!\2@:B).0A
M:!]SZ_?V@\$^/^OJK;(!WN]^PKA\-5TLY^>KJECR,%Z<U>*VD;2VD =H0>B
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M_L]?<)[&BW6_^V]_^0TS'_F<(X4'Y/SE5'ER52UTDX%BALSHV&9:BM8!_D%
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M&;@2#<T^&Q%S)8_LUJSY:7&"'Z+EYO)L>/FQ^_'[&ID6!4')2*D!N:0#1]L
MP>0$A4EOE93!NQXY!0_+33:,OMO*= #.J?5#V+LEV6/U6G^=K1^\5IYK""RX
M6JQDC&0$K>@*+8+65J RUA79^FGX#CC/Z]J@E5X&N)W? >UBJ70!-]"UP9W
M'N;>H)D:NYE'#QT,$B'>!=)I3+KF8#M3WYB*1(J+F0.=E3>80G*N=7/B!S"0
M>VX.'L8^]A'] ':Q[3'HRMZZJ4^TS+(@!7BO JC(%;C !"2F2Q29.95:9]=T
M G9\UZ2A,F=#:V* >X;-[<?/7S[1JL*-IURD+V@%H*>(6'EM(#IRHXS.(065
MF6E>6K,5R"F90W])#[!;7/A9F^2%S>[H>-8*G87@I >E/(+364-4(B4E7"JE
M=6?.[4B>EU_:0!L#/-K?1O4M$_Q^7 -YH[LP/8PCVD)O]YI"#Z$?9>/8=!,(
MR+#$ "76WN<YRTK"\?^S]Z;=;>W&FO O0C?FX:/M<YSKM<ZQU;9/\O;[A:LP
MV;R128>DE.C^^BZ0H@:*DO8F@4V*<K*B:*#W?E!5 *J JJ<T"=)SZ2VS,M?.
M7QO6&)YQ.H>TA3ZR;G)U^43*V_7^QJPU*E)$E\'@<A@E 6E*W:GQ&:P!(VL'
M(AU@#>]7U-'A@QO,N@IHX%]^G$[B#<IU#R3NA3,<(RY>AJPUNKQ. *'@G8%8
MN%-JI\QL@7$B-K"O@!]=%^I64VVM(8=)W$9@N&ZZ-LU;>'MV+ZRJ#:%&C553
ML6R46UD1J102(L0L>99 $^,LA,RI9CG"]CK_/<!4XH!X,Y^GI?/]QQC\^'SI
M=E\CC)\F-SP$^ &<"[/UCV]A/KZ3[>@<%S%S($R6NH! #?%4.Z*T,!R70I],
M[7VHZ@#V78=7&&X@W88M;_Q\>2$S E.B6!5)DJ)T*XR4.,XBD<:#-]':)&O'
M_,^".B"7QN!6M[FPU]58B_8[,/]>LLSQ_TJ7H4LXOT>U=@MXE(,3GCE-J)88
M$W.)^QL/FG#GE::>)1]KDQIV!C>\B556[&9'C29::<--'G'&?"E39W64DOQB
ME*3#'4E$8B5-1 H(Q 84@N40=+).*E[;5+8".36SV%_:#2X[WURBGU!.S=Y/
M9U_04.^CN_WI'2ZN:,4C+Z,2)8Q)#.U4 H[=&\D(MUI[D76.6=7>HOI!/#6S
M::FAIO5%*[&L87&C/9JY)2'E$F#Y0)PRBC"K T]<2B=KY\T^ N74#*2&Q"MF
MWBSS@AX=\1J<#HQ)1G4A?$5P05MBLP.B9 8M7$H/BLD>2;5Z[DVGHNWZ8FW0
MGF?5ZO)V37K_]X\?T#</U^@H8Y''TFI;>TDD>M[$62:(HL)+S3$<]K4/II]&
M="K&T4#^#:C^N^YD=Q K;:4/&E>NR&UAQ6,$E-(DNNBECY$%6;OA37^4IV9%
MC?74@"%Y<PN\@RS&1"&RPF@52\L4S@D8DXB-ADE+%<NA'?_/)II3LY1*<J](
M0?GT-GD'GY,V)!,E$3*)DO6AB(5,21+))PLI"QKV<T!.3^U-A/M0^6[?Y>#.
M>>%3(N">!6:,Q_7*HIUJ(U$$SA =LU 4E%>\]H%T-V2O^<RU@>YJTU+>WP4W
M=\OU *[6/GG$"14XHE0YX4IH?23.!$5<#HEZY;S,M--*T^^]PQM1"]5-AY'[
M@4SDSI+)0*+"T7D*(H:2M):)I5X3$3C@K[*5W->TDD/N3D=B*#M*O\$I[(8?
M=6W!-RFP=YH,GDWG2^7\7BZ6YV,<U>^3BQ_7A5<CA?&=S^A\"Z\8D9DQX@3@
M6$( %:GRTM5.&JT$_35O>8?0?GLCOIU=_4=BC0["* P9<O0K?C9K!!"A?6 4
MM,FZ=BN2>NA_F?+@-M#@'J.&3%?IZ)9;&1@*4 !0'$B(.)"2AII5=E[PE&/M
M0I]JX(?B43L>"SZ,WH^%9VU[ZL**Y\<++2AU190H5 !%@*)/S;6P*F@02M8V
MX\?1'*HHY4#6T2G!I+>6&F24?$[HNX_#(L7M&+?_]CIGM@OV1L4L^^ ^3,%+
M+1N8'EB!QV:$%HQ-#%UGK[DDTI5$<)=H*1I1@5J&D[1V9OSQ&=\S!3;':'M]
M]-; YOZ<3M+5GS#[9UJ\OYC$-2INF<_2<))E+*UGG2?@K2>*!6]<UEI6MZ;M
M2(8/2H;3YK2Z*EJDZDY_8&BS#'L '8YUZ7DP(*@PQ";+B90\$"M-N91A/%/T
M!!2OG16U%<@K,H_]%=%@^7B79HM5-XXT_Y1_2S]+:'P-+3*@.5I+C#0EL2?H
MLK@*0A,S+F66:/6J@"?@O"9+J:24!F=M6^J!EMNO"8%9R171J9 IVI2)R]X2
MIT/,S'H)KGI'\>U07G>$5D,_#<SFZPPF\YQF12Q?TNQR''#(=T[D[E27%7:X
M^?8_79=,=AE+HW"MYC@.U)N\AH$\+# XK';;E*C4&Y/#,:DL--$LA#*C*?&E
MTC='Y<'D) 2K?81U_);Z7"OT8S?4/DIMX;EM=2>E<]1*C(!%#K+D'F0"BI?Z
MG@S&N4!9.E&__G"Z[>3G]U%,BRCP"9<RI!#1K11$Y9 Q!-$8@MBH"00%PFK*
MG:Y=6G54?O[Q6$XE)358;?[Z\K?I99I-RE#O9[FLXQU3,F,PU#%!H=,:A")>
M&4>2I1 HE5Y5Y[1]#M,KMJ2JZFJ2LK$%D\Q9,;1SPD1)(U&I'.8"(UIFESES
M7++Z?;Y^F4U-M;3(A]A.WL^BY4I92D(H!$<"@V2(AI$@\3_@G62T^H'#D?1)
M.!ISJ:":!LSK-P<Q;Z\>\M/\D2[3^3*.$-'S1 OKO,V>2*T< 5SUB'):VD!=
M$+%ZHXU.R%[Y 59][;5,TKI+E[2%#6DUQ[J ;71@U0OH@4ZD&FC\,:-JIJX6
M#8)Z@=8"E+"%GKCD*N*67!H9H7\G>%;:@17,U&X3=02V]=P9TK&95A\MM32I
M#Y.?%XOY4@)L'1$PDV.PB,IPC9*0DMCB$GC/F+96^!AJL^\\ >> N<SU%?F8
MR>RIA0;'1-N@\35=.=/4JD)-Z4J&C?>46)T=B=(YPR1SN-L/8"#\=1K(+EH8
M: 41ZZMI!<;&K$BF4>&0B]LGN"#<I4*#KI2NWJGP"3BOS4!VT4*+!(';+?>.
M&-[/TK\NTB1<+?=;FH*FY;0)M,/]EF5-+.!RAW$ADUIGZ6UM<HT.L'[%737U
MUC*PWP;P>E9U@3A@J+4![^ !5AW5=G"!:^AEH)AJ$RHS8&FBB3 .N(#J4O^5
M<77.2?N07<(?FCG"0YM.]_CI8);31QU#1>$W:_'UGBMHEMDR("%%07 -Y@2"
MH20(<$Q*JT2H7?[<!==QN$![*;1+M+V/-AK$4"LNM#_3XOLT?IA<IOFBH"P5
MJ=/)?'H^CH6M?_6'E)93B"%>YQ,0L+AER]*T%*ATQ(4$.D/T3M7VAWJ#?-W>
M45N=-B-$[ AX/3$[0&[D.^T ]S"^5&-#V,?L]M!B@WUS%^C&6I]UTH0*CS,T
M<X:3TU+"E$\.MPAE?.VBI:,QO&<\L>.WNS[*J\UZ]'G58>46ZLU5M.4)I >"
M7H8FD@>*XX=$4F$^!X6PZ,:9Y2/D1H^]87@7J[ENIK4%6]''6H)Z=[68_G,\
M28MQF)=".]SF2\[E>'&G]96BM' U&5*HG(BT/.-W-*!F/3CJHM&;?:8>47R'
MEYVX#=06]Q%VG?H(L]F2/&:@%E,/WC=T/ZFG![S1/"H9ZJ24-%EM9$(/6@01
M$MI2U-KJI'HUCWKPYJIL.5L"@F4$\-=DZN=I=ED"@>69.?X99PN&$7 MZ6L&
M%V&EH!9#4J%MZ<F+BYO'81*#X[9>9HPA&W/F[#N$O9;6^UAN".ON(_FR&)^?
M_U<ZCW]AG 7GX_])<=WO^@[;TJJ;\BW%TA_C.:Y0BVNZO13?G\.WD?<FNN 4
M,59+C,F4)I8R19CV@8>@ PW=V/@'!GYPJJU!#?W>=G#,)M+R1GS'X8Y2E$:H
MG(B$97L$98G+*1(M,G"J):.^=F+\OIA?IW4?1.,-(N\OZ!<D!)DBNFFEW_RJ
M$S%NNY-ORXGW]NKV(V=PM:RL*WF\=P=^\>-G^5?STK&^5,#_?7J.CUG* :?O
MB#'AT6\41%-1JMM!$Z>U($I8$36*7MC:V^0 PWK==G]L=M,@.:'J$#^/Y_]\
M/TNHD$6:8:2U'& &SUW L6E3FF!YC) Q&C:X;\5,K9+,T-HY,,T']6M:'(_-
M5,QE[\!8_?&BZ.E37@YP?G8Q"]_+*$?99&9IN471$<-]F2RQ+F="17+X-T@9
M:C#+/_+ZUVF/ ZFK=D.VIQ&O*790.F=I-I[&D32:2F,$$9ZJTL.%H[OO @'A
MO.(J1!IJT-$_>/$OHVJBHHI7FQVPOOM>%N4/DV5%VO3\]TM<BZ]!:\:UI#D2
MXU.I8K2*>/"4<)XA^U*OYFLL68\C^&5@;956L6]<!]#_2.-OW]&_?7.99O M
MO9O.%Y_R._@Y7L#YB/, E-M8&NKBAFY01DZH0)32%*P.U(*J8&M/8?AE;:T5
MUZ";7!T1KK)=LJ&!*AI)!I>(9+%TXW4XLNPC=U(XEYIE,>X/_T#T[T=T[C2<
M]H^% OXQPB< "YY925(TCDC@CG@I"HDJC9'*:+.HGEQYU-2"PUE&1W+!/AHZ
M=JJV+F/Y12[XF*'6,)"6G&V[:/?H+3;RR*SAA)ERIIJ4)@!>D, 8=4HF'F3M
M(\?CM]0=R06/QU![*+5V-MW=A)];,KL_X&(2OE\G *VKE6V*7BE%<C8"_66G
M"-@DB:*E3Y+BUBK1*=#I_,H7SK;32ZV/)6'5TTF#^_(S5'.:H7?R93$-_UQ3
M2 G*+&2&KH;(.*VT(<Y33C(M5>T"$>G:B;W;<+Q"XZFFEI:E54^S<VAM+/?*
MD,26U^G,87BN(Z&2&N<T"U'4IJ%_441-APL'ZNNO94%ZMZK\#F!_4375U/A^
M?#H[J.O@5$V6)\IM@D*V:8B,3);^T)D$&4%SH;C9S$T_!=NJ0]4TG&GUT=+0
M1"O1:; X=)5-Z4^=<;WFP1/M/:-)9&E=LQWQY1&M]%)D'Z*5'EIHX&C?Y-&^
M.X<Y.HY+QVXY1QSW :@T)&:-$4",'/U$A>@B-3A_@DB^-C7JHV!>NX]41TL-
M&"SOXEE3P79 U,CW>8CF, Y.)75M\KK7D76+)A(/D0EK!/6.$>:SPRC3 W&!
M6?Q.0LC&9VUKLW /I?UG7)#!E-]'Q"T2Q-.L7(QO/1)0GH,U1A&6.!#)A20^
M1TN2,BGAYZ.,HO;>\3B<X5V+?;6UN?Q7$G7+PI:W5\L]<CGRI;4K]*T%H(TG
ML 'W.Z6(U]J34C2>P$D;6$-ZMOM@7KO_4$=++<G8]A+0W5%=3[<NXVI] E-Y
M3 <_K-G'=)IDJ532>\NXN_;X&+ALM PD!,UPN2_,OCI[8G+P,2>(U#6CSWT1
M]MS]@.@EF',?=3>CWWG0R\6#E28D1Z+PBDBI,K'"&Z*=R=+8Z*VL;83;D;S4
M_-1]-;V5:&<O-55T#>>SQ>C=]*+4)OV$V>+J(_Q8<0D)*YACZ+P85YH.RU2:
M5 ,CP9HHDM-)ZTX'COB".R:#/]V:RV/O?JT.8!5=5*R^*'@^IY_7-45OOLW2
M*E3>@'@3,ST/LH\3]XSA= 8VK"=61X?3H110<1OJ"3;1Z+3-Q $KD7 TQ#L=
MB4DZ\*@DLZ'3KG3<5O*(?W-((^DA]]I)9F_'TW>SJ_GB;,EB%-+%8AS@?/YA
M$M8,8X*C3R<42=1+(A$. 6YP@]4AI.!HT+H;-<QS;QK.%6FHG6DKT=8F;_MS
M.OOY??KE:NWJ1$&-EU23(-%OEUX+@D:?272"LI ULU%V4O/&@T].J_L([@@I
MU[Y<_/@!LZMI7I7_C2?O8#:[0K=J^8!I7EVU;LV&&X:C;7^ 0Y.Z51;I!@N<
M\"Q24))KY:66RF=.O?&&FQB%9*X7"]S^4(_AE.>/V[HOKVFTN#E'*7$=+5/;
M.2%Q@36*VIAM=,U2>@Y+&U<7SCLX#Q?GRV\_3\_/KQN,CD14//O24108!E#2
M*&)3H8S'T)OKX'* 9C<2#<;S4@\_=K/W-D=N%2REY:7:G37P'^/%]P>#F=\?
MS?VA+P6S?,P(&"ZU&@)QJE!W)&F(,]02%H6UE.40-IE6FN0*[C.&EVKM-2RL
M0P;B8.8Q4-[KCN-9L]7,1S0GR9@091"E3T/6)3J1Z"$KICQSP=DA.IGN.XY?
M9G\\9E*QK. ^!^K^ UJS1GZ:?"CV >?E7WQ;F<HH^<2<U9IX;_TJ[\AJ:XA1
M25AJC<@R=@J.!P+\R^:/USX:Y)!NWEZ]O_PXOF%!#9Q+S6)A[(E+EBA)+%>.
M:)1=!N4%I-H4H4_A^66:]=76(*VHX/@T^2W-QI=+EO@[D?_9#$/__XP,#3(Y
MX,3$<H!&G2 N:$=\1L<G6R% U<Y/?1;4+^-JI, &G;$:K,T?)N'\(I:.&Y\6
MW].L\(3.TO=R[U/&7SC.5U,+,K?)X6HM$@Y<EM;-(0F"XU7:@-<J-SO%&'JP
MOV;$"S.XBO1Y@PS\=YA-\"-S-DJ<)\>R)]2B1G#'<L26SD3< S4.'2,7FQ'L
M-QW9KSETS*94D?^O=LRP7!0^3B?3GZGTVIE\*VSLDWD: 8W"2NY)TLP1R0TG
MD#%HB!!L\#Q1\-W:H0T ]I?U'Z==/+1[>T0;Q9>T6*QX"7'[4]3P3#.A 7U,
MF0PC-NM(@C1 %6/6A]JU3&U&\FLJ').I/)P [H@FP WCT*>+Q:?K>_21LTI9
MA]$64RAV*:DB8!PE!KAS&E2D; C&B8I#^C4ECM)XMMPQ[9<N5G%PGU-,UVTX
M1M)2;WDP)*I"(V*@Q$C"$L:\3(%K@;-^:$?H#KY?UGTTVM]BT<=T;;JZ!HXI
MI6@T1O9>*B*M .)\B?LQ</$JRI#3$9\L;<D2Z+E*O$-C S]=-1:]TYKG<^%Z
M+]Q[G_SY^-OR_?,_X3_C'Q<_;EO8?IT6 L51">Y0A)3D0-%(<T[$IP0D2\&L
M14=8Q8X=@_<'\U+G_WX)0@=1Y=&6D%Z7#N$RQ8UF1!LNB<1 C'B-XU%*2-R8
M 7!P1YGY]K)I_ ^>WM9?^T=#X_]HG2YH+710E@0*.!KK$K%>.V*8U(I!-F";
M12$GR2O1QSHZ\TKTT=+1+IY;RG2[C.L7K\1>O!*]3&>H0OQ=]/Z2[#HF(0*U
MF=!LT?<'R]#W-[AA&1:$P*%KVRQ#^$78\\Z\$D=ISGW4/2"OA-6V]/XC(KNR
M%4E#P  E3H-4E&GN8^VDG)/GE>BEZ8Z\$CW4U(*R] DV-!>8<EDIPH/$F$UA
MN ;:!Z*YBS$DL+QZEZ>C(IX[2C.JI; 6^^GJ;''9-!+"8FWASN&B7-(7M4F!
MR! $^L3,$A>ML])'2E7U9)"M2'Y94"TU54_>7[5+N3TU6H,2VELT7442Y^58
M&%='+Q,C5D,Y$+"%ZK';I< C;WCE-E%/^O6[H*_359<#O484(L]2A,+(J7"W
M9,$1EW,F(#GUH#,.LUNVS-;'_S*&&G)OD(+^>56)OZ99\!X\F,+MGA!,E@K-
M$JT4-SWKN5%:F=I^R3T K]Q,]E=*RQ3RIWM5.% \6=#$6H.;'$^*0$R<X#J7
MA1').]JLD/'T&Q?5.?RLI;^#-R[J O97XZ*:&M^KN\PNZCIXXR)E"]^Y3H0[
M58A614#0WN$^S71BDBN1^>G95IW&1<.95A\M#=RXR" :;80BEAE!I',8]G'E
M"1<^JB0@<U"M#.CE-2[JI<@>C8OZ:*'!*6!I=/DIWTGM6,Z/S(R,I1>E*5 D
M.OS$0\9-782<C).4L=HGR%N!O';?:'_M-"@TOP.GI !]G$[@]C?+I%4(JXR@
ME85W@=O(&>H)]3#N4 4E3X?74(/-JB]LQXRC*@/1:ID8)!P!ET298SR)K )N
MY:=H4,_X0(>WISZ*:=%'ZY&LQ3M(2W+L62$#_3I][-/78X&DHQ>.D>A3:4(O
M* &5$A&>!0T.8C:U\Z1JXA_>K6IJ+)OMO ZEZ2%X_IEWVH(I5#+ B32L%(Q;
M390V6@G-,HN=.%M>*\__#GY7%5U4/ 7OQV;<!>0KYOGOI<.=*-QW4<#!>/Z#
M4B8[Q0GC(N)REQ"LL8HDFXV(^!_A.WE/QVTE?7G^VQM)'[G7YOG?I"WWT5IF
MDD:G,$!AG$_$Z92),"F6;2]*NW&&^++YWGO)_BF^]SZ">]17."#?>_B>XL5Y
MFN;?YXOQ#UBD>///Y[C%IHA@EJ=4JQ.KH5C>=X0U.+=[#?%M,+JS$)P.)EK&
MC<2(S'(=*4LB6IV\\K0?H_N. "L=-O\VGI<B%P2Y].,P"OAC#![=,YR,T\7:
MJWNSN/D'?]P4^R@>H\G1DR YSE"J.?$A:L(\KK\NX92SS0ZE=X>]7PK42H&3
M;^C%IO'2J9UOP53B$\6M4\13C$IDB D7+PSH+0ANO>9)BM!IL>[XP@.>R ]D
M0/=SH1JHH26I^2VD3[FCE%:!4; 8"WDC"011*/^,(-:&C .0*!^%8;AKE@FQ
M*^C!:Q<'ML##:/<(JQ2?NK7E C"D]Y88:RB1(C'BC,HDH \6F0HF@&YEN,>=
MPC.,M>R6N--':P=/JN@"]E?B3DV-[Y5=L8NZ#FYCV:<4&46H2ED$K2D!DQ/A
MRB0G7,Y4-5O&7GKBSG"FU4=+ R?N>,X"%8*39 N3K$$/%%0VQ,?DF>6)<=DL
M\^OE)>[T4F2/Q)T^6F@9![R]NB.&%8]/F2G:^02&4F*R5D0JB5ZHII*HA+@%
M2.%";N<L;8/TZKVDO?74(*_Y;#I;ZN!VR%O$=6WQ7: V<HYZP#RX:[2_FJ?#
MZJCE]G4+L 3';WZ4<_EU"8K2##R&RB0J5P[1P>*,"HQ$!\E0(<$,<1#Q ->A
M_9_J]E-=&0T,IH^->QZ,4T&B!*(L)W"6+'_D'OT_KY(RP9[&^K/SL>F>^MUC
M >JCG 9NT?J^XU/N@#5%GY4,0' 2&2*Y0*Q<<Z)"4E$XZA6M74[8!]_PEM1,
MT9N,&*VTU"*;\+H9\N?T$Z6#WN%R6CT.EV:>K&2">(9?9);+-F :(U;%M&8L
M1UJ;)+ GQ-.UJY:Z>M3YKGR-O[[.O2ZR767"W;3HWO[G?>[G]WE?E8OW:@/>
MN%&/$35KJ.0J9YE$8=_5+LFDM4.]LS3:Z\U[IKJ'L-R<,>I,)4OVCRE,YK<7
MC[>72=%0!XH%PDI]FC0F$2N\)5&G:( %ZVCM2IRNV/9=6)?/OWWNWV:E2U*R
M.0NZ;)V(SJYT^ 6HU,0GCH,W)2FB]K'%-AP'2)MN81&;Z^/>(J_HL3UVZ?[F
M_'SZ;_QE>C^=O9NE.%Z4!D'OOI=L[?F'2>F2$G!I?P?S[^_QDR@0;6,("H@&
MYDGAJR%.9TVR8,P+E:-@]+E5L!:8$[.;@^BH=M+CML2.-WF19KU'D:-ATJ9
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MKM%:0T5+?L)^!5OO=XXJXR0E*2X;;6*8Y:VVQ'F,A5%:UL9N"2O]WGM*1M%
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M!/248KKVFFK@G_4"/9+*)[LD9V><$>G1K?0^6YQY0FM*C1&Y]H;9"^#PYC2
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MDT.[])^C>O&2[9SJ^YR/(>;H1#-*VBW@(,9!-OV$J3L-\(5HH7"[==A=+?+
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M#]P#=+Q=U!<']T NAR9&\0*\6.>X_&,3[3&3(K7"Q'H:\S7&(B<:^8%:;UN
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MJ*'"@35L7YD'RTDUG1K["A#*$7YJ PTH8Z7^'/8X472[<(VQO""Z<(T-.3B
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M\=-[94S(SB\-S6 ?(@A;QW>]EN#,7IQYVZ'J@4'NRA<55 4:TN_%C[I=)E5
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MTU-\(O?UI>X]0,0I"""#X4ZK,Q]O:)W<'58/\#'XP4DV!_7ICEOTTE#7,M]
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MDLNSDMT[ -;3O/J%#<=J3DUW)Q&#3+O#U-X(M5$3FX1W<:U<^%3OP6]OBG#
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M=4]S"ND=_EZAG<F?8C;*4I\%<WVL/2?9GUS!!T$OF'T=8VIL\ 4#YBA:]<(
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M6,D.JS G>ZLN'^+,"M'JKQ*T]1TGT^<B=("WB1IIU0@*,>@79*!J1W76ELE
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MBB=Q$W_CVYWVC-IH&SU+_@9^4E_7)C:;@[,U0ISBF]\,T?\=R##4H[2=S'X
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M;0,YV():.&RM!!CB=*>.[&1'73!=/U6Q8.A$&"V&^MX5.W'S#7 #1'P1G?2
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MK-_81U40]4L$W_6UGI.&EIM\@,&5Q5(-2,/&&"W.\_UN]..N"ZFF;NB1OM-
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M(+5 E-:ZWP$$FDSL[Q@/ZRWJ?[FH$;]!R0XA#C<G>G>?]6>M8OC?:Q7U>M;
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MUQ\9JJH:XF<N;'V/?4-ZA-56)E5'+7GF*7_LP2S45Y0,U,&BPKOB-6(0L0=
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MHY3TW\]8[Y[Y0!DS_P\V45NOC*XX]_#_^0"H(?:&&T$M)N7IX>_U6W:\G"M
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MW-\;AV8?W6V7((PT-.RS9LY/D??'55]JB .G'$MSE:E(+=U!>%5:O'@7V]<
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M?U1(PU%L-399J96O0F:9U!0:O9P35Z1KT3TUTCT4MN@_X3/-POZC^N9@L>!
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MI9C+"3Z"3HEX)EN9"+*1*^.;<ZO%A[-G)8(8/16]&*(D,;)7@C]9=.B(#C
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M J2/5#54 0P,# "!_@%NUTB/5* 06P!X\@3@!0  #\#"D 7NH"5B].!1) 3
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M,&Y[ 18 P,#&^!O]6U^ <0<3"QL'%P^?@!"]H($4N(.!B7D'"Q,;&PL+_6D
M^G, BPR;G$U8"8?BJ04NNQNE2$A2/A['@YIN*MUQ!*>HI7LH/@$U#2T=/===
M;IY[O&+B$I)2TC+*#U54U=0U'CU[_D)/W^"EH96UC:V=/>25AZ>7MP_4UR_L
M=7A$Y)NHZ.24MZEIZ>_>9WPH*"PJ+BG]6%9;5]_0V-3<TOJEI[>O?V!PZ.O$
MY-2/Z9G9N?FU=?C&YL^M[5\[R*/CD].SWZCSB[_LP@ P,?Z-_DN[R-!VW<'"
MPL3"_<LNC#L^?RT@P\)F$\8A5WJ*:^%&P2X2@D?Y("F_IAN?0U07067I/DY
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M!SZT'\,%>XU6(A4HF]K'*_8/&O@RXY+ZW!A:\7YH^+"I2['P[%X]:)]<FQD
MLUP]0&9WA#@YK VSL<LE&\L7'FY^B$VF&:&3QQ&1&<,=GWI.#?%,<[N?+R:Z
M&'Z]D?C 4E4AGU 8<\'M8NH$>*I"B>;G/RB>!MSW&K_;$'H+N!R8'E"GL7J,
MI[[4PAL<E+.3@V/=6:(Z3NAQF:?I"Q1&115NT^?D%J@X^'-\2G#!*EO%LEU]
MC_9=0P"3(C;ET[\SE;;&CT_B2R(":NHMFFW2,7@_$PXZIGG5Y?N5MO)WI,K?
M D^-M^*O'$J@F%_T90[*TPT&XVFI@B&;8"\:\ /M/*S5]686@MSH987Q_2O5
M&[X:1$/J3YN&FC#-^.WZAU=%<X,<'&,G6[&K@#\QU;IA;J_9&P4*I%[8FB 5
M9%JWX^/'>26<SS:I\?:QVYS/&.YA?,TN)'):2IJ="4)*FLS !%?]EWQZ[+0@
MGB?'MA$W-%Y)(A@$3V<@6W(;S%E>>22MT<BJ4!::TUL@RJ^_'%(Y#VE$SG4E
MJSJN)VEP57NT+$2?&0(\'Z+_ U>WV_E^@G10=$S!Y 5B?;QU/G<;;3,;;#Q7
MM<SE^*BKSB(IM166%4P\S]=U0PKS0DKV@EC4\G<E9!Y3?W?B+-IG2S+CBW6?
M$!I02#U\^X_#0?,++\V2FO'#^^L$UJ&X2<HD^"\X[1:BD9U8J!FX=KRG_:D3
M6!V1FOJZZYU=AU'XL:NK:SF'I(XO*PD/YD)I55J[\J7:E2)BYLWAB=&^;(^N
M\:S6V"-$MZM.;18Y_EO& ,4JU8Z9#LEYJ*.#Q+Q=F!?>S<A]A=%7]V$3A9A=
M/CKJN%*X-?U:&,#I!5\RRFB][9#A2GSB2KFLSX5X:2O[)U=M;;_$XVTAVI1Q
MM<"&Z3$,%4J=_S[_;UR,/,*W^J,K3(%W49?=-Q(UDS#1FT@+,1[DH\88X=;$
M&FR1KMA8C'J+EE$W4WC>TO(*RN5)^P^GP*$ -PAEDP2*8R@ID?HQLRH^1^XC
M8.SO4?H/+GL55=J1+K.=8M@=U/1;T(=0DU1Z^^NG$BQK:V;1'+>P8^:V2_6K
MAXB#S_X%.QG@R(*VVO?YJ7KX;P8/0-F#\BI @+:*!51UZV7G6,4IL?LMH/GY
MTEIX%&-2P)3GQTN/WSEJRW@<N(0GGP[?^.5&G8"(5QQR&%K&>V4""M,IC'8D
M:EL2V=-D33B-R0& 2N[W7W=LK8/&(5 <"8ZTF)&SP4FR<_$G&+9SLB(*?1 7
M6KDW(03$/PC)4>+TK/R)3F^5#@,7:6T?H))/IV&2][/N3CH5MB;S7?HDV3S4
M[5-2TRT!5H] F/'U&!/CI@R(9W"S-S<<J(E#]1G^^F:!M<GE7X8C]ZB&\3ET
M\"&T5B3^?OHM_^%D?+GC%7AVCF&*#2A_Q(XL1+RE$[YS R>F>H?I1GOP(%3+
MSQ7@1'H'L*S_#'OEQ6=&#>G@2<4Y%\O,%A9X$2&B)ZVSY6/1AED<P(,Y65HE
MC5)#$NJB(EKWETO,/4=KC <<TQ[[B/%3; WQEG#5=3-Z5E+ JWI76*#@_FD9
MEXB@L;V[X<SW],9M)76I68L-R)*")6(EI0]X,+?I^<!*;9\[$<N9OF7SU\D7
MZQ/WG)T0:BD<K/SOY&+)U112\_^5>/Z9@#;,J#OD7E[)38%KQ,JYIDZSHX\B
M4QSUUB(4'=T-8IG:7;NV:E:O[EV^6.FHH500'=]+[M<G^"T#33($@MX4B+I@
M-F,Q>HX(*2J\__">:'Q1B7&L&KJAL]U3<$>$V/?3"C6+,2IK&0?Q4&+2>"'2
M84EW5Q"+ ?<;M3CKH!);X%$L\E"1.5/%USL7:1G L>Z9@XU<]'8U57\^NZ/G
M&[^\*L2ES-%&.XO(<W9L]#?/U<JPKUB#.'.J%RBE^9CGJ[6( 1=\_>TNEX^@
M1CW#7%619 V7:UWVF3:MR*FA*Q,_'NEN.JKM'(R9@_9GJTPLQE,<$;*9NQ;\
M47<2@[-.L%(2>L=PE57<5T@[6"%!)#"1^8Y/5:*BYWIG-:3,OGC;HF,DA<<A
MLUF8Q\CK\BO-ZT)C:-"C2Q)5MB7N#%PZ9ML]OUL MZ2$E>7%4^.98)A',>P!
MHE!F.9%9G-\R!U_AA#R8D$T>9:[$I,0D0Y+V'^KP'_[O\D8'[RTPQ(%4NP[=
MN@7&B+T:AF O;H%DM?6$2^S16R"/'CA//[-#SPR KJ&C5^'^,_OXI09S5U33
MK)VI>IH]1'K(E(AD)=YFS&W*FC.<#B<4R]H9NHR\GDS1GSKQ=M P-H'X,#_N
M"I9:"NL^D)W6CG,27P'!'J8-#^B:[#XS6+Q_V+@XN.+PFBR4Q<V\LJ!4FFX
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M1YMP6^@5F?&KRMK>,]=JB,7\A#2$IJP2=UF._#E1,M_T;A:B"ITL":%<-K?
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ML+4C3"D5"%%N!=LI[$7?A%Q:%\(NMV2SK+VZN3RVL7T3]M56^Z?0I6\]4TQ
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M;V>/5/$)[R[G"3$$RZU&3WV(!LY+X(?]ZC93D:_KL=&Q-V_CI--&\=_8>\N
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M?C9+I0R52;LW357UAG$=7$?:U.OGI1Q8/OS@F$#VS4;P5 AJ0N>/X!1G.:A
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M/BH( 'V[4]]JV_QA\I=K^KS6#_&?[%N7 %_2::,$*UW[4*B9+RI$&RYOU(H
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MXQ+3<X/+'EIV;_M]H_32\O?_N(\S$7(<70K#7Q4_#(CP..7JL29H01GH$%Q
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M@H-?>3:0!/YC$P<[VZ;F( ![R.EYT5OW+F<$<)\W!J<@J,9[F'@_V6/B7+]
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M+V0X\XB2TNQ0W.7C?4IO5TH:/>AV:4>I#_48+QN?S#5[EC=*H$"O.E%4];H
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M^6T4&+#3"DT6=]\B#_EC56C :5!9>'#9;2QWGQ,$T0"U8ZS27!&[J,!(I!%
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MJU,TI6M&5U,&/V;:=9F9G$1UIG7)B[Y?(3\6>^RAK$+BPS\I(ES XS:V\"(
M*ZJPC**D&#)"X.^-+$'M?LVWH_<" >!VEXDEF#/FX62Q]'A=[%A(UGC@R*P(
MBEXGGPZC[S[46SY4+9FU^<@VF#7I2A*'MLDP-X9'"B+80 YLZQ&DU"[V(0%O
M1_F0K5Z,UI213XV-L2:54QO7E%89; (:41J'RA+"24WXU9;O-D6H5L3)=Q
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MT4B$V)<IA/%)-GB^ZD 3^Z#) %U=D=D'N67HR\ 3"BH+)\=(N(2O6",#UQ"
MO[W8<:@6]RY#:?_589>U/DP2;#=ZCX/(.E!49+83=/606<A9/Y]$5DI:TKI0
MQ^:6%Q-/CVYYD68L'ELBPT2E,?&6\Y/:1UDCYO_G)1\K$J7YEGD8FI;S>]U+
M\O.@EA?F1Q0WL4&P0<#*=5?A5?&1S^/HO&C6Y'H(U4:#SCW]BFMDIE/>I*>G
MRO,%"1MBI9TC:+I\)07Z-]<9G*U->(M79\5JT&1B!!#C+>/@24.36>X4#DQ]
M[OQ\#"_I_P#ZFK&>7,!8X,MQU=\0>H8C<<-21@24#O0\5:11L_['WG&2$8,
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M0G-Y%W_.M?XWO_=_!EE_T1.0DN18;5'"1KQW7&[74W!JK*S_&",K 3\DVCZ
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M-D%IEC0T \IO<@T[4[I\M [6$-$A>DP"R25\^,\>RW^NU/8/47DEWKN*!<]
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MA$A#F2F?_"(!$54::P5:<#MS\#T[B).?N$G#HI:;?D9^3MT2CF)KM 1?\2N
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M#W7_E7!TQL0E>M+AH4'&\F$QSN1@L$/.T6:W[?SZ080^XK ^Y"Z]\F\^\)"
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MG)>CF:DJ>GWT\Z>F<YK5T=WF+F1P/.JLAY@XN,91M+8T)\@W0LDU6N-F<*K
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M&()D9=JVBJ+%:EB2\^R21UP%/$*:/C#YKC>B, ;F @8U$;9ZJS8FKCMS84+
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MXH*[*FBXI"0TLJA?*E\#^LI#<<>P\08XD1?!,F<1,IQQGM:$S%"=WOK=I8G
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M7&G>:-JA0;5OIXJ7 BST!9C!-B?T!<8@D@$%Z.W"NG5G1P:>]VGJ'-,A)5\
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MH\MECJ80850NM[8&Z_KRG@I/(W@$=/0301O.JOD*]G::(Z=1\#>>;U$ ,10
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MN4O8,+JN'?._/.K>X0HB),2^)HI\@!#2)"TS)]Y*2?TU1SA-'=/:ZB1"<'6
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M*I$BEMS_M5%SH&Z&UF4?4+;]^Q-)SQA-=^]77=VIELEI\J3-)1&<EV_]5'Y
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M?/.D+9.()'D8H"TIFN>U5RGCJ6'(W7J^L*;GW+IZTXF6?%](K=^_NQ@N@)5
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M>1]F]!?B)]@ETAX$S+SA5 #Z$ZC";_'<.9+8N-<.LP<GUS]ICS4I%YMC/UH
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MQ<F7^<B4$?,P'K^J>)5^0=X2/;L_K09XJ&M,79'FS9WB$@P18<8@R[3]D2W
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M9.O=)TZ/Z[^UBYYH-T'3-HYT:GPO(_2'O28^GBK5(#X>VL!IDB_N;"=Y85G
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MOO>%]]ZWUK-8-51W[][55;NZZE?=??WK>@6@OJ>IHPG@X.  2.P?< VC/M"
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MY\!$\0O*$B?E\%V!5Y.O+-Y%!^H6H\WT9<\G%GI?Y+]+9Y4OH0F5>'I9ZUS
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M7></L@\Z?GN^"-N3,4KK4W,VOLL:/4*X$%-^P3-\"*W&74]VW&I%8,QP0](
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M]S#Y=*1Y3[7J &]_JNBC=EK'TK(-;%E^_5Y0JOY A8T*CJOQT.2J(O?XU35
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MAA\.KP7"6JBKOFZ.8 K84.!:A\MD=A-,RU]/Y=8J#2M%_\,S5^C,3BFVYS?
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M7'59T-;;I2>KQ=S>[@M,C_#6E*JDL<,KYYNW0.W^T+\*9_CHBO]RJXZ_X_
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M&$53+F<UX\<7KYSB)02_)VMR]IW2"R?HM (! FCSKJ;MF$!61V;S\*-X1*[
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M-(]L>[E\6T!G".YS_\#?XG2AJ!;P-B?&W8-W]J$@?E^[-<EO6B*63V0Z%K8
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M"ATKYU1I@N,K%$W891?7KLXY[0!=T!B""#6=5SBK7@*M.]%^TCWC%NPC(3V
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M@MMV>;B4<#$6_COW1<EW36D3=T9?\$[MD3FI@2G&>/7&N"N+<TR2Y'BMV?>
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M&J$S;-^51/ V.'RUP@"N7D]_4PV>-P&PG.>!2Y5G]OGYJ@>'S@SJC_9>Q:Q
MF8X7J$/-/.?8,[O>(3;"K-!$H_O>:;63:18/<AJJH'RP_1\A.(D>FH+#[B]^
MHF['[[>*_L0@'+RR9*?%(UJ&"EJ.)X23]]@2K>3]V*Z7*\O46JM03=C9:6OB
MXB%')I$((X"N_UYQ:+6<B(2'R)P]QN0NCU#N#.799Q[?-ERN, J3_/710[/7
M]B86-U@73+_UXJ!7($XT&&_,=N)X=MSBUGQ?]!T\W[=%ER9R1?3M^^Z]0N;/
MD36F<O"YI^?<'*8US.*W8@&)PXX+'MC%%[E5_=&VG6O]>GP3V)4EQ2#E9["L
M!?;^/I]=O<WD-*,7.JV2G]["S<YX3[!Z>K^%I5Z.8(?UIQR>,*GZ^?62U3T4
M'G0[-I,DE_03J@G6ZQ\6>C<BK\'@VR.W1ZH[/7AY2XL!?E%H$S?2,':J1+N.
MYUE[26W'<0J,@M+!17W3C9Q[8AR+PK$.7@G\]V('1&E-7]E/O5F1B][G&]$F
M[/6)/3Z@WI(4Z\XFG%\":_XFCCM16%WX.4R3#_>P3 ZE-Z!GM A]&Z G^Q 3
MM*(5]W"A^OLTO"Q+:)9QTWW]R6 D?/#3HY50X"@225^..]/,B(2$^I^TUA4M
M@FH>.2>>SE,Q91\/Z\D\$NKH/Y9@ H)NH$T1T&S4D6**^%JBBP^"=Q9.T43/
M0<1D8X4#VE8&>3QJ)01? 4^FF^\5VN/I.64%<]V#;M-&RON]3WNYYO/N*+SC
MX,7!'NA+61-*H,O_VYT$MP,7U\<L7UC@!GT[9GT=Q:UC*+G'43]2!!Y-*RTQ
M6J4_$N^720"<MR$4@0+Y"NXRT_GC<W")Q/4 *>.REW7N(08J,?0ZWU1(%& P
M=J.)FCU^9G7EYLC38>\?GH_G0D]/V7-!;\$B1VEQ!%FY@3+HC2CI.Z7JB#B:
MJH"XN:U;"DYVAP_U$SQZC1G=>!_6*TD@01:GD"3M!@P/8LZ%Y57LI5J1J8H!
MNTWOPN,*]MSAQ:!BO*D3\IA%B@F!LMV-J?B)G[VVC:;7;5%J)+']U!U/37*4
MPLU*AC5&&<:>%!]GX9F<FQU_^9$<E&;3K_-ND(T9!/-CW3V2S<[#6/2FP;M4
M; -NQO!_;F2DM]*S2B/]23E[/"\TJ=\V^XW96A5E%U.C_L'&3"),W3ZEA)@C
M.M$L?8X1A[U,IAAO5L2-$1/P9)*A\PK0875.E!-5=P+;0%7S>M4;>[_JN ^O
MM],S'9EDOBJQ_KJ%MG P?+UH\J,I+_,VR5?9O%^&P]E5M97EU]813_/UPY0(
M8UV84X8WJ1+LY^K@]XC(Q_-0?YS#F?Q 6DP00B[*_U5)$2;R\OLV'&&T5J.N
M9N/.:/4F8[XT'ILE0PKXN_P_"GR:6YP_4:3.)C@AXDB@1T)QX[\3/;;5?AW@
MWN,?X9>^1WP%<%CH70%ETU? ;Q%[O$\7'X7/99ZOL)3:E9AT>;OPEW,W/V>S
MM;1\XT'ZFARV@+V)6? K=*AZ*BW%BVZN_5;I;<_T8%YJ_]E;<HMTD(3$<=*L
M[Z5:9-X58!4#.7XFLB973>>BCG2>]E&=>.%'BR*<21G^3H@WO\^:!029EN[
M#<(+(?8[DA$MJ5!Y*@TV?8YCO,EL!7TOR.U-_Y/56G_OK7.;I\Q[_'=2%FUU
M'S$.)NM7J$CT2AI>LRGJ&JDYMT06DK%[X/7:\1O1L?2O#G/]GH7S#]74AD?@
M+R\+/#TFM6L/%IN1%=B4%2+/<W!W&*!I1BD6:PBI$R;#G['>(7C:KTS.Y)U#
M%KF#% AUKDD?=ZWQ0TZRIP\X/2]<H!?;P)&G.%3;2FQ U(D<T&^VTB>.G92X
M+JOWZD6\TZI_+U2WH%A)QG3Z/'S/_,'Y,XS^GFMU.<-6M'4JLTM9?H(*R:,Q
MB;/E,JW/24^/Y8C L:PQ$_8,W_KHZ\9A:8=K>K:T%U-Y/R66>UNM+</<>>W"
MY9D3*Q%FK%V_G7U_+V -1 ]O568<?MWUYU(\HKT";$A.$!G_L>Y "3#MS,Q8
MU 2GOWHB5)C.>VO6='Z>[B4_&C1@":M.?_V(^EV-2J'4V+( _4*@2R6Z>WQ+
M,NBK.W' 1_6 K4('=K@"4V?(H4+'IOSU<OD1S*:<?#D--TR+_5@C(_+1OE=S
M\Y?LR3'T/]","VCR2\TYU2N@(BWCVN)4,9&5GBH7$8!W/9XH?^0B/#>H5),0
M]5T,/_E#P+X,9);E/<X^W"W^F,]0__)'73/8F[)I^OLIW-1XP7_?:$W_%1.+
M/'OXIF-2K.P]\/..]#$X^*-.6J>Q86# UR)O]R6G+S3B_?V@^"-SF7/-Q7F'
MX'LH:&[1]^FSM"WAY&>?'GVKMF$Z9V@X?S8OLQ32+.C.[><FO*ZLM?^.5O6:
MA7Q$6G0-^BW'6E"VLWBK/%/D 9@5^1%4Q%TD^[T2('PF;X:ZZ.J6VPHNCI<K
M;56I^ GN;L3#N83#5\!"I)3[\/Z'\CMHBRBORG,.XU^T!FAI$]O40_%XVU=N
MO$WA%^OS[=G*7]I(O*5:5$X-T4]\(V:=8=[$]O0#$DF[Y[U"/V^SHZ[;$(X4
M".'WBDO0E*/HY./+LD[.#]-[^8,(1_^]$!/>F4+IM!R5-&,QQ@-I5H.^43(!
M^\ QWKKYP]D?-Q[/9GG9&CI;SGR1[M7$N"#6?6@&5Q1JB"1PN$6U]JUU[134
M5LZ2FGK.;SSW EQEG EF3U,/T+//F)$UYE56R>VCWQDXR2$/1I4G-0LBK=RO
M ,)>&/.1*7)(BP]I"\J%+U/*M/>\F,;JY(&]8<BI@Q3Z_8\N+8T\:L(;8^SR
M9DU>H.*3\D^79#ANYT^=M-M+F4P/WMXM!KC20T!6[:7F+&B"TB_!4YD_QGJ<
M_/SPTWT,WBXNTE'HWM6[8<7X:<] G'C8:*-,7C9\#*N1MW/Z?,'^K-0G;=?
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ML>E18/C<A8PT?<)TMTA]DMLM$#6?V!S-C>)-=[L)9D:BVR9^R-QH> *,JI^
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M$N87P.!%12FAZU7_J$V$+\O>]O-+G.$K.:52,YH[I.F;7:0X6*4]4L 8*.#
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MW!["Y^&S.S!V4\X<&/'ZH\V.JBM,:\1%V</MNTZ6T8/%G.G4LIOMSP[,BXK
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M.%F^SH3U!B'G/WLY%+M)Q49RT7_EEQ^1Q:8FFS*<E7H[FML2B8Z<F>ONO$]
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M[?V\R[V$_]P8G'*#T,DD>)-WZS^P(+8PV21X&_\< C]G0#0USD@):QR*+/>
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MF<B0 _K@&Y.$5-2=XT"8/, 1<9K F@T'8K<\I-?>ER4N";8&/WYX^N[SP(A
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M"U/I-KXZR*5NF#W"2^0@#KXG:#PA=$EMCADI2[>'7^LI<(L8O=;NSIDT5^Z
M]['W,&1L=>T^!X,96[M]@RZ=;W%TDHR-?$#S(&A=EVS3!<_^6D3X=]?2_$/3
MS974+.U9/[?4*L?R:N_&%D=)=I&6E?*#4)'$[F4#KF);U/!>_B/)E^Q5OE*H
MDFWZ9*BDJ;=C!O1J?X*_^/T-183I$JC/F?_I&9^VCE>T7QO!WC0>GN'6>Q7F
M)[N]-O (CMYD&'(L9BZ43A-JU?=G;2#Z1Z-XS"F4'C_FU<;[DPN_ =CXQ$F
M/K3R=_S,/)+^9Q?0\QP+H^)Z1LU"HP8?;)AXQ:'Q@"",-0S?2GU361E" F1O
MAP)W*S7L?)/BM#/X(C^=M[K2U, >XFC9)N.'Y8TQEGN[9O]ZUO905QHV43R8
MT?7T[P.!\AY;BPIQG\2_QI.1 TT[Z"6!*\<+0OD=V4>$XB<O8XK!]<AQ]M7K
MRFP588(1RW&=;V/.RPLGY#AFC+V/Z\'2Z-V5"O-V1R7:]%>=A]>>3";S;U#]
MN6.%I4]'7-K8\3L)) #PX*/&'&*D^;*HBM&R'69^\TJ:^+1=AKR\?M4GI'IE
MS,"JB"IC'7!).KO2H^5#7CC8)"68-_ '$7LRIYIE&H[QM/CK1K&5B#?(RG-%
MZ9D.=>$C,EX!66$728!^8_K2.Y(!C-S$_3$C--D5.'OYP-[?"YSS_-LU6S->
M$L"!@/DP;73,O0_58M&K4;*4M$N><-&E[]TO$8[M$LA:8<*,FD%/H5>A/P39
M9Q#UL<U+ =4OR K \VLWQ:+7^>E$P^J1ZO)>SF_\7Y\[6L[O.J$PR5O25>_H
MM\'^4IKI^#JY<-UNLS'&*7W#]>K#_H#M!9MIB?$-1(B+QC&;H,S%6PX.A=5-
M,XG@LKH]MI32G"^Z] .SC7HR]2F?I/BG$@4;#4Y[Y(5SW2<4WFZ:?WZ0 US^
MJE?ISB^TTD'6U;3_Q0XJZ 4^'<<'I%PT;],PBS4NTQCCUGR2032XL;W%2O1-
MU B4D2S:8 CHZ%V-URHY]B0WZ*!C;/0P8G]#<K"5*2;=[:.U&Y-_NN178R-Q
M]\=.;>>)'JYY[=(T;AW\(?,@R\ \._.*LLBY)4B<E7Y%I*39NW M-7EY^J6+
M?K]%,7\(@D,8C9&U GL@">"AJ_WAA7YZ&:H%X=+%D5B"GQT)L$SV(!84<G03
M58EWBA';PR3 %H=NSE! ;3C_&AE[[K_XM1;GXQ#LJU5LP=B#9BT=*;9Z#W9-
MW<RT'NMVJZ*U<*-NE[?"8^#5&V<B,\[+(4L0U?U+F](<>J7=+D?+T%)AK$!%
MZ.1@]A!L=*G,R^VSQ4W,,0T=NR6;.<<2Q3M&W?@'2_=S5^F39K8TY=WGE?Z,
M9_'^3?< _*'V_O&D2QH*C,_%<0D<LU+4Z.6$#-KUSE B/R43!=<7P&Q?^R[-
M7]?A6@FQ#P'3(?(?1M4EL920 $$)O@QN-Y'X'6W"*425MR?0!REY3KEEIC<]
M1OF#N[EKI.*CSK6G^DG*W*4?!@M5XC*8.9*TRK]#ZE]M)L4Z]!3N$CX(B\H?
M%_%23;\K4B U7BUY4+*.9YL_<\GWQ0UY^(?P'*BE04->UH=[#\O0KY69PV%R
M2R>:.4HX(56'G[L:95A>-1A<@^I]*]1$4W&-V\T?]O:Q.ZX=+_%(ZH1VK.R0
M  *;XLO:<T;-'2G!H!ZQVK_;0&<@ 0?:V*IBLY 6\T5/=FR=CPIP'FH*S<52
MA2Q//$X <NTS\J=UI0)Q $CLN$&+F;?TQZ_*1T.9#W4F20"^[XG)JQ.PY34)
MO?Q[_G_Q!RCZ\;]T1$<J?L#29K+H!"+Z@<_).J-S_S?L'HIN.*C1(_:%\%:?
M\\ $\T,[V[>$J(SDW2WI\"E@/Y%]L(@$H+,4V:\*YSJP:N+SV5(;N^AZI>IZ
M7ANVJ9X9<\2F5B/.]M:,7\7GKG'V"=A.P'+O8EM@\NK/$)J?DORI$MU7A!?8
M6AR8ZID]&J$2</DYL:I?V)T+^[\3.$&2]4R' 7Y;U(FF>MZ?=Y9K?;^I'$9X
M*PNG1NN:1T33RIJ;BYVBTE+S*L793%'">^O!%OE/A3R/\SXA^ZJY=IL1ZZ-?
MO-7L%:*R0,Y<6I_$,1?P.?=QL8$9_6B%O9D]TR"-ME,T@55UV^+2R^>"04/*
M5Q\[D0'SWF]RF<O!+V&;>L[L^RL3^_PY(3_ZIL%(RBVFKUNKOT3)[,YT$N"R
M(69_A038I\WN7Y'#*L9\M]R9LK]E.0RAC(,3<GV"E_FM1-MN 376@8[Z13HZ
M+ZWE&PUOI7(S.'MJ?5)F4J4.NA(AQY&%?9Y2@C@*]VU];27ZZ1$O<%]2= .\
MZQ.P=VA3>NF%[!)H!D=W]4X&2#K8A5YI[*0\'43\_?\YL+P_ 3-8]'!I3,YL
MS1\Q:'P<H[!"M;V3ZG#3RW&:68,2;JZFM7"MF,:K7/61@WD46<U9E8EID!:)
MSUGNN4N#$C'I-^.6YN0XPSRC",\6J$Q -DU50N6XKJ#T/CLW^2?(<G1QY]V;
M.^S:?4B8">@=ZI$?NP6KF_@LB$QW0>]?_\!@,JK9A.)KH%<.M#F,K'9!,Q,&
MOO4%27@I.U;%J5L4PFV:RFG];]GEER6<13J.S;WC*>E9OZ]F);')J"&V']R>
M!\."0_FQ9\@(1MNJ\,Z;RY;;E 1@BTI"RIOBCWBWY#7=ST?>P\3TK(JT,#85
ML ;N"(\&?)PIO5I&@&R7-A@@065#N>0U?O#LE_ DG%YG )5SNM@F=Z7Y_;YO
M7#L^]M%G'['2&(%MT<Q83>3].K),O(_GH,'AEP_<?+?.Z-X>.W[ J+0:=M_G
M-M&E*5 OP6SS$"'GX=&0VD6F&Q'?G0]6V ^!TLJ<:ABB'K9#4494A8*,PO&1
M>ZSW\630I9?_K3R"+6/#9NKV1F?JH5]N.^*3 (O[TYM3 ]H$:*OGOLLV*HW1
M]?,9+W'870(M_J5+I10<IO_V<[+ER^'F^7<I[#5(72),#NK#%SX:WCYP;J'K
M 7F-NH3_U]5CT =,@^E'X:#:8HF&9D@TPLV&FL6]!UDFDZB\<SQ.7;T9*(%?
MG>Y:66;'WRW*<G1Z^GR;"IK%.&NZ7ZR]&FZPM_]QB<FO,R?+"#;1VFOTM9FL
M$TOMZFIZ*.MH876IS+FH'PS^KW\^^-]T;OC7MOM*9.]#@A::C+5U.K!7'94T
MWQRBN(X(]13%#\;JKK+KQ"OV7ZGP3<R@P4QH]T'8!&AR>HMU"RJ9DCHA"QZS
M=$,6P6LCH!R]L=.MC,"M#$AK46^AM/<?YB _4?'L[9]X.2#IMUB9[]?=ZT3_
ME'U]QO=G/?+\_L(EF@]5/OAY',":+/:-X,7SQS\5>HTK!1P^J</[O"(0HQ>1
M]%)/I!@F=T4B_?I=  ^+ (3FF]^420 *JO"GH%FN1RL/6LRY.:,BU=RP5K )
M<^W8[S>';MW[#_W_RL%J*!>;S,;40EE(>H5\>JU:49Y[Q3/$2>EAA. @\NV@
MGVZNJ%9%C["DMYQ:XNI:[E=ENJQ^):+IT(8B7>):.NN7.+4'2>.MNL'YY.4]
ML:AL<&/)U4=L8P2/5)%E;:5ER[+$;#8:>>.(+<O()1K!G-Y47=WP6U)[-;5Z
M#^7I]-+^!A\VG. 1)!"]"O:]6F(X%("(74<>S)CB/L9]W7BYR!Z8^L++731P
MH(?RZXU)'Q.(#)=HVL@B:BPKE]LJM34SARDT?G$DL?\-QF?</*@J6XD8#2U0
M7YI[3EYBCC\UHOEC'%S")]DEW5ID=]^KXUA'Q0NE-.W6_.R^^U1#4"J<=W&8
M%.AX+D!_C6(S;Y+J4"<5->D1;FI\S"MCH[")?Q)Y@3/V6I-J1;UHH"1-U[:6
MTU;S.DS/[(%NJIFS"2.KNASE%U^HM >TT^")LP)$]KO]_TW>R'^OL_@TRQS@
MAHHEWH)/$,]U78B79!2U\GAXH\:W/ISPU(?3Q!/HL2,0(G.3!'BI40,\EA8O
MS \1V3#9# I/) $XGGGK,^V95YZ^"O[<GJU*=GOH%QA_5V#KOX,__Z+1]%8;
M= ZS*Y781]Z!'O$4=2$@N@Q6]R&O&D UMU2IZ;[?$R_Q0H)INX-;2\U4Z<7>
M#4;_81T$=1AF&@9^]W#/;-6T<*)O*Q]]O93]SAB=)E1VZ/]*^%'$"HLNCIE;
MDP\>/WI+E8/EZ/U;R@3>_AD$N]3#P_CD.NPKWIM.F13\P]JMM<!6S 87>R32
MH">!92;EY5ATUR6\[S1CA>W4<J+R+G\V<:GG"J*_7L*'.VM7N%U3WM,Q./B3
M>#%9I]_^L_%9!9Y+F;E,HLXI>I\0-%"2RAF%89,X^DQV666W=[@JX_4^H?5S
MT6I,]D6+$B_</Q?25&_++2C>8T.<M9E7V4+Y045]U2,UJ/%A3RS+?'V6]$B
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M5HU8(0&H2("CM6@9L_9B'K(I7TSXJQ]SO+((-I)T''?\7?]TD/U#ULT _GT
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M&I?_U)G;\M>>B"MHR9*!#]J[D5I?EKX>6@%+-F[M'1J>4.,OM;OWX-WSV][
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ML#Y9D\[!W[K"M7HLFJ*\C[P69Z0(D'0:C02BK.F5)J(7:KN<@E*"0;+_GUI
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M66I<H)#^V'7ZN;K"+"<+>R9*%D]-WE1ZH\3*#V0N;/,&-T%X Z,E,TR]91)
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M"#_M(5*9_CZG'KTZ0&';[6@@G9BZ;OS.)+12-FQ*W16-^0Q@&/M)AF@>IH4
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M:0WVQ]?UC[\V(@"XM B 2BG\+>AG0NZ8^#DS K I@P!4JS^&\0R'(@ [3[)
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M2J,WP?RX[EW4[5FQ@;)&*'RTX?6-*+ZVU$WX14R-J+<35=:T^B/U IL-Q0]
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MU8WT7;O5^-YPNI=*&6U%*BU<//(H.$/PI-=(3K^#KK;%K4B(B=E.O@_OX,R
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M[CYG!KU(E_77(6]=!T=]T_Q]H<CR;WQ9WQ;[W%P.Z[.3CX=%<"BY#L=KF!&
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M:(L1@&5H*W22ZK=MO?6R>-+[KS845?Q2D.0T82YVM)59[.>7&J.M_\ 8U"$
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M-XU9.BB_ND2]5WOB\R17TO>&ZA_EX:9W^X>?LR.4(UUV7,.9ENR@6-;59/>
M@ :'%OS3^ ]D7;8*(A 9NZ$'W72(!NH!-LY+*_]ZBZ)2EP.M)]=W);2N4M'
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MK,[-K^X3O,!-\?Z1\A*V1TCUF?9ELH /-<:)*CT6C0DX>EM.UR<50M&*99^
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M(_=JZ8F5V*T75$9V7:+4%/P2R56;@'[_8O_SF/>&ZJ(4QQ=?'5%QS?L7LB7
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M7R:8^1P4W&"F V+][["*!4)(]#J$B[ 2?'D&7F "<6T^-5'>2,-OU6A$%K\
M<%8MK(_.%UA(?;N<";GF0.LJS7EQCQ5DIF/A$Z"C7^,>[C@EEM,7Q*'*D&@N
M;$/[;/.;EET%<>Z7-7\4-ZA1)Y1F)Y0 )WT"-V]&*]?P(#X)\"JM\'CF\<WP
M&,WX2OM47U*9%0P!F6/4OA:=-]>A5@5ENG4-U/PW?WB$;%#=O8BUPIL!URN(
M\),"TJ5YP*[K-W,S=V=;J4@R8W/^([YVNRBOD9_&TAY7F&2O!3B>P9R" -D0
M(DLN^B@EMQQVC.^8.#3R<:/.U?LP3=0LM],+YUX+Z)ZPC9!,'DYO.?/PZ U3
M96G-6<"5;(=K)S%:<D3_B5.06RHE/"3&C_]'\.173T<VU)<@!IZV%T[QZVG3
MOE5KORS5ENKST6H;'=M/Z"5*O8,8&$W86R;]"CXDNZ6+I=/=+$U7]?AV0P\G
M57&9[^9EFF<>E%X2-4PGE:C5MY!:U1VIBBUU\5T_W/+8Q[H?7S1:I5O[,\.^
M0:@NZ=<:\\KPM/HZ?.+QC[WQD<9<6[,[06KC%)2R@K4" ^*Q.WVXZPAZTI?\
M!GM^)IQ]FW%U= W,[UXD9I=;-U[DB7+-[UN^WX?J]%IXR^A-),YLT4MMHLZ=
M@KHL3T&KKY<E@)=.6%>PU_ZY+2WI:;Z+M['["4D+,DMK5[NES2 ##/J?87?>
M9&F<R_G-\D<NURGI2QVQQGF_63]\T/.06;[#KW/;5[)#GR=;;>O#XR]44__L
M2G_Q'P+!3M8^V8#-LWW@&-(%(/041$4"(!B&*BE3W'*^5L?:H(R8?&>1*V\W
M@Y%03Z6,I*E(XGB263"5P!S37 W>%( 0+B"&.QE.7B"8@>!)TXGVRP5=4"E;
M[0LK#E&0!D=#[5_K.0X'U_@-7!8I40K@U9U]0"2[?V41BD8^14)KYL.Z0O+$
M<) >Z+4J<&\>QP1:87F;6Z-2U*"J")+C>>FY_FU#AM:O\G=NP_PJ4*OY^5A[
MTSE%_,N33.+5-53"*:A1+P)^=NVUZJV8%8QXE$8H)M&!_Q1D,"V8;/Y#WJ'=
M&_ORIH+AFS)+T.[]3V_XZUT)6J01U/OFOOU4)/;.5HVTALQ;V&+7@FXQ3O!^
M'7-W^O?$\F&M=XM:Q+HN6,)V.8-RJ=_+;U[ Q"+I/".P5H[HMD41V4KT3U(:
MK "*(N HD$OI9;N+)%#NH[:LXWI2?L$N5P?L^?+BSKN;*\<?&0>^RRV*'=N3
M3U#R*=JEI@6&7SIY212H>I=?#4B&,8%@]59-*BK+LAW,#;TV;Q<?J$2O);"U
M!5EO*+3I=2JQ@+^)Q>*@7:U@(K<Q!CEG<@JZHZ^EH-JG3Y0^!3&LGX5K!X$!
MPZI&0=#D*6AMM7G^2W[+M/ZVO+9 &1A[3PZ09<O>D2-0$Q7(#,01J0'E8J(Y
M5J"WRJ1_8M"WW4(V+8A^>6XLU$_"S%--S<[3_)9S4FK#?>(B'(+/.P4]34%Z
M^,T=[*\*](,7&$AT/ZGCL4_7LEZR34<?\JMSY%UJ2AUJ2/<<>?N0=NILFX%0
M5$NH2_]/JNA"TS1R0#=#J-IU"%QDL6N1=:>@G61<B75#/0[_>FU)Y> 4U#/I
M*-@:->A293_&J>W_PW<V37NO1<>Y"*RPF?SGT5JR<%F<^PX%V2,/$KM1%PX=
M3(R0%#+KO;:(8M8Q5H:2[U\:4DI[R^.=<C1>P;&?.LR>@$Z$<)M$#B-\[ F9
M^]52)#W8*76A!R_X'NL>TZF<J(3UK8&N1:&FO1T/MG9E.I?./:)EN?FP-+V'
M-Z66[KK-NX7K*$(0F>% +7E$'Q)[#T))?J,J#79.-.6SA^M.'A)6&*#JJJG)
MC9_+0@."H*S^=B-NPO&],S4M27WL"KS-9_5Z\[$0OQ0!:F4DH":'Y\<ATG N
M/=F/=6,K /"=F2 [!R\ZF4H?$9RDO<C!4*6YVL*YVUQQU H"U_25_4@,4)QX
M%]FP9.:W4N>-,*E)05R"7QI2*0'_GV:=C8WIFX--W*--CCZU4HI"U0YQ-/3%
MK6>T!1XB1L%8VYI$(W*2,.P@F_H.8@5<K_L4^[/_=_4K928*Z#(3+K"U*;M"
MUR=G_;Y[SC+-.>>4^W4^=R9NC/_R,LQJQ@F3&/0P8_P(<G)IH-G)); 39;%-
M91B_^=FN9N[C!-].P1\A6095FJT;&PO=4E!/+>L7;WV4)O1>BCJDM;I=QPGT
M#A)5R8]7))NN%L%!-#M)(=HXK9E2$06Q*9DA:Z9\,$N<7& %LEYF]PND\8:M
MN()!P-GW] .R]LAAU47(VB:1564?_Z?4J"=-K-2&].W'(F2Q[^+1-3305O&G
M[8Q85%=(<@718*;*Y4!Z<Z9&"4B>PNNJAKTHS,34'20Y/KK/E$/Q^R+977Z3
M-^F3([):D>A2,2N+;6C5+GTEU$68,,%\S!YKTEA3MZ!2X.+)MC; M_-0\9?Y
M=8W;U4Y#]6R7=J41E@#/*8A&&3&3W[B_@\0(I.37,1%9C'J7U7&Q,? '.6XH
M-.H\+,;'</'V9!XG/T^3QRY+V,MW:9M)=HN])//%]HG6RSI(#K(6[I,4X$I8
M4R(S [X8BTR"6[!GAA;^Z!2:5G:;<D[G"3/R)()=_!@,'FX+68469+(K$.8*
MNG,.R?6!0D"O(X/?G!PF->K-;,,:1A3HT%R:>=%L@*]]$-AQ5>AET2B.^=GM
M ESS0Z=73[7YK':1! B1:1RUV@FNAW1#%FZ2Z!+1/J889!SQ6N$2H(CQ1EWP
M[5Q$YT*'$WLOC#DW%2YCPJ O?)O80^BM-7RCX_CW \BV>XX[[LL')++[_.88
M\$: $Y9@.4NZL%5KH)6YML]O7.3%K])Q\#E;Y;&^D4V:UBC(,MT^<O3\=))2
MT>H^("W>EQK].X3(%T&0@3:?@IB5]+WARF]@7L.]5NG;:=*V#F/X_FJ214]6
MKUP=S+KBV8VA**S. V17R"G(%3+GCD\&BG%M^&& @F#HN7(6[)D:P5V3CTD]
MYZ4E;*>"R[%=L!OS+-TJD1]JKKG8QZW$\U,)RE->7[E#\5N>X$$.4U^X,N$\
MZ2.*!N7I%Y]_9E].2P+N,7Y8BT9&/=H6F[DU[2MS/VN/KEHDJ>'.PJ!Z[_YZ
MMC2NNJL]L[&(O-H6'H25(]%?(TLBAMS]@6WNX::)UQ(%W/CLT,?)&G357QVV
MK +:QK@F?85;8RX[97]N2F/1=G@@=V&1"\[TV0^05NTV74Q<8]JA(="2]],_
M!7GNTWD=MV;W?'#Q2VIKV.!0#U3EL+R[Z&5UIW!#3H'G^F9Z.8N-L#GK^S.S
MX-7"3@8PUAP%7)7#VV;CM7$F^6N:9]"0V'9-3 T?T-Q]/!A6\GVF:6%ZM) %
M^L)(-]V(]9&TEXGUUX&(R(<4AV-]8X#LRD!J3#[6ZA?Y]$C/XSZ)DFZ'5#MH
M_X0%.$QH"<=IS:06:Q6<,67K2Z^JDRR]^#[])K=T,O=HEPNBB$0G3K9_ >YX
M=Y=PE^AY$@?VR)]?,0&0..'5O>( OF^/:>+LS&O;8Y:/*JM!:6LWN*^VMU\9
M^E3WC6KQ*38[$2%!5($ FO4]"\,P@BY[\&\7CY_+2$^==;W2?)JOBXFZX8NW
M^H.MX74AH4D7>5(DR %*#S<%_,BM5]<PJDD'G[:VQ+_!Q&H/JVU7UN!^?COG
M/;](I+G/"Q7QDX6&?#'_!&OXFQS0R020BQ/N@M!H\4)/0>PDD1_8+4<^;&=R
M4 6T]75_L*W-8N_$B)2+2/0MEX@Q7JN-\%0B+Q>NIS?_?7,\:K4RC^4D5<D
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M+1)KF\J/[-)$K;X1.(MT,<J?SS#$Z:;BBBPGO1OVV<23'S1^F.P<+^US532
MXL6MYES/?WCNQ\OW'$*6UDLC%$U.(;*I9/\.P.GM#!;+=+91'0>#+WC#H2(I
M,KJI 66]CH.5S^F8YHGOS.3I[1ZZ]3.1:^1 X^GF'G+1<EENYR;!#LB[R]%3
M)=QG:>[E*!VCDC.Z)'.4R#,@IM_%N[B7IKT^S5L=_.JA%;*1J0N<!,;"QKI/
M02GDXC1!_*G?H5R=!TEDNB",Q^'V(!I*@+DV>W9S">:$LJN][9^/O\L5%.@&
M.F2T)W<$Y!S_X'PGB_<I",VL'([\4[V&K#'Q$^U/WFG1(_KRZ34NEWNAZE9B
M91LA',,X!OOV>I_0*JI^/*,6#]2=PMF#6T[=\RX\7:]),^J3UJ49A#11UA30
MS#7!783K?.E_S?Y\X79KQ+30 <LIB%P!W2=<S@@>5WUUR]$Q)#1*3/61S2F(
M%[E:H+K29$ID%<=_/$G7DH&KX9#1WD35U7R6[R@F$C?Q"M9X<Y$86F6KHUS5
M04*%.''D/Z)_)RN4@)[H<PE<:B]5>!)^C$62&(S6_!9I2+2U:W_4F+K3C+UI
M4(M#1@3*^!K[=3O*S3X@L$7/O'3'MV4;%$1U+,1QB:9HOG_)%>6-"[CTBT!B
M;#UY!_8CZQ'\WC2U4Q$80(]%$ -*8*D#G1(SC?ELL)*!8\N%E***!O:=F507
M_I?2\@O/V,Y4#CBC;UV[1X_+!U01P4 ].3[72#,"]2$]'5JG($M<U4A^BG/S
MEYW#^?GU=$+/E>N>W%HCJ2+I1>7]G)U6[ZY OZ!6IU,7LE?=(U"K&9VJ@!1F
MG^]Z"2RV1TL,QU^!J8!^S^-LN'81ZLV".0BE[*-L6[^@2!UL0%EV\$V" D7V
M,^63-BT>X"F);H2@#4>00\87V275KKCJ8-3%+Z2>26X1VTSCK;*-,?%G\Q=$
M#O;%ZM/UWUI/I_,\C)$9\/H5%E]3@%Q]F8^UE[E+HI<B4!(=3AK)'G$;L.K*
M!C.X=ER$.?X<4/SZE*TJ<KGA^&XBJPI.G?W>@Q3[%V_'EOK@Y)1'?0O6W#V
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M.+"R$>@3P^Y^W(-6'$<\Z6.\")VBJX&G8)[5BTWF/I$G\A2FZYM$CE3\+=P
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M3 -Y3H+$&TJ4,-F&A>3CWF1_<7)M@,@QNYI/9%5$@W?& \J)JL#=$H^<X)K
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MKU5WCO4VYY&L:P'$D9N2/3^=7*1,&EYG-&WG+-N>5+55O=SY:<S8(/?HD>0
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M!7W4\+^^1F6%? .#:F,[DAZ'Q!Z^D'%.4=863*+4WLJ83FW9S+"JN+K^(6F
MT43M=[(!5-3$/$GTV]&&I^<TQ*Y")2%%-HN]89E;U=1=*=<16H@4][,(B 42
ML8BUOAR-Q[Y/,6V+E&Z46[;^@QHR/67[K]^FS>4QE4ZT F;HW%2FYAC,A\[(
MN<5?$I?:727>W'?9<E"^#BW;:IXT]7$MO:Z4->'=DG+YII)QTNY]IJ%'HXQ!
MR ?WB^.KXAZVE^OH6OE46P1!-85>'S56[X;?1G0X*I5-;-0E^EX31Y""F[([
M4E6QTUF-Z!%AQTD-*+3<T=Z#^:6,W)M0E>T+F:+R242B4ZQW:H"M #V)YZL>
MNA%'DZ@L-3MUY&W_M5_6QA*D:WY%L7_ZD@"R..1HF'B?'!ZF$7ET^0,K%QI5
MFFMC=%*4$C0/QJ3<O1_5X.2[-)^ TK6I9K5L>E[$NSS$)AO,!$X5F<A9A6KR
MA T9LD?ZV06H5KZT)F*B>46],ED]^Q;N9@U*5,'3_9:AT'GO-"<2%\S1V%@Y
M.V5U:8 N7I9QV)?6Q'!S4IBX4280*7#>SHJTXL.:.Z;ZF7#]^=[*R7Y-!VP_
M!KQ:DE^/;T;+V$&F=X\T)0DFEE '_HT+!RM):*K;+^\," O&+:;[:XMU2.'=
M3HJ(EPE&P!D2RRF(:=[(-00J\=1RTNU:<L/<Z)E5&O.KYT#'(!S$*N>AKDMD
M@21 9"R@JVC147HWDVYJUV83("<:-B^@FO4HR_@%1C#VXQIKB5K3\P=[F+RR
MZM>_'-O:;'=^(/\I1:3^4ZS4R)\4(;W" U:S>TWIX5?'25SVV^:PG#V)R7M9
M#DW?W]U)ESQ[-D^'2I[&@^+YSXQ4M\K:J[Z*_P=[;Q459Q/M?78""1!"D.!.
M<&D([O"2! _N'H*[0^,!@@0-GJ#!M?'&W3H- 8*[=#>NW6BCF;PS%W/.S#G?
M6M_%S'?S7>S+6JMJU=ZU?__GV;4+)[(HIHKF3:4K[]XJNUUA@%-ILT1=6QXA
M52PXNH1[/$[%<<P(XE-EO%>3^;JFFP[D><[82?$2=Y-$@;45"($J4.TJ@FU6
M@ABF:Z4\"&-KA56_,S;5\QLM4R5:I7\[2?5KW[ ZL) )6;^4I94APOP!R-^7
M/U!ANH^\QV3$G$^:=CJ2X5':$V="+(>GQ6;E"WVK$3/AHMVT?^7INW.+6 NJ
M.V[4=-\:=D<79.Y\YF&V]8M2QLAUIA<'P:??@UAN(1O'YA0$!P9_919QEHV0
M%ZV$7L6!MOY5<,Y>X%SN6O.4UO&%ZKOUZ!=2?3;77:8M% '"+S4C+RZ3*PK=
M&Z:.]\TZCC,;,;L8''C+9[<[+Z1TP/[H^^D/ JLKTM,Y+SX!Q&U9/@$V4P '
M>C)DCG]W-$0 ] **$ V'T"FHB6J2^#_U7Z0E32[Z,)H:3J5!-@T:[3,GQ43"
M1_-Q,<O_-,^<+P\N>SCXT&^Y;MR$$S)%X3(2R56N$W138P3A#!%@*;P-(!6/
M][*PC*F*LMU'S_%#?UOV%#5_Y:V>Q009MVJO*A<8S"Y4QM7)W_!RZ=<? .2E
MNJS!IM]Z?M[^FFEGRUG;<,AO62(9NH?Q'D(+!$5<ODYKW)&'B<GBTEK()4)1
MJM*5T9K1;S.1:-8B_ ^ )M2N)RGZ,/]%IX^/\(W<CD:)F2J+*#\'(XE>ZP<\
M0!J/..U\*2AU@)X6G9@D&MUI]&-Q7Y\"_TOU"7C.<"6PZC'WIL42X0,>%*&/
M22K#1%P:@X0D:0[\7\V^RM1+8:D/(C(R 3(ID\6F:;K+/9#WWCR/P.EORZ,V
M-/4QTJP]$9MQD?!558+9SXW/!;0X'2;E(FCMR&U Y0B44)%Y='N),ENE69<-
M165@U:I]^E&'3-U_2T:=C9?LH4E9LI^%DZ+7FPAJ:FXR(LIY]*FC?I2C34T$
M'A=R]@%E<%D:O9]7Y83CU"T[M;-N5WD5&!V0-ZP;L;CYV]'U-]5Q[UAZXW#1
M.'U('G\A81#Q?>MTM'[V];YC8?128KW#TIC,^,%.P;FXK14M])$&R<9>V_WW
M/9;9XZSCZ@?CM/\8A*VA%'_AJ?0[XMM1)[=[9KMKB0>UHM"OC;T?']K<:7:T
M"]HV-I&)@OT/Z_DO'\3OB!I0\T,:G^=/A\H65\;<:A4YE('69R*4[Y(9LE-J
M1"LH?U(]B0P4[?N;5B0TADZBC-D'$RC+XPSJE+-8G:^U@Q>9;XJB=!Z.O.R"
M..,&-RF# L <.A5L;16P"@6M=O=\C0!1IV @JP,+-!TM0FS7&@^9[E+Q4)].
MZN 8F4L+N&V8/*K)*OU5L3U)@Z!E(#SO"#RH>))MNF_ 64[4[#3YB&XQR147
MF]Y)=O /X/F=6R$H[&(]>G[X80T56NJ0E?%CG_DK #L&V0QX$OKS4$IXPP6G
MOWVX%KSG[I)OU/%RE9\.U_1#H.O*NH%PHP5OPR];RZA0\W*DEJYG1.GA7LGQ
M$+M; 'K.%+8*JS+B#J89^CV@9V$0Z[&E8CIR-^'G$\QSKN]D??OM*XA=W9ZX
MQK9#^1G6*]:#U_I01GH!:13G.NJS T[)[,Y?*@GZ<FL(VD%$'_'?:@S<OKH3
M1/-=AB3;PH7%"WUU,^0HL@5_Z6[-"4MB!SW>N&),JKTC@-^_[<_#GPKBJSRP
MTVZ;]EYPL9LQ9N!9:;(G_6G@Y0*,3TZ%U?X6-&?(4,NTK#*HS#6>W+GT]8MG
M&&"[O(),JP9?8JJ+8JQR;<4JA3AE;11,\Z;VI[(PA1D/QUD7IU,/_$C"B#^
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MV2PR<X<+*O[S3>5KPM4C;0SU*/3&($9*T0<9M[NND76N6E37ME(O?V;C[FZ
M98?,NKZKY1_6CN?XJ).KK*X2E#6<V7'$C"<SPLNO4>5P(<UC2_YYI5)[BHL3
MFNU_\',STW?:Q=M 7&,)JC(=PG9'@LX?R&4>O!*Y@21&LOV8:Q8D]<>VMS;,
MCQ>0>9S^!V!O0/#OH[:8L%#$'\#B?BBAXU):RTM,J%'*W".AR%@3(0>6#R\G
MY1Q(7_2Y<\^?'V$IH.83(4ZU)(YSIZN@=DNZ],9W<O8%T4^E3F7V8'MYW%OK
M"XJ7/O<_NFGO7&;=:K=FSV5Q]^9;^#5H1\B!MH:+\'A_Y]X&P"^$9K&- J$X
M0QDJ3T2\!6O;4"I82;M"H5:*;/8J)=[;Y6P\ZS/X_OPP^;J%!%YED^.5:>7N
MO:--YM#NY6"?V7X-:=B*7_F[@/:YVK<'NU(N&[>Y.KJ33&CIL,Y)/1.#YEOM
MZ$;]>"4P(SM'":X+--YO8R:/%NT6&63I /P#^!RD5K9?)R<>[M!TL+"CM 7@
M5^!0>H[%V;?S7-II:/F297H:J1@O(V@&VD=JAI+N9D7F7]J,%=8NKFUA6Y$\
MO4ZV&GG"1?@V-?8L%,.2%&-V!T1J/%%7@624./DRN[ZP44QH_0-HYL[O;\XG
MM/%ID%*0Q8GQH2-3_>ZY-%Z:8KP_8]WDNWSBHQ'3:"Q^3,,W#$\7-IO;"IIO
M+ZVE*/TRPJ<7S+#2W5O[%XC=^!:0.IBKTK+!T,>.%(0(:;:)D225+.3KM7_P
M^97Z$.*>RCB?5E^\P#V1=:9\D";\3&+Q,"'J0EYO!<HT,)<;&\R8K")/).7J
M5P0V;DG_P_A8B6PE2%"#$HHZ>\= 5"L_W.[=2F.8]J8^PE.3"J '>,[/_$G"
M@%SO"]3]W'Z'4N7WSK;'9M>6=?IU>C<5N\O)<OO16-T"/7.Z<S:%0E!.?:8T
MF*;Y:)3[3LOQUJ3'[FS]$.>6%?0'L,$7 \FG!)T:'2UK3O$@&ENBX,^UKV,:
M?C5 PP]8!!Y1B@.V4+BO.L""E[4]/??5-;*V<?E1+?J_ETW:7*Q_6:^M:8_1
MI.L->C1L6M=?QR:*DQW.#(;C;ODC(\DVH=_@_P##PE+7\B1C,CR^&0S;ZNHI
MST3S.*_HLJ2H&)M?*J]*TP23A_>ZKU_RFKU]DJ'O#5</FFK7]HIS:75R-6F&
M&!>W=RE.RI.=*4Y'DBEA,@>J$(_@(O/.P^4N\C^GU4:NMTE^%<K1^Y&-U*W&
M6U-WZ'&HD&_K=Q</N^=>FQV5_>(HC$T)C^7>F4B@AAY1588LT#]&340%B58M
M@01&D!-M,\Z\>I9=K'C?QA=L].2OW[EBB9@X/$G/G!HY7;1-WU+3C1>WY&QA
M2[G2\35;7AJ=MYX0%/Z%3->,5%37V<YA3--Q6TLQ\%T$+H=D-P78';U$%ZE@
ML%"I>IC4BG>IJBZ42>I-OM E5XL8Y,5PB%7BFRKZV3.[0RK4R^'UEYU^?$<)
M:"_3MA2GY>^;4P4D M(KWY=L/Q9_)!MX!8VG*_I4B>77@](D_,1 W6//[8:_
M*TMP"+:=.N1CR=15YM,7)9$9-!+IQL+6>(WR]/OZ)/ JLE.X"",ZH$]/@KHO
M[+,J-8*Z.#Q+)!?2K)1ELM!Z*]"_:<I8\#G'G)UTLU+8CD,G,2?/]':]\ES_
MVOC:EEL&22%ES5*W($^A)ED^7@W9.=M<6F6HZN*+67\11(>VZ[L*P4(??^5K
MZMCHL6\Y,Q=0J;-A^AJ.^P%WI[P,@].[1HNQW,@5[0TA:['W7F6;_-!LQ !L
M\K&57LA)"4QQPA]X$$67Q=_YBZ-6([^AQK-]6-.W!H^#EK^DV>1)O8AU[X[V
MD#U>1>/$9.NB-T.?=0_3+UV]S4)J?6>U3N$8]7<DK7V?XG1&Z2$O<>V4(*ZZ
M*-%9I[XO6'X_RW'B?;FC:KU6P7QN9.U1EG39\#FXEKV+U8Z5,"Z]!WCMUG$\
MA/%'YNI -1W;#XVMK51C+^"3Q0D]_MX5 ^(3E#PR.E#W -MRC"@"$CT8K'_2
M9QP="2'@1=Z*%V=P;Y"VG_"W:F@2TG1Y0<EF[:GIL^&YY/,#-^_HS2#%W*3<
M.3F/9O(V+]C;A,D; ^&Y3T&051>PRU;RU!1-FZ8;Z_)6O(A@>*!W#1<H"(G_
MED"_&<B.W]ZBFF$PNV0L5MY1?FV\8[K_P4FW"E?+157)J*/*H7+NZF GD%Y-
M]'  _@?P:?WQG4?QPX1!>W-FY;ZQR<KR2MQVBH4,MFV")I*[(QUY.PL-[1/N
ML;? &*X3\LG0@N:'7ZZ#LM]W9R%DCV@R4P*SE9\UWQ\K!S<(1L!ZN1=BK_*_
MK(G] 40&PTO0CYH<#(XNT2IO2.J'IP"'@\&3+8POAQ%%74'UMQ\>QO.D,'QH
M[='+NOMLH2B#V$VU:H<Y(O+34G8"CH20<^UP?7DZ//8BDIYJ]TN/3+3:>UOY
M;WI_ ([YK$HS&?N^:594R@<.Y4V0J=4E62""MI&F_P0OUV:F9[&"4R>7XP^
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M!2M9GS0B\,)7)0"M 1Y*YU*I"2.*KAJ2I0#+,.UGQB'PK(D==$0VE5;_LDG
ML5&)C?-G5USSXLWYB+<$GPLD'I;:$U0L'FMMQV^6.%E8@RO;&P\6;IYAJFU
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MJ2.!=*V^3; $D?8#F1FW;JO9_!7%W>NR'9FD7GD>S-0.A*HE$;-70O7I;,]
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M;IC B_':T5S>N++O/CPP5+*7QH*P:^Y;L W?;_P"_$I2/B 6Y_;G<E4QH4/
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M^TOI-^)KTNQ?T_))>X&+,A! 0^ZUF8JI?UMYG*A3$*N:(H6U<V]^3#'(R-M
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M!D-D&S5E-$2\$Z\B3FK=/"-4TBHZ#]BBZ*V6) 1X?'Y NC?3%D^GF[WBI>9
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MC7\>*/7^XW-/4<G3?\ERC04MC^=B0[L0^*<-XM-T@8--><Z0>]:SZ2!F24G
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M9ZB?L4#TE&>G>&HZ(D!5V2[])-A;Y3SA_=G3;@S./=0X%3RKKPL71"=DFXZ
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M@M?\$F]M@GS/8"0@>GL>K\3R\ UTXM)P*F1"0?(6\#$<&ZF,<L@.'C8C _<
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MF=QU/!.JIS:E>:YWYLPNLRX-=Q!]R PAD7AI![19L[1FUL1E3>R>:SY8ZQ9
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M'_Q+HV<'_A=Y[QG4]+>%C4914&FB]*Z -.F]!15I(B!=0(A()_1>0J+2NX"
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M0:^B>&A>:WO;K0OO]B]]*07+ /E^>\>4>QGB*#_[3OGN*W6%SQ"+HDT30$_
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M^N27#&>J%1G,"QTTY )O?HJ3&BO55?&3;<DQR@+O7=36*M_=.M,.AQ=VV)U
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MER?"0CRK0UJ#KC6PLS,5WKR2]C-G("SE:.)YZ#G@!<*;X=H.%G]B/QO(FF5
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M$F^VJGI GH[3WMQ%+2)CIO5+9:)NL5Z$!$.%2< +D:AC$$?$)SY&_EZL;E9
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M0BYL7 T2G^D--ISQ>6W71_-6$"7&:HU\<H>97[9@@.[3Y-WRB-ES0!.N":M
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M&T0+#*WP>%:A$2T*7,5^UPO9Q20%921N?NC3)GNVGO&2?BQILY>5Z(&'8)M
MLX'@.$T!U;+6K.K)<@]Y&@ZDE<SCC-+"Y3^5B)ZD>\X9E*)CYI'JEJ;_M:E;
MBF#'UW/[$0M-2-TV[,"Z6S+S74Q;O*3#;YMO[UOR';TOTS:]BN7Y#J!2,WM[
M.<R8TEK'!#.?T.Q[/3@ A/6-]]6<JMC->63_W2[$J]!+CO^9=RV9M/F+/D#*
M(;G]14J4& 5ZR"P-X(!GR3=G!,^J(H [O+3>+L[A2G0FS^5!W"[WLJZN6_@Q
ML=^9?LEH6"E)Q0$X[I1(GT>X\T45<N.M';%-C_!OW@-C%8/17/?F]GUB9U6+
M.\5;JR ;OVZ#U%0E#:X]SR[0IA"D+KG("7S[QY1]/;:XJ-E>J1T<+_U7NG[/
MTZTJ/YS^4<?CK+%\FNS7$DM?,B/0Q1D6=_#:70DLEU8?.3@19",65ALGT05(
M-&CP'-!X#AA&,PQ;= IAFN:R# MB3J$;3%7J3.+C5(^I['?)R)6_T/E 9<Y*
M-,F)7EB^Q&XA3#1J.!85?K<O%VN%+Z=C>&187&ZO'SM'92-G[KPH9ZJ6VTX1
MJ2;^WZ.@'KA>-+(:O=JD-S".2 ;S$ ,]D>FTD$V*4OBN/FKZL_P5BWP=DP8Q
M5W/:C<N?2U7XC2D==4(JXH!>P 7$,*_RE";G3A&S(^D'5N!!+]^,KP+AC;4B
M,RV#GVC\E\0KL8ZI&S<,;I@51O4PF\_N/[.7V[:>W3I$U_&'U M^M_40SW&*
MI%(G^WCEZY4C2RX"D/05>!7H 8[)MQP!1_;*@:X%@VP]LZ=;@NN$7_C0LLLM
M&<84,'YDOGMSHY+21]<L*DS\/PY<J?=<IQP&Q<*:+I)R@2%J>QC.!RGDP,RE
M<_:6UNZ>:(LZ+B,9_2-^=S66O!M7DZN.TJ=\>_8&Z'FPD(OKPRAN#Z8O%*U;
MQ*_3<3WLS1PW[9S^]7"/ZQ6'NUMJ_RA9Y%WO#+-L_K2K"I=^LEB288IPI7AR
M[+AU.!G2<K!+RF&/H.!AD<AM,MP95^A\.'3\1C^IK366!&K^Z!SO1Q:A/RF
M(?R;-2::X\\!?@0IJ-I9E;I 33!IQ?#U10?)U3+[(B=$:I2=\>/&U5^\4O">
MFV[.WPF1W[\#<&,2@Z2;YX ^/80C.*:(MQ;ARI<(:Q&)>0;FV67/P;T,CC@'
MF%S="U"-CUHQD-T<4$@:&V5)J4=^K2[8*_+Z'XRHN%K7ZWVT2W>>LQB+U_[-
MQ/?^@-'%:AK9(P!3Z*4[3(_L@!\1BY9KM]'RI7N<)Q]!2:%Z2=[=&O63)7L3
M9<L^WFJ/8L1RII_Q*YCR!RZG7.+8,%4W)1A!R3%NPS^8<=Y8OL$S)0:^X'0C
M;[U[F!BOZ5UV"X_]5/\;J=8QXI_6/MW1:FC4G8FD__5O,/":W5-0_-&;NC"'
M;U+[7E[>*R@<[C P22(XPU ];?^.COF5'$' )>'N+!SD'! 5'3$$:[WP$>GD
M$9]7F^/CH(ZU[M>DAJO*?N8ZV^GX?&;U85-AM=&G$K_RB5/..L+WM3/9]QTX
ML/&LZAS@AM9#!1'%]F02Y^0\5Q<;?QI0C\@L;,R6Q$Q*O\VU58_OT;][?Z[F
M1H&3A?\+LXQ1HO'% ],C^A'DO:I6I DPZS_I<T=3>=:G#OWN:R"=OD#94']<
M%)7S2.Z51C$+_0T7-]HR+=J.?ZIKY!P .5@ZP<F?I<@T]\CC2LY*H"IKXW6N
M2KF@EF\^MA/!=V/D&W5KI_JY8^7:K?J4?^0?@QCPT5I8GV@G%)QZ[WE^86[5
MHEY0A8=J^-@$^2R3:/!FVCTA>PY]%Q?!:UJ4%)'2_WF99 AXT'?)%V=S8;3K
M;/M6KT7(6/\\T>1)$E,W#<2I)7I!U3/Y,^6K'/2X;']VE=X8671.%NV+']-Z
MQV!6TM1] S5)'WS2'PI.Z^:I&:J$<,X5D).R89>$I+W+4YV3S"?5K#FLPCBG
M+FI,>ZQ4\@YO><Z_]QX2<7@.PGTH\UF95#<H!&,X0E6OL[;*MHQW&TS+N7TM
M/-V\+8G#M57S&:2[VD[;4'AC_+&L^,<@A0OB@%767DFH IX#\]L<WX1-'E%U
MBR,JEMC^.:UOJ;6O5<)]LA+_Y?KK\UAUJ5!>MAG3'7X>.M:MHB89="I!AK3@
MP#JK#B'<(GI]);I4_&3?&K?TEO87^M!.IFF&^<2F;Y5V)] N35?'%F]/,(V8
M/ =PJNNNL."=L*HC%CV>'#*U.:*;^L<2RIO71H-<!!.JPGTR&X=GEIHS:CJK
M'EMK 8ZH)0:)8A<#$=ZS6/4 PCU#@DCPA7/ I)X,*O_R\<X=N+5[=Z(0M0IT
M;TO\=+B5+WDK4W2A@%K9A<N6<@B.%SW9E\ (K+O$[__$QE_\+#T>"JF<]+W"
MR5M6=<5]JYTC2NS]2*[/X65JP=H4Y*M*_J@[&HW_O8E*?"):$IZ31GLI\155
MT&M8T+":(>BZ.T[[Q 2S9&6ON-E3+"@U?J^![="6DBD]HV& $W \)I&%5\&N
MKU6@Z9"6V)&/Z<F:/-BT#)Z9Q<E*O*]5W*&H#_-!G\"]D?%L_]NZWUU^D0>^
M^J^QX\_'JZD.%3[+BV#V!'/WJ@3W*/!1XY]/U!\7V!@:5+!]K1Q72;L2PD4F
MLFGR5)0,7E+MKKJ5B_*F'Q_,YYDO<JFTT0MP4QH&RXFQR"E=ORSWGOO:U5_B
M/P LCQQT",:DE:*&U7V;9X-G54!W&0:\G+T+KY'2JEE!2M.]6/.MPW4+EUCK
M5PJUE\4>TUS6 82B64?PZ>L7O1V,FB@W0Y+;765J+L<,?VB-OSLGZ:,S&UK5
M*2YE\O5N3_V*_\Y-_;O-L9%W!I.*@6@C@MH"E.T;T#W5$H5+=ESKH?V2O]53
MM7R6HZ%DY7+HVM9NK=W-_'Y@S%W0/-OY#_6O/^YDB)+N-IS_62O"^6!QM2]T
M9)!O87)]/K[;]#W^^68=\:Z?6]!F;_;-*G]IIU>".>< 45<*'6/M3+E+M8B%
M 1(U#X&1-!^A\*V7FS0!:T;$$L'U.SDE>\;3S[IFMI.?])%_]D ^P/B(J^^<
MZ.6"WVS9188I_NOH!GKW(L* VN> MLE]Z<O.Z:FA4VNPV0ZH)WH7 Z*_* ,@
MD:Z"-!./>XN%#\OPXH?W'F(?%J-D*((]A_(_6X8&Q1P<>+'U;]8"_873!'QX
M3"BR2U(FY<4I'H]=^@T:!N%%9=#6F', 3NZLA23C7J@XO3H(;&H;'$?+?VS+
M5:65XIE(477(#OZPHGNKL77OYZON".L_QM@HKJ^:@E#7LTY-?EC?/:(+@1,J
MA,<B@5?=C2,F%T&IS5*.1'(<85QBO,"$-%KB*#6?JV3S6=;_<K6L%J._L#T\
M;16C=Q!]#N#YI2G_DS,>388%WL'DCL2E;8^0*#"XBHJA"J,JJ;J>XMF;04UA
ME9ONWL5T?(7>/W(#!O& 4)EXF*,O7; O+KWWK%J*I(H_71\*C>\G@"X;"2UW
MVGY4V/-,K'=\+?+]$N%.(0I"DVF<=\O4W1S =SMBH@ACRI#.U[(ZP+"PU,_)
M%ET)*;R%K\!(GXR09&>[63W+%3]33&\-CXPW)EL6>$\)MG>&V"'>CG)[<E;)
M<92<OL'Q8?G0WBB92"489JF7:KH9G*#$6;!9@)VJYW</Y++:<O0,=8J"9*X8
M/)9M?IEX7? --E:<,LD>UL="NG21HJYH7B.*XGVQ!ZBVZ./5%\8_;(B*^%SD
M1.@87<3P\/9E5+\;&\RUL_6E.(7!XR?/Z4.\5Q]"F?%:I40&?+CGFH;,X.)6
MEZ3/[UV'FUC-8ER/H45G0)ZTCRMU\88/@+J*4_R]7XEN0M*EWPCT,4$>JG%6
M0F1=@WTW1,['[-?5%Z&$$]<U3(V;8GPQK06.-=*E 55Y*F*!(8+RUL.#><*9
MARA0@6.["PKFG%",C[\(/H&SWL?XSF0_\NY"6LS1\[9H_[OO&.A&GS;4A^H(
MYN9F9GSM3K<O6R4R!: =Y+ R*:B+I)@6,6/ACT=89SW"TI7GK7N+3TM4N)@=
M]L4;&MQ,?6*>>,6G7'G*G'J-\2>8#>CH&P]D@H:@@ F]W-CM)'7FRN"EOJ]X
MVQ'O-4*RE2ZB7&L[O$!(?FGL2;Y@1T>:6L(#_]H@^J[&ANL?-4,N'J8 U?Y*
M5+PH6%>\!,$0&C(MU(.]BK?T?)<<[>$32/=PF&L4.?,,?^VW0I;$G43.WQ+=
MC[=ITOEG@:[ ZQ$CJNS[EP@"^/JKD@K)!XOR-EB1I.9PS<=SG,]KI.H;:A<@
M&;?ZFY5FEA7\U@!HCT8 O>SQA>&&XX7CHR+$EO&75Y'G +0$U@GY,!4S<,=>
MI,_A.AY<^W/.@A/JR?Y2F"; \>F6HV\"ZS@QP]><9FM\R_.B15_!X\/",)HC
M:R=I)'FH+C:BXCU^<6GH5&80R+KWU7[OU*?%:\>[OCAW?^_RU:DKVC+\@UB%
MQ)O*.48?>4TO;.3IEZ*+FND[JU2_42Q?0/T;&139XNVCN*5\[-\9VP@L^81[
M.?S^V*4M79U_9-%\&WSY'.!:1 ZEF2>"U\=YG$SGNZW7SVSH[@YK2L[3"A\\
M"I::7ER4^J#'\DCKBFRMWQ"G>$I7P;2! *+D/[TKIAP&8HQ!"P>XKRUGY=TR
MA.<7_8\*T18IY8D"1JDS^B%7V: WL2V?DF:&>/FZNFRSK7Q8HAT#MQ=OYTH\
M4:$-=J5A+OVSW7^ %R^*AFIA)$RQX'[PPJH#/A ;-@QN=LA> R:LTA,-R;OL
M@\,&YY^W8L=5_V1JD4_W9+]T%W1+%7Y=H[SYZLP7"\19=F%'1J["W,%7B# L
M/*I;AS).X*L#SZ5:UP_=+8:)/H".EN[6/.?'AP7U78):+^N+-^BV"^4NHN5A
MQ 0?L^:5X(.UR4%TT%#^7!66;P@3W#2XROC&/&E^4,"^]5I=3K&W1K/L$$2H
MVE:+FXK%D%,PV"7\D!V F5Q$X"HN_DHE:1369#E\#D@\K<]]/U 6;&N#:490
M=YNN%Z@]>&/^3?+@ %W;PB7Q2>%-J2_+!P/59DMMJ?KTN)C&7W5\B7S-?$06
MKC4]M N*8>'V.L-($;UG*'@0_H(DB T:2.? FWZLJG (UC.??G 3-3F:[_GZ
MES>QJ[)0Q769@+E^ZTL ;*VLJ($O59/KH@(D(H2),IB107 JD%L]!+5W0&<K
MW5)CJ]E2;^ )J;=>OEJ<;-2LCTR['OMY:5 K+YD]R/M=N"T2N,#U<1&>+AVA
M0GR ;4N$^J%X##]F!MN,&&-UZEK>_%S4&*AMNZ5#7M?R(<DP7M_&S7GE 6/E
MX3<E8\I/B(9<M 9VIN\<T#"_[T90_XY'#&K>P-X>3H\>&33%1_7/&*H6I,85
ME/[T5>SIF!5*6[&->V,<^WGFS\1F[9_41$LC.%_$+!AC+A-=2(77>@>U;<.X
MQ4.U4).+Q9J\H[ J]Y<.AO5X5]3B[M: >8X$UU;<V$8METBKKEH>59J^^:OY
M8@\P1E?FQ0FLJ6@ '-D)0S-BGP^8X>4CFH@B^%Q'E)JR^EUD ML/;YT4IB'7
MG ,/[V^.P9LO/E>7?G;SS>\"7;LH.$42'[ZK'TC?#43!TXN8%7D,D:N#-;Z\
M%4DR+;94QSPP^RC*MK2PDYS14O=!INLQMP1EJ\7%*[^W _Z,#YT#FN%$EGC=
MYC-X!#=DM7D[!M&,<)U071WLI$QRP7MS@>"VRW@8P49##G7IZ8THT1451\A+
MA4;)A(_#3IHN*E C[ &N]"*2\BX29S)&#Z6;BMD>+%0^BRF;\PFLF:2#>=7G
MM]EL93R=ZO/Y?:^^WX#QKO[G8C)H68+ KH8OB6H2LVJ/91]!,-D1';'+_J0I
M&Z'>[/7@DJ('A_MHY =O36 #V9,'1CA79^&[T@%=!P"/\HR+CF<) XY6!V'6
M40P#?.FKU]154+YQ"%H8$@PA\;>J&@UV5L0/]-U<LA_R<Q0DGS-TYW%)4BZ2
M)0Z]:GS)4 AS.P?@Q1!H/>S#@3Z^QI%!(/TP@DTZ0B3X=U^$/%8D<G\_V]>T
MOUPH_[?1?V'ONZ*:"L)U@X@T,?0.4:J*@'05)"+21(P5I$:E$R B E%# DBO
MB@H*2J2KE$B7EM 1%9$NH80$!14""6#8DL*-YYR[[CIWW??[<A[VXYX]L^?_
MOS+_GME)5UZ&+.0LT"*S4LZ]3<T]ELPN,H=+[8""P,#AM4Y\$G&O,3@E###J
M+CC @-$NA]"YY*OCFX[W!QJ&1.=L+";<7@Q?FZLWC3IU9L"D15+#8-$LYI@Z
MB:#'FSA-HA\Y90<D:'& /M0]I\-+_X@U/E3C6J^E#) _3[L;PG9 5,T-',E+
MV)@9D$XQG[-8SX_/-LT\!8@47M#= 4EB.XW8 @OZ_(!@U]P13B'A8- )7 Q7
M<PI@<26G!UU@^9<F(Z:OI1\=O#<R96QK$I\<?]1N[PV94\I^,2?]*;!N8HHS
MD3^$JX@9X356:1&-A_E'!5(A$H$$"+<OZ5*BJZ:(0&6XPW<)_I)@9^L<V["F
MR&$>32@0^ !'9B*GE2 X!XAV3S@[0^JB%TLK$&YSN. :W1>3>9>O30&8/:=
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M3B7:V%W8%\X5#F&$,W]QWK!U(30!QO1"_X,E^H^D5+0_)9\L^!,#,AV!.]W
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MF8_HBZ4+2@VYEQKHDVEWTA#W4=[.UW2O"Y[U3Q6Z^DPM])B^>K9/MAVRW,*
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MI&2E*G+K!):27XV1O]@]7419I*@C$"DABOS@I\S;X@</5S87&/R'0SW&\._
M*K#%WP&3#'#W%D02?8&TU8-4 K 7WR6Y,U2ZU<X,>SAHOGA8VIPHOW_]1J+)
M^O5KA 7[:KY/F"%XG5T,UP@S 5&!!K/((B1B'/<(X'Z&'HF[>6,:G';$^$<K
MRQ9_(NO/UQDE8FW78$_CQ$VK%IUX;6M/X% A]RN.?CEK%W?$2VKT0-.H)3\
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M<_YI&WU[/=/-)N@1>\U]<%=1H^G+Q)!82 A,KD,'.,L1W*F9X4\OZX<IGCV
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MR#^NC3T$AJ<^%[+J%+QC85RQ'WSAY)=%!)8Z"0K_-1B!L)P'.S'&[+W&F6W
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MSUNV\V$W7=/UC*A\<Y^G'1[P]D*X:U(K\H$*W[]$ZU2O[T3K@BJOI4&N/$$
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M7Q2!GSAE9D\WIES-Z8/MG1&&[0UHT4W*G#1H51W/\%,Z)) -LE7\2=[+:>'
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MMHR=@/=5EC [APOQ)DAQ!K'\G$-HBW$S:<J?R@.3VLMT/EEC\7:R5MCG.;O
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M:<@<[R%(H'G?E&27[WV<GY)]):+:EG^^^LC AZ8D"_[<5XJSJC#YE04A>Q#
MW[7OGY?M-HGY:_4 '<54[Z) DS?+WM^,4[;0W?M8-MZW>UX85?"DROEMEI&0
M^G0><(6"6\_?N4A"&^BNG''C[)&DC??@E>!>MD@Y(-(><*>3NF)F5S&ROLA]
M^5:W+2<DF]5\7_!D1<MI?;OH?(94BA#&WL1'(X0-\$KLPML!U^BRO5_0!!A
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MSK6:CGTC LE/CL-K-5_/#IK[MMZ?WPYDKADG'&^YUQPP>B5J?(D%8EQAV$%
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M_$X*/B,>$CBF"?29])0Y)!G$ 9,PY &721R&S&<VYI!E_U,SDUKQP<^M K^
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M$QXS: P-QAY#TLW:PP(],(%O8[PM]OJ^2"4YT**#2G:'48SV@#D*5;+H>-3
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MPYSH<6HLIF0#2KB^L1RG<#6P$UVC-3 9[<5O; D,?FY _.7BT)A3</8-CG$
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M^9&$E(L()DQ$2<A\*@.C+"AG^ID:=6S$5'O@C$.U0V:UI';T<0I6,]YP -;
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MY51"PCU/_8%]Q#R<2-^<T4]V,S4&W[[Q(96D@"I1+3CE-)X&_.P$I<'WED<
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MTK4=$A1"1+P$4C\AD%*)!6(^\U*K9?5X-U-;0M?U EHQ>Q[7G@#5;+Y?#M7
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M2%=:5@1-8\77-.&,QWZ<A)S85F<\TL_4./==7A3Y=[7V]JCF=PQ&,X9T ,[
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M(9DH"BM:!L=YY[8'[B0'6]'!@>SZ]P/\ U>M@<7N-@ZRHSOS%T$U<ONT$G!
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M A&-!,0Y3R&.8\&I2$0FK8HYKI)B;E92?[L*-T?.#WP[;VYT2$<VKD9^:!0
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M_\TPT2QRE-$XXQPR0B/#,J9/_JC ,"IR54@E$,VI]:G 9L:Y6;964% UDMZ
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MF: L2CFR-N%G)IF;S=9B@E9.T OJ8$+.(6EAAP/@,[+A/0&-3Q'].8P<[&H
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M<QI!Q B!1! .>9:;%G)QG&;VA??^<LS-Z'?2 4[KK^"IE='!4;UB02S. ]/
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M/YY@VDKULPH>U:>?_Z0[(]G[U49[<0_/;%GR#\LUW2P2FO,X(RE4@N00,55
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MZ@39G?R[T-GAP(Z6H7P-Z*^>G1P&?LSLY'/P79&9?#3D5+*2S^GJD9%\=HC
M=CR>A4C-!XPYO#ZH2_K;K@1;J9$6&G.H46GC:DH%:2(3B(@B*<FT+(53<8Q!
MI)O:]A-<9-A^JJMF6W7XM]#">G&_!&[V]*LM[<#[W*NLJG^OFR'0C]4-)ZIL
MX_;+&0+6HXXZ@TP2</(P1YJUF4Z]4_7O'Y=5(:?58J&$M6<V=\L3W7\VLZ+D
MG"JL8('MG1[""'*>,TAIEF<V';@HA?,1)%"(J6T&5:$S44M=,X.NI68+L&YR
M8EBUWAX6<>@".9Q#1H!]>$=))3GXI=7A5_!Q65><Z^@![I;@5$NR,=;!XX@R
MPGJ,=%89;%W\#BU7 MI[>@D=>[QCS)7:'YQGKATK8&>Z_3E?+&Q0:]."&@M"
M.:$)5 7'$&-60$(2 C4ODD2GYL2"G7*/3@T^M9VD%0]\]&"HEX Y[ !7P# P
ML^\1"&EA_A(*#Q*^ I*1R-7AR^%'DV=4[J6_E\^,1VMGI#V@JW.?\:,AJ>:S
M6[.@TB[JAP7[/E,4"XVR#"(I-<0YDY"3DD-,DKPDD@G,G-I+'HT\.0)JA0-6
M.K<W[QBN?@:Z"H2AZ<=-?^?W[*RN)\[;&R7^[?OJYU_,,_51V_QA?\(^'FF4
M5^^L NU[=_X#P>49K(GQ>;WZ.9=*OGG^?:/DQV4=MFI/Q,;N^%D=EV=9D@F&
M)88YTKFMY\(A05Q"77"IC(U 1<8]*S,X3NWUVHY4E*&JCOYD) ;S91.'7KFF
M=D)[%UYP70<WI^$PZ [,!Q;8ZO32BFW[=_SR>XWRKV G/+B]#'-(H05/Q.+5
M6'"=>.SR"IZ G*BLX#M"2!+S]H=:?VA]0$U9E,KCU]BEI$2EPB4Q9YI40EPJ
M BGF.51<)UJ7/,DSY)[#?&&VJ=D8E;P^J;67T'0X\,3$:&#*J40%.UEW574J
M:4,.11?Q\\E,CHCC6(G)?7C&2D=VA*4_&_G2(",F(SOJ<YB+[/I0F&%HK]9M
MC^5U]:7Y8!:[;JX\2S5F6&$)TS)'$',J(*-8PX2D:8Y$08M$^UQ<GYMH:CQ:
M!8;4.<@W@#WX%YLYBZB;01<#IX&YM()H+^,-L%(VO=CCV6F7@(ADE9V=9E0;
M[)*R+RVNBY\/L*_>?[[]ZVIA>^9MFBTLPWF*A#&C!*69X0"E($5$&4H@:9GE
M"9*Y>U&8H^&G]N8; 4$KH8<A< R;@^5T%1@#O]Y='$(LHV- /$RAJX 9R?9Q
M^J+XF3IGU>ZU;8Z?&L^8.2OQ@?5R_E,!!-6MD?7BPLS^J+:-S"&SOC*S$1\?
MS7=A^7W.%TUDR*R4N:)42W-$+%*(#;]!GJ4,*F)^C)E64DAG1KM>GJE18#?F
MHKI2KNOR[:0.#[R(L'8.M#KNB@S,P[OZ?5;TX]O^ZJ<[C4"KDHT"V"O5!-R-
MNU >=#_N@HVT/XRQ<'[;2SR8>_>C"-.,MX'%P^1@QXLX;-B)OG(8O%T]/*[5
M#[7<F#GV56\_J>V=OF=_SG!12B- :F]US.E>2G.Z%SF&22&,K4]3K27SN>1Q
MF71JUSNU"TMTA0:_+&SUY[_4I;C]SOU.N+OY &*C.8IO]4#>PVK:-^!37;[7
MR!W/0>"#4B1G@=.4HSH.?$!XZ43P>C:XTN'+T7?O A$T*Y.TA!E'VMCBMNYA
MPC74&C&:X"3C-NC9G8-ZYIH:]1R^*\Z%_[T+(9[%WHV'(B$Z,/TX$L_-4;NW
MSRQ.2I\'7/'J)IZ=:>S:B9=4/E$_\>(C <Z!+^J1/5<%V [+9G\5/Y1\6BCY
MN?GG&4J(QE3DMH!:#K&6&:2EUC"3B5(E$C*C:+94W]E6R7M'5X#S[$[O#:W?
MFR,9AGN'=G*"]4Z3XS+\'L=(]^5P.-;'17<<5MK+#.Z:BOO;MN+^#=CCW8H^
M"+8>)_%!,![IP!T-:[]3M3=DO8=G]]'&.R-[:WAP%/9_.L0IW(QQO[H5_WR:
MKU5C-K5%B6YW=?S_-E^8OZ^6:O=Z4))2:@@?)LPF9Z.D@"0K)$1,)I3+% O-
MW;W!X8),S0W<RF6-)%8KL_/\[@J[W71;)#RT*H%'?SZ[9@E=G,+C+,S0WN!V
M3>Y7H-%C=T)H-3$F[GY)=LJ$;#'7+(F/^W><I1G+[SO@$GGZ>Z_'M=_1>\7X
M(WIXKT?AT+4;8;PP-\K+DB<O"J((\_5^6MBSPG^LS;'W]^5:L<7\7^:O;+Y\
MH_1JK>RAOT2:D802B'2B(4Z0@IPS!)7"E)<Y+PKM54L^BE13V_OV8M8^!+7Y
M]2]68,] _S@KYN:F&7T=!M[JSM=F@D986-=FZJ@%*KU 9^6L9C> 5[K%=3I'
MQ3J2-RB.3*/ZC:+"^-+#%'=P_RS']\OMOAJ5.02MUC8)PA8Z?#)GCK3$J) *
MTERF$.=E"5FB4T@*FZ' 9:F04T&H2Q--C5=K67?]GW?2@EI<]Z3(7G3["3,F
M9@-S8"A<7CF4+E@$I53V#CQ:AJ6+>MV$2Z?/![@H_H,9 W&IUD\/C#<1D3R3
M7!<TAP(Q8XK1E$.2IPB60@K# YDN$O<XM./QI_;R=R7T.(6> ,[AO'\=' ._
MUUWA0H)K3T#B<=Z^#IJ1CM%.7Q:_\_!YO7N/N2<>&^_T>E[F@T-IS\?"SIJM
M=_9.OV?KI8W<_:S65:>SJBWVF^>ZW<;;!=ML[JV5-4-:$B)8 BDG".),($B3
M3,!4E(D6&<Y0X52]+%B"J=%=JX"]06M5 $:'NEM?TSK^QB8]-WUC*E5N[-WU
MXLD&2X/[/U;U#]O>7M\J13VK6/HOI=N!<] %&IB 7V%MO ^9P?A&.E#ZSS_J
MX3$8GI<'Q?"!PJCU/U8K^<=\L;A=RI=!G^_F&[%8V4*5MWRS73/AFB_H->:$
MWL-6[JK*ZU'<,]C+#KZUTD=\PX)0B_1V^<T]ZIL5!,O+MRILD)"0G];];F.(
MJF#&MK@=EY06>0Y92A.("6>0<)5"P1!.5)*2##GU4>Z=96I&1QV%N[^F=8]@
M[@?3X<05 Z*!Z69_#V=EO $U6@$'L+,X^<3:1,!KK-":4[C%BI^Y $-_N,RY
MAT>,CKD@_V$PS*4/7Y'MT:EVO6MJ4RB9)&4*"\X%Q(F6D&O*(2L9R4G&"&%.
M36TNS#--$FS:TG1;U03D<IQ U<TDBX#5P&Q8P]01,6*#$T<48F9DG)AE_"2,
M\ZJ>S+OH^?@53%";6;8]7_.-I0DJ"1<2YAHIB'7*(*=*08X1$3G1"+LU)^V=
M99HLX).CW ^BQVM_#32CO/2U@#=@+V+D5_X< C%?^*,YQG_=SZEY\F4_^^'P
MHDWG^R$=7FC;&):9$I1+EFG(4$+,@4B5D&980-MS F>DI*62'BD/H7(XO0SC
M)S_483Y_^>6[#?/YU7::8!?[X/G7A/):,#?&&03_"<7XO(CH:9*ZXI:8"L$O
M8NDIK^E'+TD5 LZI4E5!XP1XA X; >T:PWTYZ/3S=3M?+/ZJ%O)X[ETSTCM=
M']3>_[FUB6K<=IG;;#^MMHT'2\FJ)'>9YBHEFD)ESE40I]H85@6UG> +B621
M$DS=NRB,+/S4C+9]F["F*.<.@4Y+L+H#6 4"L"@<480%HM/J]TZW":%[,(!%
MP]@_6[##PZ,N^ZM\SQQ\<!/^]@R\E?S_7YSS7QP/I^2$OT C^3JG^T7R\ZN^
MTDKVNFO'EFD\+_ KH7W@7'XM&<(O[>H3\>?58BZ>ZU_OU9_;-P;5?\PTDTR2
MK+0'U03BC$M(*,.PD%6*OF84*=_KNY[YIF8(M5<NWC7V'*!UO\R+!-A(UWJM
M5ZN6%'QK?K<B@TKF@"N^/AS]+_LBX3GRM=\AKG'O_1P0<;D![!MF]+M !YU.
MW0JZ/.;'M9OU=O;65H16ZT>VWCY_,HM]^^=\,RMRQ0D6.62HJKI4"$C+)(>X
M9#015*($E2[D>FZ"J;%I5T9@A03?K)B.?' 6QGXBC0'.P,SIC8OS.WY)^3[O
MF7FVXSDS?]M[S<X..\I+?DFI]JV^^+EK@[*_J"IU[;,=_'[-EAM6%Y>LXA/W
M&Y1 J$!*<X@XI1 S\ZXSF6>P2 N5&L61Q$X))J$"3(T&NF&_C0:@4@%T=0@-
MKW9<%#>O_I!0#TPJ;B@W =-.UMD5L=-^Z$4/G7:<_I4BI_W .1\X[3E.C"8U
MOYMOH$W-,^=7>RJU9/MYK1[F3P^W2UE]=+-Y8@:/MZO-UA:RG'%!J2S,,1+A
MTE9\PQ*R/"<P3W/,6*I*\\4.O/Z\0JR)WH9V]*@O/66C316I/6^4 ,)J<4UG
M'/]E%%RE>:HHE!C9/*-"04XRL\5E.LFQ(A(QI_YN8Z[?J)4K.@O77;/%BBU?
M+)R]Y ZI[1=K*=WOMT=:H#&NN[LMD[J+U6H#?FGT^;5:MOJ9=MDJI:IZID.U
M6 K&=Y!.3/[2O&+#IF#H^OLZA0\;6*V9;7Z8D>UO[__Y-/_)%K9V477>38M<
M2F(.$"E#!&**J>T*;+@W94P6">*8.[6"NCS5U&BUZM]@W\?J#QUAO1P)#A"[
M<6(<X(9V+H1BYE]S^2(<L4HNGY]HW(K+%Q4^*KA\^8EKG1)?M\;(?_/<223.
M,*4EQ2DD2J36_Z @XYA!4A"N<9[E*78JK>DPU]0(HWL(KH2MDHFKA.$KL[B/
M8?;U*%P%WHC. T_<KO 2G$4DND/@>*97.ON?5?G\,?_\(V'4\?'S79,VQTJ&
M!&<24DG-V=R0!&1($JBS@F<<,2(Q\R&*W<A3HP4CF-][O\?([2T/TGS@=]K(
M=#G)TOOM/=(TTKNZ'W?4-_-(G9?OX?$'0HO2V>B.]>-J75T?5U$?U67%^OGM
M2JI929.BE(F"B2YM=T2,(-<(0U5B026GJ:).A5P<YYO:&]K47#N0^:8.Y3(P
M@T9R8$7W+5?7CWO_^ST F@._]3& #"ADYP3/%?7L^L<?N:R=D[+'U>W<'@L\
M#U@CX<=J89[8V)/&]KE*?II1JA+!*88IH896!$H@3W@*)<<RTR3!Q@8(<+^?
MF6ZB;O4Z^T[]*7Z8G_KF#YU#UM'\OP*HD4S_CH3_"]0R1JLUX A#+'O_S"SC
MVOK]JA[9^1<^'I*)\[2TQ;)NOZ]5%5CZG_/MCS?SU=OU\V;;6+6II$)EPI8C
M9\;REX1 GAIK(^<:9U)IA85[]XW+\TW-VF@D!CN1@949M$+[)!5<QKJ?* 9
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M%RV9'E;K[?Q?-LMQLZWFG.48)V61)Q!ID4/,$@8YX264A<8)00DFU*O<O:\
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MQ)G6.4F05\OM<Q--;5MY6[?)!(\V/'FUK/(CHP0#G47:C:9BX#<P(YTJJC?
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M*7A!&<0HS2!.D=F(%-,P9QP7(B&IV8S\&U6?F6UJ6\>^-?67IC7U;7!KZG,
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ME$)42F9KEAA3 B4::H%ER01*L#4E''NE^\X^-3HP\H-* 5!I *P*H-$!U$J
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M8XW>Q;YT&OUX<++SJCCLFE%!'F=+M"*#7ZS0OUHR[+0"V@<5?1P66(^=; B
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M<:MI:.)\K7WSC].T#O[>14:F++.?*QU#7?\L1)V*41__W]%E]K/>&FD2A'&
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MEV\2J<!AA",?V;#TY2[G1L'5F[LU66^QMT:K][TRV^FHW@!\,W8=%M*1J7,
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MCY=5Y'8G'\B?]WFAPX;K=1U!Z,CA(?^F@-C&"[=-N+"(221$2B@,!>$Z:9Q
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MF) *[J=(HM!"LMBR>Z,W>WIEXL9<4-3V@F)CL,7>DL4@&&S3#8SI^RFMWZY
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MNE51K[VGMK(X4A%],)SH-9G.84&[Q[' ( >KN=81=0E=(NP@]/B7B)ZC1#L
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M<1]-H>KHI)R@H'!D#2P';PQ"(=?$<:<*RM;WFD>2V.\!/UR\-E'IBVN-NF5
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MX ,YN<*RR!!5T ^[M/?T)%>\Z J5-@HX\[7B;],\I!>YLC:YDAPANQ!JX4V
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MK2/!D8.9I#><(Z< NK4;=@!9AP'MI>7Q6^MC !![,TVS2_P4OC]R)0V3CID
M,:VV2B'3+&N+[AQR$CY8WKR'TRY:#@/32\GO-Y7\ !#T\!'V0W9TUJPVD0?'
M=9U%%F1-X5G(/.;H-$:?6V>\GB#I,#R]M&Q^2ST,MIAY_X#(3ZL) Z>4,!_T
MN<\QXW(;"\\_Z9+.+N1:6"C1:%"2W'2?@@=>ZP1=#CJ%UL\JGF_2Y?ZH=Z6
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M[(@^A6F>%O)V:U5Z)OBFE4B]3#(B RTJ#]$H)U$)6LEI!.Q->;J>! N'X^X
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M@6!@)YY]+-(!L)IVY= V9E2NOLA5+N^4 D6?I-F<K),J.Z.Y:(S&Y]^)9R]
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MUW_/8-HD+)X%I2)#SZ P86J^/^W0,CLP4@=ADB$7VAZ-ILU0P^#TC-XT1K!
M!R?C0Q/ZN%[._GGI _ S81A#*:J/6FC3]=H#Q5ZUY;4.SB@?,;=F'Q\JVS H
M/L.'CU&,][1:B7R\^/HU+'\LRO7?KLA5^("I^K6S,DN;@5>M.XWL.^Z(C4B.
M4D$'?4I,$5I;6@%V<P)S7QG40X(@O50I.9-R:]_[2?8I$2)X1#2T:DVI[?HX
M>&LTV.*+*QFE,:?H__#,^Y3L@\9V?4KVL6T'7L.#'1&2C44PGL :7C5H"X3Z
M!Y?H3*Q]J=D@.NPC<?K4^Y3L!8E]^I3L8Y^NL'9'5X42N47F(A@52$E2U=1(
MFHL7VG&1%:)OS<KW1/N4[&7U??J4[&."#N#TNI99X&I=VVE\_#-\V]9$1'*T
MN?(%'%>.U!,8Q$2^>-8EI\RS5+>S:HX&TMV2] *A8RV]:*[V#L#S,]M@8-QX
MX028DGQMZ>+(2S"BMJ?-CAP'^DEKNHO]"1Y/<*'7&"J'*[D#A+Q:+/\,RWR[
M28\RR*UE!C2-65L74RB>. .:B?3&U.J_YB11=TK22R9R8\PT4/O4E[N/]7DJ
M3N52'(>43 85,@-7HB%M92-BKJTNAB7AM>BA=8++M$8(::[;J7%R9V7G3\3N
M%#8D(Z4&Y)(.56T#!),3%":]55(&[XXHGMV;,_\$J<$ML=)6OQT<2:_G:?$5
M/Y)=-I7&;Q:7]X&;J" $%ERE.3-&,II*T74J$;2V I6QKC3O$?R .+TX-*<,
MU5M9IU^@[4K9-29=:5*<<;7'DT0*0)D#G94WF$)RS0NR'A1HVD"KF=F'P>D
M&W0 J%K\^F:Q6MV3[K[CN+/,LB %>*\"J,@5N, $)*9+%)DYE5I7^ \2K$N
M'0*$Q=A6Z0!JN_N)W__]#><KW/F%1?J"5@#Z6J3HM8'HZ. W.H<45&:F>97]
MG8),>S".!Z7CM=X!=+;^P5]P-?L\O][%'<]:H;,0G/2@E$=P.FN(2J2DA$NE
MV,;8N5N27D+^4WI5#6S2);*V:RX&9%AB@!+K(V7.LK(3&T@J"A4==ZJTKI&Z
M3Y9I3[D6=GX4.@<HO0/P[": ^<5J.Z?K%;C=:;ES5F=&LRG!TA++"H*RE271
MQA*<#13.-G\^>U2LWB!UB/U_>4%K:XP.\/5V,<]7L]IUWQ51>BLH7A%51<:0
MT^=E !:BMR%7-NK63_]WB#&MMS0*?HY5=@=X.2Y-,ALG8J+9&94H)F;U)D\F
M!59KG3(*QW$\RJ"Q:-RZ2DD=)^MD' MW .=WZR^X?+GX2N-_H=AE,^D:)M7(
M^&58?7EUOOBS3AQWX?+M?,QK5B]6N)*.]GQF)0?R6RB"LCZ!]5*$7$**KO4%
M1COI>\E7&!URMW.OI[%_!\B_UOE=-T%O<7T60M+:) <Z8B#W.T7PV4J"(=H0
M<PSM$R,>%>KIO2VTP6E;:W4%OQNJ?+M8/^ABKW:3KQ.V.4I'_A*D7&^L+ KP
M449@G@6&205N6T?/1PO]]"YQ6L/W%-;N -X_4W_>7J]5Z9ONMWFV_G&5Q7"6
MI$K!4,!HL;;J\^@@Z,# 2,,<Q8[9F-;I18?(^?2<XC8@'MVFW=9LW=E*(\SS
M76TG/Z8OF"_.<5'N:)-U>/E6:Q':5'*-JIA&15U7H]U8$%=U,C$*[866@*[>
M/@C&P7FE0>:LC-*2.SE:V\L[Y&G6C>>2J)26Y)M9B+/SS8:PM5%^-[_J D._
M\'9!RWK[[6]A-=M&T$XXE;CQ( .M5F53+2"J5]%%%SIX!);<.IIK)GPG?7V.
MQ=N]#7U.:MP.G(D:B-;3A?ZO5@5_#^>;,V]3#Q*ED8QYB,R0UQ^"AL!B!F$D
M*=@$J55KF-XO32>X.RT\;A/QM+%5!ZC[@+1F9XE\\[OG=/=/M[?:+EBW(<2*
M1BAR>^HMN4=67_)T8HZ3/EL_(1PC[[3(;869Q40&[ "L?RSF^../L/PGKE]=
MS/-N%N3/QZ*L@%)I+U7T$4)T$31/T?IBC&H.P[LEF19@IT/"HKE9.@!7#>LJ
MDUHX?Q^^X7*7&I=LD$Q:<.@$*"42.&4SH.*B,#HIM&A=:WBG(-->B4X&K>.-
MT@.R<+F^?$K U;OR%_RV6,UVB029!U:R<V"5-:!D,O40D,"06X^%(U.MLQ8?
M$&?:F\OI4-;(0!U@[8X[B8V+85/B3@D-!FMIIL,"OD0'WJ1<N(LJ^.:=N.\6
M9=J=K(_XH865.@#;IV68KVCDJL:/N/P^2Z2B=^6N>[%:[;6Z^Z^V*3>>YJZ+
M-&!X2E6?#&+-NRE9QV +2LE;![DMY9\X+&X!J$4GUNT V7?['<I[YA2%:+(D
M.F-<+!"T0#H52K#>)\:Q'V=P-*Q-AXM!SN$^1NH!:0_X'@E3)O]#@BZ5N5D9
M\G-=-A"2#M(9)KQIS;9VK',XVL'=#^H:&:P#[/WMXU\7WW$YKZKYN<GESJFV
MFM'B495@C7R<)#5$;3V@8R$QIJ)N7G+\F$S3ABC=H+"IZ3J XIUS4*5H7KO8
M<*EY37"M-Z2!@U'%%\&]4+P]B^*!D!LM%:(;R!UMH@Y@=@_W#,].:.T8I%1K
M.B3%<B%;#DG1?R%ZQ5GSZ/APRI_12#JZ@5H#,_4 MMU=PV\_?DT&>8/?\7P3
MH\D<!;)*?.)*!&6TAT"[,VAOE$O,)YE'R\YX4+)IC]I.;FK:V[ G9-[,:+HC
M8>ER)1L9M'2U:MS* +2A5T8W\BRD*-KXX"2WK5/$]Q*PDXR$A@BY#X3-S=43
M%E_/OUVL5QN-\9T3RVW)R=$L;&W0X)0"5T^3&#DWSLG:T6@LY/TJ3B<X:P^"
M^^!VI$4Z!9?845=PPYRN19V^9EW$R,"9XB$K[RU7W--Q<0)PB1YN5Z8%UR$6
MZ11<<O=LJ(-UN6@H+&M24?4YI) @/-8:3:U-\[*J!\3IQ).;!%R'6*0G</WV
MXX;:7BWQ7Q<X3S\V/@7#9%B]U G&DT_!BP$7:%NF,(@K8XJ*3HT7.=PGUK37
M)=V%#4VLUQ,@[YK0=NUR&QQ#AL!%H#5F4( KM( +FIB*1_IF-'_M?K$Z\=M:
M06% <'",73J%VNIJQ6[W<\F**HX'2)@ET$H5$))ED&3P7"FG96K-V35$KD[
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MG436UW;O"A.0Q!R2LUFB-VC,H$L2&N &W.B[:ZC=-W97C+TG/].;6&1B1'W
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M% JJ<D@N18$LQ&'%<R<0]CGPXW4<=S?!2#_M!QIJYB.NU^>7:7UG23,K"BO
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ML3*=;4M3%DM:*+/EQG[ORGM";V4N9LFA(<\:1,$"*B4Z#CP=#$YF'5S(:-)
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M8VG?SF?+^?4TE2D>Y;VSW)U<%$U.*/->*I&)RYP2J:(FSG)?6C-&R:1(/.S
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M\_QY,9W%Z7=__7'V"?Y:??D3KG_ [_/9ZNMR(@WGTE)*,HVX42!$$GR9UBB
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MJ(=K\AE('"#6L0^1,]007=\.?)R5[H^EY2BRL[5^3O+$BB%EN71$\D!L::#
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M/\P7)0-BHD$G(8OIC"4+2#E/T'P"T6 RD]DSX6H_S?8BK,66$WL!8#ZT-AJ
M6">?!QD5'V?Q^J98V\]EP!8J:[5:3,/-JFS)+_.G;_<G O>CHHP3L"HCUSX0
MGUS"K0K""V/Q?_5'Q]2@?%R0#@"IIXH;3JO?@U']O<O2NEQA1%^AK/1)1I#Y
M!?@E?$!5E,N$CG,4PG)B5,*PT0@2A%%$!@W$42^(,$X&GTK'(MK+ =MSX7&?
M>88#X.!*&-N%?YJW+PL_6R(Q>/3<5=O2Z*4RVJ'4(D?Y:71D@F4$C 0G@#H;
M>I8P]UYSW&A_%%@=+?H&CN-=<;V#NZWR;KJ\VRK/6>I_7YOZB?/<&$H-^L[H
M,4M3QEV6[LD>* V94IM8KNT45J)]W(!D^"-Y%!T?6RC[94"/\WSU%8/ZF*E5
M#'WQ9"6Z&"*ABV%4]\:<,:R'J'8/X %<R(Z4<;O*C.$3[J^!=O#T>3'/T]5O
M\^5RDI07JIMD @HW1$X<'0F;",NZC*260:3:0\'O5A^WS\SPJ#E0SF.[:8_!
M_H>_OH'W.4-<G>?W?\6OI0;Q;)8NP%]W'X8JFS":<DZ6$V:Y1TD%E)05@I3J
M%K!>^T<3&IYQV0Y;?]QF- .[;R=020.N7,=E*<^&].YF4>+M+KSM6/T$?W:_
M64Z EI86RA F92"224HLPSA;,1U 6["A^B207H2-V[7F1&=@5>TT +GN&"^Y
MO OX"K/E] =@J#W_!G^?H8-Y70KA-@\I?_/36;'DY[-+B,C^:@K+L\5TB;^Z
M+XU/@-OQB_]KDI)P@7L@7ED4-Y1Q@Z 82;CKO!?.@ZE]L [%R[AM=(8'=A,8
M:'@O%)8O();7@6F>KH^6L_1_;Y:KHI<2@YV=O_V(FKCTW:O4K6QN!1$A^<1C
M(HE)]'Z8L<2FR(DP*G(.4:"K?*+-<#0S(S?S&6\[G!8&[;2I.OXI0&FAG>B>
MT%)) Z>EOWK.Q%AGC?59^5R[U\0IGWK^_UO//@H^\JWG_:P.M'<E>IMZ@F=8
MF4GIK^#-SX?LKO]D(L!!MF7\B':&=#GG3I3!)APZUR_94+O[VL'$MMB;_Z@'
M]9-HK=G.#>_]8E:2FKYOFF<>T9?AN8^JTW6A%Z&U>BILUMIV%+VMLC<T 4>H
ME4;&G$BMT2K1H$E4RE*E'0^[;VC'U_T^0TN]/@N[*Y36\/'-SW7WMWN94)E+
M&REW)$)Y?M>E7:_*NDP2<YSEZ$%6OR78E\B1ZUAKX.;Y[@Q#*&KD).2W\YMB
M=U&\JY^W \&C]-('-*QXT <B90K$6G1J0VF5$[WFKE\NV2\RD9]:NY6.#(.H
M>EY1[B/CYJ[YZ=G5 CJ7=I>E;<(O<]1Z#L2Z,O/+"49<B)9XC)4$U<[IU.M%
M[Q=@ZDW0>*G0Q^M\/K0"QGZGZ57:I2)$C$ B\3Z6MO4N$\LLZ_[1GB:>Z(F+
MY0:!RT :WKN2;A]QCXV?%TI'RT/2Y\L/7S9<V12B%"67D?(R5-HZY,_Q,BI.
MIJAH=KMS O8OQWVXY#B!VXF0-(S@QX93=]"_V63:;+=#8-GD((AWS!/I#2.^
MI,.F$'AF+KM'SM%SUN?QAX^3KW<J8W.D,!MX3GC2*[R[!N'")&-U(GATHVAX
MR8]F>)9SC28T<66XK7V-]#)%K72/&=*;'D WK2+M-IQE"G(,)=V/.MPV24>"
M^\43 R9'D:-Q8NAKD <$M17U'Z/Y/J Z2 T-8.H3K.Z>O<Y^^.GU^@7@WIB!
MS;O!0S8]IX)ZI?"<YI9(E12QY5NAI7,RQYA5]59IAY':( X/ \MN-[43:*X!
M@-Y++O2\9)H&3P+$4MR+V]=+7L;S!J_17;2"UWY?W#.)<S 8G439SZ=U[B/Y
M\2?8/A36@X?-SYVT/R^F\\67^7E&ZLHH3>;1CP!K""LSGJ50R*CDBN1,M409
M91GZS='>=^5Q?;%3@FIXQ31@JU[@[YD7]2B-4$Y)8D)YKLS"$N=*-;L!QDSF
M3/C:T<'>1(Y;,#:&Y1M6C\T!]9="G=CD9<AH^A.$<C^#]A^%F @(@:YSTCJH
M86'Z2Q+'+0T;'Z1U=7@X1,O,C1-#]-WT^F8%:1*"=JPD)F4ET$E1DF),)P/)
M/(C,HY4TU,Z^W)O(<0O(VH;I(7IL *C_@.G5US)T!OU7?P4/IT/>&]C^4*0.
M>30!.,E"F]+KCI:G%$Y4H"DZZUU2M>?1'43HN![J<-'S\%IKX)C?B\F)5 &L
MM>BT,,Z(#.AVAY M[G*A-:7&B%S[D-^+P'$C\!, YAB([J6]44/T+7M=KX_R
MIM0-Z2IGP7J>[@-W^_'HQ[O!D,L)2T;IP(%HYLI\'1/0 &A&F ? !2/EJ?:)
M?SS5XUK4T\/XQ'INU^QN_)M'HI[P*(5-&#=:J3F>8UX3:P4CV6<9+<O&^!/Y
M L^1..X50#.FMXH&&W!9GW2K)EE;31V@HQV+E^]\(I;'TFTU9"JI3DK4'L3U
M)"'CAO*G!]OQVFCB/-]E8QO.:299"C22E$HU7%*&N,P-R1),L-$%5;T!X#.D
MC!M\CP^L0S12$5JUJV0^HK@6$%=O_?+KA^OYGT=4R3SW476J9'H16JE*YO+F
M._*[<;<VZ[U?_V!Y"RJNP$O@G%@!JEP%2N(TS81;R:G@C(7Z#95ZT%7QJ9AG
M$:BU0)2,992 !.*#  )*0^99@4BUFYRU\E1<'0$OO OO(^8&'/.[,N[EEWD9
M^#R+TVMX<$/Y95YDABS^F.)F?//S[QB2?)R=?T>;O4);>A97TQ_KA@A;40)E
M.46TT(E+5:J]<ZG+-40X1X%A](T^8&6H#<''R&F!0X-V=-6/G;:\;:VZ[2GX
M<;:>KC7UUQ?K8^MLN00,ME7"_W'#T#OPC$B%[-EH/,&?*0N6"L7SK\[3O58<
MUUR.#XSYT%IJJB/?C^D2-?MAOECWWT!2UF<)+-'7-4!UD(31DD4.T1%GC</3
MA(*W.0)4?V5^D:!Q36(SP*ROO!9<@6^E[\5_=]KLN@+[V=4T7,-F>SDP"B)W
MQ"M:)H5E@2&2+H],UG./(N351W"\3-&X-W#-8;&B^IH#X\;BSZ[>SI>K4BGU
M;KJ,I>YF.3&)9@,J$0JA=$%/FMAL*,G>.,6Y#$[7KO;O2]NXMW:- [222AN
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MYFP.A(67$S'K*Z8]\)W%N+B!M$DUO>-KXDWV//M F*:&2,^ A*04B4H'P54
M%?NU5^^_YKC9EZ- K(KXQS]7G^&N<QLVO*W=AGL<:@_"*VV)" S]5UKFJ09
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M[DI3'7:GTL?P-Y*;7Y1_@E_"__E?_P]02P,$%     @ :TA/5C^P*B': P
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M92%3T/'OQ_OA2"/DE<K61U%^AM57!.AK@-/Y57!V>C:=!&>+"\SFJ^7KR44
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MQYVNSB$D]O@'(=;_)+$LQ]K+B&$+RUP1IM.<5=72L$Z81-H+24M-<%N+">>
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M185W>&G("JF:Z=0FUA#KFC)CD5XX\&G(W^J)[YHFJH&%<8#2'$;6"IWJHID
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M5'-8.NDH&)D%['38XT&U 2]74YWX%7).#+Y/P.M$333!1+[A6Q\6@V]&*TO
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MHKP8P+-E5;<)".!MU"(1,P_49* 8=J4O\A"O?\&ZJ%<T4ZU5S7#\E2$7<U_
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MV>=8*?<K7$>^7D2D#CTZ_?V"[=".2$@N&HC^YD>57G+1N!0KDI0DX?^XDNB
M/F #85-;P7UT]6*<*=AFU >;8A1D)(G=250"EG3+$)F6:!H#D,0Z;5VR&'+7
M]P_';.=V4%I2&H(]&U-+V1=,]ZP63.36OPA3B7DF@6A7'.;4=]8'H'L/XQ'[
M1Z?3[<^&/,'K_J#M<#%8B+Q!2J[*>PCOG16V(L\6\^WD(_I>7:,0(Y=>AU).
MY&/DW#!WU/J4Q'8X5^CV%6>LUW *46\&<-%2!'Z]C#K_A:/J'N>(6Q7Z"]GV
M^0W+,9P=:X/Z;L)5 +U:G+6 -$5CBW7RAZ6$=)^XHQ/@-Z]$.,:4M,O6L]*(
MT\V>?EO)1Q&%W*16EZL#SO9S8"W*I41T:7<GS=H">&PHIHZI,MS&$#Z5M\_F
M\99]1B=O/'0O4$[*%;MY,8EX==)C:XF9'><T0<IZLJQ=Z-I2TD8*.\0[XZQA
MTLW"MNSG)[I?'40)5KH3%%]D:>"KPS;(@UL>OK[RH0[T6RXI!-+SV??0+=]>
M,)6YY=H5"!&?KI7-V6IAHLF*BI/*)I3R^Y= 5&#=,(5-.<3<5%@6AU$WCIA%
M,4/ZD)EL<WS,:XU]U+I7%'$<))0'(9B/)FEJN3(E2JN)F>MLZB^F?\$Q7]Y?
M*UF((W0ZKDR1>MJVHNS@ICF,X;K)72KL.H'!$!YH"H1.HRRG9K)TP#"II-RG
MA%B28  5R96N +%?K4 /Y?MXP.];>0OR$9Q,5%6&!;R/HGI(XL!![>.6-Q?6
M;HMDCW8(+P<N6N<AB\7?ZQRM[DN6*6T+:VD>+.<-;?-+!K^F6'F/2)MN(H*C
MA/H#'A,'SRETI=S"< B+$9=LKQR0#*O6H!K^X@6;S:?P$(LGXU1-7O5J.%L%
M2T^1:\Q&W4*O*._G&_'31G#'DC0[>0#N"34AT"N/I4F;D.L*%CIFO,"6F&X2
ML'PJU99CT?[W(6PMP#V<0^"SD70*56],?M_VGW.8;!]:ZEE>.20P9NBQ\"$)
MVQ35P(?E<X/@*>3 DO.JG]CK6,<;9"SV_<Y<.O,)HZ;:47X.\>"!!U#Q9&TG
M7-ZE#W&2*/,9EI0;:&]:WC;--W0P3'Z/E^OM9%KJ!D6\$5!H"Z*4U!Q2@O0R
M9K* -7RVJWMNDB7=1\F$;DV#C>/H#*\0P]QBF5Z-GX_!)JZY0A-HWMHY,SP8
MSH"QT5=R$:0T6/34!PJARI(^2U'[=RFL%*]H._)IH-QT=%/?]X$>^N.N@2JL
M,.@DMAN H_7 :NZJ@BL.*(U6 G=3L\#"G<#]<NZDU-4;@X0.1]\L6WD1W:*!
M<32IA.VG$%]R?3M#1DF:45X!4[R2AHV:5=^GZLF/&JL!@6) )!]5.\/?>'#D
MVE)LQ[3EMB_X?0?O]]@!'GAQ=4Y_?G?U3KU>P#&\+)+QVC W,M5!"W#R[XD[
M/T2 +ESB.653".(P&M:&I)VTO\(1[5M"=@^ E-$O>'Q>(C():^-N.("U71+Z
MCQL'Q;=A R^Z*<_98\J1+PNX<29N:1I75K?TU<5JWX&!G3J=8,SX2 VI7&NX
MF!C+4ET]]_>4L :L*8+][QF)'8':HX8J1#/D"[ 4:B)S]"_IE0.6T$=EHY^L
MB*#4J!5=40C,0@(S SS;+V6QW77^D>G[C7LK?B8.%FLC,(1TVMQD_3"<!QG0
M]'LR!>83([((8#*ZY!L&[**7!Y5@*7@<-6E6J,HLEZ%T?\J%S''LJLW*L360
MXBQV0-5LE&M1,1N:!0)>Z#L.@F"/<),V1DNVJ;<!F;:103X;SN5*?S#N&FCV
MIH5__!Y^,@N,+>D^AR<4=OFMW<=>BM^!-)5&9=1FQ&#D%T/3!8BTW-O"%!!V
MY \D35D2 IFT/0C91K?P30;QT$#\&#%PX6'09 SZ7YX*/HO\8E%O*(8)%=0*
MZ1_ "BF8/O?%DCN?:] \F7I999I:._+'\$^Z-#_HXH"R%]*3KUVR*8 186.1
M3D7H^KGC=(X_2[:R?S"($P O$9^3<'LX;7PE_,(AB0ZJ.)7@/+>,\H9GL)U?
M4M1"(-T^,-<A0F++I,E!$-+/$B14["(9H/ ;!8+^A9<ZJY%V:[R&1EJW=)\0
MP8E9'W 0<[-TY0=/;O&? P6P/##@LR+Q93F?@NV?&H2T4VZBAW#L38O<@V#9
MT$FA;#+3CWX QU$=J/3;@O4S(/42GE6/O=SM#,R 5+%O[Q1T2](Y51_%W:T@
M0EW)+0_"3\YQC6V(K4G!%>5S!<,,8V9@R*2K&*TK$1E^W&/6,6##D?W$4:0W
MJN#U . R!OURM1+RT]GQ7T)9FYQL%[P:[,>[A@@!+VW4.Z[=Z3WBGYR*0=9Q
M'M1G;D.%#1>/=?MLTM$,'0GV2[4^;STP!0U&+:$<)QT*]9#'HA6N@Y,["_=%
MZ<(W.VPUO@,Z-"'==!V41SM6/@J&J@Y50>NJA!UTU]H*1VH2'.Y)S-B[NIB?
MRQK'8V=ZE:2C1^AB2]LCL5T[JF?$[56%^.*LC0:J+WW\,;2#0/1-U-*[-0(U
M:.P#_D$':@=+U;==1>F:&N=/(U /=7-9E!B!6.\'2]UUJEJ^#Q6^7+P5&<Y1
M@%]JO#PQ*(*_OE/P1T*F)M31G)Q*]'D?(PH#?9.\G>+6+!7F=$P;")TPU7C
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M,C R,C$R,S$N:'1M4$L! A0#%     @ :TA/5BV]A;8\&P  ^48! !$
M         ( !\ L% ')P<G@M,C R,C$R,S$N>'-D4$L! A0#%     @ :TA/
M5AD[G.+=)P  :XT! !4              ( !6R<% ')P<G@M,C R,C$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( &M(3U92_[_I9JH  ,QA!P 5
M  "  6M/!0!R<')X+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !K2$]6
MNB#&?X78   7# $ %               @ $$^@4 <G!R>"TR,#(R,3(S,5]G
M,2YJ<&=02P$"% ,4    " !K2$]6#,8L%XQT 0"";0( %
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M ')P<G@M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &M(3U8_L"HAV@,
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M#@!R<')X+3(P,C(Q,C,Q97@T,BYH=&U02P4&     !  $  H!   /R4.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
